PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Graham, DP; Cardon, AL				Graham, David P.; Cardon, Aaron L.			An Update on Substance Use and Treatment following Traumatic Brain Injury	ADDICTION REVIEWS 2008	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article						traumatic brain injury; substance abuse; prevalence; treatment outcome; review	ALCOHOL-USE PATTERNS; ABUSE TREATMENT; HEAD-INJURY; DRUG-USE; REHABILITATION; PREVALENCE; OUTCOMES; PROGRAM; INDIVIDUALS; POPULATION	Traumatic brain injury (TBI) is a leading cause of mortality and morbidity among young adults. Substance abusers constitute a disproportionate percentage of these patients. A history of substance abuse predicts increased disability, poorer prognosis, and delayed recovery. While consensus in the literature indicates that substance-abuse rates decline following injury, conflicting literature shows a significant history of brain injury in addicts. We reviewed the literature on substance abuse after TBI to explore the state of knowledge on TBI as a risk factor for substance abuse. While recent reviews regarding substance abuse in TBI patients concur that substance-abuse rates decline even after mild TBI, an emerging literature suggests mild TBI may cause subtle impairments in cognitive, executive, and decision-making functions that are often poorly recognized in early diagnosis and treatment. When combined with difficulties in psychosocial adjustment and coping skills, these impairments may increase the risk for chronic substance abuse in a subset of TBI patients. Preliminary results from veterans indicate these patterns hold in a combat-related post-traumatic stress disorder population with TBI. This increasingly prevalent combination presents a specific challenge in rehabilitation. While this comorbidity presents a challenge for the successful treatment and rehabilitation of both disorders, there is sparse evidence to recommend any specific treatment strategy for these individuals. Mild TBI and substance abuse are bidirectionally related both for risks and treatment. Further understanding the neuropsychiatric pathology and different effects of different types of injuries will likely improve the implementation of effective treatments for each of these two conditions.	[Graham, David P.] Michael E DeBakey VAMC 152, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res, Houston, TX 77030 USA; [Graham, David P.] Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA; [Graham, David P.] Menninger Dept Psychiat & Behav Sci, Houston, TX USA; [Graham, David P.] Vet Affairs S Cent Mental Illness Res Educ & Clin, Houston, TX USA; [Cardon, Aaron L.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA		Graham, DP (corresponding author), Michael E DeBakey VAMC 152, Houston Ctr Qual Care & Utilizat Studies, Hlth Serv Res, 2002 Holcombe, Houston, TX 77030 USA.	david.graham@med.va.gov	Graham, David/J-1158-2014				[Anonymous], 1998, REH PERS TRAUM BRAIN; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Blackerby W.F., 1990, J HEAD TRAUMA REHAB, V5, P47; Bogner JA, 1997, J HEAD TRAUMA REHAB, V12, P57, DOI 10.1097/00001199-199710000-00006; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Bombardier CH, 1997, ARCH PHYS MED REHAB, V78, P592, DOI 10.1016/S0003-9993(97)90424-X; Bombardier CH, 1999, REHABIL PSYCHOL, V44, P52, DOI 10.1037/0090-5550.44.1.52; Corrigan J.D., 2005, REHABILITATION TRAUM, P133; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; Corrigan JD, 2005, PSYCHOL ADDICT BEHAV, V19, P131, DOI 10.1037/0893-164X.19.2.131; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Corrigan JD, 2008, BRAIN INJURY, V22, P223, DOI 10.1080/02699050801938967; Corrigan JD, 2007, BRAIN INJURY, V21, P343, DOI 10.1080/02699050701253103; Cox WM, 2003, J ADDICT DIS, V22, P93, DOI 10.1300/J069v22n01_07; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; DONOVAN NJ, 1994, AM J PSYCHIAT, V151, P618; Ederoth P, 2004, BRIT J CLIN PHARMACO, V57, P427, DOI 10.1046/j.1365-2125.2003.02032.x; Felde AB, 2006, BRAIN INJURY, V20, P41, DOI 10.1080/02699050500309718; Heinemann AW, 2004, REHABIL PSYCHOL, V49, P156, DOI 10.1037/0090-5550.49.2.156; HENSOLD TC, 1997, BRAIN INJURY, V20, P369; HESTAD K, 1995, SCAND J PSYCHOL, V36, P246, DOI 10.1111/j.1467-9450.1995.tb00984.x; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; HOOFT PJ, 1994, INT J LEGAL MED, V106, P328, DOI 10.1007/BF01224781; Hornstein A, 1996, BRAIN INJURY, V10, P145, DOI 10.1080/026990596124647; Iverson GL, 2005, BRAIN INJURY, V19, P11, DOI 10.1080/02699050410001720068; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LANGLEY MJ, 1991, ADV BRAIN INJURY REH; Martin CD, 2006, PSYCHIATRY, V69, P351, DOI 10.1521/psyc.2006.69.4.351; McCullagh S, 2005, TXB TRAUMATIC BRAIN, P321; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Payne HC, 2000, BRAIN INJURY, V14, P479, DOI 10.1080/026990500120583; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Regard M, 2003, COGN BEHAV NEUROL, V16, P47, DOI 10.1097/00146965-200303000-00006; Robaei D, 2004, MED J AUSTRALIA, V181, P329, DOI 10.5694/j.1326-5377.2004.tb06302.x; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Suarez JI, 1999, CRIT CARE MED, V27, P262, DOI 10.1097/00003246-199902000-00025; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Turner AP, 2003, ARCH PHYS MED REHAB, V84, P358, DOI 10.1053/apmr.2003.50107; Vungkhanching M, 2007, J HEAD TRAUMA REHAB, V22, P167, DOI 10.1097/01.HTR.0000271117.19652.98; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Walker R, 2001, SUBST USE MISUSE, V36, P757, DOI 10.1081/JA-100104089; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003	54	78	81	0	20	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND	0077-8923			ANN NY ACAD SCI	Ann.NY Acad.Sci.		2008	1141						148	162		10.1196/annals.1441.029			15	Multidisciplinary Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Neurosciences & Neurology	BIM56	WOS:000260859100008	18991956				2022-02-06	
J	Lefebvre, H; Cloutier, G; Levert, MJ				Lefebvre, Helene; Cloutier, Genevieve; Levert, Marie Josee			Perspectives of survivors of traumatic brain injury and their caregivers on long-term social integration	BRAIN INJURY			English	Article						brain injuries; community reintegration; qualitative research; psychosocial aspects of illness	COMMUNITY INTEGRATION	Background: Traumatic brain injury (TBI) has damaging impacts on victims and family members' lives and their long-term social integration constitutes a major challenge. Purpose: The objective of the study was to document the repercussions of TBI on victims' long-term social integration (10 years post-trauma) and the contribution made by the services received from the point of view of TBI victims and family caregivers. This article examines the determinants of long-term social integration as well as the impact of TBI on family caregivers. Methods: A qualitative design was used (semi-directed interviews). The sample consisted of 22 individuals who had sustained a moderate or severe TBI and 21 family caregivers. Results: The results show that TBI is an experience that continues to present difficulties, even 10 years after the accident, and that different barriers contribute to this difficulty: not going back to work, depressive episodes, problems in relationships and sequellae. Family caregivers must help TBI victims confront the barriers in their path. Implications: This study adopts a longitudinal perspective to help professionals determine how to intervene with TBI victims and their families. It validates the importance of having clients and family caregivers describe their reality.	[Lefebvre, Helene] Univ Montreal, Fac Nursing, Lucie Bruneau Rehabil Ctr, Res Dept, Montreal, PQ H2H 2N8, Canada		Lefebvre, H (corresponding author), Univ Montreal, Fac Nursing, Lucie Bruneau Rehabil Ctr, Res Dept, 2275 Laurier St E, Montreal, PQ H2H 2N8, Canada.	helene.lefebvre@umontreal.ca					ANGUS DE, 1999, EC BURDEN UNINTENTIO; CARRIER S, 2003, CAN J PSYCHOL, V31, P339; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DUMONT C, 2003, THESIS U MONTREAL MO; Durgin CJ, 2000, J HEAD TRAUMA REHAB, V15, P1195, DOI 10.1097/00001199-200012000-00002; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; FAWCETT G, 2004, MESURES SERVICES SOU; FOUGEYROLLAS P, 2001, CAHIERS MEDICAUX SOC, P101; FOUGEYROLLAS P, 1997, RESEAU INT CIDIH, V9, P6; GADOURY M, 1999, CADRE REFERENCE CLIN; Guba EG., 1989, 4 GENERATION EVALUAT; HABERMAS J, 1987, THEORIE AGIR COMMUNI, V1, P448; Kaufman S. R., 1994, QUALITATIVE METHODS, P123; Kendall E, 2000, DISABIL REHABIL, V22, P435, DOI 10.1080/09638280050045901; Lapierre A., 1997, RECHERCHE QUALITATIV, p309 ; Lefebvre H, 2005, BRAIN INJURY, V19, P585, DOI 10.1080/02699050400025026; Lefebvre H, 2004, PARTICIPATION SOCIAL; McCabe P, 2007, BRAIN INJURY, V21, P231, DOI 10.1080/02699050701201631; McColl MA, 2000, ARCH PHYS MED REHAB, V81, P817, DOI 10.1016/S0003-9993(00)90117-5; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; Miczo N, 2003, QUAL HEALTH RES, V13, P469, DOI 10.1177/1049732302250756; Minnes P, 2001, NEUROREHABILITATION, V16, P3; *MSSS, 2004, POUR VER PART COMM O; NOLTE M, 2000, DISS ABSTR INT B, V60, P4900; *OPHQ, 1999, QUEB INT SOC PERS HA; Paterson BL, 2001, METASTUDY QUALITATIV; POUPART J., 1997, RECHERCHE QUALITATIV, P173; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; VANIER M, 1992, SYSTEME EVALUATION G; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004	31	78	78	1	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	7-8					535	543		10.1080/02699050802158243			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	318MG	WOS:000257095300004	18568706				2022-02-06	
J	Miller, JR; Adamson, GJ; Pink, MM; Sweet, JC				Miller, Jennifer R.; Adamson, Gregory J.; Pink, Marilyn M.; Sweet, John C.			Comparison of preseason, midseason, and postseason neurocognitive scores in uninjured collegiate football players	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	30th Annual Meeting of the American-Orthopaedic-Society-for-Sports-Medicine (AOSSM)	JUN, 2004	Quebec City, CANADA	Amer Orthopaed Soc Sports Med		concussion; athletic injury; neurocognitive tests; head injury	STANDARDIZED ASSESSMENT; COGNITIVE IMPAIRMENT; CONCUSSION; HEAD; RECOVERY; SOCCER; PERFORMANCE; INJURIES	Background: College football players sustain an average of 3 subconcussive blows to the head per game. Concussions correlate with decreases in standardized neurocognitive test scores. It is not known whether repetitive, subconcussive microtrauma associated with participation in a full season of collision sport affects neurocognitive test scores. Hypothesis: No difference exists between preseason, midseason, and postseason Standardized Assessment of Concussion (SAC) and Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) scores when collegiate football players sustain subconcussive microtrauma from forceful, repetitive contact activity. Study Design: Case series; Level of evidence, 4. Methods: Fifty-eight members of a Division III collegiate football team who had no known concussion during the season voluntarily completed the SAC and ImPACT instruments preseason, midseason, and postseason. A repeated measures analysis of variance was used to compare the scores at the 3 time intervals (P <.05). Results: No statistically significant decreases were found in overall SAC or ImPACT scores or in any of the domains or composites of the tests (P <.05) when preseason, midseason, and postseason scores were evaluated. Conclusions: ImPACT and SAC neurocognitive test scores are not significantly altered by a season of repetitive contact in collegiate football athletes who have not sustained a concussion. Clinical Relevance: A diminution in SAC or ImPACT scores in concert with clinical symptoms and findings should be interpreted as evidence of a postconcussive event.	Congress Med Associates, Pasadena, CA 91105 USA; Idaho Sports Med Inst, Boise, ID USA; Occidental Coll, Los Angeles, CA 90041 USA		Adamson, GJ (corresponding author), Congress Med Associates, 39 Congress St, Pasadena, CA 91105 USA.	susan@congressmedical.com	Adamson, Gregory/L-2794-2019				Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2001, PSYCHOL REP, V89, P457, DOI 10.2466/pr0.2001.89.2.457; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LOVELL MR, 2006, ORTHOP TECH REV, V8, P24; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M., 2000, STANDARDIZED ASSESSM; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; STRAUMENAESHEIM TM, 2005, BR J SPORTS MED S1, V39, P70; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006	33	78	78	0	19	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	AUG	2007	35	8					1284	1288		10.1177/0363546507300261			5	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Orthopedics; Sport Sciences	196AB	WOS:000248452500007	17405886				2022-02-06	
J	Stocchetti, N; Colombo, A; Ortolano, F; Videtta, W; Marchesi, R; Longhi, L; Zanier, ER				Stocchetti, Nino; Colombo, Angelo; Ortolano, Fabrizio; Videtta, Walter; Marchesi, Roberta; Longhi, Luca; Zanier, Elisa R.			Time course of intracranial hypertension after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						clinical management of CNS injury; intracranial pressure; traumatic brain injury	HEAD-INJURY; CELLULAR EDEMA; PRESSURE; SECONDARY; DEXANABINOL	High intracranial pressure (HICP) may be a very early event after traumatic brain injury (TBI), but in most cases, especially when contusions and edema develop over time, HICP will worsen over succeeding days. This study describes the incidence and severity of elevated intracranial pressure (ICP) after TBI and attempts to document its time course. In this prospective study, 201 TBI patients in whom ICP was monitored for more than 12 h were evaluated. ICP was measured, digitalized, and analyzed after manual filtering. The number of episodes of HICP and the mean ICP value for every 12-h interval were calculated. When monitoring was concluded, the highest mean ICP collected in every patient was identified. A total of 21,000 h of ICP monitoring were recorded. Active treatment to prevent or reduce HICP was used in 200 patients. HICP was documented in 155 cases. Half of the patients had their highest mean ICP during the first 3 days after injury, but many showed delayed ICP elevation, with 25% showing highest mean ICP after day 5. In these cases, HICP was significantly worse and required more intense therapies.	Univ Milan, Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Neurosci ICU, I-20122 Milan, Italy		Stocchetti, N (corresponding author), Univ Milan, Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Neurosci ICU, Via F Sforza 35, I-20122 Milan, Italy.	stocchet@policlinico.mi.it	Longhi, Luca/AAF-9903-2021; Stocchetti, Nino/O-7444-2017; Zanier, Elisa/AAA-8095-2020	Longhi, Luca/0000-0001-9894-8788; Stocchetti, Nino/0000-0003-3250-6834; Zanier, Elisa/0000-0002-3011-8718; Ortolano, Fabrizio/0000-0003-1996-948X			Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bloomfield GL, 1995, J TRAUMA, V39, P1168, DOI 10.1097/00005373-199512000-00028; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CLARK WC, 1989, NEUROSURGERY, V25, P20; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; KLAUBER MR, 1984, J NEUROSURG, V61, P695, DOI 10.3171/jns.1984.61.4.0695; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; LOBATO RD, 1983, INTRACRANIAL PRESSUE, P543; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Rebuck JA, 2000, J NEUROL NEUROSUR PS, V69, P381, DOI 10.1136/jnnp.69.3.381; Souter MJ, 1999, CRIT CARE MED, V27, P177, DOI 10.1097/00003246-199901000-00048; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P479, DOI DOI 10.1089/NEU.2000.17.479; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Verweij BH, 2001, J NEUROSURG, V95, P569, DOI 10.3171/jns.2001.95.4.0569; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zanier ER, 2007, CRIT CARE, V11, DOI 10.1186/cc5155	23	78	80	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1339	1346		10.1089/neu.2007.0300			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500005	17711395				2022-02-06	
J	Catena, RD; van Donkelaar, P; Chou, LS				Catena, Robert D.; van Donkelaar, Paul; Chou, Li-Shan			Altered balance control following concussion is better detected with an attention test during gait	GAIT & POSTURE			English	Article						concussion; cognition; secondary task; attention; gait	TRAUMATIC BRAIN-INJURY; CENTER-OF-MASS; DIVIDED ATTENTION; OBSTACLE; MOTION	The purpose of this study was to examine the effects of concussion on gait stability when either a cognitive or motor perturbation is imposed. Fourteen individuals suffering from a grade II concussion and 14 matched controls performed a single task of level walking, a continuous sequential question and answer task while walking, and an obstacle-crossing task. Common gait spatial/temporal measurements, whole-body center of mass motion, and center of pressure trajectory were assessed. Concussed individuals adopted a more conservative strategy to maintain gait stability. Some measurements indicating conservative gait were seen during obstacle crossing, but this was most evident during the Q&A task. Concussed individuals also displayed signs of possible instability during the Q&A task. The question and answer task was most sensitive to distinguishing concussed individuals from healthy individuals, supporting the use of a similar dual-task modality in future testing after concussion to determine a proper time for return to activity. (C) 2006 Elsevier B.V. All rights reserved.	Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA; Univ Oregon, Dept Human Physiol, Eye Hand Lab, Eugene, OR 97403 USA		Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA.	chou@uoregon.edu	Catena, Robert/AAT-1510-2021	Catena, Robert/0000-0001-9128-1343	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR023203, R49/CCR021735] Funding Source: Medline		BELL R, 1977, AM FAM PHYSICIAN, V16, P145; Brown LA, 2005, J GERONTOL A-BIOL, V60, P924, DOI 10.1093/gerona/60.7.924; BRUKNER P, 2001, CLIN SPORTS MED; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Chou LS, 2001, GAIT POSTURE, V13, P17, DOI 10.1016/S0966-6362(00)00087-4; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Gage WH, 2003, EXP BRAIN RES, V150, P385, DOI 10.1007/s00221-003-1468-7; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Kelly JP, 1997, NEUROLOGY, V48, P581; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; PASHLER H, 1990, J EXP PSYCHOL HUMAN, V16, P826, DOI 10.1037/0096-1523.16.4.826; Said CM, 2001, ARCH PHYS MED REHAB, V82, P1712, DOI 10.1053/apmr.2001.26247; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vallis LA, 2004, EXP BRAIN RES, V157, P94, DOI 10.1007/s00221-003-1824-7; Weerdesteyn V, 2003, J MOTOR BEHAV, V35, P53, DOI 10.1080/00222890309602121; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	19	78	78	0	18	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0966-6362			GAIT POSTURE	Gait Posture	MAR	2007	25	3					406	411		10.1016/j.gaitpost.2006.05.006			6	Neurosciences; Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Orthopedics; Sport Sciences	148LH	WOS:000245075600011	16787746				2022-02-06	
J	Lincoln, AE; Hinton, RY; Almquist, JL; Lager, SL; Dick, RW				Lincoln, Andrew E.; Hinton, Richard Y.; Almquist, Jon L.; Lager, Sean L.; Dick, Randall W.			Head, face, and eye injuries in scholastic and collegiate lacrosse - A 4-year prospective study	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						sports; injury; lacrosse; epidemiology	RISK HOMEOSTASIS THEORY; TRAFFIC ACCIDENT DATA; WOMENS LACROSSE; PREVENTION	Background: Risks and mechanisms of head, face, and eye injuries in high school and college lacrosse are not well documented. Purpose: To identify (1) primary mechanisms of head, face, and eye injuries in lacrosse and (2) differences in injury risk between the men's and women's game and between high school and collegiate levels. Study Design: Descriptive epidemiological study. Methods: The authors gathered data on 507 000 girls' and boys' high school and 649 573 women's and men's college lacrosse athletic exposures using sport-specific injury surveillance systems over 4 seasons. They identified the most common scenarios for head, face, and eye injuries. Results: The high school girls' head, face, and eye injury rate (0.54 per 1000 athletic exposures) was significantly higher (incident rate ratio, 1.42; 95% confidence interval, 1.09-1.86) than that for boys (0.38 per 1000 athletic exposures); college women (0.77 per 1000 athletic exposures) sustained a higher rate of injuries (incident rate ratio, 1.76; 95% confidence interval, 1.42-2.19) than did men (0.44 per 1000 athletic exposures). Concussions constituted a higher percentage of injuries among boys (73%) and men (85%) than among girls (40%) and women (41 %). Men sustained few facial injuries, whereas a substantial proportion of women's injuries involved the face and orbital area. Conclusion: Although permitting only incidental contact, women's lacrosse had higher rates of head, face, and eye injuries at both the high school and collegiate levels. Concussion was the most common injury. For men, the primary injury mechanism was player-to-player contact; women's injuries primarily resulted from stick or ball contact. High school injury rates were lower than were college rates, but the nature of injuries, body parts affected, and mechanisms were similar.	Medstar Res Inst, Hyattsville, MD USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Union Mem Hosp, Fairfax Cty Publ Sch, Baltimore, MD USA; Fairfax Cty Publ Sch, Athletic Training Program, Fairfax, VA USA; Natl Coll Athlet Assoc, Indianapolis, IN USA		Lincoln, AE (corresponding author), Union Mem Orthopaed, Johnston Professional Bldg 400,3333 N Calvert St, Baltimore, MD 21218 USA.	lyn.camire@medstar.net					Adams J, 2001, Inj Prev, V7, P89, DOI 10.1136/ip.7.2.89; CRISCO T, FAQS HELMETS HEAD NE; Diamond PT, 2001, BRAIN INJURY, V15, P537, DOI 10.1080/02699050010007362; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; EVANS L, 1986, RISK ANAL, V6, P81, DOI 10.1111/j.1539-6924.1986.tb00196.x; Goldenberg Michael S., 1995, Journal of Athletic Training, V30, P37; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; LAPIDUS CS, 1992, J TRAUMA, V32, P555, DOI 10.1097/00005373-199205000-00003; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; *NAT COLL ATHL ASS, POS REG EYE PROT WOM; *NAT COLL ATHL ASS, 2002, INJ SURV SYST 2001 0; *NAT COLL ATHL ASS, 2004, 1981 82 2003 04 NCAA; Thompson D C, 2001, Inj Prev, V7, P86, DOI 10.1136/ip.7.2.86; *US LACR, 2003 US LACR PART SU; *US LACR, WOM LACR EYEW UPD; VENNUM T, 1994, CREATORS GAME BRIEF; VINGER PF, 1994, DUANES CLIN OPHTHALM, P1; Webster DA, 1999, MED SCI SPORT EXER, V31, P938, DOI 10.1097/00005768-199907000-00004; WILDE GJS, 1986, RISK ANAL, V6, P95, DOI 10.1111/j.1539-6924.1986.tb00197.x	20	78	79	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2007	35	2					207	215		10.1177/0363546506293900			9	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	132ZD	WOS:000243980500004	17204586				2022-02-06	
J	Nadebaum, C; Anderson, V; Catroppa, C				Nadebaum, Caroline; Anderson, Vicki; Catroppa, Cathy			Executive function outcomes following traumatic brain injury in young children: A five year follow-up	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CHILDHOOD HEAD-INJURY; BEHAVIOR RATING INVENTORY; PROBLEM-SOLVING SKILLS; LONG-TERM OUTCOMES; COGNITIVE-DEVELOPMENT; WORKING-MEMORY; WHITE-MATTER; FRONTAL-LOBE; PERFORMANCE; RECOVERY	Little is known about the long-term effects of traumatic brain injury (TBI) in very young children. This study used a prospective, cross-sectional design to investigate the impact of TBI on executive function (EF) outcomes in children who sustained a TBI before the age of seven. The study aimed to identify specific or global EF deficits five years post-TBI, and to explore factors that predicted outcomes. Fifty-four children with a TBI and 17 uninjured comparison children participated. Their performance on several cognitive and behavioral EF measures was examined. Results suggested that executive difficulties were present following severe TBI, however children with mild and moderate injuries were relatively unaffected. Skills that develop early appeared to be relatively robust. Injury severity was found to be most predictive of long-term EF, however other injury, child and family-related variables also contributed to outcomes.	Univ Melbourne, Dept Psychol, Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Dept Psychol, Murdoch Childrens Res Inst, Melbourne, Vic, Australia		Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P319, DOI 10.1080/713755568; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, 2001, DEV NEUROPSYCHOLOGY; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anderton S, 2005, CHEM WORLD-UK, V2, P19; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; BELL MA, 1992, CHILD DEV, V63, P1142, DOI 10.1111/j.1467-8624.1992.tb01685.x; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Catroppa C, 2003, NEUROPSYCHOL REHABIL, V13, P517, DOI 10.1080/09602010343000084; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; Chugani HT, 1998, PREV MED, V27, P184, DOI 10.1006/pmed.1998.0274; Ciccetti D., 1984, VINELAND ADAPTIVE BE; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DANIEL A, 1983, POWER PRIVELEGE OCCU; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P89; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Evans DW, 2004, BRAIN COGNITION, V55, P220, DOI 10.1016/s0278-2626(03)00274-4; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Fenwick T, 1999, CHILD NEUROPSYCHOL, V5, P213, DOI 10.1076/0929-7049(199912)05:04;1-R;FT213; Fuster J M, 1993, Curr Opin Neurobiol, V3, P160, DOI 10.1016/0959-4388(93)90204-C; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; HUTTENLOCHER PR, 1997, DEV ANATOMY PREFRONT; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Jordan FM, 1996, BRAIN INJURY, V10, P91, DOI 10.1080/026990596124575; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Lehnung M, 2001, CHILD NEUROPSYCHOL, V7, P59, DOI 10.1076/chin.7.2.59.3129; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Levin HS, 2001, NEUROPSYCHOLOGY, V15, P557, DOI 10.1037//0894-4105.15.4.557; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Luis CA, 2002, J CLIN EXP NEUROPSYC, V24, P270, DOI 10.1076/jcen.24.3.270.982; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; MANLY T, 1999, TEST EVERDAY ATTENTI; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Noller P., 1988, ICPS FAMILY FUNCTION; Nybo T, 1999, BRAIN INJURY, V13, P759; OCONNOR P, 2002, HOSP DUE TRAUMATIC B; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Pentland L, 1998, NEUROPSYCHOL REHABIL, V8, P301, DOI 10.1080/713755572; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/PMS.73.8.1139-1150; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Segalowitz SJ, 2004, BRAIN COGNITION, V55, P116, DOI 10.1016/s0278-2626(03)00283-5; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Smidts DP, 2004, DEV NEUROPSYCHOL, V26, P385, DOI 10.1207/s15326942dn2601_2; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Stanton B R, 1999, Pediatr Rehabil, V3, P193, DOI 10.1080/136384999289469; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 2005, INT NEUR M DUBL; TEASDALE G, 1974, LANCET, V2, P81; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Weschler D., 1992, MANUAL WESCHLER INTE, V3rd ed; Willmott C, 2000, DEV NEUROPSYCHOL, V17, P361, DOI 10.1207/S15326942DN1703_5	95	78	78	0	18	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2007	32	2					703	728		10.1080/87565640701376086			26	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	212NJ	WOS:000249603000006	17931126				2022-02-06	
J	Sifri, ZC; Homnick, AT; Vaynman, A; Lavery, R; Liao, W; Mohr, A; Hauser, CJ; Manniker, A; Livingston, D				Sifri, Ziad C.; Homnick, Adena T.; Vaynman, Artem; Lavery, Robert; Liao, Wesley; Mohr, Alicia; Hauser, Carl J.; Manniker, Allen; Livingston, David			A prospective evaluation of the value of repeat cranial computed tomography in patients with minimal head injury and an intracranial bleed	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; cranial computed axial tomography; neurologic status; neurosurgical intervention; intracranial bleed	TRAUMATIC BRAIN-INJURY; CT SCANS; MANAGEMENT; UTILITY; PREDICTORS; ADMISSION; MODERATE; TRENDS	Background: Patients with minimal head injury (MHI) and intracranial bleed (ICB) detected on cranial computed tomography (CT) scan routinely undergo a repeat cranial CT within 24 hours after injury to assess for progression of intracranial injuries. While this is clearly beneficial in patients with a deteriorating neurologic status, it is of questionable value in patients with a normal neurologic examination. The goal of this study was to prospectively assess the value of a repeat cranial CT in patients with a MHI and an ICB who have a normal neurologic examination. Methods. A prospective analysis of all adult patients admitted to a Level I trauma center after blunt trauma causing a MHI (defined as the loss of consciousness or posttraumatic amnesia with a Glasgow Coma Scale (GCS) score of greater or equal to 13) and an ICB on the initial cranial CT during a 12-month period (July 2002 through July 2003) was performed. All patients with MHI were prospectively evaluated and followed until discharge. Data collected included demographics, neurologic examination and findings on the initial and repeat cranial CT scan. Outcome data included neurologic deterioration, neurosurgical intervention, and Glasgow Outcome Scale (GOS) on discharge. Results: In all, 161 consecutive patients with MM and a positive cranial CT scan were identified. The initial cranial CT lead to a neurosurgical intervention (1 craniotomy, 4 intracranial pressure monitors) in 4% of cases. The remaining 130 patients who met inclusion criteria, underwent a repeat cranial CT scan within 24 hours post-admission. Ninety nine (76%) patients had a normal neurologic examination at the time of their repeat cranial CT. After the repeat cranial CT none required immediate neurosurgical intervention or had delayed neurologic deterioration related to their head injury. Fifteen patients underwent additional neuroradiologic studies but none showed further progression of their ICB or lead to a change in management. One patient died from non-traumatic brain injury related causes and of the remaining 26 patients, 98% had an overall favorable GOS score (> 3) on discharge. In this group of patients with MHI and ICB, the negative predictive value of a normal neurologic examination was 100%. Conclusions: Repeat cranial CT, in patients with a MHI and a normal neurologic examination, resulted in no change in management or neurosurgical intervention and is therefore not indicated. A multicenter prospective study would further validate these conclusions, reduce unnecessary CT scans, and likely improve our current standard of care in these patients.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA		Sifri, ZC (corresponding author), 150 Bergen St,M-229, Newark, NJ 07103 USA.	sifrizi@umdnj.edu	Hauser, Carl J./Y-1189-2019; Mohr, Alicia M/E-3016-2015	Mohr, Alicia/0000-0003-1732-1313; Hauser, Carl/0000-0003-3167-1846			*AG HLTH CAR POL R, 1998, REH TRAUM BRAIN INJ; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MORAN SG, 1994, AM SURGEON, V60, P533; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Valadka A, 2000, TRAUMA, P377	24	78	83	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2006	61	4					862	867		10.1097/01.ta.0000224225.54982.90			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	096YU	WOS:000241413700019	17033552				2022-02-06	
J	Macpherson, A; Rothman, L; Howard, A				Macpherson, A; Rothman, L; Howard, A			Body-checking rules and childhood injuries in ice hockey	PEDIATRICS			English	Article						sports; hockey; body-checking rules		BACKGROUND. Body checking is the predominant mechanism of youth ice hockey injuries. The Canadian Hockey Association has allowed body checking from ages 12 to 13 (peewee level) and up. One Canadian province (Ontario) introduced body checking at ages 10 to 11 (atom level) in the competitive leagues, whereas in Quebec body checking has only been allowed at ages 14 to 15 (bantam Level). The purpose of this study was to compare body-checking injuries, fractures, and concussions in boys' minor hockey between jurisdictions in which checking is allowed and jurisdictions in which body checking is not allowed. METHODS. Data from the Canadian Hospitals Injury Reporting and Prevention Program (CHIRPP) were used to characterize children's ice hockey injuries from September 1995 to the end of August 2002. Children treated at CHIRPP hospitals in areas in which checking was allowed were compared with children in areas in which checking was not allowed. RESULTS. Of the 4736 hockey injuries, 3006 (63%) were in Ontario and 1730 (37%) were in Quebec. Most of the injuries occurred in areas in which checking was allowed (2824 [59.6%]). At ages 10 to 13, players had significantly greater odds of suffering a checking injury where checking was allowed (odds ratio [OR]: 1.86; 95% confidence interval [CI]: 1.6 - 2.11). Players in this age group were also more likely to suffer a concussion (OR: 1.42; 95% CI: 0.98 - 2.05) or fracture (OR: 1.25; 95% CI: 1.06 - 1.47) where checking was allowed. Among older players, when checking was allowed in both provinces, there were higher odds (OR: 1.90; 95% CI: 1.36 - 2.66) of receiving a checking injury in the province that had introduced checking at a younger age, suggesting that there is no protective effect from learning to check earlier. CONCLUSIONS. Increased injuries attributable to checking were observed where checking was allowed. This study supports policies that disallow body checking to reduce ice hockey injuries in children.	York Univ, Bethune Coll 337, Sch Kinesiol & Hlth Sci, Toronto, ON M3J 1P3, Canada; Inst Clin Evaluat Sci, Toronto, ON, Canada; Hosp Sick Children, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada		Macpherson, A (corresponding author), York Univ, Bethune Coll 337, Sch Kinesiol & Hlth Sci, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	alison3@yorku.ca	Howard, Andrew/C-7163-2009	Howard, Andrew/0000-0001-7226-6471			Anderson AJ, 2000, PEDIATRICS, V105, P657, DOI 10.1542/peds.105.3.640; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; *CAN AC SPORT MED, 1998, VIOL INJ ICE HOCK; *CAN I HLTH INF, NEWS EV HOCK INJ; GOULET C, 1997, SAFETY CANADIAN CHIL; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Macarthur C, 1997, AM J EPIDEMIOL, V145, P834; Mackenzie S G, 1999, Inj Prev, V5, P208; Marchie A, 2003, CAN MED ASSOC J, V169, P124; MCFAULL S, 2001, CHIRPP NEWS, V19, P1; Pickett W, 2000, Inj Prev, V6, P9, DOI 10.1136/ip.6.1.9; REGNIER G, 1986, ASTM STP, V1050, P84; Reid SR, 1999, PEDIATR EMERG CARE, V15, P310, DOI 10.1097/00006565-199910000-00002; Tator CH, 1998, CLIN SPORT MED, V17, P183, DOI 10.1016/S0278-5919(05)70072-7	14	78	78	0	12	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2006	117	2					E143	E147		10.1542/peds.2005-1163			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	014PC	WOS:000235491100055	16452323				2022-02-06	
J	Truettner, JS; Alonso, OF; Dietrich, WD				Truettner, JS; Alonso, OF; Dietrich, WD			Influence of therapeutic hypothermia on matrix metal loproteinase activity after traumatic brain injury in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						blood-brain barrier; brain trauma; extracellular matrix; fluid-percussion injury; hypothermia; MMPs; proteolysis	NECROSIS-FACTOR-ALPHA; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; GENE KNOCK-OUT; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; INTRACEREBRAL HEMORRHAGE; ENDOTHELIAL-CELLS; GROWTH-FACTOR; METALLOPROTEINASE EXPRESSION	Recent evidence suggests that matrix metal loproteinases (MMPs) contribute to acute edema and lesion formation following ischemic and traumatic brain injuries (TBI). Experimental and clinical studies have also reported the beneficial effects of posttraurnatic hypothermia on histopathological and behavioral outcome. The purpose of this study was to determine whether therapeutic hypothermia would affect the activity of MMPs after TBI. Male Sprague-Dawley rats were traumatized by moderate parasagittal fluid-percussion (F-P) brain injury. Seven groups (n=5/ group) of animals were investigated: sham-operated, TBI with normothermia (37 degrees C), and TBI with hypothermia (33 degrees C). Normothermia animals were killed at 4, 24, 72h and 5 days, and hypothermia animals at 24 or 72 h. Brain temperature was reduced to target temperature 30 mins after trauma and maintained for 4h. lpsilateral and contralateral cortical, hippocampal, and thalamic regions were analyzed by gelatin and in situ zymography. In traumatized normothermic animals, TBI significantly (P<0.005) increased MMP-9 levels in ipsilateral (right) cortical and hippocampal regions, compared with contralateral or sham animals, beginning at 4 h and persisting to 5 days. At 1, 3, and 5 days after TBI, significant increases in MMP-2 levels were observed. In contrast to these findings observed with normothermia, posttraumatic hypothermia significantly reduced MMP-9 levels. Hypothermic treatment, however, did not affect the delayed activation of MMP-2. Clarifying the mechanisms underlying the beneficial effects of posttraumatic hypothermia is an active area of research. Posttraumatic hypothermia may attenuate the deleterious consequences of brain trauma by reducing MMP activation acutely.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg,Neurotrauma Res Ctr, Miami, FL 33101 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg,Neurotrauma Res Ctr, POB 016960,R-48, Miami, FL 33101 USA.	ddietrich@miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42133, NS30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER		Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Asahi M, 2001, NEUROREPORT, V12, P3003, DOI 10.1097/00001756-200109170-00050; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Bradham WS, 2002, CARDIOVASC RES, V53, P822, DOI 10.1016/S0008-6363(01)00503-X; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Corbel M, 2001, EUR J PHARMACOL, V426, P113, DOI 10.1016/S0014-2999(01)01209-2; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; del Zoppo GJ, 2003, J CEREBR BLOOD F MET, V23, P879, DOI 10.1097/01.WCB.0000078322.96027.78; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dietrich WD, 1996, NEUROTRAUMA, P1491; Ding YH, 2004, NEUROSCI LETT, V372, P35, DOI 10.1016/j.neulet.2004.09.010; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Fowlkes JL, 2002, CYTOKINE GROWTH F R, V13, P277, DOI 10.1016/S1359-6101(02)00005-9; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gasche Y, 2001, J CEREBR BLOOD F MET, V21, P1393, DOI 10.1097/00004647-200112000-00003; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; Hamann GF, 2004, STROKE, V35, P764, DOI 10.1161/01.STR.0000116866.60794.21; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HAYASHI N, 2004, BRAIN HYPOTHERMIA TR; Horstmann S, 2003, STROKE, V34, P2165, DOI 10.1161/01.STR.0000088062.86084.F2; Jiang H, 2000, T NONFERR METAL SOC, V10, P87; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knittel T, 1999, J HEPATOL, V30, P48, DOI 10.1016/S0168-8278(99)80007-5; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lee SR, 2004, J CEREBR BLOOD F MET, V24, P720, DOI 10.1097/01.WCB.0000122747.72175.47; Lee SR, 2004, J NEUROSCI, V24, P671, DOI 10.1523/JNEUROSCI.4243-03.2004; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Levkau B, 2002, CELL DEATH DIFFER, V9, P1360, DOI 10.1038/sj.cdd.4401106; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lukes A, 1999, MOL NEUROBIOL, V19, P267, DOI 10.1007/BF02821717; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Noble LJ, 2002, J NEUROSCI, V22, P7526; Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851; Pagenstecher A, 1998, AM J PATHOL, V152, P729; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Power C, 2003, ANN NEUROL, V53, P731, DOI 10.1002/ana.10553; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; ROSENBERG GA, 1992, BRAIN RES, V576, P203, DOI 10.1016/0006-8993(92)90681-X; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Tang S, 2004, CHINESE J ORG CHEM, V24, P1133; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; von Gertten C, 2003, J NEUROSCI RES, V73, P803, DOI 10.1002/jnr.10729; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Winkler MK, 2002, AM J PHYSIOL-LUNG C, V283, pL1, DOI 10.1152/ajplung.00489.2001; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; Zalewska T, 2003, BRAIN RES, V977, P62, DOI 10.1016/S0006-8993(03)02742-2; Zalewska T, 2002, ACTA NEUROBIOL EXP, V62, P53	85	78	82	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2005	25	11					1505	1516		10.1038/sj.jcbfm.9600150			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	977PF	WOS:000232815000010	15959464	Bronze			2022-02-06	
J	Testa, JA; Malec, JF; Moessner, AM; Brown, AW				Testa, JA; Malec, JF; Moessner, AM; Brown, AW			Outcome after traumatic brain injury: Effects of aging on recovery	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; aging; rehabilitation	CLOSED-HEAD INJURY; PORTLAND ADAPTABILITY INVENTORY; DISABILITY RATING-SCALE; ALZHEIMERS-DISEASE; OLDER-ADULTS; NEUROBEHAVIORAL CONSEQUENCES; COGNITIVE IMPAIRMENT; SIGNIFICANT OTHERS; UNITED-STATES; RISK-FACTORS	Objective: To identify differences in outcome after traumatic brain injury (TBI) compared with orthopedic injuries as a function of age. Design: Longitudinal data analyses from an inception cohort. Setting: Outpatient rehabilitation program. P articipants: Eighty-two orthopedic injury patients and 195 TBI patients. Interventions: Not applicable. Main Outcome Measures: Independent living, employment, and level of functioning 1 to 2 years after injury. Results: Older patients and those with TBI were more likely to have increased dependence postinjury. Older TBI patients were more likely to have changes in employment status compared with orthopedic injury patients younger or TBI. The Mayo-Portland Adaptability Inventory and Disability Rating Scale were moderately predictive of level of functioning, return to employment, and independent living status 1 to 2 years postinjury. Injury severity was only mildly predictive of outcome. Conclusions: The effect of age on outcome affects recovery from neurologic injuries and, to a lesser extent, orthopedic injuries. Outcome after TBI is best predicted by patients' age and estimates of level of function at discharge. Findings suggest that older patients and those with TBI have a greater likelihood of becoming physically and financially dependent on others. Rehabilitation efforts should focus on maximizing levels of independence to limit financial and emotional costs to patients and their families.	Mayo Clin, Dept Psychiat & Psychol, Rochester, MN 55905 USA; Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; Mayo Clin, Dept Nursing, Rochester, MN 55905 USA		Testa, JA (corresponding author), Mayo Clin, Dept Psychiat & Psychol, 200 1st St SW, Rochester, MN 55905 USA.	testa.julie@mayo.edu		Brown, Allen W./0000-0001-7228-3351			AharonPeretz J, 1997, BRAIN INJURY, V11, P871; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Cifu D X, 1993, Clin Geriatr Med, V9, P473; Cifu D X, 1993, Arch Phys Med Rehabil, V74, pS406; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Coleman P, 2004, NEUROBIOL AGING, V25, P3, DOI 10.1016/j.neurobiolaging.2003.10.001; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Goleburn CR, 2001, J CLIN GEROPSYCHOL, V7, P161; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; GOODMAN H, 1992, PHYS MED REH CLIN N, V3, P441; Graafmans WC, 1996, AM J EPIDEMIOL, V143, P1129; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; LINACRE JM, 2003, FACETS WINDOWS; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Malec J. F., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Malec JF, 2004, BRAIN INJURY, V18, P563, DOI 10.1080/02699050310001646134; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; MALEC JF, 1995, MAYO CLIN PROC, V70, P1165, DOI 10.4065/70.12.1165; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Malec JF, 2005, MANUAL MAYO PORTLAND; MAX W, 1990, INQUIRY-J HEALTH CAR, V27, P332; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; MORRIS JC, 1987, J GERONTOL, V42, P412, DOI 10.1093/geronj/42.4.412; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Rapoport MJ, 2001, BRAIN INJURY, V15, P857, DOI 10.1080/02699050110065303; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Saunders RL, 2002, J TRAUMA, V53, P391, DOI 10.1097/00005373-200208000-00040; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shaw FE, 2003, BRIT MED J, V326, P73, DOI 10.1136/bmj.326.7380.73; Shaw FE, 2002, CLIN GERIATR MED, V18, P159, DOI 10.1016/S0749-0690(02)00003-4; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Sosin DM, 1996, BRAIN INJURY, V10, P47; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tate RL, 2004, ARCH PHYS MED REHAB, V85, P538, DOI 10.1016/j.apmr.2003.08.078; TEASDALE GM, 1979, ACTA NEUROCHIR S, V75, pS37; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456	63	78	79	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2005	86	9					1815	1823		10.1016/j.apmr.2005.03.010			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	962QM	WOS:000231747300017	16181948				2022-02-06	
J	Lin, AH; Luo, J; Mondshein, LH; ten Dijke, P; Vivien, D; Contag, CH; Wyss-Coray, T				Lin, AH; Luo, J; Mondshein, LH; ten Dijke, P; Vivien, D; Contag, CH; Wyss-Coray, T			Global analysis of Smad2/3-dependent TGF-beta signaling in living mice reveals prominent tissue-specific responses to injury	JOURNAL OF IMMUNOLOGY			English	Article							GROWTH-FACTOR-BETA; IN-VIVO; TRANSGENIC MICE; WILD-TYPE; EXPRESSION; GENE; SMAD2; ACTIVATION; PROTEINS; RECEPTOR	Smad2 and Smad3 (Smad2/3) proteins are key signaling molecules for TGF-beta and some related family members regulating the transcription of several hundred genes. TGF-beta have key roles in development, tissue homeostasis, and the pathogenesis of many human diseases, including cancer, fibrotic disorders, developmental defects, and neurodegeneration. To study the temporal and spatial patterns of Smad2/3-dependent signaling in normal and pathological conditions in the living organism, we engineered transgenic mice with a Smad-responsive luciferase reporter construct (SBE-luc mice). Using bioluminescent imaging, we assessed Smad2/3 signaling activity noninvasively in living mice. At baseline, this activity was highest in brain, intestine, heart, and skin, and correlated with biochemical measurements of reporter activity. Primary astrocytes cultured from SBE-luc mice showed specific activation of the reporter in response to Smad2/3-activating TGF-beta family members. Treatment of mice with the endotoxin LPS resulted in a fast and vigorous, but transient activation of the reporter in the intestine. Although the response was similarly rapid in brain, it remained increased, indicating important but different cellular responses to endotoxin. challenge in these organs. Traumatic brain injury with a needle stab resulted in local activation of Smad2/3-dependent genes and a severalfold increase in bioluminescence in living mice. SBE-luc mice can therefore be used to study temporal, tissue-specific activation of Smad2/3-dependent signaling in living mice in normal or pathological conditions as well as for the identification of endogenous or synthetic modulators of this pathway.	Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Div Neonatal & Dev Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Dept Radiol, Stanford, CA 94305 USA; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Univ Caen, INSERM Avenir, GIP Cyceron, F-14032 Caen, France; Vet Affairs Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA		Wyss-Coray, T (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, SUMC Room A343, Stanford, CA 94305 USA.	twc@stanford.edu	Wyss-Coray, Tony/AAF-3380-2019; Luo, Jian/B-8449-2014; Dijke, Peter ten/AAG-4660-2021	Wyss-Coray, Tony/0000-0001-5893-0831; Luo, Jian/0000-0002-2064-8467; Dijke, Peter ten/0000-0002-7234-342X; Contag, Christopher/0000-0002-1011-8278; VIVIEN, DENIS/0000-0002-7636-2185	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG020603] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG20603] Funding Source: Medline		Boche D, 2003, J CEREBR BLOOD F MET, V23, P1174, DOI 10.1097/01.WCB.0000090080.64176.44; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; Brionne TC, 2003, NEURON, V40, P1133, DOI 10.1016/S0896-6273(03)00766-9; Buckwalter MS, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-10; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Carmel JB, 2001, PHYSIOL GENOMICS, V7, P201, DOI 10.1152/physiolgenomics.00074.2001; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2002, J LEUKOCYTE BIOL, V71, P731; Dunn NR, 2005, GENE DEV, V19, P152, DOI 10.1101/gad.1243205; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Flanders KC, 2001, DEV DYNAM, V220, P141, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1096>3.0.CO;2-4; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Herber DL, 2004, EXP NEUROL, V190, P245, DOI 10.1016/j.expneurol.2004.07.007; Huang SX, 2000, GENE, V258, P43, DOI 10.1016/S0378-1119(00)00396-6; JAKOWLEW SB, 1994, DIFFERENTIATION, V55, P105, DOI 10.1046/j.1432-0436.1994.5520105.x; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Ling ZD, 2004, NEUROSCIENCE, V124, P619, DOI 10.1016/j.neuroscience.2003.12.017; Lopes SMCD, 2003, GENE EXPR PATTERNS, V3, P355, DOI 10.1016/S1567-133X(03)00029-2; MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mazerbourg S, 2004, MOL ENDOCRINOL, V18, P653, DOI 10.1210/me.2003-0393; Monteiro RM, 2004, J CELL SCI, V117, P4653, DOI 10.1242/jcs.01337; Moore FA, 1999, AM J SURG, V178, P449, DOI 10.1016/S0002-9610(99)00231-7; Oh SP, 2002, GENE DEV, V16, P2749, DOI 10.1101/gad.1021802; Rebbapragada A, 2003, MOL CELL BIOL, V23, P7230, DOI 10.1128/MCB.23.20.7230-7242.2003; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Sadikot RT, 2003, J IMMUNOL, V170, P1091, DOI 10.4049/jimmunol.170.2.1091; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Sanyal S, 2004, NEURON, V41, P845, DOI 10.1016/S0896-6273(04)00152-7; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sly LM, 2004, IMMUNITY, V21, P227, DOI 10.1016/j.immuni.2004.07.010; Wahl SM, 2004, J LEUKOCYTE BIOL, V76, P15, DOI 10.1189/jlb.1103539; Wang XJ, 1999, P NATL ACAD SCI USA, V96, P8483, DOI 10.1073/pnas.96.15.8483; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; WYSSCORAY T, 1995, AM J PATHOL, V147, P53; Xu X, 1999, P NATL ACAD SCI USA, V96, P7547, DOI 10.1073/pnas.96.13.7547; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100	39	78	84	0	2	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	JUL 1	2005	175	1					547	554		10.4049/jimmunol.175.1.547			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	939CW	WOS:000230050900069	15972691	Bronze			2022-02-06	
J	Hillman, J; Aneman, O; Anderson, C; Sjogren, F; Saberg, C; Mellergard, P				Hillman, J; Aneman, O; Anderson, C; Sjogren, F; Saberg, C; Mellergard, P			A microdialysis technique for routine measurement of macromolecules in the injured human brain	NEUROSURGERY			English	Article						cerebral microdialysis; head trauma; intensive care; interleukin-6; monitoring; protein; subarachnoid hemorrhage	IN-VIVO; CYTOKINES; RELEASE; MARKERS; LINE	OBJECTIVE: To evaluate a new intracerebral microdialysis catheter with a high-cutoff membrane and its potential for the study of macromolecules in the human brain. METHODS: Paired intracerebral microdialysis catheters were inserted in 10 patients who became comatose after subarachnoid hemorrhage or traumatic brain injury and were then treated in our neurosurgical unit. The only differences from the routine use of microdialysis in our clinic were the length (20 mm) and cutoff properties of the catheter membranes (100 kD) and the perfusion fluids used (standard perfusion fluid, 3.5% albumin, or Ringer-dextran 60). Samples were weighed (for net fluid fluxes) and analyzed at bedside (for routine metabolites) and later in the laboratory (for total protein and interleukin-6). The in vitro recovery of glucose, glutamate, and glycerol were also investigated under different conditions. RESULTS: Even brief perfusion with standard perfusion fluid resulted in a significant loss of volume from the microdialysis system. For albumin and Ringer-dextran 60 fluid, recovery was comparable to standard settings. Interleukin-6 (highest value close to 25,000 pg/ml) was sampled from all catheters, and total protein was analyzed from catheters perfused with Ringer-dextran 60 (average concentration, 234 mu g protein/ml). There were detectable patterns of variations in the concentration of interleukin-6, seemingly related to concomitant variations in intracerebral conditions. In the present study, no direct comparison was made with the standard CMA 70 catheter (CMA Microdialysis, Stockholm, Sweden), but in vivo, the measured mean concentrations of glucose, glycerol, lactate, and pyruvate were comparable to those previously reported from standard catheters. In vitro, the recovery of metabolites was better when using Ringer-dextran 60 compared with albumin. CONCLUSION: Microdialysis catheters with high-cutoff membranes can be used in routine clinical practice, allowing for sampling and analysis of cytokines and other macromolecules.	Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden; Linkoping Univ Hosp, Dept Dermatol, S-58185 Linkoping, Sweden		Hillman, J (corresponding author), Linkoping Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden.	Jan.Hillman@lio.se					Anderson C, 1995, Curr Probl Dermatol, V23, P121; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; Billman G, 2002, CLIN CHEM, V48, P2030; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Gozal E, 2002, J NEUROCHEM, V83, P331, DOI 10.1046/j.1471-4159.2002.01134.x; Hamani C, 1997, NEUROL RES, V19, P281, DOI 10.1080/01616412.1997.11740814; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; McGlennen RC, 2001, CLIN CHEM, V47, P393; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sjogren S, 2002, BRIT J DERMATOL, V146, P375, DOI 10.1046/j.1365-2133.2002.04621.x; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X	23	78	80	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2005	56	6					1264	1268		10.1227/01.NEU.0000159711.93592.8D			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	934ES	WOS:000229690300020	15918942				2022-02-06	
J	Congedo, M; Lubar, JF; Joffe, D				Congedo, M; Lubar, JF; Joffe, D			Low-resolution electromagnetic tomography neurofeedback	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						brain-computer interfaces (BCI); electroencephalograin (EEG) biofeedback; electromagnetic tomography; inverse solution; low-resolution electromagnetic tomography (LORETA); neurofeedback; p-value combination	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; ANTERIOR CINGULATE CORTEX; EEG BIOFEEDBACK; ELECTRICAL-ACTIVITY; ALPHA RHYTHMS; BRAIN; LOCALIZATION; FEEDBACK; BEHAVIOR; ANXIETY	Through continuous feedback of the electroencephalogram (EEG) humans can learn how to shape their brain electrical activity in a desired direction. The technique is known as EEG biofeedback, or neurofeedback, and has been used since the late 1960s in research and clinical applications. A major limitation of neurofeedback relates to the limited information provided by a single or small number (if electrodes placed on the scalp. We establish a method for extracting and feeding back intracranial current density and we carry out an experimental study to ascertain the ability of the,participants to drive their own EEG power in a desired direction. To derive current density within the brain volume; we used the low-resolution electromagnetic tomography (LORETA). Six undergraduate students (three males, three females) underwent tomographic neurofeedback (based on 19 electrodes placed according,to the 10-20 system) to enhance the current density power ratio between the frequency bands beta (16-20 Hz) and alpha (8-10 Hz). According to LORETA modeling, the region of interest corresponded to the Anterior Cingulate (cognitive division). The protocol was designed to in prove the performance of the subjects on the dimension of sustained attention. Two hypotheses were tested: 1) that the beta/alpha current density power ratio increased over sessions and 2) that by the end of the training subjects acquired the ability of increasing that ratio at will. Both. hypotheses received substantial experimental support in this study. This is the first application of an EEG inverse solution to neurofeedback. Possible applications of the technique include the treatment of epileptic foci, the rehabilitation of specific brain regions damaged as, a consequence of traumatic brain injury and, in general, the training of any spatial specific cortical electrical activity. These findings may also have relevant consequences for the development of brain-computer interfaces.	Univ Tennessee, Dept Psychol, Knoxville, TN 37996 USA; Lexicor Med Technol, Boulder, CO 80301 USA		Congedo, M (corresponding author), Inst Res Informat & Random Syst IRISA, F-35042 Rennes, France.	loretabiofeedback@yahoo.com					Anderson MJ, 1999, J STAT COMPUT SIM, V62, P271, DOI 10.1080/00949659908811936; Barabasz M., 1996, CHILD STUDY J, V26, P1; Barry RJ, 2003, CLIN NEUROPHYSIOL, V114, P171, DOI 10.1016/S1388-2457(02)00362-0; BLOM JL, 1982, ELECTROEN CLIN NEURO, V54, P591, DOI 10.1016/0013-4694(82)90046-3; Bosch-Bayard J, 2001, CLIN ELECTROENCEPHAL, V32, P47, DOI 10.1177/155005940103200203; Bush G, 1999, BIOL PSYCHIAT, V45, P1542, DOI 10.1016/S0006-3223(99)00083-9; CADE B. S., 1999, USER MANUAL BLOSSOM; Cichocki A., 2003, ADAPTIVE BLIND SIGNA; Congedo M., 2003, Journal of Neurotherapy, V7, P1, DOI 10.1300/J184v07n03_01; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; EBRAHIMI T, IN PRESS SIGNAL PROC; Edgington E, 1995, RANDOMIZATION; ENGSTROM DR, 1970, NATURE, V227, P1261, DOI 10.1038/2271261a0; Fernandez-Bouzas A, 1999, CLIN ELECTROENCEPHAL, V30, P46, DOI 10.1177/155005949903000205; Fuchs M, 1999, J CLIN NEUROPHYSIOL, V16, P267, DOI 10.1097/00004691-199905000-00006; HARDT JV, 1976, BIOFEEDBACK SELF-REG, V1, P63, DOI 10.1007/BF00998691; Harland CJ, 2002, APPL PHYS LETT, V81, P3284, DOI 10.1063/1.1516861; Hernandez J L, 1994, Int J Neurosci, V76, P267; Hyvarinen A, 2001, INDEPENDENT COMPONENT ANALYSIS: PRINCIPLES AND PRACTICE, P71; Isotani T, 2001, INT J PSYCHOPHYSIOL, V41, P143, DOI 10.1016/S0167-8760(00)00197-5; James LC, 1996, BEHAV MED, V22, P77, DOI 10.1080/08964289.1996.9933767; Kennedy PE, 1996, COMMUN STAT-SIMUL C, V25, P923, DOI 10.1080/03610919608813350; Kotchoubey B, 2002, CONSCIOUS COGN, V11, P98, DOI 10.1006/ccog.2001.0535; Kubler A, 2001, PSYCHOL BULL, V127, P358, DOI 10.1037//0033-2909.127.3.358; Lancaster JL, 1997, HUM BRAIN MAPP, V5, P238, DOI 10.1002/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Leuchter AF, 1999, PSYCHIAT RES-NEUROIM, V90, P125, DOI 10.1016/S0925-4927(99)00006-2; Linden M, 1996, BIOFEEDBACK SELF-REG, V21, P35, DOI 10.1007/BF02214148; LUBAR JF, 1976, BIOFEEDBACK SELF-REG, V1, P77, DOI 10.1007/BF00998692; Lubar JF, 2003, INT J PSYCHOPHYSIOL, V49, P175, DOI 10.1016/S0167-8760(03)00115-6; LUBAR JF, 1981, ARCH NEUROL-CHICAGO, V38, P700, DOI 10.1001/archneur.1981.00510110060009; LUBAR JF, 1991, BIOFEEDBACK SELF-REG, V16, P201, DOI 10.1007/BF01000016; LUBAR JF, 1976, BIOFEEDBACK SELF-REG, V1, P293, DOI 10.1007/BF01001170; LUBAR JF, APPL PSYCHOPHYSIOL B, V22, P111; Manly BFJ, 1997, RANDOMIZATION BOOTST, V2; Moore NC, 2000, CLIN ELECTROENCEPHAL, V31, P1, DOI 10.1177/155005940003100105; NOWLIS DP, 1970, PSYCHOPHYSIOLOGY, V6, P476, DOI 10.1111/j.1469-8986.1970.tb01756.x; Nunez P.L., 1995, NEOCORTICAL DYNAMICS; Nunez PL, 2001, HUM BRAIN MAPP, V13, P125, DOI 10.1002/hbm.1030; Nunez PL, 2000, BRAIN TOPOGR, V13, P79, DOI 10.1023/A:1026683200895; NUNEZ PL, 1995, SOURCE LOCALIZATION, V6, P16; NUNEZ PL, 1999, INT J BIOELECTROMAGN, V1; Pascual-Marqui R, 2002, JPN J CLIN NEUROPHYS, V30, P81; Pascual-Marqui R.D., 1999, INT J BIOELECTROMAGN, V1, P75; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P91; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; PASCUALMARQUI RD, 1994, INT J PSYCHOPHYSIOL, V18, P49, DOI 10.1016/0167-8760(84)90014-X; PESARIN E, 2001, MULTIVARIATE PERMUTA; Pizzagalli D, 2001, AM J PSYCHIAT, V158, P405, DOI 10.1176/appi.ajp.158.3.405; Prichep LS, 2001, CLIN ELECTROENCEPHAL, V32, P62, DOI 10.1177/155005940103200204; Rosenfeld J, 2000, AMYOTROPH LATERAL SC, V1, P1, DOI 10.1080/14660820050515638; ROSSITER T, 2003, J NEUROTHERAPY, V6, P9; STERMAN MB, 1981, NEUROSCI BIOBEHAV R, V5, P405, DOI 10.1016/0149-7634(81)90036-1; STERMAN MB, 1973, SEMIN PSYCHIAT, V5, P507; Swingle PG, 1998, BIOL PSYCHIAT, V44, P1196, DOI 10.1016/S0006-3223(97)00541-6; Talairach J., 1988, COPLANAR STEREOTAXIC; TANSEY MA, 1983, BIOFEEDBACK SELF-REG, V8, P25, DOI 10.1007/BF01000534; THOMTON KE, 2002, NEUROREHABILITATION, V17, P69; TOWLE VL, 1993, ELECTROEN CLIN NEURO, V86, P1, DOI 10.1016/0013-4694(93)90061-Y; TRAVIS TA, 1974, J NERV MENT DIS, V158, P163, DOI 10.1097/00005053-197403000-00001; Vorobyov S, 2002, BIOL CYBERN, V86, P293, DOI 10.1007/s00422-001-0298-6; Worrell GA, 2000, BRAIN TOPOGR, V12, P273, DOI 10.1023/A:1023407521772; Yoo SS, 2002, NEUROREPORT, V13, P1377, DOI 10.1097/00001756-200208070-00005	63	78	80	0	19	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	DEC	2004	12	4					387	397		10.1109/TNSRE.2004.840492			11	Engineering, Biomedical; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Rehabilitation	879UN	WOS:000225744500003	15614994	Green Published			2022-02-06	
J	Keenan, HT; Marshall, SW; Nocera, MA; Runyan, DK				Keenan, HT; Marshall, SW; Nocera, MA; Runyan, DK			Increased incidence of inflicted traumatic brain injury in children after a natural disaster	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							SEQUELAE; ABUSE	Background: The incidence of child abuse following natural disasters has not been Studied thoroughly. However, parental stress and decreased social support have been linked to increased reports of child maltreatment. We hypothesized that a large-scale natural disaster (North Carolina's Hurricane Floyd) would increase the incidence of inflicted traumatic brain injury (TBI) in young children. Methods: An ecologic Study design was used to compare regions affected to those regions unaffected by the disaster. Cases of inflicted TBI resulting in admission to an intensive care unit or death from September 1998 through December 2001 in North Carolina were ascertained. Poisson regression modeling was employed to calculate rate ratios of injury for each geographic area by time period. Results: Inflicted TBI in the most affected counties increased in the G months post disaster in comparison to the same region pre-disaster (rate ratio 5.1, 95% confidence interval [CI] = 1.3-20.4), as did non-inflicted TBI (rate ratio 10.7, 95% CI = 2.0-59.4). No corresponding increased incidence was observed in counties less affected or unaffected by the disaster. The rate of inflicted injuries returned to baseline in the severely affected counties 6 months post-hurricane; however, the rate Of non-inflicted injuries appeared to remain elevated for the entire post-hurricane study period. Conclusions: Families are Vulnerable to an elevated risk of inflicted and non-inflicted child TBI following a disaster. This information may be useful in future disaster planning.	Univ N Carolina, Sch Med, Dept Social Med, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA		Keenan, HT (corresponding author), Univ N Carolina, Sch Med, Dept Social Med, Injury Prevent Res Ctr, Wing D,CB 7240, Chapel Hill, NC 27599 USA.	hkeenan@med.unc.elu	Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029; Marshall, Stephen/0000-0002-2664-9233	ODCDC CDC HHS [R49/CCR402444] Funding Source: Medline		Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; BRAVO M, 1990, AM J COMMUN PSYCHOL, V18, P661, DOI 10.1007/BF00931236; Briere J, 2000, J TRAUMA STRESS, V13, P661, DOI 10.1023/A:1007814301369; *CDCP, 2000, MMWR-MORBID MORTAL W, V49, P369; Curtis T, 2000, CHILD ABUSE NEGLECT, V24, P1151, DOI 10.1016/S0145-2134(00)00176-9; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KOTCH JB, 1995, CHILD ABUSE NEGLECT, V19, P1115, DOI 10.1016/0145-2134(95)00072-G; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; Morgenstern H, 1998, MODERN EPIDEMIOLOGY, P459; *NC DIV EM MAN, FLOYD BUYOUT PROGR; OLDS DL, 1992, AM J DIS CHILD, V146, P704, DOI 10.1001/archpedi.1992.02160180062018; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; SHORE JH, 1986, AM J PUBLIC HEALTH, V76, P76, DOI 10.2105/AJPH.76.Suppl.76; Warheit GJ, 1996, J CHILD PSYCHOL PSYC, V37, P435, DOI 10.1111/j.1469-7610.1996.tb01424.x	14	78	79	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	APR	2004	26	3					189	193		10.1016/j.amepre.2003.10.023			5	Public, Environmental & Occupational Health; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; General & Internal Medicine	804SU	WOS:000220319200001	15026097				2022-02-06	
J	Dimopoulou, L; Tsagarakis, S; Kouyialis, AT; Roussou, P; Assithianakis, G; Christoforaki, M; Ilias, I; Sakas, DE; Thalassinos, N; Roussos, C				Dimopoulou, L; Tsagarakis, S; Kouyialis, AT; Roussou, P; Assithianakis, G; Christoforaki, M; Ilias, I; Sakas, DE; Thalassinos, N; Roussos, C			Hypothalamic-pituitary-adrenal axis dysfunction in critically ill patients with traumatic brain injury: Incidence, pathophysiology, and relationship to vasopressor dependence and peripheral interleukin-6 levels	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; low-dose corticotropin stimulation test; human corticotropin releasing hormone test; primary adrenal dysfunction; interleukin-6	CORTICOTROPIN-RELEASING HORMONE; SEVERE CRANIOCEREBRAL TRAUMA; 250 MU-G; HEAD-INJURY; SEPTIC SHOCK; INSUFFICIENCY; HYPOPITUITARISM; ABNORMALITIES; STIMULATION; SYSTEM	Objective: To investigate hypothalamic-pituitary-adrenal axis function in patients requiring mechanical ventilation for traumatic brain injury and to assess the relation of hypothalamic-pituitary-adrenal axis abnormalities with vasopressor dependence and peripheral cytokine levels. Design: Prospective study. Setting: General intensive care unit in a university teaching hospital. Patients: Forty patients (33 men and 7 women) with moderate to severe traumatic brain injury (mean age, 37 +/- 16 yrs) were studied the day after termination of mechanical ventilation (7-60 days after trauma). Interventions: First, a morning blood sample was obtained to measure baseline cortisol, corticotropin, interleukin-6, and tumor necrosis factor alpha. Subsequently, 1 mug of synthetic corticotropin was injected intravenously, and 30 mins later, a second blood sample was drawn to determine stimulated plasma cortisol. Based on data derived from healthy volunteers, patients having stimulated cortisol levels <18 mug/dL were defined as nonresponders to the low-dose stimulation test. Thirty-one patients underwent also a human corticotropin releasing hormone test. Measurements and Main Results: In traumatic brain injury patients, mean baseline and low-dose stimulation test-stimulated cortisol levels were 17.2 +/- 5.4 mug/dL and 24.0 +/- 6.6 mug/dL, respectively. The median increment in cortisol was 5.9 mug/dL Basal corticotropin levels ranged from 3.9 to 118.5 pg/mL Six of the 40 patients (15%) failed the low-dose stimulation test The human corticotropin releasing hormone test (performed in 26 responders and five nonresponders) revealed diminished cortisol release only in the low-dose stimulation test nonresponder patients. Corticotropin responses to corticotropin releasing hormone were consistent with both primary (three patients) and/or secondary (two patients) adrenal dysfunction. In retrospect, nonresponders to the low-dose stimulation test more frequently required vasopressors (6/6 [100%] vs. 16/34 [47%]; p = .02) and for a longer time interval (median, 0 vs. 293 hrs; p = .006) compared with responders. Furthermore, nonresponders had higher interleukin-6 levels compared with responders (56.03 vs. 28.04 pg/mL; p = .01), whereas tumor necrosis factor alpha concentrations were similar in the two groups (2.42 vs. 1.55 pg/mL; p = .53). Conclusions: Adrenal cortisol secretion after dynamic stimulation is deficient in a subset of critically ill patients with moderate to severe head injury. This disorder is associated with prior vasopressor dependency and higher interleukin-6 levels.	Evangelismos Med Ctr, Dept Crit Care Med, Athens, Greece; Evangelismos Med Ctr, Dept Diabet Endocrinol & Metab, Athens, Greece; Evangelismos Med Ctr, Dept Neurosurg, Athens, Greece; Univ Athens, Athens Chest Hosp, Dept Internal Med, Athens, Greece		Dimopoulou, L (corresponding author), Evangelismos Med Ctr, Dept Crit Care Med, Athens, Greece.		ILIAS, IOANNIS/AAI-4033-2020; Ilias, Ioannis/AAA-2927-2020	ILIAS, IOANNIS/0000-0001-5718-7441; 			Ambrosi B, 1998, EUR J ENDOCRINOL, V139, P575, DOI 10.1530/eje.0.1390575; BARRECA T, 1980, J CLIN ENDOCR METAB, V51, P1279, DOI 10.1210/jcem-51-6-1279; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2002, METABOLISM, V51, P1363, DOI 10.1053/meta.2002.34714; Bornstein SR, 1999, J CLIN ENDOCR METAB, V84, P1729; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; CLARK JDA, 1992, CLIN ENDOCRINOL, V36, P481, DOI 10.1111/j.1365-2265.1992.tb02249.x; Della Corte F, 1998, CRIT CARE MED, V26, P1419; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Dimopoulou I, 2003, CRIT CARE MED, V31, P1113, DOI 10.1097/01.CCM.0000059644.54819.67; Dimopoulou L, 2002, INTENS CARE MED, V28, P1168, DOI 10.1007/s00134-002-1360-0; EDWARDS OM, 1986, MEDICINE, V65, P281; Gonzalbez J, 2000, CLIN ENDOCRINOL, V53, P199; GOTTARDIS M, 1990, INTENS CARE MED, V16, P163, DOI 10.1007/BF01724795; GRINSPOON SK, 1994, J CLIN ENDOCR METAB, V79, P923, DOI 10.1210/jc.79.4.923; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Hoen S, 2002, ANESTHESIOLOGY, V97, P807, DOI 10.1097/00000542-200210000-00010; Keh D, 2003, AM J RESP CRIT CARE, V167, P512, DOI 10.1164/rccm.200205-446OC; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; Lamberts SWJ, 1997, NEW ENGL J MED, V337, P1285, DOI 10.1056/NEJM199710303371807; LENZEN J, 1993, NEUROSURG REV, V16, P183, DOI 10.1007/BF00304325; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Marik PE, 2003, CRIT CARE MED, V31, P141, DOI 10.1097/00003246-200301000-00022; Marik PE, 2002, CHEST, V122, P1784, DOI 10.1378/chest.122.5.1784; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASTORAKOS G, 1993, J CLIN ENDOCR METAB, V77, P1690, DOI 10.1210/jc.77.6.1690; MATSUURA H, 1985, NEUROSURGERY, V16, P791, DOI 10.1227/00006123-198506000-00009; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056/NEJM199610173351607; Papanicolaou DA, 1996, J CLIN ENDOCR METAB, V81, P2303, DOI 10.1210/jc.81.6.2303; SCHLAGHECKE R, 1992, NEW ENGL J MED, V326, P226, DOI 10.1056/NEJM199201233260403; Schroeder S, 2001, CRIT CARE MED, V29, P310, DOI 10.1097/00003246-200102000-00017; SONI A, 1995, AM J MED, V98, P266, DOI 10.1016/S0002-9343(99)80373-8; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; TEASDALE G, 1974, LANCET, V2, P81; Tordjman K, 2000, CLIN ENDOCRINOL, V52, P633, DOI 10.1046/j.1365-2265.2000.00984.x; Tsagarakis S, 1998, CRIT REV ONCOL HEMAT, V28, P73, DOI 10.1016/S1040-8428(98)00005-5; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x	41	78	84	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2004	32	2					404	408		10.1097/01.CCM.0000108885.37811.CA			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774ME	WOS:000188982600012	14758155				2022-02-06	
J	Shum, D; Ungvari, GS; Tang, WK; Leung, JP				Shum, D; Ungvari, GS; Tang, WK; Leung, JP			Performance of schizophrenia patients on time-, event-, and activity-based prospective memory tasks	SCHIZOPHRENIA BULLETIN			English	Article						prospective memory; schizophrenia; prefrontal lobe function; rehabilitation	TRAUMATIC BRAIN-INJURY; FORMS	The present study aimed to determine whether individuals with long-term schizophrenia have impaired prospective memory (PM), the ability to remember to perform intended actions in the future. Three PM tasks (time-, event-, and activity-based) were administered to 60 schizophrenia patients and 60 matched controls. Patients performed significantly more poorly than controls on all three tasks. The between-group difference was disproportionately larger on the time-based task, a task that required a prefrontal. lobe process called self-initiated retrieval. To examine the relationship between PM and prefrontal lobe functions, subjects were also administered the Design Fluency Test (DFT), the Tower of London (TOL), and the Wisconsin Card Sorting Test (WCST). For patients, performance on the event-based task was found to correlate significantly with performance on the DFT, and performance on the time-based task was found to correlate significantly with performance on the TOL. Results of this study support the importance and contribution of prefrontal lobe processes in prospective remembering and have implications for the assessment and treatment of individuals with schizophrenia.	Shatin Hosp, Dept Psychiat, Shatin, Hong Kong, Peoples R China; Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia; Chinese Univ Hong Kong, Dept Psychiat, Sha Tin 100083, Peoples R China; Chinese Univ Hong Kong, Dept Psychol, Sha Tin 100083, Peoples R China		Ungvari, GS (corresponding author), Shatin Hosp, Dept Psychiat, Shatin, Hong Kong, Peoples R China.	gsungvari@cuhk.edu.hk	Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262			*AM PSYCH ASS, 1994, DSM, V4; BRANDIMONTE M, 1996, PROSPECTIVE MEMORY T, pR9; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Chen EYH, 1996, SCHIZOPHRENIA NEUROP, P107; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; ESLINGER PJ, 1993, NEUROPSYCHOLOGIA, V31, P17, DOI 10.1016/0028-3932(93)90077-D; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; Gold J.M, 1992, CLIN NEUROPSYCHOL, V6, P367; GOLD JM, 1992, J ABNORM PSYCHOL, V101, P487, DOI 10.1037/0021-843X.101.3.487; GOLDMAN RS, 1996, NEUROPSYCHOLOGICAL A, P504; Gourovitch ML, 1996, SCHIZOPHRENIA NEUROP, P72; Graf P, 2001, CONSCIOUS COGN, V10, P437, DOI 10.1006/ccog.2001.0504; Heaton PDRK., 1993, WISCONSIN CARD SORTI; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, V6, P183; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P657; Neulinger K., 2002, BRAIN IMPAIR, V3, P1, DOI [10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Paulsen J S, 1995, J Int Neuropsychol Soc, V1, P88; SHALLICE T, 1982, BIOL SCI, V298, P199, DOI DOI 10.1098/RSTB.1982.0082; Shum D, 2000, BRAIN COGNITION, V44, P59; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); TAMLYN D, 1992, PSYCHOL MED, V22, P101, DOI 10.1017/S0033291700032773; Taylor D, 1999, BETHLEM MAUDSLEY NHS, V5th; Tunstall J., 1999, THESIS GRIFFITH U BR; WEINBERGER DR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P275	28	78	90	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0586-7614	1745-1701		SCHIZOPHRENIA BULL	Schizophr. Bull.		2004	30	4					693	701		10.1093/oxfordjournals.schbul.a007123			9	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	910FN	WOS:000227916000003	15954184	Green Submitted, Bronze			2022-02-06	
J	Mellick, D; Gerhart, KA; Whiteneck, GG				Mellick, D; Gerhart, KA; Whiteneck, GG			Understanding outcomes based on the post-acute hospitalization pathways followed by persons with traumatic brain injury	BRAIN INJURY			English	Article							SICKNESS IMPACT PROFILE; FUNCTIONAL ASSESSMENT; UNITED-STATES; REHABILITATION; SCALES; CARE	Primary objectives : To identify the factors that determine the pathways of care people with traumatic brain injury (TBI) follow after acute care discharge, and to identify differences in outcome based on those pathways. Research design : Telephone survey of a statewide, population-based sample of persons surviving through acute hospitalization for TBI. Methods and procedures : Included were 1059 individuals who: (a) were discharged from acute care in 1996 and 1997; (b) were eligible for inclusion in the statewide, population-based TBI follow-up system, (c) had either a severe TBI or were among a 20% random sample with milder injuries, and (d) consented to participate in a 1-year post-injury follow-up survey. The survey included administration of the Functional Independence Measure (FIM), the Craig Handicap Assessment and Reporting Technique (CHART), the Alertness Behaviour Sub-scale of the Sickness Impact Profile (SIP), and the Health Status Questionnaire (HSQ-12). Medical records for all participants were abstracted for injury severity, pre-injury history (aetiologic and demographic) and discharge disposition data. Data were weighted to represent the population from which the sample was derived prior to analyses. Main outcomes and results : Almost 2/3 of TBI survivors in this population-based sample received no additional services following discharge from the acute care hospital. Six post-acute-hospitalization pathways were identified based on combinations of inpatient rehabilitation, community-based services and long-term care (LTC). In each category except for the one involving a discharge directly from acute care to home people with the most severe TBIs were disproportionately over-represented. Older people and people whose care was funded by government payers were over-represented in both care pathways involving LTC, while members of minority groups were under represented. Those who went to LTC had the poorest outcomes, but even those completing rehabilitation had relatively poor outcomes compared with those discharged directly to home. Conclusions : Of concern are the relatively large numbers of people receiving no rehabilitation and other services in all severity categories. Those in LTC typically older and government funded people reported the poorest outcomes. Unanswered questions remain relating to the poor perceived quality of life reported by those completing rehabilitation programmes. Further study is also needed to more fully understand the affects of such characteristics as gender, minority status, employment and funding sources on the care pathway that is followed.	Craig Hosp Res Dept, Englewood, CO 80110 USA		Gerhart, KA (corresponding author), Craig Hosp Res Dept, 3425 S Clarkson St, Englewood, CO 80110 USA.				ODCDC CDC HHS [U17/CCU812447] Funding Source: Medline		BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; BROOKS WB, 1990, MED CARE, V28, P793, DOI 10.1097/00005650-199009000-00009; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Damiano AM, 1996, SICKNESS IMPACT PROF; DEYO RA, 1986, SPINE, V11, P951, DOI 10.1097/00007632-198611000-00017; DEYO RA, 1983, MED CARE, V21, P180, DOI 10.1097/00005650-198302000-00006; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; GRANGER CV, 1997, ASSESSING MED REHABI, P103; *HLTH OUTC I, 1998, HSQ 12 US GUID; HOSACK KR, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199504000-00007; *J HOPK U, 1993, INJ SEV SCOR ICD MAP; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Sosin DM, 1996, BRAIN INJURY, V10, P47; SPSS Inc, 1999, SPSS WIND VERS 10 0; *STAT U NY BUFF, 1996, GUID UN DAT SET MED; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Whiteneck G, 2001, COLORADO TRAUMATIC B; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; *WHO, 1989, INT CLASS DIS 9 REV; World Health Organization, 2007, INT CLASS FUNCT DIS	27	78	79	0	10	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2003	17	1					55	71		10.1080/0269905021000010159			17	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	633LK	WOS:000180284600005	12519648				2022-02-06	
J	Zhang, LJ; Ravdin, LD; Relkin, N; Zimmerman, RD; Jordan, B; Lathan, WE; Ulug, AM				Zhang, LJ; Ravdin, LD; Relkin, N; Zimmerman, RD; Jordan, B; Lathan, WE; Ulug, AM			Increased diffusion in the brain of professional boxers: A preclinical sign of traumatic brain injury?	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							AXONAL INJURY; HEAD-INJURY; DAMAGE	BACKGROUND AND PURPOSE: Professional boxing is associated with chronic, repetitive head blows that may cause brain injuries. Diffusion-weighted imaging is sensitive to microscopic changes and may be a useful tool to quantify the microstructural integrity of the brain. In this study, we sought to quantify microscopic alterations associated with chronic traumatic brain injury in professional boxers. METHODS: MR and diffusion-weighted imaging were performed in 24 boxers and in 14 age and sex-matched control subjects with no history of head trauma. Using distribution analysis, the average diffusion constant of the entire brain (BDav) and diffusion distribution width (a) were calculated for each subject; findings in professional boxers were compared with those of control subjects. In the boxer group, correlations between diffusion changes and boxing history and diffusion changes and MR imaging findings were assessed. RESULTS: The measured diffusion values in the boxer group were significantly higher than those measured in the control group (BDav, P < .0001; sigma, P <.01). In the boxer group, a robust correlation was found between increased BD., and frequency of hospitalization for boxing injuries (r = 0.654, P < .05). The most common MR finding in the boxer group was volume loss inappropriate to age followed by cavum septum pellucidum, subcortical white matter disease, and periventricular white matter disease. CONCLUSION. Boxers had higher diffusion constants than those in control subjects. Our data suggest that microstructural damage of the brain associated with chronic traumatic brain injury may elevate whole-brain diffusion. This global elevation can exist even when routine MR findings are normal.	Cornell Univ, Weill Med Coll, Dept Radiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10021 USA; Burke Rehabil Hosp, New York, NY USA; New York State Athlet Commiss, New York, NY USA		Ulug, AM (corresponding author), Cornell Univ, Weill Med Coll, Dept Radiol, Box 141, New York, NY 10021 USA.		Ulug, Aziz M/F-6592-2011	Ulug, Aziz M/0000-0002-2315-0322			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; [Anonymous], 1992, J NEUROIMAGING; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; Chun T, 2000, AM J NEURORADIOL, V21, P1078; CHUN T, 2000, P 8 M INT SOC MAGN R; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; DORAN M, 1990, J COMPUT ASSIST TOMO, V14, P865, DOI 10.1097/00004728-199011000-00001; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; LeBihan D, 1995, NMR BIOMED, V8, P375; LEBIHAN D, 1992, AM J ROENTGENOL, V159, P591, DOI 10.2214/ajr.159.3.1503032; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.0.CO;2-6; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MOONEN CTW, 1991, MAGNET RESON MED, V19, P327, DOI 10.1002/mrm.1910190223; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Ulug AM, 1999, JMRI-J MAGN RESON IM, V9, P804; ULUG AM, 2001, P 30 ANN M AM AG ASS, P72	28	78	80	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	2003	24	1					52	57					6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	645EC	WOS:000180962400012	12533327				2022-02-06	
J	Bombardier, CH; Rimmele, CT; Zintel, H				Bombardier, CH; Rimmele, CT; Zintel, H			The magnitude and correlates of alcohol and drug use before traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; substance-related disorders	CHANGE QUESTIONNAIRE; READINESS; ABUSE; COCAINE; INTERVENTIONS; CONSUMPTION; PREVALENCE; POPULATION; VALIDITY; DRINKERS	Objective: To describe preinjury alcohol and drug use and opportunities for secondary prevention among persons with recent traumatic brain injury (TBI). Design: Survey. Setting: Acute inpatient rehabilitation program. Participants: A total of 142 (91%) of 156 consecutive admissions who met inclusion criteria and were screened. Interventions: Not applicable. Main Outcome Measures: Alcohol and drug use questionnaires, alcohol problem questions, toxicology results, readiness to change, and treatment preference questions. Results: Subjects were on average 37 years old, 80% were men, and 80% were white. Fifty-nine percent of the sample was considered "at-risk" drinkers and, as a group, subjects reported a high degree of preinjury alcohol-related problems. Thirty-four percent reported recent illicit drug use, and 42 (37%) of 114 cases with toxicology results were positive for illicit drugs. Motivation to change alcohol use correlated positively with greater self-reported alcohol consumption and problem severity. Most at-risk drinkers wanted to change on their own, whereas a minority were interested in treatment or Alcoholics Anonymous. Conclusion: Both alcohol abuse and drug use are common before TBI. Inpatient brain injury rehabilitation represents an important opportunity to identify and intervene in substance abuse problems. (C) 2002 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, Seattle, WA 98104 USA; Dept Psychiat & Behav Sci, Seattle, WA USA; Seattle Vet Adm Med Ctr, Seattle, WA USA		Bombardier, CH (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Rehabil Med, 325 9Th Ave,Box 359740, Seattle, WA 98104 USA.		Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283	ODCDC CDC HHS [R49/CCR011714-01] Funding Source: Medline		American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Babor T. F., 1992, PROJECT IDENTIFICATI; Bombardier CH, 1997, ARCH PHYS MED REHAB, V78, P592, DOI 10.1016/S0003-9993(97)90424-X; Bombardier CH, 1998, ARCH PHYS MED REHAB, V79, P1110, DOI 10.1016/S0003-9993(98)90180-0; Bombardier CH, 2000, J HEAD TRAUMA REHAB, V15, P696, DOI 10.1097/00001199-200002000-00008; BRADLEY KA, 1993, ARCH INTERN MED, V153, P2734, DOI 10.1001/archinte.153.24.2734; Budney AJ, 1997, DRUG ALCOHOL DEPEN, V45, P1, DOI 10.1016/S0376-8716(97)01351-3; Cooney N, 1995, HDB ALCOHOLISM TREAT, P45; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; DIKMEN SS, 1995, ANN EMERG MED, V26, P221; Drubach D A, 1993, Md Med J, V42, P989; Fiellin DA, 2000, ARCH INTERN MED, V160, P1977, DOI 10.1001/archinte.160.13.1977; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; HARBURG E, 1988, J STUD ALCOHOL, V49, P522, DOI 10.15288/jsa.1988.49.522; HEATHER N, 1993, ADDICTION, V88, P1667, DOI 10.1111/j.1360-0443.1993.tb02042.x; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Institute of Medicine Division of Mental Health and Behavioral Medicine, 1990, BROAD BAS TREATM ALC; JACOBSON GR, 1989, HDB ALCOHOLISM TREAT, P54; Jones G.A., 1992, NEUROREHABILITATION, V2, P27; Jong CN, 1999, BRAIN INJURY, V13, P1017; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; KAROL R, 1991, ALCOHOL DRUGS BRAIN; KISHLINE A, 1994, MODERATE DRINKING MO, P168; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1991, J HEAD TRAUMA REHAB, V6, P12; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LANGLEY M J, 1990, Brain Injury, V4, P77, DOI 10.3109/02699059009026151; LEIRER VO, 1991, AVIAT SPACE ENVIR MD, V62, P221; MATCH P, 1977, J STUD ALCOHOL, V58, P7; McKay JR, 1999, J STUD ALCOHOL, V60, P566, DOI 10.15288/jsa.1999.60.566; Miller WR, 1998, ADDICTION, V93, P163, DOI 10.1046/j.1360-0443.1998.9321632.x; MILLER WR, 1990, HOW CONTROL YOUR DRI; Miller WR, 1987, BRIEF DRINKER PROFIL; Pope HG, 1996, JAMA-J AM MED ASSOC, V275, P1547, DOI 10.1001/jama.1996.03530440025030; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Raven MA, 2000, EXP CLIN PSYCHOPHARM, V8, P117, DOI 10.1037/1064-1297.8.1.117; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; Rivara FP, 1993, ARCH SURG-CHICAGO, V128, P912; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; SELZER ML, 1975, J STUD ALCOHOL, V36, P127; SOBELL LC, 1990, BEHAV ASSESS, V12, P77; Sobell LC, 1996, AM J PUBLIC HEALTH, V86, P966, DOI 10.2105/AJPH.86.7.966; WILLIAMS GD, 1992, BRIT J ADDICT, V87, P643; WINDLE M, 1991, J DRUG EDUC, V21, P133, DOI 10.2190/F497-8GKY-0U31-XMJJ; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955	49	78	78	0	8	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2002	83	12					1765	1773		10.1053/apmr.2002.36085			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	622ZF	WOS:000179677700013	12474184				2022-02-06	
J	Hukkelhoven, CWPM; Steyerberg, EW; Farace, E; Habbema, JDF; Marshall, LF; Maas, AIR				Hukkelhoven, CWPM; Steyerberg, EW; Farace, E; Habbema, JDF; Marshall, LF; Maas, AIR			Regional differences in patient characteristics, case management, and outcomes in traumatic brain injury: experience from the tirilazad trials	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; clinical trial; case management; referral policy; geographic region; Glasgow Outcome Scale	CLINICAL-TRIALS; NEUROPROTECTIVE AGENTS; HEAD-INJURY; EFFICACY; COMA; CARE	Object. Regional differences have been shown in patient characteristics and case management within multiple unselected series of patients suffering from traumatic brain injury (TBI). One might expect that such regional heterogeneity would be small in a more selected population of a randomized clinical trial. The goal of this study was to examine what regional differences in patient characteristics, case management, and outcomes exist between continents and among countries within a patient population included in a randomized clinical trial. Methods. Data were extracted from two concurrently conducted randomized clinical trials of the drug tirilazad; the designs of these studies were similar. The studies included 1701 patients with severe and 476 patients with moderate TBI. Differences were primarily investigated between studies performed in Europe and North America, but also among European regions and between Canada and the United States. Associations among regions and outcomes (6-month mortality rate and Glasgow Outcome Scale scores) were studied using multivariable logistic regression analysis. Comparisons between continents and among regions within Europe showed differences in the distribution of patient ages, causes of injury, and several clinical characteristics (motor score, pupillary reactivity, hypoxia, hypotension, intracranial pressure [ICP]), and findings on computerized tomography scans. Secondary referrals occurred 2.5 times more frequently in Europe. Within Europe secondary referral was mainly associated with an increased proportion of patients with mass lesions (46% in the European Study compared with 40% in the North American Study). Therapy for lowering ICP was more frequently applied in North America. After adjustments for case mix and management, mortality and unfavorable outcomes were significantly higher in Europe (odds ratios = 1.58 and 1.46, respectively). Significant differences in outcome between regions within Europe or within North America were not observed. Conclusions. Despite the use of a strict study protocol, considerable differences in patient characteristics and case management exist between continents and among countries, reflecting variations in social, cultural, and organizational aspects. Outcomes of TBI may be worse in Europe compared with North America, but this finding requires further study.	Erasmus MC, Dept Publ Hlth, Ctr Clin Decis Sci, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Neurol Surg, Ctr Clin Decis Sci, NL-3000 DR Rotterdam, Netherlands; Univ Virginia, Hlth Sci Ctr, Dept Neurol Surg, Charlottesville, VA USA; Univ Calif San Diego, Dept Neurol Surg, San Diego, CA 92103 USA		Hukkelhoven, CWPM (corresponding author), Erasmus MC, Dept Publ Hlth, Ctr Clin Decis Sci, Ee20-42,POB 1738, NL-3000 DR Rotterdam, Netherlands.	hukkelhoven@mgz.fgg.eur.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Hukkelhoven, Chantal/0000-0002-0015-1883; Steyerberg, Ewout/0000-0002-7787-0122			Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; LITTLE RJA, 1992, J AM STAT ASSOC, V87, P1227, DOI 10.2307/2290664; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; ROBINSON LD, 1991, INT STAT REV, V59, P227, DOI 10.2307/1403444; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; TEASDALE G, 1974, LANCET, V2, P81	24	78	82	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2002	97	3					549	557		10.3171/jns.2002.97.3.0549			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	593JA	WOS:000177986400008	12296638				2022-02-06	
J	Hadley, M				Hadley, M			Blood pressure management after acute spinal cord injury	NEUROSURGERY			English	Article							POST-TRAUMATIC ISCHEMIA; BRAIN; FLOW		Univ Alabama, Div Neurol Surg, Birmingham, AL 35294 USA		Hadley, M (corresponding author), Univ Alabama, Div Neurol Surg, 516 Med Educ Bldg,1813 6th Ave S, Birmingham, AL 35294 USA.						Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DOLAN EJ, 1982, J NEUROSURG, V56, P350, DOI 10.3171/jns.1982.56.3.0350; DUCKER TB, 1971, J NEUROSURG, V35, P700, DOI 10.3171/jns.1971.35.6.0700; FLOHR H, 1971, BRAIN BLOOD FLOW, P406; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; KINDT GW, 1971, BRAIN BLOOD FLOW, P401; King BS, 2000, SURG CLIN N AM, V80, P855, DOI 10.1016/S0039-6109(05)70100-6; Kobrine A I, 1975, Clin Neurosurg, V22, P573; KOBRINE AI, 1976, J NEUROSURG, V44, P12, DOI 10.3171/jns.1976.44.1.0012; LEDSOME JR, 1981, AM REV RESPIR DIS, V124, P41; LEHMANN KG, 1987, J AM COLL CARDIOL, V10, P46, DOI 10.1016/S0735-1097(87)80158-4; LEVI L, 1993, NEUROSURGERY, V33, P1007, DOI 10.1097/00006123-199312000-00008; LEVI L, 1991, NEUROSURGERY, V29, P216, DOI 10.1227/00006123-199108000-00008; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; OSTERHOLM JL, 1974, J NEUROSURG, V40, P5, DOI 10.3171/jns.1974.40.1.0003; Piepmeier J M, 1985, Cent Nerv Syst Trauma, V2, P153; SENTER HJ, 1979, J NEUROSURG, V50, P198, DOI 10.3171/jns.1979.50.2.0198; Tator C H, 1984, J Neurosurg Sci, V28, P115; Tator C H, 1996, J Spinal Cord Med, V19, P206; TATOR CH, 1992, J NEUROTRAUM, V9, P139, DOI 10.1089/neu.1992.9.139; TATOR CH, 1984, CAN J SURG, V27, P289; TATOR CH, 1994, NEUROBIOLOGY CENTRAL, P209; Turnbull I M, 1973, Clin Neurosurg, V20, P56; TURNBULL IM, 1971, J NEUROSURG, V35, P141, DOI 10.3171/jns.1971.35.2.0141; Vale FL, 1997, J NEUROSURG, V87, P239, DOI 10.3171/jns.1997.87.2.0239; WALLACE MC, 1987, NEUROSURGERY, V20, P710; WOLF A, 1991, J NEUROSURG, V75, P883, DOI 10.3171/jns.1991.75.6.0883; Zach G A, 1976, Paraplegia, V14, P58	29	78	84	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAR	2002	50	3		S			S58	S62					5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	527VU	WOS:000174209300020					2022-02-06	
J	Hicks, RR; Zhang, L; Atkinson, A; Stevenon, M; Veneracion, M; Seroogy, KB				Hicks, RR; Zhang, L; Atkinson, A; Stevenon, M; Veneracion, M; Seroogy, KB			Environmental enrichment attenuates cognitive deficits, but does not alter neurotrophin gene expression in the hippocampus following lateral fluid percussion brain injury	NEUROSCIENCE			English	Article						neurotrophins; neural plasticity; traumatic brain injury	FACTOR MESSENGER-RNA; NERVE GROWTH-FACTOR; RAT HIPPOCAMPUS; SPATIAL MEMORY; FULL-LENGTH; BDNF; FOREBRAIN; INCREASES; RECOVERY; NEURONS	Environmental enrichment attenuates neurological deficits associated with experimental brain injury. The molecular events that mediate these environmentally induced improvements in function after injury are largely unknown, but neurotrophins have been hypothesized to be a neural substrate because of their role in cell survival and neural plasticity. Furthermore, exposure to complex environments in normal animals increases neurotrophin gene expression. However, following an ischemic injury, environmental enrichment decreases neurotrophin mRNA levels. Whether these contrasting findings are attributable to differences between injured and uninjured animals or are dependent upon the specific type of brain injury has not been determined. We examined the effects of 14 days of environmental enrichment following a lateral fluid percussion brain injury on behavior and gene expression of brain-derived neurotrophic factor, its high-affinity receptor, TrkB, and neurotrophin-3 in the rat hippocampus. Environmental enrichment attenuated learning deficits in the injured animals, but neither the injury nor housing conditions influenced neurotrophin/receptor mRNA levels. From these data we suggest that following brain trauma, improvements in learning associated with environmental enrichment are not mediated by alterations in brain-derived neurotrophic factor, TrkB or neurotrophin-3 gene expression. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Div Phys Therapy, Lexington, KY 40536 USA		Hicks, RR (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490,1959 NE Pacific St, Seattle, WA 98195 USA.	rhicks@u.washington.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35164] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035164] Funding Source: NIH RePORTER		Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; Black IB, 1999, J NEUROBIOL, V41, P108, DOI 10.1002/(SICI)1097-4695(199910)41:1<108::AID-NEU14>3.0.CO;2-U; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; EINON DF, 1980, Q J EXP PSYCHOL, V32, P137, DOI 10.1080/00335558008248239; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; ESCANDON E, 1994, J NEUROSCI, V14, P2054; FALKENBERG T, 1992, NEUROSCI LETT, V138, P153, DOI 10.1016/0304-3940(92)90494-R; Fryer RH, 1996, J COMP NEUROL, V374, P21, DOI 10.1002/(SICI)1096-9861(19961007)374:1<21::AID-CNE2>3.0.CO;2-P; FULLER KS, 1998, PATHOLOGY IMPLICATIO, P763; GALL CM, 1992, TRENDS PHARMACOL SCI, V13, P401, DOI 10.1016/0165-6147(92)90123-N; Goodness TP, 1997, EUR J NEUROSCI, V9, P1574, DOI 10.1111/j.1460-9568.1997.tb01515.x; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; Jennett B., 1997, HEAD INJURY, P439; KatohSemba R, 1997, J NEUROCHEM, V69, P34; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kesslak JP, 1998, BEHAV NEUROSCI, V112, P1012, DOI 10.1037/0735-7044.112.4.1012; Kokaia Z, 1996, MOL BRAIN RES, V38, P139, DOI 10.1016/0169-328X(96)00002-2; Kolb B, 1991, CEREB CORTEX, V1, P189, DOI 10.1093/cercor/1.2.189; LAUTERBORN JC, 1994, MOL CELL NEUROSCI, V5, P46, DOI 10.1006/mcne.1994.1005; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu B, 1999, J NEUROSCI RES, V58, P76, DOI 10.1002/(SICI)1097-4547(19991001)58:1<76::AID-JNR8>3.3.CO;2-S; McAllister AK, 1997, NEURON, V18, P767, DOI 10.1016/S0896-6273(00)80316-5; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Rosenzweig MR, 1996, BEHAV BRAIN RES, V78, P57, DOI 10.1016/0166-4328(95)00216-2; SCHWARTZ S, 1964, J COMP PHYSIOL PSYCH, V57, P72, DOI 10.1037/h0045518; SEROOGY KB, 1994, J COMP NEUROL, V342, P321, DOI 10.1002/cne.903420302; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; WHISHAW IQ, 1984, BEHAV NEURAL BIOL, V42, P183, DOI 10.1016/S0163-1047(84)91046-X; WILL BE, 1976, PHYSIOL BEHAV, V16, P603, DOI 10.1016/0031-9384(76)90221-3; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449; Zhang L, 2000, MOL BRAIN RES, V79, P174, DOI 10.1016/S0169-328X(00)00124-8; Zhao LR, 2000, NEUROSCIENCE, V97, P177, DOI 10.1016/S0306-4522(00)00023-3; [No title captured]	47	78	79	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2002	112	3					631	637	PII S0306-4522(02)00104-5	10.1016/S0306-4522(02)00104-5			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	572JF	WOS:000176770200013	12074904				2022-02-06	
J	Wagner, AK; Hammond, FM; Sasser, HC; Wiercisiewski, D				Wagner, AK; Hammond, FM; Sasser, HC; Wiercisiewski, D			Return to productive activity after traumatic brain injury: Relationship with measures of disability, handicap, and community integration	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; disabled persons; employment; productivity; rehabilitation; work	QUALITY-OF-LIFE; SUPPORTED EMPLOYMENT; WORK	Objectives: To identify which factors are associated with successful return to productive activity (RTPA) 1 year after hospitalization with traumatic brain injury (TBI) and to examine the relations between successful RTPA and other measures of impairment, disability, handicap, and integration into the community. Design: Prospective study with 1-year follow-up. Setting: Level I trauma center. Participants: One hundred five respondents from a cohort of 378 adults hospitalized with TBI admitted between September 1997 and May 1998. Interventions: Not applicable. Main Outcome Measures: Return to productive work 1 year after injury; Disability Rating Scale (DRS); and Community Integration Scale (CIQ). Results: Of the 105 participants, 72% achieved RTPA. Logistic regression showed an association between RPTA and the following factors: premorbid educational level, premorbid psychiatric history, violent mechanism of injury, discharge status after acute hospitalization, prior alcohol and drug use, and injury severity. Handicap and community integration at 1-year postinjury, as measured by subscales of the DRS and the CIQ, were also associated with RTPA. Conclusion: Premorbid and injury-related variables and measures of handicap and community integration were associated with RTPA at 1 year. To understand and effectively support vocational pursuits in the TBI population, future studies are needed to define further causality and origin of these relationships.	Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Charlotte, NC USA; Carolinas Med Ctr, Dept Res Epidemiol, Charlotte, NC 28203 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Kaufmann Bldg Ste 901, Pittsburgh, PA 15213 USA.						Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009	20	78	81	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2002	83	1					107	114		10.1053/apmr.2002.27470			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	509JU	WOS:000173145300017	11782840				2022-02-06	
J	Kelly, KD; Lissel, HL; Rowe, BH; Vincenten, JA; Voaklander, DC				Kelly, KD; Lissel, HL; Rowe, BH; Vincenten, JA; Voaklander, DC			Sport and recreation-related head injuries treated in the emergency department	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						head injury, sport and recreation related; emergency department; epidemiology, outcomes	UNITED-STATES; BRAIN-INJURY; NEW-ZEALAND; EPIDEMIOLOGY; MILD; HOSPITALIZATION; ACCIDENT	Objective: Head injury (HI) in sport is common and can have serious consequences. This study examines the epidemiology of sport/recreational (SR)-related HI presenting to the emergency department (ED). Design: Retrospective review of medical records. Setting: Five EDs in the Capital Health Region (Edmonton) located in the province of Alberta, Canada. Patients: All persons in a 1-year period reporting to the EDs with an HI. HI was defined as IC9-CM coded skull fracture, loss of consciousness, or concussion. Main Outcome Measures: Hospitalization, utilization of diagnostic testing, and discharge destination. Results: In total, 10,877 (3%) of 288,948 ED encounters were for sports and recreational injuries; 358 (3%) were for HI. Males (71%) were more frequently injured; patients < 20 years old were involved in 66% of all HI cases. The highest proportion of HI occurred during ice hockey (21%), cycling (13%), and playground-related activities (8%). 9% of HI were hospitalized (versus 4% admission rate for other SR injuries; p < 0.01). Conclusions: These results demonstrate the utility of an ED-based injury registry and indicate that patients with HI presenting to the ED from SR activities are common. These injuries appear to be more severe than other types of SR injuries treated in the ED.	Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Rural Hlth, Shepparton, Vic 3632, Australia; Univ Alberta, Alberta Ctr Injury Control & Res, Edmonton, AB, Canada; Univ Alberta, Div Emergency Med, Edmonton, AB, Canada		Kelly, KD (corresponding author), Univ Melbourne, Fac Med Dent & Hlth Sci, Dept Rural Hlth, POB 6500, Shepparton, Vic 3632, Australia.	karendk@unimelb.edu.au					*ALB CTR INJ CONTR, 1999, HEAD INJ FACTS; BAKER SP, 1994, AM J PUBLIC HEALTH, V84, P649, DOI 10.2105/AJPH.84.4.649; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Body C, 1996, BRAIN INJURY, V10, P567, DOI 10.1080/026990596124133; BRUST JD, 1998, MED J ALLINA, V7, P27; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Chorley Joseph N., 1998, Current Opinion in Pediatrics, V10, P350, DOI 10.1097/00008480-199808000-00004; DAVIS JM, 1993, AM J DIS CHILD, V147, P1001, DOI 10.1001/archpedi.1993.02160330091027; DELOES M, 1995, INT J SPORTS MED, V16, P134, DOI 10.1055/s-2007-972980; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Finch C, 1998, BRIT J SPORT MED, V32, P220, DOI 10.1136/bjsm.32.3.220; HARMON KG, 1999, AM FAM PHYSICIAN, V60, P738; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; LeBlanc K E, 1998, J La State Med Soc, V150, P312; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; MACKELLAR A, 1989, J PEDIATR SURG, V24, P577, DOI 10.1016/S0022-3468(89)80510-X; Mummery WK, 1998, CAN J PUBLIC HEALTH, V89, P53, DOI 10.1007/BF03405796; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Puder DR, 1999, AM J PUBLIC HEALTH, V89, P1736, DOI 10.2105/AJPH.89.11.1736; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; Sosin DM, 1996, BRAIN INJURY, V10, P47; *SPECTR RES, 1996, SURV CYCL CHAR CYCL; STRANG I, 1978, INJURY, V10, P154; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; Terrell TR, 1999, AM FAM PHYSICIAN, V60, P738; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; WATTERS DAK, 1984, ARCH EMERG MED, V1, P105; Wrightson P, 1998, NEW ZEAL MED J, V111, P99; Ytterstad B, 1996, BRIT J SPORT MED, V30, P64, DOI 10.1136/bjsm.30.1.64	32	78	78	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	APR	2001	11	2					77	81		10.1097/00042752-200104000-00003			5	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	438LU	WOS:000169055800003	11403118				2022-02-06	
S	Riccio, CA; Reynolds, CR		Wasserstein, J; Wolf, LE; LeFever, FF		Riccio, CA; Reynolds, CR			Continuous performance tests are sensitive to ADHD in adults but lack specificity - A review and critique for differential diagnosis	ADULT ATTENTION DEFICIT DISORDER: BRAIN MECHANISMS AND LIFE OUTCOMES	Annals of the New York Academy of Sciences		English	Article						continuous performance tests; attention; executive control; ADHD	DEFICIT-HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; CHILDHOOD-ONSET SCHIZOPHRENIA; IDENTICAL PAIRS VERSION; FRONTAL-LOBE FUNCTIONS; GLUCOSE METABOLIC-RATE; CLOSED-HEAD-INJURY; SUSTAINED ATTENTION; BIPOLAR DISORDER; COLLEGE-STUDENTS	Historically, the focus for Attention Deficit Hyperactivity Disorder (ADHD) has been on children, with considerable research and many opinions available in this area. More recently, the focus has been expanded to include ADHD in adults. Assessment of ADHD in adults is complicated by the high rate of co-occurring disorders as well as symptom overlap with a number of disorders. One popular family of measures for the assessment of attention and executive control is the continuous performance test (CPT). A review of the available research on CPTs reveals that they are quite sensitive to CNS dysfunction. This is both a strength and a limitation of CPTs in that multiple disorders can result in impaired performance on a CPT. The high sensitivity of CPTs is further complicated by the multiple variations of CPTs available, some of which may be more sensitive or demonstrate better specificity to ADHD in adults than others. If CPTs are to be used clinically, further research will be needed to answer the questions raised by this review.	Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA		Riccio, CA (corresponding author), Texas A&M Univ, Dept Educ Psychol, Mail Stop 4225, College Stn, TX 77843 USA.	criccio@acs.tamu.edu					Addington J, 1998, SCHIZOPHR RES, V32, P171, DOI 10.1016/S0920-9964(98)00042-5; ADDINGTON J, 1998, J ABNORM CHILD PSYCH, V17, P371; ALEXANDER DA, 1973, PSYCHOL REP, V32, P229, DOI 10.2466/pr0.1973.32.1.229; ALLEN LF, 1993, THESIS TEXAS A M U C; AMAN MG, 1991, J AUTISM DEV DISORD, V21, P211, DOI 10.1007/BF02284761; AMAN MG, 1993, J AUTISM DEV DISORD, V23, P491, DOI 10.1007/BF01046052; American Educational Research Association American Psychological Association National Council on Measurement in Education, 1999, STAND ED PSYCH TEST; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANDERSON VE, 1969, J ABNORM PSYCHOL, V74, P358, DOI 10.1037/h0027611; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Arthur G, 1947, POINT SCALE PERFORMA; ASARNOW RF, 1978, J ABNORM PSYCHOL, V87, P597, DOI 10.1037/0021-843X.87.6.597; AUGUST GJ, 1989, J AM ACAD CHILD PSY, V28, P739, DOI 10.1097/00004583-198909000-00016; AYLWARD GP, 1990, J PSYCHOEDUC ASSESS, V8, P497, DOI 10.1177/073428299000800405; BAER RA, 1987, J APPL BEHAV ANAL, V20, P225, DOI 10.1901/jaba.1987.20-225; Barkley R.A., 1996, J ATTEN DISORD, V1, P41, DOI [10.1177/108705479600100104, DOI 10.1177/108705479600100104]; BARKLEY RA, 1991, J AM ACAD CHILD PSY, V30, P752, DOI 10.1097/00004583-199109000-00009; BARKLEY RA, 1992, J ABNORM CHILD PSYCH, V20, P163, DOI 10.1007/BF00916547; BARKLEY RA, 1990, J CONSULT CLIN PSYCH, V58, P775, DOI 10.1037/0022-006X.58.6.775; BARKLEY RA, 1994, CLIN NEUROPSYCHOL, V8, P121, DOI 10.1080/13854049408401552; Barkley RA, 1997, J DEV BEHAV PEDIATR, V18, P271; Barkley Russell Alan, 2006, ATTENTION DEFICIT HY, V3rd; BEALE IL, 1987, J ABNORM CHILD PSYCH, V15, P229, DOI 10.1007/BF00916351; BENEDICT RHB, 1994, SCHIZOPHRENIA BULL, V20, P537, DOI 10.1093/schbul/20.3.537; BERGMAN A, 1991, RITALIN THEORY PATIE, P223; BERNSTEIN GA, 1994, J AM ACAD CHILD PSY, V33, P407, DOI 10.1097/00004583-199403000-00016; Biederman J, 1998, J AFFECT DISORDERS, V51, P101, DOI 10.1016/S0165-0327(98)00177-3; BOCK RD, 1982, THESIS NEW YORK U NE; BOWEN L, 1994, J PSYCHIAT RES, V28, P289, DOI 10.1016/0022-3956(94)90012-4; BREEN MJ, 1989, J CHILD PSYCHOL PSYC, V30, P711, DOI 10.1111/j.1469-7610.1989.tb00783.x; Brown TE, 1996, BROWN ATTENTION DEFI; BRUMM VL, 1994, THESIS U SO CALIFORN; Buchanan RW, 1997, AM J PSYCHIAT, V154, P363; BUCHSBAUM MS, 1990, BRIT J PSYCHIAT, V156, P216, DOI 10.1192/bjp.156.2.216; BUCHSBAUM MS, 1992, ARCH GEN PSYCHIAT, V49, P935; BURG JS, 1995, BRAIN INJURY, V9, P395, DOI 10.3109/02699059509005779; BURKLAND SG, 1985, THESIS U WATERLOO CA; BYRNE DG, 1976, BRIT J SOC CLIN PSYC, V15, P267, DOI 10.1111/j.2044-8260.1976.tb00034.x; Carlson GA, 1998, J AFFECT DISORDERS, V51, P177, DOI 10.1016/S0165-0327(98)00179-7; CARTER CS, 1995, PSYCHIAT RES, V56, P59, DOI 10.1016/0165-1781(94)02509-H; CHEE P, 1989, EFFECTS EVENT RATE D; Chen WJ, 1997, J ABNORM PSYCHOL, V106, P649, DOI 10.1037/0021-843X.106.4.649; Chen WJ, 1998, SCHIZOPHRENIA BULL, V24, P163, DOI 10.1093/oxfordjournals.schbul.a033308; CICCHETTI DV, 1994, J CLIN EXP NEUROPSYC, V16, P155, DOI 10.1080/01688639408402625; Clure C, 1999, AM J DRUG ALCOHOL AB, V25, P441, DOI 10.1081/ADA-100101871; COHEN MJ, 1994, J EMOT BEHAV DISORD, V2, P31, DOI 10.1177/106342669400200104; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; COHLER BJ, 1977, J CHILD PSYCHOL PSYC, V18, P115, DOI 10.1111/j.1469-7610.1977.tb00424.x; Conners C. K., 1998, CONNERS ADULT ADHD R; Conners C. K., 1999, ATTENTION DEFICIT HY; Conners C. K., 1992, CONNERS CONTINUOUS P; Conners CK, 1996, J AM ACAD CHILD PSY, V35, P1314, DOI 10.1097/00004583-199610000-00018; Conners CK., 1995, CONNERS CONTINUOUS P; CONNERS CK, 1993, DEV HIST FORM ADHD R; Cornblatt B., 1989, SCHIZOPHRENIA SCI PR, P83; CORNBLATT BA, 1989, PSYCHIAT RES, V29, P65, DOI 10.1016/0165-1781(89)90188-1; CRAIG S, 1983, THESIS BOSTON U BOST; Cuffe S. P., 1994, J CHILD FAM STUD, V3, P327, DOI DOI 10.1007/BF02234689; DAS JP, 1992, J PSYCHOEDUC ASSESS, V10, P37, DOI 10.1177/073428299201000103; Denckla MB, 1996, J DEV BEHAV PEDIATR, V17, P114; DERAGOTIS LR, 1986, MANUAL SYMPTOM CHECK; Downey KK, 1997, J NERV MENT DIS, V185, P32, DOI 10.1097/00005053-199701000-00006; Downey KK, 1996, J SUBST ABUSE, V8, P129, DOI 10.1016/S0899-3289(96)90139-X; DRAEGER S, 1986, J ABNORM CHILD PSYCH, V14, P411, DOI 10.1007/BF00915435; DUPAUL GJ, 1992, J CLIN CHILD PSYCHOL, V21, P394, DOI 10.1207/s15374424jccp2104_10; DYKMAN RA, 1993, EXCEPT CHILDREN, V60, P132, DOI 10.1177/001440299306000207; EARLEBOYER EA, 1991, PSYCHIAT RES, V37, P47, DOI 10.1016/0165-1781(91)90105-X; EBERT J, 1995, J PSYCHOL PRACTICE, V1, P81; Edwards G, 1998, ADHD REPORT, V6, P11; ELIASON MJ, 1987, J LEARN DISABIL, V20, P614, DOI 10.1177/002221948702001007; Epstein JN, 1998, CLIN NEUROPSYCHOL, V12, P155, DOI 10.1076/clin.12.2.155.2000; ERLENMEYERKIMLING L, 1978, J PSYCHIAT RES, V14, P93, DOI 10.1016/0022-3956(78)90011-0; Ernst M, 1997, NEUROPSYCHOPHARMACOL, V16, P276, DOI 10.1016/S0893-133X(96)00243-6; ESTRIN WJ, 1988, CLIN PHARMACOL THER, V43, P86, DOI 10.1038/clpt.1988.15; FEINBERG AG, 2000, ATTENTION, V6, P20; Finkelstein JRJ, 1997, J ABNORM PSYCHOL, V106, P203; FISCHER M, 1995, J CLIN CHILD PSYCHOL, V24, P427, DOI 10.1207/s15374424jccp2404_6; FISCHER M, 1990, J CONSULT CLIN PSYCH, V58, P580, DOI 10.1037/0022-006X.58.5.580; FITZPATRICK PA, 1998, J AM ACAD CHILD ADOL, V31, P226; FLEMING KL, 1991, THESIS CALIFORNIA SC; FRANKE P, 1994, PSYCHIAT RES, V54, P259, DOI 10.1016/0165-1781(94)90020-5; FRIED PA, 1992, NEUROTOXICOL TERATOL, V14, P299, DOI 10.1016/0892-0362(92)90036-A; GARFINKEL BD, 1986, J AM ACAD CHILD PSY, V25, P503, DOI 10.1016/S0002-7138(10)60009-X; Garfinkel BD., 1983, PSYCHIAT HOSP, V14, P163; GARRETSON HB, 1985, THESIS BOSTON U BOST; GIRARDI NL, 1995, PEDIATR RES, V38, P539, DOI 10.1203/00006450-199510000-00011; Golier J, 1997, INTEGR PHYS BEH SCI, V32, P52, DOI 10.1007/BF02688613; Gordon M., 1998, ATTENTION DEFICIT HY, P294; GORDON M, 1999, ADHD REPORT, V7, P1; Gordon M, 1983, GORDON DIAGNOSTIC SY; GORENSTEIN EE, 1989, J CLIN PSYCHOL, V45, P619, DOI 10.1002/1097-4679(198907)45:4<619::AID-JCLP2270450419>3.0.CO;2-M; GREENBERG LM, 1993, J CHILD PSYCHOL PSYC, V34, P1019, DOI 10.1111/j.1469-7610.1993.tb01105.x; GREENBERG LM, 1988, TEST VARIABLES ATTEN; GREENBERG OLM, 1996, TOVA TEST VARIABLES; GRIBBLE MW, 1989, THESIS OHIO STATE U; GRODZINSKY GM, 1992, DEV NEUROPSYCHOL, V8, P427, DOI 10.1080/87565649209540536; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1974, PSYCHOL EFFECTS CONC; Grove WM, 1996, PSYCHOL PUBLIC POL L, V2, P293, DOI 10.1037/1076-8971.2.2.293; GUICH SM, 1989, SCHIZOPHR RES, V2, P439, DOI 10.1016/0920-9964(89)90012-1; HAIN C, 1993, PSYCHOPATHOLOGY, V26, P62, DOI 10.1159/000284801; Halperin J. M., 1991, PSYCHOL ASSESSMENT, V3, P803; HALPERIN JM, 1990, J CHILD PSYCHOL PSYC, V31, P455, DOI 10.1111/j.1469-7610.1990.tb01582.x; HALPERIN JM, 1988, J AM ACAD CHILD PSY, V27, P326, DOI 10.1097/00004583-198805000-00010; HALPERIN JM, 1991, DEV NEUROPSYCHOL, V7, P207, DOI 10.1080/87565649109540488; HARPER GW, 1992, J CHILD PSYCHOL PSYC, V33, P1365, DOI 10.1111/j.1469-7610.1992.tb00956.x; Hart RP, 1998, J CLIN EXP NEUROPSYC, V20, P111, DOI 10.1076/1380-3395(199802)20:1;1-P;FT111; Hathaway S. R., 1989, MANUAL ADM SCORING M; HAZLETT EA, 1993, J ABNORM PSYCHOL, V102, P39, DOI 10.1037/0021-843X.102.1.39; Heaton RK, 1981, MANUAL WISCONSIN CAR; HOOKS K, 1994, J CLIN CHILD PSYCHOL, V23, P69, DOI 10.1207/s15374424jccp2301_9; Horner B, 1996, PSYCHOL ADDICT BEHAV, V10, P55, DOI 10.1037/0893-164X.10.1.55; HOY E, 1978, J ABNORM CHILD PSYCH, V6, P311, DOI 10.1007/BF00924734; Ito M, 1997, SCHIZOPHR RES, V23, P205, DOI 10.1016/S0920-9964(96)00108-9; JERISON HJ, 1967, HUM FACTORS, V9, P285, DOI 10.1177/001872086700900310; Karatekin C, 1998, PSYCHIAT RES, V80, P165, DOI 10.1016/S0165-1781(98)00061-4; Karatekin C, 1998, J ABNORM CHILD PSYCH, V26, P367, DOI 10.1023/A:1021903923120; KARDELL EG, 1994, THESIS PACE U NEW YO; KEEFE R, 1990, THESIS NEW YORK U NE; Keilp JG, 1997, PSYCHIAT RES-NEUROIM, V74, P35, DOI 10.1016/S0925-4927(96)02881-8; Kern R. M., 1999, J INDIV PSYCHOL, V55, P186; KLEE SH, 1986, PSYCHIAT ANN, V16, P52, DOI 10.3928/0048-5713-19860101-12; KLORMAN R, 1991, J ABNORM CHILD PSYCH, V19, P263, DOI 10.1007/BF00911231; KOELEGA HS, 1989, HUM FACTORS, V31, P45, DOI 10.1177/001872088903100104; KORNETSKY C, 1978, J PSYCHIAT RES, V14, P69, DOI 10.1016/0022-3956(78)90009-2; Kovner R, 1998, INT J NEUROSCI, V96, P225, DOI 10.3109/00207459808986470; LAIDLAW TM, 1993, INT J CLIN EXP HYP, V41, P97, DOI 10.1080/00207149308414541; LAM CM, 1991, REM SPEC EDUC, V12, P40, DOI 10.1177/074193259101200208; LEVAV ML, 1991, THESIS U MARYLAND CO; Levin ED, 1996, PSYCHOPHARMACOLOGY, V123, P55, DOI 10.1007/BF02246281; Levin ED, 1998, PSYCHOPHARMACOLOGY, V140, P135, DOI 10.1007/s002130050750; Levy F, 1997, J PAEDIATR CHILD H, V33, P384; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; Lin CCH, 1999, J ABNORM CHILD PSYCH, V27, P403, DOI 10.1023/A:1021932119311; LIST MA, 1985, THESIS U WATERLOO CA; Liu SK, 1997, SCHIZOPHR RES, V25, P211, DOI 10.1016/S0920-9964(97)00026-1; Lomas B, 1999, PSYCHIATR SERV, V50, P705, DOI 10.1176/ps.50.5.705; LOWE PA, 1998, ANN C NAT AC NEUR WA; Luria A.R., 1966, HIGHER CORTICAL FUNC; MAHAN SM, 1996, THESIS INDIANA STATE; Mancini C, 1999, PSYCHOL MED, V29, P515, DOI 10.1017/S0033291798007697; Mansour CS, 1996, PERS INDIV DIFFER, V20, P183, DOI 10.1016/0191-8869(95)00167-0; Marks DJ, 1999, J ABNORM CHILD PSYCH, V27, P167, DOI 10.1023/A:1021967632515; Marshall RM, 1997, J LEARN DISABIL, V30, P635, DOI 10.1177/002221949703000607; MCGRATH NF, 1985, THESIS NW U EVANSTON; MICHAELS KL, 1996, THESIS U GEORGIA ATH; Milin R, 1997, PSYCHIAT SERV, V48, P1378; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mirsky A. F., 1989, INTEGRATING THEORY P, P75; MIRSKY AF, 1987, ENVIRON HEALTH PERSP, V74, P191, DOI 10.2307/3430449; Morgan AE, 1996, J AM ACAD CHILD PSY, V35, P325, DOI 10.1097/00004583-199603000-00014; MORROW LA, 1992, NEUROPSYCHOLOGIA, V30, P911, DOI 10.1016/0028-3932(92)90035-K; *MULT SYST INC, 1994, STRUCT CLIN INT DSM; Murphy K, 1996, COMPR PSYCHIAT, V37, P393, DOI 10.1016/S0010-440X(96)90022-X; Murphy K., 1996, J ATTEN DISORD, DOI [10.1177/108705479600100303, DOI 10.1177/108705479600100303]; MUSSGAY L, 1990, SCHIZOPHR RES, V3, P303, DOI 10.1016/0920-9964(90)90014-X; NEHEMKIS AM, 1972, PERCEPT MOTOR SKILL, V35, P787, DOI 10.2466/pms.1972.35.3.787; Nelson EB, 1998, AM J PSYCHIAT, V155, P137, DOI 10.1176/ajp.155.1.137; NUECHTERLEIN KH, 1983, J ABNORM PSYCHOL, V92, P4, DOI 10.1037/0021-843X.92.1.4; OBIOLS JE, 1992, PSYCHOL REP, V71, P1131, DOI 10.2466/PR0.71.8.1131-1136; OBRIEN JD, 1992, J DEV BEHAV PEDIATR, V13, P274; ODOUGHERTY M, 1984, J ABNORM PSYCHOL, V93, P178, DOI 10.1037/0021-843X.93.2.178; Oie M, 1999, NEUROPSYCHOLOGIA, V37, P1351, DOI 10.1016/S0028-3932(99)00043-3; PARASURAMAN R, 1979, SCIENCE, V205, P924, DOI 10.1126/science.472714; PARSONS OA, 1978, J CONSULT CLIN PSYCH, V46, P608, DOI 10.1037/0022-006X.46.4.608; PASS HL, 1980, BIOL PSYCHIAT, V15, P9; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Porteus SD., 1965, PORTEUS MAZE TESTS 5; QUILLAN RE, 1994, THESIS MIAMI U OXFOR; RAPOPORT JL, 1980, ARCH GEN PSYCHIAT, V37, P933; RASILE DA, 1995, INT J PSYCHOL, V30, P35, DOI 10.1080/00207599508246972; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reschly D.J., 1989, HDB CLIN NEUROPSYCHO, P503; Reynolds C. R., 1997, HDB CLIN CHILD NEURO, P296; REYNOLDS CR, 1986, SCHOOL PSYCHOL REV, V15, P256; REYNOLDS CR, 1999, J FORENSIC NEUROPSYC, V1, P55; REYNOLDS CR, 1982, NEUROPSYCHOLOGY COGN, V3, P55; REYNOLDS CR, HDB NEURODEVELOPMENT; Riccio CA, 1996, J LEARN DISABIL, V29, P561, DOI 10.1177/002221949602900510; RICCIO CA, IN PRESS ARCH CLIN N; Richards TL, 1999, J COLL STUDENT DEV, V40, P299; Riordan HJ, 1999, ARCH CLIN NEUROPSYCH, V14, P217, DOI 10.1016/S0887-6177(98)00015-8; RIS MD, 1994, J CLIN EXP NEUROPSYC, V16, P21, DOI 10.1080/01688639408402615; ROBINS PM, 1992, J ABNORM CHILD PSYCH, V20, P65, DOI 10.1007/BF00927117; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; RoyByrne P, 1997, COMPR PSYCHIAT, V38, P133, DOI 10.1016/S0010-440X(97)90065-1; Rueckert L, 1996, NEUROPSYCHOLOGIA, V34, P953, DOI 10.1016/0028-3932(96)00016-4; Rund BR, 1998, SCAND J PSYCHOL, V39, P101, DOI 10.1111/1467-9450.00062; RUND BR, 1992, ACTA PSYCHIAT SCAND, V86, P207, DOI 10.1111/j.1600-0447.1992.tb03253.x; RUTSCHMANN J, 1977, ARCH GEN PSYCHIAT, V34, P571; Sachdev P, 1999, PSYCHOL MED, V29, P507, DOI 10.1017/S003329179800720X; SANDFORD JA, 1994, INTEGRATED VISUAL AU; SANDOVAL J, 1981, ANN M AM PSYCH ASS A; Saykin A J, 1995, Appl Neuropsychol, V2, P79, DOI 10.1207/s15324826an0202_5; SCHECHTER MD, 1985, J CLIN PHARMACOL, V25, P269, DOI 10.1002/j.1552-4604.1985.tb02837.x; SCHEIN JD, 1962, J CONSULT PSYCHOL, V26, P115, DOI 10.1037/h0047461; SEIDEL WT, 1990, CLIN NEUROPSYCHOL, V5, P53; SEIDMAN LJ, 1995, J AM ACAD CHILD PSY, V34, P1015, DOI 10.1097/00004583-199508000-00011; Seidman LJ, 1997, J CONSULT CLIN PSYCH, V65, P150, DOI 10.1037/0022-006X.65.1.150; Seidman LJ, 1998, SCHIZOPHR RES, V34, P101, DOI 10.1016/S0920-9964(98)00097-8; SERPER MR, 1990, PSYCHIAT RES, V32, P281, DOI 10.1016/0165-1781(90)90033-2; Sitarenios, 1999, J ATTEN DISORD, V3, P153, DOI [DOI 10.1177/108705479900300304, 10.1177/108705479900300304]; SLICKER EK, 1991, THESIS TEXAS A M U C; SMITH A, 1967, ARCH NEUROL-CHICAGO, V17, P78, DOI 10.1001/archneur.1967.00470250082008; Smith A., 1968, SYMBOL DIGIT MODALIT; Smith EV, 1998, MEAS EVAL COUNS DEV, V31, P164, DOI 10.1080/07481756.1998.12068963; Sparrow E., 1999, J ATTEN DISORD, V3, P141, DOI [10.1177/108705479900300303, DOI 10.1177/108705479900300303]; STANFORD LD, 1994, J LEARN DISABIL, V27, P243, DOI 10.1177/002221949402700406; Stein MA, 1999, J AM ACAD CHILD PSY, V38, P940, DOI 10.1097/00004583-199908000-00004; Stein MA, 1999, J AM ACAD CHILD PSY, V38, P1208, DOI 10.1097/00004583-199910000-00004; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Suslow T, 1997, PSYCHIAT RES, V72, P103, DOI 10.1016/S0165-1781(97)00104-2; Suzuki Masahiko, 1995, Research Communications in Biological Psychology and Psychiatry, V20, P29; Teicher MH, 1996, J AM ACAD CHILD PSY, V35, P334, DOI 10.1097/00004583-199603000-00015; TEIXEIRA LCH, 1993, THESIS U RHODE ISLAN; THOMPSON TL, 1988, THESIS TEXAS A M U C; TROMMER BL, 1988, J DEV BEHAV PEDIATR, V9, P339; Tsai SY, 1996, NEUROTOXICOL TERATOL, V18, P463, DOI 10.1016/0892-0362(96)00035-9; TUPLER LA, 1989, THESIS EMORY U ATLAN; van der Feltz-Cornelis CM, 1999, J NERV MENT DIS, V187, P243, DOI 10.1097/00005053-199904000-00008; WAGENER DK, 1986, PSYCHIAT RES, V18, P365, DOI 10.1016/0165-1781(86)90021-1; WALKER E, 1982, J ABNORM PSYCHOL, V91, P261, DOI 10.1037/0021-843X.91.4.261; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WEINGARTNER H, 1980, J ABNORM PSYCHOL, V89, P25, DOI 10.1037/0021-843X.89.1.25; WEINSTEIN JA, 1996, THESIS EMORY U ATLAN; WELLER EB, 1995, J AM ACAD CHILD PSY, V34, P709, DOI 10.1097/00004583-199506000-00010; WENDER PH, 1995, ATTENTION DEFICIT HY; WERRY JS, 1987, J ABNORM CHILD PSYCH, V15, P409, DOI 10.1007/BF00916458; Weyandt LL, 1998, DEV NEUROPSYCHOL, V14, P643, DOI 10.1080/87565649809540734; WEYANDT LL, 1995, J PSYCHOPATHOL BEHAV, V17, P293, DOI 10.1007/BF02229304; WIEGARTZ PS, 1996, J ATTEN DISORD, V1, P87; WILLIAMS MA, 1997, CRIT ISS NE, P231; WILLSON VL, 1982, CLIN NEUROPSYCHOLOGY, V4, P134; WOLGIN DM, 1994, THESIS U HOUSTON HOU; [No title captured]	236	78	82	0	16	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-255-X	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2001	931						113	139					27	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	BT11H	WOS:000172009700007	11462737				2022-02-06	
J	Elting, JW; de Jager, AEJ; Teelken, AW; Schaaf, MJ; Maurits, NM; van der Naalt, J; Sibinga, CTS; Sulter, GA; De Keyser, J				Elting, JW; de Jager, AEJ; Teelken, AW; Schaaf, MJ; Maurits, NM; van der Naalt, J; Sibinga, CTS; Sulter, GA; De Keyser, J			Comparison of serum S-100 protein levels following stroke and traumatic brain injury	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						S-100; serum; stroke; traumatic brain injury; TIA; comparison	MINOR HEAD-INJURY; ASTROGLIAL 5-HT1A RECEPTORS; NEURON-SPECIFIC ENOLASE; POSITIVE GLIAL-CELLS; SPONTANEOUS REPERFUSION; PROLIFERATIVE RESPONSE; CEREBROSPINAL-FLUID; CEREBRAL INFARCTS; ISCHEMIC STROKE; NERVOUS-SYSTEM	Temporal changes in serum S-100 protein levels were compared between patients with ischemic stroke, transient ischemic attack (TIA) and traumatic brain injury (TBI). In addition, S-100 levels were correlated with clinical severity and outcome. Measurements were done with a LIA-mat Sangtec(R) 100 using an automated immunoluminometric assay. Serum S-100 was measured in 21 stroke patients, 18 TIA patients and ten TBI patients on days 1 (0-24 h), 2, 3, 4, 5 or 6 and 8 or 9. In a control group of 28 healthy volunteers one measurement was done. For the stroke and TIA patients, National Institutes of Health Stroke Scale (NIHSS) scores were obtained on admission and on day 10. For the TBI patients, Glasgow Coma Scale (GCS) scores were obtained on admission and Glasgow Outcome Scale (GOS) scores were obtained after 6 months:. Changes in serum S-100 levels over the first 3 days were significantly different between stroke and TBI patients (P = 0.014) and between stroke and TIA patients (P = 0.006). Peak concentrations of S-100 were most often observed on day 3 or 4 after stroke and on day 1 or 2 after TBI. In the stroke patients individual S-100 peak levels correlated well with the NIHSS score on admission (r = 0.58 P = 0.014) and the change in NIHSS score between day 10 and day 1 (r = 0.65, P = 0.005). In the TBI patients a good correlation between individual peak levels of S-100 and the GCS score on admission (r = -0.81, P = 0.010) and the GOS score 6 months after the trauma was found (r = -0.87, P = 0.004). We conclude that there is a significant difference in temporal changes of S-100 levels between ischemic stroke and TBI patients. This suggests different pathophysiological mechanisms. The results of this study further confirm that peak levels of serum S-100 correlate with neurological deficit resulting from either stroke or TBI. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Groningen Hosp, Dept Neurol, NL-9700 RB Groningen, Netherlands; Blood Bank Noord Nederland, NL-9713 GG Groningen, Netherlands		Elting, JW (corresponding author), Univ Groningen Hosp, Dept Neurol, Hanzenpl 1,POB 30-001, NL-9700 RB Groningen, Netherlands.		De Keyser, Jacques/D-3725-2013	De Keyser, Jacques/0000-0002-3394-7757; Maurits, Natasha/0000-0001-6231-7044; van der Naalt, Joukje/0000-0001-9873-2418			Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P366, DOI 10.1177/000456329703400405; AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; AZMITIA EC, 1991, J CLIN PSYCHIAT, V52, P4; Bowler JV, 1998, J NEUROL NEUROSUR PS, V64, P90, DOI 10.1136/jnnp.64.1.90; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Ciccarelli R, 1999, GLIA, V27, P275, DOI 10.1002/(SICI)1098-1136(199909)27:3<275::AID-GLIA9>3.3.CO;2-S; DUNNETT CW, 1980, J AM STAT ASSOC, V75, P796, DOI 10.2307/2287161; Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8; HACHITANDA Y, 1992, ACTA PATHOL JAPON, V42, P639; HAYASHI K, 1991, ACTA NEUROPATHOL, V81, P657, DOI 10.1007/BF00296376; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; HIDAKA H, 1983, J BIOL CHEM, V258, P2705; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; ISHIGURO Y, 1983, CANCER RES, V43, P6080; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; JANECZKO K, 1994, INT J DEV NEUROSCI, V12, P431, DOI 10.1016/0736-5748(94)90027-2; JANECZKO K, 1991, BRAIN RES, V564, P86, DOI 10.1016/0006-8993(91)91355-5; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JORGENSEN HS, 1994, ARCH NEUROL-CHICAGO, V51, P865, DOI 10.1001/archneur.1994.00540210037011; MARSHAK DR, 1990, PROG BRAIN RES, V86, P169; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; MIYAKE T, 1989, BRAIN RES, V489, P31, DOI 10.1016/0006-8993(89)90005-X; NAKAJIMA T, 1982, BIOMED RES, V8, P226; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; RUDOLPHI KA, 1992, CEREBROVAS BRAIN MET, V4, P346; SHASHOUA VE, 1984, J NEUROCHEM, V42, P1536, DOI 10.1111/j.1471-4159.1984.tb12739.x; SMIDTKASTNER R, 1990, NEUROSCIENCE, V38, P527; STEFANSSON K, 1982, AM J PATHOL, V106, P261; STEFANSSON K, 1982, NATURE, V295, P63, DOI 10.1038/295063a0; SUZUKI F, 1987, J NEUROCHEM, V49, P1557, DOI 10.1111/j.1471-4159.1987.tb01027.x; TAKANA H, 1992, EXP NEUROL, V116, P264; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; WHITAKERAZMITIA PM, 1994, PERSPECT DEV NEUROBI, V2, P233; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977	44	78	92	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	DEC 1	2000	181	1-2					104	110		10.1016/S0022-510X(00)00442-1			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	384HK	WOS:000165936600015	11099719				2022-02-06	
J	Mayou, RA; Black, J; Bryant, B				Mayou, RA; Black, J; Bryant, B			Unconsciousness, amnesia and psychiatric symptoms following road traffic accident injury	BRITISH JOURNAL OF PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN INJURY; MOTOR-VEHICLE ACCIDENTS; MINOR HEAD-INJURY	Background Although road traffic accident injury is the most common cause of traumatic brain injury, little is known of the prevalence of psychiatric complications or the significance of unconsciousness and amnesia. Aims To describe amnesia and unconsciousness following a road traffic accident and to determine whether they are associated with later psychological symptoms. Method Information was obtained from medical and ambulance records for 1441 consecutive attenders at an emergency department aged 17-69 who had been involved in a road traffic accident. A total of 1148 (80%) subjects completed a self-report questionnaire at baseline and were followed up at 3 months and I year. Results Altogether, 1.5% suffered major head (and traumatic brain) injury and 21% suffered minor head injury. Posttraumatic stress disorder (PTSD) and anxiety and depression were more common at 3 months in those who had definitely been unconscious than in those who had not, but there were nt, differences at I year. Conclusions PTSD and other psychiatric complications are as common in those who were briefly unconscious as in those who were not.	Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England; Univ Oxford, Dept Psychiat, Oxford OX3 7JX, England; John Radcliffe Hosp, Dept Accid & Emergency, Oxford OX3 9DU, England		Mayou, RA (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.						American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; BRYANT RA, 2000, AM J PSYCHIAT, V157, P627; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; Murray J., 1997, THESIS U OXFORD; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	14	78	81	0	3	ROYAL COLLEGE OF PSYCHIATRISTS	LONDON	BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON SW1X 8PG, ENGLAND	0007-1250			BRIT J PSYCHIAT	Br. J. Psychiatry	DEC	2000	177						540	545		10.1192/bjp.177.6.540			6	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	382WW	WOS:000165851200012	11102330				2022-02-06	
J	DeLuca, J; Schultheis, MT; Madigan, NK; Christodoulou, C; Averill, A				DeLuca, J; Schultheis, MT; Madigan, NK; Christodoulou, C; Averill, A			Acquisition versus retrieval deficits in traumatic brain injury: Implications for memory rehabilitation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						memory; recall; brain injuries; rehabilitation	CLOSED-HEAD-INJURY; VERBAL-LEARNING TEST; MULTIPLE-SCLEROSIS; PATTERNS; RECOVERY; STORAGE; RECALL; SCALE	Objective: To examine whether impaired memory in persons with traumatic brain injury (TBI) is caused by impaired initial acquisition or compromised retrieval from long-term storage. Design: Prospective matched controlled trial. Setting: Postacute rehabilitation institute. Participants: Patients with moderate to severe TBI (n = 28) and 21 matched, healthy controls (HCs). Main Outcome Measures: Patients with TBI and HC subjects were equated on initial acquisition on a verbal list-learning task. Recall and recognition performance was then evaluated at 30- and 90-minutes after learning. Results: All HC subjects and 20 subjects with TBI (TBI-MET) were able to meet the learning criterion, but the TBI-MET group took significantly more trials than HC subjects to do so. However, after equating groups on acquisition, the TBI-MET group did not differ from controls on recall and recognition at both the 30- and 90-minute delays. Eight TBI subjects showed severe learning deficits (TBI-NOT MET) because they never learned the task, and showed significantly impaired recall and recognition performance. The 2 TBI groups did not differ on measures of severity of injury, but the TBI-NOT MET group performed significantly below the TBI-MET group on executive functioning. Rate of forgetting did not differ across the 3 groups. Conclusions: Results suggest that memory impairment after TBI is caused primarily by deficiencies in initial acquisition of verbal information rather than in compromised retrieval. The findings have significant implications for the rehabilitation and treatment of individuals with TBI.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neursci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, W Orange, NJ 07052 USA; Massachusetts Mental Hlth Ctr, Dept Psychiat, Boston, MA 02115 USA		DeLuca, J (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neursci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.			Schultheis, Maria/0000-0002-6558-548X			BAUER RM, 1993, CLIN NEUROPSYCHOLOGY, P523; Baum KM, 1996, CLIN NEUROPSYCHOL, V10, P340; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BEGG I, 1988, MEM COGNITION, V16, P232, DOI 10.3758/BF03197756; BELLEZZA FS, 1989, J EXP PSYCHOL LEARN, V15, P990, DOI 10.1037/0278-7393.15.5.990; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BLACHSTEIN H, 1993, NEUROPSYCHOLOGY, V7, P530, DOI DOI 10.1037/0894-4105.7.4.530; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Carlesimo GA, 1997, CORTEX, V33, P131, DOI 10.1016/S0010-9452(97)80009-3; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; DEMERY JA, 1999, P INT NEUR SOC ANN C; Diamond BJ, 1997, BRAIN, V120, P1015, DOI 10.1093/brain/120.6.1015; GASS CS, 1995, ARCH CLIN NEUROPSYCH, V10, P475, DOI 10.1016/0887-6177(95)98192-G; GOLDSTEIN FC, 1989, CORTEX, V25, P541, DOI 10.1016/S0010-9452(89)80016-4; GORDON WA, 1989, J HEAD TRAUMA REHAB, V4, P76; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hart R. P., 1994, NEUROPSYCHOLOGY, V8, P325, DOI [10.1037/0894-4105.8.3.325, DOI 10.1037/0894-4105.8.3.325]; Haut M., 1992, NEUROPSYCHOLOGY, V6, P51; Heaton PDRK., 1993, WISCONSIN CARD SORTI; JANOWSKY JS, 1993, J CLIN EXP NEUROPSYC, V15, P159, DOI 10.1080/01688639308402554; KEARCOLWELL JJ, 1980, J CLIN PSYCHOL, V36, P782, DOI 10.1002/1097-4679(198007)36:3<782::AID-JCLP2270360334>3.0.CO;2-K; Lange G, 2000, ARCH PHYS MED REHAB, V81, P89, DOI 10.1016/S0003-9993(00)90227-2; Levin H. S., 1989, J CLIN EXP NEUROPSYC, V12, P129; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MCKINLAY W, 1999, REHABILITATION ADULT, P74; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PANIAK CE, 1989, J CLIN EXP NEUROPSYC, V11, P631, DOI 10.1080/01688638908400921; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; STALLINGS G, 1995, J CLIN EXP NEUROPSYC, V17, P706, DOI 10.1080/01688639508405160; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D, 1981, WESCHLER ADULT INTEL; Wilde MC, 1995, J CLIN EXP NEUROPSYC, V17, P849, DOI 10.1080/01688639508402434; WITOL A, 1990, REHABILITATION ADULT, P167; [No title captured]	39	78	79	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2000	81	10					1327	1333		10.1053/apmr.2000.9390			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	360WA	WOS:000089689300002	11030497				2022-02-06	
J	Malec, JF; Buffington, ALH; Moessner, AM; Degiorgio, L				Malec, JF; Buffington, ALH; Moessner, AM; Degiorgio, L			A medical/vocational case coordination system for persons with brain injury: An evaluation of employment outcomes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; vocational; employment; case management	CLOSED-HEAD-INJURY; FOLLOW-UP; SUPPORTED EMPLOYMENT; EARLY INTERVENTION; SOCIAL-ADJUSTMENT; REHABILITATION; RECOVERY; RETURN; WORK; TRAUMA	Objective: To evaluate initial placement and 1-year employment outcomes of a Medical/Vocational Case Coordination System (MVCCS) for persons with brain injury (BI) that provides: (1) early case identification and coordination, (2) appropriate medical and vocational rehabilitation interventions, (3) work trials, and (4) supported employment interventions including job coaching. Participants: One hundred fourteen Minnesota residents, ages 18 to 65 years, with acquired BI. Main Outcome Measures: Outcome: Five levels of Vocational Independence Scale (VIS). Predictor: Preinjury employment status (VIS) and years of education, severity of initial injury, time since injury, current impairment/disaibility as measured by the Rasch-analyzed Staff Mayo-Portland Adaptability Inventory (MPAI), and impaired self-awareness measured by staff rating and the difference between Staff MPAI and Survivor MPAI. Results: At placement, 46% in independent work; 25% in transitional placements; 9% in long-term supported employ ment; 10% in sheltered work; and 10% not placed. At 1-year follow-up (n = 101), 53% in independent work; 19% in transitional placement; 9% in supported work; 6% in sheltered work; and 13% unemployed. Regression analyses showed time since injury and Rasch Staff MPAI predicted VIS at placement; only VIS at placement independently predicted VIS at I-year follow-up; Rasch Staff MPAI and preinjury education level predicted time to placement. Conclusions: The MVCCS optimized vocational outcome after BI. Time since injury and impairment/disability best predicted Vocational placement. Level of initial placement best predicted employment status at follow-up. Persons with greater disability required more extended time and more extensive rehabilitation services before placement.	Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Rochester, MN 55905 USA		Malec, JF (corresponding author), Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Rochester, MN 55905 USA.						Adey C, 1967, Bristol Med Chir J, V82, P58; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BENYISHAY Y, 1990, REHABILITATION ADULT, P393; Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BRUCKNER FE, 1972, RHEUMATOL PHYS MED, V2, P344; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; EVANS RW, 1991, J INSUR MED, V3, P192; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FAHY TJ, 1967, LANCET, V2, P475; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; Gjone R, 1972, Scand J Rehabil Med, V4, P2; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HPAY H, 1971, INT S HEAD INJ 1970, P110; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; Kreutzer J S, 1991, Int Disabil Stud, V13, P162; LEWIN W, 1959, P ROY SOC MED, V52, P880; LEWIN W, 1967, P ROY SOC MED, V60, P1208, DOI 10.1177/003591576706011P204; LEWIN W, 1976, BRIT MED J, V2, P1234, DOI 10.1136/bmj.2.6046.1234; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LONDON P S, 1967, Annals of the Royal College of Surgeons of England, V41, P460; MACIVER IN, 1958, LANCET, V2, P544; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Malec J. F., 1994, J HEAD TRAUMA REHAB, V9, P1, DOI [10. 1097/ 00001199- 199412000- 00003, DOI 10.1097/00001199-199412000-00003]; Malec J. F., 1992, NEURO REHABILITATION, V2, P1, DOI [10.3233/NRE-1992-2303, DOI 10.3233/NRE-1992-2303]; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MALEC JF, 1995, MAYO CLIN PROC, V70, P1165, DOI 10.4065/70.12.1165; MALEC JF, IN PRESS REHABIL PSY; MATHESON JM, 1982, AUSTR APPROACHES REH, P32; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MILLER H, 1965, LANCET, V1, P225; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; RICHARDSON JC, 1971, INT S HEAD INJ 1970, P127; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROWBOTHAM GF, 1954, BRIT MED J, V1, P726, DOI 10.1136/bmj.1.4864.726; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RUSK H A, 1969, Medical Clinics of North America, V53, P677; RUSK HA, 1966, CLIN NEUROSURG, V12, P312; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEHMAN P, 1989, J APPL BEHAV ANAL, V22, P395, DOI 10.1901/jaba.1989.22-395; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; WEHMAN P, 1993, COMMUNITY BASED EMPL; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Wright B, 1982, RATING SCALE ANAL RA; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	79	78	79	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2000	81	8					1007	1015		10.1053/apmr.2000.6980			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	349JJ	WOS:000089041700001	10943747				2022-02-06	
J	Natale, JE; Joseph, JG; Helfaer, MA; Shaffner, DH				Natale, JE; Joseph, JG; Helfaer, MA; Shaffner, DH			Early hyperthermia after traumatic brain injury in children: Risk factors, influence on length of stay, and effect on short-term neurologic status	CRITICAL CARE MEDICINE			English	Article						pediatric intensive care; length of stay; Glasgow Coma Scale; secondary brain injury; hyperthermia; multiple logistic regression; traumatic brain injury; resource utilization	SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; CEREBRAL-ISCHEMIA; ACUTE STROKE; TEMPERATURE; RATS; COMA; PATIENT; HYPOXIA; DAMAGE	Objectives: a) To determine the risk factors for early hyperthermia after traumatic brain injury in children; b) to identify the contribution of early hyperthermia to neurologic status at pediatric intensive care unit (PICU) discharge and to PICU length of stay in head-injured children. Study Design: Observational cohort study. Setting: PICU at a tertiary care, university medical center. Patients: Children (n = 117) admitted to a PICU from July 1995 to May 1997 with traumatic brain injury. These children had a median age of 5.4 yrs (3 wks to 15.2 yrs old), and 33.4% were girls. Measurements and Main Results: Early hyperthermia (temperature >38.5 degrees C within the first 24 hrs of admission) occurred in 29.9% of patients admitted to the PICU with traumatic brain injury. Risk factors predicting early hyperthermia included Glasgow Coma Scale score in the emergency department less than or equal to 8, pediatric trauma score less than or equal to 8, cerebral edema or diffuse axonal injury on initial head computed tomography scan, admission blood glucose >150 mg/dL (8.2 mmol/L), admission white cell count >14,300 cells/mm3 (14.3 x 10(9) cells/L), and systolic hypotension. The presence of early hyperthermia significantly increased the risk for Glasgow Coma Scale score <13 at PICU discharge (odds ratio [OR] 9.7, 95% confidence interval [CI] 2.8, 24.4) and PICU stay greater than or equal to 3 days (OR 13.8, GI 5.1, 37.5). When we used multiple logistic regression models including injury severity and hypotension, early hyperthermia remained an independent predictor of lower Glasgow Coma Scale score at PICU discharge (OR 4.7, CI 1.4, 15.6) and longer PICU length of stay (OR 8.5, CI 2.8, 25.6). Conclusions: Early hyperthermia is independently associated with a measure of early neurologic status and resource utilization in children with traumatic brain injury serious enough to require PICU admission. These results support the prevention of hyperthermia in the management of traumatic brain injury in children. Further research is required to understand the mechanisms of this response and to identify appropriate preventive or therapeutic interventions.	Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; George Washington Univ, Sch Med, Ctr Hlth Serv & Clin Res, Childrens Natl Med Ctr, Washington, DC USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA		Natale, JE (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA.			SHAFFNER, DONALD/0000-0001-5530-0746			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BENEDEK G, 1987, CAN J NEUROL SCI, V14, P145; Bullock MR, 1996, J NEUROTRAUM, V13, P653; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Guyer B, 1997, PEDIATRICS, V100, P905, DOI 10.1542/peds.100.6.905; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; LINDSAY JT, 1998, J NEUROTRAUM, V15, P573; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McKeating EG, 1998, ANESTH ANALG, V86, P759, DOI 10.1097/00000539-199804000-00016; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; RUDY TA, 1979, THERMOREGULATORY MEC, P75; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	30	78	78	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JUL	2000	28	7					2608	2615		10.1097/00003246-200007000-00071			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336QW	WOS:000088315300065	10921603				2022-02-06	
J	Fassbender, K; Schneider, S; Bertsch, T; Schlueter, D; Fatar, M; Ragoschke, A; Kuhl, S; Kischka, U; Hennerici, M				Fassbender, K; Schneider, S; Bertsch, T; Schlueter, D; Fatar, M; Ragoschke, A; Kuhl, S; Kischka, U; Hennerici, M			Temporal profile of release of interleukin-1 beta in neurotrauma	NEUROSCIENCE LETTERS			English	Article						interleukin-1 beta; neurotrauma; microdialysis; inflammation	RAT-BRAIN; CONVERTING-ENZYME; MESSENGER-RNA; EXPRESSION; INJURY; MICRODIALYSIS; LOCALIZATION; CYTOKINES; MICROGLIA; ISCHEMIA	Timing and extent of trauma-induced release of interleukin-1 beta (IL-1 beta) in extracellular fluid of the CNS were analyzed. In brain tissue perfusates obtained by in vivo microdialysis a marked release of IL-1 beta was unexpectedly detected within less than 60 min. At such an early stage of neurotrauma, mRNA expression of IL-1 beta was detected whereas immunoreactivity for the IL-1 beta protein was negative. Concentrations of extracellularly secreted IL-1 beta protein gradually increased, peaked at day 2 and decreased thereafter. Drugs acting on mononuclear phagocytes significantly modulated IL-1 beta secretion. This so far unrecognized acuity of IL-1 beta release demonstrated here, may represent a precondition for the orchestrating role of this mediator in the cascade of inflammatory host response. (C) 2000 Elsevier Science Ireland Ltd. AII rights reserved.	Heidelberg Univ, Univ Clin Mannheim, Dept Neurol, D-68135 Mannheim, Germany; Heidelberg Univ, Univ Clin Mannheim, Dept Clin Chem, D-68135 Mannheim, Germany; Heidelberg Univ, Univ Clin Mannheim, Dept Microbiol, D-68135 Mannheim, Germany		Fassbender, K (corresponding author), Heidelberg Univ, Univ Clin Mannheim, Dept Neurol, Theodor Kutzer Ufer 1-3, D-68135 Mannheim, Germany.	fass@neuro.ma.uni-heidelberg.de	Fatar, Marc/E-6892-2015	Fassbender, Klaus/0000-0003-3596-868X			ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; ANDERSSON U, 1994, CYTOKINE PRODUCING C, P48; Fassbender K, 1997, J NEUROIMMUNOL, V74, P130, DOI 10.1016/S0165-5728(96)00214-7; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; Knauber J, 1999, J NEURAL TRANSM, V106, P35, DOI 10.1007/s007020050139; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Masson S, 1999, AM J PHYSIOL-GASTR L, V277, pG838; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; PHELPS CP, 1995, BRAIN RES, V688, P193, DOI 10.1016/0006-8993(95)00491-8; Rouquet N, 1996, CURR BIOL, V6, P1192, DOI 10.1016/S0960-9822(02)70688-X; SCHLUTER D, 1995, AM J PATHOL, V146, P999; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; van der Meer JWM, 1998, ANN NY ACAD SCI, V856, P243; WONG ML, 1995, NEUROIMMUNOMODULAT, V2, P141, DOI 10.1159/000096884; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMASAKI Y, 1992, NEUROSCI LETT, V142, P45, DOI 10.1016/0304-3940(92)90616-F; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; Zhang ZG, 1998, BRAIN RES, V784, P210, DOI 10.1016/S0006-8993(97)01317-6	20	78	82	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	APR 28	2000	284	3					135	138		10.1016/S0304-3940(00)00977-0			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	312FD	WOS:000086931800002	10773417				2022-02-06	
J	Hibbard, MR; Bogdany, J; Uysal, S; Kepler, K; Silver, JM; Gordon, WA; Haddad, L				Hibbard, MR; Bogdany, J; Uysal, S; Kepler, K; Silver, JM; Gordon, WA; Haddad, L			Axis II psychopathology in individuals with traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; PERSONALITY-DISORDERS; FOLLOW-UP; PSYCHIATRIC-DISORDERS; SOCIAL-ADJUSTMENT; RELATIVES; CATECHOLAMINES	Primary Objectives: To determine the frequency and nature of post-TBI personality disorders (PDs) in a community-based sample of individuals with TBI. Research design: One hundred individuals with TBI were administered a structural clinical interview to determine Axis II psychopathology. Methods of procedures: The Structured Clinical Interview for DSM-IV Personality Disorders, Clinician Version (SCID II) was used to determine 12 Axis II personality disorders. SCID II questions were modified so that symptom onset could be rated as occurring pre-injury vs. posr-TBI Data were analysed using student T-tests, chi-square analysis and one way analyses of variance. Outcomes and results: Pre-TBI PDs were diagnosed in 24% of the sample; antisocial PD and obsessive-compulsive PD were the most common diagnoses. Post-TBI, 66% of the: sample met criteria for at least une PD, with PDs independent of TBI severity, age at injury, and time since injury. The most common post-TBI PDs were: borderline, avoidant, paranoid, obsessive-compulsive and narcissistic. Men were more likely to be diagnosed with antisocial PD and narcissistic PD. Individuals with pre TBI PDs were at greater risk of acquiring additional psychopathology posr-TBI. Personalty traits endorsed by more than 30% of the sample post-TBI reflected loss of self-confidence, attempts to cope with cognitive and interpersonal failures and negative affect. Conclusion: These findings argue against a specific TBI personality syndrome,but rather a diversity of personality disorders reflective of the: persistent challenges and compensatory coping strategies developed by individuals post-TBI. Prospective need for clinical assessment, pro-active education and focused treatment. approaches are discussed.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; Lenox Hill Hosp, New York, NY 10021 USA		Hibbard, MR (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1425 Madison Ave, New York, NY 10029 USA.		Carneiro D'Albuquerque, Luiz Augusto/A-8812-2013	Carneiro D'Albuquerque, Luiz Augusto/0000-0001-7607-7168; Haddad, Lisa/0000-0002-7631-6760			[Anonymous], 1994, DIAGNOSTIC STAT MANU; BOND RM, 1986, NEUROPSYCHOLOGICAL A, P347; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V46, P764; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; BURNS S, 1994, BRAIN INJURY, V8, P412; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLONINGER CR, 1987, ARCH GEN PSYCHIAT, V44, P573; DENIS JF, 1990, CAN J PSYCHIAT, V35, P208, DOI 10.1177/070674379003500302; EPSTEIN RS, 1994, NEUROPSYCHIATRY TRAU, P228; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; First M.B., 1996, STRUCTURED CLIN INTE; FIRST MB, 1995, J PERS DISORD, V9, P92, DOI 10.1521/pedi.1995.9.2.92; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FROSCH JP, 1983, HOSP COMMUNITY PSYCH, V34, P243; GALLOP R, 1989, HOSP COMMUNITY PSYCH, V40, P815; GERSHANIK O, 1983, NEUROLOGY, V33, P1489, DOI 10.1212/WNL.33.11.1489; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; KAY T, 1986, NATL HEAD INJURY FDN; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kinsella G, 1989, Int Disabil Stud, V11, P9; KURSTZ JE, 1998, J HEAD TRAUMA REHAB, V13, P1; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lezak, 1989, ASSESSMENT BEHAV CON, V7, P113; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MAIER W, 1992, J PERS DISORD, V6, P187, DOI 10.1521/pedi.1992.6.3.187; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; OLDHAM JM, 1994, JAMA-J AM MED ASSOC, V272, P1770, DOI 10.1001/jama.272.22.1770; OSHANICK GJ, 1994, NEUROPSYCHIATRY TRAU, P163; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; PERLINE H, 1979, COMPUTER INTERPRETED; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; SIEVER LJ, 1991, AM J PSYCHIAT, V148, P1647; SILVER JM, 1992, AM PSYCHIAT PRESS TX, P363; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEISSMAN MM, 1993, J PERS DISORD, V7, P44; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; 1996, SPSS WINDOWS 95 V 7	52	78	81	0	8	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2000	14	1					45	61		10.1080/026990500120925			17	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	274CY	WOS:000084747200006	10670661				2022-02-06	
J	LaPlaca, MC; Raghupathi, R; Verma, A; Saatman, KE; Snyder, SH; McIntosh, TK				LaPlaca, MC; Raghupathi, R; Verma, A; Saatman, KE; Snyder, SH; McIntosh, TK			Temporal patterns of poly(ADP-ribose) polymerase activation in the cortex following experimental brain injury in the rat	JOURNAL OF NEUROCHEMISTRY			English	Article						poly(ADP-ribose) polymerase; DNA repair; traumatic brain injury; nicotinamide adenine dinucleotide; caspases; apoptosis	DNA STRAND BREAKS; FOCAL CEREBRAL-ISCHEMIA; NEURONAL CELL-DEATH; DAMAGE; APOPTOSIS; SYNTHETASE; REPAIR; CLEAVAGE; FRAGMENTATION; INHIBITION	The activation of poly(ADP-ribose) polymerase, a DNA base excision repair enzyme, is indicative of DNA damage. This enzyme also undergoes site-specific proteolysis during apoptosis. Because both DNA fragmentation and apoptosis are known to occur following experimental brain injury, we investigated the effect of lateral fluid percussion brain injury on poly(ADP-ribose) polymerase activity and cleavage. Male Sprague-Dawley rats (n = 52) were anesthetized, subjected to fluid percussion brain injury of moderate severity (2.5-2.8 atm), and killed at 30 min, 2 h, 6 h, 24 h, 3 days, or 7 days postinjury. Genomic DNA from injured cortex at 24 h, but not at 30 min, was both fragmented and able to stimulate exogenous poly(ADP-ribose) polymerase. Endogenous poly(ADP-ribose) polymerase activity, however, was enhanced in the injured cortex at 30 min but subsequently returned to baseline levels. Slight fragmentation of poly(ADP-ribose) polymerase was detected in the injured cortex in the first 3 days following injury, but significant cleavage was detected at 7 days postinjury. Taken together, these data suggest that poly(ADP-ribose) polymerase-mediated DNA repair is initiated in the acute posttraumatic period but that subsequent poly(ADP-ribose) polymerase activation does not occur, possibly owing to delayed apoptosis-associated proteolysis, which may impair the repair of damaged DNA.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA		McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3320 Smith Walk,105B Hayden Hall, Philadelphia, PA 19104 USA.		Pieper, Andrew A/R-5552-2016	Pieper, Andrew/0000-0001-6299-6577	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM3690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P01-NS08803] Funding Source: Medline		Ashkenas J, 1996, J EXP MED, V183, P1947, DOI 10.1084/jem.183.5.1947; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; Budihardjo II, 1998, MOL CELL BIOCHEM, V178, P245, DOI 10.1023/A:1006808001462; Chen J, 1997, J NEUROCHEM, V69, P232; Chopp M, 1996, STROKE, V27, P363, DOI 10.1161/01.STR.27.3.363; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Didier M, 1996, J NEUROSCI, V16, P2238; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GAUBATZ JW, 1994, ANN NY ACAD SCI, V719, P97, DOI 10.1111/j.1749-6632.1994.tb56822.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; LAMARRE D, 1986, BIOCHEM CELL BIOL, V64, P368, DOI 10.1139/o86-051; LAPLACE MC, 1997, J NEUROTRAUM, V14, P785; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI Y, 1995, MOL BRAIN RES, V28, P164, DOI 10.1016/0169-328X(94)00220-9; LINDAHL T, 1995, PHILOS T ROY SOC B, V347, P57, DOI 10.1098/rstb.1995.0009; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lindahl T, 1995, J CELL SCI, P73; LINNIK MD, 1995, MOL BRAIN RES, V32, P116, DOI 10.1016/0169-328X(95)00069-5; Liu PK, 1996, J NEUROSCI, V16, P6795; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; Mandavilli BS, 1996, J NEUROCHEM, V67, P1559; MAZZARELLO P, 1992, J NEUROL SCI, V112, P4, DOI 10.1016/0022-510X(92)90125-5; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NILSSON P, 1990, J CEREB BLOOD FLOW M, V10, P607; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pieper A. A., 1997, Society for Neuroscience Abstracts, V23, P2178; PURNELL MR, 1980, BIOCHEM J, V185, P775, DOI 10.1042/bj1850775; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RAO KS, 1992, MUTAT RES, V275, P317; RINK A, 1995, AM J PATHOL, V147, P1575; ROBBINS JH, 1988, JAMA-J AM MED ASSOC, V260, P384; Rosenthal DS, 1997, EXP CELL RES, V232, P313, DOI 10.1006/excr.1997.3536; Sallmann FR, 1997, BIOCHEM CELL BIOL, V75, P451, DOI 10.1139/bcb-75-4-451; SATOH MS, 1994, CANCER RES, V54, pS1899; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHANRAUFSTATTE.IU, 1986, J CLIN INVEST, V77, P1312; Schwartz LM, 1996, TRENDS NEUROSCI, V19, P555, DOI 10.1016/S0166-2236(96)10067-9; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Soares HD, 1995, J NEUROSCI, V15, P8223; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZHANG J, 1995, J NEUROCHEM, V65, P1411; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	67	78	78	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	1999	73	1					205	213		10.1046/j.1471-4159.1999.0730205.x			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	207PV	WOS:000080946000024	10386972				2022-02-06	
J	Tate, RL; Broe, GA				Tate, RL; Broe, GA			Psychosocial adjustment after traumatic brain injury: what are the important variables?	PSYCHOLOGICAL MEDICINE			English	Article							BLUNT HEAD-INJURY; COGNITIVE RISK-TAKING; TEMPORAL LOBECTOMY; CONSECUTIVE SERIES; FOLLOW-UP; PREDICTORS; IMPAIRMENT; TESTS; INDEPENDENCE; INFORMATION	Background. The common legacy of severe degrees of traumatic brain injury is varying degrees and types of impairments, which impact significantly upon the individual's resumption of pre-morbid psychosocial roles. Yet there are few data to indicate the relative contribution of these and other non-injury related variables. Methods. Seventy individuals with varying levels of disability after severe traumatic brain injury were examined neurologically and neuropsychologically, on average at 6 years post-trauma. A range of biographical, injury, impairment and psychological variables were examined with multiple regression analyses to identify those that contributed to successful psychosocial reintegration. Results. Severity of injury and impairments. along with chronicity and level of self-esteem were significant predictors of psychosocial adjustment. Further analyses revealed that within the neuropsychological domain, the variable measuring behavioural regulation of abilities was the most significant. Examination of specific domains of psychosocial functioning (occupational activities, interpersonal relationships and independent living skills) revealed different patterns of significant predictor variables, in addition to indices of the severity of initial injury: neurophysical impairments and memory functioning predicted successful occupational activities; chronicity, cognitive speed and behavioural regulation predicted success in interpersonal relationships; and neurophysical impairments, behavioural regulation and memory functioning predicted independent living skills. Conclusions. These results reinforce the overriding importance of injury severity and neurological factors (both neurophysical as well as neuropsychological) in predicting psychosocial adjustment after traumatic brain injury. Support for the contribution of non-neurological factors was also found.	Univ Sydney, Dept Med, Rehabil Studies Unit, Royal Rehabil Ctr, Sydney, NSW 2006, Australia; Ctr Educ & Res Aging, Sydney, NSW, Australia		Tate, RL (corresponding author), Univ Sydney, Rehabil Studies Unit, Dept Med, Royal Rehabil Ctr, POB 6, Ryde, NSW 1680, Australia.						ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BOKS N, 1989, BRAIN INJURY, V3, P325; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Coopersmith S., 1981, SEI SELF ESTEEM INVE; CROWE SF, 1992, J CLIN EXP NEUROPSYC, V14, P327, DOI 10.1080/01688639208402832; Daniel A., 1983, POWER PRIVILEGE PRES; DeFilippis NA, 1979, BOOKLET CATEGORY TES; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Folkman S., 1984, STRESS; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Johnstone B, 1996, BRAIN INJURY, V10, P627, DOI 10.1080/026990596124052; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; Luria A.R., 1973, WORKING BRAIN; Luria AR, 1969, HDB CLINICAL NEUROLO, P725; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MILLER L, 1985, NEUROPSYCHOLOGIA, V23, P359, DOI 10.1016/0028-3932(85)90022-3; MILLER L, 1985, NEUROPSYCHOLOGIA, V23, P371, DOI 10.1016/0028-3932(85)90023-5; Milner B., 1964, FRONTAL GRANULAR COR, P313; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Schacter D. L., 1990, NEUROPSYCHOLOGY EVER, P231; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SmithKnapp K, 1996, BRAIN INJURY, V10, P651, DOI 10.1080/026990596124070; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TATE RL, 1989, ACTA NEUROL SCAND, V79, P97, DOI 10.1111/j.1600-0404.1989.tb03719.x; TATE RL, 1999, IN PRESS CORTEX; TATE RL, 1996, INT PERSPECTIVES TRA, P415; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Walsh KW., 1991, UNDERSTANDING BRAIN; [No title captured], DOI DOI 10.1080/09602019108520164	54	78	79	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	0033-2917			PSYCHOL MED	Psychol. Med.	MAY	1999	29	3					713	725		10.1017/S0033291799008466			13	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	205CE	WOS:000080803100021	10405093				2022-02-06	
J	Prins, ML; Hovda, DA				Prins, ML; Hovda, DA			Traumatic brain injury in the developing rat: Effects of maturation on Morris water maze acquisition	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cognition; concussion; development; fluid percussion; Morris water maze	FLUID-PERCUSSION MODEL; HIPPOCAMPAL-FORMATION; SPATIAL LOCALIZATION; BEHAVIORAL DEFICITS; ASSOCIATION CORTEX; CHOLINERGIC SYSTEM; SENSORIMOTOR TESTS; PLACE NAVIGATION; DENTATE GYRUS; FETAL KITTENS	Previous work has demonstrated that postnatal and adult rats show different physiological responses to lateral fluid percussion (FP) brain injury. Compared to adult animals, the younger rats showed longer apnea and shorter unconsciousness, and sustained hypotension at all injury severities, with higher mortality following severe traumatic brain injury (TBI), To determine if these younger rats exhibit differential cognitive impairments, the Morris water maze (MWM) was used to compare the degree of spatial learning deficits between moderately injured postnatal day 17 (P17), P28, and adult rats, as well as their age-matched controls. Comparisons between shams of different ages showed a maturational time course for MWM acquisition, where adult rats learned the task 34-58% faster than younger age groups. Injured adults showed escape latency deficits throughout the entire training period, took 39% fewer direct paths to the platform during training, took 24% longer to reach criterion performance, and showed poor probe trial performance than adult shams, Injured P28s exhibited escape latency deficits during the first week, with 23% more trials to criterion and 24% fewer direct paths compared to P28 shams. In contrast, injured P17 rats showed no significant difference from age-matched controls in terms of escape latency, number of direct paths taken, or time to criterion performance. This work suggests that, upon surviving the insult, P17 injured rats show remarkable sparing compared to P28 and adult injured animals.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Inst Brain Res, Los Angeles, CA 90024 USA		Prins, ML (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Box 980709, Richmond, VA 23298 USA.		Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544] Funding Source: NIH RePORTER		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; COTMAN C, 1973, BRAIN RES, V63, P205, DOI 10.1016/0006-8993(73)90089-9; CRAIN B, 1973, BRAIN RES, V63, P195, DOI 10.1016/0006-8993(73)90088-7; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GOLDMAN PS, 1978, BRAIN RES, V152, P451, DOI 10.1016/0006-8993(78)91103-4; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hovda D.A., 1996, NEUROTRAUMA, P1459; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; Kennard MA, 1936, AM J PHYSIOL, V115, P138, DOI 10.1152/ajplegacy.1936.115.1.138; Kennard MA, 1938, J NEUROPHYSIOL, V1, P477, DOI 10.1152/jn.1938.1.6.477; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; KOLB B, 1993, BEHAV NEUROSCI, V107, P799, DOI 10.1037/0735-7044.107.5.799; KOLB B, 1978, BRAIN RES, V151, P135, DOI 10.1016/0006-8993(78)90956-3; KRAEMER PJ, 1995, PSYCHOBIOLOGY, V23, P144; LEE SM, 1993, SOC NEUR ABSTR, V3, P1882; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MEIBACH RC, 1981, BRAIN RES, V204, P431, DOI 10.1016/0006-8993(81)90603-X; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; Panigrahy A., 1995, Society for Neuroscience Abstracts, V21, P2119; Pike BR, 1997, EXP NEUROL, V147, P55, DOI 10.1006/exnr.1997.6582; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; RAUCH TM, 1989, PHYSIOL BEHAV, V46, P315, DOI 10.1016/0031-9384(89)90273-4; ROSEN GD, 1995, BRAIN RES, V681, P177, DOI 10.1016/0006-8993(95)00312-E; RUDY JW, 1987, BEHAV NEUROSCI, V101, P62, DOI 10.1037/0735-7044.101.1.62; SCHAPIRO S, 1970, SCIENCE, V168, P147, DOI 10.1126/science.168.3927.147; SCHENK F, 1985, BEHAV NEURAL BIOL, V43, P69, DOI 10.1016/S0163-1047(85)91510-9; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; SMITH ML, 1995, J CEREB BLOOD FLOW M, V15, pS723; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TAKANO N, 1979, JPN J PHYSIOL, V29, P173; VANDERWOLF CH, 1978, J COMP PHYSIOL PSYCH, V92, P156, DOI 10.1037/h0077447; VICEDOMINI JP, 1982, PHYSIOL BEHAV, V28, P797, DOI 10.1016/0031-9384(82)90196-2; VILLABLANCA JR, 1993, BEHAV BRAIN RES, V57, P63, DOI 10.1016/0166-4328(93)90062-U; VILLABLANCA JR, 1986, BEHAV BRAIN RES, V19, P205, DOI 10.1016/0166-4328(86)90021-5; VILLABLANCA JR, 1993, BEHAV BRAIN RES, V57, P79, DOI 10.1016/0166-4328(93)90063-V; WHISHAW IQ, 1984, BEHAV BRAIN RES, V11, P123, DOI 10.1016/0166-4328(84)90135-9	54	78	78	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1998	15	10					799	811		10.1089/neu.1998.15.799			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	132LW	WOS:000076632400005	9814636				2022-02-06	
J	Colantonio, A; Dawson, DR; McLellan, BA				Colantonio, A; Dawson, DR; McLellan, BA			Head injury in young adults: Long-term outcome	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; SICKNESS IMPACT PROFILE; FOLLOW-UP; ADOLESCENTS; RECOVERY; SCALE; COMMUNITY; CHILDREN; SEVERITY; LIFE	Objective: To describe the long-term outcome 5 years after injury of young adults who were 15 to 19 years old at the time of their head injuries. Design: A retrospective cohort. The health records of 62 consecutive eligible subjects were abstracted for baseline sociodemographic, health, and injury variables. A telephone interview was administered to assess quality of life, impairment, disability, and handicap. Setting: Canada's largest trauma center, Sunnybrook Health Science Centre, Toronto, Canada. Subjects: Of the 58 subjects (94%) who were traced at follow-up, 51 agreed to participate. Main Outcome Measures: The Medical Outcomes Study SF-36, Head Injury Symptom Checklist, selected disability measures, Community Integration Questionnaire. Results: Of the 8 summary items of the Medical Outcomes Study SF-36, subjects scored lowest on mental health. There were no significant differences between mild and more severely injured groups in all quality of life measures. Subjects classified with mild head injury overall reported more symptoms from the Head Injury Symptom Checklist. Subjects with more severe injuries had lower community integration scores (p < .05). Conclusions: Overall, mental health is an important area of concern at follow-up for all subjects. Adolescents with apparent mild head injury can have disabling symptoms many years after injury. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Toronto, Dept Occupat Therapy, Toronto, ON M5T 1W5, Canada; Univ Toronto, Dept Surg, Toronto, ON M5T 1W5, Canada; Sunnybrook Hlth Sci Ctr, Dept Occupat Therapy, Toronto, ON M4N 3M5, Canada; Sunnybrook Hlth Sci Ctr, Trauma Program, Toronto, ON M4N 3M5, Canada		Colantonio, A (corresponding author), Univ Toronto, Dept Occupat Therapy, 256 McCaul St, Toronto, ON M5T 1W5, Canada.		Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121; Colantonio, Angela/0000-0003-2094-4765			Badley E M, 1993, Disabil Rehabil, V15, P161; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BURKE W H, 1990, Brain Injury, V4, P371, DOI 10.3109/02699059009026190; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; DEJONG G, 1982, ARCH PHYS MED REHAB, V63, P68; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; FAHY TJ, 1967, LANCET, V2, P475; FURRIE A, 1987, NATL DATABASE DISABL; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Hays RD, 1995, USERS MANUAL MED OUT; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KLASBEEK WD, 1980, J NEUROSURG, V53, P519; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P185; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; *NAT HEAD INJ FDN, 1981, SIL EP; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ROBERTS AH, 1976, P ROY SOC MED, V69, P137, DOI 10.1177/003591577606900228; RUSK H A, 1969, Medical Clinics of North America, V53, P677; RUSONIS ES, 1990, MED CLIN N AM, V74, P1311, DOI 10.1016/S0025-7125(16)30518-1; SLATER EJ, 1988, AM J DIS CHILD, V142, P1048, DOI 10.1001/archpedi.1988.02150100042022; SLATER EJ, 1989, J ADOLESCENT HEALTH, V10, P237, DOI 10.1016/0197-0070(89)90240-4; *STAT CAN, 1991, LAB FORC ACT CAT 324; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; TEMKIN NR, 1989, MED CARE, V27, pS44, DOI 10.1097/00005650-198903001-00004; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Ware J.E., 1993, SF 36 HLTH SURVEY MA; WARE JE, 1987, J CHRON DIS, V40, P473; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	42	78	78	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	1998	79	5					550	558		10.1016/S0003-9993(98)90072-7			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	ZM198	WOS:000073514500014	9596398				2022-02-06	
J	An, SF; Giometto, B; Groves, M; Miller, RF; Beckett, AAJ; Gray, F; Tavolato, B; Scaravilli, F				An, SF; Giometto, B; Groves, M; Miller, RF; Beckett, AAJ; Gray, F; Tavolato, B; Scaravilli, F			Axonal damage revealed by accumulation of beta-APP in HIV-positive individuals without AIDS	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						axonal changes; beta-APP; HIV-positive asymptomatic patients; immune activation; neuropsychological disorder; polymerase chain reaction (PCR); reversible	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN INJURY; RAT-BRAIN; HEAD-INJURY; CEREBROSPINAL-FLUID; ENVELOPE PROTEIN; PRE-AIDS; INFECTION; EXPRESSION	The presence of neuropsychological disturbances in HIV-positive, pre-symptomatic individuals is a controversial issue. Neuroimaging studies have not shown brain atrophy or hyperintensity in the white matter, whereas proton magnetic resonance spectroscopy has revealed some abnormality of cerebral biochemistry. Using an antibody to beta-amyloid precursor protein (beta-APP), we previously demonstrated frequent and widespread axonal changes in the brains of AIDS patients. In this study, we extended the use of beta-APP to asymptomatic patients in order to establish a possible morphological correlation with neuropsychological disorders. Brain samples from 29 patients were examined. Results showed bundles of beta-APP-positive axons in 8/29 cases (27%). The changes, seen in both superficial and deep white matter, were either focal or diffuse, could not be visualized by silver or ubiquitin stains, and did not coexist with any change in distribution or morphology of astrocytes and microglial cells. We conclude that in HIV-positive asymptomatic individuals, axonal changes: (a) may be related to the state of immune activation with consequent presence of toxic substances, including cytokines, observed in these patients; (b) may represent mild changes that could undergo repair, unless other pathological events, such as the supervening of the AIDS stage and the specific encephalitis, make them permanent.	INST NEUROL,DEPT NEUROPATHOL,LONDON WC1N 3BG,ENGLAND; UNIV PADUA,NEUROL CLIN 2,PADUA,ITALY; UCL,SCH MED,MORTIMER MARKET CTR,DIV PATHOL & INFECT DIS,DEPT SEXUALLY TRANSMITTED DIS,LONDON WC1E 6AU,ENGLAND; HOP HENRI MONDOR,DEPT NEUROPATHOL,F-94010 CRETEIL,FRANCE				Giometto, Bruno/AAG-3236-2019	giometto, bruno/0000-0003-2311-9752; Miller, Robert/0000-0003-2067-4291			An SF, 1996, ACTA NEUROPATHOL, V91, P169, DOI 10.1007/s004010050409; An SF, 1996, ANN NEUROL, V40, P611, DOI 10.1002/ana.410400411; AN SF, 1994, J CLIN PATHOL, V47, P990, DOI 10.1136/jcp.47.11.990; An SF, 1996, ACTA NEUROPATHOL, V91, P494, DOI 10.1007/s004010050457; BORNSTEIN RA, 1993, AIDS, V7, P1607, DOI 10.1097/00002030-199312000-00010; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; BRENNEMAN DE, 1990, SOC NEUR ABSTR, V16, P615; BUZY J, 1992, BRAIN RES, V598, P10, DOI 10.1016/0006-8993(92)90161-2; CHONG WK, 1994, AM J NEURORADIOL, V15, P21; CHONG WK, 1993, RADILOGY, V43, P509; COCHRAN E, 1991, AM J PATHOL, V139, P485; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GIANGASPERO F, 1988, ARCH PATHOL LAB MED, V112, P1259; Giometto B, 1997, ANN NEUROL, V42, P34, DOI 10.1002/ana.410420108; GLASS JD, 1993, NEUROLOGY, V43, P2230, DOI 10.1212/WNL.43.11.2230; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828; GRAY F, 1992, J NEUROPATH EXP NEUR, V51, P177, DOI 10.1097/00005072-199203000-00007; HARRISON MJG, 1995, AIDS NEUROLOGY, P31; HAYES RL, 1991, J NEUROTRAUM, V8, pS173; HO DD, 1985, NEW ENGL J MED, V313, P1493, DOI 10.1056/NEJM198512123132401; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KAISER PK, 1990, NEUROLOGY, V40, P1757, DOI 10.1212/WNL.40.11.1757; KARLSEN NR, 1992, ACTA NEUROL SCAND, V86, P242, DOI 10.1111/j.1600-0404.1992.tb05078.x; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; Lipton SA, 1991, BRAIN PATHOL, V1, P193, DOI 10.1111/j.1750-3639.1991.tb00659.x; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; NEWTON TF, 1994, CLIN ELECTROENCEPHAL, V25, P18, DOI 10.1177/155005949402500107; NUWER MR, 1992, NEUROLOGY, V42, P1214, DOI 10.1212/WNL.42.6.1214; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PANLILIO L V, 1990, Society for Neuroscience Abstracts, V16, P1330; PERT C B, 1989, Society for Neuroscience Abstracts, V15, P1387; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pittaluga A, 1996, AIDS, V10, P463, DOI 10.1097/00002030-199605000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Price RW, 1991, BRAIN PATHOL, V1, P155, DOI 10.1111/j.1750-3639.1991.tb00655.x; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; SCARAVILLI F, 1993, NEUROPATHOLOGY HIV I, P99; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TENHULA WN, 1992, AM J OPHTHALMOL, V113, P14, DOI 10.1016/S0002-9394(14)75746-0; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; VIONDURY J, 1995, LANCET, V345, P60, DOI 10.1016/S0140-6736(95)91184-7; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; Wilkinson ID, 1997, AIDS, V11, P289, DOI 10.1097/00002030-199703110-00005; WILKINSON ID, 1997, IN PRESS J NEUROL NE; WILT SG, 1995, ANN NEUROL, V37, P381, DOI 10.1002/ana.410370315; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S	55	78	80	0	1	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	NOV	1997	56	11					1262	1268		10.1097/00005072-199711000-00011			7	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	YG291	WOS:A1997YG29100011	9370237	Bronze			2022-02-06	
J	Eclancher, F; Kehrli, P; Labourdette, G; Sensenbrenner, M				Eclancher, F; Kehrli, P; Labourdette, G; Sensenbrenner, M			Basic fibroblast growth factor (bFGF) injection activates the glial reaction in the injured adult rat brain	BRAIN RESEARCH			English	Article						brain injury; astrocyte; glial fibrillary acidic protein; glial fibrillary acidic protein mRNA; basic fibroblast growth factor; rat	FIBRILLARY ACIDIC PROTEIN; FACTOR-LIKE IMMUNOREACTIVITY; MOUSE CEREBRAL-CORTEX; MESSENGER-RNA; CELL-PROLIFERATION; ASTROGLIAL RESPONSE; NERVOUS-SYSTEM; STAB WOUNDS; CNS INJURY; FACTOR FGF	Reactive gliosis is a reaction of glial cells to trauma which is characterized by a phenotypic modification of astrocytes, as well as by a proliferation and a migration of some of these cells to form a glial scar. This scar is currently considered as a physical impediment to neuronal regrowth but it may also be involved in wound healing since the astrocytes beside microglia play a phagocytic role in the clearance of post-traumatic debris. Growth factors are released in the area of the injury and at least some of them could be involved in gliosis. In order to test directly this possibility, we have injected one of them, the basic fibroblast growth factor (bFGF), into several brain areas (cortex, striatum, hippocampus or corpus calIosum) of adult 2-month-old rats in the absence of lesion. A glial reaction was observed after 3 days and was maximum after 7 days. It was characterized by an increase in astrocyte proliferation and in glial fibrillary acidic protein (GFAP) expression, resulting in a higher number of GFAP-positive cells per surface unit, and by an increase in the size and branching of the astroglial processes. The GFAP mRNA levels were also strongly increased following the bFGF injection. These effects resemble the reactive gliosis observed after lesion and suggest that bFGF is actually involved in the triggering of glial reactions which follow brain injury. In further experiments, bFGF was injected in the site of electrolytic lesions made in the same various parts of the brain. These injections did not increase significantly the normal reactive gliosis induced by the lesion alone, but it accelerated some of the effects. It also resulted in a higher labeling index and GFAP mRNA levels were strongly enhanced after a 3-day-post-operative delay. This last observation strengthens the idea that one of the main factors driving the astrogliosis is the bFGF normally released in and around the site of the lesion.			Eclancher, F (corresponding author), CNRS,CTR NEUROCHIM,LAB NEUROBIOL ONTOGEN,5 RUE BLAISE PASCAL,F-67084 STRASBOURG,FRANCE.						ADRIAN EK, 1978, J COMP NEUROL, V180, P815, DOI 10.1002/cne.901800412; AMADUCCI L, 1981, NEUROSCI LETT, V21, P27, DOI 10.1016/0304-3940(81)90052-5; AQUINO DA, 1988, J NEUROCHEM, V51, P1085, DOI 10.1111/j.1471-4159.1988.tb03072.x; BAKHIT C, 1991, BRAIN RES, V560, P76, DOI 10.1016/0006-8993(91)91217-O; BARRETT CP, 1984, EXP NEUROL, V84, P374, DOI 10.1016/0014-4886(84)90234-6; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BIGNAMI A, 1977, J HISTOCHEM CYTOCHEM, V25, P466, DOI 10.1177/25.6.69656; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BILLINGSLEY ML, 1982, BRAIN RES, V247, P325, DOI 10.1016/0006-8993(82)91257-4; BOCHELEN D, 1992, NEUROSCIENCE, V51, P827, DOI 10.1016/0306-4522(92)90523-5; CADAY CG, 1990, DEV BRAIN RES, V52, P241, DOI 10.1016/0165-3806(90)90240-Y; CAVANAGH JB, 1970, J ANAT, V106, P471; CINTRA A, 1991, NEUROREPORT, V2, P597, DOI 10.1097/00001756-199110000-00011; CONDORELLI DF, 1989, METAB BRAIN DIS, V4, P41, DOI 10.1007/BF00999492; CONDORELLI DF, 1990, J NEUROSCI RES, V26, P251, DOI 10.1002/jnr.490260216; DUBOIS M, 1985, CELL TISSUE RES, V242, P17, DOI 10.1007/BF00225558; DUSART I, 1991, NEUROSCIENCE, V45, P541, DOI 10.1016/0306-4522(91)90269-T; ECLANCHER F, 1990, GLIA, V3, P502, DOI 10.1002/glia.440030609; ENG LF, 1982, ADV CELL NEUROBIOL, V3, P145; ERNFORS P, 1990, J NEUROSCI RES, V27, P10, DOI 10.1002/jnr.490270103; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; GAGE FH, 1988, EXP NEUROL, V102, P2, DOI 10.1016/0014-4886(88)90073-8; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; GROTHE C, 1991, J COMP NEUROL, V305, P328, DOI 10.1002/cne.903050213; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HERRERA DG, 1992, NEUROSCIENCE, V49, P781, DOI 10.1016/0306-4522(92)90356-7; HOMMES OR, 1967, J COMP NEUROL, V129, P269, DOI 10.1002/cne.901290304; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; HOZUMI I, 1990, BRAIN RES, V534, P291, DOI 10.1016/0006-8993(90)90142-X; KALMAN M, 1989, EXP BRAIN RES, V78, P147; KITAMURA T, 1980, PATHOL RES PRACT, V168, P301, DOI 10.1016/S0344-0338(80)80271-8; KITAMURA T, 1978, ACTA NEUROPATHOL, V44, P31, DOI 10.1007/BF00691636; KIYOTA Y, 1991, BRAIN RES, V545, P322, DOI 10.1016/0006-8993(91)91307-M; KONIGSMARK BW, 1965, J NEUROPATH EXP NEUR, V24, P142; KORR H, 1975, J COMP NEUROL, V160, P477, DOI 10.1002/cne.901600405; KOTHAVALE A, 1995, GLIA, V14, P216, DOI 10.1002/glia.440140307; KRAUSRUP.R, 1973, J COMP NEUROL, V148, P211, DOI 10.1002/cne.901480206; LABOURDETTE G, 1990, J CELL PHYSIOL, V144, P473, DOI 10.1002/jcp.1041440315; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOGAN A, 1986, NEUROSCI LETT, V69, P162, DOI 10.1016/0304-3940(86)90596-3; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; LUDWIN SK, 1985, LAB INVEST, V52, P20; MATSUYAMA A, 1992, BRAIN RES, V587, P49, DOI 10.1016/0006-8993(92)91427-G; MCCARTHY GF, 1988, J COMP NEUROL, V271, P589, DOI 10.1002/cne.902710409; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; MIYAKE T, 1989, BRAIN RES, V489, P31, DOI 10.1016/0006-8993(89)90005-X; MORI S, 1969, J COMP NEUROL, V137, P197, DOI 10.1002/cne.901370206; MORSHEAD CM, 1990, BRAIN RES, V535, P237, DOI 10.1016/0006-8993(90)91606-H; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V91, P276, DOI 10.1016/0304-3940(88)90693-3; NIETOSAMPEDRO M, 1985, BRAIN RES, V343, P320, DOI 10.1016/0006-8993(85)90750-4; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; PATERSON JA, 1973, J COMP NEUROL, V149, P83, DOI 10.1002/cne.901490106; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; PETTMANN B, 1985, FEBS LETT, V189, P102, DOI 10.1016/0014-5793(85)80851-6; PETTMANN B, 1986, NEUROSCI LETT, V68, P175, DOI 10.1016/0304-3940(86)90137-0; PRESTA M, 1988, NEUROSCI LETT, V90, P608; RIVA MA, 1991, DEV BRAIN RES, V62, P45, DOI 10.1016/0165-3806(91)90188-O; ROSE G, 1976, BRAIN RES BULL, V1, P87, DOI 10.1016/0361-9230(76)90052-6; SHEHAB SAS, 1990, BRAIN RES, V518, P347, DOI 10.1016/0006-8993(90)90996-O; SKOFF RP, 1971, J COMP NEUROL, V141, P133, DOI 10.1002/cne.901410202; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TAKAMIYA Y, 1986, BRAIN RES, V383, P305, DOI 10.1016/0006-8993(86)90029-6; TREHERNE JE, 1988, CELL TISSUE RES, V251, P339, DOI 10.1007/BF00215842; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; WESTERMARK B, 1976, BIOCHEM BIOPH RES CO, V69, P304, DOI 10.1016/0006-291X(76)90522-2; YAMAGUCHI F, 1991, NEUROSCI LETT, V128, P273, DOI 10.1016/0304-3940(91)90278-2	72	78	80	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 21	1996	737	1-2					201	214		10.1016/0006-8993(96)00732-9			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VR614	WOS:A1996VR61400024	8930367				2022-02-06	
J	STABLUM, F; LEONARDI, G; MAZZOLDI, M; UMILTA, C; MORRA, S				STABLUM, F; LEONARDI, G; MAZZOLDI, M; UMILTA, C; MORRA, S			ATTENTION AND CONTROL DEFICITS FOLLOWING CLOSED-HEAD INJURY	CORTEX			English	Article							SUSTAINED ATTENTION; RECOVERY; TASK	This study was aimed at identifying the impaired attentional components in patients who had sustained a severe CHI several years before. A group of 14 CHI patients and a Control group (matched for age, sex and education) were tested. Experiment 1 used a dual-task paradigm (Umilta et al., 1992). The double task-single task difference was greater for the CHI group, indicating a specific damage at a central executive stage where decision are made and responses are coordinated. Experiment 2 used a task-shifting paradigm (Morra and Roncato, 1986). The cost of shifting from one task to the other was greater for the CHI group, but only in the Short Series Condition where a new task-program could be pre-activated. Experiment 3 studied visual selective attention using Navon paradigm (1977); in this case, there was no difference between patients and controls.	UNIV TRIESTE,DIPARTIMENTO PSICOL,TRIESTE,ITALY; OSPED GEN BOLZANO,SERV PSICOL,BOLZANO,ITALY; UNIV CAGLIARI,IST PSICOL,CAGLIARI,ITALY		STABLUM, F (corresponding author), UNIV PADUA,DIPARTIMENTO PSICOL GEN,PIAZZA CAPITANIATO 3,I-35139 PADUA,ITALY.		Morra, Sergio/ABF-7487-2020; Leonardi, Giuseppe/F-9052-2018; Leonardi, Giuseppe/S-4088-2019	Stablum, Franca/0000-0003-0123-5090; MORRA, SERGIO/0000-0001-8537-181X; Leonardi, Giuseppe/0000-0003-0159-4851			Allport A., 1989, FDN COGNITIVE SCI, P631; BIRREN JE, 1974, AM PSYCHOL, V29, P808, DOI 10.1037/h0037433; BOOKS N, 1987, BRAIN INJURY, V1, P5; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; BUCHTEL HA, 1987, NEUROBEHAVIORAL RECO, P372; CERELLA J, 1991, J EXP PSYCHOL GEN, V120, P215, DOI 10.1037/0096-3445.120.2.215; CERELLA J, 1985, PSYCHOL BULL, V98, P67, DOI 10.1037/0033-2909.98.1.67; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; Davies DR., 1982, PSYCHOL VIGILANCE; DELIS DC, 1986, NEUROPSYCHOLOGIA, V24, P205, DOI 10.1016/0028-3932(86)90053-9; DENKER SJ, 1958, ACTA PSYCHIATRICA S, V33, P122; DOYON J, 1991, NEUROPSYCHOLOGIA, V29, P343, DOI 10.1016/0028-3932(91)90024-3; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FOOTE SL, 1987, ANNU REV NEUROSCI, V10, P67, DOI 10.1146/annurev.ne.10.030187.000435; GENTILINI M, 1989, MILD HEAD INJURY, P163; GOLDBERG E, 1989, CORTEX, V25, P687, DOI 10.1016/S0010-9452(89)80029-2; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GRONWALL DMA, 1981, J NEUROL NEUROSUR PS, V44, P880; HARTLEY AA, 1991, HDB AGING COGNITION, P3; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1975, J NEUROL NEUROSUR PS, V39, P647; JOHNSTON WA, 1986, ANNU REV PSYCHOL, V37, P43, DOI 10.1146/annurev.ps.37.020186.000355; KAIL R, 1991, ADV CHILD DEV BEHAV, P151; LAMB MR, 1988, NEUROPSYCHOLOGIA, V27, P471; LEVIN HS, 1988, BRAIN COGNITION, V7, P283, DOI 10.1016/0278-2626(88)90003-6; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2d; Miller E, 1970, Cortex, V6, P121; MORRA S, 1988, GIORNALE ITALIANO PS, V15, P101; MORRA S, 1986, 4 C DIV SIPS RIC BAS, P193; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; NEWCOMBE F, 1979, HDB BEHAVIORAL NEURO, V2; Norman D., 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Parasuraman R, 1984, VARIETIES ATTENTION; PASCUALLEONE J, 1987, INT J PSYCHOL, V22, P531, DOI 10.1080/00207598708246795; Posner JB., 1980, DIAGNOSIS STUPOR COM, V3; POSNER MI, 1985, ATTENTION PERFORMANC, V11; Prigatano GP, 1985, NEUROPSYCHOLOGICAL R; ROBERTSON LC, 1988, J NEUROSCI, V8, P3757; Salthouse TA, 1985, THEORY COGNITIVE AGI, V28th; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SPINNLER H, 1987, ITALIAN J NEUROLOGIC; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TEASDALE G, 1974, LANCET, V13, P81; UMILTA C, 1992, EUR J COGN PSYCHOL, V4, P21, DOI 10.1080/09541449208406241; Umilta C, 1988, HDB NEUROPSYCHOLOGY, P175; Umilta C., 1988, CONSCIOUSNESS CONT S, P334; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P, P75; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P41	58	78	78	0	8	MASSON DIVISIONE PERIODICI	MILAN	VIA STATUTO 2/4, 20121 MILAN, ITALY	0010-9452			CORTEX	Cortex	DEC	1994	30	4					603	618		10.1016/S0010-9452(13)80238-9			16	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	PY931	WOS:A1994PY93100004	7697987				2022-02-06	
J	LEVY, ML; MASRI, LS; LAVINE, S; APUZZO, MLJ				LEVY, ML; MASRI, LS; LAVINE, S; APUZZO, MLJ			OUTCOME PREDICTION AFTER PENETRATING CRANIOCEREBRAL INJURY IN A CIVILIAN POPULATION - AGGRESSIVE SURGICAL-MANAGEMENT IN PATIENTS WITH ADMISSION GLASGOW-COMA-SCALE OF SCORE-3, SCORE-4, OR SCORE-5	NEUROSURGERY			English	Article						HEAD INJURY; OUTCOME; PENETRATING CRANIOCEREBRAL INJURY	GUNSHOT WOUNDS; LEBANESE CONFLICT; MISSILE INJURIES; HEAD-INJURY; DATA-BANK; BRAIN	In an attempt to evaluate the response of patients who have low admission Glasgow Coma Scale scores (CCS) after a penetrating craniocerebral injury to aggressive management, we evaluated a series of 190 patients with penetrating injuries who presented with a GCS score of 3, 4, or 5 during a 6-year period. Entrance criteria required replicable neurological examinations that were not altered by the presence of hypotension, drugs/toxins, or systemic injury. The surgical patients included 21 patients with an admission CCS score of 3, 24 with an admission GCS score of 4, and 15 with an admission CCS score of 5. All patients underwent surgical intervention and aggressive perioperative management in the neurosurgical intensive care, including resuscitative protocols. Five of the patients with a CCS score of 3 survived, all with poor outcomes. Seven of the patients with a GCS score of 4 survived, although only one had a good outcome. Eleven of the patients with a GCS score of 5 survived. Five had a Glasgow Outcome Score of 2, five had a Glasgow Outcome Score of 3, and one had a Glasgow Outcome Score of 4. We have devised a prospective model of outcome based on our series in an attempt to predict nonsurvivors at admission (while overpredicting for survivors). The variables most predictive of mortality include admission GCS score and subarachnoid hemorrhage in one model and admission CCS score and pupillary changes in a second, when pupillary response was definitive at admission (P less than or equal to 0.00005). Important variables most predictive of morbidity include admission GCS score, bihemispheric injury when associated with intraventricular hemorrhage, and diffuse fragmentation (P < 0.001). It should be noted that disseminated intravascular coagulation was not included in our model. Disseminated intravascular coagulation was always associated with poor outcome when present in any traumatic injury. In considering outcome, we conclude that patients with admission GCS scores of 3, 4, or 5 are not likely to benefit (have a good outcome) from surgical intervention. Patients presenting with admission GCS scores of 3, 4, or 5 without radiological evidence of subarachnoid hemorrhage, ventricular involvement, or fragmentation in the presence of reactive pupils potentially should be followed more closely. We will continue to expand our series to define those prognostic variables that suggest good outcome in patients with GCS scores of 5 or higher.	UNIV SO CALIF, SCH MED, DEPT NEUROL SURG, LOS ANGELES, CA 90033 USA								AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BRANDT F, 1983, NEUROCHIRURGIA, V26, P164; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; CAVALIERE R, 1988, ACTA NEUROCHIR, V94, P133, DOI 10.1007/BF01435866; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; HELLING TS, 1992, J TRAUMA, V32, P398, DOI 10.1097/00005373-199203000-00019; KAUFMAN HH, 1991, SURG NEUROL, V36, P370, DOI 10.1016/0090-3019(91)90026-6; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1983, ACTA NEUROCHIR, V67, P115, DOI 10.1007/BF01401671; KAUFMAN HH, 1991, NEUROSURGERY, V29, P479; LEVI L, 1990, ISRAEL J MED SCI, V26, P548; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; MANCAL P, 1988, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V32, P189; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; ONUBA O, 1987, ARCH EMERG MED, V4, P73; SELDEN BS, 1988, ANN EMERG MED, V17, P247, DOI 10.1016/S0196-0644(88)80117-3; SHAFFREY ME, 1991, AM ASS NEUROLOGICAL; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; SUDDABY L, 1987, CAN J NEUROL SCI, V14, P268, DOI 10.1017/S0317167100026597; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007; TAHA JM, 1991, NEUROSURGERY, V29, P864, DOI 10.1227/00006123-199112000-00010	26	78	82	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	1994	35	1					77	84		10.1227/00006123-199407000-00012			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	NV277	WOS:A1994NV27700034	7936156				2022-02-06	
J	BROOKE, MM; PATTERSON, DR; QUESTAD, KA; CARDENAS, D; FARRELROBERTS, L				BROOKE, MM; PATTERSON, DR; QUESTAD, KA; CARDENAS, D; FARRELROBERTS, L			THE TREATMENT OF AGITATION DURING INITIAL HOSPITALIZATION AFTER TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						AGITATION; BRAIN INJURY; PROPRANOLOL	PROPRANOLOL; BEHAVIOR	Agitation after traumatic brain injury is disruptive for patient care, distressing, and difficult to treat. The use of propranolol has been advocated to control agitation after brain injury. It reportedly lacks some of the deleterious cognitive and emotional effects of other medications and physical restraints. This study was designed to test if propranolol is effective in reducing agitated behavior. Subjects had traumatic closed-head injury treated at a combined Level I Trauma Center and Rehabilitation Center. Twenty-one subjects met the criteria of agitation and were treated with propranolol or placebo in a double-blind fashion. The intensity of agitation was significantly lower in the treatment group although the number of episodes were similar. The use of restraints was also significantly lower in the treatment group. The results support the effectiveness of propranolol in reducing the intensity of agitation during the initial hospitalization after closed-head injury.	UNIV WASHINGTON,SCH MED,SEATTLE,WA 98195		BROOKE, MM (corresponding author), TUFTS UNIV,SCH MED,DEPT REHABIL MED,136 HARRISON AVE,BOSTON,MA 02111, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR49-002570] Funding Source: Medline		BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; COLE J O, 1979, Mclean Hospital Journal, V4, P40; ELLIOTT FA, 1977, ANN NEUROL, V1, P489, DOI 10.1002/ana.410010516; GREENDYKE RM, 1986, J NERV MENT DIS, V174, P290, DOI 10.1097/00005053-198605000-00005; JOHNSON G, 1976, MED J AUSTRALIA, V1, P909, DOI 10.5694/j.1326-5377.1976.tb141167.x; PETRIE WM, 1981, LANCET, V1, P324; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; SWONGER AK, 1983, DRUGS THERAPY HDB PS, P305; Tyer PJ, 1975, BMJ-BRIT MED J, V2, P14; WHITLOCK FA, 1974, DRUGS, V8, P109, DOI 10.2165/00003495-197408020-00004; YEOH PN, 1968, J PHARM SCI, V57, P340, DOI 10.1002/jps.2600570227; YORKSTON NJ, 1974, BRIT MED J, V4, P633, DOI 10.1136/bmj.4.5945.633; YOUNG RR, 1975, NEW ENGL J MED, V293, P950, DOI 10.1056/NEJM197511062931902; YUDOFSKY S, 1981, AM J PSYCHIAT, V138, P218; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; 1985, LANCET, V8448, P193	16	78	79	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1992	73	10					917	921					5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	JU061	WOS:A1992JU06100005	1417466				2022-02-06	
J	Zyryanova, AF; Weis, F; Faille, A; Alard, AA; Crespillo-Casado, A; Sekine, Y; Harding, HP; Allen, F; Parts, L; Fromont, C; Fischer, PM; Warren, AJ; Ron, D				Zyryanova, Alisa F.; Weis, Felix; Faille, Alexandre; Alard, Akeel Abo; Crespillo-Casado, Ana; Sekine, Yusuke; Harding, Heather P.; Allen, Felicity; Parts, Leopold; Fromont, Christophe; Fischer, Peter M.; Warren, Alan J.; Ron, David			Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B	SCIENCE			English	Article							PHOSPHORYLATION; MUTATIONS	The integrated stress response (ISR) is a conserved translational and transcriptional program affecting metabolism, memory, and immunity. The ISR is mediated by stress-induced phosphorylation of eukaryotic translation initiation factor 2a (eIF2a) that attenuates the guanine nucleotide exchange factor eIF2B. A chemical inhibitor of the ISR, ISRIB, reverses the attenuation of eIF2B by phosphorylated eIF2a, protecting mice from neurodegeneration and traumatic brain injury. We describe a 4.1-angstrom-resolution cryo-electron microscopy structure of human eIF2B with an ISRIB molecule bound at the interface between the b and d regulatory subunits. Mutagenesis of residues lining this pocket altered the hierarchical cellular response to ISRIB analogs in vivo and ISRIB binding in vitro. Our findings point to a site in eIF2B that can be exploited by ISRIB to regulate translation.	[Zyryanova, Alisa F.; Weis, Felix; Faille, Alexandre; Crespillo-Casado, Ana; Sekine, Yusuke; Harding, Heather P.; Warren, Alan J.; Ron, David] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England; [Weis, Felix; Faille, Alexandre; Warren, Alan J.] Univ Cambridge, Dept Haematol, Cambridge, England; [Weis, Felix; Faille, Alexandre; Warren, Alan J.] Univ Cambridge, Wellcome Trust Med Res Council Stem Cell Inst, Cambridge, England; [Weis, Felix; Warren, Alan J.] MRC, Mol Biol Lab, Francis Crick Ave, Cambridge CB2 0QH, England; [Alard, Akeel Abo; Fromont, Christophe; Fischer, Peter M.] Univ Nottingham, Sch Pharm, Div Biomol Sci & Med Chem, Nottingham NG7 2RD, England; [Allen, Felicity; Parts, Leopold] Wellcome Trust Sanger Inst, Wellcome Genome Campus, Hinxton CB10 1SA, Cambs, England		Zyryanova, AF; Warren, AJ; Ron, D (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England.; Warren, AJ (corresponding author), Univ Cambridge, Dept Haematol, Cambridge, England.; Warren, AJ (corresponding author), Univ Cambridge, Wellcome Trust Med Res Council Stem Cell Inst, Cambridge, England.; Warren, AJ (corresponding author), MRC, Mol Biol Lab, Francis Crick Ave, Cambridge CB2 0QH, England.	az310@cam.ac.uk; ajw1000@cam.ac.uk; dr360@medschl.cam.ac.uk	; Allen, Felicity/K-8688-2016	Parts, Leopold/0000-0002-2618-670X; Ron, David/0000-0002-3014-5636; Weis, Felix/0000-0002-8137-3532; Allen, Felicity/0000-0002-8694-3936; Harding, Heather P/0000-0002-7359-7974; Sekine, Yusuke/0000-0003-0345-1416; Fromont, Christophe/0000-0002-7295-6023	Wellcome TrustWellcome TrustEuropean Commission [200848/Z/16/Z, 100140]; Specialist Programme from Bloodwise [12048]; UK Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_U105161083]; Higher Committee for Education Development, Iraq [4241047]; Royal Commission for the Exhibition of 1851; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/L003368/1, MC_U105161083] Funding Source: UKRI	We acknowledge funding by a Wellcome Trust Principal Research Fellowship (Wellcome 200848/Z/16/Z) to D.R.; a Specialist Programme from Bloodwise (12048), the UK Medical Research Council (MC_U105161083), and core support from the Wellcome Trust Medical Research Council Cambridge Stem Cell Institute to A.J.W.; and a Wellcome Trust Strategic Award to the Cambridge Institute for Medical Research (Wellcome 100140). Support from A Higher Committee for Education Development, Iraq, Scholarship (4241047) to A. A. A. and a Research Fellowship from Royal Commission for the Exhibition of 1851 to F.A. is greatly appreciated.	Bogorad AM, 2017, NUCLEIC ACIDS RES, V45, P11962, DOI 10.1093/nar/gkx845; Chou A, 2017, P NATL ACAD SCI USA, V114, pE6420, DOI 10.1073/pnas.1707661114; CLEMENS MJ, 1982, NATURE, V296, P93, DOI 10.1038/296093a0; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P3208, DOI 10.1128/MCB.14.5.3208; Halliday M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.49; Hearn BR, 2016, CHEMMEDCHEM, V11, P870, DOI 10.1002/cmdc.201500483; Kashiwagi K, 2016, NATURE, V531, P122, DOI 10.1038/nature16991; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Sekine Y, 2015, SCIENCE, V348, P1027, DOI 10.1126/science.aaa6986; Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.07314; Sidrauski C, 2013, ELIFE, V2, DOI 10.7554/eLife.00498; SIEKIERKA J, 1981, P NATL ACAD SCI-BIOL, V78, P220, DOI 10.1073/pnas.78.1.220; Tsai JC, 2018, SCIENCE, V359, P1483, DOI 10.1126/science.aaq0939	15	77	79	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 30	2018	359	6383					1533	1536		10.1126/science.aar5129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA9JI	WOS:000428657000048	29599245	Green Accepted, Green Submitted			2022-02-06	
J	Dikmen, S; Machamer, J; Temkin, N				Dikmen, Sureyya; Machamer, Joan; Temkin, Nancy			Mild Traumatic Brain Injury: Longitudinal Study of Cognition, Functional Status, and Post-Traumatic Symptoms	JOURNAL OF NEUROTRAUMA			English	Article						cognition; control group; Glasgow Outcome Scale; mild traumatic brain injury; post-traumatic symptoms	HEAD-INJURY; RECOVERY; OUTCOMES; PREVENTION; CONCUSSION; PHENYTOIN; VALPROATE; ACCURACY; MEMORY	More than 75% of traumatic brain injuries (TBIs) seeking medical attention are mild, and outcome in that group is heterogeneous. Until sensitive and valid biomarkers are identified, methods are needed to classify mild TBI into more homogeneous subgroups. Four hundred twenty-one adults with mild TBI were divided into groups based on Glasgow Coma Scale (GCS) 13-15 without computed tomography (CT) abnormalities, GCS 15 with CT abnormalities, and GCS 13-14 with CT abnormalities, and were compared with 120 trauma controls on 1-month and 1-year outcomes. At 1 month post-injury, almost all neuropsychological variables differed significantly among the groups. Compared with trauma controls, the GCS 13-15 CT normal group showed no significant differences on any neuropsychological measure or Glasgow Outcome Scale (GOS). The GCS 15 CT abnormal group performed significantly worse on only a measure of episodic memory and learning (Selective Reminding Recall [SRCL]) and GOS, and the GCS 13-14 CT abnormal group performed significantly worse on most neuropsychological measures and GOS. At 1 year post-injury, except for an isolated difficulty on SRCL in the GCS 13-14 CT abnormal group, no differences were observed on any neuropsychological measures nor on GOS. Mean percent of total post-traumatic symptoms endorsed as new or worse and percent endorsing three or more symptoms differed significantly (p < 0.001), with each TBI subgroup reporting significantly more symptoms than the trauma controls at both 1 month and 1 year. In conclusion, this subgrouping improves granularity within mild TBI. While most neuropsychological and functional differences abate by 1 year, reporting three or more posttraumatic symptoms remain for about half of individuals.	[Dikmen, Sureyya; Machamer, Joan; Temkin, Nancy] Univ Washington, Dept Rehabil Med, Box 359612,325 Ninth Ave, Seattle, WA 98104 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Dikmen, Sureyya; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA		Machamer, J (corresponding author), Univ Washington, Dept Rehabil Med, Box 359612,325 Ninth Ave, Seattle, WA 98104 USA.	machamer@u.washington.edu			NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS19643]; DoDUnited States Department of Defense [W81XWH-14-2-0176]; NIDILRRUnited States Department of Health & Human Services [90-DP-0031];  [U01NS086090];  [HS04146];  [HS05304]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643, U01NS086090] Funding Source: NIH RePORTER	This work was supported by grants U01NS086090, HS04146, HS05304, NIH-NINDS R01NS19643, DoD W81XWH-14-2-0176, and NIDILRR 90-DP-0031.	Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Faul M, 2010, TRAUMATIC BRAIN INJU; Jaiswal MK, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00148; JENNETT B, 1975, LANCET, V1, P480; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus JF, 2014, BRAIN INJURY, V28, P1248, DOI 10.3109/02699052.2014.916420; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Losoi H, 2016, J NEUROTRAUM, V33, P766, DOI 10.1089/neu.2015.4070; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Papoutsis J, 2014, DEV NEUROPSYCHOL, V39, P638, DOI 10.1080/87565641.2014.979926; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Wang KKW, 2016, J NEUROTRAUM, V33, P1270, DOI 10.1089/neu.2015.3881; Wechsler D., 1955, MANUAL WECHSLER ADUL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wolfson, 1993, HALSTEAD REITAN NEUR	39	77	78	1	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2017	34	8					1524	1530		10.1089/neu.2016.4618			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ES1ZM	WOS:000399325500003	27785968	Green Published			2022-02-06	
J	Kim, CC; Nakamura, MC; Hsieh, CL				Kim, Charles C.; Nakamura, Mary C.; Hsieh, Christine L.			Brain trauma elicits non-canonical macrophage activation states	JOURNAL OF NEUROINFLAMMATION			English	Article						Innate immunity; Macrophage; Monocyte; Traumatic brain injury; Single-cell RNA sequencing; Neuroinflammation; RNA flow cytometry; Polarization; Neurotrauma; Myeloid cells	ALTERNATIVE ACTIVATION; INJURY; INFLAMMATION; CCR2; POLARIZATION; HETEROGENEITY; MICROGLIA; DIVERSITY; RESPONSES; PATHWAYS	Background: Macrophage polarization programs, commonly referred to as "classical" and "alternative" activation, are widely considered as distinct states that are exclusive of one another and are associated with different functions such as inflammation and wound healing, respectively. In a number of disease contexts, such as traumatic brain injury (TBI), macrophage polarization influences the extent of pathogenesis, and efforts are underway to eliminate pathogenic subsets. However, previous studies have not distinguished whether the simultaneous presence of both classical and alternative activation signatures represents the admixture of differentially polarized macrophages or if they have adopted a unique state characterized by components of both classical and alternative activation. Methods: We analyzed the gene expression profiles of individual monocyte-derived brain macrophages responding to TBI using single-cell RNA sequencing. RNA flow cytometry was used as another single-cell analysis technique to validate the single-cell RNA sequencing results. Results: The analysis of signature polarization genes by single-cell RNA sequencing revealed the presence of diverse activation states, including M(IL4), M(IL10), and M(LPS, IFN gamma). However, the expression of a given polarization marker was no more likely than at random to predict simultaneous expression or repression of markers of another polarization program within the same cell, suggesting a lack of exclusivity in macrophage polarization states in vivo in TBI. Also unexpectedly, individual TBI macrophages simultaneously expressed high levels of signature polarization genes across two or three different polarization states and in several distinct and seemingly incompatible combinations. Conclusions: Single-cell gene expression profiling demonstrated that monocytic macrophages in TBI are not comprised of distinctly polarized subsets but are uniquely and broadly activated. TBI macrophage activation in vivo is deeply complex, with individual cells concurrently adopting both inflammatory and reparative features with a lack of exclusivity. These data provide physiologically relevant evidence that the early macrophage response to TBI is comprised of novel activation states that are discordant with the current paradigm of macrophage polarization-a key consideration for therapeutic modulation.	[Nakamura, Mary C.; Hsieh, Christine L.] Univ Calif San Francisco, Dept Med, Div Rheumatol, 4150 Clement St 111R, San Francisco, CA 94121 USA; [Nakamura, Mary C.; Hsieh, Christine L.] San Francisco VA Med Ctr, Res Dept, Immunol Sect, 4150 Clement St 111R, San Francisco, CA 94121 USA; [Kim, Charles C.] Univ Calif San Francisco, Dept Med, Div Expt Med, 1001 Potrero Ave,Bldg 3,Room 603,Box 1234, San Francisco, CA 94143 USA; [Kim, Charles C.] Verily, Mountain View, CA 94043 USA		Hsieh, CL (corresponding author), Univ Calif San Francisco, Dept Med, Div Rheumatol, 4150 Clement St 111R, San Francisco, CA 94121 USA.; Hsieh, CL (corresponding author), San Francisco VA Med Ctr, Res Dept, Immunol Sect, 4150 Clement St 111R, San Francisco, CA 94121 USA.	Christine.hsieh@ucsf.edu	Nakamura, Mary/ABI-2887-2020	Kim, Charles/0000-0001-6474-8227; Nakamura, Mary C./0000-0001-8127-9426	NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P30 AI027763]; NIDDKUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30 DK063720]; United States Department of Veterans Affairs Biomedical Laboratory Research and Development Program [I01 BX002690]; NIH R01 grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG046282]; Rheumatology Research Foundation; Russell/Engleman Rheumatology Research Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK063720] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG046282] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX002690] Funding Source: NIH RePORTER	CCK was supported by NIAID P30 AI027763 and NIDDK P30 DK063720. CLH and this work was supported by a Career Development Award-2 and a Merit Review Award #I01 BX002690 from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Program to CLH. MCN is supported by NIH R01 grant AG046282, the Rheumatology Research Foundation, and the Russell/Engleman Rheumatology Research Center.	Ansari MA, 2015, J NEUROL SCI, V357, P41, DOI 10.1016/j.jns.2015.06.062; Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071; Clausen BH, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-46; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Darmanis S, 2015, P NATL ACAD SCI USA, V112, P7285, DOI 10.1073/pnas.1507125112; Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gyoneva S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0443-0; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Kumar A., 2015, J NEUROTRAUMA; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood-2012-06-436212; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Pollen AA, 2014, NAT BIOTECHNOL, V32, P1053, DOI 10.1038/nbt.2967; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shalek AK, 2014, NATURE, V510, P363, DOI 10.1038/nature13437; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Treutlein B, 2014, NATURE, V509, P371, DOI 10.1038/nature13173; Van Dyken SJ, 2013, ANNU REV IMMUNOL, V31, P317, DOI 10.1146/annurev-immunol-032712-095906; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006	31	77	80	1	12	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 24	2016	13								117	10.1186/s12974-016-0581-z			12	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	DN7UW	WOS:000377286500002	27220367	gold, Green Published			2022-02-06	
J	Miller, JH; Gill, C; Kuhn, EN; Rocque, BG; Menendez, JY; O'Neill, JA; Agee, BS; Brown, ST; Crowther, M; Davis, RD; Ferguson, D; Johnston, JM				Miller, Joseph H.; Gill, Clarence; Kuhn, Elizabeth N.; Rocque, Brandon G.; Menendez, Joshua Y.; O'Neill, Jilian A.; Agee, Bonita S.; Brown, Steven T.; Crowther, Marshall; Davis, R. Drew; Ferguson, Drew; Johnston, James M.			Predictors of delayed recovery following pediatric sports-related concussion: a case-control study	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						concussion; SCAT2 score; pediatric; trauma; recovery; head injury	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; NCAA CONCUSSION; MANAGEMENT; AGE	OBJECTIVE Pediatric sports-related concussions are a growing public health concern. The factors that determine injury severity and time to recovery following these concussions are poorly understood. Previous studies suggest that initial symptom severity and diagnosis of attention deficit hyperactivity disorder (ADHD) are predictors of prolonged recovery (> 28 days) after pediatric sports-related concussions. Further analysis of baseline patient characteristics may allow for a more accurate prediction of which patients are at risk for delayed recovery after a sports-related concussion. METHODS The authors performed a single-center retrospective case-control study involving patients cared for at the multidisciplinary Concussion Clinic at Children's of Alabama between August 2011 and January 2013. Patient demographic data, medical history, sport concussion assessment tool 2 (SCAT2) and symptom severity scores, injury characteristics, and patient balance assessments were analyzed for each outcome group. The control group consisted of patients whose symptoms resolved within 28 days. The case group included patients whose symptoms persisted for more than 28 days. The presence or absence of the SCAT2 assessment had a modifying effect on the risk for delayed recovery; therefore, stratum-specific analyses were conducted for patients with recorded SCAT2 scores and for patients without SCAT2 scores. Unadjusted ORs and adjusted ORs (aORs) for an association of delayed recovery outcome with specific risk factors were calculated with logistic regression analysis. RESULTS A total of 294 patients met the inclusion criteria of the study. The case and control groups did not statistically significantly differ in age (p = 0.7). For the patients who had received SCAT2 assessments, a previous history of concussion (aOR 3.67, 95% CI 1.51-8.95), presenting SCAT2 score < 80 (aOR 5.58, 95% CI 2.61-11.93), and female sex (aOR 3.48, 95% CI 1.43-8.49) were all associated with a higher risk for postconcussive symptoms lasting more than 28 days. For patients without SCAT2 scores, female sex and reporting a history of ADHD significantly increased the odds of prolonged recovery (aOR 4.41, 95% CI 1.93-10.07 and aOR 3.87, 95% C11.13-13.24, respectively). Concussions resulting from playing a nonhelmet sport were also associated with a higher risk for prolonged symptoms in patients with and without SCAT2 scores (OR 2.59, 95% CI 1.28-5.26 and OR 2.17, 95% CI 0.99-7.73, respectively). Amnesia, balance abnormalities, and a history of migraines were not associated with symptoms lasting longer than 28 days. CONCLUSIONS This case-control study suggests candidate risk factors for predicting prolonged recovery following sports-related concussion. Large prospective cohort studies of youth athletes examined and treated with standardized protocols will be needed to definitively establish these associations and confirm which children are at highest risk for delayed recovery.	[Miller, Joseph H.; Gill, Clarence; Kuhn, Elizabeth N.; Rocque, Brandon G.; Menendez, Joshua Y.; O'Neill, Jilian A.; Agee, Bonita S.; Brown, Steven T.; Johnston, James M.] Univ Alabama Birmingham, Dept Neurosurg, FOT 1030,1720 2nd Ave S, Birmingham, AL 35294 USA; [Crowther, Marshall; Davis, R. Drew; Ferguson, Drew; Johnston, James M.] Univ Alabama Birmingham, Dept Sports Med, Birmingham, AL USA		Johnston, JM (corresponding author), Univ Alabama Birmingham, Dept Neurosurg, FOT 1030,1720 2nd Ave S, Birmingham, AL 35294 USA.	james.johnston@childrensa1.org	Alford, Elizabeth/W-1666-2019	Alford, Elizabeth/0000-0003-1779-089X; Rocque, Brandon/0000-0002-7333-4808; Johnston, James/0000-0001-8564-1808	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001417, KL2TR001419] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2 TR001419, UL1 TR001417] Funding Source: Medline		Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Johnson EW, 2011, CLIN SPORT MED, V30, P73, DOI 10.1016/j.csm.2010.08.007; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91	19	77	77	1	18	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	APR	2016	17	4					491	496		10.3171/2015.8.PEDS14332			6	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	DH3EF	WOS:000372669600017	26684762	Bronze, Green Accepted			2022-02-06	
J	Cheng, T; Wang, WZ; Li, Q; Han, XN; Xing, J; Qi, CF; Lan, X; Wan, JR; Potts, A; Guan, FX; Wang, J				Cheng, Tian; Wang, Wenzhu; Li, Qian; Han, Xiaoning; Xing, Jing; Qi, Cunfang; Lan, Xi; Wan, Jieru; Potts, Alexa; Guan, Fangxia; Wang, Jian			Cerebroprotection of flavanol (-)-epicatechin after traumatic brain injury via Nrf2-dependent and -independent pathways	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						(-)-Epicatechin; NF-E2-related factor; Traumatic brain injury	OXIDATIVE STRESS; INTRACEREBRAL HEMORRHAGE; LIQUID-CHROMATOGRAPHY; SIGNALING PATHWAY; COCOA FLAVANOLS; RAT MODEL; NRF2; METABOLITES; EXPRESSION; IMPACT	Traumatic brain injury (TBI), which leads to disability, dysfunction, and even death, is a prominent health problem worldwide with no effective treatment. A brain-permeable flavonoid named (-)-epicatechin (EC) modulates redox/oxidative stress and has been shown to be beneficial for vascular and cognitive function in humans and for ischemic and hemorrhagic stroke in rodents. Here we examined whether EC is able to protect the brain against TBI-induced brain injury in mice and if so, whether it exerts neuro-protection by modulating the NF-E2-related factor (Nrf2) pathway. We used the controlled cortical impact model to mimic TBI. EC was administered orally at 3 h after TBI and then every 24 h for either 3 or 7 days. We evaluated lesion volume, brain edema, white matter injury, neurologic deficits, cognitive performance and emotion-like behaviors, neutrophil infiltration, reactive oxygen species (ROS), and a variety of injury-related protein markers. Nrf2 knockout mice were used to determine the role of the Nrf2 signaling pathway after EC treatment. In wild-type mice, EC significantly reduced lesion volume, edema, and cell death and improved neurologic function on days 3 and 28; cognitive performance and depression-like behaviors were also improved with EC administration. In addition, EC reduced white matter injury, heme oxygenase-1 expression, and ferric iron deposition after TBI. These changes were accompanied by attenuation of neutrophil infiltration and oxidative insults, reduced activity of matrix metalloproteinase 9, decreased Keap 1 expression, increased Nrf2 nuclear accumulation, and increased expression of superoxide dismutase 1 and quinone 1. However, EC did not significantly reduce lesion volume or improve neurologic deficits in Nrf2 knockout mice after TBI. Our results show that EC protects the TBI brain by activating the Nrf2 pathway, inhibiting heme oxygenase-1 protein expression, and reducing iron deposition. The latter two effects could represent an Nrf2-independent mechanism in this model of TBI. (C) 2015 Elsevier Inc. All rights reserved.	[Cheng, Tian; Guan, Fangxia; Wang, Jian] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450000, Henan, Peoples R China; [Cheng, Tian; Wang, Wenzhu; Li, Qian; Han, Xiaoning; Xing, Jing; Qi, Cunfang; Lan, Xi; Wan, Jieru; Potts, Alexa; Wang, Jian] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 370B, Baltimore, MD 21205 USA; [Guan, Fangxia] Zhengzhou Univ, Sch Life Sci, Zhengzhou 450000, Henan, Peoples R China		Wang, J (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, 720 Rutland Ave,Ross Bldg 370B, Baltimore, MD 21205 USA.; Guan, FX (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China.	13613813972@126.com; jwang79@jhmi.edu	Wang, Jian/I-4874-2019	Wang, Jian/0000-0003-2291-640X; Li, Qian/0000-0003-0359-5604	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81071008]; Excellent Youth Foundation of Henan Scientific Committee [114100510005]; Technology Foundation for Selected Overseas Chinese Scholars; American Heart AssociationAmerican Heart Association [13GRNT15730001]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078026, R01AT007317]; China Scholarship Council Joint Ph.D. Training awardChina Scholarship Council; National Center for Complementary & Integrative HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AT007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078026] Funding Source: NIH RePORTER	This study was supported by the National Natural Science Foundation of China (81071008), the Excellent Youth Foundation of Henan Scientific Committee (114100510005), the Technology Foundation for Selected Overseas Chinese Scholars, American Heart Association Grant 13GRNT15730001, and National Institutes of Health Grants R01NS078026 and R01AT007317. T.C. is the recipient of the China Scholarship Council Joint Ph.D. Training award.	Abd El Mohsen MM, 2002, FREE RADICAL BIO MED, V33, P1693, DOI 10.1016/S0891-5849(02)01137-1; Arent AM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/723060; Baba S, 2001, J NUTR, V131, P2885, DOI 10.1093/jn/131.11.2885; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Chang CF, 2014, ANN CLIN TRANSL NEUR, V1, P258, DOI 10.1002/acn3.54; Chang Q, 2005, J CLIN PHARMACOL, V45, P106, DOI 10.1177/0091270004270500; Chen L, 2015, J NEUROPATH EXP NEUR, V74, P557, DOI 10.1097/NEN.0000000000000199; Chen LS, 1997, DRUG METAB DISPOS, V25, P1045; Cheng T, 2015, CELL MOL NEUROBIOL, V35, P641, DOI 10.1007/s10571-015-0159-9; Cox CJ, 2015, NEUROBIOL AGING, V36, P178, DOI 10.1016/j.neurobiolaging.2014.07.032; Cuevas E, 2009, EUR J PHARMACOL, V616, P122, DOI 10.1016/j.ejphar.2009.06.013; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Fernandez-Gajardo R, 2014, CNS DRUGS, V28, P229, DOI 10.1007/s40263-013-0138-y; Fraga CG, 2011, FREE RADICAL BIO MED, V51, P813, DOI 10.1016/j.freeradbiomed.2011.06.002; Han XN, 2016, J CEREBR BLOOD F MET, V36, P1059, DOI 10.1177/0271678X15606462; Harada H, 2008, FREE RADICAL RES, V42, P297, DOI 10.1080/10715760801975735; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Hsieh HL, 2014, MOL NEUROBIOL, V50, P520, DOI 10.1007/s12035-013-8628-y; Hsieh HL, 2010, ANTIOXID REDOX SIGN, V13, P1829, DOI 10.1089/ars.2009.2957; Jin W, 2011, INJURY, V42, P714, DOI 10.1016/j.injury.2011.03.009; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007; Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556; Mak JCW, 2012, CLIN EXP PHARMACOL P, V39, P265, DOI 10.1111/j.1440-1681.2012.05673.x; Miller DM, 2015, EXP NEUROL, V264, P103, DOI 10.1016/j.expneurol.2014.11.008; Miller DM, 2014, J NEUROTRAUM, V31, P1194, DOI 10.1089/neu.2013.3218; Nehlig A, 2013, BRIT J CLIN PHARMACO, V75, P716, DOI 10.1111/j.1365-2125.2012.04378.x; Raivich G, 2006, PROG NEUROBIOL, V78, P347, DOI 10.1016/j.pneurobio.2006.03.006; Ramkumar KM, 2013, CURR MED CHEM, V20, P1127; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Rodriguez-Mateos A, 2015, MOL NUTR FOOD RES, V59, P1504, DOI 10.1002/mnfr.201500091; Roura E, 2005, J AGR FOOD CHEM, V53, P6190, DOI 10.1021/jf050377u; Ruijters EJB, 2013, EUR J PHARMACOL, V715, P147, DOI 10.1016/j.ejphar.2013.05.029; Schroeter H, 2006, P NATL ACAD SCI USA, V103, P1024, DOI 10.1073/pnas.0510168103; Shah ZA, 2010, J CEREBR BLOOD F MET, V30, P1951, DOI 10.1038/jcbfm.2010.53; Sokolov AN, 2013, NEUROSCI BIOBEHAV R, V37, P2445, DOI 10.1016/j.neubiorev.2013.06.013; Sugawara T, 2009, STROKE, V40, P1530, DOI 10.1161/STROKEAHA.108.531699; van Praag H, 2007, J NEUROSCI, V27, P5869, DOI 10.1523/JNEUROSCI.0914-07.2007; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Wang J, 2012, J NEUROSCI, V32, P5144, DOI 10.1523/JNEUROSCI.6437-11.2012; Wang W., 2015, MOL NEUROBI IN PRESS; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0; Wu H, 2015, NEUROBIOL AGING, V36, P1439, DOI 10.1016/j.neurobiolaging.2014.12.029; Wu H, 2012, NEUROBIOL DIS, V45, P388, DOI 10.1016/j.nbd.2011.08.028; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Wu L, 2012, J AGR FOOD CHEM, V60, P9377, DOI 10.1021/jf301787f; Wu T, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-22; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Zan L, 2014, NEUROSCIENCE, V262, P118, DOI 10.1016/j.neuroscience.2013.12.060; Zhao JB, 2014, TRANSL STROKE RES, V5, P586, DOI 10.1007/s12975-014-0353-y; Zhao XC, 2015, BRAIN BEHAV IMMUN, V46, P293, DOI 10.1016/j.bbi.2015.02.011; Zhu HT, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-59; Zhu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097423	59	77	82	5	29	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	MAR	2016	92						15	28		10.1016/j.freeradbiomed.2015.12.027			14	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	DE5BJ	WOS:000370645400002	26724590	Green Accepted			2022-02-06	
J	Logsdon, AF; Lucke-Wold, BP; Turner, RC; Huber, JD; Rosen, CL; Simpkins, JW				Logsdon, Aric F.; Lucke-Wold, Brandon P.; Turner, Ryan C.; Huber, Jason D.; Rosen, Charles L.; Simpkins, James W.			Role of Microvascular Disruption in Brain Damage from Traumatic Brain Injury	COMPREHENSIVE PHYSIOLOGY			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CAPILLARY ENDOTHELIAL-CELLS; CEREBRAL-BLOOD-FLOW; GLASGOW COMA SCALE; BARRIER DISRUPTION; AXONAL INJURY; HEAD-INJURY; ER STRESS	Traumatic brain injury (TBI) is acquired from an external force, which can inflict devastating effects to the brain vasculature and neighboring neuronal cells. Disruption of vasculature is a primary effect that can lead to a host of secondary injury cascades. The primary effects of TBI are rapidly occurring while secondary effects can be activated at later time points and may be more amenable to targeting. Primary effects of TBI include diffuse axonal shearing, changes in blood-brain barrier (BBB) permeability, and brain contusions. These mechanical events, especially changes to the BBB, can induce calcium perturbations within brain cells producing secondary effects, which include cellular stress, inflammation, and apoptosis. These secondary effects can be potentially targeted to preserve the tissue surviving the initial impact of TBI. In the past, TBI research had focused on neurons without any regard for glial cells and the cerebrovasculature. Now a greater emphasis is being placed on the vasculature and the neurovascular unit following TBI. A paradigm shift in the importance of the vascular response to injury has opened new avenues of drug-treatment strategies for TBI. However, a connection between the vascular response to TBI and the development of chronic disease has yet to be elucidated. Long-term cognitive deficits are common amongst those sustaining severe or multiple mild TBIs. Understanding the mechanisms of cellular responses following TBI is important to prevent the development of neuropsychiatric symptoms. With appropriate intervention following TBI, the vascular network can perhaps be maintained and the cellular repair process possibly improved to aid in the recovery of cellular homeostasis. (C) 2015 American Physiological Society.	[Logsdon, Aric F.; Huber, Jason D.] W Virginia Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, Morgantown, WV 26506 USA; [Logsdon, Aric F.; Lucke-Wold, Brandon P.; Turner, Ryan C.; Huber, Jason D.; Rosen, Charles L.] W Virginia Univ, Hlth Sci Ctr, Dept Neurosurg, Morgantown, WV 26506 USA; [Simpkins, James W.] W Virginia Univ, Hlth Sci Ctr, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA; [Logsdon, Aric F.; Lucke-Wold, Brandon P.; Turner, Ryan C.; Huber, Jason D.; Rosen, Charles L.; Simpkins, James W.] W Virginia Univ, Hlth Sci Ctr, Ctr Neurosci, Morgantown, WV 26506 USA		Simpkins, JW (corresponding author), W Virginia Univ, Hlth Sci Ctr, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA.	jwsimpkins@hsc.wvu.edu	Lucke-Wold, Brandon/AAW-1881-2021; Lucke-Wold, Brandon/AAW-3525-2021	Lucke-Wold, Brandon/0000-0001-6577-4080; Turner, Ryan/0000-0001-5523-0645	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 AG022550, P01 AG027956, P20 GM109098, U54GM104942]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM081741, P20GM109098, U54GM104942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG022550, P01AG027956] Funding Source: NIH RePORTER	This review was supported in part by NIH grants P01 AG022550, P01 AG027956, P20 GM109098, and U54GM104942 (J. W. Simpkins).	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Abdul-Muneer PM, 2014, MOL NEUROBIOL; Adalbert R, 2009, BRAIN, V132, P402, DOI 10.1093/brain/awn312; Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Amantini A, 2012, MINERVA ANESTESIOL, V78, P1067; Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Asakuno Keizoh, 2014, Surg Neurol Int, V5, P61, DOI 10.4103/2152-7806.132031; Asl SZ, 2013, J NEUROSURG, V119, P353, DOI 10.3171/2013.4.JNS121636; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Badaut J, 2014, TRANSL STROKE RES, V5, P394, DOI 10.1007/s12975-013-0304-z; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bauer AM, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00072; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423; Biancardi VC, 2014, HYPERTENSION, V63, P572, DOI 10.1161/HYPERTENSIONAHA.113.01743; Bor-Seng-Shu E, 2013, NEUROSURG REV, V36, P361, DOI 10.1007/s10143-013-0453-2; Brandner S, 2015, J NEUROSURG ANESTH, V27, P26, DOI 10.1097/ANA.0000000000000083; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bukovics P, 2014, PEPTIDES, V60, P18, DOI 10.1016/j.peptides.2014.07.001; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chalouhi N, 2014, J NEUROSURG, V121, P904, DOI 10.3171/2014.6.JNS132638; Chen B, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-77; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Covey Dana C, 2010, J Surg Orthop Adv, V19, P8; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Cui T, 2014, CELL BIOCH BIOPHYS; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Cullen NK, 2009, PM&R, V1, P1069, DOI 10.1016/j.pmrj.2009.09.013; Dagher JH, 2010, BRAIN INJURY, V24, P1389, DOI 10.3109/02699052.2010.523042; Dapul HR, 2013, J NEUROTRAUM, V30, P382, DOI 10.1089/neu.2012.2536; Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; Depreitere B, 2014, J NEUROSURG, V120, P1451, DOI 10.3171/2014.3.JNS131500; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; DiLeonardi AM, 2012, J NEUROPATH EXP NEUR, V71, P959, DOI 10.1097/NEN.0b013e31826f5876; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Dore-Duffy P, 2011, NEUROL RES, V33, P176, DOI 10.1179/016164111X12881719352372; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Faust K, 2014, CLIN NEUROL NEUROSUR, V125, P36, DOI 10.1016/j.clineuro.2014.06.023; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Foster KA, 2014, J NEUROTRAUM, V31, P1625, DOI 10.1089/neu.2014.3372; Fujita M, 2012, J NEUROTRAUM, V29, P1491, DOI 10.1089/neu.2011.2278; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Gurkoff G, 2013, PHARMACEUTICALS, V6, P788, DOI 10.3390/ph6070788; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hartmann DA, 2014, MICROCIRCULATION; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Ho KM, 2014, J NEUROSURG, V121, P674, DOI 10.3171/2014.6.JNS132838; Hochstadter E, 2014, NEUROCRIT CARE, V21, P505, DOI 10.1007/s12028-014-9986-7; Hoozemans JJM, 2007, BIOCHEM BIOPH RES CO, V354, P707, DOI 10.1016/j.bbrc.2007.01.043; Huh JW, 2008, EXP NEUROL, V213, P84, DOI 10.1016/j.expneurol.2008.05.009; Huh JW, 2006, DEV NEUROSCI-BASEL, V28, P466, DOI 10.1159/000094172; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Izzy S, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-013-0278-x; Jalloh I, 2015, J CEREBR BLOOD F MET, V35, P111, DOI 10.1038/jcbfm.2014.177; Ji XT, 2012, J SURG RES, V178, pE9, DOI 10.1016/j.jss.2011.12.038; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kelman Craig, 2014, Neurosurg Focus, V37, P1, DOI 10.3171/2014.V2.FOCUS14172; Kim H, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0186-2; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Korczyn AD, 2012, J ALZHEIMERS DIS, V29, P275, DOI 10.3233/JAD-2011-110359; Kramer AH, 2012, CURRENT TREAT OPTION; Kramer DR, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/415813; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lazaridis C, 2012, NEUROCRIT CARE, V16, P478, DOI 10.1007/s12028-012-9685-1; Le Heron CJ, 2014, J CEREBR BLOOD F MET, V34, P964, DOI 10.1038/jcbfm.2014.40; Lee HC, 2010, WORLD NEUROSURG, V74, P654, DOI 10.1016/j.wneu.2010.06.019; Levy AS, 2014, WORLD NEUROSURG, V82, pE319, DOI 10.1016/j.wneu.2013.11.008; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Li SH, 2013, ANN NEUROL, V74, P768, DOI 10.1002/ana.24005; Liao GP, 2014, J SURG RES, V190, P628, DOI 10.1016/j.jss.2014.05.011; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu HD, 2013, NEUROL SCI, V34, P1173, DOI 10.1007/s10072-012-1214-7; Liu S, 2014, BRAIN INJURY, V28, P133, DOI 10.3109/02699052.2013.860479; Liu YQ, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-141; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782; Mangat Halinder S, 2012, Continuum (Minneap Minn), V18, P532, DOI 10.1212/01.CON.0000415426.76524.e1; Marchesi VT, 2014, CELL MOL LIFE SCI, V71, P949, DOI 10.1007/s00018-013-1542-7; Marmarou CR, 2014, BRAIN RES, V1581, P89, DOI 10.1016/j.brainres.2014.06.005; Mata-Mbemba D, 2014, J NEUROTRAUMA; Mata-Mbemba D, 2014, ACAD RADIOL, V21, P605, DOI 10.1016/j.acra.2014.01.017; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Miyauchi T, 2014, J NEUROTRAUM, V31, P773, DOI 10.1089/neu.2013.3181; Miyauchi T, 2013, J NEUROTRAUM, V30, P1664, DOI 10.1089/neu.2013.2995; Molino Y, 2014, JOVE-J VIS EXP, V88; Moreno JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006767; Moreno JA, 2012, NATURE, V485, P507, DOI 10.1038/nature11058; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Munoz P, 2006, BIOL RES, V39, P189, DOI 10.4067/S0716-97602006000100021; Munoz P, 2011, J BIOL CHEM, V286, P13382, DOI 10.1074/jbc.M110.213785; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Neuhof C, 2014, WORLD J CARDIOL, V6, P638, DOI 10.4330/wjc.v6.i7.638; Newcomb JK, 1999, J NEUROTRAUM, V16, P1, DOI 10.1089/neu.1999.16.1; Nirula R, 2014, J TRAUMA ACUTE CARE, V76, P944, DOI 10.1097/TA.0000000000000194; Nisenbaum EJ, 2014, J NEUROTRAUM, V31, P301, DOI 10.1089/neu.2013.3102; O'Connor T, 2008, NEURON, V60, P988, DOI 10.1016/j.neuron.2008.10.047; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Padayachy LC, 2012, CHILD NERV SYST, V28, P1911, DOI 10.1007/s00381-012-1837-2; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; Paradis A, 2013, CURR VASC PHARMACOL, V11, P594, DOI 10.2174/1570161111311050004; Park E, 2013, NEUROBIOL DIS, V52, P150, DOI 10.1016/j.nbd.2012.12.002; Pechmann A, 2015, NEUROPEDIATRICS, V46, P5, DOI 10.1055/s-0034-1393707; Peek-Asa C, 2001, BRAIN INJURY, V15, P801, DOI 10.1080/02699050010025768; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Qutub AA, 2008, MOL CELL BIOL, V28, P5106, DOI 10.1128/MCB.00060-08; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Razumovsky A, 2013, ACTA NEUROCHIR SUPPL, V115, P87, DOI 10.1007/978-3-7091-1192-5_19; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; RINK A, 1995, AM J PATHOL, V147, P1575; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rosenbaum BP, 2014, J CLIN NEUROSCI, V21, P1874, DOI 10.1016/j.jocn.2014.05.006; Rostami E, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00114; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Rubino S, 2014, J NEUROSURG, V121, P944, DOI 10.3171/2014.6.JNS132204; Rubovitch V, 2011, NEUROCHEM INT, V58, P443, DOI 10.1016/j.neuint.2011.01.009; Ruhe A, 2014, SPORTS HEALTH, V6, P427, DOI 10.1177/1941738114541238; Russell KL, 2014, PROSTAG LEUKOTR ESS, V90, P5, DOI 10.1016/j.plefa.2013.11.003; Saito T, 2011, NEUROSCI LETT, V497, P116, DOI 10.1016/j.neulet.2011.04.043; Salminen A, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-41; Sanelli PC, 2014, AM J NEURORADIOL, V35, P1714, DOI 10.3174/ajnr.A3947; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Schafer DP, 2009, J NEUROSCI, V29, P13242, DOI 10.1523/JNEUROSCI.3376-09.2009; Schaible EV, 2014, J NEUROCHEM, V129, P940, DOI 10.1111/jnc.12708; Scheper W, 2011, AUTOPHAGY, V7, P910, DOI 10.4161/auto.7.8.15761; Schiera G, 2003, J CELL MOL MED, V7, P165, DOI 10.1111/j.1582-4934.2003.tb00215.x; Shahlaie K, 2011, J NEUROSURG, V115, P602, DOI 10.3171/2011.5.JNS101667; Shin SS, 2014, PROG NEUROL SURG, V28, P86, DOI 10.1159/000358767; Shohami E, 2014, CNS NEUROL DISORD-DR, V13, P567, DOI 10.2174/18715273113126660196; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith DW, 2012, NEUROSURGERY, V70, P740, DOI 10.1227/NEU.0b013e318235b991; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Szmydynger-Chodobska J, 2010, J NEUROTRAUM, V27, P1449, DOI 10.1089/neu.2010.1331; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Turner RC, 2013, J NEUROSURG, V118, P1072, DOI 10.3171/2012.11.JNS12408; Turner RC, 2012, J NEUROSURG, V117, P1110, DOI 10.3171/2012.8.JNS12358; Ueda Y, 2006, ACTA NEUROPATHOL, V112, P85, DOI 10.1007/s00401-005-0029-5; van der Eerden AW, 2014, RADIOLOGY, V270, P506, DOI 10.1148/radiol.13122720; Wang Y, 2014, J NEUROTRAUM, V31, P498, DOI [10.1089/NEU.2013.3074, 10.1089/neu.2013.3074]; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Wilson CD, 2014, CAN J NEUROL SCI, V41, P314, DOI 10.1017/S031716710001725X; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu FF, 2014, BRAIN INJURY, V28, P1594, DOI 10.3109/02699052.2014.943289; Xu ZNS, 2014, J ULTRAS MED, V33, P1763, DOI 10.7863/ultra.33.10.1763; Yeh DD, 2012, WORLD J SURG, V36, P966, DOI 10.1007/s00268-012-1500-9; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhang YP, 2014, TRANSL STROKE RES, V5, P454, DOI 10.1007/s12975-014-0327-0; Zhong N, 2009, J BIOL CHEM, V284, P27273, DOI 10.1074/jbc.M109.014464	191	77	80	2	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2040-4603			COMPR PHYSIOL	Compr. Physiol.	JUL	2015	5	3					1147	1160		10.1002/cphy.c140057			14	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	CM3PY	WOS:000357596400005	26140712	Green Accepted			2022-02-06	
J	Cairelli, MJ; Fiszman, M; Zhang, H; Rindflesch, TC				Cairelli, Michael J.; Fiszman, Marcelo; Zhang, Han; Rindflesch, Thomas C.			Networks of neuroinjury semantic predications to identify biomarkers for mild traumatic brain injury	JOURNAL OF BIOMEDICAL SEMANTICS			English	Article						Semantic predications; Semantic networks; Natural language processing; Degree centrality; Traumatic brain injury	LITERATURE-BASED DISCOVERY; LANGUAGE SYSTEM UMLS; CEREBROSPINAL-FLUID; CONCUSSION; CENTRALITY; KNOWLEDGE; PATTERNS; BIOLOGY	Objective: Mild traumatic brain injury (mTBI) has high prevalence in the military, among athletes, and in the general population worldwide (largely due to falls). Consequences can include a range of neuropsychological disorders. Unfortunately, such neural injury often goes undiagnosed due to the difficulty in identifying symptoms, so the discovery of an effective biomarker would greatly assist diagnosis; however, no single biomarker has been identified. We identify several body substances as potential components of a panel of biomarkers to support the diagnosis of mild traumatic brain injury. Methods: Our approach to diagnostic biomarker discovery combines ideas and techniques from systems medicine, natural language processing, and graph theory. We create a molecular interaction network that represents neural injury and is composed of relationships automatically extracted from the literature. We retrieve citations related to neurological injury and extract relationships (semantic predications) that contain potential biomarkers. After linking all relationships together to create a network representing neural injury, we filter the network by relationship frequency and concept connectivity to reduce the set to a manageable size of higher interest substances. Results: 99,437 relevant citations yielded 26,441 unique relations. 18,085 of these contained a potential biomarker as subject or object with a total of 6246 unique concepts. After filtering by graph metrics, the set was reduced to 1021 relationships with 49 unique concepts, including 17 potential biomarkers. Conclusion: We created a network of relationships containing substances derived from 99,437 citations and filtered using graph metrics to provide a set of 17 potential biomarkers. We discuss the interaction of several of these (glutamate, glucose, and lactate) as the basis for more effective diagnosis than is currently possible. This method provides an opportunity to focus the effort of wet bench research on those substances with the highest potential as biomarkers for mTBI.	[Cairelli, Michael J.; Fiszman, Marcelo; Rindflesch, Thomas C.] NIH, Natl Lib Med, Bethesda, MD 20892 USA; [Zhang, Han] China Med Univ, Dept Med Informat, Shenyang 110001, Liaoning, Peoples R China		Cairelli, MJ (corresponding author), NIH, Natl Lib Med, 38A 9N912A,8600 Rockville Pike, Bethesda, MD 20892 USA.	mike.cairelli@nih.gov	Zhang, Han/N-5849-2018		National Library of Medicine Research Participation Program; Intramural Research Program of the National Institutes of Health, National Library of MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)	This research was supported in part by an appointment to the National Library of Medicine Research Participation Program administered by the Oak Ridge Institute for Science and Education through an inter-agency agreement between the US Department of Energy and the National Library of Medicine. This study was supported in part by the Intramural Research Program of the National Institutes of Health, National Library of Medicine.	Ahlers Caroline B, 2007, AMIA Annu Symp Proc, P6; Andronis C, 2011, BRIEF BIOINFORM, V12, P357, DOI 10.1093/bib/bbr005; Aronson AR, 2010, J AM MED INFORM ASSN, V17, P229, DOI 10.1136/jamia.2009.002733; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bodenreider O, 2004, NUCLEIC ACIDS RES, V32, pD267, DOI 10.1093/nar/gkh061; Bray Bruce E, 2008, AMIA Annu Symp Proc, P887; Cairelli Michael J, 2013, AMIA Annu Symp Proc, V2013, P164; Cameron D, 2013, J BIOMED INFORM, V46, P238, DOI 10.1016/j.jbi.2012.09.004; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen GC, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003666; Cohen T, 2014, CPT-PHARMACOMET SYST, V3, DOI 10.1038/psp.2014.37; Cohen T, 2012, J BIOMED INFORM, V45, P1049, DOI 10.1016/j.jbi.2012.07.003; Cohen Trevor, 2009, AMIA Annu Symp Proc, V2009, P114; DeFazio MV, 2014, WORLD NEUROSURG, V81, P151, DOI 10.1016/j.wneu.2013.01.015; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Dong WW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100436; Faul M, 2010, TRAUMATIC BRAIN INJU; Fiszman Marcelo, 2008, AMIA Annu Symp Proc, P187; Forde CT, 2014, BRIT J NEUROSURG, V28, P8, DOI 10.3109/02688697.2013.815317; Gabetta M, 2013, STUD HEALTH TECHNOL, V192, P412, DOI 10.3233/978-1-61499-289-9-412; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Goodwin JC, 2012, IEEE INT C BIO BIO W; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; He Ying, 2008, AMIA Annu Symp Proc, P293; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Hristovski D, 2005, INT J MED INFORM, V74, P289, DOI 10.1016/j.ijmedinf.2004.04.024; Hristovski Dimitar, 2006, AMIA Annu Symp Proc, P349; Hristovski Dimitar, 2009, AMIA Annu Symp Proc, V2009, P255; Hristovski Dimitar, 2007, AMIA Annu Symp Proc, P979; Hristovski Dimitar, 2013, Cardiovascular & Hematological Agents in Medicinal Chemistry, V11, P14; Hur J, 2012, J BIOMED SEMANT, V3, DOI 10.1186/2041-1480-3-18; Hur J, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-49; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Jonnalagadda SR, 2013, J AM MED INFORM ASSN, V20, P995, DOI 10.1136/amiajnl-2012-001347; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jordan Rick, 2014, J Clin Bioinforma, V4, P13, DOI 10.1186/2043-9113-4-13; Kastrin Andrej, 2008, AMIA Annu Symp Proc, P358; Kilicoglu H, 2012, BIOINFORMATICS, V28, P3158, DOI 10.1093/bioinformatics/bts591; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5; Levy ML, 2012, WORLD NEUROSURG, V78, P535, DOI 10.1016/j.wneu.2011.10.032; Li C, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat030; Liang R, 2013, CHINESE MED J-PEKING, V126, P2472, DOI 10.3760/cma.j.issn.0366-6999.20122846; Liu Ying, 2012, AMIA Annu Symp Proc, V2012, P587; Lo TYM, 2009, J NEUROTRAUM, V26, P1479, DOI [10.1089/neu.2008.0753, 10.1089/neu.2008-0753]; Maver A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/848952; Miller CM, 2012, SLEEP, V35, P279, DOI 10.5665/sleep.1640; Nadkarni PM, 2011, J AM MED INFORM ASSN, V18, P544, DOI 10.1136/amiajnl-2011-000464; Ozgur A, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/426479; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Pellman Elliot J, 2006, Neurosurg Focus, V21, pE12; Rindflesch TC, 2003, J BIOMED INFORM, V36, P462, DOI 10.1016/j.jbi.2003.11.003; Rutherford GW, 2009, J HEAD TRAUMA REHAB, V24, P421, DOI 10.1097/HTR.0b013e3181c13439; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Shang N, 2014, J BIOMED INFORM, V52, P293, DOI 10.1016/j.jbi.2014.07.011; Shang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023862; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; Timmons SD, 2012, J NEUROSURG SCI, V56, P191; Trugenberger CA, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-51; van Haagen HHHBM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078665; Vos R, 2014, J AM MED INFORM ASSN, V21, P139, DOI 10.1136/amiajnl-2012-001448; Wang K, 2010, DIS MARKERS, V28, P199, DOI [10.1155/2010/130861, 10.3233/DMA-2010-0697]; Weeber M, 2005, BRIEF BIOINFORM, V6, P277, DOI 10.1093/bib/6.3.277; West TD, 2007, REBUILDING TRUST REP; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zeng Qing T, 2012, AMIA Annu Symp Proc, V2012, P1050; Zhang H, 2011, J BIOMED INFORM, V44, P830, DOI 10.1016/j.jbi.2011.05.001; Zhang R, 2014, J BIOMED INFORM, V49, P134, DOI 10.1016/j.jbi.2014.01.004; Zhang Xiang, 2007, WWW, DOI DOI 10.1145/1242572.1242668	76	77	82	0	15	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1480			J BIOMED SEMANT	J. Biomed. Semant.	MAY 18	2015	6								25	10.1186/s13326-015-0022-4			14	Mathematical & Computational Biology	Science Citation Index Expanded (SCI-EXPANDED)	Mathematical & Computational Biology	CI7DH	WOS:000354922600001	25992264	gold, Green Submitted, Green Published			2022-02-06	
J	Baugh, CM; Kiernan, PT; Kroshus, E; Daneshvar, DH; Montenigro, PH; McKee, AC; Stern, RA				Baugh, Christine M.; Kiernan, Patrick T.; Kroshus, Emily; Daneshvar, Daniel H.; Montenigro, Philip H.; McKee, Ann C.; Stern, Robert A.			Frequency of Head-Impact-Related Outcomes by Position in NCAA Division I Collegiate Football Players	JOURNAL OF NEUROTRAUMA			English	Article						American football; mild traumatic brain injury; concussion; college; linemen	CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL FOOTBALL; SPORT-RELATED CONCUSSION; STATES HIGH-SCHOOL; BRAIN-INJURY; PROFESSIONAL FOOTBALL; UNITED-STATES; SUBCONCUSSIVE IMPACTS; EPIDEMIOLOGY; INTERVENTION	Concussions and subconcussive impacts sustained in American football have been associated with short- and long-term neurological impairment, but differences in head impact outcomes across playing positions are not well understood. The American Medical Society for Sports Medicine has identified playing position as a key risk factor for concussion in football and one for which additional research is needed. This study examined variation in head impact outcomes across primary football playing positions in a group of 730 National Collegiate Athletic Association Division I Football Championship Series athletes, using a self-report questionnaire. Although there were no significant differences between position groups in the number of diagnosed concussions during the 2012 football season, there were significant differences between groups in undiagnosed concussions (p=0.008) and "dings" (p<0.001); offensive linemen reported significantly higher numbers than most other positions. Significant differences were found between position groups in the frequencies of several postimpact symptoms, including dizziness (p<0.001), headache (p<0.001), and seeing stars (p<0.001) during the 2012 football season, with offensive linemen reporting significantly more symptoms compared to most other groups. There were also positional differences in frequency of returning to play while symptomatic (p<0.001) and frequency of participating in full-contact practice (p<0.001). Offensive linemen reported having returned to play while experiencing symptoms more frequently and participating in more full-contact practices than other groups. These findings suggest that offensive linemen, a position group that experiences frequent, but low-magnitude, head impacts, develop more postimpact symptoms than other playing positions, but do not report these symptoms as a concussion.	[Baugh, Christine M.] Harvard Univ, Harvard Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Baugh, Christine M.] Harvard Univ, Edmond J Safra Ctr Eth, Cambridge, MA 02138 USA; [Baugh, Christine M.] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Kiernan, Patrick T.; Daneshvar, Daniel H.; Montenigro, Philip H.; McKee, Ann C.; Stern, Robert A.] Boston Univ, Chron Traumat Encephalopathy Ctr, Boston, MA 02215 USA; [Kroshus, Emily] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA; [Kroshus, Emily] Natl Collegiate Athlet Assoc, Sport Sci Inst, Indianapolis, IN USA; [Daneshvar, Daniel H.] Boston Univ, Sch Med, Dept Behav Neurosci, Boston, MA 02118 USA; [Montenigro, Philip H.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Daneshvar, Daniel H.] Sports Legacy Inst, Boston, MA USA; [McKee, Ann C.] VA Boston Healthcare Syst, Boston, MA USA; [McKee, Ann C.; Stern, Robert A.] Boston Univ, Alzheimers Dis Ctr, Boston, MA 02215 USA		Baugh, CM (corresponding author), Harvard Univ, Harvard Interfac Initiat Hlth Policy, 14 Story St,4th Floor, Cambridge, MA 02138 USA.	cbaugh@g.harvard.edu	, Bob/ABA-8507-2020; Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Stern, Robert/0000-0002-5008-077X; Montenigro, Philip/0000-0003-4442-9207; Daneshvar, Daniel/0000-0003-3691-9513	Edmond J. Safra Center for Ethics at Harvard University; NCAA Sports Science Institute; Athena Diagnostics; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	Christine M. Baugh received funding from the Edmond J. Safra Center for Ethics at Harvard University to conduct the larger study from which data for this manuscript was derived. Emily Kroshus receives funding from the NCAA Sports Science Institute as a postdoctoral research fellow. Robert A. Stern is a paid consultant to Athena Diagnostics and receives royalties from Psychological Assessment Resources, Inc. He also provides expert consultation to legal teams involved with NCAA and NFL-related litigation.	[Anonymous], 2013, PAC 12 C EST NEW FOO; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2014, J LAW MED ETHICS, V42, P297, DOI 10.1111/jlme.12147; Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio S. P., 2014, CONCUSSIONS ATHLETIC, P313; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.10.FOCUS10222; Funk J. R., 2006, ANN P ASS ADV AUTOMO, V51, P343; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Ivy League Ad Hoc Concussion Committee, 2011, REP REG IV LEAG REV; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kroshus E., 2014, ANN BEHAV M IN PRESS; Kroshus E., 2014, CLIN J SPOR IN PRESS; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; Mueller F. O., 2002, ANN SURVEY FOOTBALL; National Collegiate Athletic Association, 2014, CONC GUID DIAGN MAN; Nicholas J. A, 1970, FOOTBALL INJURIES, P233; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211	72	77	77	0	29	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2015	32	5					314	326		10.1089/neu.2014.3582			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CC0SD	WOS:000350045700004	25155288	Green Published			2022-02-06	
J	Fann, JR; Bombardier, CH; Vannoy, S; Dyer, J; Ludman, E; Dikmen, S; Marshall, K; Barber, J; Temkin, N				Fann, Jesse R.; Bombardier, Charles H.; Vannoy, Steven; Dyer, Joshua; Ludman, Evette; Dikmen, Sureyya; Marshall, Kenneth; Barber, Jason; Temkin, Nancy			Telephone and In-Person Cognitive Behavioral Therapy for Major Depression after Traumatic Brain Injury: A Randomized Controlled Trial	JOURNAL OF NEUROTRAUMA			English	Article						head trauma; clinical trial; rehabilitation; TBI; behavior	PRIMARY-CARE PATIENTS; QUALITY-OF-LIFE; ANTIDEPRESSANT TREATMENT; PSYCHIATRIC-DISORDERS; RATING-SCALE; SYMPTOMS; OUTCOMES; PSYCHOTHERAPY; SEVERITY; IMPACT	Major depressive disorder (MDD) is prevalent after traumatic brain injury (TBI); however, there is a lack of evidence regarding effective treatment approaches. We conducted a choice-stratified randomized controlled trial in 100 adults with MDD within 10 years of complicated mild to severe TBI to test the effectiveness of brief cognitive behavioral therapy administered over the telephone (CBT-T) (n=40) or in-person (CBT-IP) (n=18), compared with usual care (UC) (n=42). Participants were recruited from clinical and community settings throughout the United States. The main outcomes were change in depression severity on the clinician-rated 17 item Hamilton Depression Rating Scale (HAMD-17) and the patient-reported Symptom Checklist-20 (SCL-20) over 16 weeks. There was no significant difference between the combined CBT and UC groups over 16 weeks on the HAMD-17 (treatment effect=1.2, 95% CI: -1.5-4.0; p=0.37) and a nonsignificant trend favoring CBT on the SCL-20 (treatment effect=0.28, 95% CI: -0.03-0.59; p=0.074). In follow-up comparisons, the CBT-T group had significantly more improvement on the SCL-20 than the UC group (treatment effect=0.36, 95% CI: 0.01-0.70; p=0.043) and completers of eight or more CBT sessions had significantly improved SCL-20 scores compared with the UC group (treatment effect=0.43, 95% CI: 0.10-0.76; p=0.011). CBT participants reported significantly more symptom improvement (p=0.010) and greater satisfaction with depression care (p<0.001), than did the UC group. In-person and telephone-administered CBT are acceptable and feasible in persons with TBI. Although further research is warranted, telephone CBT holds particular promise for enhancing access and adherence to effective depression treatment.	[Fann, Jesse R.; Marshall, Kenneth] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Bombardier, Charles H.; Dyer, Joshua; Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Barber, Jason; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Vannoy, Steven] Univ Massachusetts, Dept Counseling & Sch Psychol, Boston, MA 02125 USA; [Ludman, Evette] Grp Hlth Res Inst, Seattle, WA USA		Fann, JR (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA.	fann@uw.edu	Bombardier, Charles H./AAZ-3260-2021; vannoy, steven/W-2737-2019	Bombardier, Charles H./0000-0003-4758-6283; 	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21HD53736]; Department of Education, National Institute on Disability and Rehabilitation Research [H133G070016]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD053736] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health (grant R21HD53736) and the Department of Education, National Institute on Disability and Rehabilitation Research (grant H133G070016). We thank Douglas Weeks at St. Luke's Rehabilitation Institute, Tessa Hart, at Moss Rehabilitation Research Institute, and Thomas Novack at the University of Alabama, Birmingham for assistance with study recruitment.	Armento MEA, 2007, BEHAV THER, V38, P107, DOI 10.1016/j.beth.2006.05.003; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Bagby RM, 2004, AM J PSYCHIAT, V161, P2163, DOI 10.1176/appi.ajp.161.12.2163; Baldwin SA, 2009, J CONSULT CLIN PSYCH, V77, P203, DOI 10.1037/a0015235; Barker-Collo S, 2013, BRAIN INJURY, V27, P1124, DOI 10.3109/02699052.2013.801513; Baumeister H, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008381.pub2; Baumeister H, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008012.pub3; Bedard M, 2014, J HEAD TRAUMA REHAB, V29, pE13, DOI 10.1097/HTR.0b013e3182a615a0; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bell KR, 2004, J HEAD TRAUMA REHAB, V19, P502, DOI 10.1097/00001199-200411000-00007; Beltman MW, 2010, BRIT J PSYCHIAT, V197, P11, DOI 10.1192/bjp.bp.109.064675; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Block CK, 2013, BRAIN INJURY, V27, P775, DOI 10.3109/02699052.2013.775487; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Burke BL, 2003, J CONSULT CLIN PSYCH, V71, P843, DOI 10.1037/0022-006X.71.5.843; Busseri MA, 2003, PSYCHOL ASSESSMENT, V15, P193, DOI 10.1037/1040-3590.15.2.193; Christensen AL, 1994, BRAIN INJURY NEUROPS; Cohen RM, 2013, JAMA PSYCHIAT, V70, P343, DOI 10.1001/jamapsychiatry.2013.286; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P818, DOI 10.1016/j.apmr.2010.12.008; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Deb S, 1999, AM J PSYCHIAT, V156, P374; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; Dimidjian S, 2011, ANNU REV CLIN PSYCHO, V7, P1, DOI 10.1146/annurev-clinpsy-032210-104535; DOWNHILL JE, 1994, J NERV MENT DIS, V182, P425, DOI 10.1097/00005053-199408000-00001; Dwight-Johnson M, 2011, PSYCHIAT SERV, V62, P936, DOI 10.1176/ps.62.8.pss6208_0936; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2009, J HEAD TRAUMA REHAB, V24, P272, DOI 10.1097/HTR.0b013e3181a66342; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Faul M, 2010, TRAUMATIC BRAIN INJU; Fava M, 2003, BIOL PSYCHIAT, V53, P649, DOI 10.1016/S0006-3223(03)00231-2; First Michael B, 2001, USERS GUIDE STRUCTUR; Furukawa TA, 2007, J CLIN PSYCHOPHARM, V27, P531, DOI 10.1097/JCP.0b013e31814f30b1; Furukawa TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035330; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Guy W., 1976, CLIN GLOBAL IMPRESSI; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hart T, 2008, NEUROPSYCHOL REHABIL, V18, P1, DOI 10.1080/09602010601082359; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hibbard M. R., 2005, COGNITIVE BEHAV THER, P189; Hibbard M. R., 1987, COGNITIVE THERAPY AP, P183; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOLLON SD, 1980, COGNITIVE THER RES, V4, P383, DOI 10.1007/BF01178214; Horvath A.O., 1994, WORKING ALLIANCE THE; Horvitz-Lennon M, 2003, AM J PSYCHIAT, V160, P720, DOI 10.1176/appi.ajp.160.4.720; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Iosifescu DV, 2007, PSYCHIAT CLIN N AM, V30, P77, DOI 10.1016/j.psc.2006.12.008; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; KUNY S, 1995, PSYCHOPATHOLOGY, V28, P190, DOI 10.1159/000284922; Lavori PW, 2001, BIOL PSYCHIAT, V50, P792, DOI 10.1016/S0006-3223(01)01223-9; Lerner D, 2012, J OCCUP ENVIRON MED, V54, P128, DOI 10.1097/JOM.0b013e31824409d8; Linde JA, 2011, ANN BEHAV MED, V41, P119, DOI 10.1007/s12160-010-9232-2; Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006; Ludman EJ, 2007, J CONSULT CLIN PSYCH, V75, P257, DOI 10.1037/0022-006X.75.2.257; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; McGrath CL, 2013, JAMA PSYCHIAT, V70, P821, DOI 10.1001/jamapsychiatry.2013.143; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Miranda J, 2003, HEALTH SERV RES, V38, P613, DOI 10.1111/1475-6773.00136; Mohr DC, 2008, CLIN PSYCHOL-SCI PR, V15, P243, DOI 10.1111/j.1468-2850.2008.00134.x; Montgomery S. A., 1994, EUROPEAN NEUROPSYCHO, V4, P283; Osenbach JE, 2013, DEPRESS ANXIETY, V30, P1058, DOI 10.1002/da.22165; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Pinsoff, 1986, PSYCHOTHERAPEUTIC PR, P529; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ricker, 1994, Assessment, V1, P47, DOI 10.1177/1073191194001001007; RINTALA DH, 1986, ARCH PHYS MED REHAB, V67, P118; Rockhill CM, 2012, J NEUROTRAUM, V29, P1038, DOI 10.1089/neu.2010.1562; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Sheehan DV, 1996, INT CLIN PSYCHOPHARM, V11, P89, DOI 10.1097/00004850-199606003-00015; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Simon GE, 2001, ARCH GEN PSYCHIAT, V58, P395, DOI 10.1001/archpsyc.58.4.395; Simon GE, 2004, JAMA-J AM MED ASSOC, V292, P935, DOI 10.1001/jama.292.8.935; Simon GE, 2011, J GEN INTERN MED, V26, P698, DOI 10.1007/s11606-011-1679-8; Sirey JA, 2005, PSYCHIAT SERV, V56, P1564, DOI 10.1176/appi.ps.56.12.1564; Smith JL, 2001, MED CARE, V39, P910, DOI 10.1097/00005650-200109000-00002; Stalder-Luthy F, 2013, ARCH PHYS MED REHAB, V94, P1386, DOI 10.1016/j.apmr.2013.02.013; SWEET JJ, 1992, CLIN PSYCHOL REV, V12, P21, DOI 10.1016/0272-7358(92)90090-U; Topolovec-Vranic J, 2010, BRAIN INJURY, V24, P762, DOI 10.3109/02699051003709599; Tutty S, 2010, BEHAV THER, V41, P229, DOI 10.1016/j.beth.2009.03.002; Wallace ML, 2013, JAMA PSYCHIAT, V70, P1241, DOI 10.1001/jamapsychiatry.2013.1960; Wang PS, 2000, J GEN INTERN MED, V15, P284, DOI 10.1046/j.1525-1497.2000.9908044.x; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Weissman M., 1979, THESIS U PENNSYLVANI; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; WILLIAMS JBW, 1988, ARCH GEN PSYCHIAT, V45, P742; Young AS, 2001, ARCH GEN PSYCHIAT, V58, P55, DOI 10.1001/archpsyc.58.1.55; Zimmerman M, 2013, J AFFECT DISORDERS, V150, P384, DOI 10.1016/j.jad.2013.04.028	99	77	77	0	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2015	32	1					45	57		10.1089/neu.2014.3423			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	AX4JX	WOS:000346900100007	25072405	Green Published			2022-02-06	
J	Klinger, DR; Madden, C; Beshay, J; White, J; Gambrell, K; Rickert, K				Klinger, Daniel R.; Madden, Christoper; Beshay, Joseph; White, Jonathan; Gambrell, Kenneth; Rickert, Kim			Autologous and Acrylic Cranioplasty: A Review of 10 Years and 258 Cases	WORLD NEUROSURGERY			English	Article						Cranioplasty; Craniotomy/craniectomy; Hemorrhage; Infection; Traumatic brain injury	DECOMPRESSIVE CRANIECTOMY; SURGERY; COMPLICATIONS; MULTICENTER; INFARCTION; INFECTION; HEAD	INTRODUCTION: Cranioplasty is a well-accepted neurosurgical procedure that has application to a wide range of pathologies. Given the varied need for both autologous and synthetic cranial grafts, it is important to establish rates of procedural complication. METHODS: A retrospective review identified 282 patients undergoing cranioplasty at our institution over a 10-year period, of which 249 patients underwent 258 cranioplasties with either autologous or acrylic flaps. A database including patient age, gender, presenting diagnosis, hospital of surgery, presence of a drain, and surgical complications was created in order to analyze the autologous and acrylic cranioplasty data. RESULTS: A total of 28 complications were noted, yielding a rate of 10.9% (28/ 258). There was no statistically significant difference in infection rate between autologous and acrylic cranioplasty (7.2% vs. 5.8%, P = 0.80). Male patients (P = 0.007), tumor patients (P = 0.02), and patients undergoing surgery at the county hospital (P = 0.06) sustained a statistically higher rate of infection. Among traumatic brain injury patients, complex injuries and surgical involvement of the frontal sinus carried a significantly higher infection rate of 17% and 38.5%, respectively (P = 0.03, P = 0.001). Postoperative epidural hematoma requiring reoperation occurred in 3.5% (9/258) with no difference in hematoma rate with placement of a drain (P = 1). CONCLUSIONS: Cranioplasty carries a significant risk of infection and postoperative hematoma. In this large series comparing autologous and acrylic flaps, male patients, tumor patients, and those undergoing surgery at the county hospital were at increased risk of postoperative infection. Among traumatic brain injury cases, complex injuries and cases with surgical involvement of the frontal sinus may portend a higher risk.	[Klinger, Daniel R.; Madden, Christoper; Beshay, Joseph; White, Jonathan; Rickert, Kim] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA; [Gambrell, Kenneth] Univ Texas SW Med Ctr Dallas, Dept Oral & Maxillofacial Surg, Dallas, TX 75390 USA		Klinger, DR (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Dallas, TX 75390 USA.	danielrklinger@gmail.com					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; AZIZ T Z, 1990, British Journal of Neurosurgery, V4, P417, DOI 10.3109/02688699008992764; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chiang HY, 2011, J NEUROSURG, V114, P1746, DOI 10.3171/2011.1.JNS10782; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Guresir E, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0954; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Lee SC, 2009, J CLIN NEUROSCI, V16, P56, DOI 10.1016/j.jocn.2008.04.001; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; OSAWA M, 1990, ACTA NEUROCHIR, V102, P38, DOI 10.1007/BF01402184; Penel N, 2001, HEAD NECK-J SCI SPEC, V23, P447, DOI 10.1002/hed.1058; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Stiver SI, 2009, J NEUROSURG, V110, P1242, DOI 10.3171/2008.8.JNS08314; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Weiner GM, 2010, NEUROSURGERY, V66, P1111, DOI 10.1227/01.NEU.0000369607.71913.3E; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	24	77	78	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	SEP-OCT	2014	82	3-4					E525	E530		10.1016/j.wneu.2013.08.005			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AQ6HV	WOS:000342912300029	24036124				2022-02-06	
J	Tate, R; Kennedy, M; Ponsford, J; Douglas, J; Velikonja, D; Bayley, M; Stergiou-Kita, M				Tate, Robyn; Kennedy, Mary; Ponsford, Jennie; Douglas, Jacinta; Velikonja, Diana; Bayley, Mark; Stergiou-Kita, Mary			INCOG Recommendations for Management of Cognition Following Traumatic Brain Injury, Part III: Executive Function and Self-Awareness	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive rehabilitation; executive function; guidelines; knowledge translation; neuropsychology; rehabilitation; self-awareness; traumatic brain injury	PROBLEM-SOLVING PROGRAM; OF-THE-LITERATURE; POSTACUTE REHABILITATION; METHODOLOGICAL QUALITY; CONTROLLED-TRIAL; N-OF-1 TRIALS; PEOPLE; DEFICITS; SKILLS; INTERVENTIONS	Introduction: Traumatic brain injury (TBI) results in complex cognitive (and other) sequelae. Impairments in executive function and self-awareness are among the most characteristic neuropsychological sequelae and can exert a profound effect on resuming previous life roles. An international group of researchers and clinicians (known as INCOG) convened to develop recommendations for interventions to improve impairments in executive functioning and self-awareness after TBI. Methods: The team reviewed the available literature and ensured the recommendations were current. To promote implementation, the team developed decision algorithms incorporating the recommendations based on inclusion and exclusion criteria of published trials. The team then prioritized the recommendations for implementation and developed audit criteria to evaluate the adherence to the best practice recommendations. Results: Intervention programs incorporating metacognitive strategy instruction for planning, problem-solving, and other cognitive-executive impairments have a solid evidence base. New evidence supports the use of strategies to specifically improve reasoning skills. Substantial support exists for use of direct corrective feedback to improve self-awareness. Conclusions: An increasing number of scientifically well-designed studies are available that demonstrate the effectiveness of a variety of interventions for the remediation of impairments in executive function and self-awareness after TBI.	[Tate, Robyn] Univ Sydney, Kolling Inst, Sydney Med Sch Northern, Rehabil Res Ctr, St Leonards, NSW 2065, Australia; [Tate, Robyn] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia; [Kennedy, Mary] Chapman Univ Orange, Dept Commun Sci & Disorders, Orange, CA USA; [Ponsford, Jennie] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Epworth Med Fdn, Melbourne, Vic, Australia; [Ponsford, Jennie] Monash Univ, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Alfred Hosp, Melbourne, Vic, Australia; [Douglas, Jacinta] La Trobe Univ, Sch Human Commun Sci, Melbourne, Vic, Australia; [Douglas, Jacinta] Summer Fdn, Melbourne, Vic, Australia; [Velikonja, Diana] Hamilton Hlth Sci, Acquired Brain Injury Program, Neuropsychol, Hamilton, ON, Canada; [Velikonja, Diana] McMaster Univ, DeGroote Sch Med, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [Bayley, Mark] Univ Toronto, UHN Toronto Rehabil Inst, Toronto, ON, Canada; [Bayley, Mark] Univ Toronto, Dept Med, Div Physiatry, Toronto, ON, Canada; [Stergiou-Kita, Mary] Univ Toronto, Toronto, ON, Canada; [Stergiou-Kita, Mary] Toronto Rehabil Inst, Toronto, ON, Canada		Tate, R (corresponding author), Univ Sydney, Kolling Inst Med Res, Sydney Med Sch Northern, Rehabil Studies Unit,Royal North Shore Hosp, Level 9, St Leonards, NSW 2065, Australia.	rtate@med.usyd.edu.au		Bayley, Mark/0000-0001-7860-9463; Douglas, Jacinta/0000-0003-0940-6624	Victorian Transport Accident Commission through its Victorian Neurotrauma Initiative, Monash University; Ontario Neurotrauma Foundation	We gratefully acknowledge the support of the Victorian Transport Accident Commission through its Victorian Neurotrauma Initiative, Monash University and the Ontario Neurotrauma Foundation for their support of this project.	Appraisal of Guidelines Research and Evaluation, AGREE ADV SCI PRACT; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Boelen DHE, 2011, J NEUROPSYCHOL, V5, P73, DOI 10.1348/174866410X516434; Bragge P, 2014, J HEAD TRAUMA REHAB, V29, P277, DOI 10.1097/HTR.0000000000000066; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; Cattelani R, 2010, NEUROPSYCHOL REV, V20, P52, DOI 10.1007/s11065-009-9125-y; Chandrashekar R, 2007, J REHABIL, V73, P50; Cheng SKW, 2006, BRAIN INJURY, V20, P621, DOI 10.1080/02699050600677196; Chittum WR, 1996, BRAIN INJURY, V10, P763; Chung CSY, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008391.pub2; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; CICERONE KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Cicerone KA, 2009, ARCH PHYS MED REHAB, V90, pS52, DOI 10.1016/j.apmr.2009.05.019; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Coetzer BR, 2001, J COGN REHABIL, V19, P8; Constantinidou F, 2005, J HEAD TRAUMA REHAB, V20, P143, DOI 10.1097/00001199-200503000-00003; Constantinidou F, 2008, J HEAD TRAUMA REHAB, V23, P312, DOI 10.1097/01.HTR.0000336844.99079.2c; Davis D, 2003, BMJ-BRIT MED J, V327, P33, DOI 10.1136/bmj.327.7405.33; Dawson DR, 2009, CAN J OCCUP THER, V76, P115, DOI 10.1177/000841740907600209; Delazer M, 1998, NEUROPSYCHOL REHABIL, V8, P401; Driscoll DM, 2011, J NEUROTRAUM, V28, P319, DOI 10.1089/neu.2010.1523; Ehlhardt LA, 2008, NEUROPSYCHOL REHABIL, V18, P300, DOI 10.1080/09602010701733190; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Fleming JM, 2006, NEUROPSYCHOL REHABIL, V16, P474, DOI 10.1080/09602010500505518; Fleming Jennifer M, 2006, Can J Occup Ther, V73, P44; Fong KNK, 2009, AM J OCCUP THER, V63, P525, DOI 10.5014/ajot.63.5.525; FOXX RM, 1989, BEHAV THER, V20, P61, DOI 10.1016/S0005-7894(89)80118-2; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Graham Ian D, 2005, Evid Based Nurs, V8, P68, DOI 10.1136/ebn.8.3.68; Grant M, 2012, NEUROPSYCHOL REHABIL, V22, P852, DOI 10.1080/09602011.2012.693455; Grimshaw Jeremy, 2004, J Contin Educ Health Prof, V24 Suppl 1, pS31, DOI 10.1002/chp.1340240506; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hewitt J, 2006, NEUROPSYCHOLOGIA, V44, P1468, DOI 10.1016/j.neuropsychologia.2005.11.016; Howick J, 2011 OXFORD CEBM EVI; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Landa-Gonzalez BELKIS, 2001, Occup Ther Int, V8, P49, DOI 10.1002/oti.131; Lane-Brown AT, 2009, NEUROPSYCHOL REHABIL, V19, P481, DOI 10.1080/09602010902949207; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00009; Lindsay P, 2008, CAN MED ASSOC J, V179, pS1, DOI 10.1503/cmaj.081148.R2; Lucas SE, 2005, AUSTR OCCUPATIONAL T, V52, P160, DOI DOI 10.1111/J.1440-1630.2005.00485.X; Lundqvist A, 2010, BRAIN INJURY, V24, P823, DOI 10.3109/02699051003724986; Luria A.R., 1966, HIGHER CORTICAL FUNC; Luria A.R., 1973, WORKING BRAIN INTRO; Maher CG, 2003, PHYS THER REHABIL J, V83, P713, DOI 10.1093/ptj/83.8.713; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; Man DWK, 2006, NEUROREHABILITATION, V21, P205; Man DWK, 2006, BRAIN INJURY, V20, P981, DOI 10.1080/13561820600909852; Marshall RC, 2004, APHASIOLOGY, V18, P659, DOI 10.1080/02687030444000237; McGraw-Hunter M, 2006, BRAIN INJURY, V20, P1061, DOI 10.1080/02699050600912163; McPherson KM, 2009, CLIN REHABIL, V23, P296, DOI 10.1177/0269215509102980; Miotto EC, 2009, NEUROPSYCHOL REHABIL, V19, P517, DOI 10.1080/09602010802332108; Moseley A, 2000, BRAIN IMPAIR, V1, P130; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth T, 2008, J REHABIL MED, V40, P81, DOI 10.2340/16501977-0124; Ownsworth T, 2010, NEUROPSYCHOL REHABIL, V20, P59, DOI 10.1080/09602010902949223; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Papathanasiou I, 2011, APHASIA RELATED DISO, P365; Perdices M., 2006, BRAIN IMPAIR, V7, P119, DOI DOI 10.1375/BRIM.7.2.119; Ponsford J, 2014, J HEAD TRAUMA REHAB, V29, P321, DOI 10.1097/HTR.0000000000000072; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rebmann MJ, 1995, REHABIL PSYCHOL, V40, P279, DOI 10.1037/0090-5550.40.4.279; Richardson W. S., 2000, EVIDENCE BASED MED P, V2nd; Roberts CB, 2006, BRAIN INJURY, V20, P485, DOI 10.1080/02699050600664665; Satish U, 2008, DISABIL REHABIL, V30, P468, DOI 10.1080/09638280701625401; Schmidt J, 2013, NEUROREHAB NEURAL RE, V27, P316, DOI 10.1177/1545968312469838; Schmidt J, 2011, J REHABIL MED, V43, P673, DOI 10.2340/16501977-0846; Soong W, 2005, INT J REHABIL RES, V28, P341, DOI 10.1097/00004356-200512000-00006; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Stuss D., 1991, AWARENESS DEFICIT BR, P63; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; Tate R, 2004, NEUROPSYCHOL REHABIL, V14, P517, DOI 10.1080/09602010343000182; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Tate RL, 2014, NEUROPSYCHOL REHABIL, V24, P315, DOI 10.1080/09602011.2013.875043; Tate RL, 2013, NEUROPSYCHOL REHABIL, V23, P619, DOI 10.1080/09602011.2013.824383; Tate RL, 2011, BRAIN IMPAIR, V12, P1, DOI 10.1375/brim.12.1.1; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; The ADAPTE Collaboration, 2009, ADAPTE PROC RES TOOL; Togher L, 2014, J HEAD TRAUMA REHAB, V29, P353, DOI 10.1097/HTR.0000000000000071; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Turkstra LS, 2002, J COMMUN DISORD, V35, P467, DOI 10.1016/S0021-9924(02)00118-1; van Heugten C, 2012, NEUROPSYCHOL REHABIL, V22, P653, DOI 10.1080/09602011.2012.680891; Vas AK, 2011, J HEAD TRAUMA REHAB, V26, P224, DOI 10.1097/HTR.0b013e318218dd3d; Velikonja D, 2014, J HEAD TRAUMA REHAB, V29, P369, DOI 10.1097/HTR.0000000000000069; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Warner M., 1991, HERDERS WARRIORS TRA, P3, DOI DOI 10.4095/134069; WEBB PM, 1994, REHABIL PSYCHOL, V39, P179, DOI 10.1037/h0080321; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Ylvisaker M. E., 1998, TRAUMATIC BRAIN INJU; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; YOUNGJOHN JR, 1989, REHABIL PSYCHOL, V34, P217, DOI 10.1037//0090-5550.34.3.217; Zhou J, 1996, J HEAD TRAUMA REHAB, V11, P51, DOI 10.1097/00001199-199602000-00007; Zoccolotti P, 2011, EUR J PHYS REHAB MED, V47, P123	105	77	78	0	51	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					338	352		10.1097/HTR.0000000000000068			15	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300010	24984096				2022-02-06	
J	Keightley, ML; Saluja, RS; Chen, JK; Gagnon, I; Leonard, G; Petrides, M; Ptito, A				Keightley, Michelle L.; Saluja, Rajeet Singh; Chen, Jen-Kai; Gagnon, Isabelle; Leonard, Gabriel; Petrides, Michael; Ptito, Alain			A Functional Magnetic Resonance Imaging Study of Working Memory in Youth after Sports-Related Concussion: Is It Still Working?	JOURNAL OF NEUROTRAUMA			English	Article						concussion; fMRI; working memory; youth	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; SCHOOL FOOTBALL PLAYERS; DIFFUSE AXONAL INJURY; TEMPORAL WINDOW; WHITE-MATTER; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; WILD BOOTSTRAP; RUGBY PLAYERS	In children, the importance of detecting deficits after mild traumatic brain injury (mTBI) or concussion has grown with the increasing popularity of leisure physical activities and contact sports. Whereas most postconcussive symptoms (PCS) are similar for children and adults, the breadth of consequences to children remains largely unknown. To investigate the effect of mTBI on brain function, we compared working memory performance and related brain activity using blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) in 15 concussed youths and 15 healthy age-matched control subjects. Neuropsychological tests, self-perceived PCS, and levels of anxiety and depression were also assessed. Our results showed that, behaviorally, concussed youths had significantly worse performances on the working memory tasks, as well as on the Rey figure delayed recall and verbal fluency. fMRI results revealed that, compared to healthy children, concussed youths had significantly reduced task-related activity in bilateral dorsolateral prefrontal cortex, left premotor cortex, supplementary motor area, and left superior parietal lobule during performance of verbal and nonverbal working memory tasks. Additionally, concussed youths also showed less activation than healthy controls in the dorsal anterior cingulate cortex, left thalamus, and left caudate nucleus during the nonverbal task. Regression analysis indicated that BOLD signal changes in bilateral dorsolateral prefrontal cortex were significantly correlated with performance such that greater activities in these regions, relative to the control condition, were associated with greater accuracy. Our findings confirmed functional alterations in brain activity after concussion in youths, a result similar to that observed in adults. However, significant differences were noted. In particular, the observation of reduced working memory accuracy suggests that youths may be unable to engage compensatory strategies to maintain cognitive performance after mTBI. This has significant implications for safe return to daily activities, including competitive sport.	[Keightley, Michelle L.; Chen, Jen-Kai] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON M4G 1R8, Canada; [Keightley, Michelle L.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Keightley, Michelle L.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada; [Keightley, Michelle L.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Keightley, Michelle L.] Toronto Rehabil Inst, Toronto, ON, Canada; [Saluja, Rajeet Singh; Chen, Jen-Kai; Leonard, Gabriel; Petrides, Michael; Ptito, Alain] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Gagnon, Isabelle] McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Montreal, PQ H3H 1P3, Canada; [Ptito, Alain] McGill Univ, Ctr Hlth, Dept Psychol, Montreal, PQ H3H 1P3, Canada		Keightley, ML (corresponding author), Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, 150 Kilgour Rd, Toronto, ON M4G 1R8, Canada.	mkeightley@hollandbloorview.ca	Meijer, Anna/K-5118-2016; Soddu, Andrea/K-7087-2014; Laureys, Steven/A-3349-2011	Soddu, Andrea/0000-0001-6833-745X; Gagnon, Isabelle/0000-0003-2043-1644	CIHRCanadian Institutes of Health Research (CIHR) [484706]	The authors thank CIHR (grant no. 484706; primary investigator: M. Keightley; coinvestigators: A. Ptito, K. Johnston, and N. Lobaugh) for their financial support of this study as well as the members of the Trauma Program of the Montreal Children's Hospital, McGill University Health Center, for their collaboration.	AFL Community Club, 2013, CONC MAN BOOKL; AFL Community Club, 2011, GUID MAN CONC AUSTR; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; [Anonymous], 2013, Br J Sports Med, V47, P259; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Boffano P, 2011, J CRANIOFAC SURG, V22, P2053, DOI 10.1097/SCS.0b013e318231988d; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Chen J, 2012, ASIAN PAC J TROP MED, V5, P67, DOI 10.1016/S1995-7645(11)60248-4; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Cimatti M, 2006, J Neurosurg Sci, V50, P83; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Dimou S, 2013, NEUROSURG REV, V36, P205, DOI 10.1007/s10143-012-0436-8; Dimou S, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00500; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Filippi M, 2001, NEUROLOGY, V56, P304, DOI 10.1212/WNL.56.3.304; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Forbes JA, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12288; Fourtassi M, 2011, CLIN NEUROL NEUROSUR, V113, P716, DOI 10.1016/j.clineuro.2011.07.010; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gosselin N, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12253; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Gosselin N, 2010, PHYSICIAN SPORTSMED, V38, P27, DOI 10.3810/psm.2010.10.1805; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Jung RE, 2009, INTELLIGENCE, V37, P192, DOI 10.1016/j.intell.2008.10.009; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kalsbeek A, 2010, ANN NY ACAD SCI, V1212, P114, DOI 10.1111/j.1749-6632.2010.05800.x; Keightley M. L., 2013, J NEUROTRAUMA, V31; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kelly JP, 1997, NEUROLOGY, V48, P581; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Kutcher JS, 2013, BRIT J SPORT MED, V47, P299, DOI 10.1136/bjsports-2013-092257; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; Luther N, 2012, NEUROSURGERY, V71, pE558, DOI 10.1227/01.neu.0000417733.09300.04; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Medina D, 2006, NEUROBIOL AGING, V27, P663, DOI 10.1016/j.neurobiolaging.2005.03.026; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; National Rugby League, 2013, MAN CONC RUGB LEAG; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Perron AD, 2001, ACAD EMERG MED, V8, P296, DOI 10.1111/j.1553-2712.2001.tb01312.x; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Teel E. F., 2013, CLIN NEUROPHYSIOL, V17, P01044; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Whitcher B, 2008, HUM BRAIN MAPP, V29, P346, DOI 10.1002/hbm.20395; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhu T, 2008, NEUROIMAGE, V40, P1144, DOI 10.1016/j.neuroimage.2008.01.016	112	77	78	1	36	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2014	31	5					437	451		10.1089/NEU.2013.3052			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AB4ZV	WOS:000331799600242	24070614	Green Published, Bronze			2022-02-06	
J	Covassin, T; Elbin, RJ; Bleecker, A; Lipchik, A; Kontos, AP				Covassin, Tracey; Elbin, R. J.; Bleecker, Alisha; Lipchik, Adam; Kontos, Anthony P.			Are There Differences in Neurocognitive Function and Symptoms Between Male and Female Soccer Players After Concussions?	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						sex difference; soccer; cognitive function; concussion	SEGMENT DYNAMIC STABILIZATION; INJURY SURVEILLANCE SYSTEM; SPORTS-RELATED CONCUSSION; STATES HIGH-SCHOOL; SEX-DIFFERENCES; DESCRIPTIVE EPIDEMIOLOGY; INTERNATIONAL-CONFERENCE; AGREEMENT STATEMENT; HEAD ACCELERATION; BASE-LINE	Background: Researchers have suggested that there are sex differences in outcomes after sport-related concussions. Factors such as sport type/rules, age, and body mass index (BMI) may influence these differences. Hypotheses/Purpose: The purposes of this study were (1) to examine neurocognitive performance after concussions between male and female soccer players and (2) to compare concussion symptoms between male and female soccer players. We hypothesized that female concussed soccer players would report more concussion symptoms and worse cognitive performance compared with male concussed soccer players. Study Design: Cohort study; Level of evidence, 2. Methods: A total of 39 male (mean BMI, 22.21 2.34 kg/m(2); mean age, 17.69 2.10 years) and 56 female (mean BMI, 23.47 +/- 2.66 kg/m(2); mean age, 17.78 +/- 2.30 years) concussed soccer players participated in this study. Participants were similar in age, history of concussion, sport, and time since injury. Participants completed computerized neurocognitive tests and symptom reports at baseline and 8 days after injury. Body mass index served as a covariate in all analyses. Results: After adjusting for BMI, results from a repeated-measures analysis of covariance (ANCOVA) revealed a group by time interaction for visual memory (F-1,F-82 = 5.50; P = .021). Specifically, female concussed soccer players (mean score, 68.7 +/- 15.2) performed worse at 8 days after a concussion compared with male concussed athletes (mean score, 77.2 +/- 8.9). Results of another ANCOVA for total concussion symptoms indicated an interaction for group by time (F-1,F-82 = 4.26; P = .04). Specifically, female concussed soccer players (mean score, 11.9 +/- 15.7) reported more total concussion symptoms at 8 days compared with male concussed athletes (mean score, 5.3 +/- 7.4). There were significant main effects for sex on verbal (F-1,F-82 = 5.98; P = .017) and visual (F-1,F-82 = 4.65; P = .034) memory, with female athletes reporting lower scores than male athletes. Female athletes also reported more symptoms on the migraine-cognitive-fatigue (F-1,F-82 = 10.8; P = .001) and sleep (F-1,F-82 = 9.2; P = .003) clusters than male athletes. Conclusion: In contrast to recent studies, after controlling for BMI, female athletes exhibited lower performance on visual memory composite scores and higher scores on total symptoms than male athletes after concussions.	[Covassin, Tracey; Elbin, R. J.; Bleecker, Alisha; Lipchik, Adam; Kontos, Anthony P.] Michigan State Univ, E Lansing, MI 48824 USA		Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 308 West Circle Dr,Room 105, E Lansing, MI 48824 USA.	covassin@msu.edu		Kontos, Anthony/0000-0002-3749-4310			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Dick R, 2007, J ATHL TRAINING, V42, P278; Dick R, 2007, J ATHL TRAINING, V42, P194; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Mansell J, 2005, J ATHL TRAINING, V40, P310; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	25	77	77	1	36	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2013	41	12					2890	2895		10.1177/0363546513509962			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	258QH	WOS:000327473300023	24197616				2022-02-06	
J	Ichai, C; Payen, JF; Orban, JC; Quintard, H; Roth, H; Legrand, R; Francony, G; Leverve, XM				Ichai, Carole; Payen, Jean-Francois; Orban, Jean-Christophe; Quintard, Herve; Roth, Hubert; Legrand, Robin; Francony, Gilles; Leverve, Xavier M.			Half-molar sodium lactate infusion to prevent intracranial hypertensive episodes in severe traumatic brain injured patients: a randomized controlled trial	INTENSIVE CARE MEDICINE			English	Article						Intracranial pressure; Intracranial hypertension; Lactate solution; Osmotherapy; Traumatic brain injury	POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL BLOOD-FLOW; HYPERTONIC SALINE; COGNITIVE DEFICITS; METABOLISM; RAT; COTRANSPORTERS; MICRODIALYSIS; HYPOGLYCEMIA; PRESSURE	Preventive treatments of traumatic intracranial hypertension are not yet established. We aimed to compare the efficiency of half-molar sodium lactate (SL) versus saline serum solutions in preventing episodes of raised intracranial pressure (ICP) in patients with severe traumatic brain injury (TBI). This was a double-blind, randomized controlled trial including 60 patients with severe TBI requiring ICP monitoring. Patients were randomly allocated to receive a 48-h continuous infusion at 0.5 ml/kg/h of either SL (SL group) or isotonic saline solution (control group) within the first 12 h post-trauma. Serial measurements of ICP, as well as fluid, sodium, and chloride balance were performed over the 48-h study period. The primary outcome was the number of raised ICP (a parts per thousand yen20 mmHg) requiring a specific treatment. Raised ICP episodes were reduced in the SL group as compared to the control group within the 48-h study period: 23 versus 53 episodes, respectively (p < 0.05). The proportion of patients presenting raised ICP episodes was smaller in the SL group than in the saline group: 11 (36 %) versus 20 patients (66 %) (p < 0.05). Cumulative 48-h fluid and chloride balances were reduced in the SL group compared to the control group (both p < 0.01). A 48-h infusion of SL decreased the occurrence of raised ICP episodes in patients with severe TBI, while reducing fluid and chloride balances. These findings suggest that SL solution could be considered as an alternative treatment to prevent raised ICP following severe TBI.	[Ichai, Carole; Orban, Jean-Christophe; Quintard, Herve] Univ Nice Sophia Antipolis, St Roch Hosp, Medicosurg Intens Care Unit, F-06000 Nice, France; [Payen, Jean-Francois; Legrand, Robin; Francony, Gilles] Albert Michallon Hosp, Dept Anesthesiol & Intens Care, F-38043 Grenoble, France; [Payen, Jean-Francois; Francony, Gilles] Univ Grenoble 1, Grenoble Inst Neurosci, INSERM, U836, F-38042 Grenoble, France; [Roth, Hubert; Leverve, Xavier M.] Univ Grenoble 1, Albert Michallon Hosp, INSERM, U1055,Lab Biol Fondamentale & Appl, F-38042 Grenoble, France		Ichai, C (corresponding author), Univ Nice Sophia Antipolis, St Roch Hosp, Medicosurg Intens Care Unit, F-06000 Nice, France.	ichai@unice.fr	Payen, Jean-Francois/L-6667-2014	ROTH, Hubert/0000-0002-1980-3220			Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Berthet C, 2009, J CEREBR BLOOD F MET, V29, P1780, DOI 10.1038/jcbfm.2009.97; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Gordon GRJ, 2008, NATURE, V456, P745, DOI 10.1038/nature07525; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Jourdain P, 2011, J NEUROSCI, V31, P11846, DOI 10.1523/JNEUROSCI.0286-11.2011; Kahle KT, 2008, NAT CLIN PRACT NEURO, V4, P490, DOI 10.1038/ncpneuro0883; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; King P, 1998, CLIN SCI, V94, P157, DOI 10.1042/cs0940157; Levasseur JE, 2006, NEUROSURGERY, V59, P1122, DOI 10.1227/01.NEU.0000245581.00908.AF; Leverve XM, 2008, INTENS CARE MED, V34, P1796, DOI 10.1007/s00134-008-1165-x; MARAN A, 1994, LANCET, V343, P16, DOI 10.1016/S0140-6736(94)90876-1; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meierhans R, 2012, MINERVA ANESTESIOL, V78, P185; Mustafa I, 2002, SHOCK, V18, P306, DOI 10.1097/00024382-200210000-00003; Oddo M, 2012, STROKE, V43, P1418, DOI 10.1161/STROKEAHA.111.648568; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; PANNIER JL, 1974, STROKE, V5, P324, DOI 10.1161/01.STR.5.3.324; Prieto R, 2011, BRAIN RES, V1404, P39, DOI 10.1016/j.brainres.2011.06.006; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; STEWART PA, 1978, RESP PHYSIOL, V33, P9, DOI 10.1016/0034-5687(78)90079-8; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Yoon S, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00365	40	77	78	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	AUG	2013	39	8					1413	1422		10.1007/s00134-013-2978-9			10	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182UC	WOS:000321769100009	23749153				2022-02-06	
J	Roth, RM; Lance, CE; Isquith, PK; Fischer, AS; Giancola, PR				Roth, Robert M.; Lance, Charles E.; Isquith, Peter K.; Fischer, Adina S.; Giancola, Peter R.			Confirmatory Factor Analysis of the Behavior Rating Inventory of Executive Function-Adult Version in Healthy Adults and Application to Attention-Deficit/Hyperactivity Disorder	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Executive function; Factor analysis; Psychometrics; Self-regulation; Neuropsychology; ADHD	COVARIANCE STRUCTURE-ANALYSIS; TRAUMATIC BRAIN-INJURY; ANTERIOR CINGULATE CORTEX; FRONTAL LOBES; FIT INDEXES; ORBITOFRONTAL CORTEX; SOCIAL-BEHAVIOR; TEST STATISTICS; DAILY-LIFE; CHILDREN	The Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) is a questionnaire measure designed to assess executive functioning in everyday life. Analysis of data from the BRIEF-A standardization sample yielded a two-factor solution (labeled Behavioral Regulation and Metacognition). The present investigation employed confirmatory factor analysis (CFA) to evaluate four alternative models of the factor structure of the BRIEF-A self-report form in a sample of 524 healthy young adults. Results indicated that a three-factor model best fits the data: a Metacognition factor, a Behavioral Regulation factor consisting of the Inhibit and Self-Monitor scales, and an Emotional Regulation factor composed of the Emotional Control and Shift scales. The three factors contributed 14%, 19%, and 24% of unique variance to the model, respectively, and a second-order general factor accounted for 41% of variance overall. This three-factor solution is consistent with recent CFAs of the Parent report form of the BRIEF. Furthermore, although the Behavioral Regulation factor score in the two-factor model did not differ between adults with attention-deficit/hyperactivity disorder and a matched healthy comparison group, greater impairment on the Behavioral Regulation factor but not the Emotional Regulation factor was found using the three-factor model. Together, these findings support the multidimensional nature of executive function and the clinical relevance of a three-factor model of the BRIEF-A.	[Roth, Robert M.; Isquith, Peter K.; Fischer, Adina S.] Dartmouth DHMC, Geisel Sch Med, Dept Psychiat, Lebanon, NH 03756 USA; [Lance, Charles E.] Univ Georgia, Dept Psychol, Athens, GA 30602 USA; [Giancola, Peter R.] Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA		Roth, RM (corresponding author), Dartmouth DHMC, Geisel Sch Med, Dept Psychiat, Neuropsychol Program, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	robert.m.roth@dartmouth.edu	Isquith, Peter/AAY-4851-2020		National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01-AA-11691]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA011691] Funding Source: NIH RePORTER	This work was supported by grants from the National Institute on Alcohol Abuse and Alcoholism (R01-AA-11691 to PRG) and the National Center for Research Resources to PRG.	American Psychatric Association, 2000, DIAGN STAT MAN MENT; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Baird AA, 2010, SOC NEUROSCI-UK, V5, P519, DOI 10.1080/17470911003747386; Barkley R.A., 1997, ADHD NATURE SELF CON; Barkley R.A., 2011, EXECUTIVE FUNCTIONIN; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Beer JS, 2006, J COGNITIVE NEUROSCI, V18, P871, DOI 10.1162/jocn.2006.18.6.871; Biederman J, 2011, EUR NEUROPSYCHOPHARM, V21, P508, DOI 10.1016/j.euroneuro.2010.11.005; Brown TM, 2008, CHILD NEUROPSYCHOL, V14, P118, DOI 10.1080/09297040601147605; BROWNE MW, 1984, BRIT J MATH STAT PSY, V37, P62, DOI 10.1111/j.2044-8317.1984.tb00789.x; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Chang WP, 2009, J PSYCHOPHYSIOL, V23, P113, DOI 10.1027/0269-8803.23.3.113; Chaytor N, 2007, BRAIN INJURY, V21, P615, DOI 10.1080/02699050701426949; CHOU CP, 1991, BRIT J MATH STAT PSY, V44, P347, DOI 10.1111/j.2044-8317.1991.tb00966.x; Christ SE, 2010, NEUROPSYCHOLOGY, V24, P590, DOI 10.1037/a0019176; Cortina JM, 2001, ORGAN RES METHODS, V4, P324, DOI 10.1177/109442810144002; Dawson EL, 2012, J CLIN EXP NEUROPSYC, V34, P297, DOI 10.1080/13803395.2011.639297; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; Egeland J, 2010, CHILD NEUROPSYCHOL, V16, P326, DOI 10.1080/09297041003601462; Garcia-Molina A, 2012, BRAIN INJURY, V26, P864, DOI 10.3109/02699052.2012.655362; Garlinghouse MA, 2010, SCHIZOPHR RES, V120, P71, DOI 10.1016/j.schres.2010.02.1067; Garon N, 2008, PSYCHOL BULL, V134, P31, DOI 10.1037/0033-2909.134.1.31; Giancola PR, 2012, PSYCHOL ADDICT BEHAV, V26, P201, DOI 10.1037/a0025207; Gioia G.A., 2000, BRIEF BEHAV RATING I; Gioia GA, 2001, PSYCHOLOGICAL AND DEVELOPMENTAL ASSESSMENT, P317; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gioia GA, 2005, PSYCHOL ASSESS RESOU; Godefroy O, 1999, CORTEX, V35, P1, DOI 10.1016/S0010-9452(08)70782-2; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Hu LT, 1998, PSYCHOL METHODS, V3, P424, DOI 10.1037/1082-989X.3.4.424; HU LT, 1992, PSYCHOL BULL, V112, P351, DOI 10.1037//0033-2909.112.2.351; Joreskog K. G., 2004, LISREL 8 80; Jurado MB, 2007, NEUROPSYCHOL REV, V17, P213, DOI 10.1007/s11065-007-9040-z; Klenberg L, 2001, DEV NEUROPSYCHOL, V20, P407, DOI 10.1207/S15326942DN2001_6; Kompus K, 2009, NEUROSCI LETT, V467, P76, DOI 10.1016/j.neulet.2009.10.005; Koven NS, 2010, PERS INDIV DIFFER, V49, P24, DOI 10.1016/j.paid.2010.02.034; Kumbhani SR, 2010, J NEUROPSYCH CLIN N, V22, P304, DOI 10.1176/appi.neuropsych.22.3.304; Latzman RD, 2010, ASSESSMENT, V17, P172, DOI 10.1177/1073191109356254; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; MARSH HW, 1988, PSYCHOL BULL, V103, P391, DOI 10.1037/0033-2909.103.3.391; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Mohanty A, 2007, PSYCHOPHYSIOLOGY, V44, P343, DOI 10.1111/j.1469-8986.2007.00515.x; Mur M, 2007, J CLIN PSYCHIAT, V68, P1078, DOI 10.4088/JCP.v68n0715; Nigg JT, 2005, J ABNORM PSYCHOL, V114, P706, DOI 10.1037/0021-843X.114.3.706; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Rabin LA, 2011, J CLIN EXP NEUROPSYC, V33, P344, DOI 10.1080/13803395.2010.518597; Reid RC, 2010, INT J NEUROSCI, V120, P120, DOI 10.3109/00207450903165577; Rotenberg-Shpigelman S., 2008, ISRAELI J OCCUPATION, V17, P77; Roth RM, 2006, FOCUS ON NEUROPSYCHOLOGY RESEARCH, P1; Schroeder VM, 2008, FAM RELAT, V57, P404, DOI 10.1111/j.1741-3729.2008.00509.x; Slick DJ, 2006, CHILD NEUROPSYCHOL, V12, P181, DOI 10.1080/09297040600611320; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Swick D, 2002, P NATL ACAD SCI USA, V99, P16354, DOI 10.1073/pnas.252521499; TRANEL D, 1994, HDB NEUROPSYCHOLOGY, P125; Turken U, 2008, NEUROSCI LETT, V441, P7, DOI 10.1016/j.neulet.2008.05.115; van Veen V, 2002, PHYSIOL BEHAV, V77, P477, DOI 10.1016/S0031-9384(02)00930-7; Viskontas IV, 2007, ANN NY ACAD SCI, V1121, P528, DOI 10.1196/annals.1401.025; Waber DP, 2006, DEV NEUROPSYCHOL, V29, P459, DOI 10.1207/s15326942dn2903_5; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Zelazo P. D., 2002, HDB CHILDHOOD COGNIT, P445, DOI DOI 10.1002/9780470996652.CH20; [No title captured]	63	77	79	0	53	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2013	28	5					425	434		10.1093/arclin/act031			10	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	186CN	WOS:000322019600005	23676185	Bronze, Green Published			2022-02-06	
J	Xu, JS; Li, Y; Lin, HQ; Sinha, R; Potenza, MN				Xu, Jiansong; Li, Yang; Lin, Haiqun; Sinha, Rajita; Potenza, Marc N.			Body mass index correlates negatively with white matter integrity in the fornix and corpus callosum: A diffusion tensor imaging study	HUMAN BRAIN MAPPING			English	Article						DTI; obese; overweight; neuroimaging; BMI; brain structure	TRAUMATIC BRAIN-INJURY; MIDDLE-AGED ADULTS; MAGNETIC-RESONANCE; WALLERIAN DEGENERATION; COGNITIVE IMPAIRMENT; MEASURED HEIGHT; HUMAN OBESITY; VISCERAL FAT; VOLUME; WEIGHT	Overweight or obese body habitus is associated with cognitive deficits, impaired brain function, gray matter atrophy, and white matter (WM) hyperintensities. However, few diffusion tensor imaging (DTI) studies have assessed WM integrity in relation to overweight or obese status. This study assessed relationships between body mass index (BMI) and values of DTI parameters among 51 normal weight (lean), overweight, and obese participants who were otherwise healthy. BMI correlated negatively with fractional anisotropy and axial eigenvalues (1) in the body of corpus callosum (CC), positively with mean diffusivity and radial eigenvalues () in the fornix and splenium of CC, and positively with 1 in the right corona radiata (CR) and superior longitudinal fasciculus (SLF). These data indicate that BMI correlates negatively with WM integrity in the fornix and CC. Furthermore, the different patterns of BMI-related differences in DTI parameters at the fornix, body, and splenium of the CC, and the right CR and SLF suggest that different biological processes may underlie BMI-related impairments of WM integrity in different brain regions. Hum Brain Mapp, 2013. (c) 2011 Wiley Periodicals, Inc.	[Xu, Jiansong; Sinha, Rajita; Potenza, Marc N.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Li, Yang; Lin, Haiqun] Yale Univ, Sch Publ Hlth, Div Biostat, New Haven, CT USA; [Potenza, Marc N.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA; [Potenza, Marc N.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA		Xu, JS (corresponding author), 2 Church St,Suite 215, New Haven, CT USA.	Jiansong.xu@yale.edu		Lin, Haiqun/0000-0002-3114-9671	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Veteran's AdministrationUS Department of Veterans Affairs; Mohegan Sun Casino; National Center for Responsible Gaming, and its affiliated Institute for Research on Gambling Disorders; Forest Laboratories; Psyadon pharmaceuticals; NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K01 DA027750R01 DA020908R01 DA019039RL1 AA017539P50 DA09241P20 DA027844]; VA VISN1 MIRECC; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [RL1AA017539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P20DA027844, P50DA009241, R03DA022364, R01DA020908, K01DA027750, R01DA019039] Funding Source: NIH RePORTER	Dr. Potenza has consulted for and advised Boehringer Ingelheim; He has financial interests in Somaxon; He has received research support from the National Institutes of Health, Veteran's Administration, Mohegan Sun Casino, the National Center for Responsible Gaming, and its affiliated Institute for Research on Gambling Disorders, and Forest Laboratories and Psyadon pharmaceuticals; He has participated in surveys, mailings, or telephone consultations related to drug addiction, impulse control disorders or other health topics; He has consulted for law offices on issues related to addictions or impulse control disorders; He has provided clinical care in the Connecticut Department of Mental Health and Addiction Services Problem Gambling Services Program; He has performed grant reviews for the National Institutes of Health and other agencies; He has given academic lectures in grand rounds, CME events and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts.; Contract grant sponsor: NIDA; Contract grant number: K01 DA027750R01 DA020908R01 DA019039RL1 AA017539P50 DA09241P20 DA027844; Contract grant sponsor: VA VISN1 MIRECC.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Anan F, 2009, EUR J CLIN INVEST, V39, P368, DOI 10.1111/j.1365-2362.2009.02103.x; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Bennett IJ, 2010, HUM BRAIN MAPP, V31, P378, DOI 10.1002/hbm.20872; Bruce-Keller AJ, 2009, BBA-MOL BASIS DIS, V1792, P395, DOI 10.1016/j.bbadis.2008.10.004; Burzynska AZ, 2010, NEUROIMAGE, V49, P2104, DOI 10.1016/j.neuroimage.2009.09.041; Cazettes F, 2011, BRAIN RES, V1373, P101, DOI 10.1016/j.brainres.2010.12.008; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Cournot M, 2006, NEUROLOGY, V67, P1208, DOI 10.1212/01.wnl.0000238082.13860.50; Debette S, 2010, ANN NEUROL, V68, P136, DOI 10.1002/ana.22062; Di Paola M, 2010, J ALZHEIMERS DIS, V20, P67, DOI 10.3233/JAD-2010-1370; Fergenbaum JH, 2009, OBESITY, V17, P1957, DOI 10.1038/oby.2009.161; First M., 1997, STRUCTURED CLIN INTE; First M.B., 1996, STRUCTURED CLIN INTE; Fitzpatrick AL, 2009, ARCH NEUROL-CHICAGO, V66, P336, DOI 10.1001/archneurol.2008.582; Fujiwara S, 2008, NEURORADIOLOGY, V50, P131, DOI 10.1007/s00234-007-0317-y; Gazdzinski S, 2008, ANN NEUROL, V63, P652, DOI 10.1002/ana.21377; Gazdzinski S, 2010, ALCOHOL CLIN EXP RES, V34, P2089, DOI 10.1111/j.1530-0277.2010.01305.x; Gorber SC, 2007, OBES REV, V8, P307, DOI 10.1111/j.1467-789X.2007.00347.x; Griebeler ML, 2011, J WOMENS HEALTH, V20, P599, DOI 10.1089/jwh.2009.1850; Gunstad J, 2008, INT J NEUROSCI, V118, P1582, DOI 10.1080/00207450701392282; Gunstad J, 2010, NEUROEPIDEMIOLOGY, V34, P222, DOI 10.1159/000297742; Gustafson D, 2004, NEUROLOGY, V63, P1876, DOI 10.1212/01.WNL.0000141850.47773.5F; Gustafson DR, 2004, INT PSYCHOGERIATR, V16, P327, DOI 10.1017/s1041610204000353; Haltia LT, 2007, J CLIN ENDOCR METAB, V92, P3278, DOI 10.1210/jc.2006-2495; Hill A, 1998, J PUBLIC HEALTH MED, V20, P206, DOI 10.1093/oxfordjournals.pubmed.a024744; Ho AJ, 2010, NEUROBIOL AGING, V31, P1326, DOI 10.1016/j.neurobiolaging.2010.04.006; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Jagust W, 2005, ARCH NEUROL-CHICAGO, V62, P1545, DOI 10.1001/archneur.62.10.1545; Jbabdi S, 2010, NEUROIMAGE, V49, P247, DOI 10.1016/j.neuroimage.2009.08.039; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Marks B, BR J SPORTS IN PRESS; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Mori S, 2009, CURR OPIN NEUROL, V22, P362, DOI 10.1097/WCO.0b013e32832d954b; Mueller K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018544; Neil JJ, 2008, J MAGN RESON IMAGING, V27, P1, DOI 10.1002/jmri.21087; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Pannacciulli N, 2006, NEUROIMAGE, V31, P1419, DOI 10.1016/j.neuroimage.2006.01.047; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Pistell PJ, 2010, J NEUROIMMUNOL, V219, P25, DOI 10.1016/j.jneuroim.2009.11.010; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; SENA A, 1985, J NEUROL SCI, V68, P233, DOI 10.1016/0022-510X(85)90104-2; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2004, BRIT J RADIOL, V77, pS167, DOI 10.1259/bjr/33553595; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith S, 2007, NEUROIMAGE, V34, P127, DOI 10.1016/j.neuroimage.2006.09.019; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sriram K, 2002, NEUROSCIENCE, V115, P1335, DOI 10.1016/S0306-4522(02)00306-8; Stanek KM, 2011, OBESITY, V19, P500, DOI 10.1038/oby.2010.312; Stranahan AM, 2008, HIPPOCAMPUS, V18, P1085, DOI 10.1002/hipo.20470; Taki Y, 2008, OBESITY, V16, P119, DOI 10.1038/oby.2007.4; Thomalla G, 2004, NEUROIMAGE, V22, P1767, DOI 10.1016/j.neuroimage.2004.03.041; Volkow ND, 2011, TRENDS COGN SCI, V15, P37, DOI 10.1016/j.tics.2010.11.001; Walther K, 2010, HUM BRAIN MAPP, V31, P1052, DOI 10.1002/hbm.20916; Ward MA, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-23; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Zarei M, 2006, J ANAT, V209, P311, DOI 10.1111/j.1469-7580.2006.00615.x; Zhang Y, 2010, NEUROBIOL AGING, V31, P1991, DOI 10.1016/j.neurobiolaging.2008.10.009	61	77	78	0	32	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAY	2013	34	5					1044	1052		10.1002/hbm.21491			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	122DT	WOS:000317297500005	22139809	Green Accepted, Green Published			2022-02-06	
J	Cooper, DJ; Myburgh, J; Heritier, S; Finfer, S; Bellomo, R; Billot, L; Murray, L; Vallance, S				Cooper, D. James; Myburgh, John; Heritier, Stephane; Finfer, Simon; Bellomo, Rinaldo; Billot, Laurent; Murray, Lynette; Vallance, Shirley		SAFE-TBI Investigators; Australian & New Zealand Intensive	Albumin Resuscitation for Traumatic Brain Injury: Is Intracranial Hypertension the Cause of Increased Mortality?	JOURNAL OF NEUROTRAUMA			English	Article						albumin; ICP; resuscitation; saline; TBI	QUALITY-OF-LIFE; SUBARACHNOID HEMORRHAGE; PROGRESSION; PRESSURE; MODELS	Mortality is higher in patients with traumatic brain injury (TBI) resuscitated with albumin compared with saline, but the mechanism for increased mortality is unknown. In patients from the Saline vs. Albumin Fluid Evaluation (SAFE) study with TBI who underwent intracranial pressure (ICP) monitoring, interventional data were collected from randomization to day 14 to determine changes in ICP (primary outcome) and in therapies used to treat increased ICP. Pattern mixture modelling, designed to address informative dropouts, was used to compare temporal changes between the albumin and saline groups, and 321 patients were identified, of whom 164 (51.1%) received albumin and 157 (48.9%) received saline. There was a significant linear increase in mean ICP and significantly more deaths in the albumin group compared with saline when ICP monitoring was discontinued during the first week (1.30 +/- 0.33 vs. -0.37 +/- 0.36, p = 0.0006; and 34.4% vs. 17.4%; p = 0.006 respectively), but not when monitoring ceased during the second week (-0.08 +/- 0.44 vs. -0.23 +/- 0.38, p = 0.79; and 18.6% vs. 12.1%; p = 0.36 respectively). There were statistically significant differences in the mean total daily doses of morphine (-0.42 +/- 0.07 vs. -0.66 +/- 0.0, p = 0.0009), propofol (-0.45 +/- 0.11 vs. -0.76 +/- 0.11; p = 0.034) and norepinephrine (-0.50 +/- 0.07 vs. -0.74 +/- 0.07) and in temperature (0.03 +/- 0.03 vs. 0.16 +/- 0.03; p = 0.0014) between the albumin and saline groups when ICP monitoring ceased during the first week. The use of albumin for resuscitation in patients with severe TBI is associated with increased ICP during the first week. This is the most likely mechanism of increased mortality in these patients.	[Cooper, D. James; Vallance, Shirley] Alfred Hosp, Dept Intens Care, Melbourne, Vic, Australia; [Cooper, D. James; Bellomo, Rinaldo; Murray, Lynette] Monash Univ, Australia & New Zealand Intens Care Res Ctr, Melbourne, Vic 3004, Australia; [Myburgh, John; Heritier, Stephane; Finfer, Simon; Billot, Laurent] George Inst Global Hlth, Sydney, NSW 2000, Australia; [Myburgh, John] Univ New S Wales, Fac Med, Sydney, NSW, Australia; [Myburgh, John] St George Hosp, Dept Intens Care Med, Sydney, NSW, Australia; [Heritier, Stephane; Finfer, Simon] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; [Finfer, Simon] Royal N Shore Hosp, Dept Intens Care Med, Sydney, NSW, Australia; [Bellomo, Rinaldo] Austin Hosp, Dept Intens Care Med, Melbourne, Vic 3084, Australia; [Bellomo, Rinaldo] Univ Melbourne, Fac Med, Melbourne, Vic, Australia		Myburgh, J (corresponding author), George Inst Global Hlth, Div Crit Care & Trauma, Level 7,341 George St, Sydney, NSW 2000, Australia.	jmyburgh@georgeinstitute.org.au	Billot, Laurent/Y-1241-2019; Cooper, D. James/G-7961-2013	Billot, Laurent/0000-0002-4975-9793; Cooper, D. James/0000-0002-5872-9051; Bellomo, Rinaldo/0000-0002-1650-8939; Finfer, Simon/0000-0002-2785-5864	Victorian Neurotrauma Initiative, Australia [DP016]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [57281]; Division of Critical Care and Trauma of the George Institute for Global Health, Sydney, Australia; CSL Limited; George Institute for Global Health and the University of Sydney	This study was funded by a project grant (number DP016) from the Victorian Neurotrauma Initiative (grant number DP016), Australia. Associate Professor Heritier is supported by a program grant (number 57281) from the National Health and Medical Research Council of Australia. Statistical analysis was partially funded by the Division of Critical Care and Trauma of the George Institute for Global Health, Sydney, Australia. The Management Committee consisted of D James Cooper, (co-chair), John Myburgh, (co-chair), Michael Bailey, Rinaldo Bellomo, Laurent Billot, Simon Finfer, Parisa Glass, Stephane Heritier, Michael Fitzharris, Alisa Higgins, Daryl Jones, Siouxzy Morrison, Lynette Murray, Alistair Nichol, Gillian Syres, and Shirley Vallance. Associate Professor Michael Bailey assisted with the initial statistical analyses. Associate Professor Dinesh Varma, Alfred Hospital, Melbourne conducted the blind review of cranial CT scans. The Site investigators (Australia unless stated) were Alfred Hospital, Melbourne: D James Cooper, and Shirley Vallance; Austin Hospital, Melbourne: Rinaldo Bellomo, and Donna Goldsmith; Australian and New Zealand Research Centre, Melbourne: Michael Bailey, Rinaldo Bellomo, D James Cooper, Andrew Forbes, Alisa Higgins, Daryl Jones, Siouxzy Morrison, Lynette Murray, Alistair Nichol, and Gillian Syres; Royal Darwin Hospital: Diane Stephens, and Jane Thomas; Fremantle Hospital: David Blythe, and Anna Palermo; John Hunter Hospital, Newcastle: Peter Harrigan, Brett McFadyen, and Agness Tembo; George Institute for Global Health, Sydney: Laurent Billot, Simon Finfer, Michael Fitzharris, Parisa Glass, Stephane Heritier, Serigne Lo, Mathieu Rose, and John Myburgh; Middlemore Hospital, New Zealand: Judy Tai, and Anthony Williams; Nepean Hospital, Sydney: Louise Cole, Iveta Nalos, Ian Seppelt, and Leonie Weisbrodt; Princess Alexandra Hospital, Brisbane: Sally Gipps, Chris Joyce, Ben Mackie, and Bala Venkatesh; Royal Adelaide Hospital: Marianne Chapman, Stephanie O'Connor, and Justine Rivett; Royal Hobart Hospital: Anthony Bell, Kathryn Marsden, and Andrew Turner; Royal Melbourne Hospital: Deborah Barge, Jack Cade, Tania Caf, and Megan Robertson; Royal North Shore Hospital, Sydney: Simon Finfer, Anne O'Connor, Julie Potter, and Naresh Ramakrishnan; St George Hospital, Sydney: Vanessa Dhiacou, Alina Jovanovska, and John Myburgh.; Professor Cooper has no competing financial interests in relation to this study. Professor Myburgh has no competing financial interests exist in relation to this study. In relation to ongoing fluid resuscitation research, The George Institute for Global Health and the University of Sydney have received a speaker's fee, unrestricted research grant support, and refund of travel expenses incurred on Professor Myburgh's behalf from Fresenius Kabi. Associate Professor Heritier has no competing financial interests in relation to this study. Professor Finfer has no competing financial interests in relation to this study. The SAFE Study was partially funded by CSL Limited. CSL Limited paid travel expenses for Professor Finfer to present results of the SAFE Study at scientific and industry-sponsored meetings. In relation to ongoing fluid resuscitation research, The George Institute for Global Health and the University of Sydney have received unrestricted research grant support and refund of travel expenses incurred on Professor Finfer's behalf from Fresenius Kabi. Professor Bellomo has no competing financial interests in relation to this study. The SAFE Study was part funded by CSL Limited. CSL Limited paid travel expenses for Professor Bellomo to present results of the SAFE Study at scientific and industry-sponsored meetings. Laurent Billot has no competing financial interests in relation to this study. Lynette Murray has no competing financial interests in relation to this study. Shirley Vallance has no competing financial interests in relation to this study.	Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; BTF Guidelines, 2000, J NEUROTRAUM, V17, P591; BTF Guidelines The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, AGE J NEUROTRAUMA, V17, P573; BTF Guidelines The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P563; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Jeffcote T, 2010, ANAESTH INTENS CARE, V38, P274, DOI 10.1177/0310057X1003800208; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Molenberghs G, 2004, BIOSTATISTICS, V5, P445, DOI 10.1093/biostatistics/kxh001; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Pauler DK, 2003, STAT MED, V22, P795, DOI 10.1002/sim.1397; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; TEASDALE G, 1974, LANCET, V2, P81; van der Heijde D, 2007, ARTHRITIS RHEUM, V56, P3928, DOI 10.1002/art.23141; Vangeneugden T, 2004, CONTROL CLIN TRIALS, V25, P13, DOI 10.1016/j.cct.2003.08.009; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; Weintraub WS, 2008, NEW ENGL J MED, V359, P677, DOI 10.1056/NEJMoa072771	17	77	81	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	7					512	518		10.1089/neu.2012.2573			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	133PD	WOS:000318150300002	23194432	Green Published			2022-02-06	
J	Hosp, JA; Luft, AR				Hosp, Jonas A.; Luft, Andreas R.			Dopaminergic meso-cortical projections to M1: role in motor learning and motor cortex plasticity	FRONTIERS IN NEUROLOGY			English	Article						dopamine; motor cortex; motor learning; cortical plasticity; memory		Although the architecture of a dopaminergic (DA) system within the primary motor cortex (M1) was well characterized anatomically, its functional significance remained obscure for a long time. Recent studies in rats revealed that the integrity of DA fibers in M1 is a prerequisite for successful acquisition of motor skills. This essential contribution of DA for motor learning is plausible as it modulates M1 circuitry at multiple levels thereby promoting plastic changes that are required for information storage: at the network level, DA increases cortical excitability and enhances the stability of motor maps. At the cellular level, DA induces the expression of learning-related genes via the transcription factor c-Fos. At the level of synapses, DA is required for the formation of long-term potentiation, a mechanism that likely is a fingerprint of a motor memory trace within M1. DA fibers innervating M1 originate within the midbrain, precisely the ventral tegmental area (VTA) and the medial portion of substantia nigra (SN). Thus, they could be part of the meso-cortico-limbic pathway a network that provides information about saliency and motivational value of an external stimulus and is commonly referred as "reward system." However, the behavioral triggers of the release of dopamine in M1 are not yet identified. As alterations in DA transmission within M1 occur under various pathological conditions such as Parkinson disease or ischemic and traumatic brain injury, a deeper understanding of the interaction of VTA/SN and M1 may reveal a deeper insight into a large spectrum of neurological disorders.	[Hosp, Jonas A.; Luft, Andreas R.] Univ Zurich, Dept Neurol, Clin Neurorehabil, CH-8091 Zurich, Switzerland; [Hosp, Jonas A.; Luft, Andreas R.] RITZ, Rehabil Initiat & Technol Ctr Zurich, Zurich, Switzerland; [Luft, Andreas R.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA		Luft, AR (corresponding author), Univ Zurich, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	andreas.luft@usz.ch					ARIANO MA, 1993, BRAIN RES, V609, P71, DOI 10.1016/0006-8993(93)90857-J; Asanuma H, 1997, NEUROREPORT, V8, pR1; Awenowicz PW, 2002, J NEUROPHYSIOL, V88, P3439, DOI 10.1152/jn.00078.2002; Berardelli A, 1996, BRAIN, V119, P71, DOI 10.1093/brain/119.1.71; BERGER B, 1991, TRENDS NEUROSCI, V14, P21, DOI 10.1016/0166-2236(91)90179-X; BERGER B, 1985, NEUROSCIENCE, V15, P983, DOI 10.1016/0306-4522(85)90248-9; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; Boroojerdi B, 2002, J CLIN NEUROPHYSIOL, V19, P255, DOI 10.1097/00004691-200208000-00002; Bromberg-Martin ES, 2010, NEURON, V68, P815, DOI 10.1016/j.neuron.2010.11.022; Buitrago MM, 2004, BEHAV BRAIN RES, V155, P249, DOI 10.1016/j.bbr.2004.04.025; Chudasama Y, 2004, NEUROPSYCHOPHARMACOL, V29, P1628, DOI 10.1038/sj.npp.1300490; Conner JM, 2003, NEURON, V38, P819, DOI 10.1016/S0896-6273(03)00288-5; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DEUTCH AY, 1988, ANN NY ACAD SCI, V537, P27, DOI 10.1111/j.1749-6632.1988.tb42095.x; FALLON JH, 1981, J NEUROSCI, V1, P1361; Floel A, 2005, NEUROLOGY, V65, P472, DOI 10.1212/01.wnl.0000172340.56307.5e; Floel A, 2005, ANN NEUROL, V58, P121, DOI 10.1002/ana.20536; Floel A, 2008, EUR J NEUROSCI, V27, P1301, DOI 10.1111/j.1460-9568.2008.06079.x; Floresco SB, 2006, PSYCHOPHARMACOLOGY, V188, P567, DOI 10.1007/s00213-006-0404-5; FOOTE SL, 1987, CURR TOP DEV BIOL, V21, P391; FRITH CD, 1986, PSYCHIATRY, V49, P661, DOI DOI 10.1136/JNNP.49.6.661; GARRIS PA, 1994, J NEUROSCI, V14, P442; GASPAR P, 1991, ANN NEUROL, V30, P365, DOI 10.1002/ana.410300308; GASPAR P, 1989, J COMP NEUROL, V279, P249, DOI 10.1002/cne.902790208; GERMAN DC, 1993, J COMP NEUROL, V331, P297, DOI 10.1002/cne.903310302; Hikosaka O, 2002, CURR OPIN NEUROBIOL, V12, P217, DOI 10.1016/S0959-4388(02)00307-0; Hosp JA, 2009, NEUROSCIENCE, V159, P692, DOI 10.1016/j.neuroscience.2008.12.056; Hosp JA, 2011, NEURAL PLAST, V2011, DOI 10.1155/2011/871296; Hosp JA, 2011, J NEUROSCI, V31, P2481, DOI 10.1523/JNEUROSCI.5411-10.2011; Hosp JA, 2011, NEUROIMAGE, V54, P154, DOI 10.1016/j.neuroimage.2010.07.029; IRIKI A, 1989, SCIENCE, V245, P1385, DOI 10.1126/science.2551038; Kishore A, 2012, BRAIN, V135, P2074, DOI 10.1093/brain/aws124; Kishore A, 2012, CLIN NEUROPHYSIOL, V123, P822, DOI 10.1016/j.clinph.2011.06.034; Kleim JA, 2004, J NEUROSCI, V24, P628, DOI 10.1523/JNEUROSCI.3440-03.2004; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321, DOI 10.1152/jn.1998.80.6.3321; Kleim JA, 1996, J NEUROSCI, V16, P4529; Lammel S, 2008, NEURON, V57, P760, DOI 10.1016/j.neuron.2008.01.022; LEPORE F, 1986, 2 HEMISPHERES ONE BR; LEWIS DA, 1987, J NEUROSCI, V7, P279; Lokk J, 2011, ACTA NEUROL SCAND, V123, P266, DOI 10.1111/j.1600-0404.2010.01395.x; LOUGHLIN SE, 1984, NEUROSCIENCE, V11, P425, DOI 10.1016/0306-4522(84)90034-4; Luft AR, 2005, MOL NEUROBIOL, V32, P205, DOI 10.1385/MN:32:3:205; Luft AR, 2004, J NEUROSCI, V24, P6515, DOI 10.1523/JNEUROSCI.1034-04.2004; McRitchie DA, 1997, EXP NEUROL, V144, P202, DOI 10.1006/exnr.1997.6418; Meintzschel F, 2006, CEREB CORTEX, V16, P1106, DOI 10.1093/cercor/bhj052; Molina-Luna K, 2008, NEUROIMAGE, V40, P1748, DOI 10.1016/j.neuroimage.2007.11.018; Molina-Luna K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007082; Monfils MH, 2005, NEUROSCIENTIST, V11, P471, DOI 10.1177/1073858405278015; Moore RY, 2008, NEUROBIOL DIS, V29, P381, DOI 10.1016/j.nbd.2007.09.004; Morgante F, 2006, BRAIN, V129, P1059, DOI 10.1093/brain/awl031; Mundorf ML, 2001, J NEUROCHEM, V79, P130, DOI 10.1046/j.1471-4159.2001.00554.x; Nudo RJ, 1996, J NEUROSCI, V16, P785; PASCUALLEONE A, 1995, J NEUROPHYSIOL, V74, P1037, DOI 10.1152/jn.1995.74.3.1037; Pearson-Fuhrhop KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061197; Raghanti MA, 2008, NEUROSCIENCE, V155, P203, DOI 10.1016/j.neuroscience.2008.05.008; Rioult-Pedotti MS, 2007, J NEUROPHYSIOL, V98, P3688, DOI 10.1152/jn.00164.2007; Rioult-Pedotti MS, 1998, NAT NEUROSCI, V1, P230, DOI 10.1038/678; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; ROSE SPR, 1991, TRENDS NEUROSCI, V14, P390, DOI 10.1016/0166-2236(91)90027-R; SAKAMOTO T, 1989, BRAIN RES, V503, P258, DOI 10.1016/0006-8993(89)91672-7; SAVASTA M, 1986, BRAIN RES, V375, P291, DOI 10.1016/0006-8993(86)90749-3; Scheidtmann K, 2001, LANCET, V358, P787, DOI 10.1016/S0140-6736(01)05966-9; Schultz W, 2007, ANNU REV NEUROSCI, V30, P259, DOI 10.1146/annurev.neuro.28.061604.135722; Schultz W, 2007, TRENDS NEUROSCI, V30, P203, DOI 10.1016/j.tins.2007.03.007; Seamans JK, 2004, PROG NEUROBIOL, V74, P1, DOI 10.1016/j.pneurobio.2004.05.006; Suppa A, 2011, EXP NEUROL, V227, P296, DOI 10.1016/j.expneurol.2010.11.020; SWANSON LW, 1982, BRAIN RES BULL, V9, P321, DOI 10.1016/0361-9230(82)90145-9; Ueki Y, 2006, ANN NEUROL, V59, P60, DOI 10.1002/ana.20692; Verschueren SMP, 1997, EXP BRAIN RES, V113, P497, DOI 10.1007/PL00005602; Wang JQ, 1997, J PHARMACOL EXP THER, V281, P972; Williams SM, 1998, CEREB CORTEX, V8, P321, DOI 10.1093/cercor/8.4.321; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Ziemann U, 1997, ELECTROMYOGR MOTOR C, V105, P430, DOI 10.1016/S0924-980X(97)00050-7	74	77	77	0	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								145	10.3389/fneur.2013.00145			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V42QT	WOS:000209629000144	24109472	Green Accepted, Green Published, gold			2022-02-06	
J	Rosenbaum, SB; Lipton, ML				Rosenbaum, Sara B.; Lipton, Michael L.			Embracing chaos: the scope and importance of clinical and pathological heterogeneity in mTBI	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild traumatic brain injury (mTBI); Heterogeneity; Biomechanics; Diffusion tensor imaging (DTI); Post-concussive symptoms PCS)	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; POST-CONCUSSIVE SYMPTOMS; APOLIPOPROTEIN-E POLYMORPHISM; COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; DIFFUSE AXONAL INJURY; GLASGOW COMA SCALE; QUALITY-OF-LIFE; POSTCONCUSSION SYNDROME	Mild traumatic brain injury (mTBI) manifests a wide array of clinical features, indicating great heterogeneity of its underlying pathologic features. mTBI diversity is related to pre-injury inter-individual differences and differences in the characteristics of each injury. This review summarizes key features of mTBI patients, their injuries and outcomes to give context to the scope of complexity inherent in this disorder. These differences are underscored by heterogeneity in postmortem pathology and in vivo imaging studies. Recognition, understanding and accounting for disease heterogeneity in mTBI are needed to enhance diagnosis and patient management, as approaches that do not account for inter-individual variation in pathology and patient characteristics relevant to real-life clinical trial participants, may entirely miss therapeutic targets. Refining our approach to TBI diagnosis, in light of inter-individual differences, can facilitate the development of effective prognostic tools and algorithms. New paradigms, which embrace heterogeneity of mTBI, in both preclinical and clinical investigation as well the appreciation of this variability in clinical care, offer much promise for enhancing outcomes and mitigating the burden of mTBI on its victims.	[Rosenbaum, Sara B.; Lipton, Michael L.] Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Dept Radiol, Bronx, NY 10461 USA; [Rosenbaum, Sara B.; Lipton, Michael L.] Albert Einstein Coll Med, Dept Psychiat, Bronx, NY 10461 USA; [Rosenbaum, Sara B.; Lipton, Michael L.] Albert Einstein Coll Med, Dept Behav Sci, Bronx, NY 10461 USA; [Rosenbaum, Sara B.; Lipton, Michael L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA; [Rosenbaum, Sara B.; Lipton, Michael L.] Montefiore Med Ctr, Bronx, NY 10461 USA		Lipton, ML (corresponding author), Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Dept Radiol, Bronx, NY 10461 USA.	michael.lipton@einstein.yu.edu					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Acerini CL, 2006, EUR J ENDOCRINOL, V155, P663, DOI 10.1530/eje.1.02284; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Aiken AH, 2010, SEMIN ROENTGENOL, V45, P63, DOI 10.1053/j.ro.2009.09.007; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Alexander MP, 1995, NEUROLOGY; Allen DN, 2009, APPL NEUROPSYCHOL, V16, P186, DOI 10.1080/09084280903098687; ALTERMAN AI, 1985, J STUD ALCOHOL, V46, P256, DOI 10.15288/jsa.1985.46.256; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Bandak, 1999, DEV IMPROVED INJURY; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Baugh C. M., 2012, BRAIN IMAGING BEHAV; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler E. D, 2012, BRAIN IMAGING BEHAV; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Boran BO, 2006, PEDIATR NEUROSURG, V42, P203, DOI 10.1159/000092355; Bordignon KC, 2002, ARQ NEURO-PSIQUIAT, V60, P204, DOI 10.1590/S0004-282X2002000200004; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Bose D, 2010, ACCIDENT ANAL PREV, V42, P1398, DOI 10.1016/j.aap.2010.03.004; Brandstack N, 2006, BRAIN INJURY, V20, P409, DOI 10.1080/02699050500487951; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chou YC, 2009, BRAIN INJURY, V23, P1095, DOI 10.3109/02699050903379396; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; De Guise E, 2009, BRAIN INJURY, V23, P853, DOI 10.1080/02699050903283221; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Demakis GJ, 2010, ARCH CLIN NEUROPSYCH, V25, P191, DOI 10.1093/arclin/acq004; DeRosia John, 2004, Traffic Inj Prev, V5, P50, DOI 10.1080/15389580490269182; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Drew LB, 2004, NEUROCRIT CARE, V1, P385, DOI 10.1385/NCC:1:3:385; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Elliott MR, 2006, J TRAUMA, V61, P1244, DOI 10.1097/01.ta.0000195983.48529.0d; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hajek CA, 2010, BRAIN INJURY, V24, P100, DOI 10.3109/02699050903508226; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Hault-Dubrulle A, 2011, ACCIDENT ANAL PREV, V43, P75, DOI 10.1016/j.aap.2010.07.013; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Hulkower M. B., 2011, AM AC NEUR HON HAW; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; ICHISE M, 1994, J NUCL MED, V35, P217; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Ives JC, 2007, J ATHL TRAINING, V42, P431; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kim N., 2011, ISMRM MONTR QUEB CAN; KING AI, 1995, J TRAUMA, V38, P570, DOI 10.1097/00005373-199504000-00017; King AI, 2011, CLIN ANAT, V24, P294, DOI 10.1002/ca.21151; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Koura SS, 1998, ACT NEUR S, V71, P244; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lange RT, 2007, NEUROPSYCHOLOGY, V21, P590, DOI 10.1037/0894-4105.21.5.590; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lipton M. L., 2012, BRAIN IMAGING BEHAV; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MADDOCKS DL, 1995, AUST PSYCHOL, V30, P125, DOI 10.1080/00050069508258916; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M., 2009, CLIN NEUROPSYCHOLOGI; McCrory P., 2009, S AFRICAN J SPORTS M, V21; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; McKeever CK, 2003, APPL NEUROPSYCHOL, V10, P4, DOI 10.1207/S15324826AN1001_2; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; Newman J, 2000, NEW BIOMECHANICAL 2; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Nolle C, 2004, J NEUROTRAUM, V21, P251, DOI 10.1089/089771504322972040; Oehmichen M, 2003, J NEUROTRAUM, V20, P87, DOI 10.1089/08977150360517218; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Peterson TD, 1999, ANN EMERG MED, V34, P384, DOI 10.1016/S0196-0644(99)70135-6; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Pruthi N, 2010, NEUROL INDIA, V58, P264, DOI 10.4103/0028-3886.63810; Reed N, 2010, INT J SPORTS MED, V31, P826, DOI 10.1055/s-0030-1263103; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Roudsari BS, 2004, INJURY PREV, V10, P154, DOI 10.1136/ip.2003.003814; Ruff R. M., 1990, J HEAD TRAUMA REHABI; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwartz I, 2008, BRAIN INJURY, V22, P255, DOI 10.1080/02699050801941763; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Shenton M. E., 2012, BRAIN IMAGING BEHAV; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; Shukla D, 2010, J NEUROSCI RURAL PRA, V1, P82, DOI 10.4103/0976-3147.71723; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stapert S, 2006, BRAIN INJURY, V20, P161, DOI 10.1080/02699050500442949; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stevens MC, 2012, BRAIN IMAGING BEHAV; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Suh M, 2006, NEUROSCI LETT, V410, P203, DOI 10.1016/j.neulet.2006.10.001; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Tait RJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-171; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teasdale TW, 2003, J NEUROL NEUROSUR PS, V74, P933, DOI 10.1136/jnnp.74.7.933; Tellier A, 2009, BRAIN INJURY, V23, P879, DOI 10.1080/02699050903200555; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tierney RT, 2010, CLIN J SPORT MED, V20, P464, DOI 10.1097/JSM.0b013e3181fc0a81; Tung GA, 2006, PEDIATRICS, V118, P626, DOI 10.1542/peds.2006-0130; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Vickery CD, 2008, ARCH PHYS MED REHAB, V89, P48, DOI 10.1016/j.apmr.2007.07.047; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599; [No title captured], DOI DOI 10.1037/0894-4105.5.4.253	237	77	77	0	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		255	282		10.1007/s11682-012-9162-7			28	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	967LI	WOS:000305908900008	22549452				2022-02-06	
J	Baker, JG; Freitas, MS; Leddy, JJ; Kozlowski, KF; Willer, BS				Baker, John G.; Freitas, Michael S.; Leddy, John J.; Kozlowski, Karl F.; Willer, Barry S.			Return to Full Functioning after Graded Exercise Assessment and Progressive Exercise Treatment of Postconcussion Syndrome	REHABILITATION RESEARCH AND PRACTICE			English	Article							TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; RECURRENT CONCUSSION; UP-REGULATION; RECOVERY; IMPACT	Exercise assessment and aerobic exercise training for postconcussion syndrome (PCS) may reduce concussion-related physiological dysfunction and symptoms by restoring autonomic balance and improving cerebral blood flow autoregulation. In a descriptive pilot study of 91 patients referred to a university clinic for treatment of PCS, a subset of 63 patients were contacted by telephone for assessment of symptoms and return to full daily functioning. Those who experienced symptoms during a graded exercise treadmill test (physiologic PCS, n = 40) were compared to those who could exercise to capacity (PCS, n = 23). Both groups had been offered progressive exercise rehabilitation. Overall 41 of 57 (72%) who participated in the exercise rehabilitation program returned to full daily functioning. This included 27 of 35 (77%) from the physiologic PCS group, and 14 of 22 (64%) from the PCS group. Only 1 of the 6 patients who declined exercise rehabilitation returned to full functioning. Interpretation of these results is limited by the descriptive nature of the study, the small sample size, and the relatively few patients who declined exercise treatment. Nonetheless, exercise assessment indicates that approximately one third of those examined did not have physiologic PCS.	[Baker, John G.] SUNY Buffalo, Univ Buffalo, Dept Nucl Med, Buffalo, NY 14214 USA; [Baker, John G.; Leddy, John J.] SUNY Buffalo, Univ Buffalo, Dept Orthoped, Buffalo, NY 14214 USA; [Freitas, Michael S.] SUNY Buffalo, Univ Buffalo, Dept Family Med, Buffalo, NY 14215 USA; [Kozlowski, Karl F.] Canisius Coll, Dept Kinesiol, Buffalo, NY 14208 USA; [Willer, Barry S.] SUNY Buffalo, Univ Buffalo, Dept Psychiat, Buffalo, NY 14215 USA		Baker, JG (corresponding author), SUNY Buffalo, Univ Buffalo, Dept Nucl Med, Buffalo, NY 14214 USA.	jgbaker@buffalo.edu	Kozlowski, Karl/H-5253-2019				Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Carter JB, 2003, SPORTS MED, V33, P33, DOI 10.2165/00007256-200333010-00003; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Doering TJ, 1998, AM J PHYS MED REHAB, V77, P490, DOI 10.1097/00002060-199811000-00006; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Giza CC, 2001, J ATHL TRAINING, V36, P228; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy J. J., SPORTS HLTH IN PRESS; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; World Health Organization, 1992, ICD 10 CLASSIFICATIO	27	77	78	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-2867	2090-2875		REHABIL RES PRACT	Rehabil. Res. Pract.		2012	2012								705309	10.1155/2012/705309			7	Rehabilitation	Emerging Sources Citation Index (ESCI)	Rehabilitation	V18NK	WOS:000214757900030	22292122	Green Published, Green Submitted, gold			2022-02-06	
J	Hemphill, MA; Dabiri, BE; Gabriele, S; Kerscher, L; Franck, C; Goss, JA; Alford, PW; Parker, KK				Hemphill, Matthew A.; Dabiri, Borna E.; Gabriele, Sylvain; Kerscher, Lucas; Franck, Christian; Goss, Josue A.; Alford, Patrick W.; Parker, Kevin Kit			A Possible Role for Integrin Signaling in Diffuse Axonal Injury	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; FOCAL ADHESION KINASE; RHO-ASSOCIATED KINASE; MECHANICAL STRETCH; ACTIVATION; CELLS; CALCIUM; NEURONS; MECHANOTRANSDUCTION; RETRACTION	Over the past decade, investigators have attempted to establish the pathophysiological mechanisms by which non-penetrating injuries damage the brain. Several studies have implicated either membrane poration or ion channel dysfunction pursuant to neuronal cell death as the primary mechanism of injury. We hypothesized that traumatic stimulation of integrins may be an important etiological contributor to mild Traumatic Brain Injury. In order to study the effects of forces at the cellular level, we utilized two hierarchical, in vitro systems to mimic traumatic injury to rat cortical neurons: a high velocity stretcher and a magnetic tweezer system. In one system, we controlled focal adhesion formation in neurons cultured on a stretchable substrate loaded with an abrupt, one dimensional strain. With the second system, we used magnetic tweezers to directly simulate the abrupt injury forces endured by a focal adhesion on the neurite. Both systems revealed variations in the rate and nature of neuronal injury as a function of focal adhesion density and direct integrin stimulation without membrane poration. Pharmacological inhibition of calpains did not mitigate the injury yet the inhibition of Rho-kinase immediately after injury reduced axonal injury. These data suggest that integrin-mediated activation of Rho may be a contributor to the diffuse axonal injury reported in mild Traumatic Brain Injury.	[Hemphill, Matthew A.; Dabiri, Borna E.; Gabriele, Sylvain; Kerscher, Lucas; Franck, Christian; Goss, Josue A.; Alford, Patrick W.; Parker, Kevin Kit] Harvard Univ, Dis Biophys Grp, Sch Engn & Appl Sci, Wyss Inst Biol Inspired Engn, Cambridge, MA 02138 USA		Hemphill, MA (corresponding author), Harvard Univ, Dis Biophys Grp, Sch Engn & Appl Sci, Wyss Inst Biol Inspired Engn, Cambridge, MA 02138 USA.	kkparker@seas.harvard.edu	GABRIELE, Sylvain/N-6412-2014; Franck, Christian/C-6077-2012	GABRIELE, Sylvain/0000-0001-8696-8052; Franck, Christian/0000-0002-2347-620X	Defense Advance Research Projects Agency (Office of Naval) [N66001-09-c-2064]; Harvard School of Engineering and Applied Sciences	Financial support from the Defense Advance Research Projects Agency's PREVENT Program (Office of Naval Research SPAWAR N66001-09-c-2064) and the Harvard School of Engineering and Applied Sciences. The authors acknowledge Harvard University's Center for Nanoscale Systems (CNS) for the use of cleanroom facilities. S.G. is Charge de Recherches of the F.R.S.-FNRS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alford PW, 2003, J BIOMECH, V36, P1135, DOI 10.1016/S0021-9290(03)00089-7; Amano M, 2003, J NEUROCHEM, V87, P780, DOI 10.1046/j.1471-4159.2003.02054.x; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Billuart P, 2001, CELL, V107, P195, DOI 10.1016/S0092-8674(01)00522-0; Birukova AA, 2010, AM J PHYSIOL-LUNG C, V298, pL837, DOI 10.1152/ajplung.00263.2009; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chan CS, 2003, J NEUROSCI, V23, P7107, DOI 10.1523/JNEUROSCI.23-18-07107.2003; Cullen DK, 2007, ANN BIOMED ENG, V35, P835, DOI 10.1007/s10439-007-9292-z; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Fass JN, 2004, BIOPHYS J, V87, P2099, DOI 10.1529/biophysj.104.900105; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Hashimoto R, 1998, BIOCHEM BIOPH RES CO, V245, P407, DOI 10.1006/bbrc.1998.8446; Hoang B, 1998, J NEUROSCI, V18, P7847; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jaalouk DE, 2009, NAT REV MOL CELL BIO, V10, P63, DOI 10.1038/nrm2597; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Kam Z, 2001, TRENDS CELL BIOL, V11, P329, DOI 10.1016/S0962-8924(01)02067-0; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kilinc D, 2009, EXP NEUROL, V219, P553, DOI 10.1016/j.expneurol.2009.07.014; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Lemons ML, 2006, EXP NEUROL, V202, P324, DOI 10.1016/j.expneurol.2006.06.008; Lin CY, 2008, MOL CELL NEUROSCI, V37, P770, DOI 10.1016/j.mcn.2008.01.001; Lin YW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004293; Luo LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/annurev.neuro.28.061604.135632; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Matthews BD, 2006, J CELL SCI, V119, P508, DOI 10.1242/jcs.02760; Meyer CJ, 2000, NAT CELL BIOL, V2, P666, DOI 10.1038/35023621; Milner R, 2002, J NEUROSCI RES, V69, P286, DOI 10.1002/jnr.10321; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Mueller BK, 2005, NAT REV DRUG DISCOV, V4, P387, DOI 10.1038/nrd1719; Nakayama K, 2008, NEUROSCI LETT, V444, P127, DOI 10.1016/j.neulet.2008.08.034; Nishimura SL, 1998, BRAIN RES, V791, P271, DOI 10.1016/S0006-8993(98)00118-8; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Pinkstaff JK, 1999, J NEUROSCI, V19, P1541; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Robles E, 2006, NAT NEUROSCI, V9, P1274, DOI 10.1038/nn1762; Rodriguez MA, 2000, P NATL ACAD SCI USA, V97, P3550, DOI 10.1073/pnas.050589797; Schmid RS, 2003, CEREB CORTEX, V13, P219, DOI 10.1093/cercor/13.3.219; SCHMIDT CE, 1995, J NEUROSCI, V15, P3400; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Shi Y, 2006, J NEUROSCI, V26, P1813, DOI 10.1523/JNEUROSCI.4091-05.2006; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Staubli U, 1998, J NEUROSCI, V18, P3460; Stevens GR, 1996, J NEUROSCI RES, V46, P445, DOI 10.1002/(SICI)1097-4547(19961115)46:4<445::AID-JNR6>3.0.CO;2-G; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Su L, 2008, NEUROMOL MED, V10, P316, DOI 10.1007/s12017-008-8042-1; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; UPTON GJG, 1992, J ROY STAT SOC A STA, V155, P395, DOI 10.2307/2982890; Wang N, 2001, P NATL ACAD SCI USA, V98, P7765, DOI 10.1073/pnas.141199598; Watson PMD, 2007, MOL CELL NEUROSCI, V34, P147, DOI 10.1016/j.mcn.2006.10.007; Webb DJ, 2007, J BIOL CHEM, V282, P6929, DOI 10.1074/jbc.M610981200; Wernig F, 2003, HYPERTENSION, V41, P903, DOI 10.1161/01.HYP.0000062882.42265.88; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Zamir E, 1999, J CELL SCI, V112, P1655	67	77	78	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2011	6	7							e22899	10.1371/journal.pone.0022899			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	797BJ	WOS:000293097300082	21799943	Green Published, gold, Green Submitted			2022-02-06	
J	Chase, TN				Chase, Thomas N.			Apathy in Neuropsychiatric Disease: Diagnosis, Pathophysiology, and Treatment	NEUROTOXICITY RESEARCH			English	Article						Depression; Alzheimer's disease; Parkinson's disease; Schizophrenia; Depression; Prefrontal cortex; Basal ganglia; Therapeutics	UNIFIED PARKINSONS-DISEASE; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; SUBTHALAMIC NUCLEUS STIMULATION; SUSTAINED CEREBRAL-ISCHEMIA; DOPAMINE TRANSPORTER LEVELS; SYSTEMS BEHAVIOR SCALE; EFFORT-RELATED CHOICE; QUALITY-OF-LIFE; ALZHEIMERS-DISEASE	Apathy is an increasingly recognized concomitant of a broad range of central nervous system disorders. Nevertheless, its nosology, pathogenesis and therapy remain shrouded in confusion and controversy. As yet, there is little consensus regarding methods for detecting apathy, or distinguishing it from depression, or for assessing its severity. Many now regard the apathy syndrome as primarily reflecting a lack of motivation that compromises emotional, cognitive, and overt behavioral function. Even though under-recognized and under-diagnosed, apathy hardly appears uncommon: current epidemiologic studies suggest over 10 million Americans may be affected. Its reported frequency in various neurologic and psychiatric conditions varies widely, from less than 10 to over 80%, reflecting differences in population characteristics and assessment procedures. Often apathy has been associated with such neurodegenerative disorders as Alzheimer's disease, Parkinson's disease, and fronto-temporal dementia. But it also occurs in those with psychiatric disorders such as schizophrenia and major depression. Clinical, neuropathologic, and neuroimaging observations increasingly suggest that apathy reflects dysfunction of frontal-subcortical circuits, especially those linking the ventromedial prefrontal cortex to related regions in the basal ganglia. Therapeutically, numerous small studies suggest that psychostimulants, dopaminergics, and cholinesterase inhibitors may benefit those manifesting this syndrome. However, no adequately powered, randomized controlled trials have reported success and no medication have ever been approved for this disorder. The accelerating pace of current research nevertheless promises to improve our understanding of apathy and to better address the unmet medical needs of those suffering its consequences.	Chase Pharmaceut Corp, Washington, DC USA		Chase, TN (corresponding author), Chase Pharmaceut Corp, Washington, DC USA.	tchase@chasepharmaceuticals.com					Aalten P, 2005, INT J GERIATR PSYCH, V20, P523, DOI 10.1002/gps.1316; Aalten P, 2006, INT PSYCHOGERIATR, V18, P3, DOI 10.1017/S1041610205002772; Aarsland D, 2007, J NEUROL NEUROSUR PS, V78, P36, DOI 10.1136/jnnp.2005.083113; ACQUAS E, 1989, PSYCHOPHARMACOLOGY, V99, P151, DOI 10.1007/BF00442800; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Alves GS, 2009, ARQ NEURO-PSIQUIAT, V67, P173, DOI 10.1590/S0004-282X2009000200001; Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Andersson S, 2002, NEUROPSY NEUROPSY BE, V15, P184, DOI 10.1097/01.WNN.0000026596.88167.8E; Angelelli P, 2004, ACTA PSYCHIAT SCAND, V110, P55, DOI 10.1111/j.1600-0447.2004.00297.x; Apostolova LG, 2007, DEMENT GERIATR COGN, V24, P91, DOI 10.1159/000103914; Barbas NR, 2006, CLIN GERIATR MED, V22, P773, DOI 10.1016/j.cger.2006.06.004; Benoit M, 2004, INT J GERIATR PSYCH, V19, P864, DOI 10.1002/gps.1163; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Borek Leora L, 2007, Expert Rev Neurother, V7, P711, DOI 10.1586/14737175.7.6.711; Borroni B, 2008, ARCH GERONTOL GERIAT, V46, P101, DOI 10.1016/j.archger.2007.03.003; Borroni B, 2009, INT PSYCHOGERIATR, V21, P463, DOI 10.1017/S1041610209008862; Bressan RA, 2005, ACTA PSYCHIAT SCAND, V111, P14, DOI 10.1111/j.1600-0447.2005.00540.x; Brodaty H, 2005, PSYCHOL MED, V35, P1707, DOI 10.1017/S0033291705006173; Bruen PD, 2008, BRAIN, V131, P2455, DOI 10.1093/brain/awn151; Cattelani R, 2008, EUR J PHYS REHAB MED, V44, P245; Chilovi BV, 2009, DEMENT GERIATR COGN, V27, P390, DOI 10.1159/000210045; Clarke DE, 2007, J NEUROPSYCH CLIN N, V19, P57, DOI 10.1176/appi.neuropsych.19.1.57; Corcoran C, 2004, J PSYCHOPHARMACOL, V18, P133, DOI 10.1177/0269881104043284; Craig D, 2005, AM J GERIAT PSYCHIAT, V13, P460, DOI 10.1176/appi.ajgp.13.6.460; Crespi Francesco, 2002, Curr Opin Investig Drugs, V3, P788; Cummings JL, 2008, ALZHEIMERS DEMENT, V4, P49, DOI 10.1016/j.jalz.2007.10.011; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Czernecki V, 2008, MOVEMENT DISORD, V23, P964, DOI 10.1002/mds.21949; Daiello Lori A, 2007, Med Health R I, V90, P191; David R, 2008, CLIN NEUROL NEUROSUR, V110, P19, DOI 10.1016/j.clineuro.2007.08.007; DeFord SM, 2001, PHARMACOL BIOCHEM BE, V69, P611, DOI 10.1016/S0091-3057(01)00559-7; Dellu F, 1996, NEUROPSYCHOBIOLOGY, V34, P136, DOI 10.1159/000119305; Derouesne Christian, 2004, Psychol Neuropsychiatr Vieil, V2, P19; DeVito EE, 2007, ACTA NEUROL SCAND, V116, P328, DOI 10.1111/j.1600-0404.2007.00906.x; Drapier D, 2008, NEUROPSYCHOLOGIA, V46, P2796, DOI 10.1016/j.neuropsychologia.2008.05.006; Drijgers RL, 2009, DEMENT GERIATR COGN, V28, P13, DOI 10.1159/000228840; Dujardin K, 2008, MOVEMENT DISORD, V23, P845, DOI 10.1002/mds.21968; Dujardin K, 2007, MOVEMENT DISORD, V22, P778, DOI 10.1002/mds.21316; Faerden A, 2008, EUR PSYCHIAT, V23, P33, DOI 10.1016/j.eurpsy.2007.09.002; Faerden A, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-1; Farrar AM, 2008, NEUROSCIENCE, V152, P321, DOI 10.1016/j.neuroscience.2007.12.034; Farrar AM, 2007, PSYCHOPHARMACOLOGY, V191, P579, DOI 10.1007/s00213-006-0554-5; Fava M, 2006, J CLIN PSYCHIAT, V67, P1754, DOI 10.4088/JCP.v67n1113; Feil D, 2003, INT J GERIATR PSYCH, V18, P479, DOI 10.1002/gps.869; Ferreri F, 2006, CAN MED ASSOC J, V175, P1545, DOI 10.1503/cmaj.060542; Figved N, 2005, ACTA PSYCHIAT SCAND, V112, P463, DOI 10.1111/j.1600-0447.2005.00624.x; Filali M, 2009, GENES BRAIN BEHAV, V8, P143, DOI 10.1111/j.1601-183X.2008.00453.x; FREELS S, 1992, J GERONTOL, V47, pM177; Funkiewiez A, 2004, J NEUROL NEUROSUR PS, V75, P834, DOI 10.1136/jnnp.2002.009803; Galvin JE, 2007, NEUROLOGY, V68, P1895, DOI 10.1212/01.wnl.0000263131.80945.ad; Gauthier S, 2007, INT J CLIN PRACT, V61, P886, DOI 10.1111/j.1742-1241.2007.01387.x; Ghobrial MW, 2002, SOUTHERN MED J, V95, P552; Goetz CG, 2008, MOVEMENT DISORD, V23, pS192; GOULIAEV AH, 1994, BRAIN RES REV, V19, P180, DOI 10.1016/0165-0173(94)90011-6; Haegelen C, 2009, MED HYPOTHESES, V72, P421, DOI 10.1016/j.mehy.2008.07.065; Hamilton JM, 2003, J NEUROL NEUROSUR PS, V74, P120, DOI 10.1136/jnnp.74.1.120; Hasegawa M, 1996, BEHAV BRAIN RES, V78, P93, DOI 10.1016/0166-4328(95)00235-9; Jin JJ, 2002, PHARMACOLOGY, V64, P119, DOI 10.1159/000056160; Joseph R, 1999, PSYCHIATRY, V62, P138, DOI 10.1080/00332747.1999.11024862; Ketter TA, 1999, NEUROLOGY, V53, pS53; Kiang M, 2003, SCHIZOPHR RES, V63, P79, DOI 10.1016/S0920-9964(02)00433-4; Kingma EM, 2008, GEN HOSP PSYCHIAT, V30, P155, DOI 10.1016/j.genhosppsych.2007.11.005; Kirsch-Darrow L, 2006, NEUROLOGY, V67, P33, DOI 10.1212/01.wnl.0000230572.07791.22; Kirsch-Darrow L, 2009, MOVEMENT DISORD, V24, P684, DOI 10.1002/mds.22437; Kulisevsky J, 2008, MOVEMENT DISORD, V23, P1889, DOI 10.1002/mds.22246; Lanctot KL, 2007, DEMENT GERIATR COGN, V24, P65, DOI 10.1159/000103633; Landes AM, 2005, J NEUROPSYCH CLIN N, V17, P342, DOI 10.1176/appi.neuropsych.17.3.342; Landes AM, 2001, J AM GERIATR SOC, V49, P1700, DOI 10.1046/j.1532-5415.2001.49282.x; LANEBROWN A, 2009, COCHRANE DB SYST REV, V15; Lauterbach EC, 2004, PSYCHIAT CLIN N AM, V27, P801, DOI 10.1016/j.psc.2004.07.001; Lavretsky H, 2007, AM J GERIAT PSYCHIAT, V15, P386, DOI 10.1097/JGP.0b013e3180325a16; Lechowski L, 2009, INT J GERIATR PSYCH, V24, P341, DOI 10.1002/gps.2125; Leentjens AFG, 2008, MOVEMENT DISORD, V23, P2004, DOI 10.1002/mds.22229; Leentjens AFG, 2009, CLIN THER, V31, P89, DOI 10.1016/j.clinthera.2009.01.012; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; Levy R, 2006, CEREB CORTEX, V16, P916, DOI 10.1093/cercor/bhj043; Levy R, 2006, J NEUROL, V253, P54, DOI 10.1007/s00415-006-7012-5; Lueken U, 2007, AM J GERIAT PSYCHIAT, V15, P376, DOI 10.1097/JGP.0b013e3180437db3; LUTHMAN J, 1994, ARCH INT PHARMACOD T, V328, P125; MALLA AK, 1993, CAN J PSYCHIAT, V38, P617, DOI 10.1177/070674379303800910; Malloy P, 2005, COGN BEHAV NEUROL, V18, P18, DOI 10.1097/01.wnn.0000152232.47901.88; Marangell LB, 2002, J CLIN PSYCHIAT, V63, P391, DOI 10.4088/JCP.v63n0503; Marin, 1996, Semin Clin Neuropsychiatry, V1, P304; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; Marin RS, 2005, J HEAD TRAUMA REHAB, V20, pCP1; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; Marin RS, 2003, J GERIATR PSYCH NEUR, V16, P112, DOI 10.1177/0891988703016002009; Marshall GA, 2006, DEMENT GERIATR COGN, V21, P144, DOI 10.1159/000090674; Marshall GA, 2007, ARCH NEUROL-CHICAGO, V64, P1015, DOI 10.1001/archneur.64.7.1015; Massimo L, 2009, DEMENT GERIATR COGN, V27, P96, DOI 10.1159/000194658; Mayo NE, 2009, STROKE, V40, P3299, DOI 10.1161/STROKEAHA.109.554410; McAllister T W, 2000, Semin Clin Neuropsychiatry, V5, P275, DOI 10.1053/scnp.2000.9557; Mendez MF, 2008, J NEUROPSYCH CLIN N, V20, P130, DOI 10.1176/appi.neuropsych.20.2.130; Migneco O, 2001, NEUROIMAGE, V13, P896, DOI 10.1006/nimg.2000.0741; Mizrahi R, 2007, DRUG AGING, V24, P547, DOI 10.2165/00002512-200724070-00003; Moriguchi S, 2007, MOL PHARMACOL, V71, P580, DOI 10.1124/mol.106.027607; OHTOMO E, 1994, IGAKU AYUMI, V170, P777; Okada K, 1997, STROKE, V28, P2437, DOI 10.1161/01.STR.28.12.2437; Padala PR, 2007, ANN PHARMACOTHER, V41, P346, DOI 10.1345/aph.1H302; Padala PR, 2010, AM J GERIAT PSYCHIAT, V18, P371, DOI 10.1097/JGP.0b013e3181cabcf6; Pedersen KF, 2008, PARKINSONISM RELAT D, V14, P183, DOI 10.1016/j.parkreldis.2007.07.015; Pedersen KF, 2009, PARKINSONISM RELAT D, V15, P295, DOI 10.1016/j.parkreldis.2008.07.006; Peters F, 2006, DEMENT GERIATR COGN, V21, P373, DOI 10.1159/000091898; Pluck GC, 2002, J NEUROL NEUROSUR PS, V73, P636, DOI 10.1136/jnnp.73.6.636; Ramirez SM, 2001, PSYCHOL REP, V88, P189, DOI 10.2466/PR0.88.1.189-200; Reijnders JSAM, 2009, PARKINSONISM RELAT D, V15, P379, DOI 10.1016/j.parkreldis.2008.09.003; Remy P, 2005, BRAIN, V128, P1314, DOI 10.1093/brain/awh445; Reyes S, 2009, NEUROLOGY, V72, P905, DOI 10.1212/01.wnl.0000344166.03470.f8; Robert P, 2009, EUR PSYCHIAT, V24, P98, DOI 10.1016/j.eurpsy.2008.09.001; Robert PH, 2002, INT J GERIATR PSYCH, V17, P1099, DOI 10.1002/gps.755; Robert PH, 2006, CLIN NEUROL NEUROSUR, V108, P733, DOI 10.1016/j.clineuro.2006.02.003; ROBINSON RG, 1977, BIOL PSYCHIAT, V12, P669; Robinson RG, 2009, J NEUROPSYCH CLIN N, V21, P144, DOI 10.1176/appi.neuropsych.21.2.144; Rodda J, 2009, INT PSYCHOGERIATR, V21, P813, DOI 10.1017/S1041610209990354; Roselli F, 2009, MOVEMENT DISORD, V24, pS171; Rosen HJ, 2005, BRAIN, V128, P2612, DOI 10.1093/brain/awh628; Roth RM, 2004, AM J PSYCHIAT, V161, P157, DOI 10.1176/appi.ajp.161.1.157; Roth Robert M, 2007, Curr Treat Options Neurol, V9, P363, DOI 10.1007/s11940-007-0022-5; Rushworth MFS, 2007, TRENDS COGN SCI, V11, P168, DOI 10.1016/j.tics.2007.01.004; Sakurai T, 1998, NEUROSCI LETT, V246, P69, DOI 10.1016/S0304-3940(98)00244-4; Samus QM, 2005, GERONTOLOGIST, V45, P19, DOI 10.1093/geront/45.suppl_1.19; Santa N, 2008, INT J REHABIL RES, V31, P321, DOI 10.1097/MRR.0b013e3282fc0f0e; Siddique H, 2009, J CLIN PSYCHIAT, V70, P915, DOI 10.4088/JCP.08m04828; Sockeel P, 2006, J NEUROL NEUROSUR PS, V77, P579, DOI 10.1136/jnnp.2005.075929; Spiegel DR, 2009, J NEUROPSYCH CLIN N, V21, P216, DOI 10.1176/appi.neuropsych.21.2.216; Starkstein SE, 2008, J NEUROL NEUROSUR PS, V79, P1088, DOI 10.1136/jnnp.2007.136895; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; Starkstein SE, 2006, J NEUROL NEUROSUR PS, V77, P8, DOI 10.1136/jnnp.2005.069575; Starkstein SE, 2001, AM J PSYCHIAT, V158, P872, DOI 10.1176/appi.ajp.158.987.872; Starkstein SE, 2007, MOVEMENT DISORD, V22, P2156, DOI 10.1002/mds.21521; Starkstein SE, 2009, MOVEMENT DISORD, V24, P1211, DOI 10.1002/mds.22577; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; Svetel M, 2009, PARKINSONISM RELAT D, V15, P772, DOI 10.1016/j.parkreldis.2009.01.010; Swanberg MM, 2007, ALZ DIS ASSOC DIS, V21, P164, DOI 10.1097/WAD.0b013e318047df5d; Tagariello P, 2009, ARCH GERONTOL GERIAT, V49, P246, DOI 10.1016/j.archger.2008.09.002; Takeo S, 2003, BRIT J PHARMACOL, V138, P642, DOI 10.1038/sj.bjp.0705096; Takeo S, 2003, J PHARMACOL EXP THER, V304, P513, DOI 10.1124/jpet.102.043653; Tekin S, 2002, J PSYCHOSOM RES, V53, P647, DOI 10.1016/S0022-3999(02)00428-2; Thompson JC, 2002, J NEUROPSYCH CLIN N, V14, P37, DOI 10.1176/appi.neuropsych.14.1.37; Turro-Garriga O, 2009, REV NEUROLOGIA, V48, P7, DOI 10.33588/rn.4801.2008565; van Duijn E, 2007, J NEUROPSYCH CLIN N, V19, P441, DOI 10.1176/appi.neuropsych.19.4.441; van Reekum R, 2005, J NEUROPSYCH CLIN N, V17, P7, DOI 10.1176/appi.neuropsych.17.1.7; Velligan DI, 2002, PSYCHIAT RES, V113, P227, DOI 10.1016/S0165-1781(02)00264-0; von Cramon D Y, 1994, Appl Neuropsychol, V1, P2, DOI 10.1207/s15324826an0101&2_2; WATABE S, 1994, ARZNEIMITTEL-FORSCH, V44-1, P195; Weintraub D, 2004, J AM GERIATR SOC, V52, P784, DOI 10.1111/j.1532-5415.2004.52219.x; Wicks P, 2009, J NEUROL, V256, P234, DOI 10.1007/s00415-009-0078-0; Wongpakaran Nahathai, 2007, Ann Gen Psychiatry, V6, P7, DOI 10.1186/1744-859X-6-7; Yeager CA, 2008, PSYCHOL REP, V102, P718, DOI 10.2466/PR0.102.3.718-722; Yoshii M, 2000, ALZ DIS ASSOC DIS, V14, pS95, DOI 10.1097/00002093-200000001-00014; Zahodne LB, 2009, MOVEMENT DISORD, V24, P677, DOI 10.1002/mds.22441; Zamboni G, 2008, NEUROLOGY, V71, P736, DOI 10.1212/01.wnl.0000324920.96835.95	153	77	80	3	21	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1029-8428			NEUROTOX RES	Neurotox. Res.	FEB	2011	19	2					266	278		10.1007/s12640-010-9196-9			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	721QK	WOS:000287369500005	20473601				2022-02-06	
J	Reneer, DV; Hisel, RD; Hoffman, JM; Kryscio, RJ; Lusk, BT; Geddes, JW				Reneer, Dexter V.; Hisel, Richard D.; Hoffman, Joshua M.; Kryscio, Richard J.; Lusk, Braden T.; Geddes, James W.			A Multi-Mode Shock Tube for Investigation of Blast-Induced Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						helium; overpressure; oxyhydrogen; pressure-time signature; RDX	EXPLOSIVE BLAST; RAT-BRAIN; PRESSURE; OVERPRESSURE; EXPOSURE; MODEL; WAVE; NEUROTRAUMA; CARE	Blast-induced mild traumatic brain injury (bTBI) has become increasingly common in recent military conflicts. The mechanisms by which non-impact blast exposure results in bTBI are incompletely understood. Current small animal bTBI models predominantly utilize compressed air-driven membrane rupture as their blast wave source, while large animal models use chemical explosives. The pressure-time signature of each blast mode is unique, making it difficult to evaluate the contributions of the different components of the blast wave to bTBI when using a single blast source. We utilized a multi-mode shock tube, the McMillan blast device, capable of utilizing compressed air- and compressed helium-driven membrane rupture, and the explosives oxyhydrogen and cyclotrimethylenetrinitramine (RDX, the primary component of C-4 plastic explosives) as the driving source. At similar maximal blast overpressures, the positive pressure phase of compressed air-driven blasts was longer, and the positive impulse was greater, than those observed for shockwaves produced by other driving sources. Helium-driven shockwaves more closely resembled RDX blasts, but by displacing air created a hypoxic environment within the shock tube. Pressure-time traces from oxyhydrogen-driven shockwaves were very similar those produced by RDX, although they resulted in elevated carbon monoxide levels due to combustion of the polyethylene bag used to contain the gases within the shock tube prior to detonation. Rats exposed to compressed air-driven blasts had more pronounced vascular damage than those exposed to oxyhydrogen-driven blasts of the same peak overpressure, indicating that differences in blast wave characteristics other than peak overpressure may influence the extent of bTBI. Use of this multi-mode shock tube in small animal models will enable comparison of the extent of brain injury with the pressure-time signature produced using each blast mode, facilitating evaluation of the blast wave components contributing to bTBI.	[Reneer, Dexter V.; Geddes, James W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Reneer, Dexter V.; Geddes, James W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Hoffman, Joshua M.; Lusk, Braden T.] Univ Kentucky, Dept Min Engn, Lexington, KY 40536 USA; [Kryscio, Richard J.] Univ Kentucky, Dept Biostat, Lexington, KY 40536 USA; [Kryscio, Richard J.] Univ Kentucky, Dept Stat, Lexington, KY 40536 USA; [Hisel, Richard D.] GLR Enterprises LLC, Nicholasville, KY USA		Geddes, JW (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B477 Biomed & Biol Sci Res Bldg BBSRB,741 S Limes, Lexington, KY 40536 USA.	jgeddes@uky.edu	Ritter, Stefanie L/D-9312-2012		National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32DA022738, P30NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	D.V.R. was supported by National Institutes of Health (NIH) grant T32DA022738. We would also like to thank GLR Enterprises, L.L.C., for their generous donation of time and materials, without which this work would not have been possible. Additional support was provided by NIH grant P30NS051220.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Baker W.E., 1973, EXPLOSIONS AIR; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI [10.1089/neu.2009.0885, 10.1089/neu.2009-0885]; CASSEN BK, 1950, J AVIAT MED, V23; CELANDER H, 1955, ACTA PHYSIOL SCAND, V33, P6, DOI 10.1111/j.1748-1716.1955.tb01188.x; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Clemedson C.J., 1949, ACTA PHYSL SCAND S61, V18; CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336, DOI 10.1152/physrev.1956.36.3.336; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Garner JP, 2009, WORLD J SURG, V33, P2194, DOI 10.1007/s00268-009-0105-4; Gruss E, 2006, J TRAUMA, V60, P1284, DOI 10.1097/01.ta.0000220015.21948.ec; Health Effects, 1995, TOX PROF RDX; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; KOPP C, 2008, DEFENCE TODAY, P46; LEVI L, 1990, ISRAEL J MED SCI, V26, P555; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lu FK, 2003, SHOCK WAVES, V12, P457, DOI 10.1007/s00193-003-0186-1; Marks ME, 2002, EMERGENCY RESPONDERS, P30; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; MICHAL J, 1983, FIRE MATER, V7, P163, DOI 10.1002/fam.810070402; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; MURTHY JMK, 1979, J NEUROSURG, V50, P260, DOI 10.3171/jns.1979.50.2.0260; Richmond D. R., 1967, 1854 DASA FISS PROD, P1; RICHMOND DR, 1968, ANN NY ACAD SCI, V152, P103, DOI 10.1111/j.1749-6632.1968.tb11970.x; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; SCOTT BA, 1986, NEUROSURGERY, V18, P107, DOI 10.1227/00006123-198601000-00020; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; *USA, 1984, 91300214 TM US ARM; WARREN WR, 1970, P 7 INT SHOCK TUB S, P143; Zhang JK, 1996, J TRAUMA, V40, pS77	40	77	79	1	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2011	28	1					95	104		10.1089/neu.2010.1513			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	710DT	WOS:000286491800009	21083431	Green Published			2022-02-06	
J	Caplan, LJ; Ivins, B; Poole, JH; Vanderploeg, RD; Jaffee, MS; Schwab, K				Caplan, Leslie J.; Ivins, Brian; Poole, John H.; Vanderploeg, Rodney D.; Jaffee, Michael S.; Schwab, Karen			The Structure of Postconcussive Symptoms in 3 US Military Samples	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; neuropsychology; postconcussive symptoms; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; COMPUTER; INTERVIEW; QUESTIONNAIRE; NUMBER; RISK	Objective: To evaluate alternative models of symptom clusters for the 22-item Neurobehavioral Symptom Inventory. Participants: Three military samples, including 2 nonclinical samples (n = 2420, n = 4244) and 1 sample of individuals with recent head injury (n = 617). Methods: In the first sample, exploratory factor analysis of Neurobehavioral Symptom Inventory responses was performed with tests of significant factors and model fit. In the other 2 samples, confirmatory factor analysis evaluated the fit of 3 models: 2- and 3-factor models based on the initial exploratory factor analysis, and a 9-factor model based on prior research. Main Outcome Measures: The exploratory factor analysis used 2 tests for the number of factors: Parallel Analysis and Minimum Average Partial test. Confirmatory factor analysis models were evaluated using 2 measures of model fit, Root Mean Square Error of Approximation and Comparative Fit Index. Results: Postconcussive symptoms can be described accurately by the 9 factors. However, the model of 3 intercorrelated factors, reflecting cognitive, affective, and somatic/sensory symptoms, fits the data more parsimoniously with little loss in model fit. Conclusion: Although the 9-cluster result from prior research provides a valid description of the relations among items of the inventory, a 3-factor model, consisting of somatic/sensory, affective, and cognitive factors, provides nearly as good a fit to the data, with greater parsimony. We encourage clinicians and researchers to conceptualize the Neurobehavioral Symptom Inventory in terms of 3 coherent clusters of symptoms rather than as 22 individual items.	[Caplan, Leslie J.] NIMH, NIH, Bethesda, MD 20892 USA; [Ivins, Brian; Jaffee, Michael S.; Schwab, Karen] Def & Vet Brain Injury Ctr, Washington, DC USA; [Poole, John H.] Vet Affairs Hlth Care Syst, Palo Alto, CA USA; [Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, James A Haley Vet Affairs Med Ctr, Palo Alto, CA USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Behav Sci & Psychol, Tampa, FL USA		Caplan, LJ (corresponding author), US Dept Educ, Natl Inst Disabil & Rehabil Res, 400 Maryland Ave SW, Washington, DC 20202 USA.	Leslie.Caplan@ed.gov					ALVESW, 1993, J Head Trauma Rehabi, V8, P48; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; BROWNE W, 1993, TESTING STRUCTURAL E, P126; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; ERDMAN HP, 1992, J PSYCHIAT RES, V26, P85, DOI 10.1016/0022-3956(92)90019-K; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LOCKE SE, 1992, JAMA-J AM MED ASSOC, V268, P1301, DOI 10.1001/jama.268.10.1301; LUCAS RW, 1977, BRIT J PSYCHIAT, V131, P160, DOI 10.1192/bjp.131.2.160; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; MILLSTEIN SG, 1987, EDUC PSYCHOL MEAS, V47, P523, DOI 10.1177/0013164487472028; Muthen L.K., 2012, MPLUS USERS GUIDE, V7; NAVALINE HA, 1994, AIDS RES HUM RETROV, V10, pS281; O'Connor BP, 2000, BEHAV RES METH INS C, V32, P396, DOI 10.3758/BF03200807; O'Reilly James M, 1994, J Off Stat, V10, P197; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Tiersky LA, 1998, CLIN NEUROPSYCHOL, V12, P503, DOI 10.1076/clin.12.4.503.7237; Velicer W.F, 2000, PROBLEMS SOLUTIONS H, P41, DOI DOI 10.1007/978-1-4615-4397-8_3; WILSON RF, 1985, COMPUT HUM BEHAV, V1, P265; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; [No title captured]	29	77	77	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2010	25	6					447	458		10.1097/HTR.0b013e3181d5bdbd			12	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	679HA	WOS:000284151300007					2022-02-06	
J	Wade, SL; Walz, NC; Carey, J; Williams, KM; Cass, J; Herren, L; Mark, E; Yeates, KO				Wade, Shari L.; Walz, Nicolay C.; Carey, JoAnne; Williams, Kendra M.; Cass, Jennifer; Herren, Luke; Mark, Erin; Yeates, Keith Owen			A Randomized Trial of Teen Online Problem Solving for Improving Executive Function Deficits Following Pediatric Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adolescent; brain injury; executive functions; family; pediatric; problem solving; telehealth	SOCIAL COMPETENCE; ADOLESCENTS; CHILDREN; INTERVENTION; EFFICACY; BEHAVIOR	Objective: To examine the efficacy of teen online problem solving (TOPS) in improving executive function (EF) deficits following traumatic brain injury (TBI) in adolescence. Methods: Families of adolescents (aged 11-18 years) with moderate to severe TBI were recruited from the trauma registry of 2 tertiary-care children's hospitals and then randomly assigned to receive TOPS (n = 20), a cognitive-behavioral, skill-building intervention, or access to online resources regarding TBI (Internet resource comparison; n = 21). Parent and teen reports of EF were assessed at baseline and a posttreatment follow-up (mean = 7.88 months later). Results: Improvements in self-reported EF skills were moderated by TBI severity, with teens with severe TBI in the TOPS treatment reporting significantly greater improvements than did those with severe TBI in the Internet resource comparison. The treatment groups did not differ on parent ratings of EF at the follow up. Conclusions: Findings suggest that TOPS may be effective in improving EF skills among teens with severe TBI.	[Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, Cincinnati, OH 45229 USA; [Wade, Shari L.; Walz, Nicolay C.; Carey, JoAnne; Williams, Kendra M.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Cass, Jennifer; Herren, Luke; Mark, Erin; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Cass, Jennifer; Herren, Luke; Mark, Erin; Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA		Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institute of Disability and Rehabilitation Research [H133G050239]; Ohio Department of Safety [10503]	This work was supported by grant H133G050239 to the first author from the National Institute of Disability and Rehabilitation Research, US Department of Education and Emergency Medical Services grant 10503 from the Ohio Department of Safety. These results were presented in part at the 2009 Meeting of the Ohio Brain Injury Association and the American Psychological Association Conference in San Diego, California, on August 15, 2010.	Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Guy SC, 2004, BRIEF SR BEHAV RATIN; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2009, J PEDIATR PSYCHOL, V34, P517, DOI 10.1093/jpepsy/jsn081; Ylvisaker M., 1998, COLLABORATIVE BRAIN; Ylvisaker M., 2006, BRAIN IMPAIR, V7, P246, DOI [10.1375/brim.7.3.246, DOI 10.1375/BRIM.7.3.246]; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	13	77	77	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2010	25	6					409	415		10.1097/HTR.0b013e3181fb900d			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	679HA	WOS:000284151300002	21076241				2022-02-06	
J	Highton, D; Elwell, C; Smith, M				Highton, David; Elwell, Clare; Smith, Martin			Noninvasive cerebral oximetry: is there light at the end of the tunnel?	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						cerebral ischemia; cerebral oximetry; near infrared spectroscopy; neuromonitoring	NEAR-INFRARED SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; TIDAL CARBON-DIOXIDE; CAROTID-ENDARTERECTOMY; OXYGEN-SATURATION; CARDIAC-SURGERY; INSPIRED OXYGEN; NIRO 300; ISCHEMIA; PERFUSION	Purpose of review There is increasing interest in the application of near infrared spectroscopy (NIRS) as a noninvasive monitor of cerebral oxygenation. This review will briefly describe the principles of NIRS and examine current evidence for its clinical application as a monitor of the adequacy of cerebral oxygenation in adults. Recent findings There has been a recent surge of interest in the clinical application of NIRS following studies that have quantified the benefits of NIRS-guided management of cerebral oxygenation during cardiopulmonary bypass. However, there are limited data to support its widespread application in other clinical scenarios. New NIRS systems are being introduced to the market and technological advancements have improved their accuracy and extended the range of variables measured. Summary NIRS offers noninvasive monitoring of cerebral oxygenation over multiple regions of interest in a wide range of clinical scenarios. It has many potential advantages over other neuromonitoring techniques, but further technological advances are necessary before it can be introduced more widely into clinical practice.	[Highton, David; Smith, Martin] Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, Dept Neurocrit Care, London WC1N 3BG, England; [Elwell, Clare; Smith, Martin] UCL, Dept Med Phys & Bioengn, London, England		Smith, M (corresponding author), Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, Dept Neurocrit Care, London WC1N 3BG, England.	martin.smith@uclh.nhs.uk	Highton, David/K-9544-2017; Smith, Martin/B-2616-2009	Highton, David/0000-0002-4608-4081; Elwell, Clare/0000-0002-7281-7234	Department of Health's Institute for Health Research Centres; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0701458] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701458] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2009-18-001] Funding Source: researchfish	M.S. is partially funded by the Department of Health's Institute for Health Research Centres funding scheme.	Al-Rawi PG, 2001, STROKE, V32, P2492, DOI 10.1161/hs1101.098356; Al-Rawi PG, 2006, STROKE, V37, P2720, DOI 10.1161/01.STR.0000244807.99073.ae; Banaji M, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000212; de Letter JAM, 1998, NEUROL RES, V20, pS23; DUNCAN A, 1995, PHYS MED BIOL, V40, P295, DOI 10.1088/0031-9155/40/2/007; Dunham CM, 2004, J TRAUMA, V56, P482, DOI 10.1097/01.TA.0000114537.52540.95; Fedorow C, 2010, CURR OPIN ANESTHESIO, V23, P89, DOI 10.1097/ACO.0b013e3283346d10; Fischer GW, 2010, BRIT J ANAESTH, V104, P59, DOI 10.1093/bja/aep335; Fischer GW, 2009, PAIN PRACT, V9, P304, DOI 10.1111/j.1533-2500.2009.00282.x; Germon TJ, 1999, BRIT J ANAESTH, V82, P831, DOI 10.1093/bja/82.6.831; GILL A, 2010, J NEUROSURG, DOI DOI 10.3171/2010/.2.JNS091017; Giustiniano E, 2010, J CARDIOVASC MED, V11, P522, DOI 10.2459/JCM.0b013e32833246e7; Goldman S, 2004, HEART SURG FORUM, V7, pE376, DOI 10.1532/HSF98.20041062; Hirofumi O, 2003, J CLIN NEUROSCI, V10, P79, DOI 10.1016/S0967-5868(02)00268-0; Hoshi Y, 2003, PSYCHOPHYSIOLOGY, V40, P511, DOI 10.1111/1469-8986.00053; Hueber DM, 2001, PHYS MED BIOL, V46, P41, DOI 10.1088/0031-9155/46/1/304; Hunt K, 2006, PHYSIOL MEAS, V27, P777, DOI 10.1088/0967-3334/27/9/002; Kakihana Y, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2940583; Kurth CD, 2002, J CEREBR BLOOD F MET, V22, P335, DOI 10.1097/00004647-200203000-00011; Lee JK, 2009, STROKE, V40, P1820, DOI 10.1161/STROKEAHA.108.536094; Li ZY, 2010, MICROVASC RES, V80, P142, DOI 10.1016/j.mvr.2010.02.004; Manwaring ML, 2010, VASC ENDOVASC SURG, V44, P252, DOI 10.1177/1538574410361785; Mille T, 2004, EUR J VASC ENDOVASC, V27, P646, DOI 10.1016/j.ejvs.2004.02.012; Moritz S, 2007, ANESTHESIOLOGY, V107, P563, DOI 10.1097/01.anes.0000281894.69422.ff; Murkin J M, 2009, Br J Anaesth, V103 Suppl 1, pi3, DOI 10.1093/bja/aep299; Murkin JM, 2009, J EXTRA-CORP TECHNOL, V41, P11; Murkin JM, 2007, ANESTH ANALG, V104, P51, DOI 10.1213/01.ane.0000246814.29362.f4; Newman MF, 2006, LANCET, V368, P694, DOI 10.1016/S0140-6736(06)69254-4; Pennekamp CWA, 2009, EUR J VASC ENDOVASC, V38, P539, DOI 10.1016/j.ejvs.2009.07.008; Picton P, 2010, ANESTH ANALG, V110, P581, DOI 10.1213/ANE.0b013e3181c5f160; Pugliese F, 2009, EUR J ANAESTH, V26, P643, DOI 10.1097/EJA.0b013e32832b89c2; Rigamonti A, 2005, J CLIN ANESTH, V17, P426, DOI 10.1016/j.jclinane.2004.09.007; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P591, DOI 10.1089/neu.1995.12.591; Samra SK, 2000, ANESTHESIOLOGY, V93, P964, DOI 10.1097/00000542-200010000-00015; Slater JP, 2009, ANN THORAC SURG, V87, P36, DOI 10.1016/j.athoracsur.2008.08.070; Smith M, 2008, NEUROSURG CLIN N AM, V19, P489, DOI 10.1016/j.nec.2008.07.008; Smith M, 2009, ANESTH ANALG, V108, P1055, DOI 10.1213/ane.0b013e31819a0301; Springett RJ, 2003, ADV EXP MED BIOL, V530, P555; SUZUKI S, 1999, SPIE P, V3597, P592; Thavasothy M, 2002, ANAESTHESIA, V57, P999, DOI 10.1046/j.1365-2044.2002.02826.x; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Tisdall MM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2718541; Tisdall MM, 2009, ANESTH ANALG, V109, P906, DOI 10.1213/ane.0b013e3181aedcdc; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vohra Hunaid A, 2009, Interact Cardiovasc Thorac Surg, V9, P318, DOI 10.1510/icvts.2009.206367; Wabnitz H, 2010, ADV EXP MED BIOL, V662, P143, DOI 10.1007/978-1-4419-1241-1_20; Wolf M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2804899	48	77	77	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2010	23	5					576	581		10.1097/ACO.0b013e32833e1536			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	646RR	WOS:000281560500007	20830845				2022-02-06	
J	Hancock, M; Tapscott, JL; Hoaken, PNS				Hancock, Megan; Tapscott, Jennifer L.; Hoaken, Peter N. S.			Role of Executive Dysfunction in Predicting Frequency and Severity of Violence	AGGRESSIVE BEHAVIOR			English	Article						executive functioning; violence; Delis-Kaplan Executive Function System; Poisson regression; binary logistic regression	TRAUMATIC BRAIN-INJURY; COUNT DATA; AGGRESSION; CHILDREN; BEHAVIOR; ADOLESCENTS; IMPULSIVITY; PERFORMANCE; PREVALENCE; REGRESSION	The adverse consequences of violence on society are tremendous. The proportion of offenders incarcerated for violent offenses is large, and the cost of keeping these offenders incarcerated is startling. Understanding and treating the causal underpinnings of violent crime is of utmost importance for individuals and society as a whole. Several factors have been identified as potential contributors to violent crime, including cognitive deficits in executive functioning [Hoaken et al., 2007]. To investigate this further, 77 offenders from Fenbrook Institution, a federal facility, were tested on a battery of executive functioning measures. Offenders were found to have broad and pervasive dysfunction in their executive abilities. In addition, specific scores from the battery were found using regression techniques, to predict the frequency and severity of past violent offending but not nonviolent offending. This speaks of the possibility of a new type of correctional rehabilitation program, one that focuses on the rehabilitation of basic executive functions. Aggr. Behav. 36:338-349, 2010. (C) 2010 Wiley-Liss, Inc.	[Hancock, Megan] Univ Western Ontario, Dept Psychol, London, ON N6A 3K7, Canada		Hancock, M (corresponding author), Univ Western Ontario, Dept Psychol, Westminster Hall, London, ON N6A 3K7, Canada.	mhancoc6@uwo.ca			Social Sciences and Humanities Research Council of CanadaSocial Sciences and Humanities Research Council of Canada (SSHRC) [410-2008-2461]	Grant sponsor: Social Sciences and Humanities Research Council of Canada; Grant number: 410-2008-2461.	Andrews D. A., 2003, LEVEL SERVICE INVENT; Baker SF, 2007, INT J LAW PSYCHIAT, V30, P492, DOI 10.1016/j.ijlp.2007.09.010; Barker ED, 2007, ARCH GEN PSYCHIAT, V64, P592, DOI 10.1001/archpsyc.64.5.592; Baron IS, 2004, CHILD NEUROPSYCHOL, V10, P147, DOI 10.1080/09297040490911140; BORNSTEIN RA, 1990, PSYCHIAT RES, V33, P73, DOI 10.1016/0165-1781(90)90150-4; Broomhall L., 2005, PSYCHIAT PSYCHOL LAW, V12, P367, DOI DOI 10.1375/PPLT.12.2.367; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; BUFKIN JL, 2005, ABUSE, V6, P176; Bureau of Justice Statistics, 2009, NAT CRIM VICT SURV C; Burt SA, 2009, CLIN PSYCHOL REV, V29, P163, DOI 10.1016/j.cpr.2008.12.004; Bushman BJ, 2001, PSYCHOL REV, V108, P273, DOI 10.1037//0033-295X.108.1.273; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Cormier, 2006, VIOLENT OFFENDERS AP; Cornell D.G., 1996, CODING GUIDE VIOLENT; Coxe S, 2009, J PERS ASSESS, V91, P121, DOI 10.1080/00223890802634175; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Flannery D., 2005, HDB ADOLESCENT BEHAV, P415; Greenfield R, 2007, PSYCHOL REP, V101, P323, DOI 10.2466/PR0.101.1.323-333; Hart S.D., 1997, HCR 20 ASSESSING RIS; Hoaken PNS, 2007, AGGRESSIVE BEHAV, V33, P412, DOI 10.1002/ab.20194; Hoaken PNS, 2003, AGGRESSIVE BEHAV, V29, P15, DOI 10.1002/ab.10023; Homack S, 2005, J CLIN EXP NEUROPSYC, V27, P599, DOI 10.1080/13803390490918444; Hutchinson MK, 2005, RES NURS HEALTH, V28, P408, DOI 10.1002/nur.20093; Jurado MB, 2007, NEUROPSYCHOL REV, V17, P213, DOI 10.1007/s11065-007-9040-z; Kashani JH, 1999, J EMOT BEHAV DISORD, V7, P200, DOI 10.1177/106342669900700402; Kaufman NL, 2004, KAUFMAN BRIEF INTELL; Krpan KM, 2007, J CLIN EXP NEUROPSYC, V29, P36, DOI 10.1080/13803390500376816; Marsh NV, 2006, BRAIN INJURY, V20, P61, DOI 10.1080/02699050500110645; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; Meloy JR, 2006, AUST NZ J PSYCHIAT, V40, P539, DOI 10.1080/j.1440-1614.2006.01837.x; Miura H, 2009, PSYCHIAT CLIN NEUROS, V63, P161, DOI 10.1111/j.1440-1819.2009.01935.x; Morgan AB, 2000, CLIN PSYCHOL REV, V20, P113, DOI 10.1016/S0272-7358(98)00096-8; Pliszka S, 2007, J AM ACAD CHILD PSY, V46, P894, DOI 10.1097/chi.0b013e318054e724; Raaijmakers MAJ, 2008, J ABNORM CHILD PSYCH, V36, P1097, DOI 10.1007/s10802-008-9235-7; Rath JF, 2004, ARCH CLIN NEUROPSYCH, V19, P613, DOI 10.1016/j.acn.2003.08.006; RIDOUT M, 1998, P INT BIOM C CAP TOW, V98, P179; Scarpa A, 2007, CAMB HANDB PSYCHOL, P151; Seguin JR, 2004, J ABNORM PSYCHOL, V113, P603, DOI 10.1037/0021-843X.113.4.603; Serin RC, 2001, TREATING ADULT AND JUVENILE OFFENDERS WITH SPECIAL NEEDS, P249, DOI 10.1037/10390-009; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shunk AW., 2006, APPL NEUROPSYCHOLOGY, V13, P275, DOI [DOI 10.1207/S15324826AN1304_9, DOI 10.1207/S15324826AN1304_]; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Suchy Y, 2009, ANN BEHAV MED, V37, P106, DOI 10.1007/s12160-009-9097-4; *UCLA AC TECHN SER, 2008, STAT DAT AN EX LOG R; Velligan D I, 1999, Semin Clin Neuropsychiatry, V4, P24; Walters GD, 2007, CRIM JUSTICE BEHAV, V34, P1659, DOI 10.1177/0093854807307030; WHO, 2002, WORLD REP VIOL HLTH; WORTHINGTON A, 2005, EFFECTIVENESS REHABI, P257	50	77	79	0	45	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0096-140X	1098-2337		AGGRESSIVE BEHAV	Aggressive Behav.	SEP-OCT	2010	36	5					338	349		10.1002/ab.20353			12	Behavioral Sciences; Psychology, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Psychology	641MS	WOS:000281131500007	20593426				2022-02-06	
J	Carmona, A; Omenaca, F; Tejedor, JC; Merino, JM; Vaman, T; Dieussaert, I; Gillard, P; Aristegui, J				Carmona, Alfonso; Omenaca, Felix; Tejedor, Juan C.; Merino, Jose M.; Vaman, Tejaswini; Dieussaert, Ilse; Gillard, Paul; Aristegui, Javier			Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months	VACCINE			English	Article						Influenza vaccines; Adjuvant; Children	CRITICALLY-ILL PATIENTS; PANDEMIC INFLUENZA; ANTIBODY-RESPONSES; YOUNG-CHILDREN; H5N1; CANDIDATE; INFECTION; A(H1N1); VIRUS; STRATEGIES	We report on the evaluation of the immunogenicity and reactogenicity/safety of AS03-adjuvanted vaccine against pandemic influenza A/H1N1/2009 in young children. In this open-label, randomized study, 157 healthy children aged 6-35 months received two doses (21 days apart) of split-virion inactivated A/California/7/2009 H1N1 vaccine containing either (i) 1.9 mu g hemagglutinin (HA) and AS03(B) (5.93 mg tocopherol)(N = 104) or (ii) 3.75 mu g HA and AS03(A) (11.86 mg tocopherol) (N = 53). At 21 days following the first dose of AS03(B)-adjuvanted vaccine (1.9 mu g HA) the percentage of children with hemagglutination-inhibition titers of >= 40 against the vaccine strain rose from 3.0% before vaccination to 100%. The seroconversion rate was 99% and the geometric mean titer (GMT) increased from 6 to 313. After the second dose the GMT increased further to 2008. The higher dose AS03(A)-adjuvanted 3.75 g HA vaccine did not further increase the immune response. Solicited symptoms reported within 7 days following vaccination were mainly mild to moderate. After the first dose of AS03(B)-adjuvanted vaccine (1.9 mu g HA) the most common solicited symptoms were pain at the injection site (35.6%) and irritability (31.7%). Fever (axillary >= 37.5 degrees C) was reported with an incidence of 20.2%. After the second dose reactogenicity tended to increase (injection site pain: 41.3%; irritability: 46.2%; fever >= 37.5 degrees C: 67.3%). Spontaneously reported adverse events with an intensity that prevented normal activities were documented for 2.9-6.7% of doses with only one event (vomiting) considered related to vaccination. There was one serious adverse event reported in the AS03(A)-adjuvanted 3.75 mu g HA vaccine group (traumatic brain injury) which was not considered as related to vaccination. In conclusion, these data suggest that a first dose of AS03(B)-adjuvanted A/H1N1/2009 vaccine containing 1.9 mu g HA in children 6-35 months old is highly immunogenic and that the overall reactogenicity profile is acceptable although reactions including fever tend to increase after a second dose. (C) 2010 Elsevier Ltd. All rights reserved.	[Carmona, Alfonso] Inst Hispalense & Pediat, Seville, Spain; [Omenaca, Felix] Hosp La Paz, Madrid, Spain; [Tejedor, Juan C.] Mostoles Hosp, Madrid, Spain; [Merino, Jose M.] Hosp Gen Yague, Burgos, Spain; [Vaman, Tejaswini; Dieussaert, Ilse; Gillard, Paul] GlaxoSmithKline Biol, Wavre, Belgium; [Aristegui, Javier] Basurto Hosp, Bilbao, Spain		Omenaca, F (corresponding author), Univ Hosp La Paz, Neonatol Unit, Paseo Castellana 241, Madrid, Spain.	fomenaca.hulp@salud.madrid.org	Tejedor, Juan Carlos/G-5111-2015	Tejedor, Juan Carlos/0000-0002-1748-6663			*AM AC PED, 2007, PAND INFL WARN CHILD; Banzhoff A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004384; Basta NE, 2009, AM J EPIDEMIOL, V170, P679, DOI 10.1093/aje/kwp237; Bhat N, 2005, NEW ENGL J MED, V353, P2559, DOI 10.1056/NEJMoa051721; Chu DWS, 2009, VACCINE, V27, P7428, DOI 10.1016/j.vaccine.2009.07.102; Clark TW, 2009, NEW ENGL J MED, V361, P2424, DOI 10.1056/NEJMoa0907650; Coffin SE, 2007, PEDIATRICS, V119, P740, DOI 10.1542/peds.2006-2679; Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535; Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810; Diez-Domingo J, 2010, PEDIATR INFECT DIS J, V29, pE35, DOI 10.1097/INF.0b013e3181daf921; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Donaldson LJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5213; Echevarria-Zuno S, 2009, LANCET, V374, P2072, DOI 10.1016/S0140-6736(09)61638-X; Englund JA, 2005, PEDIATRICS, V115, P1039, DOI 10.1542/peds.2004-2373; *EUR COMM PROPR ME, 2006, EMEACHMPVWP263499200; Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795; Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062; Germann TC, 2006, P NATL ACAD SCI USA, V103, P5935, DOI 10.1073/pnas.0601266103; Gonzalez M, 2000, ARCH DIS CHILD, V83, P488, DOI 10.1136/adc.83.6.488; Greenberg ME, 2009, NEW ENGL J MED, V361, P2405, DOI 10.1056/NEJMoa0907413; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; Hehme NW, 2002, CLIN DRUG INVEST, V22, P751, DOI 10.2165/00044011-200222110-00004; Jennings LC, 2008, LANCET INFECT DIS, V8, P650, DOI 10.1016/S1473-3099(08)70232-9; King JC, 2009, VACCINE, V27, P6589, DOI 10.1016/j.vaccine.2009.08.032; Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496; Leroux-Roels I, 2007, LANCET, V370, P580, DOI 10.1016/S0140-6736(07)61297-5; Levie K, 2008, J INFECT DIS, V198, P642, DOI 10.1086/590913; Loeb M, 2010, JAMA-J AM MED ASSOC, V303, P943, DOI 10.1001/jama.2010.250; Mitchell DK, 2005, PEDIATR INFECT DIS J, V24, P925, DOI 10.1097/01.inf.0000180978.66362.d9; Nicoll A, 2008, ARCH DIS CHILD, V93, P433, DOI 10.1136/adc.2006.101477; NIH Bulletin, NIH B; Nolan T, 2010, JAMA-J AM MED ASSOC, V303, P37, DOI 10.1001/jama.2009.1911; *NOV SWIN OR INFL, 2009, NEW ENGL J MED, V361, P102; Osterhaus ADME, 2007, VACCINE, V25, P4983, DOI 10.1016/j.vaccine.2007.05.033; Plennevaux E, 2010, LANCET, V375, P41, DOI 10.1016/S0140-6736(09)62026-2; Rojo JC, 2006, PEDIATR INFECT DIS J, V25, P596, DOI 10.1097/01.inf.0000220208.59965.95; Roman F, 2010, VACCINE, V28, P1740, DOI 10.1016/j.vaccine.2009.12.014; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; Rumke HC, 2008, VACCINE, V26, P2378, DOI 10.1016/j.vaccine.2008.02.068; SCHWARZ TF, 2009, INFLUENZA VACCINES W; Schwarz TF, 2009, VACCINE, V27, P6284, DOI 10.1016/j.vaccine.2009.01.040; *US FDA, 2007, FDA GUID IND CLIN DA; Vesikari T, 2009, PEDIATR INFECT DIS J, V28, P563, DOI 10.1097/INF.0b013e31819d6394; *WHO, AV CAND REASS VACC V; Zarocostas J, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4313; Zhu FC, 2009, NEW ENGL J MED, V361, P2414, DOI 10.1056/NEJMoa0908535; STUDY NO 100351 056; STUDY NO 104858 FLUA	49	77	78	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X	1873-2518		VACCINE	Vaccine	AUG 16	2010	28	36					5837	5844		10.1016/j.vaccine.2010.06.065			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	645IW	WOS:000281449000011	20600478				2022-02-06	
J	Kim, J; Whyte, J; Patel, S; Avants, B; Europa, E; Wang, JJ; Slattery, J; Gee, JC; Coslett, HB; Detre, JA				Kim, Junghoon; Whyte, John; Patel, Sunil; Avants, Brian; Europa, Eduardo; Wang, Jiongjiong; Slattery, John; Gee, James C.; Coslett, H. Branch; Detre, John A.			Resting Cerebral Blood Flow Alterations in Chronic Traumatic Brain Injury: An Arterial Spin Labeling Perfusion fMRI Study	JOURNAL OF NEUROTRAUMA			English	Article						arterial spin labeling; cerebral blood flow; lesion; magnetic resonance imaging; traumatic brain injury	CLOSED-HEAD-INJURY; DEFAULT-MODE NETWORK; ALZHEIMERS-DISEASE; WORKING-MEMORY; COGNITIVE REHABILITATION; UNITED-STATES; SPECT; CORTEX; PET; CONNECTIVITY	Non-invasive measurement of resting state cerebral blood flow (CBF) may reflect alterations of brain structure and function after traumatic brain injury (TBI). However, previous imaging studies of resting state brain in chronic TBI have been limited by several factors, including measurement in relative rather than absolute units, use of crude spatial registration methods, exclusion of subjects with substantial focal lesions, and exposure to ionizing radiation, which limits repeated assessments. This study aimed to overcome those obstacles by measuring absolute CBF with an arterial spin labeling perfusion fMRI technique, and using an image preprocessing protocol that is optimized for brains with mixed diffuse and focal injuries characteristic of moderate and severe TBI. Resting state CBF was quantified in 27 individuals with moderate to severe TBI in the chronic stage, and 22 demographically matched healthy controls. In addition to global CBF reductions in the TBI subjects, more prominent regional hypoperfusion was found in the posterior cingulate cortices, the thalami, and multiple locations in the frontal cortices. Diffuse injury, as assessed by tensor-based morphometry, was mainly associated with reduced CBF in the posterior cingulate cortices and the thalami, where the greatest volume losses were detected. Hypoperfusion in superior and middle frontal cortices, in contrast, was associated with focal lesions. These results suggest that structural lesions, both focal and diffuse, are the main contributors to the absolute CBF alterations seen in chronic TBI, and that CBF may serve as a tool to assess functioning neuronal volume. We also speculate that resting reductions in posterior cingulate perfusion may reflect alterations in the default-mode network, and may contribute to the attentional deficits common in TBI.	[Kim, Junghoon; Whyte, John; Patel, Sunil; Europa, Eduardo; Slattery, John] Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Coslett, H. Branch; Detre, John A.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Avants, Brian; Gee, James C.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Avants, Brian; Wang, Jiongjiong; Gee, James C.; Coslett, H. Branch; Detre, John A.] Univ Penn, Ctr Funct Neuroimaging, Philadelphia, PA 19104 USA		Kim, J (corresponding author), Albert Einstein Healthcare Network, Moss Rehabil Res Inst, 60 Township Line Rd, Elkins Pk, PA 19027 USA.	kimj@einstein.edu	Kim, Junghoon/A-6669-2012; Wang, Danny JJ/O-2482-2018; Kim, Junghoon John/I-6702-2019	Wang, Danny JJ/0000-0002-0840-7062; Kim, Junghoon John/0000-0001-5729-8993; Whyte, John/0000-0002-4381-1474; avants, brian/0000-0002-4212-3362	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24HD39621, R24HD050836, P30NS045839, RR002305, NS045839]; Albert Einstein Society; Pennsylvania Department of Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836, R24HD039621] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR002305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045839] Funding Source: NIH RePORTER	The authors wish to thank Kathy Z. Tang, B. A., John Pluta, B. S., Gang Song, M. S., and Allen Osman, Ph.D. for their help with subject recruitment, data analysis, and manuscript review. The assistance of MRI technicians Doris Cain, Patricia O'Donnell, and Norman Butler is also gratefully acknowledged. This study was supported by grant R24HD39621, R24HD050836 (www.ncrrn.org), P30NS045839, RR002305, and NS045839 from the NIH. This project was also funded in part by the Albert Einstein Society and the Pennsylvania Department of Health. The Department specifically disclaims responsibility for any analyses, interpretations, or conclusions included in this article.	Ances BM, 2000, J CEREBR BLOOD F MET, V20, P921, DOI 10.1097/00004647-200006000-00004; ANDERSON KE, 2005, TXB TRAUMATIC BRAIN, P107; Avants B, 2004, NEUROIMAGE, V23, pS139, DOI 10.1016/j.neuroimage.2004.07.010; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Borghammer P, 2009, NEUROIMAGE, V47, P1514, DOI 10.1016/j.neuroimage.2009.05.040; Borghammer P, 2009, NEUROIMAGE, V45, P249, DOI 10.1016/j.neuroimage.2008.07.042; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Casanova R, 2007, NEUROIMAGE, V34, P137, DOI 10.1016/j.neuroimage.2006.09.011; Detre JA, 2002, CLIN NEUROPHYSIOL, V113, P621, DOI 10.1016/S1388-2457(02)00038-X; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Grunder G, 2009, NEUROIMAGE, V45, P258, DOI 10.1016/j.neuroimage.2008.10.042; Hattori N, 2003, ACTA NEUROCHIR SUPPL, V86, P49; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; ICHISE M, 1994, J NUCL MED, V35, P217; Inoue Y, 2005, J NEUROTRAUM, V22, P1411, DOI 10.1089/neu.2005.22.1411; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kim E, 2009, BRAIN, V132, P369, DOI 10.1093/brain/awn311; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kim J, 2006, NEUROIMAGE, V31, P376, DOI 10.1016/j.neuroimage.2005.11.035; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Kogure D, 2000, J NUCL MED, V41, P1155; Lannoo E, 2001, BRAIN INJURY, V15, P1, DOI 10.1080/02699050150209084; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Mai JK, 2004, ATLAS HUMAN BRAIN; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; NGAI AC, 1988, AM J PHYSIOL, V254, pH133, DOI 10.1152/ajpheart.1988.254.1.H133; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PRAYER L, 1993, ACTA RADIOL, V34, P593; Rao HY, 2007, HUM BRAIN MAPP, V28, P593, DOI 10.1002/hbm.20288; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Rombouts SARB, 2005, HUM BRAIN MAPP, V26, P231, DOI 10.1002/hbm.20160; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; SASAKI K, 1979, EXP BRAIN RES, V37, P193, DOI 10.1007/BF01474266; Schmahmann JD, 1997, J NEUROSCI, V17, P438, DOI 10.1523/JNEUROSCI.17-01-00438.1997; Schwartz MF, 2005, ARCH PHYS MED REHAB, V86, P1807, DOI 10.1016/j.apmr.2005.03.009; Shin YB, 2006, BRAIN INJURY, V20, P661, DOI 10.1080/02699050600677071; Stamatakis EA, 2002, J NUCL MED, V43, P476; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Troiani V, 2008, NEUROIMAGE, V40, P932, DOI 10.1016/j.neuroimage.2007.12.002; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Wang JJ, 2005, RADIOLOGY, V235, P218, DOI 10.1148/radiol.2351031663; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wolf RL, 2007, NEUROTHERAPEUTICS, V4, P346, DOI 10.1016/j.nurt.2007.04.005; Wong SBC, 2006, PROG BRAIN RES, V157, P173, DOI 10.1016/S0079-6123(06)57011-6	55	77	78	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2010	27	8					1399	1411		10.1089/neu.2009.1215			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	639OU	WOS:000280984900005	20528163	Green Published			2022-02-06	
J	Lange, RT; Iverson, GL; Rose, A				Lange, Rael T.; Iverson, Grant L.; Rose, Alice			Post-concussion Symptom Reporting and the "Good-Old-Days" Bias Following Mild Traumatic Brain Injury(dagger)	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Post-concussion symptoms; Good-old-days bias	POSTCONCUSSION-LIKE SYMPTOMS; PERSONAL-INJURY CLAIMANTS; COMPLAINT BASE RATES; HEAD-INJURY; COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; CHRONIC PAIN; ETIOLOGY; INDIVIDUALS; EXPECTATION	The purpose of this study was to examine the influence of the "good-old-days" bias on symptom reporting following mild traumatic brain injury (MTBI). The MTBI sample consisted of 86 patients (51.2% men) referred to a hospital-based concussion clinic in Vancouver, Canada. The majority of patients (83.7%) were evaluated within 3 months following their injury (M = 1.8 months, SD = 1.7, range = 0.2-8.0 months). Patients provided retrospective preinjury symptom ratings on the British Columbia Post-Concussion Symptom Inventory (BC-PSI). Ratings were compared with 177 healthy controls recruited from the community and a local university. MTBI retrospective ratings were significantly lower than the control group on the BC-PSI total score (p < .01, d = 0.27, small effect size) and 6 of the 13 individual items (all p < .05, d = 0.23-0.36, small to small-medium effect sizes). Patients who were currently in litigation reported more post-injury symptoms (p = .009, d = 0.63, medium-large effect size). However, litigation status was not associated with self-reported preinjury retrospective symptom ratings. Consistent with the "good-old-days" bias, patients with MTBI appear to misperceive their preinjury functioning as better than the average person.	[Lange, Rael T.] Univ British Columbia, British Columbia Mental Hlth & Addict Serv, PHSA Res & Networks, Vancouver, BC V5Z 4C2, Canada; [Rose, Alice] GF Strong Rehab Ctr, Vancouver, BC, Canada		Lange, RT (corresponding author), Univ British Columbia, British Columbia Mental Hlth & Addict Serv, PHSA Res & Networks, Suite 201,601 W Broadway St, Vancouver, BC V5Z 4C2, Canada.	rael.lange@gmail.com		Iverson, Grant/0000-0001-7348-9570			Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2009, J HEAD TRAUMA REHAB, V24, P76, DOI 10.1097/HTR.0b013e31819c2190; Carroll Linda J., 2004, Journal of Rehabilitation Medicine Supplement, P113; Cohen J., 2013, STAT POWER ANAL BEHA; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Epley N, 2000, J PERS SOC PSYCHOL, V79, P861, DOI 10.1037//0022-3514.79.6.861; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Furnham A, 2004, BRIT J PSYCHOL, V95, P149, DOI 10.1348/000712604773952395; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Greiffenstein MF, 2002, PSYCHOL ASSESSMENT, V14, P202, DOI 10.1037//1040-3590.14.2.202; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kinard EM, 2001, CHILD ABUSE NEGLECT, V25, P33; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kruger J, 1999, J PERS SOC PSYCHOL, V77, P1121, DOI 10.1037/0022-3514.77.6.1121; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Ruff R, 2009, J HEAD TRAUMA REHAB, V24, P131, DOI 10.1097/01.HTR.0000348755.42649.e9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stone CA, 2002, J LEARN DISABIL-US, V35, P370, DOI 10.1177/00222194020350040801; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 2004, ICD 10 INT STAT CLAS	49	77	77	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2010	25	5					442	450		10.1093/arclin/acq031			9	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	627BN	WOS:000280013100009	20447932	Bronze			2022-02-06	
J	Xu, YQ; McArthur, DL; Alger, JR; Etchepare, M; Hovda, DA; Glenn, TC; Huang, SC; Dinov, I; Vespa, PM				Xu, Yueqiao; McArthur, David L.; Alger, Jeffry R.; Etchepare, Maria; Hovda, David A.; Glenn, Thomas C.; Huang, Sungcheng; Dinov, Ivo; Vespa, Paul M.			Early nonischemic oxidative metabolic dysfunction leads to chronic brain atrophy in traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						atrophy; metabolism; MRI; positron emission tomography; traumatic brain injury	IRREVERSIBLE TISSUE-DAMAGE; ISCHEMIC-INJURY; HEAD-INJURY; CHILDREN; MODERATE; CRISIS; MRI; MICRODIALYSIS; VOLUME; SCALE	Chronic brain atrophy after traumatic brain injury (TBI) is a well-known phenomenon, the causes of which are unknown. Early nonischemic reduction in oxidative metabolism is regionally associated with chronic brain atrophy after TBI. A total of 32 patients with moderate-to-severe TBI prospectively underwent positron emission tomography (PET) and volumetric magnetic resonance imaging (MRI) within the first week and at 6 months after injury. Regional lobar assessments comprised oxidative metabolism and glucose metabolism. Acute MRI showed a preponderance of hemorrhagic lesions with few irreversible ischemic lesions. Global and regional chronic brain atrophy occurred in all patients by 6 months, with the temporal and frontal lobes exhibiting the most atrophy compared with the occipital lobe. Global and regional reduction in cerebral metabolic rate of oxygen (CMRO2), cerebral blood flow (CBF), oxygen extraction fraction (OEF), and cerebral metabolic rate of glucose were observed. The extent of metabolic dysfunction was correlated with the total hemorrhage burden on initial MRI (r = 0.62, P = 0.01). The extent of regional brain atrophy correlated best with CMRO2 and CBF. Lobar values of OEF were not in the ischemic range and did not correlate with chronic brain atrophy. Chronic brain atrophy is regionally specific and associated with regional reductions in oxidative brain metabolism in the absence of irreversible ischemia. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 883-894; doi:10.1038/jcbfm.2009.263; published online 23 December 2009	[Vespa, Paul M.] Univ Calif Los Angeles, Dept Neurosurg, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, Los Angeles, CA 90095 USA; [Alger, Jeffry R.; Vespa, Paul M.] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Huang, Sungcheng] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Huang, Sungcheng] Univ Calif Los Angeles, DOE Ctr Mol Med, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Xu, Yueqiao] Capital Med Univ, Dept Neurosurg, Xuanwu Hosp, Beijing, Peoples R China		Vespa, PM (corresponding author), Univ Calif Los Angeles, Dept Neurosurg, David Geffen Sch Med, Ronald Reagan UCLA Med Ctr, 757 Westwood Blvd,Room RR 6236A, Los Angeles, CA 90095 USA.	PVespa@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Dinov, Ivo/0000-0003-3825-4375; Glenn, Thomas/0000-0003-4273-3408	California State Neurotrauma Initiative;  [NS049471];  [NS02089]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049471] Funding Source: NIH RePORTER	The research was supported by Grant nos NS049471, NS02089, and the California State Neurotrauma Initiative.	Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Coles JP, 2009, J CEREBR BLOOD F MET, V29, P965, DOI 10.1038/jcbfm.2009.22; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; DINOV I, 2009, NEUROINFORMATICS, V3, P22, DOI DOI 10.3389/NEURO.11.022.2009; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Fiehler J, 2002, STROKE, V33, P79, DOI 10.1161/hs0102.100884; GOLDBERG KM, 1992, TECHNOMETRICS, V34, P307, DOI 10.2307/1270037; Hayman LA, 1992, CLIN BRAIN IMAGING N, P130; Kidwell CS, 2000, ANN NEUROL, V47, P462, DOI 10.1002/1531-8249(200004)47:4<462::AID-ANA9>3.3.CO;2-P; Kidwell CS, 2002, ANN NEUROL, V52, P698, DOI 10.1002/ana.10380; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; LIN KP, 1994, IEEE T NUCL SCI, V41, P2850, DOI 10.1109/23.340657; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; OHTA S, 1992, J CEREBR BLOOD F MET, V12, P179, DOI 10.1038/jcbfm.1992.28; Okauchi M, 2009, STROKE, V40, P1858, DOI 10.1161/STROKEAHA.108.535765; Press W., 1986, NUMERICAL RECIPES AR; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Shattuck DW, 2002, MED IMAGE ANAL, V6, P129, DOI 10.1016/S1361-8415(02)00054-3; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith SM, 2002, NEUROIMAGE, V17, P479, DOI 10.1006/nimg.2002.1040; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Verger K, 2001, BRAIN INJURY, V15, P211; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wilcox RR, 2005, INTRO ROBUST ESTIMAT; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	36	77	77	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2010	30	4					883	894		10.1038/jcbfm.2009.263			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	577BZ	WOS:000276197200023	20029449	Green Published, Bronze			2022-02-06	
J	Johansson, B; Starmark, A; Berglund, P; Rodholm, M; Ronnback, L				Johansson, Birgitta; Starmark, Anders; Berglund, Peter; Rodholm, Martin; Ronnback, Lars			A self-assessment questionnaire for mental fatigue and related symptoms after neurological disorders and injuries	BRAIN INJURY			English	Article						Mental fatigue; self-assessment questionnaire	TRAUMATIC BRAIN-INJURY; COGNITIVE COMPLAINTS; POSTSTROKE FATIGUE; PROCESSING SPEED; MILD; STROKE; DEPRESSION; MEMORY; RELIABILITY; SCALE	Primary objective: The purpose was to evaluate a new self-reporting scale for assessment of mental fatigue and its usefulness in describing mental fatigue after neurological diseases and injuries. Mental fatigue is suggested to comprise a spectrum of items including sensory, emotional and cognitive symptoms. Methods and procedures: Mental fatigue and related symptoms were measured with a self-assessment scale on different diagnostic groups with neurological injuries and diseases as well as healthy controls. The scale covers sleep, sensory, emotional and cognitive domains, mental recovery and 24-hour variation. Results: There were significant correlations between all the questions in the self-assessing scale and also a high internal consistency among items (Cronbach's alpha of 0.944). Despite the different aetiologies of mental fatigue and related symptoms, the individuals rated the questions in a similar way. The total sum of scores, as well as the separate questions showed significantly lower values for healthy controls compared to mental fatigue groups. Conclusion: In spite of the different aetiology of mental fatigue, the items included in the scale were significant for different diseases with co-occurring mental fatigue. The self-reported scale is suggested to be a valuable tool for assessment of mental fatigue in different diagnoses.	[Johansson, Birgitta; Starmark, Anders; Berglund, Peter; Ronnback, Lars] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, SE-41345 Gothenburg, Sweden; [Rodholm, Martin] Kungalv Hosp, Psychiat Clin, Kungalv, Sweden		Johansson, B (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Dubbsgatan 14, SE-41345 Gothenburg, Sweden.	birgitta.johansson2@vgregion.se		, Birgitta/0000-0003-0240-1142; Berglund, Peter/0000-0003-2367-1686	Health & Medical Care Committee of the Vastra Gotaland Region; Swedish Research CouncilSwedish Research CouncilEuropean Commission [21X-13015]; Fyrbodalinstitutet; Swedish Association of Survivors of Traffic Accidents and Polio	This work was supported by grants from The Health & Medical Care Committee of the Vastra Gotaland Region, The Swedish Research Council (grant no 21X-13015), Fyrbodalinstitutet and The Swedish Association of Survivors of Traffic Accidents and Polio.	ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P33, DOI 10.1097/01.HTR.0000308719.70288.22; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; BELOMONT A, 2006, ANN READAPTIVE MED P, V49, P283; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Carlsson GE, 2003, CEREBROVASC DIS, V16, P383, DOI 10.1159/000072561; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chiaravalloti ND, 2003, J CLIN EXP NEUROPSYC, V25, P489, DOI 10.1076/jcen.25.4.489.13878; Christodoulou C, 2005, ISS CLIN COGN NEUROP, P19; DELUCA J, 2007, INFORM PROCESSING SP, P265; DeLuca J, 2008, J NEUROL SCI, V270, P28, DOI 10.1016/j.jns.2008.01.018; Dittner AJ, 2004, J PSYCHOSOM RES, V56, P157, DOI 10.1016/S0022-3999(03)00371-4; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Glader EL, 2002, STROKE, V33, P1327, DOI 10.1161/01.STR.0000014248.28711.D6; Hagell P, 2009, J NEUROL NEUROSUR PS, V80, P489, DOI 10.1136/jnnp.2008.159772; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Joy S, 2004, ARCH CLIN NEUROPSYCH, V19, P759, DOI 10.1016/j.acn.2003.09.009; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; Lange G, 2005, NEUROIMAGE, V26, P513, DOI 10.1016/j.neuroimage.2005.02.011; LINDQVIST G, 1993, ACTA PSYCHIAT SCAND, V88, P5, DOI 10.1111/j.1600-0447.1993.tb05611.x; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Naess H, 2005, CEREBROVASC DIS, V20, P245, DOI 10.1159/000087706; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Rasquin SMC, 2004, DEMENT GERIATR COGN, V18, P138, DOI 10.1159/000079193; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Rodholm M, 2001, ACTA NEUROL SCAND, V103, P379, DOI 10.1034/j.1600-0404.2001.103006379.x; Schepers VP, 2006, ARCH PHYS MED REHAB, V87, P184, DOI 10.1016/j.apmr.2005.10.005; Shah A, 2009, PHYS MED REH CLIN N, V20, P363, DOI 10.1016/j.pmr.2008.12.003; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; STULEMEIJER M, 2006, J NEUROL, V253, P1432; SVANBORG P, 1994, ACTA PSYCHIAT SCAND, V89, P21, DOI 10.1111/j.1600-0447.1994.tb01480.x; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D., 2003, WECHSLER ADULT INTEL; Winward C, 2009, STROKE, V40, P757, DOI 10.1161/STROKEAHA.108.527101; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	51	77	80	4	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2010	24	1					2	12		10.3109/02699050903452961			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	554AA	WOS:000274406700001	20001478				2022-02-06	
J	Rickels, E; von Wild, K; Wenzlaff, P				Rickels, Eckhard; von Wild, Klaus; Wenzlaff, Paul			Head injury in Germany: A population-based prospective study on epidemiology, causes, treatment and outcome of all degrees of head-injury severity in two distinct areas	BRAIN INJURY			English	Article						Head injury; all degrees of severity; causes; epidemiology; outcome	TRAUMATIC BRAIN-INJURY; CLINICAL-TRIALS; MANAGEMENT; MORTALITY; VALIDATION; AGE	Introduction: Little is known about the ratio of mild traumatic brain injury (TBI) to moderate and severe TBI, about the time that elapses until primary care is given, about the number of patients requiring immediate surgery and about the early outcome and the costs. Method: In a prospective study two regions taken as model examples were investigated: the City of Hanover with its surrounding catchment area and Munster with its regions. Results: From 1 March 2000 until 28 February 2001 all patients were recruited who were admitted to a hospital emergency department due to a TBI; 6783 patients (58.4% male, 41.6% female; 29.7% children < 16 years) were included; 5220 (73%) received in-hospital treatment; and 258 were given early rehabilitation. The incidence of TBI is 332 per 100 000 head of population. The GCS (Glasgow Coma Scale) or other forms of neurological examinations were performed in only 56% of all cases. According to the GCS status, 90.2% are classified as mild, 3.9% as moderate and 5.2% as severe. Intubation is given only to 76.1% of patients with severe TBI. Lethality was 1%. The predominant cause of TBI is falls, with 52.5% of all cases, while 26.3% were due to road accidents. The time elapsing between the accident event and initial examination at the hospital is less than 1 hour in 63% of all cases. X-rays were taken in 82% of all cases of TBI, with 19.3% of the patients receiving a CT scan; 58.7% of all TBI patients have additional injuries of the facial skull, 8.8% of the vertebral column, 7.2% of the thorax, 2.6% of the abdomen, 3.4% of the pelvis and 19.6% of one or more extremities. One year after the accident, 50% of all patients still required treatment even after mild TBI. Conclusion: It is necessary to follow the TBI guidelines, e. g. regarding intubation and neurological examination. The indication for cranial x-rays and CT should be reconsidered.	[Rickels, Eckhard] AKH Celle, Neurosurg, DE-29223 Celle, Germany; [von Wild, Klaus] Kvw Neurosci Consulting, Munster, Germany; [Wenzlaff, Paul] Zentrum Qualitatsmanagement, Hannover, Germany		Rickels, E (corresponding author), AKH Celle, Neurosurg, Siemenspl 4, DE-29223 Celle, Germany.	emrickels@t-online.de			'Hannelore-Kohl-Stiftung- Kuratorium ZNS', Bonn, Germany; World Federation of Neurology Research and Education Foundation; Winston-Salem, NC/USA; Forderverein fur neurotraumatologische Rehabilitation e. V.; Munster, Germany	This study was supported by grants from 'Hannelore-Kohl-Stiftung- Kuratorium ZNS', Bonn, Germany; World Federation of Neurology Research and Education Foundation, Winston-Salem, NC/USA, Forderverein fur neurotraumatologische Rehabilitation e. V.; (Cerebprotect), Munster, Germany. The authors want to thank all colleagues in the participating hospitals for their efforts to include and to document the patients.	Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; BADER MK, 2004, WORLDVIEWS EVIDIDENC, V1, P227; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chiu WT, 1997, NEUROL RES, V19, P261, DOI 10.1080/01616412.1997.11740811; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Farin A, 2004, ACT NEUR S, V89, P101; GREINER W, 2000, GESUNDHEITSOKONOMISC; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Hillier SL, 1997, BRAIN INJURY, V11, P649; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Keris V, 2007, WORLD J SURG, V31, P1352, DOI 10.1007/s00268-007-9002-x; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Langlois J, TRAUMATIC BRAIN INJU; LEIDL R, 2003, PUBLIC HLTH BUCH GES, P461; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; Servadei F, 2002, J Neurosurg Sci, V46, P111; *STAT BUND, 2001, TOD S02 S09 NACH ICD; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; von Wild, 2000, SCHMIDEK SWEET OPERA, P45; von Wild KRH, 2002, ACT NEUR S, V79, P3; VONWILD KRH, 2005, EUROPEAN J TRAUMA, V4, P344; VONWILD KRH, 1998, PATHOPHYSIOLOGICAL P; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wirth A, 2004, ACT NEUR S, V89, P119; Zhang J, 2001, Chin J Traumatol, V4, P152	38	77	83	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	12					1491	1504		10.3109/02699052.2010.498006			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	667NR	WOS:000283200800012	20645706				2022-02-06	
J	Shein, NA; Grigoriadis, N; Alexandrovich, AG; Simeonidou, C; Lourbopoulos, A; Polyzoidou, E; Trembovler, V; Mascagni, P; Dinarello, CA; Shohami, E				Shein, Na'ama A.; Grigoriadis, Nikolaos; Alexandrovich, Alexander G.; Simeonidou, Constantina; Lourbopoulos, Athanasios; Polyzoidou, Eleni; Trembovler, Victoria; Mascagni, Paolo; Dinarello, Charles A.; Shohami, Esther			Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury	FASEB JOURNAL			English	Article						epigenetic; closed head injury; regeneration	FOCAL CEREBRAL-ISCHEMIA; CLOSED-HEAD INJURY; SUBEROYLANILIDE HYDROXAMIC ACID; AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MOUSE MODEL; BINDING-PROTEIN CBP; HUNTINGTONS-DISEASE; ANTILEUKEMIC ACTIVITY; NERVOUS-SYSTEM; VALPROIC ACID	Despite efforts aimed at developing novel therapeutics for traumatic brain injury (TBI), no specific pharmacological agent is currently clinically available. Here, we show that the pan-histone deacetylase (HDAC) inhibitor ITF2357, a compound shown to be safe and effective in humans, improves functional recovery and attenuates tissue damage when administered as late as 24 h postinjury. Using a well-characterized, clinically relevant mouse model of closed head injury (CHI), we demonstrate that a single dose of ITF2357 administered 24 h postinjury improves neurobehavioral recovery from d 6 up to 14 d postinjury (improved neurological score vs. vehicle; P <= 0.05), and that this functional benefit is accompanied by decreased neuronal degeneration, reduced lesion volume (22% reduction vs. vehicle; P <= 0.01), and is preceded by increased acetylated histone H3 levels and attenuation of injury-induced decreases in cytoprotective heat-shock protein 70 kDa and phosphorylated Akt. Moreover, reduced glial accumulation and activation were observed 3 d postinjury, and total p53 levels at the area of injury and caspase-3 immunoreactivity within microglia/macrophages at the trauma area were elevated, suggesting enhanced clearance of these cells via apoptosis following treatment. Hence, our findings underscore the relevance of HDAC inhibitors for ameliorating trauma-induced functional deficits and warrant consideration of applying ITF2357 for this indication.-Shein, N. A., Grigoriadis, N., Alexandrovich, A. G., Simeonidou, C., Lourbopoulos, A., Polyzoidou, E., Trembovler, V., Mascagni, P., Dinarello, C. A., Shohami, E. Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J. 23, 4266-4275 (2009). www.fasebj.org	[Shein, Na'ama A.; Alexandrovich, Alexander G.; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Grigoriadis, Nikolaos; Lourbopoulos, Athanasios; Polyzoidou, Eleni] AHEPA Univ Hosp, Dept Neurol, Thessaloniki, Greece; [Simeonidou, Constantina] Aristotle Univ Thessaloniki, Dept Physiol, GR-54006 Thessaloniki, Greece; [Mascagni, Paolo] Res Ctr, Balsamo, Italy; [Dinarello, Charles A.] Univ Colorado Denver, Dept Med, Aurora, CO USA		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il	Dinarello, Charles/C-8524-2013		U. S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI-15614]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI015614, R37AI015614] Funding Source: NIH RePORTER	E. S. is the incumbent of the Dr. Leon and Mina Deutch Chair in psychopharmacology at the Hebrew University. This work was supported by U. S. National Institutes of Health grant AI-15614 (to C. A. D.). P. M. is an employee of Italfarmaco, S. p. A., Italy. The authors thank Prof. A. Rubinstein (Hebrew University) for his assistance in obtaining antibodies used in this series of experiments.	Albert MS, 2007, NEW ENGL J MED, V357, P502, DOI 10.1056/NEJMcibr073273; Armeanu S, 2005, J HEPATOL, V42, P210, DOI 10.1016/j.jhep.2004.10.020; Atweh GF, 1999, BLOOD, V93, P1790; Barbetti V, 2008, ONCOGENE, V27, P1767, DOI 10.1038/sj.onc.1210820; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Brown IR, 2007, ANN NY ACAD SCI, V1113, P147, DOI 10.1196/annals.1391.032; Camelo S, 2005, J NEUROIMMUNOL, V164, P10, DOI 10.1016/j.jneuroim.2005.02.022; Carlisi D, 2008, INT J ONCOL, V32, P177; Carta S, 2006, BLOOD, V108, P1618, DOI 10.1182/blood-2006-03-014126; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Delgado-Esteban M, 2007, J NEUROCHEM, V102, P194, DOI 10.1111/j.1471-4159.2007.04450.x; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Gardian G, 2005, J BIOL CHEM, V280, P556, DOI 10.1074/jbc.M410210200; Gerstner T, 2008, EXPERT OPIN PHARMACO, V9, P285, DOI [10.1517/14656566.9.2.285, 10.1517/14656566.9.2.285 ]; Glauben R, 2008, GUT, V57, P613, DOI 10.1136/gut.2007.134650; Glauben R, 2006, J IMMUNOL, V176, P5015, DOI 10.4049/jimmunol.176.8.5015; Golay J, 2007, LEUKEMIA, V21, P1892, DOI 10.1038/sj.leu.2404860; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; Hahnen E, 2008, EXPERT OPIN INV DRUG, V17, P169, DOI 10.1517/13543784.17.2.169; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin KL, 2001, J MOL NEUROSCI, V16, P49, DOI 10.1385/JMN:16:1:49; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Khan O, 2008, NAT CLIN PRACT ONCOL, V5, P714, DOI 10.1038/ncponc1238; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Langley B, 2005, CNS NEUROL DISORD-DR, V4, P41, DOI 10.2174/1568007053005091; Leoni F, 2005, MOL MED, V11, P1, DOI 10.2119/2006-00005.Dinarello; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Moussaieff A, 2008, J CEREBR BLOOD F MET, V28, P1341, DOI 10.1038/jcbfm.2008.28; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; OSBORNE KA, 1987, J NEUROL NEUROSUR PS, V50, P402, DOI 10.1136/jnnp.50.4.402; Perrine SP, 2005, ANN NY ACAD SCI, V1054, P257, DOI 10.1196/annals.1345.033; Petri S, 2006, NEUROBIOL DIS, V22, P40, DOI 10.1016/j.nbd.2005.09.013; Qi X, 2004, MOL PHARMACOL, V66, P899, DOI 10.1124/mol.104.001339; Rouaux C, 2004, BIOCHEM PHARMACOL, V68, P1157, DOI 10.1016/j.bcp.2004.05.035; Rouaux C, 2003, EMBO J, V22, P6537, DOI 10.1093/emboj/cdg615; Ryu H, 2005, J NEUROCHEM, V93, P1087, DOI 10.1111/j.1471-4159.2005.03077.x; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Thomas EA, 2008, P NATL ACAD SCI USA, V105, P15564, DOI 10.1073/pnas.0804249105; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Vojinovic J, 2008, ARTHRITIS RHEUM-US, V58, pS943; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Ying MY, 2006, J BIOL CHEM, V281, P12580, DOI 10.1074/jbc.M511677200; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085	51	77	78	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2009	23	12					4266	4275		10.1096/fj.09-134700			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	525DL	WOS:000272193700021	19723705	Green Published			2022-02-06	
J	Tejima, E; Guo, SZ; Murata, Y; Arai, K; Lok, J; van Leyen, K; Rosell, A; Wang, XY; Lo, EH				Tejima, Emiri; Guo, Shuzhen; Murata, Yoshihiro; Arai, Ken; Lok, Josephine; van Leyen, Klaus; Rosell, Anna; Wang, Xiaoying; Lo, Eng H.			Neuroprotective Effects of Overexpressing Tissue Inhibitor of Metalloproteinase TIMP-1	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; neuroprotection; neurovascular unit; stroke; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; BLOOD-BRAIN-BARRIER; GENE KNOCK-OUT; MATRIX METALLOPROTEINASES; ALZHEIMERS-DISEASE; CELL-DEATH; PLASMINOGEN-ACTIVATOR; MMP-9/TIMP-1 RATIO; REPERFUSION INJURY; ENDOTHELIAL-CELLS	Accumulating data suggest that matrix metalloproteinases (MMPs) may be important mediators in the pathophysiology of acute brain injury after trauma or stroke. Here, we test the hypothesis that the endogenous tissue inhibitor of metalloproteinase (TIMP-1) is neuroprotective in vitro and in vivo. For in vitro studies, primary cortical neuronal cultures were subjected to hypoxia and reoxygenation. Treatment with recombinant TIMP-1 protein significantly decreased neuronal death. In vivo studies in models of brain trauma and stroke supported these cell culture results. After controlled cortical impact, 24-h MMP-9 levels were significantly reduced in transgenic mice overexpressing TIMP-1 compared to wild-type mice. And at 7 days post-trauma, brain lesion volumes were also significantly decreased by TIMP-1 overexpression as well. In a model of transient 2-h focal cerebral ischemia, MMP-9 levels were lower in TIMP-1 transgenic mice compared with wild-types. Correspondingly, blood-brain barrier leakage was ameliorated by TIMP-1 overexpression, and 24-h infarction volumes were also reduced. Taken together, these cell culture and in vivo data provide initial proof-of-principle that TIMP-1 is neuroprotective against traumatic and ischemic brain injury in mice.	[Tejima, Emiri; Guo, Shuzhen; Murata, Yoshihiro; Arai, Ken; Lok, Josephine; van Leyen, Klaus; Rosell, Anna; Wang, Xiaoying; Lo, Eng H.] Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Neurol, Charlestown, MA 02129 USA; [Tejima, Emiri; Guo, Shuzhen; Murata, Yoshihiro; Arai, Ken; Lok, Josephine; van Leyen, Klaus; Rosell, Anna; Wang, Xiaoying; Lo, Eng H.] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; [Tejima, Emiri; Guo, Shuzhen; Murata, Yoshihiro; Arai, Ken; Lok, Josephine; van Leyen, Klaus; Wang, Xiaoying; Lo, Eng H.] Harvard Univ, Sch Med, Program Neurosci, Charlestown, MA USA; [Lok, Josephine] Harvard Univ, Sch Med, Boston, MA USA; [Lok, Josephine] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA		Lo, EH (corresponding author), Massachusetts Gen Hosp, Neuroprotect Res Lab, Dept Neurol, MGH E 149-2401, Charlestown, MA 02129 USA.	Lo@helix.mgh.harvard.edu	van Leyen, Klaus/C-9126-2013	van Leyen, Klaus/0000-0003-1032-3754; Rosell Novel, Anna/0000-0003-1082-3599	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); American Stroke Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS057339] Funding Source: NIH RePORTER	This research was supported in part by grants from NINDS and a Bugher award from the American Stroke Association.	Adair JC, 2004, STROKE, V35, pE159, DOI 10.1161/01.STR.0000127420.10990.76; Aoki T, 2002, STROKE, V33, P2711, DOI 10.1161/01.STR.0000033932.34467.97; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Asahina M, 2001, CLIN NEUROPATHOL, V20, P60; Baker AH, 2007, P NATL ACAD SCI USA, V104, P3597, DOI 10.1073/pnas.0611112104; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Chirco R, 2006, CANCER METAST REV, V25, P99, DOI 10.1007/s10555-006-7893-x; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Fujimoto M, 2008, J CEREBR BLOOD F MET, V28, P1674, DOI 10.1038/jcbfm.2008.59; Gardner J, 2003, J NEUROSCI RES, V74, P801, DOI 10.1002/jnr.10835; Gidday JM, 2005, AM J PHYSIOL-HEART C, V289, pH558, DOI 10.1152/ajpheart.01275.2004; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Guedez L, 2001, AM J PATHOL, V158, P1207, DOI 10.1016/S0002-9440(10)64070-9; Jiang XF, 2001, NEUROSCI LETT, V305, P41, DOI 10.1016/S0304-3940(01)01800-6; Jung KK, 2006, EMBO J, V25, P3934, DOI 10.1038/sj.emboj.7601281; Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723; Kruger A, 1998, ONCOGENE, V16, P2419, DOI 10.1038/sj.onc.1201774; Lee SR, 2006, J NEUROSCI, V26, P3491, DOI 10.1523/JNEUROSCI.4085-05.2006; Lee SR, 2004, J CEREBR BLOOD F MET, V24, P720, DOI 10.1097/01.WCB.0000122747.72175.47; Lee SR, 2004, J NEUROSCI, V24, P671, DOI 10.1523/JNEUROSCI.4243-03.2004; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Lorenzl S, 2003, NEUROCHEM INT, V43, P191, DOI 10.1016/S0197-0186(03)00004-4; Magnoni S, 2007, GENE THER, V14, P621, DOI 10.1038/sj.gt.3302894; Montaner J, 2006, DRUG NEWS PERSPECT, V19, P523, DOI 10.1358/dnp.2006.19.9.1050422; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Reeves TM, 2003, J NEUROSCI, V23, P10182; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosell A, 2006, STROKE, V37, P1399, DOI 10.1161/01.STR.0000223001.06264.af; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 2001, STROKE, V32, P1162, DOI 10.1161/01.STR.32.5.1162; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Sellner J, 2006, NEUROBIOL DIS, V21, P647, DOI 10.1016/j.nbd.2005.09.007; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Stetler-Stevenson WG, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127re6; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Tejima E, 2007, J CEREBR BLOOD F MET, V27, P460, DOI 10.1038/sj.jcbfm.9600354; Thirumangalakudi L, 2006, J ALZHEIMERS DIS, V10, P111; Tsuji K, 2005, STROKE, V36, P1954, DOI 10.1161/01.STR.0000177517.01203.eb; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang L, 2006, J NEUROSCI, V26, P5996, DOI 10.1523/JNEUROSCI.5380-05.2006; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Waubant E, 2003, NEUROLOGY, V60, P52, DOI 10.1212/WNL.60.1.52; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Zhao BQ, 2007, STROKE, V38, P748, DOI 10.1161/01.STR.0000253500.32979.d1; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	49	77	83	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1935	1941		10.1089/neu.2009.0959			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600009	19469687	Green Published			2022-02-06	
J	Salim, A; Ley, EJ; Cryer, HG; Margulies, DR; Ramicone, E; Tillou, A				Salim, Ali; Ley, Eric J.; Cryer, H. Gill; Margulies, Daniel R.; Ramicone, Emily; Tillou, Areti			Positive Serum Ethanol Level and Mortality in Moderate to Severe Traumatic Brain Injury	ARCHIVES OF SURGERY			English	Article							BETA-BLOCKER EXPOSURE; HEAD-INJURY; HEMORRHAGIC-SHOCK; ALCOHOL; INTOXICATION; OUTCOMES; IMPACT; MODEL; RATS; ASSOCIATION	Hypothesis: Ethanol exposure is associated with decreased mortality in patients with moderate to severe traumatic brain injury. Design: Retrospective database review. Setting: Trauma centers contributing to the National Trauma Data Bank (NTDB). Patients: Version 6.2 of the NTDB (2000-2005) was queried for all patients with moderate to severe traumatic brain injury (head Abbreviated Injury Score >= 3) and ethanol levels measured on admission. Demographics and outcomes were compared between patients with traumatic brain injuries with and without ethanol in their blood. Logistic regression analysis was used to investigate the relationship between mortality and ethanol. Main Outcome Measures: Mortality and complications. Results: A total of 38 019 patients with severe traumatic brain injuries were evaluated. Thirty-eight percent tested positive for ethanol. Ethanol-positive patients were younger (mean [SD], 37.7 [15.1] vs; 44.1 [22.0] years, P<.001), had a lower Injury Severity Score (22.3 [10.0] vs 23.0 [10.3], P<.001), and a lower Glasgow Coma Scale score (10.0 [5.1] vs 11.0 [4.9], P<.001) compared with their ethanol-negative counterparts. After logistic regression analysis, ethanol was associated with reduced mortality (adjusted odds ratio, 0.88; 95% confidence interval, 0.80-0.96; P=.005) and higher complications (adjusted odds ratio, 1.24; 95% confidence interval, 1.15-1.33; P<.001). Conclusions: Serum ethanol is independently associated with decreased mortality in patients with moderate to severe head injuries. Additional research is warranted to investigate the potential therapeutic implications of this association.	[Salim, Ali; Ley, Eric J.; Margulies, Daniel R.; Ramicone, Emily] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Cryer, H. Gill; Tillou, Areti] Univ Calif Los Angeles, Div Trauma, Los Angeles, CA USA		Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Ste 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org					Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/0897715042441828; Fabbri A, 2002, EMERG MED J, V19, P210, DOI 10.1136/emj.19.3.210; Fabian MJ, 2002, J TRAUMA, V53, P864, DOI 10.1097/00005373-200211000-00010; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; *NAT HIGHW TRAFF A, 2000, EC IMP MOT VEH CRASH; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Plurad D, 2006, J AM COLL SURGEONS, V202, P919, DOI 10.1016/j.jamcollsurg.2006.02.024; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Salim A, 2008, J TRAUMA, V64, P46, DOI 10.1097/TA.0b013e31815eb15a; Shih HC, 2003, AM J EMERG MED, V21, P91, DOI 10.1053/ajem.2003.50025; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WOOLF PD, 1991, J TRAUMA, V31, P1271, DOI 10.1097/00005373-199109000-00012; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7; Zink BJ, 2001, ALCOHOL CLIN EXP RES, V25, P916; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983	31	77	80	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0004-0010			ARCH SURG-CHICAGO	Arch. Surg.	SEP	2009	144	9					865	871		10.1001/archsurg.2009.158			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	494RQ	WOS:000269833500012	19797113	Bronze			2022-02-06	
J	Brophy, GM; Pineda, JA; Papa, L; Lewis, SB; Valadka, AB; Hannay, HJ; Heaton, SC; Demery, JA; Liu, MC; Tepas, JJ; Gabrielli, A; Robicsek, S; Wang, KKW; Robertson, CS; Hayes, RL				Brophy, Gretchen M.; Pineda, Jose A.; Papa, Linda; Lewis, Stephen B.; Valadka, Alex B.; Hannay, H. Julia; Heaton, Shelley C.; Demery, Jason A.; Liu, Ming Cheng; Tepas, Joseph J., III; Gabrielli, Andrea; Robicsek, Steven; Wang, Kevin K. W.; Robertson, Claudia S.; Hayes, Ronald L.			alpha II-Spectrin Breakdown Product Cerebrospinal Fluid Exposure Metrics Suggest Differences in Cellular Injury Mechanisms after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; CSF; exposure; spectrin; traumatic brain injury	CALPAIN; PROTEIN; MARKERS	Traumatic brain injury (TBI) produces alpha II-spectrin breakdown products (SBDPs) that are potential biomarkers for TBI. To further understand these biomarkers, the present study examined (1) the exposure and kinetic characteristics of SBDPs in cerebrospinal fluid (CSF) of adults with severe TBI, and (2) the relationship between these exposure and kinetic metrics and severity of injury. This clinical database study analyzed CSF concentrations of 150-, 145-, and 120-kDa SBDPs in 38 severe TBI patients. Area under the curve (AUC), mean residence time (MRT), maximum concentration (C-max), time to maximum concentration (T-max), and half-life (t(1/2)) were determined for each SBDP. Markers of calpain proteolysis (SBDP150 and SBDP145) had a greater median AUC and C-max and a shorter MRT than SBDP120, produced by caspase-3 proteolysis in the CSF in TBI patients (p < 0.001). AUC and MRT for SBDP150 and SBDP15 were significantly greater in patients with worse Glasgow Coma Scale (GCS) scores at 24 h after injury compared to those whose GCS scores improved (AUC p = 0.013, MRT p = 0.001; AUC p = 0.009, MRT p = 0.021, respectively). A positive correlation was found between patients with longer elevations in intracranial pressure (ICP) measurements of 25 mm Hg or higher and those with a greater AUC and MRT for all three biomarkers. This is the first study to show that the biomarkers of proteolysis differentially associated with calpain and caspase-3 activity have distinct CSF exposure profiles following TBI that suggest a prominent role for calpain activity. Further studies are being conducted to determine if exposure and kinetic metrics for biofluid-based biomarkers can predict clinical outcome.	[Brophy, Gretchen M.] Virginia Commonwealth Univ, Dept Pharm & Neurosurg, Richmond, VA 23298 USA; [Pineda, Jose A.] Washington Univ, Dept Pediat, St Louis, MO 63130 USA; [Pineda, Jose A.] Washington Univ, Dept Neurol, St Louis, MO USA; [Papa, Linda] Orlando Reg Healthcare, Dept Emergency Med, Orlando, FL USA; [Lewis, Stephen B.] Univ Florida, Dept Neurosurg, Gainesville, FL USA; [Heaton, Shelley C.; Demery, Jason A.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; [Tepas, Joseph J., III; Gabrielli, Andrea] Univ Florida, Dept Surg, Gainesville, FL USA; [Tepas, Joseph J., III] Univ Florida, Dept Pediat, Gainesville, FL USA; [Gabrielli, Andrea; Robicsek, Steven] Univ Florida, Dept Anesthesia, Gainesville, FL USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Valadka, Alex B.] Univ Texas Houston, Hlth Sci Ctr, Dept Neurosurg, Houston, TX USA; [Hannay, H. Julia] Univ Houston, Dept Psychol, Houston, TX USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Liu, Ming Cheng; Wang, Kevin K. W.; Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA		Brophy, GM (corresponding author), Virginia Commonwealth Univ, Dept Pharm & Neurosurg, Med Coll Virginia Campus,410 N 12th St,POB 980533, Richmond, VA 23298 USA.	gbrophy@vcu.edu	Pineda, Jose/W-2806-2019	Brophy, Gretchen/0000-0002-4749-2693; Wang, Kevin/0000-0002-9343-6473; Hannay, H. Julia/0000-0001-7023-912X	Department of Defense AwardUnited States Department of Defense [DAMD17-03-1-0772, DAMD17-03-1-0066]; National Institutes of Health AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01, R01-NS052831-01, R01 NS051431-01, P01-NS38660]; Navy [N00014-06-1-1029]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660, R01NS052831, R01NS049175, R01NS051431] Funding Source: NIH RePORTER	This study was supported in part by Department of Defense Award numbers DAMD17-03-1-0772 and DAMD17-03-1-0066; National Institutes of Health Award numbers R01 NS049175-01, R01-NS052831-01, and R01 NS051431-01; Navy grant number N00014-06-1-1029 (University of Florida); and National Institutes of Health grant #P01-NS38660 (Baylor College of Medicine).	Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P493; Foerch C, 2005, ARCH NEUROL-CHICAGO, V62, P1130, DOI 10.1001/archneur.62.7.1130; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Gibaldi M., 1982, PHARMACOKINETICS; Korfias S, 2006, BRAIN INJURY, V20, P867, DOI 10.1080/02699050600832395; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; LOUNEVA N, 2008, AM J PATHOL; Nath R, 2000, NEUROCHEM INT, V36, P119, DOI 10.1016/S0197-0186(99)00112-6; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Tanaka Y, 2007, BRAIN RES, V1137, P140, DOI 10.1016/j.brainres.2006.12.025; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wu HV, 2006, MOL NEUROBIOL, V33, P215, DOI 10.1385/MN:33:3:215; Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006	16	77	81	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					471	479		10.1089/neu.2008.0657			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300001	19206997	Green Published, Green Submitted			2022-02-06	
J	Hu, X; Xu, P; Scalzo, F; Vespa, P; Bergsneider, M				Hu, Xiao; Xu, Peng; Scalzo, Fabien; Vespa, Paul; Bergsneider, Marvin			Morphological Clustering and Analysis of Continuous Intracranial Pressure	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						Hydrocephalus; injury; intracranial pressure (ICP); traumatic brain pulse morphology	FLUID PULSE-WAVE; APPROXIMATE ENTROPY; SYSTEMS-ANALYSIS; FORM ANALYSIS; SIGNALS; HYPERTENSION; VARIABILITY; REACTIVITY; ALGORITHM	The continuous measurement of intracranial pressure (ICP) is an important and established clinical tool that is used in the management of many neurosurgical disorders such as traumatic brain injury. Only mean ICP information is used currently in the prevailing clinical practice, ignoring the useful information in ICP pulse waveform that can be continuously acquired and is potentially useful for forecasting intracranial and cerebrovascular pathophysiological changes. The present study introduces and validates an algorithm of performing automated analysis of continuous ICP pulse waveform. This algorithm is capable of enhancing ICP signal quality, recognizing nonartifactual ICP pulses, and optimally designating the three well-established subcomponents in an ICP pulse. Validation of the proposed algorithm is done by comparing nonartifactual pulse recognition and peak designation results from a human observer with those from automated analysis based on a large signal database built from 700 h of recordings from 66 neurosurgical patients. An accuracy of 97.84% is achieved in recognizing nonartifactual ICP pulses. An accuracy of 90.17%, 87.56%, and 86.53% was obtained for designating each of the three established ICP subpeaks. These results show that the proposed algorithm can be reliably applied to process continuous ICP recordings from real clinical environment to extract useful morphological features of ICP pulses.	[Hu, Xiao; Xu, Peng; Scalzo, Fabien; Bergsneider, Marvin] Univ Calif Los Angeles, Dept Neurosurg, Neural Syst & Dynam Lab, Los Angeles, CA 90024 USA; [Vespa, Paul] Univ Calif Los Angeles, Neurocrit Care Program, Dept Neurosurg, Los Angeles, CA 90095 USA		Hu, X (corresponding author), Univ Calif Los Angeles, Dept Neurosurg, Neural Syst & Dynam Lab, Los Angeles, CA 90024 USA.	xiaohu@ucla.edu; pengxu@mednet.ucla.edu; fscalzo@mednet.ucla.edu; pvespa@mednet.ucla.edu; mbergsneider@mednet.ucla.edu	Scalzo, Fabien/AAM-6328-2020	Scalzo, Fabien/0000-0001-9755-8104	National institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21-NS055998, R21-NS055045, R21-NS059797, R01-NS054881]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054881, R21NS055998, R21NS059797, R21NS055045] Funding Source: NIH RePORTER	This work was supported in part by the National institute of Neurological Disorders and Stroke (NINDS) under Grant R21-NS055998, Grant R21-NS055045. Grant R21-NS059797, and Grant R01-NS054881.	Aboy M, 2005, IEEE T BIO-MED ENG, V52, P1662, DOI 10.1109/TBME.2005.855725; ADOLPH RJ, 1967, AM J PHYSIOL, V212, P840, DOI 10.1152/ajplegacy.1967.212.4.840; Afonso VX, 1999, IEEE T BIO-MED ENG, V46, P192, DOI 10.1109/10.740882; BRANCH C, 1991, BIOMED SCI INSTRUM, V17, P45; CARDOSO ER, 1988, J NEUROSURG, V69, P712, DOI 10.3171/jns.1988.69.5.0712; CARDOSO ER, 1983, J NEUROSURG, V59, P817, DOI 10.3171/jns.1983.59.5.0817; Chopp M, 1980, Biomed Sci Instrum, V16, P149; CHOPP M, 1980, J NEUROSURG, V53, P516, DOI 10.3171/jns.1980.53.4.0516; CONTANT CF, 1995, J NEUROSCI METH, V57, P15, DOI 10.1016/0165-0270(94)00106-Q; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Eide PK, 2006, MED ENG PHYS, V28, P579, DOI 10.1016/j.medengphy.2005.09.008; Ellis T, 2007, IEEE T BIO-MED ENG, V54, P1552, DOI 10.1109/TBME.2007.892918; HAMER J, 1977, J NEUROSURG, V46, P36, DOI 10.3171/jns.1977.46.1.0036; Hornero R, 2005, IEEE T BIO-MED ENG, V52, P1671, DOI 10.1109/TBME.2005.855722; HU X, ACTA NEUR S IN PRESS; Hu X, 2008, PHYSIOL MEAS, V29, P459, DOI 10.1088/0967-3334/29/4/004; Hu X, 2008, MED ENG PHYS, V30, P631, DOI 10.1016/j.medengphy.2007.07.002; Hu X, 2007, IEEE T BIO-MED ENG, V54, P1407, DOI 10.1109/TBME.2007.900802; Hu X, 2007, IEEE T BIO-MED ENG, V54, P597, DOI 10.1109/TBME.2006.890130; Kaufman L., 2005, WILEY SERIES PROBABI; Kirkness C J, 2000, J Neurosci Nurs, V32, P271; Morgalla MH, 1999, J NEUROL SCI, V168, P90, DOI 10.1016/S0022-510X(99)00137-9; PIPER IR, 1990, J NEUROSURG, V73, P871, DOI 10.3171/jns.1990.73.6.0871; PORTNOY HD, 1982, J NEUROSURG, V56, P666, DOI 10.3171/jns.1982.56.5.0666; PORTNOY HD, 1981, NEUROSURGERY, V9, P14, DOI 10.1227/00006123-198107000-00004; Rabiner L., 1993, FUNDAMENTALS SPEECH; SYMON L, 1975, J NEUROSURG, V42, P258, DOI 10.3171/jns.1975.42.3.0258; TAKIZAWA H, 1987, NEUROSURGERY, V20, P355, DOI 10.1227/00006123-198703000-00001; WILKINSON HA, 1979, J NEUROSURG, V50, P758, DOI 10.3171/jns.1979.50.6.0758	29	77	77	0	8	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855 USA	0018-9294			IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	MAR	2009	56	3					696	705		10.1109/TBME.2008.2008636			10	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	437KQ	WOS:000265486800016	19272879	Green Accepted			2022-02-06	
J	Nishisaki, A; Hales, R; Biagas, K; Cheifetz, I; Corriveau, C; Garber, N; Hunt, E; Jarrah, R; McCloskey, J; Morrison, W; Nelson, K; Niles, D; Smith, S; Thomas, S; Tuttle, S; Helfaer, M; Nadkarni, V				Nishisaki, Akira; Hales, Roberta; Biagas, Katherine; Cheifetz, Ira; Corriveau, Christine; Garber, Nan; Hunt, Elizabeth; Jarrah, Rima; McCloskey, John; Morrison, Wynne; Nelson, Kristen; Niles, Dana; Smith, Sophia; Thomas, Samuel; Tuttle, Stephanie; Helfaer, Mark; Nadkarni, Vinay			A multi-institutional high-fidelity simulation "boot camp" orientation and training program for first year pediatric critical care fellows	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						pediatric critical care fellowship; simulation; orientation; team training; patient safety	RESOURCE-MANAGEMENT; PERFORMANCE; SKILLS; COMPETENCE	Objective: Simulation training has been used to integrate didactic knowledge, technical skills, and crisis resource management for effective orientation and patient safety. We hypothesize multi-Institutional simulation-based training for first year pediatric critical care (PCC) fellows is feasible and effective. Design. Descriptive, educational intervention study. Setting. The simulation facility at the host institution. Interventions., A multicentered simulation-based orientation training "boot camp" for first year PCC fellows was held at a large simulation center. Immediate posttraining evaluation and 6-month follow-up surveys were distributed to participants. Measurements and Main Results: A novel simulation-based orientation training for first year PCC fellows was facilitated by volunteer faculty from seven institutions. The two and a half day course was organized to cover common PCC crises. High-fidelity simulation was integrated Into each session (airway management, vascular access, resuscitation, sepsis, trauma/traumatic brain injury, delivering bad news). Twenty-two first year PCC fellows from nine fellowship programs attended, and 13 faculty facilitated, for a total of 15.5 hours (369 person-hours) of training. This consisted of 2.75 hours for whole group didactic sessions (17.7%), 1.08 hours for a small group interactive session (7.0%), 4.67 hours for task training (30.1%), and 7 hours for training (45.2%) with high-fidelity simulation and crisis resource management. A "train to success" approach with repetitive practice of critical assessment and interventional skills yielded higher scores in training effectiveness in the end-of-course evaluation. A follow-up survey revealed this training was highly effective in improving clinical performance and self-confidence. Conclusions: The first PCC orientation training integrated with simulation was effective and logistically feasible. The train to success concept with repetitive practice was highly valued by participants. Continuation and expansion of this novel multi-institutional training is planned. (Pediatr Crit Care Med 2009; 10:157-162)	[Nishisaki, Akira; Hales, Roberta; Niles, Dana; Thomas, Samuel; Nadkarni, Vinay] Childrens Hosp Philadelphia, Ctr Simulat Adv Educ & Innovat, Philadelphia, PA 19104 USA; [Biagas, Katherine] Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10027 USA; [Cheifetz, Ira] Duke Univ, Dept Anesthesiol, Durham, NC USA; [Corriveau, Christine; Smith, Sophia] Childrens Natl Med Ctr, Crit Care Med Div, Washington, DC 20010 USA; [Garber, Nan] Univ Maryland, Dept Pediat, Baltimore, MD 21201 USA; [Hunt, Elizabeth; Nelson, Kristen] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA; [Tuttle, Stephanie] Jersey Shore Med Ctr, Dept Pediat, Div Crit Care Med, Neptune, NJ USA		Nishisaki, A (corresponding author), Childrens Hosp Philadelphia, Ctr Simulat Adv Educ & Innovat, Philadelphia, PA 19104 USA.	nishisaki@email.chop.edu	Cheifetz, Ira/I-8692-2019	Cheifetz, Ira/0000-0002-1174-1571; Biagas, Katherine/0000-0002-4669-703X			Ahlberg G, 2005, ENDOSCOPY, V37, P1198, DOI 10.1055/s-2005-921049; *AM BOARD PED, SUBSP CERT EX; Blum RH, 2004, MED EDUC, V38, P45, DOI 10.1046/j.1365-2923.2004.01696.x; Davis DA, 2006, JAMA-J AM MED ASSOC, V296, P1094, DOI 10.1001/jama.296.9.1094; DeVita MA, 2004, CRIT CARE MED, V32, pS61, DOI 10.1097/01.CCM.0000110872.86812.1C; Dieckmann Peter, 2007, Simul Healthc, V2, P183, DOI 10.1097/SIH.0b013e3180f637f5; DOWNES JJ, 1992, CRIT CARE CLIN, V8, P1; DUNN WF, 2005, SIMULATORS CRITICAL; Fanning Ruth M, 2007, Simul Healthc, V2, P115, DOI 10.1097/SIH.0b013e3180315539; Fortenberry JD, 2007, PEDIATR CRIT CARE ME, V8, pS1, DOI 10.1097/01.PCC.0000257734.84591.1F; Hamman WR, 2004, QUAL SAF HEALTH CARE, V13, pI72, DOI 10.1136/qshc.2004.009910; Hunt EA, 2008, PEDIATRICS, V121, pE34, DOI 10.1542/peds.2007-0029; Issenberg SB, 2005, MED TEACH, V27, P10, DOI 10.1080/01421590500046924; JELLINEK MS, 1993, CRIT CARE MED, V21, P775, DOI 10.1097/00003246-199305000-00023; Kim J, 2006, CRIT CARE MED, V34, P2167, DOI 10.1097/01.CCM.0000229877.45125.CC; Knudson MM, 2008, J TRAUMA, V64, P255, DOI 10.1097/TA.0b013e31816275b0; Kory PD, 2007, CHEST, V132, P1927, DOI 10.1378/chest.07-1554; Malec James F, 2007, Simul Healthc, V2, P4, DOI 10.1097/SIH.0b013e31802b68ee; Nishisaki Akira, 2007, Anesthesiol Clin, V25, P225, DOI 10.1016/j.anclin.2007.03.009; Norman, 2003, HLTH MEASUREMENT SCA; Reznick RK, 2006, NEW ENGL J MED, V355, P2664, DOI 10.1056/NEJMra054785; Rudolph Jenny W, 2006, Simul Healthc, V1, P49; Rudolph Jenny W, 2007, Simul Healthc, V2, P161, DOI 10.1097/SIH.0b013e31813d1035; Savoldelli GL, 2005, CAN J ANAESTH, V52, P944, DOI 10.1007/BF03022056; Seymour NE, 2002, ANN SURG, V236, P458, DOI 10.1097/00000658-200210000-00008; Slonim Anthony D, 2005, Pediatr Crit Care Med, V6, P264, DOI 10.1097/01.PCC.0000160592.87113.C6; Sundar Eswar, 2007, Anesthesiol Clin, V25, P283, DOI 10.1016/j.anclin.2007.03.011; [No title captured]	28	77	77	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2009	10	2					157	162		10.1097/PCC.0b013e3181956d29			6	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	419VK	WOS:000264247600001	19188876				2022-02-06	
J	Menon, DK				Menon, David K.			Unique challenges in clinical trials in traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						clinical trials; research ethics in unconscious subjects; traumatic brain injury; outcome prediction; neuroprotection; neurocritical care	SEVERE HEAD-INJURY; THERAPEUTIC HYPOTHERMIA; CEREBRAL-ISCHEMIA; CONSENT; CARE; MANAGEMENT; GUIDELINES; PRESSURE; EFFICACY; QUALITY	Clinical trials in traumatic brain injury have shown little success in providing an evidence base for the introduction of successful new therapies into clinical practice. In addition to the problems that are common to all such studies in critical illness, trials in traumatic brain injury are complicated by the extremely short temporal window for intervention, failure of many candidate drugs to cross the blood-brain barrier, ethical and regulatory obstacles associated with research in subjects who cannot provide consent, the tendency to use small sample sizes in anticipation of unrealistic treatment benefits, and difficulty in translating experimental success into clinical practice. This article reviews the potential causes of these problems and suggests some solutions. These include the changes in regulatory frame-works that are making waived consent an acceptable strategy once more, and an increasing trend toward appropriately large trials. Other encouraging developments include the increasing use of human experimental medicine strategies before phase III trials to assess blood-brain barrier penetration and dose ranging, and provide proof of concept and proof of mechanism. Novel approaches to trial design, such as sliding dichotomy, coupled with robust outcome prediction models, can increase statistical power and improve trial design. (Crit Care Med 2009; 37[Suppl.]:S129-S135)	Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England		Menon, DK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk			Medical Research Council, UKUK Research & Innovation (UKRI)Medical Research Council UK (MRC); British Oxygen Professorship of the Royal College of Anaesthetists, UK; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0600986, G0001237] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001237, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	These studies were supported by a grant from the Medical Research Council, UK and the British Oxygen Professorship of the Royal College of Anaesthetists, UK.	[Anonymous], 2008, BMJ-BRIT MED J, V336, P425, DOI DOI 10.1136/bmj.39461.643438.25; BARER D, 1998, CEREBROVASC DIS, V8, P47; Booth MG, 2005, EUR J ANAESTH, V22, P933, DOI 10.1017/S0265021505001596; *BRAIN TRAUM FDN A, 2000, MAN PROGN SEV TRAU 1; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chesnut RM, 2002, CRIT CARE MED, V30, P1927, DOI 10.1097/00003246-200208000-00055; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P1121, DOI 10.1089/08977150260337930; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Contant C, 2006, CRIT CARE MED, V34, P2049, DOI 10.1097/01.CCM.0000227649.72651.F1; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Fish SS, 2004, ANN EMERG MED, V43, P449, DOI 10.1016/j.annemergmed.2003.11.004; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; Garner RC, 2006, BRIT J CLIN PHARMACO, V61, P367, DOI 10.1111/j.1365-2125.2006.02575.x; Hall ED, 1996, ACT NEUR S, V66, P107; Houlden H, 2006, J NEUROL NEUROSUR PS, V77, P1106, DOI 10.1136/jnnp.2006.095513; Jansen TC, 2007, INTENS CARE MED, V33, P894, DOI 10.1007/s00134-007-0580-8; JENNETT B, 1975, LANCET, V1, P480; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liddell K, 2006, RESUSCITATION, V69, P9, DOI 10.1016/j.resuscitation.2005.12.004; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Magnotti Louis J, 2004, Surg Infect (Larchmt), V5, P237, DOI 10.1089/sur.2004.5.237; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Menon D, 2008, BMJ-BRIT MED J, V336, P397, DOI 10.1136/bmj.39461.616991.80; Menon David, 2004, Curr Opin Crit Care, V10, P91, DOI 10.1097/00075198-200404000-00002; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Reid CL, 2007, BMJ-BRIT MED J, V335, P415, DOI 10.1136/bmj.39311.480949.3A; Roberts I, 2004, EMERG MED J, V21, P703, DOI 10.1136/emj.2002.004788; Robertson CS, 2007, CLIN TRIALS, V4, P631, DOI 10.1177/1740774507084977; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sakr Y, 2005, CHEST, V128, P3098, DOI 10.1378/chest.128.5.3098; Sterz F, 2002, RESUSCITATION, V53, P237, DOI 10.1016/S0300-9572(02)00103-X; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Upton RN, 2007, CLIN EXP PHARMACOL P, V34, P695, DOI 10.1111/j.1440-1681.2007.04649.x; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vanpee D, 2004, J EMERG MED, V26, P127, DOI 10.1016/j.jemermed.2003.04.007; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	57	77	79	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2009	37	1		S			S129	S135		10.1097/CCM.0b013e3181921225			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391YO	WOS:000262270300018	19104212				2022-02-06	
J	Reid-Arndt, SA; Yee, A; Perry, MC; Hsieh, C				Reid-Arndt, Stephanie A.; Yee, Albert; Perry, Michael C.; Hsieh, Catherine			Cognitive and Psychological Factors Associated with Early Posttreatment Functional Outcomes in Breast Cancer Survivors	JOURNAL OF PSYCHOSOCIAL ONCOLOGY			English	Article						breast cancer; cognitive; quality of life; social support; community integration	QUALITY-OF-LIFE; LONG-TERM SURVIVORS; TRAUMATIC BRAIN-INJURY; CELL LUNG-CANCER; RECEIVING ADJUVANT CHEMOTHERAPY; STANDARD-DOSE CHEMOTHERAPY; FOLLOW-UP; PREMORBID INTELLIGENCE; SOCIAL SUPPORT; NEED-SATISFACTION	Breast cancer survivors experience cognitive difficulties following chemotherapy, yet the effects of these deficits on functional outcomes have not been systematically evaluated. This study assessed the relationships between postchemotherapy cognitive difficulties and functional outcomes. Forty-six women with breast cancer were seen at 1-month postchemotherapy; data were collected on cognitive functioning, psychological variables, and physical symptoms. Wilcoxon signed-rank analyses revealed cognitive deficits in executive functioning and verbal fluency. Subsequent regression analyses demonstrated that poorer executive functioning was associated with decreased productivity, community involvement, and social role functioning. Poorer quality of life was predicted by depression and reluctance to seek social support, but not cognitive functioning. These findings indicate that executive functioning deficits are associated with important functional outcomes among breast cancer survivors 1-month postchemotherapy. Thus, treatment efforts should focus on addressing cognitive, as well as psychological and physical, issues among cancer survivors.	[Reid-Arndt, Stephanie A.] Univ Missouri, Dept Hlth Psychol, Columbia, MO 65212 USA; [Yee, Albert] Atascadero State Hosp, Atascadero, CA USA; [Perry, Michael C.] Univ Missouri, Div Hematol & Med Oncol, Columbia, MO 65212 USA; [Hsieh, Catherine] Univ Missouri, Dept Educ Sch & Counseling Psychol, Columbia, MO 65212 USA		Reid-Arndt, SA (corresponding author), Univ Missouri, Dept Hlth Psychol, 1 Hosp Dr,DC116-88, Columbia, MO 65212 USA.	reidarndts@health.missouri.edu			NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R03CA108340] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R03 CA108340, R03 CA108340-02] Funding Source: Medline		Ahles TA, 2001, CANCER INVEST, V19, P812, DOI 10.1081/CNV-100107743; Ahles TA, 2002, J CLIN ONCOL, V20, P485, DOI 10.1200/JCO.2002.20.2.485; Ahles TA, 1998, J CLIN ONCOL, V16, P1954, DOI 10.1200/JCO.1998.16.5.1954; *AM CANC SOC, 2006, FACTS FIG 2006; Anderson-Hanley C, 2003, J INT NEUROPSYCH SOC, V9, P967, DOI 10.1017/S1355617703970019; Antoni MH, 2006, J CONSULT CLIN PSYCH, V74, P1143, DOI 10.1037/0022-006X.74.6.1152; Baker F, 2002, PSYCHO-ONCOLOGY, V11, P273, DOI 10.1002/pon.564; Bettencourt BA, 2001, J PERS SOC PSYCHOL, V81, P1131, DOI 10.1037/0022-3514.81.6.1131; Bradley CJ, 2005, J HEALTH ECON, V24, P137, DOI 10.1016/j.jhealeco.2004.07.003; Brady MJ, 1997, J CLIN ONCOL, V15, P974, DOI 10.1200/JCO.1997.15.3.974; Brezden CB, 2000, J CLIN ONCOL, V18, P2695, DOI 10.1200/JCO.2000.18.14.2695; Carver CS, 2006, PSYCHO-ONCOLOGY, V15, P749, DOI 10.1002/pon.1006; Carver CS, 2005, HEALTH PSYCHOL, V24, P508, DOI 10.1037/0278-6133.24.5.508; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Falleti MG, 2005, BRAIN COGNITION, V59, P60, DOI 10.1016/j.bandc.2005.05.001; Farmer JE, 2003, J HEAD TRAUMA REHAB, V18, P116, DOI 10.1097/00001199-200303000-00003; Ferguson RJ, 2007, PSYCHO-ONCOL, V16, P772, DOI 10.1002/pon.1133; Figueiredo MI, 2004, PSYCHO-ONCOLOGY, V13, P96, DOI 10.1002/pon.717; Freeman Jason R, 2002, Clin Breast Cancer, V3 Suppl 3, pS91, DOI 10.3816/CBC.2002.s.019; Friedman LC, 2006, PSYCHO-ONCOLOGY, V15, P595, DOI 10.1002/pon.992; Ganz PA, 2002, JNCI-J NATL CANCER I, V94, P39; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Golden CJ, 1978, STROOP COLOR WORD TE; Griffin SL, 2002, ARCH CLIN NEUROPSYCH, V17, P497, DOI 10.1016/S0887-6177(01)00136-6; Hack TF, 2006, PSYCHO-ONCOL, V15, P9, DOI 10.1002/pon.907; Hamsher K., 1989, MULTILINGUAL APHASIA; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Helgeson VS, 2005, PSYCHO-ONCOLOGY, V14, P307, DOI 10.1002/pon.848; Holland KD, 2003, PSYCHOL HEALTH, V18, P15, DOI 10.1080/0887044031000080656; Johnstone B, 1996, ARCH CLIN NEUROPSYCH, V11, P513, DOI 10.1016/0887-6177(96)82330-4; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; KAREKEN DA, 1995, ARCH CLIN NEUROPSYCH, V10, P147, DOI 10.1016/0887-6177(94)E0012-E; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Main DS, 2005, PSYCHO-ONCOLOGY, V14, P992, DOI 10.1002/pon.913; MEYERS CA, 1995, LUNG CANCER, V12, P231, DOI 10.1016/0169-5002(95)00446-8; MICELI G, 1981, Journal of Clinical Neuropsychology, V3, P53, DOI 10.1080/01688638108403113; Minisini A, 2004, LANCET ONCOL, V5, P273, DOI 10.1016/S1470-2045(04)01465-2; Mols F, 2005, EUR J CANCER, V41, P2613, DOI 10.1016/j.ejca.2005.05.017; *NAT CANC I, 2005, DEXM RED SOM SYMPT C; Neisser U, 1996, AM PSYCHOL, V51, P77, DOI 10.1037/0003-066X.51.2.77; Osoba D, 2006, QUAL LIFE RES, V15, P273, DOI 10.1007/s11136-005-0580-5; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RAO SM, 1991, NEUROLOGY, V41, P692, DOI 10.1212/WNL.41.5.692; Reid-Arndt SA, 2006, NEUROREHABILITATION, V21, P51; REITAN RM, 1955, J CONSULT PSYCHOL, V16, P383; Rugo HS, 2003, SEMIN ONCOL, V30, P749, DOI 10.1053/j.seminoncol.2003.09.008; Saykin Andrew J, 2003, Semin Clin Neuropsychiatry, V8, P201; Schagen SB, 2002, ANN ONCOL, V13, P1387, DOI 10.1093/annonc/mdf241; Schagen SB, 1999, CANCER, V85, P640, DOI 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G; Schou I, 2005, QUAL LIFE RES, V14, P1813, DOI 10.1007/s11136-005-4344-z; SHACHAM S, 1983, J PERS ASSESS, V47, P305, DOI 10.1207/s15327752jpa4703_14; Sheldon KM, 2002, BRIT J SOC PSYCHOL, V41, P25, DOI 10.1348/014466602165036; SILBERFARB PM, 1980, AM J PSYCHIAT, V137, P597; Spreen O, 1991, COMPENDIUM NEUROPSYC; STANTON AL, 1993, HEALTH PSYCHOL, V12, P16, DOI 10.1037/0278-6133.12.1.16; Stewart A, 2006, CLIN NEUROPSYCHOL, V20, P76, DOI 10.1080/138540491005875; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; TALLEY AE, PSYCHOL HLT IN PRESS; Tannock IF, 2004, J CLIN ONCOL, V22, P2233, DOI 10.1200/JCO.2004.08.094; Taylor E., 1959, PSYCHOL APPRAISAL CH; Tchen N, 2003, J CLIN ONCOL, V21, P4175, DOI 10.1200/JCO.2003.01.119; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; VanOosterhout AGM, 1996, INT J RADIAT ONCOL, V34, P1037, DOI 10.1016/0360-3016(95)02257-0; Visser MRM, 1998, SUPPORT CARE CANCER, V6, P101, DOI 10.1007/s005200050142; Wechsler D, 1997, WMS 3 ADM SCORING MA; Wechsler D., 1997, WAIS 3 ADM SCORING M WAIS 3 ADM SCORING M; Wefel JS, 2004, CANCER-AM CANCER SOC, V100, P2292, DOI 10.1002/cncr.20272; WEINS AN, 1993, CLIN NEUROPSYCHOL, V7, P70; Wenzel LB, 1999, CANCER, V86, P1768, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1768::AID-CNCR19>3.3.CO;2-F; WIENEKE MH, 1995, PSYCHO-ONCOL, V4, P61, DOI 10.1002/pon.2960040108; Wilkinson G., 1993, WIDE RANGE ACHIEVEME, V3; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009	72	77	77	0	14	HAWORTH PRESS INC	BINGHAMTON	10 ALICE ST, BINGHAMTON, NY 13904-1580 USA	0734-7332			J PSYCHOSOC ONCOL	J. Psychosoc. Oncol.		2009	27	4					415	434		10.1080/07347330903183117			20	Psychology, Social	Social Science Citation Index (SSCI)	Psychology	504CZ	WOS:000270592800003	19813133	Green Accepted			2022-02-06	
J	Green, RE; Colella, B; Christensen, B; Johns, K; Frasca, D; Bayley, M; Monette, G				Green, Robin E.; Colella, Brenda; Christensen, Bruce; Johns, Kadeen; Frasca, Diana; Bayley, Mark; Monette, Georges			Examining Moderators of Cognitive Recovery Trajectories After Moderate to Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Prognosis; Rehabilitation	CLOSED-HEAD-INJURY; NEUROPSYCHOLOGICAL RECOVERY; FOLLOW-UP; SPEED; PERFORMANCE; ATTENTION; RESERVE; MEMORY; ADULTS; DAMAGE	Objectives: To examine the influence of cognitive reserve-related moderator variables on recovery trajectories during the first year after traumatic brain injury (TBI). Using mixed effects models, we measured (1) the level of cognitive function at 2 and 12 months postinjury and (2) the trajectories of cognitive recovery during the first 12 months postinjury. Design: Repeated-measures design with neuropsychological testing at 2. 5, and 12 months postinjury. Setting: Large, urban inpatient neurorehabilitation program. Participants: Patients (N=75) with moderate-to-severe TBI. Interventions: Not applicable. Main Outcome Measures: Primary outcomes: neuropsychological composite scores including simple speed of processing, complex speed of processing, memory, untimed executive functions, and attention span. Primary predictors: age, estimated premorbid intelligence quotient (IQ), and years of education. Results: Only age significantly moderated trajectories. Decreasing age significantly enhanced recovery of speed of processing, both simple (2-12mo postinjury, P<.001) and complex (2-12mo postinjury, P<.05; 5-12mo postinjury, P<.005). Decreasing age and increasing estimated premorbid IQ were associated with higher performance at 2 and 12mo postinjury for simple speed of processing (premorbid IQ, 2 and 12mo), complex speed of processing (age, 2 and 12mo), untimed executive functions (premorbid IQ, 2 and 12mo), and memory (premorbid IQ, 2 and 12mo). Conclusions: Recovery of speed of processing (both simple and complex) was favorably moderated by younger age. Older age is associated with more neuronal loss and less integrity of white matter, and speed of processing is associated with white matter networks. The recuperative effects of younger age may therefore be attributable to greater reserve capacity (as indexed by white matter integrity). Lower age and higher estimated premorbid IQ were associated with higher functioning on a variety of cognitive outcomes. This may reflect the buffering effects of reserve capacity or premorbid differences in age and IQ-related cognitive functioning. Implications for rehabilitation and recovery mechanisms are discussed.	[Green, Robin E.; Colella, Brenda; Frasca, Diana; Bayley, Mark] Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Green, Robin E.; Frasca, Diana; Bayley, Mark] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Monette, Georges] York Univ, Dept Math & Stat, Toronto, ON M3J 2R7, Canada; [Christensen, Bruce] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada		Green, RE (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	green.rohin@torontorehab.on.ca		Green, Robin/0000-0001-9451-3963; Bayley, Mark/0000-0001-7860-9463	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-67072, MOP-86704]	Supported by the Canadian Institutes of Health Research (grant nos. MOP-67072, MOP-86704).	Burgess P.W., 1997, HAYLING BRIXTON TEST; Charlton RA, 2006, NEUROLOGY, V66, P217, DOI 10.1212/01.wnl.0000194256.15247.83; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Formisano R, 2004, ACTA NEUROCHIR, V146, P457, DOI 10.1007/s00701-004-0225-4; Green REA, 2008, J CLIN EXP NEUROPSYC, V30, P163, DOI 10.1080/13803390701300524; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; HOLM S, 1979, SCAND J STAT, V6, P65; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Lannoo E, 2001, BRAIN INJURY, V15, P1, DOI 10.1080/02699050150209084; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1979, GLAVESTON ORIENTATIO; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; Luria A.R., 1975, HDB CLIN NEUROLOGY, P368; Luria AR, 1963, RESTORATION FUNCTION; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Ropacki MT, 2003, ARCH CLIN NEUROPSYCH, V18, P643, DOI 10.1016/S0887-6177(02)00153-1; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; Singer J, 2003, APPL LONGITUDINAL DA APPL LONGITUDINAL DA, DOI [10.1093/acprof:oso/ 9780195152968.003.0001, DOI 10.1093/ACPROF:OSO/9780195152968.003.0001]; Smith A., 1982, SYMBOL DIGIT MODALIT; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; Stern Y, 2005, CEREB CORTEX, V15, P394, DOI 10.1093/cercor/bhh142; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Wechsler D., 1999, WECHSLER ADULT INTEL; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WechslerD, 2001, WECHSLER TEST ADULT; Wong PP, 2001, BRAIN INJURY, V15, P519, DOI 10.1080/02699050010005995; Zahn TP, 1999, INT J PSYCHOPHYSIOL, V33, P113, DOI 10.1016/S0167-8760(99)00030-6; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	54	77	77	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12					S16	S24		10.1016/j.apmr.2008.09.551			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	388DB	WOS:000261999400003	19081437				2022-02-06	
J	Behan, LA; Phillips, J; Thompson, CJ; Agha, A				Behan, L. A.; Phillips, J.; Thompson, C. J.; Agha, A.			Neuroendocrine disorders after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							GROWTH-HORMONE DEFICIENCY; ANTI-DIURETIC HORMONE; ANTERIOR-PITUITARY INSUFFICIENCY; SEVERE HEAD-INJURY; QUALITY-OF-LIFE; INAPPROPRIATE SECRETION; BODY-COMPOSITION; POSTTRAUMATIC HYPOPITUITARISM; SUBARACHNOID HEMORRHAGE; ADULT PATIENTS	Traumatic brain injury (TBI) is the most common cause of death and disability in young adults living in industrialised countries, in which 180-250 persons per 100 000 per year die or are hospitalised as a result. Neuroendocrine derangements after TBI have received increasing recognition in recent years because of their potential contribution to morbidity, and possibly mortality, after trauma. Marked changes of the hypothalamo-pituitary axis have been documented in the acute phase of TBI, with as many as 80% of patients showing evidence of gonadotropin deficiency, 18% of growth hormone deficiency, 16% of corticotrophin deficiency and 40% of patients demonstrating vasopressin abnormalities leading to diabetes insipidus or the syndrome of inappropriate anti-diuresis. Longitudinal prospective studies have shown that some of the early abnormalities are transient, whereas new endocrine dysfunctions become apparent in the post-acute phase. There remains a high frequency of hypothalamic-pituitary hormone deficiencies among long-term survivors of TBI, with approximately 25% patients showing one or more pituitary hormone deficiencies. This is a higher frequency than previously thought and suggests that most cases of post-traumatic hypopituitarism (PTHP) remain undiagnosed and untreated. PTHP has been associated with adverse outcome both in the acute and chronic phases after injury. These data underscore the need for the identification and appropriate timely management of hormone deficiencies, in order to optimise patient recovery from head trauma, improve quality of life and avoid the long-term adverse consequences of untreated hypopituitarism.	[Behan, L. A.; Thompson, C. J.; Agha, A.] Beaumont Hosp, Acad Dept Endocrinol, Dublin 9, Ireland; [Behan, L. A.; Phillips, J.; Thompson, C. J.; Agha, A.] RCSI Med Sch, Dublin, Ireland; [Phillips, J.] Beaumont Hosp, Acad Dept Neurosurg, Dublin 9, Ireland		Agha, A (corresponding author), Beaumont Hosp, Acad Dept Endocrinol, Dublin 9, Ireland.	amaragha@beaumont.ie					Acerini CL, 2006, EUR J ENDOCRINOL, V155, P663, DOI 10.1530/eje.1.02284; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; ASA S, 2002, PITUITARY, P4; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; BECKER RM, 1973, J TRAUMA, V13, P112, DOI 10.1097/00005373-197302000-00003; BENVENGA S, J CLIN ENDOCRINOL ME, V85, P1353; BESHYAH SA, 1995, CLIN ENDOCRINOL, V42, P179, DOI 10.1111/j.1365-2265.1995.tb01860.x; BINNERTS A, 1992, AM J CLIN NUTR, V55, P918, DOI 10.1093/ajcn/55.5.918; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Boughey JC, 2004, AM SURGEON, V70, P500; Breuil V, 2001, JOINT BONE SPINE, V68, P26, DOI 10.1016/S1297-319X(00)00235-9; Ceballos R, 1966, Ala J Med Sci, V3, P185; Cernak I, 1999, BRAIN INJURY, V13, P1005; CITTADINI A, 1994, AM J PHYSIOL, V267, pE219, DOI 10.1152/ajpendo.1994.267.2.E219; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1919, DOI 10.1210/jc.84.6.1919; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; CUNEO RC, 1992, CLIN ENDOCRINOL, V37, P387, DOI 10.1111/j.1365-2265.1992.tb02347.x; CYRAN E, 1918, DEUT MED WOCHENSCHR, V44, P261; DANIEL PM, 1959, LANCET, V2, P927; DASHE AM, 1963, JAMA-J AM MED ASSOC, V185, P699, DOI 10.1001/jama.1963.03060090031011; DEBOER H, 1992, J CLIN ENDOCR METAB, V75, P833, DOI 10.1210/jc.75.3.833; Della Corte F, 1998, CRIT CARE MED, V26, P1419; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; EDWARDS OM, 1986, MEDICINE, V65, P281; EINAUDI S, 2006, J PAEDIAT ENDOCRINOL, V19, P687; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HARPER CG, 1986, J CLIN PATHOL, V39, P769, DOI 10.1136/jcp.39.7.769; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; HOLMES SJ, 1994, J CLIN ENDOCR METAB, V78, P669, DOI 10.1210/jc.78.3.669; Kalantaridou SN, 1998, ENDOCRIN METAB CLIN, V27, P989, DOI 10.1016/S0889-8529(05)70051-7; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; KLASBEEK WD, 1980, J NEUROSURG, V53, P519; Klose M, 2007, J CLIN ENDOCR METAB, V92, P3861, DOI 10.1210/jc.2007-0901; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Lanfranco F, 2004, LANCET, V364, P273, DOI 10.1016/S0140-6736(04)16678-6; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEE SC, 1994, BRAIN INJURY, V8, P571; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lissett CA, 2003, CLIN ENDOCRINOL, V59, P773, DOI 10.1046/j.1365-2265.2003.01884.x; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jcem.77.6.8263155; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Oh MS, 1999, NEPHRON, V82, P110, DOI 10.1159/000045385; PETERS JP, 1950, T ASSOC AM PHYSICIAN, V63, P57; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; RAO RH, 1987, METABOLISM, V36, P658, DOI 10.1016/0026-0495(87)90150-8; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Seoane LM, 2006, J ENDOCRINOL INVEST, V29, DOI 10.1007/BF03344190; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TWIJNSTRA A, 1980, CLIN NEUROL NEUROSUR, V82, P263, DOI 10.1016/0303-8467(80)90018-9; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; VIGERHOETS F, 1988, ACTA NEUROCHIR, V91, P50; Wong M. F. M., 1998, Annals Academy of Medicine Singapore, V27, P340; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; 1998, NIH             1026, P1	79	77	82	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2008	79	7					753	759		10.1136/jnnp.2007.132837			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	314LI	WOS:000256810500006	18559460				2022-02-06	
J	Macciocchi, S; Seel, RT; Thompson, N; Byams, R; Bowman, B				Macciocchi, Stephen; Seel, Ronald T.; Thompson, Nicole; Byams, Rashida; Bowman, Brock			Spinal cord injury and co-occurring traumatic brain injury: Assessment and incidence	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; diagnosis; incidence; rehabilitation; spinal cord injuries	CLOSED-HEAD-INJURY; POSTTRAUMATIC AMNESIA; COGNITIVE DYSFUNCTION; ASSOCIATION; SCALE; MODEL	Objectives: To examine prospectively the incidence and severity of co-occurring traumatic brain injury (TBI) in persons with traumatic spinal cord injury (SCI) and to describe a TBI assessment process for SCI rehabilitation professionals. Design: A prospective, cohort design to collect and analyze clinical variables relevant for diagnosing co-occurring TBI. Setting: An urban, single-center National Institute of Disability and Rehabilitation Research Model Spinal Cord Injury System in the Southeastern United States. Participants: People (N=198) who met inclusion criteria and provided consent within an 18-month recruitment window. Interventions: Not applicable. Main Outcome Measure: FIM cognitive scale. Results: Based on participants' presence and duration of posttraumatic amnesia, initial Glasgow Coma Scale total score, and presence of cerebral lesion documented by neuroimaging, 60% of our traumatic SCI sample also sustained a TBI (n = 118). Most co-occurring TBIs were mild (34%). Co-occurring mild complicated (10%), moderate (6%), and severe TBI (10%) were less common but still occurred in a significant percentage (26%) of persons with traumatic SCI. Persons with traumatic SCI who were injured in motor vehicle collisions and falls were more likely to sustain a co-occurring TBI. Cervical level traumatic SCI was associated with greater rates of TBI but not more severe injuries. Tree analyses established a practical algorithm for classifying TBI severity associated with traumatic SCI. Analysis of variance established criterion validity for the algorithm's TBI severity classifications. Conclusions: Findings from our prospective study provide strong support that TBI is a common co-occurring injury with traumatic SCI. Incomplete acute care medical record documentation of TBI in the traumatic SCI population remains a considerable issue, and there is a significant need to educate emergency department and acute care personnel on the TBI clinical data needs of acute rehabilitation providers. A systematic algorithm for reviewing acute care medical records can yield valid estimates of TBI severity in the traumatic SCI population.	[Macciocchi, Stephen; Seel, Ronald T.; Thompson, Nicole; Bowman, Brock] Shepherd Ctr, Atlanta, GA 30309 USA; [Macciocchi, Stephen] Univ Georgia, Athens, GA 30602 USA; [Byams, Rashida] Georgia State Univ, Atlanta, GA 30303 USA; [Bowman, Brock] Emory Univ, Atlanta, GA 30322 USA		Macciocchi, S (corresponding author), Shepherd Ctr, 2020 Peachtree Rd, Atlanta, GA 30309 USA.	stephen_macciocchi@shepherd.org					Bowman BK, 2004, TOP SPINAL CORD INJ, V10, P58; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P489; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Elovic E, 1999, TOP SPINAL CORD INJ, V5, P1, DOI DOI 10.1310/V75J-RE76-20GH-X7BY; Go Bette K., 1995, P21; Harris P, 1968, Paraplegia, V5, P215; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Meinecke F W, 1968, Paraplegia, V5, P196; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; National Data and Statistical Center, TRAUM BRAIN INJ MOD; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; PAGNI CA, 1991, ACTA NEUROCHIR, V111, P1, DOI 10.1007/BF01402506; RICHARDS JS, 1991, ARCH PHYS MED REHAB, V72, P275; RICHARDS JS, 1988, AM J PHYS MED REHAB, V67, P211, DOI 10.1097/00002060-198810000-00005; Rimel R W, 1981, J Neurosurg Nurs, V13, P132; ROTH E, 1989, PARAPLEGIA, V27, P480, DOI 10.1038/sc.1989.75; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SABOE LA, 1991, J TRAUMA, V31, P43, DOI 10.1097/00005373-199101000-00010; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHRAGO GG, 1973, AM J ROENTGENOL, V118, P670, DOI 10.2214/ajr.118.3.670; SILVER JR, 1980, INJURY, V12, P219, DOI 10.1016/0020-1383(80)90011-X; Sipski ML, 2006, AM J PHYS MED REHAB, V85, P310, DOI 10.1097/01.phm.0000202105.87011.bf; Steudel W I, 1988, Acta Neurochir Suppl (Wien), V43, P85; Strubreither W, 1997, SPINAL CORD, V35, P487, DOI 10.1038/sj.sc.3100495; STUTTS M, 1991, NEUROREHABILITATION, V3, P79; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Young JS, 1982, SPINAL CORD INJURY S, P14; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; ZAFONTE RD, 2002, SPINAL CORD MED, P261	37	77	80	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2008	89	7					1350	1357		10.1016/j.apmr.2007.11.055			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	323LK	WOS:000257447400020	18586138				2022-02-06	
J	Chen, JK; Johnston, KM; Petrides, M; Ptito, A				Chen, Jen-Kai; Johnston, Karen M.; Petrides, Michael; Ptito, Alain			Recovery from mild head injury in sports: Evidence from serial functional magnetic resonance imaging studies in male athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; mild head injury; post-concussive symptoms; fMRI; recovery	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL DEFICITS; AGREEMENT STATEMENT; FOOTBALL PLAYERS; CONCUSSION; ACTIVATION; FMRI; PERFORMANCE; SYMPTOMS; CORTEX	Objective: To examine functional brain activation patterns before and after postconcussive symptoms (PCS) resolution. Design: Prospective serial study with male athletes using functional magnetic resonance imaging (fMRI). Setting: Hospital laboratory and imaging facility. Participants: 9 symptomatic concussed athletes who experienced persisting PCS at least I month postinjury and 6 healthy athletes. Interventions: All athletes filled out a PCS checklist and underwent an fMRI session during which they performed a working-memory task. Main outcome measurements: Behavioral outcomes were response speed and accuracy on the working memory tasks performed during the fMRI session. Functional imaging outcomes were blood oxygen level-dependent fMRI activation patterns associated with a working memory task. Results: There was no difference in behavioral performance between the groups. Despite normal structural MRI findings, all symptomatic concussed athletes initially showed atypical brain activation patterns in the dorsolateral prefrontal cortex (DLPC). Compared to the initial postinjury evaluation, those athletes at follow-up with PCS resolved showed significant increases in activation in the left DLPC. Concussed athletes whose PCS status remained unchanged at follow-up continued to show atypical activation in DLPC. Healthy athletes showed remarkably clear and consistent brain activations in DLPC initially as well as in follow-up, highlighting the test-retest reliability of fMRI. Conclusions: The results demonstrate the feasibility of using fMRI to detect an underlying pathology in symptomatic concussed athletes with normal structural imaging results and its potential to document recovery. Such information may be of considerable value for clinical judgment and patient management.	[Chen, Jen-Kai; Petrides, Michael; Ptito, Alain] McGill Univ, Montreal Neurol Inst, Neuropsychol Dept, Cognit Neurosci Unit, Montreal, PQ H3A 2B4, Canada; [Johnston, Karen M.] Univ Toronto, Concuss Clin Rehabil Program, Toronto Rehabil Div Neurosurg, Toronto, ON, Canada		Ptito, A (corresponding author), McGill Univ, Montreal Neurol Inst, Neuropsychol Dept, Cognit Neurosci Unit, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	alain.ptito@mcgill.ca					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; DELANEY IS, 1997, CLIN J SPORT MED, V10, P9; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jansen HML, 1996, J NEUROL NEUROSUR PS, V60, P221, DOI 10.1136/jnnp.60.2.221; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2005, Clin J Sport Med, V15, P48; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Petrides M, 2005, PHILOS T ROY SOC B, V360, P781, DOI 10.1098/rstb.2005.1631; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; PETRIDES M, 2001, 7 INT C FUNCT MAPP H, V7, pS721; Ptito A, 2007, NEUROREHABILITATION, V22, P217; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; Worsley KJ, 2003, STAT METHODS MED RES, V12, P401, DOI 10.1191/0962280203sm340ra	40	77	77	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2008	18	3					241	247		10.1097/JSM.0b013e318170b59d			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	298SG	WOS:000255706800004	18469565				2022-02-06	
J	Meachen, SJ; Hanks, RA; Millis, SR; Rapport, LJ				Meachen, Sarah-Jane; Hanks, Robin A.; Millis, Scott R.; Rapport, Lisa J.			The reliability and validity of inventory-18 in persons with the brief symptom traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; reliability and validity	DEPRESSION; DISORDERS; INDIVIDUALS; VALIDATION; DISABILITY; COMMUNITY; SEQUELAE; RETURN	Objective: To investigate the psychometric properties of the Brief Symptom Inventory-18 (BSI-18) among persons with traumatic brain injury (TBI). Design: Inception cohort design with cross-sectional follow-up of 6 months to 15 years. Setting: Rehabilitation hospital. Participants: Adults (N=257) with moderate to severe TBI (81 inpatients and 176 follow-up participants, analyzed separately). Interventions: Not applicable. Main Outcome Measures: The BSI-18 is a brief screen of psychologic distress with a Global Severity Index (GSI), and 3 clinical subscales: somatization. anxiety, and depression. Results: Internal consistency of the GSI was high in both follow-up participants (alpha = .91) and inpatients (alpha = .84), whereas estimates for the somatization, anxiety, and depression subscales were more variable (alpha range, .61-.84). As Would be expected for a measure of affective state, retest reliability estimates were only moderate. The BSI-18 GSI correlated with multiple measures of psychosocial adjustment. After accounting for demographics, injury severity, inpatient functional status, years Since injury, and various psychosocial factors. the BSI-18 showed incremental validity in predicting concurrent functional, psychosocial, and psychologic status. Conclusions: The BSI-18 GSI had excellent reliability and validity among inpatients and follow-up participants. Modest reliability estimates may place an upper bound on the validity of the BSI-18 clinical subscales in inpatient TBI populations.	[Meachen, Sarah-Jane; Hanks, Robin A.; Millis, Scott R.] Rehabil Inst Michigan, Detroit, MI USA; [Meachen, Sarah-Jane; Rapport, Lisa J.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Hanks, Robin A.; Millis, Scott R.] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI 48202 USA		Meachen, SJ (corresponding author), 261 Mack Blvd, Detroit, MI 48201 USA.	smeachett@wayne.edu		Rapport, Lisa/0000-0001-8014-9523	National Institute on Disability and Rehabilitation Research [H133A020515]	Supported by the National Institute on Disability and Rehabilitation Research (grant no. H133A020515).	Allison PD, 2001, MISSING DATA; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Asner-Self Kimberly K, 2006, Cultur Divers Ethnic Minor Psychol, V12, P367, DOI 10.1037/1099-9809.12.2.367; Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Christensen B, 1994, ADV MED PSYCHOTHERAP, V7, P23; CORTINA JM, 1993, J APPL PSYCHOL, V78, P98, DOI 10.1037/0021-9010.78.1.98; Cutrona EC., 1987, ADV PERSONAL RELATIO, V1, P37, DOI DOI 10.1037/0882-7974.1.1.47; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Deb S, 1999, AM J PSYCHIAT, V156, P374; Derogatis L R, 1974, Mod Probl Pharmacopsychiatry, V7, P79; Derogatis L.R., 2001, BRIEF SYMPTOM INVENT; Derogatis L. R., 1977, SCL 90 MANUAL 1 SCOR; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Leathem JM, 2000, J HEAD TRAUMA REHAB, V15, P1246, DOI 10.1097/00001199-200012000-00005; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Prelow HM, 2005, J COMMUNITY PSYCHOL, V33, P139, DOI 10.1002/jcop.20041; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUTHERFORD WH, 1977, LANCET, V1, P1; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Slaughter J, 1999, BRAIN INJURY, V13, P125, DOI 10.1080/026990599121782; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Zabora J, 2001, PSYCHOSOMATICS, V42, P241, DOI 10.1176/appi.psy.42.3.241	42	77	78	1	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					958	965		10.1016/j.apmr.2007.12.028			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	341ST	WOS:000258735900023	18452746				2022-02-06	
J	Chen, Q; Nakajima, A; Choi, SH; Xiong, XL; Sisodia, SS; Tang, YP				Chen, Qian; Nakajima, Akira; Choi, Se Hoon; Xiong, Xiaoli; Sisodia, Sangram S.; Tang, Ya-Ping			Adult neurogenesis is functionally associated with AD-like neurodegeneration	NEUROBIOLOGY OF DISEASE			English	Article						Alzheimer's disease; adult neurogenesis; neuronal loss; presenilin 1; neurodegeneration; conditional knockout; mice	FAMILIAL ALZHEIMERS-DISEASE; TRAUMATIC BRAIN-INJURY; NEURAL STEM-CELLS; HIPPOCAMPAL NEUROGENESIS; DENTATE GYRUS; MOUSE MODEL; NEUROFIBRILLARY TANGLES; SENILE DEMENTIA; CEREBRAL-CORTEX; GRANULE CELLS	Alzheimer's disease (AD) is predominantly characterized by progressive neuronal loss in the brain. It has been recently found that adult neurogenesis in the hippocampal dentate gyrus of AD patients is significantly enhanced, while its functional significance is still unknown. By using an AD-like neurodegeneration mouse model, we show here that neurogenesis in the dentate gyrus was neurodegenerative stage-dependent. At early stages of neurodegeneration, neurogenesis was significantly enhanced and newly generated neurons migrated into the local neuronal network. Up to late stages of neurodegeneration, however, the survival of newly generated neurons was impaired so that the enhanced neurogenesis could not be detected anymore. Most interestingly, these dynamic changes in neurogenesis were correlated with the severity of neuronal loss in the dentate gyros, indicating that neurogenesis may work as a self-repairing mechanism to compensate for neurodegeneration. Therefore, to enhance endogenous neurogenesis at early stages of neurodegeneration may be a valuable strategy to delay neurodegenerative progress. (C) 2007 Elsevier Inc. All rights reserved.	[Chen, Qian; Nakajima, Akira; Xiong, Xiaoli; Tang, Ya-Ping] Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA; [Choi, Se Hoon; Sisodia, Sangram S.] Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA		Tang, YP (corresponding author), Knapp Learning Ctr, 924 E 57th St,R-020, Chicago, IL 60637 USA.	yptang@bsd.uchicago.edu	Nakajima, Akira/I-7077-2014; Tang, Ya-Ping/A-1035-2011	Xiong, Xiaoli/0000-0002-4623-4326	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH066243] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG040185, R01AG027854] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG027854-01A1, R01 AG040185, R01 AG027854, AG027854] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH066243-05, R01 MH066243-04, R01 MH066243, R01 MH066243-03, R01 MH066243-02, R01 MH066243-01A1, MH066243] Funding Source: Medline		Aimone JB, 2006, NAT NEUROSCI, V9, P723, DOI 10.1038/nn1707; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Amrein I, 2004, HIPPOCAMPUS, V14, P1000, DOI 10.1002/hipo.20018; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Barber R, 2001, DEMENT GERIATR COGN, V12, P198, DOI 10.1159/000051258; Becker M, 2007, P NATL ACAD SCI USA, V104, P1691, DOI 10.1073/pnas.0610180104; BONDAREFF W, 1982, NEUROLOGY, V32, P164, DOI 10.1212/WNL.32.2.164; Bondolfi L, 2004, NEUROBIOL AGING, V25, P333, DOI 10.1016/S0197-4580(03)00083-6; Bussiere T, 2003, J COMP NEUROL, V463, P281, DOI 10.1002/cne.10760; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chevallier NL, 2005, AM J PATHOL, V167, P151, DOI 10.1016/S0002-9440(10)62962-8; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Donovan MH, 2006, J COMP NEUROL, V495, P70, DOI 10.1002/cne.20840; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Duman RS, 2004, BIOL PSYCHIAT, V56, P140, DOI 10.1016/j.biopsych.2004.02.033; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Feng RB, 2004, P NATL ACAD SCI USA, V101, P8162, DOI 10.1073/pnas.0402733101; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Greenberg DA, 2007, INT REV NEUROBIOL, V77, P1, DOI 10.1016/S0074-7742(06)77001-5; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; Hayes NL, 2002, DEV BRAIN RES, V134, P77, DOI 10.1016/S0165-3806(01)00324-8; HESTON LL, 1981, ARCH GEN PSYCHIAT, V38, P1085; Hoglinger GU, 2004, NAT NEUROSCI, V7, P726, DOI 10.1038/nn1265; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mirescu C, 2006, HIPPOCAMPUS, V16, P233, DOI 10.1002/hipo.20155; Overstreet-Wadiche LS, 2006, J NEUROSCI, V26, P4095, DOI 10.1523/JNEUROSCI.5508-05.2006; Qiu L, 2007, J CEREBR BLOOD F MET, V27, P785, DOI 10.1038/sj.jcbfm.9600385; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; SAMUEL W, 1994, ARCH NEUROL-CHICAGO, V51, P772, DOI 10.1001/archneur.1994.00540200048015; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; TEHANTCHOU F, 2007, FASEB J; Thompson PM, 2004, NEUROIMAGE, V22, P1754, DOI 10.1016/j.neuroimage.2004.03.040; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; VERRET L, 2007, PSYCHONEUROENDOCRINO, V27, P6771; Wang R, 2004, NEUROSCIENCE, V126, P305, DOI 10.1016/j.neuroscience.2004.03.048; Warner-Schmidt JL, 2006, HIPPOCAMPUS, V16, P239, DOI 10.1002/hipo.20156; Wen PH, 2004, EXP NEUROL, V188, P224, DOI 10.1016/j.expneurol.2004.04.002; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; Zhang C, 2007, EXP NEUROL, V204, P77, DOI 10.1016/j.expneurol.2006.09.018	54	77	84	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2008	29	2					316	326		10.1016/j.nbd.2007.09.005			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	255GW	WOS:000252647000015	17980611	Green Accepted			2022-02-06	
J	Parker, TM; Osternig, LR; van Donkelaar, P; Chou, LS				Parker, Tonya M.; Osternig, Louis R.; van Donkelaar, Paul; Chou, Li-Shan			Recovery of cognitive and dynamic motor function following concussion	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							MILD HEAD-INJURY; SPORT; GAIT; STATEMENT; ATTENTION; DEFICITS; IMPACT; TIME	Objective: Neuropsychological testing has been advocated as an important tool of proper post-concussion management. Although these measures provide information that can be used in the decision of when to return an individual to previous levels of physical activity, they provide little data on motor performance following injury. The purpose of this investigation was to examine the relationship between measures of dynamic motor performance and neuropsychological function following concussion over the course of 28 days. Methods: Participants completed two experimental protocols: gait stability and neuropsychological testing. The gait stability protocol measured whole-body centre of mass motion as subjects walked under conditions of divided and undivided attention. Neuropsychological testing consisted of a computerised battery of tests designed to assess memory, reaction time, processing speed and concussion symptoms. Correlation coefficients were computed between all neuropsychological and gait variables and comparisons of neuropsychological and gait stability post-concussion recovery curves were assessed. Results: Dynamic motor tasks, such as walking under varying conditions of attention, are complex and demanding undertakings, which require a longer recovery time following a concussion than cognitive measures. Little statistical relationship was found between the neuropsychological and gait variables, and the recovery curves of neuropsychological and gait domains were observed to be independent. Conclusions: In order to fully examine the effects of concussion and determine the optimal time for a safe return to activity, a multi-factorial approach, including both cognitive and motor tasks, should be employed.	[Parker, Tonya M.; Osternig, Louis R.; van Donkelaar, Paul; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Mot Anal Lab, Eugene, OR 97403 USA		Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, Mot Anal Lab, 1240, Eugene, OR 97403 USA.	chou@uoregon.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR021735, CCR023203] Funding Source: Medline		Aubry Mark, 2002, Phys Sportsmed, V30, P57, DOI 10.3810/psm.2002.02.176; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BELL R, 1977, AM FAM PHYSICIAN, V16, P145; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Haggard P, 2000, J NEUROL NEUROSUR PS, V69, P479, DOI 10.1136/jnnp.69.4.479; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kelly JP, 1997, NEUROLOGY, V48, P581; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; WINTER DA, 1990, BIOMECHANICS MOTOR C, P56; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	27	77	78	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC	2007	41	12					868	873		10.1136/bjsm.2006.033761			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	239YS	WOS:000251554800007	17517857	Green Published			2022-02-06	
J	Yuan, W; Holland, SK; Schnnithorst, VJ; Walz, NC; Cecil, KM; Jones, BV; Karunanayaka, P; Michaud, L; Wade, SL				Yuan, W.; Holland, S. K.; Schnnithorst, V. J.; Walz, N. C.; Cecil, K. M.; Jones, B. V.; Karunanayaka, P.; Michaud, L.; Wade, S. L.			Diffusion tensor MR Imaging reveals persistent white matter alteration after traumatic brain injury experienced during early childhood	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CLOSED-HEAD-INJURY; CORPUS-CALLOSUM; CHILDREN; ADOLESCENCE; ANISOTROPY; RECOVERY; OUTCOMES; LESIONS; AGE	BACKGROUND AND PURPOSE: Diffusion tensor imaging (DTI) can noninvasively quantify white matter (WM) integrity. Although its application in adult traumatic brain injury (TBI) is common, few studies in children have been reported. The purposes of this study were to examine the alteration of fractional anisotropy (FA) in children with TBI experienced during early childhood and to quantify the association between FA and injury severity. MATERIALS AND METHODS: FA was assessed in 9 children with TBI (age = 7.89 +/- 1.00 years; Glasgow Coma Scale [GCS] = 10.11 +/- 4.68) and a control group of 12 children with orthopedic injuries without central nervous system involvement (age = 7.51 +/- 0.95 years). All of the subjects were at minimum 12 months after injury. We examined group differences in a series of predetermined WM regions of interest with t test analysis. We subsequently conducted a voxel-wise comparison with Spearman partial correlation analysis. Correlations between FA and injury severity were also calculated on a voxel-wise basis. RESULTS: FA values were significantly reduced in the TBI group in genu of corpus callosum (CC), posterior limb of internal capsule (PLIC), superior longitudinal fasciculus (SLF), superior fronto-occipital fasciculus (SFO), and centrum semiovale (CS). GCS scores were positively correlated with FA in several WM areas including CC, PLIC, SLF, CS, SFO, and inferior fronto-occipital fasciculus (IFO). CONCLUSION: This DTI study provides evidence that WM integrity remains abnormal in children with moderate-to-severe TBI experienced during early childhood and that injury severity correlated strongly with FA.	Univ Cincinnati, Childrens Hosp & Med Ctr, Coll Med, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; Univ Cincinnati, Childrens Hosp & Med Ctr, Coll Med, Dept Radiol, Cincinnati, OH USA; Univ Cincinnati, Childrens Hosp & Med Ctr, Coll Med, Dept Pediat, Cincinnati, OH USA		Wade, SL (corresponding author), Univ Cincinnati, Childrens Hosp & Med Ctr, Coll Med, Div Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org		Cecil, Kim/0000-0001-8233-5485; Holland, Scott/0000-0003-3719-0875	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R43HD044279] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA112181] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P01ES011261] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA112181, P01 CA112181] Funding Source: Medline; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 08084, M01 RR008084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729, R43 HD044279, HD044279] Funding Source: Medline; NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P01 ES011261, R21 ES012524] Funding Source: Medline		Anderson VA, 2000, BRAIN INJURY, V14, P679; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Brett M, 2001, NEUROIMAGE, V13, pS85; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HASAN KM, 2004, DIFFUSION TENSOR MRI, P1350; HEMOYE L, 2006, NEUROIMAGE, V29, P493; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Schmithorst VJ, 2006, NEUROIMAGE, V31, P1366, DOI 10.1016/j.neuroimage.2006.01.010; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; SCHMITHORST VJ, 2005, SEX DIFFERENCES WHIT; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Suzuki Y, 2003, NMR BIOMED, V16, P257, DOI 10.1002/nbm.848; TALAIRACH J, 1988, COPLANAR STERCOTAXIC; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; XU J, 2006, 12 ANN M HUM BRAIN M	33	77	80	0	7	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	NOV-DEC	2007	28	10					1919	1925		10.3174/ajnr.A0698			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	234XT	WOS:000251198600024	17905895	Green Accepted, hybrid, Green Published			2022-02-06	
J	Donders, J; Warschausky, S				Donders, Jacobus; Warschausky, Seth			Neurobehavioral outcomes after early versus late childhood traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						childhood; outcome; traumatic brain injury	CLOSED-HEAD-INJURY; FOLLOW-UP; SHORT-TERM; CHILDREN; ADOLESCENTS; RECOVERY; REHABILITATION; PREDICTORS; STABILITY; VARIABLES	Objectives: To examine differences in outcomes at transition age (17-21 years) between individuals who sustained complicated mild-to-severe traumatic brain injury (TBI) in early or middle childhood and those who were injured in late adolescence. Participants: Fifteen persons who sustained TBI between the ages of 6 and 12 years (early-onset) and 30 persons who sustained TBI between the ages of 16 and 20 years (late-onset). Measures: Peabody Picture Vocabulary Test-Third. Edition, Trail-Making Test, Buschke Selective Reminding Test, Benton Visual Retention Test, Dysexecutive Questionnaire, Community Integration Questionnaire, Satisfaction with Life Scale. Results: The groups did not differ in overall cognitive ability level, postinjury education or vocational accomplishments, or current living situation. However the early-onset group demonstrated worse outcomes in higher-level cognitive skills, social integration, driving, and legal guardianship. Conclusions: Complicated mild-to-severe TBI earlier in childhood is associated with worse long-term neurocognitive and psychosocial outcomes than injury sustained in late adolescence. Findings provide further support for theories that early brain injury onset interferes with development of immature or rapidly developing skills, and may be associated with further magnification of deficits during the course of later development.	Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA		Donders, J (corresponding author), Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy,SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133G000038] Funding Source: Medline		Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Donders J., 2006, TREATING NEURODEVELO, P23; Dunn L.M., 1997, PEABODY PICTURE VOCA, V3rd Edition; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Goldstein G, 1989, CLIN NEUROPSYCHOL, V3, P265, DOI DOI 10.1080/13854048908404088; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kieslich M, 2001, DISABIL REHABIL, V23, P665; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; Martin TA, 2003, APPL NEUROPSYCHOL, V10, P163, DOI 10.1207/S15324826AN1003_05; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Moses P, 2002, DEV PSYCHOBIOL, V40, P266, DOI 10.1002/dev.10031; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Nybo T, 1999, BRAIN INJURY, V13, P759; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sivan AB., 1992, BENTON VISUAL RETENT; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Van Heugten CM, 2006, BRAIN INJURY, V20, P895, DOI 10.1080/02699050600832015; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Wolfson, 1993, HALSTEAD REITAN NEUR; Woodhead J C, 1985, Semin Adolesc Med, V1, P171; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	44	77	77	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2007	22	5					296	302		10.1097/01.HTR.0000290974.01872.82			7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	216RA	WOS:000249895500005	17878771				2022-02-06	
J	Arango-Lasprilla, JC; Rosenthal, M; DeLuca, J; Cifu, DX; Hanks, R; Komaroff, E				Arango-Lasprilla, Juan Carlos; Rosenthal, Mitchell; DeLuca, John; Cifu, David X.; Hanks, Robin; Komaroff, Eugene			Functional outcomes from inpatient rehabilitation after traumatic brain injury: How do Hispanics fare?	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	82nd Annual Meeting of the American-Congress-of-Rehabilitation-Medicine	SEP 28-OCT 02, 2005	Chicago, IL	Amer Congress Rehabil Med			RISK-FACTORS; SYSTEMS; HEALTH; IMPACT; SCALE; MINORITIES; ETHNICITY; CARE; RACE	Objective: To examine the relation between Hispanic ethnicity and rehabilitation outcome in traumatic brain injury (TBI) survivors. Design: Retrospective study. Setting: Longitudinal dataset of the Traumatic Brain Injury Model Systems national database. Participants: Persons (N=3056; 2745 whites vs 311 Hispanics) with moderate to severe TBI hospitalized between 1989 and 2003. Interventions: Not applicable. Main Outcome Measures: Functional outcomes at discharge and 1-year follow-up (Disability Rating Scale [DRS], FIM instrument). Glasgow Outcome Scale-Extended (GOS-E), and the Community Integration Questionnaire (CIQ) were measured at follow-up only. Results: At admission, Hispanics were less educated (P <=.001), earned less money (P <=.05), and were younger (P <=.001) than whites. Hispanics had lower GOS-E scores (P <=.01) at acute hospital admission compared with whites. Despite similar functional status at inpatient rehabilitation discharge, Hispanic ethnicity was associated with poorer functional outcomes at I year postinjury (DRS, FIM, CIQ), after controlling for age, length of posttraumatic amnesia, injury severity, DRS score at admission, FIM score at admission, and preinjury educational level (P <.05). Conclusions: Hispanics showed significantly reduced long-term functional outcome after rehabilitation relative to whites. Rehabilitation professionals should recognize the possible impact of individual differences and diverse sociodemographic, injury, and rehabilitation characteristics so that differential	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA		Arango-Lasprilla, JC (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 300 Execut Dr,Ste 010, W Orange, NJ 07052 USA.			Cifu, David/0000-0003-1600-9387	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD07522-05, T32 HD007522-5] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007522] Funding Source: NIH RePORTER		[Anonymous], 1997, GUID UN DAT SET MED; ARTIOLA I, 2005, J CLIN EXP NEUROPSYC, V27, P555; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burnett DM, 2000, BRAIN INJURY, V14, P713; CAVALLO MM, 1995, J HEAD TRAUMA REHAB, V10, P66, DOI 10.1097/00001199-199504000-00008; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P937; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; ELLIOTT P, 1994, INT J GYNECOL CANCER, V4, P84, DOI 10.1046/j.1525-1438.1994.04020084.x; Ferdinand KC, 2005, J NATL MED ASSOC, V97, P459; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; HOBBS F, 2002, DEMOGRAPHIC TRENDS 2; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; MCCULLAGH P, 1989, GEN LINEAR MODELS; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; O'Brien K, 2003, CA-CANCER J CLIN, V53, P208, DOI 10.3322/canjclin.53.4.208; Penn NE, 1995, HEALTH PSYCHOL, V14, P641, DOI 10.1037/0278-6133.14.7.641; Pole Nnamdi, 2005, Cultur Divers Ethnic Minor Psychol, V11, P144, DOI 10.1037/1099-9809.11.2.144; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAMIREZ RR, 2002, HISPANIC POPULATION, P20; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ricker J H, 1998, Appl Neuropsychol, V5, P184, DOI 10.1207/s15324826an0504_3; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; Rubin D.B., 1987, MULTIPLE IMPUTATION; Sabogal F, 1996, HISPANIC J BEHAV SCI, V18, P367, DOI 10.1177/07399863960183007; Satcher D, 2001, MENT HLTH CULT RAC E; Shai I, 2006, DIABETES CARE, V29, P1585, DOI 10.2337/dc06-0057; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *TRAUM BRAIN INJ N, 2005, TRAUM BRAIN INJ MOD; *US CENS BUR, 2000, 2000 CENS POP HOUS; Uswatte G, 1997, REHABIL PSYCHOL, V42, P61, DOI 10.1037/0090-5550.42.1.61; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZWEIFLER RM, 1995, STROKE, V26, P245, DOI 10.1161/01.STR.26.2.245; [No title captured]	40	77	81	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2007	88	1					11	18		10.1016/j.apmr.2006.10.029			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	126GY	WOS:000243502000002	17207669				2022-02-06	
J	Pierce, CA; Hanks, RA				Pierce, Christopher A.; Hanks, Robin A.			Life satisfaction after traumatic brain injury and the World Health Organization model of disability	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						brain injuries; quality of life; health; World Health Organization	QUALITY-OF-LIFE; SCALE; DISABLEMENT; OUTCOMES	Objective: To determine which components of the World Health Organization's International Classification of Functioning, Disability, and Health (ICF) are most predictive of global life satisfaction after traumatic brain injury (TBI). Design: Prospective evaluation of 180 individuals enrolled in a TBI model system project site. Results: Multiple regression analysis indicated that the combination of ICF components (body function and structure, activities, and participation) and demographic factors significantly predicted life satisfaction and accounted for 17% of the variance. Participation was the strongest predictor; activities were a significant, but weaker predictor; and body function and structure did not add to the prediction of life satisfaction. Of all the individual variables evaluated, only social integration and productivity were found to be significant, unique predictors. Conclusions: When considering the effects of various aspects of disabling conditions on the life satisfaction of individuals who have suffered a TBI, restriction of participation in life activities was found to have the greatest impact. Although the model accounted for a significant percentage in the variation of life satisfaction, a large proportion of the predictive picture (> 82%) remains unclear. Doubtless, other variables impinge on life satisfaction that would further clarify the complex relationship between disabling conditions and life satisfaction in TBI.	Denver Hlth Med Ctr, Dept Behav Hlth Serv, Denver, CO 80204 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI USA		Pierce, CA (corresponding author), Denver Hlth Med Ctr, Dept Behav Hlth Serv, 777 Bannock St,Unit 9,OBHS,Mail Code 3450, Denver, CO 80204 USA.						*AM SPIN INJ ASS, 1990, AM SPIN INJ ASS STAN; ARRINDELL WA, 1991, PERS INDIV DIFFER, V12, P117, DOI 10.1016/0191-8869(91)90094-R; BLAIS MR, 1989, CAN J BEHAV SCI, V21, P210, DOI 10.1037/h0079854; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; DIJKERS M, 2006, COMMUNITY INTEGRATIO; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; Fuhrer MJ, 1996, TOPICS SPINAL CORD I, V4, P56; Hamilton BB, 1987, REHABILITATION OUTCO, P137; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; JUDGE TA, 1990, THESIS U ILLINOIS UR; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Pierce C. A., 1999, SCI PSYCHOSOCIAL PRO, V12, P124; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Smead V. S., 1991, ANN CONV AM ASS APPL; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Withrow SJ, 1998, CLIN TECH SMALL AN P, V13, P1; World Health Organization, 1999, INT CLASS FUNCT DIS; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 2007, INT CLASS FUNCT DIS	26	77	77	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV	2006	85	11					889	898		10.1097/01.phm.0000242615.43129.ae			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	098OL	WOS:000241532400005	17079961				2022-02-06	
J	Farr, TD; Liu, L; Colwell, KL; Whishaw, IQ; Metz, GA				Farr, Tracy D.; Liu, Lily; Colwell, Keri L.; Whishaw, Ian Q.; Metz, Gerlinde A.			Bilateral alteration in stepping pattern after unilateral motor cortex injury: A new test strategy for analysis of skilled limb movements in neurological mouse models	JOURNAL OF NEUROSCIENCE METHODS			English	Article						motor system; movement performance; skilled walking; rotorod; ladder rung task; mouse behaviour	TRAUMATIC BRAIN-INJURY; DOPAMINE-DEPLETED RATS; MICE MUS-MUSCULUS; ADULT-RATS; SENSORIMOTOR DYSFUNCTION; BEHAVIORAL-DIFFERENCES; CORTICOSPINAL TRACT; TRANSGENIC MICE; END-POINT; FORELIMB	Mice are becoming increasingly popular to model neurological disease and motor system dysfunction. For evaluation of discrete, chronic motor impairments, skilled limb movements represent a valuable extension of standard mouse test batteries. This study introduces an efficient and sensitive test strategy for comprehensive assessment of skilled fore- and hind-limb stepping in mice. Adult C57BL/6 mice were trained and video-recorded in two walking tasks, the widely used rotorod test and a new ladder rung task. The animals then received a unilateral ischemic lesion in the motor cortex forelimb and hind limb area and were video-recorded on days 12 and 26 post-lesion. Forelimb and hind limb stepping movements were rated using a combination of endpoint measures and qualitative assessment. The results showed that while animals maintained a weight-supported gait, posture and stepping movements were abnormal at both post-operative intervals. The rotorod analysis revealed stepping deficits in both forelimbs that led to adoption of compensatory movement strategies. The ladder rung task revealed stepping errors in ipsi- and contralateral fore- and hind-limbs. The findings demonstrate that this test strategy provides comprehensive assessment of motor impairments in mice and that qualitative movement analysis is a valuable tool for elaborating subtle motor disturbances. (c) 2005 Elsevier B.V. All rights reserved.	Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada; Univ Glasgow, Div Clin Neurosci, Wellcome Surg Inst, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Div Clin Neurosci, 7TMRI Facil, Glasgow G61 1QH, Lanark, Scotland		Farr, TD (corresponding author), Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada.	0309845f@student.gla.ac.uk	Farr, Tracy D/I-2876-2019	Farr, Tracy D/0000-0002-6781-5226; Metz, Gerlinde/0000-0002-5801-7716			Anagnostopoulos AV, 2001, PHYSIOL BEHAV, V73, P675, DOI 10.1016/S0031-9384(01)00525-X; Augustsson H, 2004, PHYSIOL BEHAV, V81, P685, DOI 10.1016/j.physbeh.2004.03.014; Baird AL, 2001, BRAIN RES BULL, V54, P243, DOI 10.1016/S0361-9230(00)00457-3; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Bothe GWM, 2004, GENES BRAIN BEHAV, V3, P149, DOI 10.1111/j.1601-183x.2004.00064.x; Brambilla G, 2004, TOXICOLOGY, V196, P1, DOI 10.1016/j.tox.2003.11.003; Branchi I, 2002, GENES BRAIN BEHAV, V1, P135, DOI 10.1034/j.1601-183X.2002.10301.x; Bucan M, 2002, NAT REV GENET, V3, P114, DOI 10.1038/nrg728; Caston J, 2003, BEHAV BRAIN RES, V141, P35, DOI 10.1016/S0166-4328(02)00319-4; Chapillon P, 1998, BEHAV BRAIN RES, V93, P77, DOI 10.1016/S0166-4328(97)00137-X; Chu CJ, 2000, EXP NEUROL, V166, P403, DOI 10.1006/exnr.2000.7509; Cook MN, 2002, BEHAV NEUROSCI, V116, P600, DOI 10.1037//0735-7044.116.4.600; Dijkstra JR, 2000, J NEUROSCI METH, V96, P89, DOI 10.1016/S0165-0270(99)00174-0; DONATELLE JM, 1977, J COMP NEUROL, V175, P207, DOI 10.1002/cne.901750205; Farr TD, 2002, STROKE, V33, P1869, DOI 10.1161/01.STR.0000020714.48349.4E; Fleming SM, 2004, J NEUROSCI, V24, P9434, DOI 10.1523/JNEUROSCI.3080-04.2004; Fouad K, 2000, BEHAV BRAIN RES, V115, P107, DOI 10.1016/S0166-4328(00)00244-8; FOX WM, 1965, ANIM BEHAV, V13, P234, DOI 10.1016/0003-3472(65)90041-2; Goldstein LB, 2003, ILAR J, V44, P125, DOI 10.1093/ilar.44.2.125; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Karl T, 2003, EXP TOXICOL PATHOL, V55, P69, DOI 10.1078/0940-2993-00301; Kim D, 2001, NEUROREHAB NEURAL RE, V15, P141, DOI 10.1177/154596830101500207; KUNKELBAGDEN E, 1992, EXP NEUROL, V116, P40, DOI 10.1016/0014-4886(92)90174-O; Lalonde R, 2003, BEHAV PROCESS, V63, P9, DOI 10.1016/S0376-6357(03)00013-5; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; MIKLYAEVA EI, 1994, J NEUROSCI, V14, P7148; Muir GD, 1999, EXP BRAIN RES, V126, P307, DOI 10.1007/s002210050739; OLSSON M, 1995, J NEUROSCI, V15, P3863; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Pecaut MJ, 2002, COGN AFFECT BEHAV NE, V2, P329, DOI 10.3758/CABN.2.4.329; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Smith LK, 2005, PHYSIOL BEHAV, V85, P581, DOI 10.1016/j.physbeh.2005.06.013; Soblosky JS, 1997, J NEUROSCI METH, V78, P75, DOI 10.1016/S0165-0270(97)00131-3; Starkey ML, 2005, EXP NEUROL, V195, P524, DOI 10.1016/j.expneurol.2005.06.017; Tillerson JL, 2002, EXP NEUROL, V178, P80, DOI 10.1006/exnr.2002.8021; van der Staay FJ, 2001, BEHAV BRAIN RES, V125, P3, DOI 10.1016/S0166-4328(01)00278-9; WAGNER GC, 1987, PSYCHOPHARMACOLOGY, V92, P470; Wahlsten D, 2003, GENES BRAIN BEHAV, V2, P71, DOI 10.1034/j.1601-183X.2003.00012.x; Whishaw IQ, 2000, NEUROPHARMACOLOGY, V39, P788, DOI 10.1016/S0028-3908(99)00259-2; WHISHAW IQ, 1992, BEHAV BRAIN RES, V48, P113, DOI 10.1016/S0166-4328(05)80147-0; WHISHAW IQ, 1994, BEHAV BRAIN RES, V60, P15, DOI 10.1016/0166-4328(94)90058-2; Whishaw IQ, 2003, J NEUROSCI METH, V126, P13, DOI 10.1016/S0165-0270(03)00049-9; WHISHAW IQ, 1991, BEHAV BRAIN RES, V42, P77, DOI 10.1016/S0166-4328(05)80042-7; Whishaw IQ, 1996, BEHAV BRAIN RES, V78, P101, DOI 10.1016/0166-4328(95)00236-7; WOLGIN DL, 1983, PHYSIOL BEHAV, V31, P197, DOI 10.1016/0031-9384(83)90118-X; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0	47	77	78	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAY 15	2006	153	1					104	113		10.1016/j.jneumeth.2005.10.011			10	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	047MC	WOS:000237882400012	16309746				2022-02-06	
J	Einaudi, S; Matarazzo, P; Peretta, P; Grossetti, R; Giordano, F; Altare, F; Bondone, C; Andreo, M; Ivani, G; Genitori, L; de Sanctis, C				Einaudi, S.; Matarazzo, P.; Peretta, P.; Grossetti, R.; Giordano, F.; Altare, F.; Bondone, C.; Andreo, M.; Ivani, G.; Genitori, L.; de Sanctis, C.			Hypothalamo-hypophysial dysfunction after traumatic brain injury in children and adolescents: A preliminary retrospective and prospective study	JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM			English	Article							SALT-WASTING SYNDROME; ASSESS GROWTH-HORMONE; PITUITARY DYSFUNCTION; SUBARACHNOID HEMORRHAGE; HYPOPITUITARISM; HYPONATREMIA; SECRETION; MANAGEMENT; GLUCAGON; DISEASE	With two study protocols, one retrospective and the other prospective, we evaluated hypothalamo-hypophysial dysfunction (HHD) in paediatric patients treated for traumatic brain injury (TBI) in the neurosurgical or intensive care department at our hospital. The retrospective group comprised 22 patients who had experienced TBI 0.7-7.25 years before the study. The prospective group included 30 patients assessed at TBI (T0), 26 of 30 after 6 months (U), and 20 of 26 after 12 months (T12). Auxological and hormonal basal parameters of hypothalamo-hypophysial function were evaluated at recall in the retrospective group, and at T0, T6 and T12 in the prospective group. Basal data and standard dynamic tests in selected patients revealed one with precocious puberty, one with total anterior hypopituitarism, one with central hypogonadism, and one with growth hormone (GH) deficiency in the retrospective group; three patients with cerebral salt-wasting syndrome, one with diabetes insipidus and seven with low T-3 syndrome at T0 (all transient), one with hypocorticism at T6 confirmed at T12, and one with GH deficiency at T12 in the prospective group. The results of our study show that post-TBI HHD in our paediatric cohort is not uncommon. Of the 48 patients who underwent a complete evaluation (22 retrospective study patients and 26 prospective study patients evaluated at T6) five (10.4%) developed HHD 6 months or more after TBI. HHD was newly diagnosed in one previously normal patient from the prospective group at 12 months after TBI. GH deficiency was the most frequent disorder in our paediatric cohort.	Regina Margherita Childrens Hosp, Dept Paediat Endocrinol, I-10126 Turin, Italy; Regina Margherita Childrens Hosp, Dept Paediat Neurosurg, I-10126 Turin, Italy; Regina Margherita Childrens Hosp, Dept Pediat Intens Care Unit, I-10126 Turin, Italy; Regina Margherita Childrens Hosp, Dept Clin Pathol, I-10126 Turin, Italy		Einaudi, S (corresponding author), Regina Margherita Childrens Hosp, Dept Paediat Endocrinol, Piazza Polonia 94, I-10126 Turin, Italy.	silvein@libero.it	altare, frederic/K-8664-2015; Bondone, Claudia/AAI-7088-2021; Genitori, Lorenzo/K-9682-2016	altare, frederic/0000-0002-5077-4616; Bondone, Claudia/0000-0003-4120-2533; Peretta, Paola/0000-0001-5415-4230; Genitori, Lorenzo/0000-0002-4359-0798			Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, GROWTH HORM IGF RES, V14, pS114, DOI 10.1016/j.ghir.2004.03.025; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Albanese A, 2001, ARCH DIS CHILD, V85, P246, DOI 10.1136/adc.85.3.246; Ballerini MG, 2004, J PEDIATR ENDOCR MET, V17, P749; BARZILAY Z, 1988, J MED, V19, P47; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Berkenbosch JW, 2002, PEDIATR NEUROSURG, V36, P75, DOI 10.1159/000048356; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bussmann C, 2001, CHILD NERV SYST, V17, P58; CHANOINE JP, 1995, J CLIN ENDOCR METAB, V80, P3032, DOI 10.1210/jc.80.10.3032; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; DANIEL PM, 1959, LANCET, V2, P927; DATTANI MT, 2001, CLIN PEDIAT ENDOCRIN, P477; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; EDWARDS OM, 1986, MEDICINE, V65, P281; Ghigo E, 1996, J CLIN ENDOCR METAB, V81, P3323, DOI 10.1210/jc.81.9.3323; Greulich WW., 1959, RADIOGRAPHIC ATLAS S; JAFFE D, 1991, NEW ENGL J MED, V324, P1477; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leong KS, 2001, CLIN ENDOCRINOL, V54, P463, DOI 10.1046/j.1365-2265.2001.01169.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LOPEZ AMC, 2001, MED INT, V18, P105; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; Matarazzo P, 2004, J PEDIATR ENDOCR MET, V17, P1487; MELVER B, 1997, THYROID, V7, P125; NELSON PB, 1981, J NEUROSURG, V55, P938, DOI 10.3171/jns.1981.55.6.0938; Oh MS, 1999, NEPHRON, V82, P110, DOI 10.1159/000045385; RAO RH, 1987, METABOLISM, V36, P658, DOI 10.1016/0026-0495(87)90150-8; Robertson G. L., 1985, DIABETES INSIPIDUS M, P176; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; Tenedieva VD, 2000, ACT NEUR S, V76, P385; ZADIK Z, 1992, HORM RES, V38, P250, DOI 10.1159/000182553	36	77	77	0	1	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-018X	2191-0251		J PEDIATR ENDOCR MET	J. Pediatr. Endocrinol. Metab.	MAY	2006	19	5					691	703					13	Endocrinology & Metabolism; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Pediatrics	053HT	WOS:000238296900003	16789636				2022-02-06	
J	Gerlach, R; Demel, G; Konig, HG; Gross, U; Prehn, JHM; Raabe, A; Seifert, V; Kogel, D				Gerlach, R.; Demel, G.; Koenig, H. G.; Gross, U.; Prehn, J. H. M.; Raabe, A.; Seifert, V.; Koegel, D.			Active secretion of S100B from astrocytes during metabolic stress	NEUROSCIENCE			English	Article						S100B; CNS damage; ischemia; transcription; glial secretion; metabolic stress	TRANSGENIC MICE; PROTEINS; BRAIN; SUSCEPTIBILITY; INFUSION; DAMAGE; GENE	In patients suffering from cerebrovascular diseases and traumatic brain damage, increases in serum levels of protein S100B are positively correlated with the severity of the insult. Since high concentrations of S100B have been shown to exert neurotoxic effects, the objective of this study was to characterize the regulatory mechanisms underlying control of S100B release from astrocytes. To that end, we analyzed the kinetics and amount of S100B release in correlation with regulation of S100B gene expression in an in vitro ischemia model. Astrocyte cultures were treated with combined oxygen, serum and glucose deprivation, serum and glucose deprivation or hypoxia alone for 6, 12 and 24 h, respectively. While oxygen, serum and glucose deprivation triggered the most rapid release of S100B, serum and glucose deprivation provoked comparable levels of released S100B at the later time points. In contrast to oxygen, serum and glucose deprivation and serum and glucose deprivation, hypoxia alone elicited only marginal increases in secreted S100B. Parallel analysis of extracellular lactate dehydrogenase and the number of viable cells revealed only moderate cell death in the cultures, indicating that S100B was actively secreted during in vitro ischemia. Interestingly, S100B mRNA expression was potently downregulated after 12 and 24 h of oxygen, serum and glucose deprivation, and prolonged oxygen, serum and glucose deprivation for 48 h was associated with a significant reduction of S100B release at later time intervals, whereas lactate dehydrogenase levels remained constant. Our data suggest that secretion of S100B during the glial response to metabolic injury is an early and active process. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Frankfurt, Dept Neurosurg, D-60528 Frankfurt, Germany; Royal Coll Surgeons Ireland, Dept Physiol, Dublin 2, Ireland		Gerlach, R (corresponding author), Univ Frankfurt, Dept Neurosurg, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	r.gerlach@em.uni-frankfurt.de	Prehn, Jochen HM/A-3928-2010	Prehn, Jochen HM/0000-0003-3479-7794; Kogel, Donat/0000-0003-1209-0210			Adami C, 2004, BBA-MOL CELL RES, V1742, P169, DOI 10.1016/j.bbamcr.2004.09.008; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Craft JM, 2005, GLIA, V51, P209, DOI 10.1002/glia.20194; Davey GE, 2001, J BIOL CHEM, V276, P30819, DOI 10.1074/jbc.M103541200; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kogel D, 2004, NEUROSCIENCE, V127, P913, DOI 10.1016/j.neuroscience.2004.06.013; LOFFNER E, 1986, BRAIN RES, V363, P205; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Tsoporis JN, 2003, AM J PHYSIOL-HEART C, V284, pH193, DOI 10.1152/ajpheart.00161.2002; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Wainwright MS, 2004, ANN NEUROL, V56, P61, DOI 10.1002/ana.20142	16	77	83	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2006	141	4					1697	1701		10.1016/j.neuroscience.2006.05.008			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	080BO	WOS:000240222000005	16782283				2022-02-06	
J	Langlois, JA; Marr, A; Mitchko, J; Johnson, RL				Langlois, JA; Marr, A; Mitchko, J; Johnson, RL			Tracking the silent epidemic and educating the public - CDC's traumatic brain injury-associated activities under the TBI act of 1996 and the children's health act of 2000	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; craniocerebral trauma; education; surveillance	HOSPITALIZATIONS; SERVICES; TRENDS; NEEDS	The Traumatic Brain Injury Act of 1996 and the Children's Health Act of 2000 authorized the Centers for Disease Control and Prevention to conduct several activities associated with traumatic brain injury. This aricle describes how the Centers for Disease Control and Prevention responded to the legislation in 2 key areas: traumatic brain injury surveillance, and education and awareness.	Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA		Langlois, JA (corresponding author), 4770 Buford Highway,NE,MS F-41, Atlanta, GA 30341 USA.	JAL7@cdc.gov					Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; BUTLER JA, 2002, CENTRAL NERVOUS SYST; BUTLER JA, 2001, CENTRAL NERVOUS SYST; *CDCP, 1999, TRAUM BRAIN INJ US; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P276; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P209; *CDCP NAT CTR HLTH, SURV DAT COLL SYST; *CDCP NAT CTR HLTH, 1999, FACTS CONC BRAIN INJ; *CDCP NAT CTR HLTH, 2002, INF AC LES CER LEV; *CDCP NAT CTR HLTH, 2003, HEADS BRAIN INJ YOUR; Centers for Disease Control and Prevention, 2003, MILD TRAUM BRAIN INJ; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Cusick CP, 2003, BRAIN INJURY, V17, P931, DOI 10.1080/0269905031000110391; Cusick CP, 2001, ARCH PHYS MED REHAB, V82, P1018, DOI 10.1053/apmr.2001.25098; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; *HARR INT INC, PUBL PERC BRAIN HEAD; Kegler SR, 2003, J HEAD TRAUMA REHAB, V18, P469, DOI 10.1097/00001199-200311000-00001; KLAUCKE DN, 1988, MMWR S5, V37, P1; Langlois J, 2005, TRAUMATIC BRAIN INJU; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Leith KH, 2004, BRAIN INJURY, V18, P1191, DOI 10.1080/02699050410001719943; Marr A., 2004, CENTRAL NERVOUS SYST; McCarthy ML, 2005, J TRAUMA, V58, P154, DOI 10.1097/01.TA.0000119690.32257.B0; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; National Institutes of Health (NIH) National Cancer Institute (NCI) & Office of Cancer Communications (OCC), 2002, MAK HLTH COMM PROGR; PICKELSIMER E, 2002, BRIAN INJ SOURCE, V6, P18; Reid SR, 2001, ARCH PEDIAT ADOL MED, V155, P784, DOI 10.1001/archpedi.155.7.784; Rutland-Brown W, 2005, J HEAD TRAUMA REHAB, V20, P205, DOI 10.1097/00001199-200505000-00004; Sample PL, 2005, J HEAD TRAUMA REHAB, V20, P270, DOI 10.1097/00001199-200505000-00009; Sample PL, 2004, BRAIN INJURY, V18, P1177, DOI 10.1080/02699050410001719925; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Selassie AW, 2003, ACAD EMERG MED, V10, P1260, DOI 10.1197/S1069-6563(03)00497-4; SHORE AD, IN PRESS BRAIN INJ; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP HHS, 1989, INT CLASS DIS; Whiteneck G, 2001, COLORADO TRAUMATIC B; WHITTY RW, 1985, SOFTW MICROSYST, V4, P2, DOI 10.1049/sm.1985.0002; *WHO, 2001, INT CLASS DIS REL HL	48	77	79	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2005	20	3					196	204		10.1097/00001199-200505000-00003			9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	926ZZ	WOS:000229163500003	15908820				2022-02-06	
J	Ernst, A; Basta, D; Seidl, RO; Todt, I; Scherer, H; Clarke, A				Ernst, A; Basta, D; Seidl, RO; Todt, I; Scherer, H; Clarke, A			Management of posttraumatic vertigo	OTOLARYNGOLOGY-HEAD AND NECK SURGERY			English	Article; Proceedings Paper	107th Annual Meeting of the American-Academy-of-Otolaryngology-Head-and-Neck-Surgery-Foundation	SEP 21-24, 2003	ORLANDO, FL	Amer Acad Otolaryngol Head & Neck Surg Fdn			PAROXYSMAL POSITIONAL VERTIGO; HEAD TRAUMA; DIFFERENTIAL-DIAGNOSIS; VESTIBULAR DEFICITS; POSTURAL STABILITY; WHIPLASH INJURIES; SUPPORT-SURFACE; DIZZINESS; POSTUROGRAPHY; DISORDERS	OBJECTIVE: To evaluate patients after blunt trauma of the head, neck, and craniocervical junction (without fractures) with vertigo and to report the results of treatment after extensive diagnostics. STUDY DESIGN: Prospective study of consecutive new cases with vertigo after trauma at different periods of onset. During 2000-2002, 63 patients were examined and treated. SETTING: Regional trauma medical center for the greater Berlin Area, tertiary referral unit. RESULTS: The primary disorders included labyrinthine concussion (18), rupture of the round window membrane (6), and cervicogenic vertigo (12). The secondary disorders included otolith disorders (5), delayed endolymphatic hydrops (12), and canalolithiasis (9). The patients were free of vertigo symptoms (except cervicogenic and otolith disorder) after treatment, which consisted of habituation training, medical and surgical therapy options. The follow-up was 1 year. CONCLUSION: Posttraumatic vertigo can be treated with a high success rate once the underlying disorder has been identified. The extent of the neurotological test battery determines the precision and quality of diagnostics. Surgical measures should be an integral part of treatment modalities if conservative treatment is not effective. SIGNIFICANCE. Minor trauma of the head, neck, and craniocervical junction can have major impact on the vestibular system at different sites. Patients need to be carefully diagnosed, even if the onset of vertigo occurs a few weeks or months after the initial trauma.	UKB, Med Ctr, Dept Otolaryngol, D-12683 Berlin, Germany; Univ Hosp Berlin Charite, Benjamin Franklin Med Ctr, Dept Otolaryngol, Vestibular Res Labs, Berlin, Germany		Ernst, A (corresponding author), UKB, Med Ctr, Dept Otolaryngol, Warener Str 7, D-12683 Berlin, Germany.	ArneborgE@ukb.de					Allum JHJ, 2002, GAIT POSTURE, V16, P264, DOI 10.1016/S0966-6362(02)00011-5; Allum JHJ, 2001, GAIT POSTURE, V14, P217, DOI 10.1016/S0966-6362(01)00142-4; Allum JHJ, 1999, J VESTIBUL RES-EQUIL, V9, P223; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Clarke AH, 2003, J VESTIBUL RES-EQUIL, V13, P215; Clarke AH, 1998, EXP BRAIN RES, V121, P457, DOI 10.1007/s002210050481; COLEBATCH JG, 1994, J NEUROL NEUROSUR PS, V57, P190, DOI 10.1136/jnnp.57.2.190; Epley JM, 1996, OTOLARYNG CLIN N AM, V29, P323; Fitzgerald DC, 1996, J TRAUMA, V40, P488, DOI 10.1097/00005373-199603000-00034; Guyot JP, 2001, ANN OTO RHINOL LARYN, V110, P562, DOI 10.1177/000348940111000611; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Nolle C, 2004, J NEUROTRAUM, V21, P251, DOI 10.1089/089771504322972040; PARNES LS, 1991, OTOLARYNG HEAD NECK, V104, P52, DOI 10.1177/019459989110400111; PARNES LS, 1993, ANN OTO RHINOL LARYN, V102, P325, DOI 10.1177/000348949310200501; RUBIN AM, 1995, AM J OTOL, V16, P216; SANNA M, 1983, ORL J OTO-RHINO-LARY, V45, P216, DOI 10.1159/000275645; SHEA JJ, 1995, AM J OTOL, V16, P235; Shea JJ, 2001, OTOL NEUROTOL, V22, P465, DOI 10.1097/00129492-200107000-00009; Sjostrom H, 2003, SPINE, V28, P1725, DOI 10.1097/00007632-200308010-00018; SPITZER WO, 1995, SPINE, V20, pS1; Vibert D, 2003, ANN OTO RHINOL LARYN, V112, P246, DOI 10.1177/000348940311200310	21	77	80	0	19	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0194-5998	1097-6817		OTOLARYNG HEAD NECK	Otolaryngol. Head Neck Surg.	APR	2005	132	4					554	558		10.1016/j.otohns.2004.09.034			5	Otorhinolaryngology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Otorhinolaryngology; Surgery	912WZ	WOS:000228111900007	15806044				2022-02-06	
J	Monson, KL; Goldsmith, W; Barbaro, NM; Manley, GT				Monson, KL; Goldsmith, W; Barbaro, NM; Manley, GT			Significance of source and size in the mechanical response of human cerebral blood vessels	JOURNAL OF BIOMECHANICS			English	Article						traumatic brain injury; cerebral vessel mechanical properties; cadaver tissue; autopsy tissue	BRIDGING VEINS; BRAIN INJURY; FAILURE; FRESH	Cerebral blood vessels are frequently damaged in traumatic brain injury. Mechanical properties of fresh human cerebral vessels obtained through surgeries have been reported. Because surgical sources of human specimens are rare and produce a limited amount of material, we sought to compare the properties of more readily available cerebral arteries and veins obtained from cadavers to fresh vessel data. Additionally, because the previous study was limited to small vessels available in surgery, it was unknown how generally applicable the results were to larger cerebral arteries and veins. In the current study, large and small cerebral vessels from autopsy were stretched axially. Data from these and similar tests on fresh vessels were combined to determine the significance of source and size on mechanical properties. Structural comparisons of histological samples were additionally utilized to characterize differences. Results indicate that specimens from autopsy and surgery behave similarly except that vessels from autopsy tend to be less extensible. While tests on large vessels were limited, small arteries obtained from autopsy tended to be slightly stiffer than large arteries. In contrast, bridging veins from cadavers were typically stiffer and stretched less before structural failure than cortical veins from the same source. These effects are, however, secondary to differences identified between arteries and veins in the previous study. (c) 2004 Elsevier Ltd. All rights reserved.	Univ Calif Berkeley, Dept Mech Engn, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA		Monson, KL (corresponding author), Univ Calif Berkeley, Dept Neurol Surg, 2163 Etcheverry Hall, Berkeley, CA 94720 USA.	kmonson@me.berkeley.edu	Monson, Ken/L-4702-2019	Monson, Ken/0000-0002-8461-6034	ODCDC CDC HHS [R49 CCR919722-01] Funding Source: Medline		ALCOLADO R, 1988, NEUROPATH APPL NEURO, V14, P1, DOI 10.1111/j.1365-2990.1988.tb00862.x; Bandak F.A., 1994, P 38 STAPP CAR CRASH; Brossollet LJ, 1997, J BIOMECH ENG-T ASME, V119, P1, DOI 10.1115/1.2796059; BUSBY DE, 1965, CAN J PHYSIOL PHARM, V43, P185, DOI 10.1139/y65-018; CHALUPNIK JD, 1971, MATERIAL PROPERTIES; Gentner JM, 1998, CELL MOL BIOL, V44, P251; Graham D.I., 1996, NEUROTRAUMA, P43; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Pang Q, 2001, J VASC RES, V38, P83, DOI 10.1159/000051033; SCOTT S, 1972, CAN J PHYSIOL PHARM, V50, P328, DOI 10.1139/y72-049; SMITH RW, 1979, P 23 STAPP CAR CRASH, P545; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; VOSSOUGHI J, 1996, TRAUMATIC BRAIN INJU, pCH23; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121; Zhang Liying, 2002, Stapp Car Crash J, V46, P145	17	77	77	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	APR	2005	38	4					737	744		10.1016/j.jbiomech.2004.05.004			8	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	905SQ	WOS:000227590400011	15713294				2022-02-06	
J	Esen, F; Erdem, T; Aktan, D; Orhan, M; Kaya, M; Eraksoy, H; Cakar, N; Telci, L				Esen, F; Erdem, T; Aktan, D; Orhan, M; Kaya, M; Eraksoy, H; Cakar, N; Telci, L			Effect of magnesium sulfate administration on blood-brain barrier in a rat model of intraperitoneal sepsis: a randomized controlled experimental study	CRITICAL CARE			English	Article						blood-brain barrier; brain edema; magnesium; sepsis; septic encephalopathy	CLOSED-HEAD INJURY; SEPTIC ENCEPHALOPATHY; CEREBRAL EDEMA; PERMEABILITY; THERAPY	Introduction Permeability changes in the blood - brain barrier (BBB) and their possible contribution to brain edema formation have a crucial role in the pathophysiology of septic encephalopathy. Magnesium sulfate has been shown to have a protective effect on BBB integrity in multiple experimental models. In this study we determine whether magnesium sulfate administration could have any protective effects on BBB derangement in a rat model of sepsis. Methods This randomized controlled experimental study was performed on adult male Sprague Dawley rats. Intraperitoneal sepsis was induced by using the infected fibrin - thrombin clot model. To examine the effect of magnesium in septic and sham-operated rats, a dose of 750 mu mol/kg magnesium sulfate was given intramuscularly immediately after surgery. Control groups for both infected and sham-operated rats were injected with equal volume of saline. Those rats surviving for 24 hours were anesthetized and decapitated for the investigation of brain tissue specific gravity and BBB integrity by the spectrophotometric assay of Evans blue dye extravasations. Another set of experiments was performed for hemodynamic measurements and plasma magnesium level analysis. Rats were allocated into four parallel groups undergoing identical procedures. Results Sepsis significantly increased BBB permeability to Evans blue. The dye content of each hemisphere was significantly lower in the magnesium-treated septic rats ( left hemisphere, 0.00218 +/- 0.0005; right hemisphere, 0.00199 +/- 0.0007 [ all results are means +/- standard deviation]) than in control septic animals ( left hemisphere, 0.00466 +/- 0.0002; right hemisphere, 0.00641 +/- 0.0003). In septic animals treated with magnesium sulfate, specific gravity was higher ( left hemisphere, 1.0438 +/- 0.0007; right hemisphere, 1.0439 +/- 0.0004) than in the untreated septic animals ( left hemisphere, 1.0429 +/- 0.0009; right hemisphere, 1.0424 +/- 0.0012), indicating less edema formation with the administration of magnesium. A significant decrease in plasma magnesium levels was observed 24 hours after the induction of sepsis. The dose of magnesium that we used maintained the baseline plasma magnesium levels in magnesium-treated septic rats. Conclusions Magnesium administration attenuated the increased BBB permeability defect and caused a reduction in brain edema formation in our rat model of intraperitoneal sepsis.	Univ Istanbul, Istanbul Fac Med, Dept Anesthesiol & Intens Care, Istanbul, Turkey; Univ Istanbul, Istanbul Fac Med, Dept Physiol, Istanbul, Turkey; Univ Istanbul, Istanbul Fac Med, Dept Infect Dis & Clin Microbiol, Istanbul, Turkey		Esen, F (corresponding author), Univ Istanbul, Istanbul Fac Med, Dept Anesthesiol & Intens Care, Istanbul, Turkey.	esenf@istanbul.edu.tr	Esen, Figen/AAS-6115-2020; Sungur, Mukadder Orhan/A-6574-2017; ERAKSOY, HALUK/AAE-4843-2020	Sungur, Mukadder Orhan/0000-0002-0770-8904; Cakar, Nahit/0000-0002-1302-9596; ESEN, FIGEN/0000-0003-4419-4903			ARNOLD A, 1995, ANAESTHESIA, V50, P203, DOI 10.1111/j.1365-2044.1995.tb04556.x; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Basler T, 2002, INTENS CARE MED, V28, P293, DOI 10.1007/s00134-002-1217-6; Bogdanski R, 2000, ANESTHESIOLOGY, V93, P793, DOI 10.1097/00000542-200009000-00029; BOLTON CF, 1993, ANN NEUROL, V33, P94, DOI 10.1002/ana.410330115; CLAWSON CC, 1966, J COMP NEUROL, V127, P183; DENG XM, 1995, J APPL PHYSIOL, V78, P2052, DOI 10.1152/jappl.1995.78.6.2052; Esen F, 2003, J NEUROSURG ANESTH, V15, P119, DOI 10.1097/00008506-200304000-00009; FREUND HR, 1985, J SURG RES, V38, P267, DOI 10.1016/0022-4804(85)90037-X; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; JEPPSSON B, 1981, AM J SURG, V141, P136, DOI 10.1016/0002-9610(81)90026-X; Kaya M, 2001, CAN J PHYSIOL PHARM, V79, P793, DOI 10.1139/cjpp-79-9-793; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; Mathiak G, 2000, CRIT CARE MED, V28, P1947, DOI 10.1097/00003246-200006000-00043; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MILLER CF, 1987, AM J PHYSIOL, V253, pH956, DOI 10.1152/ajpheart.1987.253.4.H956; MOULIN GC, 1985, BRAIN RES, V340, P261; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OPPELT WW, 1963, AM J PHYSIOL, V205, P959, DOI 10.1152/ajplegacy.1963.205.5.959; Papadopoulos MC, 1999, CLIN SCI, V96, P461, DOI 10.1042/CS19980327; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; PENDLEBURY WW, 1989, J NEUROPATH EXP NEUR, V48, P290, DOI 10.1097/00005072-198905000-00006; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; Ustun ME, 2001, INTENS CARE MED, V27, P264, DOI 10.1007/s001340000780; VANDENBRINK WA, 1990, ACTA NEUROCHIR SUPP, V55, P261	28	77	79	0	9	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1466-609X			CRIT CARE	Crit. Care	FEB	2005	9	1					R18	R23		10.1186/cc3004			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	905RQ	WOS:000227587700005	15693962	Green Published, gold			2022-02-06	
J	Hang, CH; Shi, JX; Li, JS; Li, WQ; Wu, W				Hang, CH; Shi, JX; Li, JS; Li, WQ; Wu, W			Expressions of intestinal NF-kappa B, TNF-alpha, and IL-6 following traumatic brain injury in rats	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; NF-kappa B; TNF-alpha; IL-6; inflammation; intestine	MULTIPLE ORGAN DYSFUNCTION; IN-VIVO; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; GENE-EXPRESSION; CECAL LIGATION; ACTIVATION; PERMEABILITY; CYTOKINE; ENDOTOXEMIA	Background. NF-kappaB regulates a large number of genes involved in the inflammatory response to critical illness, but it is not well known if and how NF-kappaB is activated in the gut following traumatic brain injury (TBI) and what is the role of cytokine-mediated inflammation in the pathogenesis of acute gut mucosal injury. Materials and methods. Male Wistar rats were randomly divided into control and TBI groups, each of which was subgrouped at hours 3, 12, 24, and 72 and on day 7. Parietal brain contusion was produced by a free-falling weight on the exposed dura of the right parietal lobe. NF-kappaB binding activity in jejunal tissue was measured using EMSA and the concentrations of TNF-alpha and IL-6 were detected using ELISA. Results. NF-kappaB binding activity in the jejunum was significantly increased at 3 h following TBI, was maximal at 72 h, and remained elevated by 7 days post-injury. TNF-alpha and IL-6 concentrations were also significantly increased by 3 h postinjury, but peaked at 24 h and remained elevated on Day 7 postinjury. Conclusions. TBI induced a rapid and persistent up-regulation of NF-kappaB and proinflammatory cytokines in the gut, which may play an important role in the pathogenesis of acute gut mucosal injury mediated by inflammation. (C) 2004 Elsevier Inc. All rights reserved.	Nanjing Univ, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China; Nanjing Univ, Jinling Hosp, Sch Clin Med, Res Inst Gen Surg, Nanjing 210002, Peoples R China		Hang, CH (corresponding author), Nanjing Univ, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Peoples R China.	hang1965@public1.ptt.js.cn					BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blackwell TS, 1996, J IMMUNOL, V157, P1630; BLACKWELL TS, 1994, AM J RESP CELL MOL, V11, P464, DOI 10.1165/ajrcmb.11.4.7917314; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; Essani NA, 1997, SHOCK, V7, P90, DOI 10.1097/00024382-199702000-00003; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fiocchi C, 1997, AM J PHYSIOL-GASTR L, V273, pG769, DOI 10.1152/ajpgi.1997.273.4.G769; Gong JP, 2002, WORLD J GASTROENTERO, V8, P923, DOI 10.3748/wjg.v8.i5.923; Gong JP, 2002, WORLD J GASTROENTERO, V8, P346; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; HUANG L, 1994, IMMUNOLOGY, V83, P65; LANGKAMPHENKEN B, 1995, CRIT CARE MED, V23, P660, DOI 10.1097/00003246-199504000-00013; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Liu SF, 1997, J IMMUNOL, V159, P3976; Magnotti LJ, 1998, ANN SURG, V228, P518, DOI 10.1097/00000658-199810000-00008; MESTER M, 1993, J SURG RES, V54, P584, DOI 10.1006/jsre.1993.1089; MEYER TA, 1995, SURGERY, V118, P336, DOI 10.1016/S0039-6060(05)80342-3; Neurath MF, 1997, IMMUNOBIOLOGY, V198, P91, DOI 10.1016/S0171-2985(97)80030-7; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Parikh AA, 1997, J SURG RES, V69, P139, DOI 10.1006/jsre.1997.5061; Pritts TA, 2000, ARCH SURG-CHICAGO, V135, P860, DOI 10.1001/archsurg.135.7.860; Pritts TA, 1998, ARCH SURG-CHICAGO, V133, P1311, DOI 10.1001/archsurg.133.12.1311; Schottelius AJG, 1999, INT J COLORECTAL DIS, V14, P18, DOI 10.1007/s003840050178; Shenkar R, 1996, AM J PHYSIOL-LUNG C, V270, pL729, DOI 10.1152/ajplung.1996.270.5.L729; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405; Spies M, 2002, AM J PHYSIOL-GASTR L, V283, pG703, DOI 10.1152/ajpgi.00149.2001; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Tu B, 2003, WORLD J GASTROENTERO, V9, P179, DOI 10.3748/wjg.v9.i1.179; Wang JP, 1998, J MATER PROCESS TECH, V74, P1, DOI 10.1016/S0924-0136(97)00241-0; Wu RQ, 2002, WORLD J GASTROENTERO, V8, P131, DOI 10.3748/wjg.v8.i1.131; Wu RQ, 2001, WORLD J GASTROENTERO, V7, P128; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zhou W, 2003, WORLD J GASTROENTERO, V9, P1567, DOI 10.3748/wjg.v9.i7.1567	39	77	91	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	FEB	2005	123	2					188	193		10.1016/j.jss.2004.08.002			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	902ER	WOS:000227337500004	15680377				2022-02-06	
J	Shacka, JJ; Roth, KA				Shacka, John J.; Roth, Kevin A.			Regulation of Neuronal Cell Death and Neurodegeneration by Members of the Bcl-2 Family: Therapeutic Implications	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article								The Bcl-2 family of proteins contains both anti and pro-apoptotic members that have been shown to regulate neuronal cell death during development and in many models of acute and chronic neurodegeneration. This family of proteins can be divided into three distinct classes based on structure and function: the antiapoptotic sub-group; the pro-apoptotic, multi-domain sub-group; and the pro-apoptotic, BH3 domain-only sub-group. Alterations in the expression of Bcl-2 family members occur in several animal and human neurodegenerative diseases including Alzheimer's, Huntington's and Parkinson's diseases and Amyotrophic Lateral Sclerosis. Similar changes are seen in in vivo and in vitro models of acute neurodegeneration, including stroke and traumatic brain injury. Methods to increase the overall expression and/or function of anti-apoptotic Bcl-2 family members, and thus promote neuron survival, have been studied extensively in these models. Most treatment efforts focus on either the targeted delivery via viral vectors of anti-apoptotic members of Bcl-2 family members into the affected brain regions of interest, the generation of direct interactions of small molecule inhibitors with Bcl-2 family members, or the induced expression of Bcl-2 family members secondary to pharmacological manipulation. Although many challenges exist in the design of safe and efficacious Bcl-2 family mimetics for the treatment of neurodegeneration, such strategies offer great promise for preserving neuron viability, and hopefully function, in a variety of human neurological diseases.	[Shacka, John J.; Roth, Kevin A.] Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA		Shacka, JJ (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA.	jshacka@path.uab.edu		Roth, Kevin/0000-0002-0643-995X			Aleyasin H, 2004, J NEUROSCI, V24, P2963, DOI 10.1523/JNEUROSCI.0155-04.2004; Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Antonawich FJ, 1999, EXP NEUROL, V156, P130, DOI 10.1006/exnr.1998.7004; Antonawich FJ, 2002, BRAIN RES BULL, V57, P647, DOI 10.1016/S0361-9230(01)00761-4; Antonawich FJ, 1998, J CEREBR BLOOD F MET, V18, P882, DOI 10.1097/00004647-199808000-00008; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Arango-Davila CA, 2004, NEUROREPORT, V15, P1437, DOI 10.1097/01.wnr.0000131010.74494.75; Ay I, 2001, MOL BRAIN RES, V87, P71, DOI 10.1016/S0169-328X(00)00285-0; Azzouz M, 2000, HUM MOL GENET, V9, P803, DOI 10.1093/hmg/9.5.803; Baba N, 1999, BRAIN RES, V827, P122, DOI 10.1016/S0006-8993(99)01315-3; Bahr BA, 2002, J NEUROCHEM, V83, P481, DOI 10.1046/j.1471-4159.2002.01192.x; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Belcredito S, 2001, BRAIN RES REV, V37, P335, DOI 10.1016/S0165-0173(01)00138-2; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, BIOCHEM CELL BIOL, V72, P463, DOI 10.1139/o94-062; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cantara S, 2004, J VASC RES, V41, P202, DOI 10.1159/000077408; Cao GD, 2002, J NEUROSCI, V22, P5423; Cao YJ, 2002, GENE THER, V9, P415, DOI 10.1038/sj.gt.3301676; Cardona-Gomez GP, 2001, BRAIN RES REV, V37, P320, DOI 10.1016/S0165-0173(01)00137-0; Cartron PF, 2004, J BIOL CHEM, V279, P11503, DOI 10.1074/jbc.M311922200; Castro R.E, 2004, J PHARM EXP THER; Cataldo AM, 1996, J NEUROSCI, V16, P186; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chen G, 1999, J NEUROCHEM, V72, P879, DOI 10.1046/j.1471-4159.1999.720879.x; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Chen RW, 1999, J BIOL CHEM, V274, P6039, DOI 10.1074/jbc.274.10.6039; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Chiu SM, 2003, BRIT J CANCER, V89, P1590, DOI 10.1038/sj.bjc.6601298; Choi JM, 2002, J PHARMACOL EXP THER, V300, P787, DOI 10.1124/jpet.300.3.787; Chuang DM, 2002, BIPOLAR DISORD, V4, P129, DOI 10.1034/j.1399-5618.2002.01179.x; D'Sa C, 2003, J NEUROSCI RES, V74, P435, DOI 10.1002/jnr.10738; D'Sa-Eipper C, 2001, DEVELOPMENT, V128, P137; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; delPeso L, 1997, SCIENCE, V278, P687; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Dhar S, 2002, ANN NEUROL, V51, P448, DOI 10.1002/ana.10143; Dubal DB, 1999, J NEUROSCI, V19, P6385; Eberspacher E, 2003, J NEUROSURG ANESTH, V15, P200, DOI 10.1097/00008506-200307000-00007; Ekegren T, 1999, ACTA NEUROL SCAND, V100, P317; Embacher N, 2001, ACTA NEUROPATHOL, V102, P426; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Fernando RI, 2004, MOL BIOL CELL, V15, P3266, DOI 10.1091/mbc.E03-11-0823; FERRANTE RJ, 1991, J NEUROSCI, V11, P3877; Ferrer I, 2003, J NEUROPATH EXP NEUR, V62, P329, DOI 10.1093/jnen/62.4.329; Ferrer I, 1998, EXP BRAIN RES, V121, P167, DOI 10.1007/s002210050448; Fink DJ, 2003, EXP NEUROL, V184, pS19, DOI 10.1016/S0014-4886(03)00358-3; Frankel SR, 2003, SEMIN ONCOL, V30, P300, DOI 10.1053/sonc.2003.50041; Galas MC, 2004, NEUROBIOL DIS, V15, P152, DOI 10.1016/j.nbd.2003.09.013; Ghribi O, 2001, NEUROBIOL DIS, V8, P764, DOI 10.1006/nbdi.2001.0429; GILLARDON F, 1994, EUR J NEUROSCI, V6, P1641, DOI 10.1111/j.1460-9568.1994.tb00555.x; Gillardon F, 1996, J NEUROSCI RES, V43, P726, DOI 10.1002/(SICI)1097-4547(19960315)43:6<726::AID-JNR9>3.3.CO;2-Z; Gillardon F, 1996, BRAIN RES, V739, P244, DOI 10.1016/S0006-8993(96)00829-3; Gillardon F, 1996, NEUROSCI LETT, V207, P113, DOI 10.1016/0304-3940(96)12508-8; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guegan C, 2002, MOL CELL NEUROSCI, V20, P553, DOI 10.1006/mcne.2002.1136; Guegan C, 1998, EXP NEUROL, V154, P371, DOI 10.1006/exnr.1998.6913; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; Hartmann A, 2002, NEUROBIOL DIS, V10, P28, DOI 10.1006/nbdi.2002.0494; Hartmann A, 2001, J NEUROCHEM, V76, P1785, DOI 10.1046/j.1471-4159.2001.00160.x; Hashimoto Y, 2001, J NEUROSCI, V21, P9235, DOI 10.1523/JNEUROSCI.21-23-09235.2001; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; Hata R, 1999, METAB BRAIN DIS, V14, P117, DOI 10.1023/A:1020709814456; Hayashi K, 2001, GENE THER, V8, P1167, DOI 10.1038/sj.gt.3301498; Higuchi H, 2001, J PHARMACOL EXP THER, V299, P866; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; Hong KW, 2002, J PHARMACOL EXP THER, V301, P210, DOI 10.1124/jpet.301.1.210; Horowitz JM, 2003, BRAIN RES BULL, V62, P55, DOI 10.1016/j.brainresbull.2003.08.005; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Imaizumi K, 1999, J BIOL CHEM, V274, P7975, DOI 10.1074/jbc.274.12.7975; Imaizumi K, 2004, J NEUROSCI, V24, P3721, DOI 10.1523/JNEUROSCI.5101-03.2004; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Ingall Timothy, 2004, J Insur Med, V36, P143; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Isenmann S, 1997, EUR J NEUROSCI, V9, P1763, DOI 10.1111/j.1460-9568.1997.tb01534.x; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Ji JF, 2002, J NEUROSCI RES, V69, P406, DOI 10.1002/jnr.10300; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kanazawa K, 1998, MOL BRAIN RES, V54, P316, DOI 10.1016/S0169-328X(97)00360-4; Kawatani M, 2003, J BIOL CHEM, V278, P19732, DOI 10.1074/jbc.M213038200; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kilic E, 2002, NEUROBIOL DIS, V11, P275, DOI 10.1006/nbdi.2002.0552; Kim ES, 1998, MOL BRAIN RES, V62, P122, DOI 10.1016/S0169-328X(98)00217-4; Kim GW, 2001, STROKE, V32, P1401, DOI 10.1161/01.STR.32.6.1401; Kim KY, 2004, EUR J PHARMACOL, V497, P267, DOI 10.1016/j.ejphar.2004.06.058; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; Klasa RJ, 2002, ANTISENSE NUCLEIC A, V12, P193, DOI 10.1089/108729002760220798; Kopnisky KL, 2003, NEUROSCIENCE, V116, P425, DOI 10.1016/S0306-4522(02)00573-0; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Kupsch A, 2001, J NEURAL TRANSM, V108, P985, DOI 10.1007/s007020170018; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Leinninger G.M, 2004, FASEB J; Lenhard T, 2002, MOL CELL NEUROSCI, V20, P181, DOI 10.1006/mcne.2002.1134; Leonard JR, 2001, DEV BRAIN RES, V128, P187, DOI 10.1016/S0165-3806(01)00174-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Linseman DA, 2002, J NEUROSCI, V22, P9287; Luetjens CM, 2001, NEUROSCIENCE, V102, P139, DOI 10.1016/S0306-4522(00)00458-9; Luo Chun, 2002, Chin J Traumatol, V5, P299; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Marshall KA, 1997, BIOCHEM BIOPH RES CO, V240, P84, DOI 10.1006/bbrc.1997.7604; Martin LJ, 1999, J NEUROPATH EXP NEUR, V58, P459, DOI 10.1097/00005072-199905000-00005; Maruyama W, 2002, NEUROTOXICOL TERATOL, V24, P675, DOI 10.1016/S0892-0362(02)00221-0; MERRY DE, 1994, DEVELOPMENT, V120, P301; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Minami M, 2000, NEUROSCI LETT, V279, P193, DOI 10.1016/S0304-3940(99)00987-8; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Mladenovic A, 2004, BRAIN RES, V996, P237, DOI 10.1016/j.brainres.2003.10.035; Mogi M, 1996, NEUROSCI LETT, V215, P137, DOI 10.1016/0304-3940(96)12961-X; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Mu XJ, 1996, ANN NEUROL, V40, P379, DOI 10.1002/ana.410400307; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Natsume A, 2001, EXP NEUROL, V169, P231, DOI 10.1006/exnr.2001.7671; Niikura T, 2004, J NEUROSCI RES, V77, P54, DOI 10.1002/jnr.20139; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; OBarr S, 1996, NEUROBIOL AGING, V17, P131, DOI 10.1016/0197-4580(95)02024-1; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Offen D, 2001, NEUROSCI LETT, V316, P129, DOI 10.1016/S0304-3940(01)02344-8; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Otake Yoko, 2004, Curr Opin Investig Drugs, V5, P616; Panizzon KL, 1998, NEUROREPORT, V9, P4131, DOI 10.1097/00001756-199812210-00024; Paradis E, 1996, J NEUROSCI, V16, P7533; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; Pepper C, 2002, LEUKEMIA LYMPHOMA, V43, P2003, DOI 10.1080/1042819021000015961; Perovic S, 1998, MECH AGEING DEV, V101, P1, DOI 10.1016/S0047-6374(97)00152-8; Pike CJ, 1999, J NEUROCHEM, V72, P1552, DOI 10.1046/j.1471-4159.1999.721552.x; Plesnila N, 2002, EUR SURG RES, V34, P37, DOI 10.1159/000048885; Prehn JHM, 1996, MOL PHARMACOL, V49, P319; Przedborski S, 2004, NEUROLOGIST, V10, P1, DOI 10.1097/01.nrl.0000106920.84668.37; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Putcha GV, 2002, J CELL BIOL, V157, P441, DOI 10.1083/jcb.200110108; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Ramalho RM, 2004, J NEUROCHEM, V90, P567, DOI 10.1111/j.1471-4159.2004.02517.x; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; REGEUR L, 1994, NEUROBIOL AGING, V15, P347, DOI 10.1016/0197-4580(94)90030-2; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rodrigues CMP, 2003, P NATL ACAD SCI USA, V100, P6087, DOI 10.1073/pnas.1031632100; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Roth KA, 2000, P NATL ACAD SCI USA, V97, P466, DOI 10.1073/pnas.97.1.466; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; Roth W, 2003, CELL DEATH DIFFER, V10, P1178, DOI 10.1038/sj.cdd.4401287; Sagi Y, 2003, J NEUROCHEM, V86, P290, DOI 10.1046/j.1471-4159.2003.01801.x; Saille C, 1999, NEUROSCIENCE, V92, P1455, DOI 10.1016/S0306-4522(99)00089-5; SATOU T, 1995, BRAIN RES, V697, P35, DOI 10.1016/0006-8993(95)00748-F; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schabitz WR, 2000, STROKE, V31, P2212, DOI 10.1161/01.STR.31.9.2212; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Selznick LA, 2000, J NEUROPATH EXP NEUR, V59, P271, DOI 10.1093/jnen/59.4.271; Sengupta TK, 2004, J BIOL CHEM, V279, P10855, DOI 10.1074/jbc.M309111200; Seo S.Y, 2004, J BIOL CHEM; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Shibata M, 2002, J CEREBR BLOOD F MET, V22, P810, DOI 10.1097/00004647-200207000-00006; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Shimazaki K, 2000, GENE THER, V7, P1244, DOI 10.1038/sj.gt.3301211; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimohama S, 1998, BIOCHEM BIOPH RES CO, V252, P92, DOI 10.1006/bbrc.1998.9577; Shindler KS, 1998, CELL DEATH DIFFER, V5, P901, DOI 10.1038/sj.cdd.4400421; Shinoe T, 2001, NEUROSCI LETT, V313, P153, DOI 10.1016/S0304-3940(01)02250-9; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Sribnick EA, 2004, J NEUROSCI RES, V76, P688, DOI 10.1002/jnr.20124; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Stern MB, 2004, MOVEMENT DISORD, V19, P916, DOI 10.1002/mds.20145; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; Su JH, 1996, NEUROREPORT, V7, P437, DOI 10.1097/00001756-199601310-00015; Su JH, 1997, J NEUROPATH EXP NEUR, V56, P86, DOI 10.1097/00005072-199701000-00009; Sugioka R, 2003, ONCOGENE, V22, P8432, DOI 10.1038/sj.onc.1207180; Sun W, 2003, J NEUROSCI, V23, P7298, DOI 10.1523/jneurosci.23-19-07298.2003; Sun Y, 2003, GENE THER, V10, P115, DOI 10.1038/sj.gt.3301868; Terradillos O, 2002, FEBS LETT, V522, P29, DOI 10.1016/S0014-5793(02)02871-5; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Tortosa A, 1998, ACTA NEUROPATHOL, V95, P407, DOI 10.1007/s004010050817; Tortosa A, 1997, NEUROSCI LETT, V238, P78, DOI 10.1016/S0304-3940(97)00837-9; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Tsuzuki N, 2001, NEUROL RES, V23, P417, DOI 10.1179/016164101101198659; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vis JC, 2001, NEUROPATH APPL NEURO, V27, P68, DOI 10.1046/j.0305-1846.2001.00305.x; Vukosavic S, 1999, J NEUROCHEM, V73, P2460, DOI 10.1046/j.1471-4159.1999.0732460.x; Vyas S, 1997, J NEUROCHEM, V69, P223; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wang GQ, 2001, J EXP MED, V194, P1325, DOI 10.1084/jem.194.9.1325; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang LH, 2004, ANNU REV PHARMACOL, V44, P451, DOI 10.1146/annurev.pharmtox.44.101802.121840; Wang R, 2001, NEUROREPORT, V12, P2629, DOI 10.1097/00001756-200108280-00009; Wang R, 2001, EUR J PHARMACOL, V421, P149, DOI 10.1016/S0014-2999(01)01030-5; Wang ZM, 2002, OTOL NEUROTOL, V23, P397, DOI 10.1097/00129492-200205000-00029; Wei H, 2001, NEUROSCIENCE, V106, P603, DOI 10.1016/S0306-4522(01)00311-6; Wei HF, 2000, EUR J PHARMACOL, V392, P117, DOI 10.1016/S0014-2999(00)00127-8; Wei MC, 2000, GENE DEV, V14, P2060; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; White FA, 1998, J NEUROSCI, V18, P1428; Wiessner C, 1999, NEUROSCI LETT, V268, P119, DOI 10.1016/S0304-3940(99)00392-4; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamada M, 2001, EXP NEUROL, V168, P225, DOI 10.1006/exnr.2000.7597; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yan CH, 2000, J CEREBR BLOOD F MET, V20, P620, DOI 10.1097/00004647-200003000-00020; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yin XM, 2002, J BIOL CHEM, V277, P42074, DOI 10.1074/jbc.M204991200; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Youdim MBH, 2004, NEUROPHARMACOLOGY, V46, P1130, DOI 10.1016/j.neuropharm.2004.02.005; Youdim MBH, 2003, BIOCHEM PHARMACOL, V66, P1635, DOI 10.1016/S0006-2952(03)00535-5; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zaidi AU, 2001, J NEUROSCI, V21, P169, DOI 10.1523/JNEUROSCI.21-01-00169.2001; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zhang HM, 2003, APOPTOSIS, V8, P229, DOI 10.1023/A:1023616620970; Zhang HY, 2003, NEUROSCI LETT, V340, P91, DOI 10.1016/S0304-3940(03)00023-5; Zhang Y, 2002, J CELL BIOL, V156, P519, DOI 10.1083/jcb.200110119; Zhang Y, 2003, J NEUROCHEM, V87, P1184, DOI 10.1046/j.1471-4159.2003.02105.x; Zhao H, 2003, J NEUROCHEM, V85, P1026, DOI 10.1046/j.1471-4159.2003.01756.x; Zhao LQ, 2004, BRAIN RES, V1010, P22, DOI 10.1016/j.brainres.2004.02.066; Zhu WW, 2004, MOL BRAIN RES, V126, P45, DOI 10.1016/j.molbrainres.2004.03.019; Zhu Y, 2002, J NEUROSCI, V22, P3898, DOI 10.1523/JNEUROSCI.22-10-03898.2002; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	263	77	78	1	2	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2005	4	1					25	39		10.2174/1568007053005127			15	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	VI5XE	WOS:000497826100003	15723611				2022-02-06	
J	Leith, KH; Phillips, L; Sample, PL				Leith, KH; Phillips, L; Sample, PL			Exploning the service needs and experiences of persons with TBI and their families: the South Carolina expertience	BRAIN INJURY			English	Article; Proceedings Paper	Annual Meeting of the South-Carolina-Public-Health-Association	2003	Myrtle Beach, SC	S Carolina Public Hlth Assoc			TRAUMATIC BRAIN-INJURY; QUALITATIVE RESEARCH; DECISION-MAKING; REHABILITATION; PERCEPTIONS; NARRATIVES; ACCESS; SELF	Primary objective: This article presents the results of four focus groups with persons with traumatic brain injury (TBI) and their families living in South Carolina. The objective was to learn what participants perceive their service needs to be and where they experience service gaps in the existing system of TBI services. Methods and procedures: Four focus groups were conducted. In each group, a convenience sample of persons <5 years post-injury and family members responded to 10 semi-structured questions. Main outcomes: Qualitative content analysis revealed overwhelming consensus regarding the need for (1) early, continuous, comprehensive service delivery; (2) information/education; (3) formal/informal advocacy; (4) empowerment of persons with TBI/families; and (5) human connectedness/social belonging. Conclusions: Persons with TBI and families in South Carolina experience the service system as unorganized, uneducated, unresponsive and uncaring. Effective strategies are needed that link services into an ongoing continuum of TBI care, increase TBI-specific education and awareness and foster social re-integration.	Univ S Carolina, Norman J Arnold Sch Publ Hlth, Ctr Hlth Serv & Policy Res, Columbia, SC 29208 USA; Colorado State Univ, Dept Occupat Therapy, Colorado Injury Control Res Ctr, Ft Collins, CO 80523 USA		Leith, KH (corresponding author), Carolina Plaza,Room 1121, Columbia, SC 29201 USA.	leith@sc.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U17/VVU419436-01] Funding Source: Medline		Abreu BC, 2002, BRAIN INJURY, V16, P691, DOI 10.1080/02699050210128942; American Speech and Hearing Association, 1995, ASHA S14, V37, P23; *BRAIN INJ ASS AM, 2002, WHAT IS BRAIN INJ; BRYANT B, 2002, HEALTHCARE REV NE NE, V3, P5; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CONEELY AL, 2002, BRIT J OCCUPATIONAL, V65, P356; CORRIGAN JD, IN PRESS J HEAD TRAU; Creswell JW., 1998, QUAL INQ; Darragh AR, 2001, AM J OCCUP THER, V55, P191, DOI 10.5014/ajot.55.2.191; Dean S, 2000, PSYCHOL REP, V86, P653, DOI 10.2466/pr0.2000.86.2.653; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Forbes S, 1998, QUAL HEALTH RES, V8, P736, DOI 10.1177/104973239800800602; Foster M, 2003, SOC SCI MED, V56, P2201, DOI 10.1016/S0277-9536(02)00236-8; FYFEE C, 1996, AUSTR J RURAL HLTH, V4, P232; GUILMETTE TJ, 2003, IN PRESS ARCH CLIN N; HAAS JF, 1988, ARCH PHYS MED REHAB, V69, P329; HOOPER SR, 2001, N CAROLINA MED J N, V62, P341; KAYSERJONES J, 1995, MED ANTHROPOL Q, V9, P236, DOI 10.1525/maq.1995.9.2.02a00070; Lincoln Yvonna S., 1985, NATURALISTIC INQUIRY; MCCULLOUGH LB, 1993, GERONTOLOGIST, V33, P324, DOI 10.1093/geront/33.3.324; MCDANIEL RW, 1994, NURS SCI QUART, V7, P4, DOI 10.1177/089431849400700103; MCMORDIE W R, 1991, Brain Injury, V5, P43, DOI 10.3109/02699059108998510; Miles M. B., 1994, QUALITATIVE DATA ANA, V2nd; MORGAN DL, 1998, FOCUS GROUP KIT 1 FO; Morse JM, 1995, QUALITATIVE RES METH; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Patton M.Q., 2001, QUALITATIVE RES EVAL, V3rd ed.; Patton M.Q., 1990, QUALITATIVE EVALUATI; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rauch RJ, 2001, NEUROREHABILITATION, V16, P11; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; SAMPLE PL, UNPUB THEY LAUNCHED; SANDELOWSKI M, 1995, RES NURS HEALTH, V18, P179, DOI 10.1002/nur.4770180211; Sandelowski M, 1999, RES NURS HEALTH, V22, P79, DOI 10.1002/(SICI)1098-240X(199902)22:1<79::AID-NUR9>3.0.CO;2-3; Selassie A, 2003, S CAROLINA TRAUMATIC; Silverman D., 2001, INTERPRETING QUALITA; Smith B, 1998, Perspectives, V22, P2; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Tashakkori A., 1998, MIXED METHODOLOGY CO	40	77	78	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2004	18	12					1191	1208		10.1080/02699050410001719943			18	Neurosciences; Rehabilitation	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	871BW	WOS:000225105300002	15666564				2022-02-06	
J	Cruz, J; Minoja, G; Okuchi, K; Facco, E				Cruz, J; Minoja, G; Okuchi, K; Facco, E			Successful use of the new high-dose mannitol treatment in patients with Glasgow Coma Scale scores of 3 and bilateral abnormal pupillary widening: a randomized trial	JOURNAL OF NEUROSURGERY			English	Article						head injury; brain swelling; impending brain death; mannitol; outcome	CEREBRAL BLOOD-FLOW; ACUTE BRAIN INJURY; SEVERE HEAD-INJURY; INTRACRANIAL HYPERTENSION; PERFUSION-PRESSURE; MANAGEMENT STRATEGIES; OXYGEN-CONSUMPTION; PRACTICAL SCALE; METABOLIC-RATE; ACUTE ANEMIA	Object. The authors evaluated long-term clinical outcomes in selected acutely comatose patients with severe diffuse brain swelling and recent clinical signs of impending brain death who received a novel high-dose mannitol treatment compared with those who received conventional-dose mannitol in the emergency room. Methods. Forty-four adult patients with traumatic, nonmissile-inflicted, acute, severe diffuse brain swelling were prospectively and randomly evaluated. All patients were selected based on the presence of recent clinical signs of impending brain death on the first emergency room evaluation. These signs included bilateral abnormal pupillary widening and lack of motor responses to painful stimulation (Glasgow Coma Scale score of 3). The study group (23 patients) received ultra-early and fast intravenous high-dose mannitol treatment (similar to1.4 g/kg), whereas the control group (21 patients) received half that dose (similar to0.7 g/kg). Ultra-early improvement of bilateral abnormal pupillary widening was significantly more frequent in the high-dose mannitol group than in the conventional-dose group (p < 0.02). High-dose mannitol treatment in the emergency room was also associated with significantly better 6-month clinical outcomes (p < 0.02); the best rate of favorable outcomes was 43.5%, compared with only 9.5% in the conventional-dose mannitol group. The two groups of patients were well matched with respect to all emergency room and head computerized tomography findings, as well as the timing of initial mannitol treatment (similar to80-90 minutes after the first evaluation at the scene of the injury). Comparative evaluation of bilateral pupillary widening between the scene of the injury and the emergency room showed no significant differences between groups, whereas mannitol dose dependence was statistically significant (p < 0.05), insofar as early pupillary improvement in the emergency room was concerned. Conclusions. Ultra-early high-dose mannitol administration in the emergency room is the first known treatment strategy significantly to reverse recent clinical signs of impending brain death, and also to contribute directly to improved long-term clinical outcomes for these patients who have previously been considered unsalvageable.	Comprehens Int Ctr Neuroemergencies, BR-04093970 Sao Paulo, Brazil; Univ Fed Sao Paulo, Sao Paulo, Brazil; Univ Insubria, Dept Anesthesiol & Crit Care Med, Varese, Italy; Nara Med Univ, Dept Emergency & Crit Care Med, Nara, Japan; Univ Padua E Meneghetti, Dept Pharmacol & Anesthesiol, Padua, Italy		Cruz, J (corresponding author), Comprehens Int Ctr Neuroemergencies, POB Cx Postal 57011, BR-04093970 Sao Paulo, Brazil.						BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CRUZ J, 1994, CRIT CARE MED, V22, P1465, DOI 10.1097/00003246-199409000-00018; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; CRUZ J, 1993, CRIT CARE MED, V21, P1218, DOI 10.1097/00003246-199308000-00024; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Cruz J, 1996, CRIT CARE MED, V24, P953, DOI 10.1097/00003246-199606000-00013; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; CRUZ J, 1994, J NEUROSURG, V80, P143, DOI 10.3171/jns.1994.80.1.0143; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; Cruz J, 2001, NEUROSURGERY, V49, P864; CRUZ J, 1998, NEUROLOGIC NEUROSURG, P405; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; FINNERTY FA, 1954, J CLIN INVEST, V33, P1227, DOI 10.1172/JCI102997; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Iida K, 2003, J NEUROSURG, V98, P793, DOI 10.3171/jns.2003.98.4.0793; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Narayan RK, 2001, NEW ENGL J MED, V344, P602, DOI 10.1056/NEJM200102223440810; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TEASDALE G, 1974, LANCET, V2, P81; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013	40	77	80	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2004	100	3					376	383		10.3171/jns.2004.100.3.0376			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	802TS	WOS:000220186400006	15035271				2022-02-06	
J	Rodriguez-Baeza, A; La Torre, FRD; Poca, A; Marti, M; Garnacho, A				Rodriguez-Baeza, A; La Torre, FRD; Poca, A; Marti, M; Garnacho, A			Morphological features in human cortical brain microvessels after head injury: A three-dimensional and immunocytochemical study	ANATOMICAL RECORD PART A-DISCOVERIES IN MOLECULAR CELLULAR AND EVOLUTIONARY BIOLOGY			English	Article						human cerebral cortex; head injury; cortical microvessels; morphological changes; cell damage; apoptosis	SCANNING ELECTRON-MICROSCOPE; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; CORROSION CASTS; BLOOD-FLOW; CEREBRAL MICROVESSELS; DNA FRAGMENTATION; NERVOUS-SYSTEM; CELL-DEATH; APOPTOSIS; RATS	We studied the morphology of cortical microvessels in the brains of 10 patients who had died after receiving a traumatic head injury (THI). Scanning electron microscopy (SEM) of vascular corrosion casts, confocal microscopy of histological sections after immunocytochemistry, and detection of apoptosis by terminal dUTP nick end labeling (TUNEL) were used. Microvascular casts showed an angioarchitectonic distribution that was defined as normal according to results obtained in a previous, nontraumatic series of subjects. However, when we compared them with previous works, the cast surface of some of the microvessels showed three types of morphological alterations: longitudinal folds, sunken surfaces with craters, and a significant flattening with reduction of lumen. The vessels that were primarily affected were the arterioles and capillaries of the middle and deep cortical vascular zones. Immunostaining with the monoclonal antibody MAS-336 against endothelial cells also showed the presence of longitudinal folds with a thinning of the vascular lumen, cytoplasmic round bodies, and a thickening of the endothelial cell membrane. The TUNEL technique revealed a positive staining of some endothelial cells. The structural alterations we observed indicate that microvessels undergo endothelial cell damage after THI. We suggest that this kind of lesion and the secondary functional injury to the blood-brain barrier (BBB) could play an important role in the development of the secondary lesions that these patients show in the subacute phase. (C) 2003 Wiley-Liss, Inc.	Univ Autonoma Barcelona, Dept Morphol Sci, Anat & Embryol Unit, Fac Med, Bellaterra 08193, Barcelona, Spain; Vall Hebron Hosp, Neurotraumatol Unit, Dept Neurosurg, Barcelona, Spain; Univ Autonoma Barcelona, Electron Microscopy Serv, E-08193 Barcelona, Spain; Vall hebron Traumatol Hosp, Intens Care Unit, Barcelona, Spain		Rodriguez-Baeza, A (corresponding author), Univ Autonoma Barcelona, Dept Morphol Sci, Anat & Embryol Unit, Fac Med, Bellaterra 08193, Barcelona, Spain.	alfonso.rodriguez@uab.es	Rodriguez-Baeza, Alfonso/L-8284-2014; Poca, Maria A./B-8475-2008; Garnacho, Angel/A-9309-2013	Rodriguez-Baeza, Alfonso/0000-0002-9181-5613; Poca, Maria A./0000-0002-3831-0536; 			Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Bhutto IA, 1997, OPHTHALMIC RES, V29, P12, DOI 10.1159/000267986; Bouma G J, 1995, New Horiz, V3, P384; Castejon OJ, 1998, J SUBMICR CYTOL PATH, V30, P145; CASTENHOLZ A, 1982, MIKROSKOPIE, V39, P95; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; CHRISTOFFERSON RH, 1988, SCANNING, V10, P43, DOI 10.1002/sca.4950100202; CLOWER BR, 1994, ANAT REC, V240, P104, DOI 10.1002/ar.1092400110; CLOWER BR, 1981, STROKE, V12, P501, DOI 10.1161/01.STR.12.4.501; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; DELZOPPO GJ, 1994, CEREBROVAS BRAIN MET, V6, P47; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; DUVERNOY HM, 1981, BRAIN RES BULL, V7, P519, DOI 10.1016/0361-9230(81)90007-1; FEIN JM, 1974, J NEUROSURG, V41, P49, DOI 10.3171/jns.1974.41.1.0049; Gajkowska B, 1997, ACTA NEUROBIOL EXP, V57, P203; GARCIA JH, 1994, AM J PATHOL, V145, P728; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; HIRANO A, 1994, MICROSC RES TECHNIQ, V27, P543, DOI 10.1002/jemt.1070270609; Huppertz B, 1999, ANAT EMBRYOL, V200, P1, DOI 10.1007/s004290050254; Hutchins JB, 1998, ANAT REC, V253, P79, DOI 10.1002/(SICI)1097-0185(199806)253:3<79::AID-AR4>3.0.CO;2-9; JOO F, 1989, Neurological Research, V11, P67; KAPP JP, 1982, SURG NEUROL, V18, P40, DOI 10.1016/0090-3019(82)90011-8; KONERDING MA, 1991, SCANNING MICROSCOPY, V5, P851; Konerding MA, 1995, SCANNING MICROSCOPY, V9, P1233; Lafuente JV, 1998, REV NEUROLOGIA, V26, P224, DOI 10.33588/rn.26150.981062; LAMETSCHWANDTNER A, 1984, SCAN ELECTRON MICROS, P663; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MENDELOW AD, 1983, BRIT J SURG, V70, P641, DOI 10.1002/bjs.1800701102; MIRONOV V, 1994, BRAIN RES, V660, P73, DOI 10.1016/0006-8993(94)90840-0; Murayama N, 1997, CERAMICS, V32, P445; MURILLO F, 1996, TRAUMATISMO CRANEOEN, P10; OHTANI O, 1992, SCANNING ELECT MICRO; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Reina-De La Torre F, 1998, ANAT RECORD, V251, P87, DOI 10.1002/(SICI)1097-0185(199805)251:1<87::AID-AR14>3.0.CO;2-7; RICKELS E, 1992, NEUROCHIRURGIA, V35, P99; Rodriguez-Baeza A, 1998, ANAT RECORD, V252, P176, DOI 10.1002/(SICI)1097-0185(199810)252:2<176::AID-AR3>3.0.CO;2-1; Sbarbati A, 1996, ACTA NEUROPATHOL, V92, P56, DOI 10.1007/s004010050489; SCHMIDT EE, 1988, AM J ANAT, V181, P253, DOI 10.1002/aja.1001810304; Takahashi A, 1997, ACTA NEUROPATHOL, V93, P354, DOI 10.1007/s004010050627; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAN PB, 1999, SCI MED, V6, P18; Vaz R, 1998, ACTA NEUROCHIR, V140, P76, DOI 10.1007/s007010050061; Vaz R, 1997, ACTA NEUROCHIR, V139, P215, DOI 10.1007/BF01844754; Willingham MC, 1999, J HISTOCHEM CYTOCHEM, V47, P1101, DOI 10.1177/002215549904700901; WISNIEWSKI HM, 1995, ACTA NEUROPATHOL, V90, P432; YOSHIDA Y, 1984, J CEREBR BLOOD F MET, V4, P290, DOI 10.1038/jcbfm.1984.40; Zhang J, 1998, ANAT REC, V253, P58, DOI 10.1002/(SICI)1097-0185(199804)253:2<58::AID-AR9>3.0.CO;2-A	49	77	78	1	4	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	1552-4884	1552-4892		ANAT REC PART A	Anat. Rec. Part A	JUL	2003	273A	1					583	593		10.1002/ar.a.10069			11	Anatomy & Morphology	Science Citation Index Expanded (SCI-EXPANDED)	Anatomy & Morphology	697ZU	WOS:000183973800002	12808643	Bronze			2022-02-06	
J	Witol, AD; Webbe, FM				Witol, AD; Webbe, FM			Soccer heading frequency predicts neuropsychological deficits	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						soccer; neuropsychological deficits; soccer heading; injury	TRAUMATIC BRAIN INJURY; COMPUTED-TOMOGRAPHY; FOOTBALL PLAYERS; TEST-PERFORMANCE; CONCUSSION; RECOVERY; SPORTS; MEMORY; IMPAIRMENT; IMPACT	This study investigated the presence of neuropsychological deficits associated with hitting the ball with one's head (heading) during soccer play. A neuro-cognitive test battery was administered to 60 male soccer players, high school, amateur and professional level, and 12 nonplaying control participants. The effects of currently reported heading behavior as well as that of estimated lifetime heading experience on neuropsychological test performance were examined. Players with the highest lifetime estimates of heading had poorer scores on scales measuring attention, concentration, cognitive flexibility and general intellectual functioning. Players' current level of heading was less predictive of neuro-cognitive level. Comparison of individual scores to age-appropriate norms revealed higher probabilities of clinical levels of impairment in players who reported greater lifetime frequencies of heading. Because of the worldwide popularity of the game, continued research is needed to assess the interaction between heading and soccer experience in the development of neuropsychological deficits associated with soccer play. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	Florida Inst Technol, Sch Psychol, Melbourne, FL 32901 USA		Webbe, FM (corresponding author), Florida Inst Technol, Sch Psychol, Melbourne, FL 32901 USA.		Webbe, Frank/A-8074-2009	Webbe, Frank/0000-0002-4370-5698			Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; ASHWORTH B, 1985, SCOT MED J, V30, P240, DOI 10.1177/003693308503000413; Barth JT, 1989, MILD HEAD INJURY, P257; BIGLER ED, 1988, DIAGNOSTIC CLIN NEUR; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2001, ATHLET THER TODAY, V6, P28, DOI 10.1123/att.6.1.28; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ekstrand J, 1990, Br J Sports Med, V24, P117; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; FIELDS KB, 1989, PHYSICIAN SPORTSMED, V17, P69, DOI 10.1080/00913847.1989.11709682; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HARRISON D W, 1990, Journal of Emergency Medicine, V8, P21, DOI 10.1016/0736-4679(90)90381-5; Hunt M, 1990, Br J Sports Med, V24, P265; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; KRAUS R, 1983, Z EEGEMG, V14, P209; LAMBERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676; LEHMAN LB, 1988, AM FAM PHYSICIAN, V38, P181; LEVIN HS, 1975, J PSYCHOL, V91, P223, DOI 10.1080/00223980.1975.9923946; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LUNBERG GD, 1986, JAMA-J AM MED ASSOC, V255, P2483; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MATHEWS WB, 1972, BRIT MED J, V2, P327; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROSENBERG SJ, 1984, J CLIN PSYCHOL, V40, P785, DOI 10.1002/1097-4679(198405)40:3<785::AID-JCLP2270400325>3.0.CO;2-4; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Sandelin J, 1985, Br J Sports Med, V19, P30; SHELL D, 1993, PHYSICIAN SPORTSMED, V21, P74, DOI 10.1080/00913847.1993.11710364; Shipley WC, 1940, J PSYCHOL, V9, P371, DOI 10.1080/00223980.1940.9917704; SMITH MD, 1992, PERCEPT MOTOR SKILL, V75, P955, DOI 10.2466/PMS.75.7.955-961; SMODLAKA VN, 1981, PHYSICIAN SPORTSMED, V9, P100; Smodlaka VN, 1984, PHYSICIAN SPORTSMED, V12, P127, DOI DOI 10.1080/00913847.1984.11701777; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Spreen O, 1991, COMPENDIUM NEUROPSYC; Taylor L B, 1969, Clin Neurosurg, V16, P269; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; UNTERHARNSCHEIDT F, 1970, TEX REP BIOL MED, V28, P421; Van Allen MW, 1968, CORTEX, V93, P38, DOI [10.1016/S0010-9452(68)80018-8, DOI 10.1016/S0010-9452(68)80018, 10.1016/S0010-9452(68)80018]; VANDEGEER JP, 1971, INTRO MULTIVARIATE A; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; WITOL A, 1994, ARCH CLIN NEUROPSYCH, V9, P204; ZACHARY RA, 1985, J CLIN PSYCHOL, V41, P532, DOI 10.1002/1097-4679(198507)41:4<532::AID-JCLP2270410414>3.0.CO;2-D; ZACHARY RA, 1986, SKIPLEY I LIVING SCA	59	77	77	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2003	18	4					397	417	PII S0887-6177(02)00151-8	10.1016/S0887-6177(02)00151-8			21	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	678GA	WOS:000182857100005	14591454				2022-02-06	
J	Hart, T; Whyte, J; Polansky, M; Millis, S; Hammond, FM; Sherer, M; Bushnik, T; Hanks, R; Kreutzer, J				Hart, T; Whyte, J; Polansky, M; Millis, S; Hammond, FM; Sherer, M; Bushnik, T; Hanks, R; Kreutzer, J			Concordance of patient and family report of neurobehavioral symptoms at 1 year after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; neurobehavioral manifestations; rehabilitation; treatment outcome	HEAD-INJURY; IMPAIRED AWARENESS; SELF-REPORT; DISABILITY; RELATIVES; REHABILITATION; COMMUNITY; RECOVERY; ADULTS	Objective: To determine concordance between patient and family report of neurobehavioral symptoms and problems across 6 domains of function and 3 levels of injury severity at 1 year after traumatic brain injury (TBI). Design: Prospective longitudinal design with follow-up between 10 and 14 months postinjury. Setting: Seventeen Traumatic Brain Injury Model Systems centers. Participants: A total of 267 adults with primarily moderate and severe TBI who had completed self-ratings and whose neurobehavioral symptoms had also been rated by their significant others. Interventions: Not applicable. Main Outcome Measures: Neurobehavioral Functioning Inventory-Revised, a 70-item scale with subscales assessing frequency of symptoms in motor, somatic, memory and attention, depression, communication, and aggression domains. Results: Twenty-three items showed significant differences or trends between the self- and other ratings; 18 of these were in the direction of the injured individual reporting less frequent problems. Differences were most pronounced on the depression, aggression, and memory and attention subscales. On the latter 2 subscales, patient-family concordance was higher for those with less severe injuries. However, severity effects were not clear cut. Analyses of selected rating patterns indicating clinically significant "underreporting" of symptoms revealed that these affected the depression, aggression, and memory and attention subscales more than the motor or somatic subscales. Conclusions: At 1 year post-TBI, concordance between self- and other report of neurobehavioral symptoms was moderately high overall, but varied by symptom domain. For per- sons with moderate and severe TBI, reports from significant others may be needed for a full picture of the range, severity, and clinical importance of the patient's emotional, behavioral, and cognitive difficulties.	Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19141 USA; MCP Hahnemann Sch Publ Hlth, Philadelphia, PA USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Carolinas HealthCare Syst, Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Charlotte, NC USA; Univ Mississippi, Med Ctr, Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Psychiat, Jackson, MS 39216 USA; Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; Rehabil Inst Michigan, Detroit, MI USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA		Hart, T (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474; Bushnik, Tamara/0000-0003-3328-257X			BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; WHYTE J, 1998, REHABILITATION MED P, P1191; [No title captured], DOI DOI 10.1097/00001199-199412000-00004; [No title captured]; [No title captured]; [No title captured]	27	77	77	1	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					204	213		10.1053/apmr.2003.50019			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	643QV	WOS:000180872700009	12601651				2022-02-06	
J	Cernak, I; O'Connor, C; Vink, R				Cernak, I; O'Connor, C; Vink, R			Inhibition of cyclooxygenase 2 by nimesulide improves cognitive outcome more than motor outcome following diffuse traumatic brain injury in rats	EXPERIMENTAL BRAIN RESEARCH			English	Article						neurotrauma; COX; cognition; diffuse axonal injury	INDUCIBLE CYCLOOXYGENASE; EXPRESSION; DAMAGE; INDOMETHACIN; NEURONS; COX-2; MODEL	Prostanoid synthesis is regulated by the enzyme cyclo-oxygenase (COX) that is present in at least two isoforms: COX-1, the constitutive form, and COX-2, the inducible form. Expression of COX-2 has recently been shown to be an important determinant of the cytotoxicity connected with inflammation following ischemic injury to the brain. The present study examines the temporal and spatial profiles of COX-2 expression following diffuse traumatic brain injury (TBI) in rats, and the effects of the COX-2 inhibitor nimesulide on cognitive and motor outcomes. Adult, male Sprague-Dawley rats were injured using the 2-meter impact acceleration model of diffuse TBI. At preselected time points after injury, animals were killed and the expression of COX-2 was measured in the hippocampus and parietal cortex by immunohistochemistry and Western blotting techniques. Effects of nimesulide (6 mg/kg daily over ten days) on cognitive and motor outcome was assessed in a separate group of animals using the Barnes circular maze and rotarod test, respectively. A highly significant up-regulation of COX-2 expression was found in the hippocampus as early as 3 h post-trauma and persisting for at least 12 days after TBI. In contrast, a slight but significant upregulation of COX-2 expression occurred in the cortex only at 3 days after trauma. Administration of the COX-2 inhibitor nimesulide resulted in a significant and substantial improvement in cognitive function compared to vehicle-treated controls, while motor deficits after injury was only improved at 24 It after injury. We conclude that COX-2 is involved in the development of functional deficits following diffuse TBI, particularly cognitive deficits, and that these can be improved by administration of COX-2 inhibitors.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA		Vink, R (corresponding author), Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia.	Robert.Vink@adelaide.edu.au	Cernak, Ibolja/A-6399-2008; Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X			Adams J, 1996, J NEUROCHEM, V66, P6; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BENEDEK G, 1987, CAN J NEUROL SCI, V14, P145; Brian JE, 1998, STROKE, V29, P2600, DOI 10.1161/01.STR.29.12.2600; Buccellati C, 1998, NEUROSCI LETT, V257, P123, DOI 10.1016/S0304-3940(98)00745-9; Buttar NS, 2000, MAYO CLIN PROC, V75, P1027, DOI 10.4065/75.10.1027; Candelario-Jalil E, 2000, EUR J PHARMACOL, V390, P295, DOI 10.1016/S0014-2999(99)00908-5; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; DeWitt DS, 1998, CRIT CARE MED, V26, P819, DOI 10.1097/00003246-199805000-00008; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; Koyfman L, 2000, J NEUROSURG ANESTH, V12, P44, DOI 10.1097/00008506-200001000-00009; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Parsadaniantz SM, 2000, J NEUROENDOCRINOL, V12, P766, DOI 10.1046/j.1365-2826.2000.00517.x; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Tardieu D, 2000, CARCINOGENESIS, V21, P973, DOI 10.1093/carcin/21.5.973; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wakita H, 1999, NEUROREPORT, V10, P1461, DOI 10.1097/00001756-199905140-00013; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WILLARD LB, 2000, CIRC RES, V48, P95; Willoughby DA, 2000, LANCET, V355, P646, DOI 10.1016/S0140-6736(99)12031-2; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	34	77	83	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	NOV	2002	147	2					193	199		10.1007/s00221-002-1245-z			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	621EM	WOS:000179575600007	12410334				2022-02-06	
J	Imberti, R; Bellinzona, G; Langer, M				Imberti, R; Bellinzona, G; Langer, M			Cerebral tissue PO2 and SjvO(2) changes during moderate hyperventilation in patients with severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						hyperventilation; brain tissue partial pressure of oxygen; jugular venous oxygen saturation; cerebral oxygen metabolism; intracranial pressure	SEVERE HEAD-INJURY; VENOUS OXYGEN-SATURATION; BLOOD-FLOW; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; COMATOSE PATIENTS; MANAGEMENT; METABOLISM; VASORESPONSIVITY; EXPERIENCE	Object. The aim of this study was to investigate the effects of moderate hyperventilation on intracranial pressure (ICP), jugular venous oxygen saturation ([SjvO(2)], an index of global cerebral perfusion), and brain tissue PO. (an index of local cerebral perfusion). Methods. Ninety-four tests consisting of 20-minute periods of moderate hyperventilation (27-32 mm Hg) were performed on different days in 36 patients with severe traumatic brain injury (Glasgow Coma Scale score less than or equal to 8). Moderate hyperventilation resulted in a significant reduction in average ICP, but in seven tests per-formed in five patients it was ineffective. The response of SjvO(2) and brain tissue PO2 to CO2 changes was widely variable and unpredictable. After 20 minutes of moderate hyperventilation in most tests (79.8%), both SjvO(2) and brain tissue PO2 values remained above the lower limits of normality (50% and 10 mm Hg, respectively). In contrast, in 15 tests performed in six patients (16.6% of the studied population) brain tissue PO2 decreased below 10 min Hg although the corresponding SjvO(2) values were greater than 50%. The reduction of brain tissue PO2 below 10 mm Hg was favored by the low prehyperventilation values (10 tests), higher CO, reactivity, and, possibly, by lower prehyperventilation values of cerebral per-fusion pressure. In five of those 15 tests, the prehyperventilation values of SjvO(2) were greater than 70%, a condition of relative hyperemia. The SjvO(2) decreased below 50% in four tests; the corresponding brain tissue PO. values were less than 10 min Hg in three of those tests, whereas in the fourth, the jugular venous O-2 desaturation was not detected by brain tissue PO2. The analysis of the simultaneous relative changes (prehyperventilation - posthyperventilation) of SjvO(2) and brain tissue PO2 showed that in most tests (75.5%) there was a reduction of both SjvO(2) and brain tissue PO2. In two tests moderate hyperventilation resulted in an increase of both SjvO(2) and brain tissue PO2. In the remaining 17 tests a redistribution of the cerebral blood flow was observed, leading to changes in SjvO(2) and brain tissue PO2 in opposite directions. Conclusions. Hyperventilation, even if moderate, can frequently result in harmful local reductions of cerebral perfusion that cannot be detected by assessing SjvO(2). Therefore, hyperventilation should be used with caution and should not be considered safe. This study confirms that SjvO(2) and brain tissue PO2 are two parameters that provide complementary information on brain oxygenation that is useful to reduce the risk of secondary damage. Changes in SjvO(2) and brain tissue PO2 in opposite directions indicate that data obtained from brain tissue PO2 monitoring cannot be extrapolated to evaluate the global cerebral perfusion.	IRCCS, Policlin San Matteo, Serv Anestesia & Rianimaz 2, I-27100 Pavia, Italy		Imberti, R (corresponding author), IRCCS, Policlin San Matteo, Serv Anestesia & Rianimaz 2, I-27100 Pavia, Italy.						Bruzzone P, 1998, ACT NEUR S, V71, P111; Chesnut RM, 1997, CRIT CARE MED, V25, P1275, DOI 10.1097/00003246-199708000-00011; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; FARRAR JK, 1991, J CEREB BLOOD FLOW M, V11, pS553; Feldman Z, 1997, CRIT CARE CLIN, V13, P51, DOI 10.1016/S0749-0704(05)70296-7; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Imberti R, 2000, J NEUROSURG ANESTH, V12, P124, DOI 10.1097/00008506-200004000-00011; KARIMAN K, 1983, J APPL PHYSIOL, V55, P1057, DOI 10.1152/jappl.1983.55.4.1057; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; MILLER JD, 1994, INTENS CARE MED, V20, P249, DOI 10.1007/BF01708957; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; RAICHLE ME, 1970, ARCH NEUROL-CHICAGO, V23, P394, DOI 10.1001/archneur.1970.00480290014002; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; TEASDALE G, 1974, LANCET, V2, P81; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	37	77	83	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	2002	96	1					97	102		10.3171/jns.2002.96.1.0097			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	508FY	WOS:000173079100015	11794610				2022-02-06	
J	Neugebauer, E; Bouillon, B; Bullinger, M; Wood-Dauphinee, S				Neugebauer, E; Bouillon, B; Bullinger, M; Wood-Dauphinee, S			Quality of life after multiple trauma - summary and recommendations of the consensus conference	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article; Proceedings Paper	Consensus Conference on Quality of Life after Multiple Trauma	SEP 29-OCT 02, 1999	WERMELSKIRCHEN, GERMANY	German Minist Educ & Res		quality of life; consensus conference; multiple injuries; traumatic brain injury; spinal cord injury	BRAIN INJURY	In October 1999, an international and interdisciplinary consensus conference was held about the assessment and application of quality of life (QoL) measures after multiple trauma. Four working groups represented the following patients: children with traumatic brain injury (TBI); adults with TBI, adults with multiple injuries (but without TBI), and adults with spinal cord injury. According to predefined questions, the groups tried to identify the relevant problems of the patients, at different time points after the traumatic event. A review of the existing instruments for quality of life assessment and the evidence of their application in trauma patients in the scientific literature was performed by each group. Based on the results of these literature reviews it was concluded that there are not enough data to establish "evidence-based" guidelines for QoL assessments in these patients. Nevertheless, the groups comprised of experts clinicians and methodologists, agreed on the Glasgow Outcome Scale and the SF-36 as generic tools for QoL assessment across all trauma patients. It was further recommended to use these generic tools in combination with condition-specific instruments to better reflect the specific problems of the patients. Finally, the whole group suggested that it was not appropriate to view this conference as a "final report" about QoL assessment in trauma patients, but rather it should be seen as a starting point for increased efforts to initiate clinical research projects using QoL as an outcome, to develop better instruments, and to include QoL assessments into daily routines.	Univ Cologne, Biochem & Expt Div, Dept Surg 2, D-51109 Cologne, Germany; Univ Cologne, Surg Clin, Dept Surg 2, D-51109 Cologne, Germany; Univ Hamburg, Dept Med Psychol, Hamburg, Germany; McGill Univ, Sch Phys & Occupat Therapy, Montreal, PQ, Canada		Neugebauer, E (corresponding author), Univ Cologne, Biochem & Expt Div, Dept Surg 2, Ostmerheimerstr 200, D-51109 Cologne, Germany.						Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Melchers P, 1999, RESTOR NEUROL NEUROS, V14, P153; Pirente N, 2002, UNFALLCHIRURG, V105, P413	3	77	77	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2002	20	3-4					161	167					7	Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	633MR	WOS:000180287500010	12454364				2022-02-06	
J	Zhao, XR; Bausano, B; Pike, BR; Newcomb-Fernandez, JK; Wang, KKW; Shohami, E; Ringger, NC; DeFord, SM; Anderson, DK; Hayes, RL				Zhao, XR; Bausano, B; Pike, BR; Newcomb-Fernandez, JK; Wang, KKW; Shohami, E; Ringger, NC; DeFord, SM; Anderson, DK; Hayes, RL			TNF-alpha stimulates caspase-3 activation and apoptotic cell death in primary septo-hippocampal cultures	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						apoptosis; calpain; caspase; cytokine; neural injury; proteolysis	TUMOR-NECROSIS-FACTOR; EXPERIMENTAL BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; MAITOTOXIN INDUCES CALPAIN; CLOSED-HEAD INJURY; NEURONAL APOPTOSIS; MICE LACKING; SEPTOHIPPOCAMPAL CULTURES; CEREBROSPINAL-FLUID; PROTEIN-SYNTHESIS	Primary septo-hippocampal cell cultures were incubated in varying concentrations of tumor necrosis factor (TNF-alpha; 0.3-500 ng/ml) to examine proteolysis of the cytoskeletal protein alpha -spectrin (240 kDa) to a signature 145 kDa fragment by calpain and to the apoptotic-linked 120-kDa fragment by caspase-3, The effects of TNF-alpha incubation on morphology and cell viability were assayed by fluorescein diacetate-propidium iodide (FDA-PI) staining, assays of lactate dehydrogenase (LDH) release, nuclear chromatin alterations (Hoechst 33258), and internucleosomal DNA fragmentation. Incubation with varying concentrations of TNF-alpha produced vapid increases in LDH release and nuclear PI uptake that were sustained over 48 hr. Incubation with 30 ng/ml TNF-alpha yielded maximal, 3-fold, increase in LDH release and was associated with caspase-specific 120-kDa fragment but not calpain-specific 145-kDa fragment as early as 3.5 hr after injury. Incubation with the pan-caspase inhibitor, carbobenzosy-Asp-CH2-OC (O)-2-6-dichlorobenzene (Z-D-DCB, 50-140 muM) significantly reduced LDH release produced by TNF-alpha. Apoptotic-associated oligonucleosomal-sized DNA fragmentation on agarose gels was detected from 6 to 72 hr after exposure to TNF-alpha. Histochemical changes included chromatin condensation, nuclear fragmentation, and formation of apoptotic bodies. Results of this study suggest TNf-alpha may induce caspase-3 activation but not calpain activation in septo-hippocampal cultures and that this activation of caspase-3 at least partially contributes to TNF-alpha -induced apoptosis. J. Neurosci. Res. 64,121-131, 2001. (C) 2001 Wiley-Liss, Inc.	Univ Florida, Dept Neurosci, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, Houston, TX USA; Pfizer Inc, Ann Arbor, MI USA; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Malcolm Randall VAMC, Gainesville, FL 32610 USA		Hayes, RL (corresponding author), Univ Florida, Dept Neurosci, Ctr Traumat Brain Injury Studies, 100 Newell Dr,POB 100244, Gainesville, FL 32610 USA.			Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS21458-15, R01 NS40182] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, R01NS040182] Funding Source: NIH RePORTER		Aggarwal S, 1999, J IMMUNOL, V162, P2154; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Buttini M, 1996, NEUROSCIENCE, V71, P1, DOI 10.1016/0306-4522(95)00414-9; Chen X, 1999, J COLD REG ENG, V13, P139, DOI 10.1061/(ASCE)0887-381X(1999)13:3(139); CHUNG IY, 1990, J IMMUNOL, V144, P2999; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/S0304-3940(96)13116-5; deBock F, 1996, NEUROREPORT, V7, P1125, DOI 10.1097/00001756-199604260-00004; Eldadah BA, 1997, J NEUROSCI, V17, P6105; ENDRES M, 1998, J CEREB BLOOD FLOW M, V18, P238, DOI DOI 10.1097/00004647-199803000-00002; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; GARCIAVILLALON D, 1992, ANTIVIR CHEM CHEMOTH, V3, P9, DOI 10.1177/095632029200300102; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; GELBARD HA, 1993, DEV NEUROSCI-BASEL, V15, P417, DOI 10.1159/000111367; Gillardon F, 1999, NEUROSCIENCE, V93, P1219, DOI 10.1016/S0306-4522(99)00292-4; Goeddel DV, 1999, CHEST, V116, p69S, DOI 10.1378/chest.116.suppl_1.69S; Gong C, 1998, BRAIN RES, V801, P1, DOI 10.1016/S0006-8993(98)00489-2; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; GRELL M, 1994, J IMMUNOL, V153, P1963; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KONDRATYEV A, 2000, BRAIN RES MOL BRAIN, V75, P216; Ksontini R, 1998, ARCH SURG-CHICAGO, V133, P558, DOI 10.1001/archsurg.133.5.558; Leker RR, 1999, J NEUROL SCI, V162, P114, DOI 10.1016/S0022-510X(98)00301-3; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MEIRSTRELL ME, 1997, SHOCK, V8, P341; MIOSSEC C, 1997, J BIOL CHEM, V272, P13489; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Nath R, 1998, J NEUROCHEM, V71, P186; NATH R, 1995, J NEUROSCI, V15, P1001; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; OBERHAMMER F, 1993, J CELL SCI, V104, P317; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pulliam L, 1998, J NEUROSCI RES, V54, P530, DOI 10.1002/(SICI)1097-4547(19981115)54:4<530::AID-JNR10>3.0.CO;2-1; RUFF MR, 1981, INFECT IMMUN, V31, P380, DOI 10.1128/IAI.31.1.380-385.1981; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SHARIEF MK, 1993, ANN NEUROL, V33, P591, DOI 10.1002/ana.410330606; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Uno H, 1997, J CEREBR BLOOD F MET, V17, P491, DOI 10.1097/00004647-199705000-00002; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Wang KKW, 2000, TRENDS NEUROSCI, V23, P59, DOI 10.1016/S0166-2236(99)01536-2; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; WANG XK, 1994, MOL CHEM NEUROPATHOL, V23, P103, DOI 10.1007/BF02815404; WEISSNER C, 2000, CELL MOL BIOL, V46, P53; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xu IS, 1998, NEUROSCIENCE, V85, P827, DOI 10.1016/S0306-4522(97)00676-3; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; YUEN P, 1996, BIOCHEM J, V319, P683; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	76	77	82	0	5	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	APR 15	2001	64	2					121	131		10.1002/jnr.1059			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	416UX	WOS:000167799500003	11288141				2022-02-06	
J	Naredi, S; Olivecrona, M; Lindgren, C; Ostlund, AL; Grande, PO; Koskinen, LOD				Naredi, S; Olivecrona, M; Lindgren, C; Ostlund, AL; Grande, PO; Koskinen, LOD			An outcome study of severe traumatic head injury using the "Lund therapy" with low-dose prostacyclin	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						head injury; outcome; prostacyclin	BRAIN VOLUME REGULATION; PRINCIPLES; MANAGEMENT; EDEMA	Background: There are two independent head injury outcome studies using the "Lund concept", and both showed a mortality rate of about 10%, and a favourable outcome (Glasgow outcome scale, GOS 4 and 5) of about 70%. The Lund concept aims at controlling intracranial pressure, and improving microcirculation around contusions. Intracranial pressure is controlled by maintaining a normal colloid osmotic pressure and reducing the hydrostatic capillary pressure. Microcirculation is improved by ensuring strict normovolaemia and reducing sympathetic discharge. The endogenous substance prostacyclin with its antiaggregatory/antiadhesive effects may further improve microcirculation, which finds support from a microdialysis-based clinical study and an experimental brain trauma study. The present clinical outcome study aims at evaluating whether the previously obtained good outcome with the Lund therapy can be reproduced, and whether the addition of prostacyclin has any adverse side-effects. Methods: All 31 consecutive patients with severe head injury, Glasgow coma scale (GCS) less than or equal to8, admitted to the University Hospital of Umea during 1998 were included. The Lund therapy including prostacyclin infusion for the first three days at a dose of 0.5 ng kg(-1) min(-1). Outcome was evaluated according to the GOS >10 months after the injury. Results: One patient died, another suffered vegetative state and 7 severe disability. Of the 22 patients with favourable outcome, 19 showed good recovery and 3 moderate disability. No adverse side-effects of prostacyclin were observed. Conclusion: The outcome results from previous studies using the Lund therapy were reproduced, and no adverse side-effects of low-dose prostacyclin were observed.	Univ Umea Hosp, Dept Anaesthesia & Intens Care, SE-90185 Umea, Sweden; Univ Umea Hosp, Dept Neurosurg, SE-90185 Umea, Sweden; Lund Univ, Dept Anaesthesia & Intens Care, Lund, Sweden; Univ Lund Hosp, Dept Anaesthesia & Intens Care, S-22185 Lund, Sweden		Naredi, S (corresponding author), Univ Umea Hosp, Dept Anaesthesia & Intens Care, SE-90185 Umea, Sweden.	silvana.naredi.us@vll.se	Koskinen, Lars-Owe/AAQ-8957-2020	Naredi, Silvana/0000-0002-4409-6089; Lindgren, Cecilia/0000-0002-4903-9374; Koskinen, Lars-Owe/0000-0003-3528-8502; Olivecrona, Magnus/0000-0001-8457-4711			ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; BENTZER P, 1999, J NEUROTRAUM, V16, pA979; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Eker C, 2000, BRAIN INJURY, V14, P605; Grande PO, 2000, ACTA ANAESTH SCAND, V44, P886, DOI 10.1034/j.1399-6576.2000.440718.x; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; GRYGLEWSKI RJ, 1983, STROKE, V14, P197, DOI 10.1161/01.STR.14.2.197; JENNETT B, 1975, LANCET, V1, P480; JONES G, 1984, J PATHOL, V142, P51, DOI 10.1002/path.1711420110; Moller AD, 1997, AM J PHYSIOL-HEART C, V273, pH200, DOI 10.1152/ajpheart.1997.273.1.H200; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; MONCADA S, 1978, PHARMACOL REV, V30, P293; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; ORFEO T, 1994, J TRAUMA, V37, P347, DOI 10.1097/00005373-199409000-00003; PLUTA R, 1994, ACTA NEUROCHIR, P303; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Scheeren T, 1997, INTENS CARE MED, V23, P146, DOI 10.1007/s001340050309; VANE JR, 1995, AM J CARDIOL, V75, pA3, DOI 10.1016/S0002-9149(99)80377-4	20	77	79	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2001	45	4					402	406		10.1034/j.1399-6576.2001.045004402.x			5	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	417PQ	WOS:000167843700002	11300376				2022-02-06	
J	Suehiro, E; Povlishock, JT				Suehiro, E; Povlishock, JT			Exacerbation of traumatically induced axonal injury by rapid posthypothermic rewarming and attenuation of axonal change by cyclosporin A	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; hypothermia; cyclosporin A; axonal injury; rat	AMYLOID PRECURSOR PROTEIN; DIFFUSE BRAIN INJURY; POSTTRAUMATIC HYPOTHERMIA; HEAD-INJURY; INTRACRANIAL HYPERTENSION; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; DAMAGE; MODEL	Object. Although considerable attention has been focused on the use of posttraumatic hypothermia, little consideration has been given to the issue of posthypothermic rewarming and its potentially damaging consequences. In this communication, the authors examine the issue of rapid posthypothermic rewarming compared with gradual rewarming while exploring the potential utility of cyclosporin A (CsA) administration for attenuatings any rapid rewarming-induced axonal change. Methods. Male Sprague-Dawley rats were subjected to impact-acceleration injury and then their body temperature was lowered to 32 degreesC for 1 hour postinjury. After hypothermia, rewarming to normothermic levels was accomplished either within a 20-minute period (rapid rewarming) or over a 90-minute period (slow rewarming). Some animals in the rapid rewarming group received intrathecal infusion of either CsA or its vehicle, whereas the rats in the slow rewarming group received vehicle alone. Both the CsA and its vehicle were administered immediately before initiation of rewarming. Twenty-four hours postinjury the animals' brains were processed for visualization of amyloid precursor protein (APP), a marker of traumatic axonal injury. The APP-positive axonal density in the gradual ly rewarmed group receiving vehicle was statistically significantly reduced in comparison with the rapidly rewarmed, vehicle-treated group. For the group undergoing rapid rewarming and treatment with CsA, a statistically significant reduction was also found in the density of the APP profiles compared with the rapidly rewarmed, vehicle-treated group. Conclusions. The results of this study show that rapid rewarming exacerbates traumatically induced axonal injury, which can be significantly attenuated by administering CsA.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Yamaguchi Univ, Sch Med, Dept Neurosurg, Yamaguchi, Japan		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Virginia Campus,POB 980709, Richmond, VA 23298 USA.		Suehiro, Eiichi/I-5852-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOIZUMI H, IN PRESS BRAIN RES; LeDucq N, 1998, BIOCHEM J, V336, P501, DOI 10.1042/bj3360501; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSH DC, 1991, HEPATOLOGY, V13, P500, DOI 10.1002/hep.1840130318; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Sabatini DM, 1997, MOL NEUROBIOL, V15, P223, DOI 10.1007/BF02740635; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; Wakiyama S, 1997, BRIT J SURG, V84, P459; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	31	77	79	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2001	94	3					493	498		10.3171/jns.2001.94.3.0493			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	405KB	WOS:000167157600018	11235956				2022-02-06	
J	Crouchman, M; Rossiter, L; Colaco, T; Forsyth, R				Crouchman, M; Rossiter, L; Colaco, T; Forsyth, R			A practical outcome scale for paediatric head injury	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article						head injury; traumatic brain injury; outcome scale	TRAUMATIC BRAIN INJURY; CHILDREN; CONSEQUENCES; CHILDHOOD; SEQUELAE; DAMAGE	Traumatic brain injury (TBI) is the commonest cause of acquired disability in childhood. A major obstacle to the evaluation of acute and rehabilitative therapies after TBI is the lack of simple descriptors of outcome. We developed the King's Outcome Scale for Childhood Head Injury (KOSCHI), as a specific paediatric adaptation of the original adult Glasgow Outcome Scale (GOS). The KOSCHI expands the five category GOS to provide increased sensitivity at the milder end of the disability range. The GOS category of "persistent vegetative state" was replaced by "vegetative". "Good recovery" was allocated two categories, in acknowledgement of the long term importance of relatively minor sequelae in a developing child. The scale was quick and easy to use. Inter-rater reliability studies show that even with such an apparently simple scale, some training may be required. The KOSCHI provides a practical scale for paediatric head injury which will enable clinicians to describe rate and extent of recovery, and evaluate the effects of service and research interventions.	Kings Coll London Hosp, London SE5 9RS, England; Royal Victoria Infirm, Dept Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England		Crouchman, M (corresponding author), Kings Coll London Hosp, Denmark Hill, London SE5 9RS, England.	marion.crouchman@kcl.ac.uk	Forsyth, Rob J/I-9226-2012; Forsyth, Rob/H-9193-2019	Forsyth, Rob J/0000-0002-5657-4180; Forsyth, Rob/0000-0002-5657-4180			Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; *BRIT PAED ASS, 1991, DIAGN BRAIN STEM DEA; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; CROUCHMAN MR, 1998, INJURY YOUNG, P263; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; DUNN G, 1989, DESIGN ANAL RELIABIL, P154; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P22; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; JENNETT B, 1975, LANCET, V1, P480; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Sharples PM, 1998, INJURY YOUNG, P151	21	77	79	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888			ARCH DIS CHILD	Arch. Dis. Child.	FEB	2001	84	2					120	124		10.1136/adc.84.2.120			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	395ZV	WOS:000166612600010	11159284	Green Published, Bronze			2022-02-06	
S	Weinstock, M; Kirschbaum-Slager, N; Lazarovici, P; Bejar, C; Youdim, MBH; Shoham, S		Slikker, W; Trembly, B		Weinstock, M; Kirschbaum-Slager, N; Lazarovici, P; Bejar, C; Youdim, MBH; Shoham, S			Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs	NEUROPROTECTIVE AGENTS	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	5th International Conference on Neuroprotective Agents	SEP 17-21, 2000	LAKE TAHOE, NV	Natl Ctr Toxicol Res /FDA, Cent Arkansas Chapter Sigma Xi		PC12 cells; glucose-oxygen deprivation; closed head injury; streptozotocin memory deficits	OXIDASE-B INHIBITOR; NERVE GROWTH-FACTOR; CLOSED-HEAD INJURY; RAT PHEOCHROMOCYTOMA CELLS; OXIDATIVE STRESS; PC12 CELLS; CYTOCHROME-OXIDASE; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; ENERGY-METABOLISM	TV3326, (N-propargyl-(3R)-aminoindan-5-yl-ethyl,methyl carbamate) was prepared in order to combine the neuroprotective effects of rasagiline, a selective inhibitor of monoamine oxidase (MAO)-B with the cholinesterase (ChE) inhibitory activity of rivastigmine as a potential treatment for Alzheimer's disease. The study reported here examined the neuropotective effects of TV3326 against various insults in vitro and in vivo. TV3326 caused a dose related (10-500 muM) reduction in death induced in NGF differentiated rat pheochromocytoma (PC12) cells by 3-4 hour exposure to oxygen-glucose deprivation. A single sc injection of TV3326 given five minutes after closed head injury in mice significantly reduced the cerebral edema, and accelerated the recovery of motor function and spatial memory several days later. Unilateral icv injection of streptozotocin (STZ) 1.5 mg in rats, caused specific damage to myelinated neurones in the fornix and corpus callosum accompanied by microgliosis. Three bilateral injections of STZ, 0.25 mg each, caused more widespread damage, and a marked impairment in spatial memory. Chronic oral treatment with TV3326 (75 mu mols/kg) reduced the neuronal damage and microgliosis and almost completely prevented the memory impairment. The neuroprotective effect in PC12 cells may be due to a combination of ChE inhibition and antiapoptotic activity. The latter does not result from ChE inhibition. It is associated with the presence of the propargyl group, since it occurs with other propargylamines that do not inhibit MAO, but not with drugs that inhibit only ChE.	Hebrew Univ Jerusalem, Dept Pharmacol, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel; Technion Israel Inst Technol, Fac Med, Eve Topf Ctr, Haifa, Israel; Technion Israel Inst Technol, Fac Med, NPF Ctr, Haifa, Israel		Weinstock, M (corresponding author), Hebrew Univ Jerusalem, Dept Pharmacol, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel.	martar@cc.huji.ac.il					Abu-Raya S, 1999, J NEUROSCI RES, V58, P456, DOI 10.1002/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S; Aragno M, 1999, FREE RADICAL BIO MED, V26, P1467, DOI 10.1016/S0891-5849(99)00012-X; Bastar I, 1998, RES COMMUN MOL PATH, V102, P265; Bejar C, 1999, EUR J PHARMACOL, V383, P231, DOI 10.1016/S0014-2999(99)00643-3; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BLOKLAND A, 1994, PHARMACOL BIOCHEM BE, V47, P833, DOI 10.1016/0091-3057(94)90284-4; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Calderon FH, 1999, J NEUROSCI RES, V56, P620; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; COLTON CA, 1993, ADV NEUROL, V59, P321; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DELEO JA, 1986, NEUROSCI LETT, V67, P63, DOI 10.1016/0304-3940(86)90209-0; DUELLI R, 1994, INT J DEV NEUROSCI, V12, P737, DOI 10.1016/0736-5748(94)90053-1; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Filip V, 1999, J PSYCHIATR NEUROSCI, V24, P234; Finberg JPM, 1996, J NEURAL TRANSM-SUPP, P95; Finberg JPM, 1998, NEUROREPORT, V9, P703; GALLYAS F, 1990, ACTA NEUROPATHOL, V79, P620, DOI 10.1007/BF00294239; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; HALLIWELL B, 1984, LANCET, V1, P1396; HELLWEG R, 1992, J NEUROSCI RES, V31, P479, DOI 10.1002/jnr.490310310; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x; KNOLLEMA S, 1995, STROKE, V26, P1883, DOI 10.1161/01.STR.26.10.1883; Lannert H, 1998, BEHAV NEUROSCI, V112, P1199, DOI 10.1037/0735-7044.112.5.1199; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Magyar K, 1998, J NEURAL TRANSM-SUPP, P109; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; MCGEER PL, 1994, ALZ DIS ASSOC DIS, V8, P149, DOI 10.1097/00002093-199408030-00001; MESNER PW, 1992, J CELL BIOL, V119, P1669, DOI 10.1083/jcb.119.6.1669; Morris RGM., 1983, NEUROBIOLOGY HIPPOCA, P405; Muller D, 1998, J NEURAL TRANSM, V105, P1271, DOI 10.1007/s007020050130; MULLER D, 1995, ADV BEHAV BIOL, V44, P389; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; NOAI M, 2001, IN PRESS J PHARM PHA; Prickaerts J, 1999, BEHAV BRAIN RES, V102, P73, DOI 10.1016/S0166-4328(98)00158-2; Russell JW, 1999, NEUROBIOL DIS, V6, P347, DOI 10.1006/nbdi.1999.0254; Saini KS, 1996, BIOCHEM MOL BIOL INT, V39, P1229; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Shoham S, 1997, EXP NEUROL, V147, P361, DOI 10.1006/exnr.1997.6622; SMITH MA, 1996, ALZHEIMER DIS REV, V1, P63; Svensson AL, 1998, NEUROREPORT, V9, P1519, DOI 10.1097/00001756-199805110-00050; Tatton WG, 1996, NEUROLOGY, V47, pS171, DOI 10.1212/WNL.47.6_Suppl_3.171S; TATTON WG, 1994, J NEUROCHEM, V63, P1572; Weinstock M, 1999, CNS DRUGS, V12, P307, DOI 10.2165/00023210-199912040-00005; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.3.CO;2-Q; Wu RM, 1996, ANN NY ACAD SCI, V786, P379, DOI 10.1111/j.1749-6632.1996.tb39078.x; Xiao XQ, 2000, NEUROSCI LETT, V286, P155, DOI 10.1016/S0304-3940(00)01088-0; Xiao XQ, 1999, NEUROSCI LETT, V275, P73, DOI 10.1016/S0304-3940(99)00695-3; YOUDIM MBH, 1999, NEUROSCI LETT, V54, pS45	52	77	78	0	2	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-353-X; 1-57331-352-1	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2001	939						148	161					14	Multidisciplinary Sciences; Clinical Neurology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Neurosciences & Neurology	BT12V	WOS:000172028600018	11462767				2022-02-06	
J	Thomas, S; Prins, ML; Samii, M; Hovda, DA				Thomas, S; Prins, ML; Samii, M; Hovda, DA			Cerebral metabolic response to traumatic brain injury sustained early in development: A 2-deoxy-D-glucose autoradiographic study	JOURNAL OF NEUROTRAUMA			English	Article						age; cerebral glucose metabolism; concussion; 2-deoxy-D-glucose; development; fluid percussion	CLOSED HEAD-INJURY; EXCITATORY AMINO-ACIDS; FLUID-PERCUSSION MODEL; FREELY MOVING RATS; METHYL-D-ASPARTATE; GLUCOSE-UTILIZATION; BLOOD-FLOW; CORTICAL-LESIONS; NERVOUS-SYSTEM; VISUAL-CORTEX	Following fluid percussion (FP) traumatic brain injury (TBI), adult rats exhibit dynamic regional changes in cerebral glucose metabolism characterized by an acute (hours) increase and subsequent chronic (weeks) decrease in metabolic rates, The injury-induced hyperglycolysis is the result of ionic fluxes across cell membranes and the degree and extent of metabolic depression is predictive of neurobehavioral deficits, Given that younger animals appear to exhibit similar physiological responses to injury yet show an improved rate of recovery compared to adults, we wanted to determine if this injury-induced dynamic metabolic response to TBI is different if the injury is sustained early in life, Local cerebral metabolic rates for glucose (ICMRglc: mu mol/100 g/min) using [C-14]2-deoxy-D-glucose were measured immediately, 30 min, 1 day, and 3 days following a mild to moderate level of lateral FP injury in postnatal day 17 (P17) rats. Even though gross morphological damage was not evident, injured pups exhibited ipsilateral hyperglycolysis immediately after injury, predominantly in cortical regions (ranging from 59.2% to 116.5% above controls), This hyperglycolytic state subsided within 30 min, and by I day all cerebral structures, except the ipsilateral cerebellar cortex, showed lower rates of glucose metabolism (ranging from 5.7% to 63.0% below controls). This period of posttraumatic metabolic depression resolved within 3 days for all structures measured, Compared to previous adult studies these results suggest that the young rat pup, although exhibiting acute hyperglycolysis, is not subjected to a prolonged period of metabolic depression, which supports the findings that at this level of injury severity, these young animals show remarkable neurological sparing following TBI.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Surg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Hannover Med Sch, D-3000 Hannover, Germany; Norstadt Med Ctr, Hannover, Germany		Hovda, DA (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Dept Surg, Room 18-228,Box 957039, Los Angeles, CA 90095 USA.	dhovda@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS30308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, P50NS030308] Funding Source: NIH RePORTER		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; ADELSON PD, 1998, J NEUROTRAUM, V18, P853; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BLUE ME, 1983, J NEUROCYTOL, V12, P599, DOI 10.1007/BF01181526; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COYLE JT, 1976, BRAIN RES, V111, P119, DOI 10.1016/0006-8993(76)91053-2; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; Dalmady-Israel Christina, 1993, Brain Injury, V7, P263, DOI 10.3109/02699059309029679; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EDMOND J, 1992, CAN J PHYSIOL PHARM, V70, pS118, DOI 10.1139/y92-253; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HAHN JS, 1988, P NATL ACAD SCI USA, V85, P6556, DOI 10.1073/pnas.85.17.6556; HATASHITA S, 1988, STROKE, V19, P91, DOI 10.1161/01.STR.19.1.91; Hovda D.A., 1996, NEUROTRAUMA, P1459; HOVDA DA, 1989, BEHAV BRAIN RES, V32, P231, DOI 10.1016/S0166-4328(89)80056-7; HOVDA DA, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P327; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1990, NIMODIPINE PHARM CLI, P235; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; INSEL TR, 1990, NEUROSCIENCE, V35, P31, DOI 10.1016/0306-4522(90)90117-M; JENNETT B, 1972, DEV MED CHILD NEUROL, V14, P137; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kennard MA, 1936, AM J PHYSIOL, V115, P138, DOI 10.1152/ajplegacy.1936.115.1.138; Kennard MA, 1938, J NEUROPHYSIOL, V1, P477, DOI 10.1152/jn.1938.1.6.477; Kennard MA, 1942, ARCH NEURO PSYCHIATR, V48, P227, DOI 10.1001/archneurpsyc.1942.02290080073002; KOLB B, 1986, BRAIN RES, V397, P315, DOI 10.1016/0006-8993(86)90633-5; KOLB B, 1988, BEHAV BRAIN RES, V28, P259, DOI 10.1016/0166-4328(88)90129-5; KOLB B, 1985, BEHAV BRAIN RES, V17, P25, DOI 10.1016/0166-4328(85)90005-1; KREISMAN NR, 1993, BRAIN RES, V376, P67; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LANDRY CF, 1990, J NEUROSCI RES, V25, P194, DOI 10.1002/jnr.490250207; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MARTINS AN, 1977, J NEUROSURG, V47, P346, DOI 10.3171/jns.1977.47.3.0346; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MCDONALD JW, 1990, EXP NEUROL, V110, P237, DOI 10.1016/0014-4886(90)90035-Q; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOSS ML, 1972, ACTA ANAT, V81, P161; NEHLIG A, 1989, J CEREBR BLOOD F MET, V9, P579, DOI 10.1038/jcbfm.1989.83; NEHLIG A, 1993, PROG NEUROBIOL, V40, P163, DOI 10.1016/0301-0082(93)90022-K; NEHLIG A, 1988, J NEUROSCI, V8, P2321; NEHLIG A, 1987, J CEREB BLOOD FLO S1, V7, pS522; OSTEEN C, 1998, J NEUROTRAUM, V15, P889; PICCOLI F, 1971, J NEUROCHEM, V18, P1135, DOI 10.1111/j.1471-4159.1971.tb12042.x; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; PRINS MI, 1997, J NEUROTRAUM, V14, P780; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SCHULZE C, 1992, DEV BRAIN RES, V69, P85, DOI 10.1016/0165-3806(92)90125-G; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SOKOLOFF L, 1993, DEV NEUROSCI-BASEL, V15, P194, DOI 10.1159/000111335; SPATZ M, 1978, BRAIN RES, V151, P619, DOI 10.1016/0006-8993(78)91097-1; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Villablanca JR, 2000, NEUROSCIENCE, V95, P625; VILLABLANCA JR, 1993, BEHAV BRAIN RES, V57, P63, DOI 10.1016/0166-4328(93)90062-U; WHISHAW IQ, 1988, BRAIN RES, V451, P97, DOI 10.1016/0006-8993(88)90753-6; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	83	77	77	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2000	17	8					649	665		10.1089/089771500415409			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	347WF	WOS:000088951600003	10972242				2022-02-06	
J	Weyland, A; Buhre, W; Grund, S; Ludwig, H; Kazmaier, S; Weyland, W; Sonntag, H				Weyland, A; Buhre, W; Grund, S; Ludwig, H; Kazmaier, S; Weyland, W; Sonntag, H			Cerebrovascular tone rather than intracranial pressure determines the effective downstream pressure of the cerebral circulation in the absence of intracranial hypertension	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						cerebral perfusion pressure; effective downstream pressure; intracranial pressure; pressure-flow relationship; cerebrovascular tone; cerebrovascular CO2 reactivity	CRITICAL CLOSING PRESSURE; VELOCITY RELATIONSHIPS; PERFUSION-PRESSURE; STARLING RESISTOR; FLOW; MANAGEMENT; HINDLIMB; MODEL; DOG	Cerebral perfusion pressure is commonly calculated from the difference between mean arterial pressure and intracranial pressure because intracranial pressure is known to represent the effective downstream pressure of the cerebral circulation. Studies of other organs, however, have shown that effective downstream pressure is determined by a critical closing pressure located at the arteriolar level. This study was designed to investigate the effects of PCO2-induced variations in cerebrovascular tone on the effective downstream pressure of the cerebral circulation. Sixteen patients recovering from head injury were studied. Intracranial pressure was assessed by epidural pressure transducers. Blood flow velocity in the middle cerebral artery was monitored by transcranial Doppler sonography. Effective downstream pressure was derived from the zero flow pressure as extrapolated by regression analysis of instantaneous arterial pressure/middle cerebral artery flow velocity relationships. PaCO2 was varied between 30 and 47 mm Hg in randomized sequence. Intracranial pressure decreased from 18.5 +/- 5.2 mm Hg, during hypercapnia to 9.9 +/- 3.1 mm Hg during hypocapnia. In contrast, effective downstream pressure increased from 13.7 +/- 9.6 mm Hg to 23.4 +/- 8.6 mm Hg and exceeded intracranial pressure at hypocapnic PaCO2 levels. Our results demonstrate that, in the absence of intracranial hypertension, intracranial pressure does not necessarily represent the effective downstream pressure of the cerebral circulation. Instead, the tone of cerebral resistance vessels seems to determine effective downstream pressure. This suggests a modified model of the cerebral circulation based on the existence of two Starling resistors in a series connection.	Univ Gottingen, Dept Anesthesiol Emergency & Intens Care Med, D-3400 Gottingen, Germany; Univ Gottingen, Dept Neurosurg, D-3400 Gottingen, Germany		Weyland, A (corresponding author), Staedt Kliniken Oldenburg, Dept Anesthesia & Intens Care Med, Dr Eden Str 10, D-26133 Oldenburg, Germany.		Buhre, Wolfgang/X-9192-2018	Buhre, Wolfgang/0000-0002-8296-9426			BELLAMY RF, 1978, CIRC RES, V43, P92, DOI 10.1161/01.RES.43.1.92; BRAAKMAN R, 1990, AM J PHYSIOL, V258, pH1806; BURTON AC, 1951, AM J PHYSIOL, V164, P319, DOI 10.1152/ajplegacy.1951.164.2.319; Czosnyka M, 1999, J NEUROL NEUROSUR PS, V66, P606, DOI 10.1136/jnnp.66.5.606; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; DOLE WP, 1984, CARDIOVASC RES, V18, P548, DOI 10.1093/cvr/18.9.548; EARLY CB, 1974, J NEUROSURG, V41, P590, DOI 10.3171/jns.1974.41.5.0590; GREENFIELD JC, 1965, J CLIN INVEST, V44, P1343, DOI 10.1172/JCI105239; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; HASINOFF I, 1990, J APPL PHYSIOL, V68, P462, DOI 10.1152/jappl.1990.68.2.462; HOLM S, 1979, SCAND J STAT, V6, P65; JACKMAN AP, 1990, ANN BIOMED ENG, V18, P89, DOI 10.1007/BF02368419; LEEMAN M, 1990, J APPL PHYSIOL, V69, P293, DOI 10.1152/jappl.1990.69.1.293; LOPEZMUNIZ R, 1968, J APPL PHYSIOL, V24, P625, DOI 10.1152/jappl.1968.24.5.625; LUCE JM, 1982, J APPL PHYSIOL, V53, P1496, DOI 10.1152/jappl.1982.53.6.1496; MAGDER S, 1990, CIRC RES, V67, P209, DOI 10.1161/01.RES.67.1.209; MICHEL E, 1995, NEUROL RES, V17, P149, DOI 10.1080/01616412.1995.11740304; PANERAI RB, 1993, PHYSIOL MEAS, V14, P411, DOI 10.1088/0967-3334/14/4/002; PERMUTT S, 1963, J APPL PHYSIOL, V18, P924, DOI 10.1152/jappl.1963.18.5.924; RILEY RL, 1982, CIRCULATION, V66, P683, DOI 10.1161/01.CIR.66.4.683; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHRIER I, 1995, J APPL PHYSIOL, V79, P1531, DOI 10.1152/jappl.1995.79.5.1531; SILVESTER JT, 1981, CIRC RES, V49, P980; WAGNER EM, 1986, CRIT CARE MED, V14, P484, DOI 10.1097/00003246-198605000-00011; WEYLAND A, 1996, ANASTHESIOL INTENSIV, V31, P453	26	77	82	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JUL	2000	12	3					210	216		10.1097/00008506-200007000-00002			7	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	330PB	WOS:000087969500002	10905568				2022-02-06	
J	Kohen, R; Vellaichamy, E; Hrbac, J; Gati, I; Tirosh, O				Kohen, R; Vellaichamy, E; Hrbac, J; Gati, I; Tirosh, O			Quantification of the overall reactive oxygen species scavenging capacity of biological fluids and tissues	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						invasive and noninvasive techniques; cyclic voltammetry; total antioxidant capacity; free radicals; antioxidant profile; oxidative stress; low-molecular weight antioxidants	CLOSED-HEAD INJURY; RADICAL ABSORBENCY CAPACITY; TOTAL ANTIOXIDANT STATUS; CYCLIC VOLTAMMETRY; OXIDATIVE STRESS; IN-VIVO; PLASMA; SAMPLES; POWER; ASSAY	A method has been developed for measuring and evaluating the overall antioxidant activity derived from the low-molecular weight antioxidants (scavengers). The principle governing this method is based on a common chemical characteristic of the scavengers, their reducing properties. It was hypothesized and then demonstrated that an evaluation of the overall reducing power of a biological sample correlates with the overall scavenging activity of the sample. In order to quantify the total reducing power, the cyclic voltammetry methodology was applied. The resulting measurements correlated with the antioxidant activity of both hydrophilic and lipophilic scavengers. The method is suitable for use in biological fluids and in tissue homogenates, and can supply information concerning the type of antioxidants and their total concentration without having to determine specific compounds. A noninvasive procedure for determining skin overall scavenging activity is also described. This method is based on a well containing an extraction solution that is attached to the skin's surface. Following incubation time the extraction solution is analyzed using the cyclic voltammeter instrument and other methods. We have found these methods suitable for evaluating the reducing capacity status in various clinical conditions such as diabetes, ionizing and nonionizing irradiation, brain degenerative diseases, head trauma, and inflammatory bowel diseases. This method is also an efficient tool for evaluating the overall antioxidant capacity of mixtures of antioxidant preparations in vitro. The measurements themselves are simple and rapid. Furthermore, they do not require manipulation of the samples. (C) 2000 Elsevier Science Inc.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA		Kohen, R (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel.		Hrbac, Jan/A-1007-2009				Bard Allen J., 1980, ELECTROCHEMICAL METH, V2; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Benzie IFF, 1999, METHOD ENZYMOL, V299, P15; Blau S, 1999, MOL CELL BIOCHEM, V194, P185, DOI 10.1023/A:1006994800272; BLAU S, 2000, IN PRESS DIGEST DIS; CAO GH, 1993, FREE RADICAL BIO MED, V14, P303, DOI 10.1016/0891-5849(93)90027-R; Cao GH, 1999, METHOD ENZYMOL, V299, P50; Chevion S, 1997, FREE RADICAL BIO MED, V22, P411, DOI 10.1016/S0891-5849(96)00337-1; Chevion S, 1999, BIOCHEM MOL BIOL INT, V47, P1019; COOPER MJ, 1991, CLIN CHIM ACTA, V202, P105, DOI 10.1016/0009-8981(91)90261-A; Elangovan V, 2000, FREE RADICAL RES, V32, P125, DOI 10.1080/10715760000300131; GHISELLI A, 1995, FREE RADICAL BIO MED, V18, P29, DOI 10.1016/0891-5849(94)00102-P; HALLIWELL B, 1995, FOOD CHEM TOXICOL, V33, P601, DOI 10.1016/0278-6915(95)00024-V; Halliwell B., 1989, FREE RADICAL BIOL ME, V2; Heineman W. R., 1984, LAB TECHNIQUES ELECT; KISSINGER PT, 1973, BRAIN RES, V55, P209, DOI 10.1016/0006-8993(73)90503-9; Kohen R, 1999, BIOMED PHARMACOTHER, V53, P181, DOI 10.1016/S0753-3322(99)80087-0; Kohen R, 1999, METHOD ENZYMOL, V300, P428; Kohen R, 1997, REDOX REP, V3, P253, DOI 10.1080/13510002.1997.11747118; Kohen R., 1996, Cellular Pharmacology, V3, P355; KOHEN R, 1992, FREE RADICAL RES COM, V17, P239, DOI 10.3109/10715769209079516; KOHEN R, 1993, J PHARMACOL TOXICOL, V29, P185, DOI 10.1016/1056-8719(93)90024-9; Kohen R, 1999, METHOD ENZYMOL, V300, P285; Kohen R, 1997, ARCH GERONTOL GERIAT, V24, P103, DOI 10.1016/S0167-4943(96)00744-3; KOHEN R, 1993, INT S ANT DIS PREV S; LISSI E, 1995, FREE RADICAL BIO MED, V18, P153, DOI 10.1016/0891-5849(94)00117-3; MILLER NJ, 1993, CLIN SCI, V84, P407, DOI 10.1042/cs0840407; MOTCHNIK PA, 1994, METHOD ENZYMOL, V234, P269; O'Neill RD, 1998, CRIT REV NEUROBIOL, V12, P69, DOI 10.1615/CritRevNeurobiol.v12.i1-2.40; Ornoy A, 1999, TERATOLOGY, V60, P376, DOI 10.1002/(SICI)1096-9926(199912)60:6<376::AID-TERA10>3.3.CO;2-H; RICEEVANS C, 1994, METHOD ENZYMOL, V234, P279; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; WHITE JA, 1992, J PROPUL POWER, V8, P257, DOI 10.2514/3.23471	34	77	78	1	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0891-5849			FREE RADICAL BIO MED	Free Radic. Biol. Med.	MAR 15	2000	28	6					871	879		10.1016/S0891-5849(00)00191-X			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	311PN	WOS:000086893200006	10802217				2022-02-06	
J	Bryant, RA; Marosszeky, JE; Crooks, J; Baguley, IJ; Gurka, JA				Bryant, RA; Marosszeky, JE; Crooks, J; Baguley, IJ; Gurka, JA			Interaction of posttraumatic stress disorder and chronic pain following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							HEAD-INJURY; PSEUDOMEMORIES; VETERANS; COMBAT; SCALE	Objective: To investigate the association between posttraumatic stress disorder (PTSD) and chronic pain in patients who had sustained a severe traumatic brain Injury (TBI). Design: Correlational relationships between pain variables and PTSD measures were examined in a cohort study. Setting: An adult tertiary care center brain injury clinic. Patients: Ninety-six persons with severe TBI. Outcome Measures: The Posttraumatic Stress Disorder interview (PTSD-I), a modified McGill Pain Questionnaire, the Beck Depression Inventory (BDI), the General Health Questionnaire (GHQ), the Community Integration Questionnaire (CIQ), the Satisfaction with Life Scale (SWL), and the Coping Style Questionnaire (CSQ). Results: More persons with chronic pain reported PTSD than did those without pain. The relationship between pain severity and depression, functional adjustment, and satisfaction with life was mediated by severity of PTSD. Pain severity was significantly associated with an avoidant coping style. Conclusions: Effective rehabilitation of persons with chronic pain following severe TBI should recognize the role of posttraumatic stress in the maintenance of dysfunctional reactions. Specific interventions that address adaptive coping mechanisms to reduce PTSD may enhance rehabilitation for persons with TDI who suffer chronic pain.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Westmead Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Baguley, Ian J/K-6878-2013; Bryant, Richard/AAA-6479-2019; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; Bryant, Richard/0000-0002-9607-819X; 			American Psychiatric Association, 1988, DIAGN STAT MAN MENT; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Beckham JC, 1997, J PSYCHOSOM RES, V43, P379, DOI 10.1016/S0022-3999(97)00129-3; Billings A G, 1981, J Behav Med, V4, P139, DOI 10.1007/BF00844267; BRYAN S, 1995, HEALTH POLICY, V33, P31, DOI 10.1016/0168-8510(94)00699-F; BRYANT RA, 1995, J ABNORM PSYCHOL, V104, P537, DOI 10.1037/0021-843X.104.3.537; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; BRYANT RA, IN PRESS AM J PSYCHI; BRYANT RA, 1993, PAIN, V52, P379; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Difede JA, 1997, PAIN, V72, P245, DOI 10.1016/S0304-3959(97)00045-6; DROTTNING M, 1995, NORD J PSYCHIAT, V49, P293, DOI 10.3109/08039489509011919; Hall K, 1992, NEUROREHABILITATION, V2, P98, DOI DOI 10.3233/NRE-1992-2410; JENSEN MP, 1991, PAIN, V47, P249, DOI 10.1016/0304-3959(91)90216-K; KEEFE FJ, 1990, BEHAV THER, V21, P49, DOI 10.1016/S0005-7894(05)80188-1; King LA, 1998, J PERS SOC PSYCHOL, V74, P420, DOI 10.1037/0022-3514.74.2.420; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LAHZ S, 1997, J HEAD TRAUMA REHAB, V12, P86; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; MUSE M, 1985, PAIN, V23, P295, DOI 10.1016/0304-3959(85)90108-3; O'Toole BI, 1998, AUST NZ J PSYCHIAT, V32, P32, DOI 10.3109/00048679809062703; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHREIBER S, 1993, PAIN, V54, P107, DOI 10.1016/0304-3959(93)90105-X; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SMITH TW, 1986, J CONSULT CLIN PSYCH, V54, P573, DOI 10.1037/0022-006X.54.4.573; WARDA G, IN PRESS BEHAV RES T; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x	31	77	77	0	9	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1999	14	6					588	594		10.1097/00001199-199912000-00007			7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	269AV	WOS:000084454300006	10671704				2022-02-06	
J	Shiozaki, T; Kato, A; Taneda, M; Hayakata, T; Hashiguchi, N; Tanaka, H; Shimazu, T; Sugimoto, H				Shiozaki, T; Kato, A; Taneda, M; Hayakata, T; Hashiguchi, N; Tanaka, H; Shimazu, T; Sugimoto, H			Little benefit from mild hypothermia therapy for severely head injured patients with low intracranial pressure	JOURNAL OF NEUROSURGERY			English	Article						severe head injury; intracranial pressure; mild hypothermia; normothermia	TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; ACUTE SUBDURAL-HEMATOMA; MODERATE HYPOTHERMIA; CEREBROSPINAL-FLUID; RELEASE; MORTALITY; ISCHEMIA; RAT	Object. This study was performed to determine whether mild hypothermia therapy is essential for the treatment of severely head injured patients in whom intracranial pressure (ICP) can be maintained below 20 mm Hg by using conventional therapies. Methods. Sixteen consecutive severely head injured patients fulfilled the following criteria: the patient's ICP was maintained below 20 mm Hg by using fluid restriction, hyperventilation, and high-dose barbiturate therapy; and the patient had a Glasgow Coma Scale score of 8 or less on admission. After conventional therapies had been applied, the patients were divided randomly into two groups: the mild hypothermia group (HT group; eight patients) and the normothermia group (NT group; eight patients). The HT group received mild hypothermia (intracranial temperature 34 degrees C) therapy for 48 hours followed by rewarming at 1 degrees C per day for 3 days, whereas the NT group received normothermia (intracranial temperature 37 degrees C) therapy for 5 days. Specimens of cerebrospinal fluid (CSF) taken from an intraventricular catheter every 24 hours were analyzed for the presence of excitatory amino acids ([EAAs] glutamate, aspartate, and glycine) and cytokines (tumor necrosis factor-alpha, interleukin [IL]-1 beta, IL-6, IL-8, and IL-10). The two groups did not differ significantly in patient age, neurological status, or level of ICP. There were no significant differences in daily changes in CSF concentrations of EAAs and cytokines between the two groups. The incidence of pneumonia was slightly higher in the HT group compared with the NT group (p = 0.059). The incidence of diabetes insipidus associated with hypernatremia was significantly higher in the HT group compared with that in the NT group (p < 0.01). The two groups did not differ with respect to their clinical outcomes. Conclusions. The authors recommend normothermia therapy for the treatment of severely head injured patients in whom ICP can be maintained at lower than 20 mm Hg by using conventional therapies, because mild hypothermia therapy does not convey any advantage over normothermia therapy in such patients.	Osaka Univ, Sch Med, Dept Traumatol, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Neurosurg, Suita, Osaka 565, Japan; Kinki Univ, Sch Med, Dept Neurosurg, Osaka 589, Japan		Shiozaki, T (corresponding author), Osaka Univ, Sch Med, Dept Traumatol, 2-2 Yamadaoka, Suita, Osaka 565, Japan.						BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; JENNETT B, 1975, LANCET, V1, P480; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MILLER JD, 1982, CLIN NEUR, V29, P162; Ogura H, 1999, J TRAUMA, V46, P774, DOI 10.1097/00005373-199905000-00004; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; SAUL TG, 1987, CLIN NEUROSURG, V34, P560; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SEGAR WE, 1956, AM J PHYSIOL, V185, P528, DOI 10.1152/ajplegacy.1956.185.3.528; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SMITH D H, 1990, Society for Neuroscience Abstracts, V16, P779; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TEASDALE G, 1974, LANCET, V2, P81; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212	26	77	78	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	1999	91	2					185	191		10.3171/jns.1999.91.2.0185			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	220RT	WOS:000081681800003	10433305				2022-02-06	
J	Dias, MS; Backstrom, J; Falk, M; Li, V				Dias, MS; Backstrom, J; Falk, M; Li, V			Serial radiography in the infant shaken impact syndrome	PEDIATRIC NEUROSURGERY			English	Article						computerized tomography; magnetic resonance imaging; child abuse; shaken baby syndrome; traumatic brain injury; skull fractures; subdural hemorrhage; epidural hemorrhage; cerebral hemorrhage; cerebral edema	CRANIAL COMPUTED-TOMOGRAPHY; NONACCIDENTAL HEAD-INJURY; CHILD-ABUSE SYNDROME; CRANIOCEREBRAL TRAUMA; SUBDURAL-HEMATOMA; CT FINDINGS; SHAKING	Certain CT and/or MRI abnormalities have been used medicolegally to time intracranial injuries from the infant shaken impact syndrome (ISIS). For example, parenchymal hypodensities on CT scans are said to arise only after 6-48 h have elapsed postinjury, and the presence of chronic or mixed subdural hematomas suggests injury that occured 1-4 weeks prior. However, these statements are based largely upon inference from data obtained in other conditions such as ischemic anoxic injury and chronic subdural hemorrhage in adults. Direct evidence about the evolution of intracranial injuries in infants with ISIS is sparse, and the radiographic changes following ISIS have never been systematically studied on serial imaging studies. One hundred-seventeen serial CT and MRI scans obtained from 33 infants with ISIS were reviewed retrospectively. The exact scan dates and times were obtained directly from the scans. Acute subdural hemorrhage was the most common intracranial abnormality and was present in 27 (81 %) of the 33 infants. Other intracranial abnormalities included chronic subdural collections, subarachnoid hemorrhage, epidural hematomas, parenchymal hypodensities, edema and contusions, and atrophy and encephalomalacia. In 15 of the 33 infants, the injury could be timed with reasonable certainty, and the evolution of the radiographic changes followed over time. Six of the 15 infants had evidence of prior cranial trauma such as chronic subdural collections (5 infants) or mild atrophy (1 infant). Of the remaining 9 infants, parenchymal abnormalities such as hypodensities, edema and contusion appeared in virtually all of the initial scans performed approximately 3 h following the report of injury. One 'chronic' subdural collection was absent on the first scan performed 2.75 h postinjury, but appeared on a second scan performed 17 h later, suggesting that some 'chronic' subdural fluid collections may arise much sooner than previously thought. These findings challenge some of the current dogma about the timing of radiographic changes following abuse and are important in timing the alleged abuse for legal purposes.	SUNY Buffalo, Childrens Hosp Buffalo, Dept Neurosurg, Buffalo, NY USA; SUNY Buffalo, Childrens Hosp Buffalo, Dept Radiol, Buffalo, NY USA; SUNY Buffalo, Childrens Hosp Buffalo, Dept Pediat, Buffalo, NY USA		Dias, MS (corresponding author), Childrens Hosp Buffalo, Dept Neurosurg, 219 Bryant St, Buffalo, NY 14222 USA.	mdias@chob.edu					ALEXANDER RC, 1986, J PEDIATR-US, V109, P975, DOI 10.1016/S0022-3476(86)80279-7; ARONYK KE, 1994, PEDIAT NEUROSURGERY, P279; BALL WS, 1989, RADIOLOGY, V173, P609, DOI 10.1148/radiology.173.3.2813759; BARKOVICH AJ, 1995, PEDIAT NEUROIMAGING, P107; BERNARDI B, 1993, TOP MAGN RESON IMAG, V5, P161; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; Carter J E, 1983, Child Abuse Negl, V7, P279, DOI 10.1016/0145-2134(83)90005-4; COHEN RA, 1986, AM J ROENTGENOL, V146, P97, DOI 10.2214/ajr.146.1.97; Cox L A, 1996, Radiol Technol, V67, P513; ELLISON PH, 1978, PEDIATRICS, V62, P151; ENGLISH PC, 1983, PEDIATR ANN, V12, P870, DOI 10.3928/0090-4481-19831201-04; FELDMAN KW, 1995, CHILD ABUSE NEGLECT, V19, P307, DOI 10.1016/S0145-2134(94)00130-8; FOBBEN ES, 1989, AM J NEURORADIOL, V10, P687; GIANGIACOMO J, 1988, OPHTHALMOLOGY, V95, P295; HAHN YS, 1983, CHILD BRAIN, V10, P229; HAN BK, 1989, AM J NEURORADIOL, V10, P1191; HARWOODNASH DC, 1992, AM J NEURORADIOL, V13, P569; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KLEINMAN PK, 1987, DIAGNOSTIC IMAGING C, P159; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; LEVIN A V, 1989, Pediatric Emergency Care, V5, P181, DOI 10.1097/00006565-198909000-00011; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; LUERSSEN TG, 1991, CONC PED N, V11, P87; MERTEN DF, 1984, PEDIATR RADIOL, V14, P272, DOI 10.1007/BF01601874; MERTEN DF, 1983, PEDIATR ANN, V12, P882, DOI 10.3928/0090-4481-19831201-06; MERTEN DF, 1983, RADIOLOGY, V146, P377, DOI 10.1148/radiology.146.2.6849085; Sargent S, 1996, J FORENSIC SCI, V41, P314; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; STARLING SP, 1995, PEDIATRICS, V95, P259; TSAI FY, 1980, CT-J COMPUT TOMOGR, V4, P277, DOI 10.1016/0149-936X(80)90020-X; ZEPP F, 1992, NEUROPEDIATRICS, V23, P188, DOI 10.1055/s-2008-1071338; Zimmerman R A, 1994, Neuroimaging Clin N Am, V4, P349; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P39, DOI 10.1007/BF00395197	38	77	78	0	6	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	AUG	1998	29	2					77	85		10.1159/000028694			9	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	138CZ	WOS:000076955000006	9792961				2022-02-06	
J	Nawashiro, H; Messing, A; Azzam, N; Brenner, M				Nawashiro, H; Messing, A; Azzam, N; Brenner, M			Mice lacking GFAP are hypersensitive to traumatic cerebrospinal injury	NEUROREPORT			English	Article						astrocytes ultrastructure; glial fibrillary acidic protein deficiency; glial fibrillary acidic protein genetics; hemorrhage; sequence deletion; spinal cord injuries; transgenic mice; traumatic brain injury	BRAIN INJURY; INTERMEDIATE FILAMENTS; RAT; ARCHITECTURE; INCREASES; RECEPTORS; DEVELOP	GLIAL fibrillary acidic protein (GFAP) is an intermediate filament protein expressed primarily in astrocytes. We have tested whether GFAP protects against mechanical stress by inducing percussive head injury in GFAP-null mice with a weight drop device. When mice were positioned on a foam bed which allowed head movement at impact, all 14 wild-type mice tested survived, but 12 of 15 GFAP-null mice died within a few minutes. The cause of death appeared to be upper cervical spinal cord injury resulting in respiratory arrest. When the foam bed was replaced by a firm support, both GFAP-null and wild-type mice survived. These results indicate that mice lacking GFAP are hypersensitive to cervical spinal cord injury caused by sudden acceleration of the head. (C) 1998 Rapid Science Ltd.	NINDS, Stroke Branch, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Sch Vet Med, Madison, WI 53706 USA		Brenner, M (corresponding author), NINDS, Stroke Branch, NIH, Bldg 36,Room 4A03,6 Convent Dr,MSC 4128, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS022475] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-22475] Funding Source: Medline		DELATORRE JC, 1995, NEUROSURGERY, V37, P273, DOI 10.1227/00006123-199508000-00012; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FUCHS E, 1994, J CELL BIOL, V125, P511, DOI 10.1083/jcb.125.3.511; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; GOSHGARIAN HG, 1981, J COMP NEUROL, V201, P441, DOI 10.1002/cne.902010309; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; Liedtke W, 1998, AM J PATHOL, V152, P251; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; McCall MA, 1996, P NATL ACAD SCI USA, V93, P6361, DOI 10.1073/pnas.93.13.6361; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; OKUYAMA S, 1993, RES COMMUN CHEM PATH, V82, P91; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1; SUN FY, 1994, BRAIN RES, V661, P63, DOI 10.1016/0006-8993(94)91181-9	23	77	79	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0959-4965			NEUROREPORT	Neuroreport	JUN 1	1998	9	8					1691	1696		10.1097/00001756-199806010-00004			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZU455	WOS:000074198700004	9665584				2022-02-06	
J	Gollaher, K; High, W; Sherer, M; Bergloff, P; Boake, C; Young, ME; Ivanhoe, C				Gollaher, K; High, W; Sherer, M; Bergloff, P; Boake, C; Young, ME; Ivanhoe, C			Prediction of employment outcome one to three years following traumatic brain injury (TBI)	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; GLASGOW COMA SCALE; PROGNOSIS; RECOVERY; SELECTION; COMMUNITY; CHILDREN; RETURN; WORK	The current study investigated the relationship between age, education (EDUC), pre-injury productivity (PIP), Glasgow Coma Scale score, and a functional rating score at admittance and discharge from rehabilitation (Disability Rating Scale [DRS]) to employment status at one to three years following traumatic brain injury. EDUC, admit DRS, discharge DRS, and PIP all correlated significantly with follow-up employment status, 0.29, -0.32, -0.36, and 0.25 respectively. ALI possible combinations were then evaluated by Mallow's C-p statistic. The best fitting model was then used in a discriminant function analysis. The discriminant function correctly classified 84% of the employed subjects, 66% of the unemployed, and 75% across both groups. The current results compare favourably with those obtained in previous studies.	Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; Inst Res & Rehabil, Houston, TX USA		Gollaher, K (corresponding author), Baylor Coll Med, Dept Psychiat, 1 Baylor Plaza, Houston, TX 77030 USA.						BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CORTHELL D, 1988, CLIENT INVOLVEMENT P; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HOCKING RR, 1976, BIOMETRICS, V32, P1, DOI 10.2307/2529336; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; Levin HS., 1982, NEUROBEHAVIORAL CONS; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; OVERGAARD J, 1973, LANCET, V2, P631; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SAS Institute Inc, 1988, SAS STAT US GUID REL; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; YOUNG ME, 1994, REHABIL COUNS BULL, V37, P229	38	77	78	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1998	12	4					255	263		10.1080/026990598122557			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	ZF942	WOS:000072948700001	9562908				2022-02-06	
J	Bell, MJ; Kochanek, PM; Carcillo, JA; Mi, ZC; Schiding, JK; Wisniewski, SR; Clark, RSB; Dixon, CE; Marion, DW; Jackson, E				Bell, MJ; Kochanek, PM; Carcillo, JA; Mi, ZC; Schiding, JK; Wisniewski, SR; Clark, RSB; Dixon, CE; Marion, DW; Jackson, E			Interstitial adenosine, inosine, and hypoxanthine are increased after experimental traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						ATP; cAMP; contusion; head injury; microdialysis; purines	PIAL ARTERIOLAR DIAMETER; HIPPOCAMPAL SLICES; CEREBRAL-ISCHEMIA; CORTICAL-NEURONS; NEWBORN PIGLET; CYCLIC-AMP; HYPOXIA; RELEASE; HYPOGLYCEMIA; THEOPHYLLINE	Adenosine is a putative neuroprotectant in ischemia, but its role after traumatic brain injury (TBI) is not clear. Metabolites of adenosine, particularly inosine and hypoxanthine, are markers of ischemia and energy failure. Adenosine triphosphate (ATP) breakdown early after injury and metabolism of cyclic adenosine monophosphate (cAMP) are potential sources of adenosine. Further delineation of the magnitude, location, time course, and source of production of adenosine after TBI is needed. We measured adenosine, inosine, and hypoxanthine in brain interstitial fluid after controlled cortical impact (CCI) in the rat. Rats (n = 15) were prepared for TBI induced by CCI. A microdialysis probe was placed in the cortex, and samples were collected every 10 min. After 3 h of equilibration, the catheter was removed, CCI was performed (4 m/sec, depth 2.5 mm), and the catheter was replaced. In the shams, the catheter was removed and replaced without CCI. The injury group included rats (n = 10) subjected to CCI. Within the injury group, the microdialysis probe was placed in the center of the eventual contusion (center, n = 5) or in the penumbral region (penumbra, n = 5). Purine metabolites were measured using ultraviolet-based high-pressure liquid chromatography. Adenosine, inosine, and hypoxanthine were dramatically increased after injury (61-fold, 37-fold, and 16-fold, respectively sham, all p < 0.05, two-way analysis of variance for repeated measures). No changes in cAMP were observed (p = 0.62 vs. sham). Adenosine peaked in the first 20 min and returned to near baseline 40 min, whereas inosine and hypoxanthine peaked at 30 min and remained increased for 40 min after CCI. Interstitial brain adenosine, inosine, and hypoxanthine were increased early after CCI in rats in the contusion and penumbra. ATP breakdown is a potential source of adenosine in this early period while metabolism of cAMP does not appear to play a role. Confirmation of these data in humans may suggest new strategies targeting this important metabolic pathway.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Clin Pharmacol, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Clin Pharmacol, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Clin Pharmacol, Dept Pharmacol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Clin Pharmacol, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Clin Pharmacol, Dept Neurosurg, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Ctr Clin Pharmacol, Dept Anesthesiol & Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; Jackson, Edwin/0000-0002-8101-6009			ANGELLO DA, 1991, AM J PHYSIOL, V260, pH193, DOI 10.1152/ajpheart.1991.260.1.H193; BOWERY NG, 1988, BRIT J PHARMACOL, V93, P944, DOI 10.1111/j.1476-5381.1988.tb11484.x; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; DONAGHY KM, 1994, BRAIN RES, V656, P174, DOI 10.1016/0006-8993(94)91380-3; FASTBOM J, 1987, NEUROSCIENCE, V22, P813, DOI 10.1016/0306-4522(87)92961-7; FOWLER JC, 1993, NEUROSCI LETT, V157, P83, DOI 10.1016/0304-3940(93)90648-5; GEIGER JD, 1997, PURINERGIC APPROACHE, P59; GIDDAY JM, 1995, PEDIATR RES, V38, P306, DOI 10.1203/00006450-199509000-00006; HAGBERG H, 1987, J NEUROCHEM, V49, P227, DOI 10.1111/j.1471-4159.1987.tb03419.x; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; HENDRICH KS, 1997, J CEREB BLOOD FLOW M, V17, pS76; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; JARVIS MF, 1989, BRAIN RES, V484, P111, DOI 10.1016/0006-8993(89)90353-3; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; LAUDIGNON N, 1990, J APPL PHYSIOL, V68, P1534, DOI 10.1152/jappl.1990.68.4.1534; MENO JR, 1993, J CEREBR BLOOD F MET, V13, P214, DOI 10.1038/jcbfm.1993.26; MENO JR, 1991, J CEREBR BLOOD F MET, V11, P986, DOI 10.1038/jcbfm.1991.165; MI ZC, 1995, J PHARMACOL EXP THER, V273, P728; MITCHELL HL, 1995, NEUROSURGERY, V36, P1003, DOI 10.1227/00006123-199505000-00017; MORI M, 1992, NEUROSCIENCE, V46, P301, DOI 10.1016/0306-4522(92)90052-4; MORII S, 1986, J CEREBR BLOOD F MET, V6, P34, DOI 10.1038/jcbfm.1986.5; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PEDATA F, 1993, J NEUROCHEM, V61, P284, DOI 10.1111/j.1471-4159.1993.tb03566.x; PHILLIS JW, 1994, BRAIN RES, V652, P353, DOI 10.1016/0006-8993(94)90248-8; PHILLIS JW, 1975, EUR J PHARMACOL, V30, P125, DOI 10.1016/0014-2999(75)90214-9; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; RUDOLPHI KA, 1987, J CEREBR BLOOD F MET, V7, P74, DOI 10.1038/jcbfm.1987.11; RUTH VJ, 1993, AM J PHYSIOL, V265, pH1762; SEGAL M, 1982, EUR J PHARMACOL, V79, P193, DOI 10.1016/0014-2999(82)90625-2; SIGGINS GR, 1981, NEUROSCI LETT, V23, P55, DOI 10.1016/0304-3940(81)90186-5; TOMINAGA K, 1992, NEUROSCI LETT, V145, P67, DOI 10.1016/0304-3940(92)90205-L; VANWYLEN DGL, 1986, J CEREBR BLOOD F MET, V6, P522, DOI 10.1038/jcbfm.1986.97; VANWYLEN DGL, 1988, AM J PHYSIOL, V24, pH1211; VONLUBITZ DKJE, 1994, EUR J PHARMACOL, V263, P59, DOI 10.1016/0014-2999(94)90523-1; WALLMANJOHANSSON A, 1994, LIFE SCI, V55, P721, DOI 10.1016/0024-3205(94)00680-6; WINN HR, 1981, AM J PHYSIOL, V241, pH235, DOI 10.1152/ajpheart.1981.241.2.H235; ZHOU JG, 1994, J CEREBR BLOOD F MET, V14, P166, DOI 10.1038/jcbfm.1994.22	39	77	79	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	1998	15	3					163	170		10.1089/neu.1998.15.163			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ZA547	WOS:000072375500001	9528916				2022-02-06	
J	Assaf, Y; BeitYannai, E; Shohami, E; Berman, E; Cohen, Y				Assaf, Y; BeitYannai, E; Shohami, E; Berman, E; Cohen, Y			Diffusion- and T-2-weighted MRI of closed-head injury in rats: A time course study and correlation with histology	MAGNETIC RESONANCE IMAGING			English	Article						magnetic resonance imaging (MRI); T-2 and diffusion MRI; closed-head injury; head trauma	EXPERIMENTAL CEREBRAL-ISCHEMIA; ACUTE HUMAN STROKE; BRAIN INJURY; SPECTROSCOPY; CATS; PERFUSION; DAMAGE; ECHOES; TISSUE	Diffusion- and T-2-weighted MRI were used to evaluate changes in brain water characteristics following closed-head injury in rats, Images were collected within the first 2 h and at 24 h and 7 days following the traumatic event and then compared with histology, The ratios between the apparent diffusion coefficients (ADCs) of the traumatized tissues and normal brain tissues were significantly different from unity and were found to be 0.79 +/- 0.25 (p < 0.01), 0,49 +/- 0.33 (p < 0.0002), and 3.47 +/- 1.36 (p < 10(-6)) at 1-2 h, 24 h, and 1 week after the trauma, respectively, In severe trauma, areas of hyperintensity which were not apparent on the T-2-weighted images could he detected on the diffusion-weighted images within 1-2 h after the trauma, At 24 h following the traumatic event, large areas of hyperintensity are observed in both types of images, One week following the trauma, the ADCs of the traumatized tissues (1,84 +/- 0.69 x 10(-5) cm(2)/s) are much larger than those of normal brain (0.57 +/- 0.19 x 10(-5) cm(2)/s) and approach the value of free water, At 7 days, the areas of hyperintensity in the T-2-weighted images seem to underestimate the injured areas found by histology, At this time point a good correlation is obtained between the areas of hypointensity observed on the diffusion-weighted images and the infarct areas obtained by histology (r = 0.88), (C) 1997 Elsevier Science Inc.	TEL AVIV UNIV,SCH CHEM,IL-69978 RAMAT AVIV,ISRAEL				Beit-Yannai, Elie/F-2141-2012	Beit-Yannai, Elie/0000-0001-9347-822X; assaf, yaniv/0000-0001-6828-7595			ALSOP DC, 1994, 2 ANN M SOC MAGN RES, V3, P1370; BACK T, 1994, STROKE, V25, P494, DOI 10.1161/01.STR.25.2.494; BENVENISTE H, 1992, STROKE, V23, P746, DOI 10.1161/01.STR.23.5.746; BOSE B, 1988, STROKE, V19, P28, DOI 10.1161/01.STR.19.1.28; BOUMA GJ, 1992, CENT NERVOUS SYSTEM, P333; BRANTZAWADZKI M, 1987, AM J ROENTGENOL, V148, P579, DOI 10.2214/ajr.148.3.579; BUSZA AL, 1992, STROKE, V23, P1602, DOI 10.1161/01.STR.23.11.1602; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; DARDZINKI BJ, 1994, MAGNET RESON MED, V30, P318; DAVIS D, 1994, MAGNET RESON MED, V31, P454, DOI 10.1002/mrm.1910310416; DECRESPIGNY AJ, 1995, MAGN RESON MED, V33, P720, DOI 10.1002/mrm.1910330518; EHMAN RL, 1989, RADIOLOGY, V173, P255, DOI 10.1148/radiology.173.1.2781017; FRAHM J, 1985, J MAGN RESON, V65, P130, DOI 10.1016/0022-2364(85)90381-6; GENTRY LR, 1994, RADIOLOGY, V191, P1; GILL R, 1995, J CEREBR BLOOD F MET, V15, P1, DOI 10.1038/jcbfm.1995.1; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HELPERN JA, 1993, MAGN RESON IMAGING, V11, P241, DOI 10.1016/0730-725X(93)90028-C; KNIGHT RA, 1991, STROKE, V22, P802, DOI 10.1161/01.STR.22.6.802; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LATOUR L, 1994, P NATL ACAD SCI USA, V84, P4910; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1988, RADIOLOGY, V168, P497, DOI 10.1148/radiology.168.2.3393671; LEBIHAN D, 1992, AM J ROENTGENOL, V159, P591, DOI 10.2214/ajr.159.3.1503032; MANSFIELD P, 1977, J PHYS C SOLID STATE, V10, pL55, DOI 10.1088/0022-3719/10/3/004; MERBOLDT KD, 1992, MAGNET RESON MED, V23, P179, DOI 10.1002/mrm.1910230119; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; MOSELEY ME, 1992, NEUROIMAG CLIN N AM, V2, P693; ORDIDGE RJ, 1994, MAGN RESON IMAGING, V12, P455, DOI 10.1016/0730-725X(94)92539-9; SCHWARTING R, 1987, NEUROPHARMACOLOGY, V26, P457, DOI 10.1016/0028-3908(87)90027-X; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; TAKAHASHI M, 1993, MAGNET RESON MED, V30, P485, DOI 10.1002/mrm.1910300411; TURNER R, 1990, J MAGN RESON, V86, P445, DOI 10.1016/0022-2364(90)90023-3; UMEDA M, 1994, 2 ANN M SOC MAGN RES, V3, P1372; VANBRUGGEN N, 1992, STROKE, V23, P576, DOI 10.1161/01.STR.23.4.576; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, J BIOL CHEM, V263, P757; WARACH S, 1992, NEUROLOGY, V42, P1717, DOI 10.1212/WNL.42.9.1717; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214	41	77	77	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0730-725X			MAGN RESON IMAGING	Magn. Reson. Imaging		1997	15	1					77	85		10.1016/S0730-725X(96)00246-9			9	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	WP120	WOS:A1997WP12000010	9084028				2022-02-06	
J	King, NS; Crawford, S; Wenden, FJ; Moss, NEG; Wade, DT; Caldwell, FE				King, NS; Crawford, S; Wenden, FJ; Moss, NEG; Wade, DT; Caldwell, FE			Measurement of post-traumatic amnesia: How reliable is it?	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						post-traumatic amnesia; measurement reliability	CLOSED HEAD-INJURY; PRACTICAL SCALE; BRAIN-DAMAGE; SEVERITY; COMA	Objective-To develop and test a clinical protocol for determining post-traumatic amnesia by retrospective questioning. To establish its limits and factors which influence reliability. Design-Two independent assessments using the Rivermead post-traumatic amnesia protocol were undertaken by separate observers on various groups of patients at various time intervals. Analysis investigated the correlations between assessments, the percentage difference between assessments, the number of patients changing category, and the differences between these analyses in the different patient subgroups. Assessments were undertaken both in hospital and in the patients' homes. Four different patient groups were studied. These were group A: 12 inpatients with very severe head injury late after injury; Group B: 40 patients interviewed at home six months after injury; group C: 22 patients interviewed within a few weeks of injury at home; group D: 116 patients interviewed initially within a few weeks and then at six months, on both occasions at home. The Rivermead post-traumatic amnesia protocol involved clinical questioning of the patient to establish how long after injury (in hours/days/weeks) the patient regained continuous day to day memory. All periods of coma were included. Severity was categorised with standard criteria. Results-Overall correlation was good (Spearman's r 0 . 79), but the correlation was lower for patients with post-traumatic amnesia < 24 hours and when there was a long delay between assessments. In all groups 19%-25% of patients changed categories between assessments, but only 2% changed by two categories. Conclusions-The assessment of posttraumatic amnesia with the Rivermead post-traumatic amnesia protocol is reasonably reliable. The misclassification rate however, is significant enough that some caution should be taken in individual cases. Other evidence does show post-traumatic amnesia to be valid, and it DT Wade probably remains the best simple prognostic item available. In clinical practice one should avoid placing too much weight on post-traumatic amnesia alone.			King, NS (corresponding author), RIVERMEAD REHABIL CTR,OXFORD HEAD INJURY SERV,ABINGDON RD,OXFORD OX1 4XD,ENGLAND.			Wade, Derick/0000-0002-1188-8442			ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; JENNETT B, 1975, LANCET, V1, P480; KARZMARK P, 1992, Brain Injury, V6, P213, DOI 10.3109/02699059209029662; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A, P165; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; WILSON JTL, 1993, J NEUROL NEUROSUR PS, V56, P198; WITTY CWM, 1977, AMNESIA, P118	20	77	78	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	1997	62	1					38	42		10.1136/jnnp.62.1.38			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	WD449	WOS:A1997WD44900010	9010398	Green Published, Bronze			2022-02-06	
J	Kim, DH; Gutin, PH; Noble, LJ; Nathan, D; Yu, JS; Nockels, RP				Kim, DH; Gutin, PH; Noble, LJ; Nathan, D; Yu, JS; Nockels, RP			Treatment with genetically engineered fibroblasts producing NGF or BDNF can accelerate recovery from traumatic spinal cord injury in the adult rat	NEUROREPORT			English	Article						spinal cord contusion; spinal cord injury; nerve growth factor; brain-derived neurotrophic factor; neurotrophin; transplantation; neuroprotection	NERVE GROWTH-FACTOR; FACTOR RECEPTOR; NEURONS; NEUROTROPHINS; LOCALIZATION; DISEASE; LESIONS; PREVENT; SYSTEM; DEATH	WE tested the hypothesis that NGF or BDNF can protect damaged neural structures following spinal cord injury. Spinal contusions were produced in adult rats by a weight drop method. Thereafter, unmodified Rat 1 fibroblasts or fibroblasts engineered to secrete NGF or BDNF were injected into the injury site. Weekly assessments of recovery were made for 6 weeks using a locomotor rating scale. All rats were immediately paraplegic, then began to recover. At 1 week after injury, the ratings of locomotor performance in rats implanted with NGF- or BDNF-secreting fibroblasts were significantly increased over those of rats implanted with unmodified fibroblasts. This trend toward enhanced recovery persisted during the duration of the experiment, although the difference became smaller. Histological examination after 6 weeks showed a larger cross-sectional area of spinal cord at the maximal injury site in the animals treated with NGF or BDNF. these results demonstrate a significant biological effect of treatment with neurotrophins in traumatic spinal cord injury.	SAN FRANCISCO GEN HOSP,SAN FRANCISCO,CA 94143; MASSACHUSETTS GEN HOSP,NEUROSURG SERV,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129		Kim, DH (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROSURG,SAN FRANCISCO,CA 94143, USA.			Kim, Dong/0000-0002-1523-6396; Yu, John/0000-0003-1230-8494; Rui, Yanning/0000-0002-4482-5579			BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.ne.18.030195.001255; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DIENER PS, 1994, NEUROREPORT, V5, P1913, DOI 10.1097/00001756-199410000-00018; EIDE FF, 1993, EXP NEUROL, V121, P200, DOI 10.1006/exnr.1993.1087; ERKENSTEIN F, 1988, BRAIN RES, V446, P149; FRIEDMAN B, 1995, J NEUROSCI, V15, P1044; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; FRIM DM, 1994, P NATL ACAD SCI USA, V91, P5104, DOI 10.1073/pnas.91.11.5104; GALL C, 1989, SCIENCE, V24, P758; KOLIATSOS VE, 1990, J NEUROSCI, V10, P3801, DOI 10.1523/JNEUROSCI.10-12-03801.1990; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; OLSON L, 1993, EXP NEUROL, V124, P5, DOI 10.1006/exnr.1993.1167; PECHAN PA, 1995, NEUROREPORT, V6, P660; RENDE M, 1993, J COMP NEUROL, V338, P560, DOI 10.1002/cne.903380406; REYNOLDS ME, 1991, BRAIN RES, V559, P149, DOI 10.1016/0006-8993(91)90298-A; SCHNELL L, 1994, NATURE, V367, P169; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; TUSZYNSKI MH, 1994, EXP NEUROL, V129, P1	23	77	84	1	2	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	SEP 2	1996	7	13					2221	2225		10.1097/00001756-199609020-00033			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	WD441	WOS:A1996WD44100035	8930993				2022-02-06	
J	YANG, KY; MU, XS; HAYES, RL				YANG, KY; MU, XS; HAYES, RL			INCREASED CORTICAL NUCLEAR FACTOR-KAPPA-B(NF-KAPPA-B) DNA-BINDING ACTIVITY AFTER TRAUMATIC BRAIN INJURY IN RATS	NEUROSCIENCE LETTERS			English	Article						BRAIN TRAUMA; DNA BINDING PROTEIN; GENE EXPRESSION; NUCLEAR FACTOR; NF-KAPPA-B; TRANSCRIPTION FACTOR	NF-KAPPA-B; TRANSCRIPTION FACTOR; ACTIVATION	Nuclear factor-kappa B (NF-kappa B) DNA binding factor is an inducible transcription factor that responds to various cellular signals. Levels of cortical NF-kappa B DNA binding activity were measured in a controlled lateral cortical impact model of traumatic brain injury (TBI) in rats. Using electrophoretic mobility shift assays (EMSAs), we found that NF-kappa B DNA binding activity in cerebral cortex ipsilateral to the injury site increased at 1, 3, 5 and 7 days after injury. Binding activity peaked at 3 days after injury and subsided by 10 days after injury. These data indicate that TBI produces transient increases in NF-kappa B DNA binding activity. Further insights into the role of NF-kappa B in TBI may provide new therapeutic opportunities for head trauma.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,HOUSTON,TX 77030						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021458, P01NS031998] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS31998, R01 NS21458] Funding Source: Medline		AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; DENT P, 1994, EMBO J, V15, P2842; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EICHER DM, 1994, J IMMUNOL, V152, P2710; HALL ED, 1993, RES P ARNMD, V71, P81; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; KALTSCHMIDT B, 1993, MOL ASPECTS MED, V14, P171, DOI 10.1016/0098-2997(93)90004-W; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V13, P13760; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MAYER R, 1991, P NATL ACAD SCI USA, V88, P966; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; PRASAD AV, 1994, NEUROSCI LETT, V170, P145, DOI 10.1016/0304-3940(94)90260-7; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1994, J NEUROTRAUM, V11, P523, DOI 10.1089/neu.1994.11.523; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287	23	77	84	0	0	ELSEVIER SCI PUBL IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	SEP 8	1995	197	2					101	104		10.1016/0304-3940(95)11919-N			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	RW406	WOS:A1995RW40600005	8552270				2022-02-06	
J	RESNICK, DK; MARION, DW; DARBY, JM				RESNICK, DK; MARION, DW; DARBY, JM			THE EFFECT OF HYPOTHERMIA ON THE INCIDENCE OF DELAYED TRAUMATIC INTRACEREBRAL HEMORRHAGE	NEUROSURGERY			English	Article						COAGULOPATHY; DELAYED TRAUMATIC HEMORRHAGE; HEAD INJURY; HYPOTHERMIA	INDUCED PLATELET-AGGREGATION; BRAIN INJURY; TEMPERATURE; COLD	HYPOTHERMIA HAS BEEN shown to cause coagulation abnormalities, primarily related to platelet dysfunction. We reviewed coagulation function and the incidence of delayed traumatic intracerebral hemorrhage in a series of 36 patients with severe head injuries (Glasgow Coma Scale 3-7) enrolled in a prospective, randomized, clinical trial of therapeutic moderate hypothermia. Patients were randomized to a normothermic group (n = 16) or to a group cooled to 32 to 33 degrees C within 6 hours of injury (n = 20). Prothrombin times, partial thromboplastin times, and platelet counts were obtained in the emergency room and then again within 24 hours of randomization. Delayed traumatic intracerebral hemorrhage occurred in 6 of 20 (30%) hypothermic patients and 5 of 16 (31%) normothermic patients. In the hypothermic group, 9 of 17 patients had an increased prothrombin time during hypothermic therapy, as opposed to 11 of 16 in the normothermic group during the corresponding time period. The partial thromboplastin time was prolonged in 2 of 17 hypothermic patients and 2 of 16 normothermic patients. Three patients in the hypothermic group and one in the normothermic group developed thrombocytopenia (a platelet count of less than 100,000). There were no significant differences between the two groups in the incidence of delayed traumatic intracerebral hemorrhage, in measured coagulopathy, or in the mean values of measured coagulation parameters. Although the possibility of a hypothermia-induced coagulopathy has not yet been excluded, the short-term use of hypothermia does not appear to increase the risk for intracranial hemorrhagic complications in head injuries.	UNIV PITTSBURGH,SCH MED,DEPT ANESTHESIA CRIT CARE,PITTSBURGH,PA 15213		RESNICK, DK (corresponding author), UNIV PITTSBURGH,SCH MED,DEPT NEUROL SURG,230 LOTHROP ST,ROOM F948,PITTSBURGH,PA 15213, USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 P20 NS30318-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318] Funding Source: NIH RePORTER		BERNABEI AF, 1992, J TRAUMA, V33, P835, DOI 10.1097/00005373-199212000-00007; BIGELOW WG, 1950, ANN SURG, V132, P849, DOI 10.1097/00000658-195011000-00001; Brass LF, 1991, HEMATOLOGY BASIC PRI, P1176; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COHEN IJ, 1987, BRIT J HAEMATOL, V65, P331, DOI 10.1111/j.1365-2141.1987.tb06862.x; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; FAY T, 1940, NY STATE J MED  0915, P1351; FAY T, 1943, ASS RES NERV MENT DI, V24, P611; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GUDEMAN SK, 1979, NEUROSURGERY, V5, P309, DOI 10.1227/00006123-197909000-00002; KATTLOVE HE, 1971, BLOOD-J HEMATOL, V38, P39, DOI 10.1182/blood.V38.1.39.39; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MINER ME, 1985, NEUROSURGERY, P1666; REED RL, 1992, J TRAUMA, V33, P465, DOI 10.1097/00005373-199209000-00022; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; TRENCHARD PM, 1989, CLIN PHYS PHYSIOL M, V10, P65, DOI 10.1088/0143-0815/10/1/007; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; VANDERSANDE JJ, 1981, J NEUROSURG, V55, P718, DOI 10.3171/jns.1981.55.5.0718; WOODMAN RC, 1990, BLOOD, V76, P1680	21	77	80	0	7	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	FEB	1994	34	2					252	255		10.1227/00006123-199402000-00007			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	MU697	WOS:A1994MU69700021	8177385				2022-02-06	
J	HAMM, RJ; ODELL, DM; PIKE, BR; LYETH, BG				HAMM, RJ; ODELL, DM; PIKE, BR; LYETH, BG			COGNITIVE IMPAIRMENT FOLLOWING TRAUMATIC BRAIN INJURY - THE EFFECT OF PRE-INJURY AND POSTINJURY ADMINISTRATION OF SCOPOLAMINE AND MK-801	COGNITIVE BRAIN RESEARCH			English	Article						TRAUMATIC BRAIN INJURY; MORRIS WATER MAZE; SCOPOLAMINE; MK-801; RAT	CLOSED HEAD-INJURY; EXTRACELLULAR POTASSIUM; AMINO-ACIDS; RAT	In order to examine the effectiveness of pre- and post-injury administration of muscarinic cholinergic and NMDA antagonists in reducing cognitive deficits following traumatic brain injury (TBI), rats were injected with either scopolamine (1 mg/kg) or MK-801 (0.3 mg/kg) 15 min prior to or 15 min after fluid percussion TBI. Cognitive performance was assessed with the Morris water maze procedure on days 11-15 after TBI or sham injury. When scopolamine and MK-801 were injected 15 min before injury, Morris water maze deficits were significantly reduced (P < 0.01 and P < 0.05, respectively). When scopolamine and MK-801 were injected 15 min after TBI, neither drug was effective in attenuating Morris water maze deficits. Consistent with other research, these results suggest that the cognitive deficits produced by TBI are the consequence of a brief period of excessive excitation of cholinergic and NMDA receptor systems. The results of this experiment also suggest that the temporal therapeutic window for the treatment of cognitive dysfunction with receptor antagonist intervention appears to be quite brief (< 15 min) in the rat.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROSURG,RICHMOND,VA 23284		HAMM, RJ (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,VCU BOX 2018,RICHMOND,VA 23284, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BROOKS D N, 1975, Cortex, V11, P329; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HUBSCHMANN OR, 1983, J NEUROSURG, V59, P289, DOI 10.3171/jns.1983.59.2.0289; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; TABADDOR K, 1984, NEUROSURGERY, V14, P702; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TAKAHASHI H, 1981, J NEUROSURG, V55, P717; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WEHMAN A, 1989, J HEAT TRAUMA REHAB, V4, P6	22	77	78	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0926-6410			COGNITIVE BRAIN RES	Cognit. Brain Res.	DEC	1993	1	4					223	226		10.1016/0926-6410(93)90006-Q			4	Computer Science, Artificial Intelligence; Neurosciences; Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Neurosciences & Neurology	ND501	WOS:A1993ND50100004	8003921				2022-02-06	
J	SALVANT, JB; MUIZELAAR, JP; MORAWETZ, RB; GROSSMAN, RG				SALVANT, JB; MUIZELAAR, JP; MORAWETZ, RB; GROSSMAN, RG			CHANGES IN CEREBRAL BLOOD-FLOW AND METABOLISM RELATED TO THE PRESENCE OF SUBDURAL-HEMATOMA	NEUROSURGERY			English	Article						CEREBRAL BLOOD FLOW; HEAD INJURY; SUBDURAL HEMATOMA	HEAD-INJURED PATIENTS; COMPUTERIZED-TOMOGRAPHY; AUTO-REGULATION; BRAIN INJURY; CIRCULATION; PRESSURE; ISCHEMIA; VOLUME	ACUTE SUBDURAL HEMATOMA (SDH) remains an important factor in head injury. The early effects of SDH on cerebral blood flow (CBF) and cerebral metabolic rate of oxygen consumption (CMRO2) in humans have not been clearly demonstrated. Patients admitted to the Medical College of Virginia with severe closed-head injury between 1982 and 1990 were studied with Xenon-133 regional CBF measurement. Data were reviewed retrospectively with regard to the presence of SDH (n = 54). A comparison group consisted of patients with head injuries without mass lesions or midline shift on admission computed tomographic scans (n = 76). CBF measurements made in patients less than 16 years of age, with concurrent administrations of mannitol or vasopressors, or with cerebral perfusion pressure under 50 mm Hg were excluded. CBF measurements were made on multiple occasions during the first 6 days after injury, and in many instances, simultaneous determinations of cerebral arteriovenous oxygen difference (AVDO2) were made through sampling of jugular bulb and arterial oxygen content. Not all patients underwent CBF measurements on each day. Differences in mean CBF, CMRO2, and AVDO2 were evaluated on each day after injury with the application of Student's t-test for independent groups. Significant reductions in CBF were demonstrated in patients with SDH on Days 1 (P < 0.0005) and 2 (P < 0.01). CMRO2 differed notably on Days 1 (P < 0.005) and 2 (P < 0.05) in patients with SDH, but when corrected for the lower Glasgow Coma Score in patients with SDH, the P values were only 0.07 and 0.12, respectively (analysis of covariance). CBF less-than-or-equal-to 18 ml/100 g/min (the threshold for infarction) occurred in 9% of patients with SDH within the first 24 hours, compared with none in those patients without mass lesions (p < 0.05 chi2). Mean PaCO2 values were compared, in which CBF was significantly reduced and no differences between groups could be demonstrated. These data demonstrate clear reductions in CBF that are paralleled by reduction in CMRO2 in the first 48 hours after injury in patients with SDH. These changes were not associated with increased AVDO2 in most patients. The lack of increased AVDO2 suggests that reductions in CBF may be related to diminished energy requirements or diminished ability for normal oxidative metabolism of the more severely injured brain.			SALVANT, JB (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,BOX 631 MCU STN,RICHMOND,VA 23298, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER		BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CLUBB RJ, 1980, J NEUROSURG, V52, P189, DOI 10.3171/jns.1980.52.2.0189; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; HANSON EJ, 1975, CIRC RES, V36, P18, DOI 10.1161/01.RES.36.1.18; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; KURODA Y, 1992, NEUROSURGERY, V30, P687; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Mendelow A D, 1984, Neurol Res, V6, P189; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1984, ADV NEUROTRAUMATOLOG, P92; OBRIST WD, 1979, NEURAL TRAUMA, P41; OBRIST WD, 1980, CEREBRAL CIRCULATION, P119; OBRIST WD, 1975, CEREBRAL CIRCULATION, P398; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Petruk KC, 1973, STROKE, V4, P431, DOI 10.1161/01.STR.4.3.431; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SCHETTINI A, 1989, J NEUROSURG, V71, P578, DOI 10.3171/jns.1989.71.4.0578; SIESJO BK, 1984, J NEUROSURG, V60, P883, DOI 10.3171/jns.1984.60.5.0883; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185, DOI 10.1152/jappl.1991.71.4.1185; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015	26	77	78	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	SEP	1993	33	3					387	393					7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	LV014	WOS:A1993LV01400006	8413868				2022-02-06	
J	DEWITT, DS; PROUGH, DS; TAYLOR, CL; WHITLEY, JM; DEAL, DD; VINES, SM				DEWITT, DS; PROUGH, DS; TAYLOR, CL; WHITLEY, JM; DEAL, DD; VINES, SM			REGIONAL CEREBROVASCULAR RESPONSES TO PROGRESSIVE HYPOTENSION AFTER TRAUMATIC BRAIN INJURY IN CATS	AMERICAN JOURNAL OF PHYSIOLOGY			English	Article						CEREBRAL BLOOD FLOW; RADIOACTIVE MICROSPHERES; HEMORRHAGIC SHOCK; HEMORRHAGIC TRAUMA; CENTRAL NERVOUS SYSTEM	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; AUTO-REGULATION; AUTOREGULATION; METABOLISM; ANESTHESIA; ISOFLURANE; HALOTHANE; PRESSURE; ISCHEMIA	We investigated the effects of hypotension on cerebral blood flow (CBF) after traumatic brain injury (TBI) in cats. Isoflurane-anesthetized cats were prepared for TBI and for microsphere measurements of total (T) and regional (r) CBF. Four groups were studied: sham injury (group I, n = 6); TBI (group II, n = 6); isoflurane anesthesia, no TBI or hypotension (group III, n = 4); and isoflurane and TBI, no hypotension (group IV, n = 8). After TBI or sham trauma, mean arterial pressure (MAP) was reduced to 80, 60, and 40 mmHg by hemorrhage. Group I TCBF did not change significantly from baseline until MAP reached 40 mmHg, but rCBF was more dependent on MAP in anterior hemispheric than in brain stem regions. Group II TCBF was significantly lower than baseline, and group I TCBF at all levels of hypotension and autoregulation was impaired at higher MAP levels in anterior than in posterior brain regions. Groups III and IV indicated that decreases in TCBF were not due to duration of the preparation or to TBI in the absence of hemorrhagic hypotension. We conclude that global and regional autoregulation are absent in response to hemorrhagic hypotension after TBI.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, MED CTR, DEPT ANESTHESIA, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, MED CTR, DEPT ANAT, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, MED CTR, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27157 USA				Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HOFFBRAND BI, 1969, CARDIOVASC RES, V3, P426, DOI 10.1093/cvr/3.4.426; HOSSMANN KA, 1978, J NEUROL, V218, P275, DOI 10.1007/BF00312883; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371, DOI 10.1152/ajpheart.1978.234.4.H371; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MILETICH DJ, 1976, ANESTH ANALG, V55, P100; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRIOR PF, 1978, BRIT J ANAESTH, V50, P993, DOI 10.1093/bja/50.10.993; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; RUDOLPH AM, 1967, CIRC RES, V21, P163, DOI 10.1161/01.RES.21.2.163; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEASDALE G, 1974, LANCET, V2, P81; TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002; VANAKEN H, 1986, ANESTH ANALG, V65, P565; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YOSHIDA K, 1991, J NEUROSURG, V74, P87, DOI 10.3171/jns.1991.74.1.0087	31	77	77	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0002-9513			AM J PHYSIOL	Am. J. Physiol.	OCT	1992	263	4	2				H1276	H1284		10.1152/ajpheart.1992.263.4.H1276			9	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	JU806	WOS:A1992JU80600038					2022-02-06	
J	Barthelemy, NR; Horie, K; Sato, C; Bateman, RJ				Barthelemy, Nicolas R.; Horie, Kanta; Sato, Chihiro; Bateman, Randall J.			Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; AMYLOID-BETA; CEREBROSPINAL-FLUID; COGNITIVE DECLINE; PROTEIN; PATHOLOGY; KINETICS; MARKER; RATIO	Highly sensitive and specific plasma biomarkers for Alzheimer's disease (AD) have the potential to improve diagnostic accuracy in the clinic and facilitate research studies including enrollment in prevention and treatment trials. We recently reported CSF tau hyperphosphorylation, especially on T217, is an accurate predictor of beta-amyloidosis at asymptomatic and symptomatic stages. In the current study, we determine by mass spectrometry the potential utility of plasma p-tau isoforms to detect AD pathology and investigate CSF and plasma tau isoforms' profile relationships. Plasma tau was truncated as previously described in CSF. CSF and plasma measures of p-tau-217 and p-tau-181 were correlated. No correlation was found between CSF and plasma on total-tau levels and pS202 measures. We found p-tau-217 and p-tau-181 were highly specific for amyloid plaque pathology in the discovery cohort (n = 36, AUROC = 0.99 and 0.98 respectively). In the validation cohort (n = 92), p-tau-217 measures were still specific to amyloid status (AUROC = 0.92), and p-tau-181 measures were less specific (AUROC = 0.75).	[Barthelemy, Nicolas R.; Horie, Kanta; Sato, Chihiro; Bateman, Randall J.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Bateman, Randall J.] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63130 USA; [Bateman, Randall J.] Washington Univ, Sch Med, Charles F & Joanne Knight Alzheimers Dis Res Ctr, St Louis, MO 63130 USA		Barthelemy, NR; Bateman, RJ (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.; Bateman, RJ (corresponding author), Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63130 USA.; Bateman, RJ (corresponding author), Washington Univ, Sch Med, Charles F & Joanne Knight Alzheimers Dis Res Ctr, St Louis, MO 63130 USA.	barthelemy.nicolas@wustl.edu; batemanr@wustl.edu		Bateman, Randall/0000-0002-7729-1702; Sato, Chihiro/0000-0002-7639-8727	Alzheimer's Association Research Fellowship [AARF-16-443265]; Rainwater Charitable Foundation; National Institutes of Health, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS095773]; Tau SILK Consortium (AbbVie)AbbVie; Tau SILK Consortium (Biogen)Biogen; Tau SILK Consortium (Eli Lilly and Company); Coins for Alzheimer's Research Trust grant	Funding for this work includes the Alzheimer's Association Research Fellowship AARF-16-443265 (to N.R. Barth ' elemy), the Rainwater Charitable Foundation (to R.J. Bateman and N.R. Barth ' elemy), the National Institutes of Health, National Institute of Neurological Disorders and Stroke grant R01NS095773 (R.J. Bateman), the Tau SILK Consortium (AbbVie, Biogen, and Eli Lilly and Company; principal investigator, R.J. Bateman), and the Coins for Alzheimer's Research Trust grant (to C. Sato).	Bacioglu M, 2016, NEURON, V91, P56, DOI 10.1016/j.neuron.2016.05.018; Barthelemy N., 2015, ALZHEIMERS DEMENT 19, V11, P870, DOI [10.1016/j.jalz.2015.08.063, DOI 10.1016/J.JALZ.2015.08.063]; Barthelemy N.R., 2018, ALZHEIMERS DEMENT 4, V14, P273, DOI [10.1016/j.jalz.2018.06.024, DOI 10.1016/J.JALZ.2018.06.024]; Barthelemy N. R, 2017, TAU HYPERPHOSPHORYLA, DOI [10.1101/226977, DOI 10.1101/226977, 10. 1101/226977]; Barthelemy NR, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00596-4; Barthelemy NR, 2020, NAT MED, V26, P398, DOI 10.1038/s41591-020-0781-z; Barthelemy NR, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00121; Barthelemy NR, 2016, J PROTEOME RES, V15, P667, DOI 10.1021/acs.jproteome.5b01001; Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; Cicognola C, 2019, ACTA NEUROPATHOL, V137, P279, DOI 10.1007/s00401-018-1948-2; Darlix A, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5287-z; Fagan AM, 2007, ARCH NEUROL-CHICAGO, V64, P343, DOI 10.1001/archneur.64.3.noc60123; Fagan AM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007901; Geyer PE, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20156297; Janelidze S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15436-0; Janelidze S, 2020, NAT MED, V26, P379, DOI 10.1038/s41591-020-0755-1; Kasai T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188802; Mattsson N, 2016, NEUROLOGY, V87, P1827, DOI 10.1212/WNL.0000000000003246; Mielke MM, 2018, ALZHEIMERS DEMENT, V14, P989, DOI 10.1016/j.jalz.2018.02.013; Mielke MM, 2017, JAMA NEUROL, V74, P1073, DOI 10.1001/jamaneurol.2017.1359; Nakamura A, 2018, NATURE, V554, P249, DOI 10.1038/nature25456; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Ovod V, 2017, ALZHEIMERS DEMENT, V13, P841, DOI 10.1016/j.jalz.2017.06.2266; Patterson BW, 2015, ANN NEUROL, V78, P439, DOI 10.1002/ana.24454; Potter R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005615; Preische O, 2019, NAT MED, V25, P277, DOI 10.1038/s41591-018-0304-3; Roberts KF, 2014, ANN NEUROL, V76, P837, DOI 10.1002/ana.24270; Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655; Sato C, 2018, NEURON, V97, P1284, DOI 10.1016/j.neuron.2018.02.015; Schindler SE, 2019, NEUROLOGY, V93, pE1647, DOI 10.1212/WNL.0000000000008081; Tatebe H, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0206-8; Thijssen EH, 2020, NAT MED, V26, P387, DOI 10.1038/s41591-020-0762-2; Zetterberg H, 2017, NEUROPATH APPL NEURO, V43, P194, DOI 10.1111/nan.12378; Zetterberg H, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt163	36	76	77	6	22	ROCKEFELLER UNIV PRESS	NEW YORK	950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA	0022-1007	1540-9538		J EXP MED	J. Exp. Med.	NOV	2020	217	11							e20200861	10.1084/jem.20200861			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	OO5MI	WOS:000587422000017	32725127	Green Published, hybrid			2022-02-06	
J	Munji, RN; Soung, AL; Weiner, GA; Sohet, F; Semple, BD; Trivedi, A; Gimlin, K; Kotoda, M; Korai, M; Aydin, S; Batugal, A; Cabangcala, AC; Schupp, PG; Oldham, MC; Hashimoto, T; Noble-Haeusslein, LJ; Daneman, R				Munji, Roeben Nocon; Soung, Allison Luen; Weiner, Geoffrey Aaron; Sohet, Fabien; Semple, Bridgette Deanne; Trivedi, Alpa; Gimlin, Kayleen; Kotoda, Masakazu; Korai, Masaaki; Aydin, Sidar; Batugal, Austin; Cabangcala, Anne Christelle; Schupp, Patrick Georg; Oldham, Michael Clark; Hashimoto, Tomoki; Noble-Haeusslein, Linda J.; Daneman, Richard			Profiling the mouse brain endothelial transcriptome in health and disease models reveals a core blood-brain barrier dysfunction module	NATURE NEUROSCIENCE			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; P-SELECTIN; VASCULAR DEVELOPMENT; IN-VITRO; EXPRESSION; ICAM-1; CELLS; CNS; LIPOCALIN-2; INTEGRITY	Blood vessels in the CNS form a specialized and critical structure, the blood-brain barrier (BBB). We present a resource to understand the molecular mechanisms that regulate BBB function in health and dysfunction during disease. Using endothelial cell enrichment and RNA sequencing, we analyzed the gene expression of endothelial cells in mice, comparing brain endothelial cells with peripheral endothelial cells. We also assessed the regulation of CNS endothelial gene expression in models of stroke, multiple sclerosis, traumatic brain injury and seizure, each having profound BBB disruption. We found that although each is caused by a distinct trigger, they exhibit strikingly similar endothelial gene expression changes during BBB disruption, comprising a core BBB dysfunction module that shifts the CNS endothelial cells into a peripheral endothelial cell-like state. The identification of a common pathway for BBB dysfunction suggests that targeting therapeutic agents to limit it may be effective across multiple neurological disorders.	[Munji, Roeben Nocon; Soung, Allison Luen; Weiner, Geoffrey Aaron; Sohet, Fabien; Aydin, Sidar; Batugal, Austin; Cabangcala, Anne Christelle; Daneman, Richard] Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA; [Munji, Roeben Nocon; Soung, Allison Luen; Weiner, Geoffrey Aaron; Sohet, Fabien; Aydin, Sidar; Batugal, Austin; Cabangcala, Anne Christelle; Daneman, Richard] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA; [Semple, Bridgette Deanne; Trivedi, Alpa; Gimlin, Kayleen; Schupp, Patrick Georg; Oldham, Michael Clark; Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Kotoda, Masakazu; Korai, Masaaki; Hashimoto, Tomoki] Barrow Neurol Inst, Barrow Aneurysm & AVM Res Ctr, Dept Neurosurg & Neurobiol, Phoenix, AZ 85013 USA		Daneman, R (corresponding author), Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA.; Daneman, R (corresponding author), Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA.	Rdaneman@ucsd.edu		Aydin, Sidar/0000-0001-7791-7931; Korai, Masaaki/0000-0002-5326-3467; Soung, Allison/0000-0002-1590-6038	National Institutes of Health (NIH)/National Institue of Neurological Disorders and Stroke (NINDS) [R01 NS091281-01A1]; National Multiple Sclerosis Society Pilot Grant; Takeda Pharmaceuticals New Frontier Science Program; UCSF Department of Clinical Pharmacology and Therapeutics NIH T32 grant [GM007546]; UCSF Department of Anesthesia and Perioperative Care NIH T32 grant [GM008440]; NIH/National Institue of Mental Health [R01 MH113896]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS050159, NS077767, R01NS055876, R01NS082280]; Barrow Neurological Foundation grant; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008440, T32GM007198, T32GM007546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH113896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091281, R01NS082280, R01NS077767] Funding Source: NIH RePORTER	We would like to thank N. Lescano and A. Schroeder and the Parnassus Flow Cytometry Core, T. Rambaldo and the UCSD Veterans Hospital Flow Cytometry Core, R. Chadwick and the Gladstone Genomics Core, A. Williams and The Gladstone Bioinformatics Core and K. Jepsen and the UCSD Institute for Genomics Medicine Genomics Center. R.D. is funded by the National Institutes of Health (NIH)/National Institue of Neurological Disorders and Stroke (NINDS) (grant no. R01 NS091281-01A1), a National Multiple Sclerosis Society Pilot Grant and Takeda Pharmaceuticals New Frontier Science Program. R.N.M. was funded by the UCSF Department of Clinical Pharmacology and Therapeutics (grant no. GM007546) and the Department of Anesthesia and Perioperative Care (grant no. GM008440) NIH T32 grants. M.C.O. is funded by the NIH/National Institue of Mental Health (grant no. R01 MH113896). L.J.N.-H. is funded by the NIH/NINDS (grant nos. R01 NS050159 and NS077767). T.H. is funded by the NIH/NINDS (grant nos. R01NS055876 and R01NS082280) and the Barrow Neurological Foundation grant.	Aggarwal Bharat B., 2002, Current Drug Targets - Inflammation and Allergy, V1, P327, DOI 10.2174/1568010023344571; Akamatsu Y, 2015, J NEUROSCI, V35, P3851, DOI 10.1523/JNEUROSCI.3838-14.2015; Armulik A, 2010, NATURE, V468, P557, DOI 10.1038/nature09522; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; Cheng BH, 2012, PEPTIDES, V37, P171, DOI 10.1016/j.peptides.2012.07.012; Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; Daneman R, 2012, ANN NEUROL, V72, P648, DOI 10.1002/ana.23648; Daneman R, 2010, NATURE, V468, P562, DOI 10.1038/nature09513; Daneman R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013741; Daneman R, 2009, P NATL ACAD SCI USA, V106, P641, DOI 10.1073/pnas.0805165106; Doring A, 2007, J IMMUNOL, V179, P8470, DOI 10.4049/jimmunol.179.12.8470; Ferreira AC, 2015, PROG NEUROBIOL, V131, P120, DOI 10.1016/j.pneurobio.2015.06.005; Henninger DD, 1997, J IMMUNOL, V158, P1825; Huang J, 2000, STROKE, V31, P3047, DOI 10.1161/01.STR.31.12.3047; Ioannidou S, 2006, P NATL ACAD SCI USA, V103, P16770, DOI 10.1073/pnas.0603501103; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Jin AY, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-12; Keuschnigg J, 2009, BLOOD, V114, P478, DOI 10.1182/blood-2008-11-188763; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Ley K, 2003, TRENDS MOL MED, V9, P263, DOI 10.1016/S1471-4914(03)00071-6; Liebner S, 2008, J CELL BIOL, V183, P409, DOI 10.1083/jcb.200806024; Love S, 2001, NEUROPATH APPL NEURO, V27, P465, DOI 10.1046/j.1365-2990.2001.00356.x; Lui JH, 2014, NATURE, V515, P264, DOI 10.1038/nature13973; Lyck R, 2003, BLOOD, V102, P3675, DOI 10.1182/blood-2003-02-0358; Ma S, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001469; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; Oldham MC, 2008, NAT NEUROSCI, V11, P1271, DOI 10.1038/nn.2207; Pinzon-Daza ML, 2014, J CEREBR BLOOD F MET, V34, P1258, DOI 10.1038/jcbfm.2014.100; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; Semple BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143386; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; SHARIEF MK, 1993, J NEUROIMMUNOL, V43, P15, DOI 10.1016/0165-5728(93)90070-F; Shue EH, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-29; Stenman JM, 2008, SCIENCE, V322, P1247, DOI 10.1126/science.1164594; STEWART PA, 1981, DEV BIOL, V84, P183, DOI 10.1016/0012-1606(81)90382-1; Sun CR, 2013, J NEUROSCI, V33, P17314, DOI 10.1523/JNEUROSCI.2129-13.2013; Troletti CD, 2016, BBA-MOL BASIS DIS, V1862, P452, DOI 10.1016/j.bbadis.2015.10.010; Wang YS, 2012, CELL, V151, P1332, DOI 10.1016/j.cell.2012.10.042; Weidenfeller C, 2007, J NEUROCHEM, V101, P555, DOI 10.1111/j.1471-4159.2006.04394.x; Xing CH, 2014, STROKE, V45, P2085, DOI 10.1161/STROKEAHA.114.005733; Zhou T, 2019, NAT NEUROSCI, V22, P421, DOI 10.1038/s41593-018-0324-9; Zhou YL, 2014, DEV CELL, V31, P248, DOI 10.1016/j.devcel.2014.08.018; Zhou YL, 2014, J CLIN INVEST, V124, P3825, DOI 10.1172/JCI76431; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	47	76	76	11	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	NOV	2019	22	11					1892	+		10.1038/s41593-019-0497-x			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	JI3VI	WOS:000493396600016	31611708	Green Accepted, Green Submitted	Y	N	2022-02-06	
J	Broglio, SP; Katz, BP; Zhao, S; McCrea, M; McAllister, T				Broglio, Steven P.; Katz, Barry P.; Zhao, Shi; McCrea, Michael; McAllister, Thomas		CARE Consortium Investigators	Test-Retest Reliability and Interpretation of Common Concussion Assessment Tools: Findings from the NCAA-DoD CARE Consortium	SPORTS MEDICINE			English	Article							SPORT-RELATED CONCUSSION; HIGH-SCHOOL; TEST-PERFORMANCE; REACTION-TIME; VALIDITY; MANAGEMENT; STATEMENT; RECOVERY; SIDELINE; IMPACT	Background Concussion diagnosis is typically made through clinical examination and supported by performance on clinical assessment tools. Performance on commonly implemented and emerging assessment tools is known to vary between administrations, in the absence of concussion. Objective To evaluate the test-retest reliability of commonly implemented and emerging concussion assessment tools across a large nationally representative sample of student-athletes. Methods Participants (n = 4874) from the Concussion Assessment, Research, and Education Consortium completed annual baseline assessments on two or three occasions. Each assessment included measures of self-reported concussion symptoms, motor control, brief and extended neurocognitive function, reaction time, oculomotor/oculovestibular function, and quality of life. Consistency between years 1 and 2 and 1 and 3 were estimated using intraclass correlation coefficients or Kappa and effect sizes (Cohen's d). Clinical interpretation guidelines were also generated using confidence intervals to account for non-normally distributed data. Results Reliability for the self-reported concussion symptoms, motor control, and brief and extended neurocognitive assessments from year 1 to 2 ranged from 0.30 to 0.72 while effect sizes ranged from 0.01 to 0.28 (i.e., small). The reliability for these same measures ranged from 0.34 to 0.66 for the year 1-3 interval with effect sizes ranging from 0.05 to 0.42 (i.e., small to less than medium). The year 1-2 reliability for the reaction time, oculomotor/oculovestibular function, and quality-of-life measures ranged from 0.28 to 0.74 with effect sizes from 0.01 to 0.38 (i.e., small to less than medium effects). Conclusions This investigation noted less than optimal reliability for most common and emerging concussion assessment tools. Despite this finding, their use is still necessitated by the absence of a gold standard diagnostic measure, with the ultimate goal of developing more refined and sound tools for clinical use. Clinical interpretation guidelines are provided for the clinician to apply with a degree of certainty in application.	[Broglio, Steven P.] Univ Michigan, NeuroTrauma Res Lab, Injury Ctr, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA; [Katz, Barry P.; Zhao, Shi] Indiana Univ, Dept Biostat, Indianapolis, IN 46204 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [McAllister, Thomas] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA		Broglio, SP (corresponding author), Univ Michigan, NeuroTrauma Res Lab, Injury Ctr, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu		Clugston, James/0000-0002-2103-1039; Kontos, Anthony/0000-0002-3749-4310; Master, Christina/0000-0002-6717-4270; Chrisman, Sara/0000-0001-5373-7223	Grand Alliance Concussion Assessment, Research, and Education Consortium; National Collegiate Athletic Association; Department of DefenseUnited States Department of Defense; US Army Medical Research Acquisition Activity, Fort Detrick, MD, USA; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]	This publication was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education Consortium, funded by the National Collegiate Athletic Association and the Department of Defense. The US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014, USA is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award no. W81XWH-14-2-0151. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense (Defense Health Program funds).	[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Byron K, 2011, PERS SOC PSYCHOL B, V37, P269, DOI 10.1177/0146167210392788; Chin EY, 2016, AM J SPORT MED, V44, P2276, DOI 10.1177/0363546516648141; Cohen J, 1977, STAT POWER ANAL BEHA; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Eckner JT, 2015, PERCEPT MOTOR SKILL, V120, P841, DOI 10.2466/25.15.PMS.120v19x6; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Fischer K. W., 1997, DEV NEUROIMAGING MAP, P263; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Katz BP, SPORTS MED IN PRESS; Kontos AP, 2016, AM J SPORT MED, V44, P1400, DOI 10.1177/0363546516632754; Kutcher Jeffrey S, 2014, Continuum (Minneap Minn), V20, P1552, DOI 10.1212/01.CON.0000458974.78766.58; Lancaster MA, 2016, CLIN NEUROPSYCHOL, V30, P321, DOI 10.1080/13854046.2016.1138504; Leahy S., 2011, US TODAY; Leong Danielle F, 2015, J Optom, V8, P131, DOI 10.1016/j.optom.2014.12.005; Lew R., 2010, AM J BIOSTAT, V1, P1, DOI [10.3844/AMJBSP.2010.1.8, DOI 10.3844/AMJBSP.2010.1.8]; Lim J, 2010, PSYCHOL BULL, V136, P375, DOI 10.1037/a0018883; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Masson M, 2016, NEUROPSYCHOLOGY, V30, P143, DOI 10.1037/neu0000228; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; National Collegiate Athletic Association (NCAA), 2016, INT CONS DIAGN MAN S; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Portney L.G., 2009, FDN CLIN RES APPL PR, V3rd ed.; Putukian M, 2015, CLIN J SPORT MED, V25, P36, DOI 10.1097/JSM.0000000000000102; Randolph C, 2005, J ATHL TRAINING, V40, P139; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Resch JE, 2013, NEUROPSYCHOL REV, V23, P335, DOI 10.1007/s11065-013-9242-5; Resch JE., 2016, BMJ OPEN SPORT EXERC, V2, pe000012, DOI DOI 10.1136/BMJSEM-2015-000012; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Stocker RPJ, 2017, ARCH CLIN NEUROPSYCH, V32, P349, DOI 10.1093/arclin/acx003; Van der Vaart A.W., 1998, ASYMPTOTIC STAT, V3; Yakovlev PI, 1967, REGIONAL DEV BRAIN E, P3	59	76	76	0	9	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	MAY	2018	48	5					1255	1268		10.1007/s40279-017-0813-0			14	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	GM4RT	WOS:000438111000013	29138991	Green Published, hybrid			2022-02-06	
J	Iglesias, J; Morales, L; Barreto, GE				Iglesias, Jose; Morales, Ludis; Barreto, George E.			Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARs	MOLECULAR NEUROBIOLOGY			English	Article						Astrogliosis; PPAR; Glycolysis; Fatty acid oxidation; Ketone bodies; Glutamate; Neuroprotection	ACTIVATED-RECEPTOR-GAMMA; CENTRAL-NERVOUS-SYSTEM; PENTOSE-PHOSPHATE PATHWAY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CHONDROITIN SULFATE PROTEOGLYCANS; FIBRILLARY ACIDIC PROTEIN; FOCAL CEREBRAL-ISCHEMIA; RAT-BRAIN ASTROCYTES; GLUCOSE-UPTAKE; PYRUVATE CARBOXYLATION	Astrocyte-mediated inflammation is associated with degenerative pathologies such as Alzheimer's and Parkinson's diseases and multiple sclerosis. The acute inflammation and morphological and metabolic changes that astrocytes develop after the insult are known as reactive astroglia or astrogliosis that is an important response to protect and repair the lesion. Astrocytes optimize their metabolism to produce lactate, glutamate, and ketone bodies in order to provide energy to the neurons that are deprived of nutrients upon insult. Firstly, we review the basis of inflammation and morphological changes of the different cell population implicated in reactive gliosis. Next, we discuss the more active metabolic pathways in healthy astrocytes and explain the metabolic response of astrocytes to the insult in different pathologies and which metabolic alterations generate complications in these diseases. We emphasize the role of peroxisome proliferator-activated receptors isotypes in the inflammatory and metabolic adaptation of astrogliosis developed in ischemia or neurodegenerative diseases. Based on results reported in astrocytes and other cells, we resume and hypothesize the effect of peroxisome proliferator-activated receptor (PPAR) activation with ligands on different metabolic pathways in order to supply energy to the neurons. The activation of selective PPAR isotype activity may serve as an input to better understand the role played by these receptors on the metabolic and inflammatory compensation of astrogliosis and might represent an opportunity to develop new therapeutic strategies against traumatic brain injuries and neurodegenerative diseases.	[Iglesias, Jose; Morales, Ludis; Barreto, George E.] Pontificia Univ Javeriana, Fac Ciencias, Dept Nutr & Bioquim, Bogota, DC, Colombia; [Barreto, George E.] Univ Autonoma Chile, Inst Ciencias Biomed, Santiago, Chile; [Barreto, George E.] Univ Cient Sur, Lima, Peru		Iglesias, J (corresponding author), Pontificia Univ Javeriana, Fac Ciencias, Dept Nutr & Bioquim, Bogota, DC, Colombia.	joseiglesias@javeriana.edu.co	Barreto, George E./AAD-7420-2020; Morales, Ludis/AAZ-7053-2020; Barreto, George E./B-5747-2014	Barreto, George E./0000-0002-6644-1971; Barreto, George E./0000-0002-6644-1971; Morales-Alvarez, Ludis/0000-0002-8541-9729	Pontificia Universidad Javeriana	JE and GEB' work is supported by Pontificia Universidad Javeriana.	Aguirre-Rueda D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122843; Aguirre-Rueda D, 2015, INT J MED SCI, V12, P48, DOI 10.7150/ijms.10035; Ahmadian M, 2013, NAT MED, V19, P557, DOI 10.1038/nm.3159; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Aleshin S, 2014, MOL CELL NEUROSCI, V59, P127, DOI 10.1016/j.mcn.2014.01.008; Allaman I, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00023; Allaman I, 2010, J NEUROSCI, V30, P3326, DOI 10.1523/JNEUROSCI.5098-09.2010; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Amaral AI, 2013, J INHERIT METAB DIS, V36, P621, DOI 10.1007/s10545-012-9553-3; Amaral Ana I, 2011, Front Neuroenergetics, V3, P5, DOI 10.3389/fnene.2011.00005; Amaral AI, 2010, J NEUROCHEM, V113, P735, DOI 10.1111/j.1471-4159.2010.06636.x; Anbalagan Muralidharan, 2012, Nucl Recept Signal, V10, pe001, DOI 10.1621/nrs.10001; Anderson MA, 2014, NEUROSCI LETT, V565, P23, DOI 10.1016/j.neulet.2013.12.030; Posada-Duque RA, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00231; ASHWELL K, 1990, DEV BRAIN RES, V55, P219, DOI 10.1016/0165-3806(90)90203-B; Atsumi T, 2005, DIABETES, V54, P3349, DOI 10.2337/diabetes.54.12.3349; AUESTAD N, 1991, J NEUROCHEM, V56, P1376, DOI 10.1111/j.1471-4159.1991.tb11435.x; Rodriguez MA, 2014, J STEROID BIOCHEM, V144, P294, DOI 10.1016/j.jsbmb.2014.07.009; Bachoo RM, 2004, P NATL ACAD SCI USA, V101, P8384, DOI 10.1073/pnas.0402140101; Badeau RM, 2014, ANN MED, V46, P18, DOI 10.3109/07853890.2013.853369; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Barish GD, 2008, P NATL ACAD SCI USA, V105, P4271, DOI 10.1073/pnas.0711875105; Barreto G, 2007, EUR J NEUROSCI, V25, P3039, DOI 10.1111/j.1460-9568.2007.05563.x; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Barreto G, 2009, ENDOCRINOLOGY, V150, P5010, DOI 10.1210/en.2009-0352; Barreto GE, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00132; Barreto GE, 2014, NEUROSCI LETT, V565, P1, DOI 10.1016/j.neulet.2014.01.052; Barreto GE, 2012, EXP NEUROL, V238, P284, DOI 10.1016/j.expneurol.2012.08.015; Barreto GE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027881; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; Barros LF, 2010, BRAIN RES REV, V63, P149, DOI 10.1016/j.brainresrev.2009.10.002; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Becher B, 2000, GLIA, V29, P293; Benarroch EE, 2014, NEUROLOGY, V82, P1374, DOI 10.1212/WNL.0000000000000328; Benito C, 2012, BRIT J PHARMACOL, V166, P1474, DOI 10.1111/j.1476-5381.2012.01889.x; Berkich DA, 2007, J NEUROSCI RES, V85, P3367, DOI 10.1002/jnr.21500; Beurrier C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008550; Bezzi P, 2011, CELL, V144, P644, DOI 10.1016/j.cell.2011.02.027; Bigl M, 1999, J NEURAL TRANSM, V106, P499, DOI 10.1007/s007020050174; Bigl M, 2003, J NEURAL TRANSM, V110, P77, DOI 10.1007/s00702-002-0772-x; Blazquez C, 1999, J NEUROCHEM, V73, P1674, DOI 10.1046/j.1471-4159.1999.731674.x; Boneva NB, 2011, HIPPOCAMPUS, V21, P162, DOI 10.1002/hipo.20732; Bouzier-Sore AK, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00179; Bramanti Vincenzo, 2010, Front Biosci (Schol Ed), V2, P558; Brekke EMF, 2014, J CEREBR BLOOD F MET, V34, P724, DOI 10.1038/jcbfm.2014.8; Brown AM, 2007, GLIA, V55, P1263, DOI 10.1002/glia.20557; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Burda JE, 2014, NEURON, V81, P229, DOI 10.1016/j.neuron.2013.12.034; Cabezas R, 2015, MED CHEM; Cabezas R, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00211; Cabezas R, 2012, NEUROSCI RES, V74, P80, DOI 10.1016/j.neures.2012.07.008; Cabodevilla AG, 2013, J BIOL CHEM, V288, P27777, DOI 10.1074/jbc.M113.466656; CADELLI DS, 1992, EXP NEUROL, V115, P189, DOI 10.1016/0014-4886(92)90246-M; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112; CHAMAK B, 1994, J NEUROSCI RES, V38, P221, DOI 10.1002/jnr.490380213; Chen RQ, 2012, CELL REP, V2, P1329, DOI 10.1016/j.celrep.2012.09.030; Chen SH, 2015, GLIA, V63, P118, DOI 10.1002/glia.22738; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Cheong SJ, 2015, NUCL MED BIOL, V42, P85, DOI 10.1016/j.nucmedbio.2014.08.013; Ching J, 2015, J CLIN NEUROSCI, V22, P21, DOI 10.1016/j.jocn.2014.09.001; Chistyakov DV, 2015, J NEUROCHEM, V134, P113, DOI 10.1111/jnc.13101; Choi JW, 2004, J NEUROSCI RES, V75, P722, DOI 10.1002/jnr.20009; Chuquet J, 2010, J NEUROSCI, V30, P15298, DOI 10.1523/JNEUROSCI.0762-10.2010; Cimini A, 2005, NEUROSCIENCE, V130, P325, DOI 10.1016/j.neuroscience.2004.09.043; Cimini A, 2008, STEM CELL REV, V4, P293, DOI 10.1007/s12015-008-9024-2; Correa F, 2011, NEUROBIOL DIS, V44, P142, DOI 10.1016/j.nbd.2011.06.016; Cristiano L, 2005, NEUROSCIENCE, V131, P577, DOI 10.1016/j.neuroscience.2004.11.008; Cristiano L, 2001, J NEUROCYTOL, V30, P671, DOI 10.1023/A:1016525716209; Cullingford TE, 2004, PROSTAG LEUKOTR ESS, V70, P253, DOI 10.1016/j.plefa.2003.09.008; Cullingford TE, 2002, NEUROPHARMACOLOGY, V42, P724, DOI 10.1016/S0028-3908(02)00014-X; Cunnane S, 2011, NUTRITION, V27, P3, DOI 10.1016/j.nut.2010.07.021; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Defaux A, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-15; Deitmer JW, 2000, BIOESSAYS, V22, P747, DOI 10.1002/1521-1878(200008)22:8<747::AID-BIES8>3.0.CO;2-0; Del Rio-Hortega P., 1919, B SOC ESP BIOL, V9, P69; Del Rio-Hortega P., 1920, TRAB LAB INVEST BIOL, V18, P37; Dello Russo C, 2003, J BIOL CHEM, V278, P5828, DOI 10.1074/jbc.M208132200; Deng YY, 2010, BRAIN PATHOL, V20, P909, DOI 10.1111/j.1750-3639.2010.00387.x; Di Cesare ML, 2014, BIOMED RES INT, V2014, DOI [10.1155/2014/546453, DOI 10.1155/2014/546453]; Dienel GA, 2013, NEUROCHEM INT, V63, P244, DOI 10.1016/j.neuint.2013.06.015; Dill J, 2010, J NEUROSCI, V30, P963, DOI 10.1523/JNEUROSCI.5045-09.2010; Ding F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079977; Ding S, 2014, NEURAL REGEN RES, V9, P2048, DOI 10.4103/1673-5374.147929; Ding YS, 2014, PROG MOL BIOL TRANSL, V121, P451, DOI 10.1016/B978-0-12-800101-1.00014-4; DiNuzzo M, 2013, NEUROCHEM INT, V63, P458, DOI 10.1016/j.neuint.2013.08.004; DiNuzzo M, 2011, BIOESSAYS, V33, P319, DOI 10.1002/bies.201000151; Diradourian C, 2005, BIOCHIMIE, V87, P33, DOI 10.1016/j.biochi.2004.11.010; Drew PD, 2006, NEUROCHEM INT, V49, P183, DOI 10.1016/j.neuint.2006.04.003; Ebert D, 2003, J NEUROSCI, V23, P5928; El Kadmiri N, 2014, PATHOL BIOL, V62, P333, DOI 10.1016/j.patbio.2014.08.002; ELLISON JA, 1995, GLIA, V14, P123, DOI 10.1002/glia.440140207; Escartin C, 2006, J NEUROSCI, V26, P5978, DOI 10.1523/JNEUROSCI.0302-06.2006; Esposito E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041880; Fandel D, 2013, BRAIN RES, V1535, P89, DOI 10.1016/j.brainres.2013.08.022; Barros LF, 2013, TRENDS NEUROSCI, V36, P396, DOI 10.1016/j.tins.2013.04.002; Festuccia WT, 2009, J LIPID RES, V50, P1185, DOI 10.1194/jlr.M800620-JLR200; FINSEN BR, 1993, GLIA, V7, P41, DOI 10.1002/glia.440070109; Floyd ZE, 2012, BBA-MOL BASIS DIS, V1822, P1090, DOI 10.1016/j.bbadis.2012.03.014; Franke H, 2014, NEUROSCI LETT, V565, P14, DOI 10.1016/j.neulet.2013.09.056; Frigerio F, 2012, J NEUROCHEM, V123, P342, DOI 10.1111/j.1471-4159.2012.07933.x; FRISEN J, 1994, EXP NEUROL, V129, P183, DOI 10.1006/exnr.1994.1160; Fu W, 2015, J BIOL CHEM, V290, P12504, DOI 10.1074/jbc.M114.618157; Fu W, 2014, BIOGERONTOLOGY, V15, P579, DOI 10.1007/s10522-014-9525-0; Gao C, 2015, NEUROSCI LETT, V594, P99, DOI 10.1016/j.neulet.2015.03.062; Garcia MD, 2003, J NEUROCHEM, V86, P709, DOI 10.1046/j.1471-4159.2003.01892.x; Garcia-Bueno B, 2007, NEUROPSYCHOPHARMACOL, V32, P1251, DOI 10.1038/sj.npp.1301252; Gibbs ME, 2009, J NEUROCHEM, V109, P230, DOI 10.1111/j.1471-4159.2009.05800.x; GIULIAN D, 1988, J NEUROSCI, V8, P709; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; Grygiel-Gorniak B, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-17; Gubern A, 2009, J BIOL CHEM, V284, P32359, DOI 10.1074/jbc.M109.061515; Guo X, 2010, J BIOL CHEM, V285, P23711, DOI 10.1074/jbc.M110.123174; Gupta M, 2015, ARCH DERMATOL RES, V307, P767, DOI 10.1007/s00403-015-1571-1; Guzman M, 2001, TRENDS ENDOCRIN MET, V12, P169, DOI 10.1016/S1043-2760(00)00370-2; Haemmerle G, 2011, NAT MED, V17, P1076, DOI 10.1038/nm.2439; Halim ND, 2010, GLIA, V58, P1168, DOI 10.1002/glia.20996; Hamby ME, 2012, J NEUROSCI, V32, P14489, DOI 10.1523/JNEUROSCI.1256-12.2012; Hertz L, 2007, J CEREBR BLOOD F MET, V27, P219, DOI 10.1038/sj.jcbfm.9600343; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; Hihi AK, 2002, CELL MOL LIFE SCI, V59, P790, DOI 10.1007/s00018-002-8467-x; Hoft S, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0602; Hol EM, 2015, CURR OPIN CELL BIOL, V32, P121, DOI 10.1016/j.ceb.2015.02.004; Iglesias J, 2012, J CLIN INVEST, V122, P4105, DOI 10.1172/JCI42127; INNOCENTI GM, 1983, DEV BRAIN RES, V11, P55, DOI 10.1016/0165-3806(83)90201-8; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; Itoh Y, 2003, P NATL ACAD SCI USA, V100, P4879, DOI 10.1073/pnas.0831078100; Izawa Y, 2009, BRAIN RES, V1305, P64, DOI 10.1016/j.brainres.2009.09.098; Januszewicz E, 2009, INT J BIOCHEM CELL B, V41, P2599, DOI 10.1016/j.biocel.2009.08.020; Jensen MB, 1997, EXP NEUROL, V143, P103, DOI 10.1006/exnr.1996.6337; Jha MK, 2013, BBA-PROTEINS PROTEOM, V1834, P2418, DOI 10.1016/j.bbapap.2012.12.006; Joiner TE, 2002, J PERS ASSESS, V79, P472, DOI 10.1207/S15327752JPA7903_05; JORGENSEN MB, 1993, EXP NEUROL, V120, P70, DOI 10.1006/exnr.1993.1041; Juliet PAR, 2008, BRAIN RES, V1210, P230, DOI 10.1016/j.brainres.2008.02.099; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; Khatchadourian A, 2012, BBA-MOL CELL BIOL L, V1821, P607, DOI 10.1016/j.bbalip.2012.01.007; Kim TH, 2013, YONSEI MED J, V54, P545, DOI 10.3349/ymj.2013.54.3.545; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Konig B, 2008, BBA-GEN SUBJECTS, V1780, P899, DOI 10.1016/j.bbagen.2008.03.002; Korenic A, 2015, NEUROSCI LETT, V595, P128, DOI 10.1016/j.neulet.2015.04.020; Kostadinova R, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-34; Koyama Y, 2014, NEUROCHEM INT, V78, P35, DOI 10.1016/j.neuint.2014.08.005; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kumari R, 2010, J CEREBR BLOOD F MET, V30, P352, DOI 10.1038/jcbfm.2009.221; Kwok JCF, 2014, METHODS MOL BIOL, V1162, P127, DOI 10.1007/978-1-4939-0777-9_10; Laabs TL, 2007, J NEUROSCI, V27, P14494, DOI 10.1523/JNEUROSCI.2807-07.2007; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lee CH, 2011, J NEUROL SCI, V300, P120, DOI 10.1016/j.jns.2010.09.005; Lee YM, 2010, ARCH PHARM RES, V33, P231, DOI 10.1007/s12272-010-0207-4; Li CY, 2015, NEUROCHEM INT, V83-84, P9, DOI 10.1016/j.neuint.2015.03.001; Li HL, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-58; Liao SL, 2013, J NEUROCHEM, V127, P271, DOI 10.1111/jnc.12291; Lleo A, 2007, CELL MOL LIFE SCI, V64, P1403, DOI 10.1007/s00018-007-6516-1; LOTAN M, 1994, EXP NEUROL, V126, P284, DOI 10.1006/exnr.1994.1066; Lovett-Racke AE, 2004, J IMMUNOL, V172, P5790, DOI 10.4049/jimmunol.172.9.5790; Mandrekar-Colucci S, 2012, J NEUROSCI, V32, P10117, DOI 10.1523/JNEUROSCI.5268-11.2012; Martin HL, 2013, NEUROSCIENCE, V240, P191, DOI 10.1016/j.neuroscience.2013.02.058; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; Mazzola JL, 2001, J NEUROCHEM, V76, P442, DOI 10.1046/j.1471-4159.2001.00033.x; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; McKenna MC, 1996, J NEUROCHEM, V66, P386; Michalik L, 2007, BBA-MOL CELL BIOL L, V1771, P991, DOI 10.1016/j.bbalip.2007.02.004; Michalik L, 2011, PROSTAG LEUKOTR ESS, V85, P235, DOI 10.1016/j.plefa.2011.04.016; Michalik L, 2008, PPAR RES, V2008, DOI 10.1155/2008/134059; Middeldorp J, 2011, PROG NEUROBIOL, V93, P421, DOI 10.1016/j.pneurobio.2011.01.005; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Moller T, 1997, J NEUROSCI, V17, P615; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Montagner Alexandra, 2013, Biomol Concepts, V4, P53, DOI 10.1515/bmc-2012-0035; Morken TS, 2014, NEUROCHEM RES, V39, P556, DOI 10.1007/s11064-013-1014-3; Murin R, 2008, NEUROCHEM RES, V33, P279, DOI 10.1007/s11064-007-9444-4; Murin R, 2009, NEUROCHEM RES, V34, P1195, DOI 10.1007/s11064-008-9895-2; Murin R, 2009, NEUROCHEM RES, V34, P194, DOI 10.1007/s11064-008-9840-4; Nadra K, 2006, MOL CELL BIOL, V26, P3266, DOI 10.1128/MCB.26.8.3266-3281.2006; Nagele RG, 2003, BRAIN RES, V971, P197, DOI 10.1016/S0006-8993(03)02361-8; Nakagawa Takayuki, 2013, Curr Mol Pharmacol, V6, P66; Nakajima K, 2007, NEUROCHEM INT, V50, P807, DOI 10.1016/j.neuint.2007.02.006; Nalecz Katarzyna A., 2004, Molecular Aspects of Medicine, V25, P551; Navarrete M, 2011, CELL, V146, P675, DOI 10.1016/j.cell.2011.08.006; Nehlig A, 2004, J CEREBR BLOOD F MET, V24, P1004, DOI 10.1097/01.WCB.0000128533.84196.D8; Nielsen R, 2008, GENE DEV, V22, P2953, DOI 10.1101/gad.501108; Paintlia MK, 2013, J BIOL CHEM, V288, P3831, DOI 10.1074/jbc.M112.405654; Pardo Beatriz, 2013, Front Endocrinol (Lausanne), V4, P149, DOI 10.3389/fendo.2013.00149; Pardo B, 2011, J CEREBR BLOOD F MET, V31, P90, DOI 10.1038/jcbfm.2010.146; Pekny M, 2014, PHYSIOL REV, V94, P1077, DOI 10.1152/physrev.00041.2013; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Pelton P, 2006, CURR OPIN INVEST DR, V7, P360; Perea G, 2014, FRONT CELL NEUROSCI, V8, DOI [10.3389/1ncel.2014.00378, 10.3389/fncel.2014.00378]; Perea G, 2009, TRENDS NEUROSCI, V32, P421, DOI 10.1016/j.tins.2009.05.001; Perez-Alvarez A, 2013, CURR DRUG TARGETS, V14, P1220; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Phatnani H, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020628; Polak PE, 2005, J NEUROIMMUNOL, V168, P65, DOI 10.1016/j.jneuroim.2005.07.006; Polazzi E, 2002, REV NEUROSCIENCE, V13, P221; Polazzi E, 2001, GLIA, V36, P271, DOI 10.1002/glia.1115; Porta N, 2009, EPILEPSIA, V50, P943, DOI 10.1111/j.1528-1167.2008.01901.x; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Properzi F, 2005, EUR J NEUROSCI, V21, P378, DOI 10.1111/j.1460-9568.2005.03876.x; Raso GM, 2011, J NEUROENDOCRINOL, V23, P591, DOI 10.1111/j.1365-2826.2011.02152.x; Romera C, 2007, J CEREBR BLOOD F MET, V27, P1327, DOI 10.1038/sj.jcbfm.9600438; Romero J, 2014, NEUROSCI LETT, V565, P42, DOI 10.1016/j.neulet.2013.10.046; Saez PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071361; Sahebkar A, 2014, EXPERT OPIN PHARMACO, V15, P493, DOI 10.1517/14656566.2014.876992; Sartoris D J, 1990, J Foot Surg, V29, P292; Sastre M, 2003, J NEUROSCI, V23, P9796; Sastre M, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-25; Sato T, 2011, NEUROBIOL AGING, V32, P1626, DOI 10.1016/j.neurobiolaging.2009.10.009; SAWADA M, 1995, INT J DEV NEUROSCI, V13, P253, DOI 10.1016/0736-5748(94)00076-F; Sayan-Ozacmak H, 2011, CURR NEUROVASC RES, V8, P190, DOI 10.2174/156720211796558087; Schitine C, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00076; Schnegg CI, 2013, FREE RADICAL BIO MED, V61, P1, DOI 10.1016/j.freeradbiomed.2013.03.002; Sergeeva MG, 2010, J NEUROCHEM, V115, P399, DOI 10.1111/j.1471-4159.2010.06931.x; SHANK RP, 1985, BRAIN RES, V329, P364, DOI 10.1016/0006-8993(85)90552-9; Shen Y, 2014, REGUL PEPTIDES, V192, P45, DOI 10.1016/j.regpep.2014.08.005; Simard AR, 2007, J COMP NEUROL, V504, P716, DOI 10.1002/cne.21469; Simonini MV, 2010, ASN NEURO, V2, DOI 10.1042/AN20090033; Skripuletz T, 2013, BRAIN, V136, P147, DOI 10.1093/brain/aws262; Spagnolo A, 2007, NEUROSCI LETT, V417, P72, DOI 10.1016/j.neulet.2007.02.036; Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200; Sun H, 2012, NEUROL SCI, V33, P559, DOI 10.1007/s10072-011-0774-2; Sun XY, 2015, J NEUROSCI RES, V93, P1703, DOI 10.1002/jnr.23615; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Tabernero A, 2006, J NEUROCHEM, V99, P1049, DOI 10.1111/j.1471-4159.2006.04088.x; Taib B, 2013, J BIOL CHEM, V288, P37216, DOI 10.1074/jbc.M113.506238; Targett-Adams P, 2005, BBA-GENE STRUCT EXPR, V1728, P95, DOI 10.1016/j.bbaexp.2005.01.017; Tekkok SB, 2005, J NEUROSCI RES, V81, P644, DOI 10.1002/jnr.20573; Thoren AE, 2006, J NEUROCHEM, V97, P968, DOI 10.1111/j.1471-4159.2006.03778.x; Thorens B, 2015, DIABETOLOGIA, V58, P221, DOI 10.1007/s00125-014-3451-1; Tian GX, 2013, INT J IMMUNOPATH PH, V26, P757, DOI 10.1177/039463201302600320; Torrente D, 2014, HUM EXP TOXICOL, V33, P673, DOI 10.1177/0960327113509659; Tourino C, 2010, INT J OBESITY, V34, P557, DOI 10.1038/ijo.2009.262; TSACOPOULOS M, 1994, J NEUROSCI, V14, P1339, DOI 10.1523/JNEUROSCI.14-03-01339.1994; Tsukahara T, 2013, BIOCHEM BIOPH RES CO, V433, P281, DOI 10.1016/j.bbrc.2013.02.101; Vannucci SJ, 1998, DEV BRAIN RES, V107, P255, DOI 10.1016/S0165-3806(98)00021-2; Varnat F, 2006, GASTROENTEROLOGY, V131, P538, DOI 10.1053/j.gastro.2006.05.004; Verkhratsky A, 2013, GLIAL PHYSL PATHOPHY, P453; Verma R, 2011, J NEUROSCI RES, V89, P1849, DOI 10.1002/jnr.22710; Vorobyov V, 2013, J NEUROSCI, V33, P234, DOI 10.1523/JNEUROSCI.2283-12.2013; Waagepetersen HS, 2001, J NEUROSCI RES, V66, P763, DOI 10.1002/jnr.10061; Wadosky KM, 2012, AM J PHYSIOL-HEART C, V302, pH515, DOI 10.1152/ajpheart.00703.2011; Wahli W, 2012, TRENDS ENDOCRIN MET, V23, P351, DOI 10.1016/j.tem.2012.05.001; WALZ W, 1988, GLIA, V1, P366, DOI 10.1002/glia.440010603; Wang GM, 2011, NEUROSCI RES, V70, P230, DOI 10.1016/j.neures.2011.02.001; Wang HM, 2010, J ALZHEIMERS DIS, V20, P1189, DOI 10.3233/JAD-2010-091336; Wang P, 2008, BRAIN RES, V1236, P1, DOI 10.1016/j.brainres.2008.08.001; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Woods JW, 2003, BRAIN RES, V975, P10, DOI 10.1016/S0006-8993(03)02515-0; Xiong XX, 2015, STROKE, V46, P2271, DOI 10.1161/STROKEAHA.115.008897; Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772; Xu JH, 2005, J NEUROSCI RES, V81, P403, DOI 10.1002/jnr.20518; Xu JH, 2007, J NEUROCHEM, V103, P1801, DOI 10.1111/j.1471-4159.2007.04875.x; Xu JH, 2007, J IMMUNOL, V178, P1904, DOI 10.4049/jimmunol.178.3.1904; Yao J, 2011, MOL ASPECTS MED, V32, P247, DOI 10.1016/j.mam.2011.10.005; Yawata I, 2008, LIFE SCI, V82, P1111, DOI 10.1016/j.lfs.2008.03.010; Yessoufou A, 2010, SWISS MED WKLY, V140, P4, DOI 10.4414/smw.2010.13071; Yudkoff M, 1997, GLIA, V21, P92, DOI 10.1002/(SICI)1098-1136(199709)21:1<92::AID-GLIA10>3.0.CO;2-W; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhao S, 2016, CELL REP; Zhao WH, 2006, J NEUROCHEM, V99, P1176, DOI 10.1111/j.1471-4159.2006.04172.x	267	76	78	1	58	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	MAY	2017	54	4					2518	2538		10.1007/s12035-016-9833-2			21	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ES1QY	WOS:000399303300015	26984740				2022-02-06	
J	Korley, FK; Diaz-Arrastia, R; Wu, AHB; Yue, JK; Manley, GT; Sair, HI; Van Eyk, J; Everett, AD; Okonkwo, DO; Valadka, AB; Gordon, WA; Maas, AIR; Mukherjee, P; Yuh, EL; Lingsma, HF; Puccio, AM; Schnyer, DM				Korley, Frederick K.; Diaz-Arrastia, Ramon; Wu, Alan H. B.; Yue, John K.; Manley, Geoffrey T.; Sair, Haris I.; Van Eyk, Jennifer; Everett, Allen D.; Okonkwo, David O.; Valadka, Alex B.; Gordon, Wayne A.; Maas, Andrew I. R.; Mukherjee, Pratik; Yuh, Esther L.; Lingsma, Hester F.; Puccio, Ava M.; Schnyer, David M.		TRACK-TBI Investigators	Circulating Brain-Derived Neurotrophic Factor Has Diagnostic and Prognostic Value in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; brain-derived neurotrophic factor; glial fibrillary acidic protein; traumatic brain injury; ubiquitin C-terminal hydrolase-L1	FIBRILLARY ACIDIC PROTEIN; COMMON DATA ELEMENTS; C-TERMINAL HYDROLASE; RAT-BRAIN; HUMAN PLATELETS; BDNF LEVELS; TRANSFORMING RESEARCH; EMERGENCY-DEPARTMENT; CLINICAL KNOWLEDGE; FACTOR EXPRESSION	Brain-derived neurotrophic factor (BDNF) is important for neuronal survival and regeneration. We investigated the diagnostic and prognostic values of serum BDNF in traumatic brain injury (TBI). We examined serum BDNF in two independent cohorts of TBI cases presenting to the emergency departments (EDs) of the Johns Hopkins Hospital (JHH; n=76) and San Francisco General Hospital (SFGH, n=80), and a control group of JHH ED patients without TBI (n=150). Findings were subsequently validated in the prospective, multi-center Transforming Research and Clinical Knowledge in TBI (TRACK-TBI) Pilot study (n=159). We investigated the association between BDNF, glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase-L1 (UCH-L1) and recovery from TBI at 6 months in the TRACK-TBI Pilot cohort. Incomplete recovery was defined as having either post-concussive syndrome or a Glasgow Outcome Scale Extended score <8 at 6 months. Median day-of-injury BDNF concentrations (ng/mL) were lower among TBI cases (JHH TBI, 17.5 and SFGH TBI, 13.8) than in JHH controls (60.3; p=0.0001). Among TRACK-TBI Pilot subjects, median BDNF concentrations (ng/mL) were higher in mild (8.3) than in moderate (4.3) or severe TBI (4.0; p=0.004. In the TRACK-TBI cohort, the 75 (71.4%) subjects with very low BDNF values (i.e., <the 1st percentile for non-TBI controls, <14.2ng/mL) had higher odds of incomplete recovery than those who did not have very low values (odds ratio, 4.0; 95% confidence interval [CI]: 1.5-11.0). The area under the receiver operator curve for discriminating complete and incomplete recovery was 0.65 (95% CI: 0.52-0.78) for BDNF, 0.61 (95% CI: 0.49-0.73) for GFAP, and 0.55 (95% CI: 0.43-0.66) for UCH-L1. The addition of GFAP/UCH-L1 to BDNF did not improve outcome prediction significantly. Day-of-injury serum BDNF is associated with TBI diagnosis and also provides 6-month prognostic information regarding recovery from TBI. Thus, day-of-injury BDNF values may aid in TBI risk stratification.	[Korley, Frederick K.] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21209 USA; [Sair, Haris I.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21209 USA; [Everett, Allen D.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21209 USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Wu, Alan H. B.] San Francisco Gen Hosp, Clin Chem Lab, San Francisco, CA 94110 USA; [Yue, John K.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Mukherjee, Pratik; Yuh, Esther L.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Van Eyk, Jennifer] Cedars Sinai Med Ctr, Dept Med, Adv Clin Biosyst Res Inst, Los Angeles, CA 90048 USA; [Okonkwo, David O.; Valadka, Alex B.; Gordon, Wayne A.; Maas, Andrew I. R.; Mukherjee, Pratik; Yuh, Esther L.; Lingsma, Hester F.; Puccio, Ava M.; Schnyer, David M.] Transforming Res & Clin Knowledge TBI TRACK Inves, New York, NY USA; [Okonkwo, David O.; Puccio, Ava M.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Lingsma, Hester F.] Erasmas Med Ctr, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA		Korley, FK (corresponding author), Johns Hopkins Univ, Sch Med, Davis Bldg,Suite 3220,5801 Smith Ave, Baltimore, MD 21209 USA.	fkorley1@jhmi.edu	Yue, John K/P-1348-2015; Schnyer, David/ABD-6372-2021	Yue, John K/0000-0001-9694-7722; Schnyer, David/0000-0002-7472-2853; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Mukherjee, Pratik/0000-0001-7473-7409	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409, U01NS086090] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409, U01NS086090] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [HHSN268201000032C] Funding Source: Medline		Alonso M, 2002, HIPPOCAMPUS, V12, P551, DOI 10.1002/hipo.10035; Apple FS, 2003, CLIN CHEM, V49, P1331, DOI 10.1373/49.8.1331; Apple FS, 2005, CLIN CHEM, V51, P2198, DOI 10.1373/clinchem.2005.052886; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Bekinschtein P, 2008, NEUROSCIENTIST, V14, P147, DOI 10.1177/1073858407305850; Brunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; Cohen-Cory S, 2010, DEV NEUROBIOL, V70, P271, DOI 10.1002/dneu.20774; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Fidalgo TM, 2014, J ECT, V30, P47, DOI 10.1097/YCT.0b013e31828b34d8; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Golden E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010099; Green MJ, 2011, MOL PSYCHIATR, V16, P960, DOI 10.1038/mp.2010.88; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Helan M, 2014, J MOL CELL CARDIOL, V68, P89, DOI 10.1016/j.yjmcc.2014.01.006; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Hol EM, 2015, CURR OPIN CELL BIOL, V32, P121, DOI 10.1016/j.ceb.2015.02.004; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kalish H, 2010, J CHROMATOGR B, V878, P194, DOI 10.1016/j.jchromb.2009.10.022; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Karege F, 2002, NEUROSCI LETT, V328, P261, DOI 10.1016/S0304-3940(02)00529-3; Kim DH, 2005, NEUROCRIT CARE, V3, P71, DOI 10.1385/NCC:3:1:071; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; Korley FK, 2014, ACAD EMERG MED, V21, P728, DOI 10.1111/acem.12417; Korley FK, 2013, ACAD EMERG MED, V20, P463, DOI 10.1111/acem.12136; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Lommatzsch M, 2005, NEUROBIOL AGING, V26, P115, DOI 10.1016/j.neurobiolaging.2004.03.002; Lommatzsch M, 1999, AM J PATHOL, V155, P1183, DOI 10.1016/S0002-9440(10)65221-2; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mondello S, 2012, BRAIN INJURY, V26, P1629, DOI 10.3109/02699052.2012.700083; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Pan WH, 1998, NEUROPHARMACOLOGY, V37, P1553, DOI 10.1016/S0028-3908(98)00141-5; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, ACAD EMERG MED, V19, P2, DOI 10.1111/j.1553-2712.2011.01247.x; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Radka SF, 1996, BRAIN RES, V709, P122, DOI 10.1016/0006-8993(95)01321-0; Rudge JS, 1998, EXP NEUROL, V149, P398, DOI 10.1006/exnr.1997.6737; Schwartz J., 2014, CRIT CARE MED S, V42, pA1488, DOI [10.1097/01.ccm.0000458030.91776.65, DOI 10.1097/01.CCM.0000458030.91776.65]; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shulga A, 2008, J NEUROSCI, V28, P6996, DOI 10.1523/JNEUROSCI.5268-07.2008; Silva H., 2013, FRONT PSYCHIATRY, V4, P45, DOI 10.3389/fpsyt.2013.00045; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Steyerberg EW, 1999, J CLIN EPIDEMIOL, V52, P935, DOI 10.1016/S0895-4356(99)00103-1; Storzbach D., 2013, VA EVIDENCE BASED SY; Suliman S, 2013, FRONT INTEGR NEUROSC, V7, DOI 10.3389/fnint.2013.00055; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Yamada K, 2003, J PHARMACOL SCI, V91, P267; YAMAMOTO H, 1990, J NEUROSCI, V10, P3469; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhou Zheng, 2003, Journal of Basic and Clinical Physiology and Pharmacology, V14, P217	68	76	76	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2016	33	2					215	225		10.1089/neu.2015.3949			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DA7PH	WOS:000367995800007	26159676	Green Published, Green Accepted			2022-02-06	
J	Glenn, TC; Martin, NA; Horning, MA; McArthur, DL; Hovda, DA; Vespa, P; Brooks, GA				Glenn, Thomas C.; Martin, Neil A.; Horning, Michael A.; McArthur, David L.; Hovda, David A.; Vespa, Paul; Brooks, George A.			Lactate: Brain Fuel in Human Traumatic Brain Injury: A Comparison with Normal Healthy Control Subjects	JOURNAL OF NEUROTRAUMA			English	Article						brain; fuel augmentation; glucose; lactate; mass spectrometry; stable isotopes; TBI	CEREBRAL BLOOD-FLOW; EXERCISE; GLUCOSE; REST; MUSCLE; GLUCONEOGENESIS; ACCLIMATIZATION; METABOLISM; RELEASE; EXTRACTION	We evaluated the hypothesis that lactate shuttling helps support the nutritive needs of injured brains. To that end, we utilized dual isotope tracer [6,6-(2)H2]glucose, that is, D2-glucose, and [3-C-13]lactate techniques involving arm vein tracer infusion along with simultaneous cerebral (arterial [art] and jugular bulb [JB]) blood sampling. Traumatic brain injury (TBI) patients with nonpenetrating brain injuries (n=12) were entered into the study following consent of patients' legal representatives. Written and informed consent was obtained from control volunteers (n=6). Patients were studied 5.7 +/- 2.2 (mean +/- SD) days post-injury; during periods when arterial glucose concentration tended to be higher in TBI patients. As in previous investigations, the cerebral metabolic rate for glucose (CMRgluc, i.e., net glucose uptake) was significantly suppressed following TBI (p<0.001). However, lactate fractional extraction, an index of cerebral lactate uptake related to systemic lactate supply, approximated 11% in both healthy control subjects and TBI patients. Further, neither the CMR for lactate (CMRlac, i.e., net lactate release), nor the tracer-measured cerebral lactate uptake differed between healthy controls and TBI patients. The percentages of lactate tracer taken up and released as (CO2)-C-13 into the JB accounted for 92% and 91% for control and TBI conditions, respectively, suggesting that most cerebral lactate uptake was oxidized following TBI. Comparisons of isotopic enrichments of lactate oxidation from infused [3-C-13]lactate tracer and C-13-glucose produced during hepatic and renal gluconeogenesis (GNG) showed that 75-80% of (CO2)-C-13 released into the JB was from lactate and that the remainder was from the oxidation of glucose secondarily labeled from lactate. Hence, either directly as lactate uptake, or indirectly via GNG, peripheral lactate production accounted for approximate to 70% of carbohydrate (direct lactate uptake+uptake of glucose from lactate) consumed by the injured brain. Undiminished cerebral lactate fractional extraction and uptake suggest that arterial lactate supplementation may be used to compensate for decreased CMRgluc following TBI.	[Glenn, Thomas C.; Martin, Neil A.; McArthur, David L.; Hovda, David A.; Vespa, Paul] Univ Calif Los Angeles, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA; [Glenn, Thomas C.; Martin, Neil A.] Univ Calif Los Angeles, Ctr Hlth Sci, Dept Neurosurg, Los Angeles, CA 90095 USA; [Horning, Michael A.; Brooks, George A.] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA		Glenn, TC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	tglenn@mednet.ucla.edu		Martin, Neil/0000-0002-6565-4131; Glenn, Thomas/0000-0003-4273-3408; Brooks, George A./0000-0002-1389-1629	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS058489, P01NS058489] Funding Source: Medline		AHLBORG G, 1982, J CLIN INVEST, V69, P45, DOI 10.1172/JCI110440; Bergman BC, 2000, AM J PHYSIOL-ENDOC M, V278, pE244, DOI 10.1152/ajpendo.2000.278.2.E244; Bergman BC, 1999, J APPL PHYSIOL, V87, P1684, DOI 10.1152/jappl.1999.87.5.1684; Bergman BC, 2009, J PHYSIOL-LONDON, V587, P2087, DOI 10.1113/jphysiol.2008.168286; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bouzat P, 2014, INTENS CARE MED, V40, P412, DOI 10.1007/s00134-013-3203-6; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brooks G.A., 1984, COMP PHYSL BIOCH CUR; Brooks GA, 1998, AM J PHYSIOL-REG I, V275, pR1192, DOI 10.1152/ajpregu.1998.275.4.R1192; BROOKS GA, 1992, J APPL PHYSIOL, V72, P2435, DOI 10.1152/jappl.1992.72.6.2435; Brooks GA, 2002, BIOCHEM SOC T, V30, P258, DOI 10.1042/BST0300258; BROOKS GA, 1991, J APPL PHYSIOL, V71, P333, DOI 10.1152/jappl.1991.71.1.333; Brooks GA, 2009, J PHYSIOL-LONDON, V587, P5591, DOI 10.1113/jphysiol.2009.178350; Cahill G J Jr, 1968, Adv Enzyme Regul, V6, P143, DOI 10.1016/0065-2571(68)90011-3; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; Emhoff CAW, 2013, J APPL PHYSIOL, V115, P829, DOI 10.1152/japplphysiol.00538.2013; Emhoff CAW, 2013, J APPL PHYSIOL, V114, P297, DOI 10.1152/japplphysiol.01202.2012; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; GERTZ EW, 1981, CIRCULATION, V63, P1273, DOI 10.1161/01.CIR.63.6.1273; GERTZ EW, 1988, J CLIN INVEST, V82, P2017, DOI 10.1172/JCI113822; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Glenn TC, 2014, J NEUROTRAUMA; HAKIM A M, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P115; Hashimoto T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002915; Henderson GC, 2007, J APPL PHYSIOL, V103, P1604, DOI 10.1152/japplphysiol.00309.2007; Hintze JL, 1998, AM STAT, V52, P181, DOI 10.2307/2685478; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Institute of Medicine, 2005, DIET REF INT EN CARB; Jalloh I, 2013, J NEUROTRAUM, V30, P2031, DOI 10.1089/neu.2013.2947; JENSSEN T, 1993, EUR J CLIN INVEST, V23, P448, DOI 10.1111/j.1365-2362.1993.tb00789.x; Johnson ML, 2012, AM J PHYSIOL-REG I, V302, pR143, DOI 10.1152/ajpregu.00402.2011; Johnson ML, 2011, AM J PHYSIOL-REG I, V301, pR769, DOI 10.1152/ajpregu.00206.2011; MAZZEO RS, 1995, AM J PHYSIOL-REG I, V269, pR201, DOI 10.1152/ajpregu.1995.269.1.R201; MAZZEO RS, 1986, J APPL PHYSIOL, V60, P232, DOI 10.1152/jappl.1986.60.1.232; Messonnier LA, 2013, J APPL PHYSIOL, V114, P1593, DOI 10.1152/japplphysiol.00043.2013; Meyer C, 2002, AM J PHYSIOL-ENDOC M, V282, pE419, DOI 10.1152/ajpendo.00032.2001; Miller BF, 2005, J APPL PHYSIOL, V98, P856, DOI 10.1152/japplphysiol.00753.2004; Miller BF, 2002, J PHYSIOL-LONDON, V544, P963, DOI 10.1113/jphysiol.2002.027128; Miller BF, 2002, AM J PHYSIOL-ENDOC M, V283, pE889, DOI 10.1152/ajpendo.00266.2002; Patel AB, 2014, P NATL ACAD SCI USA, V111, P5385, DOI 10.1073/pnas.1403576111; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; Schurr A, 2007, NEUROSCIENCE, V147, P613, DOI 10.1016/j.neuroscience.2007.05.002; Schurr A, 2006, J CEREBR BLOOD F MET, V26, P142, DOI 10.1038/sj.jcbfm.9600174; Siesjo BK, 1996, ADV NEUROL, V71, P209; SOKOLOFF L, 1977, J NEUROCHEM, V29, P13, DOI 10.1111/j.1471-4159.1977.tb03919.x; STANLEY WC, 1986, J APPL PHYSIOL, V60, P1116, DOI 10.1152/jappl.1986.60.4.1116; STEELE R, 1959, ANN NY ACAD SCI, V82, P420, DOI 10.1111/j.1749-6632.1959.tb44923.x; Trimmer JK, 2001, AM J PHYSIOL-ENDOC M, V281, pE683, DOI 10.1152/ajpendo.2001.281.4.E683; TSERNG KY, 1984, ANAL CHEM, V56, P517, DOI 10.1021/ac00267a049; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; Wilcox R.R., 2012, INTRO ROBUST ESTIMAT; Wolfe R.R., 1982, RADIOACTIVE STABLE I; Yuen K.F., 1985, J ROYAL STAT SOC D, V34, P175	56	76	79	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2015	32	11					820	832		10.1089/neu.2014.3483			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CV0YU	WOS:000363980700007	25594628	Green Published, Green Submitted			2022-02-06	
J	Koerte, IK; Lin, AP; Willems, A; Muehlmann, M; Hufschmidt, J; Coleman, MJ; Green, I; Liao, HJ; Tate, DF; Wilde, EA; Pasternak, O; Bouix, S; Rathi, Y; Bigler, ED; Stern, RA; Shenton, ME				Koerte, Inga K.; Lin, Alexander P.; Willems, Anna; Muehlmann, Marc; Hufschmidt, Jakob; Coleman, Michael J.; Green, Isobel; Liao, Huijun; Tate, David F.; Wilde, Elisabeth A.; Pasternak, Ofer; Bouix, Sylvain; Rathi, Yogesh; Bigler, Erin D.; Stern, Robert A.; Shenton, Martha E.			A Review of Neuroimaging Findings in Repetitive Brain Trauma	BRAIN PATHOLOGY			English	Article						neuroimaging; repetitive head injury	MILD COGNITIVE IMPAIRMENT; CEREBRAL GLUCOSE-METABOLISM; WHITE-MATTER INTEGRITY; RETIRED NFL PLAYERS; PROFESSIONAL BOXERS; CORTICAL THICKNESS; FOOTBALL PLAYERS; IMAGING FINDINGS; AMATEUR BOXERS; AXONAL INJURY	Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease confirmed at postmortem. Those at highest risk are professional athletes who participate in contact sports and military personnel who are exposed to repetitive blast events. All neuropathologically confirmed CTE cases, to date, have had a history of repetitive head impacts. This suggests that repetitive head impacts may be necessary for the initiation of the pathogenetic cascade that, in some cases, leads to CTE. Importantly, while all CTE appears to result from repetitive brain trauma, not all repetitive brain trauma results in CTE. Magnetic resonance imaging has great potential for understanding better the underlying mechanisms of repetitive brain trauma. In this review, we provide an overview of advanced imaging techniques currently used to investigate brain anomalies. We also provide an overview of neuroimaging findings in those exposed to repetitive head impacts in the acute/subacute and chronic phase of injury and in more neurodegenerative phases of injury, as well as in military personnel exposed to repetitive head impacts. Finally, we discuss future directions for research that will likely lead to a better understanding of the underlying mechanisms separating those who recover from repetitive brain trauma vs. those who go on to develop CTE.	[Koerte, Inga K.; Lin, Alexander P.; Willems, Anna; Muehlmann, Marc; Hufschmidt, Jakob; Coleman, Michael J.; Green, Isobel; Pasternak, Ofer; Bouix, Sylvain; Rathi, Yogesh; Shenton, Martha E.] Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, Boston, MA 02215 USA; [Koerte, Inga K.; Lin, Alexander P.; Willems, Anna; Muehlmann, Marc; Hufschmidt, Jakob; Coleman, Michael J.; Green, Isobel; Pasternak, Ofer; Bouix, Sylvain; Rathi, Yogesh; Shenton, Martha E.] Brigham & Womens Hosp, Dept Radiol, Psychiat Neuroimaging Lab, Boston, MA 02215 USA; [Lin, Alexander P.; Liao, Huijun] Brigham & Womens Hosp, Dept Radiol, Ctr Clin Spect, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; [Stern, Robert A.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Dept Neurol, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Dept Neurosurg, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Boston, MA USA; [Koerte, Inga K.; Willems, Anna; Muehlmann, Marc] Univ Munich, Dr von Hauner Childrens Hosp, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Hufschmidt, Jakob] Univ Munich, Dr von Hauner Childrens Hosp, Dept Pediat Neurol, Munich, Germany; [Tate, David F.] San Antonio Mil Med Ctr, Def Ctr, San Antonio, TX USA; [Tate, David F.] San Antonio Mil Med Ctr, Vet Brain Injury Ctr, San Antonio, TX USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med & Rehabil, San Antonio, TX USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, San Antonio, TX USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, San Antonio, TX USA; [Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, San Antonio, TX USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA		Koerte, IK (corresponding author), Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA.	ikoerte@bwh.harvard.edu	Koerte, Inga Katharina/AAW-3031-2021; , Bob/ABA-8507-2020; Shenton, Martha/V-8780-2019; Tate, David F/I-3963-2013	Tate, David F/0000-0003-0213-1920; Stern, Robert/0000-0002-5008-077X	Else Kroner-Fresenius-Stiftung, Germany; Department of DefenseUnited States Department of Defense [W81XWH-10-1-0835, X81XWH-07-CC-CSDoD]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS078337, U01-NS086659]; VA Merit AwardUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337, U01NS086659] Funding Source: NIH RePORTER	This study was supported by the Else Kroner-Fresenius-Stiftung, Germany (IK, MM). This work was also partially funded by grants from the Department of Defense (W81XWH-10-1-0835: APL; X81XWH-07-CC-CSDoD; MES, RAS), the National Institutes of Health (R01-NS078337: APL, MES, RAS; U01-NS086659: RAS) and a VA Merit Award (MES).	Abbas K, 2014, BRAIN CONNECT; Agdeppa ED, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0004.2001; Agel J, 2010, CAN J SURG, V53, P319; Albaugh MD, 2015, J PEDIATR-US, V166, P394, DOI 10.1016/j.jpeds.2014.10.016; Amen DG, 2011, J PSYCHOACTIVE DRUGS, V43, P1, DOI 10.1080/02791072.2011.566489; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Attardo G, 2014, EUR J NUCL MED MOL I, V41, pS427; Aviv RI, 2010, CAN ASSOC RADIOL J, V61, P29, DOI 10.1016/j.carj.2009.09.002; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Banks SJ, 2014, J NEUROPSYCH CLIN N, V26, P44, DOI 10.1176/appi.neuropsych.12070185; Barnes SRS, 2009, MAGN RESON IMAGING C, V17, P47, DOI 10.1016/j.mric.2008.12.002; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Bowman KM, 1940, INJURIES SKULL BRAIN, P309; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Chang YL, 2010, CEREB CORTEX, V20, P1305, DOI 10.1093/cercor/bhp192; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Clay MB, 2013, J CHIROPR MED, V12, P230, DOI 10.1016/j.jcm.2012.11.005; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Corps K. N., 2015, JAMA NEUROL; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Critchley M., 1949, HOMMAGE CLOVIS VINCE, P131; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; De Meyer G, 2010, ARCH NEUROL-CHICAGO, V67, P949, DOI 10.1001/archneurol.2010.179; Dickerson BC, 2012, NEUROLOGY, V78, P84, DOI 10.1212/WNL.0b013e31823efc6c; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2012, NEUROSURG FOCUS, V33, P1, DOI DOI 10.3171/2012.10.F0CUS12286; Eskridge SL, 2012, INJURY, V43, P1678, DOI 10.1016/j.injury.2012.05.027; Ford JH, 2013, J NEUROTRAUM, V30, P1683, DOI 10.1089/neu.2012.2535; Gandy Sam, 2014, F1000Res, V3, P229, DOI 10.12688/f1000research.5372.1; Garcia-Panach J, 2011, J NEUROTRAUM, V28, P1707, DOI 10.1089/neu.2011.1851; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; Hahnel S, 2008, AM J NEURORADIOL, V29, P388, DOI 10.3174/ajnr.A0799; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132090, 10.3171/2013.12.JNS132093]; Hetherington HP, 2014, MAGN RESON MED, V71, P1358, DOI 10.1002/mrm.24814; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; Ibarretxe-Bilbao N, 2012, MOVEMENT DISORD, V27, P1746, DOI 10.1002/mds.25240; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Jubault T, 2011, NEUROIMAGE, V55, P462, DOI 10.1016/j.neuroimage.2010.12.043; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kaufman MS, 2014, PHYS MED REH CLIN N, V25, P707, DOI 10.1016/j.pmr.2014.06.002; KEMP PM, 1995, J NEUROL NEUROSUR PS, V59, P368, DOI 10.1136/jnnp.59.4.368; Khan AR, 2008, NEUROIMAGE, V41, P735, DOI 10.1016/j.neuroimage.2008.03.024; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lanius RA, 2006, J PSYCHIATR RES, V40, P709, DOI 10.1016/j.jpsychires.2005.07.007; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; Lin A, 2012, SEMIN NEUROL, V32, P432, DOI 10.1055/s-0032-1331814; Lin AP, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0094-5; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Little DM, 2014, ALZHEIMERS DEMENT, V10, pS188, DOI 10.1016/j.jalz.2014.04.002; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Malcolm JG, 2010, MED IMAGE ANAL, V14, P58, DOI 10.1016/j.media.2009.10.003; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATTHEWS WB, 1972, BRIT MED J, V2, P326, DOI 10.1136/bmj.2.5809.326; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; McAllister T, 2014, TASK RELATED CEREBRA; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; Millspaugh JA, 1937, US NAVAL MED B, V35, P297; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Ozarslan E, 2013, NEUROIMAGE, V78, P16, DOI 10.1016/j.neuroimage.2013.04.016; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Park H, 2013, NEUROSCI LETT, V550, P17, DOI 10.1016/j.neulet.2013.06.042; Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrie EC, 2014, J NEUROTRAUM, V31, P425, DOI [10.1089/NEU.2013.2952, 10.1089/neu.2013.2952]; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Poole VN, 2014, DEV NEUROPSYCHOL, V39, P459, DOI 10.1080/87565641.2014.940619; Provenzano FA, 2010, NUCL MED COMMUN, V31, P952, DOI 10.1097/MNM.0b013e32833e37c4; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Rathi Y, 2013, LECT NOTES COMPUT SC, V8151, P510, DOI 10.1007/978-3-642-40760-4_64; Rishiraj N, 2009, J SPORT MED PHYS FIT, V49, P159; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seo SW, 2010, J NEUROIMAGING, V20, P37, DOI 10.1111/j.1552-6569.2008.00293.x; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Shah M, 2014, J NUCL MED, V55, P871, DOI 10.2967/jnumed.113.136069; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Shoup TM, 2013, J LABELLED COMPD RAD, V56, P736, DOI 10.1002/jlcr.3098; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Singh V, 2006, BRAIN, V129, P2885, DOI 10.1093/brain/awl256; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stamm JM, 2015, NEUROLOGY; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stone JR, 2013, J NEUROTRAUM, V30, pA120; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Tartaglia MC, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00030; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; Terry DP, 2012, BRAIN INJURY, V26, P1684, DOI 10.3109/02699052.2012.722259; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Villemagne VL, 2014, ALZHEIMERS DEMENT, V10, pS254, DOI 10.1016/j.jalz.2014.04.013; Villemagne VL, 2012, FUTUR NEUROL, V7, P409, DOI 10.2217/FNL.12.34; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008; Xu L, 2014, EXP NEUROL; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zhang L, 2006, AM J NEURORADIOL, V27, P2000; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52; Zhang MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057364; Zhang W, 2012, J ALZHEIMERS DIS, V31, P601, DOI 10.3233/JAD-2012-120712; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542; Zhuo JC, 2012, NEUROIMAGE, V59, P467, DOI 10.1016/j.neuroimage.2011.07.050	173	76	76	2	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	MAY	2015	25	3					318	349		10.1111/bpa.12249			32	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	CG6CX	WOS:000353384200009	25904047	Green Published, Green Accepted			2022-02-06	
J	Samadani, U; Ritlop, R; Reyes, M; Nehrbass, E; Li, M; Lamm, E; Schneider, J; Shimunov, D; Sava, M; Kolecki, R; Burris, P; Altomare, L; Mehmood, T; Smith, T; Huang, JH; McStay, C; Todd, SR; Qian, M; Kondziolka, D; Wall, S; Huang, P				Samadani, Uzma; Ritlop, Robert; Reyes, Marleen; Nehrbass, Elena; Li, Meng; Lamm, Elizabeth; Schneider, Julia; Shimunov, David; Sava, Maria; Kolecki, Radek; Burris, Paige; Altomare, Lindsey; Mehmood, Talha; Smith, Theodore; Huang, Jason H.; McStay, Christopher; Todd, S. Rob; Qian, Meng; Kondziolka, Douglas; Wall, Stephen; Huang, Paul			Eye Tracking Detects Disconjugate Eye Movements Associated with Structural Traumatic Brain Injury and Concussion	JOURNAL OF NEUROTRAUMA			English	Article						disconjugate; eye movement tracking; cranial nerve palsy; ocular motility; concussion	MINOR HEAD-INJURY; NULL DISTRIBUTION; POST-CONCUSSION; RULE	Disconjugate eye movements have been associated with traumatic brain injury since ancient times. Ocular motility dysfunction may be present in up to 90% of patients with concussion or blast injury. We developed an algorithm for eye tracking in which the Cartesian coordinates of the right and left pupils are tracked over 200 sec and compared to each other as a subject watches a short film clip moving inside an aperture on a computer screen. We prospectively eye tracked 64 normal healthy noninjured control subjects and compared findings to 75 trauma subjects with either a positive head computed tomography (CT) scan (n=13), negative head CT (n=39), or nonhead injury (n=23) to determine whether eye tracking would reveal the disconjugate gaze associated with both structural brain injury and concussion. Tracking metrics were then correlated to the clinical concussion measure Sport Concussion Assessment Tool 3 (SCAT3) in trauma patients. Five out of five measures of horizontal disconjugacy were increased in positive and negative head CT patients relative to noninjured control subjects. Only one of five vertical disconjugacy measures was significantly increased in brain-injured patients relative to controls. Linear regression analysis of all 75 trauma patients demonstrated that three metrics for horizontal disconjugacy negatively correlated with SCAT3 symptom severity score and positively correlated with total Standardized Assessment of Concussion score. Abnormal eye-tracking metrics improved over time toward baseline in brain-injured subjects observed in follow-up. Eye tracking may help quantify the severity of ocular motility disruption associated with concussion and structural brain injury.	[Samadani, Uzma; Li, Meng; Qian, Meng] New York Univ Sch Med, Steven & Alexandra Cohen Vet Ctr Posttraumat Stre, NYU Langone Med Ctr, New York, NY USA; [Samadani, Uzma; Ritlop, Robert; Reyes, Marleen; Nehrbass, Elena; Lamm, Elizabeth; Schneider, Julia; Shimunov, David; Sava, Maria; Kolecki, Radek; Burris, Paige; Altomare, Lindsey; Mehmood, Talha; Kondziolka, Douglas; Huang, Paul] New York Univ Sch Med, Dept Neurosurg, New York, NY USA; [Smith, Theodore] New York Univ Sch Med, Dept Ophthalmol, New York, NY USA; [McStay, Christopher; Wall, Stephen] New York Univ Sch Med, Dept Emergency Med, New York, NY USA; [Todd, S. Rob] New York Univ Sch Med, Dept Trauma Surg, New York, NY USA; [Samadani, Uzma; Reyes, Marleen; Nehrbass, Elena] New York Harbor Hlth Care Syst, Dept Neurosurg, New York, NY USA; [Huang, Jason H.] Baylor Scott & White Neurosci Inst, Dept Neurosurg, Temple, TX USA		Samadani, U (corresponding author), New York Univ Sch Med, Dept Neurosurg, 423 East 23rd St,MC 112, New York, NY 10012 USA.	uzma.samadani@nyumc.org	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168; Huang, Paul/0000-0003-0563-921X; smith, theodore/0000-0002-1693-943X; Wall, Stephen/0000-0003-3965-5074	Steven and Alexandra Cohen Center for Veteran Post-Traumatic Stress and Traumatic Brain Injury; NYU Applied Research Support Fund; Veterans AffairsUS Department of Veterans Affairs [I01RX000319] Funding Source: NIH RePORTER	This work was supported by the Steven and Alexandra Cohen Center for Veteran Post-Traumatic Stress and Traumatic Brain Injury and the NYU Applied Research Support Fund. The funding sources had no role in the collection, analysis, and interpretation of data, the writing of the report, and the decision to submit the manuscript for publication.	Cavezian C, 2010, RES DEV DISABIL, V31, P1102, DOI 10.1016/j.ridd.2010.03.006; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Dickmann A, 2012, OPHTHAL EPIDEMIOL, V19, P302, DOI 10.3109/09286586.2012.694553; Ganz JC, 2014, J NEUROSURG, V120, P1238, DOI 10.3171/2013.12.JNS131520; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; Maruta J, 2014, PROG NEUROL SURG, V28, P226, DOI 10.1159/000358786; Maruta J, 2014, MIL MED, V179, P619, DOI 10.7205/MILMED-D-13-00420; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Murray NG, 2014, BRAIN INJURY, V28, P496, DOI 10.3109/02699052.2014.887144; Pagnacco Guido, 2012, Biomed Sci Instrum, V48, P332; Pollard KS, 2004, J STAT PLAN INFER, V125, P85, DOI 10.1016/j.jspi.2003.07.019; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Samadani U., 2014, J NEUROSURG, P1; Samadani U., 2013, Methods and kits for assessing central nervous system integrity, Patent No. [PCT/US 13/33672, 1333672]; Schachar JL, 2011, PEDIATR RADIOL, V41, P971, DOI 10.1007/s00247-011-2032-4; Schotter ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035608; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Szymanowicz D, 2012, J REHABIL RES DEV, V49, P1083, DOI 10.1682/JRRD.2010.07.0129; Thiagarajan P, 2011, OPHTHAL PHYSL OPT, V31, P456, DOI 10.1111/j.1475-1313.2011.00831.x; van der Laan MJ, 2006, STAT APPL GENET MOL, V5	23	76	76	1	29	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2015	32	8					548	556		10.1089/neu.2014.3687			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CF2BS	WOS:000352352900004	25582436	Green Published			2022-02-06	
J	Mitsis, EM; Riggio, S; Kostakoglu, L; Dickstein, DL; Machac, J; Delman, B; Goldstein, M; Jennings, D; D'Antonio, E; Martin, J; Naidich, TP; Aloysi, A; Fernandez, C; Seibyl, J; DeKosky, ST; Elder, GA; Marek, K; Gordon, W; Hof, PR; Sano, M; Gandy, S				Mitsis, E. M.; Riggio, S.; Kostakoglu, L.; Dickstein, D. L.; Machac, J.; Delman, B.; Goldstein, M.; Jennings, D.; D'Antonio, E.; Martin, J.; Naidich, T. P.; Aloysi, A.; Fernandez, C.; Seibyl, J.; DeKosky, S. T.; Elder, G. A.; Marek, K.; Gordon, W.; Hof, P. R.; Sano, M.; Gandy, S.			Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury	TRANSLATIONAL PSYCHIATRY			English	Article							BRAIN-INJURY; ALZHEIMERS-DISEASE; RISK-FACTOR; ASSOCIATION; LIFE	Single, severe traumatic brain injury (TBI) which elevates CNS amyloid, increases the risk of Alzheimer's disease (AD); while repetitive concussive and subconcussive events as observed in athletes and military personnel, may increase the risk of chronic traumatic encephalopathy (CTE). We describe two clinical cases, one with a history of multiple concussions during a career in the National Football League (NFL) and the second with frontotemporal dementia and a single, severe TBI. Both patients presented with cognitive decline and underwent [F-18]-Florbetapir positron emission tomography (PET) imaging for amyloid plaques; the retired NFL player also underwent [F-18]-T807 PET imaging, a new ligand binding to tau, the main constituent of neurofibrillary tangles (NFT). Case 1, the former NFL player, was 71 years old when he presented with memory impairment and a clinical profile highly similar to AD. [F-18]-Florbetapir PET imaging was negative, essentially excluding AD as a diagnosis. CTE was suspected clinically, and [F-18]-T807 PET imaging revealed striatal and nigral [F-18]-T807 retention consistent with the presence of tauopathy. Case 2 was a 56-year-old man with personality changes and cognitive decline who had sustained a fall complicated by a subdural hematoma. At 1 year post injury, [F-18]-Florbetapir PET imaging was negative for an AD pattern of amyloid accumulation in this subject. Focal [F-18]-Florbetapir retention was noted at the site of impact. In case 1, amyloid imaging provided improved diagnostic accuracy where standard clinical and laboratory criteria were inadequate. In that same case, tau imaging with [F-18]-T807 revealed a subcortical tauopathy that we interpret as a novel form of CTE with a distribution of tauopathy that mimics, to some extent, that of progressive supranuclear palsy (PSP), despite a clinical presentation of amnesia without any movement disorder complaints or signs. A key distinguishing feature is that our patient presented with hippocampal involvement, which is more frequently seen in CTE than in PSP. In case 2, focal [F-18]-Florbetapir retention at the site of injury in an otherwise negative scan suggests focal amyloid aggregation. In each of these complex cases, a combination of [F-18]-fluorodeoxyglucose, [F-18]-Florbetapir and/or [F-18]-T807 PET molecular imaging improved the accuracy of diagnosis and prevented inappropriate interventions.	[Mitsis, E. M.; Riggio, S.; Martin, J.; Aloysi, A.; Fernandez, C.; Elder, G. A.; Sano, M.; Gandy, S.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Mitsis, E. M.; Dickstein, D. L.; Fernandez, C.; Hof, P. R.; Sano, M.; Gandy, S.] Icahn Sch Med Mt Sinai, Mt Sinais Alzheimers Dis Res Ctr, New York, NY 10029 USA; [Mitsis, E. M.; Riggio, S.; Fernandez, C.; Elder, G. A.; Sano, M.; Gandy, S.] James J Peters VA Med Ctr, Bronx, NY USA; [Riggio, S.; Goldstein, M.; Elder, G. A.; Gandy, S.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Riggio, S.; Gordon, W.; Gandy, S.] Icahn Sch Med Mt Sinai, NFL Neurol Program, New York, NY 10029 USA; [Kostakoglu, L.; Machac, J.] Icahn Sch Med Mt Sinai, Dept Nucl Med, New York, NY 10029 USA; [Dickstein, D. L.; Hof, P. R.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA; [Delman, B.; Naidich, T. P.] Icahn Sch Med Mt Sinai, Dept Radiol, New York, NY 10029 USA; [Jennings, D.; Seibyl, J.; Marek, K.] Yale Univ, Inst Neurodegenerat Disorders, New Haven, CT USA; [D'Antonio, E.; Gordon, W.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [DeKosky, S. T.] Univ Virginia, Dept Neurol, Charlottesville, VA USA		Gandy, S (corresponding author), James J Peters VA Med Ctr, Mt Sinais Alzheimers Dis Res Ctr, One Gustave L Levy Pl,Box 1187, New York, NY 10029 USA.	samuel.gandy@mssm.edu	Dickstein, Dara/AAH-6603-2020	Marek, Kenneth/0000-0002-4197-5627; Fernandez, Corey/0000-0003-3901-5552; Delman, Bradley/0000-0002-9792-8942; DeKosky, Steven/0000-0003-3743-2758	Veterans Affairs AdministrationUS Department of Veterans Affairs; Icahn School of Medicine Clinical Research Center.; Cure Alzheimer's Fund; Department of Veteran AffairsUS Department of Veterans Affairs; Gideon and Sarah Gartner Foundation; Louis B. Mayer Foundation; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Baxter Pharmaceuticals; Polyphenolics; Amicus Pharmaceuticals; Icahn School of Medicine Alzheimer's Disease Research Center [P50 AG005138]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005138] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000684] Funding Source: NIH RePORTER	We gratefully acknowledge Ash Rafique for technical support. EMM received grants from the Veterans Affairs Administration and the Icahn School of Medicine Clinical Research Center. SG thanks the Cure Alzheimer's Fund, the Department of Veteran Affairs, the Gideon and Sarah Gartner Foundation and the Louis B. Mayer Foundation. SG has received grants from NIA, NINDS, Baxter Pharmaceuticals, Polyphenolics and Amicus Pharmaceuticals. He has served as a member of the Data and Safety Monitoring Board for the Pfizer-Janssen Alzheimer's Immunotherapy Alliance, as a member of the Scientific Advisory Board of DiaGenic and as a consultant to Amicus Pharmaceuticals and to Cerora. This research was supported in part by the Icahn School of Medicine Alzheimer's Disease Research Center grant P50 AG005138.	Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Goodwin Linda, 2006, J Insur Med, V38, P300; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hammers A, 2003, HUM BRAIN MAPP, V19, P224, DOI 10.1002/hbm.10123; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Landau SM, 2012, ANN NEUROL, V72, P578, DOI 10.1002/ana.23650; Ling H, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-24; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mitsis EM, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-10; Nordberg A, 2013, EUR J NUCL MED MOL I, V40, P104, DOI 10.1007/s00259-012-2237-2; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008	28	76	79	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	SEP	2014	4								e441	10.1038/tp.2014.91			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Psychiatry	AT3HS	WOS:000344827000011	25226550	Green Published, gold			2022-02-06	
J	Chrisman, SP; Schiff, MA; Chung, SK; Herring, SA; Rivara, FP				Chrisman, Sara P.; Schiff, Melissa A.; Chung, Shana K.; Herring, Stanley A.; Rivara, Frederick P.			Implementation of Concussion Legislation and Extent of Concussion Education for Athletes, Parents, and Coaches in Washington State	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						return to play; education; athletics; concussion; adolescents; legislation	TRAUMATIC BRAIN-INJURY; KNOWLEDGE; SOCCER; IMPACT	Background: Most states in the United States have passed laws regarding concussions, but little is known regarding the implementation of these laws. Hypothesis/Purpose: The purpose of this study was to survey high school coaches 3 years after the passage of a concussion law to evaluate the variation in concussion education and knowledge in the context of this law as well as measure the effects of sport (football vs soccer) and urban versus rural locations. The hypothesis was that concussion education and knowledge would be more extensive in football compared with soccer and in urban locations compared with rural locations. Study Design: Descriptive epidemiology study. Methods: A mixed-methods (paper and online) survey was conducted in 2012 to 2013 on a random sample of public high school football, girls' soccer, and boys' soccer coaches in Washington State, stratified by urban and rural locality. The survey covered the extent of concussion education for coaches, athletes, and parents as well as coaches' concussion knowledge and experience. Results: Of 496 coaches contacted, 270 responded (54.4%). Nearly all coaches answered concussion knowledge questions correctly, and nearly all coaches received education via >= 2 modalities (written, video, slide presentation, test, and in person). Athlete education was less extensive, with 34.7% exposed to >= 2 modalities and 29.5% only signing a concussion information form. Parent education was even more limited, with 16.2% exposed to >= 2 modalities and 57.9% only signing a concussion information form. Significantly more football than soccer coaches gave their athletes an in-person talk about concussions (59.1% vs 39.4%, respectively; P = .002) and provided concussion education to athletes via >= 2 modalities (44.1% vs 29.7%, respectively; P = .02). Concussion education for coaches and parents was similar between sports, and concussion education for all parties was similar in urban and rural localities. Conclusion: Three years after the passage of a concussion law in Washington State, high school football and soccer coaches are receiving substantial concussion education and have good concussion knowledge. Concussion education for athletes and parents is more limited. Football players receive more extensive concussion education than do soccer players. Clinical Relevance: Clinicians should be aware that athletes and parents may not be receiving significant concussion education.	[Chrisman, Sara P.; Schiff, Melissa A.; Chung, Shana K.; Herring, Stanley A.; Rivara, Frederick P.] Univ Washington, Seattle, WA 98104 USA		Chrisman, SP (corresponding author), Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, 325 Ninth Ave,Box 359960, Seattle, WA 98104 USA.	sara.chrisman@seattlechildrens.org		Chrisman, Sara/0000-0001-5373-7223	Public Health Law Research Program of the Robert Wood Johnson Foundation	One or more of the authors has declared the following potential conflict of interest or source of funding: S. A. H. has a nonfinancial role on the medical advisory board for X2 Biosystems, which makes monitors that measure the force of head impacts while playing sports. Support for this study was provided by a grant from the Public Health Law Research Program of the Robert Wood Johnson Foundation.	Adler RH, 2011, PM&R, V3, pS468, DOI 10.1016/j.pmrj.2011.08.006; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Broglio SP, 2010, J SPORT SCI MED, V9, P418; *CDCP, HEADS CONC YOUTH SPO; Chopp F, 2009, YOUTH SPORTS HEAD IN, V1824; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Ginns P, 2005, LEARN INSTR, V15, P313, DOI 10.1016/j.learninstruc.2005.07.001; Hailu A, 2013, GUIDELINES USING RUR; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Heffler B, 2001, EDUC STUD, V27, P307, DOI 10.1080/03055690120076583; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; National Athletic Trainers' Association, 2009, ATHL TRAIN FILL NEC; National Federation of State High School Associations, CONC SPORTS WHAT YOU; National Football League, ZACK LYST LAW; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Tomei KL, 2012, NEUROSURG FOCUS, V33, pE11; van Merrienboer JJG, 2010, MED EDUC, V44, P85, DOI 10.1111/j.1365-2923.2009.03498.x; Washington Interscholastic Activities Association, CONC MAN GUID	21	76	76	0	29	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2014	42	5					1190	1196		10.1177/0363546513519073			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	AG6ZM	WOS:000335567700022	24510067				2022-02-06	
J	Wang, Y; Wang, H; Tao, Y; Zhang, S; Wang, J; Feng, X				Wang, Y.; Wang, H.; Tao, Y.; Zhang, S.; Wang, J.; Feng, X.			NECROPTOSIS INHIBITOR NECROSTATIN-1 PROMOTES CELL PROTECTION AND PHYSIOLOGICAL FUNCTION IN TRAUMATIC SPINAL CORD INJURY	NEUROSCIENCE			English	Article						spinal cord injury; necrostatin-1; necroptosis; apoptosis; cell protection; physiological function.	OXIDATIVE STRESS; DEATH; HYPOXIA; PATHWAY; KINASE; BRAIN; RATS; STEM	Spinal cord injury (SCI) is a common and serious trauma which lacks efficient treatment. Inhibition of cell death in the trauma area is important for spinal cord protection during this process. In this study, necroptosis inhibitor necrostatin-1 (Nec-1) was used to treat SCI rats, to investigate the role of Nec-1 in the recovery of SCI. Nec-1 was found to reduce lesions, cytokines and reactive oxygen species (ROS), improve pathological conditions and blood supply in the spinal cord trauma area. Further study indicated that Nec-1 could inhibit necroptosis by inhibiting RIP1/3-MLKL recruitment and inhibit apoptosis by inhibiting Caspase 3 and Bax while activating Bcl-2. Ethological performance of SCI rats confirmed improvement and protection of physiological function by Nec-1. Nec-1 as a potential treatment for SCI warrants further study. To our knowledge, this is the first study on the role of Nec-1 in the treatment of traumatic SCI. Our research also found inhibition effects of Nec-1 on apoptosis, not only necroptosis - as reported by most publications. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Wang, Y.; Wang, H.; Tao, Y.; Zhang, S.; Wang, J.; Feng, X.] Yangzhou Univ, Subei Peoples Hosp Jiangsu Prov, Clin Med Coll, Dept Orthoped, Yangzhou 225001, Jiangsu, Peoples R China		Wang, J (corresponding author), Yangzhou Univ, Subei Peoples Hosp Jiangsu Prov, Clin Med Coll, Dept Orthoped, Yangzhou 225001, Jiangsu, Peoples R China.	0001wjc@sina.com; fxm918spine@126.com		FENG, Xinmin/0000-0001-9287-858X	Research Project Foundation on Social Development of Science and Technology of Yangzhou [YZ2011082]	This study was supported by the Research Project Foundation on Social Development of Science and Technology of Yangzhou (YZ2011082).	Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Bryden AM, 2012, J PEDIATR REHAB MED, V5, P287, DOI 10.3233/PRM-2012-00227; Chavez-Valdez R, 2012, NEUROSCIENCE, V219, P192, DOI 10.1016/j.neuroscience.2012.05.002; David Samuel, 2012, Handb Clin Neurol, V109, P485, DOI 10.1016/B978-0-444-52137-8.00030-9; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Goldsmith HS, 2004, NEUROL RES, V26, P586, DOI 10.1179/016164104225017622; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; He YD, 2013, NEUROBIOL DIS, V49, P22, DOI 10.1016/j.nbd.2012.08.014; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Karimi-Abdolrezaee S, 2012, ADV EXP MED BIOL, V760, P53; Keane RW, 2006, J NEUROTRAUM, V23, P335, DOI 10.1089/neu.2006.23.335; Liu P, 2012, SPINAL TRAUMA MAINLA, V37; Liu WM, 2011, J NEUROSCI RES, V89, P791, DOI 10.1002/jnr.22602; Loo DT, 2011, METHODS MOL BIOL, V682, P3, DOI 10.1007/978-1-60327-409-8_1; Lukens JR, 2013, NATURE, V498, P224, DOI 10.1038/nature12174; Marsala J, 2007, PROG BRAIN RES, V161, P171, DOI 10.1016/S0079-6123(06)61011-X; Moon YJ, 2012, J NEUROSCI RES, V90, P243, DOI 10.1002/jnr.22734; Naujokat C, 2009, ARCH IMMUNOL THER EX, V57, P177, DOI 10.1007/s00005-009-0019-8; Redondo-Castro E, 2013, J NEUROSCI METH, V213, P165, DOI 10.1016/j.jneumeth.2012.12.024; Sacerdote P, 2013, J NEUROIMMUNE PHARM, V8, P202, DOI 10.1007/s11481-012-9428-2; Spitzbarth I, 2012, VET IMMUNOL IMMUNOP, V147, P6, DOI 10.1016/j.vetimm.2012.04.005; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Thapa RJ, 2013, P NATL ACAD SCI USA, V110, pE3109, DOI 10.1073/pnas.1301218110; Ullah N, 2011, NEUROPHARMACOLOGY, V61, P1248, DOI 10.1016/j.neuropharm.2011.06.031; Wang YX, 2013, MOL MED REP, V8, P883, DOI 10.3892/mmr.2013.1579; Wang YX, 2012, BRAIN RES, V1448, P137, DOI 10.1016/j.brainres.2012.02.007; Wang ZY, 2007, CHINESE J PHYSIOL, V50, P211; Xu M, 2011, ACTA PHARMACOL SIN, V32, P1089, DOI 10.1038/aps.2011.50; Xu XS, 2010, BRAIN RES, V1355, P189, DOI 10.1016/j.brainres.2010.07.080; Zhang QL, 2008, INT J IMMUNOPATH PH, V21, P787, DOI 10.1177/039463200802100403	33	76	86	0	28	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 25	2014	266						91	101		10.1016/j.neuroscience.2014.02.007			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AE8VO	WOS:000334281200009	24561219				2022-02-06	
J	Lazaridis, C; DeSantis, SM; Smielewski, P; Menon, DK; Hutchinson, P; Pickard, JD; Czosnyka, M				Lazaridis, Christos; DeSantis, Stacia M.; Smielewski, Peter; Menon, David K.; Hutchinson, Peter; Pickard, John D.; Czosnyka, Marek			Patient-specific thresholds of intracranial pressure in severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; cerebrovascular pressure reactivity; neuromonitoring; clinical outcome; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; HEAD-INJURY; NEUROCRITICAL CARE; REACTIVITY; HYPERTENSION; MORTALITY; INSULTS; IMPACT	Object. Based on continuous monitoring of the pressure reactivity index (PRx), the authors defined individualized intracranial pressure (ICP) thresholds by graphing the relationship between ICP and PRx. These investigators hypothesized that an "ICP dose" based on individually assessed ICP thresholds would correlate more closely with the 6-month outcome when compared with ICP doses derived by the recommended universal thresholds of 20 and 25 mm Hg. Methods. This study was a retrospective analysis of prospectively collected data from 327 patients with severe traumatic brain injury. Results. Individualized thresholds were visually identified from graphs of PRx versus ICP; PRx > 0.2 was the cutoff. Intracranial pressure doses were then computed as the cumulative area under the curve above the defined thresholds in graphing ICP versus time. The term "Dose 20" (D20) was used to refer to an ICP threshold of 20 mm Hg; the markers D25 and DPRx were calculated similarly. Separate logistic regression models were fit with death as the outcome and each dose as the predictor, both alone and adjusted for covariates. The discriminative ability of each dose for mortality was assessed by receiver operating characteristic AUC analysis in which 5-fold cross-validation was used. A clearly identifiable PRx-based threshold was possible in 224 patients (68%). The DPRx (AUC 0.81, 95% CI 0.74-0.87) was found to have the highest area under the curve (AUC) over both D20 (0.75, 95% CI 0.68-0.81) and D25 (0.77, 95% CI 0.70-0.83); in the cross-validation model, DPRx remained the best discriminator of mortality (DPRx: AUC 0.77 [95% CI 0.68-0.89]; D20: 0.72 [95% CI 0.66-0.81]; and D25: 0.65 [95% CI 0.56-0.73]). Conclusions. The authors explored the importance of different ICP thresholds for outcome by calculating patient-specific ICP doses based on the continuous monitoring of cerebrovascular pressure reactivity. They found that these individualized doses of intracranial hypertension were stronger predictors of death than doses derived from the universal thresholds of 20 and 25 mm Hg. The PRx could offer a method that can be directed toward individualizing the ICP threshold.	[Lazaridis, Christos; Smielewski, Peter; Hutchinson, Peter; Pickard, John D.; Czosnyka, Marek] Univ Cambridge, Sch Clin, Acad Neurosurg Unit, Cambridge, England; [Lazaridis, Christos] Baylor Coll Med, Dept Neurol, Div Neurocrit Care, Houston, TX 77030 USA; [Lazaridis, Christos] Baylor Coll Med, Dept Neurol, Div Vasc Neurol, Houston, TX 77030 USA; [DeSantis, Stacia M.] Univ Texas Houston, Sch Publ Hlth Houston, Div Biostat, Houston, TX USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Univ Dept Anaesthesia, Cambridge CB2 2QQ, England		Lazaridis, C (corresponding author), Baylor Coll Med, Dept Neurol, Div Neurocrit Care, 6501 Fannin St,Mail Slot NB320, Houston, TX 77030 USA.	lazaridi@bcm.edu		Smielewski, Peter/0000-0001-5096-3938	Academy of Medical SciencesAcademy of Medical Sciences (AMS); Health Foundation Senior Scientist Fellowship; Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); National Institute for Health Research (NIHR)National Institute for Health Research (NIHR); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); NIHR Cambridge Biomedical Centre; NIHR Biomedical Research Centre (Cambridge University Hospital Foundation Trust); MRC "Acute Brain Injury Programme"; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0601025, G9439390, G0001237, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1000183B, G9439390, G0601025, G0001354, G0001237, G0600986, G0001354B] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [12/35/57, NF-SI-0508-10327, NIHR-RP-R3-12-013, NF-SI-0512-10090] Funding Source: researchfish	The software for brain monitoring ICM+ (http://www.neuro surg.cam.ac.uk/icmplus) is licensed by the University of Cambridge (Cambridge Enterprise Ltd.). Mr. Czosnyka and Mr. Smielewski have a financial interest in a part of the licensing fee. Mr. Hutchinson is supported by an Academy of Medical Sciences/Health Foundation Senior Scientist Fellowship and grants from the Medical Research Council (MRC)/National Institute for Health Research (NIHR). He has also received a lecture honorarium from Codman and is a patent holder in Technicam. Mr. Menon is supported by funding from the MRC, the NIHR Cambridge Biomedical Centre, and an NIHR Senior Investigator award. Mr. Pickard is an NIHR senior investigator awardee and a principal investigator within the NIHR Biomedical Research Centre (Cambridge University Hospital Foundation Trust) and lead principal investigator for the MRC "Acute Brain Injury Programme" grant. The remaining authors have not disclosed any potential conflict of interest.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Biousse V, 2012, J NEUROL NEUROSUR PS, V83, P488, DOI 10.1136/jnnp-2011-302029; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1998, ACT NEUR S, V71, P74; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Elf K, 2005, NEUROSURGERY, V56, P962, DOI 10.1227/01.NEU.0000158317.00603.40; Hemphill JC, 2005, PHYSIOL MEAS, V26, P373, DOI 10.1088/0967-3334/26/4/004; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; JENNETT B, 1975, LANCET, V1, P480; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kim DJ, 2009, NEUROSURGERY, V64, P494, DOI 10.1227/01.NEU.0000338434.59141.89; Lazaridis C, 2013, NEUROL RES, V35, P138, DOI 10.1179/1743132812Y.0000000150; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Smielewski P, 2008, ACTA NEUROCHIR SUPPL, V102, P145, DOI 10.1007/978-3-211-85578-2_30; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Timmons SD, 2011, NEW ENGL J MED, V365, P373, DOI 10.1056/NEJMc1106421; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678	31	76	83	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2014	120	4					893	900		10.3171/2014.1.JNS131292			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AD7IZ	WOS:000333438800014	24506248				2022-02-06	
J	McClure, DJ; Zuckerman, SL; Kutscher, SJ; Gregory, AJ; Solomon, GS				McClure, D. Jake; Zuckerman, Scott L.; Kutscher, Scott J.; Gregory, Andrew J.; Solomon, Gary S.			Baseline Neurocognitive Testing in Sports-Related Concussions The Importance of a Prior Night's Sleep	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	39th Annual Meeting of the American-Orthopaedic-Society-for-Sports-Medicine (AOSSM)	JUL, 2013	Chicago, IL			concussion; ImPACT; athletes; sleep; mild traumatic brain injury	TEST-RETEST RELIABILITY; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; SEX-DIFFERENCES; UNITED-STATES; NEUROPSYCHOLOGICAL FUNCTION; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; ADOLESCENT SLEEP; PERFORMANCE	Background: The management of sports-related concussions (SRCs) utilizes serial neurocognitive assessments and self-reported symptom inventories to assess recovery and safety for return to play (RTP). Because postconcussive RTP goals include symptom resolution and a return to neurocognitive baseline levels, clinical decisions rest in part on understanding modifiers of this baseline. Several studies have reported age and sex to influence baseline neurocognitive performance, but few have assessed the potential effect of sleep. We chose to investigate the effect of reported sleep duration on baseline Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) performance and the number of patient-reported symptoms. Hypothesis: We hypothesized that athletes receiving less sleep before baseline testing would perform worse on neurocognitive metrics and report more symptoms. Study Design: Cross-sectional study; Level of evidence, 3. Methods: We retrospectively reviewed 3686 nonconcussed athletes (2371 male, 1315 female; 3305 high school, 381 college) with baseline symptom and ImPACT neurocognitive scores. Patients were stratified into 3 groups based on self-reported sleep duration the night before testing: (1) short, <7 hours; (2) intermediate, 7-9 hours; and (3) long, >9 hours. A multivariate analysis of covariance (MANCOVA) with an a level of .05 was used to assess the influence of sleep duration on baseline ImPACT performance. A univariate ANCOVA was performed to investigate the influence of sleep on total self-reported symptoms. Results: When controlling for age and sex as covariates, the MANCOVA revealed significant group differences on ImPACT reaction time, verbal memory, and visual memory scores but not visual-motor (processing) speed scores. An ANCOVA also revealed significant group differences in total reported symptoms. For baseline symptoms and ImPACT scores, subsequent pairwise comparisons revealed these associations to be most significant when comparing the short and intermediate sleep groups. Conclusion: Our results indicate that athletes sleeping fewer than 7 hours before baseline testing perform worse on 3 of 4 ImPACT scores and report more symptoms. Because SRC management and RTP decisions hinge on the comparison with a reliable baseline evaluation, clinicians should consider sleep duration before baseline neurocognitive testing as a potential factor in the assessment of athletes' recovery.	[McClure, D. Jake; Zuckerman, Scott L.; Kutscher, Scott J.; Gregory, Andrew J.; Solomon, Gary S.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA		McClure, DJ (corresponding author), POB 32861, Charlotte, NC 28232 USA.	jake.mcclure@carolinashealthcare.org	Meijer, Anna/K-5118-2016; Solomon, Gary/K-9011-2019				Astill RG, 2012, PSYCHOL BULL, V138, P1109, DOI 10.1037/a0028204; Belenky G, 2003, J SLEEP RES, V12, P1, DOI 10.1046/j.1365-2869.2003.00337.x; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Carskadon MA, 2004, ANN NY ACAD SCI, V1021, P276, DOI 10.1196/annals.1308.032; Carskadon MA, 2002, SLEEP, V25, P606, DOI 10.1093/sleep/25.6.606; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Dinges DF, 1997, SLEEP, V20, P267; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Faul M, TRAUMATIC BRAIN INJU; Ferri R, 2010, SLEEP MED, V11, P378, DOI 10.1016/j.sleep.2010.01.006; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fredriksen K, 2004, CHILD DEV, V75, P84, DOI 10.1111/j.1467-8624.2004.00655.x; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goel N, 2009, SEMIN NEUROL, V29, P320, DOI 10.1055/s-0029-1237117; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kleitman, 1963, SLEEP WAKEFULNESS; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kribbs N.B., 1994, HARSH RDOJR SLEEP ON, P113; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell M., IMPACT VERSION 2 0 C; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lund HG, 2010, J ADOLESCENT HEALTH, V46, P124, DOI 10.1016/j.jadohealth.2009.06.016; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; Matricciani L, 2011, SLEEP, V34, P651, DOI 10.1093/sleep/34.5.651; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Murray EJ, 1965, SLEEP DREAMS AROUSAL; Oginska H, 2006, CHRONOBIOL INT, V23, P1317, DOI 10.1080/07420520601089349; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Roberts RE, 2001, J YOUTH ADOLESCENCE, V30, P1, DOI 10.1023/A:1005230820074; Saint Martin M, 2012, SLEEP MED, V13, P1146, DOI 10.1016/j.sleep.2012.06.021; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Sosin DM, 1996, BRAIN INJURY, V10, P47; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Van Dongen HPA, 2004, SLEEP, V27, P423; Weiss EM, 2005, FORTSCHR NEUROL PSYC, V73, P587, DOI 10.1055/s-2004-830296; Wolfson AR, 2003, SLEEP MED REV, V7, P491, DOI 10.1016/S1087-0792(03)90003-7; Wolfson AR, 1998, CHILD DEV, V69, P875, DOI 10.2307/1132351; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	53	76	76	0	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	FEB	2014	42	2					472	478		10.1177/0363546513510389			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Orthopedics; Sport Sciences	AH6CS	WOS:000336218900034	24256713				2022-02-06	
J	Tosun, C; Kurland, DB; Mehta, R; Castellani, RJ; deJong, JL; Kwon, MS; Woo, SK; Gerzanich, V; Simard, JM				Tosun, Cigdem; Kurland, David B.; Mehta, Rupal; Castellani, Rudy J.; deJong, Joyce L.; Kwon, Min Seong; Woo, Seung Kyoon; Gerzanich, Volodymyr; Simard, J. Marc			Inhibition of the Sur1-Trpm4 Channel Reduces Neuroinflammation and Cognitive Impairment in Subarachnoid Hemorrhage	STROKE			English	Article						cognition; memory; subarachnoid hemorrhage; sulfonylurea receptor; transient receptor potential melastatin 4	SULFONYLUREA RECEPTOR 1; TRAUMATIC BRAIN-INJURY; POTENTIAL MELASTATIN 4; LEARNING-DEFICITS; EDEMA; EXPRESSION; CELLS; MODEL; RATS	Background and Purpose Subarachnoid hemorrhage (SAH) can leave patients with memory impairments that may not recover fully. Molecular mechanisms are poorly understood, and no treatment is available. The sulfonylurea receptor 1-transient receptor potential melastatin 4 (Sur1-Trpm4) channel plays an important role in acute central nervous system injury. We evaluated upregulation of Sur1-Trpm4 in humans with SAH and, in rat models of SAH, we examined Sur1-Trpm4 upregulation, its role in barrier dysfunction and neuroinflammation, and its consequences on spatial learning. Methods We used Forster resonance energy transfer to detect coassociated Sur1 and Trpm4 in human autopsy brains with SAH. We studied rat models of SAH involving filament puncture of the internal carotid artery or injection of blood into the subarachnoid space of the entorhinal cortex. In rats, we used Forster resonance energy transfer and coimmunoprecipitation to detect coassociated Sur1 and Trpm4, we measured immunoglobulin G extravasation and tumor necrosis overexpression as measures of barrier dysfunction and neuroinflammation, and we assessed spatial learning and memory on days 7 to 19. Results Sur1-Trpm4 channels were upregulated in humans and rats with SAH. In rats, inhibiting Sur1 using antisense or the selective Sur1 inhibitor glibenclamide reduced SAH-induced immunoglobulin G extravasation and tumor necrosis overexpression. In models with entorhinal SAH, rats treated with glibenclamide for 7 days after SAH exhibited better platform search strategies and better performance on incremental and rapid spatial learning than vehicle-treated controls. Conclusions Sur1-Trpm4 channels are upregulated in humans and rats with SAH. Channel inhibition with glibenclamide may reduce neuroinflammation and the severity of cognitive deficits after SAH.	[Tosun, Cigdem; Kurland, David B.; Kwon, Min Seong; Woo, Seung Kyoon; Gerzanich, Volodymyr; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Mehta, Rupal; Castellani, Rudy J.; Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; [deJong, Joyce L.] Western Michigan Univ, Sch Med, Dept Pathol, Kalamazoo, MI 49008 USA		Simard, JM (corresponding author), Dept Neurosurg, 22 S Greene St,Suite S12D, Baltimore, MD 21201 USA.	msimard@smail.umaryland.edu	Tosun, Cigdem/AAG-4026-2020	deJong, Joyce/0000-0002-8222-3587	National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL082517]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS061808]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL082517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061808, R01NS072501] Funding Source: NIH RePORTER	This work was supported by grants to Dr Simard from the National Heart, Lung, and Blood Institute (HL082517) and the National Institute of Neurological Disorders and Stroke (NS061808).	Aittoniemi J, 2009, PHILOS T R SOC B, V364, P257, DOI 10.1098/rstb.2008.0142; Al-Khindi T, 2010, STROKE, V41, pE519, DOI 10.1161/STROKEAHA.110.581975; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Chen G, 2013, NEUROSCIENCE, V231, P136, DOI 10.1016/j.neuroscience.2012.11.024; Guiot Y, 2007, DIABETOLOGIA, V50, P1889, DOI 10.1007/s00125-007-0731-z; Hanel RA, 2002, NEUROL RES, V24, pS58; Hollenstein K, 2007, CURR OPIN STRUC BIOL, V17, P412, DOI 10.1016/j.sbi.2007.07.003; Jeon H, 2010, NEUROSCIENCE, V169, P1805, DOI 10.1016/j.neuroscience.2010.06.039; Ma JP, 2012, CRIT CARE, V16, DOI 10.1186/cc11686; Mehta RI, 2013, J NEUROPATH EXP NEUR, V72, P871, DOI 10.1097/NEN.0b013e3182a32e40; Niikawa S, 1998, NEUROL MED-CHIR, V38, P844, DOI 10.2176/nmc.38.844; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Quigley MR, 2008, SURG NEUROL, V69, P261, DOI 10.1016/j.surneu.2007.02.013; Shi NQ, 2005, J MOL CELL CARDIOL, V39, P51, DOI 10.1016/j.yjmcc.2004.11.024; Silasi G, 2009, BEHAV BRAIN RES, V198, P380, DOI 10.1016/j.bbr.2008.11.019; Simard JM, 2012, PFLUG ARCH EUR J PHY, V464, P573, DOI 10.1007/s00424-012-1166-z; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2012, TRANSL STROKE RES, V3, P286, DOI 10.1007/s12975-012-0149-x; Simard JM, 2012, TRANSL STROKE RES, V3, pS155, DOI 10.1007/s12975-012-0166-9; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Teruyama R, 2011, J NEUROENDOCRINOL, V23, P1204, DOI 10.1111/j.1365-2826.2011.02211.x; Wagner KR, 2005, CURR NEUROVASC RES, V2, P149, DOI 10.2174/1567202053586785; Woo SK, 2013, J BIOL CHEM, V288, P3655, DOI 10.1074/jbc.M112.428219; Xavier GF, 2009, PROG NEURO-PSYCHOPH, V33, P762, DOI 10.1016/j.pnpbp.2009.03.036	26	76	81	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	DEC	2013	44	12					3522	3528		10.1161/STROKEAHA.113.002904			7	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	257LR	WOS:000327386300327	24114458	Green Accepted, Bronze			2022-02-06	
J	Pedrocchi, A; Ferrante, S; Ambrosini, E; Gandolla, M; Casellato, C; Schauer, T; Klauer, C; Pascual, J; Vidaurre, C; Gfohler, M; Reichenfelser, W; Karner, J; Micera, S; Crema, A; Molteni, F; Rossini, M; Palumbo, G; Guanziroli, E; Jedlitschka, A; Hack, M; Bulgheroni, M; d'Amico, E; Schenk, P; Zwicker, S; Duschau-Wicke, A; Miseikis, J; Graber, L; Ferrigno, G				Pedrocchi, Alessandra; Ferrante, Simona; Ambrosini, Emilia; Gandolla, Marta; Casellato, Claudia; Schauer, Thomas; Klauer, Christian; Pascual, Javier; Vidaurre, Carmen; Gfoehler, Margit; Reichenfelser, Werner; Karner, Jakob; Micera, Silvestro; Crema, Andrea; Molteni, Franco; Rossini, Mauro; Palumbo, Giovanna; Guanziroli, Eleonora; Jedlitschka, Andreas; Hack, Marco; Bulgheroni, Maria; d'Amico, Enrico; Schenk, Peter; Zwicker, Sven; Duschau-Wicke, Alexander; Miseikis, Justinas; Graber, Lina; Ferrigno, Giancarlo			MUNDUS project: MUltimodal Neuroprosthesis for daily Upper limb Support	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article						Assistive device; Upper limb support; Neuromuscular electrical stimulation; Wearable exoskeleton; Neurological disorders	POST-ACUTE STROKE; ELECTRICAL-STIMULATION; EYE-TRACKING; INTERFACE; CLASSIFICATION; DESIGN; ROBOT	Background: MUNDUS is an assistive framework for recovering direct interaction capability of severely motor impaired people based on arm reaching and hand functions. It aims at achieving personalization, modularity and maximization of the user's direct involvement in assistive systems. To this, MUNDUS exploits any residual control of the end-user and can be adapted to the level of severity or to the progression of the disease allowing the user to voluntarily interact with the environment. MUNDUS target pathologies are high-level spinal cord injury (SCI) and neurodegenerative and genetic neuromuscular diseases, such as amyotrophic lateral sclerosis, Friedreich ataxia, and multiple sclerosis (MS). The system can be alternatively driven by residual voluntary muscular activation, head/eye motion, and brain signals. MUNDUS modularly combines an antigravity lightweight and non-cumbersome exoskeleton, closed-loop controlled Neuromuscular Electrical Stimulation for arm and hand motion, and potentially a motorized hand orthosis, for grasping interactive objects. Methods: The definition of the requirements and of the interaction tasks were designed by a focus group with experts and a questionnaire with 36 potential end-users. Five end-users (3 SCI and 2 MS) tested the system in the configuration suitable to their specific level of impairment. They performed two exemplary tasks: reaching different points in the working volume and drinking. Three experts evaluated over a 3-level score (from 0, unsuccessful, to 2, completely functional) the execution of each assisted sub-action. Results: The functionality of all modules has been successfully demonstrated. User's intention was detected with a 100% success. Averaging all subjects and tasks, the minimum evaluation score obtained was 1.13 +/- 0.99 for the release of the handle during the drinking task, whilst all the other sub-actions achieved a mean value above 1.6. All users, but one, subjectively perceived the usefulness of the assistance and could easily control the system. Donning time ranged from 6 to 65 minutes, scaled on the configuration complexity. Conclusions: The MUNDUS platform provides functional assistance to daily life activities; the modules integration depends on the user's need, the functionality of the system have been demonstrated for all the possible configurations, and preliminary assessment of usability and acceptance is promising.	[Pedrocchi, Alessandra; Ferrante, Simona; Ambrosini, Emilia; Gandolla, Marta; Casellato, Claudia; Ferrigno, Giancarlo] Politecn Milan, NeuroEngn & Med Robot Lab, NearLab, Dept Elect Informat & Bioengn, Milan, Italy; [Schauer, Thomas; Klauer, Christian] Tech Univ Berlin, Control Syst Grp, Berlin, Germany; [Pascual, Javier; Vidaurre, Carmen] Tech Univ Berlin, Fac Comp Sci, Machine Learning Grp, Berlin, Germany; [Gfoehler, Margit; Reichenfelser, Werner; Karner, Jakob] Vienna Univ Technol, A-1060 Vienna, Austria; [Micera, Silvestro; Crema, Andrea] Ecole Polytech Fed Lausanne, Ctr Neuroprosthet, Translat Neural Engn Lab, CH-1015 Lausanne, Switzerland; [Micera, Silvestro] Scuola Super Sant Anna, BioRobot Inst, Pisa, Italy; [Molteni, Franco; Rossini, Mauro; Palumbo, Giovanna; Guanziroli, Eleonora] Valduce Hosp, Villa Beretta Rehabil Ctr, Costa Masnaga, Lecco, Italy; [Jedlitschka, Andreas; Hack, Marco] Fraunhofer Inst Expt Software Engn, Kaiserslautern, Germany; [Bulgheroni, Maria; d'Amico, Enrico] Ab Acus, Milan, Italy; [Schenk, Peter; Zwicker, Sven; Duschau-Wicke, Alexander; Miseikis, Justinas; Graber, Lina] Hocoma AG, Volketswil, Switzerland		Pedrocchi, A (corresponding author), Politecn Milan, NeuroEngn & Med Robot Lab, NearLab, Dept Elect Informat & Bioengn, Milan, Italy.	alessandra.pedrocchi@polimi.it	Gandolla, Marta/K-8813-2016; Micera, Silvestro/AAD-6630-2021; Ferrigno, Giancarlo/O-5833-2015; Gandolla, Marta/AAL-8862-2020; Ferrante, Simona/K-4122-2016; Ambrosini, Emilia/R-1371-2016; Schauer, Thomas/J-4137-2012; Schauer, Thomas/AAX-4118-2020; Pedrocchi, Alessandra/AAF-2655-2019; Jedlitschka, Andreas/AAJ-5524-2020; Pedrocchi, Alessandra/A-6634-2012	Gandolla, Marta/0000-0001-5237-714X; Ferrigno, Giancarlo/0000-0001-5913-9451; Gandolla, Marta/0000-0001-5237-714X; Ferrante, Simona/0000-0002-7835-1965; Ambrosini, Emilia/0000-0002-6527-0779; Schauer, Thomas/0000-0002-0865-4418; Schauer, Thomas/0000-0002-0865-4418; Pedrocchi, Alessandra/0000-0001-9957-2786; Pedrocchi, Alessandra/0000-0001-9957-2786; Vidaurre, Carmen/0000-0003-3740-049X; Gfoehler, Margit/0000-0002-8977-8702; Rossini, Mauro/0000-0002-7670-5758; Jedlitschka, Andreas/0000-0003-3590-6331; casellato, claudia/0000-0002-8729-0391	EU STREP MUNDUS [ICT-2009.7.2 - Accessible, Assistive ICT GA 248326]	The work is supported by the EU STREP MUNDUS grant ICT-2009.7.2 - Accessible and Assistive ICT GA 248326. We would like to acknowledge Axelgaard Manufacturing Ltd for donating us the stimulation electrodes and all the subjects who agreed to participate to the study.	Ambrosini E, 2011, IEEE INT CONF REHABI, V2011; Ambrosini E, 2012, IEEE T NEUR SYS REH, V20, P320, DOI 10.1109/TNSRE.2012.2191574; Ambrosini E, 2011, IEEE ENG MED BIO, P4259, DOI 10.1109/IEMBS.2011.6091057; Ambrosini E, 2011, STROKE, V42, P1068, DOI 10.1161/STROKEAHA.110.599068; Ambrosini E, 2010, ARTIF ORGANS, V34, P663, DOI 10.1111/j.1525-1594.2009.00941.x; Bien Z, 2003, IEEE ASME INT C ADV, P902; Biffi E, 2012, BIOTECHNOL BIOENG, V109, P166, DOI 10.1002/bit.23310; Blankertz B, 2011, NEUROIMAGE, V56, P814, DOI 10.1016/j.neuroimage.2010.06.048; Brose SW, 2010, AM J PHYS MED REHAB, V89, P509, DOI 10.1097/PHM.0b013e3181cf569b; Casellato C, 2010, J NEUROENG REHABIL, V7, DOI 10.1186/1743-0003-7-49; Cavallaro EE, 2006, IEEE T BIO-MED ENG, V53, P2387, DOI 10.1109/TBME.2006.880883; Cincotti F, 2008, BRAIN RES BULL, V75, P796, DOI 10.1016/j.brainresbull.2008.01.007; Comolli L, 2010, MED ENG PHYS, V32, P339, DOI 10.1016/j.medengphy.2010.01.005; Davidson PR, 2003, CURR OPIN NEUROBIOL, V13, P232, DOI 10.1016/S0959-4388(03)00038-2; Dipietro L, 2003, J REHABIL RES DEV, V40, P179; Driessen BJF, 2001, P I MECH ENG H, V215, P285, DOI 10.1243/0954411011535876; Ferrante S, 2008, EUR J PHYS REHAB MED, V44, P159; Ferrante S, 2012, P 34 ANN INT C IEEE, V2012, P1; Ferrante S, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-47; Gandolla M, 2011, MED ENG PHYS, V33, P1027, DOI 10.1016/j.medengphy.2011.04.005; Herder JL, 2006, J REHABIL RES DEV, V43, P591, DOI 10.1682/JRRD.2006.05.0044; Inmann A, 2004, MED ENG PHYS, V26, P439, DOI 10.1016/j.medengphy.2004.03.002; Janssen TWJ, 1998, TOP SPINAL CORD INJ, V3, P33; Kilgore K L, 1998, IEEE Trans Rehabil Eng, V6, P424, DOI 10.1109/86.736157; Kinoshita H, 1996, EUR J APPL PHYSIOL, V74, P450; Krantz O, 2012, DISABIL REHABIL-ASSI, V7, P189, DOI 10.3109/17483107.2011.618212; Kuhn A, 2009, MED ENG PHYS, V31, P945, DOI 10.1016/j.medengphy.2009.05.006; Lee EC, 2010, J NEUROSCI METH, V190, P289, DOI 10.1016/j.jneumeth.2010.05.008; Liu YH, 2011, IEEE ENG MED BIO, P7516, DOI 10.1109/IEMBS.2011.6091853; Mele ML, 2012, DISABIL REHABIL-ASSI, V7, P261, DOI 10.3109/17483107.2011.635326; Nef T, 2007, MED BIOL ENG COMPUT, V45, P887, DOI 10.1007/s11517-007-0226-6; Niazi IK, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/6/066009; Popovic DB, 2009, J NEUROSCI METH, V178, P174, DOI 10.1016/j.jneumeth.2008.12.003; Rahman T, 2006, J REHABIL RES DEV, V43, P583, DOI 10.1682/JRRD.2005.04.0070; Riener R, 2005, IEEE T NEUR SYS REH, V13, P380, DOI 10.1109/TNSRE.2005.848628; Schill O, 2011, BIOMED TECH, V56, P35, DOI 10.1515/BMT.2010.056; Sennels S, 1997, IEEE Trans Rehabil Eng, V5, P195, DOI 10.1109/86.593293; Sheffler LR, 2007, MUSCLE NERVE, V35, P562, DOI 10.1002/mus.20758; Sinkjaer T, 2003, MED ENG PHYS, V25, P29, DOI 10.1016/S1350-4533(02)00178-9; Treder MS, 2011, J NEURAL ENG, V8	40	76	77	1	49	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1743-0003			J NEUROENG REHABIL	J. NeuroEng. Rehabil.	JUL 3	2013	10								66	10.1186/1743-0003-10-66			20	Engineering, Biomedical; Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Neurosciences & Neurology; Rehabilitation	193VE	WOS:000322588800001	23822118	Green Published, gold			2022-02-06	
J	Bigler, ED; Abildskov, TJ; Petrie, J; Farrer, TJ; Dennis, M; Simic, N; Taylor, HG; Rubin, KH; Vannatta, K; Gerhardt, CA; Stancin, T; Yeates, KO				Bigler, Erin D.; Abildskov, Tracy J.; Petrie, JoAnn; Farrer, Thomas J.; Dennis, Maureen; Simic, Nevena; Taylor, H. Gerry; Rubin, Kenneth H.; Vannatta, Kathryn; Gerhardt, Cynthia A.; Stancin, Terry; Yeates, Keith Owen			Heterogeneity of Brain Lesions in Pediatric Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						pediatric; traumatic brain injury; magnetic resonance imaging; heterogeneity; hemosiderin; white matter hyperintensities; atrophy	WHITE-MATTER HYPERINTENSITIES; VOXEL-BASED MORPHOMETRY; NEUROPATHOLOGY; DIFFUSION; CHILDREN; ATROPHY; PREVALENCE; DIAGNOSIS	Objective: Magnetic resonance imaging (MRI) provides a method to identify and quantify abnormalities resulting from traumatic brain injury (TBI). MRI abnormalities in children with TBI have not been fully characterized according to the frequency, location, and quantitative measurement of a range of pathologies critical for studies of neuropsychological outcome. Here, we report MRI findings from a large, multicenter study of childhood TBI, the Social Outcomes of Brain Injury in Kids (SOBIK) study, which compared qualitative and quantitative neuroimaging findings in 72 children with complicated mild-to-severe TBI to 52 children with orthopedic injury (OI). Method: Qualitative analyses of MRI scans coded white matter hyperintensities (WMHs), hemosiderin deposits reflecting prior hemorrhagic lesions, regions of encephalomalacia and/or atrophy, and corpus callosum atrophy and traumatic shear lesions. Two automated quantitative analyses were conducted: (a) FreeSurfer methods computed volumes for total brain, white matter (WM), gray matter (GM), corpus callosum, ventricles, amygdala, hippocampus, basal ganglia, and thalamus along with a ventricle-to-brain ratio (VBR); and (b) voxel-based morphometry (VBM) to identify WM, GM, and cerebrospinal fluid. We also examined performance on the Processing Speed Index (PSI) from the Wechsler Intelligence Scale for Children, Fourth Edition, in relation to the above-mentioned neuroimaging variables. Results: WMHs, hemosiderin deposits, and focal areas of encephalomalacia or atrophy were common in children with TBI, were related to injury severity, and were mostly observed within a frontotemporal distribution. Quantitative analyses showed volumetric changes related to injury severity, especially ventricular enlargement and reduced corpus callosum volume. VBM demonstrated similar findings, but, in addition, GM reductions in the inferior frontal, basal forebrain region, especially in the severe TBI group. The complicated mild TBI group showed few differences from the OI group. PSI was significantly associated with global atrophy, as measured by VBR. Conclusion: MRI findings after childhood TBI are diverse and particularly influenced by injury severity, and they involve common features, group heterogeneity, and individual variability.	[Bigler, Erin D.; Abildskov, Tracy J.; Petrie, JoAnn; Farrer, Thomas J.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT 84112 USA; [Dennis, Maureen; Simic, Nevena] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Dennis, Maureen] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada; [Dennis, Maureen] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Rubin, Kenneth H.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.; Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Vannatta, Kathryn; Gerhardt, Cynthia A.] Columbus Childrens Res Inst, Ctr Behav Hlth, Columbus, OH USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Psychiat, Cleveland, OH 44109 USA; [Stancin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu	Gerhardt, Cynthia/E-3109-2011; Stancin, Terry/L-7993-2019; Vannatta, Kathryn/E-4237-2011; Rubin, Kenneth H/M-5276-2018; Yeates, Keith/AAJ-4223-2020	Rubin, Kenneth H/0000-0002-2608-2484; Farrer, Thomas J./0000-0001-8092-6214; Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5R01HD048946, 3R01HD048946-05S1]; Poelman Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER	Supported by the National Institute of Child Health and Human Development (Grant Nos. 5R01HD048946 and 3R01HD048946-05S1) and the Poelman Foundation. We thank radiologists Barbara Bangert, MD (Cleveland), Jerome Rusin, MD (Columbus), and Susan Blaser, MD (Toronto), who assisted with the overseeing and clinical interpretation of scans.	Al-Holou WN, 2010, J NEUROSURG-PEDIATR, V5, P578, DOI 10.3171/2010.2.PEDS09464; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2001, NEUROIMAGE, V14, P1238, DOI 10.1006/nimg.2001.0961; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Bendfeldt K, 2012, HUM BRAIN MAPP, V33, P1225, DOI 10.1002/hbm.21279; Bergeson AG, 2004, CLIN NEUROPSYCHOL, V18, P509, DOI 10.1080/1385404049052414; Bigler ED, 2003, AM J NEURORADIOL, V24, P2066; Bigler ED, 2007, BRAIN INJURY MED PRI, P201; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bruggemann JM, 2009, J CLIN NEUROSCI, V16, P780, DOI 10.1016/j.jocn.2008.08.025; Chen SN, 2009, HUM BRAIN MAPP, V30, P2304, DOI 10.1002/hbm.20669; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Eriksson SH, 2009, HUM BRAIN MAPP, V30, P3351, DOI 10.1002/hbm.20757; Focke NK, 2011, NEUROIMAGE, V56, P1164, DOI 10.1016/j.neuroimage.2011.02.029; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gean AD, 2010, NEUROIMAG CLIN N AM, V20, P527, DOI 10.1016/j.nic.2010.08.001; Gronenschild EHBM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038234; Hartwigsen G, 2010, J COMPUT ASSIST TOMO, V34, P596, DOI 10.1097/RCT.0b013e3181d9c2bb; Hopkins RO, 2006, J NEUROIMAGING, V16, P243, DOI 10.1111/j.1552-6569.2006.00047.x; Iverson GL, 2011, BRAIN INJURY, V25, P1325, DOI 10.3109/02699052.2011.608409; Kourtidou P, 2013, J HEAD TRAUMA REHAB, V28, P433, DOI 10.1097/HTR.0b013e3182585d06; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; Maxwell WL, 2012, INT J DEV NEUROSCI, V30, P167, DOI 10.1016/j.ijdevneu.2011.12.008; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Muhlau M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029809; Nandigam RNK, 2009, AM J NEURORADIOL, V30, P338, DOI 10.3174/ajnr.A1355; Pannek K, 2011, NEUROIMAGE, V55, P133, DOI 10.1016/j.neuroimage.2010.12.010; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P231, DOI 10.1176/appi.neuropsych.22.2.231; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Tate DF, 2011, J INT NEUROPSYCH SOC, V17, P308, DOI 10.1017/S1355617710001670; TEASDALE G, 1974, LANCET, V2, P81; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wechsler D., 2003, WISC 4 ADM SCORING M; Wechsler D., 2011, WECHSLER ABBREVIATED; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates KO, 2013, J INT NEUROPSYCH SOC, V19, P518, DOI 10.1017/S1355617712001531; Zhan W, 2009, NEUROIMAGE, V47, pT58, DOI 10.1016/j.neuroimage.2009.02.004	50	76	76	0	29	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2013	27	4					438	451		10.1037/a0032837			14	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	185SC	WOS:000321989600005	23876117				2022-02-06	
J	Harvey, HH				Harvey, Hosea H.			Reducing Traumatic Brain Injuries in Youth Sports: Youth Sports Traumatic Brain Injury State Laws, January 2009-December 2012	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							HIGH-SCHOOL; FOOTBALL PLAYERS; UNITED-STATES; CONCUSSION; IMPACT	Objectives. I sought to describe current state-wide youth sports traumatic brain injury (TBI) laws and their relationship to prevailing scientific understandings of youth sports TBIs, and to facilitate further research by creating an open-source data set of current laws. Methods. I used Westlaw and LexisNexis databases to create a 50-state data set of youth sports TBI laws enacted between January 2009 and December 2012. I collected and coded the text and citations of each law and developed a protocol and codebook to facilitate future research. Results. Forty-four states and Washington, DC, passed youth sports TBI laws between 2009 and 2012. No state's youth sports TBI law focuses on primary prevention. Instead, such laws focus on (1) increasing coaches' and parents' ability to identify and respond to TBIs and (2) reducing the immediate risk of multiple TBIs. Conclusions. Existing youth sports TBI laws were not designed to reduce initial TBIs. Evaluation is required to assess their effectiveness in reducing the risk and consequences of multiple TBIs. Continued research and evaluation of existing laws will be needed to develop a more comprehensive youth TBI-reduction solution.	Temple Univ, Beasley Sch Law, Philadelphia, PA 19122 USA		Harvey, HH (corresponding author), Temple Univ, Beasley Sch Law, 1719 N Broad St, Philadelphia, PA 19122 USA.				Robert Wood Johnson FoundationRobert Wood Johnson Foundation (RWJF); Center for Health Law, Policy, and Practice at Temple University	The author thanks the Robert Wood Johnson Foundation and the Center for Health Law, Policy, and Practice at Temple University for research support.	[Anonymous], ATTENTION COLLEGE SP; [Anonymous], HIGH SCHOOLS WITH AT; [Anonymous], 2011, NATIONAL FOOTBALL LE; [Anonymous], RCW 28A 600; [Anonymous], GUIDELINES FOR THE M; Bey T, 2009, WEST J EMERG MED, V10, P6; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Centers for Disease Control and Prevention, 2000, TRAUMATIC BRAIN INJU; Danov R., 2006, PEDIATRIC TRAUMATIC; Farrey T., POP WARNER TO LIMIT; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Ibrahim JK, 2011, AM J PREV MED, V40, P659, DOI 10.1016/j.amepre.2011.02.024; Jackson S., JACKSON S PRESIDENT; Jewell CJ, 2008, MILBANK Q, V86, P177, DOI 10.1111/j.1468-0009.2008.00519.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LawAtlas, THE POLICY SURVEILLA; Lazarus Arthur, 2011, Physician Exec, V37, P6; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; National Center for Injury Prevention and Control, 2003, REPORT TO CONGRESS O; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Schwarz A., 2010, NEW YORK TIMES; Sniezek JE, 1995, GUIDELINES FOR SURVE; Tator CH, 2008, CATASTROPHIC INJURIE; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	29	76	82	1	18	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	JUL	2013	103	7					1249	1254		10.2105/AJPH.2012.301107			6	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	AA3FP	WOS:000330978600030	23678903	Green Published			2022-02-06	
J	Mathersul, D; McDonald, S; Rushby, JA				Mathersul, Danielle; McDonald, Skye; Rushby, Jacqueline A.			Understanding advanced theory of mind and empathy in high-functioning adults with autism spectrum disorder	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Autism; Asperger's; Theory of mind; Sarcasm; Empathy; Ecological validity	TRAUMATIC BRAIN-INJURY; NORMALLY DEVELOPING-CHILDREN; STRANGE STORIES TEST; CEREBRAL-BLOOD-FLOW; ASPERGER-SYNDROME; SOCIAL COGNITION; INDIVIDUAL-DIFFERENCES; EMOTION RECOGNITION; MAGNETIC-RESONANCE; REVISED VERSION	It has been argued that higher functioning individuals with autism spectrum disorders (ASDs) have specific deficits in advanced but not simple theory of mind (ToM), yet the questionable ecological validity of some tasks reduces the strength of this assumption. The present study employed The Awareness of Social Inference Test (TASIT), which uses video vignettes to assess comprehension of subtle conversational inferences (sarcasm, lies/deception). Given the proposed relationships between advanced ToM and cognitive and affective empathy, these associations were also investigated. As expected, the high-functioning adults with ASDs demonstrated specific deficits in comprehending the beliefs, intentions, and meaning of nonliteral expressions. They also had significantly lower cognitive and affective empathy. Cognitive empathy was related to ToM and group membership whereas affective empathy was only related to group membership.	[Mathersul, Danielle; McDonald, Skye; Rushby, Jacqueline A.] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		Mathersul, D (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	d.mathersul@unsw.edu.au	McDonald, Skye/G-4118-2014; Rushby, Jacqueline/D-1820-2010	McDonald, Skye/0000-0003-0723-6094; Rushby, Jacqueline/0000-0002-5018-638X; Mathersul, Danielle/0000-0003-2372-8654	Australian Postgraduate Award (APA)Australian Government; Australian National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [APP1013796]; Australian National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia	D. M. is supported by an Australian Postgraduate Award (APA). J.A.R. is supported by an Australian National Health and Medical Research Council (NHMRC) Postdoctoral Fellowship (Clinical Training; APP1013796). This research was funded by the Australian National Health and Medical Research Council (NHMRC). We would like to thank the individuals who gave their time to participate in this study and the clinicians who assisted with participant recruitment.	Adolphs R, 1999, TRENDS COGN SCI, V3, P469, DOI 10.1016/S1364-6613(99)01399-6; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Ashwin C, 2007, NEUROPSYCHOLOGIA, V45, P2, DOI 10.1016/j.neuropsychologia.2006.04.014; Baron-Cohen S, 2001, J AUTISM DEV DISORD, V31, P5, DOI 10.1023/A:1005653411471; Baron-Cohen S, 1999, EUR J NEUROSCI, V11, P1891, DOI 10.1046/j.1460-9568.1999.00621.x; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Baron-Cohen S, 2004, J AUTISM DEV DISORD, V34, P163, DOI 10.1023/B:JADD.0000022607.19833.00; BARONCOHEN S, 1988, J AUTISM DEV DISORD, V18, P379, DOI 10.1007/BF02212194; BARONCOHEN S, 1992, J CHILD PSYCHOL PSYC, V33, P1141, DOI 10.1111/j.1469-7610.1992.tb00934.x; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BARONCOHEN S, 1989, J CHILD PSYCHOL PSYC, V30, P285, DOI 10.1111/j.1469-7610.1989.tb00241.x; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; BARONCOHEN S, 1991, BRIT J DEV PSYCHOL, V9, P301, DOI 10.1111/j.2044-835X.1991.tb00879.x; Blair RJR, 2008, Q J EXP PSYCHOL, V61, P157, DOI 10.1080/17470210701508855; Brent E, 2004, AUTISM, V8, P283, DOI 10.1177/1362361304045217; Carlson SM, 2001, CHILD DEV, V72, P1032, DOI 10.1111/1467-8624.00333; Carlson SM, 1998, CHILD DEV, V69, P672, DOI 10.2307/1132197; Castelli F, 2000, NEUROIMAGE, V12, P314, DOI 10.1006/nimg.2000.0612; Castelli F, 2002, BRAIN, V125, P1839, DOI 10.1093/brain/awf189; Chung YS, 2011, SCHIZOPHRENIA BULL, V37, P1048, DOI 10.1093/schbul/sbq012; Couture SM, 2010, PSYCHOL MED, V40, P569, DOI 10.1017/S003329170999078X; Craig JS, 2004, SCHIZOPHR RES, V69, P29, DOI 10.1016/S0920-9964(03)00154-3; Critchley HD, 2000, BRAIN, V123, P2203, DOI 10.1093/brain/123.11.2203; Davis M.H., 1980, JSAS CATALOG SELECTE, V10, P85; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; Decety J, 2010, DEV NEUROSCI-BASEL, V32, P257, DOI 10.1159/000317771; Di Martino A, 2009, BIOL PSYCHIAT, V65, P63, DOI 10.1016/j.biopsych.2008.09.022; Dichter GS, 2007, NEUROIMAGE, V35, P1219, DOI 10.1016/j.neuroimage.2006.12.038; Dziobek I, 2008, J AUTISM DEV DISORD, V38, P464, DOI 10.1007/s10803-007-0486-x; Frith U., 1989, AUTISM EXPLAINING EN; Hall GBC, 2003, AM J PSYCHIAT, V160, P1439, DOI 10.1176/appi.ajp.160.8.1439; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Heberlein AS, 2004, J COGNITIVE NEUROSCI, V16, P1143, DOI 10.1162/0898929041920423; Hubert B, 2007, J AUTISM DEV DISORD, V37, P1386, DOI 10.1007/s10803-006-0275-y; Jarrold C, 2000, DEV PSYCHOL, V36, P126, DOI 10.1037/0012-1649.36.1.126; Johnston L., 2007, AUSTR J PSYCHOL, V1, P1, DOI 10.1080/00049530701449521; Jolliffe T, 1999, J AUTISM DEV DISORD, V29, P395, DOI 10.1023/A:1023082928366; Kaland N, 2005, EUR CHILD ADOLES PSY, V14, P73, DOI 10.1007/s00787-005-0434-2; Kern RS, 2009, PSYCHOL MED, V39, P645, DOI 10.1017/S0033291708003966; Kipps CM, 2009, BRAIN, V132, P592, DOI 10.1093/brain/awn314; Kohls G, 2009, DEVELOPMENTAL SCI, V12, P614, DOI 10.1111/j.1467-7687.2009.00816.x; Langleben DD, 2002, NEUROIMAGE, V15, P727, DOI 10.1006/nimg.2001.1003; Lawrence EJ, 2004, PSYCHOL MED, V34, P911, DOI 10.1017/S0033291703001624; Li AS, 2011, J AUTISM DEV DISORD, V41, P185, DOI 10.1007/s10803-010-1045-4; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lord C, 1999, AUTISM DIAGNOSTIC OB; Loveland KA, 2008, PERCEPT MOTOR SKILL, V107, P557, DOI 10.2466/PMS.107.2.557-575; Mathersul D, 2013, INT J PSYCHOPHYSIOL, V87, P88, DOI 10.1016/j.ijpsycho.2012.11.005; Mathersul D, 2013, PHYSIOL BEHAV, V109, P14, DOI 10.1016/j.physbeh.2012.10.008; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 1999, BRAIN LANG, V68, P486, DOI 10.1006/brln.1999.2124; McDonald S., 2002, AWARENESS SOCIAL INF; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; Muncer SJ, 2006, PERS INDIV DIFFER, V40, P1111, DOI 10.1016/j.paid.2005.09.020; Ohnishi T, 2000, BRAIN, V123, P1838, DOI 10.1093/brain/123.9.1838; Olson IR, 2007, BRAIN, V130, P1718, DOI 10.1093/brain/awm052; Perner J, 2002, CHILD DEV, V73, P752, DOI 10.1111/1467-8624.00436; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; Philip RCM, 2012, NEUROSCI BIOBEHAV R, V36, P901, DOI 10.1016/j.neubiorev.2011.10.008; Phillips ML, 2003, BIOL PSYCHIAT, V54, P504, DOI 10.1016/S0006-3223(03)00168-9; Pierce K, 2001, BRAIN, V124, P2059, DOI 10.1093/brain/124.10.2059; Pilowsky T, 2000, SCHIZOPHR RES, V42, P145, DOI 10.1016/S0920-9964(99)00101-2; Rankin KP, 2009, NEUROIMAGE, V47, P2005, DOI 10.1016/j.neuroimage.2009.05.077; Rankin KP, 2005, COGN BEHAV NEUROL, V18, P28, DOI 10.1097/01.wnn.0000152225.05377.ab; Reinecke DR, 1997, J AUTISM DEV DISORD, V27, P127, DOI 10.1023/A:1025835706522; Ritvo RA, 2008, J AUTISM DEV DISORD, V38, P213, DOI 10.1007/s10803-007-0380-6; Ritvo RA, 2011, J AUTISM DEV DISORD, V41, P1076, DOI 10.1007/s10803-010-1133-5; Roeyers H, 2001, J CHILD PSYCHOL PSYC, V42, P271, DOI 10.1111/1469-7610.00718; Rogers K, 2007, J AUTISM DEV DISORD, V37, P709, DOI 10.1007/s10803-006-0197-8; Shamay-Tsoory SG, 2005, NEUROPSYCHOLOGY, V19, P288, DOI 10.1037/0894-4105.19.3.288; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Shamay-Tsoory SG, 2002, NEUROCASE, V8, P245; Shamay-Tsoory SG, 2007, NEUROPSYCHOLOGIA, V45, P3054, DOI 10.1016/j.neuropsychologia.2007.05.021; Silani G, 2008, SOC NEUROSCI-UK, V3, P97, DOI 10.1080/17470910701577020; Sparks A, 2010, SCHIZOPHR RES, V122, P172, DOI 10.1016/j.schres.2010.06.011; Spek AA, 2010, J AUTISM DEV DISORD, V40, P280, DOI 10.1007/s10803-009-0860-y; Spence SA, 2004, PHILOS T R SOC B, V359, P1755, DOI 10.1098/rstb.2004.1555; Spence SA, 2001, NEUROREPORT, V12, P2849, DOI 10.1097/00001756-200109170-00019; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Talwar V, 2008, CHILD DEV, V79, P866, DOI 10.1111/j.1467-8624.2008.01164.x; Uchiyama H, 2006, BRAIN RES, V1124, P100, DOI 10.1016/j.brainres.2006.09.088; Wang AT, 2007, ARCH GEN PSYCHIAT, V64, P698, DOI 10.1001/archpsyc.64.6.698; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Yirmiya N, 1998, PSYCHOL BULL, V124, P283, DOI 10.1037/0033-2909.124.3.283	93	76	77	2	99	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL 1	2013	35	6					655	668		10.1080/13803395.2013.809700			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	238BH	WOS:000325914900009	23799244				2022-02-06	
J	Bouix, S; Pasternak, O; Rathi, Y; Pelavin, PE; Zafonte, R; Shenton, ME				Bouix, Sylvain; Pasternak, Ofer; Rathi, Yogesh; Pelavin, Paula E.; Zafonte, Ross; Shenton, Martha E.			Increased Gray Matter Diffusion Anisotropy in Patients with Persistent Post-Concussive Symptoms following Mild Traumatic Brain Injury	PLOS ONE			English	Article							PRINCIPAL EIGENVECTOR MEASUREMENTS; TENSOR IMAGING FINDINGS; FRACTIONAL ANISOTROPY; MEAN DIFFUSIVITY; HEAD-INJURY; REPRODUCIBILITY; DEGENERATION; DTI	A significant percentage of individuals diagnosed with mild traumatic brain injury (mTBI) experience persistent post-concussive symptoms (PPCS). Little is known about the pathology of these symptoms and there is often no radiological evidence based on conventional clinical imaging. We aimed to utilize methods to evaluate microstructural tissue changes and to determine whether or not a link with PPCS was present. A novel analysis method was developed to identify abnormalities in high-resolution diffusion tensor imaging (DTI) when the location of brain injury is heterogeneous across subjects. A normative atlas with 145 brain regions of interest (ROI) was built from 47 normal controls. Comparing each subject's diffusion measures to the atlas generated subject-specific profiles of injury. Abnormal ROIs were defined by absolute z-score values above a given threshold. The method was applied to 11 PPCS patients following mTBI and 11 matched controls. Z-score information for each individual was summarized with two location-independent measures: "load'' (number of abnormal regions) and "severity'' (largest absolute z-score). Group differences were then computed using Wilcoxon rank sum tests. Results showed statistically significantly higher load (p = 0.018) and severity (p = 0.006) for fractional anisotropy (FA) in patients compared with controls. Subject-specific profiles of injury evinced abnormally high FA regions in gray matter (30 occurrences over 11 patients), and abnormally low FA in white matter (3 occurrences over 11 subjects). Subject-specific profiles provide important information regarding the pathology associated with PPCS. Increased gray matter (GM) anisotropy is a novel in-vivo finding, which is consistent with an animal model of brain trauma that associates increased FA in GM with pathologies such as gliosis. In addition, the individualized analysis shows promise for enhancing the clinical care of PPCS patients as it could play a role in the diagnosis of brain injury not revealed using conventional imaging.	[Bouix, Sylvain; Pasternak, Ofer; Rathi, Yogesh; Pelavin, Paula E.; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Zafonte, Ross] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA; [Zafonte, Ross] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Shenton, Martha E.] Vet Affairs Boston Healthcare Syst, Dept Psychiat, Brockton Div, Brockton, MA USA		Bouix, S (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Psychiat, Boston, MA 02115 USA.	sylvain@bwh.harvard.edu	Shenton, Martha/V-8780-2019	Bouix, Sylvain/0000-0003-1326-6054	Center for Integration of Medicine and Innovative Technology Soldier in Medicine Award; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH082918, R01 NS078337, NAMIC-U54 EB005149]; INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium; Department of Defense Psychological Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [U54EB005149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH082918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER	This work was supported in part by the Center for Integration of Medicine and Innovative Technology Soldier in Medicine Award [to S.B.], by the National Institute of Health [R01 MH082918 to S.B., R01 NS078337 to M.E.S., NAMIC-U54 EB005149 to M.E.S.] and by the INTRuST Posttraumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium funded by the Department of Defense Psychological Health/Traumatic Brain Injury Research Program [X81XWH-07-CC-CSDoD to M.E.S., S.B., O.P., Y.R. and R.Z.]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; ARNETT JA, 1995, PSYCHOL ASSESSMENT, V7, P220; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benton LA, MULTILINGUAL APHASIA; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Blumenfeld-Katzir T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020678; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Dobson A.J., 2008, INTRO GEN LINEAR MOD, Vthird; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Hagmann P, 2006, RADIOGRAPHICS, V26, pS205, DOI 10.1148/rg.26si065510; Hannoun S, 2012, AM J NEURORADIOL, V33, P1363, DOI 10.3174/ajnr.A2983; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Jones DK, 2008, CORTEX, V44, P936, DOI 10.1016/j.cortex.2008.05.002; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kaplan, CALIFORNIA VERBAL LE; Kaufman L., 2005, FINDING GROUPS DATA; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Lezak MD, 2012, NEUROPSYCHOLOGICAL A; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Peled S, 2009, J MAGN RESON IMAGING, V30, P243, DOI 10.1002/jmri.21808; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Seber G.A.F., 2004, MULTIVARIATE OBSERVA; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; Westlye LT, 2010, CEREB CORTEX, V20, P2055, DOI 10.1093/cercor/bhp280	41	76	76	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2013	8	6							e66205	10.1371/journal.pone.0066205			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169CU	WOS:000320755400120	23776631	gold, Green Published, Green Submitted			2022-02-06	
J	Lange, RT; Brickell, TA; Ivins, B; Vanderploeg, RD; French, LM				Lange, Rael T.; Brickell, Tracey A.; Ivins, Brian; Vanderploeg, Rodney D.; French, Louis M.			Variable, Not Always Persistent, Postconcussion Symptoms after Mild TBI in U.S. Military Service Members: A Five-Year Cross-Sectional Outcome Study	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury; military service members; postconcussion symptoms	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYNDROME; MENTAL-HEALTH PROBLEMS; COMPLAINT BASE RATES; HEAD-INJURY; COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; CHRONIC PAIN; IRAQ	This study examined postconcussion symptom reporting within the first 5 years after mild traumatic brain injury (mTBI). Participants were 167 U. S. military service members (mean age, 27.6 years; 74.3% blast; 96.4% male) who were evaluated subsequent to injuries sustained in theater during Operations Iraqi and Enduring Freedom (92.8%) or from other combat-related operations. Participants completed the Neurobehavioral Symptom Inventory and Post-Traumatic Stress Disorder Checklist within 3 months of injury and at least one follow-up telephone interview at 6 (n = 46), 12 (n = 89), 24 (n = 54), 36 (n = 42), 48 (n = 30), and/or 60 months (n = 25) postinjury. Approximately half of the sample (49.7%) met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) symptom criteria for postconcussion disorder (PCD) at baseline. At all six follow-ups, 46.1-72.0% met DSM-IV criteria for PCD. However, only 20.4-48.0% reported persistent PCD from baseline to follow-up. A substantial minority had also improved (4.0-24.1%) or "developed'' new symptoms (16.9-27.8%). Using regression analyses, baseline symptoms were somewhat predictive of PCD symptom reporting at follow-up, though this was not always reliable. Follow-up for all service members who sustain a combat-related mTBI in the context of polytrauma, regardless of the presence or absence of symptom reporting in the acute recovery stage, should be considered the rule, not the exception.	[Lange, Rael T.; Brickell, Tracey A.; Ivins, Brian; Vanderploeg, Rodney D.; French, Louis M.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey A.; Ivins, Brian; French, Louis M.] Walter Reed Natl Mil Med Ctr, Rockville, MD 20852 USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Vanderploeg, Rodney D.] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat & Psychol, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Neurosci, Tampa, FL USA; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA		Lange, RT (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, 11300 Rockville Pike,Suite 1100, Rockville, MD 20852 USA.	rlange@dvbic.org	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Baker DG, 2009, MIL MED, V174, P773; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI [10.1089/neu.2009.0885, 10.1089/neu.2009-0885]; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; Defense and Veterans Brain Injury Center, 2012, DOD NUMB TRAUM BRAIN, V2012; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Ferrier-Auerbach AG, 2010, J PSYCHIATR RES, V44, P470, DOI 10.1016/j.jpsychires.2009.10.010; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson G.L., 2007, BRAIN INJURY MED PRI, P333; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Kreutzer R.D, 2012, BRAIN INJURY MED PRI; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Managment of Concussion/nTBI Working Group, 2009, VA DOD CLIN PRACT GU; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seal KH, 2008, AM J PUBLIC HEALTH, V98, P714, DOI 10.2105/AJPH.2007.115519; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100107-01, 10.3928/02793695-20100108-02]; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Uomoto JM, 2009, REHABIL PSYCHOL, V54, P259, DOI 10.1037/a0016907; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F. W., 1994, PTSD CHECKLIST CIVIL; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	85	76	76	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2013	30	11					958	969		10.1089/neu.2012.2743			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	166WD	WOS:000320589300006	23205671				2022-02-06	
J	Cloots, RJH; van Dommelen, JAW; Kleiven, S; Geers, MGD				Cloots, R. J. H.; van Dommelen, J. A. W.; Kleiven, S.; Geers, M. G. D.			Multi-scale mechanics of traumatic brain injury: predicting axonal strains from head loads	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Traumatic brain injury; TBI; Diffuse axonal injury; DAI; Injury criteria; Head model; Finite element method; Multi-scale	PREFRONTAL CORTEX; PYRAMIDAL NEURONS; SOMAL SIZE; MODEL; TISSUE; STEM; NEUROPHYSIOLOGY; CRITERION; BEHAVIOR; STRETCH	The length scales involved in the development of diffuse axonal injury typically range from the head level (i.e., mechanical loading) to the cellular level. The parts of the brain that are vulnerable to this type of injury are mainly the brainstem and the corpus callosum, which are regions with highly anisotropically oriented axons. Within these parts, discrete axonal injuries occur mainly where the axons have to deviate from their main course due to the presence of an inclusion. The aim of this study is to predict axonal strains as a result of a mechanical load at the macroscopic head level. For this, a multi-scale finite element approach is adopted, in which a macro-level head model and a micro-level critical volume element are coupled. The results show that the axonal strains cannot be trivially correlated to the tissue strain without taking into account the axonal orientations, which indicates that the heterogeneities at the cellular level play an important role in brain injury and reliable predictions thereof. In addition to the multi-scale approach, it is shown that a novel anisotropic equivalent strain measure can be used to assess these micro-scale effects from head-level simulations only.	[Cloots, R. J. H.; van Dommelen, J. A. W.; Geers, M. G. D.] Eindhoven Univ Technol, Mat Technol Inst, NL-5600 MB Eindhoven, Netherlands; [Kleiven, S.] Royal Inst Technol, Div Neuron Engn, Sch Technol & Hlth, S-14152 Huddinge, Sweden		van Dommelen, JAW (corresponding author), Eindhoven Univ Technol, Mat Technol Inst, POB 513, NL-5600 MB Eindhoven, Netherlands.	j.a.w.v.dommelen@tue.nl	Geers, Marc G.D./E-4385-2014	Geers, Marc G.D./0000-0002-0009-6351	Dutch Technology Foundation STW, applied science division of NWOTechnologiestichting STWNetherlands Organization for Scientific Research (NWO); Ministry of Economic Affairs; Swedish Research CouncilSwedish Research CouncilEuropean Commission	This work has been supported by the Dutch Technology Foundation STW, applied science division of NWO and the Technology Program of the Ministry of Economic Affairs, and the Swedish Research Council.	Abaqus, 2010, AB 6 10 MAN; Alberts B., 1994, MOL BIOL CELL, V3rd ed; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Arbogast KB, 1999, J BIOMECH, V32, P865, DOI 10.1016/S0021-9290(99)00042-1; ARBOGAST KB, 1995, P 39 STAPP CAR CRASH, P153; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Cloots RJH, 2012, J MECH BEHAV BIOMED, V5, P41, DOI 10.1016/j.jmbbm.2011.09.012; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Cotter D, 2002, CEREB CORTEX, V12, P386, DOI 10.1093/cercor/12.4.386; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Engel DC, 2005, NEUROPHARMACOLOGY, V49, P985, DOI 10.1016/j.neuropharm.2005.05.021; Floyd CL, 2005, GLIA, V51, P35, DOI 10.1002/glia.20183; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Highley JR, 2003, BRIT J PSYCHIAT, V183, P414, DOI 10.1192/bjp.183.5.414; Ho J, 2009, INT J CRASHWORTHINES, V14, P555, DOI 10.1080/13588260902895708; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Hutsler JJ, 2003, BRAIN LANG, V86, P226, DOI 10.1016/S0093-934X(02)00531-X; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kouznetsova V, 2001, COMPUT MECH, V27, P37, DOI 10.1007/s004660000212; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McCracken PJ, 2005, MAGN RESON MED, V53, P628, DOI 10.1002/mrm.20388; Miller R.T., 1998, STAPP CAR CRASH J, P155; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; National Highway Traffic Safety Administration (NHTSA), 1972, OCC CRASH PROT HEAD; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Nicolle Stephane, 2004, Stapp Car Crash J, V48, P239; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Nolte J., 2002, HUMAN BRAIN INTRO IT; Pierri JN, 2001, ARCH GEN PSYCHIAT, V58, P466, DOI 10.1001/archpsyc.58.5.466; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Prange M T, 2000, Stapp Car Crash J, V44, P205; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RAJKOWSKA G, 1995, CEREB CORTEX, V5, P307, DOI 10.1093/cercor/5.4.307; Rajkowska G, 1998, ARCH GEN PSYCHIAT, V55, P215, DOI 10.1001/archpsyc.55.3.215; Roberts VL, 1976, HDB HUMAN TOLERANCE; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Takhounts EG, 2003, STAPP CAR CRASH J, V47, P51; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; [No title captured]	52	76	81	1	32	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	JAN	2013	12	1					137	150		10.1007/s10237-012-0387-6			14	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	070BF	WOS:000313480100012	22434184	hybrid, Green Published			2022-02-06	
J	Koerte, IK; Kaufmann, D; Hartl, E; Bouix, S; Pasternak, O; Kubicki, M; Rauscher, A; Li, DKB; Dadachanji, SB; Taunton, JA; Forwell, LA; Johnson, AM; Echlin, PS; Shenton, ME				Koerte, Inga K.; Kaufmann, David; Hartl, Elisabeth; Bouix, Sylvain; Pasternak, Ofer; Kubicki, Marek; Rauscher, Alexander; Li, David K. B.; Dadachanji, Shiroy B.; Taunton, Jack A.; Forwell, Lorie A.; Johnson, Andrew M.; Echlin, Paul S.; Shenton, Martha E.			A prospective study of physician-observed concussion during a varsity university hockey season: white matter integrity in ice hockey players. Part 3 of 4	NEUROSURGICAL FOCUS			English	Article						ice hockey; mild traumatic brain injury; axial diffusivity; diffusion tensor imaging; sports-related concussion; radial diffusivity; fractional anisotropy; Canada	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; DIFFUSE AXONAL INJURY; RECURRENT CONCUSSION; SPORTS CONCUSSION; LONG-TERM; CORPUS-CALLOSUM; NCAA CONCUSSION; RUGBY UNION; HEAD-INJURY	Object. The aim of this study was to investigate the effect of repetitive head impacts on white matter integrity that were sustained during 1 Canadian Interuniversity Sports (CIS) ice hockey season, using advanced diffusion tensor imaging (DTI). Methods. Twenty-five male ice hockey players between 20 and 26 years of age (mean age 22.24 +/- 1.59 years) participated in this study. Participants underwent pre- and postseason 3-T MRI, including DTI. Group analyses were performed using paired-group tract-based spatial statistics to test for differences between preseason and postseason changes. Results. Tract-based spatial statistics revealed an increase in trace, radial diffusivity (RD), and axial diffusivity (AD) over the course of 1 season. Compared with preseason data, postseason images showed higher trace, AD, and RD values in the right precentral region, the right corona radiata, and the anterior and posterior limb of the internal capsule. These regions involve parts of the corticospinal tract, the corpus callosum, and the superior longitudinal fasciculus. No significant differences were observed between preseason and postseason for fractional anisotropy. Conclusions. Diffusion tensor imaging revealed changes in white matter diffusivity in male ice hockey players over the course of 1 season. The origin of these findings needs to be elucidated. (http://thejns.org/doi/abs/10.3171/2012.10.FOCUS12303)	[Echlin, Paul S.] Elliott Sports Med Clin, Burlington, ON L7N 2G3, Canada; [Koerte, Inga K.; Kaufmann, David; Hartl, Elisabeth; Bouix, Sylvain; Pasternak, Ofer; Kubicki, Marek; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Boston, MA 02115 USA; [Kubicki, Marek; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; [Koerte, Inga K.; Kaufmann, David] Univ Munich, Inst Clin Radiol, Munich, Germany; [Rauscher, Alexander; Li, David K. B.] Univ British Columbia, Dept Radiol, Vancouver, BC, Canada; [Dadachanji, Shiroy B.; Taunton, Jack A.] Univ British Columbia, Dept Med, Div Sports Med, Vancouver, BC, Canada; [Forwell, Lorie A.] Univ Western Ontario, Fowler Kennedy Sport Med Clin, London, ON, Canada; [Forwell, Lorie A.; Johnson, Andrew M.] Univ Western Ontario, Fac Hlth Sci, London, ON, Canada; [Shenton, Martha E.] VA Boston Healthcare Syst, Dept Psychiat, Neurosci Lab, Clin Neurosci Div, Brockton, MA USA		Echlin, PS (corresponding author), Elliott Sports Med Clin, 1100 Walkers Line,Suite 2, Burlington, ON L7N 2G3, Canada.	psechlin@gmail.com	Johnson, Andrew M/B-2048-2012; Koerte, Inga Katharina/AAW-3031-2021; Shenton, Martha/V-8780-2019	Bouix, Sylvain/0000-0003-1326-6054; Rauscher, Alexander/0000-0002-1961-8252; Johnson, Andrew M./0000-0002-7269-3016	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR013218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015902] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41 RR013218] Funding Source: Medline; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41 EB015902] Funding Source: Medline		Acosta-Cabronero J, 2010, BRAIN, V133, P529, DOI 10.1093/brain/awp257; Agel J, 2007, J ATHL TRAINING, V42, P249; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.10.FOCUS10222; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; King DA, 2009, BRIT J SPORT MED, V43, P595, DOI 10.1136/bjsm.2009.061481; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Malcolm JG, 2009, LECT NOTES COMPUT SC, V5636, P126, DOI 10.1007/978-3-642-02498-6_11; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rathi Y, 2011, MAGN RESON IMAGING, V29, P507, DOI 10.1016/j.mri.2010.10.005; Rishiraj N, 2009, J SPORT MED PHYS FIT, V49, P159; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zazryn T, 2007, SPORTS MED, V37, P467, DOI 10.2165/00007256-200737060-00001	63	76	76	0	22	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	DEC	2012	33	6							E3	10.3171/2012.10.FOCUS12303			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	048GI	WOS:000311898500004	23199426	Bronze, Green Accepted			2022-02-06	
J	Walker, PA; Bedi, SS; Shah, SK; Jimenez, F; Xue, H; Hamilton, JA; Smith, P; Thomas, CP; Mays, RW; Pati, S; Cox, CS				Walker, Peter A.; Bedi, Supinder S.; Shah, Shinil K.; Jimenez, Fernando; Xue, Hasen; Hamilton, Jason A.; Smith, Philippa; Thomas, Chelsea P.; Mays, Robert W.; Pati, Shibani; Cox, Charles S., Jr.			Intravenous multipotent adult progenitor cell therapy after traumatic brain injury: modulation of the resident microglia population	JOURNAL OF NEUROINFLAMMATION			English	Article						Multipotent adult progenitor cells; Traumatic brain injury; Stem cells; Splenocytes; Blood brain barrier; Microglia	CENTRAL-NERVOUS-SYSTEM; INFLAMMATORY RESPONSE; SPINAL-CORD	Introduction: We have demonstrated previously that the intravenous delivery of multipotent adult progenitor cells (MAPC) after traumatic brain injury affords neuroprotection via interaction with splenocytes, leading to an increase in systemic anti-inflammatory cytokines. We hypothesize that the observed modulation of the systemic inflammatory milieu is related to T regulatory cells and a subsequent increase in the locoregional neuroprotective M2 macrophage population. Methods: C57B6 mice were injected with intravenous MAPC 2 and 24 hours after controlled cortical impact injury. Animals were euthanized 24, 48, 72, and 120 hours after injury. In vivo, the proportion of CD4(+)/CD25(+)/FOXP3(+) T-regulatory cells were measured in the splenocyte population and plasma. In addition, the brain CD86(+) M1 and CD206(+) M2 macrophage populations were quantified. A series of in vitro co-cultures were completed to investigate the need for direct MAPC:splenocyte contact as well as the effect of MAPC therapy on M1 and M2 macrophage subtype apoptosis and proliferation. Results: Significant increases in the splenocyte and plasma T regulatory cell populations were observed with MAPC therapy at 24 and 48 hours, respectively. In addition, MAPC therapy was associated with an increase in the brain M2/M1 macrophage ratio at 24, 48 and 120 hours after cortical injury. In vitro cultures of activated microglia with supernatant derived from MAPC:splenocyte co-cultures also demonstrated an increase in the M2/M1 ratio. The observed changes were secondary to an increase in M1 macrophage apoptosis. Conclusions: The data show that the intravenous delivery of MAPC after cortical injury results in increases in T regulatory cells in splenocytes and plasma with a concordant increase in the locoregional M2/M1 macrophage ratio. Direct contact between the MAPC and splenocytes is required to modulate activated microglia, adding further evidence to the central role of the spleen in MAPC-mediated neuroprotection.	[Walker, Peter A.; Shah, Shinil K.; Xue, Hasen; Pati, Shibani; Cox, Charles S., Jr.] Univ Texas Houston, Sch Med, Dept Surg, Houston, TX 77030 USA; [Walker, Peter A.; Bedi, Supinder S.; Shah, Shinil K.; Jimenez, Fernando; Xue, Hasen; Smith, Philippa; Thomas, Chelsea P.; Cox, Charles S., Jr.] Univ Texas Houston, Sch Med, Houston, TX 77030 USA; [Shah, Shinil K.; Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst Comparat Cardiovasc Sci &, College Stn, TX USA; [Hamilton, Jason A.; Mays, Robert W.] Athersys Inc, Dept Regenerat Med, Cleveland, OH 44115 USA		Cox, CS (corresponding author), Univ Texas Houston, Sch Med, Dept Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	Charles.s.cox@uth.tmc.edu			Athersys, Inc.; Cord Blood Registry, Inc.; BD Biosciences, Inc.; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM 08 79201]; Texas Higher Education Coordinating Board; Children's Memorial Hermann Hospital Foundation; Texas Emerging Technology Fund; BD Biosciences;  [M01 RR 02558]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558, UL1RR024148] Funding Source: NIH RePORTER	There are no known conflicts between the authors and the information presented in this paper. Charles S. Cox Jr. MD has sponsored research agreements with Athersys, Inc. and Cord Blood Registry, Inc. Peter A. Walker MD, Fernando Jimenez MS, Shinil K. Shah DO, and Charles S. Cox, Jr. MD have received grant support from BD Biosciences, Inc. Jason A. Hamilton PhD and Robert W. Mays PhD are employed by Athersys, Inc. Athersys Inc. supplied the bone marrow derived progenitor cells for all experiments.; NIH T32 GM 08 79201; M01 RR 02558; Texas Higher Education Coordinating Board; Children's Memorial Hermann Hospital Foundation; Texas Emerging Technology Fund; Athersys, Inc.; BD Biosciences.	Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kovacsovics-Bankowski M, 2008, CYTOTHERAPY, V10, P730, DOI 10.1080/14653240802320245; Kovacsovics-Bankowski M, 2009, CELL IMMUNOL, V255, P55, DOI 10.1016/j.cellimm.2008.10.004; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Smith HS, 2010, PAIN PHYSICIAN, V13, P295; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005	18	76	76	0	12	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	SEP 28	2012	9								228	10.1186/1742-2094-9-228			13	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	087GW	WOS:000314750500002	23020860	Green Published, gold			2022-02-06	
J	Chavez-Valdez, R; Martin, LJ; Flock, DL; Northington, FJ				Chavez-Valdez, R.; Martin, L. J.; Flock, D. L.; Northington, F. J.			NECROSTATIN-1 ATTENUATES MITOCHONDRIAL DYSFUNCTION IN NEURONS AND ASTROCYTES FOLLOWING NEONATAL HYPOXIA-ISCHEMIA	NEUROSCIENCE			English	Article						astrocytes; hypoxia ischemia; mitochondria; neurons; receptor interacting protein-1 kinase; regulated necrosis	PERMEABILITY TRANSITION PORE; INDUCED CELL-DEATH; NITRIC-OXIDE; GLUTATHIONE DEPLETION; BRAIN-INJURY; PROGRAMMED NECROSIS; INDUCED NECROPTOSIS; INTRACELLULAR ATP; BNIP3 EXPRESSION; IN-VITRO	Receptor interacting protein (RIP)-1 kinase activity mediates a novel pathway that signals for regulated necrosis, a form of cell death prominent in traumatic and ischemic brain injury. Recently, we showed that an allosteric inhibitor of RIP-1 kinase activity, necrostatin-1 (Nec-1), provides neuroprotection in the forebrain following neonatal hypoxia ischemia (HI). Because Nec-1 also prevents early oxidative injury, we hypothesized that mechanisms involved in this neuroprotection may involve preservation of mitochondrial function and prevention of secondary energy failure. Therefore, our objective was to determine if Nec-1 treatment following neonatal HI attenuates oxidative stress and mitochondrial injury. Postnatal day (p) 7 mice exposed to HI were injected intracerebroventricularly with 0.1 mu L (80 mu mol) of Nec-1 or vehicle. Nec-1 treatment prevented nitric oxide (NO center dot), inducible nitric oxide synthase (iNOS) and 3-nitrotyrosine increase, and attenuated glutathione oxidation that was found in vehicle-treated mice at 3 h following HI. Similarly, Nec-1 following HI prevented: (i) up-regulation of hypoxia inducible factor-1 alpha (HIF-1 alpha) and BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) expression, (ii) decline in mitochondrial complex-I activity, (iii) decrease in ATP levels, and (iv) mitochondrial structural pathology in astrocytes and in neurons. Up-regulation of glial fibrillary acidic protein (GFAP) following HI was also prevented by Nec-1 treatment. No differences by gender were observed. We conclude that Nec-1 immediately after HI, is strongly mitoprotective and prevents secondary energy failure by blocking early NO center dot accumulation, glutathione oxidation and attenuating mitochondrial dysfunction. (C) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Chavez-Valdez, R.] Johns Hopkins Univ, Johns Hopkins Med Inst, Johns Hopkins Hosp, Div Neonatol,Sch Med,Dept Pediat, Baltimore, MD 21287 USA; [Chavez-Valdez, R.] Texas Tech Univ, Div Neonatol, Dept Pediat, Hlth Sci Ctr, Odessa, TX 79763 USA; [Martin, L. J.] Johns Hopkins Univ, Div Neuropathol, Dept Pathol, Sch Med, Baltimore, MD 21205 USA; [Martin, L. J.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA		Chavez-Valdez, R (corresponding author), Johns Hopkins Univ, Johns Hopkins Med Inst, Johns Hopkins Hosp, Div Neonatol,Sch Med,Dept Pediat, 600 N Wolfe St,CMSC 6-104, Baltimore, MD 21287 USA.	chavezva@gmail.com; frances@jhmi.edu		Chavez-Valdez, Raul/0000-0002-0788-8028	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD074593, R01HD070996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS059529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG016282] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG016282, AG 016282] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD074593, R01 HD070996] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS059529, NS 059529] Funding Source: Medline		An HJ, 2006, J BIOL CHEM, V281, P33939, DOI 10.1074/jbc.M605819200; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Blomgren K, 2006, FREE RADICAL BIO MED, V40, P388, DOI 10.1016/j.freeradbiomed.2005.08.040; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chinta SJ, 2006, FREE RADICAL BIO MED, V41, P1442, DOI 10.1016/j.freeradbiomed.2006.08.002; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; Davis CW, 2010, FREE RADICAL BIO MED, V48, P306, DOI 10.1016/j.freeradbiomed.2009.11.001; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Eguchi Y, 1997, CANCER RES, V57, P1835; Faraco G, 2007, J NEUROCHEM, V103, P590, DOI 10.1111/j.1471-4159.2007.04788.x; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; Galluzzi L, 2011, INT REV CEL MOL BIO, V289, P1, DOI 10.1016/B978-0-12-386039-2.00001-8; Ghavami S, 2009, BBA-MOL CELL RES, V1793, P546, DOI 10.1016/j.bbamcr.2009.01.002; Graham EM, 2004, NEUROBIOL DIS, V17, P89, DOI 10.1016/j.nbd.2004.05.007; Hagberg H, 2004, J BIOENERG BIOMEMBR, V36, P369, DOI 10.1023/B:JOBB.0000041770.00567.4f; Hagberg H, 2004, J NEUROCHEM, V90, P1068, DOI 10.1111/j.1471-4159.2004.02547.x; Han WD, 2009, APOPTOSIS, V14, P674, DOI 10.1007/s10495-009-0334-x; Hewett SJ, 1996, STROKE, V27, P1586, DOI 10.1161/01.STR.27.9.1586; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hsu TS, 2009, TOXICOL APPL PHARM, V235, P153, DOI 10.1016/j.taap.2008.12.012; Kim Sunja, 2010, Int J Physiol Pathophysiol Pharmacol, V2, P137; Kubli DA, 2008, AM J PHYSIOL-HEART C, V295, pH2025, DOI 10.1152/ajpheart.00552.2008; Laird MD, 2008, FREE RADICAL BIO MED, V45, P1103, DOI 10.1016/j.freeradbiomed.2008.07.003; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Lim SY, 2007, CARDIOVASC DRUG THER, V21, P467, DOI 10.1007/s10557-007-6067-6; MARKOVIC SN, 1993, CELL IMMUNOL, V151, P474, DOI 10.1006/cimm.1993.1256; Nicotera P, 1998, TOXICOL LETT, V103, P139; Nicotera P, 1999, J CEREBR BLOOD F MET, V19, P583, DOI 10.1097/00004647-199906000-00001; Northington FJ, 2007, NEUROSCIENCE, V149, P822, DOI 10.1016/j.neuroscience.2007.06.060; Northington FJ, 2011, ANN NEUROL, V69, P743, DOI 10.1002/ana.22419; Northington FJ, 2011, J CEREBR BLOOD F MET, V31, P178, DOI 10.1038/jcbfm.2010.72; Northington Frances J., 1996, Developmental Brain Research, V95, P1, DOI 10.1016/0165-3806(96)00051-X; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; Smith CCT, 2007, CARDIOVASC DRUG THER, V21, P227, DOI 10.1007/s10557-007-6035-1; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vannucci RC, 1998, J NEUROCHEM, V71, P1215; Xu XS, 2007, J NEUROCHEM, V103, P2004, DOI 10.1111/j.1471-4159.2007.04884.x; YAGER JY, 1991, AM J PHYSIOL, V261, pH1102, DOI 10.1152/ajpheart.1991.261.4.H1102; Yook YH, 2004, BIOCHEM BIOPH RES CO, V321, P298, DOI 10.1016/j.bbrc.2004.06.144; Zhu CL, 2006, J NEUROCHEM, V96, P1016, DOI 10.1111/j.1471-4159.2005.03639.x	44	76	81	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	SEP 6	2012	219						192	203		10.1016/j.neuroscience.2012.05.002			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	987KY	WOS:000307417000018	22579794	Green Accepted			2022-02-06	
J	Corral, L; Javierre, CF; Ventura, JL; Marcos, P; Herrero, JI; Manez, R				Corral, Luisa; Javierre, Casimiro F.; Ventura, Josep L.; Marcos, Pilar; Herrero, Jose I.; Manez, Rafael			Impact of non-neurological complications in severe traumatic brain injury outcome	CRITICAL CARE			English	Article							SEVERE HEAD-INJURY; ACUTE KIDNEY INJURY; ACUTE LUNG INJURY; VENTILATOR-ASSOCIATED PNEUMONIA; GOSE SCORES 6; ORGAN DYSFUNCTION; EXTRACRANIAL COMPLICATIONS; INTRACRANIAL HYPERTENSION; MANAGEMENT; FAILURE	Introduction: Non-neurological complications in patients with severe traumatic brain injury (TBI) are frequent, worsening the prognosis, but the pathophysiology of systemic complications after TBI is unclear. The purpose of this study was to analyze non-neurological complications in patients with severe TBI admitted to the ICU, the impact of these complications on mortality, and their possible correlation with TBI severity. Methods: An observational retrospective cohort study was conducted in one multidisciplinary ICU of a university hospital (35 beds); 224 consecutive adult patients with severe TBI (initial Glasgow Coma Scale (GCS) < 9) admitted to the ICU were included. Neurological and non-neurological variables were recorded. Results: Sepsis occurred in 75% of patients, respiratory infections in 68%, hypotension in 44%, severe respiratory failure (arterial oxygen pressure/oxygen inspired fraction ratio (PaO2/FiO(2)) < 200) in 41% and acute kidney injury (AKI) in 8%. The multivariate analysis showed that Glasgow Outcome Score (GOS) at one year was independently associated with age, initial GCS 3 to 5, worst Traumatic Coma Data Bank (TCDB) first computed tomography (CT) scan and the presence of intracranial hypertension but not AKI. Hospital mortality was independently associated with initial GSC 3 to 5, worst TCDB first CT scan, the presence of intracranial hypertension and AKI. The presence of AKI regardless of GCS multiplied risk of death 6.17 times (95% confidence interval (CI): 1.37 to 27.78) (P < 0.02), while ICU hypotension increased the risk of death in patients with initial scores of 3 to 5 on the GCS 4.28 times (95% CI: 1.22 to15.07) (P < 0.05). Conclusions: Low initial GCS, worst first CT scan, intracranial hypertension and AKI determined hospital mortality in severe TBI patients. Besides the direct effect of low GCS on mortality, this neurological condition also is associated with ICU hypotension which increases hospital mortality among patients with severe TBI. These findings add to previous studies that showed that non-neurological complications increase the length of stay and morbidity in the ICU but do not increase mortality, with the exception of AKI and hypotension in low GCS (3 to 5).	[Corral, Luisa; Ventura, Josep L.; Herrero, Jose I.; Manez, Rafael] Hosp Univ Bellvitge, Intens Care Unit, Barcelona 08907, Spain; [Corral, Luisa; Javierre, Casimiro F.] Univ Barcelona, Dept Ciencies Fisiol 2, Barcelona 08907, Spain; [Marcos, Pilar] Hosp Badalona Germans Trias & Pujol, Intens Care Unit, Barcelona 08916, Spain; [Manez, Rafael] Inst Invest Biomed Bellvitge IDIBELL, Barcelona 08907, Spain		Corral, L (corresponding author), Hosp Univ Bellvitge, Intens Care Unit, Feixa Llarga S-N, Barcelona 08907, Spain.	lcorral@bellvitgehospital.cat		Manez, Rafael/0000-0002-0884-5564; Corral, Luisa/0000-0002-2888-7833			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; Corral L, 2009, BRAIN INJURY, V23, P403, DOI 10.1080/02699050902788477; Davenport A, 2010, HEMODIAL INT, V14, pS27, DOI 10.1111/j.1542-4758.2010.00487.x; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Harrigan MR, 1996, NEUROSURGERY, V38, P152, DOI 10.1097/00006123-199601000-00035; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Kemp CD, 2008, AM SURGEON, V74, P866; Koutsoukou A, 2006, INTENS CARE MED, V32, P1947, DOI 10.1007/s00134-006-0406-0; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Lim HB, 2007, ANAESTHESIA, V62, P474, DOI 10.1111/j.1365-2044.2007.04998.x; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mascia L, 2005, INTENS CARE MED, V31, P373, DOI 10.1007/s00134-004-2491-2; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Miller JD, 1983, INTRACRANIAL PRESSUR, P44; Moore EM, 2010, RENAL FAILURE, V32, P1060, DOI 10.3109/0886022X.2010.510234; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Pelosi P, 2005, CURR OPIN CRIT CARE, V11, P37, DOI 10.1097/00075198-200502000-00006; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Rello J, 2011, J CRIT CARE, V26, P3, DOI 10.1016/j.jcrc.2010.04.001; Ricci Z, 2008, KIDNEY INT, V73, P538, DOI 10.1038/sj.ki.5002743; Rincon-Ferrari MD, 2004, J TRAUMA, V57, P1234, DOI 10.1097/01.TA.0000119200.70853.23; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Zygun D, 2005, CURR OPIN CRIT CARE, V11, P139, DOI 10.1097/01.ccx.0000155356.86241.c0; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54; Zygun DA, 2003, J CRIT CARE, V18, P238, DOI 10.1016/j.jcrc.2003.10.007; Zygun D, 2006, CRIT CARE, V10, DOI 10.1186/cc5007; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	41	76	81	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2012	16	2							R44	10.1186/cc11243			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	066CF	WOS:000313196800010	22410278	Green Published, gold			2022-02-06	
J	Szmydynger-Chodobska, J; Strazielle, N; Gandy, JR; Keefe, TH; Zink, BJ; Ghersi-Egea, JF; Chodobski, A				Szmydynger-Chodobska, Joanna; Strazielle, Nathalie; Gandy, Jessica R.; Keefe, Timothy H.; Zink, Brian J.; Ghersi-Egea, Jean-Francois; Chodobski, Adam			Posttraumatic invasion of monocytes across the blood-cerebrospinal fluid barrier	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						blood-cerebrospinal fluid barrier; choroid plexus; CC chemokines; monocytes; traumatic brain injury	CHEMOATTRACTANT PROTEIN-1 MCP-1; CHOROID-PLEXUS; INTESTINAL EPITHELIA; BRAIN-INJURY; RAT-BRAIN; EXPRESSION; RECEPTOR; MEDIATORS; CYTOKINE; RECRUITMENT	The invasion of inflammatory cells occurring after ischemic or traumatic brain injury (TBI) has a detrimental effect on neuronal survival and functional recovery after injury. We have recently demonstrated that not only the blood-brain barrier, but also the blood-cerebrospinal fluid (CSF) barrier (BCSFB), has a role in posttraumatic recruitment of neutrophils. Here, we show that TBI results in a rapid increase in synthesis and release into the CSF of a major chemoattractant for monocytes, CCL2, by the choroid plexus epithelium, a site of the BCSFB. Using an in vitro model of the BCSFB, we also show that CCL2 is released across the apical and basolateral membranes of the choroidal epithelium, a pattern of chemokine secretion that promotes leukocyte migration across epithelial barriers. Immunohistochemical and electron microscopic analyses of choroidal tissue provide evidence for the movement of monocytes, sometimes in tandem with neutrophils, along the paracellular pathways between adjacent epithelial cells. These data further support the pathophysiological role of BCSFB in promoting the recruitment of inflammatory cells to the injured brain. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 93-104; doi:10.1038/jcbfm.2011.111; published online 10 August 2011	[Szmydynger-Chodobska, Joanna] Brown Univ, Alpert Med Sch, Dept Emergency Med, Coro Ctr W, Providence, RI 02903 USA; [Strazielle, Nathalie] Brain I Lyon Neurosci Res Ctr, Lyon, France; [Ghersi-Egea, Jean-Francois] Univ Lyon 1, Neurooncol & Neuroinflammat Team, Lyon Neurosci Res Ctr, INSERM U1028,CNRS UMR5292, Lyon, France		Szmydynger-Chodobska, J (corresponding author), Brown Univ, Alpert Med Sch, Dept Emergency Med, Coro Ctr W, Room 112,1 Hoppin St, Providence, RI 02903 USA.	joanna_szmydynger-chodobska@brown.edu		Ghersi-Egea, Jean-Francois/0000-0002-0181-4909	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS49479]; European UnionEuropean Commission [HEALTH-F2-2009-241778]; Department of Emergency Medicine at the Alpert Medical School of Brown University; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049479] Funding Source: NIH RePORTER	This work was supported by Grant NS49479 from the NIH (to AC), HEALTH-F2-2009-241778 from the European Union (to NS), and by funds from the Department of Emergency Medicine at the Alpert Medical School of Brown University (to JSC and AC).	Bartholomaus I, 2009, NATURE, V462, P94, DOI 10.1038/nature08478; Batisson M, 2006, J INFECT DIS, V194, P341, DOI 10.1086/505428; Beech JS, 2001, J CEREBR BLOOD F MET, V21, P683, DOI 10.1097/00004647-200106000-00006; Bonini JA, 1997, DNA CELL BIOL, V16, P1249, DOI 10.1089/dna.1997.16.1249; Chen Y, 2003, J CEREBR BLOOD F MET, V23, P748, DOI 10.1097/01.WCB.0000071885.63724.20; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; COLOTTA F, 1992, J IMMUNOL, V148, P760; DEPASQUALE M, 1989, AM J PHYSIOL, V256, pF1059, DOI 10.1152/ajprenal.1989.256.6.F1059; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; ERICSSON A, 1995, J COMP NEUROL, V361, P681, DOI 10.1002/cne.903610410; Gouwy M, 2004, J LEUKOCYTE BIOL, V76, P185, DOI 10.1189/jlb.1003479; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; MCCORMICK BA, 1995, J CELL BIOL, V131, P1599, DOI 10.1083/jcb.131.6.1599; McCormick BA, 1998, J IMMUNOL, V160, P455; Mitchell K, 2009, NEUROSCIENCE, V158, P885, DOI 10.1016/j.neuroscience.2008.10.047; Neumann J, 2008, J NEUROSCI, V28, P5965, DOI 10.1523/JNEUROSCI.0060-08.2008; Newby AC, 2008, ARTERIOSCL THROM VAS, V28, P2108, DOI 10.1161/ATVBAHA.108.173898; PAINE R, 1993, J IMMUNOL, V150, P4561; Praetorius J, 2006, AM J PHYSIOL-CELL PH, V291, pC59, DOI 10.1152/ajpcell.00433.2005; PRODJOSUDJADI W, 1995, KIDNEY INT, V48, P1477, DOI 10.1038/ki.1995.437; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; SOZZANI S, 1994, J IMMUNOL, V152, P3615; Stamatovic SM, 2005, J CEREBR BLOOD F MET, V25, P593, DOI 10.1038/sj.jcbfm.9600055; Strazielle N, 1999, J NEUROSCI, V19, P6275; Strazielle N, 2000, J NEUROPATH EXP NEUR, V59, P561, DOI 10.1093/jnen/59.7.561; Strazielle Nathalie, 2003, Methods Mol Med, V89, P291; Szmydynger-Chodobska J, 2010, J NEUROTRAUM, V27, P1449, DOI 10.1089/neu.2010.1331; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; Takahashi M, 2009, J IMMUNOL, V183, P3463, DOI 10.4049/jimmunol.0802812; Thibeault I, 2001, J COMP NEUROL, V434, P461, DOI 10.1002/cne.1187; Toft-Hansen H, 2006, J IMMUNOL, V177, P7242, DOI 10.4049/jimmunol.177.10.7242; Yamasaki Y, 1997, BRAIN RES, V759, P103, DOI 10.1016/S0006-8993(97)00251-5	36	76	76	1	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2012	32	1					93	104		10.1038/jcbfm.2011.111			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	875DG	WOS:000299010000012	21829211	Green Published, Bronze			2022-02-06	
J	Kalbermatten, DF; Schaakxs, D; Kingham, PJ; Wiberg, M				Kalbermatten, Daniel F.; Schaakxs, Dominique; Kingham, Paul J.; Wiberg, Mikael			Neurotrophic activity of human adipose stem cells isolated from deep and superficial layers of abdominal fat	CELL AND TISSUE RESEARCH			English	Article						Growth factor; Nerve; Regeneration; Stem cell; Tissue engineering	GROWTH-FACTOR; BONE-MARROW; IN-VITRO; DIFFERENTIATION; TISSUE; TRANSPLANTATION; PHENOTYPE; OUTGROWTH; DELIVERY	New approaches to the clinical treatment of traumatic nerve injuries may one day utilize stem cells to enhance nerve regeneration. Adipose-derived stem cells (ASC) are found in abundant quantities and can be harvested by minimally invasive procedures that should facilitate their use in such regenerative applications. We have analyzed the properties of human ASC isolated from the deep and superficial layers of abdominal fat tissue obtained during abdominoplasty procedures. Cells from the superficial layer proliferate significantly faster than those from the deep layer. In both the deep and superficial layers, ASC express the pluripotent stem cell markers oct4 and nanog and also the stro-1 cell surface antigen. Superficial layer ASC induce the significantly enhanced outgrowth of neurite-like processes from neuronal cell lines when compared with that of deep layer cells. However, analysis by reverse transcription with the polymerase chain reaction and by enzyme-linked immunosorbent assay has revealed that ASC isolated from both layers express similar levels of the following neurotrophic factors: nerve growth factor, brain-derived neurotrophic factor and glial-derived neurotrophic factor. Thus, human ASC show promising potential for the treatment of traumatic nerve injuries. In particular, superficial layer ASC warrant further analysis of their neurotrophic molecules.	[Kalbermatten, Daniel F.; Schaakxs, Dominique; Kingham, Paul J.; Wiberg, Mikael] Umea Univ, Dept Integrat Med Biol, Sect Anat, SE-90187 Umea, Sweden; [Wiberg, Mikael] Umea Univ, Dept Surg & Perioperat Sci, Sect Hand & Plast Surg, SE-90187 Umea, Sweden; [Kalbermatten, Daniel F.; Schaakxs, Dominique] Univ Lausanne Hosp, Div Plast Reconstruct & Aesthet Surg, CHUV, Lausanne, Switzerland; [Kalbermatten, Daniel F.] Univ Basel Hosp, Dept Plast Reconstruct & Aesthet Surg, CH-4031 Basel, Switzerland		Kingham, PJ (corresponding author), Umea Univ, Dept Integrat Med Biol, Sect Anat, SE-90187 Umea, Sweden.	paul.kingham@anatomy.umu.se		Kingham, Paul/0000-0003-2596-5936; Kalbermatten, Daniel Felix/0000-0002-6626-1233	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission; Umea University; County of Vasterbotten; Magn. Bergvalls Stiftelse; Clas Groschinskys Minnesfond; Ake Wibergs Stiftelse; Gunvor and Josef Aner Foundation; SwissLife Foundation; SUVA; University of Lausanne FBM	This study was supported by the Swedish Medical Research Council, Umea University, County of Vasterbotten, Magn. Bergvalls Stiftelse, Clas Groschinskys Minnesfond, Ake Wibergs Stiftelse, the Gunvor and Josef Aner Foundation, SwissLife Foundation, the SUVA and the University of Lausanne FBM.	Aksu AE, 2008, ANN PLAS SURG, V60, P306, DOI 10.1097/SAP.0b013e3180621ff0; Anghileri E, 2008, STEM CELLS DEV, V17, P909, DOI 10.1089/scd.2007.0197; Baglioni S, 2009, FASEB J, V23, P3494, DOI 10.1096/fj.08-126946; Barrilleaux B, 2006, TISSUE ENG, V12, P3007, DOI 10.1089/ten.2006.12.3007; Bunnell BA, 2008, METHODS, V45, P115, DOI 10.1016/j.ymeth.2008.03.006; Carlson KB, 2011, GLIA, V59, P267, DOI 10.1002/glia.21099; Chen ZL, 2007, ANNU REV NEUROSCI, V30, P209, DOI 10.1146/annurev.neuro.30.051606.094337; Chernousov MA, 2000, HISTOL HISTOPATHOL, V15, P593, DOI 10.14670/HH-15.593; Choi RCY, 1997, NEUROSCI LETT, V236, P167, DOI 10.1016/S0304-3940(97)00789-1; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; di Summa PG, 2010, J PLAST RECONSTR AES, V63, P1544, DOI 10.1016/j.bjps.2009.09.012; Enzmann GU, 2006, J NEUROTRAUM, V23, P479, DOI 10.1089/neu.2006.23.479; Lambert APF, 2009, DIFFERENTIATION, V77, P221, DOI 10.1016/j.diff.2008.10.016; Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09; Jiang L, 2008, NEUROREPORT, V19, P1015, DOI 10.1097/WNR.0b013e3283040efc; Kim JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007166; Kim YJ, 2007, CELL PHYSIOL BIOCHEM, V20, P867, DOI 10.1159/000110447; Kingham PJ, 2007, EXP NEUROL, V207, P267, DOI 10.1016/j.expneurol.2007.06.029; Lundborg G, 2000, J HAND SURG-AM, V25A, P391, DOI 10.1053/jhsu.2000.4165; Oedayrajsingh-Varma MJ, 2006, CYTOTHERAPY, V8, P166, DOI 10.1080/14653240600621125; Padoin AV, 2008, PLAST RECONSTR SURG, V122, P614, DOI 10.1097/PRS.0b013e31817d5476; Pfister LA, 2007, J PERIPHER NERV SYST, V12, P65, DOI 10.1111/j.1529-8027.2007.00125.x; Quirici N, 2010, STEM CELLS DEV, V19, P915, DOI 10.1089/scd.2009.0408; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Riekstina U, 2009, STEM CELL REV REP, V5, P378, DOI 10.1007/s12015-009-9094-9; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Safford KM, 2002, BIOCHEM BIOPH RES CO, V294, P371, DOI 10.1016/S0006-291X(02)00469-2; Santiago LY, 2009, CELL TRANSPLANT, V18, P145, DOI 10.3727/096368909788341289; Schipper BM, 2008, ANN PLAS SURG, V60, P538, DOI 10.1097/SAP.0b013e3181723bbe; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Sterodimas A, 2010, J PLAST RECONSTR AES, V63, P1886, DOI 10.1016/j.bjps.2009.10.028; Terenghi G, 2009, INT REV NEUROBIOL, V87, P393, DOI 10.1016/S0074-7742(09)87021-9; Walsh S, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/FOC.2009.26.2.E2; Wei X, 2009, STEM CELLS, V27, P478, DOI 10.1634/stemcells.2008-0333; Xu YF, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-21; Zannettino ACW, 2008, J CELL PHYSIOL, V214, P413, DOI 10.1002/jcp.21210; Zimmerlin L, 2010, CYTOM PART A, V77A, P22, DOI 10.1002/cyto.a.20813	37	76	77	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0302-766X	1432-0878		CELL TISSUE RES	Cell Tissue Res.	MAY	2011	344	2					251	260		10.1007/s00441-011-1142-5			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	758LZ	WOS:000290167600007	21400216				2022-02-06	
J	Sorrentino, E; Budohoski, KP; Kasprowicz, M; Smielewski, P; Matta, B; Pickard, JD; Czosnyka, M				Sorrentino, Enrico; Budohoski, Karol P.; Kasprowicz, Magdalena; Smielewski, Peter; Matta, Basil; Pickard, John D.; Czosnyka, Marek			Critical Thresholds for Transcranial Doppler Indices of Cerebral Autoregulation in Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Head injury; Transcranial Doppler; Outcome; Thresholds; Autoregulation index	CEREBROVASCULAR PRESSURE-REACTIVITY; SEVERE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; VALIDATION; HYPERTENSION; ASSOCIATION; MANAGEMENT; HEMORRHAGE	Transcranial Doppler-derived indices of cerebral autoregulation are related to outcome after TBI. We analyzed our retrospective material to identify thresholds discriminative of outcome for these indices. 248 sedated and ventilated patients after head injury were eligible for the study. The indices of autoregulation derived from transcranial Doppler were calculated as correlation coefficients of blood flow velocity with cerebral perfusion pressure (index Mx) or arterial blood pressure (index Mxa). 2 x 2 tables were created grouping patients according to survival-death or favorable-unfavorable outcomes and varying thresholds for Mx and Mxa. Pearson's chi-square was calculated. Thresholds returning the highest chi-square value were assumed to have the best discriminative value between survival-death and favorable-unfavorable outcomes. Mx and Mxa demonstrated that worse autoregulation is associated with poorer outcome and greater mortality (P = 0.0033 for Mx and P = 0.047 for Mxa). Both indices were more effective for prediction of favorable outcome than mortality. Chi-square for Mx showed a double peak with thresholds at 0.05 and 0.3. Mxa had only one peak at 0.3. Peak chi-square for Mx (11.3) was greater than for Mxa (8.7), indicating that Mx was a better discriminant of outcome than Mxa. We propose that Mx greater than 0.3 indicates definitely disturbed autoregulation and lower than 0.05 good autoregulation. For values between 0.05 and 0.3 the state of autoregulation is uncertain.	[Sorrentino, Enrico; Budohoski, Karol P.; Kasprowicz, Magdalena; Smielewski, Peter; Pickard, John D.; Czosnyka, Marek] Addenbrookes Hosp, Dept Acad Neurosurg, Cambridge CB2 OQQ, England; [Kasprowicz, Magdalena] Wroclaw Univ Technol, Inst Biomed Engn & Instrumentat, PL-50370 Wroclaw, Poland; [Matta, Basil] Addenbrookes Hosp, Dept Anesthet, Cambridge CB2 OQQ, England		Czosnyka, M (corresponding author), Addenbrookes Hosp, Dept Acad Neurosurg, Hills Rd, Cambridge CB2 OQQ, England.	mc141@medschl.cam.ac.uk		Smielewski, Peter/0000-0001-5096-3938; Kasprowicz, Magdalena/0000-0002-2271-7737	National Institute of Health ResearchNational Institute for Health Research (NIHR); Biomedical Research Center; Cambridge University Hospital Foundation Trust; Technology Foresight Challenge Fund [FCA 234/95]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MRC G9439390]; Clifford and Mary Corbridge Trust; Foundation for Polish ScienceFoundation for Polish ScienceEuropean Commission; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G0600986, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This project was supported by the National Institute of Health Research, Biomedical Research Center, Cambridge University Hospital Foundation Trust-Neurosciences Theme and Senior Investigator Awards (JDP), Technology Foresight Challenge Fund (Grant FCA 234/95), MRC Program Grant (MRC G9439390). Clifford and Mary Corbridge Trust (KPB), and Foundation for Polish Science (MK).	Balestreri M, 2005, ACT NEUR S, V95, P25; Brady KM, 2010, ANESTH ANALG, V111, P191, DOI 10.1213/ANE.0b013e3181e054ba; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Castellani G, 2009, NEUROCRIT CARE, V11, P143, DOI 10.1007/s12028-009-9235-7; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; Czosnyka M, 2003, ACT NEUR S, V86, P581; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Guendling K, 2006, ACTA NEUROCHIR SUPPL, V96, P108; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Immink RV, 2004, CIRCULATION, V110, P2241, DOI 10.1161/01.CIR.0000144472.08647.40; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; Lewis PM, 2007, ACTA NEUROCHIR, V149, P549, DOI 10.1007/s00701-007-1160-y; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Panerai RB, 2004, BRIT J NEUROSURG, V18, P471, DOI 10.1080/02688690400012343; Piechnik SK, 1999, ANESTH ANALG, V89, P944, DOI 10.1097/00000539-199910000-00023; RANDELCASTILLA L, 2010, J NEUROTRAUM, V27, P1853; Reinhard M, 2010, INTENS CARE MED, V36, P264, DOI 10.1007/s00134-009-1698-7; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Soehle M, 2004, ANESTH ANALG, V98, P1133, DOI 10.1213/01.ANE.0000111101.41190.99; Steiner LA, 2005, ACTA NEUROCHIR SUPPL, V95, P17; Steiner LA, 2003, ANESTH ANALG, V97, P572, DOI 10.1213/01.ANE.0000070234.17226.B0; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steiner LA, 2009, NEUROCRIT CARE, V10, P122, DOI 10.1007/s12028-008-9140-5; Tzeng YC, 2010, HYPERTENSION, V56, P268, DOI 10.1161/HYPERTENSIONAHA.110.152066	28	76	77	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2011	14	2					188	193		10.1007/s12028-010-9492-5			6	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	738SY	WOS:000288663800007	21181299				2022-02-06	
J	Bigler, ED; Maxwell, WL				Bigler, Erin D.; Maxwell, William L.			Neuroimaging and neuropathology of TBI	NEUROREHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; DIFFUSION-TENSOR; WHITE-MATTER; THALAMIC NUCLEI; HEAD; MODERATE; INTEGRITY; CHILDREN; ATROPHY; MEMORY	Neuroimaging at all stages of a traumatic brain injury (TBI) provides information about gross brain pathology. In this review, post-mortem TBI cases are matched to neuroimaging findings from TBI survivors to demonstrate the close correlation between observable pathology with in vivo neuroimaging to the underlying neuropathology. An emphasis of this review focuses on neuroimaging identification of trauma induced cortical and white matter degeneration along with hydrocephalus ex vacuo expansion of the ventricular system as the injured brain exhibits atrophic changes. The role of hippocampal atrophy and thalamic injury along with the vulnerability of the corpus callosum in TBI are also reviewed. The aim of this review is to provide pathological confirmation of observable neuroimaging abnormalities that relate directly to trauma-induced effects of the injury.	[Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA; [Maxwell, William L.] Univ Glasgow, Dept Anat, Glasgow G12 8QQ, Lanark, Scotland		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1190D Kimball Tower, Provo, UT 84602 USA.	erin_bigler@byu.edu					Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Bartsch T, 2010, LANCET NEUROL, V9, P205, DOI 10.1016/S1474-4422(09)70344-8; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Biasca N, 2007, PROG BRAIN RES, V161, P263, DOI 10.1016/S0079-6123(06)61019-4; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; BRICKMAN AM, 2010, HIPPOCAMPUS; Budson AE, 2009, NEUROLOGIST, V15, P71, DOI 10.1097/NRL.0b013e318188040d; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; D 'Esposito M, 2000, SEMIN NEUROL, V20, P487, DOI 10.1055/s-2000-13182; Fearing MA, 2008, J CHILD NEUROL, V23, P729, DOI 10.1177/0883073808314159; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Izhikevich EM, 2008, P NATL ACAD SCI USA, V105, P3593, DOI 10.1073/pnas.0712231105; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kesner RP, 2007, LEARN MEMORY, V14, P771, DOI 10.1101/lm.688207; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lajiness-O'Neill R, 2010, APPL NEUROPSYCHOL, V17, P83, DOI 10.1080/09084281003708837; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lee ZI, 2003, AM J PHYS MED REHAB, V82, P556, DOI 10.1097/01.PHM.0000073830.15643.6A; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Maruichi K, 2009, NEUROPATHOLOGY, V29, P132, DOI 10.1111/j.1440-1789.2008.00956.x; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Pannek K, 2010, NEUROIMAGE, V50, P1044, DOI 10.1016/j.neuroimage.2010.01.020; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; TATEMICHI TK, 1992, NEUROLOGY, V42, P1966, DOI 10.1212/WNL.42.10.1966; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wu TC, 2010, DEV NEUROSCI; Wu Y, 2010, J MAGN RESON IMAGING, V31, P980, DOI 10.1002/jmri.22120; Zarei M, 2010, NEUROIMAGE, V49, P1, DOI 10.1016/j.neuroimage.2009.09.001	51	76	78	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2011	28	2					63	74		10.3233/NRE-2011-0633			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	768MZ	WOS:000290940300001	21447905				2022-02-06	
J	Duffy, SO; Squires, J; Fromkin, JB; Berger, RP				Duffy, Shanna O.; Squires, Janet; Fromkin, Janet B.; Berger, Rachel P.			Use of Skeletal Surveys to Evaluate for Physical Abuse: Analysis of 703 Consecutive Skeletal Surveys	PEDIATRICS			English	Article						skeletal survey; child physical abuse; apparent life-threatening event; abusive head trauma	LIFE-THREATENING EVENT; TRAUMATIC BRAIN-INJURY; CHILD-ABUSE; HEAD TRAUMA; REASONABLE SUSPICION; YOUNG-CHILDREN; INFANTS; SERUM; IDENTIFICATION; POPULATION	OBJECTIVES: The goals were to assess the use of the skeletal survey (SS) to evaluate for physical abuse in a large consecutive sample, to identify characteristics of children most likely to have unsuspected fractures, and to determine how often SS results influenced directly the decision to make a diagnosis of abuse. METHODS: A retrospective, descriptive study of a consecutive sample of children who underwent an SS at a single children's hospital over 4 years was performed. Data on demographic characteristics, clinical presentation, SS results, and effects of SS results on clinical diagnoses were collected. A positive SS result was defined as a SS which identified a previously unsuspected fracture(s). RESULTS: Of the 703 SSs, 10.8% yielded positive results. Children <6 months of age, children with an apparent life-threatening event or seizure, and children with suspected abusive head trauma had the highest rates of positive SS results. Of children with positive SS results, 79% had >= 1 healing fracture. CONCLUSIONS: This is the largest study to date to describe the use of the SS. Almost 11% of SS results were positive. The SS results influenced directly the decision to make a diagnosis of abuse for 50% of children with positive SS results. These data, combined with the high morbidity rates for missed abuse and the large proportion of children with healing fractures detected through SS, suggest that broader use of SS, particularly for high-risk populations, may be warranted. Pediatrics 2011;127:e47-e52	[Squires, Janet; Fromkin, Janet B.; Berger, Rachel P.] UPMC, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15224 USA; [Duffy, Shanna O.] Wright State Univ, Boonshoft Sch Med, Dayton, OH 45435 USA		Berger, RP (corresponding author), UPMC, Childrens Hosp Pittsburgh, Dept Pediat, 4417 Penn Ave, Pittsburgh, PA 15224 USA.	rachel.berger@chp.edu	Stryker, Shanna D./AAZ-7552-2021	Stryker, Shanna/0000-0001-9983-1346	Pediatric Clinical and Translational Research Center, Children's Hospital of Pittsburgh of UPMC; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024153] Funding Source: NIH RePORTER	Support was provided by the Summer Student Research Training Program of the Pediatric Clinical and Translational Research Center, Children's Hospital of Pittsburgh of UPMC.	ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; Altman RL, 2007, EUR J OPHTHALMOL, V17, P648, DOI 10.1177/112067210701700426; Belfer RA, 2001, AM J EMERG MED, V19, P122, DOI 10.1053/ajem.2001.21345; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bonkowsky JL, 2008, PEDIATRICS, V122, P125, DOI 10.1542/peds.2007-3376; Brand DA, 2005, PEDIATRICS, V115, P885, DOI 10.1542/peds.2004-0847; Chang DC, 2004, J TRAUMA, V57, P1189, DOI 10.1097/01.TA.0000145076.05111.E1; Day Fiona, 2006, J Clin Forensic Med, V13, P55, DOI 10.1016/j.jcfm.2005.08.001; Di Pietro MA, 2009, PEDIATRICS, V123, P1430, DOI 10.1542/peds.2009-0558; ELLERSTEIN NS, 1984, PEDIATRICS, V74, P1075; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Kairys SW, 2001, PEDIATRICS, V108, P206; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WK, 2006, PEDIATR EMERG CARE, V22, P211, DOI 10.1097/01.pec.0000208180.94166.dd; Levi BH, 2006, CHILD ABUSE NEGLECT, V30, P345, DOI 10.1016/j.chiabu.2005.05.004; Levi BH, 2005, PEDIATRICS, V116, pE5, DOI 10.1542/peds.2004-2649; Levi BH, 2004, THEOR MED BIOETH, V25, P277, DOI 10.1007/s11017-004-3136-8; MERTEN DF, 1983, RADIOLOGY, V146, P377, DOI 10.1148/radiology.146.2.6849085; Oral R, 2008, PEDIATR EMERG CARE, V24, P816, DOI 10.1097/PEC.0b013e31818e9f5d; Ravichandiran N, 2010, PEDIATRICS, V125, P60, DOI 10.1542/peds.2008-3794; Vellody K, 2008, CLIN PEDIATR, V47, P912, DOI 10.1177/0009922808320595; Waseem M, 2006, PEDIATR EMERG CARE, V22, P245, DOI 10.1097/01.pec.0000210176.48386.ae; Wood JN, 2009, PEDIATRICS, V123, pE247, DOI 10.1542/peds.2008-2467	27	76	76	0	6	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2011	127	1					E47	E52		10.1542/peds.2010-0298			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	700YT	WOS:000285782200007	21149429	Green Published			2022-02-06	
J	Hartog, CS; Bauer, M; Reinhart, K				Hartog, Christiane S.; Bauer, Michael; Reinhart, Konrad			The Efficacy and Safety of Colloid Resuscitation in the Critically III	ANESTHESIA AND ANALGESIA			English	Article							HYDROXYETHYL STARCH SOLUTION; CARDIAC-SURGERY PATIENTS; MAJOR ORTHOPEDIC-SURGERY; SEE VOL. 37; FLUID RESUSCITATION; RENAL-FUNCTION; VOLUME REPLACEMENT; ILL PATIENTS; HES 130/0.4; PULMONARY PERMEABILITY	Despite evidence from clinical studies and meta-analyses that resuscitation with colloids or crystalloids is equally effective in critically ill patients, and despite reports from high-quality clinical trials and meta-analyses regarding nephrotoxic effects, increased risk of bleeding, and a trend toward higher mortality in these patients after the use of hydroxyethyl starch (HES) solutions, colloids remain popular and the use of HES solutions is increasing worldwide. We investigated the major rationales for colloid use, namely that colloids are more effective plasma expanders than crystalloids, that synthetic colloids are as safe as albumin, that HES solutions have the best risk/benefit profile among the synthetic colloids, and that the third-generation HES 130/0.4 has fewer adverse effects than older starches. Evidence from clinical studies shows that comparable resuscitation is achieved with considerably less crystalloid volumes than frequently suggested, namely, <2-fold the volume of colloids. Albumin is safe in intensive care unit patients except in patients with closed head injury. All synthetic colloids, namely, dextran, gelatin, and HES have dose-related side effects, which are coagulopathy, renal failure, and tissue storage. In patients with severe sepsis, higher doses of HES may be associated with excess mortality. The assumption that third-generation HES 130/0.4 has fewer adverse effects is yet unproven. Clinical trials on HES 130/0.4 have notable shortcomings. Mostly, they were not performed in intensive care unit or emergency department patients, had short observation periods of 24 to 48 hours, used cumulative doses below 1 daily dose limit (50 mL/kg), and used unsuitable control fluids such as other HES solutions or gelatins. In conclusion, the preferred use of colloidal solutions for resuscitation of patients with acute hypovolemia is based on rationales that are not supported by clinical evidence. Synthetic colloids are not superior in critically ill adults and children but must be considered harmful depending on the cumulative dose administered. Safe threshold doses need to be determined in studies in high-risk patients and observation periods of 90 days. Such studies on HES 130/0.4 are still lacking despite its widespread and increasing use. Because there are safer and equally effective alternatives in the form of crystalloids, use of synthetic colloids should be avoided except in the context of clinical studies. (Anesth Analg 2011; 112:156-64)	[Hartog, Christiane S.; Bauer, Michael; Reinhart, Konrad] Univ Jena, Dept Anaesthesiol & Intens Care Med, D-07747 Jena, Germany		Reinhart, K (corresponding author), Univ Jena, Dept Anaesthesiol & Intens Care Med, Erlanger Allee 101, D-07747 Jena, Germany.	konrad.reinhart@med.uni-jena.de	Hartog, Christiane/O-7650-2016	Hartog, Christiane/0000-0003-1098-9775; Bauer, Michael/0000-0002-1521-3514	B. Braun Melsungen	Disclosure: KR has in the past received consultancy fees from B. Braun Melsungen.	Akech S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010021; Auwerda JJA, 2002, ANN INTERN MED, V137, P1013, DOI 10.7326/0003-4819-137-12-200212170-00037; Auwerda JJA, 2006, TRANSFUSION, V46, P1705, DOI 10.1111/j.1537-2995.2006.00962.x; Barron ME, 2004, ARCH SURG-CHICAGO, V139, P552, DOI 10.1001/archsurg.139.5.552; Basora M, 2007, Rev Esp Anestesiol Reanim, V54, P162; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Boldt J, 2008, BRIT J ANAESTH, V100, P457, DOI 10.1093/bja/aen016; Boldt J, 2004, INTENS CARE MED, V30, P416, DOI 10.1007/s00134-003-2110-7; Boldt J, 2006, SHOCK, V25, P103, DOI 10.1097/01.shk.0000189595.35661.40; Boldt J, 2003, INTENS CARE MED, V29, P763, DOI 10.1007/s00134-003-1702-6; Boldt J, 2001, INFUS THER TRANSFUS, V28, P144; Boldt J, 2001, ANASTH INTENSIV NOTF, V36, pS102; Boldt J, 2000, J CARDIOTHOR VASC AN, V14, P264; Boldt J, 2008, ANESTH ANALG, V107, P1496, DOI 10.1213/ane.0b013e31818370b2; Boldt J, 2007, CRIT CARE MED, V35, P2740, DOI 10.1097/01.CCM.0000288101.02556.DE; Boldt J, 2006, ANESTH ANALG, V103, P191, DOI 10.1213/01.ane.0000221179.07006.06; Boldt J, 2009, ANESTH ANALG, V108, P1574, DOI [10.1213/ane.0b013e31819e9e6c, 10.1213/ANE.0000000000005019]; Bork K, 2005, BRIT J DERMATOL, V152, P3, DOI 10.1111/J.1365-2133.2004.06272.X; Boussekey N, 2010, CRIT CARE, V14, DOI 10.1186/cc8920; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; BUNN F, 2008, COCHRANE DB SYST REV, V1; Choi PTL, 1999, CRIT CARE MED, V27, P200, DOI 10.1097/00003246-199901000-00053; Cittanova ML, 1996, LANCET, V348, P1620, DOI 10.1016/S0140-6736(96)07588-5; Dart AB, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007594.pub2; Davidson IJ, 2006, EUR J ANAESTH, V23, P721, DOI 10.1017/S0265021506000639; Davies M J, 1989, J Clin Anesth, V1, P464, DOI 10.1016/0952-8180(89)90013-5; Dellinger R Phillip, 2008, Crit Care Med, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Ertmer C, 2010, ANESTHESIOLOGY, V112, P936, DOI 10.1097/ALN.0b013e3181d3d493; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Finfer S, 2004, NEW ENGL J MED, V350, P2247; FINFER S, INTENSIVE C IN PRESS; Fluids Study Investigators, 2008, ACTA ANAESTH SCAND, V52, P750, DOI 10.1111/j.1399-6576.2008.01690.x; GAMMAGE G, 1987, INT ANESTHESIOL CLIN, V25, P37, DOI 10.1097/00004311-198702510-00005; Gandhi SD, 2007, ANESTHESIOLOGY, V106, P1120, DOI 10.1097/01.anes.0000265422.07864.37; Ginz HF, 1998, ANAESTHESIST, V47, P330, DOI 10.1007/s001010050564; Godet G, 2008, EUR J ANAESTH, V25, P986, DOI 10.1017/S026502150800447X; HAGNE C, 2009, SCHWEIZ MED FORUM, V9, P304; Haynes GR, 2006, J CARDIOTHOR VASC AN, V20, P916, DOI 10.1053/j.jvca.2006.04.011; Hitosugi T, 2007, ANESTH ANALG, V105, P724, DOI 10.1213/01.ane.0000275198.84094.ad; Huet RCGG, 2000, CAN J ANAESTH, V47, P1207; Huter L, 2009, CRIT CARE, V13, DOI 10.1186/cc7726; Ickx BE, 2003, BRIT J ANAESTH, V91, P196, DOI 10.1093/bja/aeg159; James MFM, 2008, J CARDIOTHOR VASC AN, V22, P482, DOI 10.1053/j.jvca.2008.02.017; Jonville-Bera A, 2001, NEW ENGL J MED, V345, P622, DOI 10.1056/NEJM200108233450818; Jungheinrich Cornelius, 2004, Drugs R D, V5, P1, DOI 10.2165/00126839-200405010-00001; Kasper SM, 2003, ANESTHESIOLOGY, V99, P42, DOI 10.1097/00000542-200307000-00010; Kasper SM, 2001, J CLIN ANESTH, V13, P486, DOI 10.1016/S0952-8180(01)00311-7; Kozek-Langenecker SA, 2008, ANESTH ANALG, V107, P382, DOI 10.1213/ane.0b013e31817e6eac; Lang K, 2003, CAN J ANAESTH, V50, P1009, DOI 10.1007/BF03018364; Lang K, 2001, ANESTH ANALG, V93, P405, DOI 10.1097/00000539-200108000-00034; Langeron O, 2001, ANESTH ANALG, V92, P855, DOI 10.1097/00000539-200104000-00011; LAXENAIRE MC, 1994, ANN FR ANESTH, V13, P301, DOI 10.1016/S0750-7658(94)80038-3; Levi M, 2007, SEMIN THROMB HEMOST, V33, P810, DOI 10.1055/s-2007-1000370; Liu Fu-Chao, 2009, Acta Anaesthesiol Taiwan, V47, P71, DOI 10.1016/S1875-4597(09)60027-8; Lukasewitz P, 1998, J ANAESTH INTENSIVBE, V9, P42; Madigan MC, 2008, J TRAUMA, V64, P280, DOI 10.1097/TA.0b013e3181622bb6; Mahmood A, 2007, BRIT J SURG, V94, P427, DOI 10.1002/bjs.5726; Miletin MS, 2002, INTENS CARE MED, V28, P917, DOI 10.1007/s00134-002-1337-z; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Neff TA, 2003, ANESTH ANALG, V96, P1453, DOI 10.1213/01.ANE.0000061582.09963.FD; NEFF TA, 2006, EUR J ANAESTHESI S37, V23, P206; Palumbo D, 2006, MINERVA ANESTESIOL, V72, P655; PEREL P, 2009, COCHRANE DB SYST REV, V4; Puyana J., 2005, TXB CRITICAL CARE, V5th, P1939; RACKOW EC, 1983, CRIT CARE MED, V11, P839, DOI 10.1097/00003246-198311000-00001; Rioux JP, 2009, CRIT CARE MED, V37, P1293, DOI 10.1097/CCM.0b013e31819cc1a0; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; Sakr Y, 2007, BRIT J ANAESTH, V98, P216, DOI 10.1093/bja/ael333; Schabinski F, 2009, INTENS CARE MED, V35, P1539, DOI 10.1007/s00134-009-1509-1; Schick MA, 2010, INTENS CARE MED, V36, P541, DOI 10.1007/s00134-009-1704-0; Schierhout G, 1998, BMJ-BRIT MED J, V316, P961, DOI 10.1136/bmj.316.7136.961; Schmidt-Hieber M, 2006, EUR J HAEMATOL, V77, P83, DOI 10.1111/j.1600-0609.2006.00657.x; Schortgen F, 2004, INTENS CARE MED, V30, P2222, DOI 10.1007/s00134-004-2415-1; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; Schortgen F, 2009, CRIT CARE, V13, DOI 10.1186/cc7745; Schortgen F, 2008, INTENS CARE MED, V34, P2157, DOI 10.1007/s00134-008-1225-2; SCHWARZ A, 2009, SCHWEIZ MED FORUM, V9, P882; Sedrakyan A, 2003, CHEST, V123, P1853, DOI 10.1378/chest.123.6.1853; Sort P, 1999, NEW ENGL J MED, V341, P403, DOI 10.1056/NEJM199908053410603; Sossdorf M, 2009, CRIT CARE, V13, DOI 10.1186/cc8223; Toomtong P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000991.pub2; Townsend DR, 2008, NEPHRON CLIN PRACT, V109, pC205, DOI 10.1159/000142930; Tseng MY, 2008, BRIT J NEUROSURG, V22, P257, DOI 10.1080/02688690701832100; Upadhyay M, 2005, INDIAN PEDIATR, V42, P223; van der Heijden M, 2009, CRIT CARE MED, V37, P1275, DOI 10.1097/CCM.0b013e31819cedfd; Van der Linden PJ, 2005, ANESTH ANALG, V101, P629, DOI 10.1213/01.ANE.0000175216.53374.27; VELANOVICH V, 1989, SURGERY, V105, P65; Verheij J, 2006, BRIT J ANAESTH, V96, P21, DOI 10.1093/bja/aei286; Verheij J, 2006, INTENS CARE MED, V32, P1030, DOI 10.1007/s00134-006-0195-5; VINCENT JL, 1991, CRIT CARE MED, V19, P316; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Westphal M, 2009, ANESTHESIOLOGY, V111, P187, DOI 10.1097/ALN.0b013e3181a7ec82; Wiedermann CJ, 2008, BMC EMERG MED, V8, DOI 10.1186/1471-227X-8-1; Wilkes MM, 2001, ANN THORAC SURG, V72, P527, DOI 10.1016/S0003-4975(01)02745-X; Wills BA, 2005, NEW ENGL J MED, V353, P877, DOI 10.1056/NEJMoa044057; Zaar M, 2009, BRIT J ANAESTH, V102, P221, DOI 10.1093/bja/aen350; Zarychanski Ryan, 2009, Open Med, V3, pe196; ZIKRIA BA, 1989, SURGERY, V105, P625	98	76	83	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2011	112	1					156	164		10.1213/ANE.0b013e3181eaff91			9	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	696PQ	WOS:000285454300025	21127276				2022-02-06	
J	Udy, A; Boots, R; Senthuran, S; Stuart, J; Deans, R; Lassig-Smith, M; Lipman, J				Udy, Andrew; Boots, Robert; Senthuran, Siva; Stuart, Janine; Deans, Renae; Lassig-Smith, Melissa; Lipman, Jeffrey			Augmented Creatinine Clearance in Traumatic Brain Injury	ANESTHESIA AND ANALGESIA			English	Article							GLOMERULAR-FILTRATION RATE; RENAL-FUNCTION; NOREPINEPHRINE; RESERVE	BACKGROUND: Hypertonic saline and/or norepinephrine infusion are routinely used to achieve a desired cerebral perfusion pressure (CPP) in the management of traumatic brain injury (TBI). We hypothesized that creatinine clearances (CrCls) would be significantly augmented in this setting. METHODS: This was an observational cohort study in TBI patients older than 16 years with normal serum creatinine concentrations, requiring maintenance of CPP. Eight-hour urinary CrCl collections were performed while on and off active management. Demographic data, use of vasoactive medications, fluid balance, feeding regimen, and hemodynamic variables were recorded throughout the study period. Augmented CrCl was defined as > 150 mL/min/1.73 m(2) in women and > 160 mL/min/1.73 m(2) in men. RESULTS: Twenty patients were enrolled, and augmented clearances were demonstrated in 17 (85%). The mean maximum CrCl was 179 mL/min/1.73 m(2) while receiving CPP therapy (95% confidence interval [CI], 159-198), returning to a mean of 111 mL/min/1.73 m(2) (95% CI, 91-131; P < 0.001) when measured after discharge from the intensive care unit. The mean CrCl in the intensive care unit while not receiving CPP therapy was 150 mL/min/1.73 m(2) (95% CI, 134-167; P = 0.03). The mean time to reach peak CrCl while receiving active treatment was 4.7 days (95% CI, 3.0-6.4). In a multivariate analysis, norepinephrine use, saline loading, mean arterial blood pressure, and central venous pressure were associated with augmented CrCl on the day of measurement. CONCLUSIONS: Augmented CrCls are common in TBI patients receiving active management of CPP and persist even after discontinuation of such therapy. Further work is needed to clarify the impact of such clearances on renally excreted drugs in this setting.	[Udy, Andrew; Boots, Robert; Senthuran, Siva; Stuart, Janine; Deans, Renae; Lassig-Smith, Melissa; Lipman, Jeffrey] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Herston, Qld 4029, Australia; [Udy, Andrew; Boots, Robert; Senthuran, Siva; Lipman, Jeffrey] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Herston, Qld, Australia		Boots, R (corresponding author), Royal Brisbane & Womens Hosp, Dept Intens Care Med, Herston Rd, Herston, Qld 4029, Australia.		Udy, Andrew A/G-2538-2010; Lipman, Jeffrey/G-2211-2010; Boots, Robert/K-1159-2013; Udy, Andrew/S-1314-2016	Udy, Andrew A/0000-0002-6284-2022; Lipman, Jeffrey/0000-0002-5965-9876; Boots, Robert/0000-0002-2436-7654; Udy, Andrew/0000-0002-6284-2022	Royal Brisbane and Women's Hospital Research Foundation; Queensland Health; AstraZenecaAstraZeneca; Janssen-CilagJohnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc; Wyeth Australia AstraZeneca	Supported by a special purpose grant awarded to Dr Siva Senthuran from the Royal Brisbane and Women's Hospital Research Foundation Dr Andrew Udy was supported by a Clinical Research Skills Development grant from Queensland Health The funding source had no role in protocol development, patient recruitment, study analysis, interpretation, or the decision to submit for publication Professor Lipman is a consultant to AstraZeneca and Janssen-Cilag, and has received an honoraria from AstraZeneca, Janssen-Cilag, and Wyeth Australia AstraZeneca provides an annual donation to the Burns, Trauma and Critical Care Research Center, University of Queensland	Albanese J, 2004, CHEST, V126, P534, DOI 10.1378/chest.126.2.534; ANDERSON WP, 1981, J PHYSIOL-LONDON, V321, P21, DOI 10.1113/jphysiol.1981.sp013969; BAUMANN TJ, 1987, CLIN PHARMACY, V6, P393; Benmalek F, 1999, INTENS CARE MED, V25, P399, DOI 10.1007/s001340050865; BOSCH JP, 1983, AM J MED, V75, P943, DOI 10.1016/0002-9343(83)90873-2; BROWN R, 1980, CRIT CARE MED, V8, P68, DOI 10.1097/00003246-198002000-00004; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CASTELLINO P, 1988, AM J PHYSIOL, V255, pF444, DOI 10.1152/ajprenal.1988.255.3.F444; Conil JM, 2007, BRIT J CLIN PHARMACO, V63, P583, DOI 10.1111/j.1365-2125.2006.02807.x; Garcia MD, 2007, INTENS CARE MED, V33, P279, DOI 10.1007/s00134-006-0470-5; Di Giantomasso D, 2002, INTENS CARE MED, V28, P1804, DOI 10.1007/s00134-002-1444-x; DIGLANTOMASSO D, 2003, INTENS CARE MED, V29, P1774; Fuster-Lluch O, 2008, ANAESTH INTENS CARE, V36, P674, DOI 10.1177/0310057X0803600507; Hoste EAJ, 2005, NEPHROL DIAL TRANSPL, V20, P747, DOI 10.1093/ndt/gfh707; KIM KE, 1969, BRIT MED J, V4, P11, DOI 10.1136/bmj.4.5674.11; Kohl BA, 2006, CURR OPIN CRIT CARE, V12, P325, DOI 10.1097/01.ccx.0000235210.85073.fc; Lipman J, 2003, ANESTH ANALG, V97, P1149, DOI 10.1213/01.ANE.0000077077.54084.B0; LOIRAT P, 1978, NEW ENGL J MED, V299, P915, DOI 10.1056/NEJM197810262991703; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; SHIPLEY RE, 1951, AM J PHYSIOL, V167, P676, DOI 10.1152/ajplegacy.1951.167.3.676; Stevens LA, 2006, NEW ENGL J MED, V354, P2473, DOI 10.1056/NEJMra054415; Sunder-Plassmann G, 2004, AM J KIDNEY DIS, V43, P396, DOI 10.1053/j.ajkd.2003.11.017; THOMAS DM, 1994, KIDNEY INT, V45, P411, DOI 10.1038/ki.1994.53; Toschlog EA, 2003, J TRAUMA, V55, P255, DOI 10.1097/01.TA.0000079367.23481.8D; Udy A, 2009, ANAESTH INTENS CARE, V37, P11, DOI 10.1177/0310057X0903700123; Udy AA, 2010, CLIN PHARMACOKINET, V49, P1, DOI 10.2165/11318140-000000000-00000; VALDES ME, 1979, J SURG RES, V26, P473, DOI 10.1016/0022-4804(79)90036-2; Vincent F, 2005, CHEST, V127, P2282, DOI 10.1378/chest.127.6.2282; Wan L, 2007, ANESTH ANALG, V105, P141, DOI 10.1213/01.ane.0000266438.90360.62	29	76	78	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2010	111	6					1505	1510		10.1213/ANE.0b013e3181f7107d			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	690AU	WOS:000284973300027	21048095				2022-02-06	
J	Kasahara, M; Menon, DK; Salmond, CH; Outtrim, JG; Tavares, JVT; Carpenter, TA; Pickard, JD; Sahakian, BJ; Stamatakis, EA				Kasahara, M.; Menon, D. K.; Salmond, C. H.; Outtrim, J. G.; Tavares, J. V. Taylor; Carpenter, T. A.; Pickard, J. D.; Sahakian, B. J.; Stamatakis, E. A.			Altered functional connectivity in the motor network after traumatic brain injury	NEUROLOGY			English	Article							CORTEX; ACTIVATION; MOVEMENT; MILD; DEACTIVATION; INHIBITION; IMPAIRMENT; CEREBELLUM; EXECUTION; AREAS	Background: A large proportion of survivors of traumatic brain injury (TBI) have persistent cognitive impairments, the profile of which does not always correspond to the size and location of injuries. One possible explanation could be that TBI-induced damage extends beyond obvious lesion sites to affect remote brain networks. We explored this hypothesis in the context of a simple and well-characterized network, the motor network. The aim of this cross-sectional study was to establish the residual integrity of the motor network as an important proof of principle of abnormal connectivity in TBI. Methods: fMRI data were obtained from 12 right-handed patients and 9 healthy controls while they performed the finger-thumb opposition task with the right hand. We used both conventional and psychophysiologic interaction (PPI) analyses to examine the integrity of functional connections from brain regions we found to be activated in the paradigm we used. Results: As expected, the analysis showed significant activations of the left primary motor cortex (M1), right cerebellum (Ce), and bilateral supplementary motor area (SMA) in controls. However, only the activation of M1 survived robust statistical thresholding in patients. In controls, the PPI analysis revealed that left M1, SMA, and right Ce positively interacted with the left frontal cortex and negatively interacted with the right supramarginal gyrus. In patients, we observed no negative interaction and reduced interhemispheric interactions from these seed regions. Conclusions: These observations suggest that patients display compromised activation and connectivity patterns during the finger-thumb opposition task, which may imply functional reorganization of motor networks following TBI. Neurology(R) 2010;75:168-176	[Kasahara, M.; Menon, D. K.; Outtrim, J. G.; Stamatakis, E. A.] Univ Cambridge, Div Anaesthesia, Sch Clin Med, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Kasahara, M.; Menon, D. K.; Salmond, C. H.; Outtrim, J. G.; Tavares, J. V. Taylor; Carpenter, T. A.; Pickard, J. D.; Sahakian, B. J.; Stamatakis, E. A.] Univ Cambridge, Wolfson Brain Imaging Ctr, Sch Clin Med, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Salmond, C. H.; Tavares, J. V. Taylor; Sahakian, B. J.] Univ Cambridge, Dept Psychiat, Sch Clin Med, Addenbrookes Hosp, Cambridge CB2 2QQ, England; [Pickard, J. D.] Univ Cambridge, Acad Neurosurg Unit, Sch Clin Med, Addenbrookes Hosp, Cambridge CB2 2QQ, England		Stamatakis, EA (corresponding author), Univ Cambridge, Div Anaesthesia, Sch Clin Med, Addenbrookes Hosp, Hills Rd, Cambridge CB2 2QQ, England.	eas46@cam.ac.uk	Sahakian, Barbara/AAW-1198-2020	Sahakian, Barbara/0000-0001-7352-1745; Outtrim, Joanne/0000-0001-8118-6430; Stamatakis, Emmanuel Andreas/0000-0001-6955-9601	Addenbrooke's Charitable Trust; GlaxoSmithKlineGlaxoSmithKline; Linde Gas Inc.; NHS National Institute for Health Research, the Department of Health (UK)National Institute for Health Research (NIHR); Health Technology Agency (UK); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Wellcome TrustWellcome TrustEuropean Commission; Royal College of Anaesthetists; Evelyn Trust; Queens' College; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; European UnionEuropean Commission; Royal SocietyRoyal Society of LondonEuropean Commission; McDonnell Foundation; NHS National Institute for Health ResearchNational Institute for Health Research (NIHR); Queens' College Cambridge; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0001237, G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	Dr. Kasahara was funded by Addenbrooke's Charitable Trust (Cambridge, UK). Prof. Menon serves on scientific advisory boards for Solvay Pharmaceuticals, Inc. and GlaxoSmithKline; serves as a Specialty Editor for Critical Care and on the editorial boards of Neurocritical Care and PLoS Medicine; has filed a patent re: Technique for imaging mitochondrial function; receives royalties from the publication of Textbook of Neuroanaesthesia and Critical Care (Greenwich Medical Media, 2000); and receives research support from GlaxoSmithKline, Linde Gas Inc. (formerly British Oxygen Corporation), NHS National Institute for Health Research, the Department of Health (UK), the Health Technology Agency (UK), MRC, Wellcome Trust, the Royal College of Anaesthetists (British Oxygen Professorship), the Evelyn Trust, and from Queens' College (Stephen Erskine Fellowship). Dr. Salmond was funded by the Medical Research Council. Ms. Outtrim and Dr. Taylor Tavares report no disclosures. Dr. Carpenter serves on the editorial advisory board of Magnetic Resonance Imaging; serves as a consultant for Osteotronix Ltd.; and receives research support from MRC, the European Union, and from the Royal Society. Prof. Pickard serves on a scientific advisory board for and received funding for travel and speaker honoraria from Codman (Johnson & Johnson); serves as Chief Editor for Advances and Technical Standards in Neurosurgery; receives royalties from the publication of Pseudotumor Cerebri Syndrome (Cambridge University Press, 2007), serves as Honorary Consultant Advisor to the Army; receives research support from GlaxoSmithKline, McDonnell Foundation, MRC, NHS National Institute for Health Research; serves as the executive director of Medicam/Technicam Ltd; and has provided medicolegal expert reports in neurosurgery for a large number of legal firms. Prof. Sahakian has served/serves as a consultant for Cambridge Cognition Ltd, Novartis, Shire plc, GlaxoSmithKline, Eli Lilly & Company, and Boehringer Ingelheim; serves as an Associate Editor for Psychological Medicine; receives research support from MRC and Wellcome Trust and holds stock in CeNeS. Dr. Stamatakis serves on the editorial board of Neuroscience Imaging and is funded by the Stephen Erskine Fellowship from Queens' College Cambridge.	Allison JD, 2000, NEUROLOGY, V54, P135, DOI 10.1212/WNL.54.1.135; BRUTKOWSKI S, 1964, FRONTAL GRANULAR COR, P242; CROW LJ, 2001, HUMAN MOVEMENT, P69; Cunnington R, 2002, NEUROIMAGE, V15, P373, DOI 10.1006/nimg.2001.0976; Daskalakis ZJ, 2004, J PHYSIOL-LONDON, V557, P689, DOI 10.1113/jphysiol.2003.059808; Di Russo F, 2005, J NEUROTRAUM, V22, P297; Friston KJ, 1997, NEUROIMAGE, V6, P218, DOI 10.1006/nimg.1997.0291; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hanakawa T, 2003, J NEUROPHYSIOL, V89, P989, DOI 10.1152/jn.00132.2002; HOUK JC, 1995, CEREB CORTEX, V5, P95, DOI 10.1093/cercor/5.2.95; IVERSEN SD, 1970, EXP BRAIN RES, V11, P376; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Liepert J, 2001, CLIN NEUROPHYSIOL, V112, P114, DOI 10.1016/S1388-2457(00)00503-4; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lotze M, 2006, NEUROREHAB NEURAL RE, V20, P14, DOI 10.1177/1545968305282919; Lotze M, 1999, J COGNITIVE NEUROSCI, V11, P491, DOI 10.1162/089892999563553; Manson SC, 2008, EXP BRAIN RES, V187, P25, DOI 10.1007/s00221-008-1276-1; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Mochizuki H, 2004, J PHYSIOL-LONDON, V561, P331, DOI 10.1113/jphysiol.2004.072843; Nudo RJ, 2003, J REHABIL MED, V35, P7, DOI 10.1080/16501960310010070; Pelgrims B, 2009, CEREB CORTEX, V19, P2298, DOI 10.1093/cercor/bhn248; Perez MA, 2009, J PHYSIOL-LONDON, V587, P725, DOI 10.1113/jphysiol.2008.166926; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Prigatano GP, 2004, BRAIN INJURY, V18, P661, DOI 10.1080/02699050310001646170; Reynolds JR, 2009, CEREB CORTEX, V19, P1208, DOI 10.1093/cercor/bhn164; Rizzolatti G, 2001, NEURON, V31, P889, DOI 10.1016/S0896-6273(01)00423-8; Shane MS, 2008, NEUROIMAGE, V42, P450, DOI 10.1016/j.neuroimage.2007.12.067; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; TEASDALE G, 1974, LANCET, V2, P81; Tunik E, 2008, J NEUROSCI, V28, P14422, DOI 10.1523/JNEUROSCI.4734-08.2008; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Wiese H, 2004, CLIN NEUROPHYSIOL, V115, P289, DOI 10.1016/S1388-2457(03)00348-1; Wiese H, 2006, NEUROIMAGE, V30, P1292, DOI 10.1016/j.neuroimage.2005.11.012; Ziemann U, 2001, CLIN NEUROPHYSIOL, V112, P107, DOI 10.1016/S1388-2457(00)00502-2	37	76	77	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 13	2010	75	2					168	176		10.1212/WNL.0b013e3181e7ca58			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	628GW	WOS:000280103900013	20625170	Green Published			2022-02-06	
J	Rhind, SG; Crnko, NT; Baker, AJ; Morrison, LJ; Shek, PN; Scarpelini, S; Rizoli, SB				Rhind, Shawn G.; Crnko, Naomi T.; Baker, Andrew J.; Morrison, Laurie J.; Shek, Pang N.; Scarpelini, Sandro; Rizoli, Sandro B.			Prehospital resuscitation with hypertonic saline-dextran modulates inflammatory, coagulation and endothelial activation marker profiles in severe traumatic brain injured patients	JOURNAL OF NEUROINFLAMMATION			English	Article							TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; L-SELECTIN EXPRESSION; ADHESION MOLECULE CONCENTRATIONS; REDUCES NEUTROPHIL MARGINATION; SEVERE HEAD-INJURY; HEMORRHAGIC-SHOCK; TISSUE FACTOR; FACTOR-ALPHA; INTERLEUKIN-10 RELEASE	Background: Traumatic brain injury (TBI) initiates interrelated inflammatory and coagulation cascades characterized by wide-spread cellular activation, induction of leukocyte and endothelial cell adhesion molecules and release of soluble pro/antiinflammatory cytokines and thrombotic mediators. Resuscitative care is focused on optimizing cerebral perfusion and reducing secondary injury processes. Hypertonic saline is an effective osmotherapeutic agent for the treatment of intracranial hypertension and has immunomodulatory properties that may confer neuroprotection. This study examined the impact of hypertonic fluids on inflammatory/coagulation cascades in isolated head injury. Methods: Using a prospective, randomized controlled trial we investigated the impact of prehospital resuscitation of severe TBI (GCS < 8) patients using 7.5% hypertonic saline in combination with 6% dextran-70 (HSD) vs 0.9% normal saline (NS), on selected cellular and soluble inflammatory/coagulation markers. Serial blood samples were drawn from 65 patients (30 HSD, 35 NS) at the time of hospital admission and at 12, 24, and 48-h post-resuscitation. Flow cytometry was used to analyze leukocyte cell-surface adhesion (CD62L, CD11b) and degranulation (CD63, CD66b) molecules. Circulating concentrations of soluble (s)L- and sE-selectins (sL-, sE- selectins), vascular and intercellular adhesion molecules (sVCAM-1, sICAM-1), pro/antiinflammatory cytokines [tumor necrosis factor (TNF)-alpha and interleukin (IL-10)], tissue factor (sTF), thrombomodulin (sTM) and D-dimers (D-D) were assessed by enzyme immunoassay. Twenty-five healthy subjects were studied as a control group. Results: TBI provoked marked alterations in a majority of the inflammatory/coagulation markers assessed in all patients. Relative to control, NS patients showed up to a 2-fold higher surface expression of CD62L, CD11b and CD66b on polymorphonuclear neutrophils (PMNs) and monocytes that persisted for 48-h. HSD blunted the expression of these cell-surface activation/adhesion molecules at all time-points to levels approaching control values. Admission concentrations of endothelial-derived sVCAM-1 and sE-selectin were generally reduced in HSD patients. Circulating sL-selectin levels were significantly elevated at 12 and 48, but not 24 h post-resuscitation with HSD. TNF-alpha and IL-10 levels were elevated above control throughout the study period in all patients, but were reduced in HSD patients. Plasma sTF and D-D levels were also significantly lower in HSD patients, whereas sTM levels remained at control levels. Conclusions: These findings support an important modulatory role of HSD resuscitation in attenuating the upregulation of leukocyte/endothelial cell proinflammatory/prothrombotic mediators, which may help ameliorate secondary brain injury after TBI.	[Rhind, Shawn G.; Shek, Pang N.] Def Res & Dev Canada, Toronto, ON, Canada; [Rhind, Shawn G.] York Univ, Grad Program Kinesiol & Hlth Sci, Toronto, ON M3J 2R7, Canada; [Crnko, Naomi T.; Shek, Pang N.] Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A1, Canada; [Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Keenan Res Ctr,Brain Injury Lab, Cara Phelan Ctr Trauma Res,Li Ka Shing Knowledge, Toronto, ON M5S 1A1, Canada; [Scarpelini, Sandro; Rizoli, Sandro B.] Sunnybrook Hlth Sci Ctr, Dept Surg & Crit Care Med, Toronto, ON M4N 3M5, Canada		Rhind, SG (corresponding author), Def Res & Dev Canada, Toronto, ON, Canada.	shawn.rhind@drdc-rddc.gc.ca	morrison, laurie J/A-6325-2012; Scarpelini, Sandro/H-7063-2012	morrison, laurie J/0000-0001-8369-9774; Scarpelini, Sandro/0000-0001-5727-3913; Rhind, Shawn/0000-0003-2300-0620	Defence Research & Development Canada	The authors are indebted to Sheila Petrongolo, Bartolomeu Nascimento and Maria Shiu for their skillful technical assistance; the paramedic providers employed by Ornge (formerly Ontario Air Ambulance) and Toronto Emergency Medical Services (members CUPE 416) who randomized these patients under conditions of adversity in the prehospital setting; Merita Simitciu and Tyrone Perreira (Rescu) for their study coordination and oversight. This study was funded by Defence Research & Development Canada.	Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Alam HB, 2000, J SURG RES, V94, P145, DOI 10.1006/jsre.2000.6011; Angle N, 1998, J TRAUMA, V45, P7, DOI 10.1097/00005373-199807000-00002; Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Barone M, 1997, ACT NEUR S, V70, P265; Bednar MM, 1997, NEUROL RES, V19, P588; Bernardes-Silva M, 2001, J CEREBR BLOOD F MET, V21, P1115, DOI 10.1097/00004647-200109000-00009; Bing Mei, 2007, Chin J Traumatol, V10, P263; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI 10.1089/neu.2008-0738; Boomer L, 2009, SURG INFECT, V10, P379, DOI 10.1089/sur.2008.097; Brummel-Ziedins K, 2006, J TRAUMA, V61, P1350, DOI 10.1097/01.ta.0000235525.64176.01; Bulger EM, 2008, ARCH SURG-CHICAGO, V143, P139, DOI 10.1001/archsurg.2007.41; BULGER EM, 2008, ARCH SURG-CHICAGO, V143, P149; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Carson MJ, 2006, CLIN NEUROSCI RES, V6, P237, DOI 10.1016/j.cnr.2006.09.004; Catania A, 2009, BRAIN BEHAV IMMUN, V23, P877, DOI 10.1016/j.bbi.2009.04.006; Cernak I., 2009, J CEREB BLOOD FLOW M; COWLEY HC, 1994, CRIT CARE MED, V22, P651, DOI 10.1097/00003246-199404000-00022; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cuschieri J, 2002, J IMMUNOL, V168, P1389, DOI 10.4049/jimmunol.168.3.1389; D'Mello C, 2009, J NEUROSCI, V29, P2089, DOI 10.1523/JNEUROSCI.3567-08.2009; Dietrich JB, 2002, J NEUROIMMUNOL, V128, P58, DOI 10.1016/S0165-5728(02)00114-5; Dubick MA, 2006, SHOCK, V25, P321, DOI 10.1097/01.shk.0000209525.50990.28; Elliott MB, 2009, BRAIN RES, V1305, P183, DOI 10.1016/j.brainres.2009.09.104; Engelhardt B, 2008, J NEUROL SCI, V274, P23, DOI 10.1016/j.jns.2008.05.019; Esmon CT, 2004, MATURITAS, V47, P305, DOI 10.1016/j.maturitas.2003.10.015; Ferri LE, 2009, SURGERY, V145, P384, DOI 10.1016/j.surg.2008.12.011; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Fisher Mark, 2008, Rev Neurol Dis, V5 Suppl 1, pS4; Gando S, 2006, SEMIN THROMB HEMOST, V32, P48, DOI 10.1055/s-2006-933340; GEARING AJH, 1992, ANN NY ACAD SCI, V667, P324, DOI 10.1111/j.1749-6632.1992.tb51633.x; Giddings JC, 2005, BIOCHEM SOC T, V33, P406, DOI 10.1042/BST0330406; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gushchin V, 2002, J TRAUMA, V52, P867, DOI 10.1097/00005373-200205000-00008; HAGIWARA S, 2009, SHOCK; Hammell CL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1683; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; Hatanaka E, 2007, SHOCK, V27, P32, DOI 10.1097/01.shk.0000238061.69579.a5; HESS DC, 1994, NEUROSCI LETT, V168, P201, DOI 10.1016/0304-3940(94)90450-2; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; HESS JR, 1992, J TRAUMA, V32, P40, DOI 10.1097/00005373-199201000-00009; Hirsh MI, 2008, CRIT CARE MED, V36, P3220, DOI 10.1097/CCM.0b013e31818f238e; HUANG GS, 2009, J TRAUMA; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Ke QH, 2006, DIGEST DIS SCI, V51, P2257, DOI 10.1007/s10620-006-9135-6; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Koutsi A, 2008, INT J BIOCHEM CELL B, V40, P1669, DOI 10.1016/j.biocel.2007.06.024; Lacy P, 2008, FRONT BIOSCI-LANDMRK, V13, P5559; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Langer HF, 2009, J CELL MOL MED, V13, P1211, DOI 10.1111/j.1582-4934.2009.00811.x; Lee SJ, 1999, J NEUROIMMUNOL, V98, P77, DOI 10.1016/S0165-5728(99)00084-3; Lehnardt S, 2010, GLIA, V58, P253, DOI 10.1002/glia.20928; Levi M, 2006, SEMIN THROMB HEMOST, V32, P33, DOI 10.1055/s-2006-933338; Lim HB, 2007, ANAESTHESIA, V62, P474, DOI 10.1111/j.1365-2044.2007.04998.x; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Maekawa K, 1998, J TRAUMA, V44, P460, DOI 10.1097/00005373-199803000-00007; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Maskin B, 2001, MEDICINA-BUENOS AIRE, V61, P573; McKeating EG, 1998, BRIT J ANAESTH, V80, P77, DOI 10.1093/bja/80.1.77; McKeating EG, 1998, ACT NEUR S, V71, P200; McKeating EG, 1998, ANESTH ANALG, V86, P759, DOI 10.1097/00000539-199804000-00016; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morrison LJ, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-105; Mousa SA, 2008, MOL BIOTECHNOL, V38, P33, DOI 10.1007/s12033-007-0072-7; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Oreopoulos GD, 2001, SURGERY, V130, P157, DOI 10.1067/msy.2001.115829; Pascual JL, 2002, ANN SURG, V236, P634, DOI 10.1097/00000658-200211000-00014; Powers KA, 2003, SURGERY, V134, P312, DOI 10.1067/msy.2003.246; Powers KA, 2005, SURGERY, V137, P66, DOI 10.1016/j.surg.2004.05.051; REED RL, 1991, J TRAUMA, V31, P8, DOI 10.1097/00005373-199101000-00002; Rhee P, 2000, CRIT CARE MED, V28, P74, DOI 10.1097/00003246-200001000-00012; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; Rovlias A, 2001, SURG NEUROL, V55, P190, DOI 10.1016/S0090-3019(01)00414-1; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; RuchaudSparagano MH, 1997, BRIT J HAEMATOL, V98, P612, DOI 10.1046/j.1365-2141.1997.2523070.x; Saggar V, 2009, J NEUROTRAUM, V26, P1665, DOI 10.1089/neu.2008.0799; Santucci CA, 2008, WEST J EMERG MED, V9, P81; SCARPELINI S, 2008, J ORGAN DYSFUNCTION, V4, P99; Schmidt O.I., 2004, EUR J TRAUMA, V30, P135, DOI DOI 10.1007/S00068-004-1394-9; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Seekamp A, 2001, SHOCK, V15, P254, DOI 10.1097/00024382-200115040-00002; Sell SL, 2008, ANESTHESIOLOGY, V108, P873, DOI 10.1097/ALN.0b013e31816c8a15; Sibson NR, 2004, MAGN RESON MED, V51, P248, DOI 10.1002/mrm.10723; Siemiatkowski A, 2001, ARCH IMMUNOL THER EX, V49, P317; Soriano SG, 2008, EUR J ANAESTH, V25, P154, DOI 10.1017/S0265021507003390; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Stanimirovic DB, 1997, ACT NEUR S, V70, P12; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Strandvik GF, 2009, ANAESTHESIA, V64, P990, DOI 10.1111/j.1365-2044.2009.05986.x; Summy-Long JY, 2009, AM J PHYSIOL-REG I, V297, pR1532, DOI 10.1152/ajpregu.00340.2009; Szotowski B, 2005, CIRC RES, V96, P1233, DOI 10.1161/01.RES.0000171805.24799.fa; Tan TS, 2002, ANAESTHESIA, V57, P644, DOI 10.1046/j.1365-2044.2002.02603.x; Thiel M, 2001, J LEUKOCYTE BIOL, V70, P261; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Weaver KD, 2000, J TRAUMA, V48, P1081, DOI 10.1097/00005373-200006000-00014; West MA, 1998, J TRAUMA, V45, P12; Wilder DM, 2002, THROMB RES, V107, P255, DOI 10.1016/S0049-3848(02)00335-3; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Wu Xue-Hai, 2003, Chin J Traumatol, V6, P114; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	109	76	77	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JAN 18	2010	7								5	10.1186/1742-2094-7-5			17	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	559MX	WOS:000274830600001	20082712	Green Published, gold			2022-02-06	
J	Yuen, TJ; Browne, KD; Iwata, A; Smith, DH				Yuen, Tracy J.; Browne, Kevin D.; Iwata, Akira; Smith, Douglas H.			Sodium Channelopathy Induced by Mild Axonal Trauma Worsens Outcome After a Repeat Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						axon trauma; calcium; diffuse axonal injury; repetitive injury; sodium channels; traumatic brain injury	BRAIN-INJURY; HEAD-INJURY; MULTIPLE-SCLEROSIS; MOUSE MODEL; CONCUSSION; CALCIUM; TETRODOTOXIN; PERFORMANCE; NEURONS; DAMAGE	There is great concern that one mild traumatic brain injury (mTBI) predisposes individuals to an exacerbated response with a subsequent mTBI. Although no mechanism has been identified, mounting evidence suggests traumatic axonal injury (TAI) plays a role in this process. By using a cell culture system, a threshold of mild TAI was found where dynamic stretch of cortical axons at strains lower than 5% induced no overt pathological changes. However, the axons were found to display an increased expression of sodium channels (NaChs) by 24 hr. After a second, identical mild injury, pathologic increases in [Ca2+](i) were observed, leading to axon degeneration. The central role of NaChs in this response was demonstrated by blocking NaChs with tetrodotoxin prior to the second injury, which completely abolished postinjury increases in [Ca2+](i). These data suggest that mild TAI induces a form of sodium channelopathy on axons that greatly exaggerates the pathophysiologic response to subsequent mild injuries. (C) 2009 Wiley-Liss, Inc.	[Yuen, Tracy J.; Browne, Kevin D.; Smith, Douglas H.] Univ Penn, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Yuen, Tracy J.; Browne, Kevin D.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Iwata, Akira] Nagakute Minami Clin, Aichi, Japan		Smith, DH (corresponding author), Univ Penn, Ctr Brain Injury & Repair, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	smith, douglas/A-1321-2007		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS38104]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health; Contract grant numbers: NS38104 and NS38104 (to Douglas H. Smith).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Baker MD, 2001, TRENDS PHARMACOL SCI, V22, P27, DOI 10.1016/S0165-6147(00)01585-6; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Craner MJ, 2004, P NATL ACAD SCI USA, V101, P8168, DOI 10.1073/pnas.0402765101; Graham D I, 1988, Prog Clin Biol Res, V264, P159; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEVRAM V, 1992, J NEUROPHYSIOL, V68, P1167, DOI 10.1152/jn.1992.68.4.1167; LUPA MT, 1993, J NEUROSCI, V13, P1326; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Pfister BJ, 2006, FEBS LETT, V580, P3525, DOI 10.1016/j.febslet.2006.05.030; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Rhodes TH, 2004, P NATL ACAD SCI USA, V101, P11147, DOI 10.1073/pnas.0402482101; Rosenbluth J, 2009, BRAIN RES, V1253, P191, DOI 10.1016/j.brainres.2008.11.066; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Takahashi A, 1999, PHYSIOL REV, V79, P1089, DOI 10.1152/physrev.1999.79.4.1089; Tarnawa Istvan, 2007, Recent Pat CNS Drug Discov, V2, P57, DOI 10.2174/157488907779561754; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Waxman SG, 2006, NAT REV NEUROSCI, V7, P932, DOI 10.1038/nrn2023; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	34	76	77	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC	2009	87	16					3620	3625		10.1002/jnr.22161			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	515AN	WOS:000271438600010	19565655	Green Accepted			2022-02-06	
J	Martini, RP; Deem, S; Yanez, ND; Chesnut, RM; Weiss, NS; Daniel, S; Souter, M; Treggiari, MM				Martini, Ross P.; Deem, Steven; Yanez, N. David; Chesnut, Randall M.; Weiss, Noel S.; Daniel, Stephen; Souter, Michael; Treggiari, Miriam M.			Management guided by brain tissue oxygen monitoring and outcome following severe traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; human; trauma resuscitation; neurological outcomes; cerebral ischemia	SEVERE HEAD-INJURY; CLASSIFICATION; METABOLISM; PREDICTION; PRESSURE; TENSION; PO-2; CARE	Object. The authors sought to describe changes in clinical management associated with brain tissue oxygen (PbO2) monitoring and how these changes affected outcomes and resource utilization. Methods. The cohort study comprised 629 patients admitted to a Level I trauma center with a diagnosis of severe traumatic brain injury over a period of 3 years. Hospital mortality rate, neurological outcome, and resource utilization of 123 patients who underwent both PbO2 and intracranial pressure (ICP) monitoring were compared with the same measures in 506 patients who underwent ICP monitoring only. The main outcomes were hospital mortality rate, functional independence at hospital discharge, duration of mechanical ventilation, hospital length of stay, and hospital cost. Multivariable regression with robust variance was used to estimate the adjusted differences in the main outcome measures between patient groups. The models were adjusted for patient age, severity of injury, and pathological features seen on head CT scan at admission. Results. On average, patients who underwent ICP/PbO2 monitoring were younger and had more severe injuries than patients who received ICP monitoring alone. Relatively more patients treated with PbO2 monitoring received osmotic therapy, vasopressors, and prolonged sedation. After adjustment for baseline characteristics, the hospital mortality rate was, if anything, slightly higher in patients undergoing PbO2-guided management than in patients monitored with ICP only (adjusted mortality difference 4.4%, 95% CI -3.9 to 13%). Patients who underwent PbO2-guided management also had lower adjusted functional independence scores at hospital discharge (adjusted score difference -0.75, 95% CI -1.41 to -0.09). There was a 27% relative increase (95% CI 6-53%) in the median hospital length of stay when the PbO2 group was compared with the ICP-only group. Conclusions. The mortality rate in patients with traumatic brain injury whose clinical management was guided by PbO2 monitoring was not reduced in comparison with that in patients who received ICP monitoring alone. Brain tissue oxygen monitoring was associated with worse neurological outcome and increased hospital resource utilization. (DOI: 10.3171/2009.2.JNS08998)	[Martini, Ross P.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA; [Martini, Ross P.; Deem, Steven; Souter, Michael; Treggiari, Miriam M.] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA USA; [Deem, Steven] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Yanez, N. David; Daniel, Stephen] Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Seattle, WA 98195 USA; [Chesnut, Randall M.; Souter, Michael; Treggiari, Miriam M.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; [Weiss, Noel S.] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA		Martini, RP (corresponding author), Brown Univ, Warren Alpert Med Sch, Box G-8269, Providence, RI 02912 USA.	ross_martini@brown.edu	Souter, Michael/ABE-1890-2020	Martini, Ross/0000-0001-8811-6558; Chesnut, Randall/0000-0001-6377-3666	Foundation for Anesthesia Education and Research; Harborview Anesthesiology Research Center	This study was partially supported by a medical student research fellowship from the Foundation for Anesthesia Education and Research and by the Harborview Anesthesiology Research Center.	Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MUELLER BA, 1990, AM J EPIDEMIOL, V132, P550, DOI 10.1093/oxfordjournals.aje.a115691; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Servadei F, 2002, ACT NEUR S, V81, P81; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018	30	76	79	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2009	111	4					644	649		10.3171/2009.2.JNS08998			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	503PL	WOS:000270550000003	19392603				2022-02-06	
J	Sherlock, M; O'Sullivan, E; Agha, A; Behan, LA; Owens, D; Finucane, F; Rawluk, D; Tormey, W; Thompson, CJ				Sherlock, M.; O'Sullivan, E.; Agha, A.; Behan, L. A.; Owens, D.; Finucane, F.; Rawluk, D.; Tormey, W.; Thompson, C. J.			Incidence and pathophysiology of severe hyponatraemia in neurosurgical patients	POSTGRADUATE MEDICAL JOURNAL			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; THERAPY; FLUID	Background: Hyponatraemia is a well-recognised complication of neurosurgical conditions, but the incidence and implications have not been well documented. Objective: To define the incidence, pathophysiology and clinical implications of significant hyponatraemia in several neurosurgical conditions. Methods: All patients admitted to the Irish National Neurosciences Centre at Beaumont Hospital, Dublin with traumatic brain injury, subarachnoid haemorrhage, intracranial neoplasm, pituitary disorders and spinal disorders who developed significant hyponatraemia (plasma sodium,130 mmol/l) from January 2002 to September 2003 were identified from computerised laboratory records. Data were collected by retrospective case note analysis. Results: Hyponatraemia was more common in patients with pituitary disorders (5/81, 6.25%; p = 0.004), traumatic brain injury (44/457, 9.6%; p<0.001), intracranial neoplasm (56/355, 15.8%; p<0.001) and subarachnoid haemorrhage (62/316, 19.6%; p<0.001) than in those with spinal disorders (4/489, 0.81%). The pathophysiology of hyponatraemia was: syndrome of inappropriate antidiuretic hormone secretion (SIADH) in 116 cases (62%) (31 (16.6%) drug-associated), hypovolaemic hyponatraemia in 50 cases (26.7%) ( which included patients with insufficient data to assign to the cerebral salt-wasting group (CSWS)), CSWS in nine cases (4.8%), intravenous fluids in seven cases (3.7%) and mixed SIADH/CSWS in five cases (2.7%). Hyponatraemic patients with cerebral irritation had significantly lower plasma sodium concentrations (mean (SD) 124.8 (0.34) mmol/l) than asymptomatic patients (126.6 (0.29) mmol/l) (p<0.0001). Hyponatraemic patients had a significantly longer hospital stay (median 19 days (interquartile range (IQR) 12-28)) than normonatraemic patients (median 12 days (IQR 10.5-15)) (p<0.001). Conclusions: Hyponatraemia is common in intracerebral disorders and is associated with a longer hospital stay. Cerebral irritation is associated with more severe hyponatraemia. SIADH is the most common cause of hyponatraemia and is often drug-associated.	[Sherlock, M.; O'Sullivan, E.; Agha, A.; Behan, L. A.; Owens, D.; Finucane, F.; Thompson, C. J.] Beaumont Hosp, Dept Acad Endocrinol, Dublin 9, Ireland; [Rawluk, D.] Beaumont Hosp, Dept Neurosurg, Dublin 9, Ireland; [Tormey, W.] Beaumont Hosp, Dept Chem Pathol, Dublin 9, Ireland		Thompson, CJ (corresponding author), Beaumont Hosp, Dept Acad Endocrinol, Dublin 9, Ireland.	christhompson@beaumont.ie	Finucane, Francis/G-6031-2012	Finucane, Francis/0000-0002-5374-7090			Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; ANDERSON RJ, 1986, KIDNEY INT, V29, P1237, DOI 10.1038/ki.1986.134; Arinzon ZH, 2002, ANN PHARMACOTHER, V36, P1175, DOI 10.1345/aph.1A337; Betjes Michiel G.H., 2002, Eur J Intern Med, V13, P9, DOI 10.1016/S0953-6205(01)00192-3; Boughey JC, 2004, AM SURGEON, V70, P500; BOUTROS NN, 1995, J CLIN PSYCHIAT, V56, P377; DOCZI T, 1981, NEUROSURGERY, V9, P394, DOI 10.1227/00006123-198110000-00008; Egge A, 2001, NEUROSURGERY, V49, P593, DOI 10.1097/00006123-200109000-00012; HASAN D, 1990, ANN NEUROL, V27, P106, DOI 10.1002/ana.410270118; Janicic N, 2003, ENDOCRIN METAB CLIN, V32, P459, DOI 10.1016/S0889-8529(03)00004-5; LEE ST, 1990, J NEUROSURG, V73, P541, DOI 10.3171/jns.1990.73.4.0541; Morimatsu H, 2003, ANESTHESIOLOGY, V98, P1077, DOI 10.1097/00000542-200305000-00009; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; NELSON RJ, 1991, J CEREBR BLOOD F MET, V11, P661, DOI 10.1038/jcbfm.1991.118; Olson BR, 1997, J NEUROSURG, V87, P499, DOI 10.3171/jns.1997.87.4.0499; Oropello JM, 1996, CRIT CARE CLIN, V12, P709, DOI 10.1016/S0749-0704(05)70274-8; Qureshi AI, 2002, NEUROSURGERY, V50, P749, DOI 10.1097/00006123-200204000-00012; Rabinstein AA, 2003, NEUROLOGIST, V9, P290, DOI 10.1097/01.nrl.0000095258.07720.89; Sherlock M, 2006, CLIN ENDOCRINOL, V64, P250, DOI 10.1111/j.1365-2265.2006.02432.x; Smith DM, 2000, CLIN ENDOCRINOL, V52, P667, DOI 10.1046/j.1365-2265.2000.01027.x; Story DA, 2007, ANESTH ANALG, V104, P893, DOI 10.1213/01.ane.0000258015.87381.61; TAKAKU A, 1979, SURG NEUROL, V11, P349; Wong M. F. M., 1998, Annals Academy of Medicine Singapore, V27, P340	24	76	86	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0032-5473	1469-0756		POSTGRAD MED J	Postgrad. Med. J.	APR	2009	85	1002					171	175		10.1136/pgmj.2008.072819			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	441GE	WOS:000265756500002	19417163				2022-02-06	
J	Tsaousides, T; Gordon, WA				Tsaousides, Theodore; Gordon, Wayne A.			Cognitive Rehabilitation Following Traumatic Brain Injury: Assessment to Treatment	MOUNT SINAI JOURNAL OF MEDICINE			English	Article						attention; cognitive deficits; cognitive rehabilitation; comprehensive day treatment; executive function; memory; traumatic brain injury	CLOSED-HEAD-INJURY; EXECUTIVE DYSFUNCTION; CLINICAL-PRACTICE; GOAL MANAGEMENT; MEMORY; ATTENTION; DEFICITS; THERAPY; PROGRAM; RECOMMENDATIONS	Cognitive rehabilitation refers to a set of interventions that aim to improve a person's ability to perform cognitive tasks by retraining previously learned skills and teaching compensatory strategies. Cognitive rehabilitation begins with a thorough neuropsychological assessment to identify cognitive strengths and weaknesses and the degree of change in cognitive ability following a brain injury. The conclusion of the assessment are used to formulate appropriate treatment plans. Common interventions for improvements in attention, memory, and executive function, as well as the nature of comprehensive program, which combine treatment modalities, are reviewed. Cognitive rehabilitation is effective for mild-to-severe injuries and beneficial at any time post-injury. Sufficient evidence exists supporting the efficacy and effectiveness of cognitive rehabilitation, which has become the treatment of choice for cognitive impairments and leads to improvements in cognitive and psychosocial functioning. Mt Sinai J Med 76:173-181, 2009 (C) 2009 Mount Sinai School of Medicine	[Tsaousides, Theodore; Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA		Tsaousides, T (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA.	theodore.tsaousides@mssm.edu			US Department of Education National Institute of Rehabiliation ResearchUS Department of Education [H133B040033, H133A070033]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1R49CE001171-01]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001171] Funding Source: NIH RePORTER	The preparation of this article was supported in part by grants from the US Department of Education National Institute of Rehabiliation Research (H133B040033 and H133A070033) and from the Centers for Disease Control and Prevention (1R49CE001171-01)	Ashman TA, 2006, MT SINAI J MED, V73, P999; Batchelor J, 1988, J HEAD TRAUMA REHAB, V3, P78, DOI DOI 10.1097/00001199-198809000-00012; Chen SHA, 1997, BRAIN INJURY, V11, P197; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; FOXX RM, 1989, BEHAV THER, V20, P61, DOI 10.1016/S0005-7894(89)80118-2; Goldstein G, 1998, J REHABIL RES DEV, V35, P238; Gordon WA, 2006, J HEAD TRAUMA REHAB, V21, P156, DOI 10.1097/00001199-200603000-00008; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kennedy Mary R. T, 2005, Seminars in Speech and Language, V26, P242, DOI 10.1055/s-2005-922103; Kennedy MRT, 2006, NEUROPSYCHOL REV, V16, P151, DOI 10.1007/s11065-006-9012-8; KIRSCH NL, 1992, J HEAD TRAUMA REHAB, V7, P13, DOI DOI 10.1097/00001199-199209000-00004; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; McKerracher G, 2005, NEUROPSYCHOL REHABIL, V15, P115, DOI 10.1080/09602010443000056; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Palmese CA, 2000, BRAIN INJURY, V14, P535; Parente R, 1999, NEUROREHABILITATION, V13, P157; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Pero S, 2006, BRAIN INJURY, V20, P1207, DOI 10.1080/02699050600983271; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Serino A, 2007, BRAIN INJURY, V21, P11, DOI 10.1080/02699050601151811; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; TSAOUSIDES T, TRAUMATIC B IN PRESS; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wilson BA, 2005, BRAIN INJURY, V19, P891, DOI 10.1080/02699050400002363; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; Yudofsky S.C., 2005, TXB TRAUMATIC BRAIN, P655; ZENCIUS A, 1991, Brain Injury, V5, P321, DOI 10.3109/02699059109008102; Zencius AH, 1998, BRAIN INJURY, V12, P53, DOI 10.1080/026990598122854	46	76	77	1	36	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0027-2507			MT SINAI J MED	Mt. Sinai J. Med.	MAR-APR	2009	76	2					173	181		10.1002/msj.20099			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	427OE	WOS:000264787800010	19306374				2022-02-06	
J	Qiu, WS; Guo, CC; Shen, H; Chen, K; Wen, L; Huang, HJ; Ding, M; Sun, L; Jiang, QZ; Wang, WM				Qiu, Wusi; Guo, Chenchen; Shen, Hong; Chen, Keyong; Wen, Liang; Huang, Hongjie; Ding, Min; Sun, Li; Jiang, Qizhou; Wang, Weiming			Effects of unilateral decompressive craniectomy on patients with unilateral acute post-traumatic brain swelling after severe traumatic brain injury	CRITICAL CARE			English	Article							REFRACTORY INTRACRANIAL HYPERTENSION; CEREBRAL OXYGENATION; HEAD-INJURY; EXPERIENCE; PRESSURE; HYPOTHERMIA; MANAGEMENT	Introduction Acute post-traumatic brain swelling (BS) is one of the pathological forms that need emergent treatment following traumatic brain injury. There is controversy about the effects of craniotomy on acute post-traumatic BS. The aim of the present clinical study was to assess the efficacy of unilateral decompressive craniectomy (DC) or unilateral routine temporoparietal craniectomy on patients with unilateral acute post-traumatic BS. Methods Seventy-four patients of unilateral acute posttraumatic BS with midline shifting more than 5 mm were divided randomly into two groups: unilateral DC group (n = 37) and unilateral routine temporoparietal craniectomy group (control group, n = 37). The vital signs, the intracranial pressure (ICP), the Glasgow outcome scale (GOS), the mortality rate and the complications were prospectively analysed. Results The mean ICP values of patients in the unilateral DC group at hour 24, hour 48, hour 72 and hour 96 after injury were much lower than those of the control group (15.19 +/- 2.18 mmHg, 16.53 +/- 1.53 mmHg, 15.98 +/- 2.24 mmHg and 13.518 +/- 2.33 mmHg versus 19.95 +/- 2.24 mmHg, 18.32 +/- 1.77 mmHg, 21.05 +/- 2.23 mmHg and 17.68 +/- 1.40 mmHg, respectively). The mortality rates at 1 month after treatment were 27% in the unilateral DC group and 57% in the control group (p = 0.010). Good neurological outcome (GOS Score of 4 to 5) rates 1 year after injury for the groups were 56.8% and 32.4%, respectively (p = 0.035). The incidences of delayed intracranial hematoma and subdural effusion were 21.6% and 10.8% versus 5.4% and 0, respectively (p = 0.041 and 0.040). Conclusions Our data suggest that unilateral DC has superiority in lowering ICP, reducing the mortality rate and improving neurological outcomes over unilateral routine temporoparietal craniectomy. However, it increases the incidence of delayed intracranial hematomas and subdural effusion, some of which need secondary surgical intervention. These results provide information important for further large and multicenter clinical trials on the effects of DC in patients with acute post-traumatic BS.	[Qiu, Wusi; Guo, Chenchen; Shen, Hong; Wen, Liang] Zhejiang Univ, Coll Med, Brain Med Res Inst, Hangzhou 310009, Zhejiang, Peoples R China; [Qiu, Wusi; Guo, Chenchen; Chen, Keyong; Huang, Hongjie; Ding, Min; Sun, Li; Jiang, Qizhou; Wang, Weiming] Hangzhou Normal Univ, Coll Med, Hangzhou Hosp 2, Dept Neurosurg, Hangzhou 310015, Zhejiang, Peoples R China; [Qiu, Wusi; Shen, Hong] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310009, Zhejiang, Peoples R China		Shen, H (corresponding author), Zhejiang Univ, Coll Med, Brain Med Res Inst, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	sh_2nd@163.com			Scientific Research Fund of Zhejiang Health Department; Scientific Research Fund of Hangzhou Health Department; Scientific Research Fund of Science and Technology Department of Zhejiang, China	The present study was supported by the Scientific Research Fund of Zhejiang Health Department, the Scientific Research Fund of Hangzhou Health Department and the Scientific Research Fund of Science and Technology Department of Zhejiang, China. The authors gratefully acknowledge the Brain Medicine Research Institute, College of Medicine, Zhejiang University.	Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Agrawal A., 2007, SMJ Singapore Medical Journal, V48, P492; Akins PT, 2008, NEUROCRIT CARE, V9, P269, DOI 10.1007/s12028-007-9033-z; Armonda RA, 2006, NEUROCRIT CARE, V4, P241, DOI 10.1385/NCC:4:3:241; Bassin SL, 2008, CRIT CARE, V12, DOI 10.1186/cc7020; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Citerio G, 2007, INTENS CARE MED, V33, P45, DOI 10.1007/s00134-006-0381-5; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Di Rienzo A, 2008, ACTA NEUROCHIR, V150, P1057, DOI 10.1007/s00701-008-0019-1; Figaji AA, 2007, CHILD NERV SYST, V23, P1331, DOI 10.1007/s00381-007-0388-4; Fiorot JA, 2008, ARQ NEURO-PSIQUIAT, V66, P204, DOI 10.1590/S0004-282X2008000200012; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; Kofke W Andrew, 2007, Anesthesiol Clin, V25, P579; Krishnan P, 2006, NEUROL INDIA, V54, P291; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Liu Wei-guo, 2004, Chin J Traumatol, V7, P175; Missori P, 2008, SURG NEUROL, V70, P437, DOI 10.1016/j.surneu.2007.03.029; Mitchell P, 2007, J NEUROL SCI, V261, P89, DOI 10.1016/j.jns.2007.04.040; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; Salvatore C, 2008, J NEUROSURG, V108, P74, DOI 10.3171/JNS/2008/108/01/0074; Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Yao Y, 2007, ACTA NEUROCHIR, V149, P1219, DOI 10.1007/s00701-007-1415-7; Zhao Z, 2007, NEUROCRIT CARE, V7, P263, DOI 10.1007/s12028-007-0074-0	33	76	79	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2009	13	6							R185	10.1186/cc8178			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	556DF	WOS:000274567900014	19930556	gold, Green Published			2022-02-06	
J	Tisdall, MM; Tachtsidis, I; Leung, TS; Elwell, CE; Smith, M				Tisdall, Martin M.; Tachtsidis, Ilias; Leung, Terence S.; Elwell, Clare E.; Smith, Martin			Increase in cerebral aerobic metabolism by normobaric hyperoxia after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral microdialysis; cytochrome c oxidase; near-infrared spectroscopy; normobaric hyperoxia; traumatic brain injury	NEAR-INFRARED SPECTROSCOPY; SEVERE HEAD-INJURY; CYTOCHROME-C-OXIDASE; INTRACEREBRAL MICRODIALYSIS; OXIDATIVE-METABOLISM; BLOOD-FLOW; OXYGEN; MODEL; RAT; TOMOGRAPHY	Object. Traumatic brain injury (TBI) is associated with depressed aerobic metabolism and mitochondrial dysfunction. Normobaric hyperoxia (NBH) has been suggested as a treatment for TBI, but studies in humans have produced equivocal results. In this study the authors used brain tissue O-2 tension measurement, cerebral microdialysis, and near-infrared spectroscopy to study the effects of NBH after TBI. They investigated the effects on cellular and mitochondrial redox states measured by the brain tissue lactate/pyruvate ratio (LPR) and the change in oxidized cytochrome c oxidase (CCO) concentration, respectively. Methods. The authors studied 8 adults with TBI within the first 48 hours postinjury. Inspired oxygen percentage at normobaric pressure was increased from baseline to 60% for 60 minutes and then to 100% for 60 minutes before being returned to baseline for 30 minutes. Results. The results are presented as the median with the interquartile range in parentheses. During the 100% inspired oxygen percentage phase, brain tissue O-2 tension increased by 7.2 kPa (range 4.5-9.6 kPa) (p < 0.0001), microdialysate lactate concentration decreased by 0.26 mmol/L (range 0.0-0.45 mmol/L) (p = 0.01), microdialysate LPR decreased by 1.6 (range 1.0-2.3) (p = 0.02), and change in oxidized CCO concentration increased by 0.21 mu mol/L (0.13-0.38 mu mol/L) (p = 0.0003). There were no significant changes in intracranial pressure or arterial or microdialysate glucose concentration. The change in oxidized CCO concentration correlated with changes in brain tissue O-2 tension (r(s) = 0.57, p = 0.005) and in LPR (r(s)= -0.53, p = 0.006). Conclusions. The authors have demonstrated oxidation in cerebral cellular and mitochondrial redox states during NBH in adults with TBI. These findings are consistent with increased aerobic metabolism and suggest that NBH has the potential to improve outcome after TBI. Further studies are warranted.	[Tisdall, Martin M.; Smith, Martin] Natl Hosp Neurol & Neurosurg, Dept Neuroanaesthesia & Neurocrit Care, London WC1N 3BG, England; [Tachtsidis, Ilias; Leung, Terence S.; Elwell, Clare E.] UCL, Dept Med Phys & Bioengn, London, England		Smith, M (corresponding author), Natl Hosp Neurol & Neurosurg, Dept Neuroanaesthesia & Neurocrit Care, Box 30,Queen Sq, London WC1N 3BG, England.	martin.smith@uclh.nhs.uk	Smith, Martin/B-2616-2009; Tachtsidis, Ilias/N-2747-2018	Tachtsidis, Ilias/0000-0002-8125-0313; Elwell, Clare/0000-0002-7281-7234; Tisdall, Martin/0000-0001-8880-8386	Welcome Research Fellow [075608]; Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [GR/N14248/01]; Department of Health's National Institute for Health Research Centres funding schemeNational Institute for Health Research (NIHR); Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/D060982/1, EP/G005036/1] Funding Source: researchfish; EPSRCUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/D060982/1, EP/G005036/1] Funding Source: UKRI	Terrance S. Leung, Ph.D., is supported by Hamamatsu Photonics. Martin M. Tisdall, M.B.B.S., is a Welcome Research Fellow (Grant No. 075608). Ilias Tachtsidis, Ph.D., is supported by the Engineering and Physical Sciences Research Council (Grant No. GR/N14248/01). This study was also supported in part by a donation in memory of Karolyn Margaret Jones. This work was undertaken at University College London Hospitals and partially funded by the Department of Health's National Institute for Health Research Centres funding scheme.	Alves OL, 2004, CURR PHARM DESIGN, V10, P2163, DOI 10.2174/1381612043384187; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BROWN GC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P273, DOI 10.1016/S0005-2728(05)80109-4; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Cooper CE, 1999, J CEREBR BLOOD F MET, V19, P27, DOI 10.1097/00004647-199901000-00003; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; ELWELL CE, 1994, J APPL PHYSIOL, V77, P2753, DOI 10.1152/jappl.1994.77.6.2753; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Fehlings MG, 2007, J NEUROSURG, V106, P525, DOI 10.3171/jns.2007.106.4.525; Hlatky R, 2004, NEUROSURGERY, V55, P1318, DOI 10.1227/01.NEU.0000143029.42638.2C; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; JOBSIS FF, 1977, SCIENCE, V198, P1264, DOI 10.1126/science.929199; Kakihana Y, 2002, EUR J CARDIO-THORAC, V21, P434, DOI 10.1016/S1010-7940(01)01139-3; Kirkpatrick PJ, 1998, J NEUROSURG, V89, P389, DOI 10.3171/jns.1998.89.3.0389; Levasseur JE, 2006, NEUROSURGERY, V59, P1122, DOI 10.1227/01.NEU.0000245581.00908.AF; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; MATCHER SJ, 1995, ANAL BIOCHEM, V227, P54, DOI 10.1006/abio.1995.1252; MATCHER SJ, 1994, PHYS MED BIOL, V39, P177, DOI 10.1088/0031-9155/39/1/011; McGown AD, 2003, SLEEP, V26, P710, DOI 10.1093/sleep/26.6.710; McLeod AD, 2003, ANESTH ANALG, V97, P851, DOI 10.1213/01.ANE.0000072541.57132.BA; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Okada E, 2003, APPL OPTICS, V42, P2915, DOI 10.1364/AO.42.002915; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Richter OMH, 2003, REV PHYSIOL BIOCH P, V147, P47, DOI 10.1007/s10254-003-0006-0; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Sakamoto T, 2001, PEDIATR RES, V49, P770, DOI 10.1203/00006450-200106000-00010; Siesj? BK., 1978, BRAIN ENERGY METABOL; Springett R, 2000, AM J PHYSIOL-HEART C, V279, pH2202, DOI 10.1152/ajpheart.2000.279.5.H2202; Springett RJ, 2003, ADV EXP MED BIOL, V530, P555; Tachtsidis I, 2007, PHYSIOL MEAS, V28, P199, DOI 10.1088/0967-3334/28/2/008; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Tisdall MM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2718541; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valdueza JM, 1997, AM J NEURORADIOL, V18, P1929; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643	47	76	76	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2008	109	3					424	432		10.3171/JNS/2008/109/9/0424			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	344CX	WOS:000258904400011	18759572				2022-02-06	
J	Nixon, K; Kim, DH; Potts, EN; He, J; Crews, FT				Nixon, K.; Kim, D. H.; Potts, E. N.; He, J.; Crews, F. T.			Distinct cell proliferation events during abstinence after alcohol dependence: Microglia proliferation precedes neurogenesis	NEUROBIOLOGY OF DISEASE			English	Article						alcoholism; regeneration; ethanol; hippocampus; cortex; progenitor; stem cell; adult neurogenesis; microglia; neurodegeneration	ADULT-RAT HIPPOCAMPUS; BINGE ETHANOL EXPOSURE; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; DENTATE GYRUS; INDUCED NEURODEGENERATION; BENZODIAZEPINE-RECEPTORS; COGNITIVE DEFICITS; NEURONAL LOSS; DAMAGE	Excessive alcohol intake characteristic of Alcohol Use Disorders (AUDs) produces neurodegeneration that may recover with abstinence. The mechanism of regeneration is unclear, however neurogenesis from neural stem/progenitor cells is a feasible mechanism of structural plasticity. Therefore, a timecourse of cell proliferation was examined in a rat model of an AUD and showed a striking burst in cell proliferation at 2 days of abstinence preceding the previously reported neurogenic proliferation at 7 days. New cells at 2 days, assessed by bromo-deoxy-uridine incorporation and endogenous markers, were observed throughout hippocampus and cortex. Although the majority of these new cells did not become neurons, neurogenesis was not altered at this specific time point. These new cells expressed a microglia-specific marker, Iba-1, and survived at least 2 months. This first report of microglia proliferation in a model of an AUD suggests that microgliosis could contribute to volume recovery in non-neurogenic regions during abstinence. (C) 2008 Elsevier Inc. All rights reserved.	[Kim, D. H.; Potts, E. N.; He, J.; Crews, F. T.] Univ N Carolina, Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA; [Nixon, K.] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA		Crews, FT (corresponding author), Univ N Carolina, Bowles Ctr Alcohol Studies, Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.	kim-nixon@uky.edu; FrCrews@med.unc.edu	Nixon, Kimberly/A-1217-2015; Nixon, Kimberly/Y-9270-2019; Crews, Fulton/T-1181-2019	Nixon, Kimberly/0000-0002-3466-9912; Crews, Fulton/0000-0003-2393-4976	NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P60 AA011605, R37 AA006069, R01 AA016959, R01 AA016959-02, R37 AA006069-18, P60 AA011605-11] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P60AA011605, R01AA016959, R37AA006069] Funding Source: NIH RePORTER		ADACHI J, 1991, J STUD ALCOHOL, V52, P448, DOI 10.15288/jsa.1991.52.448; Agartz I, 1999, ARCH GEN PSYCHIAT, V56, P356, DOI 10.1001/archpsyc.56.4.356; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; Bartels C, 2007, ALCOHOL ALCOHOLISM, V42, P92, DOI 10.1093/alcalc/agl104; Beresford TP, 2006, ALCOHOL CLIN EXP RES, V30, P1866, DOI 10.1111/j.1530-0277.2006.00223.x; BRANDT J, 1983, ARCH GEN PSYCHIAT, V40, P435; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Collins MA, 1996, ALCOHOL CLIN EXP RES, V20, P284, DOI 10.1111/j.1530-0277.1996.tb01641.x; Collins MA, 1998, FASEB J, V12, P221, DOI 10.1096/fasebj.12.2.221; Crews FT, 2000, ALCOHOL CLIN EXP RES, V24, P1712, DOI 10.1111/j.1530-0277.2000.tb01973.x; Crews FT, 2004, ALCOHOL CLIN EXP RES, V28, P350, DOI 10.1097/01.ALC.0000113416.65546.01; Crews FT, 2006, ALCOHOL CLIN EXP RES, V30, P720, DOI 10.1111/j.1530-0277.2006.00084.x; Crews FT, 2006, NEUROSCIENCE, V137, P437, DOI 10.1016/j.neuroscience.2005.08.090; Crews FT, 2004, ALCOHOL, V33, P63, DOI 10.1016/j.alcohol.2004.04.005; Crews F, 2006, ALCOHOL CLIN EXP RES, V30, P1938, DOI 10.1111/j.1530-0277.2006.00239.x; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Eisch AJ, 2002, PROG BRAIN RES, V138, P315, DOI 10.1016/S0079-6123(02)38085-3; Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ernst C, 2006, J NEUROSCI RES, V83, P349, DOI 10.1002/jnr.20724; FAGAN AM, 1994, NEUROSCIENCE, V58, P705, DOI 10.1016/0306-4522(94)90449-9; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Grant BF, 2004, DRUG ALCOHOL DEPEN, V74, P223, DOI 10.1016/j.drugalcdep.2004.02.004; Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114; Guillery RW, 1997, J COMP NEUROL, V386, P2, DOI 10.1002/(SICI)1096-9861(19970915)386:1<2::AID-CNE2>3.0.CO;2-6; Hailer NP, 1999, EUR J NEUROSCI, V11, P3359, DOI 10.1046/j.1460-9568.1999.00808.x; Hall W, 1997, LANCET, V349, P1897, DOI 10.1016/S0140-6736(97)04572-8; Harding AJ, 1997, HIPPOCAMPUS, V7, P78, DOI 10.1002/(SICI)1098-1063(1997)7:1<78::AID-HIPO8>3.3.CO;2-B; He J, 2008, EXP NEUROL, V210, P349, DOI 10.1016/j.expneurol.2007.11.017; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Knapp D J, 1993, Alcohol Alcohol Suppl, V2, P489; Knapp DJ, 1999, ALCOHOL CLIN EXP RES, V23, P633, DOI 10.1097/00000374-199904001-00010; Kril JJ, 1997, NEUROSCIENCE, V79, P983, DOI 10.1016/S0306-4522(97)00083-3; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Laakso MP, 2000, BEHAV BRAIN RES, V109, P177, DOI 10.1016/S0166-4328(99)00172-2; Liu JL, 1998, J NEUROSCI, V18, P7768; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Lukoyanov NV, 2000, ALCOHOL, V20, P139, DOI 10.1016/S0741-8329(99)00069-5; MAJCHROWICZ E, 1975, PSYCHOPHARMACOLOGIA, V43, P245, DOI 10.1007/BF00429258; Marella M, 2004, J NEUROSCI, V24, P620, DOI 10.1523/JNEUROSCI.4303-03.2004; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; MINION GE, 1989, J TOXICOL-CLIN TOXIC, V27, P375, DOI 10.3109/15563658909000358; Nixon K, 2006, HIPPOCAMPUS, V16, P287, DOI 10.1002/hipo.20162; Nixon K, 2004, J NEUROSCI, V24, P9714, DOI 10.1523/JNEUROSCI.3063-04.2004; Nixon K, 2002, J NEUROCHEM, V83, P1087, DOI 10.1046/j.1471-4159.2002.01214.x; Obernier JA, 2002, PHARMACOL BIOCHEM BE, V72, P521, DOI 10.1016/S0091-3057(02)00715-3; Obernier JA, 2002, ALCOHOL CLIN EXP RES, V26, P547, DOI 10.1097/00000374-200204000-00016; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Parent JM, 1997, J NEUROSCI, V17, P3727; Parsons OA, 1993, NATIONAL I ALCOHOL A, V22, P173; Penland S, 2001, ALCOHOL, V24, P45, DOI 10.1016/S0741-8329(01)00142-2; Popken GJ, 1997, J COMP NEUROL, V386, P8; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Riikonen J, 2002, ALCOHOL ALCOHOLISM, V37, P421, DOI 10.1093/alcalc/37.5.421; Stephens DN, 2005, BIOL PSYCHIAT, V58, P392, DOI 10.1016/j.biopsych.2005.04.025; STREIT WJ, 1994, ALCOHOL GLIAL CELLS, V27, P55; Sullivan EV, 2000, ALCOHOL CLIN EXP RES, V24, P611, DOI 10.1111/j.1530-0277.2000.tb02032.x; Sullivan EV, 2005, PSYCHOPHARMACOLOGY, V180, P583, DOI 10.1007/s00213-005-2267-6; Sullivan EV, 2000, NEUROPSYCHOLOGY, V14, P178, DOI 10.1037//0894-4105.14.2.178; SYAPIN PJ, 1988, EUR J PHARMACOL, V147, P101, DOI 10.1016/0014-2999(88)90638-3; URSO T, 1981, LIFE SCI, V28, P1053, DOI 10.1016/0024-3205(81)90752-9; Vela JM, 2002, J NEUROTRAUM, V19, P1503, DOI 10.1089/089771502320914723; WALKER DW, 1980, SCIENCE, V209, P711, DOI 10.1126/science.7394532; Warner-Schmidt JL, 2006, HIPPOCAMPUS, V16, P239, DOI 10.1002/hipo.20156; Weissman BA, 2004, ANN NY ACAD SCI, V1025, P584, DOI 10.1196/annals.1316.072; WILLIAMS AE, 1994, NEUROPATH APPL NEURO, V20, P47, DOI 10.1111/j.1365-2990.1994.tb00956.x; Zou JY, 1996, ALCOHOL CLIN EXP RES, V20, P1406, DOI 10.1111/j.1530-0277.1996.tb01141.x	74	76	78	0	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	AUG	2008	31	2					218	229		10.1016/j.nbd.2008.04.009			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	332XF	WOS:000258115700006	18585922	Green Accepted, Green Submitted			2022-02-06	
J	Griesbach, GS; Hovda, DA; Gomez-Pinilla, F; Sutton, RL				Griesbach, G. S.; Hovda, D. A.; Gomez-Pinilla, F.; Sutton, R. L.			Voluntary exercise or amphetamine treatment, but not the combination, increases hippocampal brain-derived neurotrophic factor and synapsin I following cortical contusion injury in rats	NEUROSCIENCE			English	Article						controlled cortical impact; norepinephrine; oxidized proteins; running wheel; traumatic brain injury	VAGUS NERVE-STIMULATION; SENSORIMOTOR CORTEX INJURY; PHYSICAL-ACTIVITY; FACTOR EXPRESSION; GENE-EXPRESSION; MOTOR RECOVERY; GROWTH-FACTOR; COGNITIVE DEFICITS; OXIDATIVE STRESS; MESSENGER-RNA	Prior work has shown that d-amphetamine (AMPH) treatment or voluntary exercise improves cognitive functions after traumatic brain injury (TBI). In addition, voluntary exercise increases levels of brain-derived neurotrophic factor (BDNF). The current study was conducted to determine how AMPH and exercise treatments, either alone or in combination, affect molecular events that may underlie recovery following controlled cortical impact (CCI) injury in rats. We also determined if these treatments reduced injury-induced oxidative stress. Following a CCI or sham injury, rats received AMPH (1 mg/kg/day) or saline treatment via an ALZET (R) pump and were housed with or without access to a running wheel for 7 days. CCI rats ran significantly less than sham controls, but exercise level was not altered by drug treatment. On day 7 the hippocampus ipsilateral to injury was harvested and BDNF, synapsin I and phosphorylated (P) -synapsin I proteins were quantified. Exercise or AMPH alone significantly increased BDNF protein in sham and CCI rats, but this effect was lost with the combined treatment. In sham-injured rats synapsin I increased significantly after AMPH or exercise, but did not increase after combined treatment. Synapsin levels, including the P-synapsin/total synapsin ratio, were reduced from sham controls in the saline-treated CCI groups, with or without exercise. AMPH treatment significantly increased the P-synapsin/total synapsin ratio after CCI, an effect that was attenuated by combining AMPH with exercise. Exercise or AMPH treatment alone significantly decreased hippocampal carbonyl groups on oxidized proteins in the CCI rats, compared with saline-treated sedentary counterparts, but this reduction in a marker of oxidative stress was not found with the combination of exercise and AMPH treatment. These results indicate that, whereas exercise or AMPH treatment alone may induce plasticity and reduce oxidative stress after TEI, combining these treatments may cancel each other's therapeutic effects. Published by Elsevier Ltd on behalf of IBRO.	[Griesbach, G. S.; Hovda, D. A.; Gomez-Pinilla, F.; Sutton, R. L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Neurosurg, Los Angeles, CA 90095 USA; [Hovda, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Gomez-Pinilla, F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol Sci, Los Angeles, CA 90095 USA		Griesbach, GS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Neurosurg, Box 957039, Los Angeles, CA 90095 USA.	ggriesbach@mednet.ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050465, R01NS027544, R21NS048535] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS50465, R01 NS027544-10A2, R01 NS050465-04, R01 NS050465, NS27544, R21 NS048535, NS048535, R01 NS050465-03, R21 NS048535-02, R01 NS027544-12, R01 NS027544, R21 NS048535-01A1] Funding Source: Medline		Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Akbarian S, 2002, J NEUROSCI, V22, P4153, DOI 10.1523/JNEUROSCI.22-10-04153.2002; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1994, AM J PHYS MED REHAB, V73, P76, DOI 10.1097/00002060-199404000-00002; Butefisch CM, 2002, ANN NEUROL, V51, P59, DOI 10.1002/ana.10056; Chen MJ, 2007, CELL SIGNAL, V19, P114, DOI 10.1016/j.cellsig.2006.05.028; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Clough RW, 2007, NEUROSCIENCE, V147, P286, DOI 10.1016/j.neuroscience.2007.04.043; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; Dishman RK, 2000, BRAIN RES BULL, V52, P337, DOI 10.1016/S0361-9230(00)00271-9; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Douglass J, 1996, GENE, V169, P241, DOI 10.1016/0378-1119(96)88651-3; Dunn AL, 1996, MED SCI SPORT EXER, V28, P204, DOI 10.1097/00005768-199602000-00008; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; DunnMeynell AA, 1997, J NEUROTRAUM, V14, P43, DOI 10.1089/neu.1997.14.43; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; Fleckenstein AE, 2007, ANNU REV PHARMACOL, V47, P681, DOI 10.1146/annurev.pharmtox.47.120505.105140; FLORIN SM, 1994, BRAIN RES, V654, P53, DOI 10.1016/0006-8993(94)91570-9; Follesa P, 2007, BRAIN RES, V1179, P28, DOI 10.1016/j.brainres.2007.08.045; Fumagalli F, 2003, MOL PSYCHIATR, V8, P898, DOI 10.1038/sj.mp.4001370; Garcia C, 2003, NEUROSCIENCE, V119, P721, DOI 10.1016/S0306-4522(03)00192-1; GOLDSTEIN LB, 1993, J NEURAL TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hovda D.A., 1996, NEUROTRAUMA, P1459; Juric DM, 2006, BRAIN RES, V1108, P54, DOI 10.1016/j.brainres.2006.06.008; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kozisek ME, 2008, NEUROPHARMACOLOGY, V54, P251, DOI 10.1016/j.neuropharm.2007.08.001; KROBERT KA, 1994, J NEUROCHEM, V62, P2233; LANTERI C, 2007, NEUROPSYCHOPHARMACOL, DOI DOI 10.1038/SJ.NPP.1301548D0I; LEVIN BE, 1995, BRAIN RES, V674, P307, DOI 10.1016/0006-8993(95)00032-L; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Luellen BA, 2007, GENES BRAIN BEHAV, V6, P482, DOI 10.1111/j.1601-183X.2006.00279.x; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; Meredith GE, 2002, BRAIN RES, V949, P218, DOI 10.1016/S0006-8993(02)03160-8; Miklic S, 2004, INT J DEV NEUROSCI, V22, P119, DOI 10.1016/j.ijdevenue.2004.03.001; Molteni R, 2002, EUR J NEUROSCI, V16, P1107, DOI 10.1046/j.1460-9568.2002.02158.x; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Navarro A, 2004, AM J PHYSIOL-REG I, V286, pR505, DOI 10.1152/ajpregu.00208.2003; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Pae CU, 2007, MED HYPOTHESES, V69, P132, DOI 10.1016/j.mehy.2006.11.009; Pan YX, 2007, HYPERTENSION, V49, P519, DOI 10.1161/01.HYP.0000256955.74461.93; Peng Q, 2008, EXP NEUROL, V210, P154, DOI 10.1016/j.expneurol.2007.10.015; Prasad RM, 1995, RESTOR NEUROL NEUROS, V9, P65, DOI 10.3233/RNN-1995-9201; Ramic M, 2006, BRAIN RES, V1111, P176, DOI 10.1016/j.brainres.2006.06.063; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; Russo-Neustadt A, 1999, NEUROPSYCHOPHARMACOL, V21, P679, DOI 10.1016/S0893-133X(99)00059-7; Russo-Neustadt A, 2001, BEHAV BRAIN RES, V120, P87, DOI 10.1016/S0166-4328(00)00364-8; Russo-Neustadt AA, 2000, NEUROSCIENCE, V101, P305, DOI 10.1016/S0306-4522(00)00349-3; Russo-Neustadt AA, 2004, NEUROPSYCHOPHARMACOL, V29, P2189, DOI 10.1038/sj.npp.1300514; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Salomon L, 2006, P NATL ACAD SCI USA, V103, P7476, DOI 10.1073/pnas.0600839103; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Smith DC, 2006, J NEUROTRAUM, V23, P1549, DOI 10.1089/neu.2006.23.1549; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; SUTTON RL, 1994, NEUROLOGICAL REHABIL, P469; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Vaynman S, 2003, NEUROSCIENCE, V122, P647, DOI 10.1016/j.neuroscience.2003.08.001; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Wu B, 2006, BIOCHEM BIOPH RES CO, V347, P656, DOI 10.1016/j.bbrc.2006.06.117; ZAFRA F, 1992, J NEUROSCI, V12, P4793	89	76	77	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUN 23	2008	154	2					530	540		10.1016/j.neuroscience.2008.04.003			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	319OB	WOS:000257172200013	18479829	Green Accepted			2022-02-06	
J	Utagawa, A; Truettner, JS; Dietrich, WD; Bramlett, HM				Utagawa, Akira; Truettner, Jessie S.; Dietrich, W. Dalton; Bramlett, Helen M.			Systemic inflammation exacerbates behavioral and histopathological consequences of isolated traumatic brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article						brain trauma; cytokine; leukocytes; inflammation; polytrauma	NEURONAL CELL-DEATH; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; BARRIER PERMEABILITY; ENDOTHELIAL-CELLS; ACUTE-PHASE; INTERLEUKIN-1; DAMAGE; CYTOKINES; DYSFUNCTION	The proinflammatory cytokine interleukin-1 beta (IL-1 beta) is induced rapidly after traumatic brain injury (TBI) and contributes to the inflammatory events that lead to neuronal loss. Although an important source of IL-1 beta is from the injured brain itself, in patients with multiple organ trauma (polytrauma) IL-1 beta is also released into the bloodstream which may potentially influence brain vulnerability. The purpose of this study was to determine the effects of systemic inflammation induced by peripheral administration of IL-1 beta on histopathological and behavioral outcome after moderate fluid percussion (FP) brain injury in rats. At 30 minor 24 h after TBI, saline, 20 mu g/kg or 40 mu g/kg of IL-1 beta was injected (n=4-9/group) intraperitoneally(IP). Sham operated animals (n=9) received either saline or IL-1 beta (20 or 40 mu g/kg) injections. The somatosensory tactile placing test was administered at 1, 2 and 3 days posttrauma. IL-1 beta-treated animals showed significant placing deficits compared to vehicle-treated TBI animals. Three days after injection, contusion areas and volumes were significantly increased (p < 0.05) with both IL-1 beta doses and at both treatment times compared to vehicle-treated animals. IL-1 beta-treated rats showed more contusion injury and hippocampal neuronal damage as well as enhanced perivascular neutrophil accumulation. Cortical IL-1rl mRNA increased as early as I It following TBI, peaking at 24 h and remained elevated 3 days posttrauma. These data show that the posttraurnatic administration of IL-1 beta significantly aggravates behavioral outcome and increases overall contusion volume after TBI. Increased systemic inflammatory processes, including extravasation of activated leukocytes and proinflammatory cytokines could participate in this detrimental outcome. Because peripherally circulating cytokines and other neurotoxic factors may be increased following multi-organ trauma, these findings may be important in targeting therapeutic interventions in this patient population. (C) 2008 Elsevier Inc. All rights reserved.	[Utagawa, Akira; Truettner, Jessie S.; Dietrich, W. Dalton; Bramlett, Helen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA		Bramlett, HM (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14th Terrace,Suite 3-18, Miami, FL 33136 USA.	hbramlett@miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042133-05, NS 30291, P50 NS030291, R01 NS042133, NS 42133, R01 NS056072, P50 NS030291-15] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056072, R01NS042133, P50NS030291] Funding Source: NIH RePORTER		Alheim K, 1998, ANN NY ACAD SCI, V840, P51, DOI 10.1111/j.1749-6632.1998.tb09548.x; Ando Tomoaki, 2007, BMC Physiology, V7, P10, DOI 10.1186/1472-6793-7-10; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Conti B, 2004, FRONT BIOSCI-LANDMRK, V9, P1433, DOI 10.2741/1341; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; *DEP VET AFF, 2005, VET HLTH AD DIR, P2; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DINARELLO CA, 1984, SURV IMMUNOL RES, V3, P29; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Gavins F, 2007, MICROCIRCULATION, V14, P667, DOI 10.1080/10739680701404903; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; McColl BW, 2007, J NEUROSCI, V27, P4403, DOI 10.1523/JNEUROSCI.5376-06.2007; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Shahbazian LM, 1999, METABOLISM, V48, P1397, DOI 10.1016/S0026-0495(99)90149-X; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672, DOI 10.1002/jlb.56.6.672; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Tian DS, 2007, BRAIN RES, V1135, P177, DOI 10.1016/j.brainres.2006.11.085; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whalen MJ, 1997, ACT NEUR S, V70, P260; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Wilson RF, 2001, NEUROL RES, V23, P117, DOI 10.1179/016164101101198415; Wong D, 2007, J NEUROIMMUNOL, V184, P136, DOI 10.1016/j.jneuroim.2006.12.003; ZILLES L, 1985, CORTEX RAT STEREOTAX	46	76	81	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2008	211	1					283	291		10.1016/j.expneurol.2008.02.001			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	298ZM	WOS:000255725600029	18355811	Green Accepted			2022-02-06	
J	Tanriverdi, F; Ulutabanca, H; Unluhizarci, K; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; Ulutabanca, Halil; Unluhizarci, Kursad; Selcuklu, Ahmet; Casanueva, Felipe F.; Kelestimur, Fahrettin			Three years prospective investigation of anterior pituitary function after traumatic brain injury: a pilot study	CLINICAL ENDOCRINOLOGY			English	Article							ADRENOCORTICOTROPIN TEST; SUBARACHNOID HEMORRHAGE; ADRENAL AXIS; HIGH-RISK; HYPOPITUITARISM; ADULTS; DYSFUNCTION; PREVALENCE; HORMONE; INSUFFICIENCY	Objective It has been recently demonstrated that traumatic brain injury (TBI)-mediated hypopituitarism could be more frequent than previously known. However, most of the previous data were obtained from retrospective studies, and the natural history of the hypopituitarism due to TBI is still unclear. So far no study has been reported in which the pituitary function of the same patients has been investigated more than 1 year after TBI. Therefore, we report the results of 3 years prospective follow-up of anterior pituitary function in patients with mild, moderate and severe TBI. Patients and design Thirty patients (25 males, 5 females; age 37.2 +/- 2.4 years) with TBI were included in the study. Pituitary function was evaluated at 1 and 3 years after TBI. Results After individual evaluation of GH deficiency from 1 year to 3 years after TBI, 7 of 13 (53.8%) GH-deficient patients at 1st year recovered after 3 years of TBI, and GH deficiency detected at 3 years in one patient was new onset. Additionally, five of six (83.3%) ACTH-deficient patients at 1st year recovered after 3 years of TBI, and ACTH deficiency detected at 3 years in one patient was new onset. Conclusions GH deficiency is the most common pituitary deficit 1 and 3 years after TBI. In patients with mild and moderate TBI, pituitary function improves over time in a considerable number of patients, but it may also worsen rarely over the 3-year period. In patients with severe TBI, ACTH and GH deficiencies at 1st year evaluation persist at 3rd year.	[Tanriverdi, Fatih; Unluhizarci, Kursad] Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; [Ulutabanca, Halil; Selcuklu, Ahmet; Kelestimur, Fahrettin] Erciyes Univ, Sch Med, Dept Neurosurg, TR-38039 Kayseri, Turkey; [Casanueva, Felipe F.] Sch Med, Dept Med, Santiago De Compostela, Spain; [Casanueva, Felipe F.] Univ Santiago Compostela, Complejo Hosp Univ Santiago, Santiago De Compostela, Spain		Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr	kelestimur, f/ABE-9873-2021				Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; Ceballos R, 1966, Ala J Med Sci, V3, P185; CROWLEY S, 1991, J ENDOCRINOL, V130, P475, DOI 10.1677/joe.0.1300475; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Dokmetas HS, 2000, J CLIN ENDOCR METAB, V85, P3713, DOI 10.1210/jc.85.10.3713; Gomez JM, 2002, CLIN ENDOCRINOL, V56, P329, DOI 10.1046/j.1365-2265.2002.01472.x; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Oelkers W, 1996, EUR J ENDOCRINOL, V135, P27, DOI 10.1530/eje.0.1350027; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81	24	76	83	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	APR	2008	68	4					573	579		10.1111/j.1365-2265.2007.03070.x			7	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	274BW	WOS:000253977800012	17970777				2022-02-06	
J	Chafetz, MD				Chafetz, Michael D.			Malingering on the social security disability consultative exam: Predictors and base rates	CLINICAL NEUROPSYCHOLOGIST			English	Article						disability; evidence-based assessment; malingering; mental retardation; social security	TRAUMATIC BRAIN-INJURY; NEUROCOGNITIVE DYSFUNCTION; MENTAL-RETARDATION; SCALE; PERFORMANCE; INDICATORS; VALIDATION; SYMPTOMS; MMPI-2	The Disability Determinations Service (DDS) obtains evidence about an applicant from sources that may include the Psychological Consultative Examination (PCE), which usually includes a mental status examination and Wechsler Scale findings. Although evidence for good effort is necessary to validate the findings, psychologists have been officially discouraged from determining effort by the use of formal tests. In Chafetz, Abrahams, and Kohlmaier (2007), indicators of effort within the PCE in WAIS-age (adults) and WISC-age (children) claimants were determined, and a PCE Malingering Rating Scale was developed. In the present study, this new scale was used along with established symptom validity tests (SVTs) to determine base rates and additional predictors of malingering within the PCE. Claimants were apportioned into separate effort groups in a "dose-response" manner: Definite Malingerers, Chance-Level, Fail Both (SVT and Rating Scale), Fail One, Fail Indicators, and Not Fail. Data from separate studies using the Test of Memory Malingering (TOMM), and the Medical Symptom Validity Test (MSVT) were used to assign claimants into separate effort groups. An evidence-based assessment approach utilized these base-rates to calculate post-test odds. Other predictors of effort within the PCE include the presence of conduct disorder symptoms, and the number of other family members on Disability.	[Chafetz, Michael D.] New Orleans Psychotherapy Associates, New Orleans, LA USA		Chafetz, MD (corresponding author), 3520 Gen DeGaulle Dr 4098, New Orleans, LA 70114 USA.	mikechaf@yahoo.com	Chafetz, Michael/AAC-2579-2020				American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ARDOLF BR, IN PRESS CLIN NEUROP; Chafetz M. D., 2006, RANDOM LETT TEST PRE; CHAFETZ MD, 2006, MALINGERING SOCIAL S; CHAFETZ MD, 2005, ANN M AM AC CLIN NEU; CHAFETZ MD, 2005, ANN M NAT AC NEUR OC; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Cohen J., 1983, APPL MULTIPLE REGRES; Drob S. L., 2000, AM J FORENSIC PSYCH, V18, P37; DUNLOP T, 2005, UNPUB COMMUNICATION; FRAZIER TW, 2006, WORKSH 4 NAT AC NEUR; GOUVIER WD, 1998, DETECTION MALINGERIN; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Hammond J., 2006, ANN M NAT AC NEUR OC; Hurley KE, 2006, MENT RETARD, V44, P112, DOI 10.1352/0047-6765(2006)44[112:AIMMUW]2.0.CO;2; Keyes D, 1997, MENT RETARD, V35, P59, DOI 10.1352/0047-6765(1997)035<0059:PWMRAD>2.0.CO;2; Larrabee G.J., 2005, FORENSIC NEUROPSYCHO; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; MILLER LS, 2006, PREVALENCE SUBOPTIMA; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Richman J., 2006, J OCCUPATIONAL ENV M, V48, P1; Rogers R, 1990, Bull Am Acad Psychiatry Law, V18, P323; Rohling M., 2004, NEWSLETTER, V22, P21; Rohling M. L., 2004, NEWSLETTER, V22, P21; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; STRUB RL, 1993, MENTAL STATUS EXAMIN; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; Victor T. L., 2007, ASSESSMENT FEIGNED C	36	76	77	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2008	22	3					529	546		10.1080/13854040701346104			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	298LU	WOS:000255690000192	17853151				2022-02-06	
J	Gentry, T; Wallace, J; Kvarfordt, C; Lynch, KB				Gentry, Tony; Wallace, Joseph; Kvarfordt, Connie; Lynch, Kathleen Bodisch			Personal digital assistants as cognitive aids for individuals with severe traumatic brain injury: A community-based trial	BRAIN INJURY			English	Article						brain injury; cognition; PDA; assistive technology; occupational therapy	ELECTRONIC MEMORY AID; MENTAL-RETARDATION; EVERYDAY MEMORY; PAGING SYSTEM; HEAD-INJURY; REHABILITATION; MICROCOMPUTER; IMPAIRMENTS; NEUROPAGE; COMPUTER	Objective: The purpose of this study was to examine the efficacy of personal digital assistants (PDAs) as cognitive aids in a sample of individuals with severe traumatic brain injury (TBI). Method: The group included 23 community-dwelling individuals at least 1 year post-severe TBI, who had difficulties in performing everyday tasks due to behavioural memory problems. Participants were trained by an occupational therapist to use PDAs as cognitive aids and assessed for occupational performance (using Canadian Occupational Performance Measure (COPM)) and participation in everyday life tasks (using Craig Handicap Assessment and Rating Technique-Revised (CHART)) before training and 8 weeks after training concluded. Results: Statistically significant improvement was noted for self-ratings of occupational performance and satisfaction with occupational performance (COPM); significant improvement in a self-rating of participation was noted (CHART-R). Conclusion: A brief training intervention utilizing PDAs as cognitive aids is associated with improved self-ratings of performance in everyday life tasks among community-dwelling individuals with severe TBI.	[Gentry, Tony; Lynch, Kathleen Bodisch] Virginia Commonwealth Univ, Dept Occupat Therapy, Richmond, VA 23298 USA; [Wallace, Joseph] Assist Technol Loan Fund Author, Richmond, VA USA; [Kvarfordt, Connie] Univ Windsor, Windsor, ON N9B 3P4, Canada		Gentry, T (corresponding author), Virginia Commonwealth Univ, Dept Occupat Therapy, 730 E Broad St,POB 980008, Richmond, VA 23298 USA.	logentry@vcu.edu	Kvarfordt, C. L./AAD-7170-2020	Kvarfordt, Connie/0000-0002-8797-6596			BAESMAN B, 2006, VISION SYSTEM 1999; Bergman MM, 2003, NEUROREHABILITATION, V18, P31; CHUTE DL, 1994, EXP AGING RES, V20, P229, DOI 10.1080/03610739408253969; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CONBOY TJ, 1986, REHABIL PSYCHOL, V31, P203, DOI 10.1037//0090-5550.31.4.203; Davies DK, 2002, EDUC TRAIN MENT RET, V37, P209; Davies DK, 2002, MENT RETARD, V40, P358, DOI 10.1352/0047-6765(2002)040<0358:EITMSO>2.0.CO;2; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; GILES GM, 1989, AM J OCCUP THER, V43, P409, DOI 10.5014/ajot.43.6.409; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Gorman P, 2003, NEUROREHABILITATION, V18, P57; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kirsch NL, 2004, BRAIN INJURY, V18, P725, DOI 10.1080/02699050310001646161; LEVINSON R, 1997, J HEAD TRAUMA REHAB, V45, P101; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mihailidis A, 2004, NEUROPSYCHOL REHABIL, V14, P135, DOI 10.1080/09602010343000156; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SOHLBERG MM, 2001, COGNITIVE REHABILIAT; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Wilson BA, 2003, NEUROREHABILITATION, V18, P3; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 1991, RIVERMEAD BEHAV MEMO; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161	29	76	76	0	15	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	1					19	24		10.1080/02699050701810688			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	250QF	WOS:000252314400003	18183505				2022-02-06	
J	Ietswaart, M; Milders, M; Crawford, JR; Currie, D; Scott, CL				Ietswaart, Magdalena; Milders, Maarten; Crawford, John R.; Currie, David; Scott, Clare L.			Longitudinal aspects of emotion recognition in patients with traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						brain damage; affect; facial expression; vocal prosody; recovery	CLOSED-HEAD INJURY; FACIAL EXPRESSIONS; PSYCHOSOCIAL ADJUSTMENT; IMPAIRED RECOGNITION; SOCIAL-BEHAVIOR; SCHIZOPHRENIA; DAMAGE; AMYGDALA; SYSTEMS; LESIONS	Changes in emotional and social behaviour are relatively common following traumatic brain injury (TBI). Impairments in recognising the emotional state of others may underlie some of the problems in social relationships that these patients experience. The few previous studies examining emotion recognition in TBI typically assessed patients once, long after the onset of brain injury, making it difficult to distinguish the direct effect of brain injury from the effects of environmental changes. This study examined 30 patients with TBI shortly after brain injury and 32 orthopaedic control patients on their recognition of emotions expressed in the face and the voice using discrimination and labelling tasks. These patients were followed up 1 year later to examine the longitudinal development of emotion recognition deficits. TBI patients were found to be impaired on emotion recognition compared to the control patients both early after injury and I year later. The fact that impairments in emotion recognition were evident early after TBI and no evidence of recovery over time was found, suggests a direct effect of brain injury. (C) 2007 Elsevier Ltd. All rights reserved.	[Ietswaart, Magdalena] Northumbria Univ, Sch Psychol & Sport Sci, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England; [Milders, Maarten; Crawford, John R.; Scott, Clare L.] Univ Aberdeen, Sch Psychol, Aberdeen AB9 1FX, Scotland; [Currie, David] Grampian Univ Hosp Trust, Dept Neurosurg, Aberdeen, Scotland		Ietswaart, M (corresponding author), Northumbria Univ, Sch Psychol & Sport Sci, Northumberland Bldg, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England.	magdalena.ietswaart@unn.ac.uk	Milders, Maarten/C-5560-2008; Crawford, John R/A-4165-2008	Crawford, John R/0000-0003-3403-3428; Ietswaart, Magdalena/0000-0003-4576-9393	Chief Scientist Office [CZH/4/14] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Adolphs R, 1996, J NEUROSCI, V16, P7678; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; Adolphs R, 2002, EMOTION, V2, P23, DOI 10.1037/1528-3542.2.1.23; Benton A. L., 1983, FACIAL RECOGNITION S; Biehl M, 1997, J NONVERBAL BEHAV, V21, P3, DOI 10.1023/A:1024902500935; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Bowers D., 1991, FLORIDA AFFECT BATTE; Braun C M, 1989, Brain Inj, V3, P345, DOI 10.3109/02699058909004559; Burgess P.W., 1997, HAYLING BRIXTON TEST; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Calder AJ, 2000, NAT NEUROSCI, V3, P1077, DOI 10.1038/80586; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; DOWNES JJ, 1993, BRAIN, V116, P887, DOI 10.1093/brain/116.4.887; Ekman P., 1976, PICTURE FACIAL AFFEC; Freeman J, 2001, BRIT J CLIN PSYCHOL, V40, P221, DOI 10.1348/014466501163562; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hooker C, 2002, PSYCHIAT RES, V112, P41, DOI 10.1016/S0165-1781(02)00177-4; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; Kington JM, 2000, J PSYCHIAT RES, V34, P341, DOI 10.1016/S0022-3956(00)00029-7; LEVIDOW L, 1992, MICROBIAL RELEASES, V1, P55; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Morris PG, 2005, BRIT J CLIN PSYCHOL, V44, P209, DOI 10.1348/014466505X34174; Mueser KT, 1996, J ABNORM PSYCHOL, V105, P271, DOI 10.1037/0021-843X.105.2.271; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/PMS.73.8.1139-1150; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Sprengelmeyer R, 1998, P ROY SOC B-BIOL SCI, V265, P1927, DOI 10.1098/rspb.1998.0522; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1998, MANUAL WECHSLER ADUL; Weniger G, 2002, CEREB CORTEX, V12, P258, DOI 10.1093/cercor/12.3.258; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	42	76	77	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2008	46	1					148	159		10.1016/j.neuropsychologia.2007.08.002			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	265ME	WOS:000253362300015	17915263				2022-02-06	
J	Scheid, R; Ott, DV; Roth, H; Schroeter, ML; Von Cramon, DY				Scheid, Rainer; Ott, Derek V.; Roth, Henrik; Schroeter, Matthias L.; Von Cramon, D. Yves			Comparative magnetic resonance imaging at 1.5 and 3 tesla for the evaluation of traumatic microbleeds	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; diagnosis; high-field MR imaging; traumatic microbleeds	DIFFUSE AXONAL INJURY; HEAD-INJURY; MRI; HEMOSIDERIN; HEMORRHAGE; CHILDREN; SCALE; COMA	Traumatic microbleeds (TMBs) can be regarded as a radiological marker of diffuse axonal injury (DAI). We sought to investigate the impact of the field strengths on the depiction of TMBs by T2*-weighted gradient echo magnetic resonance imaging (MRI). By the use of comparative MRI of 14 patients (age range, 22-62 years) on 1.5-and a 3 T (Tesla) systems at a median time interval of 61 months after traumatic brain injury (TBI), we found 239 (range 0.5-48.5, median 7.5) TMBs at 1.5 T, and 470 (range 2-118, median 18.5) TMBs at 3 T, respectively (p = 0.001). However, in all but one patients MRI at 1.5 T also clearly showed TMBs. A significant negative correlation between the number of TMBs and the time interval TBI-MRI was observed, which was weaker for the imaging at 3 T (r(s) = -0.798; p = 0.001; and r(s) = -0.649; p = 0.012, respectively). In conclusion, T2*-weighted gradient-echo MRI at 3 T is superior as compared to MRI at 1.5 T for the detection of TMBs. Nevertheless, in clinical practice, MRI at 1.5 T seems to be sufficient for this purpose. MRI at 3 T may be appropriate if there is a strong clinical suspicion of DAI, despite unremarkable routine MRI, and possibly also if evidence of DAI is sought after a long interval from trauma.	[Scheid, Rainer; Schroeter, Matthias L.; Von Cramon, D. Yves] Univ Leipzig, Day Clin Cognit Neurol, D-04103 Leipzig, Germany; [Scheid, Rainer; Ott, Derek V.; Schroeter, Matthias L.; Von Cramon, D. Yves] Max Planck Inst Human Cognit & Brain Sci, Leipzig, Germany; [Roth, Henrik] Univ Leipzig, Dept Radiol, D-7010 Leipzig, Germany		Scheid, R (corresponding author), Univ Leipzig, Day Clin Cognit Neurol, Liebigstr 22a, D-04103 Leipzig, Germany.	scheid@cbs.mpg.de					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; Ezaki Y, 2006, ACTA NEUROCHIR, V148, P547, DOI 10.1007/s00701-005-0692-2; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; Fiehler J, 2006, INT J STROKE, V1, P122, DOI 10.1111/j.1747-4949.2006.00042.x; Graham D.I., 2000, HEAD INJ, P133; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; TEASDALE G, 1974, LANCET, V2, P81; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	18	76	79	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2007	24	12					1811	1816		10.1089/neu.2007.0382			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	245BR	WOS:000251910000003	18159992				2022-02-06	
J	Diamond, PM; Harzke, AJ; Magaletta, PR; Cummins, AG; Frankowski, R				Diamond, Pamela M.; Harzke, Amy J.; Magaletta, Philip R.; Cummins, A. Gaye; Frankowski, Ralph			Screening for traumatic brain injury in an offender sample: A first look at the reliability and validity of the Traumatic Brain Injury Questionnaire	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; offenders; corrections; prisons; assessment	ASSESSMENT INVENTORY PAI; HEAD-INJURY; PSYCHOMETRIC PROPERTIES; SUBSTANCE-ABUSE; AGGRESSION; OUTCOMES; BPAQ	Objective: To assess the reliability and validity of the Traumatic Brain Injury Questionnaire (TBIQ) for assessing history of traumatic brain injury (TBI) in an offender population. Setting/Participants: Offenders (118 women and 107 men) from 6 federal prison facilities in 3 geographic regions. Measures: TBIQ and multiple measures of cognitive and behavioral functioning. Results: Preliminary results indicated good test-retest reliability for lifetime history of head injury, good internal consistency for symptom severity and frequency scales, and good criterion validity for frequency of head injury and frequency and severity of symptoms. Conclusion: The TBIQ holds promise as an instrument for the assessment of TBI history in offender populations.	Univ Texas Houston, Sch Publ Hlth, Ctr Hlth Promot & Prevent Res, Houston, TX 77030 USA; Fed Bur Prisons, Psychol Serv Branch, Washington, DC USA		Diamond, PM (corresponding author), Univ Texas Houston, Sch Publ Hlth, Ctr Hlth Promot & Prevent Res, Houston, TX 77030 USA.				NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U49CE000365] Funding Source: NIH RePORTER; NCIPC CDC HHS [U49 CE000365-01S1] Funding Source: Medline		BABE S, 2001, PERSONALITY DISORDER; Barnfield TV, 1998, BRAIN INJURY, V12, P951, DOI 10.1080/026990598122007; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; Barratt ES, 1997, BIOL PSYCHIAT, V41, P1045, DOI 10.1016/S0006-3223(96)00175-8; Bryant FB, 2001, J RES PERS, V35, P138, DOI 10.1006/jrpe.2000.2302; BUSS AH, 1992, J PERS SOC PSYCHOL, V63, P452, DOI 10.1037/0022-3514.63.3.452; COOLIDGE FL, 1992, J PERS ASSESS, V59, P223, DOI 10.1207/s15327752jpa5902_1; COOLIDGE FL, 1995, PSYCHOL REP, V77, P24, DOI 10.2466/pr0.1995.77.1.24; COOLIDGE FL, 1993, COOLIDGE AXIS 2 INVE; COOLIDGE FL, 1998, INT J REHABILITATION, V4, P193; COOLIDGE FL, 1996, INDIAN J PSYCHOL ISS, V4, P1; DAOUST SW, 2006, PSYCHOL SERV, V3, P88; Diamond PM, 2006, ASSESSMENT, V13, P227, DOI 10.1177/1073191106287666; Diamond PM, 2005, CRIM JUSTICE BEHAV, V32, P546, DOI 10.1177/0093854805278416; Eaton W. W., 2004, USE PSYCHOL TESTING, V3; *FED BUR PRIS PSYC, 2006, MENT HLTH PREV PROJ; Fossati A, 2001, J CLIN PSYCHOL, V57, P815, DOI 10.1002/jclp.1051; HARRISON PM, 2005, PRISONERS 2003; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; KOKKEVI A, 1995, COMPR PSYCHIAT, V36, P329, DOI 10.1016/S0010-440X(95)90113-2; Kraus JCL, 2005, TXB TRAUMATIC BRAIN; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEUKEFELD CG, 2002, TREATMENT DRUG OFFEN; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MCALLISTER TW, 2005, TXB TRAUMATIC BRAIN; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Morey, 1991, PERSONALITY ASSESSME; Morey L. C., 1996, INTERPRETIVE GUIDE P; Morey LC, 2002, INT J OFFENDER THER, V46, P333, DOI 10.1177/0306624X02046003007; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; National Commission on Correctional Health Care, 2002, HLTH STAT SOON TO BE, V1; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X; Walker R, 2001, SUBST USE MISUSE, V36, P757, DOI 10.1081/JA-100104089; Wang EW, 1997, BEHAV SCI LAW, V15, P469, DOI 10.1002/(SICI)1099-0798(199723/09)15:4<469::AID-BSL279>3.0.CO;2-A	40	76	76	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2007	22	6					330	338		10.1097/01.HTR.0000300228.05867.5c			9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	234RN	WOS:000251181500003	18025965				2022-02-06	
J	Rabinstein, AA				Rabinstein, Alejandro A.			Paroxysmal sympathetic hyperactivity in the neurological intensive care unit	NEUROLOGICAL RESEARCH			English	Article						sympathetic hyperactivity; fever; neurological-neurosurgical ICU; causes; predictors	TRAUMATIC BRAIN-INJURY; AUTONOMIC INSTABILITY; DIENCEPHALIC SEIZURES; DYSAUTONOMIA; STORM	Objective: To assess the incidence and associations of paroxysmal sympathetic hyperactivity (PSH) among febrile patients in the neurological intensive care unit (NICU). Methods: Prospective data collection of consecutive patients admitted to an academic NICU for >48 hours. Fever was defined as body temperature >38.3 degrees C (101.0 degrees F) on at least one measurement for two consecutive days. PSH was defined by the transient presence of four of the following six criteria: fever, tachycardia, hypertension, tachypnea, excessive diaphoresis and extensor posturing or severe dystonia in the absence of other potential causes for these clinical signs. Methods: Ninety-three patients were included. Traumatic brain injury (TBI) was the primary diagnosis in 43 patients (46%). PSH were diagnosed in 17 patients (18%). It occurred in 14/43 patients (33%) with TBI but only 3/50 patients (6%) with other primary disorders (p = 0.01). Patients with PSH were younger (mean age: 35 +/- 14 versus 51 +/- 18 years old in the rest of the population) (p = 0.01), although the difference did not reach statistical significance when only TBI patients were included in the analysis (mean age: 35 +/- 15 years old in TBI patients with PSH versus 46 +/- 19 years old in TBI patients without PSH; p = 0.07). Duration of fever in patients with PSH (mean: 10.5 +/- 7 days; median: 9 days) was significantly longer than in the rest of the population ( mean: 5.1 +/- 3 days) ( p<0.001); the difference remained significant when the analysis was restricted to TBI patients (p = 0.001). Conclusion: Episodes of PSH occur in one- third of TBI patients but are rare in other acute neurological conditions. They are more frequent in younger patients and are associated with prolonged duration of fever.	Univ Miami, Sch Med, Jackson Mem Hosp, Neurosci Intens Care Unit, Miami, FL USA		Rabinstein, AA (corresponding author), Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA.	rabinstein.alejandro@mayo.edu					Audibert G, 2006, TRANSPLANTATION, V82, P1031, DOI 10.1097/01.tp.0000235825.97538.d5; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Rabinstein AA, 2004, ARCH NEUROL-CHICAGO, V61, P1625, DOI 10.1001/archneur.61.10.1625-a; Rossitch E Jr, 1988, Br J Neurosurg, V2, P471, DOI 10.3109/02688698809029601; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Tong CY, 2000, ANESTH ANALG, V91, P1450, DOI 10.1097/00000539-200012000-00028	14	76	91	0	3	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	OCT	2007	29	7					680	682		10.1179/016164107X240071			3	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	234MJ	WOS:000251167900009	18173907				2022-02-06	
J	Hortobagyi, T; Wise, S; Hunt, N; Cary, N; Djurovic, V; Fegan-Earl, A; Shorrock, K; Rouse, D; Al-Sarraj, S				Hortobagyi, T.; Wise, S.; Hunt, N.; Cary, N.; Djurovic, V.; Fegan-Earl, A.; Shorrock, K.; Rouse, D.; Al-Sarraj, S.			Traumatic axonal damage in the brain can be detected using beta-APP immunohistochemistry within 35 min after head injury to human adults	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						antigen retrieval; beta-amyloid precursor protein (beta-APP); diffuse traumatic axonal injury; immunohistochemistry; survival time	AMYLOID PRECURSOR PROTEIN; MICROWAVE ANTIGEN RETRIEVAL; FORENSIC PRACTICE; IMPACT MODEL; IMMUNOREACTIVITY; SWELLINGS; DIAGNOSIS; TRANSPORT; MARKER; CELLS	Immunohistochemistry staining for beta-amyloid precursor protein (beta-APP) is a sensitive method to detect early axonal damage in traumatic brain injury, which was previously estimated to be of minimum 60-90 min after head injury. We present seven cases of well- documented post-traumatic survival of 35-60 min where beta-APP detects early axonal damage. Cases were selected from routine work where documentation about survival is judged to be accurate. These are divided into three groups: group 1: severe head injury (n = 7) with documented survival between 35 and 60 min. Group 2: severe head injury (n = 4) with documented survival of less than 30 min. Group 3: cases (n = 4) where death was not due to head injury but survival is documented between 45 and 109 min. The brains were fixed in formalin for 4 weeks and six regions (frontal lobe with anterior corpus callosum, parietal lobe with deep white matter, basal ganglia with posterior limb of internal capsule, cerebellum with white matter and middle cerebellar peduncle and pons with basis pontis and superior cerebellar peduncle) were sampled. All blocks were stained for haematoxylin and eosin and beta-APP and selected ones for CD68, using antigen retrieval method. In group 1 sections revealed beta-APP immunoreactivity in forms of small globules and granules and occasionally as thin and short filaments. These were detected in the pons, corpus callosum, internal capsule and cerebral white matter, with some variation in localization and intensity. In groups 2 and 3 all the sections were negative for beta-APP staining. None of the cases showed evidence of severe brain swelling, increased intracranial pressure, ischaemia or infection. Using the antigen retrieval method, beta-APP immunohistochemistry can detect axonal damage within 35 min after severe head injury. These results may have an implication in the consideration of minimal survival time after traumatic head injury in medico-legal practice.	Kings Coll Hosp London, Dept Clin Neuropathol, London SE5 9RS, England; Forens Pathol Serv, London, England; Queen Mary Univ London, JM Cameron Inst Forens Sci, London E1 4NS, England		Al-Sarraj, S (corresponding author), Kings Coll Hosp London, Dept Clin Neuropathol, Acad Neurosci Bldg, London SE5 9RS, England.	safa.al-sarraj@kch.nhs.uk			MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600676] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600676] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Dolinak D, 2000, ACTA NEUROPATHOL, V100, P553, DOI 10.1007/s004010000218; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FERREIRA A, 1993, J NEUROSCI, V13, P3112; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GEINISMAN Y, 1977, BRAIN RES, V125, P182, DOI 10.1016/0006-8993(77)90372-9; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HORTOBAGYI T, 2004, NEUROPATHOL APPL NEU, V30, P204; Iino M, 2003, INT J LEGAL MED, V117, P153, DOI 10.1007/s00414-003-0370-y; Lambri M, 2001, CLIN NEUROPATHOL, V20, P263; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; Leclercq PD, 2002, J NEUROTRAUM, V19, P1183, DOI 10.1089/08977150260337985; Lee JP, 2000, J NEUROSCI RES, V60, P565, DOI 10.1002/(SICI)1097-4547(20000515)60:4<565::AID-JNR16>3.0.CO;2-I; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Niess C, 2002, ACTA NEUROPATHOL, V104, P79, DOI 10.1007/s00401-002-0525-9; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; VIANCOUR TA, 1993, BRAIN RES, V628, P209, DOI 10.1016/0006-8993(93)90957-O; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; [No title captured]	35	76	87	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	APR	2007	33	2					226	237		10.1111/j.1365-2990.2006.00794.x			12	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	144DV	WOS:000244776700009	17359363				2022-02-06	
J	Copenhaver, BR; Rabin, LA; Saykin, AJ; Roth, RM; Wishart, HA; Flashman, LA; Santulli, RB; McHugh, TL; Mamourian, AC				Copenhaver, Brittany R.; Rabin, Laura A.; Saykin, Andrew J.; Roth, Robert M.; Wishart, Heather A.; Flashman, Laura A.; Santulli, Robert B.; McHugh, Tara L.; Mamourian, Alexander C.			The fornix and mammillary bodies in older adults with Alzheimer's disease, mild cognitive impairment, and cognitive complaints: A volumetric MRI study	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						Alzheimer's disease; mild cognitive impairment; cognitive complaints; fornix; mammillary bodies; volumetric MRI	VOXEL-BASED MORPHOMETRY; TRAUMATIC BRAIN INJURY; MEMORY; ATROPHY; BODY; VALIDATION; DEMENTIA; AMNESIA; SYSTEM; SCHIZOPHRENIA	The fomix and mammillary bodies are important limbic structures that have not been systematically investigated in the earliest stages of preclinical dementia. The present study examined volumetric changes in the fornix and mammillary bodies and improved previously established tracing guidelines to increase reliability and provide more comprehensive measurements. Volumetric measurements were made in euthymic older adults, including 16 patients with mild Alzheimer's disease (AD), 20 patients with amnestic mild cognitive impairment (MCI), 20 individuals with cognitive complaints (CC) but normal neuropsychological test performance, and 20 demographically matched healthy controls (HC). Structural magnetic resonance imaging included a T1-weighted 1.5-mm coronal volume, acquired on a GE 1.5T LX scanner. After adjustment for total intracranial volume (ICV), significant volume reductions were observed in the fornix and mammillary bodies in patients with AD as compared with HC, CC, and MCI participants. No volume differences were seen between the HC, CC, and MCI groups. Study findings are consistent with previous research showing volume decreases of the fornix and mammillary bodies in AD, and provide new data on the relative preservation of these structures in preclinical disease stages. Results suggest that atrophy of the fomix and mammillary bodies becomes apparent at the point of conversion from MCI to AD. Longitudinal assessments are needed to delineate the time course and extent of the observed volumetric changes. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Dartmouth Coll Sch Med, Dept Psychiat, DHMC, Brain Imaging Lab, Lebanon, NH 03756 USA; Dartmouth Coll, Dept Psychol, Hanover, NH 03755 USA; CUNY Brooklyn Coll, Dept Psychol, Brooklyn, NY 11210 USA; Dartmouth Coll Sch Med, Dept Radiol, DHMC, Lebanon, NH 03756 USA		Saykin, AJ (corresponding author), Dartmouth Coll Sch Med, Dept Psychiat, DHMC, Brain Imaging Lab, Lebanon, NH 03756 USA.	Andrew.J.Saykin@dartmouth.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019771] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG19771] Funding Source: Medline		Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; ANDREASEN NC, 1992, J NEUROPSYCH CLIN N, V4, P125; Anstey KJ, 2003, AGING MENT HEALTH, V7, P238, DOI 10.1080/1360786031000120732; Baron JC, 2001, NEUROIMAGE, V14, P298, DOI 10.1006/nimg.2001.0848; Bilir E, 1998, NEURORADIOLOGY, V40, P138, DOI 10.1007/s002340050554; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Callen DJA, 2001, NEUROLOGY, V57, P1669, DOI 10.1212/WNL.57.9.1669; CHARNESS ME, 1987, ANN NEUROL, V22, P595, DOI 10.1002/ana.410220506; Chetelat G, 2005, NEUROIMAGE, V27, P934, DOI 10.1016/j.neuroimage.2005.05.015; DeCarli C, 2001, CLIN GERIATR MED, V17, P255, DOI 10.1016/S0749-0690(05)70068-9; Delacourte A, 1999, NEUROLOGY, V52, P1158, DOI 10.1212/WNL.52.6.1158; DELIS D, 1987, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; DELIS DC, 2000, CALIFORNIA VERBAL LE; Duvernoy H.M., 1999, HUMAN BRAIN SURFACE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gaffan D, 2001, BEHAV BRAIN RES, V127, P5, DOI 10.1016/S0166-4328(01)00360-6; Gaffan D., 1992, NEUROPSYCHOLOGY MEMO, P336; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Goodglass H., 2001, BOSTON DIAGNOSTIC AP; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Hensel A, 2005, J NEUROL SCI, V238, P71, DOI 10.1016/j.jns.2005.06.011; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; Kapur N, 1998, NEUROCASE, V4, P509, DOI 10.1093/neucas/4.6.509; Kapur N., 1994, NEUROPSYCHOLOGICAL E, P159; Kuzniecky R, 1999, NEUROLOGY, V53, P496, DOI 10.1212/WNL.53.3.496; Lee BCP, 2003, J NEUROIMAGING, V13, P199, DOI 10.1177/1051228403013003001; Mattis S., 2001, DEMENTIA RATING SCAL; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Parker A, 1997, J COGNITIVE NEUROSCI, V9, P512, DOI 10.1162/jocn.1997.9.4.512; Pennanen C, 2005, J NEUROL NEUROSUR PS, V76, P11, DOI 10.1136/jnnp.2004.035600; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; RABIN LA, 2004, P INT NEUROPSYCHOLOG, V32, P3; SAYKIN AJ, 1991, J NEUROPSYCH CLIN N, V3, P286; SAYKIN AJ, 2003, J NEUROPSYCHIATRY CL, V15, P263; Shear PK, 1996, ALCOHOL CLIN EXP RES, V20, P1489, DOI 10.1111/j.1530-0277.1996.tb01153.x; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SQUIRE LR, 1979, BIOL PSYCHIAT, V14, P791; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; van der Flier WM, 2004, J NEUROL, V251, P671, DOI 10.1007/s00415-004-0390-7; WANG PJ, IN PRESS NEUROBIOLOG; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Whitworth AB, 2005, PSYCHIAT RES-NEUROIM, V140, P225, DOI 10.1016/j.pscychresns.2005.07.006; Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x; Wolf H, 2003, ACTA NEUROL SCAND, V107, P52, DOI 10.1034/j.1600-0404.107.s179.10.x; Xu Y, 2000, NEUROLOGY, V54, P1760, DOI 10.1212/WNL.54.9.1760; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; Zahajszky J, 2001, SCHIZOPHR RES, V47, P87, DOI 10.1016/S0920-9964(00)00051-7	52	76	78	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927			PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	OCT 30	2006	147	2-3					93	103		10.1016/j.pscychresns.2006.01.015			11	Clinical Neurology; Neuroimaging; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	095RX	WOS:000241326800001	16920336				2022-02-06	
J	Babikian, T; Freier, MC; Ashwal, S; Riggs, ML; Burley, T; Holshouser, BA				Babikian, Talin; Freier, M. Catherin; Ashwal, Stephen; Riggs, Matt L.; Burley, Todd; Holshouser, Barbara A.			MR spectroscopy: Predicting long-term neuropsychological outcome following pediatric TBI	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						MR spectroscopy; neuroimaging; neuropsychology; pediatrics; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PROTON-MAGNETIC-RESONANCE; CLOSED-HEAD INJURY; EXECUTIVE FUNCTION; N-ACETYLASPARTATE; AXONAL INJURY; CHILDREN; CHILDHOOD; SEVERITY; MEMORY	Purpose: To identify useful acute indicators of long-term neurocognitive outcome beyond clinical variables for children and adolescents treated for a traumatic brain injury (TBI). Materials and Methods: The efficacy of magnetic resonance spectroscopy (MRS) acquired 6-4 days after TBI in 20 children/ adolescents in predicting intellectual and neuropsychological functioning one to four years post injury was assessed. Short echo-time single voxel MRS (SVS) from normal-appearing brain was compared to intermediate echo-time multivoxel MR spectroscopic imaging (MRSI) from normal-appearing and visibly-injured brain acquired through the level of the corpus callosum (CC). Results: N-acetyl aspartate (NAA) was moderate to strongly correlated with cognitive scores. Mean NAA/creatine (Cre) from MRSI alone explained over 40% of the variance in cognitive scores and 18% of the variance above and beyond demographic and clinical variables alone. Mild to moderate associations were noted between SVS metabolites (glutamate/glutamine [Glx] and myoinositol [ml]) and cognitive scores, with no such associations apparent for choline (Cho) or Cre. Exploratory analyses revealed trends for regional neuroimaging data and specific cognitive abilities. Conclusion: Acute MR spectroscopy of the pediatric brain injury patient improves prognostic ability and may provide valuable information for early treatment and intervention planning.	Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Sch Med, Los Angeles, CA 90024 USA; Loma Linda Univ, Dept Psychol, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Pediat, Sch Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Radiol, Sch Med, Loma Linda, CA 92350 USA; Portland State Univ, Dept Quantitat Psychol, Portland, OR 97207 USA		Babikian, T (corresponding author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Sch Med, 760 Westwood Pl,Room 58-217, Los Angeles, CA 90024 USA.	tbabikian@rnednet.ucla.edu					Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/0897715042441756; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Chapman SB, 2001, J HEAD TRAUMA REHAB, V16, P441, DOI 10.1097/00001199-200110000-00004; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; Dennis M, 2004, DEV NEUROPSYCHOL, V25, P1, DOI 10.1207/s15326942dn2501&2_1; Duval J, 2002, BRAIN COGNITION, V48, P337, DOI 10.1006/brcg.2001.1373; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; GILLES EE, 1999, PEDIAT NEUROLOGY PRI, P898; Hanten G, 2004, DEV NEUROPSYCHOL, V25, P85, DOI 10.1207/s15326942dn2501&2_6; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Laurent-Vannier A, 2000, CHILD NERV SYST, V16, P760, DOI 10.1007/s003810000349; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	41	76	78	0	5	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	1053-1807			J MAGN RESON IMAGING	J. Magn. Reson. Imaging	OCT	2006	24	4					801	811		10.1002/jmri.20696			11	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Radiology, Nuclear Medicine & Medical Imaging	089LL	WOS:000240882000010	16941608				2022-02-06	
J	Lampert, A; Hains, BC; Waxman, SG				Lampert, Angelika; Hains, Bryan C.; Waxman, Stephen G.			Upregulation of persistent and ramp sodium current in dorsal horn neurons after spinal cord injury	EXPERIMENTAL BRAIN RESEARCH			English	Article						patch-clamp; sodium channel; pain; cell dissociation	CHANNEL MESSENGER-RNAS; SENSORY NEURONS; NERVE INJURY; CENTRAL PAIN; RAT-BRAIN; EXPRESSION; HEMISECTION; MECHANISMS; HYPEREXCITABILITY; DEPOLARIZATION	Traumatic spinal cord injury (SCI) results not only in motor impairment, but also in chronic central neuropathic pain, which often is refractory to conventional treatment approaches. Upregulated expression of sodium channel Nav1.3 has been observed within the spinal dorsal horn neurons after SCI, and appears to contribute to neuronal hyperresponsiveness and pain-related behaviors. In this study we characterized the changes in sodium current properties within dorsal horn neurons after contusive SCI. Four weeks after adult male Sprague-Dawley rats underwent T9 spinal cord contusion injury, when behavioral nociceptive thresholds were decreased to both mechanical and thermal stimuli, whole-cell patch-clamp recordings were performed on acutely dissociated lumbar dorsal horn neurons. The cells demonstrated characteristic fast-activating and fast-inactivating sodium currents. SCI led to a shift of the steady-state activation and inactivation of the sodium current towards more depolarized potentials. The shifted steady-state inactivation shows similarities to that obtained from axotomized dorsal root ganglions, which were shown to upregulate Nav1.3. Small slow depolarizations below action potential threshold produced ramp currents, which were markedly enhanced by SCI (from 182 +/- 41 to 338 +/- 55 pA). The density of the noninactivating persistent sodium current was also significantly enhanced in neurons from SCI animals (from 17.4 +/- 3.2 to 27.7 +/- 4.4 pA/pF at 50-70 ms of depolarization). The increased persistent sodium current and ramp current, which are consistent with upregulation of Nav1.3 within dorsal horn neurons, suggest a basis for the hyperresponsiveness of these neurons following SCI.	Yale Univ, Sch Med, Ctr Neurosci & Regenerat Res, New Haven, CT 06510 USA; VA Connecticut Healthcare Syst, Rehabil Res Ctr, West Haven, CT 06516 USA		Waxman, SG (corresponding author), Yale Univ, Sch Med, Ctr Neurosci & Regenerat Res, 333 Cedar St,LCI-707, New Haven, CT 06510 USA.	stephen.waxman@yale.edu	Waxman, Stephen/Z-2507-2019; Lampert, Angelika/F-7198-2010	Waxman, Stephen/0000-0001-5718-7177; Lampert, Angelika/0000-0001-6319-6272	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 F32 NS046919-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS046919] Funding Source: NIH RePORTER		Azouz R, 1996, J PHYSIOL-LONDON, V492, P211, DOI 10.1113/jphysiol.1996.sp021302; BECKH S, 1989, EMBO J, V8, P3611, DOI 10.1002/j.1460-2075.1989.tb08534.x; Black JA, 1999, J NEUROPHYSIOL, V82, P2776, DOI 10.1152/jn.1999.82.5.2776; BRYSCH W, 1991, EXP BRAIN RES, V86, P562; Christensen MD, 1997, J NEUROTRAUM, V14, P517, DOI 10.1089/neu.1997.14.517; Cummins TR, 1997, J NEUROSCI, V17, P3503; Cummins TR, 2001, J NEUROSCI, V21, P5952, DOI 10.1523/JNEUROSCI.21-16-05952.2001; Drew GM, 2004, PAIN, V109, P379, DOI 10.1016/j.pain.2004.02.007; Felts PA, 1997, MOL BRAIN RES, V45, P71, DOI 10.1016/S0169-328X(96)00241-0; FRANCESCHETTI S, 1995, BRAIN RES, V696, P127, DOI 10.1016/0006-8993(95)00807-3; FURUYAMA T, 1993, MOL BRAIN RES, V17, P169, DOI 10.1016/0169-328X(93)90087-6; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hains BC, 2003, J NEUROSCI, V23, P8881; Hains BC, 2003, BRAIN RES, V970, P238, DOI 10.1016/S0006-8993(03)02347-3; Hains BC, 2003, NEUROSCIENCE, V116, P1097, DOI 10.1016/S0306-4522(02)00729-7; Hains BC, 2002, NEUROSCI LETT, V320, P125, DOI 10.1016/S0304-3940(02)00026-5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KAY AR, 1986, J NEUROSCI METH, V16, P227, DOI 10.1016/0165-0270(86)90040-3; LOESER JD, 1968, J NEUROSURG, V29, P48, DOI 10.3171/jns.1968.29.1.0048; Pennartz CMA, 1997, J NEUROPHYSIOL, V78, P1811, DOI 10.1152/jn.1997.78.4.1811; Prescott SA, 2005, J NEUROSCI, V25, P4743, DOI 10.1523/JNEUROSCI.0356-05.2005; Safronov BV, 1999, J PHYSIOL-LONDON, V514, P729, DOI 10.1111/j.1469-7793.1999.729ad.x; Taddese A, 2002, NEURON, V33, P587, DOI 10.1016/S0896-6273(02)00574-3; Vreugdenhil M, 2004, EUR J NEUROSCI, V19, P2769, DOI 10.1111/j.1460-9568.2004.03400.x; Waxman SG, 2006, TRENDS NEUROSCI, V29, P207, DOI 10.1016/j.tins.2006.02.003; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466, DOI 10.1152/jn.1994.72.1.466; Waxman SG, 2000, PHILOS T R SOC B, V355, P199, DOI 10.1098/rstb.2000.0559; Wiesenfeld-Hallin Z, 1997, BEHAV BRAIN SCI, V20, P420, DOI 10.1017/S0140525X97261480	28	76	77	0	5	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0014-4819			EXP BRAIN RES	Exp. Brain Res.	OCT	2006	174	4					660	666		10.1007/s00221-006-0511-x			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	090VN	WOS:000240980800008	16718433				2022-02-06	
J	Korner-Bitensky, N; Bitensky, J; Sofer, S; Man-Son-Hing, M; Gelinas, I				Korner-Bitensky, Nicol; Bitensky, Jamie; Sofer, Susan; Man-Son-Hing, Malcolm; Gelinas, Isabelle			Driving evaluation practices of clinicians working in the United States and Canada	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article							RISK; COMPETENCE; DEMENTIA; CRASH	OBJECTIVE. To determine off-road and on-road driving evaluation practices of clinicians in the United States and Canada who assess individuals with disabilities for fitness to drive. PARTICIPANTS. Participants were 114 clinician attendees at the 2003 annual Association of Driver Educators for the Disabled with driving assessment experience ranging from 1 month to 25 years. MEASURES. Information was elicited regarding the clinician, clientele, referral practices, and off-road and on-road driving evaluation practices and retraining practices using a self-administered questionnaire. RESULTS. Participants were largely occupational therapists (68%) who worked in 42 different states and provinces. The most prevalent clientele-were persons with traumatic brain injury (97%) and stroke (96%). Testing times greater than 60 min were common for both the off-road (61%) and on-road (49%) evaluations. Commonly performed off-road assessments included the Brake Reaction Timer; Trail Making Test, Parts A and B; and the Motor Free Visual Perception Test, used by 73%, 72%, and 66%, respectively; comprehensive computer-based driving evaluation was rare. Sixty-one percent indicated that all clients underwent on-road evaluation regardless of the off-road results. Finally, 78% used a standard driving route, whereas 24% used a scoring system to evaluate on-road driving. CONCLUSION. Driving assessment in Canada and the United States is multidimensional and time-intensive. Although the domains being assessed are similar across clincians, specific off-road and on-road assessment practices vary greatly. The majority use nonstandardized on-road assessments.	McGill Univ, Fac Med, Sch Phys & Occupat Therapy, Montreal, PQ H3G 1Y5, Canada; McGill Univ, Ctr Hlth, Montreal, PQ, Canada; Autonomy Community Therapy Inc, Montreal, PQ, Canada; Univ Ottawa, Dept Med, Elisabeth Bruyere Res Inst, Geriatr Assessment Unit, Ottawa, ON, Canada		Korner-Bitensky, N (corresponding author), McGill Univ, Fac Med, Sch Phys & Occupat Therapy, 3630 Promenade Sir William Osler, Montreal, PQ H3G 1Y5, Canada.	nicol.korner-bitensky@mcgill.ca					Akinwuntan AE, 2002, ARCH PHYS MED REHAB, V83, P334, DOI 10.1053/apmr.2002.29662; *AM MED ASS, 2003, PHYS GUID ASS COUNS, pCH3; Ball K., 1993, J AM OPTOM ASSOC, V63, P71; Brashear A, 1998, AM J ALZHEIMERS DIS, V13, P131; CARR D, 1992, J AM GERIATR SOC, V40, P567, DOI 10.1111/j.1532-5415.1992.tb02104.x; Colarusso RP, 1972, MOTOR FREE VISUAL PE; Colarusso RP., 1996, MOTOR FREE VISUAL PE; Dobbs AR, 1998, ACCIDENT ANAL PREV, V30, P363, DOI 10.1016/S0001-4575(97)00110-3; Dobbs AR, 1997, ALZ DIS ASSOC DIS, V11, P8, DOI 10.1097/00002093-199706001-00003; Dubinsky RM, 2000, NEUROLOGY, V54, P2205, DOI 10.1212/WNL.54.12.2205; Engum E. S., 1988, COGNITIVE REHABILITA, V6, P34; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOWLER FJ, 1988, SURVEY RES METHODS; FREY JH, 1983, SURVEY RES TELEPHONE, P27; Goode KT, 1998, J CLIN PSYCHOL MED S, V5, P425, DOI 10.1023/A:1026206927686; GORDON W, 1984, SINGLE LETTER CANCEL; Harris M, 2000, ADV PSYCHIAT TREAT, V6, P261; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Hunt LA, 1997, ARCH NEUROL-CHICAGO, V54, P707, DOI 10.1001/archneur.1997.00550180029008; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; Korner-Bitensky NA, 1998, AM J OCCUP THER, V52, P916, DOI 10.5014/ajot.52.10.916; KORNERBITENSKY N, 2005, GERIATRICS, V23, P123; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; McGwin G, 2000, AM J EPIDEMIOL, V152, P424, DOI 10.1093/aje/152.5.424; MONEY J, 1976, STANDARDIZED ROAD MA; ODENHEIMER GL, 1994, J GERONTOL, V49, pM153, DOI 10.1093/geronj/49.4.M153; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; Reitan R, 1986, TRAIL MAKING TEST MA; Sekuler AB, 2000, EXP AGING RES, V26, P103, DOI 10.1080/036107300243588; Shawaryn MA, 2002, ARCH PHYS MED REHAB, V83, P1123, DOI 10.1053/apmr.2002.33730; Smith A., 1968, LEARN DISORD, V3, P83, DOI 10.1080/13803390591004428; STEPHENS B, 2004, SUMMARY REPORT INT O; Streiner D.L., 1989, HLTH MEASUREMENT SCA; Sudman S., 1982, ASKING QUESTIONS PRA; Wiseman EJ, 1996, GERIATRICS, V51, P36	35	76	77	0	14	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	JUL-AUG	2006	60	4					428	434		10.5014/ajot.60.4.428			7	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	065RN	WOS:000239177100009	16915873				2022-02-06	
J	Eriksson, G; Tham, K; Borg, J				Eriksson, G; Tham, K; Borg, J			Occupational gaps in everyday life 1-4 years after acquired brain injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						activities of daily living; rehabilitation; occupational therapy; brain injuries; cerebrovascular accident	REHABILITATION; STROKE	Objective: To explore adaptation, by examining the occupational gaps occurring between what individuals want to do and what they actually do in terms of their everyday activities before and after brain injury. In addition, the relationships between occupational gaps and impairment/activity limitations and the time lapse since the brain injury were explored. Design: A cross-sectional study. Subjects: A total of 187 persons, affected by traumatic brain injury or subarachnoid haemorrhage 1 - 4 years previously. Methods: A postal questionnaire encompassing questions concerning gaps in the performance of activities in everyday life before and after the brain injury and perceived impairment/activity limitations. Results: The numbers of occupational gaps increased after the injury, with the number of gaps having increased from 46% to 71%. The number of occupational gaps was significantly related to executive impairment/activity limitations, and motor impairment/activity limitations and other somatic impairments, such as headache, also had an impact. The time lapse since the brain injury had no significant effect on the number of occupational gaps. Conclusion: The results suggests that there is a need for adaptation in everyday activities, even several years after a brain injury, which indicates that follow-up and access to individualized rehabilitation interventions in the long-term are required.	Karolinska Inst, Div Occupat Therapy, Neurotec Dept, SE-14183 Huddinge, Sweden; Uppsala Univ, Dept Neurosci Rehabil Med, Uppsala, Sweden; Univ Uppsala Hosp, Akad Sjukhuset, Dept Occupat Therapy, Uppsala, Sweden		Eriksson, G (corresponding author), Karolinska Inst, Div Occupat Therapy, Neurotec Dept, SE-14183 Huddinge, Sweden.	gunilla.eriksson@ki.se	; Tham, Kerstin/T-3964-2018	Borg, Jorgen/0000-0002-2372-7478; Tham, Kerstin/0000-0001-7025-5226			*AM OCC THER ASS, 1995, AM J OCCUP THER, V10, P1015; BAUM CM, 1993, THESIS WASHINGTON U; BECKER G, 1993, GERONTOLOGIST, V33, P148, DOI 10.1093/geront/33.2.148; BRANHOLM IB, 1994, DISABIL REHABIL, V16, P205; Carter BS, 2000, NEUROSURGERY, V46, P1326, DOI 10.1097/00006123-200006000-00008; Carter J, 1997, CLIN REHABIL, V11, P131, DOI 10.1177/026921559701100206; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Eriksson Gunilla, 2005, Scand J Occup Ther, V12, P40, DOI 10.1080/11038120510027630; Fisher AG, 1998, AM J OCCUP THER, V52, P509, DOI 10.5014/ajot.52.7.509; Fugl-Meye KS., 1991, CLIN REHABIL, V5, P25, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105]; Hachisuka K, 1997, CLIN REHABIL, V11, P28, DOI 10.1177/026921559701100105; Jonsson ALT, 1999, AM J OCCUP THER, V53, P353; Karlsson G, 1993, PSYCHOL QUALITATIVE; KATZ N, 2005, COGNITION OCCUPATION, P3; Kielhofner G, 2002, MODEL HUMAN OCCUPATI; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McColl MA, 2002, AM J OCCUP THER, V56, P350, DOI 10.5014/ajot.56.3.350; Melin R, 2003, J REHABIL MED, V35, P84, DOI 10.1080/16501970306119; Palmer S, 2003, REHABIL PSYCHOL, V48, P255, DOI 10.1037/0090-5550.48.4.255; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; SCHULTZ S, 1992, AM J OCCUP THER, V46, P917, DOI 10.5014/ajot.46.10.917; Spencer JC, 1996, AM J OCCUP THER, V50, P526, DOI 10.5014/ajot.50.7.526; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Townsend E.A., 2002, ENABLING OCCUPATION; Von Koch L, 1998, DISABIL REHABIL, V20, P367, DOI 10.3109/09638289809166095; World Health Organization, 2007, INT CLASS FUNCT DIS; Wressle E, 2002, J REHABIL MED, V34, P5, DOI 10.1080/165019702317242640	28	76	77	0	8	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAY	2006	38	3					159	165		10.1080/16501970500415322			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	039QS	WOS:000237321900003	16702082	gold			2022-02-06	
J	Statler, KD; Alexander, H; Vayni, V; Holubkov, R; Dixon, CE; Clark, RSB; Jenkins, L; Kochanek, PM				Statler, KD; Alexander, H; Vayni, V; Holubkov, R; Dixon, CE; Clark, RSB; Jenkins, L; Kochanek, PM			Isoflurane exerts neuroprotective actions at or near the time of severe traumatic brain injury	BRAIN RESEARCH			English	Article						anaesthesia; traumatic brain injury; fentanyl; rat; narcotic; hippocampus; head injury; contusion; controlled cortical impact	CONTROLLED CORTICAL IMPACT; CEREBRAL-BLOOD-FLOW; ENDOGENOUS OPIOIDS; FENTANYL; ANESTHESIA; RATS; AUTOREGULATION; ISCHEMIA; DEFICITS; MICE	Isoflurane improves outcome vs. fentanyl anesthesia, in experimental traumatic brain injury (TBI). We assessed the temporal profile of isoflurane neuroprotection and tested whether isoflurane confers benefit at the time of TBI. Adult, male rats were randomized to isoflurane (1%) or fentanyl (10 mcg/kg iv bolus then 50 mcg/kg/h) for 30 min pre-TBI. Anesthesia was discontinued, rats recovered to tail pinch, and TBI was delivered by controlled cortical impact. Immediately post-TBI, rats were randomized to 1 h of isoflurane, fentanyl, or no additional anesthesia, creating 6 anesthetic groups (isoflurane:isoflurane, isoflurane:fentanyl, isoflurane: none, fentanyl:isoflurane, fentanyl:fentanyl, fentanyl:none). Beam balance, beam walking, and Morris water maze (MWM) performances were assessed over post-trauma d1-20. Contusion volume and hippocampal survival were assessed on d21. Rats receiving isoflurane pre- and post-TBI exhibited better beam walking and MWM performances than rats treated with fentanyl pre- and any treatment post-TBI. All rats pretreated with isoflurane had better CA3 neuronal survival than rats receiving fentanyl pre- and post-TBI. In rats pretreated with fentanyl, post-traumatic isoflurane failed to affect function but improved CA3 neuronal survival vs. rats given fentanyl pre- and post-TBI. Posttraumatic isoflurane did not alter histopathological outcomes in rats pretreated with isoflurane. Rats receiving fentanyl pre- and post-TBI had the worst CA1 neuronal survival of all groups. our data support isoflurane neuroprotection, even when used at the lowest feasible level before TBI (i.e., when discontinued with recovery to tail pinch immediately before injury). Investigators using isoflurane must consider its beneficial effects in the design and interpretation of experimental TBI research. (c) 2006 Elsevier B.V. All rights reserved.	Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84158 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA		Statler, KD (corresponding author), Univ Utah, Sch Med, Dept Pediat, POB 581289, Salt Lake City, UT 84158 USA.	kim.statler@hsc.utah.edu; alexanderHL@anes.upmc.edu; vagnva@anes.upmc.edu; rholubkov@hrc.utah.edu; dixonec@upmc.edu; clarkrs@ccm.upmc.edu; ljenkins@pitt.edu; kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P50NS030318, P20NS030318] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32-HD40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; Bickler PE, 2003, ANESTH ANALG, V97, P564, DOI 10.1213/01.ANE.0000068880.82739.7B; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Elsersy H, 2004, ANESTHESIOLOGY, V100, P1160, DOI 10.1097/00000542-200405000-00018; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HAYES RL, 1990, J NEUROSURG, V72, P252, DOI 10.3171/jns.1990.72.2.0252; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; HERNANDEZ MJ, 1978, STROKE, V9, P150, DOI 10.1161/01.STR.9.2.150; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kawaguchi M, 2004, ANESTH ANALG, V98, P798; Kawaguchi M, 2000, ANESTHESIOLOGY, V92, P1335, DOI 10.1097/00000542-200005000-00023; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kofke WA, 1996, ANESTH ANALG, V83, P141, DOI 10.1097/00000539-199607000-00025; Kozlowski DA, 2004, J NEUROTRAUM, V21, P513, DOI 10.1089/089771504774129856; Lenz C, 1998, ANESTHESIOLOGY, V89, P1480, DOI 10.1097/00000542-199812000-00026; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565, DOI 10.1152/ajpendo.1987.253.5.E565; Miura Y, 1999, ANESTH ANALG, V88, P787, DOI 10.1097/00000539-199904000-00020; Nikolaishvili L S, 2004, Neurosci Behav Physiol, V34, P467, DOI 10.1023/B:NEAB.0000022631.46176.6b; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PATEL PM, 1993, J CEREB BLOOD FLOW M, pS685; SAFO Y, 1985, ACTA ANAESTH SCAND, V29, P594, DOI 10.1111/j.1399-6576.1985.tb02261.x; Soonthon-Brant V, 1999, ANESTH ANALG, V88, P49, DOI 10.1097/00000539-199901000-00010; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Statler KD, 2003, BRAIN RES, V994, P37, DOI 10.1016/j.brainres.2003.09.042; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002	31	76	77	1	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 3	2006	1076						216	224		10.1016/j.brainres.2005.12.106			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	031GL	WOS:000236692500025	16473332				2022-02-06	
J	Berger, RP; Adelson, PD; Richichi, R; Kochanek, PM				Berger, Rachel Pardes; Adelson, P. David; Richichi, Rudolph; Kochanek, Patrick M.			Serum biomarkers after traumatic and hypoxemic brain injuries: Insight into the biochemical response of the pediatric brain to inflicted brain injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						pediatric traumatic brain injury; serum biomarkers; child abuse; neuron-specific enolase; S100B; myelin basic protein	NEURON-SPECIFIC ENOLASE; MYELIN BASIC-PROTEIN; CEREBROSPINAL-FLUID; HEAD-INJURY; NONACCIDENTAL INJURY; PROGNOSTIC MARKER; QUINOLINIC ACID; YOUNG-CHILDREN; CYTOCHROME-C; INFANTS	Inflicted traumatic brain injury (iTBI) involves a combination of mechanical trauma and hypoxemia. Serum biomarker concentrations may provide objective information about their relative importance to the pathophysiology of iTBI. We compared the time course of neuron-specific enolase (NSE), S100B and myelin basic protein after pediatric hypoxic-ischemic brain injury, iTBI and noninflicted TBI (nTBI). The time to reach peak concentrations of all three biomarkers was shorter after nTBI. Initial and peak S100B, initial and peak myelin basic protein and peak NSE concentrations were no different between the three groups. Initial NSE concentration was highest after nTBI. These results suggest that the biochemical response of the brain to iTBI is distinct from the response to nTBI and shares temporal similarities with hypoxic-ischemic brain injury. This may have important implications for the treatment and prognosis of children with iTBI. Copyright (c) 2006 S. Karger AG, Basel.	Childrens Hosp Pittsburgh, Dept Pediat, Child Advocacy Ctr, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA; Stat Anal & Measurement Consultants Inc, Lanexa, VA USA		Berger, RP (corresponding author), 3705 5th Ave, Pittsburgh, PA 15213 USA.	rberger@pitt.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; 	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD43843-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000084] Funding Source: NIH RePORTER		Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Beers SR, 2004, PEDIATR RES, V55, p70A; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Buki A, 2000, J NEUROSCI, V20, P2825; Carty H, 2002, EUR RADIOL, V12, P2919, DOI 10.1007/s00330-002-1436-9; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; LEROUX PD, 1991, CHILD NERV SYST, V7, P34, DOI 10.1007/BF00263831; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; MUKHERJEE A, 1985, CLIN BIOCHEM, V18, P304, DOI 10.1016/S0009-9120(85)80037-0; Mussack T, 2001, WORLD J SURG, V25, P539, DOI 10.1007/s002680020082; Nagdyman N, 2001, PEDIATR RES, V49, P502, DOI 10.1203/00006450-200104000-00011; NOSEWORTHY TW, 1985, CRIT CARE MED, V13, P743, DOI 10.1097/00003246-198509000-00010; Rao P, 1999, CLIN RADIOL, V54, P495, DOI 10.1016/S0009-9260(99)90845-0; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Runyan CW, 2005, AM J PREV MED, V28, P73, DOI 10.1016/j.amepre.2004.09.010; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Schnitzer PG, 2005, J PEDIATR PSYCHOL, V30, P413, DOI 10.1093/jpepsy/jsi065; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; Spack L, 1997, PEDIATR EMERG CARE, V13, P98, DOI 10.1097/00006565-199704000-00004; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; STARLING SP, 1995, PEDIATRICS, V95, P259; Tekgul H, 2004, PEDIATR NEUROL, V31, P326, DOI 10.1016/j.pediatrneurol.2004.05.004; THOMAS DGT, 1977, LANCET, V1, P113; THOMAS DGT, 1984, J NEUROL NEUROSUR PS, V47, P173, DOI 10.1136/jnnp.47.2.173; Thorngren-Jerneck K, 2004, PEDIATR RES, V55, P406, DOI 10.1203/01.PDR.0000106806.75086.D3	49	76	84	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					327	335		10.1159/000094158			9	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600009	16943655				2022-02-06	
J	Wood, RL; Rutterford, NA				Wood, RL; Rutterford, NA			Psychosocial adjustment 17 years after severe brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; RATING-SCALE; DEPRESSION	Objectives: To examine very long term psychosocial outcome following severe brain injury in a large cohort, with the aim of evaluating Thomsen's observation that even after very serious head trauma the long term outcome in some patients is reasonably good. Methods: The cohort consisted of 80 patients who had suffered severe brain injury evaluated at a mean time of 17 years post injury ( range 10 - 32 years). Information regarding employment status and relationship status was obtained during clinical interview. Psychosocial outcome measures included the Supervision Rating Scale, Satisfaction with Life Scale, Hospital Anxiety and Depression Scale ( HADS), Patient Competency Rating Scale, and Community Integration Questionnaire. Results: Of the cohort, 72.0% lived independently, 28.7% were in full time employment, and 60.0% were married or cohabiting. The mean rating of life satisfaction was "slightly dissatisfied'', but no serious emotional problems were evident from self report ratings on the HADS. Mean functional competency ratings and community integration levels were just below those reported for non-disabled patients. Conclusions: Results indicate that although long term psychosocial functioning in patients with severe head injury remains compromised, long term adjustment may be better than expected from data reported by studies assessing psychosocial outcome at earlier stages of recovery.	Univ Coll Swansea, Dept Psychol, Swansea SA2 8PP, W Glam, Wales		Wood, RL (corresponding author), Univ Coll Swansea, Dept Psychol, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk					Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Brzuzy S, 1997, SOC WORK HEALTH CARE, V26, P77, DOI 10.1300/J010v26n01_05; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; JACOBS HE, 1989, TRAUMATIC BRAIN INJU, P287; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; TEASDALE GM, 2004448 CZH; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, BRAIN INJURY REHABIL, P355; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	20	76	77	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	2006	77	1					71	73		10.1136/jnnp.2005.065540			3	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	997EJ	WOS:000234227500017	16361596	Green Published, Bronze			2022-02-06	
J	Sarajuuri, JM; Kaipio, ML; Koskinen, SK; Niemela, MR; Servo, AR; Vilkki, JS				Sarajuuri, JM; Kaipio, ML; Koskinen, SK; Niemela, MR; Servo, AR; Vilkki, JS			Outcome of a comprehensive neurorehabilitation program for patients with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	European Platform for Vocational Rehabilitation	FEB 23-24, 2001	Birmingham, ENGLAND			brain injuries; neuropsychology; outcome assessment (health care); rehabilitation	TERM-FOLLOW-UP; NEUROPSYCHOLOGICAL REHABILITATION; COGNITIVE REHABILITATION; COMMUNITY INTEGRATION; SUPPORTED EMPLOYMENT; HEAD-INJURY; RETURN; WORK; PREDICTION; COST	Objective: To evaluate the outcome of a comprehensive neurorehabilitation program compared with that of conventional clinical care and rehabilitation for patients with traumatic brain injury (TBI). Design: Nonrandomized, controlled trial with a 2-year follow-up. Setting: Nationwide rehabilitation center and level I trauma center, both in Finland. Participants: We studied 19 consecutive adults with a significant TBI who underwent a comprehensive neurorehabilitation program and 20 control patients who received conventional rehabilitation referred by physicians in the general health care system. The outcome of the control patients was not known before the selection. The groups were similar in age, sex, education, injury severity (assessed on the Glasgow Coma Scale, radiologic and neuropsychologic findings, neurosurgical interventions), time from the injury, and preinjury employment status. Interventions: A postacute, intensive, interdisciplinary, 6-week rehabilitation program for TBI patients who are considered to have adequate potential to achieve productivity by this means; focus on neuropsychologic rehabilitation and psychotherapy with vocational interventions and follow-up support. Main Outcome Measure: Status of productivity, judged as productive (defined as working, studying, or participating in volunteer activities) or nonproductive, evaluated on questionnaires filled in by patients and their significant others at the time of follow-up evaluation. Results: At follow-up, 89% of the treated patients were productive compared with 55% of the controls. The rehabilitation program was significantly predictive of the productive status at follow-up (odds ratio=6.96; 95% confidence interval, 1.26-38.44; P=.017). Other factors did not explain the better productivity of the treatment group. Two neuropsychologist-evaluators, who were blind to the rehabilitation history of patients and to each other's evaluations, were perfectly consistent in their classification of patients' productivity statuses. Conclusions: The findings support the proposition that comprehensive neuropsychologically oriented rehabilitation programs can improve psychosocial functioning in terms of productivity in postacute patients with moderate to severe TBI. Additional larger controlled studies are needed to establish the efficacy of TBI rehabilitation interventions.	Kapyla Rehabil Ctr, Dept Clin Neuropsychol, Finnish Assoc People Mobil Disabil, FIN-00251 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Neurosurg, Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Radiol, Helsinki, Finland; Univ Helsinki, Dept Psychol, SF-00100 Helsinki, Finland		Sarajuuri, JM (corresponding author), Kapyla Rehabil Ctr, Dept Clin Neuropsychol, Finnish Assoc People Mobil Disabil, Nordenskioldinkatu 18 B,POB 103, FIN-00251 Helsinki, Finland.	jaana.sarajuuri@invalidiliitto.fi	Niemela, Mika R/F-2539-2015; Sarajuuri, Jaana/AAD-8665-2019	Niemela, Mika R/0000-0003-1526-0684; Sarajuuri, Jaana/0000-0002-6432-0295; Koskinen, Sanna/0000-0002-3453-5084			Armitage P, 2002, STAT METHODS MED RES, V4th; Ashley MJ, 1997, BRAIN INJURY, V11, P677; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CHRISTENSEN AL, 1992, ACTA NEUROL SCAND, V85, P32; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EAMES P, 1989, MODELS BRAIN INJURY, P31; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Jones M L, 1992, J Insur Med, V24, P186; Kaipio M.-L., 2000, INT HDB NEUROPSYCHOL, P247; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; MACKENZIE EJ, 1988, JAMA-J AM MED ASSOC, V260, P3290, DOI 10.1001/jama.260.22.3290; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano G.P., 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199112000-00004, DOI 10.1097/00001199-199112000-00004]; Prigatano GP, 2000, JAMA-J AM MED ASSOC, V284, P1783, DOI 10.1001/jama.284.14.1783; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PRIGATANO GP, 1994, J HEAD TRAUMA REHAB, V9, P91, DOI DOI 10.1097/00001199-199403000-00011; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746; [No title captured]	42	76	77	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2005	86	12					2296	2302		10.1016/j.apmr.2005.06.018			7	Rehabilitation; Sport Sciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	995VE	WOS:000234131700010	16344026				2022-02-06	
J	Besson, VC; Chen, XR; Plotkine, M; Marchand-Verrecchia, C				Besson, VC; Chen, XR; Plotkine, M; Marchand-Verrecchia, C			Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						cerebral oedema; fenofibrate; inflammation; neuroprotection; peroxisome proliferator-activated receptor alpha; traumatic brain injury	PPAR-ALPHA; KAPPA-B; INFLAMMATION; GAMMA; RATS; METABOLISM; EXPRESSION; RILUZOLE; LIGANDS; PATHWAY	Peroxisome proliferator-activated receptor alpha (PPAR alpha) has been demonstrated to reduce inflammation in various inflammatory diseases. As traumatic brain injury (TBI) caused a neuroinflammatory response, we examined the effect of fenofibrate, a PPAR alpha agonist, on the post-traumatic consequences caused by lateral fluid percussion of brain in rats. The effects of fenofibrate (50 and 100 mg/kg) were evaluated on the consequences of TBI in the early phase (6 and 24 h) and the late phase (7 days) after TBI. Neurological deficit, brain lesion, cerebral oedema and ICAM-1 expression were evaluated. Treatment with fenofibrate (given p.o. at 1 and 6h after TBI) decreases the neurological deficit induced by TBI at 24 h. Furthermore, fenofibrate reduces brain oedema and ICAM-1 expression at 24 h post-TBI. Rats given fenofibrate at 1, 6, 24, 48 and 72 It after TBI show neurological recovery associated with a reduction of the brain lesion at 7 days post-TBI. The present data represents the first demonstration that fenofibrate, a PPAR alpha agonist, exerts neuroprotective effects in TBI. The activation of receptor PPAR alpha could be beneficial by counteracting the deleterious inflammatory response following TBI. This suggests that PPAR alpha activation could be a new and promising therapeutic strategy for the treatment of brain trauma. (C) 2005 Elsevier Ireland Ltd. All rights reserved.	Univ Paris 05, Fac Pharm, Lab Pharmacol Circulat Cerebrale, UPRES EA 2510, F-75006 Paris, France		Marchand-Verrecchia, C (corresponding author), Univ Paris 05, Fac Pharm, Lab Pharmacol Circulat Cerebrale, UPRES EA 2510, 4 Ave Observ, F-75006 Paris, France.	catherine.marchand@univ-paris5.fr	MARCHAND-LEROUX, Catherine/L-7453-2017; BESSON, VALERIE/AAZ-9989-2020; besson, valerie C/L-7388-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; BESSON, VALERIE/0000-0002-1491-2380; besson, valerie C/0000-0002-1491-2380			Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brunmair B, 2004, J PHARMACOL EXP THER, V311, P109, DOI 10.1124/jpet.104.068312; Cuzzocrea S, 2004, SHOCK, V22, P340, DOI 10.1097/01.shk.0000136704.26372.2d; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Deplanque D, 2003, J NEUROSCI, V23, P6264; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Diep QN, 2004, J MOL CELL CARDIOL, V36, P295, DOI 10.1016/j.yjmcc.2003.11.004; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; Genovese T, 2005, EXP NEUROL, V194, P267, DOI 10.1016/j.expneurol.2005.03.003; Gervois P, 2004, J BIOL CHEM, V279, P16154, DOI 10.1074/jbc.M400346200; Inoue H, 2003, NEUROSCI LETT, V352, P203, DOI 10.1016/j.neulet.2003.09.001; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Kota BP, 2005, PHARMACOL RES, V51, P85, DOI 10.1016/j.phrs.2004.07.012; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Ogata T, 2004, J AM COLL CARDIOL, V43, P1481, DOI 10.1016/j.jacc.2003.11.043; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Sedova L, 2004, INT J OBESITY, V28, P719, DOI 10.1038/sj.ijo.0802613; Soria A, 2002, J LIPID RES, V43, P74; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160, DOI 10.1002/jlb.67.2.160; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384	31	76	79	1	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	NOV 4	2005	388	1					7	12		10.1016/j.neulet.2005.06.019			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	962OW	WOS:000231743100002	16087294				2022-02-06	
J	Doctor, JN; Castro, J; Temkin, NR; Fraser, RT; Machamer, JE; Dikmen, SS				Doctor, JN; Castro, J; Temkin, NR; Fraser, RT; Machamer, JE; Dikmen, SS			Workers' risk of unemployment after traumatic brain injury: A normed comparison	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						closed head injuries; employment; unemployment; vocational rehabilitation; risk factors; neuropsychology	POSTTRAUMATIC SEIZURES; FOLLOW-UP; RANDOMIZED-TRIAL; ACUTE PREDICTORS; PRACTICAL SCALE; HEAD TRAUMA; EMPLOYMENT; RETURN; REHABILITATION; PREVENTION	We examined, among those persons working preinjury, the risk of unemployment I year after traumatic brain injury (TBI) relative to expected risk of unemployment for the sample under a validated risk-adjusted econometric model of employment in the U.S. population. Results indicate that 42% of TBI cases were unemployed versus 9% expected, relative risk (RR) = 4.5, 95% confidence interval (CI) (4.12, 4.95). The relative risk for unemployment was higher among males, those with higher education, persons with more severe injuries, and more impaired early neuropsychological or functional status. Difference in unemployment rates gave similar results for gender, severity of injury, and early neuropsychological and functional status. However, for education, the excess was smaller among those more highly educated, but the unemployment rate in the more highly educated in the general population was sufficiently small to yield a larger relative risk. In conclusion, after accounting for underlying risk of unemployment in the general population, unemployment is substantially higher after TBI for people who were employed when they were injured. The differential employment status varies depending on demographics, severity of brain injury, early functional outcome, and neurobehavioral indicators. For characteristics such as education, associated with rates of unemployment in the general population, different methods used to compare the rates may yield different results.	Univ Washington, Sch Med, MEBI, Seattle, WA 98115 USA; Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA USA; Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA		Doctor, JN (corresponding author), Univ Washington, Sch Med, MEBI, 1959 NE Pacific St, Seattle, WA 98115 USA.	jdoctor@u.washington.edu					ARMITAGE P, 1971, STAT METHODS MED RES; Army Individual Test Battery, 1944, MAN DIR SCOR; *BUR LAB STAT, 2002, 63RV US DEP LAB BUR; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DIKMEN S, 1980, J NERV MENT DIS, V168, P236, DOI 10.1097/00005053-198004000-00008; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; FRASER RT, 1986, EPILEPSIA, V27, P220, DOI 10.1111/j.1528-1157.1986.tb03532.x; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; JENNETT B, 1975, LANCET, V1, P480; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; Millimet DL, 2003, J ECONOMETRICS, V113, P83, DOI 10.1016/S0304-4076(02)00168-9; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wechsler D., 1955, MANUAL WECHSLER ADUL	24	76	76	1	8	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	OCT	2005	11	6					747	752		10.1017/S1355617705050836			6	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	980NQ	WOS:000233025600010	16248910				2022-02-06	
J	Mansell, J; Tierney, RT; Sitler, MR; Swanik, KA; Stearne, D				Mansell, J; Tierney, RT; Sitler, MR; Swanik, KA; Stearne, D			Resistance training and head-neck segment dynamic stabilization in male and female collegiate soccer players	JOURNAL OF ATHLETIC TRAINING			English	Article						cervical musculature; concussion; head acceleration	TRAUMATIC BRAIN-INJURY; IMPACT FORCES; ACCELERATION; PERFORMANCE; STRENGTH; PROPRIOCEPTION; GENDER; MOTION	Context: Cervical resistance training has been purported to aid in reducing the severity of brain injuries in athletes. Objective: To determine the effect of an 8-week resistance-training program on head-neck segment dynamic stabilization in male and female collegiate soccer players. Design: Pretest and posttest control group design. Setting: University research laboratory and fitness center. Patients or Other Participants: Thirty-six National Collegiate Athletic Association Division I collegiate soccer players (17 men, 19 women). Intervention(s): The resistance training group underwent an 8-week cervical resistance training program that consisted of 3 sets of 10 repetitions of neck flexion and extension at 55% to 70% of their 10-repetition maximum 2 times a week. Participants in the control group performed no cervical resistance exercises. Main Outcome Measure(s): Head-neck segment kinematics and stiffness, electromyographic activity of the upper trapezius and sternocleidomastoid muscles during force application to the head, and neck flexor and extensor isometric strength. Results: No kinematic, electromyographic, or stiffness training effects were seen. The posttest resistance training group isometric neck flexor strength was 15% greater than the pretest measurement. Isometric neck extensor strength in the female resistance training group was 22.5% greater at the posttest than at the pretest. Women's neck girth increased 3.4% over time regardless of training group level. Women exhibited 7% less head-neck segment length and 26% less head-neck segment mass than men. Conclusions: Despite increases in isometric strength and girth, the 8-week isotonic cervical resistance training did not enhance head-neck segment dynamic stabilization during force application in collegiate soccer players. Future researchers should examine the effect of head-neck segment training protocols that include traditional and neuromuscular activities (eg, plyometrics) with the focus of reducing head acceleration on force application.	Temple Univ, Philadelphia, PA 19122 USA; Lincoln Univ, Lincoln, PA USA		Tierney, RT (corresponding author), Temple Univ, 127 Pearson Hall, Philadelphia, PA 19122 USA.	rtierney@temple.edu					Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; BLAND JH, 1996, J MUSCULOSKEL MED, V13, P30; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Broglio SP, 2003, J ATHL TRAINING, V38, P220; Brooks GA, 2000, EXERCISE PHYSL HUMAN; BRUNT D, 1990, ARCH PHYS MED REHAB, V71, P473; Chimera NJ, 2004, J ATHL TRAINING, V39, P24; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Cross KM, 2003, CLIN SPORT MED, V22, P639, DOI 10.1016/S0278-5919(02)00099-6; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DICK RW, 1994, AM SOC TEST MATER, V1229, P13, DOI 10.1520/STP12799S; Garces GL, 2002, MED SCI SPORT EXER, V34, P464, DOI 10.1097/00005768-200203000-00013; Gennarelli T, 1982, HEAD INJURY BASIC CL, V1982, P129; Goodman R., 2000, PHYSIOTHER CAN, V52, P211; Guskiewicz KM, 2002, AM J SPORT MED, V30, P630; Heck RW, 1996, MED SCI SPORT EXER, V28, P877, DOI 10.1097/00005768-199607000-00015; Hewett TE, 1996, AM J SPORT MED, V24, P765, DOI 10.1177/036354659602400611; Ito Y, 1997, EXP BRAIN RES, V117, P266, DOI 10.1007/s002210050221; Jordan A, 1999, SPINE, V24, P1343, DOI 10.1097/00007632-199907010-00012; Kumar S, 2000, ACCIDENT ANAL PREV, V32, P233, DOI 10.1016/S0001-4575(99)00114-1; Maeda Akira, 1994, Annals of Physiological Anthropology, V13, P59; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McNair PJ, 2002, CLIN BIOMECH, V17, P536, DOI 10.1016/S0268-0033(02)00062-1; Morris CE, 1999, AVIAT SPACE ENVIR MD, V70, P851; PLAGENHOEF S, 1983, RES Q EXERCISE SPORT, V54, P169, DOI 10.1080/02701367.1983.10605290; POLLOCK ML, 1993, ARCH PHYS MED REHAB, V74, P1080, DOI 10.1016/0003-9993(93)90065-I; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Randlov A, 1998, CLIN REHABIL, V12, P200, DOI 10.1191/026921598666881319; SCHOR RH, 1988, CONTROL HEAD MOVEMEN, P141; STUMP J, 1993, J MANIP PHYSIOL THER, V16, P155; Swanik CB, 1997, J SPORT REHABIL, V6, P182, DOI 10.1123/jsr.6.2.182; Swanik KA, 2002, J SHOULDER ELB SURG, V11, P579, DOI 10.1067/mse.2002.127303; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Watkins MP., 2015, FDN CLIN RES APPL PR, V3rd	40	76	76	0	34	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2005	40	4					310	319					10	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	996MO	WOS:000234178200010	16404453				2022-02-06	
J	Lipsky, RH; Sparling, MB; Ryan, LM; Xu, K; Salazar, AM; Goldman, D; Warden, DL				Lipsky, RH; Sparling, MB; Ryan, LM; Xu, K; Salazar, AM; Goldman, D; Warden, DL			Association of COMT Val1.58Met genotype with executive functioning following traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CATECHOL-O-METHYLTRANSFERASE; PREFRONTAL FUNCTION; PHARMACOGENETICS; POLYMORPHISM; CORTEX; SCHIZOPHRENIA; PERFORMANCE; DISORDERS; GENE	Catechol-O-methyltransferase (COMT) is thought to functionally modulate dopamine neurons, thus likely influencing frontal-executive functioning. High enzyme activity (COMT Val) and low enzyme activity (COMT Met) are functional polymorphisms resulting from a G to A transition in exon 4 (codon 158) of the human COMT gene. Decreased cortical dopamine should result in poorer executive functioning. Therefore, the authors hypothesized that individuals with traumatic brain injury (TBI) and the low enzyme activity polymorphism would perform better on tests Of executive functioning than individuals with the high enzyme activity polymorphism. One hundred thirteen individuals referred to the Defense and Veterans Brain Injury Center underwent a comprehensive TBI evaluation and were genotyped for the COMT polymorphism. Comparison of mean differences among the COMT genotype groups for several measures of aspects of executive functioning was conducted using analysis of variance (ANOVA) with adjustment for multiple comparisons. Homozygotes for the higher activity allele made more perseverative responses on the Wisconsin Card Sorting Test, while homozygotes for the lower activity allele had the least number of perseverative responses. While it cannot be determined whether TBI influenced the association of COMT Val158Met to executive functioning, these data extend the known relationship of genotype to executive performance seen in healthy comparison subjects and individuals with schizophrenia to individuals with TBI.	Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Dept Neurol, Washington, DC 20012 USA; NIAAA, Neurogenet Lab, NIH, Rockville, MD 20852 USA; Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Dept Neurosurg, Washington, DC 20012 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA		Warden, DL (corresponding author), Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Dept Neurol, POB 59181, Washington, DC 20012 USA.	deborah.warden@na.amedd.army.mil	Majid, Salma/AAT-2616-2020; Goldman, David/F-9772-2010	Majid, Salma/0000-0002-1724-5405; Goldman, David/0000-0002-1724-5405; Lipsky, Robert/0000-0001-7753-1473	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [Z01AA000303, Z01AA000302] Funding Source: NIH RePORTER		BAMBAD MJ, 2003, BRAIN INJURY, V17, P1011; Benton A., 1978, MULTILINGUAL APHASIA; Bilder RM, 2002, BIOL PSYCHIAT, V52, P701, DOI 10.1016/S0006-3223(02)01416-6; Boone KB, 1998, ARCH CLIN NEUROPSYCH, V13, P585, DOI 10.1016/S0887-6177(97)00074-7; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; DeMille MMC, 2002, HUM GENET, V111, P521, DOI 10.1007/s00439-002-0809-0; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Flashman LA., 1991, CLIN NEUROPSYCHOL, V5, P190, DOI [DOI 10.1080/13854049108403303, 10.1080/13854049108403303]; Gasparini M, 1997, J NEURAL TRANSM, V104, P887, DOI 10.1007/BF01285556; Golden CJ, 1978, STROOP COLOR WORD TE; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton R. K., 1993, MANUAL REVISED EXPAN; Heaton RK, 1991, COMPREHENSIVE NORMS; Joober R, 2002, ARCH GEN PSYCHIAT, V59, P662, DOI 10.1001/archpsyc.59.7.662; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lachman HM, 1996, PHARMACOGENETICS, V6, P243, DOI 10.1097/00008571-199606000-00007; Lewis DA, 2001, J COMP NEUROL, V432, P119, DOI 10.1002/cne.1092; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652; Mazei MS, 2002, BRAIN RES, V936, P58, DOI 10.1016/S0006-8993(02)02542-8; McAllister, 2004, J NEUROPSYCHIATRY CL, V16, P238; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McLeod HL, 1998, PHARMACOGENETICS, V8, P195; Moghaddam B, 2002, BIOL PSYCHIAT, V51, P775, DOI 10.1016/S0006-3223(01)01362-2; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Weinshilboum RM, 1999, ANNU REV PHARMACOL, V39, P19, DOI 10.1146/annurev.pharmtox.39.1.19; Winterer G, 2003, BRAIN RES REV, V43, P134, DOI 10.1016/S0165-0173(03)00205-4; Wolfson, 1993, HALSTEAD REITAN NEUR	28	76	80	0	5	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2005	17	4					465	471		10.1176/appi.neuropsych.17.4.465			7	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	993PH	WOS:000233966900004	16387984				2022-02-06	
J	Bourgoin, A; Albanese, J; Leone, M; Sampol-Manos, E; Viviand, X; Martin, C				Bourgoin, A; Albanese, J; Leone, M; Sampol-Manos, E; Viviand, X; Martin, C			Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients	CRITICAL CARE MEDICINE			English	Article						severe head injury management; target-controlled infusion; ketamine; sufentanil; intensive care unit; intracranial pressure; cerebral perfusion pressure	BISPECTRAL INDEX; INTRACRANIAL-PRESSURE; HEAD TRAUMA; PROPOFOL; ANESTHESIA; MIDAZOLAM; FENTANYL; PHARMACOKINETICS; REMIFENTANIL; ALFENTANIL	Objective: The manual injection of a bolus of opioid in patients with brain injury induces an increase in intracranial pressure related to a decrease in mean arterial pressure. Such an effect has not been observed with the use of ketamine. The use of target-controlled infusion would minimize or suppress this adverse effect of opioid. This study evaluated the effects of an increase in plasma concentrations of sufentanil or ketamine administered by target-controlled infusion on cerebral hemodynamics. Design: Prospective, randomized study. Setting: Intensive care unit in a trauma center. Patients: Thirty patients with severe traumatic brain injury. Interventions. Patients were assigned to receive sedation consisting of sufentanil-midazolam or ketamine-midazolam using target-controlled infusion. Twenty-four hours after the onset of sedation, the target concentrations of sufentanil or ketamine were doubled for 15 mins. Blood samples were collected to determine the actual plasma concentration of sufentanil and ketamine, before and 15 mins after concentration change. Measurements and Main Results: The baseline values of intracranial pressure and cerebral perfusion pressure were similar in both groups. The two-fold increase in drug concentrations did not involve a significant change for intracranial pressure, cerebral perfusion pressure, and mean velocity of middle cerebral artery in both the ketamine and the sufentanil groups. The measured plasma concentrations of sufentanil and ketamine were 0.4 &PLUSMN; 0.2 ng/mL and 2.6 &PLUSMN; 2.2 &mu; g/mL, respectively, before the increase in concentrations and 0.7 &PLUSMN; 0.4 ng/mL and 5.5 &PLUSMN; 3.8 &mu; g/mL after. Conclusions. The present study shows that the increase in sufentanil or ketamine plasma concentrations using a target-controlled infusion is not associated with adverse effects on cerebral hemodynamics in patients with severe. brain injury. The use of target-controlled infusion could be of interest in the management of severely brain-injured patients. However, there is a need for specific pharmacokinetic models designed for intensive care unit patients.	Nord Hosp, Dept Anesthesiol & Intens Care, Toulouse, France; Nord Hosp, Ctr Trauma, Toulouse, France; Marseille Univ Hosp Syst, Timone Hosp, Dept Pharmacokinet, Marseille, France		Bourgoin, A (corresponding author), Nord Hosp, Dept Anesthesiol & Intens Care, Toulouse, France.		Albanese, Jacques/AAS-7466-2021; Leone, Marc/P-4835-2016	Leone, Marc/0000-0002-3097-758X			AKESON J, 1993, ACTA ANAESTH SCAND, V37, P525, DOI 10.1111/j.1399-6576.1993.tb03759.x; Albanese J, 1997, ANESTHESIOLOGY, V87, P1328, DOI 10.1097/00000542-199712000-00011; ALBANESE J, 1993, ANESTHESIOLOGY, V79, P493, DOI 10.1097/00000542-199309000-00012; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; ALVIS JM, 1985, ANESTHESIOLOGY, V63, P41, DOI 10.1097/00000542-198507000-00006; AVRAM MJ, 1983, CLIN PHARMACOL THER, V34, P505, DOI 10.1038/clpt.1983.205; BELOPAVLOVIC M, 1982, ACTA ANAESTH SCAND, V26, P458, DOI 10.1111/j.1399-6576.1982.tb01799.x; Bourgoin A, 2003, CRIT CARE MED, V31, P711, DOI 10.1097/01.CCM.0000044505.24727.16; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; De Castro V, 2003, ANESTH ANALG, V96, P33, DOI 10.1097/00000539-200301000-00008; DOMINO EF, 1984, CLIN PHARMACOL THER, V36, P645, DOI 10.1038/clpt.1984.235; GEISSLINGER G, 1991, J CHROMATOGR-BIOMED, V568, P165, DOI 10.1016/0378-4347(91)80350-L; Guignard B, 2000, ANESTH ANALG, V90, P161, DOI 10.1097/00000539-200001000-00034; Hirota K, 1999, EUR J ANAESTH, V16, P779; HUDSON RJ, 1989, ANESTHESIOLOGY, V70, P426, DOI 10.1097/00000542-198903000-00011; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; LEONE M, IN PRESS ANESTH ANAL; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MICHIELS M, 1983, J PHARM PHARMACOL, V35, P86, DOI 10.1111/j.2042-7158.1983.tb04275.x; Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004; Sakai T, 1999, ACTA ANAESTH SCAND, V43, P212, DOI 10.1034/j.1399-6576.1999.430216.x; TOMASINI JL, 1985, J CHROMATOGR, V343, P369, DOI 10.1016/S0378-4347(00)84605-8; VANDALEN R, 1990, INTENS CARE MED, V16, pS235, DOI 10.1007/BF01709707; Vereecke HEM, 2003, ANAESTHESIA, V58, P957, DOI 10.1046/j.1365-2044.2003.03403.x; Veselis RA, 1997, ANESTHESIOLOGY, V87, P1106, DOI 10.1097/00000542-199711000-00015; VIVIAND X, 1993, ANN FR ANESTH, V12, P38; Vivien B, 2003, ANESTHESIOLOGY, V99, P9, DOI 10.1097/00000542-200307000-00006; WERNER C, 1995, ANESTHESIOLOGY, V83, P721, DOI 10.1097/00000542-199510000-00011; Zheng D, 1998, ANESTH ANALG, V86, P1109	29	76	83	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	MAY	2005	33	5					1109	1113		10.1097/01.CCM.0000162491.26292.98			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	925PO	WOS:000229065200029	15891344				2022-02-06	
J	Anderson, AJ; Robert, S; Huang, WC; Young, W; Cotman, CW				Anderson, AJ; Robert, S; Huang, WC; Young, W; Cotman, CW			Activation of complement pathways after contusion-induced spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						complement cascade; demyelination; immune response; inflammation; neuron; neurodegeneration; oligodendrocyte	MEMBRANE ATTACK COMPLEX; TRAUMATIC BRAIN-INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NECROSIS-FACTOR-ALPHA; NEURONAL CELL-DEATH; CLOSED-HEAD INJURY; NERVOUS-SYSTEM; ADULT-RAT; BLOOD-BRAIN; ALZHEIMERS-DISEASE	Previous studies have shown that a cellular inflammatory response is initiated, and inflammatory cytokines are synthesized, following experimental spinal cord injury (SCI). In the present study, we tested the hypothesis that the complement cascade, a major component of both the innate and adaptive immune response, is also activated following experimental SCI. We investigated the pathways, cellular localization, timecourse, and degree of complement activation in rat spinal cord following acute contusion-induced SCI using the New York University (NYU) weight drop impactor. Mild and severe injuries (12.5 and 50 mm drop heights) at 1, 7, and 42 days post injury time points were evaluated. Classical (C1q and C4), alternative (Factor B) and terminal (C5b-9) complement pathways were strongly activated within 1 day of SCI. Complement protein immunoreactivity was predominantly found in cell types vulnerable to degeneration, neurons and oligodendrocytes, and was not generally observed in inflammatory or astroglial cells. Surprisingly, immunoreactivity for complement proteins was also evident 6 weeks after injury, and complement activation was observed as far as 20 mm rostral to the site of injury. Axonal staining by C1q and Factor B was also observed, suggesting a potential role for the complement cascade in demyelination or axonal degeneration. These data support the hypothesis that complement activation plays a role in SCI.	Univ Calif Irvine, Reeve Irvine Res Ctr, Irvine, CA 92696 USA; Univ Calif Irvine, Dept Phys Med & Rehabil, Irvine, CA 92696 USA; Univ Calif Irvine, Dept Anat, Irvine, CA 92696 USA; Univ Calif Irvine, Dept Neurobiol, Irvine, CA 92696 USA; Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA USA; State Univ New Jersey, Ctr Neurosci, Piscataway, NJ USA		Anderson, AJ (corresponding author), Univ Calif Irvine, Reeve Irvine Res Ctr, 1107 Gillespie Neurosci Facil, Irvine, CA 92696 USA.	aja@uci.edu	Anderson, Aileen J/H-5926-2012		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01-043428-01A1] Funding Source: Medline		Agoropoulou C, 1996, NEUROREPORT, V7, P997, DOI 10.1097/00001756-199604100-00009; Agoropoulou C, 1998, NEUROREPORT, V9, P927, DOI 10.1097/00001756-199803300-00030; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; Barnum SR, 1999, MOL MED, V5, P569, DOI 10.1007/BF03402070; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bhat RV, 1996, GLIA, V17, P169; Birdsall HH, 1997, CIRCULATION, V95, P684, DOI 10.1161/01.CIR.95.3.684; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; Bracken MB, 2000, J TRAUMA, V48, P558, DOI 10.1097/00005373-200003000-00036; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; BRUCK W, 1990, ACTA NEUROPATHOL, V80, P415; BRUCK W, 1995, ACTA NEUROPATHOL, V90, P601; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chen AQ, 1996, EXP NEUROL, V138, P261, DOI 10.1006/exnr.1996.0065; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Dailey AT, 1998, J NEUROSCI, V18, P6713; Dashiell SM, 1999, J NEUROCHEM, V73, P2321, DOI 10.1046/j.1471-4159.1999.0732321.x; Dashiell SM, 2000, GLIA, V30, P187, DOI 10.1002/(SICI)1098-1136(200004)30:2<187::AID-GLIA8>3.0.CO;2-7; Davoust N, 1999, J IMMUNOL, V163, P6551; DeJong BA, 1997, NEUROCHEM RES, V22, P491, DOI 10.1023/A:1027372129989; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Dyer JK, 1998, EXP NEUROL, V154, P12, DOI 10.1006/exnr.1998.6905; Eggleton P, 1998, TRENDS CELL BIOL, V8, P428, DOI 10.1016/S0962-8924(98)01373-7; Eikelenboom P, 1996, NEUROBIOL AGING, V17, P673; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Ferrari S, 1998, ACTA NEUROPATHOL, V96, P569, DOI 10.1007/s004010050937; GASQUE P, 1995, J IMMUNOL, V154, P4726; Ghirnikar RS, 2000, J NEUROSCI RES, V59, P63, DOI 10.1002/(SICI)1097-4547(20000101)59:1<63::AID-JNR8>3.3.CO;2-N; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GUTHRIE KM, 1993, P NATL ACAD SCI USA, V90, P3329, DOI 10.1073/pnas.90.8.3329; Hauben E, 2001, J CLIN INVEST, V108, P591, DOI 10.1172/JCI200112837; Hauben E, 2001, P NATL ACAD SCI USA, V98, P15173, DOI 10.1073/pnas.011585298; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Huang J, 1999, SCIENCE, V285, P595, DOI 10.1126/science.285.5427.595; ITAGAKI S, 1994, BRAIN RES, V645, P78, DOI 10.1016/0006-8993(94)91640-3; Johns TG, 1997, MOL IMMUNOL, V34, P33, DOI 10.1016/S0161-5890(97)00005-9; Johnson SA, 1996, EXP NEUROL, V138, P198, DOI 10.1006/exnr.1996.0058; Jung S, 1995, NEUROSCI LETT, V200, P167, DOI 10.1016/0304-3940(95)12115-K; Kanellopoulos GK, 1997, ANN THORAC SURG, V64, P1279, DOI 10.1016/S0003-4975(97)00903-X; Keirstead HS, 1998, EXP NEUROL, V151, P303, DOI 10.1006/exnr.1998.6806; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Lindsberg PJ, 1996, ANN NEUROL, V40, P587, DOI 10.1002/ana.410400408; Liu L, 1998, GLIA, V23, P221, DOI 10.1002/(SICI)1098-1136(199807)23:3<221::AID-GLIA5>3.3.CO;2-Z; LIU L, 1995, NEUROSCIENCE, V68, P167, DOI 10.1016/0306-4522(95)00103-P; Makrides SC, 1998, PHARMACOL REV, V50, P59; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; MORGAN BP, 1989, BIOCHEM J, V264, P1; MORGAN BP, 1995, CRIT REV CL LAB SCI, V32, P265, DOI 10.3109/10408369509084686; Mosley K, 1996, NEUROCHEM RES, V21, P481, DOI 10.1007/BF02527713; NASO WB, 1995, NEUROSCI LETT, V189, P176, DOI 10.1016/0304-3940(95)11473-A; Nesic O, 2001, J NEUROTRAUM, V18, P947, DOI 10.1089/089771501750451857; NOBLE LJ, 1989, BRAIN RES, V482, P57, DOI 10.1016/0006-8993(89)90542-8; Olby NJ, 1996, EXP NEUROL, V138, P82, DOI 10.1006/exnr.1996.0049; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Pan WH, 1997, EXP NEUROL, V146, P367, DOI 10.1006/exnr.1997.6533; Pan WH, 1997, J NEUROIMMUNOL, V76, P105, DOI 10.1016/S0165-5728(97)00034-9; PASINETTI GM, 1992, EXP NEUROL, V118, P117, DOI 10.1016/0014-4886(92)90028-O; Piddlesden SJ, 1996, J NEUROIMMUNOL, V71, P173, DOI 10.1016/S0165-5728(96)00144-0; PIDDLESDEN SJ, 1994, J IMMUNOL, V152, P5477; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Rabchevsky AG, 2002, J NEUROSCI RES, V68, P7, DOI 10.1002/jnr.10187; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; ROZOVSKY I, 1994, NEUROSCIENCE, V62, P741, DOI 10.1016/0306-4522(94)90473-1; Rus HG, 1996, J IMMUNOL, V156, P4892; SAIJA A, 1995, LIFE SCI, V56, P775, DOI 10.1016/0024-3205(95)00008-T; Schwartz M, 2002, SCIENCE, V296, P1400; SCOLDING NJ, 1989, J NEUROL SCI, V89, P289, DOI 10.1016/0022-510X(89)90030-0; SCOLDING NJ, 1989, IMMUNOLOGY, V67, P441; SHEN Y, 1995, BRAIN RES, V671, P282, DOI 10.1016/0006-8993(94)01264-I; Shen Y, 1997, BRAIN RES PROTOC, V1, P186, DOI 10.1016/S1385-299X(96)00026-8; SHIRAZI Y, 1993, J IMMUNOL, V150, P4581; Singhrao SK, 1999, EXP NEUROL, V159, P362, DOI 10.1006/exnr.1999.7170; Soane L, 1999, J IMMUNOL, V163, P6132; Soane L, 2001, J IMMUNOL, V167, P2305, DOI 10.4049/jimmunol.167.4.2305; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Storch MK, 1998, ANN NEUROL, V43, P465, DOI 10.1002/ana.410430409; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Tonai T, 2001, J NEUROCHEM, V78, P1064, DOI 10.1046/j.1471-4159.2001.00488.x; Tornqvist E, 1996, NEUROBIOL AGING, V17, P695; Van Beek J, 2000, GLIA, V31, P39, DOI 10.1002/(SICI)1098-1136(200007)31:1<39::AID-GLIA40>3.0.CO;2-1; vanderLaan LJW, 1996, J NEUROIMMUNOL, V70, P145, DOI 10.1016/S0165-5728(96)00110-5; VANGURI P, 1982, P NATL ACAD SCI-BIOL, V79, P3290, DOI 10.1073/pnas.79.10.3290; Vasthare US, 1998, BRAIN RES BULL, V45, P413, DOI 10.1016/S0361-9230(97)00408-5; Walsh MJ, 1998, J CLIN INVEST, V101, P1923, DOI 10.1172/JCI1983; Wamil AW, 1998, P NATL ACAD SCI USA, V95, P13188, DOI 10.1073/pnas.95.22.13188; Webster S, 1997, NEUROBIOL AGING, V18, P415, DOI 10.1016/S0197-4580(97)00042-0; WREN DR, 1989, P NATL ACAD SCI USA, V86, P9025, DOI 10.1073/pnas.86.22.9025	99	76	80	0	2	MARY ANN LIEBERT INC	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1831	1846		10.1089/0897715042664894			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400012	15684772				2022-02-06	
J	Pellman, EJ; Viano, DC; Casson, IR; Arfken, C; Powell, J				Pellman, EJ; Viano, DC; Casson, IR; Arfken, C; Powell, J			Concussion in professional football: Injuries involving 7 or more days out - Part 5	NEUROSURGERY			English	Article						concussion; concussion guidelines; epidemiology; injury surveillance; postconcussion syndrome; sport injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; HIGH-SCHOOL; NEUROPSYCHOLOGICAL DEFICITS; SPORTS; RECOVERY; SYMPTOMS; PERFORMANCE; PLAYERS; IMPACTS	OBJECTIVE: A 6-year study was conducted to determine the signs, symptoms, and outcome of concussions with 7 or more (7+) days out from play or extended postconcussion recovery in the National Football League (NFL). METHODS: From 1996 to 2001, reporting of concussion was performed by NFL teams using a special standardized reporting form filled out by team physicians. Signs and symptoms were grouped by general symptoms, somatic complaints, cranial nerve effects, cognition problems, memory problems, and unconsciousness. Medical action taken and management were recorded. In all, 887 concussions were reported in practices and games. RESULTS: There were 72 concussions (8.1%) involving 7+ days out from play. The highest frequency occurred in quarterbacks (14.8%), the return unit on special teams (11.8%), and secondary (10.8%). Quarterbacks had the highest odds ratio (OR) of 7+ days out with concussion (OR = 2.10, P = 0.049), whereas running backs had the lowest relative risk (OR = 0.13, P = 0.021). The greatest fraction of 7+ days out occurred in passing plays (36.1%) and kickoffs (22.2%). Many signs and symptoms occurred at a greater frequency on initial examination in players 7+ days out; the average number per player was 4.64 with 7+ days out versus 2.58 with fewer days out (t = 6.02, df = 77.1). The signs and symptoms with the highest incidence for 7+ days out were disorientation to time (chi(2) = 51.2, P = 001), retrograde amnesia (chi(2) = 33.2, P = 0.001), fatigue (chi(2) = 28.1, P = 0.001), and the general category of cognition problems (chi(2) = 21.7, P = 0.001). Loss of consciousness for more than 1 minute was a predictor of 7+ days out (chi(2) = 33.5, P = 0.001), although it only occurred in only 7.9% of cases. Of players with 7+ days out, 72.2% were removed from the game and 12.5% were hospitalized. These frequencies were significantly greater than for players with fewer than 7 days out (chi(2) = 68.03, df = 3, P < 0.0001). Approximately 90% of players were managed by rest, irrespective of days out, but a greater fraction were given drug or medical therapies with prolonged days out. CONCLUSION: The most vulnerable players for 7+ days out with concussion were quarterbacks and the secondary in professional football. Although 8.1% of concussions involved 7+ days out, only 1.6% involved a prolonged postconcussion syndrome. They recovered from symptoms and had a consistent return to play in the NFL.	Natl Football League, Mild Traumat Brain Injury Committee, New York, NY USA; ProBiomech LLC, Bloomfield Hills, MI 48304 USA; Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Wayne State Univ, Ctr Hlth Effect Res, Dept Psychiat & Behav Neurosci, Detroit, MI USA; Michigan State Univ, Dept Kinesiol, Lansing, MI USA; Michigan State Univ, Dept Phys Med & Rehabil, Lansing, MI USA		Viano, DC (corresponding author), Natl Football League, Mild Traumat Brain Injury Committee, New York, NY USA.	dviano@comcast.net					BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 2001, J ATHL TRAINING, V36, P244; CANTU RC, 2001, NEUROLOGICAL SPORTS, P25; CARTLIDGE NEF, 1978, SCOT MED J, V23, P103, DOI 10.1177/003693307802300146; *CO MED SOC, 1991, REP SPORTS MED COMM; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Denker P., 1944, NY STATE J MED, V44, P379; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Evans R. W., 1996, NEUROLOGY TRAUMA, P91; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; GRONWALL D, 1974, LANCET, V2, P605; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly JP, 1997, NEUROLOGY, V48, P581; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; MANDEL S, 1989, POSTGRAD MED, V85, P213; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory PR, 2002, PHYSICIAN SPORTSMED, V30, P43, DOI 10.3810/psm.2002.08.403; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POLIN R, 1996, NEUROLOGY TRAUMA, P166; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1977, LANCET, V1, P1; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001	45	76	77	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	2004	55	5					1100	1116		10.1227/01.NEU.0000147063.12873.F5			17	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	871FA	WOS:000225114000030	15509317				2022-02-06	
J	Daugherty, WP; Levasseur, JE; Sun, D; Rockswold, GL; Bullock, MR				Daugherty, WP; Levasseur, JE; Sun, D; Rockswold, GL; Bullock, MR			Effects of hyperbaric oxygen therapy on cerebral oxygenation and mitochondrial function following moderate lateral fluid-percussion injury in rats	JOURNAL OF NEUROSURGERY			English	Article						hyperbaric oxygen; mitochondria; brain injury; fluid-percussion injury; rat	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; METABOLISM; GLUCOSE; TISSUE; ISCHEMIA; LACTATE; MODEL	Object. In the current study, the authors examined the effects of hyperbaric O-2 (HBO) following fluid-percussion brain injury and its implications on brain tissue oxygenation (PO2) and O-2 consumption (VO2) and mitochondrial function (redox potential). Methods. Cerebral tissue PO2 was measured following induction of a lateral fluid-percussion brain injury in rats. Hyperbaric O-2 treatment (100% O-2 at 1.5 ata) significantly increased brain tissue PO2 in both injured and sham-injured animals. For VO2, and redox potential experiments, animals were treated using 30% O-2 or HBO therapy for 1 or 4 hours (that is, 4 hours 30% O-2 or 1 hour HBO and 3 hours 100% O-2). Microrespirometer measurements of VO2, demonstrated significant increases following HBO treatment in both injured and sham-injured animals when compared with animals that underwent 30% O-2 treatment. Mitochondrial redox potential, as measured by Alamar blue fluorescence, demonstrated injury-induced reductions at 1 hour postinjury. These reductions were partially reversed at 4 hours postinjury in animals treated with 30% O-2, and completely reversed at 4 hours postinjury in animals on HBO therapy when compared with animals treated for only 1 hour. Conclusions. Analysis of data in the current study demonstrates that HBO significantly increases brain tissue PO, after injury. Nonetheless, treatment with HBO was insufficient to overcome injury-induced reductions in mitochondrial redox potential at 1 hour postinjury but was able to restore redox potential by 4 hours postinjury. Furthermore, HBO induced an increase in VO2, in both injured and sham-injured animals. Taken together, these data demonstrate that mitochondrial function is depressed by injury and that the recovery of aerobic metabolic function may be enhanced by treatment with HBO.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA		Bullock, MR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Dept Neurosurg, POB 980631,1200 E Marshall St, Richmond, VA 23298 USA.	robulloc@hsc.vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Alessandri B, 1999, ACT NEUR S, V75, P21; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; ARTRU F, 1976, EUR NEUROL, V14, P351, DOI 10.1159/000114759; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; Calvert JW, 2002, BRAIN RES, V951, P1, DOI 10.1016/S0006-8993(02)03094-9; Clifton G L, 1995, New Horiz, V3, P474; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Di Piero V, 2002, EUR J NEUROL, V9, P419, DOI 10.1046/j.1468-1331.2002.00436.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Elayan IM, 2000, J NEUROPHYSIOL, V83, P2022, DOI 10.1152/jn.2000.83.4.2022; Golden ZL, 2002, INT J NEUROSCI, V112, P119, DOI 10.1080/00207450212027; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; HOLLIN SA, 1968, J NEUROSURG, V29, P229, DOI 10.3171/jns.1968.29.3.0229; JAIN KK, 1999, TXB HYPERBARIC MED, P10; Jiang XB, 2000, NEUROL MED-CHIR, V40, P16, DOI 10.2176/nmc.40.16; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MINK RB, 1995, CRIT CARE MED, V23, P1398, DOI 10.1097/00003246-199508000-00014; Mogami H, 1969, No To Shinkei, V21, P261; MUIZELAAR JP, 1989, TXB HEAD INJURY, P221; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Ogilvie R W, 1973, Adv Exp Med Biol, V37A, P299; Omae T, 1998, STROKE, V29, P94, DOI 10.1161/01.STR.29.1.94; Ren H, 2001, Chin J Traumatol, V4, P239; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Springer JE, 1998, BRAIN RES PROTOC, V2, P259, DOI 10.1016/S1385-299X(97)00045-7; Sukoff MH, 2001, J NEUROSURG, V95, P544; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Veltkamp R, 2000, BRAIN RES, V853, P68, DOI 10.1016/S0006-8993(99)02250-7; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WOODHALL B, 1971, J NEUROSURG, V34, P3, DOI 10.3171/jns.1971.34.1.0003; Woolley S M, 1999, Pediatr Rehabil, V3, P81; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	44	76	98	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2004	101	3					499	504		10.3171/jns.2004.101.3.0499			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	851NF	WOS:000223691100020	15352608				2022-02-06	
J	Hart, T; Sherer, M; Whyte, J; Polansky, M; Novack, TA				Hart, T; Sherer, M; Whyte, J; Polansky, M; Novack, TA			Awareness of behavioral, cognitive, and physical deficits in acute traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						awareness; brain injuries; rehabilitation	IMPAIRED SELF-AWARENESS; HEAD-INJURY; PRACTICAL SCALE; LIMITATIONS; REHABILITATION; DYSFUNCTION; DISABILITY; RELATIVES; ADULTS; COMA	Objective: To compare awareness of deficit in 3 domains of function (physical, cognitive, behavioral/emotional) in acute traumatic brain injury (TBI), controlling for severity of impairment in the different domains. Design: Inception cohort. Setting: Three inpatient rehabilitation programs. Participants: People with acute TBI (N=161), tested as soon as feasible after posttraumatic amnesia. Interventions: Not applicable. Main Outcome Measures: Awareness Questionnaire (AQ) completed by the person with TBI and the treating neuropsychologist; and self- and clinician-rating scores calculated in the 3 domains. Results: For participants who were rated by clinicians as more impaired in at least 1 domain (ie, scored lower on the AQ), self-ratings differed significantly from one another in all 3 domains, with behavioral self-ratings highest, physical self-ratings lowest, and cognitive self-ratings intermediate. In subgroups of participants rated at the same level by clinicians in all 3 domains, physical self-ratings were also lowest, that is, more consonant with clinician ratings. Participants tended to rate themselves as relatively unchanged in cognitive and behavioral domains regardless of the level of clinician ratings on these factors. Conclusions: Patterns of discrepant awareness of deficit in different functional areas seen in postacute TBI also appear to be present acutely and are not entirely related to differential severity of deficit. We discuss several possible reasons for discrepant awareness of deficit, including differences in internal and external feedback, cultural and psychologic factors, and different levels of ambiguity inherent in causal explanations for different types of problems.	Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19141 USA; Methodist Rehabil Ctr, Jackson, MS USA; MCP Hahnemann Sch Publ Hlth, Philadelphia, PA USA; Univ Alabama, Birmingham, AL USA		Hart, T (corresponding author), Jefferson Med Coll, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu		Whyte, John/0000-0002-4381-1474			Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Newman AC, 2000, BRAIN INJURY, V14, P333; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; OLIVER JH, 1996, BRAIN INJURY, V10, P841; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142	35	76	76	0	10	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2004	85	9					1450	1456		10.1016/j.apmr.2004.01.030			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	852DW	WOS:000223736400010	15375815				2022-02-06	
J	Hammond, FM; Hart, T; Bushnik, T; Corrigan, JD; Sasser, H				Hammond, FM; Hart, T; Bushnik, T; Corrigan, JD; Sasser, H			Change and predictors of change in communication, cognition, and social function between 1 and 5 years after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; cognition; communication; function; Functional Independence Measure; memory; outcome; prediction; problem solving; social	SEVERE HEAD-INJURY; QUALITY-OF-LIFE; INDEPENDENCE MEASURE; FOLLOW-UP; SYSTEMATIC BIAS; RETURN; WORK; DISCOURSE; RECOVERY; MODERATE	Objective: To study cognitive, communication, and social changes experienced by individuals between I and 5 years after traumatic brain injury (TBI). Design: Prospective cohort. Setting and Participants: TBI Model System Database with 927 eligible subjects using a cohort with complete 1- and 5-year data (N = 292). Main Outcome Measures: Change in Functional Independence Measure(TM)-Cognitive (FIM-Cog) items from Year I to Year 5 postinjury. Results: On the FIM-Cog Total score, 26% individuals improved, 61% stayed the same, and 14% worsened by more than I point from Year I to Year 5. On the 2 FIM Communication items, 19% individuals improved, 68% stayed the same, and 13% worsened by greater than I point. On the FIM Social Interaction item, 12% individuals improved, 76% stayed the same, and 11% worsened. On the FIM Memory and Problem Solving items, 34% individuals improved, 48% stayed the same, and 19% worsened. Several variables predicted this improvement and worsening, some of which were available at the time of injury and most were those available at I year postinjury. The Memory and Problem Solving items, taken together, showed fewer participants at ceiling at Year I and more change between Year 1 and Year 5 compared to the Communication and Social Interaction items. Conclusions: Many individuals did not demonstrate meaningful change on FIM-Cog and its component items from Year I to Year 5. In particular, a high proportion of improvement was observed in Memory/Problem Solving, and worsening in Social Interaction. Demographic and functional indicators present at I year postinjury may be predictive of subsequent change.	Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Carolinas Healthcare Syst, R Stuart Dickson Inst Hlth Studies, Charlotte, NC 28203 USA; Moss Rehabil Res Inst, TBI Clin Res Lab, Philadelphia, PA USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH USA		Hammond, FM (corresponding author), Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Carolinas Healthcare Syst, R Stuart Dickson Inst Hlth Studies, 1100 Blythe Blvd, Charlotte, NC 28203 USA.	Flora.hammond@carolinashealthcare.org	Corrigan, John D./E-2921-2011	Bushnik, Tamara/0000-0003-3328-257X			Braakman R, 1986, Acta Neurochir Suppl (Wien), V36, P112; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2003, PROBLEMATIC SUBSTANC; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DITUNNO JF, 1995, SPINAL CORD INJURY C; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; HEATON RK, 1981, COMPREHENSIVE NORMS; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JAGGER J, 1983, LANCET, V2, P97; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1976, LANCET, V1, P1031; Johansson U, 2001, DISABIL REHABIL, V23, P474; Keith R A, 1987, Adv Clin Rehabil, V1, P6; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; Lezak MD., 1983, NEUROPSYCHOLOGICAL A, V2nd ed.; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; *NAT I DIS REH RES, 1998, TRAUM BRAIN INJ MOD; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; *SAS I INC, 1995, PROGR APPR COUR NOT; Smith A., 1982, SYMBOL DIGIT MODALIT; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; [US Department of Health and Human Services and US Department of Agriculture US Department of Health and Human Services and US Department of Agriculture], 1990, NUTR YOUR HLTH DIET; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Wechsler D., 1981, WECHSLER INTELLIGENC, V3rd; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; WILSON BA, 1997, J REHABILITATION OUT, V1, P60	55	76	76	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2004	19	4					314	328		10.1097/00001199-200407000-00006			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	839CB	WOS:000222759800006	15263859				2022-02-06	
J	Hawley, CA				Hawley, CA			Behaviour and school performance after brain injury	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; CHILDREN; ADOLESCENTS; SEQUELAE; FAMILY; TEMPERAMENT; INFANTS; SCALE; MILD	Primary objective : To examine the relationship between behavioural problems and school performance following traumatic brain injury (TBI). Methods and procedures : Subjects: 67 school-age children with TBI (35 mild, 13 moderate, 19 severe) and 14 uninjured matched controls. Parents and children were interviewed at a mean of 2 years post-TBI. Teachers reported on academic performance and educational needs. Children were assessed using the Vineland Adaptive Behaviour Scales (VABS) and the Weschler Intelligence Scale for Children (WISC-III). Main outcomes and results : Two-thirds of children with TBI exhibited significant behavioural problems, significantly more than controls ( p = 0.02). Children with behavioural problems had a mean IQ similar to 15 points lower than those without ( p = 0.001, 95% CI: 7-26.7). At school, 76%(19) of children with behavioural problems also had difficulties with schoolwork. Behavioural problems were associated with social deprivation and parental marital status ( p less than or equal to 0.01). Conclusions : Children with TBI are at risk of developing behavioural problems which may affect school performance. Children with TBI should be screened to identify significant behavioural problems before they return to school.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England		Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; *AUD COMM, 2002, STAT ASS STAT SPEC E; BASSON MD, 1991, J TRAUMA, V31, P1363, DOI 10.1097/00005373-199110000-00008; Bevington J, 1999, BRIT J EDUC PSYCHOL, V69, P19, DOI 10.1348/000709999157545; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Greenberg JM, 1999, ADV SPACE RES-SERIES, V23, P289, DOI 10.1016/S0273-1177(99)00049-6; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; JONES GS, 1994, NUCL MED BIOL, V21, P117, DOI 10.1016/0969-8051(94)90138-4; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; MARTIN RP, 1988, SCHOOL PSYCHOL REV, V17, P125; Max JE, 1998, BRAIN INJURY, V12, P41; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1111/1469-7610.00708; Parmelee D X, 1989, Psychiatr Med, V7, P11; PFEFFER J, 1983, J CLIN PSYCHOL, V39, P1013, DOI 10.1002/1097-4679(198311)39:6<1013::AID-JCLP2270390634>3.0.CO;2-5; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; SCOTTJUPP R, 1992, ARCH DIS CHILD, V67, P222, DOI 10.1136/adc.67.2.222; SEMRUDCLIKEMAN M, 2001, TRAUMATIC BRAIN INJU; Sharples PM, 1998, INJURY YOUNG, P151; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Townsend P, 1986, INEQUALITIES HLTH NO; Wechsler D., 1991, MANUAL WECHSLER INTE, V3rd; YLVISAKER M, 1995, J HEAD TRAUMA REHAB, V10, P42, DOI 10.1097/00001199-199512000-00007; YLVISAKER M, 1995, J HEAD TRAUMA REHAB, V10, P25, DOI 10.1097/00001199-199512000-00006; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P271	41	76	76	1	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2004	18	7					645	659		10.1080/02699050310001646189			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	821HJ	WOS:000221450700002	15204326	Green Submitted			2022-02-06	
J	Mhatre, M; Nguyen, A; Kashani, S; Pham, T; Adesina, A; Grammas, P				Mhatre, M; Nguyen, A; Kashani, S; Pham, T; Adesina, A; Grammas, P			Thrombin, a mediator of neurotoxicity and memory impairment	NEUROBIOLOGY OF AGING			English	Article						thrombin; cognition; spatial memory; neurotoxicity; glial fibrillary acidic protein; neurofilament; memory deficits	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; INTRACEREBRAL HEMORRHAGE; ALZHEIMERS-DISEASE; WORKING-MEMORY; CELL-DEATH; NEURITE OUTGROWTH; EDEMA FORMATION; BETA-PROTEIN; RECEPTOR	Thrombin has been found in neuritic plaques in Alzheimer's disease (AD). Also, traumatic brain injury, where neurons are exposed to high thrombin levels, is associated with an increased incidence of AD. Our objective was to determine the effects of thrombin administered in vivo on cognitive function and neuropathology. Rats were trained using a radial eight-arm maze and then thrombin (25 or 100 nM, 0.25 mu/h, 28 days) or vehicle was delivered via intracerebroventricular infusion. Animals that received 100 nM thrombin demonstrated cognitive impairments including deficits in reference memory and an increase in task latency. Also, significant neuropathology was detected in these animals such as enlargement of cerebral ventricles, an increased number of TUNEL-positive cells, astrogliosis, and an increase in the immumoreactivity for phosphorylated neurofilament, and apolipoprotein-E fragments. Thrombin-induced changes in cognitive function and ventricular enlargement were inhibited by hirudin. These findings demonstrate that thrombin is a mediator of neurotoxicity and cognitive deficits and suggest that inhibition of thrombin may be a treatment strategy for AD- or head trauma-associated cognitive deficits. (C) 2003 Elsevier Inc. All rights reserved.	Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Neurosci, Oklahoma City, OK 73104 USA		Grammas, P (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, 975 NE 10th St, Oklahoma City, OK 73104 USA.	paula-grammas@ouhsc.edu	sharifkashani, shervin/AAP-3773-2020	sharifkashani, shervin/0000-0002-5226-9621	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG015964] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 15964] Funding Source: Medline		AKIYAMA H, 1992, NEUROSCI LETT, V146, P152, DOI 10.1016/0304-3940(92)90065-F; Armao D, 1997, BRAIN RES, V767, P259, DOI 10.1016/S0006-8993(97)00567-2; Bimonte-Nelson HA, 2003, BEHAV BRAIN RES, V139, P47, DOI 10.1016/S0166-4328(02)00082-7; BRETELER MMB, 1994, STROKE, V25, P1109, DOI 10.1161/01.STR.25.6.1109; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; CAVANAUGH KP, 1990, J NEUROCHEM, V54, P1735, DOI 10.1111/j.1471-4159.1990.tb01228.x; CHONG YH, 1994, LIFE SCI, V54, P1259; Ciallella JR, 1999, THROMB HAEMOSTASIS, V81, P630; Colon GP, 1996, J NEUROSURG, V85, P335, DOI 10.3171/jns.1996.85.2.0335; Conti AC, 1998, J NEUROSCI, V18, P5663; CRUTCHER KA, 1997, ALZHEIMERS DIS BIOL, P545; Dickson TC, 1999, EXP NEUROL, V156, P100, DOI 10.1006/exnr.1998.7010; Dickson TC, 2001, NEUROSCIENCE, V105, P99, DOI 10.1016/S0306-4522(01)00169-5; Donovan FM, 1997, J NEUROSCI, V17, P5316; Festoff BM, 2000, MOL MED, V6, P410, DOI 10.1007/BF03401784; Garcia JH, 1994, INTRACEREBRAL HEMORR, P45; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; Gill JS, 1998, BRAIN RES, V797, P321, DOI 10.1016/S0006-8993(98)00344-8; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Gould TJ, 2002, BRAIN RES BULL, V58, P581, DOI 10.1016/S0361-9230(02)00832-8; GRAND RJA, 1989, EMBO J, V8, P2209, DOI 10.1002/j.1460-2075.1989.tb08344.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; IGARASHI K, 1992, BIOCHEM BIOPH RES CO, V185, P1000, DOI 10.1016/0006-291X(92)91726-7; Jiang YJ, 2002, J CEREBR BLOOD F MET, V22, P404, DOI 10.1097/00004647-200204000-00004; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; LEE KR, 1995, J NEUROSURG, V83, P1045, DOI 10.3171/jns.1995.83.6.1045; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; LORET C, 1989, J BIOL CHEM, V264, P19; Marques MA, 1996, NEUROREPORT, V7, P2529, DOI 10.1097/00001756-199611040-00025; Martinez I, 2002, NEUROPSYCHOBIOLOGY, V46, P97, DOI 10.1159/000065419; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; Miyoshi E, 2002, BRAIN RES BULL, V58, P41, DOI 10.1016/S0361-9230(02)00754-2; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, P28; NELSON RB, 1990, DEV BRAIN RES, V54, P93, DOI 10.1016/0165-3806(90)90069-B; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; Perlstein WM, 2003, BIOL PSYCHIAT, V53, P25, DOI 10.1016/S0006-3223(02)01675-X; Quintana J, 2003, BIOL PSYCHIAT, V53, P12, DOI 10.1016/S0006-3223(02)01435-X; Reimann-Philipp U, 2001, J NEUROSCI RES, V64, P654, DOI 10.1002/jnr.1119; Roberts AH, 1969, BRAIN DAMAGE BOXERS; Sarker KP, 1999, THROMB HAEMOSTASIS, V82, P1071, DOI 10.1055/s-0037-1614331; Smirnova IV, 1996, J NEUROCHEM, V67, P2188; SMITHSWINTOSKY VL, 1995, J NEUROSCI, V15, P5840; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Turgeon VL, 1999, J NEUROBIOL, V38, P571, DOI 10.1002/(SICI)1097-4695(199903)38:4<571::AID-NEU11>3.0.CO;2-6; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; VAUGHAN PL, 1994, NEUROREPORT, V5, P2529; Vergnolle N, 1999, BRIT J PHARMACOL, V126, P1262, DOI 10.1038/sj.bjp.0702408; WHITE RP, 1980, STROKE, V11, P363, DOI 10.1161/01.STR.11.4.363; Xi GH, 1999, STROKE, V30, P1247, DOI 10.1161/01.STR.30.6.1247; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Xue MZ, 2001, STROKE, V32, P2164, DOI 10.1161/hs0901.095408	55	76	78	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	JUL	2004	25	6					783	793		10.1016/j.neurobiolaging.2003.07.007			11	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	834PS	WOS:000222423600014	15165703				2022-02-06	
J	Ratzliff, ADH; Howard, AL; Santhakumar, V; Osapay, I; Soltesz, I				Ratzliff, ADH; Howard, AL; Santhakumar, V; Osapay, I; Soltesz, I			Rapid deletion of mossy cells does not result in a hyperexcitable dentate gyrus: Implications for epileptogenesis	JOURNAL OF NEUROSCIENCE			English	Article						epilepsy; mossy cell; hyperexcitability; hilar cell loss; dentate gyrus; dormant basket cell hypothesis	TEMPORAL-LOBE EPILEPSY; RECEPTOR SUBUNIT EXPRESSION; GRANULE CELLS; HIPPOCAMPAL INTERNEURONS; INHIBITORY INTERNEURONS; SYNAPTIC CONNECTIONS; MOLECULAR LAYER; IN-VIVO; RAT; NEURONS	Loss of cells from the hilus of the dentate gyrus is a major histological hallmark of human temporal lobe epilepsy. Hilar mossy cells, in particular, are thought to show dramatic numerical reductions in pathological conditions, and one prominent theory of epileptogenesis is based on the assumption that mossy cell loss directly results in granule cell hyperexcitability. However, whether it is the disappearance of hilar mossy cells from the dentate gyrus circuitry after various insults or the subsequent synaptic - cellular alterations ( e. g., reactive axonal sprouting) that lead to dentate hyperexcitability has not been rigorously tested, because of the lack of available techniques to rapidly remove specific classes of nonprincipal cells from neuronal networks. We developed a fast, cell-specific ablation technique that allowed the targeted lesioning of either mossy cells or GABAergic interneurons in horizontal as well as axial ( longitudinal) slices of the hippocampus. The results demonstrate that mossy cell deletion consistently decreased the excitability of granule cells to perforant path stimulation both within and outside of the lamella where the mossy cell ablation took place. In contrast, ablation of interneurons caused the expected increase in excitability, and control aspirations of the hilar neuropil or of interneurons in the presence of GABA receptor blockers caused no alteration in granule cell excitability. These data do not support the hypothesis that loss of mossy cells from the dentate hilus after seizures or traumatic brain injury directly results in hyperexcitability.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA		Soltesz, I (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	isoltesz@uci.edu	Santhakumar, Viji/K-4856-2019; Santhakumar, Vijayalakshmi/M-4192-2013	Santhakumar, Viji/0000-0001-6278-4187; Ratzliff, Anna/0000-0002-6654-8007	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS035915, R37NS035915, R01NS035915] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35915, R01 NS035915, R29 NS035915, R37 NS035915] Funding Source: Medline		AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; AMARAL DG, 1978, J COMP NEUROL, V182, P851, DOI 10.1002/cne.901820508; Andersen P, 2000, BRAIN RES, V886, P165, DOI 10.1016/S0006-8993(00)02991-7; Arabadzisz D, 1999, NEUROSCIENCE, V92, P27, DOI 10.1016/S0306-4522(98)00736-2; Bernard C, 1998, EPILEPSY RES, V32, P93, DOI 10.1016/S0920-1211(98)00043-6; BlascoIbanez JM, 1997, HIPPOCAMPUS, V7, P307, DOI 10.1002/(SICI)1098-1063(1997)7:3<307::AID-HIPO6>3.0.CO;2-H; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brooks-Kayal AR, 2001, J NEUROCHEM, V77, P1266, DOI 10.1046/j.1471-4159.2001.00329.x; Buckmaster PS, 1996, J COMP NEUROL, V366, P270, DOI 10.1002/(SICI)1096-9861(19960304)366:2<270::AID-CNE7>3.0.CO;2-2; BUCKMASTER PS, 1992, HIPPOCAMPUS, V2, P349, DOI 10.1002/hipo.450020403; Buckmaster PS, 1999, J NEUROPHYSIOL, V81, P712, DOI 10.1152/jn.1999.81.2.712; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; FROTSCHER M, 1991, J COMP NEUROL, V312, P145, DOI 10.1002/cne.903120111; GAUGAIN B, 1978, BIOCHEMISTRY-US, V17, P5078, DOI 10.1021/bi00617a002; Geiger JRP, 1997, NEURON, V18, P1009, DOI 10.1016/S0896-6273(00)80339-6; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; Hajos N, 1997, J NEUROSCI, V17, P8427; HAUGHLAND RP, 1996, MOL PROBES HDB, P366; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412, DOI 10.1152/jn.1996.76.4.2412; Houser C R, 1999, Adv Neurol, V79, P743; Ishizuka S, 1998, NEUROREPORT, V9, P193, DOI 10.1097/00001756-199801260-00004; Kapur GK, 2000, SLOAN MANAGE REV, V41, P6; Kotti T, 1996, EUR J NEUROSCI, V8, P2371, DOI 10.1111/j.1460-9568.1996.tb01200.x; Kraushaar U, 2000, J NEUROSCI, V20, P5594, DOI 10.1523/JNEUROSCI.20-15-05594.2000; Lechner HAE, 2002, J NEUROSCI, V22, P5287; Leranth C, 1996, NEUROSCIENCE, V70, P631, DOI 10.1016/S0306-4522(96)83003-X; Liu KS, 1999, NEURON, V23, P325, DOI 10.1016/S0896-6273(00)80783-7; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Monette R, 1998, BRAIN RES PROTOC, V2, P99, DOI 10.1016/S1385-299X(97)00020-2; PATTON PE, 1995, HIPPOCAMPUS, V5, P245, DOI 10.1002/hipo.450050402; Ratzliff ADH, 2002, TRENDS NEUROSCI, V25, P140, DOI 10.1016/S0166-2236(00)02122-6; Ratzliff ADH, 2001, NEUROSCIENCE, V103, P337, DOI 10.1016/S0306-4522(01)00013-6; RIBAK CE, 1986, J NEUROSCI, V6, P3492; RIBAK CE, 1985, J NEUROCYTOL, V14, P835, DOI 10.1007/BF01170832; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916, DOI 10.1152/jn.2000.83.5.2916; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; SCHARFMAN HE, 1991, J NEUROSCI, V11, P1660; SCHARFMAN HE, 1995, J NEUROPHYSIOL, V74, P179, DOI 10.1152/jn.1995.74.1.179; Shah Eliza Mountcastle, 1993, Current Opinion in Neurobiology, V3, P738, DOI 10.1016/0959-4388(93)90146-P; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1994, ANN NEUROL, V35, P640, DOI 10.1002/ana.410350604; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; SOLTESZ I, 1993, NEUROSCIENCE, V57, P555, DOI 10.1016/0306-4522(93)90005-Z; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Toth K, 1998, NAT NEUROSCI, V1, P572, DOI 10.1038/2807; Toth Z, 1997, J NEUROSCI, V17, P8106; Wang X, 2003, NEUROSCIENCE, V117, P485, DOI 10.1016/S0306-4522(02)00659-0; Wenzel HJ, 1997, HIPPOCAMPUS, V7, P559; WESTBROOK G. L., 2000, PRINCIPLES NEURAL SC, P910; Wuarin JP, 2001, J NEUROPHYSIOL, V85, P1067, DOI 10.1152/jn.2001.85.3.1067; Zappone CA, 2001, J COMP NEUROL, V441, P324, DOI 10.1002/cne.1415	55	76	80	0	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 3	2004	24	9					2259	2269		10.1523/JNEUROSCI.5191-03.2004			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	780PX	WOS:000189391500019	14999076	Green Published, hybrid			2022-02-06	
J	Larner, SF; Hayes, RL; McKinsey, DM; Pike, BR; Wang, KKW				Larner, SF; Hayes, RL; McKinsey, DM; Pike, BR; Wang, KKW			Increased expression and processing of caspase-12 after traumatic brain injury in rats	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; calpain; caspase; traumatic brain injury; unfolded protein response	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN RESPONSE; CORTICAL IMPACT INJURY; PROGRAMMED CELL-DEATH; KAR2 BIP GENE; NERVOUS-SYSTEM; RESIDENT CASPASE; CALCIUM STORES; NEURONAL DEATH; ALPHA-SPECTRIN	Traumatic brain injury (TBI) disrupts tissue homeostasis resulting in pathological apoptotic activation. Recently, caspase-12 was reported to be induced and activated by the unfolded protein response following excess endoplasmic reticulum (ER) stress. This study examined rat caspase-12 expression using the controlled cortical impact TBI model. Immunoblots of fractionalized cell lysates found elevated caspase-12 proform (similar to60 kDa) and processed form (similar to12 kDa), with peak induction observed within 24 h post-injury in the cortex (418% and 503%, respectively). Hippocampus caspase-12 proform induction peaked at 24 h post-injury (641%), while processed form induction peaked at 6 h (620%). Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis confirmed elevated caspase-12 mRNA levels after TBI. Injury severity (1.0, 1.2 or 1.6 mm compression) was associated with increased caspase-12 mRNA expression, peaking at 5 days in the cortex (657%, 651% and 1259%, respectively) and 6 h in the hippocampus (435%, 451% and 460%, respectively). Immunohistochemical analysis revealed caspase-12 induction in neurons in both the cortex and hippocampus as well as in astrocytes at the contusion site. This is the first report of increased expression of caspase-12 following TBI. Our results suggest that the caspase-12-mediated ER apoptotic pathway may play a role in rat TBI pathology independent of the receptor- or mitochondria-mediated apoptotic pathways.	Univ Florida, Dept Psychiat, Evelyn F & William L McKnight Brain Inst, Gainesville, FL 32611 USA; Univ Florida, Dept Neurosci, Evelyn F & William L McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Gainesville, FL 32611 USA		Wang, KKW (corresponding author), Univ Florida, Dept Psychiat, Evelyn F & William L McKnight Brain Inst, POB 100256, Gainesville, FL 32611 USA.	kwang1@ufl.edu	Pike, Bruce/K-5562-2014	Pike, Bruce/0000-0001-8924-683X; Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS40182, R01 NS39091] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039091, R01NS040182] Funding Source: NIH RePORTER		Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; DeGracia DJ, 2002, J CEREBR BLOOD F MET, V22, P127, DOI 10.1097/00004647-200202000-00001; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Imaizumi K, 2001, BBA-MOL BASIS DIS, V1536, P85, DOI 10.1016/S0925-4439(01)00049-7; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Mouw G, 2003, NEUROREPORT, V14, P183, DOI 10.1097/00001756-200302100-00004; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Pelletier MR, 1999, J NEUROPHYSIOL, V81, P3054, DOI 10.1152/jn.1999.81.6.3054; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Qiu JH, 2002, J NEUROSCI, V22, P3504; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; RINK A, 1995, AM J PATHOL, V147, P1575; Shibata M, 2003, NEUROSCIENCE, V118, P491, DOI 10.1016/S0306-4522(02)00910-7; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tinhofer I, 2002, FASEB J, V16, P1295, DOI 10.1096/fj.02-0020fje; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; Yie Q, 2002, HEPATOLOGY, V36, P592, DOI 10.1053/jhep.2002.35441; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	60	76	82	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2004	88	1					78	90		10.1046/j.1471-4159.2003.02141.x			13	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	753YJ	WOS:000187275700009	14675152				2022-02-06	
J	Jorge, R; Robinson, RG				Jorge, R; Robinson, RG			Mood disorders following traumatic brain injury	INTERNATIONAL REVIEW OF PSYCHIATRY			English	Article							CORTICAL IMPACT INJURY; RAT FRONTAL-CORTEX; CLOSED-HEAD-INJURY; MAJOR DEPRESSION; PSYCHIATRIC-DISORDERS; AGGRESSIVE-BEHAVIOR; MEMORY DEFICITS; AXIS-I; MANIA; MECHANISMS	Mood disorders are a frequent complication of traumatic brain injury that exerts a deleterious effect on the recovery process and psychosocial outcome of brain injured patients. Prior psychiatric history and impaired social support have been consistently reported as risk factors for developing mood disorders after traumatic brain injury (TBI). In addition, biological factors such as the involvement of the prefrontal cortex and probably other limbic and paralimbic structures may play a significant role in the complex pathophysiology of these disorders. Preliminary studies have suggested that selective serotonin reuptake inhibitors such as sertraline, mood stabilizers such as sodium valproate, as well as stimulants and ECT may be useful in treating these disorders. Mood disorders occurring after TBI are clearly an area of neuropsychiatry in which further research in etiology as well as treatment is needed.	Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA		Jorge, R (corresponding author), Univ Iowa, Coll Med, Dept Psychiat, 200 Hawkins Dr 2887 JPP, Iowa City, IA 52242 USA.		Robinson, Robert/AAF-6191-2021				Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas DB, 2000, CURRENT TREATMENT OP, V2, P169; BAKCHINE S, 1989, NEUROLOGY, V39, P777, DOI 10.1212/WNL.39.6.777; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; BRACKEN P, 1987, BRIT J PSYCHIAT, V150, P690, DOI 10.1192/bjp.150.5.690; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CLARK AF, 1987, BRIT J PSYCHIAT, V150, P841, DOI 10.1192/bjp.150.6.841; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Cummings JL, 2000, AM J PSYCHIAT, V157, P4, DOI 10.1176/ajp.157.1.4; Cummings JL, 1998, AM J GERIAT PSYCHIAT, V6, pS64, DOI 10.1097/00019442-199821001-00009; CUMMINGS JL, 1984, AM J PSYCHIAT, V141, P1084; DAVIDSON J, 1986, BRIT J PSYCHIAT, V148, P442, DOI 10.1192/bjp.148.4.442; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Ella R, 2002, J CLIN PSYCHIAT, V63, P249, DOI 10.4088/JCP.v63n0312d; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Freo U, 2002, J NEURAL TRANSM, V109, P857, DOI 10.1007/s007020200070; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; Hegel MT, 2000, BEHAV MODIF, V24, P94, DOI 10.1177/0145445500241005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hong Jun, 2002, Chin J Traumatol, V5, P36; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; JOSHI P, 1985, J DEV BEHAV PEDIATR, V6, P352; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kulisevsky J, 2002, NEUROLOGY, V59, P1421, DOI 10.1212/WNL.59.9.1421; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Levin, 1997, Semin Clin Neuropsychiatry, V2, P207; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MARKIANOS M, 1992, ACTA NEUROL SCAND, V86, P190, DOI 10.1111/j.1600-0404.1992.tb05064.x; MCHUGH PR, 1992, J ROY SOC MED, V85, P483; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Monji A, 1999, PSYCHOSOMATICS, V40, P448, DOI 10.1016/S0033-3182(99)71215-6; Morgan JR, 2002, NEUROMOL MED, V2, P101, DOI 10.1385/NMM:2:2:101; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NIZAMIE SH, 1988, ACTA PSYCHIAT SCAND, V77, P637, DOI 10.1111/j.1600-0447.1988.tb05181.x; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Schneck Christopher D., 2002, Curr Treat Options Neurol, V4, P477, DOI 10.1007/s11940-002-0015-3; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Shao LF, 1999, J NEUROTRAUM, V16, P555, DOI 10.1089/neu.1999.16.555; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; SILVER JM, 1991, J NEUROPSYCHIAT, V3, P22; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; STARKSTEIN SE, 1988, J NERV MENT DIS, V176, P87, DOI 10.1097/00005053-198802000-00004; STEWART JT, 1988, J CLIN PSYCHIAT, V49, P74; STOLL AL, 1994, J CLIN PSYCHOPHARM, V14, P311; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; THIENHAUS OJ, 1984, AM J PSYCHIAT, V141, P1459, DOI 10.1176/ajp.141.11.1459; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Tyerman A, 2001, NEUROREHABILITATION, V16, P59; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Wilson MS, 2002, AM J PHYS MED REHAB, V81, P364, DOI 10.1097/00002060-200205000-00009; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; Yamamoto T, 1999, ACT NEUR S, V75, P17; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014	91	76	77	0	17	CARFAX PUBLISHING	BASINGSTOKE	RANKINE RD, BASINGSTOKE RG24 8PR, HANTS, ENGLAND	0954-0261			INT REV PSYCHIATR	Int. Rev. Psych.	NOV	2003	15	4					317	327		10.1080/09540260310001606700			11	Psychiatry	Social Science Citation Index (SSCI)	Psychiatry	739UD	WOS:000186364100004	15276953				2022-02-06	
J	Geijerstam, JLA; Britton, M				Geijerstam, JLA; Britton, M			Mild head injury - mortality and complication rate: meta-analysis of findings in a systematic literature review	ACTA NEUROCHIRURGICA			English	Article						mild head injury; computed tomography; in-hospital observation; clinical management; meta-analysis	CRANIAL COMPUTED-TOMOGRAPHY; SIGNIFICANT INTRACRANIAL INJURY; TRAUMATIC BRAIN INJURY; NEUROLOGIC EXAMINATION; CLINICAL PREDICTORS; PEDIATRIC-PATIENTS; SKULL FRACTURE; CT-SCANS; MANAGEMENT; CHILDREN	Background. Whether the strategy for care of mild head injury should be in-hospital observation or computed tomography (CT) investigation and home care has been discussed lately. A necessary requirement for guidelines and the design of clinical trials would be knowledge about the risks of the condition. These have not been reliably summarised. The study aims to estimate as accurately as possible the mortality, the complication rates, and the frequency of pathological findings on CT in patients with mild head injury. Methods. Mild head injury was defined as head trauma involving loss of consciousness or amnesia, but where neurological findings on arrival at hospital are normal (GCS 15). Large databases were searched to find relevant scientific literature, and the retrieved studies were critically appraised. Findings were used from all representative patient data sets that met predefined standards for minimum quality. Meta-analysis using the random-effects model was performed on the data collected. Findings. The search yielded 24 studies on 24249 patients fulfilling the requirements. The mean mortality of patients was low, 0.1% (Cl 0.05-0.15). Complications, mostly requiring surgery, occurred in 0.9% (Cl 0.6-1.2) of the cases. In approximately 8% (Cl 6.1-9.5), pathological CT findings, dominated by haemorrhages, were identified in the acute phase. Conclusions. Of 1000 patients arriving at hospital with mild head injury, 1 will die, 9 will require surgery or other intervention, and about 80 will show pathological findings on CT. At least these 8% of patients will probably need in-hospital care.	Karolinska Hosp, Dept Med N4 01, Clin Epidemiol Unit, SE-17176 Stockholm, Sweden; SBU, Swedish Council Technol Assessment Hlth Care, Stockholm, Sweden		Geijerstam, JLA (corresponding author), Karolinska Hosp, Dept Med N4 01, Clin Epidemiol Unit, SE-17176 Stockholm, Sweden.						Adams J, 2001, J PEDIATR SURG, V36, P119, DOI 10.1053/jpsu.2001.20026; af Geijerstam JL, 2000, EUR J SURG, V166, P526; AFGEIJERSTAM JL, 2003, IN PRESS EMERG MED J; Arienta C, 1997, SURG NEUROL, V48, P213, DOI 10.1016/S0090-3019(97)00019-0; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIES RL, 1995, PEDIATRICS, V95, P345; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Holmes JF, 1997, ACAD EMERG MED, V4, P788, DOI 10.1111/j.1553-2712.1997.tb03786.x; Ingebrigtsen T., 1995, Tidsskrift for den Norske Laegeforening, V115, P1601; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MIKHAIL MG, 1992, AM J EMERG MED, V10, P24, DOI 10.1016/0735-6757(92)90119-I; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MITCHELL KA, 1994, J PEDIATR SURG, V29, P851, DOI 10.1016/0022-3468(94)90001-9; Murshid WR, 1998, ACTA NEUROCHIR, V140, P56, DOI 10.1007/s007010050058; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; PELOSO LC, 2003, BRAIN INJ S, V17, P29; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; REINUS WR, 1993, ANN EMERG MED, V22, P1148, DOI 10.1016/S0196-0644(05)80981-3; Roddy SP, 1998, PEDIATRICS, V101, P575, DOI 10.1542/peds.101.4.575; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SCHYNOLL W, 1993, AM J EMERG MED, V11, P321, DOI 10.1016/0735-6757(93)90160-D; SERVADEI F, 1988, J NEUROL NEUROSUR PS, V51, P526, DOI 10.1136/jnnp.51.4.526; SERVADEI F, 1993, SURG NEUROL, V39, P269, DOI 10.1016/0090-3019(93)90003-J; SERVADEI F, 1995, J TRAUMA, V39, P696, DOI 10.1097/00005373-199510000-00015; SERVADEI F, 1988, SURG NEUROL, V30, P364, DOI 10.1016/0090-3019(88)90199-1; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; STIELL IG, 2001, ACAD EMERG MED, V8, P455; STIELL IG, 2001, ACAD EMERG MED, V8, P453; *SWED COUNC TECHN, 2001, MILD HEAD INJ IN HOS; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; Vilke GM, 2000, AM J EMERG MED, V18, P159, DOI 10.1016/S0735-6757(00)90009-3; Viola L, 2000, ACTA NEUROCHIR, V142, P1281, DOI 10.1007/s007010070026	60	76	77	0	2	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	OCT	2003	145	10					843	850		10.1007/s00701-003-0115-1			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	739AW	WOS:000186320900001	14577005				2022-02-06	
J	Stalnacke, BM; Tegner, Y; Sojka, P				Stalnacke, BM; Tegner, Y; Sojka, P			Playing ice hockey and basketball increases serum levels of S-100B in elite players - A pilot study	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						brain injury; concussion; head injury; sport; ice hockey; basketball	NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; MYELIN BASIC-PROTEIN; MINOR HEAD-INJURY; CEREBROSPINAL-FLUID; SUBARACHNOID HEMORRHAGE; CONCUSSION; DAMAGE; MARKER; QUESTIONNAIRE	Objective: To investigate changes in serum concentrations of the biochemical markers of brain damage S-100B and neuron-specific enolase (NSE) in ice hockey and basketball players during games. Design: Descriptive clinical research. Setting; Competitive games of the Swedish Elite Ice Hockey League and the Swedish Elite Basketball League. Participants: Twenty-six male ice hockey players (from two teams) and 18 basketball players (from two teams). Interventions: None. Main Outcome Measures: S-100B and NSE were analyzed using two-site immunoluminometric assays. The numbers of acceleration/deceleration events were assessed from videotape recordings of the games. Head trauma-related symptoms were monitored 24 hours after the game using the Riverimead Post Concussion Symptoms Questionnaire. Results: Changes in serum concentrations of S-100B (post-game - pregame values) were statistically significant after both games (ice hockey, 0.072 +/- 0.108 mug/L, P = 0.00004; basketball, 0.076 +/- 0.091 mug/L, P = 0.001). In basketball, there was a significant correlation between the change in S-100B (post-game - pregame values) and jumps, which were the most frequent acceleration/deceleration (r = 0.706, P = 0.002). For NSE, no statistically significant change in serum concentration was found in either game. For one ice hockey player who experienced concussion during play, S-100B was increased more than for the other players. Conclusions: S-100B was released into the blood of the players as a consequence of game-related activities and events. Analysis of the biochemical brain damage markers (in particular S-100B) seems to have the potential to become a valuable additional tool for assessment of the degree of brain tissue damage in sport-related head trauma and probably for decision making about returning to play.	Umea Univ, Dept Community Med & Rehabil Rehabil Med, SE-90185 Umea, Sweden; Umea Univ, Dept Surg & Perioperat Sci, SE-90185 Umea, Sweden; Lulea Univ Technol, Inst Hlth Sci, Winternet, Boden, Sweden		Sojka, P (corresponding author), Umea Univ, Dept Community Med & Rehabil Rehabil Med, Bldg 9A, SE-90185 Umea, Sweden.	peter.sojka@clinphys.umu.se		Tegner, Yelverton/0000-0003-3628-0705			*AB SANGT MED, 2001, LIA SANGT 100; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barzo P, 1997, ACT NEUR S, V70, P243; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BIASCA N, 1995, UNFALLCHIRURG, V98, P283; Bottiger BW, 2001, CIRCULATION, V103, P2694; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 2000, NEUROLOGIC ATHLETIC, P76; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; de Vries J, 2001, J NEUROL NEUROSUR PS, V71, P671, DOI 10.1136/jnnp.71.5.671; Ergun R, 1998, NEUROL RES, V20, P418; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; HAIMOTO H, 1987, LAB INVEST, V57, P489; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jorgensen U, 1986, Br J Sports Med, V20, P7; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LECLERC S, 1999, MED SCI SPORTS EXERC, V31; Linstedt U, 2002, ACTA ANAESTH SCAND, V46, P384, DOI 10.1034/j.1399-6576.2002.460409.x; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; McCrory PR, 1999, BRIT J SPORT MED, V33, P297; Missler U, 2000, CLIN CHEM, V46, P993; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; SHAABAN AM, 2000, ANAESTHESIA, V55, P802; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	52	76	78	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2003	13	5					292	302					11	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	728JU	WOS:000185714700004	14501312				2022-02-06	
J	Ewing-Cobbs, L; Barnes, MA; Fletcher, JM				Ewing-Cobbs, L; Barnes, MA; Fletcher, JM			Early brain injury in children: Development and reorganization of cognitive function	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	Conference on Biological and Social Determinants of Child Development	JAN 18-21, 2000	HOUSTON, TX				CLOSED-HEAD-INJURY; EARLY-ONSET HYDROCEPHALUS; DEVELOPING AGE PEERS; YOUNG-CHILDREN; SPINA-BIFIDA; COMPREHENSION SKILL; NARRATIVE DISCOURSE; SPEECH ACTS; FOLLOW-UP; ADOLESCENTS	Children who sustain congenital or acquired brain injury typically experience a diffuse insult that impacts many areas of the brain. Yet research has only recently begun to examine the development of these children, who often provide excellent examples of the presence or absence of neural plasticity. Development and recovery after such injuries reflects both restoration and reorganization of cognitive functions. To understand these processes, research should focus on questions and assessment paradigms oriented toward the acquisition (rather than the recovery) of cognitive functions. Outcomes may appear similar across types of insults, even when the sources of difficulties and their neural correlates are different. Comparisons of outcomes involving intellectual functions, memory and learning, reading, and language/discourse in children who sustain congenital injury (spina bifida meningomyelocele) and acquired injury (traumatic brain injury) illustrate these principles and the value of research on diffuse brain injury in children.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Hosp Sick Children, Toronto, ON M5G 1X8, Canada		Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7000 Fannin,UCT 2401, Houston, TX 77030 USA.	linda.ewing-cobbs@uth.tmc.edu	fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462, R01NS021889, R01NS046308] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD 27957] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 21889, R01 NS046308, R01 NS 29462] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Aram DM, 1999, CHANGING NERVOUS SYSTEM, P254; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BACKMAN J, 1999, J INT NEUROPSYCHOLOG, V5; BARKOVICH AJ, 1995, PEDIAT NEUROIMAGING; Barnes MA, 1996, READING COMPREHENSION DIFFICULTIES, P251; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Barnes MA, 1998, BRAIN LANG, V61, P309, DOI 10.1006/brln.1998.1843; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; Barnes MA, 2001, BRAIN LANG, V76, P35, DOI 10.1006/brln.2000.2389; Barnes MA, 1996, J EXP CHILD PSYCHOL, V61, P216, DOI 10.1006/jecp.1996.0015; BARNES MA, 1992, J PEDIATR PSYCHOL, V17, P445, DOI 10.1093/jpepsy/17.4.445; BARNES MA, 2002, UNPUB READING WRITIN; Bates E, 1999, CHANGING NERVOUS SYSTEM, P214; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Brewer VR, 2001, NEUROPSYCHOLOGY, V15, P185, DOI 10.1037//0894-4105.15.2.185; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Brookshire BL, 1995, CHILD NEUROPSYCHOL, V1, P106, DOI 10.1080/09297049508402242; BROOKSHIRE BL, 1995, J PEDIATR PSYCHOL, V20, P785, DOI 10.1093/jpepsy/20.6.785; BUSCHKE H, 1974, J EXP CHILD PSYCHOL, V18, P488, DOI 10.1016/0022-0965(74)90126-X; Cain K, 2001, MEM COGNITION, V29, P850, DOI 10.3758/BF03196414; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Delis DC., 1994, CALIFORNIA VERBAL LE; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1994, BRAIN LANG, V46, P129, DOI 10.1006/brln.1994.1008; DENNIS M, 1981, ARCH NEUROL-CHICAGO, V38, P607, DOI 10.1001/archneur.1981.00510100035004; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; DENNIS M, 1987, J CLIN EXP NEUROPSYC, V9, P723, DOI 10.1080/01688638708405213; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; DENNIS M, 1993, J PEDIATR PSYCHOL, V18, P639, DOI 10.1093/jpepsy/18.5.639; DENNIS M, 1987, J CLIN EXP NEUROPSYC, V9, P593, DOI 10.1080/01688638708410771; DENNIS M, 1990, DISCOURSE ABILITY BR, P1969; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; DONDERS J, 1992, J CHILD NEUROL, V7, P375, DOI 10.1177/088307389200700408; DONDERS J, 1993, CLIN NEUROPSYCHOL, V7, P430, DOI 10.1080/13854049308401533; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, IN PRESS DEV NEUROPS; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FLETCHER JM, 1992, ARCH NEUROL-CHICAGO, V49, P818, DOI 10.1001/archneur.1992.00530320042010; Fletcher JM, 2000, SCI PRACT NEUROPSYCH, P25; Fletcher JM, 1996, ARCH NEUROL-CHICAGO, V53, P549, DOI 10.1001/archneur.1996.00550060093022; Fletcher JM, 1996, DEV NEUROPSYCHOL, V12, P53, DOI 10.1080/87565649609540640; FLETCHER JM, 1994, ATYPICAL COGNITIVE D, P297; FLETCHER JM, 1995, J PEDIATR PSYCHOL, V20, P765; FLETCHER JM, 1995, SYNDROME NONVERBAL L, P206; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GOLDMANRAKIC PS, 1994, ATYPICAL COGNITIVE D, P3; Halliday M. K., 1976, COHESION ENGLISH; HALLIWELL MD, 1980, Z KINDERCHIR, V31, P375; HAMM RJ, 2000, CEREBRAL REORGANIZAT, P46; Hannay HJ, 1999, CHANGING NERVOUS SYSTEM, P149; HEBB D. O., 1942, PROC AMER PHIL SOC, V85, P275; HOLMBECK GN, 1995, J PEDIATR PSYCHOL, V20, P817, DOI 10.1093/jpepsy/20.6.817; Holmbeck GN, 1997, J PEDIATR PSYCHOL, V22, P167; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; Kintsch W., 1974, REPRESENTATION MEANI; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LANDRY SH, 2001, J INT NEUROPSYCH SOC, V7, P246; LENNEBERG EH, 1967, BIOL FORMULATIONS LA; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; MCCULLOUGH D, 1990, HYDROCEPHALUS, P180; MCDONOUGH SC, 1988, EARLY IDENTIFICATION, P318; MORROW JD, 1992, DEV MED CHILD NEUROL, V34, P488; MURDOCH BE, 1990, ACQUIRED NEUROLOGICA, P216; PARSONS JG, 1969, DEV MED CHILD NEUROL, VS, P75; PENNINGTON BF, 1994, MAC FDN MEN, P243; Povlishock J T, 2000, Clin Neurosurg, V46, P113; REIGEL DH, 1994, PEDIAT NEUROSURGERY, P51; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; SATZ P, 1981, ACQUIRED APHASIA, P399; Scott MA, 1998, NEUROPSYCHOLOGY, V12, P578, DOI 10.1037/0894-4105.12.4.578; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SOARE PL, 1977, AM J DIS CHILD, V131, P199, DOI 10.1001/archpedi.1977.02120150081017; St James-Roberts I, 1979, Adv Child Dev Behav, V14, P253, DOI 10.1016/S0065-2407(08)60116-0; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; WAGNER RK, 1994, DEV PSYCHOL, V30, P73, DOI 10.1037/0012-1649.30.1.73; Wechsler D., 1974, WECHSLER INTELLIGENC; WILLS KE, 1993, J CLIN CHILD PSYCHOL, V22, P247, DOI 10.1207/s15374424jccp2202_11; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; WOLF LS, 1992, PEDIAT PHYSICAL THER, P12; Wolf M, 1999, J EDUC PSYCHOL, V91, P415, DOI 10.1037/0022-0663.91.3.415; WOODS BT, 1978, ANN NEUROL, V3, P273, DOI 10.1002/ana.410030315; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; YEATES KO, 1995, J PEDIATR PSYCHOL, V20, P801, DOI 10.1093/jpepsy/20.6.801; [No title captured]; [No title captured]	116	76	79	0	27	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2003	24	2-3					669	704		10.1207/S15326942DN242&3_08			36	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology	738LF	WOS:000186288600008	14561566				2022-02-06	
J	Ownsworth, TL; McFarland, K; Young, RM				Ownsworth, TL; McFarland, K; Young, RM			The investigation of factors underlying deficits in self-awareness and self-regulation	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; HEAD-INJURY; IMPAIRED AWARENESS; REHABILITATION; ANOSOGNOSIA; UNAWARENESS; DYSFUNCTION; DISORDER; ADULTS	Primary objective: To examine a theoretical model which suggests that a contribution of both psychological and neuropsychological factors underlie deficits in self-awareness and self-regulation. Research design: Multivariate design including correlations and analysis of variance (ANOVA). Methods: Sixty-one subjects with acquired brain injury (ABI) were administered standardized measures of self-awareness and self-regulation. Psychological factors included measures of coping-related denial, personality-related denial and personality change. Neuropsychological factors included an estimate of IQ and two measures of executive functioning that assess capacity for volition and purposive behaviour. Main outcomes and results: The findings indicated that the relative contribution of neuropsychological factors to an outcome of deficits in self-awareness and self-regulation had a more direct effect than psychological factors. In general, measures of executive functioning had a direct relationship, while measures of coping-related and personality-related denial had an indirect relationship with measures of self-awareness and self-regulation. Conclusion: The findings highlighted the importance of measuring both neuropsychological and psychological factors and demonstrated that the relative contribution of these variables varies according to different levels of self-awareness and self-regulation.	Univ Queensland, Sch Psychol, St Lucia, Qld 4067, Australia; Univ Queensland, Dept Psychiat, St Lucia, Qld 4067, Australia		Ownsworth, TL (corresponding author), Brain Injury Assoc Queensland, POB 1519, Milton, Qld 4064, Australia.		Young, Ross/AAF-2082-2021	Ownsworth, Tamara/0000-0003-1835-7094; Young, Ross/0000-0002-6806-6503			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BLUMER D, 1975, PSYCHIATRIC ASPECTS, V1, P151; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cramer P, 1998, J PERS, V66, P919, DOI 10.1111/1467-6494.00037; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; Feinberg TE, 1997, NEUROCASE, V3, P73, DOI 10.1080/13554799708404037; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P259, DOI 10.1080/09602019308401440; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; GISI TM, 1999, DISS ABSTR INT B, V59, P4463; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Kiersky JE, 1998, INSIGHT AND PSYCHOSIS, P91; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; LANE RD, 1990, AM J PSYCHIAT, V147, P573; Langer KG., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [DOI 10.1080/09602019208401395, 10.1080/09602019208401395]; LEVINE J, 1975, J CONSULT CLIN PSYCH, V43, P751; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lezak MD., 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; LOEB PA, 1986, INDEPENDENT LIVING S; MALCOLM CD, 1993, THESIS BOSTON U; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Mesulam M., 1985, PRINCIPLES BEHAV NEU; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NOCKLEBY DM, 1987, INT J CLIN NEUROPSYC, V9, P145; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Prigatano G. P., 1993, NEUROPSYCHOL REHABIL, V3, P53; Prigatano GP, 1999, REHABIL PSYCHOL, V44, P145, DOI 10.1037/0090-5550.44.2.145; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; Prigatano GP, 1986, CLIN NEUROPSYCHOLOGY, P135; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; REYNOLDS WM, 1982, J CLIN PSYCHOL, V38, P119, DOI 10.1002/1097-4679(198201)38:1<119::AID-JCLP2270380118>3.0.CO;2-I; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rosenthal M., 1983, REHABILITATION HEAD, P197; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; STARKSTEIN SE, 1993, NEUROPSY NEUROPSY BE, V6, P43; Stuss D., 1991, AWARENESS DEFICIT BR, P63; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; TUPPER DE, 1989, ANN M NAT AC NEUR WA; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; Wechsler, 1997, WECHSLER ADULT INTEL; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO; [No title captured]	56	76	76	0	18	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK,, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2002	16	4					291	309		10.1080/02699050110103986			19	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	541CM	WOS:000174967700002	11953001				2022-02-06	
J	Biousse, V; Suh, DY; Newman, NJ; Davis, PC; Mapstone, T; Lambert, SR				Biousse, V; Suh, DY; Newman, NJ; Davis, PC; Mapstone, T; Lambert, SR			Diffusion-weighted magnetic resonance imaging in shaken baby syndrome	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article; Proceedings Paper	27th Annual Meeting of the American-Association-for-Pediatric-Ophthalmology-and-Strabismus	MAR 21-25, 2001	ORLANDO, FL	Amer Assoc Pediat Ophthalmol & Strabismus			TRAUMATIC BRAIN-INJURY; NONACCIDENTAL HEAD-INJURY; YOUNG-CHILDREN; INFANTS; NEUROPATHOLOGY; STROKE; ABUSE	PURPOSE: To evaluate the role of diffusion weighted magnetic resonance imaging (DWIMRI) in the diagnosis and management of children with suspected or confirmed Shaken Baby Syndrome (SBS). METHODS: This was a retrospective interventional case series of all infants and children younger than 2 years of age admitted to a children's hospital. We retrospectively reviewed medical records and neuroimaging findings of all children younger than 2 years of age with confirmed or suspected SBS admitted to a children's hospital. Inclusion criteria were documented ocular examination by an ophthalmologist and a brain MRI with DWI. Twenty-six infants and children were included. Other children were excluded. Children with proven SBS were diagnosed with "confirmed SBS," while children in whom the diagnosis of SBS remained uncertain were diagnosed with "suspected SBS." RESULTS: Twenty-six infants and children with mean age of 7.1 months (range, 6 weeks-24 months) were included, 18 with confirmed SBS. All 26 patients had a subdural hematoma, 10 had associated occult bone fractures, and 18 had retinal hemorrhages. Seven of the eight cases without retinal hemorrhages had isolated subdural hematoma without parenchymal brain lesions on both conventional MRI and DWIMRI. SBS was confirmed in only one case with a normal fundus. Among the 18 patients with retinal hemorrhages, SBS was confirmed in all but one case. All 18 patients with confirmed SBS had an abnormal DWIMRI. In 13 patients, DWI showed lesions that were larger than on conventional MRI. In patients with brain parenchymal lesions, the DWIMRI characteristics suggested cerebral ischemia, which appears to play a major role in SBS. CONCLUSIONS: In all patients with confirmed SBS, DWIMRI was abnormal and suggested diffuse or posterior cerebral ischemia, in addition to subdural hematomas in the pathogenesis of this disorder. (Am J Ophthalmol 2002;133:249-255. (C) 2002 by Elsevier Science Inc. All rights reserved.).	Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol Surg, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA		Biousse, V (corresponding author), Emory Eye Ctr, Neuroophthalmol Unit, 1365-B Clifton Rd NE, Atlanta, GA 30322 USA.	vbiouss@emory.edu	Newman, Nancy/AAB-2532-2021		NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY006360] Funding Source: NIH RePORTER; NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30-EY06360] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; *AM COLL RAD, 2000, AM COLL RADIOL, P805; Beauchamp NJ, 1998, RADIOGRAPHICS, V18, P1269, DOI 10.1148/radiographics.18.5.9747619; Beaulieu C, 1999, Semin Pediatr Neurol, V6, P87, DOI 10.1016/S1071-9091(99)80035-7; BIRD CR, 1987, RADIOLOGY, V163, P373, DOI 10.1148/radiology.163.2.3562816; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; *CDC, 1990, AM J DIS CHILD, V44, P627; Conway EE, 1998, PEDIATR ANN, V27, P677, DOI 10.3928/0090-4481-19981001-11; COWAN EM, 1994, NEUROPEDIATRICS, V25, P172, DOI 10.1055/s-2008-1073018; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Frodi A., 1985, INFANT CRYING, P263, DOI DOI 10.1007/978-1-4613-2381-5_12; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HAN BK, 1989, AM J NEURORADIOL, V10, P1191; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Kairys SW, 2001, PEDIATRICS, V108, P206; Kivlin J D, 1999, Trans Am Ophthalmol Soc, V97, P545; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; LEVIN A V, 1989, Pediatric Emergency Care, V5, P181, DOI 10.1097/00006565-198909000-00011; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McCabe CF, 2000, ARCH OPHTHALMOL-CHIC, V118, P373, DOI 10.1001/archopht.118.3.373; Provenzale JM, 1999, AM J ROENTGENOL, V173, P1459, DOI 10.2214/ajr.173.6.10584783; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Sane SM, 2000, PEDIATRICS, V105, P1345; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; 1998, LANCET, V352, P335	38	76	78	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9394	1879-1891		AM J OPHTHALMOL	Am. J. Ophthalmol.	FEB	2002	133	2					249	255		10.1016/S0002-9394(01)01366-6			7	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Ophthalmology	518LM	WOS:000173669900011	11812430				2022-02-06	
J	Zhang, H; Zhang, XD; Zhang, TL; Liren, C				Zhang, H; Zhang, XD; Zhang, TL; Liren, C			Excitatory amino acids in cerebrospinal fluid of patients with acute head injuries	CLINICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN INJURY; SUBDURAL-HEMATOMA; RELEASE; DAMAGE; RAT	Background: The excitatory amino acids (EAAs) glutamate (Glu) and aspartate (Asp) play a role in the pathogenesis of postischemic and posttraumatic brain insult. The changes of EAAs in cerebrospinal fluid (CSF) of patients with traumatic brain injury are incompletely understood. Methods: We used reversed-phase HPLC with precolumn derivatization with o-phthalaldehyde and fluorescence detection to measure Glu and Asp in CSF of 42 patients with acute head injury and 9 control adults without neurologic diseases. We assessed the Glasgow Coma Scale (GCS) on admission, the main lesion patterns on computed tomography (CT) scan within 24 h post trauma, and the Glasgow Outcome Scale (GOS) 3 months post injury. Results: The mean concentrations of Glu and Asp in CSF in the brain-injured group were significantly higher than those of the control group (Glu, P < 0.001; Asp, P < 0.05). In patients admitted within 24 h after severe injury (n = 13), peak Glu values appeared within 48 h in 11 patients (85%), and the mean value remained higher than control values at day 7 (P < 0.02). The concentrations of EAAs were higher in patients with severe injuries (GCS less than or equal to 8) than in those with milder injuries (Glu, P < 0.001; Asp, P < 0.05). GCS and peak EAAs correlated negatively (Glu, r(s) = -0.5706, P < 0.001; Asp, r(s) = -0.5503, P < 0.001). The patients with focal brain contusion on initial CT scan (n = 8) had a significantly lower peak Glu value than the patients with other patterns (n = 8-15; P < 0.02 to 0.001). The peak value of EAAs in the poor-outcome group (including severe disability, vegetative state, and death) was significantly higher than in the good-outcome group (good recovery and moderate disability; Glu, P < 0.001; Asp, P < 0.01); GOS was closely correlated to the EAA values (Glu, r(s) = 0.5737, P < 0.001; Asp, r(s) = 0.5470, P < 0.001). Conclusions: The EAA concentrations in CSF increase after acute head injury and remain higher for at least 1 week post injury in severely injured patients. The more severe the trauma, the more obvious the excitotoxicity induced by EAAs and the worse the outcome. (C) 2001 American Association for Clinical Chemistry.	Chinese Acad Sci, Lanzhou Inst Chem Phys, Chromatog Ctr, Lanzhou 730000, Peoples R China; Lanzhou Med Coll, Affiliated Hosp 2, Dept Neurosurg, Lanzhou 730030, Peoples R China; Lonzhou Med Coll, Affiliated Hosp 1, Dept Neurosurg, Lanzhou 730000, Peoples R China		Liren, C (corresponding author), Chinese Acad Sci, Lanzhou Inst Chem Phys, Chromatog Ctr, 342 Tianshui Rd, Lanzhou 730000, Peoples R China.						ALBIN RL, 1992, NEUROLOGY, V42, P733, DOI 10.1212/WNL.42.4.733; AMARA SG, 1992, NATURE, V360, P420, DOI 10.1038/360420d0; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CHEN MH, 1991, J NEUROSURG, V74, P944, DOI 10.3171/jns.1991.74.6.0944; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FERRARO TN, 1985, BRAIN RES, V338, P53, DOI 10.1016/0006-8993(85)90247-1; GOLDSMITH RF, 1987, CLIN CHEM, V33, P1736; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; MELDRUM B, 1993, BRAIN RES REV, V18, P293, DOI 10.1016/0165-0173(93)90014-Q; Obrenovitch TP, 1996, ACT NEUR S, V66, P50	13	76	79	0	1	AMER ASSOC CLINICAL CHEMISTRY	WASHINGTON	2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA	0009-9147			CLIN CHEM	Clin. Chem.	AUG	2001	47	8					1458	1462					5	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	456HP	WOS:000170077300019	11468237				2022-02-06	
J	Bogner, JA; Corrigan, JD; Mysiw, WJ; Clinchot, D; Fugate, L				Bogner, JA; Corrigan, JD; Mysiw, WJ; Clinchot, D; Fugate, L			A comparison of substance abuse and violence in the prediction of long-term rehabilitation outcomes after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; substance abuse; violence	COMMUNITY INTEGRATION QUESTIONNAIRE; HEAD-INJURY; EMPLOYMENT; RETURN; WORK; ALCOHOL	Objective: To determine the relative contributions of substance abuse history and violent etiology to the prediction of outcomes for individuals who sustained a traumatic brain injury (TBI) requiring inpatient rehabilitation. Design: Longitudinal study of outcomes 1 year postdischarge from rehabilitation. Setting: Specialized TBI acute rehabilitation unit. Participants: Three hundred fifty-one individuals consecutively admitted for rehabilitation. Interventions: Gathered data from patients' medical records (including etiology of injury, initial Glasgow Coma Scale scores, and FIM(TM) instrument scores at discharge), demographic details, and history of substance abuse; phone and mail survey data from individuals (Satisfaction with Life Scale [SWLS]; Community Integration Questionnaire [CIQ]). Main Outcome Measures: CIQ and SWLS; relative contributions of injury etiology, demographic and injury-related dependent variables, and substance abuse history to predictive model. Results: Almost 80% of persons with injuries from violence-related causes had a history of substance abuse. Substance abuse was found to contribute to the prediction of life satisfacton and productivity, while violent etiology was not a significant contributor to predictive models. Conclusion: Substance abuse history proved to be a strong predictor of long-term outcomes, while violent etiology of injury was less influential. The results of this study emphasize the need to include substance abuse history in all studies of outcomes after TBI, and to increase prevention efforts to limit the effects of such a history.	Ohio State Univ, Dept Phys Med & Rehabil, Ohio Reg Traumat Brain Injury Model Syst, Columbus, OH USA		Bogner, JA (corresponding author), 480 W 9th Ave, Columbus, OH 43210 USA.	bogner.1@osu.edu	Bogner, Jennifer/E-2773-2011; Corrigan, John D./E-2921-2011; Mysiw, Walter/E-3724-2011	Clinchot, Daniel/0000-0002-2810-7227			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P8; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; Drubach D A, 1993, Md Med J, V42, P989; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HOFFMANN NG, 1993, PSYCHIAT CLIN N AM, V16, P127; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JENNETT B, 1975, LANCET, V1, P480; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Leahy BJ, 1998, BRAIN INJURY, V12, P1025, DOI 10.1080/026990598121936; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MCCRADY BS, 1986, ALCOHOL CLIN EXP RES, V10, P145, DOI 10.1111/j.1530-0277.1986.tb05061.x; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SCHUCKIT MA, 1986, AM J PSYCHIAT, V143, P140; Sherer M, 1999, BRAIN INJURY, V13, P973; Substance Abuse and Mental Health Services Administration, 1999, SUMM FIND 1998 NAT H; *SUNY BUFF, 1996, GUID UN DAT SET MED; TEASDALE G, 1974, LANCET, V2, P81; TELLIER A, 1990, J CONSULT CLIN PSYCH, V58, P531; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296	39	76	76	1	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2001	82	5					571	577		10.1053/apmr.2001.22340			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	429RR	WOS:000168531200001	11346830				2022-02-06	
J	Banaclocha, MM				Banaclocha, MM			Therapeutic potential of N-acetylcysteine in age-related mitochondrial neurodegenerative diseases	MEDICAL HYPOTHESES			English	Article							ALPHA-INDUCED APOPTOSIS; TRAUMATIC BRAIN INJURY; COMPLEX I DEFICIENCY; PARKINSONS-DISEASE; HUNTINGTONS-DISEASE; ALZHEIMERS-DISEASE; FRIEDREICHS-ATAXIA; CYTOCHROME-C; CELL-DEATH; OXIDATIVE-PHOSPHORYLATION	Increasing lines of evidence suggest a key role for mitochondrial damage in neurodegenerative diseases. Brain aging, Parkinson's disease, Alzheimer's disease, Huntington's disease and Friedreich's ataxia have been associated with several mitochondrial alterations including impaired oxidative phosphorylation. Mitochondrial impairment can decrease cellular bioenergetic capacity, which will then increase the generation of reactive oxygen species resulting in oxidative damage and programmed cell death. This paper reviews the mechanisms of N-acetylcysteine action at the cellular level, and the possible usefulness of this antioxidant for the treatment of age-associated neurodegenerative diseases. First, this thiol can act as a precursor for glutathione synthesis as well as a stimulator of the cytosolic enzymes involved in glutathione regeneration. Second, N-acetylcysteine can act by direct reaction between its reducing thiol group and reactive oxygen species. Third, it has been shown that N-acetylcysteine can prevent programmed cell death in cultured neuronal cells. And finally, N-acetylcysteine also increases mitochondrial complex I and IV specific activities both in vitro and in vivo in synaptic mitochondrial preparations from aged mice. In view of the above, and because of the ease of its administration and lack of toxicity in humans, the potential usefulness of N-acetylcysteine in the treatment of age-associated mitochondrial neurodegenerative diseases deserves investigation. (C) 2001 Harcourt Publishers Ltd.	Hosp La Paz, Dept Pathol, Madrid, Spain		Banaclocha, MM (corresponding author), Urb San Blas 31, Valencia, Spain.	marbanacl@latinmail.com	Martinez-Banaclocha, Marcos/AAG-5626-2020	Martinez-Banaclocha, Marcos/0000-0003-2639-7205			ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Banaclocha MM, 1999, BRAIN RES, V842, P249, DOI 10.1016/S0006-8993(99)01819-3; Banaclocha MM, 2000, BRAIN RES, V859, P173, DOI 10.1016/S0006-8993(00)02005-9; Banaclocha MM, 1997, BRAIN RES, V762, P256, DOI 10.1016/S0006-8993(97)00493-9; Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; BENECKE R, 1992, ANN NEUROL, V32, P683, DOI 10.1002/ana.410320512; BLANCHARD BJ, 1993, NEUROREPORT, V4, P799, DOI 10.1097/00001756-199306000-00051; BORGSTROM L, 1986, EUR J CLIN PHARMACOL, V31, P217, DOI 10.1007/BF00606662; BORLONGAN CV, 1995, BRAIN RES, V697, P254, DOI 10.1016/0006-8993(95)00901-2; BRENNAN WA, 1985, J NEUROCHEM, V44, P1948, DOI 10.1111/j.1471-4159.1985.tb07192.x; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7105, DOI 10.1073/pnas.92.15.7105; Brown ASC, 1999, GREEN CHEM, V1, P17, DOI 10.1039/a807963c; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; CHANDRASEKARAN K, 1994, MOL BRAIN RES, V24, P336, DOI 10.1016/0169-328X(94)90147-3; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; DECARO L, 1989, ARZNEIMITTEL-FORSCH, V39-1, P382; DEFLORA S, 1991, AM J MED, V91, pS122, DOI 10.1016/0002-9343(91)90295-9; DONNELLY PJ, 1994, ARCH TOXICOL, V68, P110, DOI 10.1007/s002040050043; DUGAN LL, 1995, J NEUROSCI, V15, P6377; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; FERRARI G, 1995, J NEUROSCI, V15, P2857; Gibson TJ, 1996, TRENDS NEUROSCI, V19, P465, DOI 10.1016/S0166-2236(96)20054-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; Gu M, 1996, ANN NEUROL, V39, P385, DOI 10.1002/ana.410390317; Hanna MG, 1997, CURR OPIN NEUROL, V10, P351, DOI 10.1097/00019052-199708000-00012; HARMAN D, 1984, AGE, V7, P111, DOI 10.1007/BF02431866; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HAUGAARD N, 1969, BIOCHIM BIOPHYS ACTA, V172, P198, DOI 10.1016/0005-2728(69)90063-2; Helveston W, 1996, CLIN NEUROPHARMACOL, V19, P271, DOI 10.1097/00002826-199619030-00010; HOLDINESS MR, 1991, CLIN PHARMACOKINET, V20, P123, DOI 10.2165/00003088-199120020-00004; Hurd RW, 1996, NEUROLOGY, V47, P1264, DOI 10.1212/WNL.47.5.1264; HUSTLER VT, 1999, CELL DEATH DIFFER, V6, P342; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; IKEBE S, 1995, MOL BRAIN RES, V28, P281, DOI 10.1016/0169-328X(94)00209-W; JONES DP, 1995, METHOD ENZYMOL, V252, P3; Kaplan J, 1999, P NATL ACAD SCI USA, V96, P10948, DOI 10.1073/pnas.96.20.10948; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; LARSSON A, 1983, FUNCTION GLUTATHIONE; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin KT, 1997, BIOCHEM BIOPH RES CO, V230, P115, DOI 10.1006/bbrc.1996.5897; Malorni W, 1998, AIDS RES HUM RETROV, V14, P1589, DOI 10.1089/aid.1998.14.1589; MANN VM, 1990, LANCET, V336, P749, DOI 10.1016/0140-6736(90)92242-A; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; Martinez M, 2000, BRAIN RES, V855, P100, DOI 10.1016/S0006-8993(99)02349-5; MARTINEZ M, 1994, NEUROSCI LETT, V170, P121, DOI 10.1016/0304-3940(94)90254-2; Martinez M, 1999, LIFE SCI, V64, P1253, DOI 10.1016/S0024-3205(98)00472-X; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; Melkova Z, 1997, FEBS LETT, V403, P273, DOI 10.1016/S0014-5793(97)00065-3; MIQUEL J, 1995, EUR J PHARM-ENVIRON, V292, P333, DOI 10.1016/0926-6917(95)90041-1; MIZUNO Y, 1994, ANN NEUROL, V35, P204, DOI 10.1002/ana.410350212; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; OLSSON B, 1988, EUR J CLIN PHARMACOL, V34, P77, DOI 10.1007/BF01061422; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; PARKER WD, 1990, NEUROLOGY, V40, P1302, DOI 10.1212/WNL.40.8.1302; PERRY EK, 1980, NEUROSCI LETT, V18, P105, DOI 10.1016/0304-3940(80)90220-7; Priller J, 1997, ANN NEUROL, V42, P265, DOI 10.1002/ana.410420222; RATAN RR, 1994, J NEUROCHEM, V62, P376; RATAN RR, 1994, J NEUROSCI, V14, P4385; REED DJ, 1984, PHARMACOL REV, V36, P255; Sawa A, 1999, NAT MED, V5, P1194, DOI 10.1038/13518; SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0; Schapira AHV, 1997, ANN NEUROL, V41, P556, DOI 10.1002/ana.410410421; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Selwa LM, 1999, NEUROLOGY, V52, P426, DOI 10.1212/WNL.52.2.426; SHEFFNER AL, 1966, BIOCHEM PHARMACOL, V15, P1523, DOI 10.1016/0006-2952(66)90197-3; SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299; SIMONIAN NA, 1994, J NEUROPATH EXP NEUR, V53, P508, DOI 10.1097/00005072-199409000-00010; SORBI S, 1983, ANN NEUROL, V13, P72, DOI 10.1002/ana.410130116; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Swerdlow RH, 1997, NEUROLOGY, V49, P918, DOI 10.1212/WNL.49.4.918; Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417; Tabrizi SJ, 2000, ANN NEUROL, V47, P80; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Tatton WG, 1999, BBA-BIOENERGETICS, V1410, P195, DOI 10.1016/S0005-2728(98)00167-4; WHARTON DC, 1962, ARCH BIOCHEM BIOPHYS, V96, P103, DOI 10.1016/0003-9861(62)90458-7; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; YAGI T, 1984, BIOCHEMISTRY-US, V23, P2449, DOI 10.1021/bi00306a020; Yan CYI, 1998, J NEUROSCI, V18, P4042; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZHANG Y, 1990, J BIOL CHEM, V265, P16330	94	76	78	0	4	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	APR	2001	56	4					472	477		10.1054/mehy.2000.1194			6	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	428LF	WOS:000168462600011	11339849				2022-02-06	
J	Sachdev, P; Smith, JS; Cathcart, S				Sachdev, P; Smith, JS; Cathcart, S			Schizophrenia-like psychosis following traumatic brain injury: a chart-based descriptive and case-control study	PSYCHOLOGICAL MEDICINE			English	Article							HEAD-INJURY; DISEASE; ONSET	Background. Head injury has been reported to increase the likelihood of the development of schizophrenia-like psychosis (SLP), but its features and risk factors have been insufficiently investigated. Method. Between 1987 and 1997, we examined 45 referred patients with SLP following brain trauma. These subjects were matched with 45 head-injured subjects without SLP on age (current and at injury) and gender, and their case records reviewed systematically. The groups were compared and logistic regression analyses performed. Results. The psychoses had a mean age of onset of 26.3 years, a mean latency of 54.7 months after head injury, usually a gradual onset and a subacute or chronic course. Prodromal symptoms were common and depression often present at onset. Paranoid delusions and auditory hallucinations were the predominant features, with formal thought disorder, catatonic features and negative symptoms being uncommon. The SLP group had more widespread brain damage on neuroimaging, especially in the left temporal and right parietal regions, and were more impaired cognitively. Fewer (non-significantly) SLP subjects had epilepsy which was more likely to be well-controlled in this group. On regression analysis, a positive family history of psychosis and duration of loss of consciousness were the best predictors of SLP. Conclusions. Head injury-related psychosis is usually paranoid-hallucinatory and subacute or chronic in its presentation. A genetic predisposition to schizophrenia and severity of injury with significant brain damage and cognitive impairment may be vulnerability factors.	Prince Wales Hosp, NPI, Randwick, NSW 2031, Australia; Univ New S Wales, Sch Psychiat, Randwick, NSW, Australia		Sachdev, P (corresponding author), Prince Wales Hosp, NPI, Randwick, NSW 2031, Australia.		Sachdev, Perminder/ABC-1137-2020	Sachdev, Perminder/0000-0002-9595-3220			ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; Australian Bureau of Statistics, 1997, AUSTR STAND CLASS OC, V2nd; BUCKLEY P, 1993, AM J PSYCHIAT, V150, P146; Christensen H, 1997, J Int Neuropsychol Soc, V3, P631; CUTTING J, 1987, BRIT J PSYCHIAT, V151, P324, DOI 10.1192/bjp.151.3.324; Dalman C, 1999, ARCH GEN PSYCHIAT, V56, P234, DOI 10.1001/archpsyc.56.3.234; DEMOL J, 1987, ARCH PSICOLOGIA NEUR, V48, P336; FEINSTEIN A, 1990, PSYCHOL MED, V20, P793, DOI 10.1017/S0033291700036485; FRITH CD, 1988, BRIT J PSYCHIAT, V153, P437, DOI 10.1192/bjp.153.4.437; GUREJE O, 1994, AM J PSYCHIAT, V151, P368; HAFNER H, 1993, BRIT J PSYCHIAT, V162, P80, DOI 10.1192/bjp.162.1.80; HILLBOM E, 1951, ACTA PSYCHIAT NEUROL, V60, P36; JOHNSTONE EC, 1987, PSYCHOL MED, V17, P371, DOI 10.1017/S0033291700024922; Lewis S. W., 1995, P324; LEZAK MD, 1997, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; LISHMAN WA, 1998, ORGANIC PSYCHIAT PSY; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; MURRAY RM, 1987, BRIT MED J, V295, P681, DOI 10.1136/bmj.295.6600.681; OCALLAGHAN E, 1988, BRIT J PSYCHIAT, V153, P394, DOI 10.1192/bjp.153.3.394; Sachdev P, 1998, AM J PSYCHIAT, V155, P325, DOI 10.1176/ajp.155.3.325; *SPSS INC, 1999, STAT PACK SOC SCI VE; VONKRAFFTEBING R, 1918, DURCH GEHIRNERSCHUTT; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8; [No title captured]	26	76	81	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	0033-2917			PSYCHOL MED	Psychol. Med.	FEB	2001	31	2					231	239		10.1017/S0033291701003336			9	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	402TM	WOS:000167004300005	11232911				2022-02-06	
J	Li, S; Stys, PK				Li, S; Stys, PK			Na+-K+-ATPase inhibition and depolarization induce glutamate release via reverse Na+-dependent transport in spinal cord white matter	NEUROSCIENCE			English	Article						excitotoxicity; alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate; calcium; L-trans-pyrrolidine-2,4-dicarboxylic acid; myelin; Na+-Ca2+ exchange	RAT OPTIC-NERVE; ANOXIC INJURY; GLIAL-CELLS; NA+-CA2+ EXCHANGER; MULTIPLE-SCLEROSIS; MYELINATED AXONS; BRAIN ISCHEMIA; TISSUE LOSS; IN-VITRO; EXCITOTOXICITY	Excitotoxic mechanisms involving alpha -amino-3-hydroxy-5-methyl-isoxazole-4-propionate (AMPA)/kainate receptors play an important role in mediating cellular damage in spinal cord injury. However. the precise cellular mechanisms of glutamate release from non-synaptic white matter are not well understood. We examined how the collapse of transmembrane Na+ and K+ gradients induces reverse operation of Na+-dependent glutamate transporters. leading to glutamate efflux and injury to rat spinal dorsal columns in vitro. Compound action potentials were irreversibly reduced to 43% or control after ouabain/high K+/low Na+ exposure (500 muM ouabain for 30 min to increase [Na+](i), followed by 1 h ouabain+high K+ (129 mM)/low Na+ (27 mM), to further reverse transmembrane ion gradients) followed by a 2 h wash. Ca2+-free perfusate was very protective (compound action potential amplitude recovered to 87% vs. 43%). The broad spectrum glutamate antagonist kynurenic acid (I mM) or the selective AMPA antagonist GYKI52466 (30 VM) were partially protective (68% recovery). Inhibition of Na+-dependent glutamate transport with L-trans-pyrrolidine-2,4-dicarboxylic acid (I mM) also provided significant protection (71% recovery), similar to that seen with glutamate receptor antagonists. Blocking reverse Na+-Ca2+ exchange with KB-R7943 (10 muM) however, was ineffective in this paradigm (49% recovery). Semiquantitative glutamate immunohistochemistry revealed that levels of this amino acid were significantly depleted in axon cylinders and, to a lesser degree, in oligodendrocytes (but not in astrocytes) by ouabain/high K+/low Na+. which was largely prevented by glutamate transport inhibition. Our data show that dorsal column white matter contains the necessary glutamate pools and release mechanisms to induce significant injury. When Na+ and K+ gradients are disrupted, even in the absence of reduced cellular energy reserves, reverse operation of Na-dependent glutamate transport will release enough endogenous glutamate to activate AMPA receptors and cause substantial Ca2+-dependent injury. This mechanism likely plays an important role during ischemic and traumatic white matter injury. where collapse of transmembratic Na+ and K+ gradients occurs. (C) 2001 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Ottawa, Div Neurosci, Ottawa Hlth Res Inst, Ottawa Hosp, Ottawa, ON K1Y 4K9, Canada		Stys, PK (corresponding author), Univ Ottawa, Div Neurosci, Ottawa Hlth Res Inst, Ottawa Hosp, Civic Campus,725 Parkdale Ave, Ottawa, ON K1Y 4K9, Canada.						Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 1997, J NEUROSCI, V17, P1055; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Basarsky TA, 1999, J NEUROSCI, V19, P6439; Brown AM, 2001, J NEUROPHYSIOL, V85, P900, DOI 10.1152/jn.2001.85.2.900; Choi I, 1997, GLIA, V20, P184, DOI 10.1002/(SICI)1098-1136(199707)20:3<184::AID-GLIA2>3.3.CO;2-U; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; David JC, 1996, J NEUROSCI, V16, P200; Domercq M, 1999, MOL BRAIN RES, V67, P296, DOI 10.1016/S0169-328X(99)00072-8; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; FERN R, 1995, J NEUROPHYSIOL, V74, P369, DOI 10.1152/jn.1995.74.1.369; GarciaBarcina JM, 1996, EUR J NEUROSCI, V8, P2379, DOI 10.1111/j.1460-9568.1996.tb01201.x; Gegelashvili G, 1998, BRAIN RES BULL, V45, P233, DOI 10.1016/S0361-9230(97)00417-6; GEMBA T, 1994, NEUROSCIENCE, V63, P789, DOI 10.1016/0306-4522(94)90523-1; GRIFFITHS R, 1994, BIOCHEM PHARMACOL, V47, P267, DOI 10.1016/0006-2952(94)90016-7; Imaizumi T, 1999, BRAIN RES, V817, P84, DOI 10.1016/S0006-8993(98)01214-1; Imaizumi T, 1997, J NEUROTRAUM, V14, P299, DOI 10.1089/neu.1997.14.299; JENSEN AM, 1993, J NEUROSCI, V13, P1664; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; KWO S, 1989, Journal of Neurotrauma, V6, P13, DOI 10.1089/neu.1989.6.13; LEES GJ, 1995, NEUROSCI LETT, V188, P113, DOI 10.1016/0304-3940(95)11413-Q; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Li S, 1999, J Neurosci, V19, pRC16; Li SX, 2000, J NEUROSCI, V20, P1190, DOI 10.1523/JNEUROSCI.20-03-01190.2000; LoPachin RM, 1999, J NEUROPHYSIOL, V82, P2143, DOI 10.1152/jn.1999.82.5.2143; LOPACHIN RM, 1995, J NEUROSCI, V15, P6735; Matute C, 1998, P NATL ACAD SCI USA, V95, P10229, DOI 10.1073/pnas.95.17.10229; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; McAdoo DJ, 2000, BRAIN RES, V865, P283, DOI 10.1016/S0006-8993(00)02296-4; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Omar AI, 2000, NEUROSCIENCE, V95, P73; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Rutledge EM, 1996, J NEUROSCI, V16, P7803; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; Steffensen I, 1997, BRAIN RES, V776, P1, DOI 10.1016/S0006-8993(97)00868-8; Steinhauser C, 1996, TRENDS NEUROSCI, V19, P339, DOI 10.1016/0166-2236(96)10043-6; Stys P. K., 1999, J NEUROTRAUM, V16, P984; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; STYS PK, 1992, J NEUROSCI, V12, P430; STYS PK, 1994, SCI COMPUT AUTOMATIO, V10, P19; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; Takahashi M, 1997, J EXP BIOL, V200, P401; Teng YD, 1997, J NEUROSCI, V17, P4359; TRAPP BD, 1988, J NEUROCHEM, V51, P859, DOI 10.1111/j.1471-4159.1988.tb01822.x; Vandenberg RJ, 1998, CLIN EXP PHARMACOL P, V25, P393, DOI 10.1111/j.1440-1681.1998.tb02221.x; VORNOV JJ, 1995, EXP NEUROL, V133, P7, DOI 10.1006/exnr.1995.1002; White RJ, 1997, J PHYSIOL-LONDON, V498, P31, DOI 10.1113/jphysiol.1997.sp021839; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Yoshioka A, 1996, J NEUROSCI RES, V46, P427; YOSHIOKA A, 1995, J NEUROCHEM, V64, P2442; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	58	76	76	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2001	107	4					675	683		10.1016/S0306-4522(01)00385-2			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	501AV	WOS:000172661600013	11720790				2022-02-06	
J	Baskaya, MK; Dogan, A; Rao, AM; Dempsey, RJ				Baskaya, MK; Dogan, A; Rao, AM; Dempsey, RJ			Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						brain edema; blood-brain barrier; citicoline; traumatic brain injury	EXPERIMENTAL FOCAL ISCHEMIA; FREE FATTY-ACIDS; CDP-CHOLINE; GERBIL; RATS	Object. Cytidine 5'-diphosphocholine (CDPC), or citicoline, is a naturally occurring endogenous compound that has been reported to provide neuroprotective effects after experimental cerebral ischemia. However, in no study has such protection been shown after traumatic brain injury (TBI). In this study the authors examined the effect of CDPC on secondary injury factors, brain edema and blood-brain barrier (BBB) breakdown, after TBI. Methods. After anesthesia had been induced in Sprague-Dawley rats by using 1.5% halothane, an experimental TBI was created using a controlled cortical impact (CCI) device with a velocity of 3 m/second, resulting in a 2-mm deformation. Four sham-operated control animals used for brain edema and BBB breakdown studies underwent the same surgical procedure, but received no injury. Brain edema was evaluated using the wet-dry method 24 hours postinjury, and BBB breakdown was evaluated by measuring Evans blue dye (EBD) extravasation with fluorescein 6 hours after TBI. The animals received intraperitoneal injections of CDPC (50, 100, or 400 mg/kg two times after TBI [eight-10 animals in each group]) or saline (eight animals) after TBI. Traumatic brain injury induced an increase in the percentage of water content and in EBD extravasation in the injured cortex and the ipsilateral hippocampus. No significant benefit from CDPC treatment was observed at a dose of 50 mg/kg. Cytidine 5'-diphosphocholine at a dose of 100 mg/kg attenuated EBD extravasation in both regions, although it reduced brain edema only in the injured cortex. In both regions, 400 mg/kg of CDPC significantly decreased brain edema and BBB breakdown. Conclusions. This is the first report in which dose-dependent neuroprotective effects of CDPC have been demonstrated in the injured cortex as well as in the hippocampus, a brain region known to be vulnerable to injury, after experimental TBI. The results of this study suggest that CDPC is an effective neuroprotective agent on secondary injuries that appear following TBI.	Louisiana State Univ, Med Ctr, Dept Neurosurg, Shreveport, LA 71130 USA; Univ Wisconsin, Madison, WI USA; Vet Adm Hosp, Madison, WI USA		Baskaya, MK (corresponding author), Louisiana State Univ, Med Ctr, Dept Neurosurg, 1501 Kings Highway,POB 33932, Shreveport, LA 71130 USA.		Dogan, Aclan/AAF-8305-2019				BAETHMAN A, 1978, NEUROSURG REV, V1, P85; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Clark WM, 1997, NEUROLOGY, V49, P671, DOI 10.1212/WNL.49.3.671; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DORMAN RV, 1983, J NEUROCHEM, V40, P276, DOI 10.1111/j.1471-4159.1983.tb12682.x; KAKIHANA M, 1988, STROKE, V19, P217, DOI 10.1161/01.STR.19.2.217; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Onal MZ, 1997, STROKE, V28, P1060, DOI 10.1161/01.STR.28.5.1060; Rao AM, 1999, J NEUROSCI RES, V58, P697, DOI 10.1002/(SICI)1097-4547(19991201)58:5<697::AID-JNR11>3.0.CO;2-B; Schabitz WR, 1996, J NEUROL SCI, V138, P21, DOI 10.1016/0022-510X(95)00341-X; Schabitz WR, 1999, STROKE, V30, P427, DOI 10.1161/01.STR.30.2.427; SECADES JJ, 1995, METHODS FIND EXP SB, V17, P2; TROVARELLI G, 1981, NEUROCHEM RES, V6, P821, DOI 10.1007/BF00965041; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59	19	76	89	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2000	92	3					448	452		10.3171/jns.2000.92.3.0448			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	285DX	WOS:000085375400011	10701532				2022-02-06	
J	Fleming, J; Strong, J				Fleming, J; Strong, J			A longitudinal study of self-awareness: Functional deficits underestimated by persons with brain injury	OCCUPATIONAL THERAPY JOURNAL OF RESEARCH			English	Article						insight; head injury; rehabilitation; cognition	SEVERE HEAD-INJURY; ADULTS; TRAUMA	A longitudinal study of 55 adults with severe traumatic brain injury (TBI) investigated the areas of function for which they lacked self-awareness of their level of competency. Data were collected at 3 and 12 months post-injury using the Patient Competency Rating Scale. Self-awareness was measured by comparing patient self-ratings with the ratings of an infor mant. The results were consistent with previous studies, indicating that self-awareness was most impaired for activities with a large cognitive and socioemotional component, and least impaired for basic activities of daily living, memory activities, and overt emotional responses. For most areas of function that were overestimated at 3 months post-injury, self-awareness subsequently improved during the first year after injury.	Princess Alexandra Hosp, Occupat Therapy Dept, Woolloongabba, Qld, Australia; Univ Queensland, Dept Occupat Therapy, Brisbane, Qld, Australia		Fleming, J (corresponding author), Princess Alexandra Hosp, Occupat Therapy Dept, Ipswich Rd, Woolloongabba, Qld, Australia.		Strong, Jenny/F-1211-2010; Fleming, Jennifer M/B-4436-2011	Strong, Jenny/0000-0002-9367-8755; 			FAHY TJ, 1967, LANCET, V2, P475; FLEMING J, 1997, BRIT J OCCUPATIONAL, V60, P295, DOI DOI 10.1177/030802269706000703; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fleming JM, 1997, J HEAD TRAUMA REHAB, V12, P27, DOI 10.1097/00001199-199706000-00004; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; JACOBS MP, 1993, NEUROPSYCHOL REHABIL, V3, P341, DOI 10.1080/09602019308401446; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; LEVINE MJ, 1993, BRAIN INJURY, V7, P153, DOI 10.3109/02699059309008169; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; McWilliams S, 1991, BRIT J OCCUPATIONAL, V54, P246; NOCKLEBY DM, 1987, INT J CLIN NEUROPSYC, V9, P145; NORUSIS MJ, 1990, SPSS PCPLUS STAT 4 0; PONSFORD J, 1996, TRAUMATIC BRAIN INJU; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1986, CLIN NEUROPSYCHOLOGY, P135; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; PRIGATANO GP, 1998, NEUROPSYCHOLOGICAL R; ROUECHE JR, 1984, COGNITIVE REHABILITA, V2, P4; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; ZEIGLER EA, 1987, J REHABIL, V53, P50	24	76	76	0	14	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0276-1599			OCCUP THER J RES	Occup. Ther. J. Res.	WIN	1999	19	1					3	17		10.1177/153944929901900101			15	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	174VC	WOS:000079055800001					2022-02-06	
J	Fink, KB; Andrews, LJ; Butler, WE; Ona, VO; Li, M; Bogdanov, M; Endres, M; Khan, SQ; Namura, S; Stieg, PE; Beal, MF; Moskowitz, MA; Yuan, J; Friedlander, RM				Fink, KB; Andrews, LJ; Butler, WE; Ona, VO; Li, M; Bogdanov, M; Endres, M; Khan, SQ; Namura, S; Stieg, PE; Beal, MF; Moskowitz, MA; Yuan, J; Friedlander, RM			Reduction of post-traumatic brain injury and free radical production by inhibition of the caspase-1 cascade	NEUROSCIENCE			English	Article						caspase-1; interleukin-1 beta-converting enzyme; apoptosis; DNA fragmentation; TUNEL; caspase inhibition	INTERLEUKIN-1-BETA CONVERTING-ENZYME; TROPHIC FACTOR WITHDRAWAL; APOPTOTIC CELL-DEATH; NEURONAL APOPTOSIS; IL-1-BETA-CONVERTING ENZYME; MEDIATED APOPTOSIS; MAMMALIAN HOMOLOG; FAMILY PROTEASES; TRANSGENIC MICE; GENE CED-3	Necrotic and apoptotic cell death both play a role mediating tissue injury following brain trauma. Caspase-1 (interleukin-1 beta converting enzyme) is activated and oligonucleosomal DNA fragmentation is detected in traumatized brain tissue. Reduction of tissue injury and free radical production following brain trauma was achieved in a transgenic mouse expressing a dominant negative inhibitor of caspase-1 in the brain. Neuroprotection was also conferred by pharmacological inhibition of caspase-1 by intracerebroventricular administration of the selective inhibitor of caspase-1, acetyl-Tyr-Val-Ala-Asp-chloromethylketone or the non-selective caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone. These results indicate that inhibition of caspase-1-like caspases reduces trauma-mediated brain tissue injury. In addition, we demonstrate an in vivo functional interaction between interleukin-1 beta converting enyzme-like caspases and free radical production pathways, implicating free radical production as a downstream mediator of the caspase cell death cascade. (C) 1999 IBRO. Published by Elsevier Science Ltd.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg,Neurosurg Serv, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02129 USA; Univ Bonn, Sch Med, Dept Pharmacol, D-53113 Bonn, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurosurg Serv & Neurochem Lab, Boston, MA 02114 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Neurosurg Serv, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA		Friedlander, RM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg,Neurosurg Serv, 75 Francis St, Boston, MA 02115 USA.		Friedlander, Robert M/A-2845-2016; Moskowitz, Michael A/D-9916-2011	Friedlander, Robert M/0000-0003-4423-9219; 			Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHAN PH, 1994, ANN NY ACAD SCI, V738, P93; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; *DEP HHS, 1989, INT HEAD INJ TASK FO; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Estevez AG, 1998, J NEUROSCI, V18, P923; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Holtzman DM, 1997, NAT MED, V3, P954, DOI 10.1038/nm0997-954; Jordan J, 1997, J NEUROSCI, V17, P1397; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; MACMANUS JP, 1995, MOL NEUROSCI, V5, P493; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Namura S, 1998, J NEUROSCI, V18, P3659; Park DS, 1998, J NEUROSCI, V18, P830; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prehn JHM, 1997, J NEUROCHEM, V68, P1679; RINK A, 1995, AM J PATHOL, V147, P1575; Schulz JB, 1996, J NEUROSCI, V16, P4696; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shimizu S, 1996, ONCOGENE, V12, P2045; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; TOHGI H, 1995, NEUROSCI LETT, V184, P21, DOI 10.1016/0304-3940(94)11158-F; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZYCHLINSKY A, 1994, J CLIN INVEST, V94, P1328, DOI 10.1172/JCI117452	53	76	81	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		1999	94	4					1213	1218		10.1016/S0306-4522(99)00345-0			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	256PW	WOS:000083735000019	10625061				2022-02-06	
J	Durkin, MS; Hasan, ZM; Hasan, KZ				Durkin, MS; Hasan, ZM; Hasan, KZ			Prevalence and correlates of mental retardation among children in Karachi, Pakistan	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						child development; developing countries; developmental disabilities; mental retardation; prevalence	10 QUESTIONS SCREEN; CHILDHOOD DISABILITY; BANGLADESH	This paper reports estimates of the prevalence of mental retardation and associated factors based on a population survey of 2- to 9-year-old children in Greater Karachi, Pakistan. A two-phase survey was implemented during the years 1988-1989, In the first phase, a cluster sample of 6,365 children (5,748 from urban areas and 617 from rural areas) was screened for disabilities using a parental report known as the Ten Questions instrument, In the second phase, all children with positive screening results and a 10% sample of those with negative results were referred for structured medical and psychological assessments, Estimates of the prevalence of mental retardation were 19.0/1,000 children (95% confidence interval (CI) 13.5-24.4) for serious retardation and 65.3/1,000 children (95% CI 48.9-81.8) for mild retardation. Both estimates were considerably higher than respective prevalence estimates obtained in industrialized countries and in selected less developed countries. In this population, lack of maternal education was strongly associated with the prevalence of both serious (odds ratio = 3.26, 95% CI 1.26-8.43) and mild (odds ratio = 3.08, 95% CI 1.85-5.14) retardation. Other factors that were independently associated with mental retardation in Karachi included histories of perinatal difficulties, neonatal infections, postnatal brain infections, and traumatic brain injury, as well as current malnourishment. Further research is needed to assess the contribution of consanguineous marriage, improvements in child survival, and other factors to the unusually high prevalence of mental retardation in this population.	Columbia Univ, Gertrude H Sergievsky Ctr, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; New York State Psychiat Inst, New York, NY 10032 USA; Jinnah Postgrad Med Ctr, Dept Neuropsychiat, Karachi, Pakistan; Jinnah Med Coll, Karachi, Pakistan		Durkin, MS (corresponding author), Columbia Univ, Gertrude H Sergievsky Ctr, Coll Phys & Surg, 630 W 168 St, New York, NY 10032 USA.		Durkin, Maureen/B-7834-2015		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29 NS27971-01-05] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS027971] Funding Source: NIH RePORTER		Belmont L., 1986, SCI TECHNOLOGY MENTA, P389; BHUSHAN V, 1993, PEDIATRICS, V91, P1094; CHEN JH, 1993, CHILD CARE HLTH DEV, V19, P71, DOI 10.1111/j.1365-2214.1993.tb00715.x; DARR A, 1988, J MED GENET, V25, P186, DOI 10.1136/jmg.25.3.186; DRILLIEN CM, 1966, ARCH DIS CHILD, V41, P528, DOI 10.1136/adc.41.219.528; Durkin M S, 1992, Paediatr Perinat Epidemiol, V6, P166, DOI 10.1111/j.1365-3016.1992.tb00758.x; DURKIN MS, 1994, EPIDEMIOLOGY, V5, P283, DOI 10.1097/00001648-199405000-00005; DURKIN MS, 1995, J CLIN EPIDEMIOL, V48, P657, DOI 10.1016/0895-4356(94)00163-K; DURKIN MS, 1995, J EPIDEMIOL COMMUN H, V49, P431, DOI 10.1136/jech.49.4.431; DURKIN MS, IN PRESS PUBLIC HLTH; EYMAN RK, 1990, NEW ENGL J MED, V323, P584, DOI 10.1056/NEJM199008303230906; FOEGE W, 1994, JAMA-J AM MED ASSOC, V271, P1704, DOI 10.1001/jama.271.21.1704; FULLER WA, 1989, PC CARP; HASNA Z, 1981, INT J MENT HLTH, V10, P23; HASNA ZM, 1988, 8 WORLD C INT ASS SC; Hosmer DW, APPL LOGISTIC REGRES, P89; ISLAM S, 1993, MENT RETARD, V31, P412; KIELY M, 1987, EPIDEMIOL REV, V9, P194, DOI 10.1093/oxfordjournals.epirev.a036302; LEMESHOW S, 1988, SAMPLING TECHNIQUES; NARAYANAN HS, 1981, INT J MENT HEALTH, V10, P28, DOI 10.1080/00207411.1981.11448873; Reddy MA, 1996, STAT ABSTRACT WORLD; ROBERTS DF, 1969, ANN HUM GENET, V32, P407, DOI 10.1111/j.1469-1809.1969.tb00093.x; SHAMI SA, 1989, J MED GENET, V26, P267, DOI 10.1136/jmg.26.4.267; SHROUT PE, 1989, BIOMETRICS, V45, P549, DOI 10.2307/2531496; STEIN Z, 1984, STRESS DISABILITY CH, P21; Stein ZA., 1992, ASSESSMENT PEOPLE ME, P12; Thorburn M J, 1992, Disabil Rehabil, V14, P122; Thorndike R. L., 1986, STANFORD BINET INTEL	28	76	77	0	1	JOHNS HOPKINS UNIV SCHOOL HYGIENE PUB HEALTH	BALTIMORE	111 MARKET PLACE, STE 840, BALTIMORE, MD 21202-6709 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	FEB 1	1998	147	3					281	288					8	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health	YX150	WOS:000072011400014	9482503				2022-02-06	
J	Xiao, F; Safar, P; Radovsky, A				Xiao, F; Safar, P; Radovsky, A			Mild protective and resuscitative hypothermia for asphyxial cardiac arrest in rats	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						asphyxia; cardiac arrest; cardiopulmonary resuscitation; cerebral ischemia; cerebral protection; cerebral resuscitation; histopathology; hypothermia; rat model	PERMANENT FOCAL ISCHEMIA; TRAUMATIC BRAIN INJURY; MULTIFOCAL CEREBRAL HYPOPERFUSION; GLOBAL FOREBRAIN ISCHEMIA; MODERATE HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; CARDIOPULMONARY BYPASS; TEMPERATURE MODULATION; GLYCINE CONCENTRATIONS	It has been shown in dogs that mild hypothermia (34 degrees C) during or immediately after ventricular fibrillation cardiac arrest can improve cerebral outcome, The effect of mild hypothermia on outcome after 8 minutes of asphyxiation (5 minutes cardiac arrest) was studied for the first time in rats, Restoration of spontaneous circulation was with external cardiopulmonary resuscitation and observation to 72 hours, Three groups of 10 rats each were studied, At 72 hours postarrest, compared with the normothermic control group 1, final overall performance categories (OPC) and neurological deficit scores (NDS) were numerically better in the resuscitative (post arrest) hypothermia group 2 and significantly better in the protective (pre-intra arrest) hypothermia group 3 (P < .05), Total brain histopathological damage scores (HDS) were 17 +/- 5 in group 1, 14 +/- 6 in group 2 (NS), and 6 +/- 2 in group 3 (P < .001 versus group 1), HDS correlated with OPC (r = .6, P < .05) and NDS (r = .7, P < .05), Mild hypothermia improved cerebral outcome after asphyxial cardiac arrest in rats, more when induced before than after arrest, The model's insult is within the therapeutic window, which makes it also suitable for screening other cerebral resuscitation potentials. Copyright (C) 1998 by W.B. Saunders Company.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA		Safar, P (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.						ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225; ABRAMSON NS, 1992, ANN EMERG MED, V21, P1480, DOI 10.1016/S0196-0644(05)80066-6; ABRAMSON NS, 1986, NEW ENGL J MED, V314, P397; *AM HEART ASS, 1992, JAMA-J AM MED ASSOC, V268, P2199; AMES A, 1968, AM J PATHOL, V52, P437; BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BIGELOW WG, 1950, ANN SURG, V132, P849, DOI 10.1097/00000658-195011000-00001; BIGGART MJ, 1990, J PEDIATR-US, V117, P179, DOI 10.1016/S0022-3476(05)80526-8; BORISMOLLER F, 1989, J CEREB BLOOD FLOW M, V9, pS276; BUSTO R, 1994, J NEUROCHEM, V63, P1095; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; CHOPP M, 1991, STROKE, V22, P37, DOI 10.1161/01.STR.22.1.37; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; COLE SL, 1956, JAMA-J AM MED ASSOC, V161, P1454, DOI 10.1001/jama.1956.02970150022005; CONN AW, 1979, PEDIATR CLIN N AM, V26, P691; CRIPPEN D, 1991, RESUSCITATION, V21, P271, DOI 10.1016/0300-9572(91)90052-Z; DIETRICH WD, 1995, J CEREBR BLOOD F MET, V15, P960, DOI 10.1038/jcbfm.1995.122; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; EBMEYER U, 1993, CRIT CARE MED, V21, pS236; FRAZZINI VI, 1994, NEUROSURGERY, V34, P1040, DOI 10.1227/00006123-199406000-00013; GISVOLD SE, 1984, STROKE, V15, P803, DOI 10.1161/01.STR.15.5.803; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; GOTO Y, 1993, NEUROSURGERY, V32, P980, DOI 10.1227/00006123-199306000-00017; HENDRICKX HHL, 1984, RESUSCITATION, V12, P97, DOI 10.1016/0300-9572(84)90062-5; HENDRICKX HHL, 1984, RESUSCITATION, V12, P117, DOI 10.1016/0300-9572(84)90063-7; ILLIEVICH UM, 1994, ANESTHESIOLOGY, V80, P177, DOI 10.1097/00000542-199401000-00025; KADER A, 1992, NEUROSURGERY, V31, P1056, DOI 10.1227/00006123-199212000-00011; KADER A, 1994, NEUROSURGERY, V35, P272, DOI 10.1227/00006123-199408000-00013; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; KARIBE H, 1994, J NEUROSURG, V80, P112, DOI 10.3171/jns.1994.80.1.0112; KATZ L, 1995, J CEREBR BLOOD F MET, V15, P1032, DOI 10.1038/jcbfm.1995.129; KATZ L, 1994, RESUSCITATION, V28, pS10; KATZ L, 1995, CRIT CARE MED, V23, pA197; Kil HY, 1996, J CEREBR BLOOD F MET, V16, P100, DOI 10.1097/00004647-199601000-00012; Kim SH, 1997, J TRAUMA, V42, P213, DOI 10.1097/00005373-199702000-00006; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; KRISTIAN T, 1992, ACTA PHYSIOL SCAND, V146, P531, DOI 10.1111/j.1748-1716.1992.tb09457.x; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; KUBOYAMA K, 1994, RESUSCITATION, V27, P231, DOI 10.1016/0300-9572(94)90037-X; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; LEONOV Y, 1992, STROKE, V23, P45, DOI 10.1161/01.STR.23.1.45; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Marion DW, 1996, CRIT CARE MED, V24, pS81; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P315, DOI 10.1097/00000542-197009000-00008; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; NAKASHIMA K, 1995, ANESTHESIOLOGY, V82, P1199, DOI 10.1097/00000542-199505000-00015; OH SM, 1991, STROKE, V22, P915, DOI 10.1161/01.STR.22.7.915; OKU K, 1993, STROKE, V24, P1590, DOI 10.1161/01.STR.24.10.1590; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; QUAN L, 1989, PEDIATRICS, V83, P1035; RADOVSKY A, 1995, STROKE, V26, P2127, DOI 10.1161/01.STR.26.11.2127; Radovsky A, 1997, TOXICOL PATHOL, V25, P500, DOI 10.1177/019262339702500512; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; ROSOMOFF HL, 1959, ANN NY ACAD SCI, V80, P475, DOI 10.1111/j.1749-6632.1959.tb49225.x; SAFAR P, 1990, AM J EMERG MED, V8, P55, DOI 10.1016/0735-6757(90)90298-E; SAFAR P, 1976, ARCH NEUROL-CHICAGO, V33, P91, DOI 10.1001/archneur.1976.00500020019004; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; SAFAR P, 1997, YB NEUROANESTHESIA N, P557; SAFAR P, 1996, SCI PRACTICE RESUSCI, P702; SANO T, 1992, ANESTHESIOLOGY, V76, P221, DOI 10.1097/00000542-199202000-00011; SIEBKE H, 1975, LANCET, V1, P1275; STEEN PA, 1979, STROKE, V10, P522, DOI 10.1161/01.STR.10.5.522; STERZ F, 1992, RESUSCITATION, V24, P27, DOI 10.1016/0300-9572(92)90171-8; STERZ F, 1990, STROKE, V21, P1178, DOI 10.1161/01.STR.21.8.1178; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; THORESEN M, 1995, PEDIATR RES, V37, P667, DOI 10.1203/00006450-199505000-00019; VAAGENES P, 1988, J CEREBR BLOOD F MET, V8, P262, DOI 10.1038/jcbfm.1988.57; Vaagenes P, 1997, RESUSCITATION, V35, P41, DOI 10.1016/S0300-9572(97)01108-8; VERHAEGEN M, 1995, ANESTHESIOLOGY, V82, P1209, DOI 10.1097/00000542-199505000-00016; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; WHITE RJ, 1978, MAYO CLIN PROC, V53, P450; Winfree CJ, 1996, NEUROSURGERY, V38, P1216, DOI 10.1097/00006123-199606000-00034; WOLFSON SK, 1973, J SURG RES, V14, P449, DOI 10.1016/0022-4804(73)90053-X; XIAO F, 1995, RESUSCITATION, V30, P51, DOI 10.1016/0300-9572(94)00858-D; XIAO F, 1994, RESUSCITATION, V28, pS21; Yager JY, 1996, STROKE, V27, P919, DOI 10.1161/01.STR.27.5.919	96	76	80	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	JAN	1998	16	1					17	25		10.1016/S0735-6757(98)90059-6			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	YR508	WOS:000071502300005	9451308				2022-02-06	
J	Warden, DL; Labbate, LA; Salazar, AM; Nelson, R; Sheley, E; Staudenmeier, J; Martin, E				Warden, DL; Labbate, LA; Salazar, AM; Nelson, R; Sheley, E; Staudenmeier, J; Martin, E			Posttraumatic stress disorder in patients with traumatic brain injury and amnesia for the event?	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							PSYCHIATRIC CONSEQUENCES; POPULATION; ADULTS	Frequency of DSM-III-R posttraumatic stress disorder (PTSD) was studied in 47 active-duty service members (46 male, 1 female; mean age 27+/-7) with moderate traumatic brain injury and neurogenic amnesia for the event. Patients had attained ''oriented and cooperative'' recovery level. When evaluated with a modified Present State Examination and other questions at various points from study entry to 24-month follow-up, no patients met full criteria for PTSD or met criterion B (reexperience); 6 (13%) met both C (avoidance) and D (arousal) criteria. Five of these 6 also had organic mood disorder, depressed type, and/or organic anxiety disorder. Posttraumatic amnesia following moderate head injury may protect against recurring memories and the development of PTSD. Some patients with neurogenic amnesia may develop a form of PTSD without the reexperiencing symptoms.			Warden, DL (corresponding author), WALTER REED ARMY MED CTR,DEF & VET HEAD INJURY PROGRAM,BLDG 1,ROOM 209B,WASHINGTON,DC 20307, USA.						BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; BUYDENSBRANCHEY L, 1990, J NERV MENT DIS, V178, P582, DOI 10.1097/00005053-199009000-00005; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Hagen C., 1972, LEVELS COGNITIVE FUN; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; LEDOUX J, 1992, NEUROPSYCHOLOGY MEMO, P463; Levin H. S., 1992, NEUROPSYCHOLOGY MEMO, P290; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PERRY S, 1992, AM J PSYCHIAT, V149, P931; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SALAZAR AM, 1987, PROGR CLIN NEUROSCIE, V1, P225; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; WARD AA, 1966, HEAD INJURY C P, P203; WARDEN DL, 1994, NEUROLOGY, V44, pA401; Wing J. K., 1974, MEASUREMENT CLASSIFI	19	76	76	0	1	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	1997	9	1					18	22					5	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	WD688	WOS:A1997WD68800002	9017524				2022-02-06	
J	Zafonte, RD; Mann, NR; Millis, SR; Black, KL; Wood, DL; Hammond, F				Zafonte, RD; Mann, NR; Millis, SR; Black, KL; Wood, DL; Hammond, F			Posttraumatic amnesia: Its relation to functional outcome	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							GLASGOW COMA SCALE; SEVERE HEAD-INJURY; TRAUMATIC BRAIN INJURY; PREDICTION; DISABILITY; PRESSURE; RECOVERY	Objective: To investigate the relation between duration of posttraumatic amnesia (PTA) and functional outcome in a traumatically brain injured population. Patients: Two hundred seventy-six patients with traumatic brain injury (TBI) who were admitted to a Level I university trauma center and required inpatient rehabilitation. Measures: Duration of PTA was assessed by serial administrations of the Galveston Orientation Amnesia Test (GOAT). Functional Independence Measure (FIM) total scores, FIM cognitive and motor subscores, and Disability Rating Scale (DRS) scores were obtained at admission and discharge from inpatient rehabilitation. Results: Duration of PTA was a significant predictor of all admission and discharge DRS and FIM scores. Duration of PTA and age at the time of injury, in combination, contributed significantly to the prediction of the DRS score and FIM total, cognitive, and motor scores at discharge. Conclusion: Duration of PTA appears to be a useful variable in predicting specific functional outcome in the TBI population receiving inpatient rehabilitation services. The use of age as a factor in addition to duration of PTA enhances the prediction of functional outcome. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.			Zafonte, RD (corresponding author), WAYNE STATE UNIV,INST REHABIL,261 MACK BLVD,DETROIT,MI 48201, USA.						CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Cohen J., 2013, STAT POWER ANAL BEHA; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ D, 1996, BRAIN INJ ASS P 1996, P216; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NORUSIS MJ, 1995, SPSS WINDOWS RELEASE; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Stevens J.P., 1992, APPL MULTIVARIATE ST, V2nd; THATCHER R, 1983, J NEUROSURG, V59, P294; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P456, DOI 10.1097/00002060-199611000-00011	23	76	79	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1997	78	10					1103	1106		10.1016/S0003-9993(97)90135-0			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	YA044	WOS:A1997YA04400009	9339160				2022-02-06	
J	Theriault, E; Frankenstein, UN; Hertzberg, EL; Nagy, JI				Theriault, E; Frankenstein, UN; Hertzberg, EL; Nagy, JI			Connexin43 and astrocytic gap junctions in the rat spinal cord after acute compression injury	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						glial cells; gap junction proteins; neuron survival; subpial white matter; immunohistochemistry	SCANNING ELECTRON-MICROSCOPY; FIBRILLARY ACIDIC PROTEIN; VASCULAR CORROSION CASTS; KAINIC ACID; 3-DIMENSIONAL ANALYSIS; CULTURED ASTROCYTES; FREEZE-FRACTURE; NERVOUS-SYSTEM; BRAIN; EXPRESSION	To examine the possible role of interastrocytic gap junctions in the maintenance of tissue homeostasis after spinal cord damage, we initiated studies of the astrocytic gap junctional protein connexin43 (Cx43) in relation to temporal and spatial parameters of neuronal loss, reactive gliosis, and white matter survival in a rat model of traumatic spinal cord injury (SCI). Cx43 immunolocalization in normal and compression-injured spinal cord was compared by using two different sequence-specific anti-Cx43 antibodies that have previously exhibited different immunorecognition properties at lesion sites in brain. At 1- and 3-day survival times, gray matter areas with mild to moderate neuronal depletion exhibited a loss of immunolabelling with one of the two antibodies. At the lesion epicenter, these areas consisted of a zone that separated normal staining distal to the lesion from intensified labeling seen with both antibodies immediately adjacent to the lesion. Loss of immunoreactivity with only one of the two antibodies suggested masking of the corresponding Cx43 epitope. By 7 days post-SCI, Cx43 labeling was absent with both antibodies in all regions extending up to I mm from the lesion site. Reactive astrocytes displaying glial fibrillary acidic protein (GFAP) appeared by 1 day and were prominent by 3 days post-SCI. Their distribution in white and gray matter corresponded closely to that of Cx43 staining at 1 day, but less so at 3 days when GFAP-positive profiles were present at sites where Cx43 labeling was absent. By 7 days post-SCI, Cx43 again co-localized with GFAP-positive cells in the surviving subpial rim, and with astrocytic processes on radially oriented vascular profiles investing the central borders of the lesion. The results indicate that alterations in Cx43 cellular localization and Cx43 molecular modifications reflected by epitope masking, which were previously correlated with gap junction remodeling following excitotoxin-induced lesions in brain, are not responses limited to exogenously applied excitotoxins; they also occur in damaged spinal cord and are evoked by endogenous mechanisms after traumatic SCI. The GFAP/Cx43 co-localization results suggest that during their transformation to a reactive state, spinal cord astrocytes undergo a transitional phase marked by altered Cx43 localization or expression. (C) 1997 Wiley-Liss, Inc.	UNIV MANITOBA,FAC MED,DEPT PHYSIOL,WINNIPEG,MB R3E 0W3,CANADA; TORONTO HOSP,TORONTO WESTERN DIV,PLAYFAIR NEUROSCI UNIT,TORONTO,ON M5T 2S8,CANADA; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,BRONX,NY 10461					Nagy, James Imre/0000-0003-2753-091X			Anthes DL, 1996, NEUROSURGERY, V39, P804, DOI 10.1097/00006123-199610000-00032; ANTHES DL, 1995, BRAIN RES, V702, P1, DOI 10.1016/0006-8993(95)01028-6; BELLIVEAU DJ, 1994, GLIA, V12, P24, DOI 10.1002/glia.440120104; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; Beyer E C, 1993, Int Rev Cytol, V137C, P1; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BLIGHT AR, 1989, J AM PARAPLEGIA SOC, V11, P26; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Bunge R. P., 1995, Journal of Neurotrauma, V12, P354; BUNGE RP, 1993, ADV NEUROL, V59, P75; DERMIETZEL R, 1987, J CELL BIOL, V105, P1925, DOI 10.1083/jcb.105.4.1925; DERMIETZEL R, 1990, ANAT EMBRYOL, V182, P517; DERMIETZEL R, 1989, P NATL ACAD SCI USA, V86, P10148, DOI 10.1073/pnas.86.24.10148; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; FISCHER G, 1985, EXP CELL RES, V159, P273, DOI 10.1016/S0014-4827(85)80001-X; GIAUME C, 1991, NEURON, V6, P133, DOI 10.1016/0896-6273(91)90128-M; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GRAEBER MB, 1986, J NEUROCYTOL, V15, P363; HOSSAIN MZ, 1994, J NEUROCHEM, V62, P2394; HOSSAIN MZ, 1994, BRAIN RES, V652, P311, DOI 10.1016/0006-8993(94)90242-9; HOSSAIN MZ, 1994, GLIA, V10, P250, DOI 10.1002/glia.440100404; KETTENMANN H, 1988, GLIA, V1, P64, DOI 10.1002/glia.440010108; KETTENMANN H, 1983, J NEUROSCI, V3, P506; KOYANAGI I, 1993, NEUROSURGERY, V32, P260, DOI 10.1227/00006123-199302000-00015; KOYANAGI I, 1993, NEUROSURGERY, V33, P277; KOYANAGI I, 1993, NEUROSURGERY, V33, P285, DOI 10.1227/00006123-199308000-00016; KOYANAGI I, 1995, J NEUROTRAUM, V12, P357; LANG LM, 1991, AM J PHYSIOL, V260, P787; Largo C, 1996, J NEUROSCI, V16, P1219; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; Marrero H, 1996, GLIA, V16, P285; MASSA PT, 1982, NEUROSCIENCE, V7, P523; MUGNAINI E, 1986, ASTROCYTES DEV MORPH, V1, P329, DOI DOI 10.1016/B978-0-12-250451-8.50018-7; NAGY JI, 1992, GLIA, V5, P1, DOI 10.1002/glia.440050102; NAUS CCG, 1991, EXP NEUROL, V111, P198, DOI 10.1016/0014-4886(91)90007-Y; OCHALSKI PAY, 1995, GLIA, V14, P279, DOI 10.1002/glia.440140405; OCHALSKI PAY, 1996, IN PRESS NEUROSCIENC; ORKLAND RK, 1966, J NEUROPHYSIOL, V29, P788; RANSOM BR, 1986, ASTROCYTES BIOCH PHY, V2, P1; ROHLMANN A, 1993, NEUROSCI LETT, V154, P206, DOI 10.1016/0304-3940(93)90208-3; SAEZ JC, 1993, ADV SEC MESS PHOSPH, V27, P163; SAWCHUK MA, 1995, BRAIN RES, V683, P153, DOI 10.1016/0006-8993(95)00337-P; SCHMIDTKASTNER R, 1993, INT J DEV NEUROSCI, V11, P157, DOI 10.1016/0736-5748(93)90076-P; SPRAY DC, 1985, ANNU REV PHYSIOL, V47, P281, DOI 10.1146/annurev.ph.47.030185.001433; SULLIVAN R, 1993, GENE, V130, P191, DOI 10.1016/0378-1119(93)90419-4; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; THERIAULT E, 1994, J COMP NEUROL, V342, P249, DOI 10.1002/cne.903420208; THERIAULT E, 1995, J NEUROTRAUM, V12, P364; VALNES K, 1985, J HISTOCHEM CYTOCHEM, V33, P755, DOI 10.1177/33.8.3926864; VUKELIC JI, 1991, NEUROSCI LETT, V130, P120, DOI 10.1016/0304-3940(91)90242-L; WALZ W, 1989, PROG NEUROBIOL, V33, P309, DOI 10.1016/0301-0082(89)90005-1; WAXMAN SG, 1984, BRAIN RES, V308, P77, DOI 10.1016/0006-8993(84)90919-3; WHITE TW, 1995, KIDNEY INT, V48, P1148, DOI 10.1038/ki.1995.398; WILLECKE K, 1991, EUR J CELL BIOL, V56, P1; WOLBURG H, 1995, INT REV CYTOL, V157, P315, DOI 10.1016/S0074-7696(08)62161-0; YAMAMOTO T, 1990, J COMP NEUROL, V302, P853, DOI 10.1002/cne.903020414; YAMAMOTO T, 1990, BRAIN RES, V508, P313, DOI 10.1016/0006-8993(90)90415-8; YEE AG, 1978, J CELL BIOL, V78, P554, DOI 10.1083/jcb.78.2.554; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; YOUNG W, 1988, CURR OPIN NEUROL NEU, V1, P611; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391	66	76	80	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012	0021-9967			J COMP NEUROL	J. Comp. Neurol.	JUN 2	1997	382	2					199	214					16	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	XC352	WOS:A1997XC35200005	9183689				2022-02-06	
J	Prince, DA; Jacobs, KM; Salin, PA; Hoffman, S; Parada, I				Prince, DA; Jacobs, KM; Salin, PA; Hoffman, S; Parada, I			Chronic focal neocortical epileptogenesis: Does disinhibition play a role?	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article; Proceedings Paper	Symposium of the Centre-de-Recherche-en-Sciences-Neurologiques-of-the-Universite-de-Montreal on GABA Mechanisms in the Cerebral Cortex	MAY 09-10, 1996	MONTREAL, CANADA	Univ Montreal, Ctr Rech Sci Neurol		neocortex; epileptogenesis; brain lesions; inhibition; post-traumatic epilepsy; cortical microgyri	GABA(A) RECEPTOR SUBUNIT; INHIBITORY POSTSYNAPTIC CURRENTS; INTRAHIPPOCAMPAL TETANUS TOXIN; ACTIVITY-DEPENDENT REGULATION; GLUTAMIC-ACID DECARBOXYLASE; MONKEY VISUAL-CORTEX; RAT DENTATE GYRUS; CEREBRAL-CORTEX; MESSENGER-RNAS; IMMUNOREACTIVE NEURONS	Several lines of evidence have suggested that decreases in postsynaptic inhibition may have a role in epileptogenesis in cortical structures. However, other studies have suggested that GABAergic inhibition is spared, or even augmented in some forms of post-lesional epilepsy. In the studies described here, inhibitory events were recorded in two models of post-lesional chronic epileptogenesis. (i) As previously reported (D.A. Prince and G.-F. Tseng. J. Neurophysiol. 69: 1276-1291. 1993), epileptiform activity develops in slices from partially isolated rat neocortical islands 2-3 weeks after the initial in vivo lesion. In this model of post-traumatic epilepsy, large amplitude polyphasic inhibitory postsynaptic currents (IPSCs) in layer V pyramidal neurons are associated with each interictal epileptiform field potential. The frequency of spontaneous IPSCs as well as miniature IPSCs was significantly increased in neocortical slices from the epileptogenic chronically injured cortex versus controls. Immunocytochemical reactions for parvalbumin and calbindin, calcium binding proteins present in subgroups of GABAergic neurons, showed an increased staining of both neuropil and somata within the epileptogenic tissue. Immunoreactivity for glutamic acid decarboxylase (GAB) and GABA. also appeared to be increased in the neuropil. (ii) Cortical microgyri resembling human malformations were produced by freeze lesions made transcranially in PO rat cortex (K.M. Jacobs, M.J. Gutnick, and D.A. Prince. Cereb. Cortex, 6: 514-523. 1996). The boundary between the four-layered microgyrus and surrounding cortex becomes epileptogenic within about 2 weeks, as judged by evoked extracellular field potentials and cellular activities. Epileptogenesis in the surrounding cortex is not altered when the microgyrus itself is isolated by transcortical cuts. Patch-clamp recordings from layer V neurons in the epileptogenic zone showed that spontaneous IPSCs are larger and more dependent on glutamatergic synapses than in control neurons. The amplitudes of polysynaptic IPSCs evoked by threshold stimulation were also larger than in control cells. Although evaluation of inhibitory events in these models is still incomplete, results to date suggest that GABAergic inhibition may be enhanced in epileptogenic areas associated with chronic cortical injury. Sprouting of axonal arborizations of pyramidal cells onto interneurons, upregulation of GABAergic neurons, and perhaps sprouting of inhibitory axons that make increased numbers of contacts onto pyramidal cells may all contribute to the increased inhibitory drive. Results in these models do not support the disinhibitory hypothesis of chronic epileptogenesis.			Prince, DA (corresponding author), STANFORD UNIV, SCH MED, DEPT NEUROL & NEUROL SCI, ROOM M016, STANFORD, CA 94305 USA.		Jacobs, Kimberle/AAW-7526-2020	Salin, Paul/0000-0001-5221-9109	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012151, P50NS012151] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12151, NS07280, NS09806] Funding Source: Medline		AGMON A, 1992, J NEUROPHYSIOL, V68, P345, DOI 10.1152/jn.1992.68.1.345; Agmon A, 1996, J NEUROSCI, V16, P4684; ASHWOOD TJ, 1986, BRAIN RES, V367, P390, DOI 10.1016/0006-8993(86)91625-2; BABB TL, 1989, J NEUROSCI, V9, P2562; BEKENSTEIN JW, 1993, SCIENCE, V259, P97, DOI 10.1126/science.8093417; BENSON DL, 1991, J NEUROSCI, V11, P31; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BRUSSAARD AB, 1995, NEUROSCI LETT, V191, P111, DOI 10.1016/0304-3940(95)11539-6; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V62, P1149, DOI 10.1152/jn.1989.62.5.1149; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747, DOI 10.1152/jn.1989.61.4.747; CONNORS BW, 1984, NATURE, V310, P685, DOI 10.1038/310685a0; DAVENPORT CJ, 1990, EXP NEUROL, V109, P180, DOI 10.1016/0014-4886(90)90072-Z; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; DVORAK K, 1977, ACTA NEUROPATHOL, V38, P203; DVORAK K, 1978, ACTA NEUROPATHOL, V44, P121; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FLEIDERVISH IA, 1995, J NEUROPHYSIOL, V73, P2591, DOI 10.1152/jn.1995.73.6.2591; FRANCK JE, 1985, BRAIN RES, V329, P309, DOI 10.1016/0006-8993(85)90540-2; FRANCK JE, 1988, J NEUROSCI, V8, P1991; GOLDOWITZ D, 1982, BRAIN RES, V238, P413, DOI 10.1016/0006-8993(82)90116-0; GONZALES C, 1992, NEUROSCI LETT, V135, P53, DOI 10.1016/0304-3940(92)90134-S; HALPERN LM, 1972, EXPT MODELS EPILEPSY, P17; HENDRY SHC, 1994, J NEUROSCI, V14, P2383; HENDRY SHC, 1988, NEURON, V1, P701, DOI 10.1016/0896-6273(88)90169-9; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; HUMPHREYS P, 1991, J NEUROPATH EXP NEUR, V50, P145, DOI 10.1097/00005072-199103000-00006; HUNTSMAN MM, 1995, J COMP NEUROL, V352, P235, DOI 10.1002/cne.903520207; HUNTSMAN MM, 1994, J NEUROSCI, V14, P2236; Isokawa M, 1996, J NEUROPHYSIOL, V75, P1901, DOI 10.1152/jn.1996.75.5.1901; Jacobs KM, 1996, CEREB CORTEX, V6, P514, DOI 10.1093/cercor/6.3.514; KAMPHUIS W, 1995, MOL BRAIN RES, V31, P33, DOI 10.1016/0169-328X(95)00022-K; KOKAIA M, 1994, MOL BRAIN RES, V23, P323, DOI 10.1016/0169-328X(94)90242-9; KREINDLER A, 1960, ARCH ITAL BIOL, V98, P10; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; Ling DSF, 1995, J NEUROPHYSIOL, V74, P2329, DOI 10.1152/jn.1995.74.6.2329; MATHERN GW, 1995, J NEUROSCI, V15, P3990; MATSUMOTO H, 1964, EXP NEUROL, V9, P286, DOI 10.1016/0014-4886(64)90025-1; MCCARREN M, 1985, J NEUROPHYSIOL, V53, P557, DOI 10.1152/jn.1985.53.2.557; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MICHEVA KD, 1995, J COMP NEUROL, V361, P574, DOI 10.1002/cne.903610403; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; NAJLERAHIM A, 1992, EXP BRAIN RES, V90, P332; Nakajima S, 1991, Hippocampus, V1, P67, DOI 10.1002/hipo.450010107; OBENAUS A, 1993, J NEUROSCI, V13, P4470; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; PRINCE DA, 1978, ANNU REV NEUROSCI, V1, P395, DOI 10.1146/annurev.ne.01.030178.002143; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; PRINCE DA, 1992, EPILEPSY RES, P31; Purpura D P, 1968, Prog Brain Res, V22, P107; RIBAK CE, 1982, J NEUROSCI, V2, P1725; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; ROMIJN HJ, 1994, ACTA NEUROPATHOL, V87, P612; ROMIJN HJ, 1988, EXP NEUROL, V100, P332, DOI 10.1016/0014-4886(88)90112-4; Salin P, 1995, J NEUROSCI, V15, P8234; Salin PA, 1996, J NEUROPHYSIOL, V75, P1589, DOI 10.1152/jn.1996.75.4.1589; Salin PA, 1996, J NEUROPHYSIOL, V75, P1573, DOI 10.1152/jn.1996.75.4.1573; SEIL FJ, 1994, DEV BRAIN RES, V77, P123, DOI 10.1016/0165-3806(94)90219-4; SHERMAN GF, 1990, BRAIN RES, V529, P202, DOI 10.1016/0006-8993(90)90828-Y; SLOPER JJ, 1980, BRAIN RES, V198, P204, DOI 10.1016/0006-8993(80)90356-X; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; TECOMA ES, 1989, NEUROLOGY, V39, P676, DOI 10.1212/WNL.39.5.676; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501; WALKER AE, 1942, LANCET, V1, P732; WELKER E, 1989, EXP BRAIN RES, V74, P441, DOI 10.1007/BF00247346; WELKER E, 1989, EXP BRAIN RES, V78, P659, DOI 10.1007/BF00230256; WHITTINGTON MA, 1994, J PHYSIOL-LONDON, V481, P593, DOI 10.1113/jphysiol.1994.sp020466	70	76	77	0	0	CANADIAN SCIENCE PUBLISHING, NRC RESEARCH PRESS	OTTAWA	65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA	0008-4212	1205-7541		CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.	MAY	1997	75	5					500	507		10.1139/cjpp-75-5-500			8	Pharmacology & Pharmacy; Physiology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Pharmacology & Pharmacy; Physiology	XM246	WOS:A1997XM24600018	9250384				2022-02-06	
J	Chen, SHA; Thomas, JD; Glueckauf, RL; Bracy, OL				Chen, SHA; Thomas, JD; Glueckauf, RL; Bracy, OL			The effectiveness of computer-assisted cognitive rehabilitation for persons with traumatic brain injury	BRAIN INJURY			English	Article							MEMORY-IMPAIRED PATIENTS; RETENTION	This study examined the efficacy of computer-assisted cognitive rehabilitation (CACR) in persons with traumatic brain injury (TBI). Twenty persons with TBI who received hierarchically based CACR following inpatient neurorehabilitation were compared to a group of 20 persons with TBI matched for age, education, days in coma and rime between testing The comparison group received various other therapies including speech therapy and occupational therapy. The difference between pre- and posttreatment neuropsychological test scores was used to measure improvements in the domains of attention, visual spatial ability, memory and problem-solving. CACR and the comparison group showed significant post-treatment gains on the neuropsychological test scores, with CACR making significant gains on 15 measures and the comparison group on seven measures. However, we found no significant differences between the groups on their post-treatment gains. Results from this preliminary study found that, though significant cognitive gains were obtained after CACR, the extent and nature of these gains remains to be shown in controlled, prospective soup studies.	CTR NEUROSCI,INDIANAPOLIS,IN		Chen, SHA (corresponding author), INDIANA UNIV PURDUE UNIV,INDIANAPOLIS,IN 46202, USA.		Chen, SH Annabel/F-3742-2011	Chen, SH Annabel/0000-0002-1540-5516			Batchelor J, 1988, J HEAD TRAUMA REHAB, V3, P78, DOI DOI 10.1097/00001199-198809000-00012; BENYISHAY Y, 1981, INT J REHABIL RES, V4, P208, DOI 10.1097/00004356-198106000-00012; Bracy O, 1986, PROGRAMS COGNITIVE R; BRACY OL, 1983, COGNITIVE REHABILITA, V1, P7; BRACY OL, 1985, COGNITIVE REHABILITA, V4, P10; ESON ME, 1978, J NEUROL NEUROSUR PS, V41, P1036, DOI 10.1136/jnnp.41.11.1036; Ethier M, 1989, CANADIAN J REHABILIT, V2, P223; ETHIER M, 1989, CANADIAN J REHABILIT, V3, P7; FINLEY G, 1987, P AM ASSOC CANC RES, V28, P180; GIANUTSOS R, 1979, Journal of Clinical Neuropsychology, V1, P117, DOI 10.1080/01688637908414446; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; Gray J M, 1989, Brain Inj, V3, P163, DOI 10.3109/02699058909004548; KENDALL MC, ADV THEORY STATISTIC; KERNER MJ, 1985, COGNITIVE REHABILITA, V3, P36; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MIDDLETON DK, 1991, PERCEPT MOTOR SKILL, V72, P527, DOI 10.2466/PMS.72.2.527-530; NEWCOMBE F, 1982, INJURY, V14, P111, DOI 10.1016/0020-1383(82)90046-8; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; Robertson I, 1988, Brain Inj, V2, P151, DOI 10.3109/02699058809150939; ROSS FL, 1991, AM J OCCUPATIONAL TH, V46, P314; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; SOHLBERG MM, 1989, INTRO COGNITIVE REHA, P5; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 1987, WECHSLER ADULT INTEL; Wood R L, 1987, Int Disabil Stud, V9, P149; WOOD RLI, 1990, COGNITIVE REHABILITA; BEHAV RES METHODS IN, V15, P357	29	76	78	0	16	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAR	1997	11	3					197	209					13	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	WL158	WOS:A1997WL15800004	9058001				2022-02-06	
J	Coulter, DA; Rafiq, A; Shumate, M; Gong, QZ; DeLorenzo, RJ; Lyeth, BG				Coulter, DA; Rafiq, A; Shumate, M; Gong, QZ; DeLorenzo, RJ; Lyeth, BG			Brain injury-induced enhanced limbic epileptogenesis: Anatomical and physiological parallels to an animal model of temporal lobe epilepsy	EPILEPSY RESEARCH			English	Article; Proceedings Paper	3rd Workshop on the Neurobiology of Epilepsy (WONOEP III) - Mechanisms of Chronic Models of Epilepsy	AUG 29-SEP 02, 1995	KEWARRA BEACH, AUSTRALIA			traumatic brain injury; pilocarpine; mossy fiber sprouting	FIBER SYNAPTIC REORGANIZATION; HIPPOCAMPAL-FORMATION; PILOCARPINE SEIZURES; STATUS EPILEPTICUS; NEURONAL LOSS; HEAD TRAUMA; RAT; SLICE; RESPONSES; PATTERNS	Traumatic brain injury (TBI) is a leading cause of symptomatic epilepsy in young adults. This study examined physiological and anatomical epileptogenic consequences of a prior incident of TBI in rats. Rats were subjected to a fluid percussion brain injury one week prior to experimentation, and in vitro electrophysiological recording studies were conducted using combined hippocampal-entorhinal cortical slices (HEC slices). Results were compared to sham operated controls and rats in which a condition of chronic temporal lobe epilepsy was induced by a 2 h bout of pilocarpine-induced status epilepticus 2 months prior to recording (PILO). In field potential recordings, PILO HEC slices evidenced a greater degree of disinhibition in CAI than did TBI or control slices. TBI slices showed greater disinhibition in the dentate gyrus than did PILO or control rats. In in vitro kindling experiments, 86% of TBI HEC slices generated self-sustaining epileptic activity within 9 stimulus trains. This type of activity was never triggered in control slices. HEC slices prepared from PILO animals generated self-sustaining epileptic activity with fewer stimulus trains than did TBI slices. In anatomical studies, both TBI and PILO hippocampi evidenced significant loss of neurons within the hilar region. TBI induces a series of changes within the limbic system of rats, which are qualitatively similar in many aspects but quantitatively less severe than changes seen in rats with chronic temporal lobe epilepsy. These physiological and anatomical TBI-associated alterations in the limbic system may contribute to the development of epilepsy following head trauma.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYSIOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROSURG,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,COMPREHENS EPILEPSY INST,RICHMOND,VA 23298		Coulter, DA (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROL,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474; Coulter, Douglas/0000-0002-1486-119X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS-25630, NS-23350, NS-32403] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS025630, R01NS023350, R01NS032403, R37NS032403] Funding Source: NIH RePORTER		AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ANDERSON WW, 1990, BRAIN RES, V532, P288, DOI 10.1016/0006-8993(90)91771-8; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1993, TREATMENT EPILEPSY P, pCH12; BABB TL, 1984, EPILEPSIA, V25, P721, DOI 10.1111/j.1528-1157.1984.tb03483.x; CAVAZOS JE, 1990, BRAIN RES, V527, P1, DOI 10.1016/0006-8993(90)91054-K; CLIFFORD DB, 1987, NEUROSCIENCE, V23, P953, DOI 10.1016/0306-4522(87)90171-0; CRONIN J, 1992, BRAIN RES, V573, P305, DOI 10.1016/0006-8993(92)90777-7; DAM AM, 1980, EPILEPSIA, V21, P617, DOI 10.1111/j.1528-1157.1980.tb04315.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Gualtari CT, 1991, BRAIN INJURY, V5, P219; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hill S. J., 1994, Society for Neuroscience Abstracts, V20, P424; HOUSER CR, 1990, J NEUROSCI, V10, P267; JONES RSG, 1988, J NEUROPHYSIOL, V59, P1476, DOI 10.1152/jn.1988.59.5.1476; LIU Z, 1994, EPILEPSY RES, V17, P237; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MATHERN GW, 1995, J NEUROSURG, V82, P211, DOI 10.3171/jns.1995.82.2.0211; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; OBENAUS A, 1993, J NEUROSCI, V13, P4470; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; RAFIQ A, 1995, J NEUROPHYSIOL, V74, P2028, DOI 10.1152/jn.1995.74.5.2028; RAFIQ A, 1993, J NEUROPHYSIOL, V70, P1962, DOI 10.1152/jn.1993.70.5.1962; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TAUCK DL, 1985, J NEUROSCI, V5, P1016	34	76	78	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	DEC	1996	26	1					81	91		10.1016/S0920-1211(96)00044-7			11	Clinical Neurology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	VX953	WOS:A1996VX95300011	8985690				2022-02-06	
J	Dixon, CE; Bao, JL; Long, DA; Hayes, RL				Dixon, CE; Bao, JL; Long, DA; Hayes, RL			Reduced evoked release of acetylcholine in the rodent hippocampus following traumatic brain injury	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						brain injury; acetylcholine; microdialysis; scopolamine; rat	NUCLEUS BASALIS MAGNOCELLULARIS; CONTROLLED CORTICAL IMPACT; ALZHEIMERS-DISEASE; EXTRACELLULAR ACETYLCHOLINE; MEMORY IMPAIRMENT; PLACE NAVIGATION; RAT; MICRODIALYSIS; LESIONS; DEAFFERENTATION	The chronic effects of traumatic brain injury on acetylcholine release were evaluated by using in vivo microdialysis. Acetylcholine release was measured in the hippocampus of anesthetized rats 2 weeks after lateral controlled cortical impact (n = 10) or sham surgery (n = 10). Prior to microdialysis, behavioral assessments of motor and spatial memory were performed. Cortical impact (6 meter/s, 2 mm deformation) produced beam balance deficits that persisted for 1 day and beam walking deficits that persisted for 3 days after injury. In addition, spatial memory, as measured by swim latencies in a Morris water maze, was compromised between 10-14 days after injury. Immediately following behavioral testing, the animals were anesthetized with halothane, and a microdialysis probe was placed into the dorsal hippocampus. After a 160 min equilibration period, extracellular levels of acetylcholine were measured prior to and after an intraperitoneal administration of scopolamine (1 mg/kg), which evokes acetylcholine release by blocking autoreceptors. Prior to scopolamine administration, there were no differences in extracellular levels of acetylcholine between injured and sham animals. However, there was a significant reduction of hippocampal acetylcholine release evoked by scopolamine in injured animals as compared to sham controls. In separate control groups, saline administration alone did not change hippocampal acetylcholine release in injured(n = 5) or sham (n = 5) animals. This study represents the first application of in vivo microdialysis to evaluate chronic neurotransmission deficits following TBI. The present study demonstrates that a magnitude of traumatic brain injury (TBI) sufficient to produce spatial memory deficits can result in a reduction in scopolamine-evoked release of acetylcholine within the hippocampus. The data further suggest that presynaptic mechanisms mediating release of acetylcholine could play a significant role in cholinergic neurotransmission deficits following TBI.			Dixon, CE (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,6431 FANNIN ST,SUITE 7147,HOUSTON,TX 77030, USA.				NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [CDC-R49-CCR303547] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01, NS31998, NS21458] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031998, R01NS021458] Funding Source: NIH RePORTER		AMMASSARITEULE M, 1993, BEHAV BRAIN RES, V54, P145, DOI 10.1016/0166-4328(93)90073-Y; BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; COLLERTON D, 1986, NEUROSCIENCE, V19, P1, DOI 10.1016/0306-4522(86)90002-3; DAMSMA G, 1988, LIFE SCI, V43, P1161, DOI 10.1016/0024-3205(88)90475-4; DAMSMA G, 1991, LIFE SCI, V48, P2469, DOI 10.1016/0024-3205(91)90383-M; Dixon C. E., 1992, Society for Neuroscience Abstracts, V18, P171; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1995, J NEUROTRAUM, V12, P971; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GREANEY MD, 1993, J CHROMATOGR-BIOMED, V622, P125, DOI 10.1016/0378-4347(93)80258-6; HAGAN JJ, 1988, BEHAV BRAIN RES, V27, P9, DOI 10.1016/0166-4328(88)90105-2; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HUFF FJ, 1988, DRUG DEVELOP RES, V12, P271; JAMES MK, 1987, J PHARMACOL EXP THER, V240, P203; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; KILBINGER H, 1984, EUR J PHARMACOL, V103, P313, DOI 10.1016/0014-2999(84)90492-8; LEANZA G, 1993, BRAIN RES, V615, P147, DOI 10.1016/0006-8993(93)91126-D; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIN HS, 1985, CENTRAL NERVOUS SYST, P281; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MIYAMOTO M, 1987, BRAIN RES, V419, P19, DOI 10.1016/0006-8993(87)90564-6; MIZUNO T, 1991, NEUROSCIENCE, V44, P607, DOI 10.1016/0306-4522(91)90081-X; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1986, Q J EXP PSYCHOL-B, V38, P365; MORTIMER JA, 1991, INT J EPIDEMIOL S2, V20, P528; NILSSON OG, 1993, ANN NY ACAD SCI, V695, P267, DOI 10.1111/j.1749-6632.1993.tb23065.x; NORTH RA, 1986, TRENDS PHARM SCI S, V7, P19; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OGANE N, 1990, NEUROSCI LETT, V114, P95, DOI 10.1016/0304-3940(90)90434-B; Pepeu G, 1973, Prog Neurobiol, V2, P259, DOI 10.1016/0301-0082(73)90009-9; SCINTO LFM, 1994, SCIENCE, V266, P1051, DOI 10.1126/science.7973660; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STARKE K, 1989, PHYSIOL REV, V69, P864, DOI 10.1152/physrev.1989.69.3.864; STILLMAN MJ, 1993, BRAIN RES BULL, V32, P385, DOI 10.1016/0361-9230(93)90204-O; SUNDERLAND T, 1987, ARCH GEN PSYCHIAT, V44, P418; SUNDERLAND T, 1985, PSYCHOPHARMACOLOGY, V87, P247, DOI 10.1007/BF00431817; SUTHERLAND RJ, 1982, J COMP PHYSIOL PSYCH, V96, P563, DOI 10.1037/h0077914; SZERB JC, 1977, BRAIN RES, V128, P285, DOI 10.1016/0006-8993(77)90995-7; TOIDE K, 1993, EUR J PHARMACOL, V233, P21, DOI 10.1016/0014-2999(93)90344-H; [No title captured]	47	76	76	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	MAR	1996	53	3					679	686		10.1016/0091-3057(95)02069-1			8	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	TX845	WOS:A1996TX84500029	8866972				2022-02-06	
J	ALTHAUS, JS; ANDRUS, PK; WILLIAMS, CM; VONVOIGTLANDER, PF; CAZERS, AR; HALL, ED				ALTHAUS, JS; ANDRUS, PK; WILLIAMS, CM; VONVOIGTLANDER, PF; CAZERS, AR; HALL, ED			THE USE OF SALICYLATE HYDROXYLATION TO DETECT HYDROXYL RADICAL GENERATION IN ISCHEMIC AND TRAUMATIC BRAIN INJURY - REVERSAL BY TIRILAZAD MESYLATE (U-74006F)	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article						TIRILAZAD MESYLATE; HYDROXYL RADICAL; ISCHEMIC BRAIN INJURY; TRAUMATIC BRAIN INJURY; RADICAL SCAVENGER; SALICYLATE HYDROXYLATION	DEPENDENT LIPID-PEROXIDATION; CEREBRAL-ARTERY OCCLUSION; FOREBRAIN ISCHEMIA; 21-AMINOSTEROID U74006F; REPERFUSION INJURY; RAT HEARTS; IRON; INVOLVEMENT; DERIVATIVES; INITIATION	Oxygen free radicals have been implicated as a causal factor in posttraumatic neuronal cell loss following cerebral ischemia and head injury. The conversion of salicylate to dihydroxybenzoic acid (DHBA) in vivo was employed to study the formation of hydroxyl radical (.OH) following central nervous system (CNS) injury. Bilateral carotid occlusion (BCO) in gerbils and concussive head trauma in mice were selected as models of brain injury. The lipid peroxidation inhibitor, tirilazad mesylate (U-74006F), was tested for its ability to attenuate hydroxyl radical formation in these models. In addition, U-74006F was studied as a scavenger of hydroxyl radical in an in vitro assay based on the Fenton reaction. For in vivo experimentation, hydroxyl radical formation was expressed as the ratio of DHBA to salicylate (DHBA/SAL) measured in brain. In the BCO model, hydroxyl radical formation increased in whole brain with 10 min of occlusion followed by 1 min of reperfusion. DHBA/SAL was also found to increase in the mouse head injury model at 1 h postinjury. In both models, U-74006F (1 or 10 mg/kg) blocked the increase in DHBA/SAL following injury. In vitro, reaction of U-74006F with hydroxyl radical gave a product with a mol wt that was 16 greater than U-74006F, indicative of hydroxyl radical scavenging. We speculate that U-74006F may function by blocking oxyradical-dependent cell damage, and thereby maintaining free iron (which catalyzes hydroxyl radical formation) concentrations at normal levels.	UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA		ALTHAUS, JS (corresponding author), UPJOHN CO, CNS DIS RES, 7521-209-5, KALAMAZOO, MI 49001 USA.		Hall, Edward D/F-8930-2013				BECK T, 1990, BRAIN RES, V532, P336, DOI 10.1016/0006-8993(90)91779-G; BECK T, 1991, BRAIN RES, V560, P159, DOI 10.1016/0006-8993(91)91226-Q; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V7, P125, DOI 10.1016/0891-5849(89)90003-8; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; CHIUEH CC, 1992, SYNAPSE, V1116, P183; FLOYD R A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P13, DOI 10.1016/0748-5514(86)90118-2; FLOYD RA, 1991, ARCH GERONTOL GERIAT, V12, P155, DOI 10.1016/0167-4943(91)90025-L; FUJII T, 1991, ARCH BIOCHEM BIOPHYS, V284, P120, DOI 10.1016/0003-9861(91)90273-L; GELVAN D, 1991, OXIDATIVE DAMAGE & REPAIR, P825; Giovanni A., 1992, Society for Neuroscience Abstracts, V18, P1444; GROOTVELD M, 1986, BIOCHEM J, V237, P499, DOI 10.1042/bj2370499; HALL ED, 1990, PROG CLIN BIOL RES, V361, P351; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1993, J NEUROSCI RES, V34, P107, DOI 10.1002/jnr.490340111; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1989, CEREBROVASC DIS, P387; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HARALDSETH O, 1991, STROKE, V22, P1188, DOI 10.1161/01.STR.22.9.1188; HASELOFF RF, 1990, FREE RADICAL BIO MED, V9, P111, DOI 10.1016/0891-5849(90)90113-W; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; JANERO DR, 1989, RES COMMUN CHEM PATH, V63, P163; KOBAYASHI A, 1989, JPN CIRC J, V53, P1122, DOI 10.1253/jcj.53.1122; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; LESIUK H, 1991, STROKE, V22, P896, DOI 10.1161/01.STR.22.7.896; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MOORHOUSE CP, 1985, BIOCHIM BIOPHYS ACTA, V843, P261, DOI 10.1016/0304-4165(85)90147-3; PAHLMARK K, 1991, J CEREBR BLOOD FLOW, V2, pS138; PERKINS WJ, 1992, FASEB J, V5, pA1279; PIANTADOSI CA, 1990, J APPL PHYSIOL, V69, P1761, DOI 10.1152/jappl.1990.69.5.1761; POWELL SR, 1990, FREE RADICAL BIO MED, V9, P133, DOI 10.1016/0891-5849(90)90116-Z; SAKAMOTO A, 1991, BRAIN RES, V554, P186, DOI 10.1016/0006-8993(91)90187-Z; SIMPSON JA, 1988, BIOCHEM J, V254, P519, DOI 10.1042/bj2540519; SNEDECOR GW, 1967, STAT METHODS; SPINA MB, 1989, P NATL ACAD SCI USA, V86, P1398, DOI 10.1073/pnas.86.4.1398; SUTTON H C, 1985, Journal of Free Radicals in Biology and Medicine, V1, P195, DOI 10.1016/0748-5514(85)90118-7; TOSAKI A, 1990, FREE RADICAL BIO MED, V8, P363, DOI 10.1016/0891-5849(90)90102-O; YOSHIDA K, 1991, BIOCHEM BIOPH RES CO, V179, P1077, DOI 10.1016/0006-291X(91)91929-7; YOUNG W, 1988, STROKE, V19, P1013, DOI 10.1161/01.STR.19.8.1013	40	76	76	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	OCT	1993	20	2					147	162		10.1007/BF02815368			16	Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	MC691	WOS:A1993MC69100004	8297419				2022-02-06	
J	FEENEY, DM; WEISEND, MP; KLINE, AE				FEENEY, DM; WEISEND, MP; KLINE, AE			NORADRENERGIC PHARMACOTHERAPY, INTRACEREBRAL INFUSION AND ADRENAL TRANSPLANTATION PROMOTE FUNCTIONAL RECOVERY AFTER CORTICAL DAMAGE	JOURNAL OF NEURAL TRANSPLANTATION & PLASTICITY			English	Article						TRAUMATIC BRAIN INJURY; STROKE; FUNCTIONAL RECOVERY; SOFT EXCITOTOXICITY HYPOTHESIS; DIASCHISIS; ADRENAL GRAFTING	SENSORIMOTOR CORTEX INJURY; RECEPTOR ANTAGONIST; LOCOMOTOR FUNCTION; MOTOR RECOVERY; BEAM-WALKING; RAT-BRAIN; AMPHETAMINE; NOREPINEPHRINE; RELEASE; EXPERIENCE	The research described in this review briefly summarizes evidence that short term pharmacological enhancement of noradrenergic (NA) synaptic activity, combined with symptom relevant experience (SRE), promotes functional recovery of some symptoms of cortical damage in rat, cat and human beings even when treatment is initiated from days to weeks after injury. A summary is provided of the numerous drugs tested in rodent cortical injury models which have been proven useful for predicting beneficial or harmful effects on behavioral outcome in human stroke. The pattern of drug effects indicates a central role for NA in functional recovery. Additionally, studies of the effects of direct intraventricular infusion of monoamine neurotransmitters are reviewed and further support the hypothesized role of NA in recovery from some symptoms of cortical injury. The site of NA/SRE interaction to promote recovery from hemiplegia apparently involves the cerebellar hemisphere contralateral to the cortical injury. Microinfusions of NA into the contra- but not ipsilateral cerebellar hemisphere dramatically enhance recovery. Furthermore, like its systemic action, microinfusion of the alpha(1)-NA receptor antagonist, phenoxybenzamine, reinstates hemiplegia. A ''permanent'' symptom of motor cortex injury in the cat is the complete loss of tactile placing contralateral to the injury which does not spontaneously recover for as long as seven years after ablation. This postural reflex is temporarily restored for 8-12 hours following amphetamine administration. However, this permanently lost reflex can be enduringly restored by transplanting catecholamine secreting adrenal tissue into the wound cavity. The experiment is reviewed in detail and involves chromaffin cell autografts into the frontal cortex ablation wound cavity producing a restoration of tactile placing for the 7-10 month duration of the study. This enduring restoration of tactile placing is considered a result of the release of catecholamines into the CNS from the grafted chromaffin cells found, by histochemical methods, surviving 7-10 months after transplant. Lastly, we attribute these delayed treatment effects to an attenuation of a diaschisis, or remote functional depression, in morphologically intact areas anatomically connected to the area of injury. The widespread reduction of glycolytic and oxidative metabolism, produced by focal cortical injury, is normalized by the same treatment which alleviates symptoms and is worsened by drugs which exacerbate deficits. These data support the hypothesis that providing SRE during a period of enhanced NA synaptic activity produces an enduring functional recovery after cortical injury by attenuating remote functional depression. This treatment for enhancing recovery is especially attractive since it is effective even when begun weeks after cortical damage.	UNIV NEW MEXICO,DEPT PHYSIOL,ALBUQUERQUE,NM 87131		FEENEY, DM (corresponding author), UNIV NEW MEXICO,DEPT PSYCHOL,LOGAN HALL,ALBUQUERQUE,NM 87131, USA.						ALBERS GW, 1989, ANN NEUROL, V25, P398, DOI 10.1002/ana.410250412; AMASSIAN VE, 1972, CORTICOTHALAMIC PROJ, P395; AZZARO AJ, 1973, BIOCHEM PHARMACOL, V22, P2801, DOI 10.1016/0006-2952(73)90147-0; BARELA PB, UNPUB YOHIMBINE FACI; BEANI L, 1986, J PHARMACOL EXP THER, V236, P230; BOGEN J, 1975, J NEUROBIOL, V6, P125, DOI 10.1002/neu.480060115; BORUCKI S J, 1992, Neurology, V42, P329; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1993, RESTOR NEUROL NEUROS, V5, P283, DOI 10.3233/RNN-1993-5404; BOYESON MG, 1991, RESTOR NEUROL NEUROS, V3, P227, DOI 10.3233/RNN-1991-3501; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; BOYESON MG, 1993, IN PRESS AM J PHYS M; COLE JR, 1985, ARCH PHYS MED REHAB, V66, P38; Cools AR, 1977, COCAINE OTHER STIMUL, P97; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DIETRICH WD, 1990, STROKE, V21, P147; DUNBAR G, 1989, NEUR ABSTR, V19, P132; FEENEY D M, 1990, Society for Neuroscience Abstracts, V16, P779; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1983, PSYCHOPHARMACOLOGY, V79, P67, DOI 10.1007/BF00433018; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FEENEY DM, 1987, FEASIBILITY STUDY PH; Fuxe K., 1970, AMPHETAMINES RELATED, P257; GOLDSTEIN LB, 1992, BRAIN RES, V580, P129, DOI 10.1016/0006-8993(92)90936-4; GOLDSTEIN LB, 1990, BRAIN RES, V508, P305, DOI 10.1016/0006-8993(90)90413-6; GOLDSTEIN LB, 1989, ANN NEUROL, V26, P157; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P318; GOLDSTEIN LB, 1991, J NEUROL REHABIL, V5, P129; HOMAN R, 1990, Society for Neuroscience Abstracts, V16, P439; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HURWITZ BE, 1991, STROKE, V22, P648, DOI 10.1161/01.STR.22.5.648; JONASON KR, 1970, J COMP PHYSIOL PSYCH, V73, P47, DOI 10.1037/h0030013; KANNEL WB, 1983, VASCULAR DISEASE CEN, P45; Kline A. E., 1993, Society for Neuroscience Abstracts, V19, P1878; KLINE AE, 1993, UNPUB METHYLPHENIDAT; KROBERT KA, 1993, IN PRESS J NEUROCHEM; KUCZENSKI R, 1992, SYNAPSE, V11, P164, DOI 10.1002/syn.890110210; Kuczenski R., 1983, STIMULANTS NEUROCHEM, P31; LHEUREUX R, 1986, J NEUROCHEM, V46, P1794; MACKENZIE EJ, 1988, JAMA-J AM MED ASSOC, V260, P3290, DOI 10.1001/jama.260.22.3290; MALING HM, 1946, J NEUROPHYSIOL, V9, P379, DOI 10.1152/jn.1946.9.5.379; MEYER PM, 1963, J COMP PHYSIOL PSYCH, V56, P402, DOI 10.1037/h0049297; NIDDAM R, 1985, N-S ARCH PHARMACOL, V329, P123, DOI 10.1007/BF00501200; OGREN SO, 1983, NEUROSCI LETT, V43, P327, DOI 10.1016/0304-3940(83)90209-4; RITCHIE GD, 1976, EXP NEUROL, V53, P227, DOI 10.1016/0014-4886(76)90294-6; Robins M., 1981, STROKE, V12, pI45; SALO A A, 1987, Society for Neuroscience Abstracts, V13, P1268; SCHEELKRUGER J, 1971, EUR J PHARMACOL, V14, P47, DOI 10.1016/0014-2999(71)90121-X; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; SLOVITER RS, 1978, J PHARMACOL EXP THER, V206, P348; SUTTON R L, 1989, Brain Dysfunction, V2, P201; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; SUTTON RL, 1989, BEHAV NEUROSCI, V103, P837, DOI 10.1037/0735-7044.103.4.837; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; SUTTON RL, IN PRESS NEUROLOGICA; TRUNKEY D, 1985, TRAUMA CENTRAL NERVO, P9; Walker AE, 1981, STROKE S1, V12, pI13; WALKERBATSON D, 1992, RESTOR NEUROL NEUROS, V4, P47, DOI 10.3233/RNN-1992-4106; 1989, INTERAGENCY HEAD INJ; 1988, REHAB BRIEF, V9, P1	67	76	77	0	3	FREUND PUBLISHING HOUSE	LONDON	STE 500, CHESHAM HOUSE, 150 REGENT ST, LONDON, ENGLAND W1R 5FA	0792-8483			J NEURAL TRANSP PLAS	J. Neural Transplant. Plast.	JUL-SEP	1993	4	3					199	213		10.1155/NP.1993.199			15	Neurosciences; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Transplantation	NG435	WOS:A1993NG43500004	8018752	gold, Green Published			2022-02-06	
J	MUIR, JK; BOERSCHEL, M; ELLIS, EF				MUIR, JK; BOERSCHEL, M; ELLIS, EF			CONTINUOUS MONITORING OF POSTTRAUMATIC CEREBRAL BLOOD-FLOW USING LASER-DOPPLER FLOWMETRY	JOURNAL OF NEUROTRAUMA			English	Article							TRAUMATIC BRAIN INJURY; FLUID-PERCUSSION MODEL; RAT; MICROCIRCULATION; ABNORMALITIES; CATS	Traumatic brain injury causes alterations in cerebral blood flow that are thought to influence secondary pathophysiology and neurologic outcome in humans. Since it is difficult to study early changes in blood flow in head-injured patients, animal models of brain injury must be employed. However, techniques to monitor brain blood flow in animals are labor intensive and generally provide discontinuous flow measurements. The present study examines the application of laser-Doppler flowmetry for measurement of cerebral blood flow following experimental brain injury. This method allows continuous monitoring of local cerebral blood flow before, during, and after injury. Rats (n = 9) were prepared for lateral fluid percussion injury under barbiturate anesthesia. Injury (2.10 +/- 0.02 atm) was induced over the right parietal cortex, and blood flow was monitored in the contralateral cortex. Seconds after the peak hypertension after injury, blood flow in the left parietal cortex increased 226 % +/- 18% (xBAR +/- SEM). This increase was transient, with blood flow falling below control values within minutes. Five minutes after injury, blood flow was 83% +/- 8% of control, and at 1 h, this value had fallen to 56% +/- 6%. Blood flow at 60 min was 93% +/- 5% of control in the sham-injured group (n = 10). The reduction in cerebral blood flow in our laser-Doppler study was of similar magnitude as previously reported in rats injured at a similar intensity when blood flow was examined with radiolabeled microspheres. Given these results, we believe laser-Doppler flowmetry can be used to continuously monitor posttraumatic blood flow following experimental brain injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,BOX 613,MCV STN,RICHMOND,VA 23298						PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [27214, 12587] Funding Source: Medline		BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; HABERL RL, 1989, AM J PHYSIOL, V256, pH1255, DOI 10.1152/ajpheart.1989.256.4.H1255; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; SHEPHERD AP, 1987, AM J PHYSIOL, V252, pG832, DOI 10.1152/ajpgi.1987.252.6.G832; SOLOMON RA, 1985, STROKE, V16, P58, DOI 10.1161/01.STR.16.1.58; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	16	76	78	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	WIN	1992	9	4					355	362		10.1089/neu.1992.9.355			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	KH753	WOS:A1992KH75300005	1291695				2022-02-06	
J	MENTIS, M; PRUTTING, CA				MENTIS, M; PRUTTING, CA			ANALYSIS OF TOPIC AS ILLUSTRATED IN A HEAD-INJURED AND A NORMAL ADULT	JOURNAL OF SPEECH AND HEARING RESEARCH			English	Article						TOPIC ANALYSIS; DISCOURSE; CLOSED HEAD INJURY	LANGUAGE; MANIPULATION; DISCOURSE		UNIV CALIF SANTA BARBARA,SANTA BARBARA,CA 93106		MENTIS, M (corresponding author), BOSTON UNIV,DEPT COMMUN DISORDERS,635 COMMONWEALTH AVE,BOSTON,MA 02215, USA.						ATKINSON JM, 1984, STRUCTURES SOCIAL AC, P165; Bayles K. A., 1984, LANGUAGE DISORDERS A, P209; Bloom L., 1978, Q NEWSLETTER I COMP, V2, P1; BRINTON B, 1984, J SPEECH HEAR RES, V27, P350, DOI 10.1044/jshr.2703.350; Chafe Wallace, 1987, TYPOLOGICAL STUDIES, V11, P21; Crow B. K, 1983, CONVERSATION COHEREN, P136; ELLIS DG, 1983, CONVERSATINAL COHERE, P222; FORSYTH IJ, 1974, SPACE ENGLISH FOREIG, P77; FROMM D, 1989, J SPEECH HEAR DISORD, V54, P535, DOI 10.1044/jshd.5404.535; GARDNER R, 1987, SEMIOTICA, V65, P129, DOI 10.1515/semi.1987.65.1-2.129; Goodenough D. R., 1978, DISCOURSE PROCESS, V1, P395, DOI 10.1080/01638537809544447; GRIMES JE, 1981, ANAL DISCOURSE TEXT, P164; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; HALLIDAY M, 1975, LEARNING HOW MEAN; Halliday M. A. K., 1985, INTRO FUNCTIONAL GRA; Halliday M. A. K., 1970, NEW HORIZONS LINGUIS, P140; Halliday Michael, 1973, EXPLORATIONS FUNCTIO; HALPERN H, 1973, J SPEECH HEAR DISORD, V38, P162, DOI 10.1044/jshd.3802.162; HURTIG R, 1977, ADV RES THEOR, V1, P89; Jefferson Gail, 1972, STUDIES SOCIAL INTER, P294; Kertesz A, 1979, APHASIA ASS DISORDER; Kertesz A., 1980, W APHASIA BATTERY; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Levinson Stephen., 1983, PRAGMATICS; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MAYNARD DW, 1980, SEMIOTICA, V30, P263, DOI 10.1515/semi.1980.30.3-4.263; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; Morris W., 1969, AM HERITAGE DICT ENG; Myers Penelope S., 1979, CLIN APHASIOLOGY C P, P38; MYERS PS, 1984, LANGUAGE DISORDERS A, P117; OKOLO BA, 1987, STUDIES AFRICAN LING, V18, P211; Pei M., 1969, DICT LINGUISTICS; PIKE KL, 1967, LANGUAGE RELATION UN; Planalp S., 1980, COMMUNICATION YB, V4, P237, DOI [10.1080/23808985.1980, DOI 10.1080/23808985.1980]; Prigatano G. P., 1985, LANG SCI, V7, P217, DOI [10.1016/S0388-0001(85)80020-6, DOI 10.1016/S0388-0001(85)80020-6]; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Reichman R., 1978, COGNITIVE SCI, V2, P283, DOI DOI 10.1207/S15516709COG0204_1; SCHANK RC, 1977, COGNITIVE SCI, V1, P151; SCHEGLOFF EA, 1968, AM ANTHROPOL, V70, P1075, DOI 10.1525/aa.1968.70.6.02a00030; Schiffrin Deborah, 1987, DISCOURSE MARKERS; STECH EL, 1982, SEMIOTICA, V39, P75, DOI 10.1515/semi.1982.39.1-2.75; STOVER SE, 1989, CLIN LINGUIST PHONET, V3, P137, DOI 10.3109/02699208908985277; STUBBS M, 1983, DISCOURSE ANAL; van Dijk T.A., 1981, STUDIES PRAGMATICS D; VANDIJK TA, 1977, TEXT CONTEXT; WAPNER W, 1981, BRAIN LANG, V14, P15, DOI 10.1016/0093-934X(81)90061-4; Weiner S. L., 1977, DISCOURSE RELATIONS, P213; WERTZ RT, 1981, J SPEECH HEAR RES, V24, P580, DOI 10.1044/jshr.2404.580; WYCKOFF LH, 1984, THESIS U FLORIDA GAI; [No title captured]	51	76	76	0	6	AMER SPEECH-LANG-HEARING ASSN	ROCKVILLE	10801 ROCKVILLE PIKE RD, ROCKVILLE, MD 20852-3279	0022-4685			J SPEECH HEAR RES	J. Speech Hear. Res.	JUN	1991	34	3					583	595		10.1044/jshr.3403.583			13	Language & Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Linguistics; Rehabilitation	FQ361	WOS:A1991FQ36100016	2072683				2022-02-06	
J	GIULIAN, D; JOHNSON, B; KREBS, JF; GEORGE, JK; TAPSCOTT, M				GIULIAN, D; JOHNSON, B; KREBS, JF; GEORGE, JK; TAPSCOTT, M			MICROGLIAL MITOGENS ARE PRODUCED IN THE DEVELOPING AND INJURED MAMMALIAN BRAIN	JOURNAL OF CELL BIOLOGY			English	Article							CENTRAL NERVOUS-SYSTEM; COLONY-STIMULATING FACTORS; EPIDERMAL GROWTH-FACTOR; GLIA-PROMOTING FACTORS; AMEBOID MICROGLIA; ASTROGLIAL PROLIFERATION; INTERLEUKIN-1; CELLS; MACROPHAGES; PEPTIDES	The central nervous system produces growth factors that stimulate proliferation of ameboid microglia during embryogenesis and after traumatic injury. Two microglial mitogens (MMs) are recovered from the brain of newborn rat. MM1 had an approximate molecular mass of 50 kD and a pI of approximately 6.8; MM2 has a molecular mass of 22 kD and a pI of approximately 5.2. These trypsin-sensitive proteins show specificity of action upon glia in vitro serving as growth factors for ameboid microglia but not astroglia or oligodendroglia. Although the MMs did not stimulate proliferation of blood monocytes or resident peritoneal macrophage, MM1 shows granulocyte macrophage colony-stimulating activity when tested upon bone marrow progenitor cells. Microglial mitogens may help to control brain mononuclear phagocytes in vivo. The MMs first appear in the cerebral cortex of rat during early development with peak levels around embryonic day E-20, a period of microglial proliferation. Microglial mitogens are also produced by traumatized brain of adult rats within 2 days after injury. When infused into the cerebral cortex, MM1 and MM2 elicit large numbers of mononuclear phagocytes at the site of injection. In vitro study shows that astroglia from newborn brain secrete MM2. These observations point to the existence of a regulatory system whereby secretion of proteins from brain glia help to control neighboring inflammatory responses.			GIULIAN, D (corresponding author), BAYLOR UNIV, DEPT NEUROL, HOUSTON, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS25637] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS025637] Funding Source: NIH RePORTER		BOHLEN P, 1973, ARCH BIOCHEM BIOPHYS, V155, P213, DOI 10.1016/S0003-9861(73)80023-2; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DAEMS WT, 1980, RETICULOENDOTHELIAL, P549; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; FREI K, 1986, J IMMUNOL, V137, P3521; GIULIAN D, 1986, J CELL BIOL, V102, P812, DOI 10.1083/jcb.102.3.812; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1990, EOS-RIV IMMUNOL, V10, P15; GIULIAN D, 1988, J NEUROSCI, V8, P709; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1986, J NEUROSCI, V6, P2163; GIULIAN D, 1985, J CELL BIOL, V101, P2411, DOI 10.1083/jcb.101.6.2411; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1988, J NEUROSCI, V8, P4707; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GIULIAN D, 1986, J CELL BIOL, V102, P803, DOI 10.1083/jcb.102.3.803; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; KOSKI IR, 1976, IN VITRO METHODS CEL, P359; LEUTZ A, 1981, CELL TISSUE RES, V220, P393; LIM R, 1989, P NATL ACAD SCI USA, V86, P3901, DOI 10.1073/pnas.86.10.3901; LING EA, 1981, ADV CELL NEUROBIOL, V2, P33; LORET C, 1989, J BIOL CHEM, V264, P8319; MATSUMOTO Y, 1985, CELL TISSUE RES, V239, P271; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCMORRIS FA, 1988, J NEUROSCI RES, V21, P199, DOI 10.1002/jnr.490210212; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1984, HEMOPOIETIC COLONIES; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NICOLA NA, 1979, J BIOL CHEM, V254, P5290; OEHMICHEN M, 1983, PROG NEUROPATH, V5, P277; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; POEHLING HM, 1981, ELECTROPHORESIS, V2, P141, DOI 10.1002/elps.1150020304; PRUSS RM, 1981, DEV BRAIN RES, V2, P19, DOI 10.1016/0165-3806(81)90056-0; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; RIOHORTEGA P, 1932, CYTOLOGY CELLULAR PA, P481; WONG DM, 1984, METHOD ENZYMOL, V108, P307	40	76	77	0	2	ROCKEFELLER UNIV PRESS	NEW YORK	950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA	0021-9525	1540-8140		J CELL BIOL	J. Cell Biol.	JAN	1991	112	2					323	333		10.1083/jcb.112.2.323			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	ET174	WOS:A1991ET17400013	1988464	Bronze, Green Published, Green Submitted			2022-02-06	
J	EWERT, J; LEVIN, HS; WATSON, MG; KALISKY, Z				EWERT, J; LEVIN, HS; WATSON, MG; KALISKY, Z			PROCEDURAL MEMORY DURING POSTTRAUMATIC AMNESIA IN SURVIVORS OF SEVERE CLOSED HEAD-INJURY - IMPLICATIONS FOR REHABILITATION	ARCHIVES OF NEUROLOGY			English	Article									UNIV TEXAS,MED BRANCH,DIV NEUROSURG,D73,GALVESTON,TX 77550; DEL ORO HOSP,MED CTR,DEPT PHYS MED & REHABIL,HOUSTON,TX; UNIV HOUSTON,DEPT PSYCHOL,HOUSTON,TX 77004						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; BROOKS DN, 1976, NEUROPSYCHOLOGIA, V14, P111, DOI 10.1016/0028-3932(76)90012-9; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; CORKIN S, 1968, NEUROPSYCHOLOGIA, V6, P255, DOI 10.1016/0028-3932(68)90024-9; CUMMINGS JL, 1984, NEUROLOGY, V34, P679, DOI 10.1212/WNL.34.5.679; EISENBERG HM, 1988, 1988 M AM ASS NEUR S; ESLINGER PJ, 1986, J NEUROSCI, V6, P3006; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; Goodglass H, 1983, ASSESSMENT APHASIA R; GRAF P, 1984, J EXP PSYCHOL LEARN, V10, P164, DOI 10.1037/0278-7393.10.1.164; GREEN DM, 1966, SIGNAL DETECTION THE; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; HEINDEL WC, 1988, BEHAV NEUROSCI, V102, P141, DOI 10.1037/0735-7044.102.1.141; Holbourn AHS, 1943, LANCET, V2, P438; JENNETT WB, 1969, BRIT J PSYCHIAT, P40; KIHLSTROM JF, 1987, SCIENCE, V237, P1445, DOI 10.1126/science.3629249; LEINER HC, 1986, BEHAV NEUROSCI, V100, P443, DOI 10.1037/0735-7044.100.4.443; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MAUK MD, 1987, BRAIN RES, V403, P89, DOI 10.1016/0006-8993(87)90126-0; NISSEN MJ, 1987, NEUROLOGY, V37, P789, DOI 10.1212/WNL.37.5.789; Porteus S. D, 1959, MAZE TEST CLIN PSYCH; Russell WR, 1935, LANCET, V2, P762; SHIMAMURA AP, 1984, J EXP PSYCHOL GEN, V113, P556, DOI 10.1037/0096-3445.113.4.556; SQUIRE LR, 1984, NEUROPSYCHOLOGIA, V22, P145, DOI 10.1016/0028-3932(84)90057-5; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1974, LANCET, V2, P81; Thorndike E. L., 1944, TEACHERS WORD BOOK 3; [No title captured]	34	76	76	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	AUG	1989	46	8					911	916		10.1001/archneur.1989.00520440105027			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	AJ310	WOS:A1989AJ31000025	2757532				2022-02-06	
J	POVLISHOCK, JT; BECKER, DP; MILLER, JD; JENKINS, LW; DIETRICH, WD				POVLISHOCK, JT; BECKER, DP; MILLER, JD; JENKINS, LW; DIETRICH, WD			MORPHOPATHOLOGIC SUBSTRATES OF CONCUSSION	ACTA NEUROPATHOLOGICA			English	Article									MED COLL VIRGINIA,DEPT NEUROL SURG,RICHMOND,VA 23298		POVLISHOCK, JT (corresponding author), MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS020193] Funding Source: Medline		ADAMS JC, 1976, J COMP NEUROL, V170, P107, DOI 10.1002/cne.901700108; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; BASBAUM AI, 1976, P NATL ACAD SCI USA, V73, P4685, DOI 10.1073/pnas.73.12.4685; BOWSHER D, 1970, J ANAT, V106, P23; BOWSHER D, 1971, BRAIN RES, V28, P443, DOI 10.1016/0006-8993(71)90055-2; BROWN WJ, 1972, AM J PATHOL, V67, P41; CHASON JL, 1958, J NEUROSURG, V15, P135, DOI 10.3171/jns.1958.15.2.0135; CHASON JL, 1966, J TRAUM, V6, P767, DOI 10.1097/00005373-196611000-00008; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; FRIEDE RL, 1961, ARCH NEUROL-CHICAGO, V4, P449, DOI 10.1001/archneur.1961.00450100097012; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; GRIFFITHS IR, 1974, J NEUROL SCI, V22, P291, DOI 10.1016/0022-510X(74)90002-1; GROAT RA, 1944, J NEUROSURG, V2, P26; KEEFER DA, 1978, BRAIN RES, V140, P15, DOI 10.1016/0006-8993(78)90235-4; KLATZO IGOR, 1962, ACTA NEUROPATHOLOGICA, V2, P144; LAVAIL JH, 1974, J COMP NEUROL, V157, P303, DOI 10.1002/cne.901570304; NYBERGHA.R, 1965, J COMP NEUROL, V124, P71, DOI 10.1002/cne.901240107; OLSSON Y, 1970, ACTA NEUROPATHOL, V16, P103, DOI 10.1007/BF00687665; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PERSSON L, 1976, ACTA NEUROPATHOL, V34, P125, DOI 10.1007/BF00684663; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1978, NEURAL TRAUMA SEMINA, V4; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; SASAKI S, 1976, ACTA NEUROPATHOL, V36, P363, DOI 10.1007/BF00699641; SEITE R, 1971, BRAIN RES, V34, P277, DOI 10.1016/0006-8993(71)90281-2; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TURNER PT, 1974, BRAIN RES, V74, P305, DOI 10.1016/0006-8993(74)90585-X; VANEGAS H, 1978, J COMP NEUROL, V177, P193, DOI 10.1002/cne.901770203; WARD AA, 1966, HEAD INJURY C P	32	76	76	1	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.		1979	47	1					1	11		10.1007/BF00698266			11	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	HB010	WOS:A1979HB01000001	463502				2022-02-06	
J	FISHER, CM				FISHER, CM			CONCUSSION AMNESIA	NEUROLOGY			English	Article																	BLONSTEIN JL, 1957, BRIT MED J, V1, P362, DOI 10.1136/bmj.1.5015.362; BURTON HL, 1931, P ROY SOC MED, V24, P1405; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; FIELDS WS, 1963, 10 S ANN M HOUST NEU; FISHER CM, 1964, ACTA PSYCHIAT KBH S9, V40; QUIGLEY TB, 1957, HARV PUBL HLTH ALUMN, V31, P19; SYMONDS C, 1962, LANCET, V1, P1; UNPUBLISHED PERSONAL	8	76	76	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0028-3878			NEUROLOGY	Neurology		1966	16	8					826	&		10.1212/WNL.16.8.826			0	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	80732	WOS:A19668073200017					2022-02-06	
J	GURDJIAN, ES; LISSNER, HR; WEBSTER, JE; LATIMER, FR; HADDAD, BF				GURDJIAN, ES; LISSNER, HR; WEBSTER, JE; LATIMER, FR; HADDAD, BF			STUDIES ON EXPERIMENTAL CONCUSSION - RELATION OF PHYSIOLOGIC EFFECT TO TIME DURATION OF INTRACRANIAL PRESSURE INCREASE AT IMPACT	NEUROLOGY			English	Article																	GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; Walker AE, 1945, A RES NERV MENT DIS, V24, P437	2	76	78	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0028-3878			NEUROLOGY	Neurology		1954	4	9					674	681		10.1212/WNL.4.9.674			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	YD622	WOS:A1954YD62200004	13214267				2022-02-06	
J	Tatum, WO; Rubboli, G; Kaplan, PW; Mirsatari, SM; Radhakrishnan, K; Gloss, D; Caboclo, LO; Drislane, FW; Koutroumanidis, M; Schomer, DL; Trenite, DKN; Cook, M; Beniczky, S				Tatum, W. O.; Rubboli, G.; Kaplan, P. W.; Mirsatari, S. M.; Radhakrishnan, K.; Gloss, D.; Caboclo, L. O.; Drislane, F. W.; Koutroumanidis, M.; Schomer, D. L.; Trenite, D. Kastelijn-Nolst; Cook, Mark; Beniczky, S.			Clinical utility of EEG in diagnosing and monitoring epilepsy in adults	CLINICAL NEUROPHYSIOLOGY			English	Article						EEG; Epilepsy; Epileptiform; Seizure; Guideline	TEMPORAL-LOBE EPILEPSY; JUVENILE MYOCLONIC EPILEPSY; NONCONVULSIVE STATUS EPILEPTICUS; IDIOPATHIC GENERALIZED EPILEPSY; 1ST UNPROVOKED SEIZURE; QUALITY-STANDARDS-SUBCOMMITTEE; COMPLEX PARTIAL SEIZURES; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; HIGH-FREQUENCY OSCILLATIONS	Electroencephalography (EEG) remains an essential diagnostic tool for people with epilepsy (PWE). The International Federation of Clinical Neurophysiology produces new guidelines as an educational service for clinicians to address gaps in knowledge in clinical neurophysiology. The current guideline was prepared in response to gaps present in epilepsy-related neurophysiological assessment and is not intended to replace sound clinical judgement in the care of PWE. Furthermore, addressing specific pathophysiological conditions of the brain that produce epilepsy is of primary importance though is beyond the scope of this guideline. Instead, our goal is to summarize the scientific evidence for the utility of EEG when diagnosing and monitoring PWE. (C) 2018 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.	[Tatum, W. O.] Mayo Clin, Dept Neurol, Cannaday,2 East,4500 San Pablo Rd, Jacksonville, FL 32224 USA; [Rubboli, G.] Univ Copenhagen, Danish Epilepsy Ctr, Dept Neurol, Copenhagen, Diannalund, Denmark; [Kaplan, P. W.] Johns Hopkins Univ, Baltimore, MD USA; [Mirsatari, S. M.] Western Univ, Dept Clin Neurol Sci, London, ON, Canada; [Radhakrishnan, K.] Amrita Inst Med Sci, Dept Neurol, Kochi, Kerala, India; [Gloss, D.] CAMC Dept Neurol, Charleston, WV USA; [Caboclo, L. O.] Hosp Israelita Albert Einstein, Dept Neurol, Sao Paulo, Brazil; [Drislane, F. W.; Schomer, D. L.] Harvard Univ, Dept Neurol, Beth Israel Deaconess Med Ctr, Boston, MA USA; [Koutroumanidis, M.] Kings Coll London, Guys & St Thomas NHS Trust, Dept Neurol, London, England; [Trenite, D. Kastelijn-Nolst] Univ Med Ctr, Brain Ctr, Utrecht, Netherlands; [Trenite, D. Kastelijn-Nolst] Sapienza Univ, Dept Pediat, Rome, Italy; [Cook, Mark] Univ Melbourne, Dept Neurol, Melbourne, Vic, Australia; [Beniczky, S.] Aarhus Univ Hosp, Dept Clin Neurophysiol, Aarhus, Denmark		Tatum, WO (corresponding author), Mayo Clin, Dept Neurol, Cannaday,2 East,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	tatum.william@mayo.edu	Trenite, Dorothee Nolst/ABG-5804-2020; Cook, Mark/A-7096-2010	Beniczky, Sandor/0000-0002-6035-6581; Cook, Mark/0000-0002-8875-4135			Aarabi A, 2006, CLIN NEUROPHYSIOL, V117, P328, DOI 10.1016/j.clinph.2005.10.006; Abubakr A, 2010, J CLIN NEUROSCI, V17, P1503, DOI 10.1016/j.jocn.2009.12.037; Acharya JN, 2016, J CLIN NEUROPHYSIOL, V33, P308, DOI 10.1097/WNP.0000000000000316; Airoldi L, 1999, J CLIN NEUROPHYSIOL, V16, P456, DOI 10.1097/00004691-199909000-00007; Aldenkamp AP, 2004, EPILEPSY BEHAV, V5, pS25, DOI 10.1016/j.yebeh.2003.11.005; ALIBERTI V, 1994, EPILEPSIA, V35, P297, DOI 10.1111/j.1528-1157.1994.tb02433.x; Alix JJP, 2014, SEIZURE-EUR J EPILEP, V23, P662, DOI 10.1016/j.seizure.2014.04.008; Alsaadi TM, 2004, SEIZURE-EUR J EPILEP, V13, P32, DOI 10.1016/S1059-1311(03)00072-4; Alvarez V, 2013, CRIT CARE, V17, DOI 10.1186/cc12879; Alving J, 2009, SEIZURE-EUR J EPILEP, V18, P470, DOI 10.1016/j.seizure.2009.04.005; Amantini A, 2009, NEUROPHYSIOL CLIN, V39, P85, DOI 10.1016/j.neucli.2009.01.006; Angus-Leppan H, 2007, CLIN NEUROPHYSIOL, V118, P22, DOI 10.1016/j.clinph.2006.08.014; ARROYO S, 1994, EPILEPSIA, V35, P974, DOI 10.1111/j.1528-1157.1994.tb02542.x; Arts R, 2002, CAN J NEUROL SCI, V29, P216; Asano E, 2009, BRAIN, V132, P1038, DOI 10.1093/brain/awp025; Avanzini G, 2016, EPILEPTIC DISORD, V18, pS11, DOI 10.1684/epd.2016.0835; Badawy RAB, 2013, NEUROLOGY, V80, P1901, DOI 10.1212/WNL.0b013e3182929f4f; Baldin E, 2014, EPILEPSIA, V55, P1389, DOI 10.1111/epi.12720; BARRETT G, 1992, J CLIN NEUROPHYSIOL, V9, P495, DOI 10.1097/00004691-199210000-00004; Bautista RED, 1998, NEUROLOGY, V50, P1765; Beleza P, 2009, EPILEPSIA, V50, P550, DOI 10.1111/j.1528-1167.2008.01780.x; Benbadis SR, 2009, NEUROLOGY, V73, P843, DOI 10.1212/WNL.0b013e3181b78425; Benbadis SR, 2010, EXPERT REV NEUROTHER, V10, P343, DOI 10.1586/ERN.09.157; Benbadis SR, 2004, NEUROLOGY, V63, P1728, DOI 10.1212/01.WNL.0000143273.18099.50; Benbadis SR, 2003, NEUROLOGY, V61, P1793, DOI 10.1212/01.WNL.0000098891.76373.15; Benbadis SR, 2003, J CLIN NEUROPHYSIOL, V20, P42, DOI 10.1097/00004691-200302000-00005; Beniczky S, 2013, EPILEPSIA, V54, P1743, DOI 10.1111/epi.12339; Beniczky S, 2013, EPILEPSIA, V54, P28, DOI 10.1111/epi.12270; Beniczky S, 2013, EPILEPSIA, V54, P1112, DOI 10.1111/epi.12135; Beniczky S, 2013, EPILEPSIA, V54, pe58, DOI 10.1111/epi.12120; Beniczky S, 2012, EPILEPSIA, V53, P832, DOI 10.1111/j.1528-1167.2012.03454.x; Beniczky SA, 2012, EPILEPSY BEHAV, V24, P213, DOI 10.1016/j.yebeh.2012.03.036; Benifla M, 2006, NEUROSURGERY, V59, P1203, DOI 10.1227/01.NEU.0000245615.32226.83; Berg AT, 2008, EPILEPSIA, V49, P13, DOI 10.1111/j.1528-1167.2008.01444.x; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Bergey Gregory K, 2016, Continuum (Minneap Minn), V22, P38, DOI 10.1212/CON.0000000000000271; Berkovic SF, 2003, EPILEPSIA, V44, P969, DOI 10.1046/j.1528-1157.2003.59102.x; Bertram EH, 1998, EPILEPSY RES, V32, P194, DOI 10.1016/S0920-1211(98)00051-5; Bingham E, 2002, J NEUROL NEUROSUR PS, V73, P216; Binnie CD, 1999, CLIN NEUROPHYSIOL, V110, P1671, DOI 10.1016/S1388-2457(99)00125-X; BINNIE CD, 1981, NEUROLOGY, V31, P298, DOI 10.1212/WNL.31.3.298; BINNIE CD, 1994, J NEUROL NEUROSUR PS, V57, P1308, DOI 10.1136/jnnp.57.11.1308; Binnie Colin D., 1992, P299; Guaranha MSB, 2009, EPILEPSIA, V50, P2446, DOI 10.1111/j.1528-1167.2009.02126.x; Blum DE, 1996, NEUROLOGY, V47, P260, DOI 10.1212/WNL.47.1.260; Blume Warren T., 2001, Epilepsia, V42, P1212, DOI 10.1046/j.1528-1157.2001.22001.x; BLUME WT, 1993, ANN NEUROL, V34, P703, DOI 10.1002/ana.410340513; Blume WT, 2001, CURR OPIN NEUROL, V14, P193, DOI 10.1097/00019052-200104000-00010; Blumenfeld H, 2003, EPILEPSIA, V44, P7, DOI 10.1046/j.1528-1157.44.s.2.2.x; Bonakis A, 2009, EPILEPSIA, V50, P2434, DOI 10.1111/j.1528-1167.2009.02110.x; Boon P, 2002, J CLIN NEUROPHYSIOL, V19, P461, DOI 10.1097/00004691-200210000-00009; Borchers S, 2012, NAT REV NEUROSCI, V13, P63, DOI 10.1038/nrn3140; Bragin A, 2002, J NEUROSCI, V22, P2012, DOI 10.1523/JNEUROSCI.22-05-02012.2002; BRENNER RP, 1990, J CLIN NEUROPHYSIOL, V7, P249, DOI 10.1097/00004691-199004000-00007; Brigo F, 2015, EPILEPSIA, V56, pE21, DOI 10.1111/epi.12911; Brna P, 2015, EPILEPSIA, V56, P1065, DOI 10.1111/epi.12983; Brodbeck V, 2011, BRAIN, V134, P2887, DOI 10.1093/brain/awr243; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Brown P, 1999, BRAIN, V122, P461, DOI 10.1093/brain/122.3.461; Brunnhuber F, 2014, SEIZURE-EUR J EPILEP, V23, P338, DOI 10.1016/j.seizure.2014.01.009; Bubrick EJ, 2014, SEIZURE-EUR J EPILEP, V23, P699, DOI 10.1016/j.seizure.2014.05.007; Bulacio JC, 2012, EPILEPSIA, V53, P1722, DOI 10.1111/j.1528-1167.2012.03633.x; Buna DK, 1998, PHARMACOTHERAPY, V18, P235; Burkholder DB, 2016, NEUROLOGY, V86, P1524, DOI 10.1212/WNL.0000000000002592; Butler CR, 2007, ANN NEUROL, V61, P587, DOI 10.1002/ana.21111; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; CALLAGHAN N, 1988, NEW ENGL J MED, V318, P942, DOI 10.1056/NEJM198804143181502; Carpay JA, 1997, EPILEPSIA, V38, P595, DOI 10.1111/j.1528-1157.1997.tb01145.x; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Cascino GD, 2002, MAYO CLIN PROC, V77, P1111, DOI 10.4065/77.10.1111; CASCINO GD, 1993, NEUROLOGY, V43, P747, DOI 10.1212/WNL.43.4.747; CASCINO GD, 1995, EPILEPSIA, V36, P692, DOI 10.1111/j.1528-1157.1995.tb01048.x; Cascino GD, 2001, NEUROL CLIN, V19, P271, DOI 10.1016/S0733-8619(05)70019-0; CAVAZZUTI GB, 1980, EPILEPSIA, V21, P43, DOI 10.1111/j.1528-1157.1980.tb04043.x; Chadwick D, 2006, EPILEPSIA, V47, P58, DOI 10.1111/j.1528-1167.2006.00662.x; Chatrian GE, 1983, RECOMMENDATIONS PRAC, P11; Chen DK, 2008, EPILEPSY BEHAV, V13, P115, DOI 10.1016/j.yebeh.2008.02.018; Chowdhury FA, 2008, EUR J NEUROL, V15, P1034, DOI 10.1111/j.1468-1331.2008.02260.x; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2005, J CLIN NEUROPHYSIOL, V22, P92, DOI 10.1097/01.WNP.0000145006.02048.3A; Claassen J, 2003, NEUROLOGY, V60, P208, DOI 10.1212/01.WNL.0000038906.71394.DE; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Cohen-Gadol AA, 2004, J NEUROSURG, V101, P55, DOI 10.3171/jns.2004.101.1.0055; Cook MJ, 2013, LANCET NEUROL, V12, P563, DOI 10.1016/S1474-4422(13)70075-9; Craciun L, 2014, ACTA NEUROL SCAND, V129, pE9, DOI 10.1111/ane.12186; Craciun L, 2015, SEIZURE-EUR J EPILEP, V30, P90, DOI 10.1016/j.seizure.2015.06.003; Crepeau AZ, 2013, NEUROLOGY, V80, P339, DOI 10.1212/WNL.0b013e31827f089d; D'Souza WJ, 2010, EPILEPSY RES, V91, P20, DOI 10.1016/j.eplepsyres.2010.06.003; Daniel SJ, 2011, SEIZURE-EUR J EPILEP, V20, P564, DOI 10.1016/j.seizure.2011.04.006; De Marchis GM, 2016, NEUROLOGY, V86, P253, DOI 10.1212/WNL.0000000000002281; Deacon C, 2003, NEUROLOGY, V61, P1686, DOI 10.1212/01.WNL.0000090566.40544.04; DECLERCK AC, 1986, EUR NEUROL, V25, P117, DOI 10.1159/000116092; DEGEN R, 1983, EPILEPSIA, V24, P557, DOI 10.1111/j.1528-1157.1983.tb03420.x; DEGEN R, 1980, ELECTROEN CLIN NEURO, V49, P577, DOI 10.1016/0013-4694(80)90398-3; DEGEN R, 1981, J NEUROL, V225, P85, DOI 10.1007/BF00313322; DEGRAAF AS, 1995, EPILEPSIA, V36, P219; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Dericioglu N, 2008, CLIN EEG NEUROSCI, V39, P20, DOI 10.1177/155005940803900109; Dericioglu N, 2010, CLIN EEG NEUROSCI, V41, P166, DOI 10.1177/155005941004100312; Derry CP, 2009, SLEEP, V32, P1637, DOI 10.1093/sleep/32.12.1637; Dhanuka AK, 2001, SEIZURE-EUR J EPILEP, V10, P374, DOI 10.1053/seiz.2001.0522; Di Gennaro G, 2012, CLIN NEUROPHYSIOL, V123, P2346, DOI 10.1016/j.clinph.2012.05.013; Diehl B, 2000, EPILEPSIA, V41, pS61, DOI 10.1111/j.1528-1157.2000.tb01536.x; Duez L, 2016, CLIN NEUROPHYSIOL, V127, P3301, DOI 10.1016/j.clinph.2016.08.006; Ebersole JS, 1999, EEG CL N SU, V50, P167; EBERSOLE JS, 1983, NEUROLOGY, V33, P853, DOI 10.1212/WNL.33.7.853; Ebersole JS, 1996, EPILEPSIA, V37, P386, DOI 10.1111/j.1528-1157.1996.tb00577.x; El Bouzidi K, 2010, NEUROLOGY, V74, P610, DOI 10.1212/WNL.0b013e3181cff6c3; El Tallawy HN, 2010, EPILEPSY RES, V88, P179, DOI 10.1016/j.eplepsyres.2009.11.001; ELAD B, 1994, ELECTROEN CLIN NEURO, V90, P313, DOI 10.1016/0013-4694(94)90150-3; Engel J, 2003, NEUROLOGY, V60, P538, DOI 10.1212/01.WNL.0000055086.35806.2D; Engel J, 2006, EPILEPSIA, V47, P1558, DOI 10.1111/j.1528-1167.2006.00215.x; Engel J, 2012, JAMA-J AM MED ASSOC, V307, P922, DOI 10.1001/jama.2012.220; Faulkner HJ, 2012, CLIN NEUROPHYSIOL, V123, P1732, DOI 10.1016/j.clinph.2012.01.023; Faulkner HJ, 2012, SEIZURE-EUR J EPILEP, V21, P491, DOI 10.1016/j.seizure.2012.04.015; Fernandez IS, 2013, J CLIN NEUROPHYSIOL, V30, P554, DOI 10.1097/01.wnp.0000436898.10125.70; Ferrier CH, 1999, J NEUROL NEUROSUR PS, V66, P350, DOI 10.1136/jnnp.66.3.350; Ferrier CH, 2006, EPILEPSIA, V47, P1477, DOI 10.1111/j.1528-1167.2006.00619.x; Fisch BJ, 2003, J CLIN NEUROPHYSIOL, V20, P155, DOI 10.1097/00004691-200305000-00001; Fischer MH, 1933, MED KLIN, V25, P15; Fisher RS, 2017, EPILEPSIA, V58, P522, DOI 10.1111/epi.13670; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Fittipaldi F, 2001, NEUROLOGY, V56, P123, DOI 10.1212/WNL.56.1.123; Flink R, 2002, ACTA NEUROL SCAND, V106, P1, DOI 10.1034/j.1600-0404.2002.01361.x; Foldvary N, 2001, NEUROLOGY, V57, P2022, DOI 10.1212/WNL.57.11.2022; Foreman B, 2012, NEUROLOGY, V79, P1951, DOI 10.1212/WNL.0b013e3182735cd7; Fountain NB, 1998, J CLIN NEUROPHYSIOL, V15, P69, DOI 10.1097/00004691-199801000-00009; Fowle AJ, 2000, EPILEPSIA, V41, pS10, DOI 10.1111/j.1528-1157.2000.tb01529.x; Freestone DR, 2013, IEEE ENG MED BIO, P6151, DOI 10.1109/EMBC.2013.6610957; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; Friedman DE, 2009, J CLIN NEUROPHYSIOL, V26, P213, DOI 10.1097/WNP.0b013e3181b2f2da; Gadhoumi K, 2016, J NEUROSCI METH, V260, P270, DOI 10.1016/j.jneumeth.2015.06.010; Gaspard N, 2014, EPILEPSIA, V55, P1366, DOI 10.1111/epi.12653; GASTAUT H, 1969, EPILEPSIA, VS 10, pS14; Gavaret M, 2015, NEUROPHYSIOL CLIN, V45, P105, DOI 10.1016/j.neucli.2014.11.011; Gavvala JR, 2016, JAMA-J AM MED ASSOC, V316, P2657, DOI 10.1001/jama.2016.18625; Genton P, 1995, NEUROPHYSIOL CLIN, V25, P283, DOI 10.1016/0987-7053(96)80171-7; Ghougassian DF, 2004, EPILEPSIA, V45, P928, DOI 10.1111/j.0013-9580.2004.51003.x; Gibbs EL, 1947, J NERV MENT DIS, V26, P336; GILLIAM FG, 1995, NEUROLOGY, V45, P453, DOI 10.1212/WNL.45.3.453; Giorgi FS, 2013, CLIN NEUROPHYSIOL, V124, P2101, DOI 10.1016/j.clinph.2013.04.342; Glauser T, 2017, EPILEPSY CURR; GLOOR P, 1968, BRAIN, V91, P779, DOI 10.1093/brain/91.4.779; GLOOR P, 1985, J CLIN NEUROPHYSIOL, V2, P327, DOI 10.1097/00004691-198510000-00002; Gonzalez-Martinez JA, 2016, J CLIN NEUROPHYSIOL, V33, P522, DOI 10.1097/WNP.0000000000000327; GOODIN DS, 1990, ANN NEUROL, V27, P330, DOI 10.1002/ana.410270317; Goodwin E, 2014, SEIZURE-EUR J EPILEP, V23, P480, DOI 10.1016/j.seizure.2014.02.008; Gotman J, 2004, J CLIN NEUROPHYSIOL, V21, P229, DOI 10.1097/01.WNP.0000139658.92878.2A; Greiner HM, 2016, EPILEPSY RES, V122, P73, DOI 10.1016/j.eplepsyres.2016.02.011; Guaranha MSB, 2005, EPILEPSIA, V46, P69, DOI 10.1111/j.0013-9580.2005.11104.x; Guerci JR, 1999, RADAR CONF, P119, DOI 10.1109/NRC.1999.767288; Gustafsson G, 2015, CLIN NEUROPHYSIOL, V126, P1493, DOI 10.1016/j.clinph.2014.10.015; Haider HA, 2016, NEUROLOGY, V87, P935, DOI 10.1212/WNL.0000000000003034; Halford JJ, 2011, J CLIN NEUROPHYSIOL, V28, P178, DOI 10.1097/WNP.0b013e31821215e3; Harden CL, 2003, EPILEPSIA, V44, P453, DOI 10.1046/j.1528-1157.2003.33002.x; HARDING GFA, 1994, EPILEPSIA, V35, P1208, DOI 10.1111/j.1528-1157.1994.tb01791.x; Harvey AS, 1996, ANN NEUROL, V40, P91, DOI 10.1002/ana.410400115; Hauser WA, 1998, NEW ENGL J MED, V338, P429, DOI 10.1056/NEJM199802123380704; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; HAUSER WA, 1982, NEW ENGL J MED, V307, P522, DOI 10.1056/NEJM198208263070903; Hendriksen IJM, 2001, AVIAT SPACE ENVIR MD, V72, P1025; Heo K, 2006, EPILEPSIA, V47, P1931, DOI 10.1111/j.1528-1167.2006.00820.x; Herman ST, 2015, J CLIN NEUROPHYSIOL, V32, P87, DOI 10.1097/WNP.0000000000000166; Hill NJ, 2012, JOVE-J VIS EXP, DOI 10.3791/3993; Hirfanoglu T, 2007, PEDIATR NEUROL, V36, P231, DOI 10.1016/j.pediatrneurol.2006.12.002; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Hirtz D, 2003, NEUROLOGY, V60, P166, DOI 10.1212/01.WNL.0000033622.27961.B6; Holmes MD, 2000, CLIN NEUROPHYSIOL, V111, P1802, DOI 10.1016/S1388-2457(00)00389-8; Holmes MD, 2004, EPILEPSIA, V45, P618, DOI 10.1111/j.0013-9580.2004.63803.x; Hopfengartner R, 2014, CLIN NEUROPHYSIOL, V125, P1346, DOI 10.1016/j.clinph.2013.12.104; Howbert JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081920; Hughes JR, 2003, CLIN ELECTROENCEPHAL, V34, P174, DOI 10.1177/155005940303400403; Husain AM, 1999, J CLIN NEUROPHYSIOL, V16, P51, DOI 10.1097/00004691-199901000-00005; Itoh Y, 2015, BRAIN DEV-JPN, V37, P49, DOI 10.1016/j.braindev.2014.03.013; Jackson AF, 2014, PSYCHOPHYSIOLOGY, V51, P1061, DOI 10.1111/psyp.12283; Jackson J H, 1890, Br Med J, V1, P821; Jackson J H, 1890, Br Med J, V1, P765; Jackson J H, 1890, Br Med J, V1, P703; Janszky J, 2000, NEUROLOGY, V54, P1470, DOI 10.1212/WNL.54.7.1470; JANZ D, 1985, ACTA NEUROL SCAND, V72, P449; JASPER H, 1955, Electroencephalogr Clin Neurophysiol Suppl, VSuppl. 4, P168; Jayakar P, 2016, EPILEPSIA, V57, P1735, DOI 10.1111/epi.13515; Jayakar P, 2014, EPILEPSIA, V55, P507, DOI 10.1111/epi.12544; Jayalakshmi SS, 2010, ACTA NEUROL SCAND, V122, P115, DOI 10.1111/j.1600-0404.2009.01270.x; Jefferys JGR, 2010, SEIZURE-EUR J EPILEP, V19, P638, DOI 10.1016/j.seizure.2010.10.026; Jeha LE, 2006, NEUROLOGY, V66, P1938, DOI 10.1212/01.wnl.0000219810.71010.9b; Jeha LE, 2007, BRAIN, V130, P574, DOI 10.1093/brain/awl364; Jeppesen J, 2010, TECHNOL HEALTH CARE, V18, P417, DOI 10.3233/THC-2010-0606; Jirsch J, 2007, CLIN NEUROPHYSIOL, V118, P1660, DOI 10.1016/j.clinph.2006.11.312; Jonas J, 2011, J NEUROL NEUROSUR PS, V82, P928, DOI 10.1136/jnnp.2009.200329; JOOMA R, 1995, J NEUROSURG, V83, P231, DOI 10.3171/jns.1995.83.2.0231; Kalitzin S, 2005, CLIN NEUROPHYSIOL, V116, P718, DOI 10.1016/j.clinph.2004.08.021; Kanazawa O, 1996, EPILEPSIA, V37, P50, DOI 10.1111/j.1528-1157.1996.tb00511.x; Kane N, 2014, SEIZURE-EUR J EPILEP, V23, P129, DOI 10.1016/j.seizure.2013.10.010; Kaplan PW, 2007, EPILEPSIA, V48, P39, DOI 10.1111/j.1528-1167.2007.01345.x; Kaplan PW, 2013, NEUROLOGY, V80, pS43, DOI 10.1212/WNL.0b013e3182797528; Kasteleijn-Nolst Trenite D G, 1989, Acta Neurol Scand Suppl, V125, P3; KELLAWAY P, 1980, ANN NEUROL, V8, P491, DOI 10.1002/ana.410080506; Kellaway P, 1981, CURRENT CLIN NEUROPH, P151; Keranen T, 2002, SEIZURE-EUR J EPILEP, V11, P269, DOI 10.1053/seiz.2001.0608; Kerling F, 2006, EPILEPSY BEHAV, V9, P281, DOI 10.1016/j.yebeh.2006.05.010; Khan SF, 2005, CLIN NEUROPHYSIOL, V116, P2454, DOI 10.1016/j.clinph.2005.06.024; Kharbouch A, 2011, EPILEPSY BEHAV, V22, pS29, DOI 10.1016/j.yebeh.2011.08.031; Kim DW, 2004, EPILEPSIA, V45, P641, DOI 10.1111/j.0013-9580.2004.33703.x; Kim LG, 2006, LANCET NEUROL, V5, P317, DOI 10.1016/S1474-4422(06)70383-0; Kimiskidis VK, 2014, CURR OPIN NEUROL, V27, P236, DOI 10.1097/WCO.0000000000000071; King MA, 1998, LANCET, V352, P1007, DOI 10.1016/S0140-6736(98)03543-0; King-Stephens D, 2015, EPILEPSIA, V56, P959, DOI 10.1111/epi.13010; Kipervasser S, 2007, ACTA NEUROL SCAND, V116, P221, DOI 10.1111/j.1600-0404.2007.00888.x; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Knight WA, 2013, EPILEPSY RES, V106, P396, DOI 10.1016/j.eplepsyres.2013.06.018; Koepp MJ, 2016, LANCET NEUROL, V15, P92, DOI 10.1016/S1474-4422(15)00219-7; Koutroumanidis M, 2005, EPILEPSIA, V46, P96, DOI 10.1111/j.1528-1167.2005.00320.x; Koutroumanidis M, 1998, BRAIN, V121, P1409, DOI 10.1093/brain/121.8.1409; Koutroumanidis M, 2008, EPILEPSIA, V49, P2050, DOI 10.1111/j.1528-1167.2008.01702.x; Krauss GL, 2005, NEUROLOGY, V64, P1879, DOI 10.1212/01.WNL.0000163991.97456.03; Krumholz A, 2007, NEUROLOGY, V69, P1996, DOI 10.1212/01.wnl.0000285084.93652.43; Krumholz A, 2015, NEUROLOGY, V84, P1705, DOI 10.1212/WNL.0000000000001487; Kutluay E, 2001, EPILEPSIA, V42, P1563, DOI 10.1046/j.1528-1157.2001.16401.x; Kuzniecky R, 1997, ANN NEUROL, V42, P60, DOI 10.1002/ana.410420111; Kwan SY, 2005, SEIZURE-EUR J EPILEP, V14, P470, DOI 10.1016/j.seizure.2005.07.011; Langston ME, 2015, EPILEPSY RES, V109, P163, DOI 10.1016/j.eplepsyres.2014.10.018; Lascano AM, 2016, CLIN NEUROPHYSIOL, V127, P150, DOI 10.1016/j.clinph.2015.03.025; Leach JP, 2006, J NEUROL NEUROSUR PS, V77, P1040, DOI 10.1136/jnnp.2005.084871; Lee SK, 2005, EPILEPSIA, V46, P688, DOI 10.1111/j.1528-1167.2005.56604.x; Lee SK, 2000, EPILEPSIA, V41, P1450, DOI 10.1111/j.1528-1157.2000.tb00121.x; Legriel S, 2009, NEUROCRIT CARE, V11, P338, DOI 10.1007/s12028-009-9246-4; Leitinger M, 2015, EPILEPSY BEHAV, V49, P158, DOI 10.1016/j.yebeh.2015.05.007; Leitinger M, 2016, LANCET NEUROL, V15, P1054, DOI 10.1016/S1474-4422(16)30137-5; Liava A, 2012, EPILEPSY BEHAV, V25, P68, DOI 10.1016/j.yebeh.2012.05.008; Liporace J, 1998, EPILEPSY RES, V32, P357, DOI 10.1016/S0920-1211(98)00069-2; Losey TE, 2008, J CLIN NEUROPHYSIOL, V25, P357, DOI 10.1097/WNP.0b013e31818f008a; Lu HP, 2013, IEEE T BIO-MED ENG, V60, P461, DOI 10.1109/TBME.2012.2228649; LUDERS H, 1991, BRAIN, V114, P743, DOI 10.1093/brain/114.2.743; Luders H, 1998, EPILEPSIA, V39, P1006, DOI 10.1111/j.1528-1157.1998.tb01452.x; Maliia MD, 2016, CLIN NEUROPHYSIOL, V127, P2127, DOI 10.1016/j.clinph.2015.12.021; Marson A, 2005, LANCET, V365, P2007, DOI 10.1016/S0140-6736(05)66694-9; McBride AE, 2002, EPILEPSIA, V43, P165, DOI 10.1046/j.1528-1157.2002.24401.x; McGonigal A, 2002, J NEUROL NEUROSUR PS, V72, P549; McGonigal A, 2007, BRAIN, V130, P3169, DOI 10.1093/brain/awm218; McKhann GM, 2000, J NEUROSURG, V93, P44, DOI 10.3171/jns.2000.93.1.0044; Medical Research Council, 1991, LANCET, V337, P1175; Meeren H, 2005, ARCH NEUROL-CHICAGO, V62, P371, DOI 10.1001/archneur.62.3.371; Megevand P, 2014, J NEUROL NEUROSUR PS, V85, P38, DOI 10.1136/jnnp-2013-305515; Meinardi H, 2001, EPILEPSIA, V42, P136, DOI 10.1046/j.1528-1157.2001.32800.x; Mendez OE, 2006, J CLIN NEUROPHYSIOL, V23, P282, DOI 10.1097/01.wnp.0000228514.40227.12; de la Prida LM, 2011, EPILEPSY RES, V97, P308, DOI 10.1016/j.eplepsyres.2011.02.009; Merricks EM, 2015, BRAIN, V138, P2891, DOI 10.1093/brain/awv208; Meyer ACL, 2012, EPILEPSIA, V53, P2178, DOI 10.1111/epi.12002; Michel CM, 2004, J CLIN NEUROPHYSIOL, V21, P71, DOI 10.1097/00004691-200403000-00001; MILEY CE, 1977, ARCH NEUROL-CHICAGO, V34, P371, DOI 10.1001/archneur.1977.00500180065014; Mintzer S, 2004, EPILEPSIA, V45, P792, DOI 10.1111/j.0013-9580.2004.35703.x; Miskin C, 2015, J CHILD NEUROL, V30, P1767, DOI 10.1177/0883073815579969; Monnerat BZ, 2013, SEIZURE-EUR J EPILEP, V22, P287, DOI 10.1016/j.seizure.2013.01.019; Mormann F, 2007, BRAIN, V130, P314, DOI 10.1093/brain/awl241; Murray CJL, 1994, GLOBAL COMP ASSESSME; Musicco M, 1997, NEUROLOGY, V49, P991, DOI 10.1212/WNL.49.4.991; MUSICCO M, 1993, NEUROLOGY, V43, P478; Narechania AP, 2013, EPILEPSY BEHAV, V28, P172, DOI 10.1016/j.yebeh.2013.04.017; National Institute for Health and Care Excellence, 2012, EP DIAGN MAN; Nei M, 1999, EPILEPSIA, V40, P157, DOI 10.1111/j.1528-1157.1999.tb02069.x; Newton CR, 2012, LANCET, V380, P1193, DOI 10.1016/S0140-6736(12)61381-6; Nguyen DK, 2006, ARCH NEUROL-CHICAGO, V63, P1321, DOI 10.1001/archneur.63.9.1321; Noe K, 2013, JAMA NEUROL, V70, P1003, DOI 10.1001/jamaneurol.2013.209; Nuwer MR, 1998, ELECTROEN CLIN NEURO, V106, P259, DOI 10.1016/S0013-4694(97)00106-5; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; OGUNI H, 1994, EPILEPSIA, V35, P307, DOI 10.1111/j.1528-1157.1994.tb02435.x; Olejniczak P, 2006, J CLIN NEUROPHYSIOL, V23, P186, DOI 10.1097/01.wnp.0000220079.61973.6c; Oostenveld R, 2001, CLIN NEUROPHYSIOL, V112, P713, DOI 10.1016/S1388-2457(00)00527-7; Oxford Centre for Evidence-Based Medicine, 2009, LEVELS EVIDENCE; PALMINI A, 1992, NEUROLOGY, V42, P801, DOI 10.1212/WNL.42.4.801; PALMINI A, 1995, ANN NEUROL, V37, P476, DOI 10.1002/ana.410370410; PANAYIOTOPOULOS CP, 1989, BRAIN, V112, P1039, DOI 10.1093/brain/112.4.1039; PANAYIOTOPOULOS CP, 1992, J NEUROL NEUROSUR PS, V55, P1002, DOI 10.1136/jnnp.55.11.1002; Parisi P, 2009, SEIZURE-EUR J EPILEP, V18, P309, DOI 10.1016/j.seizure.2009.01.010; Pataraia E, 1998, EPILEPSIA, V39, P608, DOI 10.1111/j.1528-1157.1998.tb01429.x; Pavlova MK, 2009, EPILEPSY BEHAV, V16, P461, DOI 10.1016/j.yebeh.2009.08.022; Paz JT, 2015, NAT NEUROSCI, V18, P351, DOI 10.1038/nn.3950; Pedersen GL, 2013, CLIN NEUROPHYSIOL, V124, P44, DOI 10.1016/j.clinph.2012.06.010; Pedley T. A., 1980, American Journal of EEG Technology, V20, P101; Pelliccia V, 2013, EPILEPTIC DISORD, V15, P392, DOI 10.1684/epd.2013.0615; Penfield W, 1954, EPILEPSY FUNCTIONAL; PENRY JK, 1975, BRAIN, V98, P427, DOI 10.1093/brain/98.3.427; Perucca E, 2014, EPILEPSIA, V55, P1326, DOI 10.1111/epi.12725; Perucca E, 2011, LANCET NEUROL, V10, P446, DOI 10.1016/S1474-4422(11)70047-3; Peters ACB, 1998, NEUROLOGY, V50, P724, DOI 10.1212/WNL.50.3.724; Petroff OA, 2016, CLIN NEUROPHYSIOL, V127, P1108, DOI 10.1016/j.clinph.2015.08.004; Pillai J, 2006, EPILEPSIA, V47, P14, DOI 10.1111/j.1528-1167.2006.00654.x; POLKEY CE, 1994, ACTA NEUROL SCAND, V89, P183, DOI 10.1111/j.1600-0404.1994.tb05218.x; Praline J, 2007, CLIN NEUROPHYSIOL, V118, P2149, DOI 10.1016/j.clinph.2007.07.003; PRATT KL, 1968, ELECTROEN CLIN NEURO, V24, P11, DOI 10.1016/0013-4694(68)90061-8; Qiu B, 2014, EPILEPTIC DISORD, V16, P175, DOI 10.1684/epd.2014.0662; QUIRK JA, 1995, ANN NEUROL, V37, P733, DOI 10.1002/ana.410370606; QUIRK JA, 1995, ELECTROEN CLIN NEURO, V95, P260, DOI 10.1016/0013-4694(95)00118-I; Rai V, 2013, SEIZURE-EUR J EPILEP, V22, P656, DOI 10.1016/j.seizure.2013.05.002; Ramantani G, 2014, EPILEPSIA, V55, P278, DOI 10.1111/epi.12512; Ramgopal S, 2014, EPILEPSY BEHAV, V37, P291, DOI 10.1016/j.yebeh.2014.06.023; Rassi-Neto A, 1999, EPILEPSIA, V40, P856, DOI 10.1111/j.1528-1157.1999.tb00791.x; Rathore C, 2011, NEUROLOGY, V76, P1925, DOI 10.1212/WNL.0b013e31821d74b3; Ray A, 2007, CLIN NEUROPHYSIOL, V118, P69, DOI 10.1016/j.clinph.2006.09.010; RICCI S, 1993, J CLIN NEUROPHYSIOL, V10, P197, DOI 10.1097/00004691-199304000-00007; Rikir E, 2014, EPILEPSIA, V55, P918, DOI 10.1111/epi.12591; RISINGER MW, 1989, NEUROLOGY, V39, P1288, DOI 10.1212/WNL.39.10.1288; Ristic AJ, 2012, EPILEPTIC DISORD, V14, P22, DOI 10.1684/epd.2012.0484; Rittenberger JC, 2012, NEUROCRIT CARE, V16, P114, DOI 10.1007/s12028-011-9565-0; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Rosenow F, 2001, BRAIN, V124, P1683, DOI 10.1093/brain/124.9.1683; Rossetti AO, 2007, NEUROLOGY, V69, P255, DOI 10.1212/01.wnl.0000265819.36639.e0; Roupakiotis SC, 2000, SEIZURE-EUR J EPILEP, V9, P580, DOI 10.1053/seiz.2000.0462; ROWAN AJ, 1982, ELECTROEN CLIN NEURO, V54, P357, DOI 10.1016/0013-4694(82)90199-7; Rubboli G, 2008, NEUROLOGY, V70, P1933, DOI 10.1212/01.wnl.0000289193.89796.83; Rubboli G, 1999, EPILEPSIA, V40, P50, DOI 10.1111/j.1528-1157.1999.tb00907.x; Ruiz AR, 2017, JAMA NEUROL, V74, P181, DOI 10.1001/jamaneurol.2016.4990; Saab ME, 2005, CLIN NEUROPHYSIOL, V116, P427, DOI 10.1016/j.clinph.2004.08.004; Sadleir LG, 2009, EPILEPSIA, V50, P1572, DOI 10.1111/j.1528-1167.2008.02001.x; SALANOVA V, 1995, BRAIN, V118, P607, DOI 10.1093/brain/118.3.607; SALANOVA V, 1992, BRAIN, V115, P1655, DOI 10.1093/brain/115.6.1655; SALANOVA V, 1995, BRAIN, V118, P1289, DOI 10.1093/brain/118.5.1289; SALEEM SM, 1994, ACTA NEUROL SCAND, V89, P5; SALINSKY M, 1987, EPILEPSIA, V28, P331, DOI 10.1111/j.1528-1157.1987.tb03652.x; Salomon JA, 2012, LANCET, V380, P2129, DOI 10.1016/S0140-6736(12)61680-8; Sam MC, 2001, EPILEPSIA, V42, P1273, DOI 10.1046/j.1528-1157.2001.17101.x; Fernandez IS, 2012, PEDIATR NEUROL, V47, P390, DOI 10.1016/j.pediatrneurol.2012.06.016; Sandsmark DK, 2016, J HEAD TRAUMA REHAB, V31, P101, DOI 10.1097/HTR.0000000000000217; SATO S, 1973, NEUROLOGY, V23, P1335, DOI 10.1212/WNL.23.12.1335; Sauro KM, 2016, EPILEPSIA, V57, P1754, DOI 10.1111/epi.13564; Sauro KM, 2014, EPILEPSY BEHAV, V33, P7, DOI 10.1016/j.yebeh.2014.01.021; Scheffer IE, 2017, EPILEPSIA, V58, P512, DOI 10.1111/epi.13709; Scherg M, 2012, EPILEPSIA, V53, P1196, DOI 10.1111/j.1528-1167.2012.03503.x; Schmidt D, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g254; Schmidt D, 2009, EPILEPSY BEHAV, V15, P56, DOI 10.1016/j.yebeh.2009.02.030; Schomer DL, 2006, J CLIN NEUROPHYSIOL, V23, P294, DOI 10.1097/01.wnp.0000228495.29014.82; Schramm J, 2001, J NEUROSURG, V94, P33, DOI 10.3171/jns.2001.94.1.0033; Schreiner A, 2003, CLIN ELECTROENCEPHAL, V34, P140, DOI 10.1177/155005940303400307; SCOLLOLAVIZZARI G, 1977, EUR NEUROL, V15, P121, DOI 10.1159/000114829; Seeck M, 2006, NEUROLOGY, V66, P592, DOI 10.1212/01.wnl.0000199254.67398.a7; Seneviratne U, 2017, J CLIN NEUROPHYSIOL, V34, P213, DOI 10.1097/WNP.0000000000000358; Seneviratne U, 2012, EPILEPSIA, V53, P234, DOI 10.1111/j.1528-1167.2011.03344.x; Serletis D, 2014, J NEUROSURG, V121, P1239, DOI 10.3171/2014.7.JNS132306; SHEWMON DA, 1989, J CLIN EXP NEUROPSYC, V11, P675, DOI 10.1080/01688638908400924; Shibasaki H, 2005, MUSCLE NERVE, V31, P157, DOI 10.1002/mus.20234; Shihabuddin B, 1999, CLIN NEUROPHYSIOL, V110, P1452, DOI 10.1016/S1388-2457(99)00081-4; Shinnar S, 2000, ANN NEUROL, V48, P140, DOI 10.1002/1531-8249(200008)48:2<140::AID-ANA2>3.0.CO;2-Y; Shinnar S, 1996, PEDIATRICS, V98, P216; Shiraishi H, 2001, EPILEPSIA, V42, P393, DOI 10.1046/j.1528-1157.2001.05300.x; Sierra-Marcos A, 2011, EPILEPSY RES, V97, P30, DOI 10.1016/j.eplepsyres.2011.06.013; Sinha SR, 2016, J CLIN NEUROPHYSIOL, V33, P303, DOI 10.1097/WNP.0000000000000308; Sirin NG, 2013, J CLIN NEUROPHYSIOL, V30, P329, DOI 10.1097/WNP.0b013e31829d7482; Sirven JI, 1996, EPILEPSIA, V37, P450, DOI 10.1111/j.1528-1157.1996.tb00590.x; Smith SJM, 2005, J NEUROL NEUROSUR PS, V76, P8; SO N, 1989, ANN NEUROL, V25, P423, DOI 10.1002/ana.410250502; Sousa NAD, 2005, ARQ NEURO-PSIQUIAT, V63, P383, DOI 10.1590/S0004-282X2005000300003; SPENCER SS, 1985, NEUROLOGY, V35, P1567, DOI 10.1212/WNL.35.11.1567; St Louis Erik K, 2016, Continuum (Minneap Minn), V22, P15, DOI 10.1212/CON.0000000000000284; Staley K, 2015, NAT NEUROSCI, V18, P367, DOI 10.1038/nn.3947; Stefan H, 2008, CLIN NEUROPHYSIOL, V119, P642, DOI 10.1016/j.clinph.2007.11.046; Stefan H, 2011, SEIZURE-EUR J EPILEP, V20, P97, DOI 10.1016/j.seizure.2010.10.035; Steriade M, 2003, EPILEPSIA, V44, P9, DOI 10.1111/j.0013-9580.2003.12006.x; Stern JM, 2006, EPILEPSY BEHAV, V8, P683, DOI 10.1016/j.yebeh.2006.03.002; Strawbridge LM, 2012, EPILEPSY SPECTRUM PR; Stroink H, 2006, DEV MED CHILD NEUROL, V48, P374, DOI 10.1017/S0012162206000806; Stuve O, 2001, EPILEPSIA, V42, P778, DOI 10.1046/j.1528-1157.2001.40600.x; Stypulkowski PH, 2014, BRAIN STIMUL, V7, P350, DOI 10.1016/j.brs.2014.02.002; Stypulkowski PH, 2013, STEREOT FUNCT NEUROS, V91, P220, DOI 10.1159/000345493; Sugano H, 2007, SEIZURE-EUR J EPILEP, V16, P120, DOI 10.1016/j.seizure.2006.10.010; Sutter R, 2011, EPILEPSIA, V52, P453, DOI 10.1111/j.1528-1167.2010.02888.x; Swisher CB, 2015, J CLIN NEUROPHYSIOL, V32, P147, DOI 10.1097/WNP.0000000000000157; Takahashi T, 1999, EPILEPSIA, V40, P44, DOI 10.1111/j.1528-1157.1999.tb00906.x; Tao JX, 2007, EPILEPSIA, V48, P2167, DOI 10.1111/j.1528-1167.2007.01224.x; Tao JX, 2016, JAMA-J AM MED ASSOC, V316, P1590, DOI 10.1001/jama.2016.12047; Tao JX, 2005, EPILEPSIA, V46, P669, DOI 10.1111/j.1528-1167.2005.11404.x; Tassinari CA, 2000, CLIN NEUROPHYSIOL, V111, pS94, DOI 10.1016/S1388-2457(00)00408-9; Tassinari CA, 2008, EPILEPSY COMPREHENSI, P873; Tatum WO, 2008, SEIZURE-EUR J EPILEP, V17, P631, DOI 10.1016/j.seizure.2008.04.001; Tatum WO, 2016, J CLIN NEUROPHYSIOL, V33, P328, DOI 10.1097/WNP.0000000000000319; Tatum WO, 2013, NEUROLOGY, V80, pS1, DOI 10.1212/WNL.0b013e318279730e; Tatum WO, 2013, NEUROLOGY, V80, pS12, DOI 10.1212/WNL.0b013e3182797325; Tatum WO, 2012, J CLIN NEUROPHYSIOL, V29, P356, DOI 10.1097/WNP.0b013e31826b3ab7; Tatum WO, 2011, J CLIN NEUROPHYSIOL, V28, P252, DOI 10.1097/WNP.0b013e31821c3c93; Tatum WO, 2001, J CLIN NEUROPHYSIOL, V18, P14, DOI 10.1097/00004691-200101000-00004; Tinuper P, 2004, EPILEPTIC DISORD, V6, P27; Tinuper P, 2001, BRAIN, V124, P2361, DOI 10.1093/brain/124.12.2361; Tinuper P, 1996, NEUROLOGY, V47, P76, DOI 10.1212/WNL.47.1.76; Tonini C, 2004, EPILEPSY RES, V62, P75, DOI 10.1016/j.eplepsyres.2004.08.006; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; TRAN TA, 1995, ANN NEUROL, V38, P763, DOI 10.1002/ana.410380511; TRENITE DGAK, 1987, J NEUROL NEUROSUR PS, V50, P1546, DOI 10.1136/jnnp.50.11.1546; Trenite DGAKN, 2001, EPILEPSIA, V42, P692, DOI 10.1046/j.1528-1157.2001.30600.x; Trenite DKN, 2012, EPILEPSIA, V53, P16, DOI 10.1111/j.1528-1167.2011.03319.x; Trinka E, 2015, EPILEPSIA, V56, P1515, DOI 10.1111/epi.13121; Tripathi M, 2010, EPILEPSY RES, V89, P133, DOI 10.1016/j.eplepsyres.2009.12.007; Tsuchida TN, 2016, J CLIN NEUROPHYSIOL, V33, P301, DOI 10.1097/WNP.0000000000000315; TUUNAINEN A, 1994, EPILEPSIA, V35, P1165, DOI 10.1111/j.1528-1157.1994.tb01784.x; UGAWA Y, 1989, J NEUROL NEUROSUR PS, V52, P89, DOI 10.1136/jnnp.52.1.89; Unterberger I, 2001, EPILEPSY RES, V44, P19, DOI 10.1016/S0920-1211(00)00210-2; Usui N, 2005, EPILEPSIA, V46, P1668, DOI 10.1111/j.1528-1167.2005.00262.x; Usui N, 2008, EPILEPTIC DISORD, V10, P260, DOI 10.1684/epd.2008.0223; Usui N, 2008, EPILEPSIA, V49, P1998, DOI 10.1111/j.1528-1167.2008.01697.x; Vadlamudi L, 2004, EPILEPTIC DISORD, V6, P89; van 't Klooster MA, 2015, NEUROLOGY, V85, P120, DOI 10.1212/WNL.0000000000001727; VANDONSELAAR CA, 1992, ARCH NEUROL-CHICAGO, V49, P231, DOI 10.1001/archneur.1992.00530270045017; Varelas PN, 2004, CLIN EEG NEUROSCI, V35, P173, DOI 10.1177/155005940403500406; Vaughn BV, 2004, SEMIN NEUROL, V24, P301, DOI 10.1055/s-2004-835068; VELDHUIZEN R, 1983, ELECTROEN CLIN NEURO, V55, P505, DOI 10.1016/0013-4694(83)90161-X; Velis D, 2007, EPILEPSIA, V48, P379, DOI 10.1111/j.1528-1167.2007.00920.x; Verma A, 2006, J CLIN NEUROPHYSIOL, V23, P333, DOI 10.1097/01.wnp.0000228497.89734.7a; Verrotti A, 2000, NEUROPHYSIOL CLIN, V30, P240, DOI 10.1016/S0987-7053(00)00221-5; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Viravan S, 2011, EPILEPSIA, V52, P1273, DOI 10.1111/j.1528-1167.2011.03068.x; WALCZAK TS, 1991, J EPILEPSY, V4, P25, DOI 10.1016/0896-6974(91)90118-3; Walczak TS, 1993, NEUROLOGY, V27, P330; Walker MC, 2015, SEMIN NEUROL, V35, P193, DOI 10.1055/s-0035-1552618; Waltz S, 2000, NEUROPEDIATRICS, V31, P82, DOI 10.1055/s-2000-7478; Wassmer E, 2001, DEV MED CHILD NEUROL, V43, P735, DOI 10.1017/S0012162201001347; Wennberg R, 1998, ELECTROEN CLIN NEURO, V106, P357, DOI 10.1016/S0013-4694(97)00148-X; Wennberg RA, 1998, ELECTROEN CLIN NEURO, P105; Werhahn KJ, 2015, SEIZURE-EUR J EPILEP, V29, P20, DOI 10.1016/j.seizure.2015.03.012; Westmoreland BF, 1998, EPILEPSIA, V39, pS1, DOI 10.1111/j.1528-1157.1998.tb05121.x; Westover MB, 2015, CLIN NEUROPHYSIOL, V126, P463, DOI 10.1016/j.clinph.2014.05.037; Whitehead K, 2016, CLIN NEUROPHYSIOL, V127, P1774, DOI 10.1016/j.clinph.2015.11.050; Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; WILLIAMSON PD, 1993, ANN NEUROL, V34, P781, DOI 10.1002/ana.410340605; WILLIAMSON PD, 1992, ANN NEUROL, V31, P193, DOI 10.1002/ana.410310210; WILLIAMSON PD, 1992, ANN NEUROL, V31, P3, DOI 10.1002/ana.410310103; WOLF P, 1986, J NEUROL NEUROSUR PS, V49, P1386, DOI 10.1136/jnnp.49.12.1386; Woods RJ, 2006, EPILEPSY BEHAV, V9, P360, DOI 10.1016/j.yebeh.2006.06.015; Worrell GA, 2004, BRAIN, V127, P1496, DOI 10.1093/brain/awh149; Worrell GA, 2002, EPILEPSIA, V43, P277, DOI 10.1046/j.1528-1157.2002.37501.x; Wu JY, 2010, NEUROLOGY, V75, P1686, DOI 10.1212/WNL.0b013e3181fc27d0; WYLLIE E, 1987, NEUROLOGY, V37, P1634, DOI 10.1212/WNL.37.10.1634; Yamada K, 2014, SEIZURE-EUR J EPILEP, V23, P703, DOI 10.1016/j.seizure.2014.05.010; Yoshimura H, 2016, J NEUROL SCI, V370, P284, DOI 10.1016/j.jns.2016.09.062; Young GB, 2005, NEUROCRIT CARE, V2, P5, DOI 10.1385/NCC:2:1:005; Young GB, 1999, J CLIN NEUROPHYSIOL, V16, P40, DOI 10.1097/00004691-199901000-00003; Zakaria T, 2012, ISRN NEUROL; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88; Zeman A, 2010, CURR OPIN NEUROL, V23, P610, DOI 10.1097/WCO.0b013e32834027db; Zijlmans M, 2007, BRAIN, V130, P2343, DOI 10.1093/brain/awm141; Zijlmans M, 2012, ANN NEUROL, V71, P169, DOI 10.1002/ana.22548	443	75	78	3	23	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	MAY	2018	129	5					1056	1082		10.1016/j.clinph.2018.01.019			27	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GB3GY	WOS:000428945500027	29483017				2022-02-06	
J	Ismael, S; Nasoohi, S; Ishrat, T				Ismael, Saifudeen; Nasoohi, Sanaz; Ishrat, Tauheed			MCC950, the Selective Inhibitor of Nucleotide Oligomerization Domain (NOD)-Like Receptor Protein-3 Inflammasome, Protects Mice against Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						edema; inflammation; MCC950; neurological deficits; NLRP3-inflammasome inhibitor; traumatic brain injury	THIOREDOXIN-INTERACTING PROTEIN; NLRP3 INFLAMMASOME; ENDOTHELIAL-CELLS; CEREBRAL-CORTEX; HEAD-INJURY; MRC CRASH; KAPPA-B; ACTIVATION; NEUROPROTECTION; EDEMA	Nucleotide oligomerization domain (NOD)-like receptor protein-3 (NLRP3) inflammasome may intimately contribute to sustaining damage after traumatic brain injury (TBI). This study aims to examine whether specific modulation of NLPR3 inflammasome by MCC950, a novel selective NLRP3 inhibitor, confers protection after experimental TBI. Unilateral cortical impact injury was induced in young adult C57BL/6 mice. MCC950 (50 mg/kg, intraperitoneally) or saline was administration at 1 and 3 h post-TBI. Animals were tested for neurological function and then sacrificed at 24 or 72 h post-TBI. Immunoblotting and histological analysis were performed to identify markers of NLRP3 inflammasome and proapoptotic activity in pericontusional areas of the brains at 24 or 72h post-TBI. MCC950 treatment provided a significant improvement in neurological function and reduced cerebral edema in TBI animals. TBI upregulated NLRP3, apoptosis-associated speck-like adapter protein (ASC), cleaved caspase-1, and interlukein-1 beta (IL-1 beta) in the perilesional area. MCC950 efficiently repressed caspase-1 and IL-1 beta with a transient effect on ASC and NLRP3 post-TBI. MCC950 treatment also provided protection against proapoptotic activation of poly (ADP-ribose) polymerase and caspase-3 associated with TBI. A concurrent inhibition of inflammasome priming was also detectable at the nuclear factor kappa B/p65 and caspase-1 level. Our findings support the implication of NLRP3 inflammasome in the pathogenesis of TBI and further suggests the therapeutic potential of MCC950.	[Ismael, Saifudeen; Ishrat, Tauheed] Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Anat & Neurobiol, 855 Monroe Ave,Wittenborg Bldg,Room 231, Memphis, TN 38163 USA; [Nasoohi, Sanaz] Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran, Iran; [Ishrat, Tauheed] Univ Tennessee, Hlth Sci Ctr, Neurosci Inst, Memphis, TN 38163 USA		Ishrat, T (corresponding author), Univ Tennessee, Hlth Sci Ctr, Coll Med, Dept Anat & Neurobiol, 855 Monroe Ave,Wittenborg Bldg,Room 231, Memphis, TN 38163 USA.	tishrat@uthsc.edu	Ismael, Saifudeen/AAR-2031-2021; Ismael, Saifudeen/AAE-1679-2021		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS097800]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS097800] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (R01-NS097800; to T.I.). The authors are thankful to Dr. Anton J. Reiner, for providing a CCI device (Impact One; Leica Biosystems, Buffalo Grove, IL) to induce TBI in mice.	Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Dempsey C, 2017, BRAIN BEHAV IMMUN, V61, P306, DOI 10.1016/j.bbi.2016.12.014; Edwards P, 2005, LANCET, V365, P1957; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hay N, 2011, BBA-MOL CELL RES, V1813, P1965, DOI 10.1016/j.bbamcr.2011.03.013; Henao-Mejia J, 2012, NAT IMMUNOL, V13, P321, DOI 10.1038/ni.2257; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Ishrat T, 2018, CELLULAR MOL APPROAC, P427; Ishrat T, 2015, MOL NEUROBIOL, V51, P766, DOI 10.1007/s12035-014-8766-x; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jorgensen I, 2015, IMMUNOL REV, V265, P130, DOI 10.1111/imr.12287; Juliana C, 2012, J BIOL CHEM, V287, P36617, DOI 10.1074/jbc.M112.407130; Karmakar M, 2015, J IMMUNOL, V194, P1763, DOI 10.4049/jimmunol.1401624; Kim GS, 2012, NEUROBIOL DIS, V46, P440, DOI 10.1016/j.nbd.2012.02.008; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Korley FK, 2016, J HEAD TRAUMA REHAB, V31, P379, DOI 10.1097/HTR.0000000000000187; Kourbeti IS, 2012, CLIN MICROBIOL INFEC, V18, P359, DOI 10.1111/j.1469-0691.2011.03625.x; Kurokawa H, 2015, ATHEROSCLEROSIS, V239, P375, DOI 10.1016/j.atherosclerosis.2015.01.037; Li XN, 2009, BIOCHEM BIOPH RES CO, V381, P660, DOI 10.1016/j.bbrc.2009.02.132; Lin C, 2017, EXP NEUROL, V290, P115, DOI 10.1016/j.expneurol.2017.01.005; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Majdan M, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002331; Malik S, 2015, EUR J PHARMACOL, V748, P54, DOI 10.1016/j.ejphar.2014.12.008; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Mohamed IN, 2015, ANTIOXID REDOX SIGN, V22, P1188, DOI 10.1089/ars.2014.6126; Mridha AR, 2017, J HEPATOL, V66, P1037, DOI 10.1016/j.jhep.2017.01.022; Murray KN, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00018; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Pearn ML, 2017, CELL MOL NEUROBIOL, V37, P571, DOI 10.1007/s10571-016-0400-1; Perrone L, 2009, J CELL PHYSIOL, V221, P262, DOI 10.1002/jcp.21852; Primiano MJ, 2016, J IMMUNOL, V197, P2421, DOI 10.4049/jimmunol.1600035; Dinh QN, 2017, AGING-US, V9, P1595, DOI 10.18632/aging.101255; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Salla M, 2016, ACS MED CHEM LETT, V7, P1034, DOI 10.1021/acsmedchemlett.6b00198; Schumacher M, 2016, J STEROID BIOCHEM, V160, P53, DOI 10.1016/j.jsbmb.2015.11.010; Su N., 2016, MECH PROGRAMMED CELL; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; van Hout GPJ, 2017, EUR HEART J, V38, P828, DOI 10.1093/eurheartj/ehw247; Wali B, 2017, J NEUROTRAUM, V34, P2183, DOI 10.1089/neu.2016.4845; Wallisch JS, 2017, NEUROCRIT CARE, V27, P44, DOI 10.1007/s12028-017-0378-7; Wang ZR, 2016, ASIAN PAC J TROP MED, V9, P269, DOI 10.1016/j.apjtm.2016.01.027; Wei X, 2016, J HUAZHONG U SCI-MED, V36, P576, DOI 10.1007/s11596-016-1628-1; Winkler EA, 2016, NEUROSURG CLIN N AM, V27, P473, DOI 10.1016/j.nec.2016.05.008; Yang F, 2014, J CEREBR BLOOD F MET, V34, P660, DOI 10.1038/jcbfm.2013.242; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhao Q, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0878-6; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	58	75	79	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2018	35	11					1294	1303		10.1089/neu.2017.5344		APR 2018	10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	GG7EW	WOS:000428870000002	29295651	Green Published, Bronze			2022-02-06	
J	Xu, X; Gao, WW; Cheng, SQ; Yin, DP; Li, F; Wu, YG; Sun, DD; Zhou, S; Wang, D; Zhang, YQ; Jiang, RC; Zhang, JN				Xu, Xin; Gao, Weiwei; Cheng, Shiqi; Yin, Dongpei; Li, Fei; Wu, Yingang; Sun, Dongdong; Zhou, Shuai; Wang, Dong; Zhang, Yongqiang; Jiang, Rongcai; Zhang, Jianning			Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; Atorvastatin; Immunomodulation; Anti-inflammation; Leukocyte; Microglia/macrophage subtype	NATURAL-KILLER-CELLS; T-CELLS; INTRACEREBRAL HEMORRHAGE; MICROGLIA/MACROPHAGE POLARIZATION; MACROPHAGE INFILTRATION; INFLAMMATORY REACTION; NEUROPROTECTION; STATINS; TARGET; SYNAPTOGENESIS	Background: Neuroinflammation is an important secondary injury mechanism that has dual beneficial and detrimental roles in the pathophysiology of traumatic brain injury (TBI). Compelling data indicate that statins, a group of lipid-lowering drugs, also have extensive immunomodulatory and anti-inflammatory properties. Among statins, atorvastatin has been demonstrated as a neuroprotective agent in experimental TBI; however, there is a lack of evidence regarding its effects on neuroinflammation during the acute phase of TBI. The current study aimed to evaluate the effects of atorvastatin therapy on modulating the immune reaction, and to explore the possible involvement of peripheral leukocyte invasion and microglia/macrophage polarization in the acute period post-TBI. Methods: C57BL/6 mice were subjected to TBI using a controlled cortical impact (CCI) device. Either atorvastatin or vehicle saline was administered orally starting 1 h post-TBI for three consecutive days. Short-term neurological deficits were evaluated using the modified neurological severity score (mNSS) and Rota-rod. Brain-invading leukocyte subpopulations were analyzed by flow cytometry and immunohistochemistry. Pro-and anti-inflammatory cytokines and chemokines were examined using enzyme-linked immunosorbent assay (ELISA). Markers of classically activated (M1) and alternatively activated (M2) microglia/macrophages were then determined by quantitative real-time PCR (qRT-PCR) and flow cytometry. Neuronal apoptosis was identified by double staining of terminal deoxynucleotidyl transferase-dUTP nick end labeling (TUNEL) staining and immunofluorescence labeling for neuronal nuclei (NeuN). Results: Acute treatment with atorvastatin at doses of 1 mg/kg/day significantly reduced neuronal apoptosis and improved behavioral deficits. Invasions of T cells, neutrophils and natural killer (NK) cells were attenuated profoundly after atorvastatin therapy, as was the production of pro-inflammatory cytokines (IFN-gamma and IL-6) and chemokines (RANTES and IP-10). Notably, atorvastatin treatment significantly increased the proportion of regulatory T cells (Tregs) in both the peripheral spleen and brain, and at the same time, increased their main effector cytokines IL-10 and TGF-beta 1. We also found that atorvastatin significantly attenuated total microglia/macrophage activation but augmented the M2/M1 ratio by both inhibiting M1 polarization and enhancing M2 polarization. Conclusions: Our data demonstrated that acute atorvastatin administration could modulate post-TBI neuroinflammation effectively, via a mechanism that involves altering peripheral leukocyte invasion and the alternative polarization of )microglia/macrophages.	[Xu, Xin; Gao, Weiwei; Yin, Dongpei; Li, Fei; Wu, Yingang; Sun, Dongdong; Zhou, Shuai; Wang, Dong; Jiang, Rongcai; Zhang, Jianning] Tianjin Med Univ Gen Hosp, Dept Neurosurg, 154 Anshan Rd, Tianjin, Peoples R China; [Xu, Xin; Gao, Weiwei; Yin, Dongpei; Li, Fei; Wu, Yingang; Sun, Dongdong; Zhou, Shuai; Wang, Dong; Jiang, Rongcai; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, 154 Anshan Rd, Tianjin, Peoples R China; [Gao, Weiwei] Tianjin Huan Hu Hosp, Dept Neurol, 6 Jizhao Rd, Tianjin, Peoples R China; [Cheng, Shiqi] Nanchang Univ, Affiliated Hosp 2, Dept Neurosurg, 1 Minde Rd, Nanchang, Jiangxi, Peoples R China; [Zhang, Yongqiang] Tianjin Med Univ Gen Hosp, Dept Geriatr, 154 Anshan Rd, Tianjin, Peoples R China		Jiang, RC; Zhang, JN (corresponding author), Tianjin Med Univ Gen Hosp, Dept Neurosurg, 154 Anshan Rd, Tianjin, Peoples R China.; Jiang, RC; Zhang, JN (corresponding author), Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, 154 Anshan Rd, Tianjin, Peoples R China.	jiang116216@163.com; zhangjntjmu@163.com		Xu, Xin/0000-0003-3395-9923; Dongpei, Yin/0000-0003-2572-3689	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81330029, 81671380, 81502173, 81501055]; Tianjin Research Program of Application Foundation and Advanced Technology [16JCYBJC27200]	This work was supported by grants from the National Natural Science Foundation of China (grant 81330029, 81671380, 81502173, and 81501055), and the Tianjin Research Program of Application Foundation and Advanced Technology (grant 16JCYBJC27200).	Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chio CC, 2015, CURR MED CHEM, V22, P759, DOI 10.2174/0929867321666141106124657; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; de Oliveira DM, 2015, INFLAMMOPHARMACOLOGY, V23, P343, DOI 10.1007/s10787-015-0252-1; Dong TT, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0663-y; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Gan Y, 2014, P NATL ACAD SCI USA, V111, P2704, DOI 10.1073/pnas.1315943111; Gao Chuang, 2017, Mol Neurobiol, V54, P8348, DOI 10.1007/s12035-016-0318-0; Gao WW, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00281; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Indraswari F, 2012, J NEUROTRAUM, V29, P1388, DOI 10.1089/neu.2011.2117; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Jones TB, 2005, J NEUROSCI, V25, P6576, DOI 10.1523/JNEUROSCI.0305-05.2005; Jung KH, 2004, STROKE, V35, P1744, DOI 10.1161/01.STR.0000131270.45822.85; Kong XD, 2014, NEUROSCI BULL, V30, P903, DOI 10.1007/s12264-014-1481-9; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee J, 2014, J TRAUMA ACUTE CARE, V77, P709, DOI 10.1097/TA.0000000000000445; Li M, 2015, CHINESE MED J-PEKING, V128, P1072, DOI 10.4103/0366-6999.155094; Li MS, 2017, P NATL ACAD SCI USA, V114, pE396, DOI 10.1073/pnas.1612930114; Liu GW, 2011, IMMUNOL CELL BIOL, V89, P130, DOI 10.1038/icb.2010.70; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu Q, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-44; Rodriguez-Perea AL, 2017, J NEUROIMMUNE PHARM, V12, P152, DOI 10.1007/s11481-016-9706-5; Lumpkins K, 2008, J TRAUMA, V64, P358, DOI 10.1097/TA.0b013e318160df9b; MAY MJ, 1992, EUR J IMMUNOL, V22, P219, DOI 10.1002/eji.1830220132; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Mishra SK, 2017, MOL CELL NEUROSCI, V78, P25, DOI 10.1016/j.mcn.2016.11.008; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mountney A, 2016, J NEUROTRAUM, V33, P567, DOI 10.1089/neu.2015.4130; Potey C, 2015, BRIT J PHARMACOL, V172, P5188, DOI 10.1111/bph.13285; Ransohoff RM, 2009, IMMUNITY, V31, P711, DOI 10.1016/j.immuni.2009.09.010; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Shi H. P., 2015, ELECT J DIFFERENTIAL, V2015, P1, DOI DOI 10.1089/CELL.2015.0039; Simon-O'Brien E, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0687-3; Stout RD, 2005, J IMMUNOL, V175, P342, DOI 10.4049/jimmunol.175.1.342; Strowig T, 2008, J IMMUNOL, V180, P7785, DOI 10.4049/jimmunol.180.12.7785; Truettner JS, 2017, J CEREBR BLOOD F MET, V37, P2952, DOI 10.1177/0271678X16680003; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wang D, 2014, J NEUROL SCI, V336, P237, DOI 10.1016/j.jns.2013.11.005; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang ZQ, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9875298; Weckbach S, 2012, J NEUROTRAUM, V29, P1233, DOI 10.1089/neu.2011.2169; Wible EF, 2010, NEUROTHERAPEUTICS, V7, P62, DOI 10.1016/j.nurt.2009.11.003; Xie LK, 2015, EUR J IMMUNOL, V45, P180, DOI 10.1002/eji.201444823; Xing ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep20040; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang Y, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-79; Zhou K, 2017, J CEREBR BLOOD F MET, V37, P967, DOI 10.1177/0271678X16648712; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zouggari Y, 2009, CIRCULATION, V120, P1415, DOI 10.1161/CIRCULATIONAHA.109.875583	59	75	85	4	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 23	2017	14								167	10.1186/s12974-017-0934-2			15	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	FE5QX	WOS:000408267100001	28835272	Green Published, gold			2022-02-06	
J	Choi, YK; Maki, T; Mandeville, ET; Koh, SH; Hayakawa, K; Arai, K; Kim, YM; Whalen, MJ; Xing, CH; Wang, XY; Kim, KW; Lo, EH				Choi, Yoon Kyung; Maki, Takakuni; Mandeville, Emiri T.; Koh, Seong-Ho; Hayakawa, Kazuhide; Arai, Ken; Kim, Young-Myeong; Whalen, Michael J.; Xing, Changhong; Wang, Xiaoying; Kim, Kyu-Won; Lo, Eng H.			Dual effects of carbon monoxide on pericytes and neurogenesis in traumatic brain injury	NATURE MEDICINE			English	Article							ADULT BRAIN; DISEASE	At low levels, carbon monoxide (CO) has physiological roles as a second messenger and neuromodulator(1,2). Here we assess the effects of CO in a mouse model of traumatic brain injury (TBI). Treatment with CO-releasing molecule (CORM)-3 reduced pericyte death and ameliorated the progression of neurological deficits. In contrast, although treatment with the radical scavenger N-tert-butyl-a-phenylnitrone (PBN) also reduced pericyte death, neurological outcomes were not rescued. As compared to vehicle-treated control and PBN-treated mice, CORM-3-treated mice showed higher levels of phosphorylated neural nitric oxide synthase within neural stem cells (NSCs). Inhibition of nitric oxide synthase diminished the CORM-3-mediated increase in the number of cells that stained positive for both the neuronal marker NeuN and 5-bromo-2'-deoxyuridine (BrdU; a marker for proliferating cells) in vivo, consequently interfering with neurological recovery after TBI. Because NSCs seemed to be in close proximity to pericytes, we asked whether cross-talk between pericytes and NSCs was induced by CORM-3, thereby promoting neurogenesis. In pericyte cultures that were undergoing oxygen and glucose deprivation, conditioned cell culture medium collected after CORM-3 treatment enhanced the in vitro differentiation of NSCs into mature neurons. Taken together, these findings suggest that CO treatment may provide a therapeutic approach for TBI by preventing pericyte death, rescuing cross-talk with NSCs and promoting neurogenesis.	[Choi, Yoon Kyung; Maki, Takakuni; Mandeville, Emiri T.; Koh, Seong-Ho; Hayakawa, Kazuhide; Arai, Ken; Xing, Changhong; Wang, Xiaoying; Lo, Eng H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA; [Choi, Yoon Kyung; Maki, Takakuni; Mandeville, Emiri T.; Koh, Seong-Ho; Hayakawa, Kazuhide; Arai, Ken; Xing, Changhong; Wang, Xiaoying; Lo, Eng H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA; [Koh, Seong-Ho] Hanyang Univ, Dept Neurol, Coll Med, Seoul, South Korea; [Kim, Young-Myeong] Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon, Gangwon Do, South Korea; [Whalen, Michael J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat, Boston, MA USA; [Kim, Kyu-Won] Seoul Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, SNU Harvard NeuroVasc Protect Res Ctr, Seoul, South Korea		Choi, YK; Lo, EH (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA.; Choi, YK; Lo, EH (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA.	yoonkyung@kangwon.ac.kr; lo@helix.mgh.harvard.edu	Kim, Kyu Won/AAJ-7213-2020; 眞木, 崇州/AAO-1160-2020	Choi, Yoon Kyung/0000-0003-0242-9612; Koh, Seong-Ho/0000-0001-5419-5761	US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Rappaport Foundation; National Research Foundation of KoreaNational Research Foundation of Korea; Global Research Laboratory Program of Korea	This work was supported in part by grants from the US National Institutes of Health (K.H., K.A., M.J.W., C.X., X.W. and E.H.L.), the Rappaport Foundation (E.H.L.), the Research Abroad grant from the National Research Foundation of Korea (Y.K.C., S.-H.K., Y.-M.K. and K.-W.K.) and the Global Research Laboratory Program of Korea (K.-WK.). The vector expressing the HIF-1 alpha double mutant was kindly provided by G.L. Semenza (Johns Hopkins University School of Medicine).	Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Chen JJ, 2004, DEV BIOL, V269, P165, DOI 10.1016/j.ydbio.2004.01.024; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Goldman SA, 2011, NAT NEUROSCI, V14, P1382, DOI 10.1038/nn.2963; Hu XM, 2014, PROG NEUROBIOL, V119, P60, DOI 10.1016/j.pneurobio.2014.06.002; Lo EH, 2014, VASCULAR MECH CNS TR; Lo EH, 2010, NAT MED, V16, P1205, DOI 10.1038/nm.2226; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Motterlini R, 2010, NAT REV DRUG DISCOV, V9, P728, DOI 10.1038/nrd3228; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Xing C., 2016, PROG NEUROBIOL; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yemisci M, 2009, NAT MED, V15, P1031, DOI 10.1038/nm.2022	17	75	79	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2016	22	11					1335	1341		10.1038/nm.4188			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	EB3XK	WOS:000387302300027	27668935				2022-02-06	
J	Villapol, S; Balarezo, MG; Affram, K; Saavedra, JM; Symes, AJ				Villapol, Sonia; Balarezo, Maria G.; Affram, Kwame; Saavedra, Juan M.; Symes, Aviva J.			Neurorestoration after traumatic brain injury through angiotensin II receptor blockage	BRAIN			English	Article						candesartan; telmisartan; inflammation; apoptosis; recovery	SPONTANEOUSLY HYPERTENSIVE-RATS; PPAR-GAMMA ACTIVATION; AT(1) RECEPTOR; OXIDATIVE STRESS; FUNCTIONAL RECOVERY; STROKE-RESISTANT; ISCHEMIC-STROKE; MEMORY FUNCTION; CANDESARTAN; TELMISARTAN	Traumatic brain injury frequently leads to long-term cognitive problems and physical disability yet remains without effective therapeutics. Traumatic brain injury results in neuronal injury and death, acute and prolonged inflammation and decreased blood flow. Drugs that block angiotensin II type 1 receptors (AT1R, encoded by AGTR1) (ARBs or sartans) are strongly neuroprotective, neurorestorative and anti-inflammatory. To test whether these drugs may be effective in treating traumatic brain injury, we selected two sartans, candesartan and telmisartan, of proven therapeutic efficacy in animal models of brain inflammation, neurodegenerative disorders and stroke. Using a validated mouse model of controlled cortical impact injury, we determined effective doses for candesartan and telmisartan, their therapeutic window, mechanisms of action and effect on cognition and motor performance. Both candesartan and telmisartan ameliorated controlled cortical impact-induced injury with a therapeutic window up to 6 h at doses that did not affect blood pressure. Both drugs decreased lesion volume, neuronal injury and apoptosis, astrogliosis, microglial activation, pro-inflammatory signalling, and protected cerebral blood flow, when determined 1 to 3 days post-injury. Controlled cortical impact-induced cognitive impairment was ameliorated 30 days after injury only by candesartan. The neurorestorative effects of candesartan and telmisartan were reduced by concomitant administration of the peroxisome proliferator-activated receptor gamma (PPARg, encoded by PPARG) antagonist T0070907, showing the importance of PPARg activation for the neurorestorative effect of these sartans. AT1R knockout mice were less vulnerable to controlled cortical impactinduced injury suggesting that the sartan's blockade of the AT1R also contributes to their efficacy. This study strongly suggests that sartans with dual AT1R blocking and PPARg activating properties have therapeutic potential for traumatic brain injury.	[Villapol, Sonia; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Villapol, Sonia; Balarezo, Maria G.; Affram, Kwame; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Saavedra, Juan M.] Georgetown Univ, Med Ctr, Dept Physiol & Pharmacol, Washington, DC 20057 USA		Villapol, S (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Res Bldg,WG20,3970 Reservoir Rd NW, Washington, DC 20057 USA.	sonia.villapol@georgetown.edu	Saavedra, Juan/AAO-7149-2020; Symes, Aviva J/S-7471-2016; Villapol, Sonia/D-1949-2014	Saavedra, Juan/0000-0002-7238-9647; Symes, Aviva J/0000-0003-2557-9939; 	Department of Defense, Center for Neuroscience and Regenerative Medicine (CNRM); CNRM postdoctoral fellowship; Intramural Research Program at the National Institute of Mental Health, NIH [MH 002762-16]	This work was supported by a Department of Defense, Center for Neuroscience and Regenerative Medicine (CNRM) grant to A.J.S. S.V. was supported by a CNRM postdoctoral fellowship. J.M.S. was supported by the Intramural Research Program at the National Institute of Mental Health, NIH (MH 002762-16).	Alhusban A, 2013, J PHARMACOL EXP THER, V344, P348, DOI 10.1124/jpet.112.197483; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Armando I, 2002, NEUROENDOCRINOLOGY, V76, P137, DOI 10.1159/000064525; Benicky J, 2011, NEUROPSYCHOPHARMACOL, V36, P857, DOI 10.1038/npp.2010.225; Bennai F, 1999, J AM SOC NEPHROL, V10, pS104; Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57; Bordet R, 2006, BIOCHEM SOC T, V34, P1341, DOI 10.1042/BST0341341; Cabaleiro T, 2013, DRUG METAB DISPOS, V41, P224, DOI 10.1124/dmd.112.046292; Cernes R, 2011, VASC HEALTH RISK MAN, V7, P749, DOI 10.2147/VHRM.S22591; Deppe S, 2010, EXPERT OPIN DRUG MET, V6, P863, DOI 10.1517/17425255.2010.494597; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Fleegal-DeMotta MA, 2009, J CEREBR BLOOD F MET, V29, P640, DOI 10.1038/jcbfm.2008.158; Fogari R, 2003, J HUM HYPERTENS, V17, P781, DOI 10.1038/sj.jhh.1001613; Fukui Y, 2014, J STROKE CEREBROVASC, V23, P1545, DOI 10.1016/j.jstrokecerebrovasdis.2013.12.052; Garrido-Gil P, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-38; Gillespie W, 2011, INDIAN J BIOCHEM BIO, V48, P73; Gleiter CH, 2002, CLIN PHARMACOKINET, V41, P7, DOI 10.2165/00003088-200241010-00002; Guan WH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024551; Hajar I, 2013, J AM GERIATR SOC, V61, P194, DOI 10.1111/jgs.12100; Hajjar I, 2012, ARCH NEUROL-CHICAGO, V69, P1632, DOI 10.1001/archneurol.2012.1010; Hamai M, 2006, NEUROPHARMACOLOGY, V51, P822, DOI 10.1016/j.neuropharm.2006.05.029; Hsu CY, 2013, CIRC J, V77, P405, DOI 10.1253/circj.CJ-12-0658; Ishrat T, 2015, MOL NEUROBIOL, V51, P1542, DOI 10.1007/s12035-014-8830-6; Ito T, 2002, STROKE, V33, P2297, DOI 10.1161/01.STR.0000027274.03779.F3; Johren O, 1996, AM J PHYSIOL-ENDOC M, V271, pE104, DOI 10.1152/ajpendo.1996.271.1.E104; Joseph JP, 2014, NEUROPHARMACOLOGY, V81, P134, DOI 10.1016/j.neuropharm.2014.01.044; Jung KH, 2007, J PHARMACOL EXP THER, V322, P1051, DOI 10.1124/jpet.107.120097; Justin A, 2014, PHARMACOL BIOCHEM BE, V122, P61, DOI 10.1016/j.pbb.2014.03.009; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kasahara Y, 2010, BRAIN RES, V1340, P70, DOI 10.1016/j.brainres.2010.03.101; Kozak A, 2009, STROKE, V40, P1870, DOI 10.1161/STROKEAHA.108.537225; Kozak W, 2008, J PHARMACOL EXP THER, V326, P773, DOI 10.1124/jpet.108.139618; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Li JJ, 2009, NEUROSCIENCE, V158, P1488, DOI 10.1016/j.neuroscience.2008.11.046; Li NC, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5465; Liu H, 2008, J HYPERTENS, V26, P1435, DOI 10.1097/HJH.0b013e3283013b6e; Lu GC, 2009, STROKE, V40, P3876, DOI 10.1161/STROKEAHA.109.559989; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Meredith PA, 2004, J RENIN-ANGIO-ALDO S, V5, P59, DOI 10.3317/jraas.2004.011; Michel MC, 2013, PHARMACOL REV, V65, P809, DOI 10.1124/pr.112.007278; Mitchell K, 2014, J NEUROCHEM, V129, P155, DOI 10.1111/jnc.12612; Mogi M, 2008, BIOCHEM BIOPH RES CO, V375, P446, DOI 10.1016/j.bbrc.2008.08.032; Nishimura Y, 2000, BRAIN RES, V871, P29, DOI 10.1016/S0006-8993(00)02377-5; Noda A, 2012, NUCL MED BIOL, V39, P1232, DOI 10.1016/j.nucmedbio.2012.06.012; Ohshima K, 2013, CURR HYPERTENS REV, V9, P99, DOI 10.2174/15734021113099990004; Omura-Matsuoka E, 2009, HYPERTENS RES, V32, P548, DOI 10.1038/hr.2009.69; Ozacmak VH, 2007, NEUROCHEM RES, V32, P1314, DOI 10.1007/s11064-007-9305-1; Pelisch N, 2013, CURR HYPERTENS REV, V9, P93, DOI 10.2174/15734021113099990003; Rodriguez-Perez AI, 2015, GLIA, V63, P466, DOI 10.1002/glia.22765; Saavedra JM, 2005, CELL MOL NEUROBIOL, V25, P485, DOI 10.1007/s10571-005-4011-5; SAAVEDRA JM, 1992, ENDOCR REV, V13, P329, DOI 10.1210/er.13.2.329; Saavedra JM, 2006, J HYPERTENS, V24, pS131, DOI 10.1097/01.hjh.0000220418.09021.ee; Saavedra JM, 2012, CLIN SCI, V123, P567, DOI 10.1042/CS20120078; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; Schupp M, 2004, CIRCULATION, V109, P2054, DOI 10.1161/01.CIR.0000127955.36250.65; Soliman S, 2014, J PHARMACOL EXP THER, V349, P444, DOI 10.1124/jpet.113.212613; Stangier J, 2000, J CLIN PHARMACOL, V40, P1355; Steckelings UM, 2012, EXPERT OPIN INV DRUG, V21, P763, DOI 10.1517/13543784.2012.681046; Sumners C, 2013, CLIN EXP PHARMACOL P, V40, P580, DOI 10.1111/1440-1681.12137; Tham DM, 2002, PHYSIOL GENOMICS, V11, P21, DOI 10.1152/physiolgenomics.00062.2002; Thone-Reineke C, 2006, J HYPERTENS, V24, pS115; Timaru-Kast R, 2012, CRIT CARE MED, V40, P935, DOI 10.1097/CCM.0b013e31822f08b9; Tota S, 2009, BEHAV BRAIN RES, V199, P235, DOI 10.1016/j.bbr.2008.11.044; Tsukuda K, 2009, HYPERTENSION, V54, P782, DOI 10.1161/HYPERTENSIONAHA.109.136879; Umschweif G, 2014, NEUROTHERAPEUTICS, V11, P665, DOI 10.1007/s13311-014-0286-x; Villapol S, 2015, AM J HYPERTENS, V28, P289, DOI 10.1093/ajh/hpu197; Villapol S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00082; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Villapol S, 2009, AM J PATHOL, V175, P2111, DOI 10.2353/ajpath.2009.090257; Villela D, 2015, CLIN SCI, V128, P227, DOI 10.1042/CS20130515; Wang J, 2014, NEUROPHARMACOLOGY, V79, P249, DOI 10.1016/j.neuropharm.2013.11.022; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wright JW, 2011, PROG NEUROBIOL, V95, P49, DOI 10.1016/j.pneurobio.2011.07.001; WRIGHT JW, 1994, NEUROSCI BIOBEHAV R, V18, P21, DOI 10.1016/0149-7634(94)90034-5; Wu CY, 2013, MOL CELL BIOCHEM, V382, P47, DOI 10.1007/s11010-013-1717-4; Yamashita T, 2014, J STROKE CEREBROVASC, V23, P2240, DOI 10.1016/j.jstrokecerebrovasdis.2014.04.010; Zanchetti A, 2006, BLOOD PRESSURE, V15, P71, DOI 10.1080/08037050600771583; Zhang M, 2010, NEUROSCIENCE, V171, P852, DOI 10.1016/j.neuroscience.2010.09.029; Zhou J, 2006, STROKE, V37, P1271, DOI 10.1161/01.STR.0000217404.64352.d7; Zorad S, 2006, EUR J PHARMACOL, V552, P112, DOI 10.1016/j.ejphar.2006.08.062	80	75	77	0	15	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	NOV 1	2015	138		11							10.1093/brain/awv172			17	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CW6VF	WOS:000365135700025	26115674	Green Published, hybrid			2022-02-06	
J	Iraji, A; Benson, RR; Welch, RD; O'Neil, BJ; Woodard, JL; Ayaz, SI; Kulek, A; Mika, V; Medado, P; Soltanian-Zadeh, H; Liu, TM; Haacke, EM; Kou, ZF				Iraji, Armin; Benson, Randall R.; Welch, Robert D.; O'Neil, Brian J.; Woodard, John L.; Ayaz, Syed Imran; Kulek, Andrew; Mika, Valerie; Medado, Patrick; Soltanian-Zadeh, Hamid; Liu, Tianming; Haacke, E. Mark; Kou, Zhifeng			Resting State Functional Connectivity in Mild Traumatic Brain Injury at the Acute Stage: Independent Component and Seed-Based Analyses	JOURNAL OF NEUROTRAUMA			English	Article						functional connectivity; fMRI; functional MRI; mTBI; mild traumatic brain injury; resting state fMRI	DIFFUSE AXONAL INJURY; POSTERIOR CINGULATE CORTEX; WHITE-MATTER INJURY; HUMAN AMYGDALA; PREFRONTAL CORTEX; RHESUS-MONKEY; EMERGENCY-DEPARTMENT; FOOTBALL PLAYERS; DEFAULT NETWORK; WORKING-MEMORY	Mild traumatic brain injury (mTBI) accounts for more than 1 million emergency visits each year. Most of the injured stay in the emergency department for a few hours and are discharged home without a specific follow-up plan because of their negative clinical structural imaging. Advanced magnetic resonance imaging (MRI), particularly functional MRI (fMRI), has been reported as being sensitive to functional disturbances after brain injury. In this study, a cohort of 12 patients with mTBI were prospectively recruited from the emergency department of our local Level-1 trauma center for an advanced MRI scan at the acute stage. Sixteen age- and sex-matched controls were also recruited for comparison. Both group-based and individual-based independent component analysis of resting-state fMRI (rsfMRI) demonstrated reduced functional connectivity in both posterior cingulate cortex (PCC) and precuneus regions in comparison with controls, which is part of the default mode network (DMN). Further seed-based analysis confirmed reduced functional connectivity in these two regions and also demonstrated increased connectivity between these regions and other regions of the brain in mTBI. Seed-based analysis using the thalamus, hippocampus, and amygdala regions further demonstrated increased functional connectivity between these regions and other regions of the brain, particularly in the frontal lobe, in mTBI. Our data demonstrate alterations of multiple brain networks at the resting state, particularly increased functional connectivity in the frontal lobe, in response to brain concussion at the acute stage. Resting-state functional connectivity of the DMN could serve as a potential biomarker for improved detection of mTBI in the acute setting.	[Iraji, Armin; Mika, Valerie; Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [Benson, Randall R.] Ctr Neurol Studies, Novi, MI USA; [Welch, Robert D.; O'Neil, Brian J.; Ayaz, Syed Imran; Kulek, Andrew; Mika, Valerie; Medado, Patrick] Wayne State Univ, Dept Emergency Med, Detroit, MI USA; [Woodard, John L.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Soltanian-Zadeh, Hamid] Henry Ford Hosp, Dept Radiol, Detroit, MI 48202 USA; [Liu, Tianming] Univ Georgia, Dept Comp Sci, Athens, GA 30602 USA; [Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Dept Radiol, Detroit, MI USA		Kou, ZF (corresponding author), Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA.	Zhifeng_kou@wayne.edu	Liu, Tianming/AAA-4602-2022; Soltanian-Zadeh, Hamid/AAD-7027-2022; Soltanian-Zadeh, Hamid/K-2903-2016; Mika, Valerie H./AAO-2816-2020	Soltanian-Zadeh, Hamid/0000-0002-7302-6856; Soltanian-Zadeh, Hamid/0000-0002-7302-6856; Woodard, John/0000-0001-9196-3336; Iraji, Armin/0000-0002-0605-593X	International Society for Magnetic Resonance in Medicine (ISMRM) seed grant; Department of DefenseUnited States Department of Defense [W81XWH-11-1-0493]	This study was supported by the International Society for Magnetic Resonance in Medicine (ISMRM) seed grant and the Department of Defense (grant contract number: W81XWH-11-1-0493). The authors also thank Ms. Natalie Wiseman, MD, PhD candidate, for proofreading.	Adolphs R, 2008, CURR OPIN NEUROBIOL, V18, P166, DOI 10.1016/j.conb.2008.06.006; Adolphs R, 2010, ANN NY ACAD SCI, V1191, P42, DOI 10.1111/j.1749-6632.2010.05445.x; Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Allison T, 2000, TRENDS COGN SCI, V4, P267, DOI 10.1016/S1364-6613(00)01501-1; Amunts K, 2005, ANAT EMBRYOL, V210, P343, DOI 10.1007/s00429-005-0025-5; [Anonymous], 1999, JAMA, V282, P974; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Aron AR, 2003, BRAIN, V126, P713, DOI 10.1093/brain/awg067; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bergman K, 2010, J EMERG NURS, V36, P221, DOI 10.1016/j.jen.2009.07.001; Binder JR, 2011, TRENDS COGN SCI, V15, P527, DOI 10.1016/j.tics.2011.10.001; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Bzdok D, 2013, HUM BRAIN MAPP, V34, P3247, DOI 10.1002/hbm.22138; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; CDC, 2003, REP C MILD TRAUM BRA; Conturo TE, 1996, MAGNET RESON MED, V35, P399, DOI 10.1002/mrm.1910350319; Dettwiler A., 2014, J NEUROTRAUM, V31, P180; Gilbert SJ, 2007, SCIENCE, V317, P43, DOI 10.1126/science.1140801; GOLDMANRAKIC PS, 1984, NEUROSCIENCE, V12, P719, DOI 10.1016/0306-4522(84)90166-0; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keightley ML, 2014, J NEUROTRAUM, V31, P437, DOI [10.1089/NEU.2013.3052, 10.1089/neu.2013.3052]; Koechlin E, 2003, SCIENCE, V302, P1181, DOI 10.1126/science.1088545; Koechlin E, 2007, TRENDS COGN SCI, V11, P229, DOI 10.1016/j.tics.2007.04.005; Kou Z., CLIN MR NEUROIMAGING; Kou Z., 2007, P JOINT ANN M ISMRM; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Kou ZF, 2014, NEURAL REGEN RES, V9, P693, DOI 10.4103/1673-5374.131568; Kou ZF, 2012, RSC DRUG DISCOV, V24, P19, DOI 10.1039/9781849734745-00019; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Leech R, 2012, J NEUROSCI, V32, P215, DOI 10.1523/JNEUROSCI.3689-11.2012; Lin QH, 2010, HUM BRAIN MAPP, V31, P1076, DOI 10.1002/hbm.20919; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Maddock RJ, 2003, HUM BRAIN MAPP, V18, P30, DOI 10.1002/hbm.10075; Maratos EJ, 2001, NEUROPSYCHOLOGIA, V39, P910, DOI 10.1016/S0028-3932(01)00025-2; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M., 2008, MILD TRAUMATIC BRAIN; McCrea M., 2000, STANDARDIZED ASSESSM; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Morris R, 1999, J COMP NEUROL, V407, P183, DOI 10.1002/(SICI)1096-9861(19990503)407:2<183::AID-CNE3>3.0.CO;2-N; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; PANDYA DN, 1981, EXP BRAIN RES, V42, P319, DOI 10.1007/BF00237497; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pearson JM, 2011, TRENDS COGN SCI, V15, P143, DOI 10.1016/j.tics.2011.02.002; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Shimony JS, 1999, RADIOLOGY, V212, P770, DOI 10.1148/radiology.212.3.r99au51770; Smith S.M., 2009, NEUROIMAGE, V47, pS148; Steriade M, 2005, TRENDS NEUROSCI, V28, P317, DOI 10.1016/j.tins.2005.03.007; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Swanson LW, 1998, TRENDS NEUROSCI, V21, P323, DOI 10.1016/S0166-2236(98)01265-X; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Tian LX, 2006, NEUROSCI LETT, V400, P39, DOI 10.1016/j.neulet.2006.02.022; Wang L, 2006, NEUROIMAGE, V31, P496, DOI 10.1016/j.neuroimage.2005.12.033; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhou Y, 2007, SCHIZOPHR RES, V97, P194, DOI 10.1016/j.schres.2007.05.029	76	75	79	1	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2015	32	14					1031	1045		10.1089/neu.2014.3610			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CV0TB	WOS:000363965000001	25285363	Green Published			2022-02-06	
J	Kourbeti, IS; Vakis, AF; Ziakas, P; Karabetsos, D; Potolidis, E; Christou, S; Samonis, G				Kourbeti, Irene S.; Vakis, Antonis F.; Ziakas, Panayiotis; Karabetsos, Dimitris; Potolidis, Evangelos; Christou, Silvana; Samonis, George			Infections in patients undergoing craniotomy: risk factors associated with post-craniotomy meningitis	JOURNAL OF NEUROSURGERY			English	Article						craniotomy; meningitis; infection; ventilator-associated pneumonia; surgical site infections	VENTRICULOSTOMY-RELATED INFECTIONS; NEGATIVE BACILLARY MENINGITIS; NEUROSURGICAL SITE INFECTIONS; ACINETOBACTER-BAUMANNII; ANTIBIOTIC-PROPHYLAXIS; POSTOPERATIVE MENINGITIS; ELECTRODES; MANAGEMENT; SURGERY; ADULTS	OBJECT The authors performed a prospective study to define the prevalence and microbiological characteristics of infections in patients undergoing craniotomy and to clarify the risk factors for post-craniotomy meningitis. METHODS Patients older than 18 years who underwent nonstereotactic craniotomies between January 2006 and December 2008 were included. Demographic, clinical, laboratory, and microbiological data were systemically recorded. Patient characteristics, craniotomy type, and pre- and postoperative variables were evaluated as risk factors for meningitis RESULTS Three hundred thirty-four procedures were analyzed (65.6% involving male patients). Traumatic brain injury was the most common reason for craniotomy. Almost 40% of the patients developed at least 1 infection. Ventilator-associated pneumonia (VAP) was the most common infection recorded (22.5%) and Acinetobacter spp. were isolated in 44% of the cases. Meningitis was encountered in 16 procedures (4.8%), and CSF cultures were positive for microbial growth in 100% of these cases. Gram-negative pathogens (Acinetobacter spp., Klebsiella spp., Pseudomonas aeruginosa, Enterobacter cloaceae, Proteus mirabilis) represented 88% of the pathogens. Acinetobacter and Klebsiella spp. demonstrated a high percentage of resistance in several antibiotic classes. In multivariate analysis, the-risk for meningitis was independently associated with perioperative steroid use (OR 11.55, p = 0.005), CSF leak (OR 48.03, p < 0.001), and ventricular drainage (OR 70.52, p < 0.001). CONCLUSIONS Device-related postoperative communication between the CSF and the environment, CSF leak, and perioperative steroid use were defined as risk factors for meningitis in this study. Ventilator-associated pneumonia was the most common infection overall. The offending pathogens presented a high level of resistance to several antibiotics.	[Kourbeti, Irene S.] Gen Hosp Chalkida, Dept Internal Med, Chalkida, Greece; [Vakis, Antonis F.; Karabetsos, Dimitris] Univ Hosp Herakl, Dept Neurosurg, Iraklion, Greece; [Samonis, George] Univ Hosp Herakl, Dept Internal Med Infect Dis, Iraklion, Greece; [Potolidis, Evangelos] Gen Hosp Volos, Dept Internal Med, Volos, Greece; [Ziakas, Panayiotis] Brown Univ, Warren Alpert Med Sch, Dept Internal Med, Div Infect Dis, Providence, RI 02912 USA; [Christou, Silvana] Gen Hosp Nicosia, Dept Internal Med, Nicosia, Cyprus		Kourbeti, IS (corresponding author), Furness Gen Hosp, Dept Acute & Emergency Med, Dalton Ln, Barrow In Furness LA14 4LF, Cumbria, England.	irenekourbeti@hotmail.com	Karabetsos, Dimitris/AAA-2753-2021	Ziakas, Panayiotis/0000-0002-5943-8635; Karabetsos, Dimitris/0000-0003-1960-945X	PfizerPfizer; NovartisNovartis; GileadGilead Sciences; MSD	Dr. Samonis reports receiving non study related clinical or research support from Pfizer, Novartis, Gilead, and MSD.	Blomstedt G C, 1992, Neurosurg Clin N Am, V3, P375; Briggs S, 2004, SCAND J INFECT DIS, V36, P165, DOI 10.1080/00365540410027193; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Erdem I, 2008, NEUROL INDIA, V56, P433, DOI 10.4103/0028-3886.44629; Erman T, 2005, SURG NEUROL, V63, P107, DOI 10.1016/j.surneu.2004.04.024; Gulati S, 2001, NEUROL INDIA, V49, P134; Hersh EH, 2013, J NEUROSURG, V119, P48, DOI 10.3171/2013.3.JNS121489; Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002; Hsu Gwo-Jong, 1993, Journal of the Formosan Medical Association, V92, P317; Kim BN, 2009, LANCET INFECT DIS, V9, P245, DOI 10.1016/S1473-3099(09)70055-6; Korinek AM, 2005, BRIT J NEUROSURG, V19, P155, DOI 10.1080/02688690500145639; Korinek AM, 1997, NEUROSURGERY, V41, P1073, DOI 10.1097/00006123-199711000-00010; KORINEK AM, 1992, ANN FR ANESTH, V11, P711, DOI 10.1016/S0750-7658(05)80795-6; Kourbeti IS, 2012, CLIN MICROBIOL INFEC, V18, P359, DOI 10.1111/j.1469-0691.2011.03625.x; Kourbeti IS, 2007, NEUROSURGERY, V60, P317, DOI 10.1227/01.NEU.0000249266.26322.25; Leib SL, 1999, CLIN INFECT DIS, V29, P69, DOI 10.1086/520184; Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024; Lu CH, 1999, SURG NEUROL, V52, P438, DOI 10.1016/S0090-3019(99)00129-9; MAHE V, 1995, ANN FR ANESTH, V14, P8, DOI 10.1016/S0750-7658(05)80144-3; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; McPhee IB, 1998, SPINE, V23, P726, DOI 10.1097/00007632-199803150-00015; Metan G, 2007, INT J ANTIMICROB AG, V29, P112, DOI 10.1016/j.ijantimicag.2006.08.035; MOLLMAN HD, 1986, J NEUROSURG, V64, P902, DOI 10.3171/jns.1986.64.6.0902; NAROTAM PK, 1994, NEUROSURGERY, V34, P409, DOI 10.1227/00006123-199403000-00004; NGUYEN MH, 1994, NEUROSURGERY, V35, P851, DOI 10.1227/00006123-199411000-00008; PATIR R, 1992, ACTA NEUROCHIR, V119, P80, DOI 10.1007/BF01541786; Rebuck JA, 2000, J NEUROL NEUROSUR PS, V69, P381, DOI 10.1136/jnnp.69.3.381; Reichert MCF, 2002, AM J INFECT CONTROL, V30, P158, DOI 10.1067/mic.2002.119925; Rello J, 1999, CHEST, V115, P1226, DOI 10.1378/chest.115.5.1226; Shinoura N, 2004, BRIT J NEUROSURG, V18, P598, DOI 10.1080/02688690400022771; Srinivas D, 2011, NEUROL INDIA, V59, P195, DOI 10.4103/0028-3886.79136; Van Gompel JJ, 2008, NEUROSURGERY, V63, P498, DOI 10.1227/01.NEU.0000324996.37228.F8; Walcott BP, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.8.FOCUS12245; Wroblewska MM, 2004, J HOSP INFECT, V57, P300, DOI 10.1016/j.jhin.2004.04.009	34	75	85	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2015	122	5					1113	1119		10.3171/2014.8.JNS132557			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CG5XP	WOS:000353369500017	25343179	Bronze			2022-02-06	
J	Ji, SB; Zhao, W; Ford, JC; Beckwith, JG; Bolander, RP; Greenwald, RM; Flashman, LA; Paulsen, KD; McAllister, TW				Ji, Songbai; Zhao, Wei; Ford, James C.; Beckwith, Jonathan G.; Bolander, Richard P.; Greenwald, Richard M.; Flashman, Laura A.; Paulsen, Keith D.; McAllister, Thomas W.			Group-Wise Evaluation and Comparison of White Matter Fiber Strain and Maximum Principal Strain in Sports-Related Concussion	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; models of injury; axonal injury; finite element method; traumatic brain injury	HEAD ACCELERATION; AXONAL DAMAGE; BRAIN-TISSUE; IN-VIVO; IMPACT; FOOTBALL; MODELS; SYSTEM; IMPAIRMENT; GENERATION	Sports-related concussion is a major public health problem in the United States and yet its biomechanical mechanisms remain unclear. In vitro studies demonstrate axonal elongation as a potential injury mechanism; however, current response-based injury predictors (e.g., maximum principal strain, [GRAPHICS] ) typically do not incorporate axonal orientations. We investigated the significance of white matter (WM) fiber orientation in strain estimation and compared fiber strain ( [GRAPHICS] ) with [GRAPHICS] for 11 athletes with a clinical diagnosis of concussion. Geometrically accurate subject-specific head models with high mesh quality were created based on the Dartmouth Head Injury Model (DHIM), which was successfully validated (performance categorized as "good" to "excellent"). For WM regions estimated to be exposed to high strains using a range of injury thresholds (0.09-0.28), substantial differences existed between [GRAPHICS] and [GRAPHICS] in both distribution (Dice coefficient of 0.13-0.33) and extent (similar to 5-10-fold differences), especially at higher threshold levels and higher rotational acceleration magnitudes. For example, an average of 3.2% vs. 29.8% of WM was predicted above an optimal threshold of 0.18 established from an in vivo animal study using [GRAPHICS] and [GRAPHICS] , respectively, with an average Dice coefficient of 0.14. The distribution of WM regions with high [GRAPHICS] was consistent with typical heterogeneous patterns of WM disruptions in diffuse axonal injury, and the group-wise extent at the optimal threshold matched well with the percentage of WM voxels experiencing significant longitudinal changes of fractional anisotropy and mean diffusivity (3.2% and 3.44%, respectively) found from a separate independent study. These results suggest the significance of incorporating WM microstructural anisotropy in future brain injury studies.	[Ji, Songbai; Zhao, Wei; Greenwald, Richard M.; Paulsen, Keith D.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Ji, Songbai] Geisel Sch Med Dartmouth, Dept Surg & Orthoped Surg, Lebanon, NH USA; [Ford, James C.; Flashman, Laura A.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA; [Beckwith, Jonathan G.; Bolander, Richard P.; Greenwald, Richard M.] Simbex, Lebanon, NH USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA		Ji, SB (corresponding author), Dartmouth Coll, Thayer Sch Engn, 14 Engn Dr, Hanover, NH 03755 USA.	Songbai.Ji@Dartmouth.edu	Ford, James/AAF-7039-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS078607, R01NS055020, R01HD048638]; National Operating Committee on Standards for Athletic Equipment [NOCSAE 04-07, SAC-1]; CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01/CE001254]; NOCSAE [SAC-1, 04-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS078607, R01NS055020] Funding Source: NIH RePORTER	This work was sponsored, in part, by the NIH grant R21 NS078607 and the National Operating Committee on Standards for Athletic Equipment (NOCSAE 04-07 & SAC-1). Funding for the head impact biomechanical data collection and neuroimaging that supported this work included the NIH grants R01NS055020, R01HD048638, CDC R01/CE001254, and NOCSAE grant 04-07 & SAC-1, and are acknowledged. The authors would also like to thank Dr. Robert M. Roth in the Brain Imaging Laboratory at the Geisel School of Medicine at Dartmouth College for assistance with image segmentation in MRI, and Drs. Philip V. Bayly and Yuan Feng at Washington University in St. Louis for providing data needed for DHIM validation.	ARUN KS, 1987, IEEE T PATTERN ANAL, V9, P699, DOI 10.1109/TPAMI.1987.4767965; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Centers for Disease Control and Prevention (CDC), 2003, REP C MILD TRAUM BRA, P1; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chu, 2006, J BIOMECH, V39, DOI https://doi.org/10.1016/s0021-9290(06)83518-9; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Cloots RJH, 2013, BIOMECH MODEL MECHAN, V12, P137, DOI 10.1007/s10237-012-0387-6; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; de Lange Ronald, 2005, Stapp Car Crash J, V49, P457; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Funk JR, 2006, INT BIOM RES P 34 IN, P1; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hayek L. C., 1994, MEASURING MONITORING; Jeurissen B, 2013, HUM BRAIN MAPP, V34, P2747, DOI 10.1002/hbm.22099; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Ji SB, 2011, FINITE ELEM ANAL DES, V47, P1178, DOI 10.1016/j.finel.2011.05.007; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; Leemans A., 2009, P 17 SCI M INT SOC M, V17, P3537; Li, 2012, INT J VEH SAF, V6, P91, DOI 10.1504/IJVS.2012.049024; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McElhaney J. H., 1973, PERSPECTIVES BIOMEDI; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shugar TA, 1977, HS2893550 DOT, VI; Sigal IA, 2010, J BIOMECH, V43, P254, DOI 10.1016/j.jbiomech.2009.08.036; Slaughter W. S., 2002, LINEARIZED THEOR ELA; Takhounts EG, 2008, STAPP CAR C, V52, P1; Talavage TM, 2013, J NEUROTRAUM, V30, P1; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Yang JK, 2011, COMPUTATIONAL BIOMECHANICS FOR MEDICINE: SOFT TISSUES AND THE MUSCULOSKELETAL SYSTEM, P5, DOI 10.1007/978-1-4419-9619-0_2; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	63	75	75	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2015	32	7					441	454		10.1089/neu.2013.3268			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CE4YV	WOS:000351837400004	24735430	Green Published			2022-02-06	
J	King, D; Hume, PA; Brughelli, M; Gissane, C				King, Doug; Hume, Patria A.; Brughelli, Matt; Gissane, Conor			Instrumented Mouthguard Acceleration Analyses for Head Impacts in Amateur Rugby Union Players Over a Season of Matches	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						injury; linear; rotational; impact; instrumented mouthguard	CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL FOOTBALL; PROFESSIONAL FOOTBALL; BRAIN-INJURY; ICE HOCKEY; CONCUSSION; EXPOSURE; BIOMECHANICS; SPORTS	Background: Direct impacts with the head (linear acceleration or pressure) and inertial loading of the head (rotational acceleration or strain) have been postulated as the 2 major mechanisms of head-related injuries such as concussion. Although data are accumulating for soccer and American football, there are no published data for nonhelmeted collision sports such as rugby union. Purpose: To quantify head impacts via instrumented mouthguard acceleration analyses for rugby union players over a season of matches. Study Design: Descriptive epidemiology study. Methods: Data on impact magnitude and frequency were collected with molded instrumented mouthguards worn by 38 premier amateur senior rugby players participating in the 2013 domestic season of matches. Results: A total of 20,687 impacts >10g (range, 10.0-164.9g) were recorded over the duration of the study. The mean SD number of impacts per player over the duration of the season of matches was 564 +/- 618, resulting in a mean +/- SD of 95 +/- 133 impacts to the head per player, per match over the duration of the season of matches. The impact magnitudes for linear accelerations were skewed to the lower values (S-p = 3.7 +/- 0.02; P < .001), with a mean linear acceleration of 22.2 +/- 16.2g. Rotational accelerations were also skewed to the lower values (S-p = 2.0 +/- 0.02; P < .001), with a mean rotational acceleration of 3902.9 +/- 3948.8 rad/s(2). Conclusion: The acceleration magnitudes and number of head impacts in amateur rugby union players over a season of matches, measured via instrumented mouthguard accelerations, were higher than for most sports previously reported. Mean linear acceleration measured over a season of matches was similar to the mean linear accelerations previously reported for youth, high school, and collegiate American football players but lower than that for female youth soccer players. Mean rotational acceleration measured over a season of matches was similar to mean rotational accelerations for youth, high school, and collegiate American football players but less than those for female youth soccer players, concussed American collegiate players, collegiate American football players, and professional American football players.	[King, Doug; Hume, Patria A.; Brughelli, Matt; Gissane, Conor] Auckland Univ Technol, Auckland, New Zealand		King, D (corresponding author), Hutt Valley Dist Hlth Board, Emergency Dept, Private Bag 31-907, Lower Hutt, New Zealand.	dking@aut.ac.nz	Hume, Patria Anne/P-1084-2017; Hume, Patria/AAN-5514-2021; Gissane, Conor/I-3661-2019	Hume, Patria Anne/0000-0003-1847-8128; Hume, Patria/0000-0003-1847-8128; Gissane, Conor/0000-0003-4677-3853			Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco J, 2010, J ATHL TRAINING, V45, P459; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Gadd C, 1966, P 10 STAPP CAR RASH; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Greenwald RM, 2012, CLIN J SPORT MED, V22, P83, DOI 10.1097/JSM.0b013e31824cc5d3; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Harpham JA, 2014, ANN BIOMED ENG, V42, P1, DOI 10.1007/s10439-013-0881-8; Hopkins WG, 2007, CLIN J SPORT MED, V17, P208, DOI 10.1097/JSM.0b013e3180592a68; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; King A, 2003, IRCOBI C SEPT 24 LIS; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; Mattson J, 2012, CLIN J SPORT MED, V22, P294; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Moon D W, 1971, Med Sci Sports, V3, P44; Ng TP, 2006, BIOMED SCI INSTRUM, V42, P25; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; Patton DA, 2012, P I MECH ENG P-J SPO, V226, P177, DOI 10.1177/1754337112438305; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Reed N, 2010, INT J SPORTS MED, V31, P826, DOI 10.1055/s-0030-1263103; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Versace J, 1971, SAE TECHNICAL PAPER, DOI [10.4271/710881, DOI 10.4271/710881]; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	68	75	75	0	26	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2015	43	3					614	624		10.1177/0363546514560876			11	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	CC6JP	WOS:000350471500014	25535096				2022-02-06	
J	Taber, KH; Hurley, RA; Haswell, CC; Rowland, JA; Hurt, SD; Lamar, CD; Morey, RA				Taber, Katherine H.; Hurley, Robin A.; Haswell, Courtney C.; Rowland, Jared A.; Hurt, Susan D.; Lamar, Cory D.; Morey, Rajendra A.			White Matter Compromise in Veterans Exposed to Primary Blast Forces	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						diffusion tensor imaging (DTI); diffusivity; fractional anisotropy; mild traumatic brain injury (mTBI); military veterans; primary blast; subconcussive blast exposure; white matter	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; DIFFUSION; INTEGRITY; ABNORMALITIES; IMPAIRMENT; CONCUSSION; DEPENDENCE; TESTS; MRI	Objective: Use diffusion tensor imaging to investigate white matter alterations associated with blast exposure with or without acute symptoms of traumatic brain injury (TBI). Participants: Forty-five veterans of the recent military conflicts included 23 exposed to primary blast without TBI symptoms, 6 having primary blast with mild TBI, and 16 unexposed to blast. Design: Cross-sectional case-control study. Main Measures: Neuropsychological testing and diffusion tensor imaging metrics that quantified the number of voxel clusters with altered fractional anisotropy (FA) radial diffusivity, and axial diffusivity, regardless of their spatial location. Results: Significantly lower FA and higher radial diffusivity were observed in veterans exposed to primary blast with and without mild TBI relative to blast-unexposed veterans. Voxel clusters of lower FA were spatially dispersed and heterogeneous across affected individuals. Conclusion: These results suggest that lack of clear TBI symptoms following primary blast exposure may not accurately reflect the extent of brain injury. If confirmed, our findings would argue for supplementing the established approach of making diagnoses based purely on clinical history and observable acute symptoms with novel neuroimaging-based diagnostic criteria that "look below the surface" for pathology.	[Taber, Katherine H.; Hurley, Robin A.; Haswell, Courtney C.; Rowland, Jared A.; Lamar, Cory D.; Morey, Rajendra A.] Mid Atlantic Mental Illness Res Educ & Clin Ctr, Durham, NC USA; [Taber, Katherine H.; Hurley, Robin A.; Rowland, Jared A.; Hurt, Susan D.; Lamar, Cory D.] WG Bill Hefner VA Med Ctr, Salisbury, NC 28144 USA; [Taber, Katherine H.] Edward Via Coll Osteopath Med, Div Biomed Sci, Blacksburg, VA USA; [Taber, Katherine H.] Baylor Coll Med, Dept Phys Med, Houston, TX 77030 USA; [Taber, Katherine H.] Baylor Coll Med, Dept Rehabil, Houston, TX 77030 USA; [Hurley, Robin A.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Hurley, Robin A.; Rowland, Jared A.] Wake Forest Sch Med, Dept Psychiat & Behav Med, Winston Salem, NC USA; [Rowland, Jared A.] Wake Forest Sch Med, Dept Neurobiol & Anat, Winston Salem, NC USA; [Haswell, Courtney C.; Morey, Rajendra A.] Durham VA Med Ctr, Durham, NC USA; [Haswell, Courtney C.; Morey, Rajendra A.] Duke Univ, Duke UNC Brain Imaging & Anal Ctr, Durham, NC USA; [Morey, Rajendra A.] Duke Univ, Dept Psychiat & Behav Sci, Durham, NC USA		Taber, KH (corresponding author), WG Bill Hefner VA Med Ctr, Res & Educ Serv Line,Mailstop 11M,1601 Brenner Av, Salisbury, NC 28144 USA.	Kather-ine.taber@va.gov	Morey, Rajendra A/P-3079-2018; Taber, Katherine H/B-8260-2011; Rowland, Jared A./AAN-3030-2021	Morey, Rajendra A/0000-0002-6517-6969; Taber, Katherine H/0000-0001-7382-6151; Rowland, Jared A./0000-0002-3655-3411	Department of Defense, Joint Improvised Explosive Device Defeat OrganizationUnited States Department of Defense [51467EGJDO]; Department of Veterans Health Affairs Rehabilitation Research and Development [RX000389-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086885] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000389] Funding Source: NIH RePORTER	This research was supported by a grant from the Department of Defense, Joint Improvised Explosive Device Defeat Organization (51467EGJDO), the Department of Veterans Health Affairs Rehabilitation Research and Development (RX000389-01), and with resources of the Mid-Atlantic Mental Illness Research, Education, and Clinical Center and W. G. (Bill) Hefner VA Medical Center.	Anderson MJ, 2001, AUST NZ J STAT, V43, P75, DOI 10.1111/1467-842X.00156; Bartres-Faz D, 2011, BRAIN TOPOGR, V24, P340, DOI 10.1007/s10548-011-0195-9; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Bochicchio GV, 2008, AM SURGEON, V74, P267; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Duckworth Josh L, 2013, Pathophysiology, V20, P23, DOI 10.1016/j.pathophys.2012.03.001; Fakhran S, 2013, RADIOLOGY, V269, P249, DOI 10.1148/radiol.13122343; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Ganpule S, 2013, BIOMECH MODEL MECHAN, V12, P511, DOI 10.1007/s10237-012-0421-8; Goldstein L.E., 2012, SCI TRANSL MED, V4; Hayes JP, 2012, NEUROCASE, V18, P258, DOI 10.1080/13554794.2011.588181; Jensen KB, 2012, P NATL ACAD SCI USA, V109, P15959, DOI 10.1073/pnas.1202056109; Jones DK, 2003, MAGN RESON MED, V49, P7, DOI 10.1002/mrm.10331; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; KENNEDY PE, 1995, J BUS ECON STAT, V13, P85, DOI 10.2307/1392523; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Le Bihan D, 2012, NEUROIMAGE, V61, P324, DOI 10.1016/j.neuroimage.2011.11.006; LILLIEFORS HW, 1967, J AM STAT ASSOC, V62, P399, DOI 10.2307/2283970; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; Madden DJ, 2004, NEUROIMAGE, V21, P1174, DOI 10.1016/j.neuroimage.2003.11.004; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Moretti L, 2012, LANCET NEUROL, V11, P1103, DOI 10.1016/S1474-4422(12)70226-0; Mori S, 2005, MRI ATLAS HUMAN WHIT; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Rosen Allyson, 2009, Mil Med, V174, pv; Sams R, 2012, MIL MED, V177, P48, DOI 10.7205/MILMED-D-11-00214; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Sorg SF, 2014, J HEAD TRAUMA REHAB, V29, P21, DOI 10.1097/HTR.0b013e31828a1aa4; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Wedeen VJ, 2012, SCIENCE, V335, P1628, DOI 10.1126/science.1215280; Wheeler-Kingshott CAM, 2009, MAGN RESON MED, V61, P1255, DOI 10.1002/mrm.21965; White T, 2013, SCHIZOPHRENIA BULL, V39, P1077, DOI 10.1093/schbul/sbs106; Yeh DD, 2012, WORLD J SURG, V36, P966, DOI 10.1007/s00268-012-1500-9; Yeh PH, 2009, PSYCHIAT RES-NEUROIM, V173, P22, DOI 10.1016/j.pscychresns.2008.07.012; Zhuang L, 2010, NEUROIMAGE, V53, P16, DOI 10.1016/j.neuroimage.2010.05.068	52	75	75	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					E15	E25		10.1097/HTR.0000000000000030			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400003	24590156	Green Published, Green Accepted			2022-02-06	
J	Apolloni, S; Amadio, S; Parisi, C; Matteucci, A; Potenza, RL; Armida, M; Popoli, P; D'Ambrosi, N; Volonte, C				Apolloni, Savina; Amadio, Susanna; Parisi, Chiara; Matteucci, Alessandra; Potenza, Rosa L.; Armida, Monica; Popoli, Patrizia; D'Ambrosi, Nadia; Volonte, Cinzia			Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis	DISEASE MODELS & MECHANISMS			English	Article						ALS; Brilliant Blue G; Microglia; Motor neuron; P2X7	NF-KAPPA-B; PREVENTS ATP EXCITOTOXICITY; P2X(7) RECEPTOR; EXTRACELLULAR ATP; NEUROPATHIC PAIN; RODENT MODELS; MICROGLIA; NEURONS; ACTIVATION; INJURY	In recent years there has been an increasing awareness of the role of P2X7, a receptor for extracellular ATP, in modulating physiopathological mechanisms in the central nervous system. In particular, P2X7 has been shown to be implicated in neuropsychiatry, chronic pain, neurodegeneration and neuroinflammation. Remarkably, P2X7 has also been shown to be a 'gene modifier' in amyotrophic lateral sclerosis (ALS): the receptor is upregulated in spinal cord microglia in human and rat at advanced stages of the disease; in vitro, activation of P2X7 exacerbates pro-inflammatory responses in microglia that have an ALS phenotype, as well as toxicity towards neuronal cells. Despite this detrimental in vitro role of P2X7, in SOD1-G93A mice lacking P2X7, the clinical onset of ALS was significantly accelerated and disease progression worsened, thus indicating that the receptor might have some beneficial effects, at least at certain stages of disease. In order to clarify this dual action of P2X7 in ALS pathogenesis, in the present work we used the antagonist Brilliant Blue G (BBG), a blood-brain barrier permeable and safe drug that has already been proven to reduce neuroinflammation in traumatic brain injury, cerebral ischemia-reperfusion, neuropathic pain and experimental autoimmune encephalitis. We tested BBG in the SOD1-G93A ALS mouse model at asymptomatic, pre-symptomatic and late pre-symptomatic phases of disease. BBG at late pre-onset significantly enhanced motor neuron survival and reduced microgliosis in lumbar spinal cord, modulating inflammatory markers such as NF-kappa B, NADPH oxidase 2, interleukin-1 beta, interleukin-10 and brain-derived neurotrophic factor. This was accompanied by delayed onset and improved general conditions and motor performance, in both male and female mice, although survival appeared unaffected. Our results prove the twofold role of P2X7 in the course of ALS and establish that P2X7 modulation might represent a promising therapeutic strategy by interfering with the neuroinflammatory component of the disease.	[Apolloni, Savina; Parisi, Chiara; D'Ambrosi, Nadia; Volonte, Cinzia] CNR, Cellular Biol & Neurobiol Inst, I-00143 Rome, Italy; [Apolloni, Savina; Amadio, Susanna; Volonte, Cinzia] Santa Lucia Fdn, IRCCS, I-00179 Rome, Italy; [Matteucci, Alessandra; Potenza, Rosa L.; Armida, Monica; Popoli, Patrizia] Ist Super Sanita, Dept Therapeut Res & Med Evaluat, I-00161 Rome, Italy		Volonte, C (corresponding author), CNR, Cellular Biol & Neurobiol Inst, Via Fosso di Fiorano 65, I-00143 Rome, Italy.	cinzia.volonte@cnr.it	parisi, Chiara/K-6330-2016; Amadio, Susanna/K-5580-2016; Apolloni, Savina/N-7695-2019; Volonte, Cinzia/N-6474-2013; Apolloni, Savina/AAH-9502-2020	parisi, Chiara/0000-0003-1350-3929; Amadio, Susanna/0000-0002-9266-4597; Apolloni, Savina/0000-0002-5782-1665; Volonte, Cinzia/0000-0001-7362-8307; Potenza, Rosa Luisa/0000-0003-2342-0705; D'AMBROSI, Nadia/0000-0002-6646-7653; MATTEUCCI, Alessandra/0000-0002-8793-3422	AriSLA-Fondazione Italiana per la Ricerca sulla Sclerosi Laterale Amiotrofica; Ministry of Health [grant PRALS]; Progetto Ministero della Salute Ricerca Corrente Fondazione Santa Lucia: 'Studio molecolare e funzionale dei recettori purinergici P2 nel sistema nervoso e nelle patologie neurodegenerative e neuroinfiammatorie'	This work was supported by AriSLA-Fondazione Italiana per la Ricerca sulla Sclerosi Laterale Amiotrofica co-financed with the support of '5x1000' - Healthcare Research of the Ministry of Health [grant PRALS 2009]; and by Progetto Ministero della Salute Ricerca Corrente Fondazione Santa Lucia: 'Studio molecolare e funzionale dei recettori purinergici P2 nel sistema nervoso e nelle patologie neurodegenerative e neuroinfiammatorie'.	Amadio S, 2011, J NEUROCHEM, V116, P796, DOI 10.1111/j.1471-4159.2010.07025.x; Apolloni S, 2013, HUM MOL GENET, V22, P4102, DOI 10.1093/hmg/ddt259; Apolloni S, 2013, J IMMUNOL, V190, P5187, DOI 10.4049/jimmunol.1203262; Arbeloa J, 2012, NEUROBIOL DIS, V45, P954, DOI 10.1016/j.nbd.2011.12.014; Beers DR, 2011, BRAIN BEHAV IMMUN, V25, P1025, DOI 10.1016/j.bbi.2010.12.008; Bhattacharya A, 2013, BRIT J PHARMACOL, V170, P624, DOI 10.1111/bph.12314; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Butovsky O, 2012, J CLIN INVEST, V122, P3063, DOI 10.1172/JCI62636; Casanovas A, 2008, J COMP NEUROL, V506, P75, DOI 10.1002/cne.21527; Cervetto C, 2013, TOXICOLOGY, V311, P69, DOI 10.1016/j.tox.2013.04.004; Chu KT, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-69; D'Ambrosi N, 2009, J IMMUNOL, V183, P4648, DOI 10.4049/jimmunol.0901212; Diaz-Hernandez M, 2009, FASEB J, V23, P1893, DOI 10.1096/fj.08-122275; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Gandelman M, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-33; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; He WJ, 2012, BEHAV BRAIN RES, V226, P163, DOI 10.1016/j.bbr.2011.09.015; Henkel JS, 2009, J NEUROIMMUNE PHARM, V4, P389, DOI 10.1007/s11481-009-9171-5; Hernandez S, 2010, J NEUROPATH EXP NEUR, V69, P176, DOI 10.1097/NEN.0b013e3181cd3e33; Kairisalo M, 2009, EUR J NEUROSCI, V30, P958, DOI 10.1111/j.1460-9568.2009.06898.x; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kobayashi K, 2011, NEUROSCI LETT, V504, P57, DOI 10.1016/j.neulet.2011.08.058; Li Q, 2011, J BIOL CHEM, V286, P40151, DOI 10.1074/jbc.M111.279711; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lim H, 2013, J BIOL CHEM, V288, P7572, DOI 10.1074/jbc.M112.414904; Ludolph AC, 2010, AMYOTROPH LATERAL SC, V11, P38, DOI 10.3109/17482960903545334; Marden JJ, 2007, J CLIN INVEST, V117, P2913, DOI 10.1172/JCI31265; Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007; Monif M, 2010, INT J BIOCHEM CELL B, V42, P1753, DOI 10.1016/j.biocel.2010.06.021; Monif M, 2009, J NEUROSCI, V29, P3781, DOI 10.1523/JNEUROSCI.5512-08.2009; Nikodemova M, 2014, NEUROBIOL DIS, V69, P43, DOI 10.1016/j.nbd.2013.11.009; Parisi C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.491; Pelayes DE, 2012, OPHTHALMIC RES, V48, P21, DOI 10.1159/000339845; Peng WG, 2009, P NATL ACAD SCI USA, V106, P12489, DOI 10.1073/pnas.0902531106; Philips T, 2011, LANCET NEUROL, V10, P253, DOI 10.1016/S1474-4422(11)70015-1; Pugazhenthi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069585; Sargsyan SA, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-91; Swarup V, 2011, J EXP MED, V208, P2429, DOI 10.1084/jem.20111313; Takenouchi T, 2010, ARCH IMMUNOL THER EX, V58, P91, DOI 10.1007/s00005-010-0069-y; Thau N, 2012, NEUROBIOL DIS, V47, P248, DOI 10.1016/j.nbd.2012.04.008; Trumbull KA, 2012, NEUROBIOL DIS, V45, P137, DOI 10.1016/j.nbd.2011.07.015; Turner BJ, 2008, PROG NEUROBIOL, V85, P94, DOI 10.1016/j.pneurobio.2008.01.001; Volonte C, 2012, CNS NEUROL DISORD-DR, V11, P705, DOI 10.2174/187152712803581137; Volonte C, 2011, PHARMACOL THERAPEUT, V132, P111, DOI 10.1016/j.pharmthera.2011.06.002; Weydt P, 2003, NEUROREPORT, V14, P1051, DOI 10.1097/01.wnr.0000073685.00308.89; Yiangou Y, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-12; Zhao WH, 2013, J NEUROIMMUNE PHARM, V8, P888, DOI 10.1007/s11481-013-9489-x	50	75	76	2	16	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	1754-8403	1754-8411		DIS MODEL MECH	Dis. Model. Mech.	SEP	2014	7	9					1101	1109		10.1242/dmm.017038			9	Cell Biology; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Pathology	AT5TS	WOS:000345005600008	25038061	gold, Green Published			2022-02-06	
J	Johansson, PI; Sorensen, AM; Larsen, CF; Windelov, NA; Stensballe, J; Perner, A; Rasmussen, LS; Ostrowski, SR				Johansson, Paer I.; Sorensen, Anne Marie; Larsen, Claus F.; Windelov, Nis A.; Stensballe, Jakob; Perner, Anders; Rasmussen, Lars S.; Ostrowski, Sisse R.			Low hemorrhage-related mortality in trauma patients in a Level I trauma center employing transfusion packages and early thromboelastography-directed hemostatic resuscitation with plasma and platelets	TRANSFUSION			English	Article							BLOOD-PRODUCT RATIO; RAPID THROMBELASTOGRAPHY; ENDOTHELIAL GLYCOCALYX; MASSIVE TRANSFUSION; ACUTE COAGULOPATHY; CELL RATIOS; ADMISSION; SURVIVAL; COAGULATION; SHOCK	BackgroundHemorrhage accounts for most preventable trauma deaths, but still the optimal strategy for hemostatic resuscitation remains debated. Study Design and MethodsThis was a prospective study of adult trauma patients admitted to a Level I trauma center. Demography, Injury Severity Score (ISS), transfusion therapy, and mortality were registered. Hemostatic resuscitation was based on a massive transfusion protocol encompassing transfusion packages and thromboelastography (TEG)-guided therapy. ResultsA total of 182 patients were included (75% males, median age 43 years, ISS of 17, 92% with blunt trauma). Overall 28-day mortality was 12% with causes of death being exsanguinations (14%), traumatic brain injury (72%, two-thirds expiring within 24hr), and other (14%). One-fourth, 16 and 15% of the patients, received red blood cells (RBCs), plasma, or platelets (PLTs) within 2 hours from admission and 68, 71, and 75%, respectively, of patients transfused within 24 hours received the respective blood products within the first 2 hours. In patients transfused within 24 hours, the median number of blood products at 2 hours was 5 units of RBCs, 5 units of plasma, and 2 units of PLT concentrates. Nonsurvivors had lower clot strength by kaolin-activated TEG and TEG functional fibrinogen and lower kaolin-tissue factor-activated TEG -angle and lysis after 30 minutes compared to survivors. None of the TEG variables were independent predictors of massive transfusion or mortality. ConclusionThree-fourths of the patients transfused with plasma or PLTs within 24 hours received these in the first 2 hours. Hemorrhage caused 14% of the deaths. We introduced transfusion packages and early TEG-directed hemostatic resuscitation at our hospital 10 years ago and this may have contributed to reducing hemorrhagic trauma deaths.	Rigshosp, Copenhagen Univ Hosp, Capital Reg Blood Bank, Transfus Med Sect, DK-2100 Copenhagen, Denmark; Rigshosp, Copenhagen Univ Hosp, Dept Anesthesia, DK-2100 Copenhagen, Denmark; Rigshosp, Copenhagen Univ Hosp, TraumaCtr 3193, Ctr Head & Orthoped, DK-2100 Copenhagen, Denmark; Rigshosp, Copenhagen Univ Hosp, Dept Intens Care, DK-2100 Copenhagen, Denmark; Univ Texas Med Sch Houston, Dept Surg, Div Acute Care Surg, Ctr Translat Injury Res,CeTIR, Houston, TX USA		Johansson, PI (corresponding author), Univ Copenhagen, Rigshosp, Capital Reg Blood Bank, Transfus Med Sect, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	per.johansson@rh.regionh.dk	Ostrowski, Sisse R/E-7423-2011; Johansson, Par I/P-9283-2015	Ostrowski, Sisse R/0000-0001-5288-3851; Johansson, Par I/0000-0001-9778-5964; Perner, Anders/0000-0002-4668-0123; Rasmussen, Lars/0000-0002-7480-3004	Haemonetics Corp. (Braintree, MA); University of Copenhagen; Tryg Foundation; B. Braun Medical; Fresenius Kabi	The study was supported by an unrestricted research grant from Haemonetics Corp. (Braintree, MA). NAW received a fellowship grant from the University of Copenhagen and LSR received funding from the Tryg Foundation. AP received grant support from B. Braun Medical and Fresenius Kabi.	Amer Soc Anesthesiologists Task Fo, 2006, ANESTHESIOLOGY, V105, P198; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brown JB, 2012, J TRAUMA ACUTE CARE, V73, P358, DOI 10.1097/TA.0b013e31825889ba; Cotton BA, 2012, J TRAUMA ACUTE CARE, V73, P365, DOI 10.1097/TA.0b013e31825c1234; Cotton BA, 2011, J TRAUMA, V71, P407, DOI 10.1097/TA.0b013e31821e1bf0; Cotton BA, 2009, J TRAUMA, V66, P41, DOI 10.1097/TA.0b013e31819313bb; Dirks J, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-65; Duchesne JC, 2010, J TRAUMA, V69, P46, DOI 10.1097/TA.0b013e3181df91fa; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Frith D, 2012, CURR OPIN CRIT CARE, V18, P631, DOI 10.1097/MCC.0b013e3283599ab9; Gando S, 2011, ANN SURG, V254, P10, DOI 10.1097/SLA.0b013e31821221b1; Gando S, 2010, CRIT CARE MED, V38, pS35, DOI 10.1097/CCM.0b013e3181c9e31d; Gruen RL, 2006, ANN SURG, V244, P371, DOI 10.1097/01.sla.0000234655.83517.56; Gruen RL, 2012, LANCET, V380, P1099, DOI 10.1016/S0140-6736(12)61224-0; Haywood-Watson RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023530; Ho AMH, 2012, BRIT J SURG, V99, P132, DOI 10.1002/bjs.7732; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Holcomb JB, 2011, ANN SURG, V254, P201, DOI 10.1097/SLA.0b013e318226483d; Jeger V, 2009, J TRAUMA, V66, P1253, DOI 10.1097/TA.0b013e31819d3caf; Johansson PI, 2008, EUR J VASC ENDOVASC, V36, P397, DOI 10.1016/j.ejvs.2008.04.015; Johansson PI, 2010, MED HYPOTHESES, V75, P564, DOI 10.1016/j.mehy.2010.07.031; Johansson PI, 2009, VOX SANG, V96, P111, DOI 10.1111/j.1423-0410.2008.01130.x; Johansson PI, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-45; Johansson PI, 2008, TRANSFUSION, V48, P2377, DOI 10.1111/j.1537-2995.2008.01846.x; Johansson PI, 2007, TRANSFUSION, V47, p176S, DOI 10.1111/j.1537-2995.2007.01381.x; Johansson PI, 2007, TRANSFUSION, V47, P593, DOI 10.1111/j.1537-2995.2007.01160.x; Johansson Par I, 2012, J Emerg Trauma Shock, V5, P120, DOI 10.4103/0974-2700.96479; Johansson PI, 2011, CRIT CARE, V15, DOI 10.1186/cc10553; Johansson PI, 2012, CURR OPIN ANESTHESIO, V25, P235, DOI 10.1097/ACO.0b013e32834fab76; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Johansson PI, 2010, TRANSFUS APHER SCI, V43, P401, DOI 10.1016/j.transci.2010.09.002; Kashuk JL, 2012, TRANSFUSION, V52, P23, DOI 10.1111/j.1537-2995.2011.03264.x; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Nystrup KB, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-52; Organization W.H, 2008, GLOBAL BURDEN DIS 20; Plotkin AJ, 2008, J TRAUMA, V64, pS64, DOI 10.1097/TA.0b013e318160772d; Raza I, 2013, J THROMB HAEMOST, V11, P307, DOI 10.1111/jth.12078; Scalea TM, 2008, ANN SURG, V248, P578, DOI 10.1097/SLA.0b013e31818990ed; Schols SEM, 2008, THROMB HAEMOSTASIS, V99, P64, DOI 10.1160/TH07-07-0438; Shiraki R, 2004, THROMB RES, V113, P379, DOI 10.1016/j.thromres.2004.03.023; Snyder CW, 2009, J TRAUMA, V66, P358, DOI 10.1097/TA.0b013e318196c3ac; Tapia NM, 2013, J TRAUMA ACUTE CARE, V74, P378, DOI 10.1097/TA.0b013e31827e20e0; Tien HC, 2007, J TRAUMA, V62, P142, DOI 10.1097/01.ta.0000251558.38388.47; World Health Organization, 2011, WORLD HLTH STAT CAUS	48	75	80	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0041-1132	1537-2995		TRANSFUSION	Transfusion	DEC	2013	53	12					3088	3099		10.1111/trf.12214			12	Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Hematology	265CD	WOS:000327926400010	23614333				2022-02-06	
J	Yang, SH; Gangidine, M; Pritts, TA; Goodman, MD; Lentsch, AB				Yang, Sung H.; Gangidine, Matt; Pritts, Timothy A.; Goodman, Michael D.; Lentsch, Alex B.			INTERLEUKIN 6 MEDIATES NEUROINFLAMMATION AND MOTOR COORDINATION DEFICITS AFTER MILD TRAUMATIC BRAIN INJURY AND BRIEF HYPOXIA IN MICE	SHOCK			English	Article						Traumatic brain injury; neuroinflammation; motor coordination; hypoxia; trauma; inflammation	IMPACT; HYPOXEMIA	Traumatic brain injury (TBI) is a leading cause of mortality and disability. Acute postinjury insults after TBI, such as hypoxia, contribute to secondary brain injury and worse clinical outcomes. The functional and neuroinflammatory effects of brief episodes of hypoxia experienced following TBI have not been evaluated. Our previous studies have identified interleukin 6 (IL-6) as a potential mediator of mild TBIYinduced pathology. In the present study, we sought to determine the effects of brief hypoxia on mild TBI and whether IL-6 played a role in the neuroinflammatory and functional deficits after injury. A murine model of mild TBI was induced by a weight drop (500 g from 1.5 cm). After injury, mice were exposed to immediate hypoxia (FIO2 = 15.1%) or normoxia (FIO2 = 21%) for 30 min. Serum and brain samples were analyzed for inflammatory cytokines 24 h after TBI. Neuron-specific enolase was measured as a serum biomarker of brain injury. Evaluation of motor coordination was performed for 5 days after TBI using a rotarod device. In some animals, anti-IL-6 was administered following TBI and hypoxia to neutralize systemic IL-6. Mice undergoing TBI had significant increases in brain injury. Exposure to brief hypoxia after TBI resulted in a more than 5-fold increase in serum neuron-specific enolase. This increase was associated with increases in serum and brain cytokine expression, suggesting that brief hypoxia exacerbates systemic and brain inflammation. Neutralization of IL-6 suppressed postinjury neuroinflammation and neuronal injury. In addition, TBI and hypoxia induced significant motor coordination deficits that were completely abrogated by IL-6 blockade. Exposure to hypoxia after TBI induces neuroinflammation and brain injury. These changes can be mitigated by neutralization of systemic IL-6. Interleukin 6 blockade also corrected the TBI-induced deficit in motor coordination. These data suggest that systemic IL-6 modulates the degree of neuroinflammation and contributes to reduced motor coordination after mild TBI.	[Yang, Sung H.; Gangidine, Matt; Pritts, Timothy A.; Goodman, Michael D.; Lentsch, Alex B.] Univ Cincinnati, Inst Mil Med, Dept Surg, Cincinnati, OH 45267 USA		Lentsch, AB (corresponding author), Univ Cincinnati, Inst Mil Med, Dept Surg, 231 Albert Sabin Way,ML 0558, Cincinnati, OH 45267 USA.	alex.lentsch@uc.edu		Pritts, Timothy/0000-0003-2495-3255	US Air ForceUnited States Department of Defense [FA8650-10-2-6B01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM08478]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K08GM088589, T32GM008478] Funding Source: NIH RePORTER	This work was supported by US Air Force grant FA8650-10-2-6B01 and NIH training grant T32 GM08478.	Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Bauman RA, 2000, J NEUROTRAUM, V17, P679, DOI 10.1089/089771500415427; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Coronado Victor G, 2010, TRAUMATIC BRAIN INJU; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; DILLARD TA, 1995, CHEST, V107, P352, DOI 10.1378/chest.107.2.352; Dine CJ, 2008, CHEST, V133, P1002, DOI 10.1378/chest.07-1354; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Feng JF, 2012, J NEUROTRAUM, V29, P1167, DOI 10.1089/neu.2011.1867; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Goodman MD, 2011, J SURG RES, V165, P30, DOI 10.1016/j.jss.2010.05.055; Goodman MD, 2010, J SURG RES, V164, P286, DOI 10.1016/j.jss.2009.07.040; Grissom CK, 2006, J TRAUMA, V61, P461, DOI 10.1097/01.ta.0000221699.71596.9d; GRUBBS FE, 1969, TECHNOMETRICS, V11, P1, DOI 10.2307/1266761; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaSpina M, 2008, J SURG RES, V148, P121, DOI 10.1016/j.jss.2007.12.786; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075	25	75	76	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	DEC	2013	40	6					471	475		10.1097/SHK.0000000000000037			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	297IL	WOS:000330249000005	24088994	Green Accepted			2022-02-06	
J	Sours, C; Zhuo, JC; Janowich, J; Aarabi, B; Shanmuganathan, K; Gullapalli, RP				Sours, Chandler; Zhuo, Jiachen; Janowich, Jacqueline; Aarabi, Bizhan; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.			Default mode network interference in mild traumatic brain injury - A pilot resting state study	BRAIN RESEARCH			English	Article						Resting state fMRI; Mild traumatic brain injury; Working memory; Default mode network	NEUROPSYCHOLOGICAL ASSESSMENT METRICS; DIFFUSE AXONAL INJURY; WORKING-MEMORY LOAD; FUNCTIONAL CONNECTIVITY; HEAD-INJURY; COGNITIVE DEFICITS; EXECUTIVE CONTROL; TASK; PERFORMANCE; ATTENTION	In this study we investigated the functional connectivity in 23 Mild TBI (mTBI) patients with and without memory complaints using resting state fMRI in the sub-acute stage of injury as well as a group of control participants. Results indicate that mTBI patients with memory complaints performed significantly worse than patients without memory complaints on tests assessing memory from the Automated Neuropsychological Assessment Metrics (ANAM). Altered functional connectivity was observed between the three groups between the default mode network (DMN) and the nodes of the task positive network (TPN). Altered functional connectivity was also observed between both the TPN and DMN and nodes associated with the Salience Network (SN). Following mTBI there is a reduction in anti-correlated networks for both those with and without memory complaints for the DMN, but only a reduction in the anti-correlated network in mTBI patients with memory complaints for the TPN. Furthermore, an increased functional connectivity between the TPN and SN appears to be associated with reduced performance on memory assessments. Overall the results suggest that a disruption in the segregation of the DMN and the TPN at rest may be mediated through both a direct pathway of increased PC between various nodes of the TPN and DMN, and through an indirect pathway that links the TPN and DMN through nodes of the SN. This disruption between networks may cause a detrimental impact on memory functioning following mTBI, supporting the Default Mode Interference Hypothesis in the context of mTBI related memory deficits. (C) 2013 Elsevier B.V. All rights reserved.	[Sours, Chandler; Zhuo, Jiachen; Janowich, Jacqueline; Gullapalli, Rao P.] Univ Maryland, Sch Med, Magnet Resonance Res Ctr, Baltimore, MD 21201 USA; [Sours, Chandler; Zhuo, Jiachen; Janowich, Jacqueline; Shanmuganathan, Kathirkamanthan; Gullapalli, Rao P.] Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [Aarabi, Bizhan] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Sours, Chandler; Gullapalli, Rao P.] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA		Gullapalli, RP (corresponding author), Univ Maryland, Sch Med, Dept Diagnost Radiol & Nucl Med, 22 South Greene St, Baltimore, MD 21201 USA.	rgullapalli@umm.edu		Janowich, Jacqueline/0000-0003-3443-589X	DODUnited States Department of Defense [W81XWH-08-1-0725]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR019214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS081984] Funding Source: NIH RePORTER	The authors would like to thank Joshua Betz for his help with patient recruitment and George Makris and Steve Roys for their help with acquiring and processing the data. This study was supported by DOD award W81XWH-08-1-0725.	Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bluhm RL, 2011, HUM BRAIN MAPP, V32, P1029, DOI 10.1002/hbm.21090; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Calhoun VD, 2008, HUM BRAIN MAPP, V29, P828, DOI 10.1002/hbm.20581; Centers for Disease Control and Prevention, 2003, NAT CTR INJ PREV CON; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; D'Esposito M, 2007, PHILOS T R SOC B, V362, P761, DOI 10.1098/rstb.2007.2086; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Faul M, 2010, TRAUMATIC BRAIN INJU; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Hampson M, 2010, MAGN RESON IMAGING, V28, P1051, DOI 10.1016/j.mri.2010.03.021; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kasahara M, 2010, NEUROLOGY, V75, P168, DOI 10.1212/WNL.0b013e3181e7ca58; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M., 2000, COMPREHENSIVE NEUROP; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Reichle ME, 2010, TRENDS COGN SCI, V14, P180, DOI 10.1016/j.tics.2010.01.008; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Sonuga-Barke EJS, 2007, NEUROSCI BIOBEHAV R, V31, P977, DOI 10.1016/j.neubiorev.2007.02.005; Sporns O, 2011, ANN NY ACAD SCI, V1224, P109, DOI 10.1111/j.1749-6632.2010.05888.x; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Wu JT, 2011, NEUROSCI LETT, V504, P62, DOI 10.1016/j.neulet.2011.08.059; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	53	75	78	0	23	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 6	2013	1537						201	215		10.1016/j.brainres.2013.08.034			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	264XV	WOS:000327915200022	23994210	Green Accepted			2022-02-06	
J	Bobinski, L; Koskinen, LOD; Lindvall, P				Bobinski, Lukas; Koskinen, Lars-Owe D.; Lindvall, Peter			Complications following cranioplasty using autologous bone or polymethylmethacrylate-Retrospective experience from a single center	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Decompressive hemicraniectomy; Cranioplasty; Autologous bone; Polymethylmethacrylate; Complications	TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; DECOMPRESSIVE CRANIECTOMY; SURGICAL DECOMPRESSION; DELAYED CRANIOPLASTY; GRAFT INFECTION; PRESERVATION; INFARCTION; CHILDREN; SURGERY	Objective: A decompressive hemicraniectomy is a potentially life-saving intervention following head trauma. Once performed patients are obliged to undergo a second procedure with cranioplasty. Two of the most commonly used materials are autologous bone and polymethylmethacrylate (PMMA). We have now evaluated complications following a cranioplasty using these materials. Materials and methods: During a 7-year period (2002-2008) 49 patients were operated with a decompressive craniectomy following head trauma. Patients received a cranioplasty consisting of autologous bone (30 patients, 61.2%) or PMMA (19 patients, 38.8%) and were followed at least 24 months. Patient data were collected retrospectively. Results: Twenty patients (20/49, 40.8%) experienced a complication that prompted a re-operation. There was a significantly higher rate of complications leading to a re-operation (53.3% vs. 21.1%, p = 0.03) and a shorter survival time of the cranioplasty (mean 48.1 +/- 7.8 vs. 79.5 +/- 9.0 months, p = 0.035) in patients with autologous bone compared to PMMA. Bone resorption and the presence of postoperative hematomas were significantly more common in patients with autologous bone. The material used for cranioplasty was the only variable that significantly correlated to the rate of complications. Conclusions: In our series we had a high percentage of patients needing re-operation due to complications following a cranioplasty. Though generally considered a straightforward procedure, complications and associated morbidity in patients undergoing cranioplasty should not be underestimated. (C) 2013 Elsevier B.V. All rights reserved.	[Bobinski, Lukas; Koskinen, Lars-Owe D.; Lindvall, Peter] Univ Umea Hosp, Dept Pharmacol & Clin Neurosci, Div Neurosurg, S-90185 Umea, Sweden		Lindvall, P (corresponding author), Univ Umea Hosp, Dept Neurosurg, S-90185 Umea, Sweden.	peter_lindvall_nkk@hotmail.com	Koskinen, Lars-Owe/AAQ-8957-2020; Lindvall, Peter/AAK-1225-2020	Lindvall, Peter/0000-0002-9552-2957; Koskinen, Lars-Owe/0000-0003-3528-8502			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Blum KS, 1997, PEDIATR NEUROSURG, V26, P33, DOI 10.1159/000121158; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Grossman N., 2007, Cell and Tissue Banking, V8, P243, DOI 10.1007/s10561-006-9032-x; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	27	75	79	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	SEP	2013	115	9					1788	1791		10.1016/j.clineuro.2013.04.013			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	223EQ	WOS:000324787900039	23725651				2022-02-06	
J	Kageyama, H; Toyooka, T; Tsuzuki, N; Oka, K				Kageyama, Hiroshi; Toyooka, Terushige; Tsuzuki, Nobusuke; Oka, Kazunari			Nonsurgical treatment of chronic subdural hematoma with tranexamic acid Clinical article	JOURNAL OF NEUROSURGERY			English	Article						chronic subdural hematoma; tranexamic acid; fibrinolysis; kallikrein system; traumatic brain injury	LOCAL HYPERFIBRINOLYSIS; SPONTANEOUS RESOLUTION; FIBRINOLYSIS	Object. Chronic subdural hematoma (CSDH) is a common condition after head trauma. It can often be successfully treated surgically by inserting a bur hole and draining the liquefied hematoma. However, to the best of the authors' knowledge, for nonemergency cases not requiring surgery, no reports have indicated the best approach for preventing hematoma enlargement or resolving it completely. The authors hypothesized that hyperfibrinolysis plays a major role in liquefaction of the hematoma. Therefore, they evaluated the ability of an antifibrinolytic drug, tranexamic acid, to completely resolve CSDH compared with bur hole surgery alone. Methods. From 2007 to 2011, a total of 21 patients with CSDH seen consecutively at Kuki General Hospital, Japan, were given 750 mg of tranexamic acid orally every day. Patients were identified by a retrospective records review, which collected data on the volume of the hematoma (based on radiographic measurements) and any complications. Follow-up for each patient consisted of CT or MRI every 21 days from diagnosis to resolution of the CSDH. Results. Of the 21 patients, 3 with early stages of CSDH were treated by bur hole surgery before receiving medical therapy. The median duration of clinical and radiographic follow-up was 58 days (range 28-137 days). Before tranexamic acid therapy was initiated, the median hematoma volume for the 21 patients was 58.5 ml (range 7.5-223.2 ml); for the 18 patients who had not undergone surgery, the median hematoma volume was 55.6 ml (range 7.5-140.5 ml). After therapy, the median volume for all 21 patients was 3.7 ml (range 0-22.1 ml). No hematomas recurred or progressed. Conclusions. Chronic subdural hematoma can be treated with tranexamic acid without concomitant surgery. Tranexamic acid might simultaneously inhibit the fibrinolytic and inflammatory (kinin-kallikrein) systems, which might consequently resolve CSDH. This medical therapy could prevent the early stages of CSDH that can occur after head trauma and the recurrence of CSDH after surgery.	[Kageyama, Hiroshi; Toyooka, Terushige; Tsuzuki, Nobusuke; Oka, Kazunari] Kuki Gen Hosp, Dept Neurosurg, Kuki, Saitama 3460021, Japan; [Kageyama, Hiroshi] Juntendo Univ, Dept Neurosurg, Tokyo, Japan		Kageyama, H (corresponding author), Kuki Gen Hosp, Kamihayami 418-1, Kuki, Saitama 3460021, Japan.	kageyamahiroshi29@gmail.com					[Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; Ducloy-Bouthors AS, 2011, CRIT CARE, V15, DOI 10.1186/cc10143; Dunn CJ, 1999, DRUGS, V57, P1005, DOI 10.2165/00003495-199957060-00017; FUJISAWA H, 1995, J NEUROL NEUROSUR PS, V59, P388, DOI 10.1136/jnnp.59.4.388; Goksu E, 2009, ULUS TRAVMA ACIL CER, V15, P95; Harada K, 1989, Neurol Med Chir (Tokyo), V29, P113, DOI 10.2176/nmc.29.113; Horikoshi T, 1998, NEUROL MED-CHIR, V38, P527, DOI 10.2176/nmc.38.527; ITO H, 1976, J NEUROSURG, V45, P26, DOI 10.3171/jns.1976.45.1.0026; KASSELL NF, 1984, J NEUROSURG, V61, P225, DOI 10.3171/jns.1984.61.2.0225; KAWAKAMI Y, 1989, NEUROSURGERY, V25, P25, DOI 10.1227/00006123-198907000-00005; Ker K, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3054; NOMURA S, 1994, J NEUROSURG, V81, P910, DOI 10.3171/jns.1994.81.6.0910; Oh HJ, 2010, J KOREAN NEUROSURG S, V48, P518, DOI 10.3340/jkns.2010.48.6.518; SAITO K, 1989, J NEUROSURG, V70, P68, DOI 10.3171/jns.1989.70.1.0068; Suzuki M, 1998, ACTA NEUROCHIR, V140, P261, DOI 10.1007/s007010050093; YAMASHIMA T, 1983, J NEUROSURG, V59, P298, DOI 10.3171/jns.1983.59.2.0298	16	75	82	1	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2013	119	2					332	337		10.3171/2013.3.JNS122162			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	187CL	WOS:000322094400012	23641825				2022-02-06	
J	van der Horn, HJ; Spikman, JM; Jacobs, B; van der Naalt, J				van der Horn, Harm J.; Spikman, Jacoba M.; Jacobs, Bram; van der Naalt, Joukje			Postconcussive Complaints, Anxiety, and Depression Related to Vocational Outcome in Minor to Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Anxiety; Depression; Rehabilitation; Sex; Traumatic brain injuries; Work	MILD HEAD-INJURY; POST-CONCUSSIONAL SYNDROME; DSM-IV CRITERIA; PSYCHIATRIC-DISORDERS; RISK-FACTORS; MODERATE; EMPLOYMENT; ADULTS; RETURN; WORK	Objectives: To investigate the relation of postconcussive complaints, anxiety, and depression with vocational outcome in patients with traumatic brain injury (TBI) of various severities and to assess sex differences. Design: A prospective cross-sectional cohort study. Setting: Level I trauma center. Participants: Adults (N=242) with TBI of various severity. Interventions: Not applicable. Main Outcome Measures: Extended Glasgow Outcome Scale, return to work (RTW), Head Injury Symptom Checklist, and Hospital Anxiety and Depression Scale. Results: In 67% of the patients, complaints were present; 22% were anxious, and 18% were depressed. The frequency of complaints increased significantly with injury severity, in contrast to anxiety and depression. Frequencies of patients with anxiety and depression (9% and 5%) were lower with complete RTW than with incomplete RTW (42% and 37%; P<.001). Patients with minor TBI with complaints were more anxious (50% vs 27%; P<.05) and depressed (46% vs 23%; P<.05) compared with patients with other severity categories and patients with incomplete RTW (67% vs 36% and 60% vs 30%, respectively). A higher percentage of women with minor TBI were depressed (45% vs 13%; P=.01) and had incomplete RTW (50% vs 18%; P<.05) compared with men. Multiple regression analysis showed that injury severity, complaints, anxiety, and depression were all predictive of RTW (explained variance 45%). In all severity categories, anxiety and depression were predictive of RTW, complaints, and sex only for minor TBI. Conclusions: Anxiety and depression are related to vocational outcome after TBI, with a different profile in the minor TBI category, partly due to sex differences. Archives of Physical Medicine and Rehabilitation 2013;94:867-74 (C) 2013 by the American Congress of Rehabilitation Medicine	[van der Horn, Harm J.; Jacobs, Bram; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands; [Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neuropsychol, NL-9700 RB Groningen, Netherlands		van der Naalt, J (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, POB 30-001, NL-9700 RB Groningen, Netherlands.	j.van.der.naalt@umcg.nl		Spikman, Jacoba/0000-0002-6477-0763; van der Horn, Harm Jan/0000-0001-9923-0866; van der Naalt, Joukje/0000-0001-9873-2418			Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carroll E, 2011, NEUROPSYCHOL REHABIL, V21, P289, DOI 10.1080/09602011.2011.555972; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Guerin F, 2006, NEUROREHABILITATION, V21, P295; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Medley AR, 2010, NEUROPSYCHOL REHABIL, V20, P899, DOI 10.1080/09602011.2010.517688; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Spikman JM, 2010, J NEUROTRAUM, V27, P1195, DOI 10.1089/neu.2010.1277; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wallace CA, 2000, BRAIN INJURY, V14, P549; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	53	75	75	0	22	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2013	94	5					867	874		10.1016/j.apmr.2012.11.039			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	134HX	WOS:000318202100011	23220341				2022-02-06	
J	van Horn, JD; Irimia, A; Torgerson, CM; Chambers, MC; Kikinis, R; Toga, AW				van Horn, John Darrell; Irimia, Andrei; Torgerson, Carinna M.; Chambers, Micah C.; Kikinis, Ron; Toga, Arthur W.			Mapping Connectivity Damage in the Case of Phineas Gage	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SURFACE-BASED ANALYSIS; FUNCTIONAL CONNECTIVITY; FRONTOTEMPORAL DEMENTIA; EXECUTIVE DYSFUNCTION; UNCINATE FASCICULUS; PREFRONTAL CORTEX; NETWORK; LESIONS; GAGE,PHINEAS	White matter (WM) mapping of the human brain using neuroimaging techniques has gained considerable interest in the neuroscience community. Using diffusion weighted (DWI) and magnetic resonance imaging (MRI), WM fiber pathways between brain regions may be systematically assessed to make inferences concerning their role in normal brain function, influence on behavior, as well as concerning the consequences of network-level brain damage. In this paper, we investigate the detailed connectomics in a noted example of severe traumatic brain injury (TBI) which has proved important to and controversial in the history of neuroscience. We model the WM damage in the notable case of Phineas P. Gage, in whom a "tamping iron'' was accidentally shot through his skull and brain, resulting in profound behavioral changes. The specific effects of this injury on Mr. Gage's WM connectivity have not previously been considered in detail. Using computed tomography (CT) image data of the Gage skull in conjunction with modern anatomical MRI and diffusion imaging data obtained in contemporary right handed male subjects (aged 25-36), we computationally simulate the passage of the iron through the skull on the basis of reported and observed skull fiducial landmarks and assess the extent of cortical gray matter (GM) and WM damage. Specifically, we find that while considerable damage was, indeed, localized to the left frontal cortex, the impact on measures of network connectedness between directly affected and other brain areas was profound, widespread, and a probable contributor to both the reported acute as well as long-term behavioral changes. Yet, while significantly affecting several likely network hubs, damage to Mr. Gage's WM network may not have been more severe than expected from that of a similarly sized "average'' brain lesion. These results provide new insight into the remarkable brain injury experienced by this noteworthy patient.	[van Horn, John Darrell; Irimia, Andrei; Torgerson, Carinna M.; Chambers, Micah C.; Toga, Arthur W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuro Imaging LONI, Los Angeles, CA 90095 USA; [Kikinis, Ron] Harvard Univ, Brigham & Womens Hosp, Sch Med, Surg Planning Lab,Dept Radiol, Boston, MA 02115 USA		van Horn, JD (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuro Imaging LONI, Los Angeles, CA 90095 USA.	jvanhorn@loni.ucla.edu	Irimia, Andrei/B-8275-2008	Irimia, Andrei/0000-0002-9254-9388; Van Horn, John/0000-0003-1537-0816	NAMIC: Traumatic Brain Injury - Driving Biological Project [2U54EB005149-06]; Informatics Meta-Spaces for the Exploration of Human Neuroanatomy [1RC1MH088194]; Computational Anatomy and Multidimensional Modeling [P41RR013642]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR013642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [U54EB005149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RC1MH088194] Funding Source: NIH RePORTER	This work was supported by 2U54EB005149-06 "NAMIC: Traumatic Brain Injury - Driving Biological Project" to JVH, 1RC1MH088194 "Informatics Meta-Spaces for the Exploration of Human Neuroanatomy" to JVH, and P41RR013642 "Computational Anatomy and Multidimensional Modeling" to AWT. This work was performed as part of the Human Connectome Project (HCP; www.humanconnectomeproject.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarabi B, 2000, Neurosurg Focus, V8, pe1; Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Alstott J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000408; Aly M, 2011, BEHAV BRAIN RES, V225, P297, DOI 10.1016/j.bbr.2011.07.043; Baird AA, 2005, J COGNITIVE NEUROSCI, V17, P687, DOI 10.1162/0898929053467569; Bigelow HJ, 1850, AM J MED SCI, V20, P13; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Castellanos NP, 2011, NEUROIMAGE, V55, P1189, DOI 10.1016/j.neuroimage.2010.12.046; Chiang MC, 2011, NEUROIMAGE, V54, P2308, DOI 10.1016/j.neuroimage.2010.10.015; Clark L, 2004, NEUROCASE, V10, P398, DOI 10.1080/13554790490882799; Cobb S, 1940, ARCH INTERN MED, V66, P1341, DOI 10.1001/archinte.1940.00190180153011; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Damasio AR, DESCARTES ERROR; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Damoiseaux JS, 2009, HUM BRAIN MAPP, V30, P1051, DOI 10.1002/hbm.20563; de Haan W, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-101; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Dinov I, 2010, FRONT NEUROINFORM, V3, P1; Dinov I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013070; Dinov Ivo D, 2009, Front Neuroinform, V3, P22, DOI 10.3389/neuro.11.022.2009; Dunbar RIM, 2009, CORTEX, V45, P1119, DOI 10.1016/j.cortex.2009.05.005; Dupuy E, 1877, MED TIMES GAZ, Vii, P11; Falk D, 2005, SCIENCE, V308, P242, DOI 10.1126/science.1109727; Falk D, 2000, J HUM EVOL, V38, P695, DOI 10.1006/jhev.1999.0378; Ferrier D, 1878, Br Med J, V1, P443; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hagmann P, 2010, J NEUROSCI METH, V194, P34, DOI 10.1016/j.jneumeth.2010.01.014; Hamilton LS, 2008, NEUROREPORT, V19, P1705, DOI 10.1097/WNR.0b013e3283174415; Harlow J.M., 1993, PUBLICATIONS MASSACH, V4, P274, DOI [DOI 10.1177/0957154X9300401407, https://doi.org/10.1177/0957154X9300401407]; Harlow JM, 1848, BOSTON MED SURGICAL, V39, P389, DOI DOI 10.1056/NEJM184812130392001; Hasan KM, 2009, BRAIN RES, V1276, P67, DOI 10.1016/j.brainres.2009.04.025; Honey CJ, 2008, HUM BRAIN MAPP, V29, P802, DOI 10.1002/hbm.20579; Irimia A, 2012, NEUROIMAGE, V60, P1340, DOI 10.1016/j.neuroimage.2012.01.107; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Johnson CP, 2011, J INT NEUROPSYCH SOC, P1; Kaiser M, 2007, EUR J NEUROSCI, V25, P3185, DOI 10.1111/j.1460-9568.2007.05574.x; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Knake S, 2009, EPILEPTIC DISORD; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; Kubicki M, 2002, AM J PSYCHIAT, V159, P813, DOI 10.1176/appi.ajp.159.5.813; Lee DY, 2006, J NEUROPSYCH CLIN N, V18, P191, DOI 10.1176/appi.neuropsych.18.2.191; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; LIPSEY JR, 1983, BRIT J PSYCHIAT, V143, P266, DOI 10.1192/bjp.143.3.266; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; MacKenzie-Graham AJ, 2008, NEUROIMAGE, V42, P178, DOI 10.1016/j.neuroimage.2008.04.186; MACMILLAN M, 1992, BRAIN COGNITION, V19, P72, DOI 10.1016/0278-2626(92)90038-N; Macmillan M, 2000, ODD KIND FAME STORIE; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McDonald CR, 2005, J CLIN EXP NEUROPSYC, V27, P485, DOI 10.1080/13803390490520454; Newman MEJ, 2007, P NATL ACAD SCI USA, V104, P9564, DOI 10.1073/pnas.0610537104; Nobe MY, 2010, OPHTHAL PLAST RECONS, V26, P475, DOI 10.1097/IOP.0b013e3181cff655; Ordia JI, 2009, CLIN NEUROL NEUROSUR, V111, P368, DOI 10.1016/j.clineuro.2008.10.016; Ostry DJ, 1997, J SPEECH LANG HEAR R, V40, P1341, DOI 10.1044/jslhr.4006.1341; Pal D, 2011, CLIN NEUROL NEUROSUR; Pascual JM, 2009, ACTA NEUROCHIR, V151, P689, DOI 10.1007/s00701-009-0222-8; Phillips OR, 2009, SCHIZOPHR RES, V107, P30, DOI 10.1016/j.schres.2008.10.019; Picton TW, 2007, CEREB CORTEX, V17, P826, DOI 10.1093/cercor/bhk031; Pijnenburg YAL, 2008, CLIN NEUROPHYSIOL, V119, P1732, DOI 10.1016/j.clinph.2008.02.024; Ratiu P, 2004, J NEUROTRAUM, V21, P637, DOI 10.1089/089771504774129964; Ratiu PF, 2004, NEW ENGL J MED, V351, pE21, DOI 10.1056/NEJMicm031024; Rosen B, 2010, P ORG HUM BRAIN MAPP; Rothschild MA, 2000, INT J LEGAL MED, V113, P349; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Schoenemann PT, 2007, AM J PHYS ANTHROPOL, V132, P183, DOI 10.1002/ajpa.20499; Selvanathan S, 2007, J CLIN NEUROSCI, V14, P678, DOI 10.1016/j.jocn.2006.02.017; Shaw P, 2005, J COGNITIVE NEUROSCI, V17, P1410, DOI 10.1162/0898929054985491; Shields LBE, 1998, J FORENSIC SCI, V43, P1068; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sporns O, 2004, TRENDS COGN SCI, V8, P418, DOI 10.1016/j.tics.2004.07.008; Sporns O., 2011, NETWORKS BRAIN; Sporns O, 2011, ANN NY ACAD SCI, V1224, P109, DOI 10.1111/j.1749-6632.2010.05888.x; Stepanyants A, 2009, P NATL ACAD SCI USA, V106, P3555, DOI 10.1073/pnas.0810390106; Strangman GE, 2009, NEUROREHAB NEURAL RE, V23, P226, DOI 10.1177/1545968308324225; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Tononi G, 1999, P NATL ACAD SCI USA, V96, P3257, DOI 10.1073/pnas.96.6.3257; TUSA RJ, 1985, ANN NEUROL, V18, P583, DOI 10.1002/ana.410180512; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wilgus J, 2009, J HIST NEUROSCI, V18, P340, DOI 10.1080/09647040903018402; Zalesky A, 2011, BIOL PSYCHIAT, V69, P80, DOI 10.1016/j.biopsych.2010.08.022; Zhou J, 2010, BRAIN, V133, P1352, DOI 10.1093/brain/awq075	88	75	76	1	85	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2012	7	5			1				e37454	10.1371/journal.pone.0037454			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	959UR	WOS:000305341300116	22616011	Green Published, Green Submitted, gold			2022-02-06	
J	Thibaut, A; Bruno, MA; Chatelle, C; Gosseries, O; Vanhaudenhuyse, A; Demertzi, A; Schnakers, C; Thonnard, M; Charland-Verville, V; Bernard, C; Bahri, MA; Phillips, C; Boly, M; Hustinx, R; Laureys, S				Thibaut, Aurore; Bruno, Marie-Aurelie; Chatelle, Camille; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Demertzi, Athena; Schnakers, Caroline; Thonnard, Marie; Charland-Verville, Vanessa; Bernard, Claire; Bahri, Mohammed Ali; Phillips, Christophe; Boly, Melanie; Hustinx, Roland; Laureys, Steven			METABOLIC ACTIVITY IN EXTERNAL AND INTERNAL AWARENESS NETWORKS IN SEVERELY BRAIN-DAMAGED PATIENTS	JOURNAL OF REHABILITATION MEDICINE			English	Article; Proceedings Paper	Workshop on Consciousness and the Vegetative State - Today/2nd Conference on Consciousness and Coma	JUL 06, 2010	Salerno, ITALY			vegetative state; minimally conscious state; positron emission tomography; consciousness; self-awareness; traumatic brain injury	MINIMALLY CONSCIOUS STATE; VEGETATIVE STATE; CEREBRAL METABOLISM; POSTERIOR CINGULATE; DEFAULT NETWORK; DISORDERS; RECOVERY; INJURY; CONNECTIVITY; PERCEPTION	Objective: An extrinsic cerebral network (encompassing lateral frontoparietal cortices) related to external/sensory awareness and an intrinsic midline network related to internal/self-awareness have been identified recently. This study measured. brain metabolism in both networks in patients with severe brain damage. Design: Prospective [18F]-fluorodeoxyglucose-positron emission tomography and Coma Recovery Scale-Revised assessments in a university hospital setting. Subjects: Healthy volunteers and patients in vegetative state/unresponsive wakefulness syndrome (VS/UWS), minimally conscious state (MCS), emergence from MCS (EMCS), and locked-in syndrome (LIS). Results: A total of 70 patients were included in the study: 24 VS/UWS, 28 MCS, 10 EMCS, 8 LIS and 39 age-matched controls. VS/UWS showed metabolic dysfunction in extrinsic and intrinsic networks and thalami. MCS showed dysfunction mostly in intrinsic network and thalami. EMCS showed impairment in posterior cingulate/retrosplenial cortices. LIS showed dysfunction only in infratentorial regions. Coma Recovery Scale-Revised total scores correlated with metabolic activity in both extrinsic and part of the intrinsic network and thalami. Conclusion: Progressive recovery of extrinsic and intrinsic awareness network activity was observed in severely brain-damaged patients, ranging from VS/UWS, MCS, EMCS to LIS. The predominance of intrinsic network impairment in MCS could reflect altered internal/self-awareness in these patients, which is difficult to quantify at the bedside.	[Thibaut, Aurore; Bruno, Marie-Aurelie; Chatelle, Camille; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Demertzi, Athena; Schnakers, Caroline; Thonnard, Marie; Charland-Verville, Vanessa; Bahri, Mohammed Ali; Boly, Melanie; Laureys, Steven] Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Thibaut, Aurore; Bruno, Marie-Aurelie; Chatelle, Camille; Gosseries, Olivia; Vanhaudenhuyse, Audrey; Demertzi, Athena; Schnakers, Caroline; Thonnard, Marie; Charland-Verville, Vanessa; Bahri, Mohammed Ali; Boly, Melanie; Laureys, Steven] Univ Liege, Dept Neurol, B-4000 Liege, Belgium; [Bernard, Claire; Hustinx, Roland] Univ Hosp Liege, Dept Nucl Med, B-4000 Liege, Belgium		Laureys, S (corresponding author), Univ Liege, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium.	steven.laureys@ulg.ac.be	Laureys, Steven/A-3349-2011; Demertzi, Athena/I-1251-2019; Gosseries, Olivia/AAB-6469-2020; Laureys, Steven/AAN-2097-2021; Thibaut, Aurore/U-8101-2019; Vanhaudenhuyse, Audrey/AAP-2455-2020; Phillips, Christophe/M-3025-2017	Demertzi, Athena/0000-0001-8021-3759; Gosseries, Olivia/0000-0001-9011-7496; Laureys, Steven/0000-0002-3096-3807; Chatelle, Camille/0000-0002-7526-2107; Boly, Melanie/0000-0001-9584-0907; Phillips, Christophe/0000-0002-4990-425X			Alpert GF, 2008, J NEUROSCI, V28, P5344, DOI 10.1523/JNEUROSCI.5039-07.2008; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Baars BJ, 2003, TRENDS NEUROSCI, V26, P671, DOI 10.1016/j.tins.2003.09.015; Boly M, 2008, ANN NY ACAD SCI, V1129, P119, DOI 10.1196/annals.1417.015; Boly M, 2007, P NATL ACAD SCI USA, V104, P12187, DOI 10.1073/pnas.0611404104; Bornhovd K, 2002, BRAIN, V125, P1326, DOI 10.1093/brain/awf137; Bruno MA, 2011, PROG BRAIN RES, V193, P323, DOI 10.1016/B978-0-444-53839-0.00021-1; Bruno MA, 2011, NEUROCRIT CARE, V15, P447, DOI 10.1007/s12028-011-9547-2; Bruno MA, 2011, CURR OPIN CRIT CARE, V17, P146, DOI 10.1097/MCC.0b013e328343476d; Bruno MA, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-35; Cologan V, 2010, SLEEP MED REV, V14, P97, DOI 10.1016/j.smrv.2009.04.003; Dehaene S, 2001, COGNITION, V79, P1, DOI 10.1016/S0010-0277(00)00123-2; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Giacino JT, 1997, SEMIN NEUROL, V17, P105, DOI 10.1055/s-2008-1040919; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Goldberg II, 2006, NEURON, V50, P329, DOI 10.1016/j.neuron.2006.03.015; Gosseries O, 2011, NEUROREHABILITATION, V28, P3, DOI 10.3233/NRE-2011-0625; Graham DI, 2005, NEUROPSYCHOL REHABIL, V15, P198, DOI 10.1080/09602010443000452; Juengling FD, 2005, J NEUROL SCI, V228, P179, DOI 10.1016/j.jns.2004.11.052; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Knauff M, 2003, J COGNITIVE NEUROSCI, V15, P559, DOI 10.1162/089892903321662949; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2005, PROG BRAIN RES, V150, P495, DOI 10.1016/S0079-6123(05)50034-7; Laureys S, 2004, NEUROREHABILITATION, V19, P335; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2000, LANCET, V355, P1825, DOI 10.1016/S0140-6736(05)73084-1; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2007, CONSCIOUS COGN, V16, P722, DOI 10.1016/j.concog.2007.04.004; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lou HC, 2004, P NATL ACAD SCI USA, V101, P6827, DOI 10.1073/pnas.0400049101; Lull N, 2010, BRAIN INJURY, V24, P1098, DOI 10.3109/02699052.2010.494592; Machado C, 2010, NEUROLOGY, V74, P1156, DOI 10.1212/WNL.0b013e3181d5df0d; Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1; Majerus S, 2009, PROG BRAIN RES, V177, P49, DOI 10.1016/S0079-6123(09)17705-1; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Phillips CL, 2011, NEUROIMAGE, V56, P797, DOI 10.1016/j.neuroimage.2010.05.083; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rees G, 2007, PHILOS T R SOC B, V362, P877, DOI 10.1098/rstb.2007.2094; Schnakers C, 2008, J NEUROL, V255, P323, DOI 10.1007/s00415-008-0544-0; Schnakers C, 2006, ANN NEUROL, V60, P744, DOI 10.1002/ana.20919; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Sergent C, 2004, J PHYSIOL-PARIS, V98, P374, DOI 10.1016/j.jphysparis.2005.09.006; Shiel A, 2000, CLIN REHABIL, V14, P408, DOI 10.1191/0269215500cr326oa; Soddu A, 2011, HUM BRAIN MAPP  0411, DOI [10.1002/hbm.21249, DOI 10.1002/HBM.21249.]; Vanhaudenhuyse A, 2008, NEUROLOGY, V71, P1374, DOI 10.1212/01.wnl.0000320110.70134.60; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Vogt BA, 2005, PROG BRAIN RES, V150, P205, DOI 10.1016/S0079-6123(05)50015-3; Vogt BA, 2006, NEUROIMAGE, V29, P452, DOI 10.1016/j.neuroimage.2005.07.048; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	55	75	81	0	14	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAY	2012	44	6			SI		487	494		10.2340/16501977-0940			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	956TW	WOS:000305113000003	22366927	Green Submitted, gold, Green Published			2022-02-06	
J	Lin, KC; Niu, KC; Tsai, KJ; Kuo, JR; Wang, LC; Chio, CC; Chang, CP				Lin, Kao-Chang; Niu, Kuo-Chi; Tsai, Kuen-Jer; Kuo, Jinn-Rung; Wang, Liang-Chao; Chio, Chung-Ching; Chang, Ching-Ping			Attenuating inflammation but stimulating both angiogenesis and neurogenesis using hyperbaric oxygen in rats with traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; hyperbaric oxygen; gliosis; inflammation; angiogenesis; neurogenesis	LATERAL FLUID-PERCUSSION; NEURAL STEM-CELLS; MYELOPEROXIDASE ACTIVITY; MITOCHONDRIAL-FUNCTION; CEREBRAL-ISCHEMIA; WATER-MAZE; MODEL; THERAPY; MECHANISMS; APOPTOSIS	BACKGROUND: Inflammation, angiogenesis, neurogenesis, and gliosis are involved in traumatic brain injury (TBI). Several studies provide evidence supporting the neuroprotective effect of hyperbaric oxygen (HBO2) therapy in TBI. The aim of this study was to ascertain whether inflammation, angiogenesis, neurogenesis, and gliosis during TBI are affected by HBO2 therapy. METHODS: Rats were randomly divided into three groups: TBI + NBA (normobaric air: 21% O-2 at 1 absolute atmospheres), TBI + HBO2, and Sham operation + NBA. TBI + HBO2 rats received 100% O-2 at 2.0 absolute atmospheres for 1 hr/d for three consecutive days. Behavioral tests and biochemical and histologic evaluations were done 4 days after TBI onset. RESULTS: TBI + NBA rats displayed: (1) motor and cognitive dysfunction; (2) cerebral infarction and apoptosis; (3) activated inflammation (evidenced by increased brain myeloperoxidase activity and higher serum levels of tumor necrosis factor-alpha); (4) neuronal loss (evidenced by fewer NeuN-positive cells); and (5) gliosis (evidenced by more glial fibrillary protein-positive cells). In TBI + HBO2 rats, HBO2 therapy significantly reduced TBI-induced motor and cognitive dysfunction, cerebral infarction and apoptosis, activated inflammation, neuronal loss, and gliosis. In addition, HBO2 therapy stimulated angiogenesis (evidenced by more bromodeoxyuridine-positive endothelial and vascular endothelial growth factor-positive cells), neurogenesis (evidenced by more bromodeoxyuridine-NeuN double-positive and glial cells-derived neurotrophic factor-positive cells), and overproduction of interleukin-10 (an anti-inflammatory cytokine). CONCLUSIONS: Collectively, these results suggest that HBO2 therapy may improve outcomes of TBI in rats by inhibiting activated inflammation and gliosis while stimulating both angiogenesis and neurogenesis in the early stage. (J Trauma. 2012; 72: 650-659. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Lin, Kao-Chang; Niu, Kuo-Chi; Kuo, Jinn-Rung; Chio, Chung-Ching] So Taiwan Univ, Dept Biotechnol, Tainan, Taiwan; [Lin, Kao-Chang] Chi Mei Med Ctr, Dept Neurol, Tainan, Taiwan; [Wang, Liang-Chao] Natl Cheng Kung Univ, Grad Inst Clin Med, Sch Med, Tainan 70101, Taiwan; [Wang, Liang-Chao] Natl Cheng Kung Univ Hosp, Dept Surg, Neurosurg Serv, Tainan, Taiwan; [Kuo, Jinn-Rung; Chang, Ching-Ping] Chi Mei Med Ctr, Dept Neurosurg, Tainan, Taiwan		Chio, CC (corresponding author), Chi Mei Med Ctr, Dept Surg, Tainan, Taiwan.	liangcha@mail.ncku.edu.tw; mtlin@ym.edu.tw; jessica@mail.stut.edu.tw	Tsai, Kuen-Jer/AAZ-2714-2021; Tsai, Kuen-Jer/B-9393-2009	Tsai, Kuen-Jer/0000-0002-2170-9735; Tsai, Kuen-Jer/0000-0002-2170-9735; Chang, Ching-Ping/0000-0003-0890-9414	Taiwan National Science CouncilMinistry of Science and Technology, Taiwan [NSC99-2314-B-384-006-MY2, NSC99-2314-B-384-004-MY3, NSC98-2314-B-218-001-MY2]; Center of Excellence for Clinical Trial and Research in Neuroscience of the Taiwan Health Department [DOH99-TD-B-111-003]	Supported by the Taiwan National Science Council grant NSC99-2314-B-384-006-MY2, NSC99-2314-B-384-004-MY3, and NSC98-2314-B-218-001-MY2 and the Center of Excellence for Clinical Trial and Research in Neuroscience grant DOH99-TD-B-111-003 of the Taiwan Health Department.	Akin ML, 2002, UNDERSEA HYPERBAR M, V29, P279; Benson RM, 2003, CLIN EXP IMMUNOL, V134, P57, DOI 10.1046/j.1365-2249.2003.02248.x; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Calvert JW, 2003, J APPL PHYSIOL, V95, P2072, DOI 10.1152/japplphysiol.00630.2003; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Chio CC, 2007, SHOCK, V28, P284, DOI 10.1097/SHK.0b013e3180311e60; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Conti AC, 1998, J NEUROSCI, V18, P5663; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Feihl F, 2001, PHARMACOL THERAPEUT, V91, P179, DOI 10.1016/S0163-7258(01)00155-3; Gennarelli, 1998, Semin Clin Neuropsychiatry, V3, P160; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Kubes P, 2000, BRAIN PATHOL, V10, P127; Kuo JR, 2010, J TRAUMA, V69, P1467, DOI 10.1097/TA.0b013e3181f31b06; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Miljkovic-Lolic M, 2003, BRAIN RES, V971, P90, DOI 10.1016/S0006-8993(03)02364-3; MORENOFLORES MT, 1993, GLIA, V7, P146, DOI 10.1002/glia.440070204; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Nilsson OG, 1996, ACT NEUR S, V67, P45; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Quinones-Hinojosa A, 2006, J COMP NEUROL, V494, P415, DOI 10.1002/cne.20798; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Ren H, 2001, Chin J Traumatol, V4, P239; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tai PA, 2010, J NEUROTRAUM; Tinianow CL, 2000, BIOMED SCI INSTRUM, V395, P275; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wada K, 2000, ACT NEUR S, V76, P285; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; Wang Y, 1997, J NEUROSCI, V17, P4341; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	56	75	87	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2012	72	3					650	659		10.1097/TA.0b013e31823c575f			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	906TR	WOS:000301371100030	22491549				2022-02-06	
J	Yan, EB; Hellewell, SC; Bellander, BM; Agyapomaa, DA; Morganti-Kossmann, MC				Yan, Edwin B.; Hellewell, Sarah C.; Bellander, Bo-Michael; Agyapomaa, Doreen A.; Morganti-Kossmann, M. Cristina			Post-traumatic hypoxia exacerbates neurological deficit, neuroinflammation and cerebral metabolism in rats with diffuse traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; traumatic axonal injury; hypoxia; neurological deficit; cytokine; brain edema; ventricle; metabolism	TUMOR-NECROSIS-FACTOR; CLOSED-HEAD-INJURY; CORTICAL IMPACT INJURY; CEREBROSPINAL-FLUID; FACTOR-ALPHA; VENTRICULAR ENLARGEMENT; INFLAMMATORY RESPONSE; BARRIER PERMEABILITY; SECONDARY INSULTS; OXIDATIVE STRESS	Background: The combination of diffuse brain injury with a hypoxic insult is associated with poor outcomes in patients with traumatic brain injury. In this study, we investigated the impact of post-traumatic hypoxia in amplifying secondary brain damage using a rat model of diffuse traumatic axonal injury (TAI). Rats were examined for behavioral and sensorimotor deficits, increased brain production of inflammatory cytokines, formation of cerebral edema, changes in brain metabolism and enlargement of the lateral ventricles. Methods: Adult male Sprague-Dawley rats were subjected to diffuse TAI using the Marmarou impact-acceleration model. Subsequently, rats underwent a 30-minute period of hypoxic (12% O-2/88% N-2) or normoxic (22% O-2/78% N-2) ventilation. Hypoxia-only and sham surgery groups (without TAI) received 30 minutes of hypoxic or normoxic ventilation, respectively. The parameters examined included: 1) behavioural and sensorimotor deficit using the Rotarod, beam walk and adhesive tape removal tests, and voluntary open field exploration behavior; 2) formation of cerebral edema by the wet-dry tissue weight ratio method; 3) enlargement of the lateral ventricles; 4) production of inflammatory cytokines; and 5) real-time brain metabolite changes as assessed by microdialysis technique. Results: TAI rats showed significant deficits in sensorimotor function, and developed substantial edema and ventricular enlargement when compared to shams. The additional hypoxic insult significantly exacerbated behavioural deficits and the cortical production of the pro-inflammatory cytokines IL-6, IL-1 beta and TNF but did not further enhance edema. TAI and particularly TAI+Hx rats experienced a substantial metabolic depression with respect to glucose, lactate, and glutamate levels. Conclusion: Altogether, aggravated behavioural deficits observed in rats with diffuse TAI combined with hypoxia may be induced by enhanced neuroinflammation, and a prolonged period of metabolic dysfunction.	[Yan, Edwin B.; Hellewell, Sarah C.; Agyapomaa, Doreen A.; Morganti-Kossmann, M. Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Yan, Edwin B.; Morganti-Kossmann, M. Cristina] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Hellewell, Sarah C.; Agyapomaa, Doreen A.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia; [Bellander, Bo-Michael] Karolinska Univ Hosp, Sect Neurosurg, Dept Clin Neurosci, S-17176 Stockholm, Sweden		Morganti-Kossmann, MC (corresponding author), Alfred Hosp, Natl Trauma Res Inst, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@monash.edu		Hellewell, Sarah/0000-0002-2179-2209; Morganti-Kossmann, Cristina/0000-0002-0807-2063	National Health and Medical Research Council AustraliaNational Health and Medical Research Council of Australia; Victorian Neurotrauma Initiative	This study was supported by the National Health and Medical Research Council Australia and the Victorian Neurotrauma Initiative.	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ANDO Y, 1989, BRAIN RES, V477, P286, DOI 10.1016/0006-8993(89)91416-9; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Banks WA, 2010, NEUROBIOL DIS, V37, P26, DOI 10.1016/j.nbd.2009.07.031; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bauman RA, 2000, J NEUROTRAUM, V17, P679, DOI 10.1089/089771500415427; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bouzat P, 2011, CRIT CARE MED, V39, P2099, DOI 10.1097/CCM.0b013e31821cb7b2; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Carre E, 2004, J NEUROSCI METH, V140, P23, DOI 10.1016/j.jneumeth.2004.04.037; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gabrielian L, 2011, J NEUROTRAUMA; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gao GY, 2010, J CEREBR BLOOD F MET, V30, P628, DOI 10.1038/jcbfm.2009.235; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; Ghabriel M, 2004, PROCEEDINGS OF THE 7TH INTERNATIONAL NEUROTRAUMA SYMPOSIUM, P89; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hagberg H, 1996, PEDIATR RES, V40, P603, DOI 10.1203/00006450-199610000-00015; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Kim YJ, 2011, J CLIN NURS, V20, P1518, DOI 10.1111/j.1365-2702.2010.03618.x; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Macrez R, 2011, LANCET NEUROL, V10, P471, DOI 10.1016/S1474-4422(11)70066-7; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; MEYERS CA, 1983, J NEUROL NEUROSUR PS, V46, P1092, DOI 10.1136/jnnp.46.12.1092; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Moro N, 2011, NEUROSCI LETT, V491, P158, DOI 10.1016/j.neulet.2011.01.029; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Prieto R, 2011, BRAIN RES, V1404, P39, DOI 10.1016/j.brainres.2011.06.006; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; Robertson CL, 2000, CRIT CARE MED, V28, P3218, DOI 10.1097/00003246-200009000-00017; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; SILVERSTON P, 1989, BRIT MED J, V298, P711, DOI 10.1136/bmj.298.6675.711; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Sumbria RK, 2011, NEUROCHEM RES, V36, P109, DOI 10.1007/s11064-010-0276-2; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vaz R, 1998, ACTA NEUROCHIR, V140, P76, DOI 10.1007/s007010050061; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vespa PM, 2003, J CEREB BLOOD FLOW M, V23; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Xia WL, 2010, CLIN EXP PHARMACOL P, V37, P253, DOI 10.1111/j.1440-1681.2009.05279.x; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	115	75	80	0	12	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	OCT 28	2011	8								147	10.1186/1742-2094-8-147			16	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	849NK	WOS:000297132100001	22034986	Green Published, gold			2022-02-06	
J	Kamnaksh, A; Kovesdi, E; Kwon, SK; Wingo, D; Ahmed, F; Grunberg, NE; Long, J; Agoston, DV				Kamnaksh, Alaa; Kovesdi, Erzsebet; Kwon, Sook-Kyung; Wingo, Daniel; Ahmed, Farid; Grunberg, Neil E.; Long, Joseph; Agoston, Denes V.			Factors Affecting Blast Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavior; inflammation; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; INDUCED NEUROTRAUMA; CEREBRAL-ISCHEMIA; INFLAMMATION; NEUROPROTECTION; MECHANISMS; EXPRESSION; CYTOKINES; EXPOSURE; IMMUNE	The overlapping pathologies and functional outcomes of blast-induced TBI (bTBI) and stress-related neurobehavioral disorders like post-traumatic stress disorder (PTSD) are significant military health issues. Soldiers are exposed to multiple stressors with or without suffering bTBI, making diagnosis and treatment as well as experimental modeling of bTBI a challenge. In this study we compared anxiety levels of Naive rats to ones that were exposed to each of the following conditions daily for 4 consecutive days: C I: transportation alone; C II: transportation and anesthesia; C III: transportation, anesthesia, and blast sounds; Injured: all three variables plus mild blast overpressure. Following behavioral testing we analyzed sera and select brain regions for protein markers and cellular changes. C I, C II, and C III animals exhibited increased anxiety, but serum corticosterone levels were only significantly elevated in C III and Injured rats. C III and Injured animals also had elevated interferon-gamma (IFN-gamma) and interleukin-6 (IL-6) levels in the amygdala (AD) and ventral hippocampus (VHC). Glial fibrillary acidic protein (GFAP) levels were only significantly elevated in the VHC, prefrontal cortex (PFC), and AD of Injured animals; they showed an apparent increase in ionized calcium-binding adapter molecule (Iba1) and GFAP immunoreactivity, as well as increased numbers of TUNEL-positive cells in the VHC. Our findings demonstrate that experimental conditions, particularly the exposure to blast acoustics, can increase anxiety and trigger specific behavioral and molecular changes without injury. These findings should be taken into consideration when designing bTBI studies, to better understand the role of stressors in the development of post-traumatic symptoms, and to establish a differential diagnosis for PTSD and bTBI.	[Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Grunberg, Neil E.] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA; [Kamnaksh, Alaa; Kwon, Sook-Kyung; Ahmed, Farid; Grunberg, Neil E.; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Kovesdi, Erzsebet] US Dept Vet Affairs, Vet Affairs Cent Off, Washington, DC USA; [Long, Joseph] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurotrauma, Blast Induced Neurotrauma Branch, Silver Spring, MD USA		Agoston, DV (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.edu			Center for Neuroscience and Regenerative Medicine (CNRM)United States Department of Defense [G1703F]	We thank the Neurotrauma Team (WRAIR) for their technical help during the exposures. This work was supported by Center for Neuroscience and Regenerative Medicine (CNRM) grant no. G1703F.	Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Bannerman DM, 2004, NEUROSCI BIOBEHAV R, V28, P273, DOI 10.1016/j.neubiorev.2004.03.004; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; BLALOCK JE, 1989, PHYSIOL REV, V69, P1, DOI 10.1152/physrev.1989.69.1.1; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Breslau N, 2001, BIOL PSYCHIAT, V50, P699, DOI 10.1016/S0006-3223(01)01167-2; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Dancer A, 1998, SCAND AUDIOL, V27, P123; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Garcia-Bueno B, 2008, NEUROSCI BIOBEHAV R, V32, P1136, DOI 10.1016/j.neubiorev.2008.04.001; Guy RJ, 2004, J ROY SOC MED, V97, P255, DOI 10.1258/jrsm.97.5.255-a; Gyorgy A.B., 2010, J NEUROSCI METHODS; Haddad JJ, 2002, J NEUROIMMUNOL, V133, P1, DOI 10.1016/S0165-5728(02)00357-0; Holscher C, 2003, REV NEUROSCIENCE, V14, P253; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Keane TM, 2006, ANNU REV CLIN PSYCHO, V2, P161, DOI 10.1146/annurev.clinpsy.2.022305.095305; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kurz A, 1997, ANN NY ACAD SCI, V813, P778, DOI 10.1111/j.1749-6632.1997.tb51780.x; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Risling M., 2010, NEUROIMAGE; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Rosenstein JM, 2004, EXP NEUROL, V187, P246, DOI 10.1016/j.expneurol.2004.01.022; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saljo A, 2003, J NEUROTRAUM, V20, P787, DOI 10.1089/089771503767870014; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sorrells SF, 2009, NEURON, V64, P33, DOI 10.1016/j.neuron.2009.09.032; Stoll G, 2000, J NEURAL TRANSM-SUPP, P81; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Xiong LZ, 2003, ANESTH ANALG, V96, P233, DOI 10.1097/00000539-200301000-00047; Zhang HP, 2010, ANESTH ANALG, V111, P506, DOI 10.1213/ANE.0b013e3181e45519	46	75	76	1	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2145	2153		10.1089/neu.2011.1983			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500015	21861635				2022-02-06	
J	Schochl, H; Solomon, C; Traintinger, S; Nienaber, U; Tacacs-Tolnai, A; Windhofer, C; Bahrami, S; Voelckel, W				Schoechl, Herbert; Solomon, Cristina; Traintinger, Stefan; Nienaber, Ulrike; Tacacs-Tolnai, Astrid; Windhofer, Christian; Bahrami, Soheyl; Voelckel, Wolfgang			Thromboelastometric (ROTEM) Findings in Patients Suffering from Isolated Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; clotting time; maximum clot firmness; thromboelastometry	HEAD-INJURY; POSTINJURY COAGULOPATHY; FIBRINOGEN CONCENTRATE; MANAGEMENT; THROMBELASTOGRAPHY; HEMORRHAGE; LEVEL	Severe traumatic brain injury (sTBI) is often accompanied by coagulopathy and an increased risk of bleeding. To identify and successfully treat bleeding disorders associated with sTBI, rapid assessment of coagulation status is crucial. This retrospective study was designed to assess the potential role of whole-blood thromboelastometry (ROTEM (R), Tem International, Munich, Germany) in patients with isolated sTBI (abbreviated injury scale [AIS](head) >= 3 and AIS(extracranial) < 3). Blood samples were obtained immediately following admission to the emergency room of the Trauma Centre Salzburg in Austria. ROTEM analysis (EXTEM, INTEM, and FIBTEM tests) and standard laboratory coagulation tests (prothrombin time index [PTI, percentage of normal prothrombin time], activated partial thromboplastin time [aPTT], fibrinogen concentration, and platelet count) were compared between survivors and non-survivors. Out of 88 patients with sTBI enrolled in the study, 66 survived and 22 died. PTI, fibrinogen, and platelet count were significantly higher in survivors (p < 0.005). Accordingly, aPTT was shorter in this group (p < 0.0001). ROTEM analysis revealed shorter clotting times in extrinsically activated thromboelastometric test (EXTEM) and intrinsically activated thromboelastometric test (INTEM) (p < 0.001), shorter clot formation times in EXTEM and INTEM (p < 0.0001), and higher maximum clot firmness in EXTEM, INTEM, and FIBTEM (p < 0.01) in survivors compared with non-survivors. Logistic regression analysis revealed extrinsically activated thromboelastometric test with cytochalasin D (FIBTEM) MCF and aPTT to have the best predictive value for mortality. According to the degree of coagulopathy, non-survivors received more RBC (p = 0.016), fibrinogen concentrate (p = 0.01), and prothrombin complex concentrate (p < 0.001) within 24 h of arrival in the emergency room. ROTEM testing appeared to offer an early signal of severe life-threatening sTBI. Further studies are warranted to confirm these results and to investigate the role of ROTEM in guiding coagulation therapy.	[Schoechl, Herbert; Bahrami, Soheyl] Ludwig Boltzmann Inst Expt & Clin Traumatol, A-1200 Vienna, Austria; [Schoechl, Herbert; Bahrami, Soheyl] AUVA Res Ctr, Vienna, Austria; [Schoechl, Herbert; Solomon, Cristina; Traintinger, Stefan; Voelckel, Wolfgang] AUVA Trauma Ctr, Dept Anaesthesiol & Intens Care Med, Salzburg, Austria; [Tacacs-Tolnai, Astrid; Windhofer, Christian] AUVA Trauma Ctr, Dept Trauma Surg, Salzburg, Austria; [Solomon, Cristina] Salzburg Univ Hosp SALK, Dept Anaesthesiol Intens Care & Perioperat Med, Salzburg, Austria; [Nienaber, Ulrike] AUC Akad Unfallchirurg GmbH, Munich, Germany		Schochl, H (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, Donaueschingenstr 13, A-1200 Vienna, Austria.	herbert.schoechl@trauma.lbg.ac.at		Bahrami, Soheyl/0000-0002-4563-6251	CSL Behring; GlaxoSmithKlineGlaxoSmithKline; Tem International	Herbert Schochl has received speaker's fees from CSL Behring, GlaxoSmithKline, and Tem International. Cristina Solomon has received speaker's fees from CSL Behring and Tem International. All other authors declare that no competing financial interests exist. H.S. contributed to the design of the study, analysis of the results, interpretation of the data, and manuscript draft. Authors C.S., S.T., A.T., A.T.T., and C.W. were involved in drafting the manuscript. U.N. performed statistical analyses and contributed to the manuscript. H.R., S.B., and W.V. contributed to drafting and critically revising the manuscript. All authors read and approved the final manuscript.	Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Dzik Walter H, 2004, Curr Hematol Rep, V3, P324; Furtmuller R, 2002, J PHARMACOL EXP THER, V301, P168, DOI 10.1124/jpet.301.1.168; Gerlach R, 2002, STROKE, V33, P1618, DOI 10.1161/01.STR.0000017219.83330.FF; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Huissoud C, 2009, BJOG-INT J OBSTET GY, V116, P1097, DOI 10.1111/j.1471-0528.2009.02187.x; Johansson PI, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-45; Johansson PI, 2010, BLOOD COAGUL FIBRIN, V21, P168, DOI 10.1097/MBC.0b013e3283367882; Kashuk JL, 2010, ANN SURG, V252, P434, DOI 10.1097/SLA.0b013e3181f09191; Kashuk JL, 2010, ANN SURG, V251, P604, DOI 10.1097/SLA.0b013e3181d3599c; Kashuk JL, 2009, J SURG RES, V156, P133, DOI 10.1016/j.jss.2009.03.046; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Kitchens CS, 2005, J THROMB HAEMOST, V3, P2607, DOI 10.1111/j.1538-7836.2005.01552.x; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Kushimoto S, 2003, J NEUROTRAUM, V20, P357, DOI 10.1089/089771503765172318; Lang T, 2005, BLOOD COAGUL FIBRIN, V16, P301, DOI 10.1097/01.mbc.0000169225.31173.19; Luddington RJ, 2005, CLIN LAB HAEMATOL, V27, P81, DOI 10.1111/j.1365-2257.2005.00681.x; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Mann KG, 2003, ARTERIOSCL THROM VAS, V23, P17, DOI 10.1161/01.ATV.0000046238.23903.FC; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Rahe-Meyer N, 2009, BRIT J ANAESTH, V102, P785, DOI 10.1093/bja/aep089; Rahe-Meyer N, 2009, J THORAC CARDIOV SUR, V138, P694, DOI 10.1016/j.jtcvs.2008.11.065; Rossaint R., 1998, CRIT CARE MED, V26, P149; Rossaint R, 2010, CRIT CARE, V14, DOI 10.1186/cc8943; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Schochl H, 2010, NETH J CRIT CARE, V14, P23; Schochl H, 2010, CRIT CARE, V14, DOI 10.1186/cc8948; Schochl H, 2009, J TRAUMA, V67, P125, DOI 10.1097/TA.0b013e31818b2483; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Toulon P, 2009, THROMB HAEMOSTASIS, V101, P394, DOI 10.1160/TH08-06-0383; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; WAGNER C, 2000, LABOR DIAGNOSE, P613; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	39	75	77	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2033	2041		10.1089/neu.2010.1744			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500004	21942848				2022-02-06	
J	Alder, J; Fujioka, W; Lifshitz, J; Crockett, DP; Thakker-Varia, S				Alder, Janet; Fujioka, Wendy; Lifshitz, Jonathan; Crockett, David P.; Thakker-Varia, Smita			Lateral Fluid Percussion: Model of Traumatic Brain Injury in Mice	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Neuroscience; Issue 54; Lateral fluid percussion; hippocampus; traumatic brain injury; Morris Water Maze; mouse model of moderate injury	COGNITIVE IMPAIRMENT; RATS; MODULATION; NECROSIS; MOTOR	Traumatic brain injury (TBI) research has attained renewed momentum due to the increasing awareness of head injuries, which result in morbidity and mortality. Based on the nature of primary injury following TBI, complex and heterogeneous secondary consequences result, which are followed by regenerative processes (1,2). Primary injury can be induced by a direct contusion to the brain from skull fracture or from shearing and stretching of tissue causing displacement of brain due to movement (3,4). The resulting hematomas and lacerations cause a vascular response (3,5), and the morphological and functional damage of the white matter leads to diffuse axonal injury (6-8). Additional secondary changes commonly seen in the brain are edema and increased intracranial pressure (9). Following TBI there are microscopic alterations in biochemical and physiological pathways involving the release of excitotoxic neurotransmitters, immune mediators and oxygen radicals (10-12), which ultimately result in long-term neurological disabilities (13,14). Thus choosing appropriate animal models of TBI that present similar cellular and molecular events in human and rodent TBI is critical for studying the mechanisms underlying injury and repair. Various experimental models of TBI have been developed to reproduce aspects of TBI observed in humans, among them three specific models are widely adapted for rodents: fluid percussion, cortical impact and weight drop/impact acceleration (1). The fluid percussion device produces an injury through a craniectomy by applying a brief fluid pressure pulse on to the intact dura. The pulse is created by a pendulum striking the piston of a reservoir of fluid. The percussion produces brief displacement and deformation of neural tissue (1,15). Conversely, cortical impact injury delivers mechanical energy to the intact dura via a rigid impactor under pneumatic pressure (16,17). The weight drop/impact model is characterized by the fall of a rod with a specific mass on the closed skull (18). Among the TBI models, LFP is the most established and commonly used model to evaluate mixed focal and diffuse brain injury (19). It is reproducible and is standardized to allow for the manipulation of injury parameters. LFP recapitulates injuries observed in humans, thus rendering it clinically relevant, and allows for exploration of novel therapeutics for clinical translation (20). We describe the detailed protocol to perform LFP procedure in mice. The injury inflicted is mild to moderate, with brain regions such as cortex, hippocampus and corpus callosum being most vulnerable. Hippocampal and motor learning tasks are explored following LFP.	[Alder, Janet; Fujioka, Wendy; Crockett, David P.; Thakker-Varia, Smita] Univ Med & Dent, New Jersey Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, New Brunswick, NJ USA; [Lifshitz, Jonathan] Univ Kentucky, Chandler Med Ctr, Dept Phys Med & Rehabil, Dept Neurobiol & Anat, Lexington, KY 40506 USA		Thakker-Varia, S (corresponding author), Univ Med & Dent, New Jersey Robert Wood Johnson Med Sch, Dept Neurosci & Cell Biol, New Brunswick, NJ USA.	varia@umdnj.edu		Crockett, David Paul/0000-0002-8137-755X; Alder, Janet/0000-0002-5694-4946	New Jersey Commission on Brain Injury Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072611] Funding Source: NIH RePORTER	This work is funded by the New Jersey Commission on Brain Injury Research.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Brechot N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003950; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doll H, 2009, J NEUROTRAUM, V26, P235, DOI 10.1089/neu.2008.0741; Faden AI., 1994, NEUROBIOLOGY CENTRAL, P3; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HOVDA DA, 1990, ACT NEUR S, V51, P331; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; Lifshitz Jonathan, 2009, P369, DOI 10.1007/978-1-60327-185-1_32; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Whiting M.D., 2006, COGNITIVE IMPAIRMENT	30	75	75	2	4	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	AUG	2011		54							e3063	10.3791/3063			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V36MD	WOS:000209215100043	21876530	Bronze, Green Submitted, Green Published			2022-02-06	
J	Li, BY; Lingsma, HF; Steyerberg, EW; Lesaffre, E				Li, Baoyue; Lingsma, Hester F.; Steyerberg, Ewout W.; Lesaffre, Emmanuel			Logistic random effects regression models: a comparison of statistical packages for binary and ordinal outcomes	BMC MEDICAL RESEARCH METHODOLOGY			English	Article							LINEAR MIXED MODELS; TRAUMATIC BRAIN-INJURY; IMPACT DATABASE; DESIGN	Background: Logistic random effects models are a popular tool to analyze multilevel also called hierarchical data with a binary or ordinal outcome. Here, we aim to compare different statistical software implementations of these models. Methods: We used individual patient data from 8509 patients in 231 centers with moderate and severe Traumatic Brain Injury (TBI) enrolled in eight Randomized Controlled Trials (RCTs) and three observational studies. We fitted logistic random effects regression models with the 5-point Glasgow Outcome Scale (GOS) as outcome, both dichotomized as well as ordinal, with center and/or trial as random effects, and as covariates age, motor score, pupil reactivity or trial. We then compared the implementations of frequentist and Bayesian methods to estimate the fixed and random effects. Frequentist approaches included R (lme4), Stata (GLLAMM), SAS (GLIMMIX and NLMIXED), MLwiN (p[R]IGLS) and MIXOR, Bayesian approaches included WinBUGS, MLwiN (MCMC), R package MCMCglmm and SAS experimental procedure MCMC. Three data sets (the full data set and two sub-datasets) were analysed using basically two logistic random effects models with either one random effect for the center or two random effects for center and trial. For the ordinal outcome in the full data set also a proportional odds model with a random center effect was fitted. Results: The packages gave similar parameter estimates for both the fixed and random effects and for the binary (and ordinal) models for the main study and when based on a relatively large number of level-1 (patient level) data compared to the number of level-2 (hospital level) data. However, when based on relatively sparse data set, i.e. when the numbers of level-1 and level-2 data units were about the same, the frequentist and Bayesian approaches showed somewhat different results. The software implementations differ considerably in flexibility, computation time, and usability. There are also differences in the availability of additional tools for model evaluation, such as diagnostic plots. The experimental SAS (version 9.2) procedure MCMC appeared to be inefficient. Conclusions: On relatively large data sets, the different software implementations of logistic random effects regression models produced similar results. Thus, for a large data set there seems to be no explicit preference (of course if there is no preference from a philosophical point of view) for either a frequentist or Bayesian approach (if based on vague priors). The choice for a particular implementation may largely depend on the desired flexibility, and the usability of the package. For small data sets the random effects variances are difficult to estimate. In the frequentist approaches the MLE of this variance was often estimated zero with a standard error that is either zero or could not be determined, while for Bayesian methods the estimates could depend on the chosen "noninformative" prior of the variance parameter. The starting value for the variance parameter may be also critical for the convergence of the Markov chain.	[Li, Baoyue; Lesaffre, Emmanuel] Erasmus MC, Dept Biostat, Rotterdam, Netherlands; [Li, Baoyue; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Lesaffre, Emmanuel] Katholieke Univ Leuven, L Biostat, Leuven, Belgium		Lesaffre, E (corresponding author), Erasmus MC, Dept Biostat, Dr Molewaterpl 50, Rotterdam, Netherlands.	e.lesaffre@erasmusmc.nl	Steyerberg, Ewout/C-1509-2018	Steyerberg, Ewout/0000-0002-7787-0122			Austin PC, 2003, AM HEART J, V145, P27, DOI 10.1067/mhj.2003.23; Bates D, 2009, PACKAGE IME4; Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675; Browne W. J., 2009, MCMC ESTIMATION MLWI; Browne WJ, 2006, BAYESIAN ANAL, V1, P473, DOI 10.1214/06-BA117; DONALD H, 1996, COMPUTER METHODS PRO, V49, P157; Gelman A., 2003, BAYESIAN DATA ANAL, V2nd; Gelman A, 2006, BAYESIAN ANAL, V1, P515, DOI 10.1214/06-BA117A; GOLDSTEIN H, 1989, BIOMETRIKA, V76, P622; Goldstein H., 1995, MULTILEVEL STAT MODE; Guo G, 2000, ANNU REV SOCIOL, V26, P441, DOI 10.1146/annurev.soc.26.1.441; Hadfield JD, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i02; Lesaffre E, 2001, J ROY STAT SOC C-APP, V50, P325, DOI 10.1111/1467-9876.00237; Lin XH, 1996, J AM STAT ASSOC, V91, P1007, DOI 10.2307/2291720; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Molenberghs G., 2005, MODELS DISCRETE LONG; Ng ESW, 2006, STAT MODEL, V6, P23, DOI 10.1191/1471082X06st106oa; Pendergast JF, 1996, INT STAT REV, V64, P89, DOI 10.2307/1403425; Rabe-Hesketh S., 2004, GLLAMM MANUAL; Rasbash J., 2004, USERS GUIDE MLWIN VE; Rasbash J., WHAT ARE MULTILEVEL; RODRIGUEZ G, 1995, J ROY STAT SOC A STA, V158, P73, DOI 10.2307/2983404; Rodriguez G, 2003, STATA J, V3, P32, DOI 10.1177/1536867X0300300102; Snijders T. A., 2011, MULTILEVEL ANAL INTR; Spiegelhalter D, 2007, WINBUGS USER MANUAL; Spiegelhalter DJ, 2004, BAYESIAN APPROACHES; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Zhou XH, 1999, AM STAT, V53, P282, DOI 10.2307/2686112; COMP TIMINGS; 2009, NLMIXED PROCEDURE SA; CALLING WINBUGS 1 4; 2009, MCMC PROCEDURE SAS S; 2009, GLIMMIX PROCEDURE SA	35	75	77	2	55	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2288		BMC MED RES METHODOL	BMC Med. Res. Methodol.	MAY 23	2011	11								77	10.1186/1471-2288-11-77			11	Health Care Sciences & Services	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services	776JZ	WOS:000291531900001	21605357	gold, Green Published			2022-02-06	
J	Gosselin, N; Bottari, C; Chen, JK; Petrides, M; Tinawi, S; de Guise, E; Ptito, A				Gosselin, Nadia; Bottari, Carolina; Chen, Jen-Kai; Petrides, Michael; Tinawi, Simon; de Guise, Elaine; Ptito, Alain			Electrophysiology and Functional MRI in Post-Acute Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						electroencephalogram; neuropsychology; functional magnetic resonance imaging; mild traumatic brain injury	WORKING-MEMORY LOAD; SPORTS CONCUSSION; FRONTAL-CORTEX; AXONAL INJURY; HEAD-INJURY; SYMPTOMS; FMRI; ORGANIZATION; RECOVERY; ABNORMALITIES	Symptoms persisting beyond the acute phase (>2 months) after a mild traumatic brain injury (MTBI) are often reported, but their origin remains controversial. Some investigators evoke dysfunctional cerebral mechanisms, while others ascribe them to the psychological consequences of the injury. We address this controversy by exploring possible cerebral dysfunction with functional magnetic resonance imaging (fMRI) and event-related potentials (ERP) in a group of patients during the post-acute phase. Fourteen MTBI symptomatic patients (5.7 +/- 2.9 months post-injury) were tested with fMRI and ERP using a visual externally ordered working memory task, and were compared with 23 control subjects. Attenuated blood oxygen level dependent (BOLD) signal changes in the left and right mid-dorsolateral prefrontal cortex (mid-DLPFC), the putamen, the body of the caudate nucleus, and the right thalamus were found in the MTBI group compared with the control group. Moreover, symptom severity and BOLD signal changes were correlated: patients with more severe symptoms had lower BOLD signal changes in the right mid-DLPFC. For ERP, a group x task interaction was observed for N350 amplitude. A larger amplitude for the working memory task than for the control task was found in control subjects, but not in MTBI subjects, who had weak amplitudes for both tasks. This study confirms that persistent symptoms after MTBI cannot be uniquely explained by psychological factors, such as depression and/or malingering, and indicates that they can be associated with cerebral dysfunction. ERP reveals decreased amplitude of the N350 component, while fMRI demonstrates that the more severe the symptoms, the lower the BOLD signal changes in the mid-DLPFC.	[Gosselin, Nadia; Bottari, Carolina; Petrides, Michael; Ptito, Alain] Montreal Neurol Hosp & Inst, Cognit Neurosci Unit, Montreal, PQ H3A 2B4, Canada; [Gosselin, Nadia; Bottari, Carolina; Petrides, Michael; de Guise, Elaine; Ptito, Alain] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Tinawi, Simon; de Guise, Elaine; Ptito, Alain] McGill Univ, Montreal Gen Hosp, Ctr Hlth, Montreal, PQ H3G 1A4, Canada; [Chen, Jen-Kai] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON, Canada		Ptito, A (corresponding author), Montreal Neurol Hosp & Inst, Cognit Neurosci Unit, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	alain.ptito@mcgill.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Fonds pour la Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec	This study was supported by the Canadian Institutes of Health Research (grant to A. P. and M. P., and fellowships to N.G. and C. B.), and by the Fonds pour la Recherche en Sante du Quebec (fellowship to J.K.C.). The authors are grateful to Dr. Diane Diorio, Mitra Feyz, Isabel Roy, Dr. Gilles Lavigne, Kristina Martinu, Cindy Hovington, and Dr. Tomas Paus for their help to recruit subjects and/or for technical support. We would also like to thank the staff of the Magnetic Resonance Imaging Unit of the McConnell Brain Imaging Centre for their assistance.	ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bigler ED, 2009, J HEAD TRAUMA REHAB, V24, P76, DOI 10.1097/HTR.0b013e31819c2190; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; GOSSELIN N, 2009, TENN C MONTR CAN; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Lachapelle J, 2008, BRAIN INJURY, V22, P265, DOI 10.1080/02699050801938983; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Missonnier P, 2007, NEUROSCIENCE, V150, P346, DOI 10.1016/j.neuroscience.2007.09.009; Missonnier P, 2003, NEUROREPORT, V14, P1451, DOI 10.1097/00001756-200308060-00009; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Petrides M, 2005, PHILOS T ROY SOC B, V360, P781, DOI 10.1098/rstb.2005.1631; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; PETRIDES M, 1995, J NEUROSCI, V15, P359; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; Ptito A, 2007, NEUROREHABILITATION, V22, P217; SMITS M, 2008, HUM BRAIN MAPP; Talairach J., 1988, COPLANAR STEREOTACTI; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; YETERIAN EH, 1991, J COMP NEUROL, V312, P43, DOI 10.1002/cne.903120105	42	75	76	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2011	28	3					329	341		10.1089/neu.2010.1493			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	734WD	WOS:000288370600001	21309680				2022-02-06	
J	Dimoska-Di Marco, A; McDonald, S; Kelly, M; Tate, R; Johnstone, S				Dimoska-Di Marco, Aneta; McDonald, Skye; Kelly, Michelle; Tate, Robyn; Johnstone, Stuart			A meta-analysis of response inhibition and Stroop interference control deficits in adults with traumatic brain injury (TBI)	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Response inhibition; Interference control; Stroop task; Traumatic brain injury; Meta-analysis	CLOSED-HEAD-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; INFORMATION-PROCESSING DEFICITS; STOP-SIGNAL PROBABILITY; DIFFUSE AXONAL INJURY; WORKING-MEMORY LOAD; COLOR-WORD TEST; SUSTAINED ATTENTION; COGNITIVE CONTROL; ERROR-AWARENESS	The prominent clinical feature of behavioral impulsivity following traumatic brain injury (TBI) suggests impairment of frontal inhibitory control processes. This meta-analysis consolidates the recent surge in studies across two forms of oeffortfulo inhibition, employing well-defined paradigms of response inhibition (N = 20; i.e., go/no-go, sustained attention to response, stop-signal, Conners' continuous performance tasks) and response interference control (N = 21, i.e., Stroop color word tasks). Across 41 effect sizes involving 989 adults with mild to severe TBI and 969 controls, the overall effect of TBI on reduced inhibitory control was small to moderate (d = 0.3) and significant. The effect was larger in studies measuring response inhibition performance (d = 0.5), while Stroop interference control yielded a nonsignificant overall effect size (d = 0.05). Further analysis of the latter finding revealed a large effect size when Stroop task studies used the outcome measure ototal time on tasko (d = 1.4), but not oRT per trialo or onumber of stimulio (d = -0.8 and -0.9). Response speed in these tasks was impaired to a large degree (d = 0.96). Together these findings support a response inhibition deficit following TBI but suggest factors other than interference control, such as poor processing speed, fatigue, and underarousal, may underlie poor performance in Stroop tasks.	[Dimoska-Di Marco, Aneta; McDonald, Skye; Kelly, Michelle] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Tate, Robyn] Univ Sydney, Fac Med, No Clin Sch, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Johnstone, Stuart] Univ Wollongong, Sch Psychol, Wollongong, NSW, Australia		McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Mathews Bldg, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014; Kelly, Michelle/J-9739-2019	McDonald, Skye/0000-0003-0723-6094; Kelly, Michelle/0000-0003-0375-816X; Johnstone, Stuart/0000-0001-5380-9952			Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ARMILIO ML, 2003, THESIS U TORONTO TOR; Aron AR, 2005, BIOL PSYCHIAT, V57, P1285, DOI 10.1016/j.biopsych.2004.10.026; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Bedard AC, 2002, DEV NEUROPSYCHOL, V21, P93, DOI 10.1207/S15326942DN2101_5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Borenstein M., 2008, COMPREHENSIVE METAAN; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; Bush G, 1999, BIOL PSYCHIAT, V45, P1542, DOI 10.1016/S0006-3223(99)00083-9; Cabeza R, 1997, J NEUROSCI, V17, P391; Cantin JF, 2007, BRAIN INJURY, V21, P327, DOI 10.1080/02699050701209972; Chambers CD, 2006, J COGNITIVE NEUROSCI, V18, P444, DOI 10.1162/jocn.2006.18.3.444; Chambers CD, 2009, NEUROSCI BIOBEHAV R, V33, P631, DOI 10.1016/j.neubiorev.2008.08.016; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; COHEN J, 1988, STAT POWER ANAL BEHA, pR21; Conners CK., 1995, CONNERS CONTINUOUS P; de Zubicaray GI, 2000, NEUROPSYCHOLOGIA, V38, P1280, DOI 10.1016/S0028-3932(00)00033-6; DeHaan A, 2007, NEUROPSYCHOLOGIA, V45, P406, DOI 10.1016/j.neuropsychologia.2006.06.008; Dimoska A, 2008, BIOL PSYCHOL, V77, P324, DOI 10.1016/j.biopsycho.2007.11.005; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gagnon J, 2006, BRAIN INJURY, V20, P67, DOI 10.1080/02699050500309668; HALES MK, 1999, THESIS U UTAH UTAH; HALPERIN JM, 1994, ADV CH NEUR, V2, P1, DOI DOI 10.1007/978-1-4612-2608-6_; Hedges L.V., 1985, STAT METHODS META AN; Hunter J. E., 1990, METHODS METAANALYSIS; Incoccia C, 2004, CORTEX, V40, P111, DOI 10.1016/S0010-9452(08)70924-9; Johnstone SJ, 2005, J PSYCHOPHYSIOL, V19, P11, DOI 10.1027/0269-8803.19.1.11; Johnstone SJ, 2009, INT J PSYCHOPHYSIOL, V72, P145, DOI 10.1016/j.ijpsycho.2008.11.007; Kelly AMC, 2006, NEUROIMAGE, V31, P866, DOI 10.1016/j.neuroimage.2006.01.008; Kenemans JL, 1999, PHARMACOL BIOCHEM BE, V63, P589, DOI 10.1016/S0091-3057(99)00022-2; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Lansbergen MM, 2007, NEUROPSYCHOLOGY, V21, P251, DOI 10.1037/0894-4105.21.2.251; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1988, BRAIN COGNITION, V7, P283, DOI 10.1016/0278-2626(88)90003-6; Li CSR, 2006, NEUROIMAGE, V32, P1918, DOI 10.1016/j.neuroimage.2006.05.017; Logan G.D., 1994, ABILITY INHIBIT THOU; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Marsh NV, 1991, NEUROPSYCHOLOGY, V5, P107, DOI 10.1037/0894-4105.5.2.107; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; McDonald S., 2005, BRAIN IMPAIR, V6, P58, DOI [DOI 10.1375/BRIM.6.1.56.65481, 10.1375/brim.6.1.56.65481]; Milich R., 1994, DISRUPTIVE BEHAV DIS, P109, DOI 10.1007/978-1-4899-1501-6_5; Nee DE, 2007, COGN AFFECT BEHAV NE, V7, P1, DOI 10.3758/CABN.7.1.1; Nigg JT, 2000, PSYCHOL BULL, V126, P220, DOI 10.1037/0033-2909.126.2.220; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Park D.C., 2000, COGN AGING PRIM, V2000, P3; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD JL, 2000, NEUROPSYCHOLOGICAL A, P355; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Ramautar JR, 2004, BRAIN COGNITION, V56, P234, DOI 10.1016/j.bandc.2004.07.002; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Rosenberg MS, 2005, EVOLUTION, V59, P464, DOI 10.1111/j.0014-3820.2005.tb01004.x; Rubia K, 2001, NEUROIMAGE, V13, P250, DOI 10.1006/nimg.2000.0685; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schroeter ML, 2007, NEUROPSYCHOLOGIA, V45, P3149, DOI 10.1016/j.neuropsychologia.2007.07.004; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; Simpson A, 2000, NEUROPSYCHOLOGY, V14, P310, DOI 10.1037//0894-4105.14.2.310; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; Stewart JAL, 1999, BRAIN COGNITION, V41, P411, DOI 10.1006/brcg.1999.1141; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; Summers MJ, 2006, BRAIN INJURY, V20, P51, DOI 10.1080/02699050500309742; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; van den Wildenberg WPM, 2004, J EXP CHILD PSYCHOL, V87, P201, DOI 10.1016/j.jecp.2003.11.003; van Mourik R, 2005, J CHILD PSYCHOL PSYC, V46, P150, DOI 10.1111/j.1469-7610.2004.00345.x; Verbruggen F, 2005, ACTA PSYCHOL, V120, P307, DOI 10.1016/j.actpsy.2005.05.003; Wager TD, 2005, NEUROIMAGE, V27, P323, DOI 10.1016/j.neuroimage.2005.01.054; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	101	75	76	0	36	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2011	33	4					471	485	PII 932313901	10.1080/13803395.2010.533158			15	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	746SC	WOS:000289266300008	21229434	Green Submitted			2022-02-06	
J	Leonardi, AD; Bir, CA; Ritzel, DV; VandeVord, PJ				Leonardi, Alessandra Dal Cengio; Bir, Cynthia A.; Ritzel, Dave V.; VandeVord, Pamela J.			Intracranial Pressure Increases during Exposure to a Shock Wave	JOURNAL OF NEUROTRAUMA			English	Article						blast; improvised explosive device; intracranial pressure; overpressure; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; BLAST INJURY; TRANSMISSION; BRAIN; RAT	Traumatic brain injuries (TBI) caused by improvised explosive devices (IEDs) affect a significant percentage of surviving soldiers wounded in Iraq and Afghanistan. The extent of a blast TBI, especially initially, is difficult to diagnose, as internal injuries are frequently unrecognized and therefore underestimated, yet problems develop over time. Therefore it is paramount to resolve the physical mechanisms by which critical stresses are inflicted on brain tissue from blast wave encounters with the head. This study recorded direct pressure within the brains of male Sprague-Dawley rats during exposure to blast. The goal was to understand pressure wave dynamics through the brain. In addition, we optimized in vivo methods to ensure accurate measurement of intracranial pressure (ICP). Our results demonstrate that proper sealing techniques lead to a significant increase in ICP values, compared to the outside overpressure generated by the blast. Further, the values seem to have a direct relation to a rat's size and age: heavier, older rats had the highest ICP readings. These findings suggest that a global flexure of the skull by the transient shockwave is an important mechanism of pressure transmission inside the brain.	[Leonardi, Alessandra Dal Cengio; Bir, Cynthia A.; VandeVord, Pamela J.] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [Ritzel, Dave V.] Dyn FX Consulting Ltd, Amherstburg, ON, Canada		VandeVord, PJ (corresponding author), Wayne State Univ, Dept Biomed Engn, 818 W Hancock, Detroit, MI 48201 USA.	pvord@wayne.edu	VandeVord, Pamela/B-4606-2012	Bir, Cynthia/0000-0002-0777-0951	Department of DefenseUnited States Department of Defense [W81XWH-08-2-0207]; Office of Naval ResearchOffice of Naval Research [N00014-08-1-0585]	We would like to acknowledge the Department of Defense (award no. W81XWH-08-2-0207), and the Office of Naval Research (award no. N00014-08-1-0585) for funding this project.	Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; CELANDER H, 1954, ACTA PHYSL SCANDINAV, V33, P6; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; CLEMEDSON C, 1961, J APPL PHYSIOL, V16, P426, DOI 10.1152/jappl.1961.16.3.426; CLEMEDSON C, 1961, ACTA PHYSIOL SCAND, V51, P47, DOI 10.1111/j.1748-1716.1961.tb02112.x; CLEMEDSON CJ, 1956, ACTA PHYSL SCAND, V37, P204, DOI DOI 10.1111/J.1748-1716.1956.TB01356.X); COOPER GJ, 1991, J BIOMECH, V24, P273, DOI 10.1016/0021-9290(91)90346-O; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Guy R J, 2000, J R Nav Med Serv, V86, P27; Irwin RJ, 1997, J TRAUMA, V43, P650, DOI 10.1097/00005373-199710000-00015; LEONARDI AD, 2009, 2 JOINT S INT NAT NE; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; ROMBA JJ, 1961, 1761 US ARM ORDN HUM, P1; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; YOUNG MW, 1945, WAR MED, V8, P73	20	75	77	0	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2011	28	1					85	94		10.1089/neu.2010.1324			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	710DT	WOS:000286491800008	21091267				2022-02-06	
J	Ruff, RM				Ruff, Ronald M.			Mild traumatic brain injury and neural recovery: Rethinking the debate	NEUROREHABILITATION			English	Article							EMOTIONAL RISK-FACTORS; HEAD-INJURY; MISERABLE MINORITY; CONCUSSION; CLAIMANTS; SYMPTOMS; STRESS; MEMORY	A debate exists concerning whether a mild traumatic brain injury (MTBI) can cause permanent brain-based residuals. This debate is examined by reviewing meta-analytic studies that found no significant effect sizes between large samples of patients with and without MTBI at three months post-accident. In contrast, research studies with MTBI patients have captured cognitive deficits corroborated by positive neuroimaging, which supports the viewpoint that brain-based postconcussive disorders likely exist in a small minority of individuals. Ongoing hurdles that likely contribute to this debate are identified. This includes the lack of agreed upon definitions; substantial differences exist between the ICD-10 definition for Postconcussion Syndrome and the DSM-IV-TR definition for Postconcussional Disorder. Confining the debate to brain-based versus psychologically-based viewpoints results in a false dichotomy. Instead, a more refined sub-classification of the postconcussive complex is proposed that captures different constellations across the physical, emotional, and cognitive symptoms complex. Moreover, this diagnostic framework attempts to expand discipline-based approaches with a patient-based understanding.	San Francisco Clin Neurosci, San Francisco, CA 94109 USA		Ruff, RM (corresponding author), San Francisco Clin Neurosci, 909 Hyde St,Suite 620, San Francisco, CA 94109 USA.	ronruff@mindspring.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carroll Linda J., 2004, Journal of Rehabilitation Medicine Supplement, P113; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; *CDC INJ PREV, 2003, REP US C MILD TRAUM; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Echemendia R., 2006, SPORTS NEUROPSYCHOLO; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1981, NEUROPATHOLOGY, V7, P23; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M., 2008, MILD TRAUMATIC BRAIN; Nagin D.S., 2005, GROUP BASED MODELING; *NAT CTR HLTH STAT, 2003, 2000 NAT HOSP AMB ME; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Popper K., 1968, LOGIC SCI DISCOVERY, V4th; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff R. M., 1999, MILD HEAD INJURY CAU, P99; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruff R, 2009, J HEAD TRAUMA REHAB, V24, P131, DOI 10.1097/01.HTR.0000348755.42649.e9; Ruff RM, 2009, PSYCHOL INJ LAW, V2, P34, DOI 10.1007/s12207-009-9029-4; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Stuss Donald T, 2002, PRINCIPLES FRONTAL L; VARNEY NR, 1999, MILD HEAD INJURY CAU; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 2004, ICD 10 INT STAT CLAS; YATES OK, 2010, J INT NEUROPSYCHOGIC, V16, P953	56	75	76	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2011	28	3					167	180		10.3233/NRE-2011-0646			14	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	783MF	WOS:000292086600001	21558623				2022-02-06	
J	Vangel, SJ; Rapport, LJ; Hanks, RA				Vangel, Stephen J., Jr.; Rapport, Lisa J.; Hanks, Robin A.			Effects of Family and Caregiver Psychosocial Functioning on Outcomes in Persons With Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; craniocerebral trauma; chronic; family factors; predictors	SOCIAL SUPPORT; ASSESSMENT DEVICE; COPING STYLE; HEAD-INJURY; DISTRESS; REHABILITATION; SATISFACTION; DEPRESSION; CHILDREN; VALIDITY	Objectives: To examine the predictive value of caregiver/family status to well-being of persons with brain injury and to examine whether perceived social support to caregivers moderates their well-being. Participants: One hundred nine pairs of adults, a caregiver, and an individual with TBI. Main Measures: Brief Symptom Inventory-18, Satisfaction With Life Scale; Disability Rating Scale; Social Provision Scale, Family Assessment Device, and Disability Rating Scale. Results: Canonical correlation indicated the presence of a relationship between well-being in TBI and caregiver participants. Two canonical variates accounted for 47.5% variance. Poor psychological well-being among persons with TBI was associated with poor caregiver perceived social support and poor familial behavioral control. Individuals with high disability also had caregivers with poorer psychological well-being. In post hoc multiple regressions, caregiver/family psychosocial characteristics added unique prediction of outcome for individuals with TBI. Hierarchical multiple regressions provided evidence that social support of caregivers moderates outcome status for individuals with TBI. Conclusions: Future research efforts should focus on understanding of the specific mechanisms of reciprocal effects, to help design future therapy.	[Vangel, Stephen J., Jr.; Hanks, Robin A.] Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI 48201 USA; [Rapport, Lisa J.] Wayne State Univ, Dept Psychol, Detroit, MI 48201 USA		Vangel, SJ (corresponding author), Wayne State Univ, Dept Phys Med & Rehabil, Room 555,261 Mack Ave, Detroit, MI 48201 USA.	svangel@med.wayne.edu		Rapport, Lisa/0000-0001-8014-9523	National Institute on Disability and Rehabilitation Research [H133A080044]	This project was supported by the National Institute on Disability and Rehabilitation Research, grant H133A080044.	Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; BARAKAT LP, 1992, J PEDIATR PSYCHOL, V17, P725, DOI 10.1093/jpepsy/17.6.725; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Benton A., 1994, CONTRIBUTIONS NEUROP; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Carnes S.L., 2005, FAM SYST HEALTH, V23, P186, DOI DOI 10.1037/1091-7527.23.2.186; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; Cutrona CE, 1987, ADV PERSONAL RELATIO, V1; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; Delis DC., 2001, DELIS KAPLAN EXECUTI; Derogatis L. R., 1977, SCL 90 MANUAL 1 SCOR; Derogatis L.R, 2001, BRIEF SYMPTOM INVENT, V18; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Gerrard-Morris A, 2010, J INT NEUROPSYCH SOC, V16, P157, DOI 10.1017/S1355617709991135; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Heaton R.K., 1981, WISCONSIN CARD SORTI; Kabacoff R.I., 1990, J FAM PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Kaplan SP, 1991, CLIN NEUROPSYCHOL, V5, P360; KlOve H, 1963, MED CLIN N AM; Kosciulek JF, 1996, J REHABIL, V62, P49; Kosciulek JF, 1999, BRAIN INJURY, V13, P245, DOI 10.1080/026990599121610; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; MAITZ EA, 1995, J HEAD TRAUMA REHAB, V10, pR7; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Max JE, 1998, BRAIN INJURY, V12, P41; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Pelletier PM, 2000, BRAIN COGNITION, V44, P45; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan R, 1985, HALSTEAD REITAN NEUR; Ridenour TA, 1999, FAM PROCESS, V38, P497, DOI 10.1111/j.1545-5300.1999.00497.x; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; SANDER AM, 1999, REHABILITATION THEAD; Semlyen JK, 1998, J NEUROL REHABIL, V12, P53; Smith A., 1982, SYMBOL DIGIT MODALIT; STEWART D, 1968, PSYCHOL BULL, V70, P160, DOI 10.1037/h0026143; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Van Baalen B, 2007, BRAIN INJURY, V21, P925, DOI 10.1080/02699050701553197; Wechsler D., 1997, WECHSLER MEMORY SCAL; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; [No title captured]	51	75	75	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2011	26	1					20	29		10.1097/HTR.0b013e318204a70d			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	703GA	WOS:000285965200003	21209560				2022-02-06	
J	Senathi-Raja, D; Ponsford, J; Schonberger, M				Senathi-Raja, Dawn; Ponsford, Jennie; Schoenberger, Michael			Impact of Age on Long-Term Cognitive Function After Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						aging; neuropsychology; traumatic brain injury; brain plasticity; long-term outcome	PENETRATING HEAD-INJURY; CEREBRAL ATROPHY; DECLINE	Objective: To examine the association of age and time postinjury with cognitive outcome 5-22 years following traumatic brain injury (TBI), in relation to matched uninjured controls. Methods: One hundred twelve participants with mild to very severe TBI, aged 16-81 years at the time of injury, were cognitively assessed on measures of processing speed and attention, verbal and visual memory, executive function, and working memory. Results were compared with those of 112 healthy controls individually matched for current age, gender, education, and estimated IQ. Results: Older injured individuals performed worse than did younger injured individuals across all cognitive domains, after controlling for the performance of controls. In relation to matched controls, long-time survivors performed disproportionately worse than did more recently injured individuals, irrespective of age. Conclusions: After maximum spontaneous recovery from TBI, poorer cognitive functioning appears to be associated with both older age at the time of injury and increased time postinjury. These findings have implications for prognosis, early treatment recommendations, and long-term issues of differential diagnosis and management planning.	[Senathi-Raja, Dawn; Ponsford, Jennie; Schoenberger, Michael] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3800, Australia; [Ponsford, Jennie; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia		Ponsford, J (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3800, Australia.	Jennie.Ponsford@med.monash.edu.au					AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; BADDELEY A, 1994, DOORS PEOPLE; Barnet V., 1978, OUTLIERS STAT DATA; Benton AL, 1994, MULTILINGUAL APHASIA; Burgess P.W., 1997, HAYLING BRIXTON TEST; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cohen J., 2013, STAT POWER ANAL BEHA; CORKIN S, 1989, J NEUROSCI, V9, P3876; Goleburn CR, 2001, J CLIN GEROPSYCHOL, V7, P161; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Kolb B., 1995, BRAIN PLASTICITY BEH; Lezak MD, 1976, NEUROPSYCHOLOGICAL A; Luebke JI, 2003, J COMP NEUROL, V460, P573, DOI 10.1002/cne.10668; OCONNOR P, 1999, TRAUMATIC BRAIN INJU; PORTEUS SD, 1933, PORTEUS MAZES SCORIN; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Raz N, 2006, NEUROSCI BIOBEHAV R, V30, P730, DOI 10.1016/j.neubiorev.2006.07.001; REITAN RM, 1988, HALTEADREITAN NEUROP; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Scahill RI, 2003, ARCH NEUROL-CHICAGO, V60, P989, DOI 10.1001/archneur.60.7.989; Shimada A, 1999, NEUROBIOL AGING, V20, P125, DOI 10.1016/S0197-4580(99)00044-5; SHORES A, 1986, MED J AUSTRALIA, V144, P569; Smith, 1973, SYMBOL DIGIT MODALIT; Terry RD, 2001, NEUROBIOL AGING, V22, P347, DOI 10.1016/S0197-4580(00)00250-5; TEUBER H-L, 1975, P159; Volkow ND, 1998, ANN NEUROL, V44, P143, DOI 10.1002/ana.410440125; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WechslerD, 2001, WECHSLER TEST ADULT; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553	32	75	77	1	18	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2010	24	3					336	344		10.1037/a0018239			9	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	587IW	WOS:000276985500006	20438211				2022-02-06	
J	Sun, D; Bullock, MR; Altememi, N; Zhou, ZW; Hagood, S; Rolfe, A; McGinn, MJ; Hamm, R; Colello, RJ				Sun, Dong; Bullock, M. Ross; Altememi, Nabil; Zhou, Zhengwen; Hagood, Sarah; Rolfe, Andrew; McGinn, Melissa J.; Hamm, Robert; Colello, Raymond J.			The Effect of Epidermal Growth Factor in the Injured Brain after Trauma in Rats	JOURNAL OF NEUROTRAUMA			English	Article						epidermal growth factor; hippocampus; Morris water maze; neurogenesis; subventricular zone; traumatic brain injury	FACTOR RECEPTOR EXPRESSION; LONG-TERM POTENTIATION; DENTATE GYRUS; ENHANCED NEUROGENESIS; SUBVENTRICULAR ZONE; CELL-PROLIFERATION; COGNITIVE RECOVERY; STEM-CELLS; ADULT RATS; IN-VIVO	Epidermal growth factor (EGF) is a known mitogen for neural stem and progenitor cells (NS/NPCs) in the central nervous system (CNS). In vitro, EGF maintains NS/NPCs in the proliferative state, whereas in the normal rodent brain it promotes their proliferation and migration in the subventricular zone (SVZ). Additionally, EGF administration can augment neuronal replacement in the ischemic-injured adult striatum. Recently we found that the SVZ and the hippocampus display an injury-induced proliferative response following traumatic brain injury (TBI) that is linked to increased EGF expression. As adult neurogenesis is associated with cognitive function, we hypothesized that post-TBI administration of EGF could affect neurogenesis and cognitive recovery. Adult rats were intraventricularly infused with EGF or vehicle for 7 days following TBI. 5-Bromo-2-deoxyuridine (BrdU) was administered to label proliferating cells and the animals were sacrificed at 1 or 4 weeks post-injury. Using immunohistochemistry and stereology, we found that at 1 week post-injury, compared to vehicle-infused animals EGF-infused animals had significantly more BrdU-positive cells in the SVZ and hippocampus concomitant with enhanced EGF receptor expression. At 4 weeks post-injury, the number of BrdU-positive cells in the hippocampus was similar in both groups, suggesting that EGF does not support long-term survival of newly generated cells. Furthermore, we found that the EGF-induced proliferative population differentiated preferentially toward astroglial phenotype. Nevertheless, animals treated with EGF showed significant improvement in cognitive function, which was accompanied by reduced hippocampal neuronal cell loss. Collectively, the data from this study demonstrate that EGF exerts a neuroprotective rather than neurogenic effect in protecting the brain from injury.	[Sun, Dong; Bullock, M. Ross; Altememi, Nabil; Zhou, Zhengwen; Hagood, Sarah; Rolfe, Andrew] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [McGinn, Melissa J.; Colello, Raymond J.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Hamm, Robert] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23298 USA		Sun, D (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, POB 980631,Med Coll Virginia Campus, Richmond, VA 23298 USA.	dsun@vcu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055086]; Virginia Commonwealth University Department of Anatomy; NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463, R01NS055086] Funding Source: NIH RePORTER	This study was funded by the National Institutes of Health Grant no. NS055086 (to D. S.). The photomicrography for this study was performed at the Virginia Commonwealth University Department of Anatomy and Neurobiology Microscopy Facility, which is supported in part by funding from NIH-NINDS center core grant 5P30NS047463.	ABE K, 1992, NEUROSCI RES, V14, P117, DOI 10.1016/0168-0102(92)90087-S; ABE K, 1992, BRAIN RES, V593, P335, DOI 10.1016/0006-8993(92)91332-9; Aberg MAI, 2000, J NEUROSCI, V20, P2896; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Burrows RC, 1997, NEURON, V19, P251, DOI 10.1016/S0896-6273(00)80937-X; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.3.CO;2-E; CASPER D, 1995, J NEUROCHEM, V65, P1016; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Close JL, 2006, GLIA, V54, P94, DOI 10.1002/glia.20361; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Craig CG, 1996, J NEUROSCI, V16, P2649; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dayer AG, 2003, J COMP NEUROL, V460, P563, DOI 10.1002/cne.10675; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Enwere E, 2004, J NEUROSCI, V24, P8354, DOI 10.1523/JNEUROSCI.2751-04.2004; Gheusi C, 2000, P NATL ACAD SCI USA, V97, P1823, DOI 10.1073/pnas.97.4.1823; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Gritti A, 1999, J NEUROSCI, V19, P3287; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Imayoshi I, 2008, NAT NEUROSCI, V11, P1153, DOI 10.1038/nn.2185; ISHIYAMA J, 1991, NEUROSCI RES, V12, P403, DOI 10.1016/0168-0102(91)90071-6; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Kuruba R, 2009, EPILEPSY BEHAV, V14, P65, DOI 10.1016/j.yebeh.2008.08.020; Laskowski A, 2005, BRAIN RES, V1037, P78, DOI 10.1016/j.brainres.2004.12.035; Lillien L, 1998, MOL CELL NEUROSCI, V10, P296, DOI 10.1006/mcne.1997.0659; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; MINTURN JE, 1995, J COMP NEUROL, V355, P369, DOI 10.1002/cne.903550304; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Ninomiya M, 2006, NEUROSCI LETT, V403, P63, DOI 10.1016/j.neulet.2006.04.039; Parent JM, 1997, J NEUROSCI, V17, P3727; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Peng H, 1998, J CEREBR BLOOD F MET, V18, P349, DOI 10.1097/00004647-199804000-00002; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; SEROOGY KB, 1995, BRAIN RES, V670, P157, DOI 10.1016/0006-8993(94)01300-7; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Teramoto T, 2003, J CLIN INVEST, V111, P1125, DOI 10.1172/JCI200317170; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Trouche S, 2009, P NATL ACAD SCI USA, V106, P5919, DOI 10.1073/pnas.0811054106; TUCKER MS, 1993, BRAIN RES, V631, P65, DOI 10.1016/0006-8993(93)91187-W; Wong RWC, 2003, CELL MOL LIFE SCI, V60, P113, DOI 10.1007/s000180300007	44	75	78	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					923	938		10.1089/neu.2009.1209			16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400014	20158379	Green Published			2022-02-06	
J	Pandey, DK; Yadav, SK; Mahesh, R; Rajkumar, R				Pandey, Dilip Kumar; Yadav, Sushil Kumar; Mahesh, Radhakrishnan; Rajkumar, Ramamoorthy			Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: A model of comorbid depression and anxiety?	BEHAVIOURAL BRAIN RESEARCH			English	Article						Traumatic brain injury; Comorbid; Depression; Anxiety; Behavioural test battery; Escitalopram	SEROTONIN REUPTAKE INHIBITOR; OLFACTORY BULBECTOMIZED RAT; MARBLE-BURYING BEHAVIOR; ELEVATED PLUS-MAZE; MAJOR DEPRESSION; ANIMAL-MODELS; AMYGDALOID-LESIONS; SOCIAL-INTERACTION; SEXUAL-BEHAVIOR; HEAD-INJURY	Depression and anxiety tend to be the most prevalent conditions among the multitude of neurobehavioural disorders which cause distress in the survivors of traumatic brain injury (TBI) The objective of the present investigation was to examine depression-like and anxiety-like behaviour of rats following diffuse TBI Impact accelerated TBI was induced in anaesthetised rats by a modified weight drop method. TBI and sham-operated rats received either a chronic (14 days) regimen of escitalopram (5-20 mg/kg) or vehicle, following which they were subjected to a behavioural test battery. The results evince the depression-like behaviour of TBI rats in modified open field exploration. hyperemotionality. socio-sexual interaction and elevated plus-maze exploration paradigms. In addition. an anxiety-like behaviour was evident in social interaction and marble-burying tests Chronic escitalopram (10 and 20 mg/kg) treatment significantly attenuated the TBI associated behavioural deficits. In conclusion, the aforesaid behavioural anomalies observed in TBI rats are analogous to comorbid anxiety and depression in humans. These findings substantiate the TBI rats as a candidate model of comorbid anxiety and depression. (C) 2009 Elsevier B V All rights reserved.	[Pandey, Dilip Kumar; Mahesh, Radhakrishnan; Rajkumar, Ramamoorthy] Birla Inst Technol & Sci, Pharm Grp, FD III, Pilani 333031, Rajasthan, India; [Yadav, Sushil Kumar] Birla Inst Technol & Sci, Cent Anim Facil, Pilani 333031, Rajasthan, India		Rajkumar, R (corresponding author), Natl Univ Singapore, Dept Pharmacol, Yong Loo Lin Sch Med, Ctr Life Sci, Level 4,28 Med Dr, Singapore 117456, Singapore.	rajkumar.sai@gmail.com	Rajkumar, Ramamoorthy/M-8135-2014	Rajkumar, Ramamoorthy/0000-0002-8047-7524	Council of Scientific and Industrial ResearchCouncil of Scientific & Industrial Research (CSIR) - India	The authors thank Glenmark Pharmaceuticals Limited, India for providing escitalopram as a generous gift sample in short notice. Pandey DK wishes to thank the Council of Scientific and Industrial Research for partly funding this work.	*AM PSYCH ASS, 2000, TEXT REV, P780; Andrews G, 2000, B WORLD HEALTH ORGAN, V78, P446; Aquilani R, 2003, ARCH PHYS MED REHAB, V84, P1258, DOI 10.1016/S0003-9993(03)00148-5; Bareggi SR, 2007, EXPERT OPIN DRUG MET, V3, P741, DOI 10.1517/17425225.3.5.741; BRITTON A, 1988, BRAIN INJURY, V12, P703; BROEKKAMP CL, 1986, EUR J PHARMACOL, V126, P223, DOI 10.1016/0014-2999(86)90051-8; Carre E, 2004, J NEUROSCI METH, V140, P23, DOI 10.1016/j.jneumeth.2004.04.037; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; DENENBERG VH, 1969, ANN NY ACAD SCI, V159, P852, DOI 10.1111/j.1749-6632.1969.tb12983.x; EDWARDS DA, 1990, PHYSIOL BEHAV, V48, P447, DOI 10.1016/0031-9384(90)90342-2; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; File S E, 1990, Drug Des Deliv, V5, P195; FILE SE, 1978, BRIT J PHARMACOL, V62, P19, DOI 10.1111/j.1476-5381.1978.tb07001.x; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; GOMITA Y, 1984, PHYSIOL BEHAV, V32, P1011, DOI 10.1016/0031-9384(84)90294-4; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; Ho YJ, 2002, BEHAV BRAIN RES, V136, P1, DOI 10.1016/S0166-4328(02)00089-X; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; HOWLAND RH, 2002, J PSYCHIAT, V329, P891; ICHIMARU Y, 1995, JPN J PHARMACOL, V68, P65, DOI 10.1254/jjp.68.65; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JOSEPH AB, 1995, J HEAD TRAUMA REHAB, V10, P90, DOI 10.1097/00001199-199504000-00010; KARLOVSKY ME, 2007, ACQUIRED BRAIN INJUR, P64; Kelly JP, 1997, PHARMACOL THERAPEUT, V74, P299, DOI 10.1016/S0163-7258(97)00004-1; Kennedy Sidney H, 2008, Dialogues Clin Neurosci, V10, P271; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; KING FA, 1958, SCIENCE, V128, P655, DOI 10.1126/science.128.3325.655; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; LIGHTOWLER S, 1994, PHARMACOL BIOCHEM BE, V49, P281, DOI 10.1016/0091-3057(94)90422-7; LIJIMA M, 2007, PROG NEUROPSYCHOPHAR, V31, P622; Malin Paulajo, 2004, Expert Rev Neurother, V4, P769, DOI 10.1586/14737175.4.5.769; Markel A L, 1989, Neurosci Behav Physiol, V19, P279, DOI 10.1007/BF01236015; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; MEYERSON BJ, 1981, ACTA PHARMACOL TOX, V48, P168; Michelson A M, 1988, Free Radic Res Commun, V4, P209, DOI 10.3109/10715768809055145; Mohamed Somaia, 2006, Am J Geriatr Pharmacother, V4, P201, DOI 10.1016/j.amjopharm.2006.08.001; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; O'Neil MF, 2003, HUM PSYCHOPHARM CLIN, V18, P239, DOI 10.1002/hup.496; OCONNOR WT, 1988, PROG NEURO-PSYCHOPH, V12, P41, DOI 10.1016/0278-5846(88)90060-7; Olie JP, 2007, DEPRESS ANXIETY, V24, P318, DOI 10.1002/da.20207; Pandey DK, 2008, J PHARM PHARMACOL, V60, P1643, DOI 10.1211/jpp/60.12.0010; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Pinheiro SN, 2008, J PSYCHOPHARMACOL, V22, P132, DOI 10.1177/0269881107079866; Primeaux SD, 1999, PHYSIOL BEHAV, V67, P41, DOI 10.1016/S0031-9384(99)00027-X; RAITT JR, 1961, BRIT J PHARM CHEMOTH, V17, P473, DOI 10.1111/j.1476-5381.1961.tb01134.x; Rajkumar R, 2009, EUR J PHARMACOL, V608, P32, DOI 10.1016/j.ejphar.2009.02.041; Ramamoorthy R, 2008, BEHAV PHARMACOL, V19, P29, DOI 10.1097/FBP.0b013e3282f3cfd4; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Riggio S, 2009, MT SINAI J MED, V76, P163, DOI 10.1002/msj.20097; Rodgers RJ, 1997, BEHAV PHARMACOL, V8, P477, DOI 10.1097/00008877-199711000-00003; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Sanchez C, 2003, PSYCHOPHARMACOLOGY, V167, P353, DOI 10.1007/s00213-002-1364-z; SHIBATA S, 1982, PHYSIOL BEHAV, V28, P289, DOI 10.1016/0031-9384(82)90077-4; SHIBATA S, 1984, PHARMACOL BIOCHEM BE, V21, P225, DOI 10.1016/0091-3057(84)90219-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Stamouli S, 2008, EUR PSYCHIAT, V23, pS207, DOI 10.1016/j.eurpsy.2008.01.342; Starkstein SE, 2002, NEUROREHABILITATION, V17, P105; Stein DJ, 2006, EUR NEUROPSYCHOPHARM, V16, P33, DOI 10.1016/j.euroneuro.2005.05.004; Stein MB, 2008, LANCET, V371, P1115, DOI 10.1016/S0140-6736(08)60488-2; Sziray N, 2007, BRAIN RES BULL, V71, P376, DOI 10.1016/j.brainresbull.2006.10.006; TREIT D, 1981, PHARMACOL BIOCHEM BE, V15, P619, DOI 10.1016/0091-3057(81)90219-7; Uday G, 2007, EUR J PHARMACOL, V563, P155, DOI 10.1016/j.ejphar.2007.02.016; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Wade A, 2002, INT CLIN PSYCHOPHARM, V17, P95, DOI 10.1097/00004850-200205000-00001; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Wang DY, 2007, BEHAV BRAIN RES, V178, P262, DOI 10.1016/j.bbr.2007.01.003; Waugh J, 2003, CNS DRUGS, V17, P343, DOI 10.2165/00023210-200317050-00004; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P133, DOI 10.1080/09602010244000417; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zafonte RD, 2002, J HEAD TRAUMA REHAB, V17, P322, DOI 10.1097/00001199-200208000-00006	94	75	77	2	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	DEC 28	2009	205	2					436	442		10.1016/j.bbr.2009.07.027			7	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology	512MI	WOS:000271253100017	19660499				2022-02-06	
J	Brady, KM; Shaffner, DH; Lee, JK; Easley, RB; Smielewski, P; Czosnyka, M; Jallo, GI; Guerguerian, AM				Brady, Ken M.; Shaffner, Donald H.; Lee, Jennifer K.; Easley, R. Blaine; Smielewski, Peter; Czosnyka, Marek; Jallo, George I.; Guerguerian, Anne-Marie			Continuous Monitoring of Cerebrovascular Pressure Reactivity After Traumatic Brain Injury in Children	PEDIATRICS			English	Article						traumatic brain injury; cerebrovascular pressure reactivity; autoregulation	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; BLOOD-FLOW; WAVE-FORM; AUTOREGULATION; AGE; METABOLISM	OBJECTIVE: We hypothesized that pressure reactivity index (PRx) values indicating preserved cerebrovascular pressure autoregulation would be associated with survival in children with traumatic brain injury (TBI). This hypothesis was tested in a prospective, blinded, observational, pilot study. METHODS: Twenty-one children admitted between May 2006 and September 2008 with severe TBI necessitating invasive intracranial pressure monitoring were enrolled in this study. The PRx was continuously monitored as a moving, linear correlation coefficient between low-frequency waves of intracranial and arterial blood pressures. Positive values of PRx approaching 1 indicate impaired cerebrovascular pressure reactivity, whereas negative PRx values or values close to 0 indicate preserved cerebrovascular pressure reactivity. Survival was the primary outcome and was compared with the average PRx value obtained during the intracranial pressure-monitoring period. RESULTS: PRx was associated with survival in this cohort; survivors (N = 15) had a mean PRx +/- SD of 0.08 +/- 0.19, and nonsurvivors (N = 6) had a mean PRx of 0.69 +/- 0.21 (P = .0009). In this sample, continuous PRx monitoring suggested impaired cerebrovascular pressure reactivity at low levels of cerebral perfusion pressure (CPP) and intact cerebrovascular pressure reactivity at higher levels of CPP. CONCLUSIONS: Intact cerebrovascular pressure reactivity quantified with the PRx is associated with survival after severe head trauma in children. The PRx is CPP dependent in children. The PRx may be useful for defining age-specific and possibly patient-specific optimal targets for CPP after TBI. Pediatrics 2009; 124: e1205-e1212	[Brady, Ken M.] Johns Hopkins Univ, Div Pediat Anesthesiol & Crit Care Med, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; [Jallo, George I.] Johns Hopkins Univ, Dept Neurosurg, Sch Med, Baltimore, MD 21287 USA; [Smielewski, Peter; Czosnyka, Marek] Addenbrookes Hosp, Dept Acad Neurosurg, Cambridge, England; [Guerguerian, Anne-Marie] Hosp Sick Children, Dept Crit Care, Toronto, ON M5G 1X8, Canada; [Guerguerian, Anne-Marie] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada		Brady, KM (corresponding author), Johns Hopkins Univ, Div Pediat Anesthesiol & Crit Care Med, Sch Med, Dept Anesthesiol & Crit Care Med, 600 N Wolfe St,Blalock 904, Baltimore, MD 21287 USA.	kbrady5@jhmi.edu		SHAFFNER, DONALD/0000-0001-5530-0746; Smielewski, Peter/0000-0001-5096-3938	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0001237, G9439390] Funding Source: UKRI; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237, G0600986] Funding Source: Medline		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; GUILLAUME J, 1951, REV NEUROL, V84, P131; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LASSEN NA, 1959, PHYSIOL REV, V39, P183, DOI 10.1152/physrev.1959.39.2.183; Martin JA, 2008, PEDIATRICS, V121, P788, DOI 10.1542/peds.2007-3753; Mokri B, 2001, NEUROLOGY, V56, P1746, DOI 10.1212/WNL.56.12.1746; Monro A., 1823, OBSERVATIONS STRUCTU; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; [No title captured]	30	75	75	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	DEC	2009	124	6					E1205	E1212		10.1542/peds.2009-0550			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	524SE	WOS:000272162400049	19948619				2022-02-06	
J	Hayhurst, C; Byrne, P; Eldridge, PR; Mallucci, CL				Hayhurst, Caroline; Byrne, Patricia; Eldridge, Paul R.; Mallucci, Conor L.			Application of electromagnetic technology to neuronavigation: a revolution in image-guided neurosurgery Technical note	JOURNAL OF NEUROSURGERY			English	Article						frameless neuronavigation; electromagnetic neuronavigation; magnetic field	IDIOPATHIC INTRACRANIAL HYPERTENSION; FRAMELESS STEREOTAXY; SYSTEM; NEUROENDOSCOPY; NAVIGATION; PLACEMENT; ACCURACY; FIXATION	Object. The authors investigated the practicality of electromagnetic neuronavigation in routine clinical use, and determined the applications for which it is at the advantage compared with other systems. Methods. A magnetic field is generated encompassing the surgical volume. Devices containing miniaturized coils can be located within the field. The authors report on their experience in 150 cases performed with this technology. Results. Electromagnetic neuronavigation was performed in 44 endoscopies, 42 ventriculoperitoneal shunt insertions for slit ventricles, 21 routine shunt insertions, 6 complex shunt insertions, 14 external ventricular drain placements for traumatic brain injury, 5 awake craniotomies, 5 Ommaya reservoir placements, and for 13 other indications. Satisfactory positioning of ventricular catheters was achieved in all cases. No particular changes to the operating theater set-up were required, and no significant interference from ferromagnetic instruments was experienced. Neurophysiological monitoring was not affected, nor did it affect electromagnetic guidance. Conclusions. Neuronavigation enables safe, accurate surgery, and may ultimately reduce complications and improve outcome. Electromagnetic technology allows frameless, pinless, image-guided surgery, and can be used in all procedures for which neuronavigation is appropriate. This technology was found to be particularly advantageous compared with other technologies in cases in which freedom of head movement was helpful. Electromagnetic neuronavigation was therefore well suited to CSF diversion procedures, awake craniotomies, and cases in which rigid head fixation was undesirable, such as in neonates. This technology extends the application of neuronavigation to routine shunt placement and ventricular catheter placement in patients with traumatic brain injury. (DOI: 10.3171/2008.12.JNS08628)	[Hayhurst, Caroline; Byrne, Patricia; Eldridge, Paul R.] Walton Ctr Neurol & Neurosurg, Dept Neurosurg, Liverpool L9 7LJ, Merseyside, England; [Mallucci, Conor L.] Royal Liverpool Childrens Hosp, Dept Neurosurg, Liverpool L7 7DG, Merseyside, England		Hayhurst, C (corresponding author), Walton Ctr Neurol & Neurosurg, Dept Neurosurg, Lower Lane Fazakerley, Liverpool L9 7LJ, Merseyside, England.	carolinehayhurst@hotmail.com		Mallucci, Conor/0000-0002-5509-0547			Abu-Serieh B, 2007, NEUROSURGERY, V60, P1039, DOI 10.1227/01.NEU.0000255456.12978.31; Azeem SS, 2007, NEUROSURGERY, V60, P243, DOI 10.1227/01.NEU.0000255387.03088.53; Barazi SA, 2006, BRIT J NEUROSURG, V20, P43, DOI 10.1080/02688690600598554; Benardete EA, 2001, NEUROSURGERY, V49, P1409, DOI 10.1097/00006123-200112000-00020; Broggi G, 2000, ACTA NEUROCHIR, V142, P893, DOI 10.1007/s007010070075; Karabatsou K, 2004, ACTA NEUROCHIR, V146, P1193, DOI 10.1007/s00701-004-0392-3; KATO A, 1991, J NEUROSURG, V74, P845, DOI 10.3171/jns.1991.74.5.0845; Kestle JRW, 2003, J NEUROSURG, V98, P284, DOI 10.3171/jns.2003.98.2.0284; Leuthardt EC, 2002, STEREOT FUNCT NEUROS, V79, P256, DOI 10.1159/000070839; Mascott CR, 2005, NEUROSURGERY, V57, P295, DOI 10.1227/01.NEU.0000176411.55324.1E; Mayberg Marc R, 2005, Neurosurg Focus, V19, pE10; Reavey-Cantwell JF, 2006, J NEUROSURG, V104, P392, DOI 10.3171/ped.2006.104.6.392; Rosenow JM, 2007, STEREOT FUNCT NEUROS, V85, P75, DOI 10.1159/000097922; Rousu JS, 1998, ST HEAL T, V50, P103; SAINTEROSE C, 1992, PEDIATR NEUROSURG, V17, P2, DOI 10.1159/000120557; Schicho K, 2005, PHYS MED BIOL, V50, P2089, DOI 10.1088/0031-9155/50/9/011; Schroeder HWS, 2001, J NEUROSURG, V94, P72, DOI 10.3171/jns.2001.94.1.0072; Tirakotai W, 2004, CHILD NERV SYST, V20, P790, DOI 10.1007/s00381-004-0932-4; Vougioukas VI, 2003, CHILD NERV SYST, V19, P783, DOI 10.1007/s00381-003-0836-8; Woodworth GF, 2005, STEREOT FUNCT NEUROS, V83, P12, DOI 10.1159/000084059; Zaaroor M, 2001, NEUROSURGERY, V48, P1100, DOI 10.1097/00006123-200105000-00027	21	75	79	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2009	111	6					1179	1184		10.3171/2008.12.JNS08628			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	529CM	WOS:000272493300011	19326991				2022-02-06	
J	Garay, L; Deniselle, MCG; Meyer, M; Costa, JJL; Lima, A; Roig, P; DeNicola, AF				Garay, Laura; Gonzalez Deniselle, Maria Claudia; Meyer, Maria; Lopez Costa, Juan Jose; Lima, Analia; Roig, Paulina; DeNicola, Alejandro F.			Protective effects of progesterone administration on axonal pathology in mice with experimental autoimmune encephalomyelitis	BRAIN RESEARCH			English	Article						Axon; Axonoprotection; Experimental autoimmune encephalomyelitis; Growth-associated protein; Progesterone	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; GAP-43 EXPRESSION; STEROID-HORMONES; MOUSE MODEL; PREGNANCY; RAT; ESTROGEN	Experimental autoimmune encephalomyelitis (EAE), an induced model of Multiple Sclerosis presents spinal cord demyelination, axonal pathology and neuronal dysfunction. Previous work has shown that progesterone attenuated the clinical severity, demyelination and neuronal dysfunction of EAE mice (Garay et al., J. Steroid Biochem. Mol. Biol., 2008). Here we studied if progesterone also prevented axonal damage, a main cause of neurological disability. To this end, some axonal parameters were compared in EAE mice pretreated with progesterone a week before immunization with MOG(40-54) and in a group of steroid-free EAE mice. On day 16th after EAE induction, we determined in both groups and in control mice: a) axonal density in semithin sections of the spinal cord ventral funiculus; b) appearance of amyloid precursor protein (APP) immunopositive spheroids as an index of damaged axons; c) levels of the growth associated protein GAP43 mRNA and immunopositive cell bodies, as an index of aberrant axonal sprouting. Steroid-naive EAE mice showed decreased axonal density, shrunken axons, abundance of irregular vesicular structures, degenerating APP+ axons, increased expression of GAP43 mRNA and immunoreactive protein in motoneurons. Instead, EAE mice receiving progesterone treatment showed increased axonal counts, high proportion of small diameter axons, reduced APP+ profiles, and decreased GAP43 expression. In conclusion, progesterone enhanced axonal density, decreased axonal damage and prevented GAP43 hyperexpression in the spinal cord of EAE mice. Thus, progesterone also exerts protective effects on the axonal pathology developing in EAE mice. (C) 2009 Elsevier B.V. All rights reserved.	[DeNicola, Alejandro F.] Inst Biol & Med Expt, CONICET, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; [Garay, Laura; Gonzalez Deniselle, Maria Claudia; DeNicola, Alejandro F.] Univ Buenos Aires, Fac Med, Dept Human Biochem, RA-1053 Buenos Aires, DF, Argentina; [Lopez Costa, Juan Jose] Univ Buenos Aires, Fac Med, Inst Biol Celular & Neurociencias, RA-1053 Buenos Aires, DF, Argentina; [DeNicola, Alejandro F.] Fdn HA Barcelo, Inst Univ Ciencias Salud, Buenos Aires, DF, Argentina		DeNicola, AF (corresponding author), Inst Biol & Med Expt, CONICET, Lab Neuroendocrine Biochem, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	denicola@dna.uba.ar			FONCYTFONCyT [PICT 2004 25610, PICT 2007-01044]; National Research Council of ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [PIP 5542, PIP 112-200801-00542]; University of Buenos AiresUniversity of Buenos Aires [M016]	We thank the following institutions for financial support: FONCYT (PICT 2004 25610 and PICT 2007-01044), the National Research Council of Argentina (CONICET, PIP 5542 and PIP 112-200801-00542), and the University of Buenos Aires (M016). The assistance of Mariana Lopez Ravasio with the preparation of semithin sections is gratefully acknowledged.	Ayers MM, 2004, NEUROCHEM INT, V45, P409, DOI 10.1016/j.neuint.2003.08.018; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Bebo BF, 2001, J IMMUNOL, V166, P2080, DOI 10.4049/jimmunol.166.3.2080; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Blamire AM, 2007, MAGN RESON MED, V58, P880, DOI 10.1002/mrm.21382; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; CURTIS R, 1993, J NEUROCYTOL, V22, P51, DOI 10.1007/BF01183975; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; DELAMONTE SM, 1995, AM J PATHOL, V147, P934; Deniselle MCG, 2005, EXP NEUROL, V195, P518, DOI 10.1016/j.expneurol.2005.06.015; Deniselle MCG, 1999, BRAIN RES, V841, P78, DOI 10.1016/S0006-8993(99)01783-7; Diem R, 2007, J NEUROIMMUNOL, V184, P27, DOI 10.1016/j.jneuroim.2006.11.025; Druckmann R, 2005, J STEROID BIOCHEM, V97, P389, DOI 10.1016/j.jsbmb.2005.08.010; Dutta R, 2007, NEUROLOGY, V68, pS22, DOI 10.1212/01.wnl.0000275229.13012.32; El-Etr M, 2005, J NEUROL SCI, V233, P49, DOI 10.1016/j.jns.2005.03.004; Elliott EJ, 1997, BRAIN RES, V755, P221, DOI 10.1016/S0006-8993(97)00100-5; Elloso MM, 2005, J ENDOCRINOL, V185, P243, DOI 10.1677/joe.1.06063; EVRON S, 1984, AM J REPROD IMMUNOL, V5, P109, DOI 10.1111/j.1600-0897.1984.tb00298.x; GARAY L, 2005, MULT SCLER, V11, P43; Garay L, 2008, NEUROIMMUNOMODULAT, V15, P76, DOI 10.1159/000135627; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Giardino L, 2004, NEUROPATH APPL NEURO, V30, P522, DOI 10.1111/j.1365-2990.2004.00559.x; Herrero-Herranz E, 2008, NEUROBIOL DIS, V30, P162, DOI 10.1016/j.nbd.2008.01.001; HOLINKA CF, 1979, BIOL REPROD, V20, P1201, DOI 10.1095/biolreprod20.5.1201; Hughes MD, 2004, NEUROL CLIN, V22, P757, DOI 10.1016/j.ncl.2004.06.004; KAPFHAMMER JP, 1994, J COMP NEUROL, V340, P194, DOI 10.1002/cne.903400206; KEITH AB, 1978, J NEUROL SCI, V38, P317, DOI 10.1016/0022-510X(78)90138-7; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Linker RA, 2005, J NEUROL SCI, V233, P167, DOI 10.1016/j.jns.2005.03.021; McQualter JL, 2007, J NEUROCHEM, V100, P295, DOI 10.1111/j.1471-4159.2006.04232.x; Melcangi RC, 2005, BRAIN RES REV, V48, P328, DOI 10.1016/j.brainresrev.2004.12.021; Morales LBJ, 2006, J NEUROSCI, V26, P6823, DOI 10.1523/JNEUROSCI.0453-06.2006; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Offner H, 2004, J NEUROSCI RES, V78, P603, DOI 10.1002/jnr.20330; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; Olby NJ, 1996, J NEUROCYTOL, V25, P465, DOI 10.1007/BF02284816; Onuki I, 2001, MICROSC RES TECHNIQ, V52, P731; Palaszynski KM, 2004, J NEUROIMMUNOL, V149, P84, DOI 10.1016/j.jneuroim.2003.12.015; Papadopoulos D, 2006, EXP NEUROL, V197, P373, DOI 10.1016/j.expneurol.2005.10.033; Penkowa M, 2003, J NEUROSCI RES, V72, P574, DOI 10.1002/jnr.10615; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rovaris M, 2005, ARCH NEUROL-CHICAGO, V62, P898, DOI 10.1001/archneur.62.6.898; RUSSELL JH, 2006, NEUROBIOL DIS, V21, P626; Schumacher M, 2008, CURR OPIN PHARMACOL, V8, P740, DOI 10.1016/j.coph.2008.10.002; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Sun DM, 2003, INT IMMUNOL, V15, P261, DOI 10.1093/intimm/dxg023; Waters EM, 2008, J COMP NEUROL, V511, P34, DOI 10.1002/cne.21826; Werner P, 2000, ADV RES NEURODEGENER, V8, P375; Wujek JR, 2002, J NEUROPATH EXP NEUR, V61, P23, DOI 10.1093/jnen/61.1.23; Zawadzka M, 2007, CURR OPIN NEUROL, V20, P294, DOI 10.1097/WCO.0b013e32813aee7f	55	75	79	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 4	2009	1283						177	185		10.1016/j.brainres.2009.04.057			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	484FQ	WOS:000269029700018	19497309				2022-02-06	
J	Aguirre, CC; Baudry, M				Aguirre, Claudia C.; Baudry, Michel			Progesterone reverses 17 beta-estradiol-mediated neuroprotection and BDNF induction in cultured hippocampal slices	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						excitotoxicity; hippocampus; hormones; neurodegeneration; rat	NEUROTROPHIC FACTOR EXPRESSION; ESTROGEN-RECEPTOR-ALPHA; TRAUMATIC BRAIN-INJURY; FEMALE RATS; MEDROXYPROGESTERONE ACETATE; NERVOUS-SYSTEM; NEURONS; ALLOPREGNANOLONE; PROGESTINS; MEDIATE	Due to the many similarities in mechanisms of action, targets and effects, progesterone (P4), estrogen and neurotrophins have been implicated in synaptic plasticity as well as in neuroprotection and neurodegeneration. In this study, we examined the interactions between 17 beta-estradiol (E2) and P4 and brain-derived neurotrophic factor (BDNF) on both plasticity and excitotoxicity in rat cultured hippocampal slices. First, we evaluated the neuroprotective effects of E2 and P4 against N-methyl-d-aspartate (NMDA) toxicity in cultured rat hippocampal slices. As previously reported, pretreatment with 10 nm E2 (24 h) was neuroprotective against NMDA toxicity. However, P4 (10 nm) added 20 h after E2 treatment for 4 h reversed its protective effect. In addition, the same E2 treatment resulted in an increase in BDNF protein levels as well as in activation of its receptor, TrkB, while addition of P4 attenuated E2-mediated increase in BDNF and TrkB levels. Furthermore, E2-mediated neuroprotection was eliminated by a BDNF scavenger, TrkB-Fc. Our results indicate that E2 neuroprotective effects are mediated through the BDNF pathway and that, under certain conditions, P4 antagonizes the protective effect of estrogen.	[Baudry, Michel] HNB534 USC, Los Angeles, CA 90089 USA; [Aguirre, Claudia C.] Univ So Calif, Grad Program Neurosci, Los Angeles, CA 90089 USA		Baudry, M (corresponding author), HNB534 USC, Los Angeles, CA 90089 USA.	baudry@usc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1P01AG026572, T32 AG000093-25]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32 AG000093-25]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG026572, T32AG000093] Funding Source: NIH RePORTER	Contract grant sponsor: National Institutes of Health; Contract grant number: 1P01AG026572; Contract training grant number: T32 AG000093-25.; The authors thank Anna Knize for technical assistance. This study was supported by NIA training grant T32 AG000093-25 to C.C.A. and NIH grant 1P01AG026572 to M.B.	Alves SE, 2000, J COMP NEUROL, V427, P185, DOI 10.1002/1096-9861(20001113)427:2<185::AID-CNE2>3.0.CO;2-G; Baulieu EE, 1996, CELL MOL NEUROBIOL, V16, P143, DOI 10.1007/BF02088173; Bi RF, 2000, P NATL ACAD SCI USA, V97, P3602, DOI 10.1073/pnas.060034497; Bimonte-Nelson HA, 2004, NEUROREPORT, V15, P2659, DOI 10.1097/00001756-200412030-00021; Blurton-Jones M, 2004, J COMP NEUROL, V468, P347, DOI 10.1002/cne.10989; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Carroll JC, 2007, J NEUROSCI, V27, P13357, DOI 10.1523/JNEUROSCI.2718-07.2007; Chung WCJ, 2006, BRAIN RES, V1082, P50, DOI 10.1016/j.brainres.2006.01.109; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Daniel JM, 1997, HORM BEHAV, V32, P217, DOI 10.1006/hbeh.1997.1433; Frye CA, 2005, PHARMACOL BIOCHEM BE, V81, P907, DOI 10.1016/j.pbb.2005.06.016; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Izumi Y, 2007, EUR J NEUROSCI, V26, P1881, DOI 10.1111/j.1460-9568.2007.05809.x; Jayaraman A, 2009, J NEUROENDOCRINOL, V21, P77, DOI 10.1111/j.1365-2826.2008.01801.x; Jensen T, 2001, J EXP BIOL, V204, P2087; Kaur P, 2007, J NEUROSCI RES, V85, P2441, DOI 10.1002/jnr.21370; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; McEwen BS, 1999, ENDOCRINOLOGY, V140, P1044, DOI 10.1210/en.140.3.1044; MIRANDA RC, 1993, P NATL ACAD SCI USA, V90, P6439, DOI 10.1073/pnas.90.14.6439; Mostallino MC, 2006, J NEUROCHEM, V99, P321, DOI 10.1111/j.1471-4159.2006.04055.x; Murphy DD, 2000, NEUROENDOCRINOLOGY, V72, P133, DOI 10.1159/000054580; Nakagami Y, 1997, NEUROSCIENCE, V81, P1, DOI 10.1016/S0306-4522(97)00161-9; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Rhodes ME, 2005, EPILEPSY BEHAV, V6, P320, DOI 10.1016/j.yebeh.2005.02.006; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Rosario ER, 2006, BRAIN RES, V1099, P206, DOI 10.1016/j.brainres.2006.03.127; Scharfman HE, 2006, FRONT NEUROENDOCRIN, V27, P415, DOI 10.1016/j.yfrne.2006.09.004; SIMERLY RB, 1990, J COMP NEUROL, V294, P76, DOI 10.1002/cne.902940107; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; Sohrabji F, 2006, FRONT NEUROENDOCRIN, V27, P404, DOI 10.1016/j.yfrne.2006.09.003; Spencer JL, 2008, FRONT NEUROENDOCRIN, V29, P219, DOI 10.1016/j.yfrne.2007.08.006; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Xilouri M, 2006, EUR J NEUROSCI, V23, P43, DOI 10.1111/j.1460-9568.2005.04548.x	35	75	78	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2009	29	3					447	454		10.1111/j.1460-9568.2008.06591.x			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	401OQ	WOS:000262951200003	19175406	Green Accepted			2022-02-06	
J	Pertab, JL; James, KM; Bigler, ED				Pertab, Jon L.; James, Kelly M.; Bigler, Erin D.			Limitations of mild traumatic brain injury meta-analyses	BRAIN INJURY			English	Article; Proceedings Paper	27th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 14-17, 2007	Scottsdale, AZ	Natl Acad Neuropsychol		Mild traumatic brain injury (mTBI); concussion; post-concussion analysis; cognition; neuropsychological assessment; clinical outcome; computed tomography (CT) imaging; magnetic resonance imaging (MRI)	DIFFUSE AXONAL INJURY; COLLEGIATE FOOTBALL PLAYERS; MINOR HEAD-INJURY; PROFESSIONAL FOOTBALL; COGNITIVE SEQUELAE; NCAA CONCUSSION; IMPACT; NEUROPSYCHOLOGY; SEVERITY; TBI	Primary objective: Mild traumatic brain injury (mTBI) meta-analyses are sometimes cited as evidence that by 3 months post-injury the clinical effects are insignificant. In contrast to these conclusions are findings that long-term mTBI outcome can vary depending on (1) the mechanism of the injury, (2) which diagnostic criteria are employed, (3) which assessment tools utilized and (4) whether symptomatic groups are considered separately. Research design: The present study was designed to clarify opposing conclusions in the mTBI literature by re-analysing meta-analytic datasets. Methods and procedures: The most frequently cited mTBI meta-analysis is by Binder, Rohling and Larrabee in 1997; this study was updated in 2005 by Frencham, Fox and Maybery. Data combined in these studies were re-categorized according to the four variables above; associated effect sizes and heterogeneity statistics were calculated. Main outcomes and results: Considerable qualitative and statistical heterogeneity was identified within the meta-analytic data under consideration. Clinically significant lasting effects were identified for a sub-set of neuropsychological measures. Conclusions: Methodological and statistical heterogeneity in studies combined in mTBI meta-analyses significantly limits the conclusions that can be drawn from small or non-significant overall effect sizes; clinically relevant information can be obscured by meta-analytic procedures. Recommendations for future meta-analytic studies of mTBI are offered.	[Pertab, Jon L.; James, Kelly M.; Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Pertab, Jon L.; James, Kelly M.; Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Brain Inst Utah, Salt Lake City, UT USA		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1190D Spencer W Kimball Tower, Provo, UT 84602 USA.	erin_bigler@byu.edu					ALTERMAN AI, 1985, INT J NEUROSCI, V28, P155, DOI 10.3109/00207458508985386; Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blennow Kaj, 2005, Lakartidningen, V102, P2468; BORNSTEIN RA, 1993, NEUROPSYCHOLOGY, V7, P228, DOI DOI 10.1037/0894-4105.7.2.228; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; Casson IR, 2008, NEUROL CLIN, V26, P217, DOI 10.1016/j.ncl.2007.11.005; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Cohen J, 1977, STAT POWER ANAL BEHA; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Demakis GJ, 2006, CLIN NEUROPSYCHOL, V20, P10, DOI 10.1080/13854040500203282; Demakis GJ, 2006, CLIN NEUROPSYCHOL, V20, P5, DOI 10.1080/13854040500203266; Denney RL, 2000, J HEAD TRAUMA REHAB, V15, P804, DOI 10.1097/00001199-200004000-00005; DIKMEN S, 2009, NEUROPSYCHOLOGICAL A, P597; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; EDLUND W, 2004, CLIN PRACTISE GUIDEL; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Fijalkowski RJ, 2006, BIOMED SCI INSTRUM, V42, P108; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GRONWALL D, 1975, LANCET, V2, P995; GUILMETTE TJ, 1995, NEUROPSYCHOLOGY, V9, P338, DOI 10.1037/0894-4105.9.3.338; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Hedges L.V., 1985, STAT METHODS META AN; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Lam RW, 2005, CAN J PSYCHIAT, V50, P167, DOI 10.1177/070674370505000306; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Liu Xuejun, 2003, Traffic Inj Prev, V4, P337, DOI 10.1080/714040491; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maier W, 2005, EUR ARCH PSY CLIN N, V255, P369, DOI 10.1007/s00406-005-0607-5; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MCGAW B, 1980, AM EDUC RES J, V17, P325, DOI 10.2307/1162619; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Rosenthal R., 1991, METAANALYTIC PROCEDU, DOI 10.4135/9781412984997; Ruff R. M., 1989, MILD HEAD INJURY, P176; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Stapert S, 2006, BRAIN INJURY, V20, P161, DOI 10.1080/02699050500442949; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Streiner DL, 2005, CAN J PSYCHIAT, V50, P829, DOI 10.1177/070674370505001304; Tobin MJ, 2008, CRIT CARE MED, V36, P1, DOI 10.1097/01.CCM.0000297883.04634.11; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; von Wild KRH, 2008, ACT NEUR S, V101, P55; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Williams CW, 1999, PROF PSYCHOL-RES PR, V30, P361, DOI 10.1037/0735-7028.30.4.361; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zwahlen RA, 2007, J CRANIO MAXILL SURG, V35, P142, DOI 10.1016/j.jcms.2007.01.006	92	75	75	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	6					498	508	PII 911808900	10.1080/02699050902927984			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Rehabilitation	451SF	WOS:000266489800003	19484623				2022-02-06	
J	Sayer, NA; Rettmann, NA; Carlson, KF; Bernardy, N; Sigford, BJ; Hamblen, JL; Friedman, MJ				Sayer, Nina A.; Rettmann, Nancy A.; Carlson, Kathleen F.; Bernardy, Nancy; Sigford, Barbara J.; Hamblen, Jessica L.; Friedman, Matthew J.			Veterans with history of mild traumatic brain injury and posttraumatic stress disorder: Challenges from provider perspective	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						combat disorders; comorbidity; education; health services needs and demands; mild traumatic brain injury; pain; posttraumatic stress disorder; rehabilitation; traumatic brain injury; veterans	RAPID ASSESSMENT; CARE; AFGHANISTAN; DEPRESSION; IRAQ	The Department of Veterans Affairs (VA) has separate clinical structures and care processes for traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD). However, because veterans are returning from the wars in Iraq and Afghanistan with TBI (most frequently mild TBI [mTBI]) and PTSD, the VA needs to evaluate current service delivery systems. We conducted key informant interviews with 40 providers from across the United States who represented separate clinical teams providing specialized TBI or PTSD services. We identified challenges providers perceive in scheduling and engaging patients with co-occurring mTBI and PTSD (mTBI/PTSD) in treatment, determining the etiology of patients' presenting problems, coordinating services, and knowing whether or how to alter standard treatments. We found consensus that patients with mTBI/PTSD often have other morbidities requiring specialized treatment, including pain and sleep disturbance. Another important theme we found was the need for patient and family educational material on mTBI/PTSD or pain and mTBI/PTSD and provider education tailored to provider specialty. Together, findings point to the need for guidance for providers on best practices to assess and treat mTBI/PTSD given available information, a systematic approach toward patient and provider education, and research to build the evidence base for practice.	[Sayer, Nina A.; Rettmann, Nancy A.; Carlson, Kathleen F.; Sigford, Barbara J.] VAMC, Minneapolis Dept, Minneapolis, MN USA; [Sayer, Nina A.; Carlson, Kathleen F.; Sigford, Barbara J.] Univ Minnesota, Minneapolis, MN USA; [Bernardy, Nancy; Hamblen, Jessica L.; Friedman, Matthew J.] VAMC, Natl Ctr Posttraumat Stress Disorder, Execut Div, White River Jct, VT USA; [Hamblen, Jessica L.; Friedman, Matthew J.] Dartmouth Med Sch, Hanover, NH USA		Sayer, NA (corresponding author), Vet Adm Med Ctr, Ctr Chron Dis Outcomes Res, 1 Vet Dr 152-2E, Minneapolis, MN 55417 USA.	nina.sayer@va.gov	Sayer, Nina/E-3249-2016		VA Health Services Research and Development Quality Enhancement Research Initiative [PLY 08-05-3]	This material was based on work supported by a VA Health Services Research and Development Quality Enhancement Research Initiative Locally Initiated Project (grant PLY 08-05-3).	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; [Anonymous], 2009, NEWSWEEK; Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Beebe J, 2001, RAPID ASSESSMENT PRO; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Crabtree B. F., 1999, DOING QUALITATIVE RE; Defense and Veterans Brain Injury Center, 2006, DEF VET BRAIN INJ CT; *DEP VET AFF, 2008, VA LEARN CAT DIAGN M; *DEP VET AFF MAN P, 2004, VA DOD CLIN PRACT GU; Fitch C, 2004, SOC SCI MED, V59, P1819, DOI 10.1016/j.socscimed.2004.02.028; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; IRAQ RR, 2007, MARINES EXPERIENCE B; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Miles M. B., 1994, QUALITATIVE DATA ANA, V2nd; Needle RH, 2003, AM J PUBLIC HEALTH, V93, P970, DOI 10.2105/AJPH.93.6.970; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Sigford BJ, 2008, ARCH PHYS MED REHAB, V89, P160, DOI 10.1016/j.apmr.2007.09.015; Soo C, 2007, COCHRANE DB SYST REV, V3; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, J NEUROTRAUM, V22, P1178	32	75	75	0	3	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					703	715		10.1682/JRRD.2009.01.0008			13	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	531BQ	WOS:000272638100008	20104400	Bronze			2022-02-06	
J	Angeleri, R; Bosco, FM; Zettin, M; Sacco, K; Colle, L; Bara, BG				Angeleri, R.; Bosco, F. M.; Zettin, M.; Sacco, K.; Colle, L.; Bara, B. G.			Communicative impairment in traumatic brain injury: A complete pragmatic assessment	BRAIN AND LANGUAGE			English	Article						Communication; Cognitive Pragmatics; Irony; Deceit; Verbal; Non-verbal; Paralinguistic; Inferential process	CLOSED-HEAD-INJURY; EXTRALINGUISTIC COMMUNICATION; SOCIAL-PERCEPTION; LINGUISTIC HUMOR; COMPREHENSION; LANGUAGE; RECOGNITION; ADOLESCENTS; EXPRESSION; ABILITY	The aim of (lie present study was to examine the Communicative abilities of traumatic brain injury patients (TBI). We wish to provide a complete assessment of their Communicative ability/disability using a new experimental protocol, the Assessment Battery of Communication, (ABaCo) comprising five scales-linguistic, extralinguistic, paralinguistic, context and conversational-which investigate all the main pragmatic elements involved in a communicative exchange. The ABaCo was administered to 21 TBI subjects and to a control group. The results showed that performance by TBI patients was worse than that of controls on all scales; moreover they showed a trend of increasing difficulty in understanding and producing different pragmatic phenomena, i.e., standard communication acts, deceits and ironies, whether such phenomena are expressed through the linguistic or extralinguistic modality. (C) 2008 Elsevier Inc. All rights reserved.	[Angeleri, R.; Bosco, F. M.; Sacco, K.; Colle, L.; Bara, B. G.] Univ Turin, Ctr Cognit Sci, I-10123 Turin, Italy; [Angeleri, R.; Bosco, F. M.; Sacco, K.; Colle, L.; Bara, B. G.] Univ Turin, Dept Psychol, I-10123 Turin, Italy; [Bosco, F. M.; Sacco, K.; Colle, L.; Bara, B. G.] Neurosci Inst Turin, Turin, Italy; [Zettin, M.] Ctr Puzzle, Turin, Italy; [Sacco, K.] Univ Turin, CCS fMRI, Neuroradiol Koelliker Hosp, I-10124 Turin, Italy; [Sacco, K.] Univ Turin, Dept Psychol, I-10124 Turin, Italy		Bosco, FM (corresponding author), Univ Turin, Ctr Cognit Sci, Via 14, I-10123 Turin, Italy.	bosco@psych.unito.it	Sacco, Katiuscia/J-2133-2012; bosco, francesca marina/B-6746-2013	Sacco, Katiuscia/0000-0002-9660-5236; bosco, francesca marina/0000-0001-6101-8587			AIRENTI G, 1993, COGNITIVE SCI, V17, P197, DOI 10.1207/s15516709cog1702_2; AIRENTI G, 1993, J PRAGMATICS, V20, P303, DOI 10.1016/0378-2166(93)90055-T; AIRENTI G, 1984, COMPUTATIONAL MODELS; Altman D.G., 1990, PRACTICAL STAT MED R; Austin JL., 1962, DO THINGS WORDS, V2; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; BARA BG, 1999, P 11 EUR C COGN SCI; BARA BG, 2008, COGNITIVE PRAGMATICS; BARA BG, 1998, SPECIAL ISSUE ANAL P, P317; Bosco FM, 2008, J PRAGMATICS, V40, P583, DOI 10.1016/j.pragma.2007.05.004; Bosco FM, 2004, PROCEEDINGS OF THE TWENTY-SIXTH ANNUAL CONFERENCE OF THE COGNITIVE SCIENCE SOCIETY, P144; Braun C M, 1989, Brain Inj, V3, P345, DOI 10.3109/02699058909004559; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Bucciarelli M, 2003, J PRAGMATICS, V35, P207, DOI 10.1016/S0378-2166(02)00099-1; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Coelho C., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Coelho C. A., 1992, CLIN APHASIOLOGY, V21, P183; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; CROSSON B, 1987, CLIN NEUROPSYCHOL, V1, P335, DOI DOI 10.1080/13854048708520069; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; De Marco I, 2007, J PRAGMATICS, V39, P134, DOI 10.1016/j.pragma.2006.08.009; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J AUTISM DEV DISORD, V31, P47, DOI 10.1023/A:1005661613288; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Docking K, 1999, BRAIN INJURY, V13, P953; Duffy, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; EKMAN P, 1979, ANNU REV PSYCHOL, V30, P527, DOI 10.1146/annurev.ps.30.020179.002523; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRASER B, 1981, INT J SOCIOL LANG, P93; GLOSSER G, 1993, NARRATIVE DISCOURSE IN NEUROLOGICALLY IMPAIRED AND NORMAL AGING ADULTS, P191; Grice H. P., 1975, SYNTAX SEMANTICS, V3; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Huber W, 1996, AACHENER APHASIE TES; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; JOANNETTE Y, 1990, DISCOURSE ABILITY BR; Kasher A, 1999, BRAIN LANG, V68, P566, DOI 10.1006/brln.1999.2129; Kasher A., 1991, CHOMSKYAN TURN, P122; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; KRAUSS RM, 1991, J PERS SOC PSYCHOL, V61, P743, DOI 10.1037/0022-3514.61.5.743; Krauss RM, 1998, CURR DIR PSYCHOL SCI, V7, P54, DOI 10.1111/1467-8721.ep13175642; Lakatos I., 1970, CRITICISM GROW KNOWL, P91; LAKOFF R, 1973, PAP 9 REG M CHIC LIN; Levinson, 1987, POLITENESS SOME UNIV; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Luria AR., 1976, BASIC PROBLEMS NEURO; Marquardt TP, 2001, APHASIOLOGY, V15, P1091, DOI 10.1080/02687040143000429; McDonald, 2000, METAPHOR SYMBOL, V15, P85, DOI DOI 10.1080/10926488.2000.9678866; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; Penn C, 1999, BRAIN LANG, V68, P535, DOI 10.1006/brln.1999.2127; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; REITER R, 1980, ARTIF INTELL, V13, P81, DOI 10.1016/0004-3702(80)90014-4; Russell Bertrand, 1914, OUR KNOWLEDGE EXTERN; SACCO K, ASSESSMENT BAT UNPUB; Schegloff EA., 1978, STUDIES ORG CONVERSA, P7, DOI DOI 10.1016/B978-0-12-623550-0.50008-2; Searle John R., 1979, EXPRESSION MEANING S; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; WINNER E, 1977, BRAIN, V100, P717, DOI 10.1093/brain/100.4.717; Wozniak RJ, 1999, BRAIN INJURY, V13, P191, DOI 10.1080/026990599121700; Ylvisaker M., 1987, COMMUNITY REENTRY HE, P137	75	75	77	2	26	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0093-934X	1090-2155		BRAIN LANG	Brain Lang.	DEC	2008	107	3					229	245		10.1016/j.bandl.2008.01.002			17	Audiology & Speech-Language Pathology; Linguistics; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Psychology	379SW	WOS:000261417500006	18267340				2022-02-06	
J	Gebhard, F; Huber-Lang, M				Gebhard, F.; Huber-Lang, M.			Polytrauma - pathophysiology and management principles	LANGENBECKS ARCHIVES OF SURGERY			English	Article						trauma; damage-control orthopedics; ATLS; SIRS; MODS	EMERGENCY-ROOM MANAGEMENT; SEVERELY INJURED PATIENTS; TRAUMATIC BRAIN-INJURY; MULTIPLE TRAUMA; ABDOMINAL-TRAUMA; CARE; COMPLEMENT; PATIENT; SURGERY; NEUTROPHILS	Background Multiple injury results in a complex pathophysiological and immunological response. Depending on the individual injury pattern, the time elapsed after injury, and the systemic "danger response", the surgical treatment has to be modified. Objectives This overview provides new insights in the pathophysiology of the early danger response after polytrauma and outlines the main resulting consequences for surgical management. Results First, synchronically to the clinical assessment, life-saving procedures need to be performed rapidly, such as control of massive intra-thoracic or abdominal bleeding and decompression of the chest and brain, as standardized by advanced trauma life support guidelines. During the second phase of "day-one-surgery" damage-control interventions such as debridement, decompression and temporary fracture stabilization are needed to avoid an excessive molecular and cellular danger response. Trauma-adjusted surgical techniques are crucial to limit the systemic response known to put remote organs at risk. In the "vulnerable phase" when the patient's defense is rather uncontrolled, only "second look" debridement to minimize a "second hit" is recommended. After stabilization of the patient as indicated by improvement of tissue oxygenation, coagulation, and decreased inflammatory mediators, "reconstructive surgery" can be applied. Conclusion Individually adjusted surgical "damage control" and "immune control" are important interactive concepts in polytrauma management.	[Gebhard, F.; Huber-Lang, M.] Univ Hosp Ulm, Dept Orthopaed Trauma Hand Plast & Reconstruct Su, D-89075 Ulm, Germany		Gebhard, F (corresponding author), Univ Hosp Ulm, Dept Orthopaed Trauma Hand Plast & Reconstruct Su, Steinhoevelstr 9, D-89075 Ulm, Germany.	florian.gebhard@uniklinik-ulm.de	Huber-Lang, Markus/AAJ-2209-2020				Albers S, 2006, SHOCK, V26, P14, DOI 10.1097/00024382-200610001-00044; Beck A, 2004, UNFALLCHIRURG, V107, P862, DOI 10.1007/s00113-004-0812-0; Biffl WL, 1999, SURGERY, V126, P198, DOI 10.1067/msy.1999.98738; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Burkhardt M, 2005, UNFALLCHIRURG, V108, P812, DOI 10.1007/s00113-005-0997-x; Celso B, 2006, J TRAUMA, V60, P371, DOI 10.1097/01.ta.0000197916.99629.eb; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; DELIRE M, 1988, ANN BIOL CLIN-PARIS, V46, P272; ERTEL W, 1994, ZBL CHIR, V119, P159; Flierl MA, 2007, NATURE, V449, P721, DOI 10.1038/nature06185; Flohe S, 2007, LANGENBECK ARCH SURG, V392, P639, DOI 10.1007/s00423-007-0203-4; Frank J, 1996, ZBL CHIR, V121, P943; Gebhard F., 2000, HEFTE UNFALLCHIRURG, V276; HAAS NP, 1995, CLIN ORTHOP RELAT R, P25; Haas NP, 1997, UNFALLCHIRURG, V100, P2, DOI 10.1007/s001130050087; Hecke F, 1997, CRIT CARE MED, V25, P2015, DOI 10.1097/00003246-199712000-00019; Heinzelmann M, 2004, UNFALLCHIRURG, V107, P871, DOI 10.1007/s00113-004-0846-3; Hessmann MH, 2006, ACTA CHIR BELG, V106, P500; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Huber-Lang MS, 2002, J IMMUNOL, V169, P3223, DOI 10.4049/jimmunol.169.6.3223; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Kienlen J, 1999, J CHIR-PARIS, V136, P240; Kobbe P, 2007, UNFALLCHIRURG, V110, P235, DOI 10.1007/s00113-007-1231-9; Kohl J, 2006, IMMUNOL RES, V34, P157, DOI 10.1385/IR:34:2:157; Koller M, 2001, INFLAMMATION, V25, P53, DOI 10.1023/A:1007027712387; Kuhne CA, 2004, UNFALLCHIRURG, V107, P851, DOI 10.1007/s00113-004-0813-z; LAMPL L, 1994, ZBL CHIR, V119, P683; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Liener UC, 2006, UNFALLCHIRURG, V109, P447, DOI 10.1007/s00113-005-1048-3; Lindner T, 2004, UNFALLCHIRURG, V107, P892, DOI 10.1007/s00113-004-0849-0; Maghsudi M, 1998, CHIRURG, V69, P313, DOI 10.1007/s001040050419; Matthes G, 2001, ZBL CHIR, V126, P995, DOI 10.1055/s-2001-19658; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Moore EE, 1998, WORLD J SURG, V22, P1184, DOI 10.1007/s002689900542; Mutschler W, 2002, RADIOLOGE, V42, P506, DOI 10.1007/s00117-002-0768-4; Nast-Kolb D, 2006, CHIRURG, V77, P861, DOI 10.1007/s00104-006-1231-2; Nast-Kolb D, 2005, UNFALLCHIRURG, V108, P804, DOI 10.1007/s00113-005-1004-2; Pape HC, 1999, UNFALLCHIRURG, V102, P861, DOI 10.1007/s001130050495; Pape HC, 2004, UNFALLCHIRURG, V107, P927, DOI 10.1007/s00113-004-0848-1; PAPE HC, 2000, MULTIPLE ORGAN FAILU, P279; Platzer P, 2006, EUR SPINE J, V15, P1801, DOI 10.1007/s00586-006-0084-1; Ruchholtz S, 1997, UNFALLCHIRURG, V100, P859, DOI 10.1007/s001130050205; Sauerland S, 2004, UNFALLCHIRURG, V107, P833, DOI 10.1007/s00113-004-0851-6; Sauerland S, 2002, UNFALLCHIRURG, V105, P1022, DOI 10.1007/s00113-002-0514-4; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Seekamp A, 2004, UNFALLCHIRURG, V107, P903, DOI 10.1007/s00113-004-0831-x; Siebert H, 2006, UNFALLCHIRURG, V109, P815, DOI 10.1007/s00113-006-1154-x; Stahel PF, 2005, ORTHOPADE, V34, P852, DOI 10.1007/s00132-005-0844-3; Stahel PF, 2005, ORTHOPADE, V34, P823, DOI 10.1007/s00132-005-0842-5; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Staib L, 2004, CHIRURG, V75, P447, DOI 10.1007/s00104-004-0855-3; Toh CH, 2007, J THROMB HAEMOST, V5, P604, DOI 10.1111/j.1538-7836.2007.02313.x; TRACEY KJ, 2002, NATURE, V421, P384; Voggenreiter G, 2004, UNFALLCHIRURG, V107, P881, DOI 10.1007/s00113-004-0837-4; Walz CR, 2007, LANGENBECK ARCH SURG, V392, P339, DOI 10.1007/s00423-007-0164-7; Weber U, 2005, ORTHOPADE, V34, P821, DOI 10.1007/s00132-005-0841-6; Westhoff J, 2003, INJURY, V34, P674, DOI 10.1016/S0020-1383(03)00147-5; Woltmann A, 2004, UNFALLCHIRURG, V107, P911, DOI 10.1007/s00113-004-0829-4; WURB T, 2005, ANAESTHESIST, V54, P763	61	75	92	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1435-2443	1435-2451		LANGENBECK ARCH SURG	Langenbecks Arch. Surg.	NOV	2008	393	6					825	831		10.1007/s00423-008-0334-2			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	357AS	WOS:000259819300002	18431593				2022-02-06	
J	Spaethling, JM; Klein, DM; Singh, P; Meaney, DF				Spaethling, Jennifer M.; Klein, Donna M.; Singh, Pallab; Meaney, David F.			Calcium-Permeable AMPA Receptors Appear in Cortical Neurons after Traumatic Mechanical Injury and Contribute to Neuronal Fate	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	International Symposium on Traumatic Brain Injury Research Priorities	OCT 13-16, 2005	Johnstown, PA	John P Murtha Neursci & Pain Inst, Natl Brain Injury Res, Treatments & Training Fdn, Brain Injury Assoc Amer		calcium-permeable AMPA receptors; CaMKII; mechanical injury; trafficking; traumatic brain injury	LONG-TERM POTENTIATION; HIPPOCAMPAL-NEURONS; IN-VITRO; GLUTAMATE RECEPTORS; BRAIN-INJURY; SYNAPTIC PLASTICITY; SUBUNIT COMPOSITION; CULTURED NEURONS; NMDA RECEPTORS; RAT	Traumatic brain injury (TBI) is one of the most disabling injuries in the population, with 1.5 million Americans new cases each year and 5.3 million Americans overall requiring long-term daily care as a result of their injuries. One critical aspect in developing effective treatments for TBI is determining if new, specific receptor populations emerge in the early phase after injury that can subsequently be targeted to reduce neuronal death after injury. One specific glutamate receptor subtype, the calcium-permeable AMPA receptor (CP-AMPAR), is becoming increasingly recognized for its role in physiological and pathophysiological processes. Although present in relatively low levels in the mature brain, recent studies show that CP-AMPARs can appear following ischemic brain injury or status epilepticus, and the mechanisms that regulate the appearance of these receptors include alterations in transcription, RNA editing, and receptor trafficking. In this report, we use an in vitro model of TBI to show a gradual appearance of CP-AMPARs four hours following injury to cortical neurons. Moreover, the appearance of these receptors is mediated by the phosphorylation of CaMKII alpha following injury. Selectively blocking CP-AMPARs after mechanical injury leads to a significant reduction in the cell death that occurs 24 h following injury in untreated controls, and is similar in protection offered by broad-spectrum NMDA and AMPA receptor antagonists. These data point to a potentially new and more targeted therapeutic approach for treating TBI.	[Klein, Donna M.; Singh, Pallab; Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Spaethling, Jennifer M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA		Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu		Meaney, David/0000-0002-0954-4122	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD41699] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS035712, R01 NS035712-03, NS 35712] Funding Source: Medline		Adesnik H, 2007, J NEUROSCI, V27, P4598, DOI 10.1523/JNEUROSCI.0325-07.2007; Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Atkins CM, 2006, J CEREBR BLOOD F MET, V26, P1507, DOI 10.1038/sj.jcbfm.9600301; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bell JD, 2007, BRAIN, V130, P2528, DOI 10.1093/brain/awm164; Boehm J, 2006, NEURON, V51, P213, DOI 10.1016/j.neuron.2006.06.013; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; Calderone A, 2003, J NEUROSCI, V23, P2112; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cull-Candy S, 2006, CURR OPIN NEUROBIOL, V16, P288, DOI 10.1016/j.conb.2006.05.012; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Esteban JA, 2003, NAT NEUROSCI, V6, P136, DOI 10.1038/nn997; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Furukawa T, 2003, J NEUROTRAUM, V20, P269, DOI 10.1089/089771503321532851; Geddes-Klein DM, 2006, J NEUROCHEM, V97, P462, DOI 10.1111/j.1471-4159.2006.03761.x; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Hall BJ, 2007, J NEUROSCI, V27, P13446, DOI 10.1523/JNEUROSCI.3793-07.2007; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Huang YF, 2002, J NEUROSCI, V22, P8422; Iino M, 1996, J PHYSIOL-LONDON, V496, P431, DOI 10.1113/jphysiol.1996.sp021696; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Jia YS, 2002, J PHYSIOL-LONDON, V543, P35, DOI 10.1113/jphysiol.2002.020172; Jones TL, 2005, PAIN, V117, P259, DOI 10.1016/j.pain.2005.06.003; Jones TL, 2004, J PHARMACOL EXP THER, V310, P223, DOI 10.1124/jpet.103.064741; Kakegawa W, 2002, J NEUROSCI, V22, P4312, DOI 10.1523/JNEUROSCI.22-11-04312.2002; Kato K, 2007, NEUROSCI LETT, V418, P4, DOI 10.1016/j.neulet.2007.02.058; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; Lee SH, 2004, NEURON, V43, P221, DOI 10.1016/j.neuron.2004.06.015; Lin YC, 2002, J NEUROSCI RES, V67, P484, DOI 10.1002/jnr.10077; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; Liu BS, 2006, J NEUROSCI, V26, P5309, DOI 10.1523/JNEUROSCI.0567-06.2006; Liu SJ, 2007, TRENDS NEUROSCI, V30, P126, DOI 10.1016/j.tins.2007.01.006; Liu SQJ, 2000, NATURE, V405, P454, DOI 10.1038/35013064; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Noh KM, 2005, P NATL ACAD SCI USA, V102, P12230, DOI 10.1073/pnas.0505408102; Okada T, 2003, EUR J NEUROSCI, V17, P341, DOI 10.1046/j.1460-9568.2003.02458.x; Peng PL, 2006, NEURON, V49, P719, DOI 10.1016/j.neuron.2006.01.025; Plant K, 2006, NAT NEUROSCI, V9, P602, DOI 10.1038/nn1678; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Semyanov A, 2001, NEUROPHARMACOLOGY, V40, P203, DOI 10.1016/S0028-3908(00)00147-7; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Sorkin LS, 1999, NEUROREPORT, V10, P3523, DOI 10.1097/00001756-199911260-00011; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Thiagarajan TC, 2005, NEURON, V47, P725, DOI 10.1016/j.neuron.2005.06.037; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tian XJ, 2006, J BIOL CHEM, V281, P7578, DOI 10.1074/jbc.M512060200; Van Damme P, 2002, J NEUROPHYSIOL, V88, P1279, DOI 10.1152/jn.2002.88.3.1279; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	60	75	77	1	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2008	25	10					1207	1216		10.1089/neu.2008.0532			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	370XK	WOS:000260796200009	18986222	Green Published, Green Accepted			2022-02-06	
J	Palzur, E; Zaaroor, M; Vlodausky, E; Milman, F; Soustiel, JF				Palzur, Eilam; Zaaroor, Menashe; Vlodausky, Eugene; Milman, Felix; Soustiel, Jean F.			Neuroprotective effect of hyperbaric oxygen therapy in brain injury is mediated by preservation of mitochondrial membrane properties	BRAIN RESEARCH			English	Article						brain injury; mitochondrial transition pore; hyperbaric hyperoxia; apoptosis	TRAUMATIC BRAIN; BCL-2 FAMILY; CEREBRAL CONTUSION; HEAD-INJURY; CELL-DEATH; RAT MODEL; APOPTOSIS; GLUTATHIONE; EXPRESSION; PROTECTION	Recent experimental data have shown that hyperbaric oxygen therapy (HBOT) was associated increased Bcl-2 expression at the injury site that correlated with reduced apoptosis. We hypothesized that HBOT mediated enhancement of Bcl-2 expression and increased intracellular oxygen bio-availability may both contribute to preserve mitochondrial integrity and reduce the activation of the mitochondrial pathway of apoptosis. For this purpose, a cortical lesion was created in the parietal cortex of Sprague-Dawley rats by dynamic cortical deformation (DCD) and outcome measures in non-treated animals were compared with that of HBOT treated rats. Morphological analysis showed a profound reduction in neuronal counts in the perilesional area and a marked rarefaction of the density of the axonal-dentritic network. In treated animals, however, there was a significant attenuation of the impact of DCD over perilesional neurons, characterized by significantly higher cell counts and denser axonal network. In mitochondria isolated from injured brain tissue, there was a profound loss of mitochondrial transmembrane potential (Delta psi(M)) that proved to be substantially reversed by HBOT. This finding correlated with a significant reduction of caspases 3 and 9 activation in HBOT treated animals but not of caspase 8, indicating a selective effect over the intrinsic pathway of apoptosis. All together, our results indicate that the neuroprotective effect of HBOT may represent the consequence of preserved mitochondrial integrity and subsequent inhibition of the mPTP and reduction of the mitochondrial pathway of apoptosis. (C) 2008 Elsevier B.V. All rights reserved.	[Palzur, Eilam; Zaaroor, Menashe; Vlodausky, Eugene; Milman, Felix; Soustiel, Jean F.] Technion Israel Inst Technol, Fac Med, Acute Brain Injury Res Lab, IL-31096 Haifa, Israel		Soustiel, JF (corresponding author), Technion Israel Inst Technol, Fac Med, Acute Brain Injury Res Lab, Ephron St,POB 9649, IL-31096 Haifa, Israel.	j_soustiel@rambam.health.gov.il		Palzur, Eilam/0000-0003-2032-2974			Benedetti S, 2004, CLIN BIOCHEM, V37, P312, DOI 10.1016/j.clinbiochem.2003.12.001; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; Gurer A, 2006, TRANSPL P, V38, P3337, DOI 10.1016/j.transproceed.2006.10.184; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P435; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Papadopoulos MC, 1998, EUR J NEUROSCI, V10, P1252, DOI 10.1046/j.1460-9568.1998.00134.x; Qin ZY, 2007, STROKE, V38, P1362, DOI 10.1161/01.STR.0000259660.62865.eb; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Vlodavsky E, 2005, ACTA NEUROPATHOL, V110, P120, DOI 10.1007/s00401-004-0946-8; Wada K, 2000, ACT NEUR S, V76, P285; Wada K, 1996, BRAIN RES, V740, P15; Xu LJ, 1999, ANESTHESIOLOGY, V91, P1036, DOI 10.1097/00000542-199910000-00024; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yin DL, 2003, J CEREBR BLOOD F MET, V23, P855, DOI 10.1097/01.WCB.0000073946.29308.55; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	28	75	92	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 24	2008	1221						126	133		10.1016/j.brainres.2008.04.078			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	334XF	WOS:000258254300015	18561900				2022-02-06	
J	Chiaretti, A; Antonelli, A; Mastrangelo, A; Pezzotti, P; Tortorolo, L; Tosi, F; Genovese, O				Chiaretti, Antonio; Antonelli, Alessia; Mastrangelo, Antonio; Pezzotti, Patrizio; Tortorolo, Luca; Tosi, Federica; Genovese, Orazio			Interleukin-6 and nerve growth factor upregulation correlates with improved outcome in children with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						interleukin-6; nerve growth factor; neuroinflammation; neuroprotection; traumatic brain injury	CEREBROSPINAL-FLUID; HEAD-INJURY; CHOLINERGIC NEURONS; NEUROTROPHIC FACTOR; TRANSGENIC MICE; SERUM; ASTROCYTES; RECEPTOR; DEATH; OVEREXPRESSION	Secondary brain damage after traumatic brain injury ( TBI) involves neuro-inflammatory mechanisms that are mainly dependent on the intracerebral production of cytokines. Interleukin-6 ( IL-6) may have a role both in the pathogenesis of neuronal damage and in the recovery mechanisms of injured neurons through the modulation of nerve growth factor ( NGF) biosynthesis. However, the relationship between IL-6 and NGF expression and the severity and outcome of TBI remains controversial. We have conducted a prospective observational clinical study to determine whether the concentration of IL-6 and NGF in the cerebrospinal fluid ( CSF) of children with TBI correlates with the severity of the injury and neurologic outcome of patients. CSF samples were collected from 29 children at 2 h ( time T1) and 48 h ( time T2) after severe TBI, and from 31 matched controls. TBI severity was evaluated by Glasgow Coma Scale ( GCS) and neurologic outcome by Glasgow Outcome Score ( GOS). CSF concentrations of IL-6 and NGF were measured by immunoenzymatic assays. Early NGF concentrations ( T1) correlated significantly with head injury severity, whereas no correlation was found between GCS and IL-6. Furthermore, IL-6 and NGF upregulation after injury was associated with better neurologic outcomes. Based on these findings, we posit that NGF expression is a useful marker of brain damage following severe TBI. Moreover, the early upregulation of both IL-6 and NGF, which correlates with a favorable neurologic outcome, may reflect an endogenous attempt at neuroprotection in response to the damaging biochemical and molecular cascades triggered by traumatic insult.	[Chiaretti, Antonio] Policlin Gemelli, Terapia Intens Pediat, I-00168 Rome, Italy; [Chiaretti, Antonio; Antonelli, Alessia; Mastrangelo, Antonio; Tortorolo, Luca; Tosi, Federica; Genovese, Orazio] Catholic Univ, Sch Med, Pediat Intens Care Unit, Rome, Italy; [Pezzotti, Patrizio] Agcy Publ Hlth Lazio Reg, Rome, Italy		Chiaretti, A (corresponding author), Policlin Gemelli, Terapia Intens Pediat, 1 Largo Gemelli, I-00168 Rome, Italy.	achiaretti@yahoo.it		GENOVESE, Orazio/0000-0002-1989-1363			Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barde Y. A., 1994, PROG CLIN BIOL RES, V390, P1855; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.ne.18.030195.001255; Calza L, 2003, P NATL ACAD SCI USA, V100, P7325, DOI 10.1073/pnas.1132092100; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Cui Q, 2006, MOL NEUROBIOL, V33, P155, DOI 10.1385/MN:33:2:155; Davey F, 1998, CURR BIOL, V8, P915, DOI 10.1016/S0960-9822(07)00371-5; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; DiSanto E, 1996, BRAIN RES, V740, P239, DOI 10.1016/S0006-8993(96)00865-7; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; HARIRI RJ, 1994, BRAIN RES, V636, P139, DOI 10.1016/0006-8993(94)90188-0; Holtzman DM, 1996, ANN NEUROL, V39, P114, DOI 10.1002/ana.410390117; Johnston MV, 2005, BRAIN PATHOL, V15, P234; Jonhagen ME, 1998, DEMENT GERIATR COGN, V9, P246, DOI 10.1159/000017069; Juric DM, 2001, INT J DEV NEUROSCI, V19, P675, DOI 10.1016/S0736-5748(01)00044-2; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; Luk YO, 2004, DRUG DELIV, V11, P319, DOI 10.1080/10717540490494104; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; Robertson Charlene M T, 2002, Pediatr Crit Care Med, V3, P345, DOI 10.1097/00130478-200210000-00003; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Zhou Zheng, 2003, Journal of Basic and Clinical Physiology and Pharmacology, V14, P217	46	75	77	1	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2008	25	3					225	234		10.1089/neu.2007.0405			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	282PJ	WOS:000254579400006	18352836				2022-02-06	
J	Stocchetti, N; Zanaboni, C; Colombo, A; Citerio, G; Beretta, L; Ghisoni, L; Zanier, ER; Canavesi, K				Stocchetti, Nino; Zanaboni, Clelia; Colombo, Angelo; Citerio, Giuseppe; Beretta, Luigi; Ghisoni, Laura; Zanier, Elisa Roncati; Canavesi, Katia			Refractory intracranial hypertension and "second-tier" therapies in traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						intracranial pressure; surgical decompression; barbiturates; hyperventilation; outcome; traumatic brain injury	SEVERE HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; BLOOD-FLOW; PRESSURE; HYPERVENTILATION; MANAGEMENT; SCALE	Objective: To quantify the occurrence of high intracranial pressure (HICP) refractory to conventional medical therapy after traumatic brain injury (TBI) and to describe the use of more aggressive therapies (profound hyperventilation, barbiturates, decompressive craniectomy). Design: Prospective study of 407 consecutive TBI patients Setting: Three neurosurgical intensive care units (ICU). Measurements and results: Intracranial pressure (ICP) was studied during the first week after TBI; 153 patients had at least 1 day of ICP>20mmHg. Early surgery was necessary for 221 cases, and standard medical therapy [sedation, mannitol, cerebrospinal fluid (CSF) withdrawal, PaCO2 30-35mmHg] was used in 135 patients. Reinforced treatment (PaCO2 25-29mmHg, induced arterial hypertension, muscle relaxants) was used in 179 cases (44%), and second-tier therapies in 80 (20%). Surgical decompression and/or barbiturates were used in 28 of 407 cases (7%). Six-month outcome was recorded in 367 cases using the Glasgow outcome scale (GOS). The outcome was favorable (good recovery or moderate disability) in 195 cases (53%) and unfavorable (all the other categories) in 172 (47%). HICP was associated with worse outcome. Outcome for cases who had received second-tier therapies was significantly worse (43% favorable at 6 months, p=0.03). Conclusions: HICP is frequent and is associated with worse outcome. ICP was controlled by early surgery and first-tier therapies in the majority of cases. Profound hyperventilation, surgical decompression and barbiturates were used in various combinations in a minority of cases. The indications for surgical decompression and/or barbiturates seem restricted to less than 10% of severe TBI.	[Stocchetti, Nino; Zanaboni, Clelia; Colombo, Angelo; Ghisoni, Laura; Zanier, Elisa Roncati; Canavesi, Katia] Osped Maggiore Policlin Mangiagalli & Regina Elen, Fdn IRCCS, Neurosci Intens Care Unit, I-20122 Milan, Italy; [Citerio, Giuseppe] Terapia Intens Neurochirurg Osped S Gerardo, Monza, Italy; [Beretta, Luigi] Terapia Intens Neurochirurg Osped S Gerardo, Milan, Italy		Stocchetti, N (corresponding author), Osped Maggiore Policlin Mangiagalli & Regina Elen, Fdn IRCCS, Neurosci Intens Care Unit, Via F Sforza 35, I-20122 Milan, Italy.	stocchet@policlinico.mi.it	Zanier, Elisa/AAA-8095-2020; Citerio, Giuseppe/B-1839-2015; Stocchetti, Nino/O-7444-2017	Zanier, Elisa/0000-0002-3011-8718; Citerio, Giuseppe/0000-0002-5374-3161; Stocchetti, Nino/0000-0003-3250-6834			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Citerio G, 2000, ACTA NEUROCHIR, V142, P769, DOI 10.1007/s007010070091; Citerio G, 2007, INTENS CARE MED, V33, P45, DOI 10.1007/s00134-006-0381-5; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Compagnone C, 2005, NEUROSURGERY, V57, P1183; *DEP HUM SERV VICT, 2003, TRAUM TREATM TRIAL N; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HUKKELHOVEN CW, 2000, J NEUROSURG, V97, P549; JENNETT B, 1975, LANCET, V1, P480; Kunze E, 1998, ACT NEUR S, V71, P16; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; ROBERTS I, 2004, COCHRANE LIBRARY; ROBERTS I, 2000, COCHRANE DB SYST REV, V2; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; Schneider GH, 2002, ACT NEUR S, V81, P77; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; The Brain Trauma Foundation. The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P537; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; 1988, LANCET, V1, P1204	33	75	81	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2008	34	3					461	467		10.1007/s00134-007-0948-9			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263EQ	WOS:000253200800011	18066523				2022-02-06	
J	Byrnes, KR; Faden, AI				Byrnes, Kimberly R.; Faden, Alan I.			Role of cell cycle proteins in CNS injury	NEUROCHEMICAL RESEARCH			English	Article						brain injury; flavopiridol; proliferation; review; spinal cord injury; stroke	SPINAL-CORD-INJURY; IN-VITRO; CEREBRAL-ISCHEMIA; DEPENDENT KINASES; RAT-BRAIN; REGULATORY PROTEINS; AXONAL REGENERATION; FUNCTIONAL RECOVERY; NEURONAL APOPTOSIS; PROMOTES SURVIVAL	Following trauma or ischemia to the central nervous system (CNS), there is a marked increase in the expression of cell cycle-related proteins. This up-regulation is associated with apoptosis of post-mitotic cells, including neurons and oligodendrocytes, both in vitro and in vivo. Cell cycle activation also induces proliferation of astrocytes and microglia, contributing to the glial scar and microglial activation with release of inflammatory factors. Treatment with cell cycle inhibitors in CNS injury models inhibits glial scar formation and neuronal cell death, resulting in substantially decreased lesion volumes and improved behavioral recovery. Here we critically review the role of cell cycle pathways in the pathophysiology of experimental stroke, traumatic brain injury and spinal cord injury, and discuss the potential of cell cycle inhibitors as neuroprotective agents.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA		Byrnes, KR (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Room EP16A,New Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	krb27@georgetown.edu		Byrnes, Kimberly/0000-0002-7501-7734			ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; Akashiba H, 2006, CELL MOL LIFE SCI, V63, P2397, DOI 10.1007/s00018-006-6194-4; Becker EBE, 2004, PROG NEUROBIOL, V72, P1, DOI 10.1016/j.pneurobio.2003.12.005; Boonstra J, 2003, J CELL BIOCHEM, V90, P244, DOI 10.1002/jcb.10617; Bossenmeyer-Pourie C, 1999, NEUROSCIENCE, V91, P221, DOI 10.1016/S0306-4522(98)00565-X; BURNS KA, 2007, CEREB CORTEX; Campagne MV, 1998, NEUROSCIENCE, V84, P1097, DOI 10.1016/S0306-4522(97)00580-0; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cicero S, 2005, J NEUROSCI, V25, P9658, DOI 10.1523/JNEUROSCI.1773-05.2005; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Dai Yun, 2004, Curr Oncol Rep, V6, P123, DOI 10.1007/s11912-004-0024-3; DeGregori J, 2006, CURR MOL MED, V6, P739; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Faden AI, 2005, NEUROPHARMACOLOGY, V49, P410, DOI 10.1016/j.neuropharm.2005.04.001; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fischer Peter M, 2003, Prog Cell Cycle Res, V5, P235; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Hayashi T, 1999, NEUROL RES, V21, P695, DOI 10.1080/01616412.1999.11741000; HOKE A, 1994, PERSPECT DEV NEUROBI, V2, P269; Iannotti C, 2004, EXP NEUROL, V189, P317, DOI 10.1016/j.expneurol.2004.05.033; Ino H, 2001, J NEUROSCI, V21, P6086, DOI 10.1523/JNEUROSCI.21-16-06086.2001; Jorda EG, 2003, NEUROPHARMACOLOGY, V45, P672, DOI 10.1016/S0028-3908(03)00204-1; Kang SK, 2006, PROTEOMICS, V6, P2797, DOI 10.1002/pmic.200500621; Katano H, 2000, NEUROREPORT, V11, P2073, DOI 10.1097/00001756-200007140-00003; Kato H, 2003, BRAIN RES BULL, V60, P215, DOI 10.1016/S0361-9230(03)00036-4; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Koguchi K, 2003, J NEUROSCI RES, V74, P898, DOI 10.1002/jnr.10829; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Kuan CY, 2004, J NEUROSCI, V24, P10763, DOI 10.1523/JNEUROSCI.3883-04.2004; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; Liu DX, 2004, J NEUROSCI, V24, P8720, DOI 10.1523/JNEUROSCI.1821-04.2004; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Love S, 2003, PROG NEURO-PSYCHOPH, V27, P267, DOI 10.1016/S0278-5846(03)00022-8; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Meijer L, 2003, ACCOUNTS CHEM RES, V36, P417, DOI 10.1021/ar0201198; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Nagy Z, 2000, NEUROBIOL AGING, V21, P761, DOI 10.1016/S0197-4580(00)00223-2; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakatsuji Y, 2001, J NEUROSCI RES, V66, P487, DOI 10.1002/jnr.1240; Newcomb EW, 2004, CELL CYCLE, V3, P230; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Nguyen MD, 2002, CELL DEATH DIFFER, V9, P1294, DOI 10.1038/sj.cdd.4401108; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; OKANO HJ, 1993, J NEUROSCI, V13, P2930; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Otsuka Y, 2004, NEUROSCI LETT, V365, P180, DOI 10.1016/j.neulet.2004.04.083; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Park DS, 2000, NEUROBIOL AGING, V21, P771, DOI 10.1016/S0197-4580(00)00220-7; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; Rashidian J, 2005, P NATL ACAD SCI USA, V102, P14080, DOI 10.1073/pnas.0500099102; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sakurai M, 2000, STROKE, V31, P200, DOI 10.1161/01.STR.31.1.200; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Small DL, 2001, BRAIN RES, V900, P26, DOI 10.1016/S0006-8993(01)02102-3; Strazza M, 2004, NEUROCHEM RES, V29, P923, DOI 10.1023/B:NERE.0000021236.32785.37; Swanton C, 2004, LANCET ONCOL, V5, P27, DOI 10.1016/S1470-2045(03)01321-4; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Tanaka H, 2004, NEUROSCIENCE, V127, P155, DOI 10.1016/j.neuroscience.2004.05.010; Thornton BR, 2003, NAT CELL BIOL, V5, P1090, DOI 10.1038/ncb1066; Tian DS, 2006, J NEUROSCI RES, V84, P1053, DOI 10.1002/jnr.20999; Velardo MJ, 2004, J NEUROSCI, V24, P8562, DOI 10.1523/JNEUROSCI.3316-04.2004; Verdaguer E, 2004, J PHARMACOL EXP THER, V308, P609, DOI 10.1124/jpet.103.057497; Wang FH, 2002, J CEREBR BLOOD F MET, V22, P171, DOI 10.1097/00004647-200202000-00005; Wartiovaara K, 2002, J NEUROSCI, V22, P815, DOI 10.1523/JNEUROSCI.22-03-00815.2002; Wen Y, 2004, J BIOL CHEM, V279, P22684, DOI 10.1074/jbc.M311768200; Wiessner C, 1996, NEUROSCIENCE, V72, P947, DOI 10.1016/0306-4522(95)00601-X; Yamada J, 2006, BIOCHEM BIOPH RES CO, V349, P913, DOI 10.1016/j.bbrc.2006.08.126; Zhu Z, 2007, GLIA, V55, P546, DOI 10.1002/glia.20476	78	75	79	0	3	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	OCT	2007	32	10					1799	1807		10.1007/s11064-007-9312-2			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	212FH	WOS:000249578500025	17404835				2022-02-06	
J	Rauh, MJ; Macera, CA; Ji, M; Wiksten, DL				Rauh, Mitchell J.; Macera, Caroline A.; Ji, Ming; Wiksten, Denise L.			Subsequent injury patterns in girls' high school sports	JOURNAL OF ATHLETIC TRAINING			English	Article						epidemiology; surveillance; sports injuries; reinjuries; female athletes	RISK-FACTORS; CONCUSSION; PREVENTION; EPIDEMIOLOGY; BASKETBALL; MANAGEMENT; ATHLETICS; SOCCER; RATES	Context: Girls' participation in high school sports has increased 79.5% since 1975-1976. The incidence of injury among boys in high school sports has been well documented, but information regarding the incidence, severity, and type of injury among girls in high school sports is limited. Objective: To examine the effects of subsequent injuries among high school girls in 5 sports. Design: Observational cohort. Setting: Existing data from the 1995-1997 National Athletic Trainers' Association High School Injury Surveillance database. Patients or Other Participants: Girl athletes (n = 25 187 player-seasons) participating in 5 varsity high school sports: basketball, field hockey, soccer, softball, and volleyball. Main Outcome Measure(s): Injury status, body location, injury type, time lost from injury, and number of players at risk for injury as recorded by athletic trainers and submitted to the Sports Injury Monitoring System. Results: Overall, 23.3% of the athletes had 2 or more injuries within a sport; basketball and soccer athletes were most vulnerable. Overall, the probability of an athlete sustaining 3 or more injuries was 38.6%, and the risk was highest for field hockey players (61.9%). The risk of subsequent injury at a new body location was almost 2 times higher than reinjury at the same body location (risk ratio = 1.7, 95% confidence interval = 1.6, 1.8) and was similar for all sports except volleyball. Only in softball was the proportion of reinjuries causing 8 or more days lost from participation greater than the proportion of new injuries causing similar time loss. Softball and volleyball had the highest proportion of reinjuries at the shoulder, especially rotator cuff strains. The proportion of knee reinjuries was significantly higher than new injuries for all sports except soccer. The proportion of anterior cruciate ligament injuries was significantly higher for volleyball players only. Overall, the proportion of reinjuries was significantly higher for stress fractures and musculoskeletal condition injuries. Conclusions: Patterns of subsequent injury risk appear to vary among these 5 sports. Almost one quarter of the athletes incurred 2 or more injuries over a 3-year period, so the effects of subsequent injuries deserve more consideration.	[Rauh, Mitchell J.] Rocky Mt Univ Hlth Prof, Grad Program Orthopaed & Sports Phys Therapy, Provo, UT 84601 USA; [Rauh, Mitchell J.; Macera, Caroline A.; Ji, Ming; Wiksten, Denise L.] San Diego State Univ, San Diego, CA 92182 USA		Rauh, MJ (corresponding author), Rocky Mt Univ Hlth Prof, Grad Program Orthopaed & Sports Phys Therapy, 1662 West 820 North, Provo, UT 84601 USA.	mrauh@rmuohp.edu					Beachy G, 1997, AM J SPORT MED, V25, P675, DOI 10.1177/036354659702500515; Caine D, 2006, CLIN J SPORT MED, V16, P500, DOI 10.1097/01.jsm.0000251181.36582.a0; CAINE DJ, 1996, EPIDEMIOLOGY SPORTS, P387; CHALMERS DJ, 2002, INJ PREV S4, V8, P22; CHANDY T A, 1985, Physician and Sportsmedicine, V13, P106; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; EKSTRAND J, 1983, AM J SPORT MED, V11, P116, DOI 10.1177/036354658301100302; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; GARRICK JG, 1978, JAMA-J AM MED ASSOC, V239, P2245, DOI 10.1001/jama.239.21.2245; Gomez E, 1996, AM J SPORT MED, V24, P684, DOI 10.1177/036354659602400521; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Knowles SB, 2006, J ATHL TRAINING, V41, P207; Kucera KL, 2005, BRIT J SPORT MED, V39, P462, DOI 10.1136/bjsm.2004.013672; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lowe E B Jr, 1987, R I Med J, V70, P265; LYSENS RJ, 1989, AM J SPORT MED, V17, P612, DOI 10.1177/036354658901700504; LYSENS RJ, 1991, SPORTS MED, V12, P281, DOI 10.2165/00007256-199112050-00001; McGuine T, 2006, CLIN J SPORT MED, V16, P488, DOI 10.1097/01.jsm.0000248848.62368.43; MCKEAG D, 1993, PRIMARY CARE SPORTS; MCLAIN LG, 1989, PEDIATRICS, V84, P446; Meeuwisse WH, 2003, AM J SPORT MED, V31, P379, DOI 10.1177/03635465030310030901; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Murtaugh K, 2001, MED SCI SPORT EXER, V33, P201; *NAT FED STAT HIGH, PART HIGH SCHOOL INC; Powell JW, 1999, J ATHL TRAINING, V34, P277; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Rauh MJ, 2006, AM J EPIDEMIOL, V163, P151, DOI 10.1093/aje/kwj022; Rauh MJ, 2000, CLIN J SPORT MED, V10, P110, DOI 10.1097/00042752-200004000-00005; RENSTROM PAF, 1993, INSTR COURSE LECT, V42, P225; REQUA RK, 1991, SPORTS YOUTH SURV ST; RICE SG, 1985, WESTERN J MED, V142, P352; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shively R A, 1981, Phys Sportsmed, V9, P46, DOI 10.1080/00913847.1981.11711135; vanMechelen W, 1996, MED SCI SPORT EXER, V28, P1171, DOI 10.1097/00005768-199609000-00014; WATSON MD, 1987, AM J SPORT MED, V15, P251, DOI 10.1177/036354658701500310; Weaver NL, 2002, PATIENT EDUC COUNS, V46, P199, DOI 10.1016/S0738-3991(01)00213-0	38	75	76	0	12	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2007	42	4					486	494					9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	251AQ	WOS:000252343100008	18176621				2022-02-06	
J	Fazekas, G; Horvath, M; Troznai, T; Toth, A				Fazekas, Gabor; Horvath, Monika; Troznai, Tibor; Toth, Andras			Robot-mediated upper limb physiotherapy for patients with spastic hemiparesis: A preliminary study	JOURNAL OF REHABILITATION MEDICINE			English	Article						spasticity; hemiparesis; robotics; stroke; traumatic brain injury	THERAPY	Objective: To investigate the clinical usefulness of the REHAROB Therapeutic System, which provides passive robot-mediated physiotherapy for patients with spastic hemiparesis. Design: Controlled, randomized, preliminary study. Patients and methods: Thirty patients with hemiparesis as a consequence of upper motor neurone lesion were divided randomly into 2 groups: robotic and control. Subjects from both groups received 30 minutes of Bobath therapy sessions on 20 consecutive work days. Members of the robotic group received an additional 30 minutes of robot-mediated therapy on the same days. The clinical status of each patient was assessed before the first session and at the end of the programme. The difference in the scores was statistically evaluated by t-test for dependent variables in case of parametric data and Friedman's test in case of non-parametric data. Results: The majority of the parameters measured improved in both groups, but modified Ashworth score of shoulder adductors and elbow flexors showed a statistically significant change only in the robotic group. Conclusion: The results suggest that it could be useful to supplement traditional physiotherapy with this form of robotmediated therapy. Clinical investigation of a higher number of patients is planned in the near future.	Natl Inst Med Rehabil, H-1528 Budapest, Hungary; Budapest Univ Technol & Econ, Natl Inst Med Rehabil, Budapest, Hungary; Budapest Univ Technol & Econ, Szent Janos Hosp, Budapest, Hungary		Fazekas, G (corresponding author), Natl Inst Med Rehabil, Szanatorium Str 19th, H-1528 Budapest, Hungary.	fazekas123@t-online.hu					BOBATH B, 1990, ADULT HEMIPLEGIA EVA, P13; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; COOTE S, 2003, TECHNOL DISABIL, P27; Fasoli SE, 2004, ARCH PHYS MED REHAB, V85, P1106, DOI 10.1016/j.apmr.2003.11.028; Fazekas G, 2006, INT J REHABIL RES, V29, P251, DOI 10.1097/01.mrr.0000230050.16604.d9; Ferraro M, 2003, NEUROLOGY, V61, P1604, DOI 10.1212/01.WNL.0000095963.00970.68; FUGLMEYER AR, 1980, SCAND J REHABIL MED, P85; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hidler Joseph, 2005, Top Stroke Rehabil, V12, P22, DOI 10.1310/RYT5-62N4-CTVX-8JTE; Lum Peter, 2002, Top Stroke Rehabil, V8, P40; Lum PS, 2002, ARCH PHYS MED REHAB, V83, P952, DOI 10.1053/apmr.2001.33101; Toth A, 2005, INT C REHAB ROBOT, P127; Toth A, 2004, LECT NOTES CONTR INF, V306, P391	13	75	75	3	20	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2007	39	7					580	582		10.2340/16501977-0087			3	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	213IS	WOS:000249660700012	17724559	Green Submitted, gold			2022-02-06	
J	Kirshblum, SC; Priebe, MM; Ho, CH; Scelza, WM; Chiodo, AE; Wuermser, LA				Kirshblum, Steven C.; Priebe, Michael M.; Ho, Chester H.; Scelza, William M.; Chiodo, Anthony E.; Wuermser, Lisa-Ann			Spinal cord injury medicine. 3. Rehabilitation phase after acute spinal cord injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						electric stimulation; gait; rehabilitation; spinal cord injuries	TRAUMATIC BRAIN-INJURY; AUTONOMIC DYSREFLEXIA; SUPPORTED TREADMILL; HEAD-INJURY; PREVENTION	This self-directed learning module highlights the rehabilitation aspects of care for people with traumatic spinal cord injury (SCI). It is part of the chapter on SCI medicine in the Self-Directed Physiatric Education Program for practitioners and trainees in physical medicine and rehabilitation. This article specifically focuses on the formulation of a rehabilitation plan based on functional goals by level of injury. Such a plan includes mobility, activities of daily living, equipment needs, and adjustment issues after injury. The effect of a concomitant brain injury on rehabilitation is discussed. Medical complications seen in the rehabilitation stage such as autonomic dysreflexia, heterotopic ossification, neurogenic bowel, and orthostasis are addressed. Preparation for discharge is crucial to allow for a smooth transition to home. There have been advances in SCI rehabilitation research including in wheelchair technology, functional electric stimulation, and partial body weight-supported ambulation. Overall Article Objective: To describe outcomes and issues that may arise during the rehabilitation phase after spinal cord injury.	Kessler Inst Rehab, Spinal Cord Injury Serv, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Cleveland, OH USA; Case Western Reserve Univ, Dept Phys Med & Rehabil, Cleveland, OH 44106 USA; Carolinas Rehabil, Dept Phys Med & Rehabil, Charlotte, NC USA; Univ Michigan Hosp, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA		Kirshblum, SC (corresponding author), Kessler Inst Rehab, Spinal Cord Injury Serv, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	skirshblum@kessler-rehab.com		Ho, Chester/0000-0002-4238-5506			Algood SD, 2005, ARCH PHYS MED REHAB, V86, P380, DOI 10.1016/j.apmr.2004.05.017; Barbeau H, 2003, NEUROREHAB NEURAL RE, V17, P3, DOI 10.1177/0888439002250442; Bogie KM, 2006, ARCH PHYS MED REHAB, V87, P585, DOI 10.1016/j.apmr.2005.11.020; Boninger ML, 2005, J REHABIL RES DEV, V42, P9, DOI 10.1682/JRRD.2004.08.0103; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P869; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; DiMarco AF, 2006, AM J RESP CRIT CARE, V173, P1386, DOI 10.1164/rccm.200601-097CR; DiMarco AF, 2006, J SPINAL CORD MED, V29, P95, DOI 10.1080/10790268.2006.11753863; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Dobkin BH, 1999, NEUROREHAB NEURAL RE, V13, P157, DOI 10.1177/154596839901300301; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; Estrores IM, 2004, J SPINAL CORD MED, V27, P434, DOI 10.1080/10790268.2004.11752233; Field-Fote Edelle C, 2005, J Neurol Phys Ther, V29, P127; KIRSHBLUM S, 2002, SPINAL CORD MED, P275; Kirshblum SC, 2002, ARCH PHYS MED REHAB, V83, P1774, DOI 10.1053/apmr.2002.36070; LINDAN R, 1980, PARAPLEGIA, V18, P285, DOI 10.1038/sc.1980.51; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Massagli TL, 1999, ARCH PHYS MED REHAB, V80, P998, DOI 10.1016/S0003-9993(99)90050-3; Millis SR, 2004, J SPINAL CORD MED, V27, P428, DOI 10.1080/10790268.2004.11752232; *PAR VET AM, 1998, CONS SPIN CORD MED D; *PAR VET AM, 1997, CONS SPIN CORD MED A; *PAR VET AM, 1998, CONS SPIN CORD MED N; *PAR VET AM, 1999, CONS SPIN CORD MED O; PECKHAM PH, 2005, TOP SPINAL CORD INJ, V10, P126; Protas EJ, 2001, ARCH PHYS MED REHAB, V82, P825, DOI 10.1053/apmr.2001.23198; Rosito Olga, 2002, J Spinal Cord Med, V25, P174; Scivoletto G, 2005, ARCH PHYS MED REHAB, V86, P512, DOI 10.1016/j.apmr.2004.05.021; Singh RS, 2003, ARCH PHYS MED REHAB, V84, P1584, DOI 10.1053/S0003-9993(03)00347-2; Smith M, 2002, SPINAL CORD, V40, P11, DOI 10.1038/sj.sc.3101226; Sommer JL, 2004, BRAIN INJURY, V18, P1297, DOI 10.1080/02699050410001672288; Stiens SA, 1997, ARCH PHYS MED REHAB, V78, pS86, DOI 10.1016/S0003-9993(97)90416-0; Stiens SA, 1998, SPINAL CORD, V36, P777, DOI 10.1038/sj.sc.3100702; Strubreither W, 1997, SPINAL CORD, V35, P487, DOI 10.1038/sj.sc.3100495; Sumida M, 2001, ARCH PHYS MED REHAB, V82, P391, DOI 10.1053/apmr.2001.19780; Teasell RW, 2000, ARCH PHYS MED REHAB, V81, P506, DOI 10.1053/mr.2000.3848; Wernig A, 1998, SPINAL CORD, V36, P744, DOI 10.1038/sj.sc.3100670; WILMOT CB, 1985, ARCH PHYS MED REHAB, V66, P227, DOI 10.1016/0003-9993(85)90148-0	38	75	78	1	21	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2007	88	3		1			S62	S70		10.1016/j.apmr.2006.12.003			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	143FX	WOS:000244706500014	17321851				2022-02-06	
J	Andersson, EE; Emanuelson, I; Bjorklund, R; Stalhammar, DA				Andersson, E. Elgmark; Emanuelson, I.; Bjorklund, R.; Stalhammar, D. A.			Mild traumatic brain injuries: the impact of early intervention on late sequelae. A randomized controlled trial	ACTA NEUROCHIRURGICA			English	Article						mild traumatic brain injuries; post-concussion symptoms; randomised controlled trial; rehabilitation	SF-36 HEALTH SURVEY; 18-TO 64-YEAR-OLD SWEDES; ROUTINE FOLLOW-UP; HEAD-INJURY; LIFE SATISFACTION; WESTERN SWEDEN; ADULTS; REHABILITATION; RELIABILITY; POPULATION	Background. Positive results from early clinical intervention of mild traumatic brain injury (MTBI) patients by rehabilitation specialists have been reported. Various treatments have been used, but few controlled studies are published. We hypothesised that early rehabilitation of selected MTBI patients would reduce long term sequelae. Method. A randomised controlled trial with one year follow-up. Among 1719 consecutive patients with MTBI, 395 individuals, 16-60 years of age, met the MTBI definition. Exclusion criteria were: previous clinically significant brain disorders and/or a history of substance abuse. The control group (n = 131) received regular care. The intervention group (n = 264) was examined by a rehabilitation specialist. 78 patients were mainly referred to an occupational therapist. The problems were identified in daily activities and in terms of post-concussion symptoms (PCS), an individualised, tailored treatment was given. Primary endpoint was change in rate of PCS and in life satisfaction at one-year follow-up between the groups. Findings. No statistical differences were found between the intervention and control groups. Patients who experienced few PCS two to eight weeks after the injury and declined rehabilitation recovered and returned to their pre-injury status. Patients who suffered several PCS and accepted rehabilitation did not recover after one year. Interpretation. In this particular MTBI sample, early active rehabilitation did not change the outcome to a statistically-significant degree. Further studies should focus on patients with several complaints during the first 1-3 months and test various types of interventions.	Jonkoping Univ, Dept Rehabil, Sch Hlth Sci, SE-55111 Jonkoping, Sweden; Univ Gothenburg, Inst Clin Neurosci, Dept Rehabil Med, Gothenburg, Sweden; Univ Gothenburg, Reg Rehabil Unit, Dept Hlth & Women & Children, Gothenburg, Sweden; Sodra Alvsborgs Hosp, Rehabil Ctr, Boras, Sweden; Univ Gothenburg, Inst Clin Neurosci, Sahlgrenska Univ Hosp, Dept Neurosurg, Gothenburg, Sweden		Andersson, EE (corresponding author), Jonkoping Univ, Dept Rehabil, Sch Hlth Sci, Box 1026, SE-55111 Jonkoping, Sweden.	elisabeth.elgmark@telia.com					Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Branholm I-B, 1992, THESIS U UMEA UMEA; BRANHOLM IB, 1994, DISABIL REHABIL, V16, P205; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; EGLMARK EA, 2006, J REHABIL MED, V38, P26; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Good P., 2000, PERMUTATION TESTS PR; GREEN BS, 1997, MILD TRAUMATIC BRAIN, P2; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hoffmann B, 2002, ACT NEUR S, V79, P33; HOLM S, 1979, SCAND J STAT, V6, P65; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; KARLOWSKI TR, 1975, JAMA-J AM MED ASSOC, V231, P1038, DOI 10.1001/jama.231.10.1038; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MATSUTSUYU JS, 1969, AM J OCCUP THER, V23, P323; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ, P3; Melin R, 2003, J REHABIL MED, V35, P84, DOI 10.1080/16501970306119; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; OAKLEY F, 1986, OCCUP THER J RES, V6, P157, DOI 10.1177/153944928600600303; ODEN A, 1975, ANN STAT, V3, P518, DOI 10.1214/aos/1176343082; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Paniak C, 2000, BRAIN INJURY, V14, P219; Pocock, 1983, CLIN TRIALS PRACTICA; POCOCK SJ, 1979, BIOMETRICS, V35, P183, DOI 10.2307/2529944; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Salazar AM, 2002, J NEUROL NEUROSUR PS, V73, P239, DOI 10.1136/jnnp.73.3.239; SILVERBAGECARLS, 1986, EPIDEMIOLOGY INJURIE, P1; SIMOVICI S, 1976, WORK LEISURE SOCIOGE, P84; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Sullivan M, 1998, J CLIN EPIDEMIOL, V51, P1105, DOI 10.1016/S0895-4356(98)00102-4; SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; *WHO SWED COUNC, 1996, ICD 10 STAT CLASS DI; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009	53	75	76	0	9	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	FEB	2007	149	2					151	160		10.1007/s00701-006-1082-0			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	132UV	WOS:000243968800009	17252176				2022-02-06	
J	Mdzinarishvili, A; Kiewert, C; Kumar, V; Hillert, M; Klein, J				Mdzinarishvili, A.; Kiewert, C.; Kumar, V.; Hillert, M.; Klein, J.			Bilobalide prevents ischemia-induced edema formation in vitro and in vivo	NEUROSCIENCE			English	Article						brain water content; Ginkgo biloba; hippocampal slices; middle cerebral artery occlusion; oxygen-glucose deprivation; water intoxication	CEREBRAL-ARTERY OCCLUSION; GINKGO-BILOBA; BRAIN EDEMA; PHOSPHOLIPID BREAKDOWN; EXTRACT; WATER; INJURY; MODEL; CONSTITUENT; AQUAPORIN-4	EGb761, a standardized extract of Ginkgo biloba, has neuroprotective properties in animal models of ischemia, an activity that is partially attributed to its constituent, bilobalide. EGb761 has also been reported to inhibit edema formation induced by toxins such as triethyltin. The goal of this study was to test the activity of pure bilobalicle to prevent edema formation in models of ischemia. Oxygen-glucose deprivation (OGD) in rat hippocampal slices served as a model of in vitro-ischemia. OGD caused cellular edema formation as indicated by an increase of slice water contents in 30 min. Bilobalide (1-10 mu M) reduced slice water contents in ischemic slices in a concentration-dependent manner. As a model of in vivo-ischemia, we performed middle cerebral artery occlusion (MCAO) in mice. Permanent MCAO caused cell death and swelling of the ischemic hemisphere within 24 h. Pretreatment of the mice with bilobalicle (10 mg/kg i.p.) reduced infarct area by 43% (as judged by 2,3,5-triphenyl-tetrazolium chloride (TTC) staining) and edema formation by 70% (as judged by hemispheric enlargement). In parallel experiments, pretreatment with bilobalide also reduced fore-brain water contents in the ischemic hemisphere by 57%. As an alternative model of brain edema formation, we used water intoxication to increase brain water content; bilobalicle, was, however, inactive in this model. We conclude that bilobalide strongly and specifically attenuates edema formation in models of brain ischemia in vitro and in vivo. Bilobalide may be therapeutically effective in brain edema which occurs secondarily to large hemispheric stroke and traumatic brain injury in humans. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.	Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, Amarillo, TX 79106 USA		Klein, J (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, Amarillo, TX 79106 USA.	jochen.klein@ttuhsc.edu	Klein, Jochen/B-9730-2008	Klein, Jochen/0000-0001-6971-3381			Ahlemeyer B, 2003, CELL MOL LIFE SCI, V60, P1779, DOI 10.1007/s00018-003-3080-1; Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Biber A, 2003, PHARMACOPSYCHIATRY, V36, pS32; Chandrasekaran K, 2001, BRAIN RES, V922, P282, DOI 10.1016/S0006-8993(01)03188-2; Chatterjee S.S., 1986, US patent, Patent No. [4,571,407, 4571407]; Chatterjee SS, 2003, PHARMACOPSYCHIATRY, V36, pS68; DeFeudis F. V., 2000, Current Drug Targets, V1, P25, DOI 10.2174/1389450003349380; Defeudis FV, 2002, PHARMACOL RES, V46, P565, DOI 10.1016/S1043-6618(02)00233-5; DORMAN DC, 1992, AM J VET RES, V53, P138; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122, DOI 10.1152/ajplegacy.1949.157.1.122; Gueniau C, 1997, J PHARMACOL EXP THER, V282, P1; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.med.44.1.289; Kimelberg HK, 2005, GLIA, V50, P389, DOI 10.1002/glia.20174; Kimelberg HK, 2004, NEUROSCIENCE, V129, P851, DOI 10.1016/j.neuroscience.2004.07.033; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Klein J, 1997, BRAIN RES, V755, P347, DOI 10.1016/S0006-8993(97)00239-4; Klein J, 2003, PHARMACOPSYCHIATRY, V36, pS78; KRIEGLSTEIN J, 1995, EUR J PHARM SCI, V3, P39, DOI 10.1016/0928-0987(94)00073-9; LEES KR, 2000, BRIT MED J, V56, P400; Lopachin RM, 2001, NEUROSCIENCE, V103, P971, DOI 10.1016/S0306-4522(01)00035-5; MacGregor DG, 2003, J NEUROCHEM, V85, P1402, DOI 10.1046/j.1471-4159.2003.01772.x; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mdzinarishvili A, 2005, NEUROSCI LETT, V383, P49, DOI 10.1016/j.neulet.2005.03.042; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; OLSON JE, 1990, ANN EMERG MED, V19, P1113, DOI 10.1016/S0196-0644(05)81514-8; OTANI M, 1986, ACTA NEUROPATHOL, V69, P54, DOI 10.1007/BF00687039; Pierre S, 1999, NEUROREPORT, V10, P47, DOI 10.1097/00001756-199901180-00009; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; SANCESARIO G, 1986, ACTA NEUROPATHOL, V72, P3, DOI 10.1007/BF00687941; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Siklos L, 1997, NEUROSCIENCE, V79, P1013, DOI 10.1016/S0306-4522(97)00031-6; Steiner T, 2001, NEUROLOGY, V57, pS61, DOI 10.1212/WNL.57.suppl_2.S61; Sydserff SG, 1996, NEURODEGENERATION, V5, P81, DOI 10.1006/neur.1996.0011; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Weichel O, 1999, N-S ARCH PHARMACOL, V360, P609, DOI 10.1007/s002109900131; Westman J, 2000, AMINO ACIDS, V19, P339, DOI 10.1007/s007260070065; Zheng SX, 2000, ACTA PHARMACOL SIN, V21, P151	38	75	87	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JAN 5	2007	144	1					217	222		10.1016/j.neuroscience.2006.08.037			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	117GD	WOS:000242860100022	17014966				2022-02-06	
J	Niederland, T; Makovi, H; Gal, V; Andreka, B; Abraham, CS; Kovacs, J				Niederland, Tamas; Makovi, Helga; Gal, Veronika; Andreka, Bertalan; Abraham, Csongor S.; Kovacs, Jozsef			Abnormalities of pituitary function after traumatic brain injury in children	JOURNAL OF NEUROTRAUMA			English	Article						children; head injury; pituitary dysfunction	GROWTH-HORMONE DEFICIENCY; HEAD TRAUMA; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; CONSENSUS GUIDELINES; HYPOPITUITARISM; HYPOGONADISM; HYPOTHYROIDISM; INSUFFICIENCY; CHILDHOOD	Traumatic brain injury (TBI) is a frequent cause of neuroendocrine dysfunction typically in male adults. Head injuries are also common in childhood, but only a few case reports outlined the endocrine consequences. The aim of this study was to reveal anterior pituitary function in children with history of hospitalization due to mild to severe head trauma. Our endocrine follow-up study was performed between October 2003 and February 2004 in the Pediatric Department of Petz Al-adar County Teaching Hospital, Gyor, Hungary. Twenty-six children (17 boys and nine girls, aged 11.47 +/- 0.75 years) at 30.6 +/- 8.3 months after head injury and 21 age-matched controls were enrolled. Basal and stimulated anterior pituitary and peripheral hormone concentrations were measured by routine laboratory methods. Pituitary dysfunction was detected in 61% of patients with TBI history. All growth hormone (GH) parameters measured and calculated were significantly (P < 0.05) lower in TBI group than in controls after L-DOPA stimulation. Similar difference was detected 60 min after insulin provocation. Forty-two percent of all TBI children showed insufficient growth hormone (GH) response in both stimulation tests, 73% of these cases were boys. Cortisol levels of TBI patients were significantly (p < 0.05) lower all through the insulin test than values measured in control group. The degree of pituitary dysfunction was independent from the severity of TBI. Our study confirms the high risk for hypopituitarism in children with TBI despite the lack of obvious clinical symptoms. We suggest screening of pituitary function after any kind of brain trauma requiring hospitalization in childhood.	Peta Aladar Cty Teaching Hosp, Dept Pediat, H-9023 Gyor, Hungary; Peta Aladar Cty Teaching Hosp, Dept Isotop Diagnost, H-9023 Gyor, Hungary; Univ Debrecen, Dept Pharmaceut Technol, H-4012 Debrecen, Hungary; Univ Szeged, Dept Pediat, H-6720 Szeged, Hungary		Niederland, T (corresponding author), Peta Aladar Cty Teaching Hosp, Dept Pediat, Vasvari P U 2, H-9023 Gyor, Hungary.	niederlandt@petz.gyor.hu					Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Casanueva FF, 2005, ARCH PHYS MED REHAB, V86, P463, DOI 10.1016/j.apmr.2004.05.018; Childers MK, 1998, BRAIN INJURY, V12, P517, DOI 10.1080/026990598122476; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cryan E., 1918, DTSCH MED WOCHENSCHR, V44, P1261; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; EDWARDS OM, 1986, MEDICINE, V65, P281; EICHLER I, 1988, J ENDOCRINOL INVEST, V11, P409, DOI 10.1007/BF03349069; EIHOLZER U, 1986, EUR J PEDIATR, V145, P128, DOI 10.1007/BF00441873; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; Gandrud LM, 2004, GROWTH HORM IGF RES, V14, P185, DOI 10.1016/j.ghir.2003.11.003; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; GUNN IR, 1991, ANN CLIN BIOCHEM, V28, P327, DOI 10.1177/000456329102800402; GUZMAN AL, 1992, ACTA PAEDIATR, V81, P698, DOI 10.1111/j.1651-2227.1992.tb12337.x; Israel E, 2000, J CLIN ENDOCR METAB, V85, P3990; Juul A, 2002, HORM RES, V58, P233, DOI 10.1159/000066265; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Simmonds M, 1914, DEUT MED WOCHENSCHR, V40, P322, DOI 10.1055/s-0029-1190185; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	34	75	75	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					119	127		10.1089/neu.2005.369ER			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100011	17263675				2022-02-06	
J	Leal-Noval, SR; Rincon-Ferrari, MD; Marin-Niebla, A; Cayuela, A; Arellano-Orden, V; Marin-Caballos, A; Amaya-Villar, R; Ferrandiz-Millon, C; Murillo-Cabeza, F				Leal-Noval, Santiago Ramon; Rincon-Ferrari, Maria Dolores; Marin-Niebla, Ana; Cayuela, Aurelio; Arellano-Orden, Victoria; Marin-Caballos, Antonio; Amaya-Villar, Rosario; Ferrandiz-Millon, Carmen; Murillo-Cabeza, Francisco			Transfusion of erythrocyte concentrates produces a variable increment on cerebral oxygenation in patients with severe traumatic brain injury - A preliminary study	INTENSIVE CARE MEDICINE			English	Article						brain hypoxia; cerebral oxygenation; erythrocytes; neurotrauma; PtiO(2); red blood cells; severe brain injury; transfusion	BLOOD-CELL TRANSFUSION; INTENSIVE-CARE; STORED-BLOOD; ANEMIA; RISK; DELIVERY; INCREASE; TENSION	Objective: To investigate the long-term influence of erythrocyte transfusion on cerebral oxygenation in patients with severe traumatic brain injury. Design: Prospective and observational study. Setting: Neurotrauma intensive care unit of trauma center level I. Patients: Sixty consecutive, hemodynamically stable patients with severe traumatic brain injury, pretransfusion hemoglobin < 100 g/l, non-bleeding and monitored through intracranial pressure and brain tissue partial pressure of oxygen (PtiO(2)) catheters were included. Interventions: Transfusion of 1-2 units of red blood cells. Measurements and results: Ten sets of variables (pretransfusion, end of transfusion, and 1, 2, 3, 4, 5, 6, 12 and 24 h after transfusion) were recorded, including: PtiO(2), cerebral perfusion pressure (CPP), end-tidal CO2, peripheral saturation of oxygen, temperature, hemoglobin, lactate and PaO2/FiO(2) ratio. Transfusion was associated with an increase in PtiO(2) during a 6-h period, with a peak at 3 h (26.2%; p = 0.0001) in 78.3% of the patients. No relationship was observed between PtiO(2), CPP and hemoglobin increments. The relative increment in PtiO(2) at hour 3 was only correlated with baseline PtiO(2) (r(2) 0.166; p = 0.001). All of the patients with basal PtiO(2) < 15 mmHg showed an increment in PtiO(2) versus 74.5% of patients with basal PtiO(2) >= 15 mmHg (p < 0.01, hour 3). Conclusions: Erythrocyte transfusion is associated with a variable and prolonged increment of cerebral tissue oxygenation in anemic patients with severe traumatic brain injury. Low baseline PtiO(2) levels (< 15 mmHg) could define those patients who benefit the most from erythrocyte transfusion.	Hosp Univ Virgen Rocio, Seville 41013, Spain		Leal-Noval, SR (corresponding author), Hosp Univ Virgen Rocio, Avda Manuel Siurot S NR, Seville 41013, Spain.	sramon@cica.es	Cayuela, Aurelio/C-6698-2012; Cayuela, Aurelio/AAZ-1294-2020; Noval, Santiago/K-4515-2019	Cayuela, Aurelio/0000-0002-4936-9402; Marin Niebla, Ana/0000-0002-7592-6815			Casutt M, 1999, CRIT CARE MED, V27, P2194, DOI 10.1097/00003246-199910000-00021; Daugherty WP, 2004, NEUROSURGERY, V54, P1223, DOI 10.1227/01.NEU.0000119238.68938.5D; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Fernandes CJ, 2001, CRIT CARE, V5, P362, DOI 10.1186/cc1070; Ho J, 2003, CRIT CARE MED, V31, pS687, DOI 10.1097/01.CCM.0000099349.17094.A3; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Leal-Noval SR, 2000, CRIT CARE MED, V28, P935, DOI 10.1097/00003246-200004000-00004; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; Marin-Caballos A, 2005, CRIT CARE, V9, pR670, DOI 10.1186/cc3822; Pendem S, 2006, NEUROCRIT CARE, V4, P63, DOI 10.1385/NCC:4:1:063; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Smith MJ, 2004, J NEUROSURG, V101, P1, DOI 10.3171/jns.2004.101.1.0001; Spahn DR, 2006, ANESTHESIOLOGY, V104, P905, DOI 10.1097/00000542-200605000-00002; Suttner S, 2004, ANESTH ANALG, V99, P2, DOI 10.1213/01.ANE.0000120163.44315.47; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Walsh TS, 2006, INTENS CARE MED, V32, P100, DOI 10.1007/s00134-005-2855-2; Weiskopf RB, 2006, ANESTHESIOLOGY, V104, P911, DOI 10.1097/00000542-200605000-00005; Yamada S, 2005, CEREBROVASC DIS, V20, P164, DOI 10.1159/000087200; Yamada S, 2003, STROKE, V34, P2781, DOI 10.1161/01.STR.0000103857.13812.9A	23	75	76	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	NOV	2006	32	11					1733	1740		10.1007/s00134-006-0376-2			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	097MZ	WOS:000241453400012	17019549				2022-02-06	
J	Berger, RP				Berger, Rachel Pardes			The use of serum biomarkers to predict outcome after traumatic brain injury in adults and children	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						neuron-specific enolase; outcome; serum biomarkers; S100B; traumatic brain injury	NEURON-SPECIFIC ENOLASE; MINOR HEAD-INJURY; S-100 PROTEIN MEASUREMENTS; POST-CONCUSSION SYMPTOMS; CARDIAC-ARREST; S100B LEVELS; NEUROPSYCHOLOGICAL FUNCTION; NEUROCOGNITIVE PERFORMANCE; COMPUTED-TOMOGRAPHY; BEHAVIOR PROBLEMS	Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in adults and children. Predicting outcome after TBI is difficult, but it is important for acute management, counseling of family members, and provision of rehabilitation services. Serum biomarkers may be useful alone or in combination with clinical variables to predict outcome after TBI. This article reviews the potential uses of serum biomarkers for the clinician, current literature related to the use of serum biomarkers for outcome prediction after adult and pediatric TBI, limitations of the literature, and future direction for this field.	Childrens Hosp Pittsburgh, Dept Pediat, Div Child Advocacy, Pittsburgh, PA 15213 USA		Berger, RP (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat, Div Child Advocacy, 3705 5th Ave, Pittsburgh, PA 15213 USA.	rberger@pitt.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD43843-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER		Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BEERS S, IN PRESS J NEUROTRAU; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BLAU TH, 1977, PROF PSYCHOL, V8, P464, DOI 10.1037/0735-7028.8.4.464; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Carter BG, 2005, INTENS CARE MED, V31, P840, DOI 10.1007/s00134-005-2634-0; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; HANS P, 1983, J NEUROSURG, V58, P689, DOI 10.3171/jns.1983.58.5.0689; Hatpio R, 2004, CLIN BIOCHEM, V37, P512, DOI 10.1016/j.clinbiochem.2004.05.012; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P177; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; KARKELA J, 1993, J NEUROL SCI, V116, P100, DOI 10.1016/0022-510X(93)90095-G; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kratz A, 2002, AM J CLIN PATHOL, V118, P856, DOI 10.1092/BTWQ5YMYVQ67QK9L; Lima JE, 2004, BRAZ J MED BIOL RES, V37, P19, DOI 10.1590/S0100-879X2004000100003; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Martens P, 1996, ACAD EMERG MED, V3, P126, DOI 10.1111/j.1553-2712.1996.tb03399.x; Martz LL, 1998, DESCANT, V29, P11; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nishiyama H, 2002, P NATL ACAD SCI USA, V99, P4037, DOI 10.1073/pnas.052020999; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Portela LVC, 2002, CLIN DIAGN LAB IMMUN, V9, P164, DOI 10.1128/CDLI.9.1.164-166.2002; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 2001, NEUROSURGERY, V49, P1491, DOI 10.1097/00006123-200112000-00055; Rabinowicz AL, 1996, EPILEPSIA, V37, P122, DOI 10.1111/j.1528-1157.1996.tb00002.x; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; THOMAS DGT, 1977, LANCET, V1, P113; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VANDEPOL M, 1994, J NEURO-ONCOL, V19, P149, DOI 10.1007/BF01306456; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; Xiong ZG, 2000, EXP CELL RES, V257, P281, DOI 10.1006/excr.2000.4902; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	78	75	78	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2006	21	4					315	333		10.1097/00001199-200607000-00004			19	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	064SJ	WOS:000239109100004	16915008				2022-02-06	
J	Bermpohl, D; You, ZR; Korsmeyer, SJ; Moskowitz, MA; Whalen, MJ				Bermpohl, Daniela; You, Zerong; Korsmeyer, Stanley J.; Moskowitz, Michael A.; Whalen, Michael J.			Traumatic brain injury in mice deficient in Bid: effects on histopathology and functional outcome	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; Bid; brain injury; necrosis; trauma	CELL-DEATH; NEURONAL APOPTOSIS; SIGNALING COMPLEX; ACTIVATION; CASPASE-3; MITOCHONDRIA; RECEPTORS; CLEAVAGE; PATHWAY	Bid is a proapoptotic member of the Bcl-2 family that mediates cell death by caspase-dependent and -independent pathways. We tested mice genetically deficient in Bid in a controlled cortical impact (CCI) model to examine the hypothesis that Bid contributes to cell death and functional outcome after traumatic brain injury. After CCI, truncated Bid (15 kDa) was robustly detected in cortical brain homogenates of wild-type mice. Bid-/- mice had decreased numbers of cortical cells with acute plasmalemma injury at 6 h (wild type (WT), 1721 +/- 124; Bid-/-, 1173 +/- 129 cells/ x 200 field; P < 0.01), decreased numbers of cells expressing cleaved caspase-3 in the dentate gyrus at 48 h (WT, 113 +/- 15; Bid-/-, 65 +/- 9 cells/ x 200 field; P < 0.05), and reduced lesion volume at 12 days (Bid-/-, 5.9 +/- 0.4 mm(3); WT, 8.4 +/- 0.4 mm(3); P < 0.001), but did not differ from WT mice at later times after injury regarding lesion size (30 days) or brain tissue atrophy (40 days). Compared with naive mice, injured mice in both groups performed significantly worse on motor and Morris water maze (MWM) tests; however, mice deficient in Bid did not differ from WT in postinjury motor and MWM performance. The data show that Bid deficiency decreases early posttraumatic brain cell death and tissue damage, but does not reduce functional outcome deficits after CCI in mice.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat,Neurosci Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Charlestown, MA 02129 USA		Whalen, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat,Neurosci Ctr, 149 13th St RM 6403, Charlestown, MA 02129 USA.	mwhalen@partners.org	Moskowitz, Michael A/D-9916-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447, K08NS041969, R01NS037141] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [KO8NS41969, R01NS47447, R01NS37141] Funding Source: Medline		Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bermpohl D, 2003, J NEUROTRAUM, V20, P1053; Cevik IU, 2003, CELL DEATH DIFFER, V10, P928, DOI 10.1038/sj.cdd.4401250; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Franz G, 2002, J CEREBR BLOOD F MET, V22, P951, DOI 10.1097/00004647-200208000-00006; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Krajewska M, 2002, NEOPLASIA, V4, P129, DOI 10.1038/sj.neo.7900222; Krajewska M, 2004, EXP NEUROL, V189, P261, DOI 10.1016/j.expneurol.2004.05.020; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Sheibani N, 2004, CRIT CARE MED, V32, P2274, DOI 10.1097/01.CCM.0000145998.11686.ED; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Unal-Cevik I, 2004, STROKE, V35, P2189, DOI 10.1161/01.STR.0000136149.81831.c5; Wang X, 2003, J BIOL CHEM, V278, P29184, DOI 10.1074/jbc.M301624200; Wei MC, 2000, GENE DEV, V14, P2060; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yin XM, 2002, J BIOL CHEM, V277, P42074, DOI 10.1074/jbc.M204991200; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	32	75	78	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2006	26	5					625	633		10.1038/sj.jcbfm.9600258			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	038RA	WOS:000237239500004	16395279	Bronze			2022-02-06	
J	Liu, MC; Akle, V; Zheng, W; Dave, JR; Tortella, FC; Hayes, RL; Wang, KKW				Liu, MC; Akle, V; Zheng, W; Dave, JR; Tortella, FC; Hayes, RL; Wang, KKW			Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis	BIOCHEMICAL JOURNAL			English	Article						calpain; caspase; degradome; high throughput immunoblotting (HTPI); proteomics; traumatic brain injury (TBI)	II-SPECTRIN; PROTEOLYSIS; EXPRESSION; PROTEINS; CASPASE; INHIBITION; CHALLENGE; BREAKDOWN; TOOL	A major theme of TBI (traumatic brain injury) pathology is the over-activation of multiple proteases. We have previously shown that calpain-1 and -2, and caspase-3 simultaneously produced alpha II-spectrin BDPs (breakdown products) following TBI. In the present study, we attempted to identify a comprehensive set of protease substrates (degradome) for calpains and caspase-3. We further hypothesized that the TBI differential proteome is I likely to overlap significantly with the calpain- and caspase-3-degradomes. Using a novel HTPI (high throughput immunoblotting) approach and 1000 monoclonal antibodies (PowerB lot(TM)), we compared rat hippocampal lysates from 4 treatment groups: (i) naive, (ii) TBI (48 h after controlled cortical impact), (iii) in vitro calpain-2 digestion and (iv) in vitro caspase-3 digestion. In total, we identified 54 and 38 proteins that were vulnerable to calpain-2 and caspase-3 proteolysis respectively. In addition, the expression of 48 proteins was down-regulated following TBI, whereas that of only 9 was up-regulated. Among the proteins down-regulated in TBI, 42 of them overlapped with the calpain-2 and/or caspase-3 degradomes, suggesting that they might be proteolytic targets after TBI. We further confirmed several novel TBI-linked proteolytic substrates, including beta II-spectrin, striatin, synaptotagmin-1, synaptojanin-1 and NSF (N-ethylmaleimide-sensitive fusion protein) by traditional immunoblotting. In summary, we demonstrated that HTPI is a novel and powerful method for studying proteolytic pathways in vivo and in vitro.	Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, Gainesville, FL 32610 USA; Univ Florida, McKnight Brain Inst, Dept Neurosci, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA; Walter Reed Army Inst Res, Div Neurosci, Dept Neuropharmacol & Mol Biol, Silver Spring, MD USA; Banyan Biomarkers Inc, Alachua, FL 32615 USA		Wang, KKW (corresponding author), Univ Florida, McKnight Brain Inst, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, POB 100256, Gainesville, FL 32610 USA.	kwang1@ufl.edu	akle, veronica/AAD-7577-2019; Dave, Jitendra R/A-8940-2011	Wang, Kevin/0000-0002-9343-6473; Akle, Veronica/0000-0002-2050-5511	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS049175-01 A1, R01 NS049175] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175] Funding Source: NIH RePORTER		Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Castle JE, 2001, ELEC SOC S, V2001, P1; Cicala C, 2002, P NATL ACAD SCI USA, V99, P9380, DOI 10.1073/pnas.142287999; Clark AW, 1997, NEUROSCI LETT, V238, P53, DOI 10.1016/S0304-3940(97)00859-8; Gifford SM, 2003, ENDOCRINOLOGY, V144, P3639, DOI 10.1210/en.2002-0006; Hajimohammadreza I, 1997, J NEUROCHEM, V69, P1006; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; LEVILLIERS N, 1986, BIOCHIM BIOPHYS ACTA, V882, P113, DOI 10.1016/0304-4165(86)90062-0; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lorenz P, 2003, PROTEOMICS, V3, P991, DOI 10.1002/pmic.200300412; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; MCGINNIN KM, 1998, J BIOL CHEM, V273, P1999; Melnick M, 2001, BMC Dev Biol, V1, P15, DOI 10.1186/1471-213X-1-15; Overall CM, 2002, BIOL CHEM, V383, P1059, DOI 10.1515/BC.2002.114; Pasinetti GM, 2001, RESTOR NEUROL NEUROS, V18, P137; Phillips JB, 2000, STROKE, V31, P1686, DOI 10.1161/01.STR.31.7.1686; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, J NEUROCHEM, V68, P2328; Santella L, 2000, EXP CELL RES, V259, P117, DOI 10.1006/excr.2000.4969; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Yoo GH, 2002, CLIN CANCER RES, V8, P3910	29	75	79	1	3	PORTLAND PRESS LTD	LONDON	5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND	0264-6021	1470-8728		BIOCHEM J	Biochem. J.	MAR 15	2006	394		3				715	725		10.1042/BJ20050905			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	023OV	WOS:000236137000020	16351572	Green Published			2022-02-06	
J	Liu, WG; Qiu, WS; Zhang, Y; Wang, WM; Lu, F; Yang, XF				Liu, WG; Qiu, WS; Zhang, Y; Wang, WM; Lu, F; Yang, XF			Effects of selective brain cooling in patients with severe traumatic brain injury: a preliminary study	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						traumatic brain injury; hypothermia; intracranial pressure; superoxide dismutase; selective brain cooling	MILD SYSTEMIC HYPOTHERMIA; MODERATE HYPOTHERMIA; NEUROPROTECTION; MANAGEMENT; PERFUSION; EVEN	We prospectively investigated non-invasive selective brain cooling (SBC) in patients with severe traumatic brain injury. Sixty-six in-patients were randomized into three groups. In one group, brain temperature was maintained at 33 - 35 degrees C by cooling the head and neck (SBC); in a second group, mild systemic hypothermia (MSH; rectal temperature 33 - 35 degrees C) was produced with a cooling blanket; and a control group was not exposed to hypothermia. Natural re-warming began after 3 days. Mean intracranial pressure 24, 48 or 72 h after injury was significantly lower in the SBC group than in the control group. Mean serum superoxide dismutase levels on Days 3 and 7 after injury in the SBC and MSH groups were significantly higher than in the control group. The percentage of patients with a good neurological outcome 2 years after injury was 72.7%, 57.1% and 34.8% in the SBC, MSH and control groups, respectively. Complications were managed without severe sequelae. Non-invasive SBC was safe and effective.	Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310009, Peoples R China; Hangzhou Normal Coll, Sch Med, Hangzhou Hosp 2, Dept Neurosurg, Hangzhou, Peoples R China		Qiu, WS (corresponding author), Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310009, Peoples R China.	shihai954@163.com					Battin MR, 2003, PEDIATRICS, V111, P244, DOI 10.1542/peds.111.2.244; Clifton Guy L, 2004, Curr Opin Crit Care, V10, P116, DOI 10.1097/00075198-200404000-00007; Ding YC, 2004, NEUROSURGERY, V54, P956, DOI 10.1227/01.NEU.0000114513.96704.29; Furuse M, 2003, ACTA NEUROCHIR, V145, P983, DOI 10.1007/s00701-003-0119-x; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; GRIFFITHS AP, 1988, POSTGRAD MED J, V64, P617, DOI 10.1136/pgmj.64.754.617; Hagioka S, 2003, CRIT CARE MED, V31, P2502, DOI 10.1097/01.CCM.0000084845.76762.F4; Haranishi Y, 2005, EUR J ANAESTH, V22, P140, DOI 10.1017/S0265021505000268; Hinerfeld D, 2004, J NEUROCHEM, V88, P657, DOI 10.1046/j.1471-4159.2003.02195.x; Iwata O, 2005, ANN NEUROL, V58, P75, DOI 10.1002/ana.20528; Iwata O, 2003, PEDIATR INT, V45, P522, DOI 10.1046/j.1442-200X.2003.01784.x; Noguchi Y, 2002, ACTA MED OKAYAMA, V56, P279; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Sahuquillo J, 2004, CURR PHARM DESIGN, V10, P2193, DOI 10.2174/1381612043384051; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Suzuki T, 2003, EXP NEUROL, V184, P1017, DOI 10.1016/S0014-4886(03)00389-3; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Wen YS, 2005, J TRAUMA, V58, P577, DOI 10.1097/01.TA.0000152635.99243.30	21	75	79	0	8	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	JAN-FEB	2006	34	1					58	64		10.1177/147323000603400107			7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	025KW	WOS:000236265900007	16604824				2022-02-06	
J	Faden, AI; Movsesyan, VA; Knoblach, SM; Ahmed, F; Cernak, B				Faden, AI; Movsesyan, VA; Knoblach, SM; Ahmed, F; Cernak, B			Neuroprotective effects of novel small peptides in vitro and after brain injury	NEUROPHARMACOLOGY			English	Article						traumatic brain injury; neuroprotection; cyclic dipeptides; cell death; microarray; magnetic resonance imaging	NEURONAL CELL-DEATH; SPINAL-CORD-INJURY; NEUROTROPHIC FACTOR; CEREBRAL-ISCHEMIA; NMDA RECEPTORS; RATS; ACTIVATION; EXPRESSION; RECOVERY; TRH	Thyrotropin-releasing hormone (TRH) and TRH analogues have been reported to be neuroprotective in experimental models of spinal cord injury and head injury. We have previously shown that a diketopiperazine structurally related to the TRH metabolite cyclo-his-pro reduces neuronal cell death in vitro and in vivo. Here we report the neuroprotective activity of other cyclic dipeptides in multiple in vitro models of neuronal injury and after controlled cortical impact (CCI) in mice. Using primary neuronal cultures, three novel dipeptides were compared to the previously reported diketopiperazine as well as to vehicle controls; each of the compounds reduced cell death after direct physical trauma or trophic withdrawal. Two of these peptides also protected against glutamate toxicity and P-amyloid-induced injury; the latter also strongly inhibited glutamate-induced increases in intracellular calcium. Treatment with each of the test compounds resulted in highly significant improvement of motor and cognitive recovery after CO, as well as markedly reducing lesion volumes as shown by high field magnetic resonance imaging. DNA microarray studies following fluid percussion induced traumatic brain injury (TBI) in rats showed that treatment with one of these dipeptides after injury significantly down-regulated expression of mRNAs for cell cycle proteins, aquaporins, cathepsins and calpain in ipsilateral cortex and/or hippocampus, while up-regulating expression of brain-derived neurotrophic factor, hypoxia-inducible factor and several heat-shock proteins. Many of these mRNA expression changes were paralleled at the protein level. The fact that these small peptides modulate multiple mechanisms favoring neuronal cell survival, as well as their ability to improve functional outcome and reduce posttraumatic lesion size, suggests that they may have potential utility in clinical head injury. (c) 2005 Elsevier Ltd. All rights reserved.	Georgetown Univ, Med Ctr, Dept Neurosci, Lab Study CNS Injury, Washington, DC 20057 USA		Cernak, B (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Lab Study CNS Injury, 3970 Reservoir Rd,NW,Res Bldg,Room EP04, Washington, DC 20057 USA.	ifc@georgetown.edu		Ibolja, Cernak/0000-0003-3214-698X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041119] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS41119] Funding Source: Medline		Allen JW, 2001, EXP NEUROL, V169, P449, DOI 10.1006/exnr.2001.7672; ARIAS MJ, 1987, SURG NEUROL, V28, P335, DOI 10.1016/0090-3019(87)90054-1; Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196, DOI 10.1152/ajpregu.1999.277.4.R1196; Faden AI, 2004, J ALZHEIMERS DIS, V6, pS93; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1989, ANN NY ACAD SCI, V553, P380; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; Gulino R, 2004, BRAIN RES, V1013, P174, DOI 10.1016/j.brainres.2004.03.055; Katchanov J, 2001, J NEUROSCI, V21, P5045, DOI 10.1523/JNEUROSCI.21-14-05045.2001; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; KOSKINEN LOD, 1986, BRIT J PHARMACOL, V87, P509, DOI 10.1111/j.1476-5381.1986.tb10193.x; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Movsesyan VA, 2004, J NEUROCHEM, V89, P1528, DOI 10.1111/j.1471-4159.2004.02451.x; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; Prakash KRC, 2002, BIOORGAN MED CHEM, V10, P3043, DOI 10.1016/S0968-0896(02)00132-3; PRASAD C, 1995, PEPTIDES, V16, P151, DOI 10.1016/0196-9781(94)00017-Z; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; Seyfried DM, 2001, BRAIN RES, V901, P94, DOI 10.1016/S0006-8993(01)02289-2; Sharp FR, 2004, NAT REV NEUROSCI, V5, P437, DOI 10.1038/nrn1408; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Weishaupt JH, 2003, MOL CELL NEUROSCI, V24, P489, DOI 10.1016/S1044-7431(03)00221-5; Yakovlev Alexander G, 2004, NeuroRx, V1, P5, DOI 10.1602/neurorx.1.1.5; Yenari MA, 2002, ADV EXP MED BIOL, V513, P281; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351	40	75	77	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	SEP	2005	49	3					410	424		10.1016/j.neuropharm.2005.04.001			15	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	960DN	WOS:000231570500014	15907950				2022-02-06	
J	Kizony, R; Raz, L; Katz, N; Weingarden, H; Weiss, PLT				Kizony, R; Raz, L; Katz, N; Weingarden, H; Weiss, PLT			Video-capture virtual reality system for patients with paraplegic spinal cord injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						balance; Functional Reach Test; paraplegia; rehabilitation; spinal cord injury; therapy; training; traumatic injury; video-capture virtual reality; wheelchair	BRAIN-INJURY; FUNCTIONAL REACH; BALANCE CONTROL; REHABILITATION; EXERCISE; ENVIRONMENTS; RELIABILITY; STROKE	This article presents results from a feasibility study of a video-capture virtual reality (VR) system used with patients who have paraplegic spinal cord injury (SCI) and who need balance training. The advantages of the VR system include providing the user with natural control of movements, the ability to use as many parts of the body as are deemed suitable within the context of therapeutic goals, and flexibility in the way the system can be adapted to suit specific therapeutic objectives. Thirteen participants with SCI experienced three virtual environments (VEs). Their responses to a Short Feedback Questionnaire showed high levels of presence. We compared performance in the environments with a group of 12 nondisabled participants. Response times for the patient group were significantly higher and percentage of success was significantly lower than that for the nondisabled group. In addition, significant moderate correlations were found between performance within a VE and static balance ability as measured by the Functional Reach Test. This study is a first step toward future studies aimed at determining the potential of using this VR system during the rehabilitation of patients with SCI.	Univ Haifa, Dept Occupat Therapy, IL-31999 Haifa, Israel; Hebrew Univ & Hadassah, Sch Occupat Therapy, Jerusalem, Israel; Chaim Sheba Med Ctr, Dept Neurol Rehabil, IL-52621 Tel Hashomer, Israel		Kizony, R (corresponding author), Univ Haifa, Dept Occupat Therapy, IL-31999 Haifa, Israel.	rkizony@univ.haifa.ac.il					AXELSON PW, 1996, P 12 INT SEAT S 1996, P81; BROMLEY I, 1998, TETRAPLEGIA PARAPLEG, P63; CARDENAS DD, 2000, PHYS MED REHABILITAT, P1305; Cunningham D, 1999, ST HEAL T, V62, P90; Cunningham D, 1999, Cyberpsychol Behav, V2, P19, DOI 10.1089/cpb.1999.2.19; Dean CM, 1997, STROKE, V28, P722, DOI 10.1161/01.STR.28.4.722; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Duran FS, 2001, ARCH PHYS MED REHAB, V82, P1349, DOI 10.1053/apmr.2001.26066; Granger CV, 1993, GUIDE UNIFORM DATA S; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; HOLLAR LD, 1995, OCCUPATIONAL THERAPY, P795; HOLLAR LD, 2002, OCCUPATIONAL THERAPY, P795; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; Janssen-Potten YJ, 2002, ARCH PHYS MED REHAB, V83, P642, DOI 10.1053/apmr.2002.32437; Janssen-Potten YJ, 2001, ARCH PHYS MED REHAB, V82, P1393, DOI 10.1053/apmr.2001.25989; Kim N G, 1999, IEEE Trans Rehabil Eng, V7, P482, DOI 10.1109/86.808952; Kizony R, 2003, J VISUAL COMP ANIMAT, V14, P261, DOI 10.1002/vis.323; Ku JH, 2002, CYBERPSYCHOL BEHAV, V5, P151, DOI 10.1089/109493102753770543; Lott A, 2003, CYBERPSYCHOL BEHAV, V6, P477, DOI 10.1089/109493103769710505; Lynch SM, 1998, PHYS THER, V78, P128, DOI 10.1093/ptj/78.2.128; Mantovani F, 2003, EMERG COMMUNICAT, V5, P167; Middleton JW, 1999, ARCH PHYS MED REHAB, V80, P1558, DOI 10.1016/S0003-9993(99)90330-1; Midha M, 1999, ARCH PHYS MED REHAB, V80, P258, DOI 10.1016/S0003-9993(99)90135-1; Potten YJM, 1999, ERGONOMICS, V42, P1200, DOI 10.1080/001401399185081; Riva G, 1999, Cyberpsychol Behav, V2, P577, DOI 10.1089/cpb.1999.2.577; Riva G, 2000, REHABIL PSYCHOL, V45, P81, DOI 10.1037/0090-5550.45.1.81; Rizzo A, 2005, PRESENCE-TELEOP VIRT, V14, P119, DOI 10.1162/1054746053967094; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Rizzo AA, 2002, HUM FAC ER, P1027; Rizzo AA, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199712000-00002; Rose FD, 1999, DISABIL REHABIL, V21, P548; Schultheis MT, 2001, REHABIL PSYCHOL, V46, P296, DOI 10.1037/0090-5550.46.3.296; Seelen HAM, 1998, ERGONOMICS, V41, P302, DOI 10.1080/001401398187053; Song CG, 2004, IEEE T INF TECHNOL B, V8, P200, DOI 10.1109/TITB.2004.828887; Sveistrup H, 2003, CYBERPSYCHOL BEHAV, V6, P245, DOI 10.1089/109493103322011524; Sveistrup Heidi, 2004, J Neuroeng Rehabil, V1, P10, DOI 10.1186/1743-0003-1-10; Weiss P L, 1998, Work, V11, P277, DOI 10.3233/WOR-1998-11305; Weiss P. L., 2006, TXB NEURAL REPAIR NE, V2, P182; Weiss Patrice L, 2004, J Neuroeng Rehabil, V1, P12, DOI 10.1186/1743-0003-1-12; Weiss PL, 2004, J REHABIL RES DEV, V41, pVII; Witmer BG, 1998, PRESENCE-TELEOP VIRT, V7, P225, DOI 10.1162/105474698565686; Wu CY, 2001, STROKE, V32, P70, DOI 10.1161/01.STR.32.1.70; Youngstrom MJ, 2002, AM J OCCUP THER, V56, P609; Zhang L, 2003, ARCH PHYS MED REHAB, V84, P1118, DOI 10.1016/S0003-9993(03)00203-X	44	75	80	0	13	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	SEP-OCT	2005	42	5					595	607		10.1682/JRRD.2005.01.0023			13	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	036KD	WOS:000237069100005	16586185	Green Submitted			2022-02-06	
J	Inglese, M; Bomsztyk, E; Gonen, O; Mannon, LJ; Grossman, RI; Rusinek, H				Inglese, M; Bomsztyk, E; Gonen, O; Mannon, LJ; Grossman, RI; Rusinek, H			Dilated perivascular spaces: Hallmarks of mild traumatic brain injury	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							VIRCHOW-ROBIN SPACES; HEAD-INJURY; MR; PREVALENCE; APPEARANCE; EXPRESSION; SPECTRUM; DAMAGE; FLUID	BACKGROUND AND PURPOSE: Recent animal and human studies have shown an increased frequency of enlarged, high-convexity Virchow-Robin spaces (VRS) in several neurologic diseases, suggesting their role as neuroradiologic markers of inflammatory changes. The aim of this study was to determine the prevalence of high-convexity dilated VRS in mild traumatic brain injury (TBI). METHODS: T2-weighted, T1-weighted, fluid-attenuated inversion recovery, and T2*-weighted gradient-echo brain MR images were acquired in 24 patients with TBI (10 women, 14 men; mean age, 33.6; range, 18.1-50.8 years) and 17 age- and sex-matched healthy control subjects (nine women, eight men; mean age, 32.8; range, 18.4-47.8 years). The mean interval after TBI was 3.6 days (range, 1-9 days) in 15 patients and 3.7 years (range, 0.6-13.4 years) in nine patients. Axial T2-weighted images were used to identify dilated VRS and to measure CSF volume; T1-weighted images were used to measure brain volume. Dilated VRS were identified as punctuate areas with CSF-like signal intensity in the high-convexity white matter. RESULTS: Mean (+/- standard deviation) number of VRS was significantly higher in patients (7.1 +/- 4.6) than in controls (2.4 +/- 2.9, P < .0003). In controls, VRS were associated with age (R = 0.69, P < .001) whereas in patients, they neither correlated with brain and CSF volumes nor with age and the elapsed time from injury. CONCLUSION. Our results suggest that the increased number of dilated VRS is a radiologic marker of mild head injury that is readily detectable on T2-weighted images. Because their number does not vary with time from injury, VRS probably reflect early and permanent brain changes.	NYU, Sch Med, Dept Radiol, New York, NY 10016 USA		Inglese, M (corresponding author), NYU, Sch Med, Dept Radiol, 650 1St Ave, New York, NY 10016 USA.		Inglese, Matilde/AAH-3189-2020	Inglese, Matilde/0000-0002-9610-0297; Gonen, Oded/0000-0002-3148-2028	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039135] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00096, M01 RR000096] Funding Source: Medline; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB01015, R01 EB001015] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS039135, NS39135] Funding Source: Medline		Achiron A, 2002, AM J NEURORADIOL, V23, P376; AWAD IA, 1986, STROKE, V17, P1090, DOI 10.1161/01.STR.17.6.1090; BRAFFMAN BH, 1988, AM J ROENTGENOL, V151, P559, DOI 10.2214/ajr.151.3.559; De Santi S, 2001, NEUROBIOL AGING, V22, P529, DOI 10.1016/S0197-4580(01)00230-5; ESIRI MM, 1990, J NEUROL SCI, V100, P3, DOI 10.1016/0022-510X(90)90004-7; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HEIER LA, 1989, AM J NEURORADIOL, V10, P929; HIRABUKI N, 1994, AM J NEURORADIOL, V15, P277; Holbourn AHS, 1943, LANCET, V2, P438; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HUGHES W, 1965, LANCET, V2, P19; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; MIRFAKHRAEE M, 1986, RADIOLOGY, V158, P715, DOI 10.1148/radiology.158.3.3945745; Miszkiel KA, 1996, CLIN RADIOL, V51, P842, DOI 10.1016/S0009-9260(96)80080-8; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mueller CA, 2003, J NEUROTRAUM, V20, P1007, DOI 10.1089/089771503770195858; MURATA R, 1989, AM J NEURORADIOL, V10, P1165; ROLLINS NK, 1993, RADIOLOGY, V189, P53, DOI 10.1148/radiology.189.1.7690491; Schick S, 1999, NEURORADIOLOGY, V41, P283, DOI 10.1007/s002340050749; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Soares HD, 1995, J NEUROSCI, V15, P8223; Suzuki R, 2003, ACTA NEUROCHIR SUPPL, V86, P277; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Tsui WH, 2001, PROC SPIE, V4322, P1725, DOI 10.1117/12.431059; WAGNER HJ, 1974, ACTA NEUROPATHOL, V27, P299, DOI 10.1007/BF00690695	28	75	78	0	4	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	APR	2005	26	4					719	724					6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	915BU	WOS:000228273400010	15814911				2022-02-06	
J	Marshall, SW; Loomis, DP; Waller, AE; Chalmers, DJ; Bird, YN; Quarrie, KL; Feehan, M				Marshall, SW; Loomis, DP; Waller, AE; Chalmers, DJ; Bird, YN; Quarrie, KL; Feehan, M			Evaluation of protective equipment for prevention of injuries in rugby union	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Article						protective devices; mouth protectors; contact sports; athletic injuries; brain concussion	LONGITUDINAL DATA-ANALYSIS; PERFORMANCE PROJECT; OROFACIAL INJURIES; EGO ORIENTATION; SPORTS INJURIES; CONTACT SPORTS; ANKLE INJURIES; MOUTHGUARDS; FOOTBALL; PREVALENCE	Background Rugby union has a high rate of injury. The increased use of protective equipment may help mitigate these injuries. This study investigated the injury prevention effectiveness of the protective equipment used in rugby union. Methods A cohort of 304 rugby players in Dunedin, New Zealand was followed weekly during the 1993 club season to assess protective equipment use, participation in rugby, and injury outcomes. Generalized Poisson regression was used to model the rate of injury while adjusting for covariates such as level of competition, playing position, and injury history. Results The use of mouthguards appeared to lower the risk of orofacial injury [rate ratio (RR) = 0.56, 95% confidence interval (CI): 0.07-4.63], and padded headgear tended to prevent damage to the scalp and ears (RR = 0.59, 95% CI: 0.19-1.86). Support sleeves tended to reduce the risk of sprains and strains (RR = 0.58, 95% CI: 0.26-1.27). The risk of concussion was not lessened by the use of padded headgear (RR = 1.13, 95% CI: 0.40-3.16) or mouthguards (RR = 1.62, 95% CI: 0.51-5.11). There was no evidence of protective effects for any other equipment item (taping, shinguards, and grease). Conclusions The protective equipment used in rugby union has limited effectiveness in preventing injuries. The results are supportive, however, of a role for mouthguards and padded headgear in preventing orofacial and scalp injuries, respectively, and for support sleeves in preventing sprains and strains.	Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Orthoped, Chapel Hill, NC 27599 USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Environm Sci & Engn, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Emergency Med, Chapel Hill, NC 27599 USA; Univ Otago, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin, New Zealand; Observant LLV, Wellesley, MA USA		Marshall, SW (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, CB 7435,McGarvan Greenberg Hall, Chapel Hill, NC 27599 USA.	SMarshall@unc.edu	Loomis, Dana/AAE-3988-2019	Marshall, Stephen/0000-0002-2664-9233; Loomis, Dana/0000-0003-3297-5200; Quarrie, Ken/0000-0003-1703-8489	ODCDC CDC HHS [R49 CCR 402444] Funding Source: Medline		ALBRIGHT JP, 1995, SPORTS MED, V20, P281, DOI 10.2165/00007256-199520050-00001; BIR CA, 1995, CLIN J SPORT MED, V5, P95, DOI 10.1097/00042752-199504000-00005; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Blignaut J B, 1987, Br J Sports Med, V21, P5; Callaghan MJ, 1997, BRIT J SPORT MED, V31, P102, DOI 10.1136/bjsm.31.2.102; Carter, 1980, HEATH CARTER SOMATOT; Chalmers DJ, 1998, SPORTS MED, V25, P339, DOI 10.2165/00007256-199825050-00006; Chapman P., 1985, AUST J SCI MED SPORT, P23; Chapman P J, 1990, Br J Sports Med, V24, P156; CHAPMAN PJ, 1993, BRIT J SPORT MED, V27, P197, DOI 10.1136/bjsm.27.3.197; CHAPMAN PJ, 1989, AM J SPORT MED, V17, P690, DOI 10.1177/036354658901700518; CHAPMAN PJ, 1991, AUST J SCI MED SPORT, V23, P113; CHI LK, 1995, RES Q EXERCISE SPORT, V66, P91, DOI 10.1080/02701367.1995.10762216; de Wet F A, 1981, J Dent Assoc S Afr, V36, P249; DEWET FA, 1981, INT DENT J, V31, P313; Dixon G, 1993, NZ J SPORTS MED, V21, P18; DUDA JL, 1995, INT J SPORT PSYCHOL, V26, P40; EDGAR M, 1995, LANCET, V345, P1452, DOI 10.1016/S0140-6736(95)91031-X; Firer P, 1990, Br J Sports Med, V24, P47; GARRICK JG, 1973, MED SCI SPORT EXER, V5, P200; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Greenland S., 1998, MODERN EPIDEMIOLOGY, P401; HARCOURT JK, 1989, AUST DENT J, V34, P485; HAREL Y, 1994, AM J PUBLIC HEALTH, V84, P599, DOI 10.2105/AJPH.84.4.599; HEINTZ WD, 1975, PHYSICIAN SPORTSMED, V3, P61; Hume PA, 1998, SPORTS MED, V25, P285, DOI 10.2165/00007256-199825050-00001; Jennings D C, 1990, Br J Sports Med, V24, P159; KAMMANN R, 1983, AUST J PSYCHOL, V35, P259, DOI 10.1080/00049538308255070; KERR IL, 1986, SPORTS MED, V3, P415, DOI 10.2165/00007256-198603060-00003; KRAUS JF, 1984, ANNU REV PUBL HEALTH, V5, P163; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Marshall SW, 2002, INT J EPIDEMIOL, V31, P587, DOI 10.1093/ije/31.3.587; Marshall SW, 2001, MED SCI SPORT EXER, V33, P2131, DOI 10.1097/00005768-200112000-00024; Martens R., 1990, COMPETITIVE ANXIETY; McCullagh P., 1989, GEN LINEAR MODELS 2, V2; MEEUWISSE WH, 1991, SPORTS MED, V12, P8, DOI 10.2165/00007256-199112010-00002; Morton J G, 1979, N Z Dent J, V75, P151; *NHMRC, 1994, FOOTB INJ HEAD NECK; NICHOLAS JA, 1988, JAMA-J AM MED ASSOC, V260, P939, DOI 10.1001/jama.260.7.939; NORTON R, 1995, NZ J SPORTS MED, V22, P37; Quarrie KL, 1995, BRIT J SPORT MED, V29, P263, DOI 10.1136/bjsm.29.4.263; Robbins S, 1998, SPORTS MED, V25, P63, DOI 10.2165/00007256-199825010-00005; ROBEY JM, 1971, J AMER MED ASSOC, V217, P184, DOI 10.1001/jama.217.2.184; ROBINS JM, 1992, EPIDEMIOLOGY, V3, P319, DOI 10.1097/00001648-199207000-00007; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P69; SEALS RR, 1985, J AM DENT ASSOC, V110, P904, DOI 10.14219/jada.archive.1985.0005; SITLER M, 1994, AM J SPORT MED, V22, P454, DOI 10.1177/036354659402200404; Spielberger C.D., 1985, ANGER HOSTILITY CARD, P5; STOKES AN, 1991, NZ J SPORTS MED, V19, P66; WALLER AE, 1994, BRIT J SPORT MED, V28, P223, DOI 10.1136/bjsm.28.4.223; Wilson BD, 1998, SPORTS MED, V25, P333, DOI 10.2165/00007256-199825050-00005; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	52	75	76	0	47	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771	1464-3685		INT J EPIDEMIOL	Int. J. Epidemiol.	FEB	2005	34	1					113	118					6	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	899FF	WOS:000227129600022	15561749	Bronze			2022-02-06	
J	Mayes, SD; Calhoun, SL				Mayes, SD; Calhoun, SL			Similarities and differences in Wechsler intelligence scale for children-third edition (WISC-III) profiles: Support for subtest analysis in clinical referrals	CLINICAL NEUROPSYCHOLOGIST			English	Article						WISC-III profiles; ADHD; autism; brain injury; anxiety; depression; oppositional-defiant disorder; LD	TRAUMATIC HEAD-INJURY; LEARNING-DISABILITIES; ACADEMIC-ACHIEVEMENT; STRATEGY INSTRUCTION; ATTENTION DISORDERS; DISABLED STUDENTS; ASPERGER-SYNDROME; DEFICIT; ADHD; METHYLPHENIDATE	Our study supports the reliability and validity of profile analysis in children with neurobiological disorders. Three mutually exclusive WISC-III profiles were identified that characterized the majority of children with autism (low coding or Freedom from Distractibility Index with low Comprehension), attention deficit hyperactivity disorder and learning disability (low Coding or FDI without low comprehension), and brain injury (low Performance without low Coding or FDI). The profiles suggest attention, writing, and performance speed deficits in autism, ADHD, and LD; global visual-motor problems in brain injury; and specific difficulty with language comprehension and social reasoning in autism. Children with anxiety, depression, and behavior disorders did not exhibit distinct profiles. Our profile analysis is based on the simple rank ordering of standard scores. The profiles are clinically useful because they may alert clinicians to certain diagnostic possibilities, they reveal characteristic strengths and weaknesses that have implications for educational intervention, and they are consistent with preliminary WISC-IV data.	Penn State Coll Med, Dept Psychiat, Hershey, PA 17033 USA		Mayes, SD (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Psychiat, H073,POB 850, Hershey, PA 17033 USA.	smayes@psu.edu					ACKERMAN PT, 1995, DEV NEUROPSYCHOL, V11, P351, DOI 10.1080/87565649509540625; ALLEN MH, 1991, J AUTISM DEV DISORD, V21, P483, DOI 10.1007/BF02206872; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANASTASI A, 1998, PSYCHOL TESTING; ASARNOW RF, 1987, J CHILD PSYCHOL PSYC, V28, P273, DOI 10.1111/j.1469-7610.1987.tb00210.x; ATTWOOD T, 1998, ASPERGER SYNDROME GU; Attwood T., 2000, AUTISM, V4, P85, DOI DOI 10.1177/1362361300004001006; BARKLEY RA, 1994, CLIN NEUROPSYCHOL, V8, P121, DOI 10.1080/13854049408401552; BARKLEY RA, 1994, ADHD CLASSROOM STRAT; Bauminger N, 2002, J AUTISM DEV DISORD, V32, P283, DOI 10.1023/A:1016378718278; BIRMAHER B, 1988, J AM ACAD CHILD PSY, V27, P248, DOI 10.1097/00004583-198803000-00020; Bray MA, 1998, SCHOOL PSYCHOL INT, V19, P209, DOI 10.1177/0143034398193002; Crowell E., 1998, J ATTEN DISORD, V2, P217, DOI [10.1177/108705479800200402, DOI 10.1177/108705479800200402]; DAINER KB, 1981, J ABNORM CHILD PSYCH, V9, P79, DOI 10.1007/BF00917859; DANOFF B, 1993, J READING BEHAV, V25, P295, DOI 10.1080/10862969009547819; Donders J, 1996, PSYCHOL ASSESSMENT, V8, P312, DOI 10.1037/1040-3590.8.3.312; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; Ehlers S, 1997, J CHILD PSYCHOL PSYC, V38, P207, DOI 10.1111/j.1469-7610.1997.tb01855.x; Fessler R., 1991, BEHAV DISORDERS, V16, P97, DOI [10.1177/019874299101600205, DOI 10.1177/019874299101600205]; Fiorello CA, 2001, LEARN INDIVID DIFFER, V13, P115, DOI 10.1016/S1041-6080(02)00075-4; Fletcher JM, 1999, PEDIATR CLIN N AM, V46, P885, DOI 10.1016/S0031-3955(05)70161-9; FLETCHER JM, 1992, J CLIN EXP NEUROPSYC, V14, P593, DOI 10.1080/01688639208402847; FRANKENBERGER W, 1991, J LEARN DISABIL, V24, P495, DOI 10.1177/002221949102400809; FRIEDRICH WN, 1991, J PEDIATR PSYCHOL, V16, P423, DOI 10.1093/jpepsy/16.4.423; Glassberg LA, 1999, BEHAV DISORDERS, V25, P9; GLUTTING JJ, 1994, SCHOOL PSYCHOL REV, V23, P619; GORDON M, 1991, GSI PUBLICATIONS; GRAHAM S, 1990, J EDUC PSYCHOL, V82, P781, DOI 10.1037/0022-0663.82.4.781; Gray CA., 1993, FOCUS AUTISTIC BEHAV, V8, P1, DOI 10.1177/108835769300800101; Gresham FM, 1996, J LEARN DISABIL, V29, P570, DOI 10.1177/002221949602900601; Hale JB, 2001, SCHOOL PSYCHOL QUART, V16, P31, DOI 10.1521/scpq.16.1.31.19158; Handen BL, 2000, J AUTISM DEV DISORD, V30, P245, DOI 10.1023/A:1005548619694; HAPPE FGE, 1994, J CHILD PSYCHOL PSYC, V35, P1461, DOI 10.1111/j.1469-7610.1994.tb01287.x; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Hoskyn M, 2000, SCHOOL PSYCHOL REV, V29, P102; Jacobs R, 2001, J DEV PHYS DISABIL, V13, P389, DOI 10.1023/A:1012289513829; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Jordan R, 2003, LEARNING AND BEHAVIOR PROBLEMS IN ASPERGER SYNDROME, P212; Kaufman A, 1994, INTELLIGENT TESTING; KAVALE KA, 1994, LEARNING DISABILITIE, V9, P70; Kay JB, 1999, J CLIN EXP NEUROPSYC, V21, P186, DOI 10.1076/jcen.21.2.186.927; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; KRAMER JH, 1993, PSYCHOL ASSESSMENT, V5, P193; Kunce L, 2003, LEARNING AND BEHAVIOR PROBLEMS IN ASPERGER SYNDROME, P244; LANE SE, 1994, J PSYCHOEDUC ASSESS, V12, P142, DOI 10.1177/073428299401200204; Larsen L., 2001, LEARNING DISABILITIE, V16, P74, DOI [10.1111/0938-8982.00009, DOI 10.1111/0938-8982.00009]; LINCOLN AJ, 1988, J AUTISM DEV DISORD, V18, P505, DOI 10.1007/BF02211870; LUFI D, 1990, PSYCHOL SCHOOLS, V27, P28, DOI 10.1002/1520-6807(199001)27:1<28::AID-PITS2310270105>3.0.CO;2-L; MacArthur CA, 1996, J LEARN DISABIL, V29, P344, DOI 10.1177/002221949602900403; MacArthur CA, 2000, TOP LANG DISORD, V20, P85, DOI 10.1097/00011363-200020040-00008; Manjiviona J, 2003, LEARNING AND BEHAVIOR PROBLEMS IN ASPERGER SYNDROME, P55; Mayes S D, 1989, Brain Inj, V3, P301, DOI 10.3109/02699058909029643; Mayes SD, 1998, PSYCHOL SCHOOLS, V35, P309; Mayes SD, 2000, J LEARN DISABIL-US, V33, P417, DOI 10.1177/002221940003300502; Mayes SD, 2003, J AUTISM DEV DISORD, V33, P329, DOI 10.1023/A:1024462719081; MCDERMOTT PA, 1990, J PSYCHOEDUC ASSESS, V8, P290, DOI 10.1177/073428299000800307; Mealer C., 1996, J ATTEN DISORD, V1, P133, DOI [DOI 10.1177/108705479600100302, 10.1177/108705479600100302]; Mesibov Gary B., 1992, HIGH FUNCTIONING IND, P143, DOI DOI 10.1007/978-1-4899-2456-8_8; Naglieri JA, 2003, J PSYCHOEDUC ASSESS, V21, P32, DOI 10.1177/073428290302100103; National Research Council, 2001, ED CHILDR AUT; NEWBY R, 1993, J PSYCHOEDUCATIONAL, V11, P87; Nyden A, 2001, DEV MED CHILD NEUROL, V43, P165, DOI 10.1017/S0012162201000329; Oh HJ, 1999, J PSYCHOEDUC ASSESS, V17, P362, DOI 10.1177/073428299901700406; PARKER HC, 1988, ADD HYPERACTIVITY WO; Pfeiffer SI, 2000, SCHOOL PSYCHOL QUART, V15, P376, DOI 10.1037/h0088795; PRIFITERA A, 1993, J PSYCHOEDUC ASSESS, P43; Prinz R., 1987, ADV BEHAV ASSESSMENT, P57; PRIOR M, 2003, LEARNING BEHAV PROBL; QUINTANA H, 1995, J AUTISM DEV DISORD, V25, P283, DOI 10.1007/BF02179289; ROBINS PM, 1992, J ABNORM CHILD PSYCH, V20, P65, DOI 10.1007/BF00927117; Saklofske D. H., 1995, CANADIAN J SCH PSYCH, V10, P167, DOI [10.1177/082957359501000210, DOI 10.1177/082957359501000210]; Sattler J. M., 2002, ASSESSMENT CHILDREN; SAWYER RJ, 1992, J EDUC PSYCHOL, V84, P340, DOI 10.1037/0022-0663.84.3.340; SCHUERHOLZ LJ, 1995, J LEARN DISABIL, V28, P18, DOI 10.1177/002221949502800104; SCHWEAN VL, 1993, J PSYCHOEDUC ASSESS, P56; Shaked M, 2003, LEARNING AND BEHAVIOR PROBLEMS IN ASPERGER SYNDROME, P104; Siegel DJ, 1996, J AUTISM DEV DISORD, V26, P389, DOI 10.1007/BF02172825; Snow JB, 2000, PSYCHOL REP, V87, P759, DOI 10.2466/PR0.87.7.759-765; Stanton HC, 2000, SCHOOL PSYCHOL QUART, V15, P434, DOI 10.1037/h0088799; STRAYHORN JM, 1988, J AM ACAD CHILD PSY, V27, P244, DOI 10.1097/00004583-198803000-00019; SWANSON HL, 1983, J ABNORM CHILD PSYCH, V11, P415, DOI 10.1007/BF00914249; SWANSON L, 1981, J CHILD PSYCHOL PSYC, V22, P393, DOI 10.1111/j.1469-7610.1981.tb00563.x; Tannock R., 2000, ATTENTION DEFICIT DI; TARNOWSKI KJ, 1986, J ABNORM PSYCHOL, V95, P341, DOI 10.1037/0021-843X.95.4.341; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Vaughn S, 2000, EXCEPT CHILDREN, V67, P99, DOI 10.1177/001440290006700107; Ward TJ, 1999, SCHOOL PSYCHOL REV, V28, P629; Wechsler D., 1992, MANUAL WECHSLER INDI; Wechsler D., 2003, WISC 4 TECHNICAL INT; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WILLIAMS K, 1995, FOCUS AUTISTIC BEHAV, V10, P9, DOI DOI 10.1177/108835769501000202; 1999, FED REG         0312; [No title captured]; [No title captured]	94	75	78	1	62	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	DEC	2004	18	4					559	572		10.1080/13854040490888530			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	895BH	WOS:000226835400006	15841957				2022-02-06	
J	Sundstrom, A; Marklund, P; Nilsson, LG; Cruts, M; Adolfsson, R; Van Broeckhoven, C; Nyberg, L				Sundstrom, A; Marklund, P; Nilsson, LG; Cruts, M; Adolfsson, R; Van Broeckhoven, C; Nyberg, L			APOE influences on neuropsychological function after mild head injury - Within-person comparisons	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E GENOTYPES; PROSPECTIVE COHORT; SYMPTOMS; RECOVERY; SEQUELAE; MEMORY	Objective: To examine the relationship between neuropsychological outcome following mild head injury (MHI) and APOE genotype. Methods: Data from a population-based longitudinal study (n = 3,500) were used to identify 34 adults who experienced MHI during the course of the study. Their pre- and postinjury performances on a battery of nine neuropsychological tests were compared within person, and the postinjury performance was compared with that of age- and gender-matched control subjects. Results: The within-person comparisons showed that participants with at least one APOE epsilon4 allele (n = 11) had a significantly decreased postinjury performance on three of the tests, whereas the postinjury performance for APOE epsilon4-negative participants (n = 23) was unchanged. There was no significant difference in postinjury performance between participants with/without the epsilon4 allele, and neither group was impaired relative to controls. Conclusions: APOE genotype may influence the outcome following an MHI. Pre/postinjury within-person comparisons seem more sensitive than control group comparisons for detecting injury-related effects.	Umea Univ, Dept Psychol, S-90187 Umea, Sweden; Umea Univ, Dept Clin Sci & Psychiat, S-90187 Umea, Sweden; Univ Stockholm, Dept Psychol, S-10691 Stockholm, Sweden; Univ Antwerp VIB, Dept Mol Genet, Antwerp, Belgium		Sundstrom, A (corresponding author), Umea Univ, Dept Psychol, S-90187 Umea, Sweden.	anna.sundstrom@psy.umu.se	Van Broeckhoven, Christine/G-8362-2017; Van Broeckhoven, Christine/M-7853-2019; Nyberg, Lars/C-2514-2009; Cruts, Marc/J-6161-2013; Nyberg, Lars/M-5986-2019	Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665; Nyberg, Lars/0000-0002-3367-1746; Cruts, Marc/0000-0002-1338-992X; Nyberg, Lars/0000-0002-3367-1746; Adolfsson, Rolf/0000-0001-9785-8473			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bartres-Faz D, 1999, NEUROREPORT, V10, P2923, DOI 10.1097/00001756-199909290-00009; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; Bretsky P, 2003, NEUROLOGY, V60, P1077, DOI 10.1212/01.WNL.0000055875.26908.24; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; JORDON BD, 1997, JAMA-J AM MED ASSOC, V9, P136; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Nilsson LG, 1997, AGING NEUROPSYCHOL C, V4, P1, DOI 10.1080/13825589708256633; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Smith JD, 2002, AGEING RES REV, V1, P345, DOI 10.1016/S1568-1637(02)00005-3; Staehelin HB, 1999, ACTA NEUROL SCAND, V100, P53, DOI 10.1111/j.1600-0404.1999.tb00723.x; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Wechsler, 1997, WECHSLER ADULT INTEL; WENHAM PR, 1991, CLIN CHEM, V37, P241	23	75	75	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUN 8	2004	62	11					1963	1966		10.1212/01.WNL.0000129268.83927.A8			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	827HN	WOS:000221890400011	15184597				2022-02-06	
J	Phillips, TM				Phillips, TM			Rapid analysis of inflammatory cytokines in cerebrospinal fluid using chip-based immunoaffinity electrophoresis	ELECTROPHORESIS			English	Article						chip-based immunoaffinity capillary electrophoresis; head trauma; inflammatory cytokines; miniaturization	INDUCED FLUORESCENCE DETECTION; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; CAPILLARY-ELECTROPHORESIS; LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY; BIOLOGICAL-FLUIDS; COLUMN CLEANUP; INTERLEUKIN-6; PROTEINS	A chip-based capillary electrophoresis system has been designed for rapidly measuring the concentrations of inflammatory cytokines in the cerebrospinal fluid of patients with head trauma. Isolation of the reactive cytokines was achieved by immunoaffinity capture using a panel of six immobilized antibodies, directly attached to the injection port of the chip. The captured cytokines were labeled in situ with a red light-emitting laser dye and electroeluted into the separation channel. Separation of the isolated cytokines was achieved by electrophoresis in under 2 min with quantification of the resolved peaks being achieved by on-line laser-induced fluorescence and integration of each peak area. Comparison of the results to commercially available high-sensitivity immunoassays demonstrates that the chip-based assay provides a fast, accurate procedure for studying the concentrations of these analytes in complex biological materials. The degree of accuracy and precision achieved by the chip-based CE is comparable to conventional immunoassays, the system being able to analyze between 10-12 samples per hour. With the ever-expanding array of antibodies that are commercially available, this chip-based system can be applied to a wide variety of different analyses.	NIH, ORS, DBEPS, UAIR, Bethesda, MD 20892 USA		Phillips, TM (corresponding author), NIH, ORS, DBEPS, UAIR, 13-3E42 9000 Rockville Pike, Bethesda, MD 20892 USA.	phillipt@mail.nih.gov			OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z01OD011059] Funding Source: NIH RePORTER		Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Baldwin RP, 2000, ELECTROPHORESIS, V21, P4017, DOI 10.1002/1522-2683(200012)21:18<4017::AID-ELPS4017>3.0.CO;2-5; Bilitewski U, 2003, ANAL BIOANAL CHEM, V377, P556, DOI 10.1007/s00216-003-2179-4; Cahill LM, 1999, J CHROMATOGR A, V859, P23, DOI 10.1016/S0021-9673(99)00846-8; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; Entwisle AC, 2000, J AOAC INT, V83, P1377; Gam LH, 2003, J CHROMATOGR B, V792, P187, DOI 10.1016/S1570-0232(03)00264-2; Guzman NA, 1997, J CHROMATOGR B, V697, P37, DOI 10.1016/S0378-4347(97)00275-2; Ham AJL, 1999, CHEM RES TOXICOL, V12, P1240, DOI 10.1021/tx990150r; Hans VHJ, 1999, NEUROREPORT, V10, P409; Hennion MC, 2003, J CHROMATOGR A, V1000, P29, DOI 10.1016/S0021-9673(03)00529-6; Hu S, 2002, ELECTROPHORESIS, V23, P3136, DOI 10.1002/1522-2683(200209)23:18<3136::AID-ELPS3136>3.0.CO;2-S; Huwe JK, 2001, J CHROMATOGR B, V757, P285, DOI 10.1016/S0378-4347(01)00159-1; LEE KJ, 1991, J CHROMATOGR, V559, P317, DOI 10.1016/0021-9673(91)80081-Q; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; McWhorter S, 2000, ELECTROPHORESIS, V21, P1267, DOI 10.1002/(SICI)1522-2683(20000401)21:7<1267::AID-ELPS1267>3.0.CO;2-C; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Patel HC, 2003, ANN NY ACAD SCI, V992, P39, DOI 10.1111/j.1749-6632.2003.tb03136.x; Phillips TM, 2003, BIOMED CHROMATOGR, V17, P182, DOI 10.1002/bmc.240; Phillips TM, 1998, ANAL CHIM ACTA, V372, P209, DOI 10.1016/S0003-2670(98)00342-0; Phillips TM, 1998, ELECTROPHORESIS, V19, P2991, DOI 10.1002/elps.1150191632; PHILLIPS TM, 1992, AFFINITY IMMUNOAFFIN, P287; Regnier FE, 1999, TRENDS BIOTECHNOL, V17, P101, DOI 10.1016/S0167-7799(98)01294-3; Sen JW, 2003, ANAL CHEM, V75, P1196, DOI 10.1021/ac026174b; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stroka J, 2000, J AOAC INT, V83, P320; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Taylor J, 2001, ELECTROPHORESIS, V22, P3699, DOI 10.1002/1522-2683(200109)22:17<3699::AID-ELPS3699>3.0.CO;2-A; Thormann W, 2002, THER DRUG MONIT, V24, P222, DOI 10.1097/00007691-200204000-00004; Verpoorte E, 2002, ELECTROPHORESIS, V23, P677, DOI 10.1002/1522-2683(200203)23:5<677::AID-ELPS677>3.0.CO;2-8; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Xiong GH, 2003, ANALYST, V128, P581, DOI 10.1039/b301035j	34	75	75	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	JUN	2004	25	10-11					1652	1659		10.1002/elps.200305873			8	Biochemical Research Methods; Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	830RK	WOS:000222140400031	15188254				2022-02-06	
J	Self, ML; Blake, AM; Whitley, M; Nadalo, L; Dunn, E				Self, ML; Blake, AM; Whitley, M; Nadalo, L; Dunn, E			The benefit of routine thoracic, abdominal, and pelvic computed tomography to evaluate trauma patients with closed head injuries	AMERICAN JOURNAL OF SURGERY			English	Article; Proceedings Paper	55th Annual Meeting of the Southwestern-Surgical-Congress	APR 27-30, 2003	TUCSON, ARIZONA	Southwestern Surg Congress		computed tomography; blunt trauma; closed head injury; physical examination	DIAGNOSTIC PERITONEAL-LAVAGE; BLUNT TRAUMA; SONOGRAPHY; EXPERIENCE; ULTRASOUND; CT	Background: The evaluation of multitrauma patients for blunt truncal injuries remains open for debate. We sought to evaluate the role of routine computed tomography (CT) of the chest, abdomen, and pelvis as a screening tool for patients already undergoing cranial CT studies. Methods: Charts of blunt trauma patients admitted from June 2000 to June 2001 were reviewed for demographics, Glascow Coma Scale (GCS), physical and radiological findings, and length of stay. Results: Our study found that 38% of patients undergoing cranial CT scanning had a unexpected finding on body scans. Changes were made in 26% of the study group because results found on the adjuvant CTs. Conclusions: Additional body CTs add minimal cost to the care of trauma patients but can significantly change the management. We believe it is beneficial to perform routine body CT examinations when performing cranial imaging for blunt head injury. (C) 2003 Excerpta Medica, Inc. All rights reserved.	Methodist Hosp, Dept Surg, Dallas, TX USA; Methodist Hosp, Dept Radiol, Dallas, TX USA; Gen Surg, Dallas, TX 75265 USA		Dunn, E (corresponding author), Methodist Hosp, Dept Surg, Dallas, TX USA.						CATRE MG, 1995, CAN J SURG, V38, P117; Chiu WC, 1997, J TRAUMA, V42, P617, DOI 10.1097/00005373-199704000-00006; Demetriades D, 1998, ARCH SURG-CHICAGO, V133, P1084, DOI 10.1001/archsurg.133.10.1084; Downing SW, 2001, ANN THORAC SURG, V72, P495, DOI 10.1016/S0003-4975(01)02827-2; Fakhry SM, 2003, J TRAUMA, V54, P1, DOI 10.1097/00005373-200301000-00001; Feliciano D V, 1992, Semin Thorac Cardiovasc Surg, V4, P156; Fernandez L, 1998, J TRAUMA, V45, P841, DOI 10.1097/00005373-199810000-00047; Guillamondegui OD, 2002, J TRAUMA, V53, P1043, DOI 10.1097/00005373-200212000-00002; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; MACKERSIE RC, 1989, ARCH SURG-CHICAGO, V124, P809; McKenney MG, 1996, J TRAUMA, V40, P607, DOI 10.1097/00005373-199604000-00015; Mirvis SE, 1998, J TRAUMA, V45, P922, DOI 10.1097/00005373-199811000-00014; Ochsner MG, 2000, J TRAUMA, V49, P505, DOI 10.1097/00005373-200009000-00019; OLSEN WR, 1971, J TRAUM, V11, P824, DOI 10.1097/00005373-197110000-00002; Rhee PM, 2002, J TRAUMA, V53, P663, DOI 10.1097/00005373-200210000-00007; ROOT HD, 1965, SURGERY, V57, P633; ROZYCKI GS, 1993, J TRAUMA, V34, P516, DOI 10.1097/00005373-199304000-00008; Scaglione M, 2001, EUR RADIOL, V11, P2444, DOI 10.1007/s003300100836; Scalea TM, 1999, J TRAUMA, V46, P466, DOI 10.1097/00005373-199903000-00022; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; TSO P, 1992, J TRAUMA, V33, P39, DOI 10.1097/00005373-199207000-00009; Voggenreiter G, 2000, CRIT CARE MED, V28, P1033, DOI 10.1097/00003246-200004000-00020	22	75	77	0	0	EXCERPTA MEDICA INC	NEW YORK	650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA	0002-9610			AM J SURG	Am. J. Surg.	DEC	2003	186	6					609	614		10.1016/j.amjsurg.2003.08.003			6	Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery	753NN	WOS:000187237600006	14672766				2022-02-06	
J	Iwata, A; Chen, XH; McIntosh, TK; Browne, KD; Smith, DH				Iwata, A; Chen, XH; McIntosh, TK; Browne, KD; Smith, DH			Long-term accumulation of amyloid-beta in axons following brain trauma without persistent upregulation of amyloid precursor protein genes	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Alzheimer disease; amyloid-beta; amyloid precursor protein; axonal injury; brain atrophy; neurofilament protein; traumatic brain injury	TRANSIENT FOCAL ISCHEMIA; FLUID-PERCUSSION MODEL; FACTOR MESSENGER-RNA; SEVERE HEAD-INJURY; ALZHEIMERS-DISEASE; INHIBITOR DOMAIN; TRANSGENIC MICE; NEURON DEATH; RAT-BRAIN; EXPRESSION	Brain trauma has been shown to be a risk factor for developing Alzheimer disease (AD), and AD-like plaques containing amyloid-beta (Abeta) peptides have been found in the brain shortly following trauma. Here, we evaluated the effects of brain trauma. on the accumulation of Abeta and expression of amyloid precursor protein (APP) genes (APP695 and APP751/770) over 1 yr in a non-transgenic rodent model. Anesthetized male Sprague-Dawley rats were subjected to parasagittal fluid percussion brain injury of moderate severity (2.5-2.9 atm) or sham treatment and their brains were evaluated at 2, 4, 7, 14 days, and 1, 2, 6, 12 months following injury. Immunohistochemical analysis detected only weak Abeta staining by 2 wk following injury. However; by 1 month to 1 yr following injury, strong immunoreactivity for Abeta was found in damaged axons throughout the thalamus and white matter. Western blot analysis confirmed the accumulation of Abeta peptides in tissue from injured brains. Although in situ hybridization demonstrated an increased gene expression of APP751/770 surrounding the cortical lesion at 2 to 7 days following injury, this expression returned to baseline levels at all subsequent time points and no increase in the expression of APP695 was detected at any time point. These results demonstrate that long-term Abeta accumulation in damaged axons can be induced in a non-transgenic rodent model of brain trauma. Surprisingly, the extent of this Abeta production appeared to be dependent on the maturity of the injury, but uncoupled from the gene expression of APP Together, these data suggest a mechanism that may contribute to long-term neurodegeneration following brain trauma.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA		Smith, DH (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 21527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 08803, NS 38104] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, P50NS008803, R01NS038104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K08AG021527] Funding Source: NIH RePORTER		ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Breteler MMB, 1995, AM J EPIDEMIOL, V142, P1300, DOI 10.1093/oxfordjournals.aje.a117597; Caswell MD, 1999, EUR J BIOCHEM, V266, P509, DOI 10.1046/j.1432-1327.1999.00886.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Iwata A, 1997, J NEUROTRAUM, V14, P201, DOI 10.1089/neu.1997.14.201; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; JOHNSON SA, 1989, NEUROBIOL AGING, V10, P755, DOI 10.1016/0197-4580(89)90017-1; JOHNSON SA, 1988, EXP NEUROL, V102, P264, DOI 10.1016/0014-4886(88)90104-5; Johnston JA, 1996, MOL BRAIN RES, V43, P77, DOI 10.1016/S0169-328X(96)00160-X; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; Kalaria RN, 1996, NEUROREPORT, V7, P1377, DOI 10.1097/00001756-199605310-00009; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; Koistinaho J, 1996, NEUROREPORT, V7, P2727, DOI 10.1097/00001756-199611040-00064; Leoni MJ, 2000, EXP NEUROL, V166, P442, DOI 10.1006/exnr.2000.7513; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Moir RD, 1998, J BIOL CHEM, V273, P5013, DOI 10.1074/jbc.273.9.5013; MORTIMER JA, 1991, INT J EPIDEMIOL S2, V20, P528; Mrak RE, 1996, J NEUROPATH EXP NEUR, V55, P273, DOI 10.1097/00005072-199603000-00002; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raby CA, 1998, J NEUROCHEM, V71, P2505; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOLA C, 1993, MOL BRAIN RES, V17, P41, DOI 10.1016/0169-328X(93)90071-V; SPILLANTINI MG, 1989, P NATL ACAD SCI USA, V86, P8555, DOI 10.1073/pnas.86.21.8555; TANAKA S, 1989, BIOCHEM BIOPH RES CO, V165, P1406, DOI 10.1016/0006-291X(89)92760-5; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P281; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; WILLOUGHBY DA, 1992, EXP NEUROL, V118, P332, DOI 10.1016/0014-4886(92)90191-R; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	63	75	78	0	4	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	2002	61	12					1056	1068		10.1093/jnen/61.12.1056			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	624LY	WOS:000179762200004	12484568	Bronze			2022-02-06	
J	Smythe, GA; Braga, O; Brew, BJ; Grant, RS; Guillemin, GJ; Kerr, SJ; Walker, DW				Smythe, GA; Braga, O; Brew, BJ; Grant, RS; Guillemin, GJ; Kerr, SJ; Walker, DW			Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry	ANALYTICAL BIOCHEMISTRY			English	Article							KYNURENINE PATHWAY METABOLISM; TRAUMATIC BRAIN INJURY; RAT-BRAIN; TRYPTOPHAN-METABOLITES; NEUROLOGICAL DISEASE; CEREBROSPINAL-FLUID; HUMAN ASTROCYTES; MODULATION; MECHANISM; DEPLETION	Quinolinic, picolinic, and nicotinic acids and nicotinamide are end products of the kynurenine pathway from L-tryptophan and are intermediates in the biosynthesis of nicotinamide adenine dinucleotide. These compounds are involved in complex interrelationships with inflammatory and apoptotic responses associated with neuronal cell damage and death in the central nervous system. To facilitate the study of these compounds, we have utilized gas chromatography-mass spectrometry in electron capture negative ionization mode for their concurrent trace quantification in a single sample. Deuterium-labeled quinolinic, picolinic, and nicotinic acids were used as internal standards and the compounds were converted to their hexafluoroisopropyl esters prior to chromatography. Nicotinamide was readily quantified after conversion to nicotinic acid using gas-phase hydrolysis-a process which did not affect the deuterated internal standards. The on-column limit of quantification was less than 1 fmol for each of the analytes and calibration curves were linear. A packed column liner was used in the gas chromatograph inlet to effectively eliminate sample interference effects in the analysis of trace (femtomolar) levels of quinolinic acid. The method enables rapid and specific concurrent quantification of quinolinic, picolinic, and nicotinic acids in tissue extracts and physiological and culture media. (C) 2002 Elsevier Science.	Univ New S Wales, Fac Med, Ray Williams Biomed Mass Spectrometry Facil, Sydney, NSW 2052, Australia; St Vincents Hosp, Dept Neuroimmunol, Ctr Immunol, Sydney, NSW 2010, Australia; Sydney Adventist Hosp, Dept Microbiol, Wahroonga, NSW 2076, Australia; Natl Prescribing Serv, Surry Hills, NSW 2010, Australia; Monash Univ, Dept Physiol, Melbourne, Vic 3168, Australia		Smythe, GA (corresponding author), Univ New S Wales, Fac Med, Ray Williams Biomed Mass Spectrometry Facil, Sydney, NSW 2052, Australia.		Guillemin, Gilles J/C-3878-2015; McLean, Emma/F-4616-2012; Brew, Bruce/J-6513-2012; Kerr, Stephen J/J-6126-2012	Guillemin, Gilles J/0000-0001-8105-4470; Kerr, Stephen J/0000-0002-1919-4525			Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; BENINGER RJ, 1994, NEUROSCIENCE, V61, P603, DOI 10.1016/0306-4522(94)90438-3; Bosco MC, 2000, J IMMUNOL, V164, P3283, DOI 10.4049/jimmunol.164.6.3283; Dobbie M, 2000, AM J TROP MED HYG, V62, P284, DOI 10.4269/ajtmh.2000.62.284; Guillemin GJ, 2000, REDOX REP, V5, P108, DOI 10.1179/135100000101535375; Guillemin GJ, 1999, ADV EXP MED BIOL, V467, P125; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1988, ANAL BIOCHEM, V174, P349, DOI 10.1016/0003-2697(88)90556-8; HEYES MP, 1993, BRAIN, V116, P1425, DOI 10.1093/brain/116.6.1425; HORNING EC, 1955, ORG SYNTH, V3, P740; JANERO DR, 1993, AM J PHYSIOL, V264, pC1401; JHAMANDAS K, 1990, BRAIN RES, V529, P185, DOI 10.1016/0006-8993(90)90826-W; JHAMANDAS KH, 1994, CAN J PHYSIOL PHARM, V72, P1473, DOI 10.1139/y94-213; KALISCH BE, 1994, BRAIN RES, V668, P1, DOI 10.1016/0006-8993(94)90504-5; LEHMANN J, 1985, J PHARMACOL EXP THER, V232, P873; MELILLO G, 1994, J BIOL CHEM, V269, P8128; NARITSIN DB, 1995, ANAL CHEM, V67, P863, DOI 10.1021/ac00101a012; Nicholls T, 2001, AM J OBSTET GYNECOL, V184, P203, DOI 10.1067/mob.2001.108862; Nicholls T, 1999, AM J OBSTET GYNECOL, V181, P1452, DOI 10.1016/S0002-9378(99)70391-1; Sanni LA, 1998, AM J PATHOL, V152, P611; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; STONE TW, 1993, PHARMACOL REV, V45, P309; Stone TW, 2001, TOXICON, V39, P61, DOI 10.1016/S0041-0101(00)00156-2; STREFFER C, 1975, ACTA VITAMINOL ENZYM, V29, P262; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; VROOMAN L, 1993, BRAIN RES, V627, P193, DOI 10.1016/0006-8993(93)90320-M; WOLF H, 1974, SCAND J CLIN LAB INV, V33, P1	29	75	76	0	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0003-2697	1096-0309		ANAL BIOCHEM	Anal. Biochem.	FEB 1	2002	301	1					21	26		10.1006/abio.2001.5490			6	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	518HG	WOS:000173661300004	11811963				2022-02-06	
J	Sherer, M; Novack, TA; Sander, AM; Struchen, MA; Alderson, A; Thompson, RN				Sherer, M; Novack, TA; Sander, AM; Struchen, MA; Alderson, A; Thompson, RN			Neuropsychological assessment and employment outcome after traumatic brain injury: A review	CLINICAL NEUROPSYCHOLOGIST			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; REHABILITATION; PREDICTION; VARIABLES; RETURN; TESTS	While there may be many reasons for obtaining neuropsychological assessment after traumatic brain injury (TBI), prediction of real world functioning is generally a key goal. The present paper reviews 23 studies concerning the relationship between neuropsychological test results and employment outcome after TBI. The review was conducted in accordance with guidelines developed by the Committee on Empirically Supported Practice of Division 40 (Neuropsychology) of the American Psychological Association. Results of the review support a Category A (strongly supported) recommendation for the use of early neuropsychological assessment to predict late employment outcome. Studies of late neuropsychological assessment and subsequent employment outcome and studies of concurrent neuropsychological assessment and employment outcome were inconclusive regarding either support or contraindication for neuropsychological assessment to predict employment outcome. Almost all studies conducted at these late or concurrent time points had significant limitations with regard to study type or adequacy of methodology. However, there is no conceptual basis for believing that neuropsychological findings obtained closer in time to assessment of employment outcome should be less predictive of this outcome than neuropsychological findings obtained at an earlier time.	Univ Mississippi, Med Ctr, Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Alabama Birmingham, Spain Rehabil Ctr, Birmingham, AL USA; Baylor Coll Med, Inst Rehabil & Res, Houston, TX 77030 USA; Shepard Ctr, Atlanta, GA USA		Sherer, M (corresponding author), ABPP Cn, Neuopsychol, Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980010, H133A970015, H133A980035] Funding Source: Medline		BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; Fleming J, 1999, BRAIN INJURY, V13, P417; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Hanlon RE, 1999, BRAIN INJURY, V13, P873; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; HEATON RK, 2002, NEWSLETTER, V40, P36; Horn L.J., 1999, PHYSICAL MED REHABIL, P1281; Isaki E, 2000, BRAIN INJURY, V14, P441; LAM CS, 1991, REHABIL COUNS BULL, V35, P68; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Long, 1996, ECOLOGICAL VALIDITY, P15; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MELAMED S, 1985, SCAND J REHABIL MED, P21; Najenson T, 1980, Int Rehabil Med, V2, P17; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; Sbordone RJ, 1996, ECOLOGICAL VALIDITY; Sherer M, 2000, J HEAD TRAUMA REHAB, V15, P767, DOI 10.1097/00001199-200004000-00002; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; SHERER M, IN PRESS DEMONSTRATI; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	36	75	75	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2002	16	2					157	178		10.1076/clin.16.2.157.13238			22	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	588KH	WOS:000177700300005	12221479				2022-02-06	
J	Cruz, J; Minoja, G; Okuchi, K				Cruz, J; Minoja, G; Okuchi, K			Improving clinical outcomes from acute subdural hematomas with the emergency preoperative administration of high doses of mannitol: A randomized trial	NEUROSURGERY			English	Article						acute subdural hematoma; arteriojugular lactate difference; cerebral extraction of oxygen; head injury; intracranial pressure; mannitol	CEREBRAL BLOOD-FLOW; ACUTE BRAIN INJURY; ACUTE HEAD-INJURY; COMATOSE PATIENTS; INTRACRANIAL HYPERTENSION; OXYGEN-CONSUMPTION; ACUTE ANEMIA; METABOLISM; HYPERVENTILATION; HYPEREMIA	OBJECTIVE: To evaluate clinical outcomes and postoperative physiological findings for comatose patients with acute subdural hematomas who received preoperative high-dose mannitol (HDM) versus conventional-dose mannitol treatment. METHODS: One hundred seventy-eight adult patients with non-missile, traumatic, acute, subdural hematomas were prospectively and randomly assigned to receive emergency, preoperative, intravenous HDM treatment (91 patients), compared with a control group treated with a lower preoperative mannitol dose (87 patients). RESULTS: Preoperative improvement of abnormal pupillary widening was significantly more frequent in the study group than in the control group of patients (P < 0.0001). Preoperative HDM treatment was also associated with significantly better clinical outcomes at 6-month follow-up evaluations (P < 0.01). Postoperative physiological findings revealed statistically significant between-group differences, with higher intracranial pressure and lower cerebral extraction of oxygen (relative cerebral hyperperfusion) in the control group, compared with the HDM group. Postoperative global brain ischemia (abnormally low arteriojugular lactate difference values) was rare and was detected in 2.2 and 3.4% of the patients in the study and control groups, respectively. CONCLUSION: Emergency preoperative HDM administration was associated with improved clinical outcomes for patients with acute subdural hematomas. Preoperative improvement of abnormal pupillary widening and better postoperative control of intracranial hypertension and associated relative cerebral hyperperfusion seemed to be relevant factors associated with improved outcomes.	CICNEM, Comprehens Int Ctr Neuroemergencies, BR-04093970 Sao Paulo, SP, Brazil; Univ Sao Paulo, BR-05508 Sao Paulo, Brazil; Univ Insubria, Dept Anesthesiol & Crit Care Med, Varese, Italy; Nara Med Univ, Dept Emergency & Crit Care Med, Nara, Japan		Cruz, J (corresponding author), CICNEM, Comprehens Int Ctr Neuroemergencies, POB Cx Postal 57011, BR-04093970 Sao Paulo, SP, Brazil.						Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; CRUZ J, 1994, CRIT CARE MED, V22, P1465, DOI 10.1097/00003246-199409000-00018; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; CRUZ J, 1993, CRIT CARE MED, V21, P1218, DOI 10.1097/00003246-199308000-00024; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Cruz J, 1996, CRIT CARE MED, V24, P953, DOI 10.1097/00003246-199606000-00013; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; CRUZ J, 1994, J NEUROSURG, V80, P143, DOI 10.3171/jns.1994.80.1.0143; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; CRUZ J, 1998, NEUROLOGIC NEUROSURG, P405; FINNERTY FA, 1954, J CLIN INVEST, V33, P1227, DOI 10.1172/JCI102997; Gibbs EL, 1942, J BIOL CHEM, V144, P325; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; LANGFITT TW, 1968, JOHNS HOPKINS MED J, V122, P261; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; TEASDALE G, 1974, LANCET, V2, P81	25	75	75	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	OCT	2001	49	4					864	871					8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	477JD	WOS:000171279600023	11564247				2022-02-06	
J	Dora, C; Leunig, M; Beck, M; Rothenfluh, D; Ganz, R				Dora, C; Leunig, M; Beck, M; Rothenfluh, D; Ganz, R			Entry point soft tissue damage in antegrade femoral nailing: A cadaver study	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						femoral nailing; soft tissue damage; medial femoral circumflex artery	AVASCULAR NECROSIS; SHAFT FRACTURES; HEAD; FEMUR; ADOLESCENT; STRENGTH	Introduction: Little attention is paid to insertion site morbidity associated with antegrade femoral nailing. However, residual peritrochanteric pain after nailing is not uncommon. Additionally, the end branches of the medial femoral circumflex artery (m.f.c.a.) supplying the femoral head are in close proximity to the insertion site of the nail, and the occurrence of avascular necrosis of the femoral epiphysis after nailing in adolescents is rather frequent. Objective: The aim of this study was to assess iatrogenic soft tissue injuries at the site of nail insertion. Materials and Methods: Nailing with a reamed AO universal femoral nail was performed on sixteen adult cadavers followed by dissection of the proximal part of the femur to assess possible damage to the soft tissues. Three entry portals were defined. (A) entry portal lateral to the junction of the neck and the greater trochanter; (B) entry portal at the base of the greater trochanter anterior to a line along the longitudinal axis of the femoral neck; and (C) entry portal at the base of the greater trochanter posterior to a line along the axis of the femoral neck (at the piriformis fossa). Results: In Group A, partial avulsion of the piriformis and the obturator internus tendon were present in four and in one of five specimens, respectively. Group B showed injuries to the piriformis tendon in two and to the gluteus minimus tendon in one of four cases. In Group C, partial avulsion of the piriformis, obturator internus, and obturator externus tendon were encountered in five, six, and two of seven specimens, respectively. Anterior branches of the ramus profundus of the m.f.c.a. within the synovial fold were damaged in all of these cases. Conclusion: To select the best nail entry portal, the ease of nail insertion must be weighed against the resulting soft tissue damage at the site of insertion. The nail entry portal at the piriformis fossa, although geometrically ideal and most recommended, causes the most significant damage to muscle and tendons as well as to the blood supply to the femoral head. Therefore, even if reported only once, the occurrence of avascular necrosis of the femoral head after nailing in adults is a possible complication of this nail entry portal. The authors therefore prefer to avoid this entry portal in every case. The nail entry portal anterior to the longitudinal axis of the femoral neck, as in group B, although better with respect to the soft tissue damage, has the worst geometric and biomechanical disadvantages. The results of the current study favor the nail entry portal lateral at the greater trochanter as in Group A, which is equal to the entry portal B with respect to the soft tissue damage but allows introduction of the nail into the medullar cavity without difficulties.	Univ Zurich, Balgrist Hosp, Dept Orthopaed Surg, CH-8008 Zurich, Switzerland; Univ Bern, Inselspital, Dept Orthopaed Surg, CH-3010 Bern, Switzerland		Dora, C (corresponding author), Univ Zurich, Dept Orthopaed, Balgrist,Forchstr 340, CH-8008 Zurich, Switzerland.		Leunig, Michael/E-7951-2017	Leunig, Michael/0000-0002-2036-5416; Beck, Martin/0000-0003-0697-946X			ASTION DJ, 1995, J BONE JOINT SURG AM, V77A, P1092, DOI 10.2106/00004623-199507000-00018; Bain GI, 1997, J ORTHOP TRAUMA, V11, P93, DOI 10.1097/00005131-199702000-00004; BEATY JH, 1994, J PEDIATR ORTHOPED, V14, P178, DOI 10.1097/01241398-199403000-00009; BEDNAR DA, 1993, CAN J SURG, V36, P464; Bonnevialle P, 1999, REV CHIR ORTHOP, V85, P397; BROWNER BD, 1986, CLIN ORTHOP RELAT R, P192; BRUMBACK RJ, 1990, J BONE JOINT SURG AM, V72A, P1067, DOI 10.2106/00004623-199072070-00017; BUCHOLZ RW, 1991, J BONE JOINT SURG AM, V73A, P1561, DOI 10.2106/00004623-199173100-00015; CHUNG SMK, 1976, J BONE JOINT SURG AM, V58, P961, DOI 10.2106/00004623-197658070-00011; DANCKWARDTLILLIESTROM G, 1976, ACTA ORTHOP SCAND, V47, P101, DOI 10.3109/17453677608998980; Dodenhoff RM, 1997, J BONE JOINT SURG BR, V79B, P738, DOI 10.1302/0301-620X.79B5.7345; Gautier E, 2000, J BONE JOINT SURG BR, V82B, P679, DOI 10.1302/0301-620X.82B5.10426; HARPER MC, 1987, CLIN ORTHOP RELAT R, P155; Hernigou P, 1995, REV CHIR ORTHOP, V81, P622; JACOBS LGH, 1989, J BONE JOINT SURG AM, V71A, P1239, DOI 10.2106/00004623-198971080-00018; JOHNSON KD, 1987, J ORTHOP TRAUMA, V14, P1; KAWEBLUM M, 1993, CLIN ORTHOP RELAT R, P193; KEMPF I, 1985, J BONE JOINT SURG AM, V67A, P709, DOI 10.2106/00004623-198567050-00005; LINHART W, 1984, Z ORTHOP GRENZGEB, V122, P766, DOI 10.1055/s-2008-1045064; MARKS PH, 1988, J TRAUMA, V28, P1207, DOI 10.1097/00005373-198808000-00012; MILESKI RA, 1995, J PEDIATR ORTHOPED, V15, P24, DOI 10.1097/01241398-199501000-00006; MILLER SD, 1993, J BONE JOINT SURG BR, V75, P202, DOI 10.1302/0301-620X.75B2.8444937; Muller ME, 1991, MANUAL INTERNAL FIXA; NICHOLS PJR, 1963, J BONE JOINT SURG BR, V45, P96; OMALLEY DE, 1995, J PEDIATR ORTHOPED, V15, P21, DOI 10.1097/01241398-199501000-00005; Orler R, 1998, UNFALLCHIRURG, V101, P495, DOI 10.1007/s001130050301; ROSS PM, 1980, CLIN ORTHOP RELAT R, P131; SEVITT S, 1965, J Bone Joint Surg Br, V47, P560; SIMONIAN PT, 1994, J BONE JOINT SURG BR, V76B, P293, DOI 10.1302/0301-620X.76B2.8113296; THOMETZ JG, 1995, J BONE JOINT SURG AM, V77, P1423, DOI 10.2106/00004623-199509000-00019; TRUETA J, 1957, J BONE JOINT SURG BR, V39, P358, DOI 10.1302/0301-620X.39B2.358; Wolinsky PR, 1999, J TRAUMA, V46, P392, DOI 10.1097/00005373-199903000-00007; Yang KH, 1998, J BONE JOINT SURG BR, V80B, P673, DOI 10.1302/0301-620X.80B4.8406	33	75	82	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	SEP-OCT	2001	15	7					488	493		10.1097/00005131-200109000-00005			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	484YF	WOS:000171716600005	11602831				2022-02-06	
J	Schwab, JM; Beschorner, R; Nguyen, TD; Meyermann, R; Schluesener, HJ				Schwab, JM; Beschorner, R; Nguyen, TD; Meyermann, R; Schluesener, HJ			Differential cellular accumulation of connective tissue growth factor defines a subset of reactive astrocytes, invading fibroblasts, and endothelial cells following central nervous system injury in rats and humans	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte activation; blood-brain barrier; glial scar; secondary injury; tissue remodeling	ANGIOGENESIS IN-VIVO; BRAIN INJURY; SPINAL-CORD; FACTOR-BETA; CNS INJURY; EXPRESSION; FACTOR-BETA(1); PROLIFERATION; DEGENERATION; TGF-BETA-1	In brain injury, the primary trauma is followed by a cascade of cellular and molecular mechanisms resulting in secondary injury and scar formation. Astrogliosis and expression of transforming growth factor beta (TGF-beta) are key components of scar formation. A cytokine mediating the effects of TGF-beta is connective tissue growth factor (CTGF), a fibrogenic peptide encoded by an immediate early gene with suggested roles in tissue regeneration and aberrant deposition of extracellular matrix. In order to investigate CTGF in traumatic lesions, we evaluated 20 human brains with traumatic brain injury (TBI) and 18 rat brains with stab wound injury. Compared to remote areas and unaltered control brains, CTGF(+) cells accumulated in border zones of the traumatic lesion site (p < 0.0001). In the direct peri-lesional rim, CTGF expression was confined to invading vimentin(+), GFAP(-) fibroblastoid cells, endothelial and smooth muscle cells of laminin(+) vessels, and GFAP(+) reactive astrocytes. In the direct peri-lesional rim, CTGF(+) astrocytes (>80%) co-expressed the activation associated intermediate filaments nestin and vimentin. In injured rat brains, numbers of CTGF(+) cells peaked at day 3 and 7 and decreased to almost base level 3 weeks postinjury, whereas in humans, CTGF(+) cells remained persistently elevated up to 6 months (p < 0.0001). The restricted accumulation of CTGF(+)-reactive astrocytes and CTGF(+) fibroblastoid cells lining the adjacent laminin(+) basal lamina suggests participation of these cells in scar formation. Furthermore, peri-lesional upregulation of endothelial CTGF expression points to a role in blood-brain barrier function and angiogenesis. In addition, CTGF appears to be a sensitive marker of early astrocyte activation.	Univ Tubingen, Sch Med, Inst Brain Res, D-72076 Tubingen, Germany		Schwab, JM (corresponding author), Univ Tubingen, Sch Med, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	jmschwab@med.uni-tuebingen.de	Beschorner, Rudi/M-6397-2014	Schwab, Jan/0000-0001-6784-4919; Beschorner, Rudi/0000-0003-1109-915X			Babic AM, 1999, MOL CELL BIOL, V19, P2958; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; BIGNAMI A, 1998, NEURON GLIA INTERREL, V1, P3; CANCILLA PA, 1993, ASTROCYTES PHARM FUN, P387; Dammeier J, 1998, INT J BIOCHEM CELL B, V30, P909, DOI 10.1016/S1357-2725(98)00046-6; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; FADENIF, 1996, NEUROTRAUMA, P1479; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; GRAHAM DI, 1996, GREENFIELDS NEUROPAT, P197; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609; Hertel M, 2000, EUR J NEUROSCI, V12, P376, DOI 10.1046/j.1460-9568.2000.00930.x; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1111/j.1523-1755.1998.00820.x; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kubo M, 1998, BRIT J DERMATOL, V139, P192; Lasky JA, 1998, AM J PHYSIOL-LUNG C, V275, pL365, DOI 10.1152/ajplung.1998.275.2.L365; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MAXWELL WL, 1984, HISTOCHEM J, V16, P1219, DOI 10.1007/BF01003445; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MILLER JD, 1996, GREENFIELDS NEUROPAT, P157; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Oemar BS, 1997, CIRCULATION, V95, P831; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P654, DOI 10.1097/00005072-199906000-00010; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P313, DOI 10.1097/00005072-199904000-00001; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; Schwab JM, 2000, ACTA NEUROPATHOL, V99, P609, DOI 10.1007/s004010051170; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; Steffen CL, 1998, GROWTH FACTORS, V15, P199, DOI 10.3109/08977199809002117; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TORUDELBAUFFE D, 1992, EXP CELL RES, V202, P316, DOI 10.1016/0014-4827(92)90081-I; Wenger C, 1999, ONCOGENE, V18, P1073, DOI 10.1038/sj.onc.1202395	41	75	77	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2001	18	4					377	388		10.1089/089771501750170930			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	425TP	WOS:000168308000002	11336439				2022-02-06	
J	Wade, TK; Troy, JC				Wade, TK; Troy, JC			Mobile phones as a new memory aid: a preliminary investigation using case studies	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; REHABILITATION	Memory impairment is one of the most common concerns following a brain injury of any severity. The use of effective external memory aids can help minimize the devastating effects such memory impairment can have on an individual's everyday life. Reviewed in this report are case studies of five individuals suffering significant everyday memory problems that were given a new memory aid that utilizes standard mobile phones. Measurements included diary-format observations and qualitative feedback. The results of the study show promising outcomes for all of the cases, and have led to recent adaptations to allow for wider and more effective use of this memory aid.	Overdale Hosp, Dept Psychol, St Helier JE1 3UH, Jersey, England		Wade, TK (corresponding author), Overdale Hosp, Dept Psychol, Westmount Rd, St Helier JE1 3UH, Jersey, England.						*ABN AMR INV BANK, 1999, INF SHEET; Burgess P, 1996, BEHAV ASSESSMENT DYS; CROVITZ HF, 1979, CORTEX, V15, P131, DOI 10.1016/S0010-9452(79)80013-1; Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; *FIN TIM BUS LTD, 1998, INF SHEET; GODFREY H, 1985, J COUNSELLING CLIN P, V43, P555; GOUVIER W, 1997, NEUROPSYCHOLOGY HDB, V2, P3; HARRIS JE, 1992, CLIN MANAGEMENT MEMO, P59, DOI DOI 10.1007/978-1-4899-4523-5_3; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; Intons-Peterson M.J., 1992, MEMORY IMPROVEMENT I, P101; KAPUR N, 1994, MEMORY DISORDERS CLI; KAPUR N, 1995, HDB MEMORY DISORDERS, P533; Nelson H.E., 1982, NATL ADULT READING T; NEWCOMBE F, 1982, INJURY, V14, P111, DOI 10.1016/0020-1383(82)90046-8; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; SCHACHTER D, 1977, CORTEX, V13, P105; SLOAN S, 1995, TRAUMATIC BRAIN INJU, P103; Sohlberg MM, 1989, INTRO COGNITIVE REHA, P136; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; TWUM M, 1994, J CLIN EXP NEUROPSYC, V16, P630, DOI 10.1080/01688639408402674; WECHSLER D, 1981, WAIS R MANUAL WESCHL; WILSON B, 1987, REHABILITATION MEMOR; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113	24	75	75	0	9	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2001	15	4					305	320		10.1080/026990501750111256			16	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	420ZK	WOS:000168035000003	11299132				2022-02-06	
J	Harris, JKJ; Godfrey, HPD; Partridge, FM; Knight, RG				Harris, JKJ; Godfrey, HPD; Partridge, FM; Knight, RG			Caregiver depression following traumatic brain injury (TBI): a consequence of adverse effects on family members?	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; RELATIVES VIEW; BURDEN	Many studies have demonstrated that the behaviour of individuals with traumatic brain injury (TBI) predicts the emotional adjustment of their caregivers. The primary objective of the present study was to obtain an understanding of potential moderating and mediating variables between carer depression and analogous stressors. Seven sets of predictor variables (demographic variables, concurrent stressful life events, behavioural problems, social role problems, extent of adverse effects on family members, appraisal, and support) and the criterion variable of depression in caregivers were examined. Fifty- eight carers participated in the study at 6 months, 1 year, 2 years, or 3 years following injury. The number of adverse effects on family members (other than the informant) was the only stressor significantly related to carer depression. However, carer appraisal of adverse family effects was found to mediate the relationship between stressor and depression, and carer perception of support effectiveness was found to moderate the effect of adverse family effects on depression. Forty- six per cent of the variance in caregiver depression was accounted for by carers appraisal of adverse family effects and the interaction of adverse family effects and support effectiveness. These findings highlight the importance of supporting families as a whole in the rehabilitation of persons with TBI.	Univ Otago, Dept Psychol, Dunedin, New Zealand		Godfrey, HPD (corresponding author), Univ Otago, Dept Psychol, POB 56, Dunedin, New Zealand.	hgodfrey@psy.otago.ac.nz					BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS WP, 1986, LETT APPL MICROBIOL, V2, P1, DOI 10.1111/j.1472-765X.1986.tb01502.x; CLEARY PD, J HLTH SOCIAL BEHAV, V23, P159; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Frosch S, 1997, BRAIN INJURY, V11, P891; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; OAKLEYBROWNE MA, 1989, AUST NZ J PSYCHIAT, V23, P327, DOI 10.3109/00048678909068290; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; PLATT SD, 1983, SOCIAL BEHAV ASSESSM; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Smith LM, 1995, FAMILY SUPPORT PROGR; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	24	75	77	1	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2001	15	3					223	238					16	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	407ZM	WOS:000167302100003	11260771				2022-02-06	
J	Ylvisaker, M; Todis, B; Glang, A; Urbanczyk, B; Franklin, C; DePompei, R; Feeney, T; Maxwell, NM; Pearson, S; Tyler, JS				Ylvisaker, M; Todis, B; Glang, A; Urbanczyk, B; Franklin, C; DePompei, R; Feeney, T; Maxwell, NM; Pearson, S; Tyler, JS			Educating students with TBI: Themes and recommendations	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acquired brain injury; children; policy; research; schools; teacher training; traumatic brain injury	TRAUMATIC BRAIN INJURY; HEAD-INJURIES; CHILDREN; REHABILITATION; CHILDHOOD; RECOVERY; STATES; SCALE	Ten educational consultants and researchers. each with extensive experience working with children with traumatic brain injury (TBI) in school settings, identified seven themes related to serving this population in public schools. These themes are discussed under the headings (1) incidence of TBI and prevalence of per sistent educational disability (2) diversity and central tendencies within the population, (3) assessment, (4) intervention and support in school settings. (5) training and support for educators, (6) intervention and support for families, and (7) systems change and flexibility. For each theme. a set of recommendations is provided, forming an educational research and policy agenda for pediatric TBI.	Coll St Rose, Dept Commun Disorders, Albany, NY USA; Western Oregon State Coll, Teaching Res Div, Eugene, OR USA; Metropolitan Nashville Publ Sch, Nashville, TN USA; Vanderbilt Univ, Dept Hearing & Speech Sci, Nashville, TN USA; Univ Akron, Sch Speech Language Pathol & Audiol, Dept Communicat Disorders, Akron, OH 44325 USA; Wildwood Inst, Schenectady, NY USA; Wildwood Behav Resource Project, Schenectady, NY USA; Springs Union Free Sch Dist, Dept Special Educ, E Hampton, NY USA; Iowa Dept Educ, Iowa City, IA USA; Univ Kansas, Med Ctr, Dept Special Educ, Neurol Disabil Support Project, Kansas City, KS 66103 USA		Ylvisaker, M (corresponding author), 1171 Van Antwerp Rd, Schenectady, NY 12309 USA.						ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BORKOWSKI JG, IN PRESS ISSUES MEAS; BRAGA LW, 2000, INT HDB NEUROPSYCHOL; Carr E. G., 1999, POSITIVE BEHAV SUPPO; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DEPOMPEI R, 1995, SURVEY OHIO SPECIAL, P4; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; DROTAR D, 1997, J PEDIAT PSYCHOL; Elmore RF, 1996, HARVARD EDUC REV, V66, P1; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Forest M., 1989, ED ALL STUDENTS MAIN; FOX TJ, 1980, QUALITY ED SEVERELY; FULLAN M, 1999, CHANGE FORCES SEQUEL; GLANG A, 1997, CHILDREN ACQUIRED BR; Hostler SL, 1999, J HEAD TRAUMA REHAB, V14, P384, DOI 10.1097/00001199-199908000-00007; JOYCE B, 1980, EDUC LEADERSHIP, V37, P379; JOYCE B, 1982, EDUC LEADERSHIP, V40, P4; JOYCE B, 1995, STUDENT ACHIEVEMENT; KATSIYANNIS A, 1994, REM SPEC EDUC, V15, P319, DOI 10.1177/074193259401500507; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; Kolb B., 1995, BRAIN PLASTICITY BEH; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LeBlanc JM, 2000, J HEAD TRAUMA REHAB, V15, P1022, DOI 10.1097/00001199-200008000-00005; LENZ BK, 1987, LEARN DISABILITY Q, V10, P53, DOI 10.2307/1510755; Lincoln Yvonna S., 1985, NATURALISTIC INQUIRY; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; PRESSLEY M, 1995, COGNITIVE STRATEGY I; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Robinson TR, 1999, J EDUC PSYCHOL, V91, P195, DOI 10.1037/0022-0663.91.2.195; ROSENSHINE B, 1986, HDB RES TEACHING, P376; Schumaker J. B., 1992, CONT INTERVENTION RE; SHOWERS B, 1987, EDUC LEADERSHIP, V45, P77; SINGER GHS, 1997, CHILDREN ACQUIRED BR; SINGER GHS, 1996, REDEFINING FAMILY SU; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; Swanson H.L., 1999, INTERVENTIONS STUDEN; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Towner E., 1996, HLTH PROMOTION CHILD; Tyler J. S., 1997, STUDENTS ACQUIRED BR, P323; *US DEP ED, 1999, IMPL IND DIS ED ACT; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wilson, 1993, APPL PREV PSYCHOL, V2, P209, DOI DOI 10.1016/S0962-1849(05)80091-5; WILSON B, 1987, J CLIN EXP NEUROPSYC, V9, P527, DOI 10.1080/01688638708410767; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, Vxiv; ZIRPOLI TJ, 1989, J ASSOC PERS SEVERE, V14, P163, DOI 10.1177/154079698901400208	52	75	76	0	10	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2001	16	1					76	93		10.1097/00001199-200102000-00009			18	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	403ZC	WOS:000167072100011	11277852				2022-02-06	
J	Kabat, MH; Kane, RL; Jefferson, AL; DiPino, RK				Kabat, MH; Kane, RL; Jefferson, AL; DiPino, RK			Construct validity of selected Automated Neuropsychological Assessment Metrics (ANAM) battery measures	CLINICAL NEUROPSYCHOLOGIST			English	Article							BRAIN INJURY; MONITORING RECOVERY; PERFORMANCE; CONSISTENCY; CONCUSSION	The Automated Neuropsychological Assessment Metrics (ANAM) is a computerized library of tests designed to assess neurocognitive functioning across administrations (Kane & Reeves, 1997). This study was designed to examine neuropsychological constructs measured by selected ANAM measures and to compare them with traditional measures putatively assessing similar domains. The sample consisted of 191 outpatients with suspected neurocognitive dysfunction. Correlations and regressions indicated significant relationships between traditional and computerized tests measuring similar constructs. PCA results yielded a three-factor solution: Factor I (Processing Speed / Efficiency), Factor II (Retention / Memory), and Factor III (Working Memory).	Dept Vet Affairs Med Ctr, Mental Hlth Clin Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Loyola Coll, Baltimore, MD 21210 USA		Kane, RL (corresponding author), Dept Vet Affairs Med Ctr, Mental Hlth Clin Ctr, 10 N Greene St, Baltimore, MD 21201 USA.						Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Gorsuch R.L., 1983, FACTOR ANAL; HARRIS WD, 1996, 9602 ERPL ENG PSYCH; Heaton RK, 1991, COMPREHENSIVE NORMS; JORDAN J, 1996, EFFECT ACTIVE NOISE; Kane R. L., 1997, NEUROPSYCHOLOGY HDB; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; KANE RL, 1999, J INT NEUROPSYCH SOC, V5, P129; Kay GG, 1997, ARCH INTERN MED, V157, P2350, DOI 10.1001/archinte.157.20.2350; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; LEWANDOWSKI AG, 1995, ARCH CLIN NEUROPSYCH, V10, P357; Mirsky A. F., 1989, INTEGRATING THEORY P, P75; Reeves D, 1996, NCRFSR9601; REEVES DL, 1998, NCRFTR9801; SPSS Inc, 1998, SPSS 8 0 WIND; STARBUCK VN, 1995, NEUROPSY NEUROPSY BE, V8, P189; TINSLEY HEA, 1987, J COUNS PSYCHOL, V34, P14	20	75	77	0	10	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2001	15	4					498	507		10.1076/clin.15.4.498.1882			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	535QR	WOS:000174656100008	11935451				2022-02-06	
J	Allen, JW; Knoblach, SM; Faden, A				Allen, JW; Knoblach, SM; Faden, A			Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis but increases necrotic cell death in vitro	CELL DEATH AND DIFFERENTIATION			English	Article						metabotropic glutamate receptor; apoptosis; necrosis; neuronal death	TRAUMATIC BRAIN INJURY; CEREBELLAR GRANULE CELLS; NMDA-RECEPTORS; 1-AMINOINDAN-1,5-DICARBOXYLIC ACID; GLUCOSE DEPRIVATION; ANTAGONIST; AGONIST; CULTURE; NEUROTOXICITY; MODEL	Glutamate released during acute CNS insults acts at metabotropic glutamate receptors (mGluR), including group I mGluR, Blockade of group I mGluR during in vitro neuronal trauma provides neuroprotection, whereas activation exacerbates such injury. However, the effects of group I mGluR agonists or antagonists have been primarily studied in in vitro models characterized by necrotic cell death. We examined the role of group I mGluR in the modulation of neuronal injury induced during oxygen-glucose deprivation (OGD), a well-studied model of necrosis, and by application of two well established pro-apoptotic agents: staurosporine and etoposide. Inhibition of group I mGluR attenuated necrosis induced by OGD, whereas selective activation of group 1 mGluR exacerbated such injury. In contrast, activation of group I mGluR, including selective activation of mGluR5, significantly attenuated apoptotic cell death induced by both staurosporine and etoposide, This effect was completely reversed by coapplication of a group I mGluR antagonist. Thus, group I mGluR appear to exhibit opposite effects on necrotic and apoptotic neuronal cell death. Our findings suggest that activation of mGluR1 exacerbates neuronal necrosis whereas both mGluR1 and mGluR5 play a role in attenuation of neuronal apoptosis.	Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Interdisciplinary Program Neurosci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA		Faden, A (corresponding author), EP-04 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR306634-07] Funding Source: Medline		Allen JW, 1999, NEUROPHARMACOLOGY, V38, P1243, DOI 10.1016/S0028-3908(99)00044-1; Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Allen JW, 1999, FASEB J, V13, P1875, DOI 10.1096/fasebj.13.13.1875; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHAVIS P, 1995, J NEUROSCI, V15, P135; COPANI A, 1995, J NEUROCHEM, V64, P101; COPANI A, 1995, MOL PHARMACOL, V47, P890; Copani A, 1998, EUR J NEUROSCI, V10, P2173, DOI 10.1046/j.1460-9568.1998.00230.x; Doherty AJ, 1997, NEUROPHARMACOLOGY, V36, P265, DOI 10.1016/S0028-3908(97)00001-4; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; ITO I, 1992, NEUROREPORT, V3, P1013, DOI 10.1097/00001756-199211000-00017; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; KAKU DA, 1993, SCIENCE, V260, P1516, DOI 10.1126/science.8389056; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; MALESE K, 1999, NEUROSCI LETT, V264, P17; MANZONI OJJ, 1991, EUR J PHARM-MOLEC PH, V207, P231; Moroni F, 1997, J PHARMACOL EXP THER, V281, P721; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; PELLICCIARI R, 1995, J MED CHEM, V38, P3717, DOI 10.1021/jm00019a002; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Riedel G, 1996, PROG NEURO-PSYCHOPH, V20, P1253, DOI 10.1016/S0278-5846(96)00110-8; SCHOEPP DD, 1994, J NEUROCHEM, V63, P769; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; Vincent AM, 1999, EXP NEUROL, V155, P79, DOI 10.1006/exnr.1998.6966; YUZAKI M, 1992, J NEUROSCI, V12, P4253	39	75	81	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1350-9047	1476-5403		CELL DEATH DIFFER	Cell Death Differ.	MAY	2000	7	5					470	476		10.1038/sj.cdd.4400678			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	310MV	WOS:000086832700006	10800080	Bronze			2022-02-06	
J	Bryant, RA; Marosszeky, JE; Crooks, J; Baguley, I; Gurka, J				Bryant, RA; Marosszeky, JE; Crooks, J; Baguley, I; Gurka, J			Coping style and post-traumatic stress disorder following severe traumatic brain injury	BRAIN INJURY			English	Article							MOTOR-VEHICLE ACCIDENTS; SEVERE HEAD-INJURY; PSEUDOMEMORIES; PTSD	There is increasing evidence that a proportion of severe traumatically brain injured (TBI) patients do suffer post-traumatic stress disorder (PTSD). The aim of this study was to investigate the predictors of PTSD following severe TBI in a sample of 96 patients who sustained a severe TBI, of whom 27% satisfied diagnostic criteria for PTSD. The Post-traumatic Stress Disorder interview, the Coping Style Questionnaire, and the Functional Assessment Measure was administered to these patients 6 months after hospital discharge. Avoidant coping style, behavioural coping style, and a history of prior unemployment were the significant predictors of PTSD severity. These findings indicate that reduction of PTSD and management of severe TBI may be facilitated by teaching patients more adaptive coping strategies.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Westmead Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Baguley, Ian J/K-6878-2013; Bryant, Richard/AAA-6479-2019; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; Bryant, Richard/0000-0002-9607-819X; 			American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Billings A G, 1981, J Behav Med, V4, P139, DOI 10.1007/BF00844267; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; BRYANT RA, IN PRESS AM J PSYCHI; DAVIDSON JRT, 1993, POSTTRAUMATIC STRESS, P147; DAVIES RJ, 1991, CLIN EXP ALLERGY, V21, P1, DOI 10.1111/j.1365-2222.1991.tb01750.x; FOA EB, 1989, BEHAV THER, V20, P155, DOI 10.1016/S0005-7894(89)80067-X; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hall K, 1992, NEUROREHABILITATION, V2, P98, DOI DOI 10.3233/NRE-1992-2410; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; Jennett B, 1981, MANAGEMENT HEAD INJU; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; Price K. P., 1994, DEF LAW J, V43, P113; Robins LN, 1985, DIAGNOSTIC INTERVIEW; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SHORE JH, 1989, J NERV MENT DIS, V177, P681, DOI 10.1097/00005053-198911000-00004; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SOLOMON Z, 1988, J ABNORM PSYCHOL, V97, P302, DOI 10.1037/0021-843X.97.3.302; VANDERKOLK BA, 1906, TRAUMATIC STRESS EFF, P214; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x	27	75	75	1	9	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2000	14	2					175	180		10.1080/026990500120826			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	281GW	WOS:000085151000006	10695572				2022-02-06	
J	Hanlon, RE; Demery, JA; Martinovich, Z; Kelly, JP				Hanlon, RE; Demery, JA; Martinovich, Z; Kelly, JP			Effects of acute injury characteristics on neuropsychological status and vocational outcome following mild traumatic brain injury	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; DIFFUSE AXONAL INJURY; CONCUSSION; SYMPTOMS; PATHOPHYSIOLOGY; EPIDEMIOLOGY; MANAGEMENT; SEQUELAE; DEFICITS; ASSAULT	Despite recent attempts to define acute injury characteristics of mild traumatic brain injury (MTBI), neuropsychological outcome is often unpredictable. One hundred MTBI casts were prospectively collected, which were consecutive referrals to a concussion clinic, and thr rules of various acute neurologic variables were examined in relation to neuropsychological status and vocational outcome. Significant differents were found between subgroups of patients classified by (1) mechanism of injury (i.e. acceleration/deceleration trauma in which the head strikes an object (HSO) venus acceleration/deceleration trauma in which the head does not strike an object (HNSO) venus trauma in which an object strikes the head (OSH), and (2) type of injury (i.e. motor vehicle collision, fall, assault, motor vehicle-pedestrian collision, falling object, sports/recreation). There was no difference, with respect to neuropsychological status or vocational outcome, between patients who had positive findings on computerized tomography (CT) versus those who were CT negative. Additionally, there was no difference between patients who had suffered brief loss of consciousness (LOC) and those without LOG. These findings suggest that selective acute injury characteristics may be used to classify subtypes of MTBI patients.	Northwestern Univ, Sch Med, Dept Psychiat, Chicago, IL 60611 USA; Univ Florida, Gainesville, FL 32611 USA; Rehabil Inst Chicago, Chicago, IL 60611 USA		Hanlon, RE (corresponding author), Northwestern Univ, Sch Med, Dept Psychiat, 675 N St Clair,Ste 20-250, Chicago, IL 60611 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; [Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; Eslinger Paul J., 1996, P415; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1993, BIOMECHANICS IMPACT, P595; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GOODMAN JC, 1994, SEMIN NEUROL, V14, P19, DOI 10.1055/s-2008-1041054; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; HODGSON VR, 1993, BIOMECHANICS IMPACT, P539; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; KIKUCHI A, 1993, BIOMECHANICS IMPACT, P361; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1993, BIOMECHANICS IMPACT, P265; ONO K, 1993, BIOMECHANICS IMPACT, P509; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; Teasdale TW, 1997, BRIT MED J, V315, P569; TIRET L, 1990, INT J EPIDEMIOL, V8, P133; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; UNTERHARNSCHEIDT F, 1970, TEX REP BIOL MED, V28, P421; VASQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	43	75	75	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	1999	13	11					873	887					15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	253FZ	WOS:000083547000004	10579659				2022-02-06	
J	Taylor, PN; Burridge, JH; Dunkerley, AL; Lamb, A; Wood, DE; Norton, JA; Swain, ID				Taylor, PN; Burridge, JH; Dunkerley, AL; Lamb, A; Wood, DE; Norton, JA; Swain, ID			Patients' perceptions of the Odstock Dropped Foot Stimulator (ODFS)	CLINICAL REHABILITATION			English	Article							WALKING	Objective: To determine the perceived benefit, pattern and problems of use of the Odstock Dropped Foot Stimulator (ODFS) and the users' opinion of the service provided. Design: Questionnaire sent in a single mailshot to current and past users of the ODFS. Returns were sent anonymously. Setting: Outpatient-based clinical service. Subjects: One hundred and sixty-eight current and 123 past users with diagnoses of stroke (CVA), multiple sclerosis (MS), incomplete spinal cord injury (SCI), traumatic brain injury (TBI) and cerebral palsy (CP). Intervention: Functional electrical stimulation (FES) to correct dropped foot in subjects with an upper motor neuron lesion, using the ODFS. Main outcome measures: Purpose-designed questionnaire. Results: Return rate 64% current users (mean duration of use 19.5 months) and 43% past users (mean duration of use 10.7 months). Principal reason cited for using equipment was a reduction in the effort of walking. Principal reasons identified for discontinuing were an improvement in mobility, electrode positioning difficulties and deteriorating mobility. There were some problems with reliability of equipment. Level of service provided was thought to be good. Conclusion: The ODFS was perceived by the users to be of considerable benefit. A comprehensive clinical follow-up service is essential to achieve the maximum continuing benefit from FES-based orthoses.	Salisbury Dist Hosp, Dept Med Phys & Biomed Engn, Salisbury SP2 8BJ, Wilts, England		Taylor, PN (corresponding author), Salisbury Dist Hosp, Dept Med Phys & Biomed Engn, Salisbury SP2 8BJ, Wilts, England.		Norton, Jonathan/AAN-3076-2021	Norton, Jonathan/0000-0002-6816-3047; Burridge, Jane/0000-0003-3497-6725			ALRECK PL, 1995, SURVEY RES HDB, P115; Burridge J, 1997, ARTIF ORGANS, V21, P254, DOI 10.1111/j.1525-1594.1997.tb04662.x; Burridge J., 1997, PHYSIOTHERAPY, V83, P82, DOI [10.1016/S0031-9406(05)65582-4, DOI 10.1016/S0031-9406(05)65582-4]; Burridge JH, 1997, CLIN REHABIL, V11, P201, DOI 10.1177/026921559701100303; Burridge JH, 1998, REV CLIN GERONTOL, V8, P155; Karsznia A, 1990, ADV EXTERNAL CONTROL, V10, P251; Liberson W., 1961, ARCH PHYS MED REHAB, V42, P202; MERLETTI R, 1978, ADV EXTERNAL CONTROL, V6, P277; Nene AV., 1993, CLIN REHABIL, V7, P319; STEFANOVSKA A, 1989, IEEE T BIO-MED ENG, V36, P738, DOI 10.1109/10.32106; TAYLOR P, 1998, P 6 VIENN INT WORKSH, P189; WADE DT, 1987, SCAND J REHABIL MED, V19, P25	12	75	80	1	11	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2155			CLIN REHABIL	Clin. Rehabil.	OCT	1999	13	5					439	446		10.1191/026921599677086409			8	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation	235UR	WOS:000082561400009	10498351				2022-02-06	
J	Jaworski, DM; Kelly, GM; Hockfield, S				Jaworski, DM; Kelly, GM; Hockfield, S			Intracranial injury acutely induces the expression of the secreted isoform of the CNS-specific hyaluronan-binding protein BEHAB brevican	EXPERIMENTAL NEUROLOGY			English	Article						BEHAB; brevican; extracellular matrix; GFAP; hyaluronan; migration; nestin; PCNA; proliferation; proteoglycan; reactive gliosis	CHONDROITIN SULFATE PROTEOGLYCAN; FIBROBLAST GROWTH-FACTOR; TRAUMATIC BRAIN INJURY; CELL NUCLEAR ANTIGEN; REACTIVE ASTROCYTES; NEURITE OUTGROWTH; RAT-BRAIN; EXTRACELLULAR-MATRIX; INHIBITORY MOLECULES; HEPARAN-SULFATE	Hyaluronan (HA) plays an important role in tissue reorganization in response to injury. The mechanisms by which HA participates in these processes are likely to include HA-binding proteins. Previously, we reported the cloning and initial characterization of a central nervous system (CNS)-specific HA-binding protein, BEHAB (brain enriched hyaluronan binding), which was independently cloned in another laboratory and named brevican. BEHAB/brevican mRNA is expressed in the ventricular zone coincident with the initial proliferation and migration of glial cells and in surgical samples of human glioma, where glial-derived cells proliferate and migrate. To determine whether BEHAB/brevican is also expressed during the cellular proliferation and migration associated with CNS injury, we have examined BEHAB/brevican expression during reactive gliosis. BEHAB/brevican occurs as secreted and cell-surface, glycosylphosphatidylinositol (GPI)-anchored, isoforms. The secreted, but not the GPI-anchored, isoform is up-regulated in response to a stab wound to the adult rat brain. The temporal regulation and spatial distribution of BEHAB/brevican expression parallel the gliotic response and the expression of the intermediate filament protein nestin. The up-regulation of BEHAB/brevican in response to CNS injury suggests a role for this extracellular matrix molecule in reactive gliosis. Glial process extension, a central element in the glial response to injury, may require the reexpression of both cytoskeletal and matrix elements that are normally expressed during the glial motility seen in the immature brain. (C) 1999 Academic Press.	Univ Vermont, Coll Med, Dept Anat & Neurobiol, Burlington, VT 05405 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA		Jaworski, DM (corresponding author), Univ Vermont, Coll Med, Dept Anat & Neurobiol, Burlington, VT 05405 USA.				NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY06511] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35874] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS035874] Funding Source: NIH RePORTER		ALHO AM, 1989, J CELL BIOL, V108, P1557, DOI 10.1083/jcb.108.4.1557; Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; Burke E J, 1994, Acta Neurol (Napoli), V16, P103; Canning DR, 1996, INT J DEV NEUROSCI, V14, P153, DOI 10.1016/0736-5748(96)00004-4; CARBONETTO S, 1983, J NEUROSCI, V3, P2324; CLARKE SR, 1994, NEUROREPORT, V5, P1885, DOI 10.1097/00001756-199410000-00011; DELPECH B, 1993, EUR J CANCER, V29A, P1012, DOI 10.1016/S0959-8049(05)80214-X; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; FAWCETT JW, 1990, DEVELOPMENT, V109, P59; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; GIORDANA MT, 1994, NEUROPATH APPL NEURO, V20, P163, DOI 10.1111/j.1365-2990.1994.tb01175.x; GIULIAN D, 1994, DEV NEUROSCI-BASEL, V16, P128, DOI 10.1159/000112099; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HOCKFIELD S, 1985, J NEUROSCI, V5, P3310; HOKE A, 1994, PERSPECT DEV NEUROBI, V2, P269; JAWORSKI DM, 1995, J NEUROSCI, V15, P1352; Jaworski DM, 1996, CANCER RES, V56, P2293; JAWORSKI DM, 1994, J CELL BIOL, V125, P495, DOI 10.1083/jcb.125.2.495; KITAMURA T, 1978, ACTA NEUROPATHOL, V44, P31, DOI 10.1007/BF00691636; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; MARGOLIS RU, 1975, BIOCHEMISTRY-US, V14, P85, DOI 10.1021/bi00672a014; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MIYACHI K, 1978, J IMMUNOL, V121, P2228; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; MIYAKE T, 1992, BRAIN RES, V590, P300, DOI 10.1016/0006-8993(92)91109-R; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; ROSEN GD, 1994, DEV BRAIN RES, V82, P127, DOI 10.1016/0165-3806(94)90155-4; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; SCHIFFER D, 1993, INT J DEV NEUROSCI, V11, P269, DOI 10.1016/0736-5748(93)90085-R; SEIDENBECHER CI, 1995, J BIOL CHEM, V270, P27206, DOI 10.1074/jbc.270.45.27206; Seidenbecher CI, 1998, EUR J NEUROSCI, V10, P1621, DOI 10.1046/j.1460-9568.1998.00166.x; SMITH GM, 1993, J NEUROCHEM, V60, P1453, DOI 10.1111/j.1471-4159.1993.tb03308.x; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; Toole B.P., 1991, CELL BIOL EXTRACELLU, P305; TUSZYNSKI MH, 1995, MOL NEUROBIOL, V10, P151, DOI 10.1007/BF02740673; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; YAMADA H, 1995, BIOCHEM BIOPH RES CO, V216, P957, DOI 10.1006/bbrc.1995.2713; Yamada H, 1997, J NEUROSCI, V17, P7784; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yang HY, 1997, EXP NEUROL, V146, P199, DOI 10.1006/exnr.1997.6518; Zhang H, 1998, J NEUROSCI, V18, P2370; ZHANG LR, 1995, CANCER RES, V55, P428	57	75	78	1	2	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JUN	1999	157	2					327	337		10.1006/exnr.1999.7062			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	202LD	WOS:000080653000010	10364444				2022-02-06	
J	Fox, GB; LeVasseur, RA; Faden, AI				Fox, GB; LeVasseur, RA; Faden, AI			Behavioral responses of C57BL/6, FVB/N, and 129/SvEMS mouse strains to traumatic brain injury: Implications for gene targeting approaches to neurotrauma	JOURNAL OF NEUROTRAUMA			English	Article						Barnes maze; behavior differences; mouse; strain C57BL/6; strain FVB N; strain 129/SvEMS; water maze	CONTROLLED CORTICAL IMPACT; INBRED MICE; NICOTINE; MODEL; MAZE; SUSCEPTIBILITY; ISCHEMIA; GENOTYPE; ETHANOL	Recent studies have suggested that mouse models of traumatic brain injury may be useful for evaluating the role of single gene products in brain trauma. In the present study, we report that three background strains (C57BL/6, FVB/N, and 129/SvEMS), commonly used in genetically altered mice, exhibit significantly different behavioral responses when subjected to sham surgery (n = 9 per group) or moderate controlled cortical impact (CCI) injury (n = 12 per group), Injured animals from all three strains showed delayed recovery of pedal withdrawal and righting reflexes compared to sham-operated controls. Significant deficits in both a forepaw contraflexion and rotarod task were evident for up to 7 days after injury, with no significant difference among strains. Sham-operated C57BL/6 mice performed significantly better than FVB/N and 129/SvEMS sham controls in a beam walking task up to 4 weeks after surgery, However, CCI-injured FVB/N mice outperformed injured animals from both other strains in this same task, Significant impairment of place learning in the Morris water maze and Barnes circular maze was observed at 7-10 days and 21-24 days after injury, respectively, in C57BL/6 mice when compared with sham controls. Sham-operated FVB/N and 129/SvEMS mice were unable to learn either task, and performance did not differ significantly from respective CCI injured animals. Our results suggest that background strain should be carefully considered with experiments involving genetically altered mice, especially when planning behavioral outcome measures after CNS injury.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, 3970 Reservoir Rd NW,Rm EP-04, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR 306634] Funding Source: Medline		BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; Connolly ES, 1996, NEUROSURGERY, V38, P523, DOI 10.1097/00006123-199603000-00021; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; Deutsch SI, 1997, PHARMACOL BIOCHEM BE, V57, P315, DOI 10.1016/S0091-3057(96)00347-4; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.3.CO;2-L; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujii M, 1997, STROKE, V28, P1805, DOI 10.1161/01.STR.28.9.1805; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; Goelz MF, 1998, LAB ANIM SCI, V48, P34; Laghmouch A, 1997, BEHAV GENET, V27, P67, DOI 10.1023/A:1025667426222; Lathe R, 1996, TRENDS NEUROSCI, V19, P183, DOI 10.1016/S0166-2236(96)20022-0; LUO YH, 1994, ALCOHOL, V11, P167, DOI 10.1016/0741-8329(94)90059-0; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MELISKA CJ, 1995, PHARMACOL BIOCHEM BE, V50, P619, DOI 10.1016/0091-3057(94)00354-8; Montkowski A, 1997, BRAIN RES, V762, P12, DOI 10.1016/S0006-8993(97)00370-3; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; PICK CG, 1989, BEHAV GENET, V19, P315, DOI 10.1007/BF01065913; Robinson SF, 1996, PSYCHOPHARMACOLOGY, V124, P332, DOI 10.1007/BF02247438; ROULLET P, 1995, PHYSIOL BEHAV, V58, P1189, DOI 10.1016/0031-9384(95)02066-7; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; SEALE TW, 1984, PHARMACOL BIOCHEM BE, V20, P567, DOI 10.1016/0091-3057(84)90306-X; SEALE TW, 1984, PHARMACOL BIOCHEM BE, V21, P237, DOI 10.1016/0091-3057(84)90221-1; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Zaharia MD, 1996, PSYCHOPHARMACOLOGY, V128, P227, DOI 10.1007/s002130050130	26	75	75	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	1999	16	5					377	389		10.1089/neu.1999.16.377			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	200WC	WOS:000080562200004	10369558				2022-02-06	
J	Chesnut, RM; Carney, N; Maynard, H; Mann, NC; Patterson, P; Helfand, M				Chesnut, RM; Carney, N; Maynard, H; Mann, NC; Patterson, P; Helfand, M			Summary report: Evidence for the effectiveness of rehabilitation for persons with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						rehabilitation; systematic review; traumatic brain injury	CLOSED-HEAD-INJURY; SUPPORTED EMPLOYMENT; NEUROPSYCHOLOGICAL REHABILITATION; EARLY INTERVENTION; OUTCOMES; DEFICITS; LENGTH; RETURN; STAY; WORK	We evaluated the evidence fur effectiveness of rehabilitation methods throughout the phases of recovery from traumatic brain injury (TBI) in adults. MEDLINE, HealthSTAR, CINAHL, PsycINFO, and the Cochrane Library were searched, and a total of 3,098 abstracts were reviewed. The strongest studies were critically appraised and their data placed in evidence tables. Results showed that to determine the effectiveness of rehabilitation interventions for persons with TBI. a commitment must be made to population-based studies, strong controlled research design, standardization of measures, adequate statistical analysis, and specification of health outcomes of importance to persons with TBI and their families.	Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Div Med Informat & Outcomes Res, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Evidence Based Practice Ctr, Portland, OR 97201 USA		Chesnut, RM (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol Surg, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.			Chesnut, Randall/0000-0001-6377-3666			ANDERSEN J, 1992, J TRAUMA, V33, P219, DOI 10.1097/00005373-199208000-00009; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Ashley M J, 1994, J Insur Med, V26, P348; Batchelor J, 1988, J HEAD TRAUMA REHAB, V3, P78, DOI DOI 10.1097/00001199-198809000-00012; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CHESNUT RM, IN PRESS EVIDENCE RE; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; CURL RM, 1993, J VOCATIONAL REHABIL, V3, P72; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Gray JM, 1992, NEUROPSYCHOL REHABIL, V2, P97, DOI DOI 10.1080/09602019208401399; GREENWOOD RJ, 1994, BRIT MED J, V308, P1199, DOI 10.1136/bmj.308.6938.1199; HAFFEY WJ, 1991, J HEAD TRAUMA REHAB, V6, P24; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HELFFENSTEIN DA, 1982, CLIN NEUROPSYCHOLOGY, V4, P139; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnson D, 1989, Nurs Times, V85, P25; Jorgensen H S, 1997, Ugeskr Laeger, V159, P4093; Kerner MJ, 1985, COGNITIVE REHABILITA, V1, P26; Kock C, 1992, Rehabilitation (Stuttg), V31, P217; Kosubek C, 1996, Rehabilitation (Stuttg), V35, P29; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MALEC JF, 1995, MAYO CLIN PROC, V70, P1165, DOI 10.4065/70.12.1165; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; Najenson T, 1980, Int Rehabil Med, V2, P17; NEISTADT ME, 1992, AM J OCCUP THER, V46, P141, DOI 10.5014/ajot.46.2.141; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Sherburne E, 1986, J Neurosci Nurs, V18, P140; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; THOMASS BA, 1994, EUR J COMMUN, V9, P25, DOI 10.1177/0267323194009001002; TWUM M, 1994, J CLIN EXP NEUROPSYC, V16, P630, DOI 10.1080/01688639408402674; US Preventative Services Task Force, 1996, GUID CLIN PREV SERV, V2nd; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563; WEHMAN P, 1989, J APPL BEHAV ANAL, V22, P395, DOI 10.1901/jaba.1989.22-395; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wood R L, 1987, Int Disabil Stud, V9, P149; WRIGLEY JM, 1994, ARCH PHYS MED REHAB, V75, P149	55	75	75	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1999	14	2					176	188		10.1097/00001199-199904000-00007			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	187DN	WOS:000079771800007	10191375				2022-02-06	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Optimization of magnesium therapy after severe diffuse axonal brain injury in rats	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; HEAD-INJURY; FREE MG-2+; NEURONS; TRAUMA; METABOLISM; MG2+; PH; DEFICITS; ISCHEMIA	A number of studies have demonstrated that magnesium salts given after traumatic brain injury improve subsequent neurologic outcome. However, given that these earlier studies have used a number of different salts, dosages, and routes of administration, follow-up studies of the neuroprotective properties of magnesium are complicated, with comparisons to the earlier literature virtually impossible. The present study has therefore characterized the dose-response characteristics of the most commonly used sulfate and chloride salts of magnesium in a severe model of diffuse traumatic axonal injury in rats. Both magnesium salts improved neurologic outcome in rats when administered as a bolus at 30 min after injury. The i.v. and i.m. optima of each salt was 250 mu mol/kg and 750 mu mol/kg, respectively. The identical concentrations required for improved neurologic outcome suggest that improvement in outcome was dependent on the magnesium cation and not the associated anion. Subsequent magnetic resonance studies demonstrated that the administered magnesium penetrated the blood-brain barrier after injury and resulted in an increased brain intracellular free magnesium concentration and associated bioenergetic state as reflected in the cytosolic phosphorylation potential. Both of these metabolic parameters positively correlated with resultant neurologic outcome measured daily in the same animals immediately before the magnetic resonance determinations.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia		Vink, R (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.		Vink, Robert/J-7351-2012; Vink, Robert/S-5616-2019	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALTURA BM, 1992, BIOCHIM BIOPHYS ACTA, V1111, P271, DOI 10.1016/0005-2736(92)90320-L; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GUNTHER T, 1994, MAGNESIUM-B, V16, P38; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; KAUPPINEN RA, 1992, J NEUROCHEM, V58, P831, DOI 10.1111/j.1471-4159.1992.tb09332.x; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Povlishock JT, 1996, ACT NEUR S, V66, P81; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1991, MAGNESIUM EXCITABLE, P695; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	36	75	79	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	MAR	1999	288	3					1311	1316					6	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	172BZ	WOS:000078903600048	10027872				2022-02-06	
J	Bryant, RA; Harvey, AG				Bryant, RA; Harvey, AG			The influence of traumatic brain injury on acute stress disorder and post-traumatic stress disorder following motor vehicle accidents	BRAIN INJURY			English	Article							HEAD-INJURY; EVENTS	This study compared the acute stress disorder and post-traumatic stress disorder (PTSD) symptom profiles in motor vehicle accident survivors who sustained a mild traumatic brain injury (MTBI) or no TBI. Consecutive adult patients who sustained a MTBI (n = 79) and no TBI (n = 92) were assessed for acute stress disorder within 1 month of their trauma and reassessed for PTSD (MTBI: n = 63; non-TBI; n = 72) 6-months post-trauma. Comparable rates of acute stress disorder and PTSD were reported in MTBI and non-TBI patients. Intrusive memories and fear and helplessness in response to the trauma were reported less frequently by MTBI than non-TBI patients at the acute phase. Six-months post-trauma fewer MTBI patients than non-TBI reported fear and helplessness in response to the trauma. These findings suggest that, whereas impaired consciousness at the time of a trauma may reduce the frequency of traumatic memories in the initial month post-trauma, MTBI does not result in a different profile of longer-term PTSD.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Univ Oxford, Oxford, England		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; BOHNEN J, 1992, J NERV MENT DIS, V180, P183; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; BRYANT RA, 1995, AUST J PUBLIC HEALTH, V19, P185; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; BRYANT RA, 1998, IN PRESS J NERVOUS M; Ehlers A, 1995, Behav Cogn Psychother, V23, P217, DOI 10.1017/S135246580001585X; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; Price K. P., 1994, DEF LAW J, V43, P113; RATTOCK J, 1993, J CLIN EXPT NEUROPSY, V6, P243; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SOLOMON Z, 1988, J ABNORM PSYCHOL, V97, P302, DOI 10.1037/0021-843X.97.3.302; Van Der Kolk Bessel A., 1996, P214	31	75	77	1	8	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1999	13	1					15	22		10.1080/026990599121836			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	158TA	WOS:000078131200002	9972438				2022-02-06	
J	Meythaler, JM; Guin-Renfroe, S; Grabb, P; Hadley, MN				Meythaler, JM; Guin-Renfroe, S; Grabb, P; Hadley, MN			Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SPINAL SPASTICITY; DRUG-THERAPY; DYSFUNCTION; ORIGIN; REFLEX; BOLUS; SPACE	Objective: To determine if the long-term use of continuously infused intrathecal baclofen (ITB) over a 1-year period will control spastic-dystonic hypertonia in patients with traumatic brain injury (TBI). Setting: Tertiary care outpatient and inpatient rehabilitation center directly attached to a university hospital. Subjects: Persons with TBI and intractable spasticity and dystonia for more than 6 months' duration recruited in a consecutive manner. Design: TBI patients were admitted to the study after screening via a bolus injection of either intrathecal normal saline or 50 mu g of baclofen. Data for Ashworth rigidity scores, spasm scores, and deep tendon reflex scores were collected for both the upper extremities (UE) and lower extremities (LE). Patients whose LE Ashworth scores decreased an average of 2 points were then offered implantation of a computer-controlled pump for continuous ITB. Changes over time were assessed statistically via Friedman's analysis for ordinal data and ANOVA for linear data. Differences between set points in time were also assessed via Wilcoxon signed rank. Data Set: Seventeen patients (average age 29 +/- 11yrs) with spasticity and/or dystonia treated over 1 year via a computer-controllable intrathecal delivery system for the delivery of ITB. Results: After 1 year of continuous ITB treatment the average LE Ashworth score decreased from 3.5 +/- 1.3 (SD) to 1.7 +/- 0.9 (p < .0001), spasm score from 1.8 +/- 1.3 to 0.2 +/- 0.5 (p < .0001), and reflex score from 2.5 +/- 1.1 to 0.1 +/- 0.3 (p < .0001). The average UE Ashworth score decreased from 2.9 +/- 1.5 to 1.6 +/- 1.0 (p < .0001), spasm score from 1.2 +/- 1.5 to 0.2 +/- 0.6 (p < 0.0001), and reflex score from 2.2 +/- 0.5 to 1.0 +/- 0.8 (p < .0001). The average ITB dose required to attain these effects at 1 year was 302 mu g continuously infused per day. Conclusion: Continuous intrathecal infusion of baclofen is capable of maintaining a reduction in spasticity and dystonia in both the upper and lower extremities of TBI patients. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Alabama, Spain Rehabil Ctr R157, Dept Phys Med & Rehabil, Sch Med, Birmingham, AL 35233 USA; Univ Alabama, Div Neurol Surg, Sch Med, Birmingham, AL 35233 USA		Meythaler, JM (corresponding author), Univ Alabama, Spain Rehabil Ctr R157, Dept Phys Med & Rehabil, Sch Med, 1717 6th Ave S, Birmingham, AL 35233 USA.						Adams R. D., 1993, PRINCIPLES NEUROLOGY; AKMAN MN, 1993, PARAPLEGIA, V31, P516, DOI 10.1038/sc.1993.84; ALBRIGHT AL, 1993, JAMA-J AM MED ASSOC, V270, P2475, DOI 10.1001/jama.270.20.2475; ALBRIGHT LA, 1997, INTRATHECAL BACLOFEN; ASHBY P, 1974, J NEUROL NEUROSUR PS, V37, P1352, DOI 10.1136/jnnp.37.12.1352; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; Bullock R, 1995, GUIDELINES MANAGEMEN; BUSHMAN W, 1993, NEUROUROL URODYNAM, V12, P163, DOI 10.1002/nau.1930120210; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Denys P, 1998, ARCH PHYS MED REHAB, V79, P494, DOI 10.1016/S0003-9993(98)90061-2; Ford B, 1996, ARCH NEUROL-CHICAGO, V53, P1241, DOI 10.1001/archneur.1996.00550120049016; FROST F, 1989, AM J PHYS MED REHAB, V68, P112, DOI 10.1097/00002060-198906000-00002; Gerszten PC, 1998, J NEUROSURG, V88, P1009, DOI 10.3171/jns.1998.88.6.1009; Hattab J.R., 1980, SPASTICITY DISORDERE, P71; KATZ R, 1982, BRAIN, V105, P103, DOI 10.1093/brain/105.1.103; KATZ RT, 1988, AM J PHYS MED REHAB, V67, P108, DOI 10.1097/00002060-198806000-00004; KATZ RT, 1992, PHYS MED CLIN N AM, V3, P319; KLOCKGETHER T, 1989, NEUROSCI LETT, V97, P221, DOI 10.1016/0304-3940(89)90167-5; KNUTSSON E, 1974, J NEUROL SCI, V23, P473, DOI 10.1016/0022-510X(74)90163-4; KROIN JS, 1984, EXP BRAIN RES, V54, P191; KROIN JS, 1991, PARENTERAL DRUG THER, P73; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; M?ller H., 1988, LOCAL SPINAL THERAPY, P223; MACDONELL RAL, 1989, J NEUROL NEUROSUR PS, V52, P1110, DOI 10.1136/jnnp.52.9.1110; Mann NH, 1991, J NEUROL REHABIL, V5, P51; MENDELL LM, 1984, PHYSIOL REV, V64, P260, DOI 10.1152/physrev.1984.64.1.260; MEYTHALER JM, 1992, AM J PHYS MED REHAB, V71, P321, DOI 10.1097/00002060-199212000-00003; MEYTHALER JM, 1992, ARCH PHYS MED REHAB, V73, P794; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Meythaler JM, 1997, J HEAD TRAUMA REHAB, V12, P87, DOI 10.1097/00001199-199702000-00012; Meythaler JM, 1996, ARCH PHYS MED REHAB, V77, P461, DOI 10.1016/S0003-9993(96)90034-9; MEYTHALER JM, 1998, AM J PHYS MED REHABI, V77, P173; Meythaler JM, 1996, PERSPECT NEUROSURG, V7, P99; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, pS10, DOI 10.1016/S0003-9993(98)90114-9; Patterson, 1989, J NEUROL REHABIL, V3, P205, DOI DOI 10.1177/136140968900300406; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; ROY CW, 1986, PARAPLEGIA, V24, P318, DOI 10.1038/sc.1986.45; SABBE MB, 1993, NEUROTOXICOLOGY, V14, P397; SANDYK R, 1985, CLIN NEUROPHARMACOL, V8, P294, DOI 10.1097/00002826-198509000-00011; SHEMESH Y, 1977, PARAPLEGIA, V15, P238, DOI 10.1038/sc.1977.36; SOKOL RR, 1969, BIOMETRY; STEERS WD, 1992, J UROLOGY, V148, P1849, DOI 10.1016/S0022-5347(17)37048-9; TERRENCE CF, 1981, ARCH NEUROL-CHICAGO, V38, P588, DOI 10.1001/archneur.1981.00510090082011; WILSON PR, 1978, EUR J PHARMACOL, V51, P323, DOI 10.1016/0014-2999(78)90423-5; YAKSH TL, 1981, ANESTHESIOLOGY, V54, P451, DOI 10.1097/00000542-198106000-00004; YOUNG RR, 1981, NEW ENGL J MED, V304, P28; YOUNG RR, 1981, NEW ENGL J MED, V304, P96	48	75	76	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	1999	80	1					13	19		10.1016/S0003-9993(99)90301-5			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	155XZ	WOS:000077973000002	9915366				2022-02-06	
J	Signorini, DF; Andrews, PJD; Jones, PA; Wardlaw, JM; Miller, JD				Signorini, DF; Andrews, PJD; Jones, PA; Wardlaw, JM; Miller, JD			Adding insult to injury: the prognostic value of early secondary insults for survival after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						traumatic brain injury; prognosis; survival; secondary insults; adults	SEVERE HEAD-INJURY; INTENSIVE-CARE; INTRACRANIAL HYPERTENSION; MODELS; UNIT	Objectives-To assess the prognostic value of summary measures of secondary physiological insult in addition to baseline clinical variables for patients with traumatic brain injury. Methods-A series of 110 patients with traumatic brain injury had data on intracranial pressure (ICP), arterial blood pressure (ABP), cerebral perfusion pressure (CPP), arterial O-2 saturation (SaO(2)), temperature in degrees C (Temp), and heart rate in beats/min (HRT) monitored and recorded every minute. Secondary insults were defined according to the Edinburgh University secondary insult grading system. The prognostic value of summary measures of these secondary insults was assessed by adding them to a prognostic model for survival at 1 year after controlling for baseline clinical variables using a previously validated model. Results-Of the eight secondary insults measured, only ICP added significantly to the prediction of survival in the first 72 hours after injury. The particular type of summary measure did not seem to influence the results. After the addition of ICP to the model, none of the other secondary insult measures could improve the predictive power of the model significantly. Conclusions-Early intracranial hypertension is confirmed as a sign of poor prognosis in patients with traumatic brain injury, even after controlling for baseline clinical variables. The value or otherwise of treating such secondary insults, however, can only be definitively established in the context of prospective randomised controlled trials. The specific pathophysiological evolution of secondary insults is still the subject of much research, and a clear understanding will be necessary before the development of specific treatments is feasible.	Univ Edinburgh, Dept Clin Neurosci, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Edinburgh, Dept Anaesthet, Edinburgh EH8 9YL, Midlothian, Scotland		Signorini, DF (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Bramwell Dott Bldg,Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.						ALEXANDER E, 1992, SURG NEUROL, V38, P478, DOI 10.1016/0090-3019(92)90124-6; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; CORRIE J, 1993, BRIT J INT CARE, V3, P225; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; GENTLEMAN D, 1990, INJURY, V21, P305, DOI 10.1016/0020-1383(90)90047-X; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; LEMESHOW S, 1994, CRIT CARE MED, V22, P1351, DOI 10.1097/00003246-199409000-00003; MIDGLEY S, 1994, ANAESTHESIA INTENSIV, P373; Miller A.J, 1990, SUBSET SELECTION REG; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1992, J NEUROTRAUM, V9, pS317; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PIPER IR, 1991, BR J INTENS CARE, V1, P73; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SIGNORINI DF, 1997, CRIT CARE MED, V25; STOLL M, 1992, BIOMED TECH, V37, P37, DOI 10.1515/bmte.1992.37.3.37	22	75	82	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	1999	66	1					26	31		10.1136/jnnp.66.1.26			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	154DC	WOS:000077872500008	9886446	Bronze, Green Published			2022-02-06	
J	Skoglosa, Y; Lewen, A; Takei, N; Hillered, L; Lindholm, D				Skoglosa, Y; Lewen, A; Takei, N; Hillered, L; Lindholm, D			Regulation of pituitary adenylate cyclase activating polypeptide and its receptor type 1 after traumatic brain injury: Comparison with brain-derived neurotrophic factor and the induction of neuronal cell death	NEUROSCIENCE			English	Article						brain trauma; gene regulation; PACAP; BDNF; in situ hybridization; cell death	CEREBELLAR GRANULE NEURONS; NERVE GROWTH-FACTOR; TRANSIENT FOREBRAIN ISCHEMIA; FACTOR MESSENGER-RNA; ADULT-RAT BRAIN; CORTICAL-NEURONS; HIPPOCAMPAL-NEURONS; PACAP RECEPTORS; PC12 CELLS; NON-NMDA	Neurotrophic factors are known to promote neuronal survival during development and after acute brain injury. Recent data suggest that some neuropeptides also exhibit neurotrophic activities, as shown for the pituitary adenylate cyclase activating polypeptide, which increases the survival of various neuronal populations in culture. Employing in situ hybridization techniques, we have studied the regulation of messenger RNA for pituitary adenylate cyclase activating polypeptide and its receptor type 1 after a moderate traumatic brain injury to rat brain cortex. We have further compared their messenger RNA expression to that of brain-derived neurotrophic factor and to the amount of cell death occurring in the brain at various times after the brain injury. Levels of brain-derived neurotrophic factor messenger RNA increased rapidly within 2 h after trauma in cortex and hippocampus, and returned to control levels thereafter. The levels of messenger RNA for pituitary adenylate cyclase activating polypeptide also increased with time in the injured brains and reached maximal expression at 72 h, i.e. the end of the observation period. The alterations in pituitary adenylate cyclase activating polypeptide messenger RNA levels were particularly pronounced in the perifocal region and in the ipsilateral dentate gyrus of the brain injury. In contrast, the messenger RNA levels encoding pituitary adenylate cyclase activating polypeptide receptor type 1 first decreased after trauma and were then normalized in the dentate gyrus. There was a large increase in the number of cells labelled for DNA breaks at 12 h past-trauma, indicative of enhanced cell death. The number of labelled cells, however, decreased at later stages concomitant with an increase in the expression of pituitary adenylate cyclase activating polypeptide messenger RNA. Pituitary adenylate cyclase activating polypeptide rescued cortical neurons in cultures against ionomycin-induced cell death, supporting the concept of a neuroprotective effect for the peptide. These results demonstrate a differential regulation of messenger RNA for brain-derived neurotrophic factor and the pituitary adenylate cyclase activating polypeptide and its receptor after brain trauma. The data also suggest that pituitary adenylate cyclase activating polypeptide might have a beneficial effect in brain injury by counteracting neuronal cell death. (C) 1999 IBRO. Published by Elsevier Science Ltd.	Biomed Ctr, Dept Neurosci Dev Neurobiol, Uppsala, Sweden; Univ Uppsala Hosp, Dept Neurosci Neurosurg, Uppsala, Sweden; Univ Uppsala Hosp, Dept Med Clin Chem, Uppsala, Sweden		Lindholm, D (corresponding author), Biomed Ctr, Dept Neurosci Dev Neurobiol, Box 587, Uppsala, Sweden.		Lewen, Anders/A-5156-2013; Lindholm, Dan/B-3777-2014	Lewen, Anders/0000-0003-4925-1348; 			ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; ARIMURA A, 1994, ANN NY ACAD SCI, V739, P228, DOI 10.1111/j.1749-6632.1994.tb19825.x; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; Banks WA, 1996, ANN NY ACAD SCI, V805, P270; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BASILLE M, 1993, NEUROSCIENCE, V57, P329, DOI 10.1016/0306-4522(93)90066-O; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; CASTREN E, 1995, NEUROSCIENCE, V64, P71, DOI 10.1016/0306-4522(94)00386-J; Cavallaro S, 1996, MOL PHARMACOL, V50, P60; CHENG B, 1994, BRAIN RES, V650, P331, DOI 10.1016/0006-8993(94)91801-5; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; Clark RSB, 1997, J NEUROSCI, V17, P9172; DAgata V, 1996, EUR J NEUROSCI, V8, P310, DOI 10.1111/j.1460-9568.1996.tb01215.x; DAVIS RC, 1994, ARIEL-REV INT ENGL, V25, P133; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DESHPANDE J, 1992, EXP BRAIN RES, V88, P91, DOI 10.1007/BF02259131; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DICICCOBLOOM E, 1992, REGUL PEPTIDES, V37, P319, DOI 10.1016/0167-0115(92)90634-7; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Hashimoto H, 1996, J COMP NEUROL, V371, P567; HAYES RL, 1995, NEUROSCI LETT, V191, P121, DOI 10.1016/0304-3940(95)11561-X; HERNANDEZ A, 1995, PEPTIDES, V16, P927, DOI 10.1016/0196-9781(95)00059-S; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KAISER PK, 1990, NEURON, V5, P373, DOI 10.1016/0896-6273(90)90173-D; KIVIPELTO L, 1992, J CHEM NEUROANAT, V5, P85, DOI 10.1016/0891-0618(92)90036-P; Kokaia Z, 1996, MOL BRAIN RES, V38, P139, DOI 10.1016/0169-328X(96)00002-2; Larsen JO, 1997, MOL BRAIN RES, V46, P109, DOI 10.1016/S0169-328X(96)00279-3; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewen A, 1997, NEUROREPORT, V8, P475, DOI 10.1097/00001756-199701200-00020; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x; LINDHOLM D, 1994, J NEUROBIOL, V25, P1362, DOI 10.1002/neu.480251105; Lindholm D, 1996, EUR J NEUROSCI, V8, P1452, DOI 10.1111/j.1460-9568.1996.tb01607.x; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LINDSAY RM, 1994, NEUROBIOL AGING, V15, P249, DOI 10.1016/0197-4580(94)90124-4; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; Lioudyno M, 1998, J NEUROSCI RES, V51, P243, DOI 10.1002/(SICI)1097-4547(19980115)51:2<243::AID-JNR13>3.0.CO;2-9; LONGO FM, 1993, NEUROTROPHIC FACTORS, P565; Lu NR, 1997, P NATL ACAD SCI USA, V94, P3357, DOI 10.1073/pnas.94.7.3357; Marty S, 1996, NEURON, V16, P565, DOI 10.1016/S0896-6273(00)80075-6; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; Morio H, 1996, BRAIN RES, V741, P82, DOI 10.1016/S0006-8993(96)00920-1; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NITATORI T, 1995, J NEUROSCI, V15, P1001; OGI K, 1990, BIOCHEM BIOPH RES CO, V173, P1271, DOI 10.1016/S0006-291X(05)80924-6; PINCUS DW, 1990, BRAIN RES, V514, P355, DOI 10.1016/0006-8993(90)91433-H; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; RINK A, 1995, AM J PATHOL, V147, P1575; SCHWARTZ JP, 1992, INT REV NEUROBIOL, V34, P1, DOI 10.1016/S0074-7742(08)60096-3; Shuto Y, 1996, REGUL PEPTIDES, V67, P79, DOI 10.1016/S0167-0115(96)00116-4; SKOGLOSA Y, 1997, SOC NEUR 27 ANN M NE; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; TAKEI N, 1994, BRAIN RES, V652, P65, DOI 10.1016/0006-8993(94)90317-4; TATSUNO I, 1992, ENDOCRINOLOGY, V131, P73, DOI 10.1210/en.131.1.73; TATSUNO I, 1994, PEPTIDES, V15, P55, DOI 10.1016/0196-9781(94)90170-8; TSUKAHARA T, 1994, NEUROSURGERY, V34, P323, DOI 10.1227/00006123-199402000-00016; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; Zhang Q, 1995, BRAIN RES, V705, P149, DOI 10.1016/0006-8993(95)01150-1; ZIRRGIEBEL U, 1995, J NEUROCHEM, V65, P2241	72	75	78	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		1999	90	1					235	247		10.1016/S0306-4522(98)00414-X			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	172RE	WOS:000078937400022	10188950				2022-02-06	
J	Martins, F; Freitas, F; Martins, L; Dartigues, JF; Barat, M				Martins, F; Freitas, F; Martins, L; Dartigues, JF; Barat, M			Spinal cord injuries - Epidemiology in Portugal's central region	SPINAL CORD			English	Article						spinal cord injury; incidence; mortality; rehabilitation	EXPERIENCE; LESIONS; TAIWAN; COUNTY	This study concerns spinal cord injuries (SCI) in a region of Portugal with a population of 1721650 inhabitants. Legislation has made it possible to identify deaths occurring during collection and transport. Between 1989 and 1992, 395 new cases of spinal cord injuries were identified, of with 77% were male and 23% female. The average age nias 50, with a range of between 1 and 92. As far as the type of injury is concerned, there were 154 isolated SCI (38.7%); in 120 cases (30.1%) there were multiple associated injuries; in 66 cases (16.6%) there was an associated traumatic brain injury; in 34 cases (8.5%) there was an associated trauma of the thorax. In the hospitals concerned no Injury Severity Score (ISS) was carried out during hospitalization. Sixty-four (16%) were dead upon arrival at hospital, and 159 (40%) died before release. The average length of hospitalization was 26.6 days, with the maximum being 539 days. The annual incidence rate is 57.8 new cases per million inhabitants, including those who died before being admitted to hospital. The annual survival rate is 25.4 new cases per million inhabitants. The death rate is very high during the first week, peaking during the first 24 h.	Ctr Hosp Coimbra, Serv Med Fis & Reabilitacad, P-3000 Coimbra, Portugal; Univ Bordeaux 2, F-33000 Bordeaux, France		Martins, F (corresponding author), Rua Miguel Torga 353,4 Esq, P-3030 Coimbra, Portugal.		DARTIGUES, Jean Francois/T-4513-2019				ACTON PA, 1993, ARCH PHYS MED REHAB, V74, P1035, DOI 10.1016/0003-9993(93)90058-I; ANDERSON DW, 1980, J NEUROSURG, V53, pS32; BIERINGSORENSEN F, 1990, PARAPLEGIA, V28, P105, DOI 10.1038/sc.1990.13; BRACKEN MB, 1981, AM J EPIDEMIOL, V113, P615, DOI 10.1093/oxfordjournals.aje.a113140; BURNEY RE, 1993, ARCH SURG-CHICAGO, V128, P596; CHEN CF, 1985, PARAPLEGIA, V23, P364, DOI 10.1038/sc.1985.58; DAPAZ AC, 1992, PARAPLEGIA, V30, P636, DOI 10.1038/sc.1992.126; DAVERAT P, 1989, J NEUROL NEUROSUR PS, V52, P403, DOI 10.1136/jnnp.52.3.403; DAVERAT P, 1987, Annales de Readaptation et de Medecine Physique, V30, P369; DAVERAT P, 1990, RENCONTRES AUTOUR BL, P135; DINEER F, 1992, PARAPLEGIA, V30, P641; DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13; DOLLFUS P, 1990, RECONTRES AUTOUR BLE, P197; FINE PR, 1979, PARAPLEGIA, V17, P237, DOI 10.1038/sc.1979.47; GARCIARENESES J, 1991, PARAPLEGIA, V29, P180, DOI 10.1038/sc.1991.26; GASPAR VG, 1980, PARAPLEGIA, V18, P106, DOI 10.1038/sc.1980.17; GEHRIG R, 1986, PARAPLEGIA, V5, P93; GJONE R, 1978, PARAPLEGIA, V16, P88, DOI 10.1038/sc.1978.14; GRIFFIN MR, 1985, AM J EPIDEMIOL, V121, P884, DOI 10.1093/oxfordjournals.aje.a114058; GRIFFITHS ER, 1980, PARAPLEGIA, V18, P109, DOI 10.1038/sc.1980.18; HARLID R, 1993, PARAPLEGIA, V31, P157; HART C, 1994, PARAPLEGIA, V32, P709, DOI 10.1038/sc.1994.115; *I NAC EST CENS 91, 1993, RES DEF CTR; KARAMEHMETOGLU SS, 1995, PARAPLEGIA, V33, P469, DOI 10.1038/sc.1995.102; KNUTSDOTTIR S, 1993, PARAPLEGIA, V31, P68, DOI 10.1038/sc.1993.10; KRAUS JF, 1980, J NEUROSURG, V53, pS35; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; KRAUS JF, 1980, J NEUROSURG, V53, pS3; LAN C, 1993, PARAPLEGIA, V31, P398, DOI 10.1038/sc.1993.66; MARTINS F, 1990, ACTUALITIES REEDUCAT, P383; MASINI M, 1990, PARAPLEGIA, V28, P17, DOI 10.1038/sc.1990.3; MINAIRE P, 1978, PARAPLEGIA, V16, P76, DOI 10.1038/sc.1978.13; PRICE C, 1994, AM J EPIDEMIOL, V139, P37, DOI 10.1093/oxfordjournals.aje.a116933; SHINGU H, 1994, PARAPLEGIA, V32, P3, DOI 10.1038/sc.1994.2; SILBERSTEIN B, 1995, PARAPLEGIA, V33, P322, DOI 10.1038/sc.1995.72; SILVER JR, 1968, BRIT MED J, V4, P79, DOI 10.1136/bmj.4.5623.79; SOOPRAMANIEN A, 1994, PARAPLEGIA, V32, P715, DOI 10.1038/sc.1994.116; THURMAN DJ, 1994, PARAPLEGIA, V32, P665, DOI 10.1038/sc.1994.107; TOLONEN J, 1986, INJURY, V17, P154, DOI 10.1016/0020-1383(86)90321-9; YARKONY GM, 1990, PARAPLEGIA, V28, P321, DOI 10.1038/sc.1990.42; YELNIK A, 1990, RECONTRES AUTOUR BLE, P192; 1991, MMWR, V31, P535	42	75	76	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	AUG	1998	36	8					574	578		10.1038/sj.sc.3100657			5	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	106NR	WOS:000075136200007	9713927	Bronze			2022-02-06	
J	McCrory, PR; Bladin, PF; Berkovic, SF				McCrory, PR; Bladin, PF; Berkovic, SF			Retrospective study of concussive convulsions in elite Australian rules and rugby league footballers: Phenomenology, aetiology, and outcome	BRITISH MEDICAL JOURNAL			English	Article							SYNCOPE	Objectives: To study the ictal phenomenology, aetiology, and outcome of convulsions occurring within seconds of impact in violent collision sport. Design: Retrospective identification of convulsions associated with concussive brain injury from case records fi-om medical officers of football clubs over a 15 year period. Subjects: Elite Australian rules and rugby league footballers. Main outcome measures: Neuroimaging studies, electroencephalography, neuropsychological test data, and statistics on performance in matches to determine presence of structural or functional brain injury Clinical follow up and electroencephalography for evidence of epilepsy. Results: Twenty two cases of concussive convulsions were identified with four events documented on television videotape. Convulsions began within 2 seconds of impact and comprised an initial period of tonic stiffening followed by myoclonic jerks of all limbs lasting up to 150 seconds. Some asymmetry in the convulsive manifestations was common, and recovery of consciousness was rapid. No structural or permanent brain injury was present on clinical assessment neuropsychological testing, or neuroimaging studies. All players returned to elite competition within two weeks of the incident Epilepsy did not develop in any player over a mean (range) follow up of 3.5 (1-13) years. Conclusions: These concussive or impact convulsions are probably a non-epileptic phenomenon, somewhat akin to convulsive syncope. The mechanism may be a transient traumatic functional decerebration. In concussive convulsions the outcome is universally good, antiepileptic treatment is not indicated, and prolonged absence from sport is unwarranted.	UNIV MELBOURNE,DEPT MED NEUROL,AUSTIN,AUSTRALIA; REPATRIAT MED CTR,HEIDELBERG,VIC 3084,AUSTRALIA				McCrory, Paul/Q-8688-2019	Berkovic, Samuel/0000-0003-4580-841X			AMINOFF MJ, 1988, ANN INTERN MED, V108, P791, DOI 10.7326/0003-4819-108-6-791; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; DUVOISIN RC, 1962, ARCH NEUROL-CHICAGO, V7, P219, DOI 10.1001/archneur.1962.04210030057008; GASTAUT H, 1957, LANCET, V2, P1018; GASTAUT H, 1974, HDB CLIN NEUROLOGY, V5, P815; GASTAUT H, 1972, EPILEPTIC SEIZURES C, P197; GOWERS WR, 1881, EPILEPSY CHRONIC CON, P26; GOWERS WR, 1907, BORDERLAND EPILEPSY, P1; HOWARD P, 1951, BRIT MED J, V2, P382, DOI 10.1136/bmj.2.4728.382; JENNETT B, 1975, EPILEPSY NON MISSILE; LEMPERT T, 1994, ANN NEUROL, V36, P233, DOI 10.1002/ana.410360217; LIN JTY, 1982, ANN NEUROL, V11, P525, DOI 10.1002/ana.410110513; MADDOCKS D, 1991, J CLIN EXP NEUROPSYC, V3, P439; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MADDOCKS DL, IN PRESS BRAIN INJ; PHILLIPS G, 1954, J NEUROL NEUROSUR PS, V17, P1, DOI 10.1136/jnnp.17.1.1; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Seward H. G., 1992, AUST J SCI MED SPORT, V24, P51; Stephenson J., 1990, FITS FAINTS, P41; WALKER AE, 1969, LATE EFFECTS HEAD IN	21	75	76	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 18	1997	314	7075					171	174		10.1136/bmj.314.7075.171			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	WD911	WOS:A1997WD91100021	9022428	Green Published			2022-02-06	
J	Bellander, BM; vonHolst, H; Fredman, P; Svensson, M				Bellander, BM; vonHolst, H; Fredman, P; Svensson, M			Activation of the complement cascade and increase of clusterin in the brain following a cortical contusion in the adult rat	JOURNAL OF NEUROSURGERY			English	Article						microglia; astroglia; complement factor C3d and C9; clusterin; rat	SULFATED GLYCOPROTEIN-2 SGP-2; FIBRILLARY ACIDIC PROTEIN; PERIPHERAL-NERVE INJURY; HYPOGLOSSAL NUCLEUS; ALZHEIMERS-DISEASE; NEURONAL SURVIVAL; GENE-EXPRESSION; MESSENGER-RNA; MICROGLIA; SYSTEM	The aim of the present study was to examine the glial cell response and the possible involvement of the complement cascade following a cerebral cortical contusion. The lesion was produced using a standardized weight-drop technique in adult rats. The blood-brain barrier was damaged, as demonstrated by a decrease of immunoreactivity for a tight junction protein normally expressed by endothelial cells of small vessels in the central nervous system. Increased immunoreactivity for microglial (OX42) and astroglial cells (glial fibrillary acidic protein), as well as macrophages expressing ED1-immunoreactivity (IR) were found in the vicinity of the lesion at all postoperative survival times (2-14 days). In the present study complement factor C3d- and C9-IR was found around the lesion, indicating that activation of the complement cascade had taken place. Furthermore, immunoreactivity for the putative complement inhibitor clusterin (sulfated glycoprotein-2) was found in some of the injured neurons. The contralateral hemisphere showed no evidence of the reaction found in the ipsilateral hemisphere. The balance between complement activation and complement inhibitors may have an impact on the degenerative components in the brain following traumatic injury and in particular on the events leading to nerve cell death.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT CLIN NEUROSCI,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,DEPT NEUROSCI,NEUROSURG SECT,S-10401 STOCKHOLM,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,DEPT NEUROSCI,SECT ANAT,S-10401 STOCKHOLM,SWEDEN; GOTHENBURG UNIV,CENT HOSP MOLNDAL,DEPT CLIN NEUROSCI,MOLNDAL,SWEDEN				Svensson, Mikael/F-8662-2012	Svensson, Mikael/0000-0003-1179-7003			AGOSTONI A, 1992, INT J IMMUNOPATH PH, V5, P123, DOI 10.1177/039463209200500207; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BROWN EJ, 1991, CURR OPIN IMMUNOL, V3, P76, DOI 10.1016/0952-7915(91)90081-B; BRUCK W, 1991, J NEUROL SCI, V103, P182, DOI 10.1016/0022-510X(91)90162-Z; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CAVANAGH JB, 1970, J ANAT, V106, P471; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; DAY JR, 1990, MOL ENDOCRINOL, V4, P1995, DOI 10.1210/mend-4-12-1995; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DUGUID JR, 1989, P NATL ACAD SCI USA, V86, P7260, DOI 10.1073/pnas.86.18.7260; ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; HANSCH GM, 1992, IMMUNOPHARMACOLOGY, V24, P107, DOI 10.1016/0162-3109(92)90017-7; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; JONES J, 1990, COMPLEMENT INFLAMMAT, V7, P42, DOI 10.1159/000463125; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; KONIGSMARK BW, 1963, J NEUROPATH EXP NEUR, V22, P643; LACHMANN PJ, 1991, IMMUNOL TODAY, V12, P312, DOI 10.1016/0167-5699(91)90005-E; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; LING EA, 1981, ADV CELL NEUROBIOL, V2, P33; LIU L, 1995, NEUROSCIENCE, V68, P167, DOI 10.1016/0306-4522(95)00103-P; MAY PC, 1992, TRENDS NEUROSCI, V15, P391, DOI 10.1016/0166-2236(92)90190-J; MAY PC, 1990, NEURON, V5, P831, DOI 10.1016/0896-6273(90)90342-D; MCGEER PL, 1989, CAN J NEUROL SCI, V16, P516, DOI 10.1017/S0317167100029863; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MCNEILL T H, 1990, Society for Neuroscience Abstracts, V16, P1291; MICHEL D, 1992, SYNAPSE, V11, P105, DOI 10.1002/syn.890110203; MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366; MORGAN BP, 1992, CURR TOP MICROBIOL, V178, P115; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; NICHOLS NR, 1990, MOL BRAIN RES, V7, P1, DOI 10.1016/0169-328X(90)90066-M; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; PASINETTI GM, 1991, NEUROSCI LETT, V130, P1, DOI 10.1016/0304-3940(91)90213-D; PASINETTI GM, 1992, EXP NEUROL, V118, P117, DOI 10.1016/0014-4886(92)90028-O; ROSEN H, 1990, J LEUKOCYTE BIOL, V48, P465, DOI 10.1002/jlb.48.5.465; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; STOLL G, 1991, ANN NEUROL, V30, P147, DOI 10.1002/ana.410300205; SVENSSON M, 1993, J NEUROSCI RES, V35, P373, DOI 10.1002/jnr.490350404; SVENSSON M, 1995, MOL CHEM NEUROPATHOL, V24, P53, DOI 10.1007/BF03160112; SVENSSON M, 1992, J NEUROCYTOL, V21, P222, DOI 10.1007/BF01194980; SVENSSON M, 1992, J NEUROIMMUNOL, V40, P99, DOI 10.1016/0165-5728(92)90217-9; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; THANOS S, 1993, J NEUROSCI, V13, P455; THERY C, 1991, EUR J NEUROSCI, V3, P1155, DOI 10.1111/j.1460-9568.1991.tb00050.x; TODD NV, 1990, ACT NEUR S, V51, P296; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106	56	75	79	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	1996	85	3					468	475		10.3171/jns.1996.85.3.0468			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	VD347	WOS:A1996VD34700017	8751634				2022-02-06	
J	BeitYannai, E; Zhang, RL; Trembovler, V; Samuni, A; Shohami, E				BeitYannai, E; Zhang, RL; Trembovler, V; Samuni, A; Shohami, E			Cerebroprotective effect of stable nitroxide radicals in closed head injury in the rat	BRAIN RESEARCH			English	Article						closed-head injury; edema; free radical; neuroprotection; nitroxide	LIPID-PEROXIDATION; OXIDATIVE DAMAGE; OXYGEN RADICALS; NERVOUS-SYSTEM; BRAIN; PERMEABILITY; ISCHEMIA	Nitroxide stable radicals are unreactive toward most diamagnetic molecules, but readily undergo one-electron redox reactions with paramagnetic species such as free radicals and transition metals, thus serving as cell permeable antioxidants. The involvement of reactive oxygen species in the pathophysiology of neurotrauma has been well established, The neuroprotective properties of three nitroxides: 2,2,6,6-tetramethylpiperidine-1-N-oxyl (TPO), the hydrophilic analog: TPL, and its reduced form: TPH, were tested in a rat model of closed head injury (CHI). CHI was induced in ether anesthetized rats by a weight drop device and recovery was followed for up to 24 h. The 'clinical status' was evaluated according to a 'Neurological Severity Score' (NSS), at 1 h and 24 h, the difference between these scores, Delta NSS, reflecting the extent of recovery. Edema was assessed by measurement of water content at 24 h. The integrity of the blood-brain barrier (BBB) was investigated using Evans Blue extravasation. TPL, TPH and TPO facilitated clinical recovery, the latter causing a more pronounced effect (Delta NSS = 7.63 +/- 0.26 in treated rats vs 4.94 +/- 0.48 in control rats, P < 0.001). TPL was found to significantly reduce edema formation (80.13% +/- 0.26 vs 83.65% +/- 0.49, P < 0.001) and to ameliorate BBB disruption (P < 0.001). The therapeutic window of TPL was found to be in the range of 4 h after CHI. The mechanisms underlying the nitroxide neuroprotective activity presumably involve: (a) reoxidation of reduced transition metal ions; (b) a selective radical-radical reaction; and (c) catalytic removal of intracellular and extracellular O-.(2)-. The results indicate that nitroxides could be used in neuroprotective treatment of CHI.	HEBREW UNIV JERUSALEM,SCH PHARM,FAC MED,DEPT MOLEC BIOL & PHARMACOL,IL-91120 JERUSALEM,ISRAEL				Beit-Yannai, Elie/F-2141-2012	Beit-Yannai, Elie/0000-0001-9347-822X			CHAN PH, 1989, CELLULAR ANTIOXIDANT; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; GELVAN D, 1991, P NATL ACAD SCI USA, V88, P4680, DOI 10.1073/pnas.88.11.4680; HAHN SM, 1992, CANCER RES, V52, P1750; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1992, J NEUROTRAUM, V9, pS425; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KRISHNA MC, 1994, FREE RADICAL BIO MED, V17, P379, DOI 10.1016/0891-5849(94)90164-3; MATSUMIYA N, 1991, STROKE, V22, P1193, DOI 10.1161/01.STR.22.9.1193; MEHLHORN RJ, 1992, FREE RADICAL RES COM, V17, P157, DOI 10.3109/10715769209068163; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; NILSSON UA, 1989, J BIOL CHEM, V264, P11131; PARK CK, 1994, BRAIN RES, V645, P157; POGREBNIAK H, 1991, J SURG RES, V50, P469, DOI 10.1016/0022-4804(91)90026-I; RACHMILEWITZ D, 1994, GUT, V35, P1181, DOI 10.1136/gut.35.9.1181; SAMUNI A, 1991, BIOCHEMISTRY-US, V30, P555, DOI 10.1021/bi00216a033; SAMUNI A, 1991, J CLIN INVEST, V87, P1526, DOI 10.1172/JCI115163; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59	27	75	75	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	APR 22	1996	717	1-2					22	28		10.1016/0006-8993(95)01492-6			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	UM505	WOS:A1996UM50500003	8738249				2022-02-06	
J	Sinson, G; Voddi, M; McIntosh, TK				Sinson, G; Voddi, M; McIntosh, TK			Combined fetal neural transplantation and nerve growth factor infusion: Effects on neurological outcome following fluid-percussion brain injury in the rat	JOURNAL OF NEUROSURGERY			English	Article						fluid-percussion injury; nerve growth factor; neural transplantation; cognitive dysfunction; traumatic brain injury	FRONTAL-CORTEX ABLATION; CAT SPINAL-CORD; ADULT-RATS; PARKINSONS-DISEASE; CAUDATE-NUCLEUS; LESIONS; TISSUE; GRAFTS; RECOVERY; NEURONS	This study was designed to evaluate the histological and behavioral impact of fetal neural transplantation with and without neurotrophin infusion in rats subjected to traumatic brain injury using a clinically relevant model of lateral fluid-percussion brain injury. Adult male Sprague-Dawley rats received lateral fluid-percussion brain injury of moderate severity (2.1-2.3 aim). Twenty-four hours after injury, minced fetal cortical grafts (E16) were stereotactically transplanted into the site of injury cavity formation (in 32 rats). Ten control animals received injections of saline. A third group of 29 animals that received transplants also underwent placement of a miniosmotic pump (immediately after transplantation) to continuously infuse nerve growth factor (NGF) directly into the region of graft placement for the duration of the experiment. A fourth group of eight animals underwent transplantation of fetal cortical cells that had been dissociated and placed in suspension. Animals were evaluated at 72 hours, 1 week, and 2 weeks after injury for cognitive function (using the Morris water maze), posttraumatic motor dysfunction, and transplant survival and morphology (using Nissl and modified Palmgren's silver staining techniques). Robust survival of whole-tissue transplants was seen in 65.6% of animals and was not increased in animals receiving NGF infusion. Animals receiving transplants of cell suspension had no surviving grafts. Brain-injured animals receiving transplants showed significant cognitive improvements compared with controls at the 2-week evaluation. Significantly improved memory scores were seen at all evaluation times in animals receiving both NGF and transplants compared with injured controls and compared with animals receiving transplants alone at the 72-hour and 1-week evaluations. Neurological motor function scores were significantly improved in animals receiving transplants alone and those receiving transplants with NGF infusion. Histological evaluation demonstrated differentiation of grafted cells, decreased glial scarring around transplants when compared with control animals, and the presence of neuronal fibers bridging the interface between graft and host. This study demonstrates that fetal cortical cells transplanted into the injured cortex of the adult rat can improve both posttraumatic cognitive and motor function and interact with the injured host brain.	UNIV PENN, SCH MED, DIV NEUROSURG, PHILADELPHIA, PA 19104 USA						NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818, NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, R55NS026818, P01NS008803, P50NS008803] Funding Source: NIH RePORTER		Aguayo A, 1985, SYNAPTIC PLASTICITY, P457; ANDERSON DK, 1991, RESTOR NEUROL NEUROS, V2, P309, DOI 10.3233/RNN-1991-245621; BJORKLUND A, 1983, ACTA PHYSIOL SCAND, P1; BOVOLENTA P, 1992, PROG BRAIN RES, V94, P367; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DUNNETT SB, 1987, BEHAV NEUROSCI, V101, P489, DOI 10.1037/0735-7044.101.4.489; DUNNETT SB, 1986, BRAIN RES, V378, P357, DOI 10.1016/0006-8993(86)90939-X; FINE A, 1985, NEUROSCIENCE, V16, P769, DOI 10.1016/0306-4522(85)90093-4; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FREEMAN TB, 1994, NEUROL TRANSPL, V1, P29; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GIACOBINI MMJ, 1991, EXP BRAIN RES, V86, P73; GONZALEZ MF, 1988, EXP NEUROL, V99, P154, DOI 10.1016/0014-4886(88)90135-5; GOSHGARIAN HG, 1977, EXP NEUROL, V57, P296, DOI 10.1016/0014-4886(77)90065-6; HADANI M, 1992, J NEUROTRAUM, V9, P107, DOI 10.1089/neu.1992.9.107; HAGG T, 1988, EXP NEUROL, V101, P303, DOI 10.1016/0014-4886(88)90013-1; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HUDSON JL, 1994, J NEUROSCI, V14, P283; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; JACOBS SE, 1994, J NEUROSCI, V14, P697; JAKEMAN LB, 1991, J COMP NEUROL, V307, P311, DOI 10.1002/cne.903070211; KESSLAK JP, 1986, EXP NEUROL, V94, P615, DOI 10.1016/0014-4886(86)90241-4; KESSLAK JP, 1986, EXP NEUROL, V92, P377, DOI 10.1016/0014-4886(86)90089-0; KIMBLE DP, 1986, BRAIN RES, V363, P358, DOI 10.1016/0006-8993(86)91023-1; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; MADRAZO I, 1987, NEW ENGL J MED, V316, P831, DOI 10.1056/NEJM198704023161402; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOUTON PR, 1993, ACTA NEUROL SCAND, V87, P376; NETTO CA, 1993, BEHAV BRAIN RES, V58, P107, DOI 10.1016/0166-4328(93)90095-8; NIETOSAMPEDRO M, 1984, P NATL ACAD SCI-BIOL, V81, P6250, DOI 10.1073/pnas.81.19.6250; Obukhova G P, 1992, Neurosci Behav Physiol, V22, P1, DOI 10.1007/BF01186660; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PALMGREN AXEL, 1960, ACTA ZOOL [STOCKHOLM], V41, P239; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; REIER PJ, 1992, EXP NEUROL, V115, P177, DOI 10.1016/0014-4886(92)90245-L; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; RIDLEY RM, 1991, EXP BRAIN RES, V83, P533; RUTHERFORD A, 1987, NEUROSCI LETT, V83, P275, DOI 10.1016/0304-3940(87)90099-1; SANTUCCI AC, 1993, DEMENTIA, V4, P273, DOI 10.1159/000107333; SCHULZ MK, 1993, EXP BRAIN RES, V96, P480; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; SOARES H, 1995, IN PRESS J NEUROTRAU; Soares HD, 1995, J NEUROSCI, V15, P8223; SOTELO C, 1994, J NEUROSCI, V14, P124; SOTELO C, 1987, NATURE, V327, P421, DOI 10.1038/327421a0; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; STEIN DG, 1988, BEHAV NEUROSCI, V102, P260, DOI 10.1037/0735-7044.102.2.260; TARRICONE BJ, 1993, BRAIN RES, V632, P41, DOI 10.1016/0006-8993(93)91136-G; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; TUSZYNSKI MH, 1990, NEUROSCIENCE, V36, P33, DOI 10.1016/0306-4522(90)90349-9; WAYNE DB, 1990, DEV BIOL, V138, P473, DOI 10.1016/0012-1606(90)90213-3; WICTORIN K, 1990, NATURE, V347, P556, DOI 10.1038/347556a0; WICTORIN K, 1992, J COMP NEUROL, V323, P475, DOI 10.1002/cne.903230403	59	75	82	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	1996	84	4					655	662		10.3171/jns.1996.84.4.0655			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	UC211	WOS:A1996UC21100016	8613859				2022-02-06	
J	GUTLING, E; GONSER, A; IMHOF, HG; LANDIS, T				GUTLING, E; GONSER, A; IMHOF, HG; LANDIS, T			EEG REACTIVITY IN THE PROGNOSIS OF SEVERE HEAD-INJURY	NEUROLOGY			English	Article							SOMATOSENSORY-EVOKED-POTENTIALS; POST-TRAUMATIC COMA; BRAIN-FUNCTION; CONDUCTION; PREDICTION	We compared reactivity of EEG to external stumuli-an easily and quickly available measure-with the central conduction time (CCT) of the somatosensory evoked potentials, currently the most-used electrophysiologic method to predict outcome in severe head injury (SHI), and with the initial Glasgow Coma Scale (GCS) score. In 50 patients, comatose subsequent to SHI, we measured EEG reactivity and CCT within 48 to 72 hours and compared them with the outcome after 1.5 years. Using discriminant analysis, EEG reactivity correctly classified 92%, CCT classified 82%, and both measures together classified 98% of the patients into globally good or bad outcome groups. GCS allowed a correct classification in only 72% and, combined with either of the two electrophysiologic measures, did not further increase predictability. EEG reactivity is an excellent long-term global outcome predictor in SHI, superior to CCT and GCS. When the two electrophysiologic measures are combined, a prognostic accuracy is achieved that is better than that of any other reported method.	UNIV HOSP, DEPT NEUROL, GENEVA, SWITZERLAND		GUTLING, E (corresponding author), UNIV ZURICH HOSP, DEPT NEUROL, NEUROL KLIN, EEG UNIT, CH-8091 ZURICH, SWITZERLAND.						BRICOLO A, 1978, ELECTROEN CLIN NEURO, V45, P211, DOI 10.1016/0013-4694(78)90005-6; CHATRIAN GE, 1963, ELECTROEN CLIN NEURO, V15, P272, DOI 10.1016/0013-4694(63)90096-8; Courjon J, 1971, Rev Electroencephalogr Neurophysiol Clin, V1, P133, DOI 10.1016/S0370-4475(71)80054-0; FISCHGOLD H, 1946, SEM HOP PARIS, V22, P1245; FISCHGOLD H, 1955, PRESSE MED, V63, P1231; FOLTZ EL, 1956, J NEUROSURG, V13, P145, DOI 10.3171/jns.1956.13.2.0145; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; GUTLING E, 1993, ELECTROEN CLIN NEURO, V88, P369, DOI 10.1016/0168-5597(93)90013-F; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JASPER H, 1949, ELECTROEN CLIN NEURO, V1, P405, DOI 10.1016/0013-4694(49)90060-7; JENNETT B, 1975, LANCET, V1, P480; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; MATHIS P, 1957, ELECTROENCEPHALOGR C, V6, P453; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; MOULTON RJ, 1988, CAN J NEUROL SCI, V15, P82, DOI 10.1017/S0317167100027244; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P420, DOI 10.1016/0013-4694(83)90224-9; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; WALSER H, 1986, J NEUROL, V233, P34, DOI 10.1007/BF00313989	20	75	87	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY	1995	45	5					915	918		10.1212/WNL.45.5.915			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	QY820	WOS:A1995QY82000012	7746406				2022-02-06	
J	UHL, MW; BIAGAS, KV; GRUNDL, PD; BARMADA, MA; SCHIDING, JK; NEMOTO, EM; KOCHANEK, PM				UHL, MW; BIAGAS, KV; GRUNDL, PD; BARMADA, MA; SCHIDING, JK; NEMOTO, EM; KOCHANEK, PM			EFFECTS OF NEUTROPENIA ON EDEMA, HISTOLOGY, AND CEREBRAL BLOOD-FLOW AFTER TRAUMATIC BRAIN INJURY IN RATS	JOURNAL OF NEUROTRAUMA			English	Article							POLYMORPHONUCLEAR LEUKOCYTE ACCUMULATION; SPINAL-CORD INJURY; HEAD-INJURY; BARRIER PERMEABILITY; ISCHEMIA; NEUTROPHILS; REPERFUSION; ANTIBODY; STROKE; VINBLASTINE	Neutrophils accumulate during the acute inflammatory response to brain injury, but their role in the injury process remains controversial. We tested the hypothesis that neutrophils contribute to cerebral edema, tissue injury, and disturbed cerebral blood flow (CBF) (hyperemia or ischemia) during the first 24 h after traumatic brain injury. Wistar rats (n = 51) were injected with either vinblastine sulfate to induce neutropenia or the saline vehicle. Five days later, under halothane anesthesia, right hemispheric trauma was produced by weight drop (10 g x 5 cm) onto exposed dura. At 24 h after trauma, brain water (wet-dry weight), traumatic infarct size (percent of hemispheric section infarcted), or local CBF (lCBF,C-14-iodoantipyrine autoradiography) was assessed. Vinblastine treatment produced profound neutropenia on the day of trauma (absolute neutrophil count 0.024 +/- 0.008 x 10(9)/L vs 1.471 +/- 0.322 x 10(9)/L, p < 0.05 in neutropenic vs saline, respectively, mean +/- SEM). Neutropenia did not reduce the development of brain edema in the injured hemisphere (brain water 82.38 +/- 0.29 % vs 82.73 +/- 0.37 % in neutropenic and saline, respectively, mean +/- SEM) or traumatic infarct size (34.5 +/- 3.3% vs 33.2 +/- 2.1% in neutropenic vs saline respectively). In contrast, neutropenic rats exhibited 52 %, 41%, and 57% reductions in lCBF in the frontal cortex, parietal cortex, and amygdala, respectively, of the injured hemisphere 24 h after trauma (all p < 0.05 vs nonneutropenic controls). These data suggest that neutrophils and the acute inflammatory process contribute to the level of CBF observed 24 h after trauma, but effects on edema or early posttraumatic infarct size could not be demonstrated.	UNIV PITTSBURGH, DEPT ANESTHESIOL CRIT CARE MED, PITTSBURGH, PA USA; UNIV PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA USA; UNIV PITTSBURGH, BRAIN TRAUMA RES CTR, PITTSBURGH, PA USA				Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S07RR005507] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S07 RR 0550726] Funding Source: Medline		BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BEDNAR MM, 1991, STROKE, V22, P44, DOI 10.1161/01.STR.22.1.44; Biagas K. V., 1992, Society for Neuroscience Abstracts, V18, P1088; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CLARK WM, 1991, STROKE, V22, P877, DOI 10.1161/01.STR.22.7.877; CORVIN S, 1990, ACT NEUR S, V51, P55; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; DUTKA AJ, 1989, STROKE, V20, P390, DOI 10.1161/01.STR.20.3.390; ENGLER R, 1987, CIRC RES, V61, P20, DOI 10.1161/01.RES.61.1.20; ERNST E, 1987, JAMA-J AM MED ASSOC, V257, P2318, DOI 10.1001/jama.257.17.2318; GLANTZ SA, 1981, PRIMER BIOSTATISTICS, P156; GRAU AJ, 1992, STROKE, V23, P33, DOI 10.1161/01.STR.23.1.33; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; HERNANDEZ LA, 1987, AM J PHYSIOL, V253, pH699, DOI 10.1152/ajpheart.1987.253.3.H699; HOLTZ A, 1989, ACTA NEUROL SCAND, V79, P460, DOI 10.1111/j.1600-0404.1989.tb03815.x; Horner H. C., 1992, Society for Neuroscience Abstracts, V18, P173; ISSEKUTZ AC, 1981, LAB INVEST, V45, P435; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P903, DOI 10.1038/jcbfm.1990.147; Kochanek P, 1991, J NEUROTRAUM, V8, P19, DOI 10.1089/neu.1991.8.19; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LUCIGNANI G, 1987, J CEREBR BLOOD F MET, V7, P309, DOI 10.1038/jcbfm.1987.68; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; PFISTER HW, 1990, J CEREBR BLOOD F MET, V10, P914, DOI 10.1038/jcbfm.1990.148; RAMPART M, 1986, AM J PATHOL, V124, P66; RINALDO JE, 1988, AM REV RESPIR DIS, V137, P345, DOI 10.1164/ajrccm/137.2.345; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59, DOI 10.1152/ajpheart.1978.234.1.H59; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHURER L, 1990, ACT NEUR S, V51, P49; SHARMA HS, 1987, NEUROPHARMACOLOGY, V26, P85, DOI 10.1016/0028-3908(87)90049-9; SHARMA HS, 1986, J NEUROL SCI, V72, P61, DOI 10.1016/0022-510X(86)90036-5; SIEGAL T, 1989, ANN NY ACAD SCI, V559, P488; SILBERGLEIT A, 1970, THROMB DIATH HAEMO, V42, P155; TAKESHIMA R, 1992, STROKE, V23, P247, DOI 10.1161/01.STR.23.2.247; TATE RM, 1983, AM REV RESPIR DIS, V128, P552, DOI 10.1164/arrd.1983.128.3.552; UHL MW, 1992, ADV EXP MED BIOL, V317, P701; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; VASTHARE US, 1990, SURG NEUROL, V33, P261, DOI 10.1016/0090-3019(90)90046-R; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; ZAKHIREH B, 1980, J IMMUNOL, V125, P2143; ZIMMERMAN J, 1986, CRITICAL CARE STATE, P281	47	75	75	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1994	11	3					303	315		10.1089/neu.1994.11.303			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	PF221	WOS:A1994PF22100006	7996584				2022-02-06	
J	PARASURAMAN, R; MUTTER, SA; MOLLOY, R				PARASURAMAN, R; MUTTER, SA; MOLLOY, R			SUSTAINED ATTENTION FOLLOWING MILD CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							AUTOMATIC COGNITIVE-PROCESSES; MEMORY; VIGILANCE; PERFORMANCE; CONCUSSION; EFFORTFUL; RECOVERY; DEMENTIA; MODELS; TASKS	The sustained-attention performance of patients with mild closed-head injury (CHI) was examined within one month of injury using a high-event rate, digit-discrimination vigilance task with two levels of stimulus degradation (undegraded, highly degraded). Under undegraded stimulus conditions, vigilance performance for mild CHI subjects, uninjured case-matched control subjects, and college students was highly accurate and remained so across the entire task period. When stimuli were presented in degraded fashion, however, all three groups showed a similar decline over time (i.e., vigilance decrement) in hit rates and d' scores. Although mild CHI did not lead to a greater rate of deterioration in vigilance performance in the degraded stimulus condition, it did produce lower overall levels of sensitivity (d') in target detection. These results suggest that, during the first month after mild CHI, vigilance performance is unimpaired under normal task conditions, but may fall short under task conditions that require sustained effortful processing. These findings join a growing body of evidence showing that mild CHI can lead to measurable deficits in cognitive functioning.			PARASURAMAN, R (corresponding author), CATHOLIC UNIV AMER, DEPT PSYCHOL, WASHINGTON, DC 20064 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR302583-0] Funding Source: Medline		ASTONJONES G, 1985, PHYSIOL PSYCHOL, V13, P118; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; BUCHTEL HA, 1987, NEUROBEHAVIORAL RECO, P372; Conkey RC, 1938, ARCH PSYCHOL, P5; CRAIG A, 1987, HUM FACTORS, V29, P645, DOI 10.1177/001872088702900604; Davies DR., 1982, PSYCHOL VIGILANCE; DENCKER SJ, 1958, ACTA PSYCHIATRI S122, V33; DUSOIR AE, 1975, PERCEPT PSYCHOPHYS, V17, P167, DOI 10.3758/BF03203882; ERWIN CW, 1978, J STUD ALCOHOL, V39, P505, DOI 10.15288/jsa.1978.39.505; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FISK AD, 1981, HUM FACTORS, V23, P737, DOI 10.1177/001872088102300610; GENTILINI M, 1989, MILD HEAD INJURY, P163; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HANNAY H J, 1982, Journal of Clinical Neuropsychology, V4, P117; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JERISON HJ, 1964, SCIENCE, V143, P970, DOI 10.1126/science.143.3609.970; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1988, BRAIN COGNITION, V7, P283, DOI 10.1016/0278-2626(88)90003-6; Levin HS, 1984, NEUROPSYCHOLOGY MEMO, P247; Levin HS., 1982, NEUROBEHAVIORAL CONS; Mackie R.R., 1977, VIGILANCE THEORY OPE, P423, DOI 10.1007/978-1-4684-2529-1_21; MATTHEWS G, 1990, J PERS SOC PSYCHOL, V59, P150, DOI 10.1037/0022-3514.59.1.150; MCDONALD RD, 1964, J NEUROL NEUROSUR PS, V27, P206, DOI 10.1136/jnnp.27.3.206; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MUNRO SA, 1990, COGNITIVE NEUROPSYCH, V7, P329; MUTTER SA, 1990, COGNITIVE NEUROPSYCH, V7, P329, DOI 10.1080/02643299008253447; NESTOR PG, 1991, DEV NEUROPSYCHOL, V7, P243, DOI 10.1080/87565649109540491; NUECHTERLEIN KH, 1983, SCIENCE, V220, P327, DOI 10.1126/science.6836276; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1979, NEURAL TRAUMA, P371; PARASURAMAN R, 1979, SCIENCE, V205, P924, DOI 10.1126/science.472714; PARASURAMAN R, 1987, PERCEPT PSYCHOPHYS, V41, P17, DOI 10.3758/BF03208208; PARASURAMAN R, 1989, PSYCHOL AGING, V4, P339, DOI 10.1037/0882-7974.4.3.339; Parasuraman R, 1984, VARIETIES ATTENTION, P243; Parasuraman R, 1985, ATTENTION PERFORM, P493; PARASURAMAN R, 1986, ENERGETICS HUMAN INF, P395; Parasuraman R, 1984, VARIETIES ATTENTION; Parasuraman R, 1977, VIGILANCE THEORY OPE, P559; POSNER MI, 1985, ATTENTION PERFORMANC, V11; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROHRBAUGH JW, 1988, PSYCHOPHARMACOLOGY, V96, P442, DOI 10.1007/BF02180021; ROYBYRNE PP, 1986, ARCH GEN PSYCHIAT, V43, P265; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; Ruesch J, 1944, J NEUROSURG, V1, P243, DOI 10.3171/jns.1944.1.4.0243; Ruff R. M., 1989, MILD HEAD INJURY, P176; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; SNODGRASS JG, 1988, J EXP PSYCHOL GEN, V117, P34, DOI 10.1037/0096-3445.117.1.34; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; SWETS JA, 1986, PSYCHOL BULL, V99, P100, DOI 10.1037/0033-2909.99.1.100; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P, P75; Warm J.S., 1984, SUSTAINED ATTENTION, P15; Warm J. S., 1984, SUSTAINED ATTENTION; WARM JS, 1985, INT REV RES MENT RET, V13, P1, DOI 10.1016/S0074-7750(08)60231-1; WARM JS, 1987, J GEN PSYCHOL, V114, P423, DOI 10.1080/00221309.1987.9711080; WEINGARTNER H, 1981, J ABNORM PSYCHOL, V90, P187, DOI 10.1037/0021-843X.90.3.187; WEINGARTNER H, 1984, PSYCHIAT RES, V11, P223, DOI 10.1016/0165-1781(84)90071-4; [No title captured]	69	75	75	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	SEP	1991	13	5					789	811		10.1080/01688639108401090			23	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	GK476	WOS:A1991GK47600012	1955532				2022-02-06	
J	LEVIN, HS; HIGH, WM; EWINGCOBBS, L; FLETCHER, JM; EISENBERG, HM; MINER, ME; GOLDSTEIN, FC				LEVIN, HS; HIGH, WM; EWINGCOBBS, L; FLETCHER, JM; EISENBERG, HM; MINER, ME; GOLDSTEIN, FC			MEMORY FUNCTIONING DURING THE 1ST YEAR AFTER CLOSED HEAD-INJURY IN CHILDREN AND ADOLESCENTS	NEUROSURGERY			English	Article									UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550; UNIV TEXAS,SCH MED,DIV NEUROL,HOUSTON,TX 77025; UNIV TEXAS,SCH MED,DEPT PSYCHIAT & BEHAV SCI,HOUSTON,TX 77025; UNIV HOUSTON,DEPT PSYCHOL,HOUSTON,TX 77004		LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG D73,GALVESTON,TX 77550, USA.		fletcher, jack/Q-5975-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BUSCHKE H, 1974, J EXP CHILD PSYCHOL, V18, P488, DOI 10.1016/0022-0965(74)90126-X; FRANKEL MT, 1982, J EXP CHILD PSYCHOL, V34, P113, DOI 10.1016/0022-0965(82)90034-0; Goldman P S, 1974, Neurosci Res Program Bull, V12, P217; GOLDMAN PS, 1977, NATURE, V267, P613, DOI 10.1038/267613a0; GREEN DM, 1966, SIGNAL DETECTION THE; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; KAIL R, 1979, DEV MEMORY CHILDREN; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MORRISON FJ, 1982, J GENET PSYCHOL, V141, P233, DOI 10.1080/00221325.1982.10533478; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PRESSLEY M, 1984, J VERB LEARN VERB BE, V23, P270, DOI 10.1016/S0022-5371(84)90181-6; SCHARLOCK DP, 1963, SCIENCE, V141, P1197, DOI 10.1126/science.141.3586.1197; TEASDALE G, 1974, LANCET, V2, P81; [No title captured]	21	75	75	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUN	1988	22	6	1				1043	1052		10.1227/00006123-198806010-00012			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	P4659	WOS:A1988P465900012	3419566				2022-02-06	
J	MCINTOSH, TK; HEAD, VA; FADEN, AI				MCINTOSH, TK; HEAD, VA; FADEN, AI			ALTERATIONS IN REGIONAL CONCENTRATIONS OF ENDOGENOUS OPIOIDS FOLLOWING TRAUMATIC BRAIN INJURY IN THE CAT	BRAIN RESEARCH			English	Article									UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143		MCINTOSH, TK (corresponding author), VET ADM MED CTR,CTR NEURAL INJURY 127,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM34690-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER		AKIL H, 1984, ANNU REV NEUROSCI, V7, P223, DOI 10.1146/annurev.ne.07.030184.001255; BASKIN DS, 1982, LIFE SCI, V31, P2201, DOI 10.1016/0024-3205(82)90118-7; BOARDER MR, 1982, J CLIN ENDOCR METAB, V54, P715, DOI 10.1210/jcem-54-4-715; COX B, 1982, LIFE SCI, V31, P1655; COX BM, 1985, NEUROPEPTIDES, V5, P571, DOI 10.1016/0143-4179(85)90082-4; CROCKARD HA, 1977, J NEUROSURG, V46, P784, DOI 10.3171/jns.1977.46.6.0784; EISENBERG H, 1983, 5TH P INT S INTR PRE; EVANS SF, 1985, BRIT J ANAESTH, V57, P624, DOI 10.1093/bja/57.6.624; FADEN A I, 1983, Current Concepts of Cerebrovascular Disease and Stroke, V18, P27; FADEN AI, 1983, EUR J PHARMACOL, V91, P321, DOI 10.1016/0014-2999(83)90487-9; FADEN AI, 1984, BRIT J PHARMACOL, V81, P271, DOI 10.1111/j.1476-5381.1984.tb10074.x; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1983, STROKE, V14, P169, DOI 10.1161/01.STR.14.2.169; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; FADEN AI, 1985, PEPTIDES, V6, P15, DOI 10.1016/0196-9781(85)90006-3; FADEN AI, 1986, CENTRAL NERVOUS SYST, P123; FEUERSTEIN G, 1985, AM J PHYSIOL, V249, pE244, DOI 10.1152/ajpendo.1985.249.3.E244; FEUERSTEIN G, 1984, NEUROPEPTIDES, V5, P295, DOI 10.1016/0143-4179(84)90086-6; FEUERSTEIN G, 1982, LIFE SCI, V31, P2197, DOI 10.1016/0024-3205(82)90117-5; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; GENNARELLI TA, 1982, HEAD INJURY BASIC CL; GHAZAROSSIAN VE, 1980, LIFE SCI, V27, P75, DOI 10.1016/0024-3205(80)90021-1; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GUILLEMIN R, 1977, SCIENCE, V197, P1367, DOI 10.1126/science.197601; HASSEN AH, 1984, J NEUROSCI, V4, P2213; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; HOLLT V, 1980, NEUROSCI LETT, V18, P149, DOI 10.1016/0304-3940(80)90318-3; HOSOBUCHI Y, 1982, SCIENCE, V215, P69, DOI 10.1126/science.6274019; HUGHES J, 1983, BR MED B, V14, P1; KHACHATURIAN H, 1985, TRENDS NEUROSCI, V8, P111, DOI 10.1016/0166-2236(85)90048-7; KHACHATURIAN H, 1986, ENDOCRINOLOGY, V119, P1409, DOI 10.1210/endo-119-3-1409; KNEPEL W, 1985, ENDOCRINOLOGY, V117, P481, DOI 10.1210/endo-117-2-481; KRUMINS SA, 1986, ANN NEUROL, V19, P498, DOI 10.1002/ana.410190514; MCINTOSH T K, 1986, Society for Neuroscience Abstracts, V12, P85; MOLINEAUX CJ, 1984, J NEUROCHEM, V43, P225; PEROUTKA SJ, 1980, SCIENCE, V208, P610, DOI 10.1126/science.6102801; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETTIBONE DJ, 1982, ENDOCRINOLOGY, V110, P469, DOI 10.1210/endo-110-2-469; PFEIFFER A, 1982, LIFE SCI, V31, P1279, DOI 10.1016/0024-3205(82)90361-7; PRZEWLOCKI R, 1983, NEUROPEPTIDES, V3, P233, DOI 10.1016/0143-4179(83)90019-7; ROTH KA, 1983, SCIENCE, V219, P189, DOI 10.1126/science.6129700; SASAKI T, 1984, J CEREBR BLOOD F MET, V4, P166, DOI 10.1038/jcbfm.1984.24; SUDA T, 1985, LIFE SCI, V32, P865; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; WAHL M, 1985, J CEREBR BLOOD F MET, V5, P451, DOI 10.1038/jcbfm.1985.61; WEBER E, 1983, BRAIN RES, V260, P166, DOI 10.1016/0006-8993(83)90781-3; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; ZUKIN RS, 1981, LIFE SCI, V29, P2681	50	75	76	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 10	1987	425	2					225	233		10.1016/0006-8993(87)90505-1			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	K6621	WOS:A1987K662100004	2892572				2022-02-06	
J	Varney, NR; Martzke, JS; Roberts, RJ				Varney, N. R.; Martzke, J. S.; Roberts, R. J.			Major Depression in Patients with Closed Head Injury	NEUROPSYCHOLOGY			English	Article								One hundred and twenty patients with closed bead injury (CHI) were interviewed with regqrd to depressive symptoms at least two years after the date of injury. Seventy-seven percent of these patients met DSM-III criteria for major depressive disorder. Approximately half of the depressed CHI patients did not manifest depressive symptoms until at least six months after being injured. Bipolar affective disorder and schizophrenia were quite uncommon following CHI. These findings indicate that head injury patients are at substantially increased risk for development of major depressive disorder. Findings suggest that all CHI patients be screened for depressive symptoms at a time well after they appear to have made a seemingly "full" recovery.	VA Med Ctr, Psychol Serv, Iowa City, IA 52240 USA; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Psychol, Iowa City, IA 52242 USA		Varney, NR (corresponding author), VA Med Ctr, Psychol Serv 116 B, Iowa City, IA 52240 USA.				Veterans AdministrationUS Department of Veterans Affairs	This research was supported by funds from the Veterans Administration. Address correspondence to Nils R. Varney Ph.D., Psychology Service (116-B), VA Medical Center, Iowa City, IA 52240, USA	FEIBEL JH, 1982, ARCH PHYS MED REHAB, V63, P276; FINKLESTEIN S, 1982, ANN NEUROL, V12, P463, DOI 10.1002/ana.410120509; FOLSTEIN MF, 1977, J NEUROL NEUROSUR PS, V40, P1018, DOI 10.1136/jnnp.40.10.1018; Levin HS., 1982, NEUROBEHAVIORAL CONS; LIPSEY JR, 1984, LANCET, V1, P297; LISHMAN WA, 1978, ORGANIC PSYCHIAT; MENDEZ MF, 1986, ARCH NEUROL-CHICAGO, V43, P766, DOI 10.1001/archneur.1986.00520080014012; PERINI G, 1984, J NERV MENT DIS, V172, P287, DOI 10.1097/00005053-198405000-00006; REIFLER BV, 1982, AM J PSYCHIAT, V139, P623; Roberts A., 1980, SEVERE ACCIDENTAL HE; ROBINS AH, 1976, J CHRON DIS, V29, P279; Robinson R G, 1984, Compr Ther, V10, P19; ROBINSON RG, 1983, STROKE, V14, P736, DOI 10.1161/01.STR.14.5.736; ROBINSON RG, 1981, BRAIN LANG, V14, P282, DOI 10.1016/0093-934X(81)90080-8; ROBINSON RG, 1984, BRIT J PSYCHIAT, V144, P256, DOI 10.1192/bjp.144.3.256; ROSS ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; Varney N., 1987, J CLIN EXPT IN PRESS; Winokur G., 1981, DEPRESSION THE FACTS; Woodruff RA., 1974, PSYCHIAT DIAGNOSIS	19	75	77	1	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	1987	1	1					7	9		10.1037//0894-4105.1.1.7			3	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	V44JO	WOS:000209745500003					2022-02-06	
J	Sherman, EMS; Slick, DJ; Iverson, GL				Sherman, Elisabeth M. S.; Slick, Daniel J.; Iverson, Grant L.			Multidimensional Malingering Criteria for Neuropsychological Assessment: A 20-Year Update of the Malingered Neuropsychological Dysfunction Criteria	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; exaggeration; malingered neurocognitive dysfunction; feigning; performance validity; symptom validity; effort; response bias; PVT; SVT	SYMPTOM VALIDITY TEST; RESPONSE BIAS SCALE; SOMATIC PERCEPTION QUESTIONNAIRE; HENRY-HEILBRONNER INDEX; COGNITIVE IMPAIRMENT IMPLICATIONS; MEMORY COMPLAINTS INVENTORY; RESTRUCTURED FORM MMPI-2-RF; TRAUMATIC BRAIN-INJURY; FALSE-POSITIVE RATES; FORCED-CHOICE TEST	Objectives: Empirically informed neuropsychological opinion is critical for determining whether cognitive deficits and symptoms are legitimate, particularly in settings where there are significant external incentives for successful malingering. The Slick, Sherman, and Iversion (1999) criteria for malingered neurocognitive dysfunction (MND) are considered a major milestone in the field's operationalization of neurocognitive malingering and have strongly influenced the development of malingering detection methods, including serving as the criterion of malingering in the validation of several performance validity tests (PVTs) and symptom validity tests (SVTs) (Slick, D.J., Sherman, E.M.S., & Iverson, G. L. (1999). Diagnostic criteria for malingered neurocognitive dysfunction: Proposed standards for clinical practice and research. The Clinical Neuropsychologist, 13(4), 545-561). However, the MND criteria are long overdue for revision to address advances in malingering research and to address limitations identified by experts in the field. Method: The MND criteria were critically reviewed, updated with reference to research on malingering, and expanded to address other forms of malingering pertinent to neuropsychological evaluation such as exaggeration of self-reported somatic and psychiatric symptoms. Results: The new proposed criteria simplify diagnostic categories, expand and clarify external incentives, more clearly define the role of compelling inconsistencies, address issues concerning PVTs and SVTs (i.e., number administered, false positives, and redundancy), better define the role of SVTs and of marked discrepancies indicative of malingering, and most importantly, clearly define exclusionary criteria based on the last two decades of research on malingering in neuropsychology. Lastly, the new criteria provide specifiers to better describe clinical presentations for use in neuropsychological assessment. Conclusions: The proposed multidimensional malingering criteria that define cognitive, somatic, and psychiatric malingering for use in neuropsychological assessment are presented.	[Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA 02115 USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Charlestown, MA USA; [Iverson, Grant L.] Spaulding Res Inst, Charlestown, MA USA; [Iverson, Grant L.] Home Base, Charlestown, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp Program, Charlestown, MA USA		Sherman, EMS (corresponding author), Sherman Consulting & Assessment Inc, 3553 31 St NW,Suite 262, Calgary, AB T2L 2K7, Canada.	drsherman@drshermanbrainhealth.com					Aita SL, 2018, ARCH CLIN NEUROPSYCH, V33, P832, DOI 10.1093/arclin/acx113; Ali Shahid, 2015, Innov Clin Neurosci, V12, P12; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5, DOI [10.1176/appi.books.9780890425596.dsm02, 10.1176/appi.books.9780890425596]; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Armistead-Jehle P, 2017, APPL NEUROPSYCH-ADUL, V24, P190, DOI 10.1080/23279095.2015.1132219; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P725, DOI 10.1093/arclin/acs071; Armistead-Jehle P, 2012, ARCH CLIN NEUROPSYCH, V27, P101, DOI 10.1093/arclin/acr081; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Balasanyan M, 2018, CLIN NEUROPSYCHOL, V32, P165, DOI 10.1080/13854046.2017.1330421; Bass Christopher, 2019, Pract Neurol, V19, P96, DOI 10.1136/practneurol-2018-001950; BEABER RJ, 1985, AM J PSYCHIAT, V142, P1478; Bender SD, 2018, CLIN ASSESSMENT MALI, P42; Berry DTR, 2010, PSYCHOL INJ LAW, V3, P295, DOI 10.1007/s12207-010-9087-7; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2018, PSYCHOL ASSESSMENT, V30, P857, DOI 10.1037/pas0000532; Bianchini KJ, 2014, CLIN NEUROPSYCHOL, V28, P1376, DOI 10.1080/13854046.2014.986199; Bilder RM, 2014, CLIN NEUROPSYCHOL, V28, P1212, DOI 10.1080/13854046.2014.969774; Binder LM, 2014, CLIN NEUROPSYCHOL, V28, P1366, DOI 10.1080/13854046.2014.978383; Boone K. B., 2017, NEUROPSYCHOLOGICAL E; Boone K.B., 2013, CLIN PRACTICE FORENS; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; Boone KB, 2011, PSYCHOL INJ LAW, V4, P157, DOI 10.1007/s12207-011-9106-3; Boussahba-Bravard M, 2018, ROUTL RES GEND HIST, P1; Brooks L, 2012, CLIN NEUROPSYCHOL, V26, P816, DOI 10.1080/13854046.2012.662999; Buddin WH, 2014, CLIN NEUROPSYCHOL, V28, P525, DOI 10.1080/13854046.2014.906658; Burton V, 2012, ARCH CLIN NEUROPSYCH, V27, P262, DOI 10.1093/arclin/acs026; Bush S.S., 2013, MILD TRAUMATIC BRAIN, P57; Butcher J.N., 2001, MANUAL ADM SCORING A; Carone D.A., 2013, MILD TRAUMATIC BRAIN; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Chafetz M, 2014, CHILD ABUSE NEGLECT, V38, P1755, DOI 10.1016/j.chiabu.2014.08.015; Chafetz M, 2011, APPL NEUROPSYCHOL, V18, P143, DOI 10.1080/09084282.2011.570619; Chafetz MD, 2008, CLIN NEUROPSYCHOL, V22, P529, DOI 10.1080/13854040701346104; Chafetz MD, 2013, ARCH CLIN NEUROPSYCH, V28, P205, DOI 10.1093/arclin/act015; Chafetz MD, 2012, CLIN NEUROPSYCHOL, V26, P1358, DOI 10.1080/13854046.2012.730674; Chafetz MD, 2011, ARCH CLIN NEUROPSYCH, V26, P306, DOI 10.1093/arclin/acr030; Chmielewski M, 2017, PSYCHOL ASSESSMENT, V29, P199, DOI 10.1037/pas0000328; Crighton AH, 2014, SPINE J, V14, P2042, DOI 10.1016/j.spinee.2014.04.012; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1224, DOI 10.1080/13854046.2014.987167; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; Dionysus KE, 2011, ARCH CLIN NEUROPSYCH, V26, P81, DOI 10.1093/arclin/acq096; Erdodi LA, 2019, APPL NEUROPSYCH-ADUL, V26, P155, DOI 10.1080/23279095.2017.1384925; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Fazio RL, 2018, ARCH CLIN NEUROPSYCH, V33, P1069, DOI 10.1093/arclin/acy001; Fazio RL, 2015, ARCH CLIN NEUROPSYCH, V30, P293, DOI 10.1093/arclin/acv024; Feldman Marc D., 2018, DYING BE ILL TRUE ST; Ferrari R., 2016, J RHEUMATOL, V43, P11; Ferrari R, 2014, EUR J RHEUMATOL, V1, P150, DOI 10.5152/eurjrheumatol.2014.140061; Gaasedelen OJ, 2019, CLIN NEUROPSYCHOL, V33, P1467, DOI 10.1080/13854046.2019.1612947; Gaillard N. D., 2018, CLIN ASSESSMENT MALI, P174; Garcia-Willingham N. E., 2018, CLIN ASSESSMENT MALI, P329; Gervais RO, 2001, J RHEUMATOL, V28, P1892; Gervais RO, 2007, ASSESSMENT, V14, P196, DOI 10.1177/1073191106295861; Gervais RO, 2018, PSYCHOL ASSESSMENT, V30, P410, DOI 10.1037/pas0000506; Gottfried E, 2016, ASSESSMENT, V23, P672, DOI 10.1177/1073191115599640; Green D, 2012, INT J FORENSIC MENT, V11, P181, DOI 10.1080/14999013.2012.723665; Green P., 2003, GREENS WORD MEMORY T; Green P., 2004, MEMORY COMPLAINTS IN; Green P, 2015, APPL NEUROPSYCH-ADUL, V22, P293, DOI 10.1080/23279095.2014.925903; GREENE RL, 2008, CLIN ASSESSMENT MALI, P00159; Greiffenstein M, 2013, CLIN NEUROPSYCHOL, V27, P138, DOI 10.1080/13854046.2012.722686; Greve K. W., 2012, FORENSIC NEUROPSYCHO, P302; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P534, DOI 10.1080/13854040802232690; Greve KW, 2003, ARCH PHYS MED REHAB, V84, P1233, DOI 10.1016/S0003-9993(03)00145-X; Grossi LM, 2017, PSYCHOL ASSESSMENT, V29, P531, DOI 10.1037/pas0000364; Gu W, 2017, J PERS ASSESS, V99, P286, DOI 10.1080/00223891.2016.1149483; Gualtieri C. T., 2015, FRONTIERS, V4, P1; Hall RCW, 2006, GEN HOSP PSYCHIAT, V28, P525, DOI 10.1016/j.genhosppsych.2006.08.011; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Henry GK, 2006, CLIN NEUROPSYCHOL, V20, P786, DOI 10.1080/13854040500287749; Henry GK, 2014, BRAIN INJURY, V28, P357, DOI 10.3109/02699052.2013.865272; Henry GK, 2013, CLIN NEUROPSYCHOL, V27, P509, DOI 10.1080/13854046.2012.739644; Heyanka DJ, 2015, ARCH CLIN NEUROPSYCH, V30, P369, DOI 10.1093/arclin/acv025; Hirst RB, 2017, ARCH CLIN NEUROPSYCH, V32, P456, DOI 10.1093/arclin/acx009; Jaffe Robert J, 2016, Prim Care Companion CNS Disord, V18, DOI 10.4088/PCC.16l01934; Johnson-Greene D, 2013, CLIN NEUROPSYCHOL, V27, P148, DOI 10.1080/13854046.2012.733732; Jones A, 2016, ARCH CLIN NEUROPSYCH, V31, P786, DOI 10.1093/arclin/acw035; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Kemp S, 2008, J PSYCHOSOM RES, V65, P319, DOI 10.1016/j.jpsychores.2008.02.010; Kirkwood MW, 2010, CHILD NEUROPSYCHOL, V16, P604, DOI 10.1080/09297049.2010.495059; Lange RT, 2015, J CLIN EXP NEUROPSYC, V37, P853, DOI 10.1080/13803395.2015.1064864; Lange RT, 2013, J CLIN EXP NEUROPSYC, V35, P192, DOI 10.1080/13803395.2012.761677; Larrabee G.J., 2005, FORENSIC NEUROPSYCHO; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; Larrabee GJ, 2012, FORENSIC NEUROPSYCHO, P2; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P841, DOI 10.1080/13854040902796735; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; Marshall P, 2010, CLIN NEUROPSYCHOL, V24, P1204, DOI 10.1080/13854046.2010.514290; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; McGuire C, 2019, ARCH CLIN NEUROPSYCH, V34, P114, DOI 10.1093/arclin/acy012; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Merten T, 2013, PSYCHOL INJ LAW, V6, P122, DOI 10.1007/s12207-013-9155-x; Messer JM, 2007, J FORENSIC PSYCHOL P, V7, P33, DOI 10.1300/J158v07n03_02; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Morgan J. E., 2009, NEUROPSYCHOLOGY MALI; Musso MW, 2014, J ATTEN DISORD, V18, P186, DOI 10.1177/1087054712441970; Nguyen CT, 2015, CLIN NEUROPSYCHOL, V29, P255, DOI 10.1080/13854046.2015.1033020; Nijdam-Jones A, 2017, PSYCHOL ASSESSMENT, V29, P1321, DOI 10.1037/pas0000438; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; PANKRATZ L, 1990, CLIN NEUROPSYCHOL, V4, DOI DOI 10.1080/13854049008401832; Pearson, 2009, ADV CLIN SOL WAIS 4; Peck CP, 2013, CLIN NEUROPSYCHOL, V27, P693, DOI 10.1080/13854046.2013.779032; Peebles R, 2005, CLIN PEDIATR, V44, P237, DOI 10.1177/000992280504400307; Pierre JM, 2019, J AM ACAD PSYCHIATRY, V47, P448, DOI 10.29158/JAAPL.003867-19; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Resnick P. J., 2018, CLIN ASSESSMENT MALI, P188; Ricker J.H., 2018, TXB CLIN NEUROPSYCHO; Roberson CJ, 2013, CLIN NEUROPSYCHOL, V27, P495, DOI 10.1080/13854046.2012.737027; Rogers R., 1992, STRUCTURED INTERVIEW; Rogers R., 2018, CLIN ASSESSMENT MALI, P422; Rogers R., 2010, STRUCTURED INTERVIEW; Rogers R., 2018, CLIN ASSESSMENT MALI, P592; Rogers R, 2011, PSYCHOL INJ LAW, V4, P163, DOI 10.1007/s12207-011-9108-1; Rogers R, 2011, PSYCHOL INJ LAW, V4, P147, DOI 10.1007/s12207-011-9107-2; Ruff RM, 2016, PSYCHOL INJ LAW, V9, P143, DOI 10.1007/s12207-016-9259-1; Schroeder RW, 2016, CLIN NEUROPSYCHOL, V30, P515, DOI 10.1080/13854046.2016.1177118; Schroeder RW, 2012, CLIN NEUROPSYCHOL, V26, P129, DOI 10.1080/13854046.2011.639314; Sellbom M., 2018, FORENSIC APPL MMPI 2; Sellbom M, 2012, PSYCHIAT RES, V197, P295, DOI 10.1016/j.psychres.2011.12.043; Sherman E. M. S., 2015, VALIDITY TESTING CHI, P23; Sherman E. M. S., COMPENDIUM NEUROPSYC; Silk-Eglit GM, 2015, APPL NEUROPSYCH-ADUL, V22, P335, DOI 10.1080/23279095.2014.938809; Singhal A, 2009, ARCH CLIN NEUROPSYCH, V24, P721, DOI 10.1093/arclin/acp074; Slick D. J., 2012, VALIDITY TESTING CHI; Slick D.J., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith G., 2018, CLIN ASSESSMENT MALI, P449; Smith K, 2014, CLIN NEUROPSYCHOL, V28, P1048, DOI 10.1080/13854046.2014.931465; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; Sullivan BK, 2007, APPL NEUROPSYCHOL, V14, P189, DOI 10.1080/09084280701509083; Sullivan KA, 2013, APPL NEUROPSYCH-ADUL, V20, P20, DOI 10.1080/09084282.2012.670149; Tarescavage AM, 2013, CLIN NEUROPSYCHOL, V27, P313, DOI 10.1080/13854046.2012.744099; Tellegen, 2008, MINNESOTA MULTIPHASI; Teodoro T, 2018, J NEUROL NEUROSUR PS, V89, P1308, DOI 10.1136/jnnp-2017-317823; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tuck NL, 2019, J PAIN, V20, P133, DOI 10.1016/j.jpain.2018.07.002; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Vilar-Lopez R, 2008, J CLIN EXP NEUROPSYC, V30, P710, DOI 10.1080/13803390701684562; Weiss Kenneth J, 2017, J Am Acad Psychiatry Law, V45, P339; Whitney KA, 2013, APPL NEUROPSYCH-ADUL, V20, P83, DOI 10.1080/09084282.2012.670167; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020; Wisdom NM, 2010, ARCH CLIN NEUROPSYCH, V25, P118, DOI 10.1093/arclin/acp110; Wodushek TR, 2020, APPL NEUROPSYCH-ADUL, V27, P9, DOI 10.1080/23279095.2018.1473251; Worley C. B., 2009, PSYCHIAT TIMES, V26; Wygant DB, 2011, PSYCHOL INJ LAW, V4, P13, DOI 10.1007/s12207-011-9098-z; Wygant DB, 2010, PSYCHOL ASSESSMENT, V22, P745, DOI 10.1037/a0020042; Young JC, 2016, CLIN NEUROPSYCHOL, V30, P497, DOI 10.1080/13854046.2016.1159730	164	74	74	4	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	SEP	2020	35	6					735	764		10.1093/arclin/acaa019			30	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	OW5NS	WOS:000592933700009	32377667	hybrid, Green Published	Y	N	2022-02-06	
J	Wang, FF; Wan, H; Ma, ZR; Zhong, YT; Sun, QC; Tian, Y; Qu, LQ; Du, HT; Zhang, MX; Li, LL; Ma, HL; Luo, J; Liang, YY; Li, WJ; Hong, GS; Liu, LQ; Dai, HJ				Wang, Feifei; Wan, Hao; Ma, Zhuoran; Zhong, Yeteng; Sun, Qinchao; Tian, Ye; Qu, Liangqiong; Du, Haotian; Zhang, Mingxi; Li, Lulin; Ma, Huilong; Luo, Jian; Liang, Yongye; Li, Wen Jung; Hong, Guosong; Liu, Lianqing; Dai, Hongjie			Light-sheet microscopy in the near-infrared II window	NATURE METHODS			English	Article							IN-VIVO; FLUORESCENCE MICROSCOPY; 2-PHOTON MICROSCOPY; DEEP; BRAIN; TISSUE; LASER; DYE; NANOPARTICLES; WAVELENGTHS	Non-invasive deep-tissue three-dimensional optical imaging of live mammals with high spatiotemporal resolution is challenging owing to light scattering. We developed near-infrared II (1,000-1,700 nm) light-sheet microscopy with excitation and emission of up to approximately 1,320 nm and 1,700 nm, respectively, for optical sectioning at a penetration depth of approximately 750 mu m through live tissues without invasive surgery and at a depth of approximately 2 mm in glycerol-cleared brain tissues. Near-infrared II light-sheet microscopy in normal and oblique configurations enabled in vivo imaging of live mice through intact tissue, revealing abnormal blood flow and T-cell motion in tumor microcirculation and mapping out programmed-death ligand 1 and programmed cell death protein 1 in tumors with cellular resolution. Three-dimensional imaging through the intact mouse head resolved vascular channels between the skull and brain cortex, and allowed monitoring of recruitment of macrophages and microglia to the traumatic brain injury site.	[Wang, Feifei; Wan, Hao; Ma, Zhuoran; Zhong, Yeteng; Sun, Qinchao; Tian, Ye; Du, Haotian; Dai, Hongjie] Stanford Univ, Dept Chem & BioX, Stanford, CA 94305 USA; [Qu, Liangqiong] Univ N Carolina, Dept Radiol, Chapel Hill, NC USA; [Qu, Liangqiong] Univ N Carolina, BRIC, Chapel Hill, NC USA; [Zhang, Mingxi] Wuhan Univ Technol, State Key Lab Adv Technol Mat Synth & Proc, Wuhan, Hubei, Peoples R China; [Li, Lulin; Luo, Jian] VA Palo Alto Hlth Care Syst, Palo Alto Vet Inst Res, Palo Alto, CA USA; [Ma, Huilong; Liang, Yongye] South Univ Sci & Technol China, Dept Mat Sci & Engn, Shenzhen, Peoples R China; [Luo, Jian] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Li, Wen Jung; Liu, Lianqing] Chinese Acad Sci, Shenyang Inst Automat, State Key Lab Robot, Shenyang, Liaoning, Peoples R China; [Li, Wen Jung] City Univ Hong Kong, Dept Mech Engn, Hong Kong, Peoples R China; [Hong, Guosong] Stanford Univ, Dept Mat Sci & Engn, Stanford, CA 94305 USA		Dai, HJ (corresponding author), Stanford Univ, Dept Chem & BioX, Stanford, CA 94305 USA.	hdai@stanford.edu	Liang, Yongye/AAH-1981-2020; Sun, Qinchao/Y-9302-2019; Tian, Ye/AAJ-9782-2021; Liang, Yongye/G-6033-2018; Dai, Hongjie/ABC-4574-2021; Hong, Guosong/A-7551-2013; Tian, Ye/I-8961-2018; Ma, Zhuoran/AAM-6799-2021; Luo, Jian/B-8449-2014	Liang, Yongye/0000-0002-7416-8792; Tian, Ye/0000-0002-1833-1807; Liang, Yongye/0000-0002-7416-8792; Hong, Guosong/0000-0002-8858-4471; Tian, Ye/0000-0002-1833-1807; Ma, Zhuoran/0000-0002-1520-2129; Wang, Feifei/0000-0001-7687-3412; Luo, Jian/0000-0002-2064-8467; Liu, Lianqing/0000-0002-2271-5870	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DP1-NS-105737]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS092868, DP1NS105737] Funding Source: NIH RePORTER	We thank members of the Dai group for discussion. This study was supported by the National Institutes of Health through grant DP1-NS-105737.	Alifu N, 2017, DYES PIGMENTS, V143, P76, DOI 10.1016/j.dyepig.2017.04.017; Antaris AL, 2016, NAT MATER, V15, P235, DOI [10.1038/NMAT4476, 10.1038/nmat4476]; Balar AV, 2017, CANCER IMMUNOL IMMUN, V66, P551, DOI 10.1007/s00262-017-1954-6; Bouchard MB, 2015, NAT PHOTONICS, V9, P113, DOI [10.1038/nphoton.2014.323, 10.1038/NPHOTON.2014.323]; Bruns OT, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551-017-0056; Chung K, 2013, NATURE, V497, P332, DOI 10.1038/nature12107; Diao S, 2015, ANGEW CHEM INT EDIT, V54, P14758, DOI 10.1002/anie.201507473; Diao S, 2015, NANO RES, V8, P3027, DOI 10.1007/s12274-015-0808-9; Dodt HU, 2007, NAT METHODS, V4, P331, DOI 10.1038/NMETH1036; Escobet-Montalban A, 2018, OPT LETT, V43, P5484, DOI 10.1364/OL.43.005484; Hell SW, 2007, SCIENCE, V316, P1153, DOI 10.1126/science.1137395; Helmchen F, 2005, NAT METHODS, V2, P932, DOI 10.1038/NMETH818; Herisson F, 2018, NAT NEUROSCI, V21, P1209, DOI 10.1038/s41593-018-0213-2; Hong G. S., 2014, NAT COMMUN, V5, P4206, DOI DOI 10.1038/NCOMMS5206; Hong GS, 2014, NAT PHOTONICS, V8, P723, DOI [10.1038/nphoton.2014.166, 10.1038/NPHOTON.2014.166]; Hong GS, 2012, NAT MED, V18, P1841, DOI 10.1038/nm.2995; Horton NG, 2013, NAT PHOTONICS, V7, P205, DOI [10.1038/NPHOTON.2012.336, 10.1038/nphoton.2012.336]; Huisken J, 2004, SCIENCE, V305, P1007, DOI 10.1126/science.1100035; Itoh R, 2016, OPT LETT, V41, P5015, DOI 10.1364/OL.41.005015; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Johns M, 2005, OPT EXPRESS, V13, P4828, DOI 10.1364/OPEX.13.004828; Kawakami R, 2015, BIOMED OPT EXPRESS, V6, P891, DOI 10.1364/BOE.6.000891; Keller PJ, 2010, NAT METHODS, V7, P637, DOI [10.1038/NMETH.1476, 10.1038/nmeth.1476]; Lapadula G, 2014, CHEM MATER, V26, P1062, DOI 10.1021/cm404140q; Lee JA, 2013, OPT LETT, V38, P332, DOI 10.1364/OL.38.000332; Liu J, 2015, BIOMED OPT EXPRESS, V6, P1857, DOI 10.1364/BOE.6.001857; Liu TL, 2018, SCIENCE, V360, DOI 10.1126/science.aaq1392; Matthes R, 2000, HEALTH PHYS, V79, P431; Naczynski DJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3199; Ouzounov DG, 2017, NAT METHODS, V14, P388, DOI 10.1038/nmeth.4183; Pediredla AK, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.12.126009; Power RM, 2017, NAT METHODS, V14, P360, DOI 10.1038/nmeth.4224; Rowlands CJ, 2017, LIGHT-SCI APPL, V6, DOI 10.1038/lsa.2016.255; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shi L, 2017, DEEP IMAGING IN TISSUE AND BIOMEDICAL MATERIALS: USING LINEAR AND NONLINEAR OPTICAL METHODS, P1; Shi LY, 2016, J BIOPHOTONICS, V9, P38, DOI 10.1002/jbio.201500192; Song E, 2015, OPT LASER TECHNOL, V73, P69, DOI 10.1016/j.optlastec.2015.03.020; Song MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065821; Tang HD, 2016, CANCER CELL, V29, P285, DOI 10.1016/j.ccell.2016.02.004; Tomer R, 2015, CELL, V163, P1796, DOI 10.1016/j.cell.2015.11.061; Tomer R, 2014, NAT PROTOC, V9, P1682, DOI 10.1038/nprot.2014.123; Truong TV, 2011, NAT METHODS, V8, P757, DOI 10.1038/nmeth.1652; VANSTAVEREN HJ, 1991, APPL OPTICS, V30, P4507, DOI 10.1364/AO.30.004507; Wan H, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201804956; Wan H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03505-4; WANG LH, 1995, COMPUT METH PROG BIO, V47, P131, DOI 10.1016/0169-2607(95)01640-F; Wang TY, 2018, NAT METHODS, V15, P789, DOI 10.1038/s41592-018-0115-y; Wang WZ, 2018, ADV MATER, V30, DOI 10.1002/adma.201800106; Welsher K, 2011, P NATL ACAD SCI USA, V108, P8943, DOI 10.1073/pnas.1014501108; Welsher K, 2009, NAT NANOTECHNOL, V4, P773, DOI [10.1038/NNANO.2009.294, 10.1038/nnano.2009.294]; Won N, 2012, MOL IMAGING, V11, P338, DOI 10.2310/7290.2011.00057; Zhang MX, 2018, P NATL ACAD SCI USA, V115, P6590, DOI 10.1073/pnas.1806153115; Zhang XD, 2016, ADV MATER, V28, P6872, DOI 10.1002/adma.201600706; Zhong YT, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00917-6; Zhu SJ, 2017, P NATL ACAD SCI USA, V114, P962, DOI 10.1073/pnas.1617990114	56	74	76	19	162	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1548-7091	1548-7105		NAT METHODS	Nat. Methods	JUN	2019	16	6					545	+		10.1038/s41592-019-0398-7			11	Biochemical Research Methods	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	IA3HW	WOS:000469455200024	31086342	Green Accepted			2022-02-06	
J	Rizzo, A; Koenig, ST				Rizzo, Albert Skip; Koenig, Sebastian Thomas			Is Clinical Virtual Reality Ready for Primetime?	NEUROPSYCHOLOGY			English	Article						clinical virtual reality; psychology; rehabilitation; neuropsychology	POSTTRAUMATIC-STRESS-DISORDER; COMPUTERIZED COGNITIVE REHABILITATION; PUBLIC-SPEAKING ANXIETY; TRAUMATIC BRAIN-INJURY; MORRIS WATER TASK; EXPOSURE THERAPY; BEHAVIOR THERAPY; GRADED EXPOSURE; SERIOUS GAMES; MOTOR CONTROL	Objective: Since the mid-1990s, a significant scientific literature has evolved regarding the outcomes from the use of what we now refer to as clinical virtual reality (VR). This use of VR simulation technology has produced encouraging results when applied to address cognitive, psychological, motor, and functional impairments across a wide range of clinical health conditions. This article addresses the question, "Is clinical VR ready for primetime?" Method: After a brief description of the various forms of VR technology, we discuss the trajectory of clinical VR over the last 20 years and summarize the basic assets that VR offers for creating clinical applications. The discussion then addresses the question of readiness in terms of the theoretical basis for clinical VR assets, the research to date, the pragmatic factors regarding availability, usability, and costs of clinical VR content/systems, and the ethical issues for the safe use of VR with clinical populations. Results: Our review of the theoretical underpinnings and research findings to date leads to the prediction that clinical VR will have a significant impact on future research and practice. Pragmatic issues that can influence adoption across many areas of psychology also appear favorable, but professional guidelines will be needed to promote its safe and ethical use. Conclusions: Although there is still much research needed to advance the science in this area, we strongly believe that clinical VR applications will become indispensable tools in the toolbox of psychological researchers and practitioners and will only grow in relevance and popularity in the future. General Scientific Summary Virtual reality (VR) technology offers new opportunities for clinical research, assessment, and intervention. Advances in the underlying VR-enabling technologies and methods can now support the creation of low-cost, yet sophisticated, immersive and interactive VR systems, capable of running on consumer-level computing devices. It is predicted that the clinical use of VR will have a significant impact on mental health care in areas where the research demonstrates added value.	[Rizzo, Albert Skip] Univ Southern Calif, Inst Creat Technol, Med Virtual Real Lab, 12015 East Waterfront Dr, Playa Vista, CA 90094 USA; [Koenig, Sebastian Thomas] Katana Simulat Pty Ltd, Human Interface Technol Engineer, Adelaide, SA, Australia		Rizzo, A (corresponding author), Univ Southern Calif, Inst Creat Technol, Med Virtual Real Lab, 12015 East Waterfront Dr, Playa Vista, CA 90094 USA.	rizzo@ict.usc.edu					Adamovich SV, 2009, NEUROREHABILITATION, V25, P29, DOI 10.3233/NRE-2009-0497; Akinwuntan AE, 2012, J STROKE CEREBROVASC, V21, P478, DOI 10.1016/j.jstrokecerebrovasdis.2010.12.001; Albright Glenn, 2016, Mhealth, V2, P44, DOI 10.21037/mhealth.2016.11.02; American Psychological Association, 2003, ETH PRINC PSYCH COD; Anderson PL, 2005, DEPRESS ANXIETY, V22, P156, DOI 10.1002/da.20090; Andrade LH, 2014, PSYCHOL MED, V44, P1303, DOI 10.1017/S0033291713001943; Astur RS, 2006, CYBERPSYCHOL BEHAV, V9, P234, DOI 10.1089/cpb.2006.9.234; Astur RS, 2004, BEHAV BRAIN RES, V151, P103, DOI 10.1016/j.bbr.2003.08.024; Astur RS, 2002, BEHAV BRAIN RES, V132, P77, DOI 10.1016/S0166-4328(01)00399-0; Astur RS, 1998, BEHAV BRAIN RES, V93, P185, DOI 10.1016/S0166-4328(98)00019-9; Aukstakalnis, 1992, SILICON MIRAGE ART S; Badia SBi, 2016, NEUROREHABILITATION, P573, DOI [10.1007/978-3-319-28603-7_28, DOI 10.1007/978-3-319-28603-7_28]; Bailenson JN, 2006, COMP SUPP COMP W SER, V34, P1; Banos RM, 2011, INT J HUM-COMPUT ST, V69, P602, DOI 10.1016/j.ijhcs.2011.06.002; Banos RM, 2009, BRIT J GUID COUNS, V37, P347, DOI 10.1080/03069880902957064; Baranowski T, 2016, GAMES HEALTH J, V5, P1, DOI 10.1089/g4h.2015.0026; Barrett J., 2002, ACCESSIBLE INTERFACE; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck JG, 2007, BEHAV THER, V38, P39, DOI 10.1016/j.beth.2006.04.001; Beidel DC, 2017, J ANXIETY DISORD, V50, P23, DOI 10.1016/j.janxdis.2017.05.001; Bickmore TW, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5239; Blascovich J, 2002, PSYCHOL INQ, V13, P103, DOI 10.1207/S15327965PLI1302_01; Blume F, 2017, TRIALS, V18, DOI 10.1186/s13063-016-1769-3; Bogdanova Y, 2016, J HEAD TRAUMA REHAB, V31, P419, DOI 10.1097/HTR.0000000000000203; Bohil CJ, 2011, NAT REV NEUROSCI, V12, P752, DOI 10.1038/nrn3122; Bordnick PS, 2013, RES SOCIAL WORK PRAC, V23, P419, DOI 10.1177/1049731513482377; Botella C, 2015, NEUROPSYCH DIS TREAT, V11, P2533, DOI 10.2147/NDT.S89542; Bouchard S, 2017, BRIT J PSYCHIAT, V210, P276, DOI 10.1192/bjp.bp.116.184234; Bresnahan T., 2016, 2016 P INT C DIS VIR; Brooks BM, 1999, NEUROPSYCHOL REHABIL, V9, P63, DOI 10.1080/713755589; Brown D. J., 1998, P 2 EUR C DIS VIRT R, P11; Bryanton C, 2006, CYBERPSYCHOL BEHAV, V9, P123, DOI 10.1089/cpb.2006.9.123; Burgers C, 2015, COMPUT HUM BEHAV, V48, P94, DOI 10.1016/j.chb.2015.01.038; Carlbring P, 2001, BEHAV THER, V32, P751, DOI 10.1016/S0005-7894(01)80019-8; Casutt G, 2014, TRANSPORT RES F-TRAF, V22, P232, DOI 10.1016/j.trf.2013.12.007; Chirico A, 2016, J CELL PHYSIOL, V231, P275, DOI 10.1002/jcp.25117; Chou YH, 2012, VIRTUAL REALITY IN PSYCHOLOGICAL, MEDICAL AND PEDAGOGICAL APPLICATIONS, P203, DOI 10.5772/48445; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Clement S, 2015, PSYCHOL MED, V45, P11, DOI 10.1017/S0033291714000129; CONNOR B, 2002, P 4 INT C DIS VIRT R, P77; Costanzo ME, 2014, PSYCHOSOM MED, V76, P670, DOI 10.1097/PSY.0000000000000109; COSTAS R, 2000, P 3 INT C DIS VIRT R, P305; Cox SM, 2016, J AUTISM DEV DISORD, V46, P1379, DOI 10.1007/s10803-015-2677-1; Cromby J., 1996, P 1 EUR C DIS VIRT R, P305; Cruz-Neira C., 1993, Computer Graphics Proceedings, P135; Csikszentmihalyi M., 1990, FLOW PSYCHOL OPTIMAL; Cuijpers P, 2008, J BEHAV MED, V31, P169, DOI 10.1007/s10865-007-9144-1; Curtis M., 2017, SIMULATION AVIATION; Darejeh Ali, 2013, Journal of Computer Science, V9, P1443, DOI 10.3844/jcssp.2013.1443.1450; Dascal Julieta, 2017, Innov Clin Neurosci, V14, P14; DAVIES RC, 1998, P 2 EUR C DIS VIRT R, P61; Davis E. S., 2000, 8 ANN MED MEETS VIRT; De Vaus D.P., 2015, AAAI SPRING S TURN T, P2, DOI 10.5172/jfs.2011.17.2.126; DeFanti TA, 2011, OPEN ENG, V1, P16, DOI 10.2478/s13531-010-0002-5; Deutsch JE, 2001, PRESENCE-VIRTUAL AUG, V10, P416, DOI 10.1162/1054746011470262; Deutsch JE, 2017, PEDIATR PHYS THER, V29, pS23, DOI 10.1097/PEP.0000000000000387; Difede J, 2007, J CLIN PSYCHIAT, V68, P1639, DOI 10.4088/JCP.v68n1102; Difede J, 2014, NEUROPSYCHOPHARMACOL, V39, P1052, DOI 10.1038/npp.2013.317; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Falconer CJ, 2016, BJPSYCH OPEN, V2, P74, DOI 10.1192/bjpo.bp.115.002147; Faria AL, 2016, J NEUROENG REHABIL, V13, DOI 10.1186/s12984-016-0204-z; Fish JE, 2015, NEUROPSYCHOL REHABIL, V25, P159, DOI 10.1080/09602011.2014.921204; Fleming Theresa M, 2016, Front Psychiatry, V7, P215, DOI 10.3389/fpsyt.2016.00215; Folley BS, 2010, NEUROIMAGE, V49, P3373, DOI 10.1016/j.neuroimage.2009.11.034; Foloppe DA, 2018, NEUROPSYCHOL REHABIL, V28, P709, DOI 10.1080/09602011.2015.1094394; Freeman D, 2017, PSYCHOL MED, V47, P2393, DOI 10.1017/S003329171700040X; Freeman D, 2016, BRIT J PSYCHIAT, V209, P62, DOI 10.1192/bjp.bp.115.176438; Gamito P, 2016, METHOD INFORM MED, V55, P93, DOI 10.3414/ME14-02-0021; Gamito P, 2017, DISABIL REHABIL, V39, P385, DOI 10.3109/09638288.2014.934925; Gartner Inc., 2016, HYP CYCL EM TECHN 20; Gold JI, 2006, CYBERPSYCHOL BEHAV, V9, P207, DOI 10.1089/cpb.2006.9.207; Goldman Sachs, 2016, VIRT AUGM REAL NEXT; Goldman-Sachs, 2006, VIRT AUGM REAL UND R; Granic I, 2014, AM PSYCHOL, V69, P66, DOI 10.1037/a0034857; Gratch J, 2002, IEEE INTELL SYST, V17, P54, DOI 10.1109/MIS.2002.1024753; Gratch J., 2004, COGN SYST RES, V5, P269, DOI [DOI 10.1016/J.COGSYS.2004.02.002, DOI 10.1016/J.C0GSYS.2004.02.002]; Harrison A, 2002, DISABIL REHABIL, V24, P599, DOI 10.1080/09638280110111360; Hoffman HG, 2006, CNS SPECTRUMS, V11, P45, DOI 10.1017/S1092852900024202; Hoffman HG, 2011, ANN BEHAV MED, V41, P183, DOI 10.1007/s12160-010-9248-7; Holden MK, 2005, CYBERPSYCHOL BEHAV, V8, P187, DOI 10.1089/cpb.2005.8.187; Howard MC, 2017, COMPUT HUM BEHAV, V70, P317, DOI 10.1016/j.chb.2017.01.013; Hypergrid Business, 2016, 5 VR APPS HELP YOU B; Innes M., 2017, INPSYCH, V39; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; Jacobs WJ, 1997, LEARN MOTIV, V28, P521, DOI 10.1006/lmot.1997.0977; Jaffe DL, 2004, J REHABIL RES DEV, V41, P283, DOI 10.1682/JRRD.2004.03.0283; Jin WN, 2016, STUD HEALTH TECHNOL, V220, P154, DOI 10.3233/978-1-61499-625-5-154; John N. W., 2017, IEEE T VISUALIZATION; Johnston R., 1995, VIRTUAL REALITY SPEC, V2, P53; Josman N, 2008, INT J DISABIL HUM DE, V7, P49; Josman N, 2014, J STROKE CEREBROVASC, V23, P879, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.013; Kaplan AY, 2013, IEEE T COMP INTEL AI, V5, P141, DOI 10.1109/TCIAIG.2012.2237517; Kato PM, 2010, REV GEN PSYCHOL, V14, P113, DOI 10.1037/a0019441; Keefe RSE, 2016, SCHIZOPHR RES, V175, P90, DOI 10.1016/j.schres.2016.03.038; Klamroth-Marganska V, 2014, LANCET NEUROL, V13, P159, DOI 10.1016/S1474-4422(13)70305-3; Klinger E., 2005, CYB 2005 BAS SWITZ; Kober SE, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-17; Koenig S. T., 2012, THESIS; Koenig S. T., 2010, P INT C SER DIS VIRT; Koenig S. T., 2012, INT C SER VIRT REAL; Krch D., 2013, P INT C VIRT REH PHI; Krueger M. W., 1993, PRESENCE-VIRTUAL AUG, V2, P162; Lamson R., 1994, CYBEREDGE J, V4, P6; Lange B, 2009, PHYS THER REV, V14, P355, DOI 10.1179/108331909X12488667117258; Lange B, 2012, DISABIL REHABIL, V34, P1863, DOI 10.3109/09638288.2012.670029; Lange B, 2010, TOP STROKE REHABIL, V17, P345, DOI 10.1310/tsr1705-345; Lanyi CS, 2012, ACTA POLYTECH HUNG, V9, P225; Larson EB, 2014, NEUROREHABILITATION, V34, P759, DOI 10.3233/NRE-141078; LaViola J. J., 2017, 3D USER INTERFACES T; Levin MF, 2015, PHYS THER, V95, P415, DOI 10.2522/ptj.20130579; Levy CE, 2015, AM J PHYS MED REHAB, V94, pE31, DOI 10.1097/PHM.0000000000000248; Liu L, 1999, Cyberpsychol Behav, V2, P53, DOI 10.1089/cpb.1999.2.53; Lucas GM, 2014, COMPUT HUM BEHAV, V37, P94, DOI 10.1016/j.chb.2014.04.043; Lumbreras M., 2000, P 3 INT C DIS VIRT R, P129; Madary M, 2016, FRONTIERS ROBOTICS A; Man DWK, 2018, NEUROPSYCHOL REHABIL, V28, P1197, DOI 10.1080/09602011.2016.1251949; Maples-Keller JL, 2017, HARVARD REV PSYCHIAT, V25, P103, DOI 10.1097/HRP.0000000000000138; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; McCall C, 2009, SOC INFLUENCE, V4, P138, DOI 10.1080/15534510802517418; McComas J, 2002, CYBERPSYCHOL BEHAV, V5, P185, DOI 10.1089/109493102760147150; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; Merians A. S., 2010, P 2010 INT C DIS VIR, P213; Merians AS, 2002, PHYS THER, V82, P898, DOI 10.1093/ptj/82.9.898; Millan J. R., 2010, FRONTIERS NEUROSCIEN; MindMaze, 2017, MINDMAZE MINDMOTION; Morbini Fabrizio, 2014, NATURAL INTERACTION, P313; Morina N, 2015, BEHAV RES THER, V74, P18, DOI 10.1016/j.brat.2015.08.010; Morrison J, 1999, 42 US ARM RES I BEH; Morrongiello BA, 2015, J PEDIATR PSYCHOL, V40, P697, DOI 10.1093/jpepsy/jsv019; Mosadeghi S, 2016, JMIR MENT HEALTH, V3, DOI 10.2196/mental.5801; MOWAFY L, 1995, ABILITY, V15, P18; Muhlberger A., 2016, J ATTENTION DISORDER; Navarro MD, 2013, NEUROPSYCHOL REHABIL, V23, P597, DOI 10.1080/09602011.2013.806269; NEISSER U, 1978, PRACTICAL ASPECTS ME, P3; Neri S. G. R., 2017, CLIN REHABILITATION; Nir-Hadad S. Y., 2015, NEUROPSYCHOL REHABIL, V27, P808; Norcross JC, 2013, PROF PSYCHOL-RES PR, V44, P363, DOI 10.1037/a0034633; Norrholm SD, 2016, BEHAV RES THER, V82, P28, DOI 10.1016/j.brat.2016.05.002; Ogourtsova T., 2015, NEUROPSYCHOL REHABIL, V27, P409, DOI DOI 10.1080/09602; Opris D, 2012, DEPRESS ANXIETY, V29, P85, DOI 10.1002/da.20910; Padgett LS, 2006, J PEDIATR PSYCHOL, V31, P65, DOI 10.1093/jpepsy/jsj030; Papastergiou M, 2009, COMPUT EDUC, V53, P603, DOI 10.1016/j.compedu.2009.04.001; Park S, 2013, INT CONF AFFECT, P423, DOI 10.1109/ACII.2013.76; Parsons S., 2012, 1 INT C INN TECHN AU; Parsons TD, 2008, J BEHAV THER EXP PSY, V39, P250, DOI 10.1016/j.jbtep.2007.07.007; Parsons TD, 2008, CYBERPSYCHOL BEHAV, V11, P17, DOI 10.1089/cpb.2007.9934; Parsons TD, 2017, NEUROPSYCHOL REHABIL, V27, P777, DOI 10.1080/09602011.2015.1109524; Parsons TD, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00660; Parsons TD, 2009, DEV NEUROREHABIL, V12, P224, DOI 10.1080/17518420902991719; Passig D, 2016, COMPUT EDUC, V95, P296, DOI 10.1016/j.compedu.2016.01.009; Pertaub DP, 2002, PRESENCE-TELEOP VIRT, V11, P68, DOI 10.1162/105474602317343668; Pietrzak E, 2014, GAMES HEALTH J, V3, P202, DOI 10.1089/g4h.2014.0013; Piron L, 2002, STUD HEALTH TECHNOL, V85, P355; Powers MB, 2008, J ANXIETY DISORD, V22, P561, DOI 10.1016/j.janxdis.2007.04.006; Proffitt R, 2015, INT J TELEREHABILITA, V7, P23, DOI 10.5195/ijt.2015.6177; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Putrino D, 2014, CURR OPIN NEUROL, V27, P631, DOI 10.1097/WCO.0000000000000152; Regenbrecht H, 2014, P IEEE, V102, P170, DOI 10.1109/JPROC.2013.2294178; Remsik A, 2016, EXPERT REV MED DEVIC, V13, P445, DOI 10.1080/17434440.2016.1174572; Riva Giuseppe, 2011, J Diabetes Sci Technol, V5, P283; Rizzo A., 2016, DIGITAL PATIENT ADV, P257; Rizzo A. A., 1994, P 2 INT C VIRT REAL; Rizzo A. A., 2011, INT J VIRTUAL REALIT, V8; Rizzo A. A., 2016, 2016 P INT C DIS VIR, P57; Rizzo AA, 2006, CNS SPECTRUMS, V11, P35, DOI 10.1017/S1092852900024196; Rizzo AA, 2004, TELEMED J E-HEALTH, V10, P184, DOI 10.1089/1530562041641336; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Rizzo AA, 2000, CYBERPSYCHOL BEHAV, V3, P483, DOI 10.1089/10949310050078940; Rizzo AA, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199712000-00002; Rizzo A, 2015, J CONTEMP PSYCHOTHER, V45, P255, DOI 10.1007/s10879-015-9306-3; Rizzo A, 2016, ARTIFICIAL INTELLIGENCE IN BEHAVIORAL AND MENTAL HEALTH CARE, P53, DOI 10.1016/B978-0-12-420248-1.00003-9; Rizzo A, 2010, ANN NY ACAD SCI, V1208, P114, DOI 10.1111/j.1749-6632.2010.05755.x; Rizzo A, 2013, PSYCHIAT ANN, V43, P123, DOI 10.3928/00485713-20130306-08; Rizzo AS, 2002, STUD NEUROPSYCHOL DE, P243; Rizzo M, 1997, ARCH NEUROL-CHICAGO, V54, P545, DOI 10.1001/archneur.1997.00550170027011; ROBERTSON I, 1990, APHASIOLOGY, V4, P381, DOI 10.1080/02687039008249090; Rose FD, 2005, CYBERPSYCHOL BEHAV, V8, P241, DOI 10.1089/cpb.2005.8.241; Rose FD, 2001, PRESENCE-VIRTUAL AUG, V10, P345, DOI 10.1162/1054746011470208; Rosenthal DSH, 2000, USENIX ASSOCIATION PROCEEDINGS OF THE FREENIX TRACK, P129; Rothbaum BO, 2014, AM J PSYCHIAT, V171, P640, DOI 10.1176/appi.ajp.2014.13121625; Rothbaum BO, 2001, J CLIN PSYCHIAT, V62, P617, DOI 10.4088/JCP.v62n0808; Rothbaum BO, 1999, BEHAV MODIF, V23, P507, DOI 10.1177/0145445599234001; ROTHBAUM BO, 1995, BEHAV THER, V26, P547, DOI 10.1016/S0005-7894(05)80100-5; Roy MJ, 2014, STUD HEALTH TECHNOL, V199, P61, DOI 10.3233/978-1-61499-401-5-61; Roy MJ, 2010, ANN NY ACAD SCI, V1208, P142, DOI 10.1111/j.1749-6632.2010.05689.x; Rutten A, 2003, J VISUAL COMP ANIMAT, V14, P233, DOI 10.1002/vis.320; Sbordone RJ, 1996, ECOLOGICAL VALIDITY; Schell J., 2014, ART GAME DESIGN BOOK; Scherer S, 2014, IMAGE VISION COMPUT, V32, P648, DOI 10.1016/j.imavis.2014.06.001; Schneider SM, 2011, SUPPORT CARE CANCER, V19, P555, DOI 10.1007/s00520-010-0852-7; Schultheis MT, 2001, PRESENCE-TELEOP VIRT, V10, P431, DOI 10.1162/1054746011470271; Schwebel DC, 2014, HEALTH PSYCHOL, V33, P628, DOI 10.1037/hea0000032; Shipman SL, 2008, BEHAV BRAIN RES, V187, P433, DOI 10.1016/j.bbr.2007.10.014; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Slater M., 2016, FRONTIERS ROBOTI DEC; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Spek V, 2007, PSYCHOL MED, V37, P319, DOI 10.1017/S0033291706008944; Stamm BH, 1998, PROF PSYCHOL-RES PR, V29, P536, DOI 10.1037/0735-7028.29.6.536; Standen P, 2015, PHYS THER, V95, P350, DOI 10.2522/ptj.20130564; Stanton D, 1998, ST HEAL T, V58, P219; STRICKLAND D, 2001, ACM SIGGRAPH 2001 C; Talbot TB, 2012, INT J GAMING COMPUT-, V4, P1, DOI 10.4018/jgcms.2012070101; Tarr MJ, 2002, NAT NEUROSCI, V5, P1089, DOI 10.1038/nn948; TART CT, 1993, CULTIVATING CONSCIOUSNESS, P123; Tashjian VC, 2017, JMIR MENT HEALTH, V4, DOI 10.2196/mental.7387; Tegos S, 2016, INT J COMP-SUPP COLL, V11, P417, DOI 10.1007/s11412-016-9246-2; Thiebaux Marcus, 2008, P INT JOINT C AUT AG, P151, DOI [10.1016/j.ins.2009.01.020, DOI 10.1016/J.INS.2009.01.020]; Trost Z, 2015, PAIN MANAG, V5, P197, DOI [10.2217/pmt.15.6, 10.2217/PMT.15.6]; Valladares-Rodriguez S, 2016, J BIOMED INFORM, V64, P296, DOI 10.1016/j.jbi.2016.10.019; Valve Corporation, 2017, STEAM; Virtual Reality Society, 2017, APPL VIRT REAL; Wall K. J., 2017, DISABILITY REHABILIT; Wiederhold B.K., 1998, CYBERPSYCHOLOGY BEHA, V1, P45, DOI DOI 10.1089/CPB.1998.1.45; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; Wilson JAB, 2008, CYBERPSYCHOL BEHAV, V11, P767, DOI 10.1089/cpb.2008.0071; Yang YJD, 2017, BEHAV RES THER, V93, P55, DOI 10.1016/j.brat.2017.03.014; Yellowlees PM, 2012, TELEMED E-HEALTH, V18, P558, DOI 10.1089/tmj.2011.0195; You SH, 2005, STROKE, V36, P1166, DOI 10.1161/01.STR.0000162715.43417.91; Zhang Z, 2017, PATIENT EDUC COUNS, V100, P1730, DOI 10.1016/j.pec.2017.03.017; [No title captured]	223	74	74	1	51	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	NOV	2017	31	8			SI		877	899		10.1037/neu0000405			23	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	FT6JH	WOS:000423259900004	29376669				2022-02-06	
J	Spaite, DW; Hu, CC; Bobrow, BJ; Chikani, V; Sherrill, D; Barnhart, B; Gaither, JB; Denninghoff, KR; Viscusi, C; Mullins, T; Adelson, PD				Spaite, Daniel W.; Hu, Chengcheng; Bobrow, Bentley J.; Chikani, Vatsal; Sherrill, Duane; Barnhart, Bruce; Gaither, Joshua B.; Denninghoff, Kurt R.; Viscusi, Chad; Mullins, Terry; Adelson, P. David			Mortality and Prehospital Blood Pressure in Patients With Major Traumatic Brain Injury Implications for the Hypotension Threshold	JAMA SURGERY			English	Article							SEVERE HEAD-INJURY; SEVERITY SCORE TRISS; INTERNATIONAL CLASSIFICATION; REDEFINING HYPOTENSION; PROGNOSTIC VALUE; 110 MMHG; INSULTS; HYPOXIA; PREDICTORS; MANAGEMENT	IMPORTANCE Current prehospital traumatic brain injury guidelines use a systolic blood pressure threshold of less than 90 mm Hg for treating hypotension for individuals 10 years and older based on studies showing higher mortality when blood pressure drops below this level. However, the guidelines also acknowledge the weakness of the supporting evidence. OBJECTIVE To evaluate whether any statistically supportable threshold between systolic pressure and mortality emerges from the data a priori, without assuming that a cut point exists. DESIGN, SETTING, AND PARTICIPANTS Observational evaluation of a large prehospital database established as a part of the Excellence in Prehospital Injury Care Traumatic Brain Injury Study. Patients from the preimplementation cohort (January 2007 to March 2014) 10 years and older with moderate or severe traumatic brain injury (Barell Matrix Type 1 classification, International Classification of Diseases, Ninth Revision head region severity score of 3 or greater, and/or Abbreviated Injury Scale head-region severity score of 3 or greater) and a prehospital systolic pressure between 40 and 119 mm Hg were included. The generalized additive model and logistic regression were used to determine the association between systolic pressure and probability of death, adjusting for significant/important confounders. MAIN OUTCOMES AND MEASURES The main outcome measure was in-hospital mortality. RESULTS Among the 3844 included patients, 2565 (66.7%) were male, and the median (range) age was 35 (10-99) years. The model revealed a monotonically decreasing association between systolic pressure and adjusted probability of death across the entire range (ie, from 40 to 119 mm Hg). Each 10-point increase of systolic pressure was associated with a decrease in the adjusted odds of death of 18.8% (adjusted odds ratio, 0.812; 95% CI, 0.748-0.883). Thus, the adjusted odds of mortality increased as much for a drop from 110 to 100 mm Hg as for a drop from 90 to 80 mm Hg, and so on throughout the range. CONCLUSIONS AND RELEVANCE We found a linear association between lowest prehospital systolic blood pressure and severity-adjusted probability of mortality across an exceptionally wide range. There is no identifiable threshold or inflection point between 40 and 119 mm Hg. Thus, in patients with traumatic brain injury, the concept that 90 mm Hg represents a unique or important physiological cut point may be wrong. Furthermore, clinically meaningful hypotension may not be as low as current guidelines suggest. Randomized trials evaluating treatment levels significantly above 90 mm Hg are needed.	[Spaite, Daniel W.; Bobrow, Bentley J.; Gaither, Joshua B.; Denninghoff, Kurt R.; Viscusi, Chad] Univ Arizona, Coll Med, Dept Emergency Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA; [Spaite, Daniel W.; Hu, Chengcheng; Bobrow, Bentley J.; Chikani, Vatsal; Barnhart, Bruce; Gaither, Joshua B.; Denninghoff, Kurt R.; Viscusi, Chad] Univ Arizona, Coll Med, Arizona Emergency Med Res Ctr, Phoenix, AZ USA; [Hu, Chengcheng; Sherrill, Duane] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA; [Bobrow, Bentley J.; Chikani, Vatsal; Mullins, Terry] Arizona Dept Hlth Serv, Bur Emergency Med Serv, Phoenix, AZ 85007 USA; [Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Adelson, P. David] Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ USA		Spaite, DW (corresponding author), Univ Arizona, Coll Med, Dept Emergency Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	Dan@aemrc.arizona.edu	Adelson, David/W-2083-2019	Chikani, Vatsal/0000-0003-0904-7887	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071049]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071049] Funding Source: NIH RePORTER	Research reported in this article was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award R01NS071049.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Bell JM, 2014, REPORT C TRAUMATIC B; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Berry C, 2012, INJURY, V43, P1833, DOI 10.1016/j.injury.2011.08.014; Bruns B, 2008, J TRAUMA, V65, P1217, DOI 10.1097/TA.0b013e318184ee63; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; CARREL M, 1994, ANN FR ANESTH, V13, P326, DOI 10.1016/S0750-7658(94)80041-3; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; COOKE RS, 1995, INJURY, V26, P399, DOI 10.1016/0020-1383(95)00064-G; COOKE RS, 1995, INJURY, V26, P395, DOI 10.1016/0020-1383(95)00003-R; Eastridge BJ, 2007, J TRAUMA, V63, P291, DOI 10.1097/TA.0b013e31809ed924; Edelman DA, 2007, SHOCK, V27, P134, DOI 10.1097/01.shk.0000239772.18151.18; Edwards M, 2010, AM SURGEON, V76, P1035; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Finkelstein EA., 2007, J EPIDEMIOL COMMUNIT, V61, P926, DOI DOI 10.1136/JECH.2007.059717; GENTLEMAN D, 1992, INT SURG, V77, P297; Glance LG, 2009, ANN SURG, V249, P1032, DOI 10.1097/SLA.0b013e3181a38f28; GRAHAM DI, 1971, LANCET, V1, P265; Hannan EL, 1999, J TRAUMA, V47, P8, DOI 10.1097/00005373-199907000-00003; Hasler RM, 2012, RESUSCITATION, V83, P476, DOI 10.1016/j.resuscitation.2011.10.018; Hasler RM, 2011, RESUSCITATION, V82, P1202, DOI 10.1016/j.resuscitation.2011.04.021; HILL DA, 1993, AUST NZ J SURG, V63, P604, DOI 10.1111/j.1445-2197.1993.tb00466.x; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MacKenzie EJ, 1983, AM ASS AUTO MED QJ, V5, P25; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Osler TM, 1997, J TRAUMA, V43, P253, DOI 10.1097/00005373-199708000-00008; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; Rutledge R, 1997, J TRAUMA, V42, P477, DOI 10.1097/00005373-199703000-00016; Rutledge R, 1998, J TRAUMA, V44, P41, DOI 10.1097/00005373-199801000-00003; Shutter LA, 2008, ANN EMERG MED, V51, pS37, DOI 10.1016/j.annemergmed.2007.11.013; SILVERSTON P, 1989, BRIT MED J, V298, P711, DOI 10.1136/bmj.298.6675.711; Spaite DW, 2014, ACAD EMERG MED, V21, P818, DOI 10.1111/acem.12411; Spaite DW, 1993, PREHOSP DISASTER MED, V8, pS35; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Wood S.N., 2017, GEN ADDITIVE MODELS, DOI [10.1201/978131537027, DOI 10.1201/9781315370279]; Wood SN, 2013, BIOMETRIKA, V100, P221, DOI 10.1093/biomet/ass048; Wood SN, 2011, J R STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x	57	74	75	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	APR	2017	152	4					360	368		10.1001/jamasurg.2016.4686			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	ES7WP	WOS:000399762400015	27926759	Green Accepted			2022-02-06	
J	Kerr, ZY; Zuckerman, SL; Wasserman, EB; Covassin, T; Djoko, A; Dompier, TP				Kerr, Zachary Y.; Zuckerman, Scott L.; Wasserman, Erin B.; Covassin, Tracey; Djoko, Aristarque; Dompier, Thomas P.			Concussion Symptoms and Return to Play Time in Youth, High School, and College American Football Athletes	JAMA PEDIATRICS			English	Article							SPORTS-RELATED CONCUSSION; STATES HIGH-SCHOOL; EPIDEMIOLOGY; RECOVERY; INJURY; AGE; METAANALYSIS; MANAGEMENT; SEVERITY; OUTCOMES	IMPORTANCE To our knowledge, little research has examined concussion across the youth/adolescent spectrum and even less has examined concussion-related outcomes (ie, symptoms and return to play). OBJECTIVE To examine and compare sport-related concussion outcomes (symptoms and return to play) in youth, high school, and collegiate football athletes. DESIGN, SETTING, AND PARTICIPANTS Athletic trainers attended each practice and game during the 2012 to 2014 seasons and reported injuries. For this descriptive, epidemiological study, data were collected from youth, high school, and collegiate football teams, and the analysis of the data was conducted between July 2015 and September 2015. The Youth Football Surveillance System included more than 3000 youth football athletes aged 5 to 14 years from 118 teams, providing 310 team seasons (ie, 1 team providing 1 season of data). The National Athletic Treatment, Injury, and Outcomes Network Program included 96 secondary school football programs, providing 184 team seasons. The National Collegiate Athletic Association Injury Surveillance Program included 34 college football programs, providing 71 team seasons. MAIN OUTCOMES AND MEASURES We calculated the mean number of symptoms, prevalence of each symptom, and the proportion of patients with concussions that had long return-to-play time (ie, required participation restriction of at least 30 days). Generalized linear models were used to assess differences among competition levels in the mean number of reported symptoms. Logistic regression models estimated the odds of return to play at less than 24 hours and at least 30 days. RESULTS Overall, 1429 sports-related concussions were reported among youth, high school, and college-level football athletes with a mean (SD) of 5.48 (3.06) symptoms. Across all levels, 15.3% resulted return to play at least 30 days after the concussion and 3.1% resulted in return to play less than 24 hours after the concussion. Compared with youth, a higher number of concussion symptoms were reported in high school athletes (beta = 1.39; 95% CI, 0.55-2.24). Compared with college athletes, the odds of return to play at least 30 days after injury were larger in youth athletes (odds ratio, 2.75; 95% CI, 1.10-6.85) and high school athletes (odds ratio, 2.89; 95% CI, 1.61-5.19). The odds of return to play less than 24 hours after injury were larger in youth athletes than high school athletes (odds ratio, 6.23; 95% CI, 1.02-37.98). CONCLUSIONS AND RELEVANCE Differences in concussion-related outcomes existed by level of competition and may be attributable to genetic, biologic, and/or developmental differences or level-specific variations in concussion-related policies and protocols, athlete training management, and athlete disclosure. Given the many organizational, social environmental, and policy-related differences at each level of competition that were not measured in this study, further study is warranted to validate our findings.	[Kerr, Zachary Y.; Djoko, Aristarque; Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent Inc, 401 W Michigan St,Ste 500, Indianapolis, IN 46202 USA; [Zuckerman, Scott L.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN 37212 USA; [Wasserman, Erin B.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA		Kerr, ZY (corresponding author), Datalys Ctr Sports Injury Res & Prevent Inc, 401 W Michigan St,Ste 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org		Wasserman, Erin/0000-0001-5957-5878; Kerr, Zachary/0000-0003-1423-1259	USA Football; National Athletic Trainers' Association Research and Education Foundation; Central Indiana Corporate Partnership Foundation; National Collegiate Athletic Association; BioCrossroads	Funding for this study was provided by USA Football; the National Athletic Trainers' Association Research and Education Foundation; BioCrossroads in partnership with the Central Indiana Corporate Partnership Foundation; and the National Collegiate Athletic Association.	[Anonymous], 2014, STUD ATHL PART 1981; Bailey R, 2006, J SCHOOL HEALTH, V76, P397, DOI 10.1111/j.1746-1561.2006.00132.x; Blakemore SJ, 2010, HUM BRAIN MAPP, V31, P926, DOI 10.1002/hbm.21052; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Dompier TP, 2015, J ATHL TRAINING, V50, P862, DOI 10.4085/1062-6050-50.5.04; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Foley C, 2014, CURR SPORT MED REP, V13, P390, DOI 10.1249/JSR.0000000000000104; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Institute of Medicine, 2013, SPORTS RELATED CONCU; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lee YM, 2013, J NEUROSURG-PEDIATR, V12, P537, DOI 10.3171/2013.7.PEDS12572; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; Murphy J., 2014, NAT ATHL TRAIN ASS 6; National Council of Youth Sports, 2008, REP TRENDS PART ORG; National Federation of State High School Associations, 2014, PART STAT; Pfister T, 2016, BRIT J SPORT MED, V50, P292, DOI 10.1136/bjsports-2015-094978; Piland SG, 2003, J ATHL TRAINING, V38, P104; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Williams RM, 2015, SPORTS MED, V45, P893, DOI 10.1007/s40279-015-0325-8; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634; Zuckerman Scott L, 2012, Surg Neurol Int, V3, P130, DOI 10.4103/2152-7806.102945	35	74	74	0	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	JUL	2016	170	7					647	653		10.1001/jamapediatrics.2016.0073			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	DQ2OK	WOS:000379041800010	27135397	Bronze, Green Published			2022-02-06	
J	Tucker, LB; Fu, AH; McCabe, JT				Tucker, Laura B.; Fu, Amanda H.; McCabe, Joseph T.			Performance of Male and Female C57BL/6J Mice on Motor and Cognitive Tasks Commonly Used in Pre-Clinical Traumatic Brain Injury Research	JOURNAL OF NEUROTRAUMA			English	Article						learning and memory; motor; mouse; sex differences; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SEX-DIFFERENCES; BEHAVIORAL PERFORMANCE; MOUSE STRAINS; OPEN-FIELD; ENVIRONMENTAL ENRICHMENT; FUNCTIONAL RECOVERY; GENDER-DIFFERENCES; ANXIETY DISORDERS; REFERENCE MEMORY	To date, clinical trials have failed to find an effective therapy for victims of traumatic brain injury (TBI) who live with motor, cognitive, and psychiatric complaints. Pre-clinical investigators are now encouraged to include male and female subjects in all translational research, which is of particular interest in the field of neurotrauma given that circulating female hormones (progesterone and estrogen) have been demonstrated to exert neuroprotective effects. To determine whether behavior of male and female C57BL6/J mice is differentially impaired by TBI, male and cycling female mice were injured by controlled cortical impact and tested for several weeks with functional assessments commonly employed in pre-clinical research. We found that cognitive and motor impairments post-TBI, as measured by the Morris water maze (MWM) and rotarod, respectively, were largely equivalent in male and female animals. However, spatial working memory, assessed by the y-maze, was poorer in female mice. Female mice were generally more active, as evidenced by greater distance traveled in the first exposure to the open field, greater distance in the y-maze, and faster swimming speeds in the MWM. Statistical analysis showed that variability in all behavioral data was no greater in cycling female mice than it was in male mice. These data all suggest that with careful selection of tests, procedures, and measurements, both sexes can be included in translational TBI research without concern for effect of hormones on functional impairments or behavioral variability.	[Tucker, Laura B.; Fu, Amanda H.; McCabe, Joseph T.] Uniformed Serv Univ Hlth Sci, Preclin Studies Core, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Tucker, Laura B.; Fu, Amanda H.; McCabe, Joseph T.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA		McCabe, JT (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	Joseph.McCabe@usuhs.edu	McCabe, Joseph T/J-6293-2014	McCabe, Joseph T/0000-0002-1159-7442; Tucker, Laura/0000-0002-5984-6399			ACKERLY DD, 1990, OECOLOGIA, V82, P474, DOI 10.1007/BF00319788; Adeyemo BO, 2014, J ATTEN DISORD, V18, P576, DOI 10.1177/1087054714543371; Alstott J, 2009, BEHAV BRAIN RES, V196, P214, DOI 10.1016/j.bbr.2008.09.001; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; An XL, 2011, EXP ANIM TOKYO, V60, P111, DOI 10.1538/expanim.60.111; ARCHER J, 1975, BEHAV BIOL, V14, P451, DOI 10.1016/S0091-6773(75)90636-7; Avgustinovich D F, 2007, Neurosci Behav Physiol, V37, P731, DOI 10.1007/s11055-007-0075-7; Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002; Bekker MHJ, 2007, GENDER MED, V4, pS178, DOI 10.1016/S1550-8579(07)80057-X; BERGERSWEENEY J, 1995, BEHAV NEUROSCI, V109, P859, DOI 10.1037/0735-7044.109.5.859; Bettis T, 2012, BEHAV BRAIN RES, V233, P288, DOI 10.1016/j.bbr.2012.04.028; Bhatnagar S, 2004, BEHAV BRAIN RES, V153, P527, DOI 10.1016/j.bbr.2004.01.018; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bolivar VJ, 2000, BEHAV GENET, V30, P285, DOI 10.1023/A:1026545316455; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a; Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517; Crabbe JC, 1999, SCIENCE, V284, P1670, DOI 10.1126/science.284.5420.1670; Crawley JN, 1999, BRAIN RES, V835, P18, DOI 10.1016/S0006-8993(98)01258-X; Dang MT, 2005, EXP NEUROL, V196, P452, DOI 10.1016/j.expneurol.2005.08.025; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Davis MJ, 2012, BEHAV BRAIN RES, V229, P21, DOI 10.1016/j.bbr.2011.12.037; Driscoll I, 2005, HORM BEHAV, V47, P326, DOI 10.1016/j.yhbeh.2004.11.013; Ennaceur A, 2014, PHYSIOL BEHAV, V135, P55, DOI 10.1016/j.physbeh.2014.05.032; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.3.CO;2-L; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Frick KM, 2003, BEHAV NEUROSCI, V117, P1283, DOI 10.1037/0735-7044.117.6.1283; Frick KM, 2000, NEUROSCIENCE, V95, P293; Gresack JE, 2003, BRAIN RES, V982, P98, DOI 10.1016/S0006-8993(03)03000-2; Guzman CB, 2009, BEHAV BRAIN RES, V199, P355, DOI 10.1016/j.bbr.2009.01.005; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hughes RN, 2004, NEUROSCI BIOBEHAV R, V28, P497, DOI 10.1016/j.neubiorev.2004.06.006; Hughes RN, 2007, BEHAV PHARMACOL, V18, P583, DOI 10.1097/FBP.0b013e3282eff0e8; Jonasson Z, 2005, NEUROSCI BIOBEHAV R, V28, P811, DOI 10.1016/j.neubiorev.2004.10.006; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Karl T, 2008, EUR J NEUROSCI, V28, P173, DOI 10.1111/j.1460-9568.2008.06306.x; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; King NS, 2014, BRAIN INJURY, V28, P1639, DOI 10.3109/02699052.2014.954271; Kokras N, 2014, BRIT J PHARMACOL, V171, P4595, DOI 10.1111/bph.12710; Kundakovic Marija, 2013, Front Psychiatry, V4, P78, DOI 10.3389/fpsyt.2013.00078; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Maghool F, 2013, BRAIN RES, V1497, P61, DOI 10.1016/j.brainres.2012.12.014; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; Mallya S, 2015, J NEUROTRAUM, V32, P411, DOI 10.1089/neu.2014.3504; Mannix R, 2014, J NEUROSURG, V121, P1337, DOI 10.3171/2014.8.JNS14715; McCullough LD, 2014, BIOL SEX DIFFER, V5, DOI 10.1186/s13293-014-0015-5; McIntosh TK, 1996, LAB INVEST, V74, P315; Meziane H, 2007, GENES BRAIN BEHAV, V6, P192, DOI 10.1111/j.1601-183X.2006.00249.x; Mogil JS, 2005, PAIN, V117, P1, DOI 10.1016/j.pain.2005.06.020; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; Morgan MA, 2002, BEHAV BRAIN RES, V132, P85, DOI 10.1016/S0166-4328(01)00398-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nicolson TJ, 2010, TRENDS PHARMACOL SCI, V31, P108, DOI 10.1016/j.tips.2009.12.001; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; O'Leary TP, 2013, BEHAV GENET, V43, P34, DOI 10.1007/s10519-012-9572-8; O'Leary TP, 2012, J NEUROSCI METH, V203, P315, DOI 10.1016/j.jneumeth.2011.09.027; O'Leary TP, 2011, BEHAV BRAIN RES, V216, P531, DOI 10.1016/j.bbr.2010.08.030; Prendergast BJ, 2014, NEUROSCI BIOBEHAV R, V40, P1, DOI 10.1016/j.neubiorev.2014.01.001; Prut L, 2003, EUR J PHARMACOL, V463, P3, DOI 10.1016/S0014-2999(03)01272-X; Ramsey LCB, 2010, NEUROSCI LETT, V483, P148, DOI 10.1016/j.neulet.2010.07.082; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Rial D, 2009, BRAIN RES BULL, V79, P177, DOI 10.1016/j.brainresbull.2009.02.003; Rizk A, 2005, BRAIN RES, V1034, P132, DOI 10.1016/j.brainres.2004.12.002; Rogers E, 2006, J HEAD TRAUMA REHAB, V21, P279, DOI 10.1097/00001199-200605000-00008; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sandberg K, 2015, FASEB J, V29, P1646, DOI 10.1096/fj.14-269548; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sorge RE, 2014, NAT METHODS, V11, P629, DOI [10.1038/NMETH.2935, 10.1038/nmeth.2935]; Stein DG, 2007, PROG BRAIN RES, V161, P339, DOI 10.1016/S0079-6123(06)61024-8; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stevens LM, 2015, BEHAV BRAIN RES, V278, P496, DOI 10.1016/j.bbr.2014.10.033; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Typlt M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081270; Van Swearingen AED, 2013, PSYCHOPHARMACOLOGY, V225, P707, DOI 10.1007/s00213-012-2860-4; Viggiano D, 2008, BEHAV BRAIN RES, V194, P1, DOI 10.1016/j.bbr.2008.06.033; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Voikar V, 2001, PHYSIOL BEHAV, V72, P271, DOI 10.1016/S0031-9384(00)00405-4; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Weil ZM, 2006, BRAIN RES BULL, V68, P425, DOI 10.1016/j.brainresbull.2005.09.016; Whitley HP, 2009, AM FAM PHYSICIAN, V80, P1254; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yu FS, 2012, J NEUROTRAUM, V29, P2342, DOI 10.1089/neu.2012.2449; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	105	74	74	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 1	2016	33	9					880	894		10.1089/neu.2015.3977			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DK7SA	WOS:000375124800010	25951234	Green Published			2022-02-06	
J	Stein, MB; Kessler, RC; Heeringa, SG; Jain, S; Campbell-Sills, L; Colpe, LJ; Fullerton, CS; Nock, MK; Sampson, NA; Schoenbaum, M; Sun, XY; Thomas, ML; Ursano, RJ				Stein, Murray B.; Kessler, Ronald C.; Heeringa, Steven G.; Jain, Sonia; Campbell-Sills, Laura; Colpe, Lisa J.; Fullerton, Carol S.; Nock, Matthew K.; Sampson, Nancy A.; Schoenbaum, Michael; Sun, Xiaoying; Thomas, Michael L.; Ursano, Robert J.		Army STARRS Collaborators	Prospective Longitudinal Evaluation of the Effect of Deployment-Acquired Traumatic Brain Injury on Posttraumatic Stress and Related Disorders: Results From the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS)	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							MILITARY PERSONNEL; CLINICAL PRESENTATION; MENTAL-HEALTH; SUICIDE RISK; SYMPTOMS; PTSD; DEPRESSION; ASSOCIATION; IRAQ; TBI	Objective: Traumatic brain injury (TBI) is increasingly recognized as a risk factor for deleterious mental health and functional outcomes. The purpose of this study was to examine the strength and specificity of the association between deployment-acquired TBI and subsequent posttraumatic stress and related disorders among U.S. Army personnel. Method: A prospective, longitudinal survey of soldiers in three Brigade CombatTeams was conducted 1-2 months prior to an average 10-month deployment to Afghanistan (T0), upon redeployment to the United States (T1), approximately 3 months later (T2), and approximately 9 months later (T3). Outcomes of interest were 30-day prevalence. postdeployment of posttraumatic stress disorder (PTSD), major depressive episode, generalized anxiety disorder, and suicidality, as well as presence and severity of postdeployment PTSD symptoms. Results: Complete information was available for 4,645 soldiers. Approximately one in five soldiers reported exposure to mild (18.0%) or more-than-mild (1.2%) TBI(s) during the index deployment. Even after adjusting for other risk factors (e g., predeployment mental health status, severity of deployment stress, prior TBI history), deployment-acquired TBI was associated with elevated adjusted odds of PTSD and generalized anxiety disorder at T2 and T3 and of major depressive episode at T2. Suicidality risk at T2 appeared similarly elevated, but this association did not reach statistical significance. Conclusions: The findings highlight the importance of surveillance efforts to identify soldiers who have sustained TBIs and are therefore at risk for an array of postdeployment adverse mental health outcomes, including but not limited to PTSD. The mechanism(s) accounting for these associations need to be elucidated to inform development of effective preventive and early intervention programs.	[Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA; VA San Diego Healthcare Syst, San Diego, CA USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Univ Michigan, Inst Social Res, Ann Arbor, MI USA; NIMH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Psychiat, Ctr Study Traumat Stress, Bethesda, MD 20814 USA; Harvard Univ, Dept Psychol, Cambridge, MA USA		Stein, MB (corresponding author), Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.	mstein@ucsd.edu	Ursano, Robert/ABE-6533-2020; Nock, Matthew/AAE-8330-2019	Ursano, Robert/0000-0002-1861-9173	Department of the Army [U01MH087981]; U S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH); NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U01MH087981] Funding Source: NIH RePORTER	Army STARRS was sponsored by the Department of the Army and funded under cooperative agreement number U01MH087981 with the U S. Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH).	Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Bryant RA, 2015, BRIT J PSYCHIAT, V206, P417, DOI 10.1192/bjp.bp.114.145516; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Chase RP, 2015, J HEAD TRAUMA REHAB, V30, pE57, DOI 10.1097/HTR.0000000000000061; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Goodkind M, 2015, JAMA PSYCHIAT, V72, P305, DOI 10.1001/jamapsychiatry.2014.2206; Hart T, 2014, J NEUROTRAUM, V31, P610, DOI 10.1089/neu.2013.3041; Heeringa S., 2010, APPL SURVEY DATA ANA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2014, JAMA-J AM MED ASSOC, V312, P1685, DOI 10.1001/jama.2014.6670; Jackson JC, 2014, LANCET RESP MED, V2, P369, DOI 10.1016/S2213-2600(14)70051-7; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Kessler RC, 2013, INT J METH PSYCH RES, V22, P303, DOI 10.1002/mpr.1398; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Mallya S, 2015, J NEUROTRAUM, V32, P411, DOI 10.1089/neu.2014.3504; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Miller MW, 2014, MOL PSYCHIATR, V19, P1156, DOI 10.1038/mp.2014.111; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Peskind ER, 2013, J CLIN PSYCHIAT, V74, P180, DOI 10.4088/JCP.12011co1c; Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704; Ramsawh HJ, 2014, J AFFECT DISORDERS, V161, P116, DOI 10.1016/j.jad.2014.03.016; Roitman P, 2013, J TRAUMA STRESS, V26, P727, DOI 10.1002/jts.21862; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tanev KS, 2014, BRAIN INJURY, V28, P261, DOI 10.3109/02699052.2013.873821; Ursano RJ, 2014, PSYCHIATRY, V77, P107, DOI 10.1521/psyc.2014.77.2.107; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	40	74	74	1	22	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	NOV	2015	172	11					1101	1111		10.1176/appi.ajp.2015.14121572			11	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	CV0CJ	WOS:000363914700013	26337036	Green Accepted, Bronze, Green Submitted			2022-02-06	
J	Galetta, KM; Morganroth, J; Moehringer, N; Mueller, B; Hasanaj, L; Webb, N; Civitano, C; Cardone, DA; Silverio, A; Galetta, SL; Balcer, LJ				Galetta, Kristin M.; Morganroth, Jennifer; Moehringer, Nicholas; Mueller, Bridget; Hasanaj, Lisena; Webb, Nikki; Civitano, Courtney; Cardone, Dennis A.; Silverio, Arlene; Galetta, Steven L.; Balcer, Laura J.			Adding Vision to Concussion Testing: A Prospective Study of Sideline Testing in Youth and Collegiate Athletes	JOURNAL OF NEURO-OPHTHALMOLOGY			English	Article							VISUAL SCREENING TOOL; KING-DEVICK TEST; STANDARDIZED ASSESSMENT; RECURRENT CONCUSSION; EYE-MOVEMENTS; FOOTBALL; DEPRESSION; KNOWLEDGE; SPORT	Background:Sports-related concussion commonly affects the visual pathways. Current sideline protocols test cognition and balance but do not include assessments of visual performance. We investigated how adding a vision-based test of rapid number naming could increase our ability to identify concussed athletes on the sideline at youth and collegiate levels.Methods:Participants in this prospective study included members of a youth ice hockey and lacrosse league and collegiate athletes from New York University and Long Island University. Athletes underwent preseason baseline assessments using: 1) the King-Devick (K-D) test, a <2-minute visual performance measure of rapid number naming, 2) the Standardized Assessment of Concussion (SAC), a test of cognition, and 3) a timed tandem gait test of balance. The SAC and timed tandem gait are components of the currently used Sport Concussion Assessment Tool, 3rd Edition (SCAT3 and Child-SCAT3). In the event of a concussion during the athletic season, injured athletes were retested on the sideline/rink-side. Nonconcussed athletes were also assessed as control participants under the same testing conditions.Results:Among 243 youth (mean age 11 3 years, range 5-17) and 89 collegiate athletes (age 20 +/- 1 years, range 18-23), baseline time scores for the K-D test were lower (better) with increasing participant age (P < 0.001, linear regression models). Among 12 athletes who sustained concussions during their athletic season, K-D scores worsened from baseline by an average of 5.2 seconds; improvement by 6.4 seconds was noted for the nonconcussed controls (n = 14). The vision-based K-D test showed the greatest capacity to distinguish concussed vs control athletes based on changes from preseason baseline to postinjury (receiver operating characteristic [ROC] curve areas from logistic regression models, accounting for age = 0.92 for K-D, 0.87 for timed tandem gait, and 0.68 for SAC; P = 0.0004 for comparison of ROC curve areas).Conclusions:Adding a vision-based performance measure to cognitive and balance testing enhances the detection capabilities of current sideline concussion assessment. This observation in patients with mild traumatic brain injury reflects the common involvement and widespread distribution of brain pathways dedicated to vision.	[Morganroth, Jennifer; Moehringer, Nicholas; Mueller, Bridget; Hasanaj, Lisena; Galetta, Steven L.; Balcer, Laura J.] NYU, Sch Med, Dept Neurol, New York, NY 10016 USA; [Balcer, Laura J.] NYU, Sch Med, Dept Populat Hlth, New York, NY 10016 USA; [Galetta, Steven L.; Balcer, Laura J.] NYU, Sch Med, Dept Ophthalmol, New York, NY 10016 USA; [Cardone, Dennis A.] NYU, Sch Med, Dept Sports Med Orthopaed Surg, New York, NY 10016 USA; [Webb, Nikki] NYU, Dept Athlet, New York, NY 10016 USA; [Civitano, Courtney] Long Isl Univ, Dept Athlet, Brooklyn, NY USA; [Silverio, Arlene] Hofstra North Shore LIJ Sch Med, Cohen Childrens Med Ctr New York, Dept Emergency Med, Philadelphia, PA USA; [Silverio, Arlene] Hofstra North Shore LIJ Sch Med, Cohen Childrens Med Ctr New York, Dept Pediat, Philadelphia, PA USA; [Galetta, Kristin M.; Galetta, Steven L.; Balcer, Laura J.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Balcer, Laura J.] Univ Penn, Dept Epidemiol, Philadelphia, PA 19104 USA		Balcer, LJ (corresponding author), NYU, Sch Med, Dept Neurol, 240 East 38th St,20th Floor, New York, NY 10016 USA.	laura.balcer@nyumc.org	Meijer, Anna/K-5118-2016				DeSouza JFX, 2003, J NEUROPHYSIOL, V89, P1016, DOI 10.1152/jn.00562.2002; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Fukushima K, 2013, FRONT SYST NEUROSCI, V7, DOI 10.3389/fnsys.2013.00004; Furman GR, 2013, AM J SPORT MED, V41, P1404, DOI 10.1177/0363546513484446; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Jeon ST, 2010, J EXP CHILD PSYCHOL, V107, P423, DOI 10.1016/j.jecp.2010.05.009; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Leong DF, 2014, J SPORT MED PHYS FIT, V54, P70; Luna B, 2008, BRAIN COGNITION, V68, P293, DOI 10.1016/j.bandc.2008.08.019; Marinides Z, NEUROL CLIN IN PRESS; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Munce TA, 2014, J CHILD NEUROL, V29, P1601, DOI 10.1177/0883073813509887; Pierrot-Deseilligny C, 2004, CURR OPIN NEUROL, V17, P17, DOI 10.1097/00019052-200402000-00005; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schneiders AG, 2012, SCAND J MED SCI SPOR, V22, P85, DOI 10.1111/j.1600-0838.2010.01141.x; Tjarks BJ, 2013, J NEUROL SCI, V334, P148, DOI 10.1016/j.jns.2013.08.015; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5	31	74	74	0	35	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1070-8022	1536-5166		J NEURO-OPHTHALMOL	J. Neuro-Ophthal.	SEP	2015	35	3					235	241		10.1097/WNO.0000000000000226			7	Clinical Neurology; Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Ophthalmology	CQ4DC	WOS:000360553500002	25742059				2022-02-06	
J	Mac Donald, CL; Johnson, AM; Wierzechowski, L; Kassner, E; Stewart, T; Nelson, EC; Werner, NJ; Zonies, D; Oh, J; Fang, R; Brody, DL				Mac Donald, Christine L.; Johnson, Ann M.; Wierzechowski, Linda; Kassner, Elizabeth; Stewart, Theresa; Nelson, Elliot C.; Werner, Nicole J.; Zonies, David; Oh, John; Fang, Raymond; Brody, David L.			Prospectively Assessed Clinical Outcomes in Concussive Blast vs Nonblast Traumatic Brain Injury Among Evacuated US Military Personnel	JAMA NEUROLOGY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSIVE SYMPTOMS; NEUROBEHAVIORAL RATING-SCALE; ADMINISTERED PTSD SCALE; HEAD-INJURY; MENTAL-HEALTH; NOS-TBI; STRUCTURED INTERVIEWS; OEF/OIF VETERANS; SERVICE MEMBERS	IMPORTANCE Blast injury has been identified as the signature injury in the conflicts in Iraq and Afghanistan. However it remains to be determined whether fundamental differences may exist between blast-related traumatic brain injury (TBI) and TBI due to other mechanisms. OBJECTIVES To determine similarities and differences between clinical outcomes in US military personnel with blast-related vs. non-blast-related concussive TBI and to identify the specific domains of impairment that best correlate with overall disability. DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study involving active duty US Military personnel evacuated from Iraq or Afghanistan to Landstuhl Regional Medical Center, in Landstuhl, Germany. Four groups of participants were enrolled from 2010 to 2013: (1) blast plus impact complex TBI (n = 53), (2) non-blast related TBI with injury due to other mechanisms (n = 29), (3) blast-exposed controls evacuated for other medical reasons (n = 27) (4) non-blastexposed controls evacuated for other medical reasons (n = 69). All patients with TBI met Department of Defense criteria for concussive (mild) TBI. The study participants were evaluated 6-12 months after injury at Washington University in St Louis. In total, 255 subjects were enrolled in the study, and 183 participated in follow-up evaluations, 5 of whom were disqualified. MAIN OUTCOMES AND MEASURES In-person clinical examinations included evaluation for overall disability, a standardized neurological exam, headache questionnaires, neuropsychological test battery, combat exposure and alcohol use surveys, and structured interview evaluations for post-traumatic stress disorder (PTSD) and depression. RESULTS Global outcomes, headache severity, neuropsychological performance, and surprisingly even PTSD severity and depression were indistinguishable between the two TBI groups, independent of mechanism of injury. Both TBI groups had higher rates of moderate to severe overall disability than the respective control groups: 41/53 (77%) of blast plus impact TBI and 23/29 (79%) of nonblast TBI vs. 16/27 (59%) of blast-exposed controls and 28/69 (41%) of non-blast-exposed controls. In addition, blast-exposed controls had worse headaches and more severe PTSD than non-blast-exposed controls. Self-reported combat exposure intensity was higher in the blast plus impact TBI group than in nonblast TBI group and was higher in blast-exposed controls than in non-blast-exposed controls. However, combat exposure intensity did not correlate with PTSD severity in the TBI groups, but a modest positive correlation was observed in the controls. Overall outcomes were most strongly correlated with depression, headache severity, and number of abnormalities on neuropsychological testing. However a substantial fraction of the variance in overall outcome was not explained by any of the assessed measures. CONCLUSIONS AND RELEVANCE One potential interpretation of these results is that TBI itself, independent of injury mechanism and combat exposure intensity, is a primary driver of adverse outcomes. Many other important factors may be as yet unmeasured, and adverse outcomes following war-time injuries are difficult to fully explain.	[Mac Donald, Christine L.; Johnson, Ann M.; Werner, Nicole J.; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Mac Donald, Christine L.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Wierzechowski, Linda; Kassner, Elizabeth; Stewart, Theresa; Zonies, David; Oh, John; Fang, Raymond] Landstuhl Reg Med Ctr, Landstuhl, Germany; [Nelson, Elliot C.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; [Oh, John] Walter Reed Natl Mil Med Ctr, Dept Trauma Crit Care & Acute Care Surg, Baltimore, MD USA; [Fang, Raymond] Univ Maryland, R Adams Cowley Shock Trauma Ctr, US Air Force Ctr Sustainment Trauma & Readiness S, Baltimore, MD 21201 USA		Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave,POB 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Oh, John/AAS-9557-2020; Zonies, David/B-6497-2011	Oh, John/0000-0001-9010-0627; 	Congressionally Directed Medical Research ProgramUnited States Department of Defense [PT090444]	The study was funded by grant PT090444 from the Congressionally Directed Medical Research Program (Dr Brody, principal investigator).	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Cooper DB, 2012, MIL MED, V177, P1157, DOI 10.7205/MILMED-D-12-00098; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Defense and Veterans Brain Injury Center, 2013, DOD NUMB TRAUM BRAIN; Dempsey Kenneth E, 2009, J Trauma Nurs, V16, P6, DOI 10.1097/01.JTN.0000348063.41099.a7; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Lannsjo M, 2013, J REHABIL MED, V45, P721, DOI 10.2340/16501977-1169; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; Maguen S, 2012, J TRAUMA STRESS, V25, P3, DOI 10.1002/jts.21669; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; McCauley SR, 2010, J NEUROTRAUM, V27, P991, DOI 10.1089/neu.2009.1195; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Mora C.A., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI [10.1037/1040-3590.1.1.53, DOI 10.1037/1040-3590.1.1.53]; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Myers KM, 2007, MOL PSYCHIATR, V12, P120, DOI 10.1038/sj.mp.4001939; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Stewart WF, 1999, NEUROLOGY, V53, P988, DOI 10.1212/WNL.53.5.988; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Taniellian T., 2008, INVISIBLE WOUNDS WAR; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wilde EA, 2010, J NEUROTRAUM, V27, P975, DOI 10.1089/neu.2009.1193; Wilde EA, 2010, J NEUROTRAUM, V27, P983, DOI 10.1089/neu.2009.1194; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	54	74	75	1	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	AUG	2014	71	8					994	1002		10.1001/jamaneurol.2014.1114			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AN3IW	WOS:000340481800009	24934200	Bronze			2022-02-06	
J	Rowson, S; Duma, SM; Greenwald, RM; Beckwith, JG; Chu, JJ; Guskiewicz, KM; Mihalik, JP; Crisco, JJ; Wilcox, BJ; McAllister, TW; Maerlender, AC; Broglio, SP; Schnebel, B; Anderson, S; Brolinson, PG				Rowson, Steven; Duma, Stefan M.; Greenwald, Richard M.; Beckwith, Jonathan G.; Chu, Jeffrey J.; Guskiewicz, Kevin M.; Mihalik, Jason P.; Crisco, Joseph J.; Wilcox, Bethany J.; McAllister, Thomas W.; Maerlender, Arthur C.; Broglio, Steven P.; Schnebel, Brock; Anderson, Scott; Brolinson, P. Gunnar			Can helmet design reduce the risk of concussion in football?	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; sports; concussion incidence; football; exposure; prevention	CHRONIC TRAUMATIC ENCEPHALOPATHY; LEAGUE PLAYER; HEAD; IMPACT; INJURY	Of all sports, football accounts for the highest incidence of concussion in the US due to the large number of athletes participating and the nature of the sport. While there is general agreement that concussion incidence can be reduced through rule changes and teaching proper tackling technique, there remains debate as to whether helmet design may also reduce the incidence of concussion. A retrospective analysis was performed of head impact data collected from 1833 collegiate football players who were instrumented with helmet-mounted accelerometer arrays for games and practices. Data were collected between 2005 and 2010 from 8 collegiate football teams: Virginia Tech, University of North Carolina, University of Oklahoma, Dartmouth College, Brown University, University of Minnesota, Indiana University, and University of Illinois. Concussion rates were compared between players wearing Riddell VSR4 and Riddell Revolution helmets while controlling for the head impact exposure of each player. A total of 1,281,444 head impacts were recorded, from which 64 concussions were diagnosed. The relative risk of sustaining a concussion in a Revolution helmet compared with a VSR4 helmet was 46.1% (95% CI 28.1%-75.8%). When controlling for each player's exposure to head impact, a significant difference was found between concussion rates for players in VSR4 and Revolution helmets (chi(2) = 4.68, p = 0.0305). This study illustrates that differences in the ability to reduce concussion risk exist between helmet models in football. Although helmet design may never prevent all concussions from occurring in football, evidence illustrates that it can reduce the incidence of this injury.	[Rowson, Steven; Duma, Stefan M.] Virginia Tech Wake Forest Univ, Sch Biomed Engn & Sci, Blacksburg, VA USA; [Greenwald, Richard M.; Beckwith, Jonathan G.; Chu, Jeffrey J.] Simbex, Lebanon, NH USA; [Guskiewicz, Kevin M.; Mihalik, Jason P.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Crisco, Joseph J.; Wilcox, Bethany J.] Brown Univ, Alpert Med Sch, Dept Orthopaed, Providence, RI 02912 USA; [Crisco, Joseph J.; Wilcox, Bethany J.] Rhode Isl Hosp, Providence, RI USA; [McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Maerlender, Arthur C.] Geisel Sch Med Dartmouth, Pediat Neuropsychol Serv, Dartmouth, NS, Canada; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA; [Schnebel, Brock] Univ Oklahoma, Dept Orthoped, Norman, OK 73019 USA; [Schnebel, Brock] Univ Oklahoma, Dept Athlet, Norman, OK 73019 USA; [Anderson, Scott] Univ Oklahoma, Dept Intercollegiate Athlet, Norman, OK 73019 USA; [Brolinson, P. Gunnar] Edward Via Coll Osteopath Med, Blacksburg, VA USA		Rowson, S (corresponding author), 440 Kelly Hall,325 Stanger St, Blacksburg, VA 24061 USA.	srowson@vt.edu	Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596; Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130; Crisco, Joseph/0000-0002-8786-0905	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD048638, R01NS055020, R44HD40473]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254, 5R49CE000196]; National Operating Committee on Standards for Athletic Equipment (NOCSAE) [07-04, 14-19]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R01CE001254, R49CE000196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This work was supported in part by grant nos. R01HD048638 and R01NS055020 from the NIH, grant nos. R01CE001254 and 5R49CE000196 from the Centers for Disease Control and Prevention, and grant nos. 07-04 and 14-19 from the National Operating Committee on Standards for Athletic Equipment (NOCSAE). The HIT System technology was developed in part under NIH grant no. R44HD40473. Joseph J. Crisco, Richard M. Greenwald, Jeffrey J. Chu, Jonathan G. Beckwith, and Simbex have a financial interest in the instruments (HIT System, Sideline Response System [Riddell]) that were used to collect the biomechanical data reported in this study. The remaining authors have no financial interests associated with this study.	Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P2512, DOI 10.1007/s10439-012-0660-y; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4	17	74	74	0	76	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2014	120	4					919	922		10.3171/2014.1.JNS13916			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AD7IZ	WOS:000333438800017	24484225	Green Published, Bronze			2022-02-06	
J	Farzan, F; Barr, MS; Hoppenbrouwers, SS; Fitzgerald, PB; Chen, R; Pascual-Leone, A; Daskalakis, ZJ				Farzan, Faranak; Barr, Mera S.; Hoppenbrouwers, Sylco S.; Fitzgerald, Paul B.; Chen, Robert; Pascual-Leone, Alvaro; Daskalakis, Zafiris J.			The EEG correlates of the TMS-induced EMG silent period in humans	NEUROIMAGE			English	Article						Cortical inhibition; Motor cortex; Transcranial magnetic stimulation; Electroencephalography; Electromyography; GABA; Cortical oscillations	TRANSCRANIAL MAGNETIC STIMULATION; PRIMARY MOTOR CORTEX; DORSOLATERAL PREFRONTAL CORTEX; INTERVAL CORTICAL INHIBITION; MASS UNIVARIATE ANALYSIS; INTRACORTICAL INHIBITION; PARKINSONS-DISEASE; BRAIN-STIMULATION; SPORTS CONCUSSION; EXCITABILITY	Application of magnetic or electrical stimulation to the motor cortex can result in a period of electromyography (EMG) silence in a tonically active peripheral muscle. This period of EMG silence is referred to as the silent period (SP). The duration of SP shows intersubject variability and reflects the integrity of cortical and corticospinal pathways. A non-invasive technique for assessing the duration of SP is the combination of Transcranial Magnetic Stimulation (TMS) with EMG. Utilizing TMS-EMG, several studies have reported on the shortening or lengthening of SP in neuropsychiatric disorders such as schizophrenia, bipolar disorder, depression, obsessive compulsive disorder, epilepsy, Parkinson's disease, and stroke. However, cortical, corticospinal and peripheral components are difficult to disentangle from EMG alone. Here, we use the multimodal neuroimaging technique of TMS-EMG combined with concurrent electroencephalography (EEG) recording to further examine the cortical origin of SP and the cortical oscillatory activity that underlies SP genesis. We demonstrate that the duration of SP is related to the temporal characteristics of the cortical reactivity and the power of delta to alpha oscillations in both local and remote areas ipsilateral and contalateral to the stimulation site, and beta oscillations locally. We illustrate that, compared to EMG, the EEG indices of the SP provide additional information about the brain dynamics and propose that the EEG measures of SP may be used in future clinical and research investigations to more precisely delineate the mechanisms underlying inhibitory impairments. (C) 2013 Elsevier Inc. All rights reserved.	[Farzan, Faranak; Pascual-Leone, Alvaro] Harvard Univ, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Dept Neurol,Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Barr, Mera S.; Daskalakis, Zafiris J.] Univ Toronto, Temerty Ctr Therapeut Brain Intervent, Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Hoppenbrouwers, Sylco S.] Univ Utrecht, Dept Expt Psychol, Helmholtz Inst, NL-3508 TC Utrecht, Netherlands; [Fitzgerald, Paul B.] The Alfred, Monash Alfred Psychiat Res Ctr, Clayton, Vic, Australia; [Fitzgerald, Paul B.] Monash Univ, Cent Clin Sch, Clayton, Vic 3800, Australia; [Chen, Robert] Univ Toronto, Div Neurol, Toronto Western Res Inst, Toronto, ON, Canada; [Pascual-Leone, Alvaro] Univ Autonoma Barcelona, Inst Univ Neurorehabil Guttmann, Badalona, Spain		Farzan, F (corresponding author), Harvard Univ, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Kirstein Bldg KS 423, Boston, MA 02215 USA.	ffarzan@bidmc.harvard.edu; Jeff.Daskalakis@camh.ca	Chen, Robert/B-3899-2009; Fitzgerald, Paul B/A-1225-2008; Pascual-Leone, Alvaro/AAC-5101-2019	Chen, Robert/0000-0002-8371-8629; Fitzgerald, Paul B/0000-0003-4217-8096; Pascual-Leone, Alvaro/0000-0001-8975-0382; Barr, Mera/0000-0002-1103-1887; Farzan, Faranak/0000-0001-9249-2994	Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [201102MFE-246635-181538]; Harvard-Thomdike Clinical Research Center at Beth Israel Deaconess Medical Center integrated in the Harvard Clinical and Translational Science Center [M01-RR01066, UL1 RR025758]; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025758, M01RR001066] Funding Source: NIH RePORTER	FF was supported by the Canadian Institute of Health Research (CIHR) fellowship award (201102MFE-246635-181538). This study was supported in part by the Harvard-Thomdike Clinical Research Center at Beth Israel Deaconess Medical Center integrated in the Harvard Clinical and Translational Science Center (grants M01-RR01066 and UL1 RR025758 from the National Center for Research Resources, National Institutes of Health). PBF is supported by an NHMRC Practitioner Fellowship. This work was also supported in part by the Ontario Mental Health Foundation (OMHF), the Brain and Behavior Research Foundation and the Temerty and Grant Family through the Centre for Addiction and Mental Health (CAMH) Foundation.	Adrian ED, 1939, J PHYSIOL-LONDON, V97, P153, DOI 10.1113/jphysiol.1939.sp003798; Alagona G, 2001, NEUROSCI LETT, V314, P57, DOI 10.1016/S0304-3940(01)02288-1; Bajbouj M, 2006, BIOL PSYCHIAT, V59, P395, DOI 10.1016/j.biopsych.2005.07.036; Bajbouj MK, 2006, J PSYCHIAT RES, V40, P322, DOI 10.1016/j.jpsychires.2005.07.002; BARKER AT, 1985, LANCET, V1, P1106; Barnow S, 2009, BIOL PSYCHIAT, V65, P313, DOI 10.1016/j.biopsych.2008.08.016; Battaglia F, 2006, CLIN NEUROPHYSIOL, V117, P1009, DOI 10.1016/j.clinph.2006.01.008; Bender S, 2005, ANN NEUROL, V58, P58, DOI 10.1002/ana.20521; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benwell NM, 2007, EXP BRAIN RES, V179, P255, DOI 10.1007/s00221-006-0790-2; Bonnard M, 2009, EUR J NEUROSCI, V30, P913, DOI 10.1111/j.1460-9568.2009.06864.x; BRAUNE HJ, 1995, STROKE, V26, P550, DOI 10.1161/01.STR.26.4.550; Brignani D, 2008, HUM BRAIN MAPP, V29, P603, DOI 10.1002/hbm.20423; Bruckmann S, 2012, BRAIN, V135, P2215, DOI 10.1093/brain/aws071; Chen R, 1999, EXP BRAIN RES, V128, P539, DOI 10.1007/s002210050878; Cincotta M, 2000, CLIN NEUROPHYSIOL, V111, P1340, DOI 10.1016/S1388-2457(00)00330-8; Cincotta M, 2002, CLIN NEUROPHYSIOL, V113, P597, DOI 10.1016/S1388-2457(02)00021-4; Classen J, 1997, BRAIN, V120, P605, DOI 10.1093/brain/120.4.605; Daskalakis ZJ, 2008, NEUROPSYCHOPHARMACOL, V33, P2860, DOI 10.1038/npp.2008.22; Daskalakis ZJ, 2008, J PSYCHOPHARMACOL, V22, P203, DOI 10.1177/0269881107084002; Daskalakis ZJ, 2002, ARCH GEN PSYCHIAT, V59, P347, DOI 10.1001/archpsyc.59.4.347; DAY BL, 1989, J PHYSIOL-LONDON, V412, P449, DOI 10.1113/jphysiol.1989.sp017626; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Deisz RA, 1999, NEUROPHARMACOLOGY, V38, P1755, DOI 10.1016/S0028-3908(99)00136-7; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Di Lazzaro V, 2002, CLIN NEUROPHYSIOL, V113, P1673, DOI 10.1016/S1388-2457(02)00264-X; Engel AK, 2010, CURR OPIN NEUROBIOL, V20, P156, DOI 10.1016/j.conb.2010.02.015; Farzan F., 2011, EMG METHODS EVALUATI; Farzan F, 2010, J NEUROPHYSIOL, V104, P1339, DOI 10.1152/jn.00279.2010; Farzan F, 2010, BRAIN, V133, P1505, DOI 10.1093/brain/awq046; Farzan F, 2009, NEUROPSYCHOPHARMACOL, V34, P1543, DOI 10.1038/npp.2008.211; Fecteau S, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-21; Ferreri F, 2011, NEUROIMAGE, V54, P90, DOI 10.1016/j.neuroimage.2010.07.056; Fisher BE, 2008, ARCH PHYS MED REHAB, V89, P1221, DOI 10.1016/j.apmr.2008.01.013; Fitzgerald PB, 2004, SCHIZOPHR RES, V71, P17, DOI 10.1016/j.schres.2004.01.018; Fitzgerald PB, 2002, PSYCHIAT RES-NEUROIM, V114, P11, DOI 10.1016/S0925-4927(02)00002-1; Fries P, 2007, TRENDS NEUROSCI, V30, P309, DOI 10.1016/j.tins.2007.05.005; FUHR P, 1991, ELECTROEN CLIN NEURO, V81, P257, DOI 10.1016/0168-5597(91)90011-L; Furukawa Toshiaki, 2010, Tokai J Exp Clin Med, V35, P29; Gjini K, 2012, J PSYCHIATR RES, V46, P248, DOI 10.1016/j.jpsychires.2011.10.006; Groppe DM, 2011, PSYCHOPHYSIOLOGY, V48, P1726, DOI 10.1111/j.1469-8986.2011.01272.x; Groppe DM, 2011, PSYCHOPHYSIOLOGY, V48, P1711, DOI 10.1111/j.1469-8986.2011.01273.x; Ilmoniemi RJ, 2010, BRAIN TOPOGR, V22, P233, DOI 10.1007/s10548-009-0123-4; Ilmoniemi RJ, 1997, NEUROREPORT, V8, P3537, DOI 10.1097/00001756-199711100-00024; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; Inghilleri M, 1996, EXP BRAIN RES, V109, P467; Ives JR, 2006, CLIN NEUROPHYSIOL, V117, P1870, DOI 10.1016/j.clinph.2006.04.010; Julkunen P, 2008, CLIN NEUROPHYSIOL, V119, P475, DOI 10.1016/j.clinph.2007.09.139; Kapogiannis Dimitrios, 2008, Central Nervous System Agents in Medicinal Chemistry, V8, P234; Kicic D, 2008, NEUROSCIENCE, V152, P1119, DOI 10.1016/j.neuroscience.2008.01.043; Kimiskidis VK, 2005, EXP BRAIN RES, V163, P21, DOI 10.1007/s00221-004-2134-4; Knikou M, 2008, J NEUROSCI METH, V171, P1, DOI 10.1016/j.jneumeth.2008.02.012; Komssi S, 2004, HUM BRAIN MAPP, V21, P154, DOI 10.1002/hbm.10159; Komssi S, 2006, BRAIN RES REV, V52, P183, DOI 10.1016/j.brainresrev.2006.01.008; Korhonen RJ, 2011, MED BIOL ENG COMPUT, V49, P397, DOI 10.1007/s11517-011-0748-9; KRNJEVIC K, 1966, J PHYSIOL-LONDON, V184, P16, DOI 10.1113/jphysiol.1966.sp007902; KRNJEVIC K, 1964, NATURE, V201, P1294, DOI 10.1038/2011294a0; Lefaucheur JP, 2006, NEUROLOGY, V67, P1568, DOI 10.1212/01.wnl.0000242731.10074.3c; Lefaucheur JP, 2005, CLIN NEUROPHYSIOL, V116, P244, DOI 10.1016/j.clinph.2004.11.017; LEHMANN D, 1980, ELECTROEN CLIN NEURO, V48, P609, DOI 10.1016/0013-4694(80)90419-8; Levinson AJ, 2007, J CLIN PSYCHOPHARM, V27, P493, DOI 10.1097/jcp.0b013e31814ce524; Levinson AJ, 2010, BIOL PSYCHIAT, V67, P458, DOI 10.1016/j.biopsych.2009.09.025; Macdonell RAL, 2001, NEUROLOGY, V57, P706, DOI 10.1212/WNL.57.4.706; Maki H, 2011, NEUROIMAGE, V54, P2706, DOI 10.1016/j.neuroimage.2010.11.041; Maki H, 2010, NEUROSCI LETT, V478, P24, DOI 10.1016/j.neulet.2010.04.059; Marsden C D, 1983, Adv Neurol, V39, P387; Mathewson KE, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00099; MCCORMICK DA, 1989, J NEUROPHYSIOL, V62, P1018, DOI 10.1152/jn.1989.62.5.1018; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; MENG XL, 1992, PSYCHOL BULL, V111, P172, DOI 10.1037/0033-2909.111.1.172; Munchau A, 2002, J NEUROSCI, V22, P554, DOI 10.1523/JNEUROSCI.22-02-00554.2002; Murase N, 2005, BRAIN, V128, P104, DOI 10.1093/brain/awh315; Mutanen T, 2013, BRAIN STIMUL, V6, P371, DOI 10.1016/j.brs.2012.07.005; Nakamura H, 1997, J PHYSIOL-LONDON, V498, P817, DOI 10.1113/jphysiol.1997.sp021905; NAKASHIMA K, 1995, J NEUROL SCI, V130, P209, DOI 10.1016/0022-510X(95)00029-2; Nikulin VV, 2003, EUR J NEUROSCI, V18, P1206, DOI 10.1046/j.1460-9568.2003.02858.x; Oechsner M, 1999, J NEUROL SCI, V168, P107, DOI 10.1016/S0022-510X(99)00164-1; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Paus T, 2001, J NEUROPHYSIOL, V86, P1983, DOI 10.1152/jn.2001.86.4.1983; PRIORI A, 1994, MOVEMENT DISORD, V9, P178, DOI 10.1002/mds.870090209; PRIORI A, 1994, BRAIN, V117, P317, DOI 10.1093/brain/117.2.317; Radhu N, 2012, BRAIN STIMUL, V5, P44, DOI 10.1016/j.brs.2011.01.006; Richter MA, 2012, NEUROPSYCHOPHARMACOL, V37, P1144, DOI 10.1038/npp.2011.300; Rollnik JD, 2000, MUSCLE NERVE, V23, P112, DOI 10.1002/(SICI)1097-4598(200001)23:1<112::AID-MUS15>3.3.CO;2-2; Rosanova M, 2009, J NEUROSCI, V29, P7679, DOI 10.1523/JNEUROSCI.0445-09.2009; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Saisanen L, 2008, J NEUROSCI METH, V169, P231, DOI 10.1016/j.jneumeth.2007.12.005; Salerno A, 2000, CLIN NEUROPHYSIOL, V111, P994, DOI 10.1016/S1388-2457(00)00267-4; Sanger TD, 2001, J PHYSIOL-LONDON, V530, P307, DOI 10.1111/j.1469-7793.2001.0307l.x; Sarfeld AS, 2012, HUM BRAIN MAPP, V33, P1107, DOI 10.1002/hbm.21272; Sekiguchi H, 2011, CLIN NEUROPHYSIOL, V122, P984, DOI 10.1016/j.clinph.2010.09.004; Siebner HR, 2000, NEUROSCI LETT, V284, P147, DOI 10.1016/S0304-3940(00)00990-3; Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.0.CO;2-M; Stetkarova I, 2013, CLIN NEUROPHYSIOL, V124, P339, DOI 10.1016/j.clinph.2012.07.005; Tamburin S, 2004, CLIN NEUROPHYSIOL, V115, P348, DOI 10.1016/S1388-2457(03)00357-2; Tazoe T, 2007, EXP BRAIN RES, V177, P419, DOI 10.1007/s00221-006-0686-1; Teo JTH, 2008, MOVEMENT DISORD, V23, P378, DOI 10.1002/mds.21847; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; VALLSSOLE J, 1992, ELECTROEN CLIN NEURO, V85, P355, DOI 10.1016/0168-5597(92)90048-G; Veniero D, 2009, CLIN NEUROPHYSIOL, V120, P1392, DOI 10.1016/j.clinph.2009.04.023; WASSERMANN EM, 1991, NEUROLOGY, V41, P1795, DOI 10.1212/WNL.41.11.1795; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; Ziemann U, 2000, J CLIN NEUROPHYSIOL, V17, P397, DOI 10.1097/00004691-200007000-00005	104	74	76	1	42	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	DEC	2013	83						120	134		10.1016/j.neuroimage.2013.06.059			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	251TN	WOS:000326953700013	23800790	Green Accepted			2022-02-06	
J	Tanriverdi, F; De Bellis, A; Ulutabanca, H; Bizzarro, A; Sinisi, AA; Bellastella, G; Paglionico, VA; Dalla Mora, L; Selcuklu, A; Unluhizarci, K; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; De Bellis, Annamaria; Ulutabanca, Halil; Bizzarro, Antonio; Sinisi, Antonio A.; Bellastella, Giuseppe; Paglionico, Vanda Amoresano; Dalla Mora, Liliana; Selcuklu, Ahmed; Unluhizarci, Kursad; Casanueva, Felipe F.; Kelestimur, Fahrettin			A Five Year Prospective Investigation of Anterior Pituitary Function after Traumatic Brain Injury: Is Hypopituitarism Long-Term after Head Trauma Associated with Autoimmunity?	JOURNAL OF NEUROTRAUMA			English	Article						anti-hypothalamus antibodies; anti-pituitary antibodies; autoimmunity; growth hormone; pituitary; traumatic brain injury	ANEURYSMAL SUBARACHNOID HEMORRHAGE; GH REPLACEMENT THERAPY; ANTIPITUITARY ANTIBODIES; SHEEHANS-SYNDROME; HORMONE; INSUFFICIENCY; ADULTS; NEURONS; RATS	Traumatic brain injury (TBI) has been recently recognized as a common cause of pituitary dysfunction. However, there are not sufficient numbers of prospective studies to understand the natural history of TBI induced hypopituitarism. The aim was to report the results of five years' prospective follow-up of anterior pituitary function in patients with mild, moderate and severe TBI. Moreover, we have prospectively investigated the associations between TBI induced hypopituitarism and presence of anti-hypothalamus antibodies (AHA) and anti-pituitary antibodies (APA). Twenty five patients (20 men, five women) were included who were prospectively evaluated 12 months and five years after TBI, and 17 of them also had a third-year evaluation. Growth hormone (GH) deficiency is the most common pituitary hormone deficit at one, three, and five years after TBI. Although most of the pituitary hormone deficiencies improve over time, there were substantial percentages of pituitary hormone deficiencies at the fifth year (28% GH, 4% adrenocorticotropic hormone [ACTH], and 4% gonadotropin deficiencies). Pituitary dysfunction was significantly higher in strongly AHA- and APA-positive (titers >= 1/16) patients at the fifth year. In patients with mild and moderate TBI, ACTH and GH deficiencies may improve over time in a considerable number of patients but, although rarely, may also worsen over the five-year period. However in severe TBI, ACTH and GH status of the patients at the first year evaluation persisted at the fifth year. Therefore, screening pituitary function after TBI for five years is important, especially in patients with mild TBI. Moreover, close strong associations between the presence of high titers of APA and/or AHA and hypopituitarism at the fifth year were shown for the first time.	[Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin] Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; [Ulutabanca, Halil; Selcuklu, Ahmed] Erciyes Univ, Sch Med, Dept Neurosurg, TR-38039 Kayseri, Turkey; [De Bellis, Annamaria; Sinisi, Antonio A.; Bellastella, Giuseppe; Paglionico, Vanda Amoresano] Univ Naples 2, Dept Cardiothorac & Resp Sci, Naples, Italy; [Bizzarro, Antonio] Univ Naples 2, Dept Clin & Expt Med & Surg, Naples, Italy; [Dalla Mora, Liliana] Univ Naples 2, Dept Gen Pathol, Naples, Italy; [Casanueva, Felipe F.] Univ Santiago de Compostela, Sch Med, Dept Med, Santiago De Compostela, Spain; [Casanueva, Felipe F.] Univ Santiago de Compostela, Complejo Hosp Univ Santiago, Santiago De Compostela, Spain		Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr	kelestimur, f/ABE-9873-2021	DE BELLIS, Annamaria/0000-0002-0611-4506; DALLA MORA, Liliana/0000-0002-1160-1288			Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; AMATO G, 1993, J CLIN ENDOCR METAB, V77, P1671, DOI 10.1210/jc.77.6.1671; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; De Bellis A, 2003, J CLIN ENDOCR METAB, V88, P650, DOI 10.1210/jc.2002-021054; De Bellis A, 1999, J CLIN ENDOCR METAB, V84, P3047, DOI 10.1210/jc.84.9.3047; De Bellis A, 2008, EUR J ENDOCRINOL, V158, P147, DOI 10.1530/EJE-07-0647; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Kelestimur F, 2006, CLIN ENDOCRINOL, V64, P667, DOI 10.1111/j.1365-2265.2006.02525.x; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; Kunitomi M, 2002, INT J OBESITY, V26, P361, DOI 10.1038/sj.ijo.0801899; Lamberts SWJ, 1998, LANCET, V352, P127; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Rudehill S, 2006, ACTA NEUROCHIR, V148, P199, DOI 10.1007/s00701-005-0673-5; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Stein TD, 2002, J NEUROPATH EXP NEUR, V61, P1100, DOI 10.1093/jnen/61.12.1100; Tanriverdi F, 2005, GROWTH HORM IGF RES, V15, P231, DOI 10.1016/j.ghir.2005.03.005; Tanriverdi Fatih, 2006, Expert Rev Pharmacoecon Outcomes Res, V6, P131, DOI 10.1586/14737167.6.2.131; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tanriverdi F, 2010, EUR J ENDOCRINOL, V162, P861, DOI 10.1530/EJE-09-1024; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; Tanriverdi F, 2010, J NEUROTRAUM, V27, P301, DOI 10.1089/neu.2009.1102; TEASDALE G, 1974, LANCET, V2, P81; YUAN XQ, 1991, J NEUROSURG, V75, P408, DOI 10.3171/jns.1991.75.3.0408	30	74	77	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2013	30	16					1426	1433		10.1089/neu.2012.2752			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	199JB	WOS:000322989500006	23470214				2022-02-06	
J	Alsalaheen, BA; Whitney, SL; Mucha, A; Morris, LO; Furman, JM; Sparto, PJ				Alsalaheen, Bara; Whitney, Susan; Mucha, Anne; Morris, Laura; Furman, Joseph; Sparto, Patrick			Exercise Prescription Patterns in Patients Treated with Vestibular Rehabilitation After Concussion	PHYSIOTHERAPY RESEARCH INTERNATIONAL			English	Article						balance; concussion; dizziness; mild traumatic brain injury; physical therapy		Background and Purpose. Individuals with concussion often complain of persistent dizziness and imbalance, and these problems have been treated with vestibular rehabilitation exercises. The purpose of this study is to describe the vestibular rehabilitation exercise prescriptions provided to individuals after concussion. Methods. A retrospective chart review of vestibular rehabilitation home exercise programmes prescribed by physical therapists for 104 participants who were diagnosed with concussion was conducted. Each of the exercises was classified by exercise type, duration and frequency. Frequency counts of the most common exercise types were recorded. Exercise progression patterns were examined by determining how exercise types were modified from visit to visit. Results. Eye-head coordination exercises were the most commonly prescribed exercise type (in 95% of participants), followed by standing static balance exercises (in 88% of participants), and ambulation exercises (in 76% of participants). Conclusions. Understanding the prescription patterns of expert clinicians may elucidate the vestibular-related impairments of individuals after concussion and may provide a resource for therapists who may be starting vestibular rehabilitation programmes for management of individuals with concussion. To improve quality of care, future research should be directed to relate outcomes to the exercise prescription patterns. Copyright (C) 2012 John Wiley & Sons, Ltd.	[Alsalaheen, Bara; Whitney, Susan; Sparto, Patrick] Univ Pittsburgh, Dept Phys Therapy, Pittsburgh, PA 15260 USA; [Whitney, Susan; Mucha, Anne; Morris, Laura; Sparto, Patrick] Univ Pittsburgh, Med Ctr, Ctr Rehab Serv, Pittsburgh, PA USA; [Whitney, Susan; Furman, Joseph; Sparto, Patrick] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA		Sparto, PJ (corresponding author), Univ Pittsburgh, Dept Phys Therapy, Pittsburgh, PA 15260 USA.	psparto@pitt.edu		Sparto, Patrick/0000-0002-8351-3789	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024827] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG024827] Funding Source: Medline		Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Catena RD, 2009, J NEUROENG REHABIL, P6; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Enticott JC, 2005, OTOL NEUROTOL, V26, P265, DOI 10.1097/00129492-200503000-00024; EPLEY JM, 1992, OTOLARYNG HEAD NECK, V107, P399, DOI 10.1177/019459989210700310; GIZZI M, 1995, THE JOURNAL OF HEAD, V10, P60; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; HERDMAN SJ, 1995, OTOLARYNG HEAD NECK, V113, P77, DOI 10.1016/S0194-5998(95)70148-6; Herdman SJ, 2003, ARCH OTOLARYNGOL, V129, P819, DOI 10.1001/archotol.129.8.819; Herdman SJ, 2001, ANN NY ACAD SCI, V942, P394; Herdman SJ., 1990, J HEAD TRAUMA REHAB, V5, P63, DOI 10.1097/00001199-199012000-00008; Herdman SJ, 2007, VESTIBULAR REHABILIT, P309; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; HORAK FB, 1992, OTOLARYNG HEAD NECK, V106, P175, DOI 10.1177/019459989210600220; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Krebs DE, 2003, OTOLARYNG HEAD NECK, V128, P240, DOI 10.1067/mhn.2003.72; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maskell F, 2007, BRAIN INJURY, V21, P741, DOI 10.1080/02699050701472109; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Schubert MC, 2008, ARCH PHYS MED REHAB, V89, P500, DOI 10.1016/j.apmr.2007.11.010; Shumway-Cook A, 2007, VESTIBULAR REHABILIT, P444; SMITHWHEELOCK M, 1991, AM J OTOL, V12, P218; Whitney S. L., 2007, VESTIBULAR REHABILIT, P272; Yardley L, 1998, BRIT J GEN PRACT, V48, P1136	32	74	75	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1358-2267	1471-2865		PHYSIOTHER RES INT	Physiother. Res. Int.	JUN	2013	18	2					100	108		10.1002/pri.1532			9	Rehabilitation	Emerging Sources Citation Index (ESCI)	Rehabilitation	V75SC	WOS:000211863300005	22786783	Green Accepted, Bronze			2022-02-06	
J	Harris, JL; Yeh, HW; Choi, IY; Lee, P; Berman, NE; Swerdlow, RH; Craciunas, SC; Brooks, WM				Harris, Janna L.; Yeh, Hung-Wen; Choi, In-Young; Lee, Phil; Berman, Nancy E.; Swerdlow, Russell H.; Craciunas, Sorin C.; Brooks, William M.			Altered neurochemical profile after traumatic brain injury: H-1-MRS biomarkers of pathological mechanisms	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						animal models; brain trauma; cell death mechanisms; MR spectroscopy; neurochemistry	PROTON-MAGNETIC-RESONANCE; CORTICAL IMPACT INJURY; VIVO H-1-NMR SPECTROSCOPY; RAT-BRAIN; IN-VIVO; N-ACETYLASPARTATE; TIME-COURSE; ENERGY-METABOLISM; OXIDATIVE STRESS; REGIONAL CHANGES	Specific neurochemicals measured with proton magnetic resonance spectroscopy (H-1-MRS) may serve as biomarkers of pathological mechanism in the brain. We used high field in vivo H-1-MRS to measure a detailed neurochemical profile after experimental traumatic brain injury (TBI) in rats. We characterized neurochemical changes in the contused cortex and the normal-appearing perilesional hippocampus over a time course from 1 hour to 2 weeks after injury. We found significant changes in 19 out of 20 neurochemicals in the cortex, and 9 out of 20 neurochemicals in the hippocampus. These changes provide evidence of altered cellular metabolic status after TBI, with specific compounds proposed to reflect edema, excitotoxicity, neuronal and glial integrity, mitochondrial status and bioenergetics, oxidative stress, inflammation, and cell membrane disruption. Our results support the utility of H-1-MRS for monitoring cellular mechanisms of TBI pathology in animal models, and the potential of this approach for preclinical evaluation of novel therapies. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 2122-2134; doi:10.1038/jcbfm.2012.114; published online 15 August 2012	[Harris, Janna L.; Choi, In-Young; Lee, Phil; Brooks, William M.] Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Kansas City, KS 66160 USA; [Yeh, Hung-Wen] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66160 USA; [Choi, In-Young; Swerdlow, Russell H.; Brooks, William M.] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA; [Lee, Phil; Swerdlow, Russell H.; Brooks, William M.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Berman, Nancy E.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; [Swerdlow, Russell H.] Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; [Craciunas, Sorin C.] Carol Davila Univ Med, Neurosurg Unit 4, Bagdasar Arseni Hosp, Bucharest, Romania		Harris, JL (corresponding author), Univ Kansas, Med Ctr, Hoglund Brain Imaging Ctr, Mail Stop 1052,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	jharris2@kumc.edu	Yeh, Hung-Wen/E-8104-2015; Brooks, William/AAF-8299-2019	Yeh, Hung-Wen/0000-0003-0894-5570; Brooks, William/0000-0001-6227-7636; Lee, Phil/0000-0002-2087-8887	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1 TR000001, P30 HD002528, P30 AG035982, R01 AG031140, R03 NS077852]; University of Kansas; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS077852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG035982, R01AG031140] Funding Source: NIH RePORTER	This study was supported in part by the National Institutes of Health (UL1 TR000001 to Frontiers: The Heartland Institute for Clinical and Translational Research at the University of Kansas Medical Center; P30 HD002528 to the Kansas Intellectual and Developmental Disabilities Research Center; P30 AG035982 to the University of Kansas Alzheimer's Disease Center; R01 AG031140 to Dr Berman; and R03 NS077852 to Dr Swerdlow) and a University of Kansas Lied Endowed Basic Science grant to Dr Brooks. The Hoglund Brain Imaging Center is supported by a generous gift from Forrest and Sally Hoglund.	Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Arun P, 2006, J NEUROCHEM, V98, P2034, DOI 10.1111/j.1471-4159.2006.04068.x; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; BEHAR KL, 1993, MAGNET RESON MED, V30, P38, DOI 10.1002/mrm.1910300107; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Brooks WM, 2010, ARTHRITIS RHEUM-US, V62, P2055, DOI 10.1002/art.27458; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Buitrago MM, 2004, NEUROBIOL LEARN MEM, V81, P211, DOI 10.1016/j.nlm.2004.01.001; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Choi IY, 2011, MULT SCLER J, V17, P289, DOI 10.1177/1352458510384010; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; GRUETTER R, 1993, MAGNET RESON MED, V29, P804, DOI 10.1002/mrm.1910290613; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Holshouser BA, 2006, J MAGN RESON IMAGING, V24, P33, DOI 10.1002/jmri.20607; Imbrosci B, 2011, NEURAL PLAST, V2011, DOI 10.1155/2011/614329; Lei HX, 2009, J CEREBR BLOOD F MET, V29, P811, DOI 10.1038/jcbfm.2009.8; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lubin JH, 2004, ENVIRON HEALTH PERSP, V112, P1691, DOI 10.1289/ehp.7199; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Moffett J. R., 2006, N ACETYLASPARTATE UN; Pfeuffer J, 1999, J MAGN RESON, V141, P104, DOI 10.1006/jmre.1999.1895; Pleasant JM, 2011, J NEUROTRAUM, V28, P2245, DOI 10.1089/neu.2010.1499; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Rice ME, 1998, NEUROSCIENCE, V82, P1213; Righi V, 2009, NMR BIOMED, V22, P629, DOI 10.1002/nbm.1377; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Schafer JL, 1997, ANAL INCOMPLETE MULT; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tkac I, 2003, MAGN RESON MED, V50, P24, DOI 10.1002/mrm.10497; Tkac I, 1999, MAGNET RESON MED, V41, P649, DOI 10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Xing GQ, 2012, EXP NEUROL, V234, P31, DOI 10.1016/j.expneurol.2011.12.007; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yokobori S, 2011, J TRAUMA, V71, P1235, DOI 10.1097/TA.0b013e3182140dd7; Zacharoff L, 2012, J CEREBR BLOOD F MET, V32, P502, DOI 10.1038/jcbfm.2011.157; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhou J, 2005, NAT REV DRUG DISCOV, V4, P1015, DOI 10.1038/nrd1903	51	74	79	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	DEC	2012	32	12					2122	2134		10.1038/jcbfm.2012.114			13	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	095QJ	WOS:000315349200006	22892723	Green Published			2022-02-06	
J	Melnick, ER; Szlezak, CM; Bentley, SK; Dziura, JD; Kotlyar, S; Post, LA				Melnick, Edward R.; Szlezak, Christopher M.; Bentley, Suzanne K.; Dziura, James D.; Kotlyar, Simon; Post, Lori A.			CT Overuse for Mild Traumatic Brain Injury	JOINT COMMISSION JOURNAL ON QUALITY AND PATIENT SAFETY			English	Article								Background: Multiple, validated, evidence-based guidelines exist to inform the appropriate use of computed tomography (CT) to differentiate mild traumatic brain injury (MTBI) from clinically important brain injury and to prevent the overuse of CT. Yet, CT use is growing rapidly, potentially exposing patients to unnecessary ionizing radiation risk and costs. A study was conducted to quantify the overuse of CT in MTBI on the basis of current guideline recommendations. Methods: A retrospective analysis of secondary data from a prospective observational study was undertaken at an urban, Level I emergency department (ED) with more than 90,000 visits per year. For adult patients with minor head injury receiving CT imaging at the discretion of the treating physician, the proportion of cases meeting criteria for CT on the basis of the Canadian CT Head Rule (CCHR), American College of Emergency Physicians (ACEP) Clinical Policy, New Orleans Criteria (NOC), and National Institute for Health and Clinical Excellence (NICE) guidelines was reported. Results: All 346 patients enrolled in the original study were included in the analysis. The proportion of cases meeting criteria for CT for each of the guidelines was: CCHR 64.7% (95% confidence interval [CI], 0.60-0.70), ACEP 74.3% (95% CI, 0.70-0.79), NICE 86.7% (95% CI, 0.83-0.90), and NOC 90.5% (95% CI, 0.87-0.94). The odds ratio of the guidelines for predicting positive head CT findings were also reported. Discussion: Some 10%-35% of CTs obtained in the ED for MTBI were not recommended according to the guidelines. Successful implementation of existing guidelines could decrease CT use in MTBI by up to 35%, leading to a significant reduction in radiation-induced cancers and health care costs.	[Melnick, Edward R.; Szlezak, Christopher M.; Dziura, James D.; Kotlyar, Simon; Post, Lori A.] Yale Sch Med, Dept Emergency Med, New Haven, CT 06510 USA; [Bentley, Suzanne K.] Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA		Melnick, ER (corresponding author), Yale Sch Med, Dept Emergency Med, New Haven, CT 06510 USA.	edward.melnick@yale.edu	Post, Lori/AAQ-9653-2021				Baerlocher MO, 2010, JAMA-J AM MED ASSOC, V304, P2170, DOI 10.1001/jama.2010.1591; Bates DW, 2003, J AM MED INFORM ASSN, V10, P523, DOI 10.1197/jamia.M1370; Baumann BM, 2011, ANN EMERG MED, V58, P1, DOI 10.1016/j.annemergmed.2010.10.018; Bentley S, 2009, ACEP SCI ASS BOST; Boone John M, 2008, J Am Coll Radiol, V5, P132, DOI 10.1016/j.jacr.2007.07.008; Bovbjerg RR, 2012, URBAN I ROBERT WOOD; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Broder J, 2006, EMERG RADIOL, V13, P25, DOI 10.1007/s10140-006-0493-9; Burgers JS, 2003, BRIT J GEN PRACT, V53, P15; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Childs Dan, 2009, ABC NEWS; DEYO RA, 1987, ARCH INTERN MED, V147, P141, DOI 10.1001/archinte.147.1.141; DEYO RA, 1986, SPINE, V11, P28, DOI 10.1097/00007632-198601000-00008; Elesber AA, 2005, AM HEART J, V149, P826, DOI 10.1016/j.ahj.2004.07.024; Elstein AS, 2004, INFLAMM RES, V53, pS184, DOI 10.1007/s00011-004-0357-2; Faul M, 2010, TRAUMATIC BRAIN INJU; Formoso G, 2001, ARCH INTERN MED, V161, P2037, DOI 10.1001/archinte.161.16.2037; Franklin C, 2009, NEW YORK POST; Glasziou Paul, 2005, ACP J Club, V142, pA8; Grimshaw JM, 2001, MED CARE, V39, pII2; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Joint Commission, 2011, SENTINEL EVENT ALERT; Kline JA, 2010, ACAD EMERG MED, V17, pE69, DOI 10.1111/j.1553-2712.2010.00802.x; Kline JA, 2009, ANN EMERG MED, V53, P727, DOI 10.1016/j.annemergmed.2008.09.034; Korenstein D, 2012, ARCH INTERN MED, V172, P171, DOI 10.1001/archinternmed.2011.772; Korley FK, 2010, JAMA-J AM MED ASSOC, V304, P1465, DOI 10.1001/jama.2010.1408; Kotlyar S, 2011, J EMERG MED, V41, P285, DOI 10.1016/j.jemermed.2010.05.040; Lang ES, 2007, ANN EMERG MED, V49, P355, DOI 10.1016/j.annemergmed.2006.08.022; Lehrmann JF, 2007, ACAD EMERG MED, V14, P1090, DOI 10.1197/j.aem.2007.05.016; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Melnick ER, 2010, ANN EMERG MED, V56, P317, DOI 10.1016/j.annemergmed.2010.03.006; Melnick ER, 2010, INT J EMERG MED, V3, P97, DOI 10.1007/s12245-010-0168-x; National Institute for Health and Clinical Excellence, 2007, HEAD INJ TRIAG ASS I, V56; Papa L, 2012, ACAD EMERG MED, V19, P2, DOI 10.1111/j.1553-2712.2011.01247.x; Pham JC, 2007, ACAD EMERG MED, V14, P856, DOI 10.1197/j.aem.2007.06.035; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Smith M., 2012, BEST CARE LOWER COST; Smith-Bindman R, 2012, JAMA-J AM MED ASSOC, V307, P2400, DOI 10.1001/jama.2012.5960; Smith-Bindman R, 2011, AM J EMERG MED, V29, P656, DOI 10.1016/j.ajem.2010.01.038; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4146; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tavender EJ, 2011, ACAD EMERG MED, V18, P880, DOI 10.1111/j.1553-2712.2011.01134.x; Venkatesh AK, 2012, ARCH INTERN MED, V172, P1028, DOI 10.1001/archinternmed.2012.1804; Wears RL, 2011, ANN EMERG MED, V58, P9, DOI 10.1016/j.annemergmed.2011.02.026	54	74	75	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1553-7250	1938-131X		JT COMM J QUAL PATIE	Jt. Comm. J. Qual. Patient Saf.	NOV	2012	38	11					483	489		10.1016/S1553-7250(12)38064-1			7	Health Care Sciences & Services	Emerging Sources Citation Index (ESCI)	Health Care Sciences & Services	VF9AP	WOS:000443957200001	23173394				2022-02-06	
J	Collen, J; Orr, N; Lettieri, CJ; Carter, K; Holley, AB				Collen, Jacob; Orr, Nicholas; Lettieri, Christopher J.; Carter, Kevin; Holley, Aaron B.			Sleep Disturbances Among Soldiers With Combat-Related Traumatic Brain Injury	CHEST			English	Article							LONG-TERM DISABILITY; BREATHING DISORDERS; OBJECTIVE MEASURES; UNITED-STATES; HEAD-INJURY; INSOMNIA; APNEA; AFGHANISTAN; PREVALENCE; DEPLOYMENT	Background: Sleep complaints are common among patients with traumatic brain injury. Evaluation of this population is confounded by polypharmacy and comorbid disease, with few studies addressing combat-related injuries. The aim of this study was to assess the prevalence of sleep disorders among soldiers who sustained combat-related traumatic brain injury. Methods: The study design was a retrospective review of soldiers returning from combat with mild to moderate traumatic brain injury. All underwent comprehensive sleep evaluations. We determined the prevalence of sleep complaints and disorders in this population and assessed demographics, mechanism of injury, medication use, comorbid psychiatric disease, and polysomnographic findings to identify variables that correlated with the development of specific sleep disorders. Results: Of 116 consecutive patients, 96.6% were men (mean age, 31.1 +/- 9.8 years; mean BMI, 27.8 +/- 4.1 kg/m(2)), and 29.5% and 70.5% sustained blunt and blast injuries, respectively. Nearly all (97.4%) reported sleep complaints. Hypersomnia and sleep fragmentation were reported in 85.2% and 54.3%, respectively. Obstructive sleep apnea syndrome (OSAS) was found in 34.5%, and 55.2% had insomnia. Patients with blast injuries developed more anxiety (50.6% vs 20.0%, P = .002) and insomnia (63% vs 40%, P = .02), whereas patients with blunt trauma had significantly more OSAS (54.3% vs 25.9%, P = .003). In multivariate analysis, blunt trauma was a significant predictor of OSAS (OR, 3.09; 95% CI, 1.02-9.38; P = .047). Conclusions: Sleep disruption is common following traumatic brain injury, and the majority of patients develop a chronic sleep disorder. It appears that sleep disturbances may be influenced by the mechanism of injury in those with combat-related traumatic brain injury, with blunt injury potentially predicting the development of OSAS. CHEST 2012; 142(3):622-630	[Collen, Jacob; Lettieri, Christopher J.; Carter, Kevin; Holley, Aaron B.] Walter Reed Natl Mil Med Ctr, Dept Pulm Crit Care & Sleep Med, Bethesda, MD 20889 USA; [Orr, Nicholas] Walter Reed Natl Mil Med Ctr, Dept Med, Bethesda, MD 20889 USA; [Lettieri, Christopher J.; Holley, Aaron B.] Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA		Collen, J (corresponding author), Walter Reed Natl Mil Med Ctr, Dept Pulm Crit Care & Sleep Med, 8901 Rockville Pike, Bethesda, MD 20889 USA.	jacob.collen@us.army.mil		Lettieri, Christopher/0000-0001-7950-2908			*AM SLEEP DIS ASS, 1990, INT CLASS SLEEP DIS; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, P51; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Nguyen ATD, 2006, J CLIN SLEEP MED, V2, P170; [Anonymous], 2010, Medical Surveillance Monthly Report, V17, P12; [Anonymous], 2010, Medical Surveillance Monthly Report, V17, P8; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Beneto A, 2009, SLEEP MED REV, V13, P287, DOI 10.1016/j.smrv.2008.09.006; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chervin RD, 1999, NEUROLOGY, V52, P125, DOI 10.1212/WNL.52.1.125; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Faul M, 2010, TRAUMATIC BRAIN INJU; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fischer H, 2010, US MILITARY CASUALTY; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Iber C., 2007, AASM MANUAL SCORING, P7; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kanbayashi T, 2009, SLEEP, V32, P181, DOI 10.1093/sleep/32.2.181; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kennedy K., 2010, ARMY TIMES; Larson EB, 2010, J HEAD TRAUMA REHAB, V25, P61, DOI 10.1097/HTR.0b013e3181c1d1e1; Lavie P, 2007, SLEEP MED, V8, pS21, DOI 10.1016/S1389-9457(08)70005-4; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; O'Hara R, 2009, J REHABIL RES DEV, V46, P837, DOI 10.1682/JRRD.2008.10.0140; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Oyefeso A, 1997, DRUG ALCOHOL DEPEN, V48, P9, DOI 10.1016/S0376-8716(97)00097-5; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Rishi MA, 2010, CLIN NEUROPHARMACOL, V33, P109, DOI 10.1097/WNF.0b013e3181db8040; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Sateia MJ, 2009, CHEST, V135, P1370, DOI 10.1378/chest.08-1834; Schwab KA, 2006, NEUROLOGY, V66, pA235; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shukla D, 2010, J NEUROSCI RURAL PRA, V1, P82, DOI 10.4103/0976-3147.71723; Smith S, 2004, SLEEP MED, V5, P449, DOI 10.1016/j.sleep.2004.03.005; Stein MD, 2004, J SUBST ABUSE TREAT, V26, P175, DOI 10.1016/S0740-5472(03)00191-0; United States Department of Veterans Affairs & Department of Defense, 2009, VA DOD CLIN PRACT GU; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; Wickwire EM, 2010, SLEEP MED, V11, P772, DOI 10.1016/j.sleep.2010.03.012; Wickwire EM, 2010, CHEST, V137, P1449, DOI 10.1378/chest.09-1485; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	61	74	74	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0012-3692			CHEST	Chest	SEP	2012	142	3					622	630		10.1378/chest.11-1603			9	Critical Care Medicine; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Respiratory System	003PE	WOS:000308623000014	22459784				2022-02-06	
J	Dickerson, RN; Pitts, SL; Maish, GO; Schroeppel, TJ; Magnotti, LJ; Croce, MA; Minard, G; Brown, RO				Dickerson, Roland N.; Pitts, Stefanie L.; Maish, George O.; Schroeppel, Thomas J.; Magnotti, Louis J.; Croce, Martin A.; Minard, Gayle; Brown, Rex O.			A reappraisal of nitrogen requirements for patients with critical illness and trauma	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Enteral nutrition; parenteral nutrition; protein requirements; nitrogen balance; traumatic brain injury	SEVERE HEAD-INJURY; TOTAL PARENTERAL-NUTRITION; EARLY ENTERAL NUTRITION; METABOLIC-RESPONSE; INTENSIVE-CARE; ENERGY-EXPENDITURE; PROTEIN-METABOLISM; SUPPORT; EXCRETION; FAT	BACKGROUND: Studies regarding protein requirements for patients with critical illness are inconclusive owing to small sample size and population heterogeneity. The primary objectives of this study were to determine the amount of protein required to achieve nitrogen equilibrium or a positive nitrogen balance (NB, -4 g/d or better) and ascertain whether patients with traumatic brain injury (TBI) exhibit greater protein catabolism than those without TBI. METHODS: Adult patients admitted to the trauma center, given specialized nutrition support, and had an NB determination within 5 days to 14 days after injury were evaluated. Patients with obesity, incomplete urine collection, kidney disease, corticosteroid or pentobarbital therapy, or an oral diet were excluded. RESULTS: A total of 300 NB determinations from 249 patients were evaluated. Increasing the protein dosage generally resulted in improved NB; however, the data were highly variable. Of the patients who received a protein intake of 2 g/kg per day or greater, 54% achieved nitrogen equilibrium or positive NB (-4 g/d or better) in contrast to 38% and 29% of patients who received 1.5 g/kg per day to 1.99 g/kg per day and 1 g/kg per day to 1.49 g/kg per day, respectively (p < 0.001). There was no significant difference in NB between patients with and without TBI at similar protein intakes. CONCLUSION: A higher protein intake was generally associated with an improved NB; yet, many patients remained having a negative NB. A protein dosage of 2 g/kg per day or greater was more successful in achieving nitrogen equilibrium than were lower-dosage intakes. Patients with TBI do not exhibit significantly greater protein catabolism than do patients without TBI. (J Trauma Acute Care Surg. 2012;73: 549-557. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Dickerson, Roland N.; Pitts, Stefanie L.; Brown, Rex O.] Univ Tennessee, Ctr Hlth Sci, Dept Clin Pharm, Memphis, TN 38163 USA; [Maish, George O.; Schroeppel, Thomas J.; Magnotti, Louis J.; Croce, Martin A.; Minard, Gayle] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA		Dickerson, RN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Clin Pharm, 881 Madison Ave,Suite 345, Memphis, TN 38163 USA.	rdickerson@uthsc.edu		Dickerson, Roland/0000-0002-2086-6317; Schroeppel, Thomas/0000-0001-9164-5004	Haemonetics; Golden Helix; Expression Analysis; Illumina; Lineagan	Ernest E. Moore, MD, Editor, received research support from Haemonetics. David B. Hoyt, MD, Associate Editor/CME Editor, Ronald Maier, MD, Associate Editor, and Steven Shackford, MD, Associate Editor have nothing to disclose. Jennifer Crebs, Managing Editor, received consulting fees from Golden Helix, Expression Analysis, Illumina, and Lineagan. Jo Fields, Editorial Assistant, and Angela Sauaia, MD, Biostatistician, have nothing to disclose.	Abraham E, 2000, CRIT CARE MED, V28, P232, DOI 10.1097/00003246-200001000-00039; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BIRKHAHN RH, 1981, AM J PHYSIOL, V241, pE64, DOI 10.1152/ajpendo.1981.241.1.E64; BLACK PR, 1982, ANN SURG, V196, P420, DOI 10.1097/00000658-198210000-00005; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DEUTSCHMAN CS, 1987, J NEUROSURG, V66, P388, DOI 10.3171/jns.1987.66.3.0388; Dickerson RN, 2005, NUTRITION, V21, P332, DOI 10.1016/j.nut.2004.07.005; DICKERSON RN, 1990, J AM COLL NUTR, V9, P86; Doig GS, 2011, INJURY, V42, P50, DOI 10.1016/j.injury.2010.06.008; Frankenfield DC, 1997, JPEN-PARENTER ENTER, V21, P324, DOI 10.1177/0148607197021006324; FRIED RC, 1989, J TRAUMA, V29, P1558, DOI 10.1097/00005373-198911000-00017; Garlick PJ, 2004, J NUTR, V134, p1633S, DOI 10.1093/jn/134.6.1633S; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Hart DW, 2002, ANN SURG, V235, P152, DOI 10.1097/00000658-200201000-00020; Ishibashi N, 1998, CRIT CARE MED, V26, P1529, DOI 10.1097/00003246-199809000-00020; JEEVANANDAM M, 1990, CRIT CARE MED, V18, P467, DOI 10.1097/00003246-199005000-00001; Kompan L, 1999, INTENS CARE MED, V25, P157, DOI 10.1007/s001340050809; LARSSON J, 1990, BRIT J SURG, V77, P413, DOI 10.1002/bjs.1800770418; Manatt M. W., 1992, Modern methods in protein nutrition and metabolism., P9; Monk DN, 1996, ANN SURG, V223, P395, DOI 10.1097/00000658-199604000-00008; MORITZ F, 1993, BRIT J ANAESTH, V70, P451, DOI 10.1093/bja/70.4.451; Ostermann M, 2007, CRIT CARE MED, V35, P1837, DOI 10.1097/01.CCM.0000277041.13090.0A; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; SACKS GS, 1995, JPEN-PARENTER ENTER, V19, P387, DOI 10.1177/0148607195019005387; SHAW JHF, 1989, ANN SURG, V209, P63, DOI 10.1097/00000658-198901000-00010; SHAW JHF, 1987, ANN SURG, V205, P288, DOI 10.1097/00000658-198703000-00012; SHAWDELANTY SN, 1987, CLIN NUTR, V6, P257, DOI 10.1016/0261-5614(87)90041-0; STREAT SJ, 1987, J TRAUMA, V27, P262, DOI 10.1097/00005373-198703000-00006; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; WOLFE RR, 1983, ANN SURG, V197, P163, DOI 10.1097/00000658-198302000-00007; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668	34	74	79	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	SEP	2012	73	3					549	557		10.1097/TA.0b013e318256de1b			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	009TK	WOS:000309047900003	23007014				2022-02-06	
J	Brenner, M; Stein, DM; Hu, PF; Aarabi, B; Sheth, K; Scalea, TM				Brenner, Megan; Stein, Deborah M.; Hu, Peter F.; Aarabi, Bizhan; Sheth, Kevin; Scalea, Thomas M.			Traditional systolic blood pressure targets underestimate hypotension-induced secondary brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Continuous vital signs; outcomes; secondary brain injury; hypotension	HEAD-INJURY; VARIABLES	BACKGROUND: Vital signs, particularly blood pressure, are often manipulated to maximize perfusion and optimize recovery from severe traumatic brain injury (sTBI). We investigated the utility of automated continuously recorded vital signs to predict outcomes after sTBI. METHODS: Sixty patients with head Abbreviated Injury Scale score >= 3, age >14 years, "isolated" TBI, and need for intracranial pressure monitoring were prospectively enrolled at a single, large urban tertiary care facility. Outcome was measured by mortality and extended Glasgow Outcome Scale (GOSE) at 12 months. Continuous, automated, digital data were collected every 6 seconds for 72 hours after admission, and 5-minute means of systolic blood pressure (SBP) were recorded. We calculated SBP as pressure x time dose (PTD) to describe the cumulative amplitude and duration of episodes above and below clinical thresholds. The extent and duration of the insults were calculated as percent time (%time), PTD, and PTD per day (PTD/D) of defined thresholds (SBP: <90 mm Hg, <100 mm Hg, <110 mm Hg, and <120 mm Hg; mean arterial pressure: <60 mm Hg and <70 mm Hg; heart rate: >100 bpm and >120 bpm; and SpO(2) : <88% and <92%) for the first 12 hours, 24 hours, and 48 hours of intensive care unit admission. We analyzed their ability to predict mortality and GOSE by receiver operator characteristics. RESULTS: Mean age was 33.9 (range, 16-83) years, mean admission Glasgow Coma Scale score 6.4 +/- 3, and mean head Abbreviated Injury Scale score 4.2 +/- 0.72. The 30-day mortality rate was 13.3%. Of the 45 patients in whom GOSE at 12 months was available, 28 (62%) had good neurologic outcomes (GOSE score >4). Traditional markers of poor outcome (admission SBP, admission Glasgow Coma Scale, and Marshall score) were not different between groups with good or poor outcome. PTD, PTD/D, and %time SBP <110 mm Hg and SBP <120 mm Hg predicted mortality at 12 hours, 24 hours, and 48 hours (p < 0.04). Percent time SBP <110 mm Hg in the first 24 hours was predictive of 12-month GOSE (p = 0.02). PTD/D SBP < 120 mm Hg in the first 24 hours and PTD and PTD/D in the first 48 hours were also predictive of 12-month GOSE (p < 0.05). CONCLUSIONS: Within the first 48 hours of intensive care unit admission, hypotension was found to be predictive of mortality and functional outcomes at higher thresholds than traditionally defined. Systemic blood pressure targets closer to 120 mm Hg may be more efficacious in minimizing secondary insults and particularly useful in settings without invasive intracranial monitoring capabilities. (J Trauma. 2012; 72: 1135-1139. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Brenner, Megan] Univ Maryland, Med Ctr, Div Crit Care, Program Trauma,R Adams Cowley Shock Trauma Ctr,Sc, Baltimore, MD 21201 USA; [Stein, Deborah M.; Hu, Peter F.; Scalea, Thomas M.] Univ Maryland, Shock Trauma & Anesthesiol Res Organized Res Ctr, Sch Med, Baltimore, MD 21201 USA		Brenner, M (corresponding author), Univ Maryland, Med Ctr, Div Crit Care, Program Trauma,R Adams Cowley Shock Trauma Ctr,Sc, 22 S Greene St, Baltimore, MD 21201 USA.	mbrenner@umm.edu		Stein, Deborah/0000-0003-3683-3963	Haemonetics; Golden Helix; Expression Analysis; Illumina; Lineagan	Ernest E. Moore, MD, Editor, received research support from Haemonetics. David B. Hoyt, MD, Associate Editor/CME Editor, Ronald Maier, MD, Associate Editor, and Steven Shackford, MD, Associate Editor have nothing to disclose. Jennifer Crebs, Managing Editor, received consulting fees from Golden Helix, Expression Analysis, Illumina, and Lineagan. Jo Fields, Editorial Assistant, and Angela Sauaia, MD, Biostatistician, have nothing to disclose.	Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Berry C, 2011, INJURY          0920; Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons; Joint Section on Neurotrauma and Critical Care AANS/CNS, 2007, J NEUROTRAUMA S, V24, pS1, DOI DOI 10.1089/NEU.2007.9976; Bratton S. L., 2007, J NEUROTRAUMA S1, V24, pS37; Chestnut RM, 1987, J TRAUMA, V27, P1007; Chiara O, 2008, MINERVA ANESTESIOL, V74, P303; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x	12	74	74	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2012	72	5					1135	1139		10.1097/TA.0b013e31824af90b			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	944JD	WOS:000304195100002	22673237				2022-02-06	
J	Migliore, A; Timmons, J; Butterworth, J; Lugas, J				Migliore, Alberto; Timmons, Jaimie; Butterworth, John; Lugas, Jaime			Predictors of Employment and Postsecondary Education of Youth With Autism	REHABILITATION COUNSELING BULLETIN			English	Article						employment; vocational rehabilitation; postsecondary education; transition; autism; RSA911	TRAUMATIC BRAIN-INJURY; DEVELOPMENTAL-DISABILITIES; SPECTRUM DISORDERS; OUTCOMES; SERVICES; ADULTS; CONSUMERS; PEOPLE	Using logistic and multiple regressions, the authors investigated predictors of employment and postsecondary education outcomes of youth with autism in the Vocational Rehabilitation Program. Data were obtained from the RSA911 data set, fiscal year 2008. Findings showed that the odds of gaining employment were greater for youth who received job placement services, yet only 48% of youth received this service. In addition, postsecondary education was among the strongest predictors of better earnings, yet only 10% of youth received college services. The authors recommended providing job placement services and college services to more youth with autism. At the same time, due to the relatively moderate effect sizes of these regression models, they recommend investigating additional variables currently not included in the RSA911 data set.	[Migliore, Alberto] Univ Massachusetts, Inst Community Inclus, Boston, MA 02116 USA		Migliore, A (corresponding author), Univ Massachusetts, Inst Community Inclus, 20 Pk Plaza,Suite 1300, Boston, MA 02116 USA.	amiglior@gmail.com	Butterworth, John/J-8278-2016				Barnhill GP., 2007, FOCUS AUTISM DEV DIS, V22, P116, DOI [10.1177/10883576070220020301, DOI 10.1177/10883576070220020301]; Boeltzig H, 2008, INT J REHABIL RES, V31, P217, DOI 10.1097/MRR.0b013e3282fb7ce5; Bolton BF, 2000, REHABIL COUNS BULL, V44, P10, DOI 10.1177/003435520004400103; Butterworth J., 2011, STATEDATA NATL REPOR; Camarena PM, 2009, FOCUS AUTISM DEV DIS, V24, P115, DOI 10.1177/1088357609332675; Cimera RE, 2009, AUTISM, V13, P285, DOI 10.1177/1362361309103791; Cohen J., 2013, STAT POWER ANAL BEHA; Dew D. W., 2007, I REHABILITATION ISS, V32; Field A., 2017, DISCOVERING STAT USI, V5th; Gamble D, 2003, J REHABIL, V69, P31; Grigal Meg, 2010, THINK COLL POSTSECON; Hayward B. J., 2003, LONGITUDINAL STUDY V; Hendricks D, 2010, J VOCAT REHABIL, V32, P125, DOI 10.3233/JVR-2010-0502; Howlin P, 2004, J CHILD PSYCHOL PSYC, V45, P212, DOI 10.1111/j.1469-7610.2004.00215.x; Jung Y, 2010, REHABIL COUNS BULL, V53, P175, DOI 10.1177/0034355209356596; Lawer L, 2009, J AUTISM DEV DISORD, V39, P487, DOI 10.1007/s10803-008-0649-4; Luecking R.G., 2004, WORKING RELATIONSHIP; Migliore A, 2008, REHABIL COUNS BULL, V52, P35, DOI 10.1177/0034355208320075; Newman L., 2009, POSTHIGH SCH OUTCOME; Schaller J, 2005, REHABIL COUNS BULL, V49, P4, DOI 10.1177/00343552050490010201; Schonbrun SL, 2007, J REHABIL, V73, P26; Stevens JP., 1996, APPL MULTIVARIATE ST; Stodden RA, 2010, FOCUS AUTISM DEV DIS, V25, P131, DOI 10.1177/1088357610371637; Tabachnick B.G., 2001, USING MULTIVARIATE S; Taylor JL, 2011, J AUTISM DEV DISORD, V41, P566, DOI 10.1007/s10803-010-1070-3; Test DW, 2009, CAREER DEV TRANSIT E, V32, P160, DOI 10.1177/0885728809346960; [No title captured]; [No title captured]	28	74	74	1	36	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0034-3552			REHABIL COUNS BULL	Rehabil. Couns. Bull.	APR	2012	55	3					176	184		10.1177/0034355212438943			9	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	913HB	WOS:000301866600005					2022-02-06	
J	Leventhal, JM; Martin, KD; Gaither, JR				Leventhal, John M.; Martin, Kimberly D.; Gaither, Julie R.			Using US Data to Estimate the Incidence of Serious Physical Abuse in Children	PEDIATRICS			English	Article						abuse; epidemiology-injury; injury severity	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; FRACTURES; VIOLENCE	BACKGROUND: There are limited data on the epidemiology of serious injuries due to physical abuse of children. METHODS: We used the 2006 Kids' Inpatient Database to estimate the incidence of hospitalizations due to serious physical abuse among children <18 years of age. Abuse was defined by using International Classification of Diseases, Ninth Revision, Clinical Modification codes for injuries (800-959) and for physical abuse (995.50, 995.54, 995.55, or 995.59), selected assault codes (E960-966, 968), or child battering (E967). We examined demographic characteristics, mean costs, and length of stay in 3 groups of hospitalized children: abusive injuries, nonabusive injuries, and all other reasons for hospitalization. Incidence was calculated using the weighted number of cases of physical abuse and the number of children at risk based on 2006 intercensal data. RESULTS: The weighted number of cases due to abuse was 4569; the incidence was 6.2 (95% confidence interval [CI]: 5.5-6.9) per 100 000 children <18 years of age. The incidence was highest in children <1 year of age (58.2 per 100 000; 95% CI: 51.0-65.3) and even higher in infants covered by Medicaid (133.1 per 100 000; 95% CI: 115.2-151.0 [or 1 in 752 infants]). Overall, there were 300 children who died in the hospital due to physical abuse. CONCLUSIONS: This is the first study to provide national US data on the occurrence of serious injuries due to physical abuse in hospitalized children. Data from the 2006 Kids' Inpatient Database on hospitalizations due to serious physical abuse can be used to track trends over time and the effects of prevention programs on serious physical abuse. Pediatrics 2012; 129:458-464	[Leventhal, John M.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; [Gaither, Julie R.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; [Martin, Kimberly D.] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA; [Martin, Kimberly D.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA		Leventhal, JM (corresponding author), Yale Univ, Sch Med, Dept Pediat, POB 208064,333 Cedar St, New Haven, CT 06520 USA.	john.leventhal@yale.edu			Yale University Department of Pediatrics	Supported by Child Abuse Funds in the Yale University Department of Pediatrics.	Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project, OV KIDS INP DAT KID; [Anonymous], COST TO CHARGE RATIO; Berger LM, 2005, CHILD ABUSE NEGLECT, V29, P107, DOI 10.1016/j.chiabu.2004.02.006; Berger RP, 2011, PEDIATRICS, V128, P637, DOI 10.1542/peds.2010-2185; Ellingson KD, 2008, AM J PREV MED, V34, pS157, DOI 10.1016/j.amepre.2007.12.021; Gessner BD, 2004, CHILD ABUSE NEGLECT, V28, P9, DOI 10.1016/j.chiabu.2003.03.002; Hauck FR, 2008, PEDIATRICS, V122, P660, DOI 10.1542/peds.2007-0135; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Leventhal JM, 2007, CHILD ABUSE NEGLECT, V31, P311, DOI 10.1016/j.chiabu.2006.07.004; Lindberg DM, 2008, PEDIATRICS, V121, pE945, DOI 10.1542/peds.2007-2485; National Center for Health Statistics Centers for Medicare and Medicaid Services, 1999, INT CLASS DIS 9 REV; Sedlak A.J., 2010, 4 NATL INCIDENCE STU; Sibert JR, 2002, CHILD ABUSE NEGLECT, V26, P267, DOI 10.1016/S0145-2134(01)00324-6; *US ADM CHILDR YOU, 2008, CHILD MALTR 2006; *US BUR CENS, HLTH INS COV STAT TY; *US BUR CENS, POP EST; Wang C-T., 2007, TOTAL ESTIMATED COST; WINN DG, 1995, PUBLIC HEALTH REP, V110, P277	19	74	74	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	MAR	2012	129	3					458	464		10.1542/peds.2011-1277			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	922IQ	WOS:000302541000042	22311999				2022-02-06	
J	Khuman, J; Zhang, J; Park, J; Carroll, JD; Donahue, C; Whalen, MJ				Khuman, Jugta; Zhang, Jimmy; Park, Juyeon; Carroll, James D.; Donahue, Chad; Whalen, Michael J.			Low-Level Laser Light Therapy Improves Cognitive Deficits and Inhibits Microglial Activation after Controlled Cortical Impact in Mice	JOURNAL OF NEUROTRAUMA			English	Article						cognition; controlled cortical impact; inflammation; low-level laser light therapy; mice; microglia	TRAUMATIC BRAIN-INJURY; LONG-TERM DISABILITY; UNITED-STATES; PROMOTES REGENERATION; FUNCTIONAL RECOVERY; ISCHEMIC-STROKE; EMITTING DIODE; WATER MAZE; TNF-ALPHA; IRRADIATION	Low-level laser light therapy (LLLT) exerts beneficial effects on motor and histopathological outcomes after experimental traumatic brain injury (TBI), and coherent near-infrared light has been reported to improve cognitive function in patients with chronic TBI. However, the effects of LLLT on cognitive recovery in experimental TBI are unknown. We hypothesized that LLLT administered after controlled cortical impact (CCI) would improve post-injury Morris water maze (MWM) performance. Low-level laser light (800 nm) was applied directly to the contused parenchyma or transcranially in mice beginning 60-80 min after CCI. Injured mice treated with 60 J/cm(2) (500 mW/cm(2)x2 min) either transcranially or via an open craniotomy had modestly improved latency to the hidden platform (p<0.05 for group), and probe trial performance (p<0.01) compared to non-treated controls. The beneficial effects of LLLT in open craniotomy mice were associated with reduced microgliosis at 48h (21.8 +/- 2.3 versus 39.2 +/- 4.2 IbA-1 + cells/200 x field, p<0.05). Little or no effect of LLLT on post-injury cognitive function was observed using the other doses, a 4-h administration time point and 7-day administration of 60 J/cm(2). No effect of LLLT (60 J/cm(2) open craniotomy) was observed on post-injury motor function (days 1-7), brain edema (24h), nitrosative stress (24h), or lesion volume (14 days). Although further dose optimization and mechanism studies are needed, the data suggest that LLLT might be a therapeutic option to improve cognitive recovery and limit inflammation after TBI.	[Khuman, Jugta; Zhang, Jimmy; Park, Juyeon; Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Sch Med, Charlestown, MA 02129 USA; [Khuman, Jugta; Zhang, Jimmy; Park, Juyeon; Donahue, Chad; Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Neurosci Ctr, Sch Med, Charlestown, MA 02129 USA; [Carroll, James D.] THOR Photomed Ltd, Chesham, England		Whalen, MJ (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Sch Med, Charlestown, MA 02129 USA.	mwhalen@partners.org	Carroll, James/AAL-1739-2021	Carroll, James/0000-0002-9205-1061	Massachusetts General Hospital Center for the Integration of Medicine and Technology (CIMIT);  [RO1NS047447]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447] Funding Source: NIH RePORTER	This work was supported by grants from the Massachusetts General Hospital Center for the Integration of Medicine and Technology (CIMIT) (M.J.W.), and RO1NS047447	Ad N, 2001, INT J CARDIOL, V80, P109, DOI 10.1016/S0167-5273(01)00503-4; Anders JJ, 2004, NEUROL RES, V26, P233, DOI 10.1179/016164104225013914; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600-051X.1996.tb00580.x; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Konstantinovic LM, 2010, PAIN MED, V11, P1169, DOI 10.1111/j.1526-4637.2010.00907.x; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; Lanzafame RJ, 2007, LASER SURG MED, V39, P534, DOI 10.1002/lsm.20519; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Lubart R, 2005, PHOTOMED LASER SURG, V23, P3, DOI 10.1089/pho.2005.23.3; Lubart R, 2006, PHOTOMED LASER SURG, V24, P532, DOI 10.1089/pho.2006.24.532; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Mochizuki-Oda N, 2002, NEUROSCI LETT, V323, P207, DOI 10.1016/S0304-3940(02)00159-3; Moreira MS, 2009, J PHOTOCH PHOTOBIO B, V97, P145, DOI 10.1016/j.jphotobiol.2009.09.002; Moriyama Y, 2005, PHOTOCHEM PHOTOBIOL, V81, P1351, DOI 10.1562/2005-02-28-RA-450; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Pastore D, 2000, INT J RADIAT BIOL, V76, P863; Rochkind S, 2009, PHOTOMED LASER SURG, V27, P219, DOI 10.1089/pho.2009.9955; de Morais NCR, 2010, PHOTOMED LASER SURG, V28, P227, DOI 10.1089/pho.2008.2422; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; Simunovic-Soskic M, 2010, PHOTOMED LASER SURG, V28, P189, DOI 10.1089/pho.2008.2420; Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910; Streifler Jonathan Y, 2007, Harefuah, V146, P373; Tafur J, 2008, PHOTOMED LASER SURG, V26, P323, DOI 10.1089/pho.2007.2184; Tafur J, 2010, PHOTOMED LASER SURG, V28, P23, DOI 10.1089/pho.2008.2373; Wong SF, 2002, CANCER J, V8, P247, DOI 10.1097/00130404-200205000-00008; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Yau JLW, 2002, J NEUROSCI, V22, P1436, DOI 10.1523/JNEUROSCI.22-04-01436.2002; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	53	74	74	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					408	417		10.1089/neu.2010.1745			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300020	21851183	Green Published			2022-02-06	
J	Broglio, SP; Eckner, JT; Surma, T; Kutcher, JS				Broglio, Steven P.; Eckner, James T.; Surma, Tyler; Kutcher, Jeffrey S.			Post-Concussion Cognitive Declines and Symptomatology Are Not Related to Concussion Biomechanics in High School Football Players	JOURNAL OF NEUROTRAUMA			English	Article						acceleration; concussion; cognitive decline	TRAUMATIC BRAIN-INJURY; HEAD IMPACTS; RECOVERY; ACCELERATION; SENSITIVITY; SYMPTOMS; LOCATION	Concussion is a major public health concern with nearly 4 million injuries occurring each year in the United States. In the acute post-injury stage, concussed individuals demonstrate cognitive function and motor control declines as well as reporting increased symptoms. Researchers have hypothesized that the severity of these impairments is related to impact magnitude. Using the Head Impact Telemetry System (HITS) to record head impact biomechanics, we sought to correlate pre- and post-concussive impact characteristics with declines in cognitive performance and increases in concussion-related symptoms. Over four seasons, 19 high school football athletes wearing instrumented helmets sustained 20 diagnosed concussions. Each athlete completed a baseline computer-based symptom and cognitive assessment during the pre-season and a post-injury assessment within 24 h of injury. Correlational analyses identified no significant relationships between symptoms and cognitive performance change scores and impact biomechanics (i.e., time from session start until injury, time from the previous impact, peak linear acceleration, peak rotational acceleration, and HIT severity profile [HITsp]). Nor were there any significant relationships between change scores and the number of impacts, cumulative linear acceleration, cumulative rotational acceleration, or cumulative HITsp values associated with all impacts prior to or following the injury. This investigation is the first to examine the relationship between concussion impact characteristics, including cumulative impact profiles, and post-morbid outcomes in high school athletes. There appears to be no association between head impact biomechanics and post-concussive outcomes. As such, the use of biomechanical variables to predict injury severity does not appear feasible at this time.	[Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Neurotrauma Res Lab, Ann Arbor, MI 48109 USA; [Eckner, James T.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA		Broglio, SP (corresponding author), Univ Michigan, Sch Kinesiol, Neurotrauma Res Lab, 1402 Washington Hts, Ann Arbor, MI 48109 USA.	broglio@umich.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12 HD001097] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER		Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Broglio S.P., 2011, J NEUROTRAU IN PRESS; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner J.T., 2011, J NEUROTRAU IN PRESS; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Iverson G.L., 2003, RELIABILITY VALIDITY; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Kelly JP, 1997, NEUROLOGY, V48, P581; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell M.R, 2007, IMPACT 2007 6 0 SOFT; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	33	74	74	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2061	2068		10.1089/neu.2011.1905			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500007	21644811	Green Published, Green Submitted			2022-02-06	
J	Wang, GH; Jiang, ZL; Li, YC; Li, X; Shi, H; Gao, YQ; Vosler, PS; Chen, J				Wang, Guo-Hua; Jiang, Zheng-Lin; Li, Yong-Cai; Li, Xia; Shi, Hong; Gao, Yan-Qin; Vosler, Peter S.; Chen, Jun			Free-Radical Scavenger Edaravone Treatment Confers Neuroprotection Against Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						edaravone; inflammatory cytokines; neuroprotection; oxidative stress; TBI	CELL-DEATH; ANTIOXIDANT; PATHOPHYSIOLOGY; MICROGLIA; CYTOKINES; MCI-186; TARGETS; DAMAGE	Traumatic brain injury (TBI) is one of the leading causes of neurological disability in young adults. Edaravone, a novel synthetic small-molecule free-radical scavenger, has been shown to have a neuroprotective effect in both animal models of cerebral ischemia and stroke patients; however, the underlying mechanism is poorly understood. In this report, we investigated the potential mechanisms of edaravone treatment in a rat model of TBI. TBI was induced in the right cerebral cortex of male adult rats using Feeney's weight-drop method. Edaravone (0.75, 1.5, or 3 mg/kg) or vehicle (normal saline) was intravenously administered at 2 and 12 h after TBI. Edaravone treatment significantly decreased hippocampal CA3 neuron loss, reduced oxidative stress, and decreased neuronal programmed cell death compared to vehicle treatment. The protective effects of edaravone treatment were also related to the pathology of TBI on non-neuronal cells, as edaravone decreased astrocyte and glial activation. Lastly, edaravone treatment significantly reduced the presence of inflammatory cytokines, cerebral edema, blood-brain barrier (BBB) permeability, and, importantly, neurological deficits following TBI. Our results suggest that edaravone exerts a neuroprotective effect in the rat model of TBI. The likely mechanism is via inhibiting oxidative stress, leading to a decreased inflammatory response and glial activation, and thereby reducing neuronal death and improving neurological function.	[Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA; [Wang, Guo-Hua; Jiang, Zheng-Lin; Li, Xia] Nantong Univ, Inst Naut Med, Dept Neuropharmacol, Nantong 226001, Jiangsu, Peoples R China; [Wang, Guo-Hua; Shi, Hong; Gao, Yan-Qin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China; [Li, Yong-Cai] Peoples Hosp Ningxia, Dept Neurosurg, Ningxia, Peoples R China		Chen, J (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA.	jiangzl@ntu.edu.cn; chenj2@upmc.edu	Gao, Yanqin/I-6790-2016	Gao, Yanqin/0000-0002-4915-9819; Wang, Guohua/0000-0002-4810-8534; Vosler, Peter/0000-0002-7689-5539	Chinese Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81000497]; Priority Academic Program Development of Jiangsu Higher Education Institutions; Administration of Science and Technology of Nantong, Jiangsu Province, China [S2010011]; Qing Lan Project of Jiangsu Province, China; Chinese Ministry of Science and TechnologyMinistry of Science and Technology, China; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS36736, NS43802, NS45048]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045048, R01NS043802, R01NS036736] Funding Source: NIH RePORTER	This study was supported by the Chinese Natural Science Foundation (Grant 81000497), the Priority Academic Program Development of Jiangsu Higher Education Institutions, and the Administration of Science and Technology of Nantong, Jiangsu Province, China (Project No. S2010011). Guo-Hua Wang was sponsored by the Qing Lan Project of Jiangsu Province, China. Guo-Hua Wang, Yan-Qin Gao, and Jun Chen are supported by the Special Research Funds from Chinese Ministry of Science and Technology to State Key laboratories. Peter S. Vosler and Jun Chen are also supported by National Institutes of Health Grants NS36736, NS43802, and NS45048.	Aarabi B, 2009, CURR OPIN CRIT CARE, V15, P548, DOI 10.1097/MCC.0b013e32833190da; Besson VC, 2009, BRIT J PHARMACOL, V157, P695, DOI 10.1111/j.1476-5381.2009.00229.x; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Clausen F, 2008, J NEUROTRAUM, V25, P1449, DOI 10.1089/neu.2008.0585; Dohi K, 2007, ANTIOXID REDOX SIGN, V9, P281, DOI 10.1089/ars.2007.9.281; Dohi K, 2006, J NEUROTRAUM, V23, P1591, DOI 10.1089/neu.2006.23.1591; Eghwrudjakpor P O, 2010, Niger J Med, V19, P14; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Griesser M, 2009, J LIPID RES, V50, P2455, DOI 10.1194/jlr.M900181-JLR200; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Kikuchi K, 2010, MED HYPOTHESES, V75, P583, DOI 10.1016/j.mehy.2010.07.038; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lapchak PA, 2010, EXPERT OPIN PHARMACO, V11, P1753, DOI 10.1517/14656566.2010.493558; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Margaill I, 2005, FREE RADICAL BIO MED, V39, P429, DOI 10.1016/j.freeradbiomed.2005.05.003; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; Naritomi Hiroaki, 2010, Drugs R D, V10, P155, DOI 10.2165/11586550-000000000-00000; Pearse D, 2010, CURR OPIN INVEST DR, V11, P1207; Petronilho F, 2010, J SURG RES, V164, P316, DOI 10.1016/j.jss.2009.04.031; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Serrano-Perez MC, 2011, GLIA, V59, P94, DOI 10.1002/glia.21079; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Spickett CM, 2010, FREE RADICAL RES, V44, P1172, DOI 10.3109/10715762.2010.498476; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Tacconi MT, 1998, NEUROCHEM RES, V23, P759, DOI 10.1023/A:1022463527474; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; Vosler PS, 2009, STROKE, V40, pS119, DOI 10.1161/STROKEAHA.108.533109; Vosler PS, 2009, EXP NEUROL, V218, P213, DOI 10.1016/j.expneurol.2009.04.032; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wang GH, 2010, J NEUROTRAUM, V27, P1733, DOI 10.1089/neu.2009.1175; WATANABE T, 1988, PROSTAG LEUKOTR ESS, V33, P81, DOI 10.1016/0952-3278(88)90127-5; Yoshida H, 2006, CNS DRUG REV, V12, P9, DOI 10.1111/j.1527-3458.2006.00009.x; Zhang N, 2005, STROKE, V36, P2220, DOI 10.1161/01.STR.0000182241.07096.06; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	46	74	86	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2123	2134		10.1089/neu.2011.1939			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500013	21732763	Green Published			2022-02-06	
J	Chen, HI; Stiefel, MF; Oddo, M; Milby, AH; Maloney-Wilensky, E; Frangos, S; Levine, JM; Kofke, WA; LeRoux, PD				Chen, H. Isaac; Stiefel, Michael F.; Oddo, Mauro; Milby, Andrew H.; Maloney-Wilensky, Eileen; Frangos, Suzanne; Levine, Joshua M.; Kofke, W. Andrew; LeRoux, Peter D.			Detection of Cerebral Compromise With Multimodality Monitoring in Patients With Subarachnoid Hemorrhage	NEUROSURGERY			English	Article						Brain tissue oxygen; Cerebral metabolism; Cerebral microdialysis; Lactate/pyruvate ratio; Multimodality monitoring; Subarachnoid hemorrhage	BRAIN-TISSUE OXYGEN; RESPIRATORY-DISTRESS-SYNDROME; LACTATE-PYRUVATE RATIO; BLOOD-FLOW; INTRACRANIAL-PRESSURE; LACTATE/PYRUVATE RATIO; BEDSIDE MICRODIALYSIS; NEUROLOGICAL DEFICITS; NEUROCRITICAL CARE; PERFUSION-PRESSURE	BACKGROUND: Studies in traumatic brain injury suggest that monitoring techniques such as brain tissue oxygen (PBTO2) and cerebral microdialysis may complement conventional intracranial pressure (ICP) and cerebral perfusion pressure (CPP) measurements. OBJECTIVE: In this study of poor-grade (Hunt and Hess grade IV and V) subarachnoid hemorrhage (SAH) patients, we examined the prevalence of brain hypoxia and brain energy dysfunction in the presence of normal and abnormal ICP and CPP. METHODS: SAH patients who underwent multimodal neuromonitoring and cerebral microdialysis were studied. We examined the frequency of brain hypoxia and energy dysfunction in different ICP and CPP ranges and the relationship between PBTO2 and the lactate/pyruvate ratio (LPR). RESULTS: A total of 2394 samples from 19 patients were analyzed. There were 149 samples with severe brain hypoxia (PBTO2 <= 10 mm Hg) and 347 samples with brain energy dysfunction (LPR > 40). The sensitivities of abnormal ICP or CPP for elevated LPR and reduced PBTO2 were poor (21.2% at best), and the LPR or PBTO2 was abnormal in many instances when ICP or CPP was normal. Severe brain hypoxia was often associated with an LPR greater than 40 (86% of samples). In contrast, mild brain hypoxia (<= 20 mm Hg) and severe brain hypoxia were observed in only 53% and 36% of samples with brain energy dysfunction, respectively. CONCLUSION: Our data demonstrate that ICP and CPP monitoring may not always detect episodes of cerebral compromise in SAH patients. Our data suggest that several complementary monitors may be needed to optimize the care of poor-grade SAH patients.	[Chen, H. Isaac; Stiefel, Michael F.; Oddo, Mauro; Maloney-Wilensky, Eileen; Frangos, Suzanne; Levine, Joshua M.; Kofke, W. Andrew; LeRoux, Peter D.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Levine, Joshua M.] Hosp Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Levine, Joshua M.; Kofke, W. Andrew] Hosp Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Milby, Andrew H.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA		LeRoux, PD (corresponding author), Penn Hosp, Dept Neurosurg, Washington Sq W Bldg,235 S 8th St, Philadelphia, PA 19106 USA.	Peter.LeRoux@uphs.upenn.edu	Oddo, Mauro/R-3370-2016	Oddo, Mauro/0000-0002-6155-2525	SICPA Foundation, Switzerland; Integra Foundation; Mary Elisabeth Groff Surgical and Medical Research Trust	This research was supported in part by research grants from the SICPA Foundation, Switzerland (M.O.), the Integra Foundation (P.D.L.), and the Mary Elisabeth Groff Surgical and Medical Research Trust (P.D.L.). The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Adamides AA, 2009, J AM COLL SURGEONS, V209, P531, DOI 10.1016/j.jamcollsurg.2009.05.028; Al-Rawi PG, 2005, ACTA NEUROCHIR SUPPL, V95, P123; Barth M, 2010, NEUROCRIT CARE, V12, P234, DOI 10.1007/s12028-009-9287-8; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Bjerring PN, 2008, NEUROCRIT CARE, V9, P3, DOI 10.1007/s12028-008-9060-4; Carles M, 2008, BRIT J ANAESTH, V100, P29, DOI 10.1093/bja/aem321; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Clausen T, 2004, BRAIN RES, V1019, P113, DOI 10.1016/j.brainres.2004.05.099; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Dai YL, 2010, CARDIOVASC TOXICOL, V10, P130, DOI 10.1007/s12012-010-9071-1; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Frontera JA, 2009, STROKE, V40, P1963, DOI 10.1161/STROKEAHA.108.544700; Goodman JC, 2009, CURR OPIN CRIT CARE, V15, P110, DOI 10.1097/MCC.0b013e328325d142; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gracias VH, 2004, J TRAUMA, V56, P469, DOI 10.1097/01.TA.0000114274.95423.C0; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; Jahromi BS, 2004, MANAGEMENT CEREBRAL, P455; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Khaldi A, 2001, NEUROSURGERY, V49, P33; KOGURE K, 1975, AM J PHYSIOL, V228, P1862, DOI 10.1152/ajplegacy.1975.228.6.1862; Kreiter KT, 2009, STROKE, V40, P2362, DOI 10.1161/STROKEAHA.109.547331; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Levy B, 1997, INTENS CARE MED, V23, P282, DOI 10.1007/s001340050329; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Maloney-Wilensky E, 2010, CHILD NERV SYST, V26, P419, DOI 10.1007/s00381-009-1037-x; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Marshall RS, 2004, CURR OPIN NEUROL, V17, P705, DOI 10.1097/00019052-200412000-00010; MAYBERG MR, 1994, CIRCULATION, V90, P2592, DOI 10.1161/01.CIR.90.5.2592; Meixensberger J, 2003, NEUROL RES, V25, P445, DOI 10.1179/016164103101201823; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; MICHENFELDER JD, 1975, AM J PHYSIOL, V229, P1050, DOI 10.1152/ajplegacy.1975.229.4.1050; MICHENFELDER JD, 1977, ANESTHESIOLOGY, V46, P196, DOI 10.1097/00000542-197703000-00007; Mileski WJ, 2004, J TRAUMA, V56, P472; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; Nakasaki H, 1997, NUTRITION, V13, P110, DOI 10.1016/S0899-9007(96)00384-X; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Oddo M, 2009, STROKE, V40, P1275, DOI 10.1161/STROKEAHA.108.527911; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; Raabe A, 2005, J NEUROSURG, V103, P974, DOI 10.3171/jns.2005.103.6.0974; Ramakrishna R, 2008, J NEUROSURG, V109, P1075, DOI 10.3171/JNS.2008.109.12.1075; Reinprecht A, 2003, CRIT CARE MED, V31, P1831, DOI 10.1097/01.CCM.0000063453.93855.0A; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rose JC, 2006, CURR OPIN CRIT CARE, V12, P97, DOI 10.1097/01.ccx.0000216574.26686.e9; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Skjoth-Rasmussen J, 2004, J NEUROSURG, V100, P8, DOI 10.3171/jns.2004.100.1.0008; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Soehle M, 2003, NEUROL RES, V25, P411, DOI 10.1179/016164103101201580; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Springborg JB, 2005, BRIT J ANAESTH, V94, P259, DOI 10.1093/bja/aei004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Stein Sherman C, 2006, Neurosurg Focus, V21, pE2; Stiefel MF, 2004, J NEUROSURG, V101, P594, DOI 10.3171/jns.2004.101.4.0594; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Tinsa Faten, 2009, Tunis Med, V87, P159; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vath A, 2002, ACT NEUR S, V81, P307; Vergouwen MDI, 2008, J CEREBR BLOOD F MET, V28, P1761, DOI 10.1038/jcbfm.2008.74; Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Winn HR., 2004, MANAGEMENT CEREBRAL, P303	80	74	75	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2011	69	1					53	63		10.1227/NEU.0b013e3182191451			11	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	773XK	WOS:000291344700033	21796073				2022-02-06	
J	Wang, JQ; Hamm, RJ; Povlishock, JT				Wang, Jiaqiong; Hamm, Robert J.; Povlishock, John T.			Traumatic Axonal Injury in the Optic Nerve: Evidence for Axonal Swelling, Disconnection, Dieback, and Reorganization	JOURNAL OF NEUROTRAUMA			English	Article						anterograde and retrograde axonal change; amyloid precursor protein; axonal dieback; brain edema; traumatic brain injury; YFP mice	AMYLOID PRECURSOR PROTEIN; EXPERIMENTAL BRAIN-INJURY; HEAD-INJURY; POSTTRAUMATIC HYPOTHERMIA; WALLERIAN DEGENERATION; RETROGRADE CONVERSION; TRANSPORTED VESICLES; STRETCH-INJURY; CYCLOSPORINE-A; SPINAL-CORD	Traumatic axonal injury (TAI) is a major feature of traumatic brain injury (TBI) and is associated with much of its morbidity. To date, significant insight has been gained into the initiating pathogenesis of TAI. However, the nature of TAI within the injured brain precludes the consistent evaluation of its specific anterograde and retrograde sequelae. To overcome this limitation, we used the relatively organized optic nerve in a central fluid percussion injury (cFPI) model. To improve the visualization of TAI, we utilized mice expressing yellow fluorescent protein (YFP) in their visual pathways. Through this approach, we consistently generated TAI in the optic nerve and qualitatively and quantitatively evaluated its progression over a 48-h period in YFP axons via confocal microscopy and electron microscopy. In this model, delayed axonal swelling with subsequent disconnection were the norm, together with the fact that once disconnected, both the proximal and distal axonal segments revealed significant dieback, with the proximal swellings showing regression and reorganization, while the distal swellings persisted, although showing signs of impending degeneration. When antibodies targeting the C-terminus of amyloid precursor protein (APP), a routine marker of TAI were employed, they mapped exclusively to the proximal axonal segments without distal targeting, regardless of the survival time. Concomitant with this evolving axonal pathology, focal YFP fluorescence quenching occurred and mapped precisely to immunoreactive loci positive for Texas-Red-conjugated-IgG, indicating that blood-brain barrier disruption and its attendant edema contributed to this phenomenon. This was confirmed through the use of antibodies targeting endogenous YFP, which demonstrated the retention of intact immunoreactive axons despite YFP fluorescence quenching. Collectively, the results of this study within the injured optic nerve provide unprecedented insight into the evolving pathobiology associated with TAI.	[Wang, Jiaqiong; Hamm, Robert J.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA		Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			 [HD055813];  [5P30NS047463]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS047463] Funding Source: NIH RePORTER	This research is supported by grants HD055813 and 5P30NS047463. We thank Raymond Colello, Scott Henderson, Susan A. Walker, Lynn Carol Davis, Sharon Toussaint, and Jesse A. Sims for their technical assistance and guidance in various aspects of this study.	Beirowski B, 2010, J NEUROPATH EXP NEUR, V69, P455, DOI 10.1097/NEN.0b013e3181da84db; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 2000, J NEUROSCI, V20, P2825; Busch SA, 2009, J NEUROSCI, V29, P9967, DOI 10.1523/JNEUROSCI.1151-09.2009; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; EBBESEN TW, 1989, J PHYS CHEM-US, V93, P7139, DOI 10.1021/j100357a023; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Gao GY, 2010, J CEREBR BLOOD F MET, V30, P628, DOI 10.1038/jcbfm.2009.235; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hellman AN, 2010, LAB CHIP, V10, P2083, DOI 10.1039/b927153h; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; KILINC D, 2007, C P IEEE ENG MED BIO, P5395; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; MARTZ D, 1989, BRAIN RES, V476, P199, DOI 10.1016/0006-8993(89)91559-X; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; MAXWELL WL, 1990, J NEUROCYTOL, V19, P235, DOI 10.1007/BF01217301; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; ODA Y, 2010, J CEREB BLOOD F 1215; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Oshima J, 2006, CHEM PHYS LETT, V423, P306, DOI 10.1016/j.cplett.2006.03.073; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SAATMAN KE, 2009, HDB NEUROCHEMISTRY M, P343; SADKOWSKI PJ, 1980, CHEM PHYS, V54, P79, DOI 10.1016/0301-0104(80)80037-1; SAHENK Z, 1988, BRAIN RES, V460, P199, DOI 10.1016/0006-8993(88)91224-3; SELISKAR CJ, 1971, J AM CHEM SOC, V93, P5405, DOI 10.1021/ja00750a016; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Shagin DA, 2004, MOL BIOL EVOL, V21, P841, DOI 10.1093/molbev/msh079; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Sprecher SG, 2008, NATURE, V454, P533, DOI 10.1038/nature07062; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; SULAIMAN A, 2010, J NEUROTRAUMA; Tobita S, 2001, RES CHEM INTERMEDIAT, V27, P205, DOI 10.1163/156856701745087; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; [No title captured]	64	74	78	0	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2011	28	7					1185	1198		10.1089/neu.2011.1756			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	794BL	WOS:000292869600007	21506725	Green Published			2022-02-06	
J	Schwarzbold, ML; Rial, D; De Bem, T; Machado, DG; Cunha, MP; dos Santos, AA; dos Santos, DB; Figueiredo, CP; Farina, M; Goldfeder, EM; Rodrigues, ALS; Prediger, RDS; Walz, R				Schwarzbold, Marcelo L.; Rial, Daniel; De Bem, Tatiana; Machado, Daniele G.; Cunha, Mauricio P.; dos Santos, Alessandra A.; dos Santos, Danubia B.; Figueiredo, Claudia P.; Farina, Marcelo; Goldfeder, Eliane M.; Rodrigues, Ana Lucia S.; Prediger, Rui D. S.; Walz, Roger			Effects of Traumatic Brain Injury of Different Severities on Emotional, Cognitive, and Oxidative Stress-Related Parameters in Mice	JOURNAL OF NEUROTRAUMA			English	Article						anxiety; depression; learning and memory; oxidative stress; traumatic brain injury	GLUTATHIONE-PEROXIDASE ACTIVITY; BEHAVIORAL-TEST BATTERIES; EXPERIMENTAL HEAD-INJURY; FLUID PERCUSSION INJURY; TAIL SUSPENSION TEST; LOCOMOTOR-ACTIVITY; LIPID-PEROXIDATION; CORTICAL IMPACT; IMMATURE BRAIN; DEPRESSION	Cognitive deficits and psychiatric disorders are significant sequelae of traumatic brain injury (TBI). Animal models have been widely employed in TBI research, but few studies have addressed the effects of experimental TBI of different severities on emotional and cognitive parameters. In this study, mice were subjected to weight-drop TBI to induce mild, intermediate, or severe TBI. After neurological assessment, the mice recovered for 10 days, and were then subjected to a battery of behavioral tests, which included open-field, elevated plus-maze, forced swimming, tail suspension, and step-down inhibitory avoidance tests. Oxidative stress-related parameters (nonprotein thiols [NPSH], glutathione peroxidase [GPx], glutathione reductase [GR], and thiobarbituric acid reactive species [TBARS]) were quantified in the cortex and hippocampus at 2 and 24 h and 14 days after TBI, and histopathological analysis was performed 15 days after TBI. Mice subjected to mild TBI showed increased anxiety and depressive-like behaviors, while intermediate and severe TBI induced robust memory deficits. The severe TBI group also displayed increased locomotor activity. Intermediate and severe TBI caused extensive macroscopic and microscopic brain damage, while mild TBI typically had no histological abnormalities. Moreover, a significant increase in TBARS in the ipsilateral cortex and GPx in the ipsilateral hippocampus was observed at 24 h and 14 days, respectively, following intermediate TBI. The current experimental TBI model induced emotional and cognitive changes comparable to sequelae seen in human TBI, and it might therefore represent a useful approach to the study of mechanisms of and new treatments for TBI and related disorders.	[Walz, Roger] Univ Fed Santa Catarina, Ctr Neurociencias Aplicadas, Dept Clin Med, Hosp Univ, Florianopolis, SC, Brazil; [Rial, Daniel; De Bem, Tatiana; Prediger, Rui D. S.] Univ Fed Santa Catarina, Lab Expt Doencas Neurodegenerat, Dept Farmacol, Florianopolis, SC, Brazil; [Machado, Daniele G.; Cunha, Mauricio P.; dos Santos, Alessandra A.; dos Santos, Danubia B.; Farina, Marcelo; Rodrigues, Ana Lucia S.] Univ Fed Santa Catarina, Dept Bioquim, Florianopolis, SC, Brazil; [Figueiredo, Claudia P.] Univ Fed Santa Catarina, Programa Posgrad Neurociencias, Dept Ciencias Fisiol, Florianopolis, SC, Brazil; [Goldfeder, Eliane M.] Univ Fed Santa Catarina, Dept Ciencias Morfol, Florianopolis, SC, Brazil; [Walz, Roger] Hosp Governador Celso Ramos, Ctr Epilepsia Santa Catarina, Florianopolis, SC, Brazil		Walz, R (corresponding author), Univ Fed Santa Catarina, Ctr Neurociencias Aplicadas, Dept Clin Med, Hosp Univ, 3 Andar,Campus Trindade, Florianopolis, SC, Brazil.	rogerwalz@hotmail.com	Machado, Daniele G/C-3953-2013; Farina, Marcelo/AAH-2005-2019; Schwarzbold, Marcelo Liborio/J-8960-2014; Prediger, Rui Daniel/AAV-3419-2020; Walz, Roger/K-9096-2013; Rial, Daniel/C-3595-2013; Rial, Daniel/D-3219-2009; Figueiredo, Claudia P/F-8424-2012; Rodrigues, Ana Lucia/P-6869-2015; dos Santos, Alessandra Antunes/F-3484-2019; Cunha, Mauricio/J-7135-2013; Prediger, Rui D/C-4036-2013	Farina, Marcelo/0000-0001-8255-8515; Prediger, Rui Daniel/0000-0002-7547-6463; Walz, Roger/0000-0002-9875-6687; Rial, Daniel/0000-0002-2079-7331; Rodrigues, Ana Lucia/0000-0001-6285-8780; Cunha, Mauricio/0000-0002-0269-7521; Prediger, Rui D/0000-0002-7547-6463; Guilhermano Machado, Daniele/0000-0002-3550-1265; Figueiredo, Claudia/0000-0001-9467-9891	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), BrazilConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), BrazilCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Programa de Apoio aos Nucleos de Excelencia (PRONEX), Brazil; Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (FAPESC), Brazil	This work was supported by grants from the following Brazilian agencies: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Programa de Apoio aos Nucleos de Excelencia (PRONEX), and Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (FAPESC). M.L.S., D.R., and T.D.B. receive scholarships from CNPq, and C.P.F.from CAPES. M.F., A.L.S.R., R.D.S.P., and R.W.are supported by research fellowships from CNPq.	Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; BABCOCK AM, 1993, BRAIN RES, V625, P351, DOI 10.1016/0006-8993(93)91081-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Cunha MP, 2008, PROG NEURO-PSYCHOPH, V32, P1913, DOI 10.1016/j.pnpbp.2008.09.006; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Dringen R, 2005, J NEUROSCI RES, V79, P157, DOI 10.1002/jnr.20280; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Farina M, 2003, TOXICOLOGY, V184, P179, DOI 10.1016/S0300-483X(02)00576-0; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li SH, 2006, J NEUROSCI RES, V83, P292, DOI 10.1002/jnr.20720; LISTER RG, 1987, PSYCHOPHARMACOLOGY, V92, P180; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McArthur R, 2006, PHARMACOL BIOCHEM BE, V84, P436, DOI 10.1016/j.pbb.2006.06.005; McIlwain KL, 2001, PHYSIOL BEHAV, V73, P705, DOI 10.1016/S0031-9384(01)00528-5; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Paylor R, 2006, PHYSIOL BEHAV, V87, P95, DOI 10.1016/j.physbeh.2005.09.002; Pelegrin-Valero C, 2001, REV NEUROLOGIA, V32, P681, DOI 10.33588/rn.3207.2000180; PETRONILHO F, 2009, J SURG RES IN PRESS; PICK CG, 2009, J NEUROTRAU IN PRESS; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rial D, 2009, NEUROSCIENCE, V164, P896, DOI 10.1016/j.neuroscience.2009.09.005; Sartorius N, 1996, BRIT J PSYCHIAT, V168, P38, DOI 10.1192/S0007125000298395; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Starkstein SE, 1997, J NERV MENT DIS, V185, P108, DOI 10.1097/00005053-199702000-00007; STERU L, 1985, PSYCHOPHARMACOLOGY, V85, P367, DOI 10.1007/BF00428203; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Taylor AN, 2006, J NEUROTRAUM, V23, P1802, DOI 10.1089/neu.2006.23.1802; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Tsuru-Aoyagi K, 2009, ANN NEUROL, V65, P540, DOI 10.1002/ana.21600; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Viggiano D, 2008, BEHAV BRAIN RES, V194, P1, DOI 10.1016/j.bbr.2008.06.033; WANG D, 1990, BRAIN RES, V533, P78, DOI 10.1016/0006-8993(90)91798-L; Wendel A, 1981, Methods Enzymol, V77, P325; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; Zomkowski ADE, 2004, BRAIN RES, V1023, P253, DOI 10.1016/j.brainres.2004.07.041	71	74	74	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2010	27	10					1883	1893		10.1089/neu.2010.1318			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	665OZ	WOS:000283046600012	20649482				2022-02-06	
J	Cheng, JM; Gu, JW; Ma, YA; Yang, T; Kuang, YQ; Li, BC; Kang, JY				Cheng, Jingmin; Gu, Jianwen; Ma, Yuan; Yang, Tao; Kuang, Yongqin; Li, Bingcang; Kang, Jianyi			Development of a rat model for studying blast-induced traumatic brain injury	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Blast; Traumatic brain injury; Animal model	NEURON-SPECIFIC ENOLASE; MANAGEMENT; CASUALTIES; MARKER	Blast-induced traumatic brain injury (TBI) has been the predominant cause of neurotrauma in current military conflicts, and it is also emerging as a potential threat in civilian terrorism. The etiology of TBI, however, is poorly understood. Further study on the mechanisms and treatment of blast injury is urgently needed. We developed a unique rat model to simulate blast effects that commonly occur on the battlefield. An electric detonator with the equivalent of 400 mg TNT was developed as the explosive source. The detonator's peak overpressure and impulse of explosion shock determined the explosion intensity in a distance-dependent manner. Ninety-six male adult Sprague-Dawley rats were randomly divided into four groups: 5-cm, 7.5-cm, 10-cm, and control groups. The rat was fixed in a specially designed cabin with an adjustable aperture showing the frontal, parietal, and occipital parts of the head exposed to explosion; the eyes, ears, mouth, and nose were protected by the cabin. After each explosion, we assessed the physiologic, neuropathologic, and neurobehavioral consequences of blast injury. Changes of brain tissue water content and neuron-specific enolase (NSE) expression were detected. The results in the 7.5-cm group show that 87% rats developed apnea, limb seizure, poor appetite, and limpness. Diffuse subarachnoid hemorrhage and edema could be seen within the brain parenchyma, which showed a loss of integrity. Capillary damage and enlarged intercellular and vascular space in the cortex, along with a tattered nerve fiber were observed. These findings demonstrate that we have provided a reliable and reproducible blast-induced TBI model in rats. (C) 2010 Elsevier B.V. All rights reserved.	[Cheng, Jingmin; Gu, Jianwen; Ma, Yuan; Yang, Tao; Kuang, Yongqin] Gen Hosp Peoples Liberat Army Chengdu Mil Reg, Dept Neurosurg, Chengdu 610083, Sichuan, Peoples R China; [Li, Bingcang; Kang, Jianyi] Third Mil Med Univ, State Key Lab Trauma, Inst Surg Res,Daping Hosp, Res Inst Traff Med Peoples Liberat Army, Chongqing 400038, Peoples R China		Gu, JW (corresponding author), Gen Hosp Peoples Liberat Army Chengdu Mil Reg, Dept Neurosurg, Chengdu 610083, Sichuan, Peoples R China.	doctor_cjm@163.com; gujianwen5000@yahoo.com.cn; tianfu_47@163.com; yangtao_123@163.com; kuangyongqin_123@163.com; bingcangli_123@163.com; kangjianyi_123@163.com			Chengdu Army Region [Z07002]	This work was supported in part by Key Medical Grant of 11th five years' plan from Chengdu Army Region (No. Z07002).	BELL MK, 2008, MIL MED, V173, P5; Bochicchio GV, 2008, AM SURGEON, V74, P267; Celtik C, 2004, BRAIN DEV-JPN, V26, P398, DOI 10.1016/j.braindev.2003.12.007; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; de Ceballos JPG, 2005, CRIT CARE, V9, P104, DOI 10.1186/cc2995; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Durak Dilek, 2008, Hong Kong Medical Journal, V14, P489; Eastridge Brian J, 2008, Am J Disaster Med, V3, P301; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; Frykberg ER, 2002, J TRAUMA, V53, P201, DOI 10.1097/00005373-200208000-00001; HATFIELD RH, 1992, BRAIN RES, V577, P249, DOI 10.1016/0006-8993(92)90280-M; Kluger Yoram, 2007, Am J Disaster Med, V2, P21; Long J. B., 2009, J NEUROTRAUM, V26, P1; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; Ramasamy A, 2008, J TRAUMA, V65, P910, DOI 10.1097/TA.0b013e3181848cf6; SHANKER T, 2007, NY TIMES        0602, P1; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Vink R, 2003, ACT NEUR S, V86, P257; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	21	74	74	2	18	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	JUL 15	2010	294	1-2					23	28		10.1016/j.jns.2010.04.010			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	621IZ	WOS:000279571100004	20478573				2022-02-06	
J	Sribnick, EA; Samantaray, S; Das, A; Smith, J; Matzelle, DD; Ray, SK; Banik, NL				Sribnick, Eric A.; Samantaray, Supriti; Das, Arabinda; Smith, Joshua; Matzelle, D. Denise; Ray, Swapan K.; Banik, Naren L.			Postinjury Estrogen Treatment of Chronic Spinal Cord Injury Improves Locomotor Function in Rats	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						axonal damage; cell death; chronic spinal cord injury; estrogen; locomotor function	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; WHITE-MATTER INJURY; KAPPA-B ACTIVATION; CALPAIN INHIBITOR; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; RECEPTOR-ALPHA; CELL-DEATH; NEUROPROTECTIVE AGENT	Spinal cord injury (SCI) causes loss of neurological function and, depending on serverity, may cause paralysis. The only recommended pharmacotherapy for the treatment of SCI is high-dose methylprednisolone, and its use is controversial. We have previously shown that estrogen treatment attenuated cell death, axonal and myelin damage, calpain and caspase activities, and inflammation in acute SCI. The aim of this study was to examine whether posttreatment of SCI with estrogen would improve locomotor function by protecting cells and axons and reducing inflammation during the chronic phase following injury. Moderately severe injury (40 g . cm force) was induced in male Sprague-Dawley rats following laminectomy at T10. Three groups of animals were used: sham (laminectomy only), vehicle (dimethyl sulfoxide; DMSO)-treated injury group, and estrogen-treated injury group. Animals were treated with 4 mg/kg estrogen at 15 min and 24 hr postnjury, followed by 2 mg/kg estrogen daily for the next 5 days. After treatment, animals were sacrificed at the end of 6 weeks following injury, and 1-cm segments of spinal cord (lesion, rostral to lesion, and caudal to lesion) were removed for biochemical analyses. Estrogen treatment reduced COX-2 activity, blocked nuclear factor-kappa B translocation, prevented glial reactivity, attenuated neuron death, inhibited activation and activity of calpain and caspase-3, decreased axonal damage, reduced myelin loss in the lesion and penumbra, and improved locomotor function compared with vehicle-treated animals. These findings suggest that estrogen may be useful as a promising therapeutic agent for prevention of damage and improvement of locomotor function in chronic SCI. (C) 2010 Wiley-Liss, Inc.	[Sribnick, Eric A.; Samantaray, Supriti; Das, Arabinda; Smith, Joshua; Matzelle, D. Denise; Banik, Naren L.] Med Univ S Carolina, Div Neurol, Dept Neurosci, Charleston, SC 29425 USA; [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC USA		Banik, NL (corresponding author), Med Univ S Carolina, Div Neurol, Dept Neurosci, 96 Jonathan Lucas St,309CSB, Charleston, SC 29425 USA.	baniknl@musc.edu	Sribnick, Eric/AAH-6693-2020	Smith, Joshua/0000-0003-2172-9207	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-31622, NS-45967]; State of South Carolina Spinal Cord Injury Research Fund [SCIRF-1205]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031622, R01NS045967] Funding Source: NIH RePORTER	Contract grant sponsor: NIH; Contract grant number: NS-31622; Contract grant number: NS-45967; Contract grant sponsor: State of South Carolina Spinal Cord Injury Research Fund; Contract grant number: SCIRF-1205.	Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 2000, NEUROSCIENCE, V99, P179, DOI 10.1016/S0306-4522(00)00165-2; Aronica SM, 2004, BREAST CANCER RES TR, V84, P235, DOI 10.1023/B:BREA.0000019961.59306.f6; BANIK NL, 1983, NEUROCHEM RES, V8, P1389, DOI 10.1007/BF00964996; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Das A, 2005, J NEUROSCI RES, V81, P551, DOI 10.1002/jnr.20581; Dhillon HS, 1999, NEUROCHEM RES, V24, P751, DOI 10.1023/A:1020779413122; Dimayuga FO, 2005, J NEUROIMMUNOL, V161, P123, DOI 10.1016/j.jneuroim.2004.12.016; Dodel RC, 1999, J NEUROCHEM, V73, P1453, DOI 10.1046/j.1471-4159.1999.0731453.x; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.98.4.1952; Gao MX, 2000, NEUROIMMUNOMODULAT, V8, P78, DOI 10.1159/000026456; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Guyton MK, 2005, J NEUROSCI RES, V81, P53, DOI 10.1002/jnr.20470; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; Linford NJ, 2002, STEROIDS, V67, P1029, DOI 10.1016/S0039-128X(02)00062-4; Mills CD, 2000, NEUROREPORT, V11, P3067, DOI 10.1097/00001756-200009280-00007; Miyamoto N, 1999, J IMMUNOL, V163, P374; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; Morales LBJ, 2006, J NEUROSCI, V26, P6823, DOI 10.1523/JNEUROSCI.0453-06.2006; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633; PANT HC, 1988, BIOCHEM J, V256, P665, DOI 10.1042/bj2560665; Perot P L Jr, 1987, Cent Nerv Syst Trauma, V4, P149; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; RAY SK, 2002, ENCY MOL MED, P435; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Samantaray S, 2007, NEUROSCIENCE, V146, P741, DOI 10.1016/j.neuroscience.2007.01.056; Samantaray S, 2009, J NEUROCHEM, V108, P105; Schaecher K, 2004, NEUROCHEM RES, V29, P1443, DOI 10.1023/B:NERE.0000026410.56000.dd; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Smith JA, 2009, J NEUROCHEM, V108, P137; Sribnick E.A., 2009, BRAIN SPINAL CORD TR, pp581; Sribnick EA, 2006, NEUROSCIENCE, V137, P197, DOI 10.1016/j.neuroscience.2005.08.074; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Sribnick EA, 2004, NEUROCHEM RES, V29, P2007, DOI 10.1007/s11064-004-6874-0; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sribnick EA, 2007, NEUROCHEM RES, V32, P2210, DOI 10.1007/s11064-007-9433-7; Sribnick EA, 2009, BRAIN RES, V1276, P159, DOI 10.1016/j.brainres.2009.04.022; Sribnick EA, 2006, J NEUROSCI RES, V84, P1064, DOI 10.1002/jnr.21016; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Sur P, 2003, BRAIN RES, V971, P178, DOI 10.1016/S0006-8993(03)02349-7; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; Vegeto E, 2003, P NATL ACAD SCI USA, V100, P9614, DOI 10.1073/pnas.1531957100; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; Wingrave JM, 2004, EXP NEUROL, V187, P529, DOI 10.1016/j.expneurol.2004.02.001; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Xie LP, 2002, EUR J IMMUNOL, V32, P2837, DOI 10.1002/1521-4141(2002010)32:10<2837::AID-IMMU2837>3.0.CO;2-V; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086	65	74	79	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUN	2010	88	8					1738	1750		10.1002/jnr.22337			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	590RQ	WOS:000277245500012	20091771	Green Accepted			2022-02-06	
J	Venkatesan, C; Chrzaszcz, M; Choi, N; Wainwright, MS				Venkatesan, Charu; Chrzaszcz, MaryAnn; Choi, Nicole; Wainwright, Mark S.			Chronic upregulation of activated microglia immunoreactive for galectin-3/Mac-2 and nerve growth factor following diffuse axonal injury	JOURNAL OF NEUROINFLAMMATION			English	Article							TRAUMATIC BRAIN-INJURY; AUTONOMIC DYSREFLEXIA; HEAD-INJURY; CELL-DEATH; OLIGODENDROCYTES; NEUROPROTECTION; PHAGOCYTOSIS; REGENERATION; INVOLVEMENT; RECEPTORS	Background: Diffuse axonal injury in patients with traumatic brain injury (TBI) can be associated with morbidity ranging from cognitive difficulties to coma. Magnetic resonance imaging scans now allow early detection of axonal injury following TBI, and have linked cognitive disability in these patients to white matter signal changes. However, little is known about the pathophysiology of this white matter injury, and the role of microglial activation in this process. It is increasingly recognized that microglia constitute a heterogeneous population with diverse roles following injury. In the present studies, we tested the hypothesis that following diffuse axonal injury involving the corpus callosum, there is upregulation of a subpopulation of microglia that express the lectin galectin-3/Mac-2 and are involved in myelin phagocytosis. Methods: Adult mice were subject to midline closed skull injury or sham operation and were sacrificed 1, 8, 14 or 28 days later. Immunohistochemistry and immunofluorescence techniques were used to analyze patterns of labelling within the corpus callosum qualitatively and quantitatively. Results: Activated microglia immunoreactive for galectin-3/Mac-2 were most abundant 1 day following injury. Their levels were attenuated at later time points after TBI but still were significantly elevated compared to sham animals. Furthermore, the majority of galectin-3/Mac-2+ microglia were immunoreactive for nerve growth factor in both sham and injured animals. Conclusions: Our results suggest that galectin-3/Mac-2+ microglia play an important role in the pathogenesis of diffuse axonal injury both acutely and chronically and that they mediate their effects, at least in part by releasing nerve growth factor.	[Venkatesan, Charu; Chrzaszcz, MaryAnn; Choi, Nicole; Wainwright, Mark S.] Northwestern Univ, Feinberg Sch Med, Div Neurol, Dept Pediat, Chicago, IL 60614 USA; [Venkatesan, Charu; Chrzaszcz, MaryAnn; Choi, Nicole; Wainwright, Mark S.] Northwestern Univ, Feinberg Sch Med, Ctr Interdisciplinary Res Pediat Crit Illness & I, Chicago, IL 60614 USA		Venkatesan, C (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Neurol, Dept Pediat, Chicago, IL 60614 USA.	cvenkatesan@childrensmemorial.org	Venkatesan, Charu/D-5944-2016; venkatesan, charu/ABE-7369-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12 HD052902, KO8 NS044998]; Medical Research Junior Board Foundation; Lyndsey Whittingham Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD052902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS044998] Funding Source: NIH RePORTER	This work was supported by NIH grants K12 HD052902 (CV) and KO8 NS044998 (MSW), the Medical Research Junior Board Foundation (MSW), and the Lyndsey Whittingham Foundation (MSW).	ALTHAUS HH, 1992, NEUROSCI LETT, V135, P219, DOI 10.1016/0304-3940(92)90440-I; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; Chiaretti A, 2005, NEUROL RES, V27, P741, DOI 10.1179/016164105X35611; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Frade JM, 1996, NATURE, V383, P166; Frielingsdorf H, 2007, NEUROBIOL DIS, V26, P47, DOI 10.1016/j.nbd.2006.11.015; GONZALEZSCARANO F, 1999, ANNU REV NEUROSCI, V219, P40; HO MK, 1982, J IMMUNOL, V128, P1221; HOOFIEN D, 2001, BRAIN INJURY, V189, P10; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Krenz NR, 1999, J NEUROSCI, V19, P7405, DOI 10.1523/JNEUROSCI.19-17-07405.1999; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lynch G, 2005, AM NETW, V109, P16; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Marsh DR, 2002, J NEUROTRAUM, V19, P1531, DOI 10.1089/089771502762300201; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Neumann J, 2006, FASEB J, V20, P714, DOI 10.1096/fj.05-4882fje; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; REICHERT F, 1994, J NEUROSCI, V14, P3231; Reichert F, 1996, J NEUROIMMUNOL, V70, P153, DOI 10.1016/S0165-5728(96)00112-9; Reichert F, 1999, EXP NEUROL, V160, P508, DOI 10.1006/exnr.1999.7229; Rotshenker S, 2008, GLIA, V56, P1607, DOI 10.1002/glia.20713; Rotshenker S, 2009, J MOL NEUROSCI, V39, P99, DOI 10.1007/s12031-009-9186-7; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Srinivasan B, 2004, J BIOL CHEM, V279, P41839, DOI 10.1074/jbc.M402872200; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Sugama S, 2007, NEUROSCIENCE, V146, P1388, DOI 10.1016/j.neuroscience.2007.02.043; Thored P, 2009, GLIA, V57, P835, DOI 10.1002/glia.20810; Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100; Walther M, 2000, J NEUROSCI RES, V61, P430, DOI 10.1002/1097-4547(20000815)61:4<430::AID-JNR9>3.0.CO;2-3; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Yoon SO, 1998, J NEUROSCI, V18, P3273; Yune TY, 2007, J NEUROSCI, V27, P7751, DOI 10.1523/JNEUROSCI.1661-07.2007; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684	52	74	75	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	MAY 27	2010	7								32	10.1186/1742-2094-7-32			10	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	616YS	WOS:000279248400001	20507613	gold, Green Published			2022-02-06	
J	Douglas, JM				Douglas, Jacinta M.			Relation of Executive Functioning to Pragmatic Outcome Following Severe Traumatic Brain Injury	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article						traumatic brain injury; pragmatics; executive function	CLOSED-HEAD-INJURY; DISABILITY RATING-SCALE; COMMUNICATIVE ABILITY; COGNITIVE-ABILITIES; KINEMATIC ANALYSIS; LANGUAGE-SKILLS; SELF-AWARENESS; FRONTAL LOBES; DISCOURSE; DEFICITS	Purpose: This study was designed to explore the behavioral nature of pragmatic impairment following severe traumatic brain injury (TBI) and to evaluate the contribution of executive skills to the experience of pragmatic difficulties after TBI. Method: Participants were grouped into 43 TBI dyads (TBI adults and close relatives) and 43 control dyads. All TBI participants had sustained severe injury (mean posttraumatic amnesia duration = 45.19 days, SD = 39.15) due to a moving vehicle-related trauma. A minimum of 2 years had elapsed since injury (M = 5.36 years, SD = 3.61). The La Trobe Communication Questionnaire (LCQ; Douglas, O'Flaherty, & Snow, 2000) was administered to all participants. Measures of executive function included the following: the FAS verbal fluency task (Spreen & Benton, 1969), the Speed and Capacity of Language Processing test (Baddeley, Emslie, & Nimmo-Smith, 1992), and the Rey Auditory Verbal Learning Task (Rey, 1964). Results: Perceptions of TBI participants and their relatives were significantly correlated (r = .63, p <.001) and significantly different from those of controls, F(1, 84) = 37.2, p <.001. Pragmatic difficulties represented violations in 3 domains of Grice's (1975) Cooperative Principle (Quantity, Relation, and Manner), and executive function measures predicted 37% (32% adjusted) of the variability in LCQ scores. Conclusions: The study demonstrates evidence of a significant association between executive impairment and the pragmatic communication difficulties experienced by individuals with TBI.	La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia		Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia.	j.douglas@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624			ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Alexander MP, 2003, BRAIN, V126, P1493, DOI 10.1093/brain/awg128; Baddeley A, 1998, J INT NEUROPSYCH SOC, V4, P523, DOI 10.1017/S135561779800513X; Baddeley A., 1992, SPEED CAPACITY LANGU; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Benson D.F., 1986, FRONTAL LOBES; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bittner RM, 2006, BRAIN INJURY, V20, P971, DOI 10.1080/02699050600909763; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Body R., 2006, BRAIN IMPAIR, V7, P212, DOI DOI 10.1375/BRIM.7.3.212; Body R., 1999, BRAIN DAM B; Boone KB, 1998, ARCH CLIN NEUROPSYCH, V13, P585, DOI 10.1016/S0887-6177(97)00074-7; Bracy C., 2005, BRAIN IMPAIR, V6, P1, DOI DOI 10.1375/brim.6.1.1.65476; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Carstairs JR, 2006, AUST PSYCHOL, V41, P48, DOI 10.1080/00050060500391878; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Channon Shelley, 2003, Cogn Neuropsychiatry, V8, P243, DOI 10.1080/135468000344000002; Chelune GJ, 1986, ADV CLIN NEUROPSYCHO, V3, P95, DOI [10.1007/978-1-4613-2211-5_4, DOI 10.1007/978-1-4613-2211-5_4]; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Coelho C., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); CUMMINGS L, 2005, PRAGMATICS MULTIDISC; Cummings Louise, 2007, Seminars in Speech and Language, V28, P96, DOI 10.1055/s-2007-970568; Damico J. S., 1985, COMMUNICATION SKILLS, P165; Douglas J., 2004, EVIDENCE BASED PRACT, P59; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; ELIASON MR, 1984, PHYS THER, V64, P1357, DOI 10.1093/ptj/64.9.1357; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; Goldstein G., 1995, INT J REHABILITATION, V1, DOI [10.1007/BF02214959, DOI 10.1007/BF02214959]; Goozee JV, 2000, BRAIN INJURY, V14, P153, DOI 10.1080/026990500120817; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Grafman J, 1999, LANCET, V354, P1921, DOI 10.1016/S0140-6736(99)90438-5; Grice H. P., 1975, SYNTAX SEMANTICS, P41; Hagen C, 1984, LANGUAGE DISORDERS A, P245; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hartley L. L, 1995, COGNITIVE COMMUNICAT; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Hoofien D, 2001, BRAIN INJURY, V15, P189; Ivnik R.J., 1990, PSYCHOL ASSESSMENT J, V2, P304, DOI [10.1037/1040-3590.2.3.304, DOI 10.1037/1040-3590.2.3.304]; Jaeger M, 2000, FOLIA PHONIATR LOGO, V52, P187, DOI 10.1159/000021533; Joanette Y, 1999, BRAIN LANG, V68, P529, DOI 10.1006/brln.1999.2126; KERR C, 1995, BRAIN INJURY, V9, P777, DOI 10.3109/02699059509008234; Kim J, 2005, J INT NEUROPSYCH SOC, V11, P434, DOI 10.1017/S1355617705050563; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; MUSCOVITCH M, 2002, PRINCIPLES FRONTAL L, P188; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Perkins MR, 2005, CLIN LINGUIST PHONET, V19, P367, DOI 10.1080/02699200400027155; Perkins MR, 1998, J PRAGMATICS, V29, P291, DOI 10.1016/S0378-2166(97)00055-6; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A., 1964, EXAMEN CLIN PSYCHOL; Robertson I., 1994, TEST EVERYDAY ATTENT; Rolls ET, 1999, NEUROCASE, V5, P301, DOI 10.1093/neucas/5.4.301; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Snow PC, 2000, BRAIN INJURY, V14, P397; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Spreen O., 1969, NEUROSENSORY CTR COM; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [https://doi.org/10.1037/0894-4105.8.3.355, DOI 10.1037/0894-4105.8.3.355]; Stuss DT, 2005, CURR DIR PSYCHOL SCI, V14, P84, DOI 10.1111/j.0963-7214.2005.00340.x; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; Szatkowska I, 2000, ACTA NEUROBIOL EXP, V60, P503; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; Turkstra L., 1995, BRAIN INJURY, V10, P319; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wang YT, 2005, FOLIA PHONIATR LOGO, V57, P59, DOI 10.1159/000083569; Wechsler D., 1945, WECHSLER MEMORY SCAL; Wheeler M A, 1995, J Int Neuropsychol Soc, V1, P525; Wilson D, 2005, LINGUA, V115, P1129, DOI 10.1016/j.lingua.2004.02.005; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951	108	74	77	0	20	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1092-4388	1558-9102		J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	APR 1	2010	53	2					365	382		10.1044/1092-4388(2009/08-0205)			18	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	585EI	WOS:000276806800010	20360462				2022-02-06	
J	Ponsford, J; Schonberger, M				Ponsford, Jennie; Schoenberger, Michael			Family functioning and emotional state two and five years after traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Traumatic brain injury; Family functioning; Relatives; Anxiety; Depression; Structural Equation Modelling	RANDOMIZED CONTROLLED-TRIAL; CAREGIVER BURDEN; PSYCHOLOGICAL DISTRESS; DEPRESSION SCALE; HOSPITAL ANXIETY; SOCIAL SUPPORT; ASSESSMENT DEVICE; HEAD-INJURY; FOLLOW-UP; REHABILITATION	Previous studies have documented poor family functioning. anxiety, and depression in relatives of individuals with traumatic brain injury (TBI). However, few studies have examined family functioning over extended periods after injury. The present study aimed to investigate family functioning and relatives' emotional state 2 and 5 years following TBI, predictive factors, and their interrelationships. Participants were individuals with TBI and their relatives, with 301 seen at 2 years and 266 at 5 years post-injury. Measures included a Structured Outcome Questionnaire, Family Assessment Device (FAD), Hospital Anxiety and Depression Scale, and the Craig Handicap Assessment and Reporting Technique. Results showed that while the group did not differ greatly in family functioning from a normative group, a significant proportion showed unhealthy functioning across most FAD subscales. Both TBI participants and their relatives showed elevated rates of anxiety and depression. There was little difference between family functioning or relatives' anxiety or depression levels at 2 and 5 years post-injury. Path analysis indicated that neurobehavioral changes in the injured individual have an impact on family functioning and distress in relatives even at 5 years post-injury. These findings indicate the need for long-term Support of families with a brain-injured member. (JINS, 2010, 16, 306-317.)	[Ponsford, Jennie; Schoenberger, Michael] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia		Ponsford, J (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton Campus,Wellington Rd,Bldg 17, Clayton, Vic 3800, Australia.	Jennie.Ponsford@med.monash.edu.au			Victorian Transport Accident Commission; Victorian Neurotrauma Initiative	Funding for this study came from the Victorian Transport Accident Commission and the Victorian Neurotrauma Initiative. The authors have no conflict of interest.	ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/0090-5550.39.1.29; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; Bragg RM, 1992, J HEAD TRAUMA REHAB, V7, P94; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Chan J, 2007, INT J REHABIL RES, V30, P137, DOI 10.1097/MRR.0b013e32813a2f11; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Flora DB, 2004, PSYCHOL METHODS, V9, P466, DOI 10.1037/1082-989X.9.4.466; Gan C, 2002, BRAIN INJURY, V16, P311, DOI 10.1080/02699050110104426; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hoofien D, 2001, BRAIN INJURY, V15, P189; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kabacoff R.I., 1990, J FAM PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; PERLESZ A, 1989, RECOVERY BRAIN INJUR, P180; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rodgers ML, 2007, AM J PHYS MED REHAB, V86, P482, DOI 10.1097/PHM.0b013e31805c00a1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; SCHONBERGER M, PSYCHIAT RE IN PRESS; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; Snaith R., 1983, HOSP ANXIETY DEPRESS; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001	55	74	74	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2010	16	2					306	317		10.1017/S1355617709991342			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	562DZ	WOS:000275030900011	20128950				2022-02-06	
J	Kirkwood, MW; Kirk, JW				Kirkwood, Michael W.; Kirk, John W.			The base rate of suboptimal effort in a pediatric mild TBI sample: Performance on the Medical Symptom Validity Test	CLINICAL NEUROPSYCHOLOGIST			English	Article						Medical Symptom Validity Test; Effort testing; Children; Post-concussion; Mild traumatic brain injury	WORD MEMORY TEST; RESPONSE BIAS; BRAIN-INJURY; HEAD-INJURY; CHILDREN; NEUROPSYCHOLOGY; ADOLESCENTS; CAPACITY; ADULTS; TOMM	Performance on the Medical Symptom Validity Test (MSVT) was examined in 193 consecutively referred patients aged 8 through 17 years who had sustained a mild traumatic brain injury. A total of 33 participants failed to meet actuarial criteria for valid effort on the MSVT. After accounting for possible false positives and false negatives, the base rate of suboptimal effort in this clinical sample was 17%. Only one MSVT failure was thought to be influenced by litigation. The present results suggest that a sizable minority of children is capable of putting forth suboptimal effort during neuropsychological exam, even when external incentives are not readily apparent. The MSVT appears to have good potential value as an objective measure for detecting symptom invalidity in school-age youth.	[Kirkwood, Michael W.; Kirk, John W.] Department of Phys Medicine Rehabilitat, Univers of Colorado Denver and Childrens Hospital, Aurora, CO USA								Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Courtney JC, 2003, CHILD NEUROPSYCHOL, V9, P109, DOI 10.1076/chin.9.2.109.14507; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; FAUST D, 1988, J CONSULT CLIN PSYCH, V56, P578, DOI 10.1037/0022-006X.56.4.578; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2009, BRAIN INJURY, V23, P741, DOI 10.1080/02699050903133962; Green P., 2004, MANUAL GREENS MED SY; Green P., 2007, ASSESSMENT FEIGNED C; Greiffenstein MF, 2008, ARCH CLIN NEUROPSYCH, V23, P801, DOI 10.1016/j.acn.2008.07.005; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; McCrea M., 2008, MILD TRAUMATIC BRAIN; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; OLDERSHAW L, 1997, CLIN ASSESSMENT MALI, P153; Peebles R, 2005, CLIN PEDIATR, V44, P237, DOI 10.1177/000992280504400307; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P481, DOI 10.1076/clin.16.4.481.13914; Talwar V, 2008, CHILD DEV, V79, P866, DOI 10.1111/j.1467-8624.2008.01164.x; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	35	74	74	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2010	24	5					860	872	PII 919486568	10.1080/13854040903527287			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	616PM	WOS:000279221300008	20182954				2022-02-06	
J	Scafidi, S; Racz, J; Hazelton, J; McKenna, MC; Fiskum, G				Scafidi, Susanna; Racz, Jennifer; Hazelton, Julie; McKenna, Mary C.; Fiskum, Gary			Neuroprotection by Acetyl-L-Carnitine after Traumatic Injury to the Immature Rat Brain	DEVELOPMENTAL NEUROSCIENCE			English	Article						Controlled cortical impact; Sensorimotor function; Memory; Hippocampus; Acetyl-L-carnitine; Neuroprotection; Novel object recognition	TRANSIENT FOREBRAIN ISCHEMIA; CORTICAL IMPACT INJURY; OXIDATIVE STRESS; PYRUVATE-DEHYDROGENASE; RECOGNITION MEMORY; ENERGY-METABOLISM; OBJECT RECOGNITION; CEREBRAL-ISCHEMIA; PROTEIN OXIDATION; NEURONAL DAMAGE	Traumatic brain injury (TBI) is the leading cause of mortality and morbidity in children and is characterized by reduced aerobic cerebral energy metabolism early after injury, possibly due to impaired activity of the pyruvate dehydrogenase complex. Exogenous acetyl-L-carnitine (ALCAR) is metabolized in the brain to acetyl coenzyme A and subsequently enters the tricarboxylic acid cycle. ALCAR administration is neuroprotective in animal models of cerebral ischemia and spinal cord injury, but has not been tested for TBI. This study tested the hypothesis that treatment with ALCAR during the first 24 h following TBI in immature rats improves neurologic outcome and reduces cortical lesion volume. Postnatal day 21-22 male rats were isoflurane anesthetized and used in a controlled cortical impact model of TBI to the left parietal cortex. At 1, 4, 12 and 23 h after injury, rats received ALCAR (100 mg/kg, intraperitoneally) or drug vehicle (normal saline). On days 3-7 after surgery, behavior was assessed using beam walking and novel object recognition tests. On day 7, rats were transcardially perfused and brains were harvested for histological assessment of cortical lesion volume, using stereology. Injured animals displayed a significant increase in foot slips compared to sham-operated rats (6 +/- 1 SEM vs. 2 +/- 0.2 on day 3 after trauma; n = 7; p < 0.05). The ALCAR-treated rats were not different from shams and had fewer foot slips compared to vehicle-treated animals (2 +/- 0.4; n = 7; p < 0.05). The frequency of investigating a novel object for saline-treated TBI animals was reduced compared to shams (45 +/- 5% vs. 65 +/- 10%; n = 7; p < 0.05), whereas the frequency of investigation for TBI rats treated with ALCAR was not significantly different from that of shams but significantly higher than that of saline-treated TBI rats (68 +/- 7; p < 0.05). The left parietal cortical lesion volume, expressed as a percentage of the volume of tissue in the right hemisphere, was significantly smaller in ALCAR-treated than in vehicle-treated TBI rats (14 +/- 5% vs. 28 +/- 6%; p < 0.05). We conclude that treatment with ALCAR during the first 24 h after TBI improves behavioral outcomes and reduces brain lesion volume in immature rats within the first 7 days after injury. Copyright (C) 2011 S. Karger AG, Basel	[Racz, Jennifer; Hazelton, Julie; Fiskum, Gary] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Scafidi, Susanna; McKenna, Mary C.] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA; [Racz, Jennifer; Hazelton, Julie; Fiskum, Gary] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res, Baltimore, MD 21201 USA		Fiskum, G (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 685 W Baltimore St, Baltimore, MD 21201 USA.	gfiskum@anes.umm.edu		Scafidi, Susanna/0000-0002-1229-8778	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01HD16596]; University of Maryland Departmet of Pediatrics; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER	The study was supported by NIH grant No. P01HD16596 and by a grant from the University of Maryland Departmet of Pediatrics.	Al-Majed AA, 2006, CLIN EXP PHARMACOL P, V33, P725, DOI 10.1111/j.1440-1681.2006.04425.x; Allen GV, 2001, NEUROSCIENCE, V102, P603, DOI 10.1016/S0306-4522(00)00519-4; Ames BN, 2004, ANN NY ACAD SCI, V1033, P108, DOI 10.1196/annals.1320.010; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; AURELI T, 1994, BRAIN RES, V643, P92, DOI 10.1016/0006-8993(94)90013-2; Barhwal K, 2009, NEUROSCIENCE, V161, P501, DOI 10.1016/j.neuroscience.2009.02.086; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; BOYESON MG, 1992, BEHAV NEUROSCI, V106, P964, DOI 10.1037/0735-7044.106.6.964; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Calabrese V, 2005, J NEUROSCI RES, V79, P509, DOI 10.1002/jnr.20386; Calabrese V, 2008, NEUROCHEM RES, V33, P2444, DOI 10.1007/s11064-008-9775-9; Carter R J, 2001, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0812s15; Dardzinski BJ, 2000, PEDIATR RES, V48, P248, DOI 10.1203/00006450-200008000-00021; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Ennaceur A, 2010, BEHAV BRAIN RES, V215, P244, DOI 10.1016/j.bbr.2009.12.036; Ferraresi R, 2006, FEBS LETT, V580, P6612, DOI 10.1016/j.febslet.2006.11.016; FISKUM G, 1992, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1992, P487; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.3.CO;2-L; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Faria MHG, 2007, ACTA CIR BRAS, V22, P125, DOI 10.1590/S0102-86502007000200009; Hagberg H, 2009, J CHILD NEUROL, V24, P1141, DOI 10.1177/0883073809338212; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Ishii T, 2000, JPN J PHARMACOL, V83, P119, DOI 10.1254/jjp.83.119; Jalal FY, 2010, ANN NY ACAD SCI, V1199, P95, DOI 10.1111/j.1749-6632.2009.05351.x; Jones LL, 2010, PROG LIPID RES, V49, P61, DOI 10.1016/j.plipres.2009.08.004; Koppaka SS, 2008, ADV EXP MED BIOL, V614, P361; Liu JK, 2004, ANN NY ACAD SCI, V1033, P117, DOI 10.1196/annals.1320.011; LIU YB, 1993, FREE RADICAL BIO MED, V15, P667, DOI 10.1016/0891-5849(93)90171-P; Lolic MM, 1997, ANN EMERG MED, V29, P758, DOI 10.1016/S0196-0644(97)70197-5; Loots DT, 2004, LIFE SCI, V75, P1243, DOI 10.1016/j.lfs.2004.03.007; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; PARNETTI L, 1992, EUR J CLIN PHARMACOL, V42, P89, DOI 10.1007/BF00314926; Patel SP, 2010, J NEUROCHEM, V114, P291, DOI 10.1111/j.1471-4159.2010.06764.x; PETTEGREW JW, 1990, J NEUROPATH EXP NEUR, V49, P237, DOI 10.1097/00005072-199005000-00005; Poon HF, 2006, ANTIOXID REDOX SIGN, V8, P381, DOI 10.1089/ars.2006.8.381; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Reger ML, 2009, DEV PSYCHOBIOL, V51, P672, DOI 10.1002/dev.20402; Richards EM, 2006, FREE RADICAL BIO MED, V40, P1960, DOI 10.1016/j.freeradbiomed.2006.01.022; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; ROSENTHAL RE, 1992, STROKE, V23, P1312, DOI 10.1161/01.STR.23.9.1312; Scafidi S, 2010, J NEUROCHEM, V114, P820, DOI 10.1111/j.1471-4159.2010.06807.x; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Sharma Pushpa, 2009, J Emerg Trauma Shock, V2, P67, DOI 10.4103/0974-2700.50739; Shen W, 2008, J CELL BIOCHEM, V104, P1232, DOI 10.1002/jcb.21701; SHUAIB A, 1995, NEUROCHEM RES, V20, P1021, DOI 10.1007/BF00995555; Squire LR, 2007, NAT REV NEUROSCI, V8, P872, DOI 10.1038/nrn2154; Thomale UW, 2007, NEUROL RES, V29, P594, DOI 10.1179/016164107X166272; Vaishnav RA, 2010, J NEUROTRAUM, V27, P1311, DOI 10.1089/neu.2009.1172; Vereczki V, 2006, J CEREBR BLOOD F MET, V26, P821, DOI 10.1038/sj.jcbfm.9600234; Verweij BH, 2007, PROG BRAIN RES, V161, P111, DOI 10.1016/S0079-6123(06)61008-X; Virmani MA, 2001, ANN NY ACAD SCI, V939, P162; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; WINTER BK, 1995, BRIT J CANCER, V72, P1173, DOI 10.1038/bjc.1995.482; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Yasui F, 2002, NEUROSCI LETT, V334, P177, DOI 10.1016/S0304-3940(02)01127-8; Youle M, 2007, HIV MED, V8, P241, DOI 10.1111/j.1468-1293.2007.00467.x; Zanelli SA, 2005, ANN NY ACAD SCI, V1053, P153, DOI 10.1196/annals.1344.013	66	74	76	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					480	487		10.1159/000323178			8	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900016	21228558	Green Published, Bronze			2022-02-06	
J	Kilinc, D; Gallo, G; Barbee, KA				Kilinc, Devrim; Gallo, Gianluca; Barbee, Kenneth A.			Mechanical membrane injury induces axonal beading through localized activation of calpain	EXPERIMENTAL NEUROLOGY			English	Article						Diffuse axonal injury; Mechanoporation; Axonal bead formation; Calcium; Calpain; Poloxamer 188; Mitochondria	TRAUMATIC BRAIN-INJURY; IN-VITRO MODEL; HIPPOCAMPAL-NEURONS; SURFACTANT POLOXAMER-188; CALCIUM TRANSIENTS; CYTOSOLIC CALCIUM; STRETCH-INJURY; OPTIC-NERVE; CELL-DEATH; PROTEIN	Diffuse axonal injury (DAI), a major component of traumatic brain injury, is characterized by a sequence of neurochemical reactions initiated at the time of trauma and resulting in axonal degeneration and cell death. Calcium influx through mechanically induced axolemmal pores and subsequent activation of calpains are thought to be responsible for the cytoskeletal damage leading to impaired axonal transport. Focal disruption of cytoskeleton accompanied by the accumulation of transported membranous cargo leads to axonal beading which is the characteristic morphology of DAI. By applying fluid shear stress injury on cultured primary neurons, acute calcium (Ca2+) and calpain responses of axons to mechanical trauma were investigated. Intracellular Ca2+ concentration ([Ca2+](i)) shows a steady increase following injury that can be blocked by sealing membrane pores with Poloxamer 188 and by chelating intra- or extracellular Ca2+. Calpain activity increases in response to mechanical injury and this increase depends on Ca2+ availability and on axolemmal permeability. Both the [Ca2+](i) increase and calpain activity exhibit focal peaks along the axons which co-localize with mitochondria and predict future axonal bead locations. These findings suggest that mechanoporation may be the initiating mechanism resulting in ensuing calcium fluxes and subsequent calpain activity and that post-injury membrane repair may be a valid therapeutic approach for acute intervention in DAI. (C) 2009 Elsevier Inc. All rights reserved.	[Kilinc, Devrim; Barbee, Kenneth A.] Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, Philadelphia, PA 19104 USA; [Gallo, Gianluca] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA		Barbee, KA (corresponding author), Drexel Univ, Sch Biomed Engn Sci & Hlth Syst, 3141 Chestnut St, Philadelphia, PA 19104 USA.	barbee@drexel.edu	Barbee, Kenneth/F-4333-2014; Kilinc, Devrim/E-8733-2011; Kilinc, Devrim/I-4180-2019	Kilinc, Devrim/0000-0003-3321-5203; Kilinc, Devrim/0000-0003-3321-5203	State of Pennsylvania Tobacco Settlement Fund; National Institutes HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS048090]; Drexel University Neuroengineering Major Research Initiative; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048090, R56NS048090] Funding Source: NIH RePORTER	This research was supported in part by a grant from the State of Pennsylvania Tobacco Settlement Fund (K.A.B.); by the National Institutes Health (NS048090, G.G.); and by Drexel University Neuroengineering Major Research Initiative (K.A.B., D.K.). K.A. Barbee and G. Gallo share last authorship on this work.	Ahmad FJ, 1999, J CELL BIOL, V145, P305, DOI 10.1083/jcb.145.2.305; Baas PW, 2005, TRENDS CELL BIOL, V15, P183, DOI 10.1016/j.tcb.2005.02.001; BILLGER M, 1988, CELL CALCIUM, V9, P33, DOI 10.1016/0143-4160(88)90036-X; Blackman BR, 2000, ANN BIOMED ENG, V28, P363, DOI 10.1114/1.286; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cadichon SB, 2007, J NEUROSURG, V106, P36, DOI 10.3171/ped.2007.106.1.36; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Curry DJ, 2004, NEUROSURGERY, V55, P943, DOI 10.1227/01.NEU.0000137890.29862.2C; Detrait E, 2000, J NEUROBIOL, V44, P382, DOI 10.1002/1097-4695(20000915)44:4<382::AID-NEU2>3.0.CO;2-Q; Errico A, 2002, HUM MOL GENET, V11, P153, DOI 10.1093/hmg/11.2.153; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Frim DM, 2004, NEUROREPORT, V15, P171, DOI 10.1097/00001756-200401190-00033; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Geddes-Klein DM, 2006, J NEUROCHEM, V97, P462, DOI 10.1111/j.1471-4159.2006.03761.x; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Greenebaum B, 2004, BURNS, V30, P539, DOI 10.1016/j.burns.2004.02.009; Heidemann SR, 2003, METHOD CELL BIOL, V71, P51, DOI 10.1016/S0091-679X(03)01004-5; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kilinc D, 2009, COMPUT METH PROG BIO, V95, P62, DOI 10.1016/j.cmpb.2009.01.002; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Liu J, 2008, SCI SIGNAL, V1, DOI [10.1126/stke.114re1, 10.1126/scisignal.123tr3]; Lusardi TA, 2004, ANN BIOMED ENG, V32, P1546, DOI 10.1114/B:ABME.0000049038.75368.75; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2005, ANN NY ACAD SCI, V1066, P310, DOI 10.1196/annals.1363.018; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McIntosh TK, 1996, LAB INVEST, V74, P315; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; Merenda A, 2006, CURR OPIN CRIT CARE, V12, P90, DOI 10.1097/01.ccx.0000216573.26686.27; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; OBrien ET, 1997, CELL MOTIL CYTOSKEL, V36, P125, DOI 10.1002/(SICI)1097-0169(1997)36:2<125::AID-CM3>3.0.CO;2-8; PADANILAM JT, 1994, ANN NY ACAD SCI, V720, P111, DOI 10.1111/j.1749-6632.1994.tb30439.x; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Robles E, 2003, NEURON, V38, P597, DOI 10.1016/S0896-6273(03)00260-5; ROSSER BG, 1993, J BIOL CHEM, V268, P23593; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Schouten JW, 2007, CURR OPIN CRIT CARE, V13, P134, DOI 10.1097/MCC.0b013e3280895d5c; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; SHAPIRA Y, 1989, Neurological Research, V11, P169; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; STRICH SJ, 1961, LANCET, V2, P443; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Wang GJ, 2003, J NEUROCHEM, V87, P85, DOI 10.1046/j.1471-4159.2003.01970.x; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yoo S, 2003, J NEUROSCI RES, V74, P541, DOI 10.1002/jnr.10771; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687	66	74	80	0	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2009	219	2					553	561		10.1016/j.expneurol.2009.07.014			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	498QN	WOS:000270157300021	19619536	Green Accepted			2022-02-06	
J	Ho, J; Kleiven, S				Ho, Johnson; Kleiven, Svein			Can sulci protect the brain from traumatic injury?	JOURNAL OF BIOMECHANICS			English	Article						Human head model; Finite element analysis; Cerebral convolution; Traumatic brain injury	DIFFUSE AXONAL INJURY; WHITE-MATTER; HEAD IMPACT; MODEL; SEGMENTATION; EPIDEMIOLOGY; SIMULATIONS; PRIMATE; MATER	The influence of sulci in dynamic finite element simulations of the human head has been investigated. First, a detailed 3D FE model was constructed based on an MRI scan of a human head. A second model with a smoothed brain surface was created based on the same MRI scan as the first FE model. These models were validated against experimental data to confirm their human-like dynamic responses during impact. The validated FE models were subjected to several acceleration impulses and the maximum principle strain and strain rate in the brain were analyzed. The results suggested that the inclusion of sulci should be considered for future FE head models as it alters the strain and strain distribution in an FE model. (C) 2009 Elsevier Ltd. All rights reserved.	[Ho, Johnson; Kleiven, Svein] Royal Inst Technol, Sch Technol & Hlth, Div Neuron Engn, Stockholm, Sweden		Ho, J (corresponding author), Royal Inst Technol, Sch Technol & Hlth, Div Neuron Engn, Stockholm, Sweden.	johnsonh@kth.se; sveink@kth.se		Ho, Johnson/0000-0001-9785-2071	School of Technology and Health; Royal Institute of Technology, Stockholm, Sweden	This study was supported by the School of Technology and Health, Royal Institute of Technology, Stockholm, Sweden. Also, the authors are thankful for the comments and ideas given by Professor Hans von Hoist, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.	Aimedieu P, 2004, J NEUROSURG, V100, P111, DOI 10.3171/jns.2004.100.1.0111; [Anonymous], 2007, LS DYN KEYW US MAN V; Arbogast K., 1997, P 41 STAPP CAR CRASH; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; Bradshaw DRS, 2001, P 17 INT TECHN C ENH; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; CLOOTS RJH, 2008, J BIOMECH, V43, P804; FRANCESCHINI G, 2006, THESIS U TRENTO ITAL; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gray H, 2000, ANATOMY HUMAN BODY; HARDY WH, 2001, STAPP CAR CRASH J, P375; HO J, 2008, 20087 TRITASTH SCH T; HO J, 2009, INT J CRAS IN PRESS; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kwan RKS, 1999, IEEE T MED IMAGING, V18, P1085, DOI 10.1109/42.816072; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Nahum A. M., 1977, P 21 STAPP CAR CRASH, P339; Netter F. H., 1953, COMPILATION PAINTING; Nishimoto T, 2000, JSAE REV, V21, P117, DOI 10.1016/S0389-4304(99)00079-X; O'Connor CA, 2007, EXP NEUROL, V205, P145, DOI 10.1016/j.expneurol.2007.01.034; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Van Leemput K, 1999, IEEE T MED IMAGING, V18, P885, DOI 10.1109/42.811268; VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7; Wells WM, 1996, IEEE T MED IMAGING, V15, P429, DOI 10.1109/42.511747; Wilcox Ruth K, 2003, J Orthop Sci, V8, P432, DOI 10.1007/s10776-003-0644-9; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Zaidi H, 2006, NEUROIMAGE, V32, P1591, DOI 10.1016/j.neuroimage.2006.05.031; Zhang L, 2001, Stapp Car Crash J, V45, P369	37	74	77	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	SEP 18	2009	42	13					2074	2080		10.1016/j.jbiomech.2009.06.051			7	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	502RO	WOS:000270478000010	19679308				2022-02-06	
J	McGinn, MJ; Kelley, BJ; Akinyi, L; Oli, MW; Liu, MC; Hayes, RL; Wang, KKW; Povilshock, JT				McGinn, Melissa J.; Kelley, Brian J.; Akinyi, Linnet; Oli, Monika W.; Liu, Ming Cheng; Hayes, Ronald L.; Wang, Kevin K. W.; Povilshock, John T.			Biochemical, Structural, and Biomarker Evidence for Calpain-Mediated Cytoskeletal Change After Diffuse Brain Injury Uncomplicated by Contusion	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Biomarker; Calpain; Cytoskeleton; Diffuse axonal injury; Spectrin; Traumatic brain injury	TRAUMATIC AXONAL INJURY; ALPHA-II-SPECTRIN; CONTROLLED CORTICAL IMPACT; BREAKDOWN PRODUCTS; CEREBROSPINAL-FLUID; PROTEIN BREAKDOWN; CORPUS-CALLOSUM; IMMATURE RATS; HEAD-INJURY; ACTIVATION	Calpain-mediated degradation of the cytoskeletal protein alpha-II-spectrin has been implicated in tire pathobiology of experimental and human traumatic brain injury (TBI). Spectrin proteolysis after diffuse/widespread TBI uncomplicated by either Subtle or overt contusion and/or mass lesions, (i.e. mild to moderate TBI), has not been previously evaluated. To determine the spatiotemporal pattern and cellular localization of calpain-mediated spectrin proteolysis after diffuse/widespread TBI and the extent to which parenchymal changes in calpain-mediated spectrin proteolysis are reflected ill the cerebrospinal fluid, adult rats were subjected to a moderate midline fluid percussion injury and allowed to Survive for 3 hours to 7 days postinjury. Light and electron microscopic immunocytochemical and Western blot analyses were performed to identify the calpain-specific 145-kDa breakdown product of a-II-spectrin (SBDP145). After diffuse TBI, enhanced levels of SBDP145 immunoreactivity were observed in the neocortex, subcortical white matter, thalamus, and hippocampus. peaking between 24 and 48 hours postinjury. Immunoreactivity was localized almost exclusively to damaged axons and axonal terminal debris. Heightened levels of SBDP145 were also observed in the cerebrospinal fluid at 24 hours postinjury. These results confirm the widespread Occurrence of calpain-mediated spectrin proteolysis after diffuse TBI without contusion and support the potential utility of SBDPs as biomarkers of a diffusely injured brain.	[Povilshock, John T.] Virginia Commonwealth Univ, Sch Med, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Akinyi, Linnet; Oli, Monika W.] Banyan Biomarkers Inc, Diagnost Res & Dev Dept, Alachua, FL USA; [Liu, Ming Cheng; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat, McKnight Brain Inst, Ctr Neuroprote & Biomarkers Res,Dept Anesthesiol, Gainesville, FL 32611 USA		Povilshock, JT (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Anat & Neurobiol, 1101 E Marshall St,Sanger Hall 12-050,POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu		Wang, Kevin/0000-0002-9343-6473	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01HD055813-25, 5P30NS047463-05, R01 NS049175-01 A1]; Department of DefenseUnited States Department of Defense [DAMD17-03-1-0066, DAMD17-01-1-0765]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049175, P30NS047463] Funding Source: NIH RePORTER	This work was supported by Grant Nos. 5R01HD055813-25 (JTP), 5P30NS047463-05 (JTP). and R01 NS049175-01 A1 (KKW) from the National Institutes of Health and Grant Nos. DAMD17-03-1-0066 and DAMD17-01-1-0765 (RLH) from the Department of Defense.	Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Aikman J, 2006, DEV NEUROSCI-BASEL, V28, P457, DOI 10.1159/000094171; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cardali S, 2006, J Neurosurg Sci, V50, P25; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Huh JW, 2006, DEV NEUROSCI-BASEL, V28, P466, DOI 10.1159/000094172; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liu J, 2008, SCI SIGNAL, V1, DOI [10.1126/stke.114re1, 10.1126/scisignal.123tr3]; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; Nath R, 2000, NEUROCHEM INT, V37, P351, DOI 10.1016/S0197-0186(00)00040-1; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Vanderklish PW, 2000, INT J EXP PATHOL, V81, P323, DOI 10.1111/j.1365-2613.2000.00169.x; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4	43	74	76	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2009	68	3					241	249		10.1097/NEN.0b013e3181996bfe			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	413QG	WOS:000263807000003	19225412	Bronze, Green Accepted			2022-02-06	
J	Mbye, LH; Singh, IN; Carrico, KM; Saatman, KE; Hall, ED				Mbye, Lamin Han; Singh, Indrapal N.; Carrico, Kimberly M.; Saatman, Kathryn E.; Hall, Edward D.			Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						calpain; alpha-spectrin; motor function; mitochondrial permeability transition pore; NIM811; traumatic brain injury	MITOCHONDRIAL PERMEABILITY TRANSITION; EXPERIMENTAL HEAD-INJURY; INDUCED AXONAL INJURY; CORTICAL DAMAGE; CELL-DEATH; OXIDATIVE DAMAGE; CYTOCHROME-C; MOUSE MODEL; DYSFUNCTION; NEURODEGENERATION	Earlier experiments have shown that cyclosporin A (CsA) and its non-calcineurin inhibitory analog NIM811 attenuate mitochondrial dysfunction after experimental traumatic brain injury (TBI). Presently, we compared the neuroprotective effects of previously determined mitochondrial protective doses of CsA (20 mg/kg intraperitoneally) and NIM811 (10 mg/kg intraperitoneally) when administered at 15 mins postinjury in preventing cytoskeletal (alpha-spectrin) degradation, neuro-degeneration, and neurological dysfunction after severe (1.0 mm) controlled cortical impact (CCI) TBI in mice. In a first set of experiments, we analyzed calpain-mediated alpha-spectrin proteolysis at 24 h postinjury. Both NIM811 and CsA significantly attenuated the increased alpha-spectrin breakdown products observed in vehicle-treated animals (P<0.005). In a second set of experiments, treatment of animals with either NIM811 or CsA at 15 mins and again at 24 h postinjury attenuated motor function impairment at 48 h and 7 days (P<0.005) and neurodegeneration at 7 days postinjury (P<0.0001). Delayed administration of NIM811 out to 12 h was still able to significantly reduce a-spectrin degradation. These results show that the neuroprotective mechanism of CsA involves maintenance of mitochondrial integrity and that calcineurin inhibition plays little or no role because the non-calcineurin inhibitory analog, NIM811, is as effective as CsA.	[Mbye, Lamin Han; Singh, Indrapal N.; Carrico, Kimberly M.; Saatman, Kathryn E.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,Room B483 BBSRB, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01 NS046566, 1P30 NS051220]; Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046566, P30NS051220] Funding Source: NIH RePORTER	This research was supported by funding from the NIH (1R01 NS046566, 1P30 NS051220) and the Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT).	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212, DOI 10.1097/01.wbc.0000037994.34930.bc; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pattison James M., 1997, P331; Povlishock JT, 1999, ACT NEUR S, V73, P15; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	43	74	76	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2009	29	1					87	97		10.1038/jcbfm.2008.93			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	389QS	WOS:000262110200011	18714331	Green Accepted, Bronze			2022-02-06	
J	Chen, G; Shi, JX; Jin, W; Wang, L; Xie, WY; Sun, J; Hang, CH				Chen, Gang; Shi, Jixin; Jin, Wei; Wang, Lin; Xie, Weiying; Sun, Jie; Hang, Chunhua			Progesterone administration modulates TLRs/NF-kappa B signaling pathway in rat brain after cortical contusion	ANNALS OF CLINICAL AND LABORATORY SCIENCE			English	Article						progesterone; traumatic brain injury; toll-like receptors; nuclear factor-kappaB	TOLL-LIKE RECEPTORS; INFLAMMATORY RESPONSE; GENE-EXPRESSION; INNATE IMMUNITY; GROWTH-FACTOR; CELL-DEATH; INJURY; ALLOPREGNANOLONE; RECOVERY; CORTEX	This study investigated whether progesterone administration modulates toll-like receptors (TLRs) and the nuclear factor-kappa B (NF-kappa B) signaling pathway in the injured rat brain following traumatic brain injury (TBI). Right parietal cortical contusion was made by a weight-dropping method. Male rats were given 0 or 16 mg/kg injections of progesterone at postinjury hr 1 and 6 and on days 1, 2, 3, 4, and 5. Brain samples were extracted at 5 days after trauma. We measured mRNA expression of TLR2 and TLR4 by reverse-transcriptase polymerase chain reaction (RT-PCR), NF-kappa B binding activity by electrophoretic mobility shift assay (EMSA), concentrations of interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) by enzyme-linked immunosorbent assay (ELISA), intercellular adhesion molecule-1 (ICAM-1) expression by immunohistochemistry, and brain damage by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL). The results showed that TBI induces strong upregulation of TLR2, TLR4, NF-kappa B, pro-inflammatory cytokines, and ICAM-1 in the pericontusional area. Administration of progesterone following TBI down-regulates the cortical levels of these agents related to the TLRs/NF-kappa B signaling pathway. After progesterone administration, apoptotic TUNEL-positive cells in the injured brain were significantly decreased. In summary, post-TBI progesterone administration attenuates the TLRs/NF-kappa B signaling pathway in injured rat brain, and this may be a mechanism whereby progesterone improves the outcome following TBI.	[Chen, Gang; Shi, Jixin; Jin, Wei; Wang, Lin; Hang, Chunhua] Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, Nanjing 210002, Peoples R China; [Xie, Weiying; Sun, Jie] Nanjing Univ, Dept Anesthesiol, Jinling Hosp, Sch Med, Nanjing 210002, Peoples R China		Hang, CH (corresponding author), Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, 305 E Zhongshan Rd, Nanjing 210002, Peoples R China.	nju_neurosurgery@163.com		Chen, Gang/0000-0002-0758-1907			ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Bergeron R, 1996, J NEUROSCI, V16, P1193; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Cristofaro P, 2003, EXPERT OPIN THER TAR, V7, P603, DOI 10.1517/eott.7.5.603.22528; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Johnson GB, 2003, CRIT REV IMMUNOL, V23, P15, DOI 10.1615/CritRevImmunol.v23.i12.20; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Kariko K, 2004, J CEREBR BLOOD F MET, V24, P1288, DOI 10.1097/01.WCB.0000145666.68576.71; Laflamme N, 2001, FASEB J, V15, P155, DOI 10.1096/fj.00-0339com; Lai YC, 2006, DEV NEUROSCI-BASEL, V28, P336, DOI 10.1159/000094159; Lee Sung Joong, 2002, Current Drug Targets - Inflammation and Allergy, V1, P181; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; MANNEL DN, 1990, IMMUNOL LETT, V26, P89, DOI 10.1016/0165-2478(90)90181-O; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Miettinen M, 2001, GENES IMMUN, V2, P349, DOI 10.1038/sj.gene.6363791; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sun J, 2004, ANN CLIN LAB SCI, V34, P181; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Wang L, 2005, ANN CLIN LAB SCI, V35, P79; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2005, J CLIN PHARMACOL, V45, P640, DOI 10.1177/0091270005276201; Xie WY, 2006, ANN CLIN LAB SCI, V36, P39; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656	40	74	81	0	3	ASSOC CLINICAL SCIENTISTS	MIDDLEBURY	PO BOX 1287, MIDDLEBURY, VT 05753 USA	0091-7370	1550-8080		ANN CLIN LAB SCI	Ann. Clin. Lab. Sci.	WIN	2008	38	1					65	74					10	Medical Laboratory Technology	Science Citation Index Expanded (SCI-EXPANDED)	Medical Laboratory Technology	267ER	WOS:000253492800011	18316784				2022-02-06	
J	Ng, K; Mikulis, DJ; Glazer, J; Kabani, N; Till, C; Greenberg, G; Thompson, A; Lazinski, D; Agid, R; Colella, B; Green, RE				Ng, Kevin; Mikulis, David J.; Glazer, Joanna; Kabani, Noor; Till, Christine; Greenberg, Gahl; Thompson, Andrew; Lazinski, Dorothy; Agid, Ronit; Colella, Brenda; Green, Robin E.			Magnetic Resonance Imaging Evidence of Progression of Subacute Brain Atrophy in Moderate to Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Atrophy; Brain injuries; Magnetic resonance imaging; Follow-up studies; Rehabilitation	CLOSED-HEAD-INJURY; CORTICAL ATROPHY; RECOVERY; MEMORY; MILD; MRI; VOLUME; PERFORMANCE; TOMOGRAPHY; MORPHOLOGY	Objective: To demonstrate subacute progression of brain atrophy (from 4.5-29mo postinjury) in moderate to severe traumatic brain injury (TBI) using structural magnetic resonance imaging (MRI). Design: Within-subjects, repeated-measures design. Setting: Inpatient neurorehabilitation program and teaching hospital (MRI department). Participants: Adults (N=14) with moderate to severe TBI. Interventions: Not applicable. Main Outcome Measures: Neuroradiologist readings and volumetric measurements (total brain cerebrospinal fluid and hippocampus) at 4.5 months and 2.5 years postinjury. Results: Ten of 14 patients showed visible atrophy progression. Significant increase in cerebrospinal fluid (CSF) volume (t(13)=-4.073, P<.001) and decrease in right and left hippocampal volumes (t(13) =4.221, P<.001 and t(13)=3.078, P<.005, respectively) were observed from 4.5 months to 2.5 years. Compared with published normative data, patients with TBI showed significantly more pathologic percent annual volume change for the hippocampi (t(26)=-3.864, P<.001, right; and t(26)=-2.737, P<.01, left), and a trend for CSF (t(26)=1.655, P=.059). Conclusions: This study provides strong MRI evidence for subacute progression of atrophy, as distinct from early, acute neurologic changes observed.	[Ng, Kevin; Mikulis, David J.; Greenberg, Gahl; Thompson, Andrew; Lazinski, Dorothy; Agid, Ronit] Univ Toronto, Univ Hlth Network, Dept Med Imaging, Div Neuroradiol, Toronto, ON M5S 1A1, Canada; [Glazer, Joanna; Green, Robin E.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5S 1A1, Canada; [Till, Christine; Colella, Brenda; Green, Robin E.] Toronto Rehabil Inst, Toronto, ON, Canada; [Kabani, Noor] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada		Green, RE (corresponding author), 550 Univ Ave,Room 11004, Toronto, ON M5G 2A2, Canada.	green.robin@torontorehab.on.ca	Mikulis, David J/H-5167-2019	Mikulis, David/0000-0003-3956-0892; Till, Christine/0000-0001-5030-3155; Green, Robin/0000-0001-9451-3963	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Physicians' Services Inc [MOP-67072, 05-50]; Toronto Rehabilitation InstituteUniversity of Toronto; Ministry of Health and Long-Term Care in Ontario.Ministry of Health and Long-Term Care, Ontario	Supported by the Canadian Institutes of Health Research and the Physicians' Services Inc (grant nos. MOP-67072, 05-50) and the Toronto Rehabilitation Institute, which receives funding under the Provincial Rehabilitation Research Program from the Ministry of Health and Long-Term Care in Ontario.	ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Basso A., 1989, COGNITIVE APPROACHES; Bigler E. D., 1990, TRAUMATIC BRAIN INJU; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brooks D N, 1979, Int Rehabil Med, V1, P166; Bruns J. Jr., 2003, EPILEPSIA, V10, P2, DOI DOI 10.1046/J.1528-1157.44.S10.3.X; BYRT T, 1993, J CLIN EPIDEMIOL, V46, P423, DOI 10.1016/0895-4356(93)90018-V; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Cook RJ., 1998, ENCY BIOSTATISTICS, P2166; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Farne A, 2004, J NEUROL NEUROSUR PS, V75, P1401, DOI 10.1136/jnnp.2002.003095; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; GUGGENMOOSHOLZMANN I, 1993, STAT MED, V12, P2191, DOI 10.1002/sim.4780122305; HAYASHI N, 2004, HYPOTHERMIA ACUTE BR; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hollingshead AB, 1958, SOCIAL CLASS MENTAL; Koch GG, 1982, INTRACLASS CORRELATI; Levin H. S., 1979, GALVESTON ORIENTATIO; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; MACDONALD JD, 1996, MNI DISPLAY PROGRAM; MACKENZIE JD, 2002, AM J NEURORADIOL, V23, P1442; Mahncke HW, 2006, PROG BRAIN RES, V157, P81, DOI 10.1016/S0079-6123(06)57006-2; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; *MCCONN BRAIN IM C, BRAIN IM SOFTW TOOLB; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Novack TA, 2000, BRAIN INJURY, V14, P987; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Pruessner JC, 2000, CEREB CORTEX, V10, P433, DOI 10.1093/cercor/10.4.433; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; Talairach J., 1988, COPLANAR STEREOTAXIC; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; VALLAR G, 1988, J NEUROL NEUROSUR PS, V51, P1269, DOI 10.1136/jnnp.51.10.1269; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; WHYTE J, 1999, P NIH CONS DEV C REH, P23; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Wong PP, 2001, BRAIN INJURY, V15, P519, DOI 10.1080/02699050010005995; Zijdenbos A, 1998, LECT NOTES COMPUT SC, V1496, P439; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	74	74	75	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2008	89	12		2			S35	S44		10.1016/j.apmr.2008.07.006			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	388DB	WOS:000261999400005	19081440				2022-02-06	
J	Pagulayan, KF; Hoffman, JM; Temkin, NR; Machamer, JE; Dikmen, SS				Pagulayan, Kathleen Farrell; Hoffman, Jeanne M.; Temkin, Nancy R.; Machamer, Joan E.; Dikmen, Sureyya S.			Functional Limitations and Depression After Traumatic Brain Injury: Examination of the Temporal Relationship	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Longitudinal studies; Rehabilitation; Sickness Impact Profile	MAJOR DEPRESSION; CHRONIC PAIN; RELIABILITY; VALIDITY; SCALE; PREVALENCE; DISORDER; PANEL; INDIVIDUALS; VALIDATION	Objective: To examine the temporal relationship between self-reported injury-related functional limitations and depressive symptomatology after traumatic brain injury (TBI). Design: A longitudinal cohort study with 3 evaluation points. Setting: A level I trauma center. Participants: Adolescents and adults (N=135) with complicated mild to severe TBI (72% had complicated mild injuries) who were recruited within 24 hours of injury and then completed the measure at all 3 time points. Interventions: Not applicable. Main Outcome Measures: Sickness Impact Profile and Center for Epidemiological Studies-Depression Scale. Results: Individuals who reported more depressive symptomatology consistently endorsed more injury-related difficulties, showing the strong relationship between depression and perceived psychosocial functioning. Examination of these relationships over time revealed that increased depressive symptomatology follows higher levels of perceived injury-related changes but that reports of injury-related changes are not associated with earlier depression. These findings suggest a unidirectional temporal relationship between these variables. Conclusions: Perceived changes in daily functioning appear to influence emotional well-being over time after TBI. However, depressive symptoms do not appear to negatively impact individuals' perception of later functioning. These results further our understanding of the complicated relationship between these variables and may have important implications for treatment of depression after TBI.	[Pagulayan, Kathleen Farrell; Hoffman, Jeanne M.; Temkin, Nancy R.; Machamer, Joan E.; Dikmen, Sureyya S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Temkin, Nancy R.; Dikmen, Sureyya S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA		Pagulayan, KF (corresponding author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,S-116 MHC, Seattle, WA 98108 USA.	farkat@u.washington.edu	Pagulayan, Kati/AAR-9225-2020		National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS19643, F32 HD048030]; National Center for Medical Rehabilitation Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD048030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER	Supported by the National Institute of Neurological Disorders and Stroke, National Institutes of Health (grant no. RO1 NS19643) and the National Center for Medical Rehabilitation Research, National Institutes of Health (grant no. F32 HD048030).	ALLOY LB, 1979, J EXP PSYCHOL GEN, V108, P441, DOI 10.1037/0096-3445.108.4.441; ANDERSON TN, 1982, J ACCOUNT RES, V20, P403, DOI 10.2307/2490748; Beck AT., 1979, COGNITIVE THERAPY DE; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Burns JW, 2003, J CONSULT CLIN PSYCH, V71, P81, DOI 10.1037/0022-006X.71.1.81; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; COMSTOCK GW, 1976, PSYCHOL MED, V6, P551, DOI 10.1017/S0033291700018171; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FINKEL SE, 1995, CAUSAL ANAL PANEL DA; Geisser ME, 1997, CLIN J PAIN, V13, P163, DOI 10.1097/00002508-199706000-00011; Gotlib IH, 1988, COGNITION EMOTION, V2, P185, DOI 10.1080/02699938808410923; Gotlib IH, 2004, J ABNORM PSYCHOL, V113, P127, DOI 10.1037/0021-843X.113.1.121; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; HIMMELFARB S, 1983, J GERONTOL, V38, P333, DOI 10.1093/geronj/38.3.333; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jones JE, 2005, EPILEPSIA, V46, P731, DOI 10.1111/j.1528-1167.2005.49704.x; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Judd LL, 2000, ARCH GEN PSYCHIAT, V57, P375, DOI 10.1001/archpsyc.57.4.375; Katon W, 2002, J PSYCHOSOM RES, V53, P859, DOI 10.1016/S0022-3999(02)00313-6; KATZ R, 1995, BRIT J PSYCHIAT, V166, P100, DOI 10.1192/bjp.166.1.100; KENNY DA, 1975, PSYCHOL BULL, V82, P887, DOI 10.1037/0033-2909.82.6.887; Klinkman MS, 1997, ARCH FAM MED, V6, P567, DOI 10.1001/archfami.6.6.567; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lyness JM, 1997, ARCH INTERN MED, V157, P449, DOI 10.1001/archinte.157.4.449; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; MURRELL SA, 1983, AM J EPIDEMIOL, V117, P173, DOI 10.1093/oxfordjournals.aje.a113528; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; PARIKH RM, 1988, INT J PSYCHIAT MED, V18, P169, DOI 10.2190/BH75-EUYA-4FM1-J7QA; PELZ DC, 1964, AM SOCIOL REV, V29, P836, DOI 10.2307/2090866; Peters DJ, 1996, DISABIL REHABIL, V18, P593, DOI 10.3109/09638289609166320; Prigatano G. F., 2005, REHABILITATION TRAUM, P118; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; ROBERTS RE, 1980, PSYCHIAT RES, V2, P125, DOI 10.1016/0165-1781(80)90069-4; Rudisch B, 2003, BIOL PSYCHIAT, V54, P227, DOI 10.1016/S0006-3223(03)00587-0; Rytsala HJ, 2006, J NERV MENT DIS, V194, P570, DOI 10.1097/01.nmd.0000230394.21345.c4; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; SHINAR D, 1986, STROKE, V17, P241, DOI 10.1161/01.STR.17.2.241; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; 2004, FED REG, V64, P45744	56	74	74	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2008	89	10					1887	1892		10.1016/j.apmr.2008.03.019			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	366LY	WOS:000260484200006	18929017				2022-02-06	
J	Makley, MJ; English, JB; Drubach, DA; Kreuz, AJ; Celnik, PA; Tarwater, PM				Makley, M. J.; English, J. B.; Drubach, D. A.; Kreuz, A. J.; Celnik, P. A.; Tarwater, P. M.			Prevalence of sleep disturbance in closed head injury patients in a rehabilitation unit	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						brain injury; trauma; sleep disturbance; memory; amnesia; circadian disorder	TRAUMATIC BRAIN-INJURY; EXCESSIVE DAYTIME SLEEPINESS; GLASGOW COMA SCALE; POSTTRAUMATIC NARCOLEPSY; MEMORY CONSOLIDATION	Traumatic brain injury (TBI) is a leading cause of disability in young people in the United States. Disorders of arousal and attention are common in closed head injury (CHI). Daytime drowsiness impairs participation in rehabilitation, whereas nighttime wakefulness leads to falls and behavioral disturbances. Sleep disturbances in TBI reported in the literature have included excessive daytime somnolence, sleep phase cycle disturbance, narcolepsy, and sleep apnea. Although well known to the clinician treating these patients, the extent and prevalence of disrupted sleep in patients in an acute inpatient rehabilitation unit has not been described. Objective. To determine the prevalence of sleep wake cycle disturbance (SWCD) in patients with CHI in a TBI rehabilitation unit. Design. Prospective observational. Setting. Inpatient specialized brain injury rehabilitation unit. Patients. Thirty-one consecutive admissions to a brain injury rehabilitation unit with the diagnosis of CHI. Results. Twenty-one patients (68%) had aberrations of nighttime sleep. There was no significant difference in Glasgow Coma Score on admission to trauma nor was there any significant difference in age between the affected and unaffected groups. Patients with SWCD had longer stays in both the trauma center (P < .003) and the rehabilitation center (P < .03). Conclusions. There is a high prevalence of SWCD in CHI patients admitted to a brain injury rehabilitation unit. Patients with SWCD have longer stays in both acute and rehabilitation settings and may be a marker for more severe injury.	[Makley, M. J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [English, J. B.] MS Ctr Atlanta, Atlanta, GA USA; [Drubach, D. A.] Mayo Clin, Rochester, MN USA; [Kreuz, A. J.] Villa Julie Coll, Baltimore, MD USA; [Celnik, P. A.] Johns Hopkins Sch Med, Baltimore, MD USA; [Tarwater, P. M.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA		Makley, MJ (corresponding author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA.	mmakley@kernan.umm.edu					Arciniegas DB, 2000, CURRENT TREATMENT OP, V2, P169; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; CULEBRAS A, 1992, NEUROLOGY, V42, P19; Economo CV, 1930, J NERV MENT DIS, V71, P249, DOI 10.1097/00005053-193003000-00001; Ellenbogen JM, 2006, CURR OPIN NEUROBIOL, V16, P716, DOI 10.1016/j.conb.2006.10.006; Francisco GE, 1996, AM J PHYS MED REHAB, V75, P63, DOI 10.1097/00002060-199601000-00016; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Ji DY, 2007, NAT NEUROSCI, V10, P100, DOI 10.1038/nn1825; Katsuki H, 2004, NEUROBIOL DIS, V15, P61, DOI 10.1016/j.nbd.2003.09.003; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; PATTEN SB, 1992, J AM ACAD CHILD PSY, V31, P100, DOI 10.1097/00004583-199201000-00015; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Stickgold R, 2005, NATURE, V437, P1272, DOI 10.1038/nature04286; Taragano FE., 1994, J NEUROL REHABIL, V8, P92; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	20	74	76	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUL-AUG	2008	22	4					341	347		10.1177/1545968308315598			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	319DV	WOS:000257145200003	18663247				2022-02-06	
J	Ho, CL; Wang, CM; Lee, KK; Ng, I; Ang, BT				Ho, Chi Long; Wang, Chee Meng; Lee, Kah Keow; Ng, Ivan; Ang, Beng Ti			Cerebral oxygenation, vascular reactivity, and neurochemistry following decompressive craniectomy for severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral microdialysis; cerebral oxygenation; decompressive craniectorny; intracranial pressure; vascular reactivity	SEVERE HEAD-INJURY; TISSUE OXYGEN; INTRACRANIAL HYPERTENSION; VASOMOTOR REACTIVITY; INFARCTION; PRESSURE; AUTOREGULATION; PREVENTION; MANAGEMENT; RELEASE	Object. This study addresses the changes in brain oxygenation, cerebrovascular reactivity, and cerebral neurochemistry in patients following decompressive craniectomy for the control of elevated intracranial pressure (ICP) after severe traumatic brain injury (TBI). Methods. Sixteen consecutive patients with isolated TBI and elevated ICP, who were refractory to maximal medical therapy, underwent decompressive craniectomy over a 1-year period. Thirteen patients were male and 3 were female. The mean age of the patients was 38 years and the median Glasgow Coma Scale score on admission was 5. Results. Six months following TBI, 11 patients had a poor outcome (Group 1, Glasgow Outcome Scale [GOS] Score 1-3), whereas the remaining 5 patients had a favorable outcome (Group 2, GOS Score 4 or 5). Decompressive craniectomy resulted in a significant reduction (p < 0.001) in the mean ICP and cerebrovascular pressure reactivity index to autoregulatory values (< 0.3) in both groups of patients. There was a significant improvement in brain tissue oxygenation (PbtO(2)) in Group 2 patients from 3 to 17 mm Hg and an 85% reduction in episodes of cerebral ischemia. In addition, the durations of abnormal PbtO(2) and biochemical indices were significantly reduced in Group 2 patients after decompressive craniectomy, but there was no improvement in the biochemical indices in Group 1 patients despite surgery. Conclusions. Decompressive craniectomy, when used appropriately in protocol-driven intensive care regimens for the treatment of recalcitrant elevated ICP, is associated with a return of abnormal metabolic parameters to normal values in patients with eventually favorable outcomes.	[Ho, Chi Long; Wang, Chee Meng; Lee, Kah Keow; Ng, Ivan; Ang, Beng Ti] Natl Inst Neurosci, Dept Neurosurg, Singapore 308433, Singapore		Ang, BT (corresponding author), Natl Inst Neurosci, Dept Neurosurg, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	beng_ti_ang@nni.com.sg					Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; FORSTING M, 1995, STROKE, V26, P259, DOI 10.1161/01.STR.26.2.259; FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Johnston JB, 1902, J COMP NEUROL, V12, P1, DOI 10.1002/cne.910120102; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; MAX AR, 1996, YB INTENSIVE CARE EM, P707; Mulvey JM, 2004, NEUROCRIT CARE, V1, P391, DOI 10.1385/NCC:1:3:391; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosner Michael J., 1993, P57; Sarrafzadeh A S, 2000, Neurosurg Focus, V9, pe2; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; UNTERBERG AW, 1997, J TRAUMA, V42, P532; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Zauner A, 1996, ACT NEUR S, V67, P40	35	74	78	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2008	108	5					943	949		10.3171/JNS/2008/108/5/0943			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	293RE	WOS:000255351600007	18447711				2022-02-06	
J	Murray, CK				Murray, Clinton K.			Epidemiology of infections associated with combat-related injuries in Iraq and Afghanistan	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Iraq; Afghanistan; infection; combat	TRAUMATIC BRAIN-INJURY; ACINETOBACTER-BAUMANNII; UNITED-STATES; ENDURING FREEDOM; WAR WOUNDS; MILITARY; CASUALTIES; EXPERIENCE; SUSCEPTIBILITY; COMPLICATIONS	Enhanced medical training of front line medical personnel, personal protective equipment, and the presence of far forward surgical assets have improved the survival of casualties in the current wars in Iraq and Afghanistan. As such, casualties are at higher risk of infectious complications of their injuries including sepsis, which was a noted killer of casualties in previous wars. During the current conflicts, military personnel who develop combat-related injuries are at substantial risk of developing infections with multidrug resistant bacteria. Herein, we describe the bacteriology of combat-related injuries in Operation Iraqi Freedom and Operation Enduring Freedom that develop infections with particular attention to injuries of the extremities, central nervous system, abdomen and thorax, head and neck, and burns. In addition, the likely sources of combat-related injuries with multidrug resistant bacteria infections are explored.	Brooke Army Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA		Murray, CK (corresponding author), Brooke Army Med Ctr, Infect Dis Serv, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.	chnton.murray@amedd.army.mil					Al-Assaf DA, 2007, J CRANIOFAC SURG, V18, P606, DOI 10.1097/01.scs.0000248661.91522.c5; Albrecht MA, 2006, J AM COLL SURGEONS, V203, P546, DOI 10.1016/j.jamcollsurg.2006.06.013; ARNOLD K, 1978, MIL MED, V143, P161; Aronson NE, 2006, CLIN INFECT DIS, V43, P1045, DOI 10.1086/507539; Beitler AL, 2006, MIL MED, V171, P189, DOI 10.7205/MILMED.171.3.189; Bird SM, 2007, INT J EPIDEMIOL, V36, P841, DOI 10.1093/ije/dym103; Centers for Disease Control and Prevention, 2004, MMWR MORB MORTAL WKL, V53, P1063; Chambers LW, 2006, J TRAUMA, V60, P1155, DOI 10.1097/01.ta.0000220340.91356.7e; Cho JM, 2005, MIL MED, V170, P268, DOI 10.7205/MILMED.170.4.268; Davis KA, 2005, EMERG INFECT DIS, V11, P1218, DOI 10.3201/1108.050103; Ecker JA, 2006, J CLIN MICROBIOL, V44, P2921, DOI 10.1128/JCM.00619-06; Ellis MW, 2004, CLIN INFECT DIS, V39, P971, DOI 10.1086/423965; Fitzpatrick S., 2004, J CARIBBEAN ARCHAEOL, V5, P1; Fleming A, 1915, LANCET, V2, P638; Gagne PJ, 2007, J VASC SURG, V45, P1204; Gao Z, 2007, P NATL ACAD SCI USA, V104, P2927, DOI 10.1073/pnas.0607077104; Garzoni C, 2005, EMERG INFECT DIS, V11, P1591, DOI 10.3201/eid1110.050715; Gleeson T, 2005, J ANTIMICROB CHEMOTH, V56, P602, DOI 10.1093/jac/dki274; Griffith ME, 2007, INFECT CONT HOSP EP, V28, P720, DOI 10.1086/518966; Griffith ME, 2006, INFECT CONT HOSP EP, V27, P659, DOI 10.1086/506596; HARDAWAY RM, 1978, J TRAUMA, V18, P635, DOI 10.1097/00005373-197809000-00004; Hawley JS, 2007, ANTIMICROB AGENTS CH, V51, P376, DOI 10.1128/AAC.00858-06; HEGGERS JP, 1969, MIL MED, V134, P602, DOI 10.1093/milmed/134.8.602; Hujer KM, 2006, ANTIMICROB AGENTS CH, V50, P4114, DOI 10.1128/AAC.00778-06; Ingari John V, 2007, Tech Hand Up Extrem Surg, V11, P130, DOI 10.1097/bth.0b013e3180312738; JACOB E, 1989, MIL MED, V154, P311; Jerassy Z, 2006, J HOSP INFECT, V62, P230, DOI 10.1016/j.jhin.2005.07.007; Johnson Brent A, 2005, J Foot Ankle Surg, V44, P177, DOI 10.1053/j.jfas.2005.02.007; Johnson EN, 2007, CLIN INFECT DIS, V45, P409, DOI 10.1086/520029; Kanafani ZA, 2003, INFECT CONT HOSP EP, V24, P864, DOI 10.1086/502151; Kauvar DS, 2006, BURNS, V32, P853, DOI 10.1016/j.burns.2006.03.008; KLEIN RS, 1975, ANN SURG, V182, P15, DOI 10.1097/00000658-197507000-00003; Kortepeter MG, 2005, CLIN INFECT DIS, V41, P1604, DOI 10.1086/497598; KOVARIC JJ, 1968, MIL MED, V133, P622, DOI 10.1093/milmed/133.8.622; Leininger BE, 2006, J TRAUMA, V61, P1207, DOI 10.1097/01.ta.0000241150.15342.da; Lin DL, 2004, J ORTHOP TRAUMA, V18, P300; Mabry RL, 2000, J TRAUMA, V49, P515, DOI 10.1097/00005373-200009000-00021; Murray CK, 2006, CLIN INFECT DIS, V43, P383, DOI 10.1086/505601; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Murray CK, 2005, MIL MED, V170, P501, DOI 10.7205/MILMED.170.6.501; Murray CK, 2006, MIL MED, V171, P821, DOI 10.7205/MILMED.171.9.821; Murray CK, 2006, MIL MED, V171, P826, DOI 10.7205/MILMED.171.9.826; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Oncul O, 2002, J HOSP INFECT, V51, P47, DOI 10.1053/jhin.2002.1205; Owens BD, 2007, J ORTHOP TRAUMA, V21, P254, DOI 10.1097/BOT.0b013e31802f78fb; Peck MA, 2007, J VASC SURG, V45, P1197, DOI 10.1016/j.jvs.2007.02.003; Peoples GE, 2005, MIL MED, V170, P462, DOI 10.7205/MILMED.170.6.462; Petersen K, 2007, ANN SURG, V245, P803, DOI 10.1097/01.sla.0000251707.32332.c1; PETTIT RT, 1919, JAMA-J AM MED ASSOC, P73; RESSNER RA, IN PRESS J AM COLL S; Rotimi VO, 1998, DIAGN MICR INFEC DIS, V30, P53, DOI 10.1016/S0732-8893(97)00180-6; Scott P, 2007, CLIN INFECT DIS, V44, P1577, DOI 10.1086/518170; Sise MJ, 2006, J TRAUMA, V60, P1162; Steele SR, 2007, DIS COLON RECTUM, V50, P870, DOI 10.1007/s10350-007-0235-4; Stoddard JL, 1918, J AMER MED ASSOC, V71, P1400, DOI 10.1001/jama.1918.26020430022009g; THORESBY FP, 1967, BRIT J SURG, V54, P359, DOI 10.1002/bjs.1800540509; Tien HC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-95; TONG MJ, 1972, J AMER MED ASSOC, V219, P1044, DOI 10.1001/jama.219.8.1044; Turton JF, 2006, J CLIN MICROBIOL, V44, P2630, DOI 10.1128/JCM.00547-06; Wolf SE, 2006, ANN SURG, V243, P786, DOI 10.1097/01.sla.0000219645.88867.b7; Zouris JM, 2006, MIL MED, V171, P246, DOI 10.7205/MILMED.171.3.246	61	74	79	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2008	64	3		S			S232	S238		10.1097/TA.0b013e318163c3f5			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	276SY	WOS:000254164300004	18316967				2022-02-06	
J	Huijgen, BCH; Volienbroek-Hutten, MMR; Zampolini, M; Opisso, E; Bernabeu, M; Van Nieuwenhoven, J; Ilsbrouk, S; Magni, R; Giacomozzi, C; Marcellari, V; Marchese, SS; Hermens, HJ				Huijgen, Barbara C. H.; Volienbroek-Hutten, Miriam M. R.; Zampolini, Mauro; Opisso, Eloy; Bernabeu, Montse; Van Nieuwenhoven, Johan; Ilsbrouk, Stephan; Magni, Riccardo; Giacomozzi, Claudia; Marcellari, Velio; Marchese, Sandro Scattareggia; Hermens, Hermie J.			Feasibility of a home-based telerehabilitation system compared to usual care: arm/hand function in patients with stroke, traumatic brain injury and multiple sclerosis	JOURNAL OF TELEMEDICINE AND TELECARE			English	Article							RANDOMIZED CLINICAL-TRIAL; UPPER EXTREMITY; REHABILITATION; RECOVERY; ARM; PARESIS; PEOPLE	We conducted a randomized controlled multicentre trial to investigate the feasibility of a telerehabilitation intervention for arm/hand function (the Home Care Activity Desk [HCAD] training) in a home setting. Usual care was compared to HCAD training. The hypothesis was that the clinical outcomes of the HCAD intervention would be at least the same as those measured after a period of usual care for patients with stroke, traumatic brain injury (TBI) and multiple sclerosis (MS) with respect to their arm/hand function. Eighty-one patients with affected arm/hand function resulting from either stroke, MS or TBI were recruited in Italy, Spain and Belgium; 11 were lost during follow-up (14%). The outcome measures were the Action Research Arm Test (ARAT) and the Nine Hole Peg Test (NHPT). There were no significant differences between the two groups on the outcome measures (ARAT and NHPT); in both groups, patients maintained or even improved their arm/hand function. The HCAD training was found to be as feasible as usual care in terms of clinical outcomes, and both therapists and patients were satisfied with the HCAD intervention. A telerehabilitation intervention using HCAD may increase the efficiency of care.	[Huijgen, Barbara C. H.; Volienbroek-Hutten, Miriam M. R.; Hermens, Hermie J.] Roessingh Res & Dev BV, Enschede, Netherlands; [Zampolini, Mauro] Unita Organ Riabilitaz Intens Neuromotoria, ASL Umbria 3, Trevi, Italy; [Opisso, Eloy; Bernabeu, Montse] Inst Univ Neurorehabil, Inst Guttman, Badalona, Spain; [Van Nieuwenhoven, Johan; Ilsbrouk, Stephan] Natl Multiple Sclerosis Ctr, Melsbroek, Belgium; [Magni, Riccardo] Pragma Engn, Perugia, Italy; [Giacomozzi, Claudia; Marcellari, Velio] Inst Super Sanita, Rome, Italy; [Marchese, Sandro Scattareggia] Signo Motus Srl Messina, Messina, Italy; [Hermens, Hermie J.] Univ Twente, Fac Elect Engn Math & Comp Sci, Enschede, Netherlands		Volienbroek-Hutten, MMR (corresponding author), Roessingh Res & Dev, Roessinghbleekweg 33B, NL-7522 AH Enschede, Netherlands.	m.vollenbroek@rrd.nl	Zampolini, Mauro/B-7749-2009; Giacomozzi, Claudia/AAH-1640-2021; Giacomozzi, Claudia/G-5018-2016	Giacomozzi, Claudia/0000-0001-6950-4934; Giacomozzi, Claudia/0000-0001-6950-4934; Opisso, Eloy/0000-0002-6868-6737; Vollenbroek-Hutten, Miriam/0000-0001-8730-1487	HELLODOC; European UnionEuropean Commission; UORIN; FPING; HCAD; Pragma Engineering	The work was part of the project 'HELLODOC' health service linking telerehabilitation to disabled people and clinicians supported by the European Union. We are grateful for the scientific contribution of MF Schifini and MF Spitali (UORIN) and S Tasies and E Prats (FPING) and the technical work on the HCAD apparatus from F Magnino (Pragma Engineering)	Broens THF, 2007, J TELEMED TELECARE, V13, P303, DOI 10.1258/135763307781644951; BRONFORT G, 1997, THESIS AMSTERDAM; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; DeChant H K, 1996, Telemed J, V2, P303, DOI 10.1089/tmj.1.1996.2.303; DENNIS M, 1994, BMJ-BRIT MED J, V309, P1273, DOI 10.1136/bmj.309.6964.1273; Egner A, 2003, NEUROREHABILITATION, V18, P125; Forducey PG, 2003, NEUROREHABILITATION, V18, P103; Heinzelmann PJ, 2005, TELEMED J E-HEALTH, V11, P329, DOI 10.1089/tmj.2005.11.329; in't Veld MHAH, 2006, J TELEMED TELECARE, V12, P289, DOI 10.1258/135763306778558178; Jorgensen H S, 1999, Phys Med Rehabil Clin N Am, V10, P887; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Kuttuva M, 2006, CYBERPSYCHOL BEHAV, V9, P148, DOI 10.1089/cpb.2006.9.148; Kwakkel G, 2002, J NEUROL NEUROSUR PS, V72, P473; Legg L, 2007, BMJ-BRIT MED J, V335, P922, DOI 10.1136/bmj.39343.466863.55; LYLE RC, 1981, INT J REHABIL RES, V4, P483, DOI 10.1097/00004356-198112000-00001; Man DWK, 2006, NEUROREHABILITATION, V21, P205; OLSEN TS, 1990, STROKE, V21, P247, DOI 10.1161/01.STR.21.2.247; Parker V M, 1986, Int Rehabil Med, V8, P69; Reinkensmeyer DJ, 2002, IEEE T NEUR SYS REH, V10, P102, DOI 10.1109/TNSRE.2002.1031978; Scattareggia MS, 2004, INT J REHABIL RES, V27, P110; van der Lee JH, 1999, STROKE, V30, P2369, DOI 10.1161/01.STR.30.11.2369; Wade D T, 1989, Int Disabil Stud, V11, P89; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521; WAGENAAR RC, 1990, SCAND J REHABIL MED, V22, P1	24	74	76	0	25	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1357-633X	1758-1109		J TELEMED TELECARE	J. Telemed. Telecare		2008	14	5					249	256		10.1258/jtt.2008.080104			8	Health Care Sciences & Services	Science Citation Index Expanded (SCI-EXPANDED)	Health Care Sciences & Services	337TO	WOS:000258458600008	18633000				2022-02-06	
J	Han, SD; Drake, AI; Cessante, LM; Jak, AJ; Houston, WS; Delis, DC; Filoteo, JV; Bondi, MW				Han, S. Duke; Drake, Angela I.; Cessante, Lynne M.; Jak, Amy J.; Houston, Wes S.; Delis, Dean C.; Filoteo, J. Vincent; Bondi, Mark W.			Apolipoprotein E and traumatic brain injury in a military population: evidence of a neuropsychological compensatory mechanism?	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							HEAD-INJURY; ALZHEIMERS-DISEASE; APOE GENOTYPE; EPSILON 4; E POLYMORPHISM; FMRI EVIDENCE; GENETIC RISK; OLDER-ADULTS; ASSOCIATION; DEPOSITION	Objective: Although research has implicated the apolipoprotein E ( APOE) epsilon- 4 genotype as having a negative effect on neuropsychological outcomes following traumatic brain injury ( TBI), the potentially negative role of the epsilon 4 allele on TBI outcomes has recently been challenged. In light of this debate, the present study served to examine the role of APOE genotype on neuropsychological outcomes approximately 1 month following mild to moderate TBI in a military population. Because of the well documented role of the APOE- epsilon 4 allele in increasing the risk of Alzheimer's disease, we predicted that persons with the APOE- epsilon 4 genotype would display relatively greater deficits in cognition than their non- epsilon 4 counterparts. Methods: 78 participants were consecutively recruited following a mild to moderate TBI and were divided into two groups based on the presence or absence of an APOE epsilon 4 allele. Groups were comparable on demographic characteristics and psychosocial outcomes. Participants were administered a comprehensive neuropsychological battery. Results: Analyses revealed comparable performances on most neuropsychological measures and better performances by epsilon 4 carriers on select measures of attention, executive functioning and episodic memory encoding. Furthermore, differences remained after accounting for the effects of TBI severity. Conclusions: Evidence from these analyses supports current literature refuting the notion of relatively poorer neuropsychological functioning associated with the APOE- epsilon 4 genotype among young adult participants shortly following mild or moderate brain injury. Neuropsychological performance differences by APOE genotype following TBI are discussed in terms of the importance of considering severity of injury, timing of postinjury assessment and possible neurocognitive compensatory mechanisms.	VA San Diego Hlthcare Syst, San Diego, CA 92161 USA		Bondi, MW (corresponding author), VA San Diego Hlthcare Syst, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	mbondi@ucsd.edu	Han/N-1246-2019				Arendt T, 1997, J NEUROSCI, V17, P516; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Beffert U, 1996, ANN NY ACAD SCI, V777, P166, DOI 10.1111/j.1749-6632.1996.tb34415.x; Bondi MW, 2005, NEUROLOGY, V64, P501, DOI 10.1212/01.WNL.0000150885.00929.7E; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; BROOKS D N, 1975, Cortex, V11, P329; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; CROSSON B, 1989, CLIN NEUROPSYCHOL, V3, P29, DOI DOI 10.1080/13854048908404074; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; GRONWALL D, 1975, LANCET, V2, P995; Han SD, 2007, NEUROBIOL AGING, V28, P238, DOI 10.1016/j.neurobiolaging.2005.12.013; Hubacek JA, 2001, NEUROPSYCHOBIOLOGY, V43, P200, DOI 10.1159/000054890; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Katzman R, 1996, NEUROLOGY, V46, P889; KELTIKANGASJARVINEN L, 1993, PSYCHOSOM MED, V55, P155, DOI 10.1097/00006842-199303000-00004; Levin HS., 1982, NEUROBEHAVIORAL CONS; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Livingston M G, 1985, Int Rehabil Med, V7, P145; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; NAGY Z, 1995, NEUROSCIENCE, V69, P757, DOI 10.1016/0306-4522(95)00331-C; Nicoll J. A. R., 1995, Neuropathology and Applied Neurobiology, V21, P10; Nicoll J. A. R., 1995, Journal of Neurotrauma, V12, P434; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; Papassotiropoulos A, 2004, NEUROBIOL AGING, V25, pS490, DOI 10.1016/S0197-4580(04)81619-1; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Reiman EM, 2004, P NATL ACAD SCI USA, V101, P284, DOI 10.1073/pnas.2635903100; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Scarmeas N, 2005, J NEUROL NEUROSUR PS, V76, P1440, DOI 10.1136/jnnp.2004.053645; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tolar M, 1999, J NEUROSCI, V19, P7100, DOI 10.1523/JNEUROSCI.19-16-07100.1999	48	74	76	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	2007	78	10					1103	1108		10.1136/jnnp.2006.108183			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	211LB	WOS:000249524200016	17287237	Green Published			2022-02-06	
J	Mahmood, A; Lu, DY; Qu, CS; Goussev, A; Zhang, ZG; Lu, C; Chopp, M				Mahmood, Asim; Lu, Dunyue; Qu, Changsheng; Goussev, Anton; Zhang, Zheng Gang; Lu, Chang; Chopp, Michael			Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin	JOURNAL OF NEUROSURGERY			English	Article						carbamylated erythropoietin; erythropoietin; hematocrit; rat; traumatic brain injury	ENHANCES NEUROGENESIS; CEREBRAL-ISCHEMIA; PROTECTS NEURONS; ANGIOGENESIS; ATORVASTATIN; EXPRESSION; DEFICIT; DEATH; CELLS	Object. This study was designed to investigate the neuroprotective properties of recombinant erythropoietin (EPO) and carbamylated erythropoietin (CEPO) administered following traumatic brain injury (TBI) in rats. Methods. Sixty adult male Wistar rats were injured with controlled cortical impact, and then EPO, CEPO, or a placebo (phosphate-buffered saline) was injected intraperitoneally. These injections were performed either 6 or 24 hours after TBI. To label newly regenerating cells, bromodeoxyuridine was injected intraperitoneally for 14 days after TBI. Blood samples were obtained on Days 1, 2, 3, 7, 14, and 35 to measure hematocrit. Spatial learning was tested using the Morris water maze. All rats were killed 35 days after TBI. Brain sections were immunostained as well as processed for the enzyme-linked immunosorbent assay to measure brain-detived neurotrophic factor (BDNF). Results. A statistically significant improvement in spatial learning was seen in rats treated with either EPO or CEPO 6 or 24 hours after TBI (p < 0.05); there was no difference in the effects of EPO and CEPO. Also, these drugs were equally effective in increasing the number of newly proliferating cells within the dentate gyrus at both time points. A statistically significant increase in BDNF expression was seen in animals treated with both EPO derivatives at 6 or 24 hours after TBI. Systemic hematocrit was significantly increased at 48 hours and 1 and 2 weeks after treatment with EPO but not with CEPO. Conclusions. These data demonstrate that at the doses used, EPO and CEPO are equally effective in enhancing spatial learning and promoting neural plasticity after TBI.	Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Syst, Dept Neurosurg Res, Detroit, MI USA; Henry Ford Hlth Syst, Dept Neurol Res, Detroit, MI USA		Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042259] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259] Funding Source: NIH RePORTER		Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Day LB, 1996, BEHAV NEUROSCI, V110, P998; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Jumbe NL, 2002, ONCOLOGY-NY, V16, P91; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; Koshimura K, 1999, J NEUROCHEM, V72, P2565, DOI 10.1046/j.1471-4159.1999.0722565.x; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Marti HH, 2000, NEWS PHYSIOL SCI, V15, P225; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; POSTMANTUR R, 1997, NEUROSCIENCE, V77, P875; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sasaki R, 2001, NEWS PHYSIOL SCI, V16, P110; TAN CC, 1992, AM J PHYSIOL, V263, P474; Vescovi AL, 1999, J NEUROTRAUM, V16, P689, DOI 10.1089/neu.1999.16.689; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166	29	74	77	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2007	107	2					392	397		10.3171/JNS-07/08/0392			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	196XT	WOS:000248517300021	17695395				2022-02-06	
J	Laskowitz, DT; McKenna, SE; Song, PP; Wang, HC; Durham, L; Yeung, N; Christensen, D; Vitek, MP				Laskowitz, Daniel T.; McKenna, Suzanne E.; Song, Pingping; Wang, Haichen; Durham, Lori; Yeung, Nolan; Christensen, Dale; Vitek, Michael P.			COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						apolipoprotein E; neuroinflammation; neuroprotection; traumatic brain injury	CLOSED-HEAD INJURY; E-DEFICIENT MICE; SYSTEM INFLAMMATORY RESPONSE; APOE GENOTYPE; WATER-MAZE; MICROGLIAL ACTIVATION; OPTICAL FRACTIONATOR; MIMETIC PEPTIDES; TRANSGENIC MICE; SPATIAL MEMORY	Traumatic brain injury (TBI) is a silent epidemic affecting approximately 1.4 million Americans annually, at an estimated annual cost of $60 billion in the United States alone. Despite an increased understanding of the pathophysiology of closed head injury, there remains no pharmacological intervention proven to improve functional outcomes in this setting. Currently, the existing standard of care for TBI consists primarily of supportive measures. Apolipoprotein E ( apoE) is the primary apolipoprotein synthesized in the brain in response to injury, where it modulates several components of the neuroinflammatory cascade associated with TBI. We have previously demonstrated that COG133, an apoE mimetic peptide, improved functional outcomes and attenuated neuronal death when administered as a single intravenous injection at 30 min post-TBI in mice. Using the principles of rational drug design, we developed a more potent analog, COG1410, which expands the therapeutic window for the treatment of TBI by a factor of four, from 30 min to 2 h. Mice that received a single intravenous injection of COG1410 at 120 min post-TBI exhibited significant improvement on a short term test of vestibulomotor function and on a long term test of spatial learning and memory. This was associated with a significant attenuation of microglial activation and neuronal death in the hippocampus, the neuroanatomical substrate for learning and memory. Rationally derived apoE mimetic peptides have been demonstrated to exert neuroprotective and anti-inflammatory effects in vitro and in clinically relevant models of brain injury. This represents a novel therapeutic strategy in the treatment of TBI.	Cognosci Inc, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC USA; Duke Univ, Med Ctr, Dept Med, Div Neurol, Durham, NC USA		Vitek, MP (corresponding author), Cognosci Inc, 2 Davis Dr,POB 12076, Res Triangle Pk, NC 27709 USA.	mikevitek@cognosci.com		Vitek, Michael/0000-0001-8140-8048	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 020473] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS4487, NS 043954] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS043954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R43AG020473, R44AG020473] Funding Source: NIH RePORTER		Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Aono M, 2003, NEUROSCIENCE, V116, P437, DOI 10.1016/S0306-4522(02)00709-1; Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; *CDC, 2006, FACTS TRAUM BRAIN IN; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Dommergues MA, 2003, NEUROSCIENCE, V121, P619, DOI 10.1016/S0306-4522(03)00558-X; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gay EA, 2006, J PHARMACOL EXP THER, V316, P835, DOI 10.1124/jpet.105.095505; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; Holscher C, 1999, BEHAV BRAIN RES, V100, P225, DOI 10.1016/S0166-4328(98)00134-X; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jury MA, 2001, NEW ZEAL MED J, V114, P286; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; LINTON M, 1991, J CLIN INVEST, V81, P270; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; Maas Andrew I.R., 2000, Curr Opin Crit Care, V6, P281, DOI 10.1097/00075198-200008000-00008; MARSHALL GR, 1990, P NATL ACAD SCI USA, V87, P487, DOI 10.1073/pnas.87.1.487; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McAdoo JD, 2005, NEUROSCI LETT, V381, P305, DOI 10.1016/j.neulet.2005.02.036; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Misra UK, 2001, J LEUKOCYTE BIOL, V70, P677; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; *NAT AC SCI, 1996, GUID CAR US LAB AN; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Skelton RW, 2006, BRAIN INJURY, V20, P189, DOI 10.1080/02699050500456410; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1007/BF03206568; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wang HC, 2006, NEUROCRIT CARE, V5, P71, DOI 10.1385/NCC:5:1:71; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wolfer DP, 1998, NEWS PHYSIOL SCI, V13, P118, DOI 10.1152/physiologyonline.1998.13.3.118	62	74	79	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1093	1107		10.1089/neu.2006.0192			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200002	17610350				2022-02-06	
J	Verdonck, O; Lahrech, H; Francony, G; Carle, O; Farion, R; Van de Looij, Y; Remy, C; Segebarth, C; Payen, JF				Verdonck, Olivier; Lahrech, Hana; Francony, Gilles; Carle, Olivier; Farion, Regine; Van de Looij, Yohan; Remy, Chantal; Segebarth, Christoph; Payen, Jean-Francois			Erythropoietin protects from post-traumatic edema in the rat brain	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						erythropoietin; brain edema; traumatic brain injury; magnetic resonance imaging; neuroprotection	RECOMBINANT-HUMAN-ERYTHROPOIETIN; CEREBRAL-BLOOD-FLOW; WATER-CONTENT; NEURONAL APOPTOSIS; CELLULAR EDEMA; INJURY; DIFFUSION; MODEL; MECHANISMS; ISCHEMIA	Erythropoietin (Epo) is gaining interest in various neurological insults as a possible neuroprotective agent. We determined the effects of recombinant human Epo (rhEpo, 5000 IU per kg bw) on brain edema induced in rats by traumatic brain injury (TBI; impact-acceleration model; rhEpo administration 30 mins after injury). Magnetic resonance imaging (MRI) and a gravimetric technique were applied. In the MRI experiments, the apparent diffusion coefficient (ADC) and the tissue T, relaxation time were measured hourly in the neocortex and caudoputamen, during a 6 h time span after TBI. In the gravimetric experiments, brain water content (BWC) was determined in these two regions, 6 h after TBI. Apparent diffusion coefficient measurements showed that rhEpo decreased brain edema early and durably. Gravimetric measurements showed that rhEpo decreased BWC at H, in the neocortex as well as in the caudoputamen. No significant differences in ADC, in T, or in BWC were found between rhEpo treated-TBI rats and sham-operated rats. Our findings show that post-traumatic administration of rhEpo can significantly reduce the development of brain edema in a model of diffuse TBI. Further studies should be conducted to identify the biochemical mechanisms involved in these immediate effects and to assess the use of rhEpo as a possible therapy for post-traumatic brain edema.	Hop Albert Michallon, INSERM U594, F-38043 Grenoble, France; Univ Grenoble, Grenoble, France; CHU Grenoble, Michallons Hosp, Dept Anesthesiol & Crit Care Med, F-38043 Grenoble, France		Payen, JF (corresponding author), Hop Albert Michallon, INSERM U594, Pavillon B,BP 217, F-38043 Grenoble, France.	jfpayen@ujf-grenoble.fr	Payen, Jean-Francois/L-6667-2014; Remy, Chantal/L-9459-2014; Lahrech, Hana/M-5229-2018; fathi, mazyar/H-1722-2016	van de Looij, Yohan/0000-0003-2830-5482; Lahrech, Hana/0000-0003-3843-3410			Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Barbier EL, 2005, NMR BIOMED, V18, P499, DOI 10.1002/nbm.979; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.0.CO;2-H; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Chen IR, 2003, IEEE T MOBILE COMPUT, V2, P3, DOI 10.1109/TMC.2003.1195147; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Fatouros PP, 1999, J NEUROSURG, V90, P109, DOI 10.3171/jns.1999.90.1.0109; FATOUROS PP, 1991, MAGNET RESON MED, V17, P402, DOI 10.1002/mrm.1910170212; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FREI HJ, 1973, ACTA NEUROCHIR, V29, P15, DOI 10.1007/BF01414613; Gorio A, 2005, P NATL ACAD SCI USA, V102, P16379, DOI 10.1073/pnas.0508479102; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2005, NEUROSURGERY, V56, P821, DOI 10.1227/01.NEU.0000156493.00904.7E; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Kawakami M, 2001, J BIOL CHEM, V276, P39469, DOI 10.1074/jbc.M105832200; Kimelberg HK, 2004, NEUROSCIENCE, V129, P851, DOI 10.1016/j.neuroscience.2004.07.033; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lin WL, 2000, J CEREBR BLOOD F MET, V20, P37, DOI 10.1097/00004647-200001000-00007; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matchett G, 2006, J NEUROSCI METH, V158, P234, DOI 10.1016/j.jneumeth.2006.06.003; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Silva AC, 1999, J CEREBR BLOOD F MET, V19, P871, DOI 10.1097/00004647-199908000-00006; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; TIO J, 1996, J NEUROSURG, V84, P97; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	44	74	79	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2007	27	7					1369	1376		10.1038/sj.jcbfm.9600443			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	180OL	WOS:000247375000007	17264861	Bronze			2022-02-06	
J	Baguley, IJ; Heriseanu, RE; Gurka, JA; Nordenbo, A; Cameron, ID				Baguley, Ian J.; Heriseanu, Roxana E.; Gurka, Joseph A.; Nordenbo, Annette; Cameron, Ian D.			Gabapentin in the management of dysautonomia following severe traumatic brain injury: a case series	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							INTRATHECAL BACLOFEN; AUTONOMIC DYSFUNCTION; NEUROPATHIC PAIN; MECHANISMS; SPASTICITY; ISCHEMIA; NEURONS	The pharmacological management of dysautonomia, otherwise known as autonomic storms, following acute neurological insults, is problematic and remains poorly researched. This paper presents six subjects with dysautonomia following extremely severe traumatic brain injury where gabapentin controlled paroxysmal autonomic changes and posturing in the early post-acute phase following limited success with conventional medication regimens. In two subjects, other medications were reduced or ceased without a recurrence of symptoms. It is proposed that medications that can block or minimise abnormal afferent stimuli may represent a better option for dysautonomia management than drugs which increase inhibition of efferent pathways. Potential mechanisms for these effects are discussed.	Westmead Hosp, Brain Injury Rehabil Serv, Wentworthville, NSW 2145, Australia; Hvidovre Univ Hosp, Brain Injury Unit, DK-2650 Hvidovre, Denmark; Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia		Baguley, IJ (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, POB 533, Wentworthville, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; 			Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; ALLERTON CA, 1989, BRIT J PHARMACOL, V96, P29, DOI 10.1111/j.1476-5381.1989.tb11780.x; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 2005, BRAIN INJURY, V19, P545, DOI 10.1080/02699050400025075; Baguley IJ, 2004, BRAIN INJURY, V18, P409, DOI 10.1080/02699050310001645775; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; Cheng JK, 2006, J PHARMACOL SCI, V100, P471, DOI 10.1254/jphs.CR0050020; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; Cohen SP, 2004, AM J PHYS MED REHAB, V83, P142, DOI 10.1097/01.PHM.0000107499.24698.CA; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Dooley DJ, 2000, NEUROSCI LETT, V280, P107, DOI 10.1016/S0304-3940(00)00769-2; Guillaume D, 2005, ARCH PHYS MED REHAB, V86, P2165, DOI 10.1016/j.apmr.2005.05.018; Ivanhoe C B, 2001, Phys Med Rehabil Clin N Am, V12, P923; KROIN JS, 1993, J NEUROSURG, V79, P544, DOI 10.3171/jns.1993.79.4.0544; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lemke Denise M, 2004, J Neurosci Nurs, V36, P4; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; OTT L, 1991, J NEUROSURG, V74, P738, DOI 10.3171/jns.1991.74.5.0738; Rose MA, 2002, ANAESTHESIA, V57, P451, DOI 10.1046/j.0003-2409.2001.02399.x; Russo RN, 2000, J PAEDIATR CHILD H, V36, P283, DOI 10.1046/j.1440-1754.2000.00485.x; SANDEL ME, 1986, ARCH PHYS MED REHAB, V67, P469; Scott JS, 1997, AM J PHYS MED REHAB, V76, P200, DOI 10.1097/00002060-199705000-00007; Smith PA, 2004, DRUG NEWS PERSPECT, V17, P5, DOI 10.1358/dnp.2004.17.1.829021; Sutton KG, 2002, BRIT J PHARMACOL, V135, P257, DOI 10.1038/sj.bjp.0704439; Tremont-Lukats IW, 2000, DRUGS, V60, P1029, DOI 10.2165/00003495-200060050-00005; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013	28	74	83	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2007	78	5					539	541		10.1136/jnnp.2006.096388			3	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	156YO	WOS:000245686000028	17435191	Green Published			2022-02-06	
J	Dick, R; Romani, WA; Agel, J; Case, JG; Marshall, SW				Dick, Randall; Romani, William A.; Agel, Julie; Case, Jim G.; Marshall, Stephen W.			Descriptive epidemiology of collegiate men's lacrosse injuries: National Collegiate Athletic Association Injury surveillance system, 1988-1989 through 2003-2004	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; injury prevention; lower extremity injuries; ankle sprains; concussions; shoulder injuries		Objective: To review 16 years of National Collegiate Athletic Association (NCAA) injury surveillance data for men's lacrosse and identify potential areas for injury prevention initiatives. Background: During the sample period, the number of sponsoring institutions and the number of participants in men's college lacrosse grew significantly. Overall, an average of 18% of NCAA institutions participated in the annual NCAA Injury Surveillance System data collection for this sport. Main Results: Over the sample period, athletes were almost 4 times more likely to sustain injuries in games than in practices (12.58 versus 3.24 injuries per 1000 athlete-exposures [A-Es], rate ratio = 3.9, 95% confidence interval = 3.7, 4.1). Approximately half of all game (48.1%) and practice (58.7%) injuries were to the lower extremity, followed by the upper extremity (26.2% in games, 16.9% in practices), and the head and neck (111.7% in games, 6.2% in practices). In games and practices, the most common injuries were ankle ligament sprains (11.3% and 16.4%, respectively). The disparity among preseason, regular-season, and postseason injuries may be due to athlete acclimatization to the rigors of the sport throughout the season. Changes in helmet design may account for the rise in the concussion rate since the 1995-1996 season. Recommendations: We recommend research into the mechanism of head injuries and the implications of design changes to protective helmets, as well as further investigation of the best designs for shoulder and chest protection.	Univ Maryland, Sch Med, Dept Phys Therapy, Baltimore, MD 21201 USA; Univ Minnesota, Minneapolis, MN 55455 USA; Cornell Univ, Ithaca, NY 14853 USA; Univ N Carolina, Chapel Hill, NC 27515 USA; Natl Collegiate Athlet Assoc, Indianapolis, IN USA		Romani, WA (corresponding author), Univ Maryland, Sch Med, Dept Phys Therapy, 100 Penn St, Baltimore, MD 21201 USA.	wromani@som.umaryland.edu		Marshall, Stephen/0000-0002-2664-9233			Caswell SV, 2002, J ATHL TRAINING, V37, P164; Dick R, 2007, J ATHL TRAINING, V42, P173; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; *NAT COLL ATHL ASS, 2006, 1981 82 2004 05 NCAA	4	74	74	0	11	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	APR-JUN	2007	42	2					255	261					7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	180RC	WOS:000247382300012	17710174				2022-02-06	
J	Levin, H; Hanten, G; Max, J; Li, XQ; Swank, P; Ewing-Cobbs, L; Dennis, M; Menefee, DS; Schachar, R				Levin, Harvey; Hanten, Gerri; Max, Jeffrey; Li, Xiaoqi; Swank, Paul; Ewing-Cobbs, Linda; Dennis, Maureen; Menefee, Deleene S.; Schachar, Russell			Symptoms of attention-deficit/hyperactivity disorder following traumatic brain injury in children	JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS			English	Article						traumatic brain injury; attention-deficit/hyperactivity disorder; children	DEFICIT HYPERACTIVITY DISORDER; CLOSED-HEAD INJURY; PSYCHIATRIC-DISORDERS; RESPONSE-INHIBITION; ADOLESCENTS; ADHD; RECOVERY; BEHAVIOR; TERM; SYMPTOMATOLOGY	Methods: We investigated changes in inattentive and hyperactive symptoms over 2 years following traumatic brain injury (TBI) in relation to preinjury attention-deficit/hyperactivity disorder (ADHD), injury, and socioeconomic status (SES) variables. Postinjury stimulant medication treatment was also documented. of 175 consecutive patients of ages 5 to 15 years with acute TBI, 148 consented, including 114 without preinjury ADHD (mean age, 10.0 years, SD = 2.76) and 34 with preinjury ADHD (mean age 10.36 years, SD = 2.75). The Schedule for Affective Disorders and Schizophrenia for School-Age Children, Present and Lifetime Version, was administered at baseline and at 6, 12, and 24 months post-injury to assess the presence of nine core inattentive and nine hyperactive symptoms and associated impairment. The baseline assessment was performed within 1 month post- injury to establish preinjury diagnosis. Results: Nonlinear change in inattentive symptoms in patients without preinjury ADHD contrasted with higher and more stable symptom levels in children with preinjury diagnosis, including the cubic trend (chi(2)(1) = 6.23, p = .0126). There was also a significant interaction of group x gender effect (chi(2)(1), = 4.08, p = .0435) as males had higher numbers of inattentive symptoms than females in the preinjury ADHD group. Change in hyperactive symptoms over time also differed by group, including both linear (chi(2)(1) = 5.42, p = .0199) and cubic trends (chi(2)(1) = 8.91, p = .0029), refleding greater and more frequent fluctuations in children without preinjury ADHD. Socioeconomic level also contributed to change in hyperactive symptoms as reflected by the interaction of SES and linear time (chi(2)(1) = 6.91, p = .009), as well as quadratic time (chi(2)(1) = 4.90, p = .027). Occurrence of ADHD diagnosed post-injury ranged from 14.5% (12 months) to 18.3% (24 months) in the group without preinjury ADHD compared with a range from 86.4% (12 months) to 96.2% (6 months) in children with preinjury ADHD. In children without preinjury ADHD, SES was the only patient variable that predicted onset of ADHD, t(110) = -2.85, p = .0052. Treatment with stimulant medication post-injury was more frequently associated with preinjury ADHD (39% vs 7% of children without preinjury ADHD), p < .0001 (Fisher exact test). Children with preinjury ADHD who were treated pre-injury with stimulant medication had fewer total symptoms at 24 months post-injury relative to untreated patients with preinjury ADHD (F[1,14] = 3.93, p = 0.069, Cohen's d = 1.28). Conclusion: Change in ADHD symptoms after TBI varies with preinjury diagnosis, reflects injury severity in children without preinjury ADHD, and is treated with stimulant medication mainly in those patients with preinjury ADHD.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Childrens Hosp & Hlth Ctr, San Diego, CA USA; Univ Texas, Sch Med, Dept Pediat, Houston, TX USA; Univ Toronto, Dept Surg, Toronto, ON, Canada; Hosp Sick Children, Dept Psychiat, Toronto, ON M5G 1X8, Canada		Levin, H (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	hlevin@bcm.edu		Schachar, Russell/0000-0002-2015-4395	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Barbaresi WJ, 2006, J DEV BEHAV PEDIATR, V27, P1, DOI 10.1097/00004703-200602000-00001; Biederman J, 2005, LANCET, V366, P237, DOI 10.1016/S0140-6736(05)66915-2; Blanchard EB, 1998, J ANXIETY DISORD, V12, P21, DOI 10.1016/S0887-6185(97)00047-9; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Bush G, 2005, BIOL PSYCHIAT, V57, P1273, DOI 10.1016/j.biopsych.2005.01.034; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P842; Chen X, 2005, NEUROSCIENCE, V135, P11, DOI 10.1016/j.neuroscience.2005.05.041; Counts CA, 2005, J AM ACAD CHILD PSY, V44, P690, DOI 10.1097/01.chi.0000162582.87710.66; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; Homer CJ, 2000, PEDIATRICS, V105, P1158; Hornyak J E, 1997, Pediatr Rehabil, V1, P15; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Konrad KN, 2000, BRAIN INJURY, V14, P859; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Maegele M, 2005, J NEUROTRAUM, V22, P772, DOI 10.1089/neu.2005.22.772; Mahalick DM, 1998, PEDIATR NEUROSURG, V29, P121, DOI 10.1159/000028705; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Munson S, 2006, PEDIATRICS, V117, P1372, DOI 10.1542/peds.2005-0826; Murphy KR, 2002, J NERV MENT DIS, V190, P147, DOI 10.1097/00005053-200203000-00003; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rutter M., 1987, RISK PROTECTIVE FACT, P181; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Slomine BS, 2005, J INT NEUROPSYCH SOC, V11, P645, DOI 10.1017/S1355617705050769; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Williams SE, 1998, J HEAD TRAUMA REHAB, V13, P73, DOI 10.1097/00001199-199806000-00007; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	48	74	75	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0196-206X	1536-7312		J DEV BEHAV PEDIATR	J. Dev. Behav. Pediatr.	APR	2007	28	2					108	118		10.1097/01.DBP.0000267559.26576.cd			11	Behavioral Sciences; Psychology, Developmental; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Psychology; Pediatrics	158KG	WOS:000245789800005	17435461				2022-02-06	
J	Wilde, EA; Bigler, ED; Hunter, JV; Fearing, MA; Scheibel, RS; Newsome, MR; Johnson, JL; Bachevalier, J; Li, XQ; Levin, HS				Wilde, Elisabeth A.; Bigler, Erin D.; Hunter, Jill V.; Fearing, Michael A.; Scheibel, Randall S.; Newsome, Mary R.; Johnson, Jamie L.; Bachevalier, Jocelyne; Li, Xiaoqi; Levin, Harvey S.			Hippocampus, amygdala, and basal ganglia morphometrics in children after moderate-to-severe traumatic brain injury	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY; HEAD-INJURY; NEURONAL DAMAGE; MEMORY; RAT; VOLUME; MRI; MILD; VULNERABILITY; ISCHEMIA	While closed head injury frequently results in damage to the frontal and temporal lobes, damage to deep cortical structures, such as the hippocampus, amygdala, and basal ganglia, has also been reported. Five deep central structures (hippocampus, amygdala, globus pallidus, putamen, and caudate) were examined in 16 children (eight males, eight females; aged 9-16y), imaged 1 to 10 years after moderate-tosevere traumatic brain injury JBI), and in 16 individuallymatched uninjured children. Analysis revealed significant volume loss in the hippocampus, amydala, and globus pallidus of the TBI group. Investigation of relative volume loss between these structures and against five cortical areas (ventromedial frontal, superomedial frontal, lateral frontal, temporal, and parieto-occipital) revealed the hippocampus to be the most vulnerable structure following TBI (i.e. greatest relative difference between the groups). In a separate analysis excluding children with focal hippocampal abnormalities (e.g. lesions), group differences in hippocampal volume were still evident, suggesting that hippocampal damage may be diffuse rather than focal.	Baylor Coll Med, Cognit Neurosci Lab, Houston, TX 77030 USA; Brigham Young Univ, Provo, UT 84602 USA; Texas Childrens Hosp, Houston, TX 77030 USA; Emory Univ, Atlanta, GA 30322 USA		Wilde, EA (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, 1709 Dryden Rd,Ste 725, Houston, TX 77030 USA.	ewilde@bcm.tmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19 HD-35476] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19HD035476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Arciniegas DB, 2001, J NEUROPSYCH CLIN N, V13, P213, DOI 10.1176/appi.neuropsych.13.2.213; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brierley B, 2002, BRAIN RES REV, V39, P84, DOI 10.1016/S0165-0173(02)00160-1; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Convit A, 1999, PSYCHIAT RES-NEUROIM, V90, P113, DOI 10.1016/S0925-4927(99)00007-4; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Hattori N, 2003, J NUCL MED, V44, P1709; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; JORGENSEN MB, 1990, J CEREBR BLOOD F MET, V10, P243, DOI 10.1038/jcbfm.1990.41; Kates WR, 1997, PSYCHIAT RES-NEUROIM, V75, P31, DOI 10.1016/S0925-4927(97)00019-X; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; NAKANO S, 1990, NEUROSCIENCE, V38, P115, DOI 10.1016/0306-4522(90)90378-H; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Primus EA, 1997, BRAIN INJURY, V11, P577; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sheline YI, 1998, NEUROREPORT, V9, P2023, DOI 10.1097/00001756-199806220-00021; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TERAYAMA Y, 1991, J CEREBR BLOOD F MET, V11, P852, DOI 10.1038/jcbfm.1991.145; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; [No title captured]	45	74	75	0	3	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	APR	2007	49	4					294	299		10.1111/j.1469-8749.2007.00294.x			6	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	156HC	WOS:000245637700012	17376141	Bronze			2022-02-06	
J	Zhou, ZW; Daugherty, WP; Sun, D; Levasseur, JE; Altememi, N; Hamm, RJ; Rockswold, GL; Bullock, MR				Zhou, Zhengwen; Daugherty, Wilson P.; Sun, Dong; Levasseur, Joseph E.; Altememi, Nabil; Hamm, Robert J.; Rockswold, Gaylan L.; Bullock, M. Ross			Protection of mitochondrial function and improvement in cognitive recovery in rats treated with hyperbaric oxygen following lateral fluid-percussion injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; fraction of inspired oxygen; hyperbaric oxygen treatment; cognitive function; adenosine triphosphate; hippocampal cell count; rat	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; CEREBRAL-BLOOD-FLOW; SELECTIVE VULNERABILITY; INTRACRANIAL-PRESSURE; ARTERIAL HYPEROXIA; ENERGY-METABOLISM; DAMAGE; HIPPOCAMPUS; CONTUSION	Object. Hyperbaric oxygen (HBO2) has been shown to improve Outcome after severe traumatic brain injury, but its underlying mechanisms are unknown. Following lateral fluid-percussion injury (FPI), the authors tested the effects of HBO2 treatment as well as enhanced normobaric oxygenation on mitochondrial function, as measured by both cognitive recovery and cellular adenosine triphosphate (ATP) levels. Methods. Adult male Sprague-Dawley rats were Subjected to moderate lateral FPI or sham injury and were allocated to one of four treatment groups: 1) FPI treated with 4 hours of normobaric 30% O-2; 2) FPI treated with 4 hours of normobaric 100% O-2; 3) FPI treated with 1 hour of HBO2 Plus 3 hours of normobaric 100% O-2; and 4) sham-injured treated with normobaric 30% O-2. Cognitive outcome was assessed using the Morris water maze (MWM) on Days 11 to 15 after injury. Animals were then killed 21 days postinjury to assess hippocampal neuronal loss. Adenosine triphosphate was extracted from the neocortex and measured using hi.-h-performance liquid chromatography. The results showed that injured animals treated with HBO2 or normobaric 100% O-2 alone had significantly higher levels of cerebral ATP as compared with animals treated using normobaric 30% O-2 (p <= 0.05). The injured animals treated with HBO2 had significant improvements in cognitive recovery, as characterized by a shorter latency in MWM performance (p <= 0.05), and decreased neuronal loss in the CA2/3 and hilar regions as compared with those treated with 30% or 100% O-2 (p <= 0.05). Conclusions. Both hyperbaric and normobaric hyperoxia increased cerebral ATP levels after lateral FPI. In addition, HBO2 treatment improved cognitive recovery and reduced hippocampal neuronal cell loss after brain injury in the rat.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA		Bullock, MR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, 1200 E Broad St,W Hosp 8 S, Richmond, VA 23298 USA.	Mbullock@mcvh-vcu.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		ABDELFATTAH AS, 1987, J LIQ CHROMATOGR, V10, P2653, DOI 10.1080/01483918708066819; Alves OL, 2004, CURR PHARM DESIGN, V10, P2163, DOI 10.2174/1381612043384187; AUER RN, 1984, ACTA NEUROPATHOL, V64, P177, DOI 10.1007/BF00688108; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; BOCHICCHIO M, 1990, INTENS CARE MED, V16, P444, DOI 10.1007/BF01711223; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Buczek M, 2002, METAB BRAIN DIS, V17, P153, DOI 10.1023/A:1019973921217; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Daugherty WP, 2004, J NEUROSURG, V101, P499, DOI 10.3171/jns.2004.101.3.0499; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; Elayan IM, 2000, J NEUROPHYSIOL, V83, P2022, DOI 10.1152/jn.2000.83.4.2022; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; HENDERSON LM, 1993, EUR J BIOCHEM, V217, P973, DOI 10.1111/j.1432-1033.1993.tb18328.x; JAIN KK, 2004, TXB HYPERBARIC MED, P264; KAWAMURA S, 1990, SURG NEUROL, V34, P101, DOI 10.1016/0090-3019(90)90104-W; Kessler L, 2003, DIABETES CARE, V26, P2378, DOI 10.2337/diacare.26.8.2378; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P435; Levasseur JE, 2006, NEUROSURGERY, V59, P1122, DOI 10.1227/01.NEU.0000245581.00908.AF; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mader J T, 1990, Infect Dis Clin North Am, V4, P433; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; Muehlberger PM, 2004, AVIAT SPACE ENVIR MD, V75, P496; Nishio S, 1997, ACT NEUR S, V70, P84; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Singhal AB, 2002, NEUROLOGY, V58, P945, DOI 10.1212/WNL.58.6.945; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Springer JE, 1998, BRAIN RES PROTOC, V2, P259, DOI 10.1016/S1385-299X(97)00045-7; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Zamboni WA, 2003, CLIN PLAST SURG, V30, P67, DOI 10.1016/S0094-1298(02)00068-8	50	74	85	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2007	106	4					687	694		10.3171/jns.2007.106.4.687			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	155OJ	WOS:000245586900027	17432723				2022-02-06	
J	Onyszchuk, G; Al-Hafez, B; He, YY; Bilgen, M; Berman, NEJ; Brooks, WM				Onyszchuk, Gregory; Al-Hafez, Baraa; He, Yong-Yue; Bilgen, Mehmet; Berman, Nancy E. J.; Brooks, William M.			A mouse model of sensorimotor controlled cortical impact: Characterization using longitudinal magnetic resonance imaging, behavioral assessments and histology	JOURNAL OF NEUROSCIENCE METHODS			English	Article						traumatic brain injury; controlled cortical impact; magnetic resonance imaging; mouse model; sensorimotor cortex; lesion evolution; injury characterization; behavioral tests	TRAUMATIC BRAIN-INJURY; CONTUSION VOLUME; SPINAL-CORD; DEFICITS	The present study establishes a new mouse model for traumatic brain injury (TBI), using an electromechanically driven linear motor impactor device to deliver a lateral controlled cortical impact (CCI) injury to the sensorimotor cortex. Lesion cavity size was measured, and inter-animal consistency demonstrated, at 14 days post injury. Qualitative information regarding damage progression over time was obtained by scanning with high field magnetic resonance imaging (MRI) at five time points following injury. Functional impairment and recovery were measured with the Rotarod, gridwalk and cylinder tests, and lesion cavity volume was measured post mortem with thionin-stained tissue sections. The study establishes the reliability of a linear-motor based device for producing repeatable damage in a CCI model, demonstrates the power of longitudinal MRI in studying damage evolution, and confirms that a simple battery of functional tests record sensorimotor impairment and recovery. (c) 2006 Elsevier B.V. All rights reserved.	Univ Kansas, Ctr Med, Hoglund Brain Imaging Ctr, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Psychol, Kansas City, KS 66160 USA		Brooks, WM (corresponding author), Univ Kansas, Ctr Med, Hoglund Brain Imaging Ctr, 3901 Rainbow Blvd,MS 1052, Kansas City, KS 66160 USA.	wbrooks@kumc.edu		brooks, william/0000-0001-6227-7636	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21 AG026482] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD002528, P30 HD02528] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS039123] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM066777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG026482] Funding Source: NIH RePORTER		Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Bilgen M, 2004, MAGN RESON MED, V52, P937, DOI 10.1002/mrm.20228; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/0897715042441828; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; KCOHANEK PM, 1995, J NEUROTRAUM, V12, P1015; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Narayana PA, 2004, J NEUROSCI RES, V78, P749, DOI 10.1002/jnr.20275; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schallert T, 2000, CONT NEUROS, P131; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	20	74	76	4	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAR 15	2007	160	2					187	196		10.1016/j.jneumeth.2006.09.007			10	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	146NG	WOS:000244940600001	17049995	Green Accepted			2022-02-06	
J	Ponath, G; Schettler, C; Kaestner, F; Voigt, B; Wentker, D; Arolt, V; Rothermundt, M				Ponath, Gerald; Schettler, Christiane; Kaestner, Florian; Voigt, Bjoern; Wentker, Dennis; Arolt, Volker; Rothermundt, Matthias			Autocrine S100B effects on astrocytes are mediated via RAGE	JOURNAL OF NEUROIMMUNOLOGY			English	Article						glia; S100B proteins; proinflammatory cytokines; autocrine pathway; RAGE	GLYCATION END-PRODUCTS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; CELL-SURFACE RECEPTOR; TUMOR-NECROSIS-FACTOR; ALZHEIMERS-DISEASE; SCHIZOPHRENIC-PATIENTS; NEURITE OUTGROWTH; GLIAL ACTIVATION; GENE-EXPRESSION	To find out if the astrocytic protein S100B involves its autocrine effects via RAGE we investigated the capacity of astrocytes to upregulate IL-6 and TNF-alpha expression by stimulation with S100B. The subcellular localization of RAGE expression at the cell surface membrane of cultured astrocytes was demonstrated by immunofluorescence microscopy, flow cytometry and Western blotting. S100B was able to stimulate IL-6 and TNF-alpha secretion in cultured astrocytes in a concentration- and time-dependent manner as shown by ELISA. S100B induced IL-6 and TNF-alpha secretion was blocked by the use of RAGE siRNA specific for knocking down RAGE expression. (c) 2006 Elsevier B.V. All rights reserved.	Univ Munster, Dept Psychiat, Mol Psychiat Div, D-48149 Munster, Germany		Rothermundt, M (corresponding author), Univ Munster, Dept Psychiat, Mol Psychiat Div, Albert Schweitzer Str 11, D-48149 Munster, Germany.	rothermu@uni-muenster.de					Adami C, 2004, BBA-MOL CELL RES, V1742, P169, DOI 10.1016/j.bbamcr.2004.09.008; Basta G, 2002, CIRCULATION, V105, P816, DOI 10.1161/hc0702.104183; BRETT J, 1993, AM J PATHOL, V143, P1699; Bucciarelli LG, 2002, CELL MOL LIFE SCI, V59, P1117, DOI 10.1007/s00018-002-8491-x; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Fattori E, 1995, EUR J NEUROSCI, V7, P2441, DOI 10.1111/j.1460-9568.1995.tb01042.x; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Guo L, 2001, NEUROBIOL AGING, V22, P975, DOI 10.1016/S0197-4580(01)00295-0; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Heizmann CW, 1999, NEUROCHEM RES, V24, P1097, DOI 10.1023/A:1020700117665; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Hu JR, 1997, J NEUROCHEM, V69, P2294; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Kess D, 2003, J IMMUNOL, V171, P5697, DOI 10.4049/jimmunol.171.11.5697; Lam AGM, 2001, NEUROBIOL AGING, V22, P765, DOI 10.1016/S0197-4580(01)00233-0; Lara DR, 2001, J PSYCHIATR RES, V35, P11, DOI 10.1016/S0022-3956(01)00003-6; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; Li YK, 2000, J NEUROCHEM, V74, P143; Liu L, 2005, J NEUROCHEM, V92, P546, DOI 10.1111/j.1471-4159.2004.02909.x; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; Marz P, 1998, P NATL ACAD SCI USA, V95, P3251, DOI 10.1073/pnas.95.6.3251; Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010; Mrak RE, 2001, NEUROBIOL AGING, V22, P915, DOI 10.1016/S0197-4580(01)00293-7; Muller N, 2000, World J Biol Psychiatry, V1, P173, DOI 10.3109/15622970009150588; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Neumann H, 1997, J EXP MED, V185, P305, DOI 10.1084/jem.185.2.305; Park IH, 2004, MOL IMMUNOL, V40, P1203, DOI 10.1016/j.molimm.2003.11.027; Penkowa M, 1999, GLIA, V25, P343; Petrova TV, 2000, BRAIN RES, V853, P74, DOI 10.1016/S0006-8993(99)02251-9; Petzold A, 2003, NEUROSCI LETT, V336, P167, DOI 10.1016/S0304-3940(02)01257-0; Rothermundt M, 2001, MOL PSYCHIATR, V6, P445, DOI 10.1038/sj.mp.4000889; Rothermundt M, 2004, NEUROPSYCHOPHARMACOL, V29, P1004, DOI 10.1038/sj.npp.1300403; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Rothermundt M, 2004, MOL PSYCHIATR, V9, P897, DOI 10.1038/sj.mp.4001548; Rothermundt M, 2001, BRAIN BEHAV IMMUN, V15, P319, DOI 10.1006/brbi.2001.0648; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SELMAJ KW, 1990, J IMMUNOL, V144, P129; Valencia JV, 2004, DIABETES, V53, P743, DOI 10.2337/diabetes.53.3.743; VANELDIK LJ, 1987, BRAIN RES, V436, P367, DOI 10.1016/0006-8993(87)91681-7; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wiesmann M, 1999, BIOL PSYCHIAT, V45, P1508, DOI 10.1016/S0006-3223(98)00217-0; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	51	74	77	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	MAR	2007	184	1-2					214	222		10.1016/j.jneuroim.2006.12.011			9	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	157NR	WOS:000245727400022	17254641				2022-02-06	
J	Tweedie, D; Milman, A; Holloway, HW; Li, YZ; Harvey, BK; Shen, H; Pistell, PJ; Lahiri, DK; Hoffer, BJ; Wang, Y; Pick, CG; Greig, NH				Tweedie, David; Milman, Anat; Holloway, Harold W.; Li, Yazhou; Harvey, Brandon K.; Shen, Hui; Pistell, Paul J.; Lahiri, Debomoy K.; Hoffer, Barry J.; Wang, Yun; Pick, Chaim G.; Greig, Nigel H.			Apoptotic and behavioral sequelae of mild brain trauma in mice	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; mild (mTBI); apoptosis; amyloid-beta precursor protein; apoptosis inducing factor (AIF); cytochrome-c; Bax	AMYLOID PRECURSOR PROTEINS; COGNITIVE DEFICITS; ALZHEIMERS-DISEASE; CELL-DEATH; RAT-BRAIN; CASPASE ACTIVATION; INBRED STRAINS; HEAD-INJURY; BETA; IMPAIRMENT	Mild traumatic brain injury (mTBI) is a not uncommon event in adolescents and young adults. Although it does not result in clear morphological brain defects, it is associated with long-term cognitive, emotional, and behavioral problems. Herein, we characterized the biochemical and behavioral changes associated with experimental mTBI in mice that may act as either targets or surrogate markers for interventional therapy. Specifically, mTBI was induced by 30-g and 50-g weight drop, and at 8 and 72 hr thereafter markers of cellular apoptosis-caspase-3, Bax, apoptosis-inducing factor (AIF), and cytochrome-c (Cyt-c)-were quantified by Western blot analysis in hippocampus ipsilateral to the impact. Levels of amyloid-P precursor protein (APP) were also measured, and specific behavioral tests-passive avoidance, open field, and forced swimming (Porsolt) paradigms-were undertaken to assess learning, emotionality, and emotional memory. In the absence of hemorrhage or infarcts, as assessed by triphenyltetrazolium chloride staining, procaspase-3 and Bax levels were markedly altered following mTBI at both times. No cleaved caspase-3 was detected, and levels of AIF and Cyt-c, but not APP, were significantly changed at 72 hr. Mice subjected to mTBI were indistinguishable from controls by neurological examination at 1 and 24 hr, and by passive avoidance/open field at 72 hr, but could be differentiated in the forced swimming paradigm. In general, this model mimics the diffuse effects of mTBI on brain function associated with the human condition and highlights specific apoptotic proteins and a behavioral paradigm as potential markers for prospective interventional strategies. (c) 2007 Wiley-Liss,Inc.	NIA, Drug Design & Dev Sect, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA; Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; NIDA, Neural Protect & Regenerat Sect, Mol Neuropsychiat Branch, Intramural Res Program, Baltimore, MD 21224 USA; NIA, Lab Expt Gerontol, Intramural Res Program, Baltimore, MD 21224 USA; Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46204 USA; NIDA, Cellular Neurobiol Branch, Intramural Res Program, Baltimore, MD 21224 USA		Greig, NH (corresponding author), NIA, Drug Design & Dev Sect, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA.	greign@grc.nia.nih.gov	Harvey, Brandon Keith/AAY-4080-2021; Harvey, Brandon K/A-5559-2010; Pick, Chaim/D-4789-2009	Harvey, Brandon Keith/0000-0002-4036-1383; Milman, Anat/0000-0002-8551-4101	Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG023055] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [Z01AG000311, R01AG023055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [Z01DA000461] Funding Source: NIH RePORTER		Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; BARTUS RT, 1986, PROG BRAIN RES, V70, P345; Bolivar VJ, 2000, BEHAV GENET, V30, P285, DOI 10.1023/A:1026545316455; Bouwknecht JA, 2004, EUR J PHARMACOL, V494, P35, DOI 10.1016/j.ejphar.2004.04.036; Centers for Disease Control and Prevention, 2001, TRAUM BRAIN INJ US R; Cho SG, 2002, J BIOCHEM MOL BIOL, V35, P24, DOI 10.5483/BMBRep.2002.35.1.024; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Crawley JN, 1999, BRAIN RES, V835, P18, DOI 10.1016/S0006-8993(98)01258-X; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; LaFerla FM, 2005, TRENDS MOL MED, V11, P170, DOI 10.1016/j.molmed.2005.02.009; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; Mattson MP, 2006, NAT REV NEUROSCI, V7, P278, DOI 10.1038/nrn1886; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Pierce JES, 1996, J NEUROSCI, V16, P1083; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Sambamurti K, 2002, NEUROMOL MED, V1, P1, DOI 10.1385/NMM:1:1:1; Sosin DM, 1996, BRAIN INJURY, V10, P47; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; TAGHZOUTI K, 1985, BRAIN RES, V344, P9, DOI 10.1016/0006-8993(85)91184-9; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; WALLACE WC, 1995, J NEUROSCI, V15, P4896; Wang Y, 2003, J NEUROSCI, V23, P7958; Wang Y, 1997, J NEUROSCI, V17, P4341; WINOCUR G, 1985, BEHAV BRAIN RES, V16, P135, DOI 10.1016/0166-4328(85)90088-9; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	56	74	75	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAR	2007	85	4					805	815		10.1002/jnr.21160			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	149PK	WOS:000245158800013	17243171				2022-02-06	
J	Jones, C; Harvey, AG; Brewin, CR				Jones, Charlie; Harvey, Allison G.; Brewin, Chris R.			The organisation and content of trauma memories in survivors of road traffic accidents	BEHAVIOUR RESEARCH AND THERAPY			English	Article						PTSD; ASD; narrative memory; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; BRAIN-INJURY; HEAD-INJURY; DISSOCIATION; NARRATIVES; SYMPTOMS	We investigated the trauma narratives of 131 road traffic accident survivors prospectively, at I week, 6 weeks, and 3 months post-trauma. At I and 6 weeks, narratives of survivors with acute stress disorder (ASD) or post-traumatic stress disorder (PTSD) were less coherent and included more dissociation content. By 3 months, their narratives also contained more repetition, more non-consecutive chunks, and more sensory words. Traumatic brain injury was associated with a separate characteristic, confusion, at all three time points. Three aspects of narrative organisation at I week-repetition, non-consecutive chunks, and coherence-predicted PTSD severity at 3 months after controlling for initial symptoms. The results suggest both a strong concurrent and predictive relationship between narrative disorganisation and ASD/PTSD but that as people recover from ASD, their narratives do not necessarily become less disorganised. (c) 2006 Elsevier Ltd. All rights reserved.	Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA; Univ Oxford, Dept Expt Psychol, Oxford OX1 2JD, England; Univ Calif Berkeley, Subdept Clin Hlth Psychol, Berkeley, CA 94720 USA		Harvey, AG (corresponding author), Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall 1650, Berkeley, CA 94720 USA.	aharvey@berkeley.edu	Brewin, Chris R/C-4566-2008	Brewin, Chris R/0000-0002-7462-4460			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Brewin C. R., 2003, POSTTRAUMATIC STRESS; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; FOA EB, 1995, J TRAUMA STRESS, V8, P675, DOI 10.1007/BF02102894; Foa EB, 1998, TREATING TRAUMA RAPE; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Halligan SL, 2003, J CONSULT CLIN PSYCH, V71, P419, DOI 10.1037/0022-006X.71.3.419; Harvey AG, 1999, BRIT J CLIN PSYCHOL, V38, P401, DOI 10.1348/014466599162999; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Harvey AG, 2000, J NERV MENT DIS, V188, P602, DOI 10.1097/00005053-200009000-00007; Hellawell SJ, 2004, BEHAV RES THER, V42, P1, DOI 10.1016/S0005-7967(03)00088-3; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; KRAUS JF, 1996, NEUROLOGY TRAUMA, P3; McNally, 2003, REMEMBERING TRAUMA; Murray J, 2002, BRIT J PSYCHIAT, V180, P363, DOI 10.1192/bjp.180.4.363; Pennebaker JW, 2001, LINGUISTIC INQUIRY W; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; RYNEARSON EK, 1993, AM J PSYCHIAT, V150, P258; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Symonds CP, 1943, LANCET, V1, P7; Zoellner LA, 2002, J TRAUMA STRESS, V15, P49, DOI 10.1023/A:1014383228149	28	74	75	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0005-7967			BEHAV RES THER	Behav. Res. Ther.	JAN	2007	45	1					151	162		10.1016/j.brat.2006.02.004			12	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	115KO	WOS:000242733400013	16563341				2022-02-06	
J	Riess, P; Molcanyi, M; Bentz, K; Maegele, M; Simanski, C; Carlitscheck, C; Schneider, A; Hescheler, J; Bouillon, B; Schafer, U; Neugebauer, E				Riess, Peter; Molcanyi, Marek; Bentz, Kristine; Maegele, Mark; Simanski, Christian; Carlitscheck, Christoph; Schneider, Annette; Hescheler, Juergen; Bouillon, Bertil; Schaefer, Ute; Neugebauer, Edmund			Embryonic stem cell transplantation after experimental traumatic brain injury dramatically improves neurological outcome, but may cause tumors	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion injury; motor function; Sprautte-Dawley rats; tumorigenesis	NERVE GROWTH-FACTOR; FLUID-PERCUSSION MODEL; MARROW STROMAL CELLS; NEURAL TRANSPLANTATION; SENSORIMOTOR FUNCTION; THERAPEUTIC STRATEGY; EXPERIMENTAL STROKE; CEREBRAL-ISCHEMIA; MOTOR FUNCTION; IN-VIVO	Transplantation of embryonic stem (ES) cells may provide cures for the damaged nervous system. Pre-differentiated ES or neuronal precursor cells have been investigated in various animal models of neurodegenerative diseases including traumatic brain injury (TBI). To our knowledge, no study has yet examined the effects of undifferentiated, murine ES cells on functional recovery and tumorigenity following implantation into injured rat brains. We evaluated the effect of transplantation of undifferentiated, murine embryonic cells on the recovery of motor function following lateral fluid percussion brain injury in Sprague-Dawley rats. At 3 days post-injury, animals received stereotactic injections of either embryonic stem cell suspension or injections of phosphate buffered saline without cells (control) into the injured cortex. Neurological motor function assessments were performed before injury, 72 h, 1, 3, and 6 weeks after transplantation using a Rotatrod and a Composite Neuroscore test. During this time period brain injured animals receiving ES cell transplantation showed a significant improvement in the Rotarod Test and in the Composite Neuroscore Test as compared to phosphate buffered saline (PBS)-treated animals. At 1 week post-transplantation, ES cells were detectable in 100% of transplanted animals. At 7 weeks following transplantation, ES cells were detectable in only one animal. Two of 10 xenotransplanted animals revealed tumor formation over the observation period. These findings provide evidence for therapeutic potency of embryonic stem cell transplantation after TBI in rat, but also raise serious safety concerns about the use of such cells in human.	Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Trauma & Orthoped Surg, D-51109 Cologne, Germany; Univ Cologne, Fac Med, Clin Neurosurg, D-5000 Cologne 41, Germany; Natl Res Ctr Environm & Hlth, Inst Dev Genet, Munich, Germany; Univ Witten Herdecke, Fac Med, Inst Operat Med, Cologne, Germany; Univ Cologne, Fac Med, Dept Neurophysiol, D-5000 Cologne 41, Germany		Riess, P (corresponding author), Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Trauma & Orthoped Surg, Ostmerheimerstr 200, D-51109 Cologne, Germany.	riessp@kliniken-koeln.de					Arnhold S, 2000, J NEUROSURG, V93, P1026, DOI 10.3171/jns.2000.93.6.1026; BENTZ K, IN PRESS J NEUROSCI; Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P79, DOI 10.1016/0149-7634(95)00063-1; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chiba S, 2003, CELL TRANSPLANT, V12, P457, DOI 10.3727/000000003108747019; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Erdo F, 2003, J CEREBR BLOOD F MET, V23, P780, DOI 10.1097/01.WCB.0000071886.63724.FB; Erdo Franciska, 2004, Orvosi Hetilap, V145, P1307; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoehn M, 2002, P NATL ACAD SCI USA, V99, P16267, DOI 10.1073/pnas.242435499; Kerr DA, 2003, J NEUROSCI, V23, P5131; Longhi L, 2005, TRANSPL IMMUNOL, V15, P143, DOI 10.1016/j.trim.2005.09.003; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/neu.2004.21.1723; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOLCANYI M, IN PRESS J NEUROTRAU; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Park KI, 2006, EXP NEUROL, V199, P156, DOI 10.1016/j.expneurol.2006.04.002; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Saporta S, 1999, NEUROSCIENCE, V91, P519, DOI 10.1016/S0306-4522(98)00610-1; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROSCI, V15, P8223; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Veizovic T, 2001, STROKE, V32, P1012, DOI 10.1161/01.STR.32.4.1012; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Wilkins A, 2003, J NEUROSCI, V23, P4967, DOI 10.1523/jneurosci.23-12-04967.2003; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; Zhang C, 2005, J NEUROTRAUM, V22, P1456, DOI 10.1089/neu.2005.22.1456	39	74	78	1	8	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					216	225		10.1089/neu.2006.0141			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100021	17263685				2022-02-06	
J	Viano, DC; Pellman, EJ; Withnall, C; Shewchenko, N				Viano, David C.; Pellman, Elliot J.; Withnall, Chris; Shewchenko, Nick			Concussion in professional football: Performance of newer helmets in reconstructed game impacts - Part 13	NEUROSURGERY			English	Article						biomechanics; concussion; football; impact tolerances; neck injury; spearing; sport injury prevention		OBJECTIVE: The performance of five newer helmets was compared with the baseline VSR-4 helmet in 10 reconstructed cases of National Football League (NFL) collisions causing concussion. The laboratory reconstructions were conducted to determine changes in concussion risk with newer football helmets. METHODS: In 60 laboratory tests, translational and rotational head accelerations were measured in the striking and struck players represented by Hybrid III dummies. Six-axis upper neck loads and moments were measured in five cases with the struck player and five with the striking player. Biomechanical responses and concussion risks were evaluated for each collision to determine changes with newer helmet designs. RESULTS: Thirty-two out of 50 reconstructed cases showed greater than 10% reduction in severity index with newer helmets compared with the VSR-4; four cases increased. The average reduction in concussion risk with newer helmets was 10.8% (range, 6.9-16.7%) based on severity index. The reduction was 9.7% (range, 6.5-13.9%) based on translational acceleration and 18.9% (range, 10.6-23.4%) with rotational acceleration. Neck responses in the struck player showed a general reduction in moment and force with newer helmets. CONCLUSION: With newer football helmets, there was a trend toward 10 to 20% lower risks of concussion in reconstructed National Football League game collisions. However, a few designs and cases showed increased responses. The evaluation of football helmets to the proposed National Operating Committee on Standards for Athletic Equipment concussion standard should lead to more uniform reductions in concussion risk with future football helmets.	ProBiomech LLC, Bloomfield Hills, MI 48304 USA; Natl Football League, Mild Traumat Brain Injury Comm, New York, NY USA; ProHLTH Care Associates LLP, Lake Success, NY USA; Biokinet & Associates Ltd, Ottawa, ON, Canada		Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					Backaitis S. H., 1994, HYBRID; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Newman J A, 2000, Stapp Car Crash J, V44, P215; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; *NOCSAE, 1998, 00298703 NOCSAE; *NOCSAE, 1996, LAB PROC GUID CERT N; *NOCSAE, 2004, STAND DROP TEST METH; *NOCSAE, 1987, 71487 NOCSAE; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; *SAE, 1994, SAE J, V1733; *SAE, 1980, SAE J, V855; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C	17	74	74	0	49	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	SEP	2006	59	3					591	605		10.1227/01.NEU.0000231851.97287.C2			15	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	085SE	WOS:000240623900023	16823324				2022-02-06	
J	Leinhase, I; Holers, VM; Thurman, JM; Harhausen, D; Schmidt, OI; Pietzcker, M; Taha, ME; Rittirsch, D; Huber-Lang, M; Smith, WR; Ward, PA; Stahel, PF				Leinhase, Iris; Holers, V. Michael; Thurman, Joshua M.; Harhausen, Denise; Schmidt, Oliver I.; Pietzcker, Malte; Taha, Mohy E.; Rittirsch, Daniel; Huber-Lang, Markus; Smith, Wade R.; Ward, Peter A.; Stahel, Philip F.			Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation	BMC NEUROSCIENCE			English	Article							CLOSED-HEAD INJURY; MEMBRANE ATTACK COMPLEX; TRAUMATIC BRAIN; GENE-EXPRESSION; C5A RECEPTOR; BARRIER DYSFUNCTION; TRANSGENIC MICE; RAT-BRAIN; ADULT-RAT; APOPTOSIS	Background: Neuroprotective strategies for prevention of the neuropathological sequelae of traumatic brain injury (TBI) have largely failed in translation to clinical treatment. Thus, there is a substantial need for further understanding the molecular mechanisms and pathways which lead to secondary neuronal cell death in the injured brain. The intracerebral activation of the complement cascade was shown to mediate inflammation and tissue destruction after TBI. However, the exact pathways of complement activation involved in the induction of posttraumatic neurodegeneration have not yet been assessed. In the present study, we investigated the role of the alternative complement activation pathway in contributing to neuronal cell death, based on a standardized TBI model in mice with targeted deletion of the factor B gene (f beta-/-), a "key" component required for activation of the alternative complement pathway. Results: After experimental TBI in wild-type (f beta+/+) mice, there was a massive time-dependent systemic complement activation, as determined by enhanced C5a serum levels for up to 7 days. In contrast, the extent of systemic complement activation was significantly attenuated in f beta-/- mice (P < 0.05, f beta-/- vs. f beta+/+; t = 4 h, 24 h, and 7 days after TBI). TUNEL histochemistry experiments revealed that posttraumatic neuronal cell death was clearly reduced for up to 7 days in the injured brain hemispheres of f beta-/- mice, compared to f beta+/+ littermates. Furthermore, a strong upregulation of the anti-apoptotic mediator Bcl-2 and downregulation of the pro-apoptotic Fas receptor was detected in brain homogenates of head-injured f beta-/- vs. f beta+/+ mice by Western blot analysis. Conclusion: The alternative pathway of complement activation appears to play a more crucial role in the pathophysiology of TBI than previously appreciated. This notion is based on the findings of (a) the significant attenuation of overall complement activation in head- injured fB-/- mice, as determined by a reduction of serum C5a concentrations to constitutive levels in normal mice, and (b) by a dramatic reduction of TUNEL-positive neurons in conjunction with an upregulation of Bcl-2 and downregulation of the Fas receptor in head- injured f beta-/- mice, compared to f beta+/+ littermates. Pharmacological targeting of the alternative complement pathway during the "time-window of opportunity" after TBI may represent a promising new strategy to be pursued in future studies.	Charite, Sch Med, Dept Trauma & Reconstruct Surg, D-12200 Berlin, Germany; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Ulm, Sch Med, Dept Traumatol, D-89075 Ulm, Germany; Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Orthopaed Surg, Denver, CO 80204 USA		Smith, WR (corresponding author), Charite, Sch Med, Dept Trauma & Reconstruct Surg, Campus Benjamin Franklin, D-12200 Berlin, Germany.	iris.leinhase@charite.de; Michael.Holers@UCHSC.edu; Joshua.Thurman@UCHSC.edu; deniseharhausen@gmx.de; oliver.schmidt@charite.de; m.pietzcker@gmx.de; mohy_kom@yahoo.com; drittirs@med.umich.edu; mshuberlang2000@aol.com; wade.smith@dhha.org	Huber-Lang, Markus/AAJ-2209-2020	Rittirsch, Daniel/0000-0002-1185-2431	NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01 AI031105, R01 AI31105] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08 DK064790, K08 DK64790] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 029507, GM 61656, R01 GM061656, R01 GM029507, R37 GM029507] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI031105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08DK064790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R37GM029507, R01GM029507, R01GM061656] Funding Source: NIH RePORTER		Alexander JJ, 2005, J IMMUNOL, V175, P8312, DOI 10.4049/jimmunol.175.12.8312; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Casarsa C, 2003, EUR J IMMUNOL, V33, P1260, DOI 10.1002/eji.200323574; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cole DS, 2003, CLIN SCI, V104, P455, DOI 10.1042/CS20020362; COLE DS, 2006, EPUB MOL IMMUNOL; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Elward K, 2005, J BIOL CHEM, V280, P36342, DOI 10.1074/jbc.M506579200; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GARNUM SR, 1999, MOL MED, V5, P569; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Holers VM, 2004, MOL IMMUNOL, V41, P147, DOI 10.1016/j.molimm.2004.03.012; HUBERLANG M, 2006, EPUB NAT MED; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Marciano PG, 2004, J NEUROSCI, V24, P2866, DOI 10.1523/JNEUROSCI.5051-03.2004; Matsumoto M, 1997, P NATL ACAD SCI USA, V94, P8720, DOI 10.1073/pnas.94.16.8720; McArthur DL, 2004, BRAIN PATHOL, V14, P185, DOI 10.1111/j.1750-3639.2004.tb00052.x; Mohamad N, 2005, BIOCELL, V29, P149; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; Morgan BP, 1996, IMMUNOL TODAY, V17, P461, DOI 10.1016/0167-5699(96)20028-F; Nataf S, 2000, J IMMUNOL, V165, P5867, DOI 10.4049/jimmunol.165.10.5867; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; Ohlsson M, 2003, J NEUROTRAUM, V20, P895, DOI 10.1089/089771503322385827; OHLSSON M, 2005, EPUB NEUROSCI LETT; Pillay NS, 2005, ANN NY ACAD SCI, V1056, P450, DOI 10.1196/annals.1352.021; Qiu JH, 2002, J NEUROSCI, V22, P3504; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; RINK A, 1995, AM J PATHOL, V147, P1575; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Schmidt O.I., 2004, EUR J TRAUMA, V30, P135, DOI DOI 10.1007/S00068-004-1394-9; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Shacka JJ, 2005, CNS NEUROL DISORD-DR, V4, P25, DOI 10.2174/1568007053005127; Singhrao SK, 2000, AM J PATHOL, V157, P905, DOI 10.1016/S0002-9440(10)64604-4; SOLOMKIN JS, 1981, SURGERY, V90, P319; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1997, J IMMUNOL, V159, P861; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Stahel Philip F, 2006, Expert Rev Clin Immunol, V2, P445, DOI 10.1586/1744666X.2.3.445; Strauss KI, 2004, NEUROTOX RES, V6, P333, DOI 10.1007/BF03033444; Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305; Thurman JM, 2005, KIDNEY INT, V67, P524, DOI 10.1111/j.1523-1755.2005.67109.x; Thurman JM, 2005, MOL IMMUNOL, V42, P87, DOI 10.1016/j.molimm.2004.07.043; Thurman JM, 2003, J IMMUNOL, V170, P1517, DOI 10.4049/jimmunol.170.3.1517; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; Xiong ZQ, 2003, J NEUROSCI, V23, P955; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	67	74	74	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	JUL 14	2006	7								55	10.1186/1471-2202-7-55			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	074GN	WOS:000239800800001	16842619	Green Published, gold			2022-02-06	
J	Hurlbert, RJ				Hurlbert, R. John			Strategies of medical intervention in the management of acute spinal cord injury	SPINE			English	Article						trauma; medical management; therapy; paraplegia; quadriplegia	HIGH-DOSE METHYLPREDNISOLONE; OLFACTORY ENSHEATHING CELLS; STEM-CELLS; TIRILAZAD MESYLATE; CONTROLLED-TRIAL; RECOVERY; TRANSPLANTATION; BRAIN; DIFFERENTIATION; REGENERATION	Study Design. Literature review. Objective. The purpose of this paper is to review clinical treatment strategies and future developments in the treatment of acute spinal cord injury. Summary of Background Data. The treatment of acute spinal cord injury continues to be supportive. The search for specialized pharmacologic agents to prevent secondary injury and promote repair or regeneration remains heated. Methods. Medline search from 1996 to present limited to clinical research and basic science review articles in the English Language. Results. Steroids continue to be administered in the clinical setting of acute spinal cord injury primarily out of peer pressure and fear of litigation. Basic science experiments suggest that modulation of post-traumatic inflammation may provide the best opportunity to arrest the secondary injury cascade. Protein kinase and metalloproteinase inhibition are promising treatment strategies. Regeneration techniques are concentrating on cell transplantation and manipulating glial receptors and protein production. Clinical investigations are limited to Phase III trials on a very select few of these drugs. Conclusions. While many advances in the basic science of spinal cord injury provide optimism for future treatments, clinical science lags. At present, there are no pharmacologic strategies of proven benefit. Although steroids continue to be given to patients with spinal cord injury in many institutions, evidence of deleterious effects continues to accumulate. Current standard of care management includes support of arterial oxygenation and spinal cord perfusion pressure.	Univ Calgary, Foothills Hosp, Dept Clin Neurosci, Spine Program, Calgary, AB T2N 2T9, Canada; Med Ctr, Calgary, AB T2N 2T9, Canada		Hurlbert, RJ (corresponding author), Univ Calgary, Foothills Hosp, Dept Clin Neurosci, Spine Program, 1403 29th St NW, Calgary, AB T2N 2T9, Canada.	jhurlber@ucalgary.ca					Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Arlotta P, 2003, ANN NY ACAD SCI, V991, P229; Blesch A, 2004, YONSEI MED J, V45, P28; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.1984.03340250025015; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)02122-5; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coleman WP, 2000, J SPINAL DISORD, V13, P185, DOI 10.1097/00002517-200006000-00001; Dergham P, 2002, J NEUROSCI, V22, P6570; Diers-Fenger M, 2001, GLIA, V34, P213, DOI 10.1002/glia.1055; DOLAN EJ, 1982, J NEUROSURG, V56, P350, DOI 10.3171/jns.1982.56.3.0350; DUCKER TB, 1971, J NEUROSURG, V35, P700, DOI 10.3171/jns.1971.35.6.0700; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Glaser J, 2004, J NEUROSCI RES, V77, P701, DOI 10.1002/jnr.20204; Gonzalez R, 2003, EXP NEUROL, V184, P456, DOI 10.1016/S0014-4886(03)00257-7; Hadley M, 2002, NEUROSURGERY, V50, pS58; Hadley MN, 2002, NEUROSURGERY, V50, pS63; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Horner PJ, 2000, J NEUROSCI, V20, P2218; Hugenholtz H, 2002, CAN J NEUROL SCI, V29, P227, DOI 10.1017/S0317167100001992; Hurlbert RJ, 2000, J NEUROSURG, V93, P340; Hurlbert RJ, 2002, CAN J NEUROL SCI, V29, P236, DOI 10.1017/S0317167100002006; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Hurlbert RJ, 2001, SPINE, V26, pS39, DOI 10.1097/00007632-200112151-00009; Iwanami A, 2005, J NEUROSCI RES, V80, P182, DOI 10.1002/jnr.20436; Kadoya, 1994, SEKITSUI SEKIZUI J, V7, P633; Keyvan-Fouladi N, 2003, J NEUROSCI, V23, P9428; King BS, 2000, SURG CLIN N AM, V80, P855, DOI 10.1016/S0039-6109(05)70100-6; Knoller N, 2005, J NEUROSURG-SPINE, V3, P173, DOI 10.3171/spi.2005.3.3.0173; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; LEVI L, 1993, NEUROSURGERY, V33, P1007, DOI 10.1097/00006123-199312000-00008; LEVI L, 1991, NEUROSURGERY, V29, P216, DOI 10.1227/00006123-199108000-00008; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Monnier PP, 2003, MOL CELL NEUROSCI, V22, P319, DOI 10.1016/S1044-7431(02)00035-0; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Myckatyn TM, 2004, TRANSPL IMMUNOL, V12, P343, DOI 10.1016/j.trim.2003.12.017; Nesathurai S, 1998, J TRAUMA, V45, P1088, DOI 10.1097/00005373-199812000-00021; Nistor GI, 2005, GLIA, V49, P385, DOI 10.1002/glia.20127; OSTERHOLM JL, 1974, J NEUROSURG, V40, P5, DOI 10.3171/jns.1974.40.1.0003; Pointillart V, 2000, SPINAL CORD, V38, P71, DOI 10.1038/sj.sc.3100962; Qian T, 2005, SPINAL CORD, V43, P199, DOI 10.1038/sj.sc.3101681; Raisman G, 2004, CLONING STEM CELLS, V6, P364, DOI 10.1089/clo.2004.6.364; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Saville LR, 2004, J NEUROIMMUNOL, V156, P42, DOI 10.1016/j.jneuroim.2004.07.002; SCHWAB JM, 2002, SOC NEUR ABSTR, V204, P7; SENTER HJ, 1979, J NEUROSURG, V50, P198, DOI 10.3171/jns.1979.50.2.0198; Shapiro S, 2005, J NEUROSURG-SPINE, V2, P3, DOI 10.3171/spi.2005.2.1.0003; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; TATOR CH, 1992, J NEUROTRAUM, V9, P139, DOI 10.1089/neu.1992.9.139; TATOR CH, 1984, CAN J SURG, V27, P289; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; TURNBULL IM, 1971, J NEUROSURG, V35, P141, DOI 10.3171/jns.1971.35.2.0141; Vale FL, 1997, J NEUROSURG, V87, P239, DOI 10.3171/jns.1997.87.2.0239; Vogel G, 2005, SCIENCE, V308, P1534, DOI 10.1126/science.308.5728.1534; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Woolf CJ, 2002, SCIENCE, V297, P1132, DOI 10.1126/science.1076247; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; Zach G A, 1976, Paraplegia, V14, P58	69	74	82	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	MAY 15	2006	31	11		S			S16	S21		10.1097/01.brs.0000218264.37914.2c			6	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	042HL	WOS:000237518800004	16685230				2022-02-06	
J	Wu, AG; Ying, Z; Gomez-Pinilla, F				Wu, Aiguo; Ying, Zhe; Gomez-Pinilla, Fernando			Oxidative stress modulates Sir2 alpha in rat hippocampus and cerebral cortex	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						hippocampus; neural repair; oxidative stress; Sir2 alpha; vitamin E	DEPENDENT HISTONE DEACETYLASE; ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR FOXO3A; TRAUMATIC BRAIN-INJURY; LIFE-SPAN EXTENSION; SATURATED-FAT DIET; CALORIE RESTRICTION; NEUROTROPHIC FACTOR; SACCHAROMYCES-CEREVISIAE; SYNAPTIC PLASTICITY	Silent information regulator 2 (Sir2) helps survival and longevity in lower organisms during challenging situations. We investigated the possibility that Sir2 alpha could be involved with brain plasticity under challenging situations. A diet high in saturated fat and sucrose, which has been shown in rodents to reduce synaptic plasticity and cognition, decreased Sir2 alpha levels in the hippocampus and cerebral cortex, in proportion to an increase in protein oxidation. Vitamin E supplementation normalized, in the hippocampus and cerebral cortex, Sir2 alpha levels that had been reduced by the high-fat diet. Neither the high-fat diet nor vitamin E supplementation affected cerebellar Sir2 alpha. Vitamin E reduced, in the hippocampus, the oxidized nucleic acids that were increased by the high-fat diet. Western blot analysis showed higher contents of Sir2 alpha in the hippocampus and cerebellum than in the cerebral cortex. Sir2 alpha immunostaining was predominantly localized in the mossy fibre system and the dentate gyrus granule layer of the hippocampal formation. The high-fat diet decreased Sir2 alpha immunostaining while vitamin E supplementation reversed these effects. Given that oxidative stress is a subproduct of dysfunctional energy homeostasis, we measured AMP-activated protein kinase (AMPK) to have an indication of the energy status of cells. Hippocampal levels of total and phosphorylated AMPK were reduced after high fat consumption and levels were normalized by vitamin E treatment. The present results show that oxidative stress and energy homeostasis associated with the consumption of the high-fat diet are critical for the regulation of Sir2 alpha, with important implications for mechanisms of neural repair.	Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA		Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039522, R01NS045804] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS050465, NS45804, NS039522] Funding Source: Medline		Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff; Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Anekonda TS, 2006, J NEUROCHEM, V96, P305, DOI 10.1111/j.1471-4159.2005.03492.x; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cardozo-Pelaez F, 2000, FREE RADICAL BIO MED, V28, P779, DOI 10.1016/S0891-5849(00)00172-6; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Clayton DA, 2002, J NEUROSCI, V22, P3628; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Gadalla AE, 2004, J NEUROCHEM, V88, P1272, DOI 10.1046/j.1471-4159.2003.02253.x; Gomez-Pinilla F, 2001, BRAIN RES, V904, P13, DOI 10.1016/S0006-8993(01)02394-0; Guarente L, 2000, GENE DEV, V14, P1021; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; Hisahara S, 2005, J PHARMACOL SCI, V98, P200, DOI 10.1254/jphs.FMJ05001X2; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kelly A, 2003, J NEUROSCI, V23, P5354; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lee K, 2005, ENDOCRINOLOGY, V146, P3, DOI 10.1210/en.2004-0968; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Liu PK, 2001, TRENDS NEUROSCI, V24, P581, DOI 10.1016/S0166-2236(00)01918-4; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Mattson MP, 2003, J NEUROCHEM, V84, P417, DOI 10.1046/j.1471-4159.2003.01586.x; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Nemoto S, 2005, J BIOL CHEM, V280, P16456, DOI 10.1074/jbc.M501485200; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nunomura A, 1999, J NEUROSCI, V19, P1959; Parker JA, 2005, NAT GENET, V37, P349, DOI 10.1038/ng1534; Rafaeloff-Phail R, 2004, J BIOL CHEM, V279, P52934, DOI 10.1074/jbc.M409574200; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sakamoto J, 2004, FEBS LETT, V556, P281, DOI 10.1016/S0014-5793(03)01444-3; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Sinclair D, 2005, NAT GENET, V37, P339, DOI 10.1038/ng0405-339; Steffenach HA, 2002, P NATL ACAD SCI USA, V99, P3194, DOI 10.1073/pnas.042700999; Sugaya K, 1996, J NEUROSCI, V16, P3427; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x	52	74	76	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	MAY	2006	23	10					2573	2580		10.1111/j.1460-9568.2006.04807.x			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	046LB	WOS:000237812000004	16817860				2022-02-06	
J	Abrahamson, EE; Ikonomovic, MD; Ciallella, JR; Hope, CE; Paljug, WR; Isanski, BA; Flood, DG; Clark, RSB; DeKosky, ST				Abrahamson, EE; Ikonomovic, MD; Ciallella, JR; Hope, CE; Paljug, WR; Isanski, BA; Flood, DG; Clark, RSB; DeKosky, ST			Caspase inhibition therapy abolishes brain trauma-induced increases in A beta peptide: Implications for clinical outcome	EXPERIMENTAL NEUROLOGY			English	Article						alzheimer; apoptosis; BOC-fink; hippocampus; knockin; neurodegeneration	AMYLOID PRECURSOR PROTEIN; SEVERE HEAD-INJURY; IN-SITU HYBRIDIZATION; RAT CORTICAL-NEURONS; ALZHEIMERS-DISEASE; AXONAL INJURY; CELL-DEATH; NEUROLOGICAL DYSFUNCTION; CYTOPLASMIC DOMAIN; MULTIPLE CASPASES	The detrimental effects of traumatic brain injury (TBI) on brain tissue integrity involve progressive axonal damage, necrotic cell loss, and both acute and delayed apoptotic neuronal death due to activation of caspases. Post-injury accumulation of amyloid precursor protein (APP) and its toxic metabolite amyloid-beta peptide (A beta) has been implicated in apoptosis as well as in increasing the risk for developing Alzheimer's disease (AD) after TBI. Activated caspases proteolyze APP and are associated with increased A beta production after neuronal injury. Conversely, A beta and related APP/A beta fragments stimulate caspase activation, creating a potential vicious cycle of secondary injury after TBI. Blockade of caspase activation after brain injury suppresses apoptosis and improves neurological outcome, but it is not known whether such intervention also prevents increases in A beta levels in vivo. The present study examined the effect of caspase inhibition on post-injury levels of soluble A, APP, activated caspase-3, and caspase-cleaved APP in the hippocampus of nontransgenic mice expressing human A beta, subjected to controlled cortical injury (M). CCI produced brain tissue damage with cell loss and elevated levels of activated caspase-3, A beta (1-42) and A beta (1-40), APP, and caspase-cleaved APP fragments in hippocampal neurons and axons. Post-CCI intervention with intracerebroventricular injection of 100 nM Boc-Asp(OMe)-CH2F (BAF, a pan-caspase inhibitor) significantly reduced caspase-3 activation and improved histological outcome, suppressed increases in A beta and caspase-cleaved APP. but showed no significant effect on overall APP levels in the hippocampus after M. These data demonstrate that after TBI, caspase inhibition can suppress elevations in A beta. The extent to which A beta suppression contributes to improved outcome following inhibition of caspases after TBI is unclear, but such intervention may be a valuable therapeutic strategy for preventing the long-term evolution of A beta-mediated pathology in TBI patients who are at risk for developing AD later in life. (c) 2005 Elsevier Inc. All rights reserved.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA; Cephalon Inc, W Chester, PA 19380 USA		DeKosky, ST (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, 3471 5th Ave,Suite 811, Pittsburgh, PA 15213 USA.	DeKoskyST@upmc.edu		DeKosky, Steven/0000-0003-3743-2758	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P20NS030318, P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER		Allen JW, 2001, J NEUROSCI RES, V65, P45, DOI 10.1002/jnr.1126; AWASTHI A, 2005, EXP NEUROL; Ayala-Grosso C, 2002, BRAIN PATHOL, V12, P430; Barnes NY, 1998, J NEUROSCI, V18, P5869; Bertrand E, 2001, MOL CELL NEUROSCI, V18, P503, DOI 10.1006/mcne.2001.1030; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Cheng AG, 1999, BRAIN RES, V850, P234, DOI 10.1016/S0006-8993(99)01983-6; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; Clark D, 1999, IEEE INTERNET COMPUT, V3, P13; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dumanchin-Njock C, 2001, J NEUROCHEM, V78, P1153, DOI 10.1046/j.1471-4159.2001.00513.x; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Galvan V, 2002, J NEUROCHEM, V82, P283, DOI 10.1046/j.1471-4159.2002.00970.x; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gottlieb S, 2000, BRIT MED J, V321, P1100; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Harada J, 1999, BRAIN RES, V842, P311, DOI 10.1016/S0006-8993(99)01808-9; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; HYMAN BT, 1992, J NEUROPATH EXP NEUR, V51, P76, DOI 10.1097/00005072-199201000-00009; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; IKONOMOVIC MD, 1995, J COMP NEUROL, V359, P239, DOI 10.1002/cne.903590205; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P13122; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Lu DC, 2003, J NEUROCHEM, V87, P733, DOI 10.1046/j.1471-4159.2003.02059.x; Marin N, 2000, MECH AGEING DEV, V119, P63, DOI 10.1016/S0047-6374(00)00172-X; MARK RJ, 1995, J NEUROSCI, V15, P6239; Masliah E, 1998, J NEUROPATH EXP NEUR, V57, P1041, DOI 10.1097/00005072-199811000-00007; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mattson MP, 1998, BRAIN RES, V807, P167, DOI 10.1016/S0006-8993(98)00763-X; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MIZE RR, 1994, J NEUROSCI METH, V54, P219, DOI 10.1016/0165-0270(94)90195-3; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nishimura I, 2002, CELL DEATH DIFFER, V9, P199, DOI 10.1038/sj/cdd/4400931; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Pierce JES, 1996, J NEUROSCI, V16, P1083; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Savage MJ, 1998, J NEUROSCI, V18, P1743; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smolen A.J., 1990, METHODS NEUROSCIENCE, P208, DOI [DOI 10.1016/B978-0-12-185255-9.50016-X, 10.1016/B978-0-12-185255-9.50016-X]; SOMOGYI P, 1982, NEUROSCIENCE, V7, P1779, DOI 10.1016/0306-4522(82)90035-5; Soriano S, 2001, J BIOL CHEM, V276, P29045, DOI 10.1074/jbc.M102456200; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Su JH, 2002, ACTA NEUROPATHOL, V104, P1, DOI 10.1007/s00401-002-0548-2; Takeda K, 2004, FASEB J, V18, P1755, DOI 10.1096/fj.03-1070fje; Tesco G, 2003, J BIOL CHEM, V278, P46074, DOI 10.1074/jbc.M307809200; Troy CM, 2000, J NEUROSCI, V20, P1386; Uetsuki T, 1999, J NEUROSCI, V19, P6955, DOI 10.1523/JNEUROSCI.19-16-06955.1999; Wang CN, 2001, J BIOL CHEM, V276, P5287, DOI 10.1074/jbc.M006406200; Wei N, 2002, JCR-J CLIN RHEUMATOL, V8, P125, DOI 10.1097/00124743-200206000-00001; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; White AR, 2001, NEUROBIOL DIS, V8, P299, DOI 10.1006/nbdi.2001.0386; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhao M, 2003, NEUROBIOL DIS, V14, P391, DOI 10.1016/j.nbd.2003.07.006	91	74	76	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2006	197	2					437	450		10.1016/j.expneurol.2005.10.011			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	009RV	WOS:000235131000020	16300758				2022-02-06	
J	Dockree, PM; Bellgrove, MA; O'Keeffe, FM; Moloney, P; Aimola, L; Carton, S; Robertson, IH				Dockree, PM; Bellgrove, MA; O'Keeffe, FM; Moloney, P; Aimola, L; Carton, S; Robertson, IH			Sustained attention in traumatic brain injury (tbi) and healthy controls: enhanced sensitivity with dual-task load	EXPERIMENTAL BRAIN RESEARCH			English	Article						dual-task; sustained attention; traumatic brain injury; prefrontal cortex	INTRINSIC ALERTNESS; FUNCTIONAL-ANATOMY; FRONTAL LOBES; PERFORMANCE; DEFICITS; NETWORK; DAMAGE	Poor sustained attention or alertness is a common consequence of traumatic brain injury (TBI) and has a considerable impact on the recovery and adjustment of TBI patients. Here, we describe the development of a sensitive laboratory task in healthy subjects (Experiment 1) and its enhanced sensitivity to sustained attention errors in TBI patients (Experiment 2). The task involves withholding a key press to an infrequent no-go target embedded within a predictable sequence of numbers (primary goal) and detecting grey-coloured targets within the sequence (secondary goal). In Experiment 1, we report that neurologically healthy subjects are more likely to experience a lapse of attention and neglect the primary task goal, despite ceiling performance on the secondary task. Further, attentional lapses on the task correlated with everyday attentional failures and variability of response time. In Experiment 2, the task discriminates between TBI patients and controls with a large effect size. The dual-task yields more errors in both groups than a simple task involving only the primary goal that is commonly used to detect sustained attention deficits in neurologically impaired groups. TBI patients' errors also correlated with everyday cognitive failures and variability of response time. This was not the case in the simple version of the task. We conclude that the dual-task demand associated with this task enhances its sensitivity as a measure of sustained attention in TBI patients and neurologically healthy controls that relates to everyday slips of attention.	Univ Dublin Trinity Coll, Inst Neurosci, Dept Psychol, Dublin 2, Ireland; Univ Dublin Trinity Coll, Dept Psychiat, Dublin 2, Ireland; Natl Rehabil Hosp, Dun Laoghaire, Co Dublin, Ireland		Dockree, PM (corresponding author), Univ Dublin Trinity Coll, Inst Neurosci, Dept Psychol, Dublin 2, Ireland.	dockreep@tcd.ie	Bellgrove, Mark/AAB-3114-2019	Bellgrove, Mark/0000-0003-0186-8349; Robertson, Ian H/0000-0001-8637-561X			Bellgrove MA, 2004, NEUROREPORT, V15, P1065, DOI 10.1097/00001756-200404290-00027; Bellgrove MA, 2004, NEUROPSYCHOLOGIA, V42, P1910, DOI 10.1016/j.neuropsychologia.2004.05.007; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; DASILVA FHL, 1980, ELECTROEN CLIN NEURO, V50, P449, DOI 10.1016/0013-4694(80)90011-5; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Kondo H, 2004, NEUROIMAGE, V21, P2, DOI 10.1016/j.neuroimage.2003.09.046; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Lindgren KA, 1999, BIOL PSYCHIAT, V45, P943, DOI 10.1016/S0006-3223(98)00350-3; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P1, DOI 10.1016/S0028-3932(01)00086-0; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Portas CM, 1998, J NEUROSCI, V18, P8979; Posner MI, 2000, PSYCHOL BULL, V126, P873, DOI 10.1037/0033-2909.126.6.873; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Richardson JTE., 2000, CLIN NEUROPSYCHOLOGI; Robertson I.H., 2000, CLIN NEUROPSYCHOL, V3, P167; Robertson IH, 2004, COGNITIVE NEUROSCIENCES III, THIRD EDITION, P631; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Sturm W, 1999, NEUROPSYCHOLOGIA, V37, P797, DOI 10.1016/S0028-3932(98)00141-9; Sturm W, 2004, NEUROPSYCHOLOGIA, V42, P563, DOI 10.1016/j.neuropsychologia.2003.11.004; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Stuss DT, 1999, NEUROPSYCHOLOGIA, V37, P1005, DOI 10.1016/S0028-3932(98)00158-4; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	31	74	75	0	9	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	JAN	2006	168	1-2					218	229		10.1007/s00221-005-0079-x			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	991OG	WOS:000233822700021	16044297				2022-02-06	
J	Viant, MR; Lyeth, BG; Miller, MG; Berman, RF				Viant, MR; Lyeth, BG; Miller, MG; Berman, RF			An NMR metabolomic investigation of early metabolic disturbances following traumatic brain injury in a mammalian model	NMR IN BIOMEDICINE			English	Article						traumatic brain injury; lateral fluid percussion; rat; hippocarnpus; cortex; ascorbate; metabolomics; metabonomics	LATERAL FLUID-PERCUSSION; MAGNETIC-RESONANCE SPECTROSCOPY; CEREBROSPINAL-FLUID; PATTERN-RECOGNITION; N-ACETYLASPARTATE; OXIDATIVE STRESS; AMINO-ACIDS; HEAD-INJURY; RAT; DISORDERS	The effects of traumatic brain injury (TBI) on brain chemistry and metabolism were examined in three Groups of rats using high-resolution H-1 NMR metabolomics of brain tissue extracts and plasma. Brain injury in the TBI group (n = 6) was produced by lateral fluid percussion and regional changes in brain metabolites were analyzed at 1 h after injury in hippocampus, cortex and plasma and compared with changes in both a sham-surgery control group (n = 6) and an untreated control group (it = 6). Evidence was found of oxidative stress (e.g. decreases in ascorbate of 16.4% (P < 0.01) and 29.7% (p < 0.05) in cortex and hippocarnpus, respectively) in TBI rats versus the untreated control group, as well as excitotoxic damage (e.g. decreases in glutamate of 14.7% (p < 0.05) and 12.3% (p < 0.01) in the cortex and hippocampus, respectively), membrane disruption (e.g. decreases in the total level of phosphocholine and glycerophosphocholine of 23.0% (p < 0.01) and 19.0% (p < 0.01) in the cortex and hippocarnpus, respectively) and neuronal injury (e.g. decreases in N-acetylaspartate of 15.3% (p < 0.01) and 9.7% (p > 0.05) in the cortex and hippocampus, respectively). Significant changes in the overall pattern of NMR-observable metabolites using principal components analysis were also observed in TBI animals. Although TBI clearly had an effect on the metabolic profile found in brain tissue, no clear effects could be discerned in plasma samples. This was at least partly due to large variability in dominant Glucose and lactate peaks in plasma. However, disruption of the blood-brain barrier and the subsequent movement of metabolites from brain into blood may have been relatively small and below the detection limits of out-analytical procedures. Overall. these data indicate that TBI results in several significant changes in brain metabolism early after trauma and that a metabolomic approach based on H-1 NMR spectroscopy can provide a metabolic profile comprising several metabolite classes and allow for relative quantification of such changes within specific brain regions. The results also provide Support for further development and application of metabolomic technologies for studying TBI and for the utilization of multivariate models for classifying the extent of trauma within an individual. Copyright (c) 2005 John Wiley & Sons, Ltd.	Univ Calif Davis, Coll Agr & Environm Sci, Dept Environm Toxicol, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Neurol Surg, Davis, CA 95616 USA		Viant, MR (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	m.viant@bham.ac.uk	Viant, Mark R/B-6339-2009	Viant, Mark R/0000-0001-5898-4119; Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045136, R01NS029995, R01NS039090] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29995, NS45136, NS39090] Funding Source: Medline		Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802; Cristofori L, 2005, CLIN BIOCHEM, V38, P97, DOI 10.1016/j.clinbiochem.2004.09.013; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dunne VG, 2005, NMR BIOMED, V18, P24, DOI 10.1002/nbm.918; Eriksson L., 2001, MULTI MEGAVARIATE DA; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan WMT, 1996, PROG NUCL MAG RES SP, V28, P161, DOI 10.1016/0079-6565(95)01017-3; Forshed J, 2003, ANAL CHIM ACTA, V487, P189, DOI 10.1016/S0003-2670(03)00570-1; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Griffin JL, 2001, ANAL BIOCHEM, V293, P16, DOI 10.1006/abio.2001.5096; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Huang W, 2000, J PHARMACOL EXP THER, V295, P392; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; KUMAGAE Y, 1991, J NEUROCHEM, V56, P1169, DOI 10.1111/j.1471-4159.1991.tb11407.x; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Takahashi M, 1997, J EXP BIOL, V200, P401; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TSAI GC, 1995, PROG NEUROBIOL, V46, P531, DOI 10.1016/0301-0082(95)00014-M; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; URENJAK J, 1993, J NEUROSCI, V13, P981, DOI 10.1523/jneurosci.13-03-00981.1993; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Viant MR, 2003, BIOCHEM BIOPH RES CO, V310, P943, DOI 10.1016/j.bbrc.2003.09.092; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	32	74	80	1	20	JOHN WILEY & SONS LTD	CHICHESTER	THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND	0952-3480			NMR BIOMED	NMR Biomed.	DEC	2005	18	8					507	516		10.1002/nbm.980			10	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	997XE	WOS:000234281400004	16177961				2022-02-06	
J	Truettner, JS; Suzuki, T; Dietrich, WD				Truettner, JS; Suzuki, T; Dietrich, WD			The effect of therapeutic hypothermia on the expression of inflammatory response genes following moderate traumatic brain injury in the rat	MOLECULAR BRAIN RESEARCH			English	Article						hypothermia; trauma; gene array; protection; inflammation	MIGRATION INHIBITORY FACTOR; TUMOR-NECROSIS-FACTOR; TRANSIENT FOREBRAIN ISCHEMIA; NITRIC-OXIDE SYNTHASE; NERVE GROWTH-FACTOR; CLOSED-HEAD INJURY; MESSENGER-RNA; TNF-ALPHA; MILD HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA	Traumatic brain injury (TBI) initiates a cascade of cellular and molecular responses including both pro- and anti-inflammatory. Although post-traumatic hypothermia has been shown to improve outcome in various models of brain injury, the underlying mechanisms responsible for these effects have not been clarified. in this study, inflammation cDNA arrays and semi-quantitative RT-PCR were used to detect genes that are differentially regulated after TBI. In addition, the effect of post-traumatic hypothermia on the expression of selective genes was also studied. Rats (n = 6-8 per group) underwent moderate fluid-percussion (F-P) brain injury with and without hypothermic treatment (33 degrees C/3h). RNA from 3-h or 24-h survival was analyzed for the expression of IL1-beta, IL2, IL6, TGF-beta 2, growth-regulated oncogene (GRO), migration inhibitory factor (MIF), and MCP (a transcription factor). The interleukins IL-1 beta, IL-2, and IL-6 and TGF-beta and GRO were strongly upregulated early and transiently from 2- to 30-fold over sham at 3 h, with normalization by 24 h. In contrast, the expressions of MIF and MCP were both reduced by TBI compared to sham. Post-traumatic hypothermia had no significant effect on the acute expression of the majority of genes investigated. However, the expression of TGF-2 at 24 h was significantly reduced by temperature manipulation. The mechanism by which post-traumatic hypothermia is protective may not involve a general genetic response of the inflammatory genes. However, specific genes, including TGF-beta 2, may be altered and effect cell death mechanisms after TBI. Hypothermia differentially regulates certain genes and may target more delayed responses underlying the secondary damage following TBI. (c) 2005 Elsevier B.V. All rights reserved.	Univ Miami, Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr,Miami Project Cure Paralysis, Miami, FL 33136 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, Neurotrauma Res Ctr,Miami Project Cure Paralysis, POB 016960,R-48, Miami, FL 33136 USA.	ddietrich@miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P50-NS30291, NS42133] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291] Funding Source: NIH RePORTER		Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Allan SM, 2000, ANN NY ACAD SCI, V917, P84; Aoki M, 2001, MOL BRAIN RES, V95, P117, DOI 10.1016/S0169-328X(01)00255-8; Baugh JA, 2003, J ENDOCRINOL, V179, P15, DOI 10.1677/joe.0.1790015; Baugh JA, 2002, CRIT CARE MED, V30, pS27, DOI 10.1097/00003246-200201001-00004; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1, DOI 10.1152/ajpcell.1992.263.1.C1; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Boris-Moller F, 1998, MOL BRAIN RES, V63, P163, DOI 10.1016/S0169-328X(98)00286-1; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; D'Cruz BJ, 2002, J CEREBR BLOOD F MET, V22, P843, DOI 10.1097/00004647-200207000-00009; Daun JM, 2000, AM J PHYSIOL-REG I, V279, pR1043, DOI 10.1152/ajpregu.2000.279.3.R1043; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; Dietrich WD, 1996, ADV NEUROL, V71, P177; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Friedman LK, 2001, MOL BRAIN RES, V86, P34, DOI 10.1016/S0169-328X(00)00252-7; GHIMIKAR RS, 1996, J NEUROSCI RES, V46, P727; Glabinski AR, 1996, J IMMUNOL, V156, P4363; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gregersen PK, 2003, ARTHRITIS RHEUM-US, V48, P1171, DOI 10.1002/art.10880; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Han HS, 2003, J CEREBR BLOOD F MET, V23, P589, DOI 10.1097/01.WCB.0000059566.39780.8D; Han HS, 2002, J NEUROSCI, V22, P3921, DOI 10.1523/JNEUROSCI.22-10-03921.2002; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hicks SD, 2000, NEUROSCIENCE, V98, P677, DOI 10.1016/S0306-4522(00)00169-X; HU BR, 1995, NEUROSCIENCE, V68, P1003, DOI 10.1016/0306-4522(95)00213-3; Huang DR, 2000, IMMUNOL REV, V177, P52, DOI 10.1034/j.1600-065X.2000.17709.x; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KAMME F, 1995, EUR J NEUROSCI, V7, P2007, DOI 10.1111/j.1460-9568.1995.tb00623.x; Kamme F, 1996, MOL BRAIN RES, V43, P51, DOI 10.1016/S0169-328X(96)00151-9; Kataoka M, 2002, TRANSPLANTATION, V73, P1730, DOI 10.1097/00007890-200206150-00007; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; KINOSHITA K, 2002, NEUROSURGERY, V5, P1105; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Krieglstein K, 1996, NEUROCHEM RES, V21, P843, DOI 10.1007/BF02532308; Kumar K, 1996, MOL BRAIN RES, V42, P337, DOI 10.1016/S0169-328X(96)00181-7; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Loukinova E, 2001, INT J CANCER, V94, P637, DOI 10.1002/ijc.1514; Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5; Mancuso A, 2000, BRAIN RES, V887, P34, DOI 10.1016/S0006-8993(00)02963-2; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nishihira J, 2003, ANN NY ACAD SCI, V995, P171, DOI 10.1111/j.1749-6632.2003.tb03220.x; Ousman SS, 2001, J NEUROSCI, V21, P4649, DOI 10.1523/JNEUROSCI.21-13-04649.2001; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; RELTON JK, 1997, NEUROPROTECTION CNS, P225; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; ROBERTS AB, 1992, MOL REPROD DEV, V32, P91, DOI 10.1002/mrd.1080320203; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tomasevic G, 1998, MOL BRAIN RES, V60, P168, DOI 10.1016/S0169-328X(98)00173-9; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; UNSICKER K, 2002, EUR J BIOCHEM, V267, P6972; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843; Wu XL, 1995, NEUROREPORT, V7, P302, DOI 10.1097/00001756-199512290-00072; Zhou ZHL, 2001, FASEB J, V15, P383, DOI 10.1096/fj.00-0373com; Zhumabayeva B, 2004, ADV BIOCHEM ENG BIOT, V86, P191	91	74	80	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	AUG 18	2005	138	2					124	134		10.1016/j.molbrainres.2005.04.006			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	958VH	WOS:000231475800003	15922484				2022-02-06	
J	Sebelius, FCP; Rosen, BN; Lundborg, GN				Sebelius, FCP; Rosen, BN; Lundborg, GN			Refined myoelectric control in below-elbow amputees using artificial neural networks and data glove	JOURNAL OF HAND SURGERY-AMERICAN VOLUME			English	Article						hand prosthesis; EMG recordings; ANN; virtual hands; myoelectric control; amputee	PRIMARY MOTOR CORTEX; MASSIVE CORTICAL REORGANIZATION; BRAIN PLASTICITY; SOMATOSENSORY CORTEX; MACAQUE MONKEYS; HAND PROSTHESIS; NERVE INJURY; AMPUTATION; REPRESENTATION; PATTERNS	Purpose: To develop a system for refined motor control of artificial hands based on multiple electromyographic (EMG) recordings, allowing multiple patterns of hand movements. Methods: Five subjects with traumatic below-elbow amputations and 1 subject with a congenital below-elbow failure of formation performed 10 imaginary movements with their phantom hand while surface electrodes recorded the EMG data. In a training phase a data glove with 18 degrees of freedom was used for positional recording of movements in the contralateral healthy hand. These movements were performed at the same time as the imaginary movements in the phantom hand. An artificial neural network (ANN) then could be trained to associate the specific EMG patterns recorded from the amputation stump with the analogous specific hand movements synchronously performed in the healthy hand. The ability of the ANN to predict the 10 imaginary movements off line, when they were reflected in a virtual computer hand, was assessed and calculated. Results: After the ANN was trained the subjects were able to perform and control 10 hand movements in the virtual computer hand. The subjects showed a median performance of 5 types of movement with a high correlation with the movement pattern of the data glove. The subjects seemed to relearn to execute motor commands rapidly that had been learned before the accident, independent of how old the injury was. The subject with congenital below-elbow failure of formation was able to perform and control several hand movements in the computer hand that cannot be performed in a myoelectric prosthesis (eg, opposition of the thumb). Conclusions: With the combined use of an ANN and a data glove, acting in concert in a training phase, amputees rapidly can learn to execute several imaginary movements in a virtual computerized hand, this opens promising possibilities for motor control of future hand prostheses.	Lund Univ, Malmo Univ Hosp, Dept Elect Measurements, Lund, Sweden; Lund Univ, Malmo Univ Hosp, Dept Hand Surg, Lund, Sweden		Sebelius, FCP (corresponding author), Lund Univ, Dept Elect Measurements, Box 188, SE-22100 Lund, Sweden.	Fredrik.Sebelius@elmat.lth.se	Sebelius, Fredrik/AAG-4473-2020				ALMSTROM C, 1981, INT ORTHOP, V5, P15; Atkeson CG, 1997, ARTIF INTELL REV, V11, P11, DOI 10.1023/A:1006559212014; Behnke S, 1998, IEEE T NEURAL NETWOR, V9, P1352, DOI 10.1109/72.728387; Behnke S, 1996, IEEE IJCNN, P1439, DOI 10.1109/ICNN.1996.549111; Billock J. N., 1995, REHABILITATION HAND, P1189; Borsook D, 1998, NEUROREPORT, V9, P1013, DOI 10.1097/00001756-199804200-00011; Chen R, 2002, NEUROSCIENCE, V111, P761, DOI 10.1016/S0306-4522(02)00025-8; CODE RA, 1992, EXP BRAIN RES, V88, P341, DOI 10.1007/BF02259109; Demet K, 2003, DISABIL REHABIL, V25, P480, DOI 10.1080/0963828031000090434; DONOGHUE JP, 1988, J NEUROSCI, V8, P3221; Dubernard JM, 2003, ANN SURG, V238, P128, DOI 10.1097/01.SLA.0000078945.70869.82; Engelhart K, 1999, MED ENG PHYS, V21, P431, DOI 10.1016/S1350-4533(99)00066-1; ERIKSSON L, 2001, ARTIFICIAL NEURAL NE; Ersland L, 1996, NEUROREPORT, V8, P207, DOI 10.1097/00001756-199612200-00042; Gallant PJ, 1998, MED BIOL ENG COMPUT, V36, P485, DOI 10.1007/BF02523219; Giraux P, 2001, NAT NEUROSCI, V4, P691, DOI 10.1038/89472; HERBERTS P, 1973, ACTA ORTHOP SCAND, V44, P389, DOI 10.3109/17453677308989075; Hubbard S., 1995, REHABILITATION HAND, P1241; HUDGINS B, 1993, IEEE T BIO-MED ENG, V40, P82, DOI 10.1109/10.204774; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; KELAHAN AM, 1981, BRAIN RES, V223, P151, DOI 10.1016/0006-8993(81)90815-5; Lanzetta M, 2004, SCAND J PLAST RECONS, V38, P106, DOI 10.1080/02844310310019860; Levy LM, 2002, ANN NEUROL, V52, P755, DOI 10.1002/ana.10372; Light C. M., 2002, Journal of Medical Engineering and Technology, V26, P139, DOI 10.1080/03091900210142459; Light CM, 2000, MED ENG PHYS, V22, P679, DOI 10.1016/S1350-4533(01)00017-0; Lundborg G, 2003, J PERIPHER NERV SYST, V8, P209, DOI 10.1111/j.1085-9489.2003.03027.x; Lundborg G, 2001, HAND CLIN, V17, P481; Lundborg G, 1999, J HAND SURG-AM, V24A, P219, DOI 10.1053/jhsu.1999.0219; Lundborg G, 2000, SCAND J PLAST RECONS, V34, P97, DOI 10.1080/02844310050159927; Lundborg G, 2000, J HAND SURG-BRIT EUR, V25B, P242, DOI 10.1054/jhsb.1999.0339; Manger PR, 1996, P ROY SOC B-BIOL SCI, V263, P933, DOI 10.1098/rspb.1996.0138; Merzenich M M, 1993, J Hand Ther, V6, P89; MERZENICH MM, 1983, NEUROSCIENCE, V10, P639, DOI 10.1016/0306-4522(83)90208-7; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; Perani D, 2001, NEUROSCI LETT, V303, P62, DOI 10.1016/S0304-3940(01)01649-4; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; Qi HX, 2000, J NEUROPHYSIOL, V84, P2133, DOI 10.1152/jn.2000.84.4.2133; RAMACHANDRAN VS, 1992, NEUROREPORT, V3, P583, DOI 10.1097/00001756-199207000-00009; Ramachandran VS, 1998, BRAIN, V121, P1603, DOI 10.1093/brain/121.9.1603; ROSSINI PM, 1994, BRAIN RES, V642, P169, DOI 10.1016/0006-8993(94)90919-9; SANES JN, 1990, EXP BRAIN RES, V79, P479; SEBELIUS F, 2004, IN PRESS J MED ENG T; SEBELIUS F, 2001, INTUITIVE CONTROL AR, P9; Shoham D, 2001, J NEUROSCI, V21, P6820, DOI 10.1523/JNEUROSCI.21-17-06820.2001; SILCOX DH, 1993, J BONE JOINT SURG AM, V75A, P1781, DOI 10.2106/00004623-199312000-00007; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; Wall JT, 2002, BRAIN RES REV, V39, P181, DOI 10.1016/S0165-0173(02)00192-3; Weiss T, 2000, EXP BRAIN RES, V134, P199, DOI 10.1007/s002210000456; WINTER DA, 1994, J ELECTROMYOGR KINES, V4, P15, DOI 10.1016/1050-6411(94)90023-X; 1991, P INT JOINT C NEUR N, P2709	50	74	74	1	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0363-5023	1531-6564		J HAND SURG-AM	J. Hand Surg.-Am. Vol.	JUL	2005	30A	4					780	789		10.1016/j.jhsa.2005.01.002			10	Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Surgery	949RB	WOS:000230804700020	16039372				2022-02-06	
J	Thota, AK; Watson, SC; Knapp, E; Thompson, B; Jung, R				Thota, AK; Watson, SC; Knapp, E; Thompson, B; Jung, R			Neuromechanical control of locomotion in the rat	JOURNAL OF NEUROTRAUMA			English	Article						biomechanics; coordination; electromyograms; gait analysis; joint angles; kinematics; stance	SPINAL-CORD INJURY; GROUND REACTION FORCES; OVERGROUND LOCOMOTION; TREADMILL LOCOMOTION; FUNCTIONAL RECOVERY; QUADRUPEDAL LOCOMOTION; HINDLIMB MUSCLE; PARAPLEGIC RATS; GAIT ANALYSIS; PATTERNS	Rodent models are being extensively used to investigate the effects of traumatic injury and develop and assess the mechanisms of repair and regeneration. We present quantitative assessment of two-dimensional (2D) kinematics of overground walking and for the first time three-dimensional (3D) joint angle kinematics of all four limbs during treadmill walking in intact adult female Long-Evans rats. Gait cycle with subphases and intralimb and interlimb cyclograms are presented. Phase relationships between joint angles on a cycle-by-cycle basis and interlimb footfalls are assessed using a simple technique. Electromyogram (EMG) data from major flexor and extensor muscles for each of the hindlimb joints and elbow extensor muscles of the forelimbs synchronized to the 3D kinematics are also obtained. Overground walking kinematics, provides information on base of support, stride length, and hindfoot rotation. Treadmill walking kinematics indicate primarily monophasic angle trajectories for the hip and shoulder joints, weak double peak patterns for the knee and elbow joints, and a prominent double peak pattern for the ankle joints. Maximum flexion of the knee during swing precedes that of the ankle, which precedes that of the hip. A mild exercise regimen over 8 weeks does not alter the kinematics. EMG activity indicates specific relationships of the neural activity to joint angle kinematics. We find that the ankle flexors as well as the hip and elbow extensors maintain constant burst duration with changing cycle duration. Data and techniques described here are likely to be useful for quantitative assessment of altered gait and neural control mechanisms after neurotrauma.	Arizona State Univ, Biodesign Inst, Ctr Rehabil Neurosci & Rehabil Engn, Tempe, AZ 85287 USA; Arizona State Univ, Harrington Dept Bioengn, Tempe, AZ 85287 USA; Univ Kentucky, Ctr Biomed Engn, Lexington, KY 40506 USA		Jung, R (corresponding author), Arizona State Univ, Biodesign Inst, Ctr Rehabil Neurosci & Rehabil Engn, POB 879709, Tempe, AZ 85287 USA.	jung@asu.edu	Thota, Anil/J-3305-2019; Thota, Anil/C-5395-2015; Jung, Ranu/AAA-5112-2019	Thota, Anil/0000-0003-0605-2269; Thota, Anil/0000-0003-0605-2269; Jung, Ranu/0000-0003-2042-0638	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD 40335, R01 HD040335] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD040335] Funding Source: NIH RePORTER		Antri M, 2002, EUR J NEUROSCI, V16, P467, DOI 10.1046/j.1460-9568.2002.02088.x; Assaiante C, 2000, J MOTOR BEHAV, V32, P211, DOI 10.1080/00222890009601373; Barbeau H, 1999, BRAIN RES REV, V30, P27, DOI 10.1016/S0165-0173(99)00008-9; BARBEAU H, 1987, BRAIN RES, V412, P84, DOI 10.1016/0006-8993(87)91442-9; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BASSO DM, 1994, RESTOR NEUROL NEUROS, V7, P95, DOI 10.3233/RNN-1994-7205; Beattie MS, 2002, PROG BRAIN RES, V137, P37; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; Bregman BS, 2002, PROG BRAIN RES, V137, P257; Broton JG, 1996, J NEUROTRAUM, V13, P409, DOI 10.1089/neu.1996.13.409; Brustein E, 1998, J NEUROPHYSIOL, V80, P1245, DOI 10.1152/jn.1998.80.3.1245; Cavanagh P., 1973, BRIT J SPORT MED, V7, P129; Cheng HR, 1997, EXP NEUROL, V148, P544, DOI 10.1006/exnr.1997.6708; CLARKE KA, 1986, PHYSIOL BEHAV, V38, P345, DOI 10.1016/0031-9384(86)90105-8; COHEN AH, 1975, J MORPHOL, V146, P177, DOI 10.1002/jmor.1051460202; COLLINS JJ, 1993, J NONLINEAR SCI, V3, P349, DOI 10.1007/BF02429870; de Leon RD, 1999, J NEUROPHYSIOL, V82, P359, DOI 10.1152/jn.1999.82.1.359; de Leon RD, 2001, PHYS THER, V81, P1904, DOI 10.1093/ptj/81.12.1904; De Luca CJ, 1997, J APPL BIOMECH, V13, P135, DOI 10.1123/jab.13.2.135; DELEON R, 1994, BRAIN RES, V654, P241, DOI 10.1016/0006-8993(94)90485-5; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Edgerton VR, 2002, CURR OPIN NEUROBIOL, V12, P658, DOI 10.1016/S0959-4388(02)00379-3; ENGBERG I, 1969, ACTA PHYSIOL SCAND, V75, P614, DOI 10.1111/j.1748-1716.1969.tb04415.x; Fischer MS, 2002, J EXP BIOL, V205, P1315; Fouad K, 2000, BEHAV BRAIN RES, V115, P107, DOI 10.1016/S0166-4328(00)00244-8; Gillis GB, 2001, J EXP BIOL, V204, P2717; GOSLOW GE, 1973, J MORPHOL, V141, P1, DOI 10.1002/jmor.1051410102; GRUNER JA, 1980, EXP BRAIN RES, V40, P361; HALBERTSMA JM, 1983, ACTA PHYSIOL SCAND, P1; Hamers FPT, 2001, J NEUROTRAUM, V18, P187, DOI 10.1089/08977150150502613; Hase T, 2002, J NEUROTRAUM, V19, P267, DOI 10.1089/08977150252807009; HELGREN ME, 1993, EXP NEUROL, V123, P17, DOI 10.1006/exnr.1993.1137; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; HUTCHISON DL, 1989, BRAIN RES, V502, P233, DOI 10.1016/0006-8993(89)90618-5; JACKSON KM, 1979, IEEE T BIO-MED ENG, V26, P122, DOI 10.1109/TBME.1979.326551; JASMIN BJ, 1987, J APPL PHYSIOL, V63, P713, DOI 10.1152/jappl.1987.63.2.713; Jiang W, 1996, J NEUROPHYSIOL, V76, P849, DOI 10.1152/jn.1996.76.2.849; Jung R, 2001, IEEE T NEUR SYS REH, V9, P319, DOI 10.1109/7333.948461; JUNG R, 2002, J NEUOTRAUMA, V19, pP359; Kaegi S, 2002, EUR J NEUROSCI, V16, P249, DOI 10.1046/j.1460-9568.2002.02076.x; Kiehn O, 1996, J NEUROPHYSIOL, V75, P1472, DOI 10.1152/jn.1996.75.4.1472; Kim DH, 1999, J NEUROSCI, V19, P6213, DOI 10.1523/JNEUROSCI.19-14-06213.1999; KuhtzBuschbeck JP, 1996, EXP NEUROL, V137, P212, DOI 10.1006/exnr.1996.0020; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; Leblond H, 2003, J NEUROSCI, V23, P11411; McEwen ML, 2001, J NEUROTRAUM, V18, P1383, DOI 10.1089/08977150152725678; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Metz GAS, 2000, BRAIN RES, V883, P165, DOI 10.1016/S0006-8993(00)02778-5; Metz GAS, 2000, J NEUROTRAUM, V17, P1, DOI 10.1089/neu.2000.17.1; Muir GD, 1999, BEHAV BRAIN RES, V103, P45, DOI 10.1016/S0166-4328(99)00018-2; Muir GD, 1999, EXP BRAIN RES, V126, P307, DOI 10.1007/s002210050739; Muir GD, 2000, EUR J NEUROSCI, V12, P3079, DOI 10.1046/j.1460-9568.2000.00205.x; Multon S, 2003, J NEUROTRAUM, V20, P699, DOI 10.1089/089771503767869935; Philippson M., 1905, TRAV LAB PHYSIOL I S, V7, P1; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Raineteau O, 2002, EUR J NEUROSCI, V16, P1761, DOI 10.1046/j.1460-9568.2002.02243.x; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ribotta MGY, 1998, ANN NY ACAD SCI, V860, P521; ROSE SA, 1993, J PEDIATR ORTHOPED, V13, P727, DOI 10.1097/01241398-199311000-00007; ROY RR, 1991, J APPL PHYSIOL, V70, P2522, DOI 10.1152/jappl.1991.70.6.2522; ROY RR, 1985, BRAIN RES, V337, P175, DOI 10.1016/0006-8993(85)91627-0; Tepavac D, 2001, J APPL BIOMECH, V17, P259, DOI 10.1123/jab.17.3.259; Thota A, 2001, Biomed Sci Instrum, V37, P63; Trank TV, 1996, J NEUROPHYSIOL, V76, P2316, DOI 10.1152/jn.1996.76.4.2316; vanMeeteren NLU, 1997, ARCH PHYS MED REHAB, V78, P70, DOI 10.1016/S0003-9993(97)90013-7; WESTERGA J, 1990, DEV BRAIN RES, V57, P163, DOI 10.1016/0165-3806(90)90042-W; WESTERGA J, 1993, EXP BRAIN RES, V92, P479; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Wilson DJ, 1997, BRAIN INJURY, V11, P157, DOI 10.1080/026990597123610; WINSTEIN CJ, 1989, J MOTOR BEHAV, V21, P373; Winter D.A., 1990, BIOMECHANICS MOTOR C, VVol. 1; Witte H, 2002, J EXP BIOL, V205, P1339; Wolpaw JR, 2001, ANNU REV NEUROSCI, V24, P807, DOI 10.1146/annurev.neuro.24.1.807; [No title captured]	74	74	74	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2005	22	4					442	465		10.1089/neu.2005.22.442			24	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	920YM	WOS:000228731400003	15853462				2022-02-06	
J	Zhang, WP; Hu, H; Zhang, L; Ding, W; Yao, HT; Chen, KD; Sheng, WW; Chen, Z; Wei, EQ				Zhang, WP; Hu, H; Zhang, L; Ding, W; Yao, HT; Chen, KD; Sheng, WW; Chen, Z; Wei, EQ			Expression of cysteinyl leukotriene receptor 1 in human traumatic brain injury and brain tumors	NEUROSCIENCE LETTERS			English	Article						cysteinyl leukotriene receptor 1; traumatic brain injury; astrocytoma; ganglioglioma; metastatic adenocarcinoma; microvascular endothelium	FOCAL CEREBRAL-ISCHEMIA; TGF-BETA; INFLAMMATION; INCREASE; RHINITIS	Cysteinyl leukotrienes (CysLTs) are potent proinflammatory mediators. CysLT receptor 1 (CysLT(1)) is one of the two CysLT receptors that has been cloned. Although the expression of CysLT(1) in the brain has been demonstrated by Northern blot and RT-PCR analyses, the location of CysLT(1) in the brain remains unknown. The objective of this study was to examine the distribution of CysLT(1) by immunohistochemical analysis in human brains with traumatic injury or tumors. CysLT(1) was expressed intensely in the microvascular endothelial cells in both normal and abnormal conditions. At 8 days after traumatic injury, microvascular regeneration was found and all of the endothelial cells highly expressed CysLT(1). In gray and white matters of the normal regions of the brain, CysLT(1) was expressed weekly or not at all, However, the CysLT(1) expression increased in the neuron- and glial-appearing cells in gray and white matters after traumatic brain injury. CysLT(1) was also detected in astrocytoma, ganglioglioma and metastatic adenocarcinoma, and the expression in the neuron- and glial-appearing cells around brain tumors increased robustly. (C) 2004 Elsevier Ireland Ltd. All rights reserved.	Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China; Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou, Peoples R China; Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Pathol, Hangzhou 310027, Peoples R China		Wei, EQ (corresponding author), Zhejiang Univ, Sch Med, Dept Pharmacol, 353,Yan An Rd, Hangzhou 310031, Peoples R China.	weieq2001@yahoo.com	Zhang, Lei/F-2603-2011				Borish L, 2002, ANN ALLERG ASTHMA IM, V88, P16, DOI 10.1016/S1081-1206(10)62024-8; Busse WW, 1998, AM J RESP CRIT CARE, V157, pS210, DOI 10.1164/ajrccm.157.6.mar-1; Chibana K, 2003, J IMMUNOL, V170, P4290, DOI 10.4049/jimmunol.170.8.4290; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; Debinski W, 1998, INT J CANCER, V76, P547, DOI 10.1002/(SICI)1097-0215(19980518)76:4<547::AID-IJC17>3.0.CO;2-4; Fujita M, 1999, EUR J PHARMACOL, V369, P349, DOI 10.1016/S0014-2999(99)00037-0; Held-Feindt J, 2003, J NEURO-ONCOL, V63, P117, DOI 10.1023/A:1023943405292; Inamura Takanori, 1992, Neurological Research, V14, P405; Kjellman C, 2000, INT J CANCER, V89, P251, DOI 10.1002/1097-0215(20000520)89:3<251::AID-IJC7>3.0.CO;2-5; Lotzer K, 2003, ARTERIOSCL THROM VAS, V23, pE32, DOI 10.1161/01.ATV.0000082690.23131.CB; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Shinonaga M, 1990, Adv Neurol, V52, P475; Storms WW, 2003, ANN ALLERG ASTHMA IM, V91, P131, DOI 10.1016/S1081-1206(10)62167-9; Yang MS, 2002, GLIA, V38, P273, DOI 10.1002/glia.10057; Zhang WP, 2002, ACTA PHARMACOL SIN, V23, P871	21	74	76	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JUN 17	2004	363	3					247	251		10.1016/j.neulet.2004.03.088			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	830OY	WOS:000222133400012	15182953				2022-02-06	
J	Nicholson, BD				Nicholson, BD			Evaluation and treatment of central pain syndromes	NEUROLOGY			English	Article; Proceedings Paper	Symposium on Neurology of Special Population held at the 30th Annual Meeting of the Southern-Clinical-Neurological-Society	JAN 20, 2003	Ixtapa, MEXICO	SO Clin Neurol Soc			CENTRAL POSTSTROKE PAIN; MOTOR CORTEX STIMULATION; SPINAL-CORD STIMULATION; POST-STROKE PAIN; INTRATHECAL BACLOFEN; NEUROPATHIC PAIN; BOTULINUM TOXIN; SPASTICITY; LAMOTRIGINE; MECHANISMS	Central pain syndromes represent a form of neuropathic pain that is associated with lesions of the brain or the spinal cord after a stroke or other traumatic injury. Although spinal cord injury (SCI) pain and central post-stroke pain (CPSP) are both classified as central pain syndromes, they may have differing etiologies. The pathophysiology of SCI pain and CPSP has yet to be completely elucidated, but both spinal and supraspinal pathways may be involved. Pain resulting from an injury to the CNS may be vague or difficult to classify or characterize, and patients may describe painful sensations that are poorly localized or that change over time. Pharmacologic interventions that have demonstrated efficacy in central pain syndromes include iv lidocaine and opioids as well as the tricyclic antidepressant amitriptyline and the AEDs gabapentin and lamotrigine. Nonpharmacologic interventions have also demonstrated benefit in some patients who are refractory to pharmacologic treatments. Additional studies are needed to further evaluate the efficacy and safety of both pharmacologic and nonpharmacologic treatments for central pain syndromes.	Lehigh Valley Hosp & Hlth Network, Div Pain Med & Hospice, Allentown, PA 18105 USA; Penn State Univ, Sch Med, Dept Anesthesia, Allentown, PA 18105 USA		Nicholson, BD (corresponding author), Lehigh Valley Hosp & Hlth Network, Div Pain Med & Hospice, 1240 S Cedar Crest Blvd,Ste 307, Allentown, PA 18105 USA.						ANDERSEN G, 1995, PAIN, V61, P187, DOI 10.1016/0304-3959(94)00144-4; Attal N, 2002, NEUROLOGY, V58, P554, DOI 10.1212/WNL.58.4.554; Attal N, 2000, NEUROLOGY, V54, P564, DOI 10.1212/WNL.54.3.564; BONICA JJ, 1991, SYMP PAIN R, P13; Bouhassira D, 2000, PROG PAIN RES MANAG, V16, P401; Bowsher D, 1998, NEUROLOGY, V51, P1352, DOI 10.1212/WNL.51.5.1352; BOWSHER D, 1999, P 9 WORLD C PAIN, P435; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; BRODIE MJ, 1992, LANCET, V339, P1397, DOI 10.1016/0140-6736(92)91207-O; Canavero S, 2002, NEUROLOGY, V58, P831, DOI 10.1212/WNL.58.5.831-a; DOSTROVSKY J, 2000, 9 WORLD C PAIN PROGR, P419; Eide PK, 1998, SPINAL CORD, V36, P601, DOI 10.1038/sj.sc.3100737; Eisenberg E, 2001, NEUROLOGY, V57, P505, DOI 10.1212/WNL.57.3.505; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Finnerup NB, 2002, PAIN, V96, P375, DOI 10.1016/S0304-3959(01)00484-5; FINNERUP NB, 2001, INT ASS STUDY PAIN, P9; Gelber DA, 1999, NEUROREHAB NEURAL RE, V13, P5, DOI 10.1177/154596839901300103; Gelber DA, 2001, STROKE, V32, P1841, DOI 10.1161/01.STR.32.8.1841; GELBER DA, 2000, STROKE CLIN UPDATES, P10; Gracies JM, 1997, MUSCLE NERVE, pS92; Gruenthal M, 1997, SPINAL CORD, V35, P686, DOI 10.1038/sj.sc.3100481; Gwartz BL, 2001, AM J PHYS MED REHAB, V80, P383, DOI 10.1097/00002060-200105000-00014; JENSEN TS, 1995, PAIN, V61, P161, DOI 10.1016/0304-3959(94)00227-6; Katayama Y, 2001, STEREOT FUNCT NEUROS, V77, P183, DOI 10.1159/000064618; LEIJON G, 1989, PAIN, V36, P13, DOI 10.1016/0304-3959(89)90107-3; LEIJON G, 1989, PAIN, V36, P27, DOI 10.1016/0304-3959(89)90108-5; Linderoth B., 1993, Stereotactic and Functional Neurosurgery, V61, P157, DOI 10.1159/000100634; Maruno N, 2000, NEUROREHAB NEURAL RE, V14, P345, DOI 10.1177/154596830001400410; MCHENRY KW, 2002, INT ASS STUDY PAIN, P10; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Meythaler JA, 2001, ARCH PHYS MED REHAB, V82, P1155, DOI 10.1053/apmr.2001.25141; Meythaler JM, 2001, STROKE, V32, P2099, DOI 10.1161/hs0901.095682; *NAT SPIN CORD INJ, 2001, SPIN CORD INJ FACTS; OBrien CF, 1996, DRUG AGING, V9, P332, DOI 10.2165/00002512-199609050-00004; Roux FE, 2001, NEUROSURGERY, V48, P681, DOI 10.1097/00006123-200103000-00050; SIDDALL PJ, 2000, IASP NEWSLETTER; Stiller CO, 1996, NEUROSURGERY, V39, P367, DOI 10.1097/00006123-199608000-00026; Tai Qing, 2002, J Spinal Cord Med, V25, P100; TASKER R, 2001, BONICAS MANAGEMENT P, P432; Vestergaard K, 2001, NEUROLOGY, V56, P184, DOI 10.1212/WNL.56.2.184; Wang HC, 2002, AM J PHYS MED REHAB, V81, P272, DOI 10.1097/00002060-200204000-00005; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; [No title captured]	43	74	79	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAR 9	2004	62	5		2			S30	S36		10.1212/WNL.62.5_suppl_2.S30			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology	802DG	WOS:000220143600006	15007162				2022-02-06	
J	Hawley, CA; Ward, AB; Magnay, AR; Mychalkiw, W				Hawley, CA; Ward, AB; Magnay, AR; Mychalkiw, W			Return to school after brain injury	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							CLOSED HEAD-INJURY; FOLLOW-UP; CHILDREN; ADOLESCENTS; MEMORY; TEMPERAMENT; PERFORMANCE; CHILDHOOD; INFANTS; SCALE	Aims: To examine return to school and classroom performance following traumatic brain injury (TBI). Methods: This cross-sectional study set in the community comprised a group of 67 school-age children with TBI ( 35 mild, 13 moderate, 19 severe) and 14 uninjured matched controls. Parents and children were interviewed and children assessed at a mean of 2 years post injury. Teachers reported on academic performance and educational needs. The main measures used were classroom performance, the Children's Memory Scale (CMS), the Wechsler Intelligence Scale for Children - third edition UK (WISC-III) and the Weschler Objective Reading Dimensions ( WORD). Results: One third of teachers were unaware of the TBI. On return to school, special arrangements were made for 18 children (27%). Special educational needs were identified for 16 (24%), but only six children (9%) received specialist help. Two thirds of children with TBI had difficulties with school work, half had attention/concentration problems and 26 (39%) had memory problems. Compared to other pupils in the class, one third of children with TBI were performing below average. On the CMS, one third of the severe group were impaired/borderline for immediate and delayed recall of verbal material, and over one quarter were impaired/borderline for general memory. Children in the severe group had a mean full-scale IQ significantly lower than controls. Half the TBI group had a reading age greater than or equal to1 year below their chronological age, one third were reading greater than or equal to2 years below their chronological age. Conclusions: Schools rely on parents to inform them about a TBI, and rarely receive information on possible long-term sequelae. At hospital discharge, health professionals should provide schools with information about TBI and possible long-term impairments, so that children returning to school receive appropriate support.	Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England; N Staffordshire Rehabil Ctr, Stoke On Trent, Staffs, England; City Gen Hosp, Paediat Intens Care Unit, Stoke On Trent ST4 6QG, Staffs, England; City Gen Hosp, Dept Psychol, Stoke On Trent ST4 6QG, Staffs, England		Hawley, CA (corresponding author), Univ Warwick, Ctr Hlth Serv Studies, Coventry CV4 7AL, W Midlands, England.	c.a.hawley@warwick.ac.uk	Hawley, Carol/AAG-3830-2019				Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Bevington J, 1999, BRIT J EDUC PSYCHOL, V69, P19, DOI 10.1348/000709999157545; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; COHEN B, 1997, CHILDRENS MEMORY SCA; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; JOHNSON DA, 1998, ED NEEDS HEAD INJURY; JONES A, 1994, BR J SPEC ED, V21, P113; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; Kennard MA, 1936, AM J PHYSIOL, V115, P138, DOI 10.1152/ajplegacy.1936.115.1.138; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1982, NEUROBEHAVIOURAL CON; MARTIN RP, 1988, SCHOOL PSYCHOL REV, V17, P125; *NAT I CLIN EXC, 2002, HEAD INJ INF CHILDR; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; Parmelee D X, 1989, Psychiatr Med, V7, P11; PFEFFER J, 1983, J CLIN PSYCHOL, V39, P1013, DOI 10.1002/1097-4679(198311)39:6<1013::AID-JCLP2270390634>3.0.CO;2-5; SCOTTJUPP R, 1992, ARCH DIS CHILD, V67, P222, DOI 10.1136/adc.67.2.222; Sharples PM, 1998, INJURY YOUNG, P151; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; SNOW JH, 1994, PEDIAT TRAUMATIC BRA; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Townsend P, 1986, INEQUALITIES HLTH NO; WECHSLER D, 1993, WESCHLER OBJECTIVE R; Wechsler D., 1991, MANUAL WECHSLER INTE, V3rd; [No title captured]	37	74	75	1	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	FEB 1	2004	89	2					136	141		10.1136/adc.2002.025577			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	765UP	WOS:000188302500018	14736628	Green Published, Bronze, Green Submitted			2022-02-06	
J	Bonini, P; Cicconi, S; Cardinale, A; Vitale, C; Serafino, AL; Ciotti, MT; Marlier, LNJL				Bonini, P; Cicconi, S; Cardinale, A; Vitale, C; Serafino, AL; Ciotti, MT; Marlier, LNJL			Oxidative stress induces p53-mediated apoptosis in glia: p53 transcription-independent way to die	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						astrocyte; C6 glioma; ischemia; MDM2; cytochrome; mitochondria; caspase	CELL-DEATH; CASPASE ACTIVATION; PROTEIN; MITOCHONDRIA; BAX; NEURONS; EXPRESSION; INHIBITOR; MODEL; MDM2	Oxidative stress has been implicated in the pathogenesis of stroke, traumatic brain injuries, and neurodegenerative diseases affecting both neuronal and glial cells in the central nervous system (CNS). The tumor suppressor protein p53 plays a pivotal function in neuronal apoptosis triggered by oxidative stress. We investigated the role of p53 and related molecular mechanisms that support oxidative stress-induced apoptosis in glia. For this purpose, we exposed C6 glioma cells and primary cultures of rat cortical astrocytes to an H2O2-induced oxidative stress protocol followed by a recovery period. We evaluated the effects of pifithrin-alpha (PF-alpha), which has been reported to protect neurons from ischemic insult by specifically inhibiting p53 DNA-binding activity. Strikingly, PF-alpha was unable to prevent oxidative stress-induced astrocyte apoptosis. We demonstrate that p53 is able to mediate an apoptotic response by direct signaling at mitochondria, despite its transcriptional activity. The z-VAD-fmk-sensitive apoptotic response requires a caspase-dependent MDM-2 degradation, leading to p53 mitochondrial targeting accompanied by cytochrome c release and nucleosomal fragmentation. (C) 2003 Wiley-Liss, Inc.	CNR, Inst Neurobiol & Mol Med, Sect Mol Med, Signal Transduct Apoptot Mech Lab, I-00137 Rome, Italy; Univ Roma Tor Vergata, Dept Internal Med, Rome, Italy; Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy; San Raffaele Roma Hosp, Dept Med Sci, Rome, Italy; CNR, Inst Neurobiol & Mol Med, Sect Neurosci, I-00137 Rome, Italy		Marlier, LNJL (corresponding author), CNR, Inst Neurobiol & Mol Med, Sect Mol Med, Signal Transduct Apoptot Mech Lab, Viale Marx 15-43, I-00137 Rome, Italy.	l.marlier@in.rm.cnr.it	Marlier, Lionel NJL/G-9488-2013; Serafino, Annalucia/AAC-1719-2019	Serafino, Annalucia/0000-0002-1142-4752; MARLIER, LIONEL/0000-0002-6840-3127			Avshalumov MV, 2002, J NEUROPHYSIOL, V87, P2896, DOI 10.1152/jn.2002.87.6.2896; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Brady HJM, 1998, INT J BIOCHEM CELL B, V30, P647, DOI 10.1016/S1357-2725(98)00006-5; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Chen RW, 1999, J NEUROSCI, V19, P9654; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Chung YH, 2002, NEUROL RES, V24, P324, DOI 10.1179/016164102101199828; Culmsee C, 2001, MOL BRAIN RES, V87, P257, DOI 10.1016/S0169-328X(01)00008-0; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; de la Monte SM, 1998, LAB INVEST, V78, P401; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378; Ding HF, 1998, CRIT REV ONCOGENESIS, V9, P83, DOI 10.1615/CritRevOncog.v9.i1.60; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jordan J, 1997, J NEUROSCI, V17, P1397; Joseph JA, 1997, J NEUROCHEM, V69, P1252; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Karbowski M, 1999, FREE RADICAL BIO MED, V26, P396, DOI 10.1016/S0891-5849(98)00209-3; Kitamura Y, 1999, GLIA, V25, P154, DOI 10.1002/(SICI)1098-1136(19990115)25:2<154::AID-GLIA6>3.3.CO;2-J; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakkaraju A, 2001, J BIOL CHEM, V276, P32000, DOI 10.1074/jbc.M100138200; LASSMANN H, 1995, ACTA NEUROPATHOL, V89, P35, DOI 10.1007/BF00294257; Love S, 2003, PROG NEURO-PSYCHOPH, V27, P267, DOI 10.1016/S0278-5846(03)00022-8; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; MERCANTI D, 1987, EXP CELL RES, V168, P182, DOI 10.1016/0014-4827(87)90427-7; MIYASHITA T, 1995, CELL, V80, P293; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Richter-Landsberg C, 1998, EXP CELL RES, V244, P218, DOI 10.1006/excr.1998.4188; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Robertson J, 2001, J CELL BIOL, V155, P217, DOI 10.1083/jcb.200107058; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; SOTO AM, 1985, J STEROID BIOCHEM, V23, P87, DOI 10.1016/0022-4731(85)90265-1; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Tatton WG, 2003, ANN NEUROL, V53, pS61, DOI 10.1002/ana.10489; Teranishi M, 2000, EXP MOL PATHOL, V68, P104, DOI 10.1006/exmp.1999.2288; VOLONTE C, 1994, CYTOMETRY, V17, P274, DOI 10.1002/cyto.990170311; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiang H, 1998, J NEUROSCI, V18, P1363; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	59	74	77	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN 1	2004	75	1					83	95		10.1002/jnr.10822			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	761YB	WOS:000187942100009	14689451				2022-02-06	
J	Cook, DJ; Cusimano, MD; Tator, CH; Chipman, ML				Cook, DJ; Cusimano, MD; Tator, CH; Chipman, ML			Evaluation of the ThinkFirst Canada, Smart Hockey, brain and spinal cord injury prevention video	INJURY PREVENTION			English	Article							ICE HOCKEY; PLAYERS; IMPACT; HEAD; CONCUSSIONS; CHECKING; SPORTS; NECK	Objective: The ThinkFirst Canada Smart Hockey program is an educational injury prevention video that teaches the mechanisms, consequences, and prevention of brain and spinal cord injury in ice hockey. This study evaluates knowledge transfer and behavioural outcomes in 11-12 year old hockey players who viewed the video. Design: Randomized controlled design. Setting: Greater Toronto Minor Hockey League, Toronto Ontario. Subjects: Minor, competitive 11-12 year old male ice hockey players and hockey team coaches. Interventions: The Smart Hockey video was shown to experimental teams at mid-season. An interview was conducted with coaches to understand reasons to accept or refuse the injury prevention video. Main outcome measures: A test of concussion knowledge was administered before, immediately after, and three months after exposure to the video. The incidence of aggressive penalties was measured before and after viewing the video. Results: The number of causes and mechanisms of concussion named by players increased from 1.13 to 2.47 and from 0.67 to 1.22 respectively. This effect was maintained at three months. There was no significant change in control teams. There was no significant change in total penalties after video exposure; however, specific body checking related penalties were significantly reduced in the experimental group. Conclusion: This study showed some improvements in knowledge and behaviours after a single viewing of a video; however, these findings require confirmation with a larger sample to understand the sociobehavioural aspects of sport that determine the effectiveness and acceptance of injury prevention interventions.	St Michaels Hosp, Injury Prevent Res Off, Div Neurosurg, Toronto, ON M5B 1A6, Canada; Toronto Western Hosp, ThinkFirst Fdn Canada, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada		Cusimano, MD (corresponding author), St Michaels Hosp, Injury Prevent Res Off, Div Neurosurg, 38 Shuter St,Suite 2-018, Toronto, ON M5B 1A6, Canada.	injuryprevention@smh.toronto.on.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650			Anderson AJ, 2000, PEDIATRICS, V105, P657, DOI 10.1542/peds.105.3.640; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V83, P23; BORKENHEIM JM, 1993, ACTA ORTHOP SCAND, V64, P459; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Glaser Barney., 1992, BASICS GROUNDED THEO; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; HAYES D, 1975, PHYSICIAN SPORTS JAN; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; MCFAULL S, 2001, CHIRRP NEWS, V19; PASHBY TJ, 1992, CAN J OPHTHALMOL, V27, P226; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Stuart MJ, 2002, AM J SPORT MED, V30, P39, DOI 10.1177/03635465020300012001; Tator CH, 1997, CLIN J SPORT MED, V7, P17, DOI 10.1097/00042752-199701000-00004; TATOR CH, 1991, CAN J SURG, V34, P63; TATOR CH, 1984, CAN MED ASSOC J, V130, P875; VOLPE R, 2002, COMPENDIUM EVIDENCE, P223; Watson RC, 1996, CLIN J SPORT MED, V6, P108, DOI 10.1097/00042752-199604000-00008	24	74	74	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	DEC	2003	9	4					361	365		10.1136/ip.9.4.361			5	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	771EA	WOS:000188771600018	14693901	Bronze, Green Published			2022-02-06	
J	Rismanchi, N; Floyd, CL; Berman, RF; Lyeth, BG				Rismanchi, N; Floyd, CL; Berman, RF; Lyeth, BG			Cell death and long-term maintenance of neuron-like state after differentiation of rat bone marrow stromal cells: a comparison of protocols	BRAIN RESEARCH			English	Article						differentiation; neuron; astrocyte; NeuN; GFAP; cell death	TRAUMATIC BRAIN INJURY; STEM-CELLS; IN-VITRO; THERAPEUTIC BENEFIT; CEREBRAL-ISCHEMIA; SPINAL-CORD; TRANSPLANTATION; REGENERATION; PROGENITORS; CULTURES	Recent literature suggests that bone marrow stromal cells (BMSCs) may be differentiated into neuron-like and/or glia-like cells, implying that differentiated BMSCs may have potential use in cell replacement therapy for central nervous system disorders. However, many questions remain concerning the nature of BMSCs differentiated to express CNS antigens. For example, how long after differentiation do cells express CNS markers, and do differentiation procedures alter cell viability? This study compared neuronal differentiation methods in sister cell preparations, evaluating cell death and maintenance of the CNS antigen positivity after the Deng or Woodbury methods. Rat BMSCs were harvested, passaged, differentiated, placed in growth or maintenance media, and processed for cell viability or immunocytochemistry for NeuN and GFAP post-differentiation. We report that the Woodbury differentiation protocol produced maximally 51% neuron-like cells, yet also produced significant cell death. The Deng differentiation method produced 13% neuron-like cells and without marked cell death. No significant increases in GFAP immunoreactivity (IR) were seen after differentiation by either protocol. Following both protocols, removal of cells from the maintenance media significantly decreased expression of NeuN. Thus, differentiation procedures may be substantially affected BMSC potential, and maintenance of immunoreactivity to neuronal antigens was dependent on specific, nonphysiological environmental conditions. (C) 2003 Elsevier B.V. All rights reserved.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA		Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95616 USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29995, NS43085] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, F32NS043085] Funding Source: NIH RePORTER		Akiyama Y, 2002, J NEUROSCI, V22, P6623; ASHTON BA, 1980, CLIN ORTHOP RELAT R, P294; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365-2141.1999.01715.x; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; FRESHNEY IR, 1994, CULTURE ANIMAL CELLS, V3, P335; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Krause DS, 2002, GENE THER, V9, P754, DOI 10.1038/sj.gt.3301760; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; MOUTON PR, 2000, STEREOLOGER HDB SYST; Phinney DG, 1999, J CELL BIOCHEM, V72, P570; Phinney DG, 1999, J CELL BIOCHEM, V75, P424, DOI 10.1002/(SICI)1097-4644(19991201)75:3<424::AID-JCB8>3.0.CO;2-8; Prockop DJ, 2000, BIOCHEM SOC T, V28, P341, DOI 10.1042/0300-5127:0280341; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; Tremain N, 2001, STEM CELLS, V19, P408, DOI 10.1634/stemcells.19-5-408; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C	31	74	93	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 21	2003	991	1-2					46	55		10.1016/j.brainres.2003.07.004			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	742QU	WOS:000186530200005	14575875				2022-02-06	
J	Kent, RD; Vorperian, HK; Kent, JF; Duffy, JR				Kent, RD; Vorperian, HK; Kent, JF; Duffy, JR			Voice dysfunction in dysarthria: application of the Multi-Dimensional Voice Program (TM)	JOURNAL OF COMMUNICATION DISORDERS			English	Article						dysarthria; voice disorder; MDVP; acoustic analysis	AMYOTROPHIC-LATERAL-SCLEROSIS; COMPUTERIZED SPEECH LAB; TRAUMATIC BRAIN INJURY; PARKINSONS-DISEASE; FUNDAMENTAL-FREQUENCY; ACOUSTIC ANALYSIS; TREATMENT LSVT(R); PHONATORY DYSFUNCTION; CIGARETTE-SMOKING; ANALYSIS SYSTEMS	Phonatory dysfunction is a frequent component of dysarthria and often is a primary feature noted in clinical assessment. But the vocal impairment can be difficult to assess because (a) the analysis of voice disorder of any kind can be challenging, and (b) the voice disorder in dysarthria often occurs along with other impairments affecting articulation, resonance, and respiration. A promising assessment tool is multi-parameter acoustic analysis, such as the Multi-Dimensional Voice Program(TM) (MDVP). Part 1 of this paper recommends procedures and standards for the acoustic analysis of voice, including (1) selection of the sample to be analyzed, (2) signal quality requirements, (3) availability of normative data for both genders and different ages of speakers, (4) reliability of analysis, and (5) correlation of acoustic results with results from other methods of analysis. In Part 2, acoustic data are reviewed for the dysarthria associated with Parkinson disease (PD), cerebellar disease, amyotrophic lateral sclerosis (ALS), traumatic brain injury (TBI), unilateral hemispheric stroke, and essential tremor. Tentative profiles of voice disorder are described for these conditions. These profiles may serve as hypotheses for future research. Although several issues remain to be resolved in the acoustic analysis of voice disorder in dysarthria, steps can be taken now to promote the reliability, validity, and clinical utility of such analyses. Learning outcomes: (1) As a result of this activity, the participant will be able to describe ways in which an optimal multi-dimensional analysis of voice can be performed with modem acoustic analysis systems. (2) As a result of this activity, the participant will be able to apply multi-dimensional acoustic analysis of voice to individuals who have a dysarthria-related voice disorder. (3) As a result of this activity, the participant will be able to identify major sources of normative data on the Multi-Dimensional Voice Program. (C) 2003 Elsevier Science Inc. All rights reserved.	Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA		Kent, RD (corresponding author), Univ Wisconsin, Waisman Ctr, Rm 435,1500 Highland Ave, Madison, WI 53705 USA.	kent@waisman.wisc.edu	Kent, Raymond D/AAI-1928-2020		NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC000319] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [5 R01 DC 00319] Funding Source: Medline		ARONSON AE, 1994, BRAIN INJURY, V8, P663, DOI 10.3109/02699059409151019; ARONSON AE, 1992, ANN OTO RHINOL LARYN, V101, P511, DOI 10.1177/000348949210100612; Baumgartner CA, 2001, J VOICE, V15, P105, DOI 10.1016/S0892-1997(01)00010-8; Behrman A, 1998, J VOICE, V12, P249, DOI 10.1016/S0892-1997(98)80045-3; Bielamowicz S, 1996, J SPEECH HEAR RES, V39, P126, DOI 10.1044/jshr.3901.126; Buder EugeneH., 2000, VOICE QUALITY MEASUR, P119; Bunton K, 2001, CLIN LINGUIST PHONET, V15, P181; Callan DE, 1999, J SPEECH LANG HEAR R, V42, P355, DOI 10.1044/jslhr.4202.355; Campisi P, 2002, ARCH OTOLARYNGOL, V128, P156, DOI 10.1001/archotol.128.2.156; Campisi P, 2000, J OTOLARYNGOL, V29, P302; CARROW E, 1974, ARCH OTOLARYNGOL, V100, P212; Crevier-Buchman L, 1995, Ann Otolaryngol Chir Cervicofac, V112, P169; Damborenea Tajada J, 1999, Acta Otorrinolaringol Esp, V50, P448; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P462, DOI 10.1044/jshr.1203.462; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; Dejonckere P H, 1998, Rev Laryngol Otol Rhinol (Bord), V119, P247; DELIYSKI D, 1998, 1998 ANN CONV AM SPE; Desai, 1995, J MED SPEECH-LANG PA, V3, P41; DOHERTY ET, 1988, J SPEECH HEAR RES, V31, P485, DOI 10.1044/jshr.3103.485; Gamboa J, 1998, J VOICE, V12, P444, DOI 10.1016/S0892-1997(98)80053-2; GELFER MP, 1995, J VOICE, V9, P378, DOI 10.1016/S0892-1997(05)80199-7; GENTIL M, 1990, FOLIA PHONIATR, V42, P125, DOI 10.1159/000266056; GILMAN S, 1992, NEUROLOGIC DISORDERS, P279; Gonzalez J, 2002, Acta Otorrinolaringol Esp, V53, P256; GRIFFITHS C, 1989, Journal of Voice, V3, P148, DOI 10.1016/S0892-1997(89)80141-9; HERTRICH I, 1995, ANN OTO RHINOL LARYN, V104, P197, DOI 10.1177/000348949510400304; HERTRICH I, 1998, CLIN PHONETICS LINGU, P448; Holmes RJ, 2000, INT J LANG COMM DIS, V35, P407; Jaeger M, 2001, FOLIA PHONIATR LOGO, V53, P326, DOI 10.1159/000052686; JOANETTE Y, 1980, BRAIN LANG, V10, P39, DOI 10.1016/0093-934X(80)90036-X; KARNELL MP, 1995, J VOICE, V9, P383, DOI 10.1016/S0892-1997(05)80200-0; Kay Elemetrics, 1993, MULT VOIC PROGR MDVP; Kent R. D., 1994, J MED SPEECH-LANG PA, V2, P157; Kent Raymond D., 2000, VOICE QUALITY MEASUR; Kent RD, 1999, AM J SPEECH-LANG PAT, V8, P129, DOI 10.1044/1058-0360.0802.129; Kent RD, 2000, J SPEECH LANG HEAR R, V43, P1275, DOI 10.1044/jslhr.4305.1275; Kent RD, 1997, FOLIA PHONIATR LOGO, V49, P63, DOI 10.1159/000266440; KENT RD, 1998, PHONOSCOPE, V4, P237; KOIKE Y, 1977, ACTA OTO-LARYNGOL, V84, P105, DOI 10.3109/00016487709123948; Leeper H. A., 1996, J MED SPEECH-LANG PA, V4, P163; LOGEMANN JA, 1978, J SPEECH HEAR DISORD, V43, P47, DOI 10.1044/jshd.4301.47; MATHIESON L, 2000, VOICE QUALITY MEASUR, P3; McHenry M, 2000, LARYNGOSCOPE, V110, P1157, DOI 10.1097/00005537-200007000-00017; McHenry MA, 1996, DISORDERS MOTOR SPEE, P229; Mendoza E, 1998, J VOICE, V12, P263, DOI 10.1016/S0892-1997(98)80017-9; Murdoch BE, 1997, CLIN LINGUIST PHONET, V11, P245, DOI 10.3109/02699209708985194; MURPHY CH, 1987, OTOLARYNG HEAD NECK, V97, P376, DOI 10.1177/019459988709700406; Niedzielska G, 2001, INT J PEDIATR OTORHI, V57, P189, DOI 10.1016/S0165-5876(00)00411-0; Parsa V, 2001, J SPEECH LANG HEAR R, V44, P327, DOI 10.1044/1092-4388(2001/027); Perry C. K., 1996, AM J SPEECH-LANG PAT, V5, P86; Putzer M, 2001, FOLIA PHONIATR LOGO, V53, P73, DOI 10.1159/000052657; RAMIG L, 1996, ORGANIC VOICE DISORD, P323; Ramig L.O., 1992, INTELLIGIBILITY SPEE, P119, DOI DOI 10.1075/SSPCL.1.05RAM; Ramig LO, 2001, MOVEMENT DISORD, V16, P79, DOI 10.1002/1531-8257(200101)16:1<79::AID-MDS1013>3.0.CO;2-H; Ramig LO, 2001, J NEUROL NEUROSUR PS, V71, P493, DOI 10.1136/jnnp.71.4.493; Revis J, 1999, FOLIA PHONIATR LOGO, V51, P108, DOI 10.1159/000021485; Robert D, 1999, ACTA OTO-LARYNGOL, V119, P724; Rovirosa A, 2000, INT J RADIAT ONCOL, V47, P73, DOI 10.1016/S0360-3016(99)00524-6; Sanabria J, 2001, CLIN NEUROPHARMACOL, V24, P99, DOI 10.1097/00002826-200103000-00006; Silbergleit AK, 1997, J VOICE, V11, P222, DOI 10.1016/S0892-1997(97)80081-1; SORENSEN D, 1982, J COMMUN DISORD, V15, P135, DOI 10.1016/0021-9924(82)90027-2; Souaid JP, 1998, J OTOLARYNGOL, V27, P301; STEWART C, 1995, MOVEMENT DISORD, V10, P562, DOI 10.1002/mds.870100506; STRAND EA, 1994, J VOICE, V8, P327, DOI 10.1016/S0892-1997(05)80281-4; Theodoros DG, 1996, DISORDERS MOTOR SPEE, P205; TITZE IR, 1995, WORKSH AC VOICE ANAL; van As CJ, 1998, J VOICE, V12, P239, DOI 10.1016/S0892-1997(98)80044-1; Van Lierde K, 1996, Acta Otorhinolaryngol Belg, V50, P345; Weismer, 1998, J MED SPEECH-LANG PA, V6, P165; WHALEN DH, 1990, BEHAV RES METH INSTR, V22, P550, DOI 10.3758/BF03204440; Xue SA, 2000, PERCEPT MOTOR SKILL, V91, P951, DOI 10.2466/PMS.91.7.951-958; Xue SA, 2001, EDUC GERONTOL, V27, P159, DOI 10.1080/03601270151075561; Yiu E, 2000, CLIN LINGUIST PHONET, V14, P295; Ziegler W., 2000, VOICE QUALITY MEASUR, P397; ZWIRNER P, 1992, J SPEECH HEAR RES, V35, P761, DOI 10.1044/jshr.3504.761; ZWIRNER P, 1991, J COMMUN DISORD, V24, P287, DOI 10.1016/0021-9924(91)90004-3; [No title captured]	77	74	78	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	JUL-AUG	2003	36	4					281	306		10.1016/S0021-9924(03)00016-9			26	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	700GX	WOS:000184105200003	12837587				2022-02-06	
J	Satchell, MA; Zhang, XP; Kochanek, PM; Dixon, CE; Jenkins, LW; Melick, J; Szabo, C; Clark, RSB				Satchell, MA; Zhang, XP; Kochanek, PM; Dixon, CE; Jenkins, LW; Melick, J; Szabo, C; Clark, RSB			A dual role for poly-ADP-ribosylation in spatial memory acquisition after traumatic brain injury in mice involving NAD(+) depletion and ribosylation of 14-3-3 gamma	JOURNAL OF NEUROCHEMISTRY			English	Article						14-3-3; DNA damage; head injury; 5-iodo-6-amino-1,2-benzopyrone; nicotinamide adenine dinucleotide; poly(ADP-ribose) synthetase	NITRIC-OXIDE SYNTHASE; LONG-TERM POTENTIATION; NF-KAPPA-B; POLY(ADP-RIBOSE) POLYMERASE; CEREBRAL-ISCHEMIA; RIBOSE POLYMERASE; DNA-DAMAGE; RATS; ACTIVATION; TRANSCRIPTION	Poly(ADP-ribose) polymerase-1 (PARP-1) is a homeostatic enzyme that paradoxically contributes to disturbances in spatial memory acquisition after traumatic brain injury (TBI) in transgenic mice, thought to be related to depletion of its substrate nicotinamide adenine dinucleotide (NAD(+)). In this study, systemic administration of the PARP-1 inhibitor 5-iodo-6-amino-1,2-benzopyrone (INH2BP) after TBI preserved brain NAD(+) levels and dose-dependently reduced poly-ADP-ribosylation 24 h after injury. While moderate-dose INH2BP improved spatial memory acquisition after TBI; strikingly, both injured- and sham-mice receiving high-dose INH2BP were unable to learn in the Morris-water maze. Poly-ADP-ribosylated peptides identified using a proteomics approach yielded several proteins potentially associated with memory, including structural proteins (tubulin alpha and beta, gamma-actin, and alpha-internexin neuronal intermediate filament protein) and 14-3-3gamma. Nuclear poly-ADP-ribosylation of 14-3-3gamma was completely inhibited by the dose of INH2BP that produced profound memory disturbances. Thus, partial inhibition of poly-ADP-ribosylation preserves NAD(+) and improves functional outcome after TBI, whereas more complete inhibition impairs spatial memory acquisition independent of injury, and is associated with ribosylation of 14-3-3gamma.	Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA; Inotek Pharmaceut Corp, Beverly, MA USA		Clark, RSB (corresponding author), Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Szabo, Csaba/ABG-2644-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44 NS37985, P50 NS30318, R01 NS38620] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS037985, R01NS038620, P50NS030318] Funding Source: NIH RePORTER		Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Bauer PI, 2000, INT J MOL MED, V5, P533; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BENARI Y, 1995, TRENDS NEUROSCI, V18, P519, DOI 10.1016/0166-2236(95)98371-5; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; DAWSON TM, 1995, NEW HORIZONS, V3, P86; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Fountoulakis M, 1999, J NEURAL TRANSM-SUPP, P323; Frick KM, 2000, NEUROREPORT, V11, P3461, DOI 10.1097/00001756-200011090-00013; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; KASLOW HR, 1981, J CELL BIOL, V91, P410, DOI 10.1083/jcb.91.2.410; Kendrick KM, 1997, NATURE, V388, P670, DOI 10.1038/41765; Kleppisch T, 1999, J NEUROSCI, V19, P48, DOI 10.1523/JNEUROSCI.19-01-00048.1999; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Mendoza-Alvarez H, 2001, J BIOL CHEM, V276, P36425, DOI 10.1074/jbc.M105215200; Nagayama T, 2000, J NEUROCHEM, V74, P1636, DOI 10.1046/j.1471-4159.2000.0741636.x; NISSELBA.JS, 1969, ANAL BIOCHEM, V27, P212, DOI 10.1016/0003-2697(69)90025-6; Oei SL, 2001, BIOCHEM BIOPH RES CO, V285, P27, DOI 10.1006/bbrc.2001.5115; Oei SL, 2001, BIOCHEM BIOPH RES CO, V284, P450, DOI 10.1006/bbrc.2001.4985; Peyrl A, 2002, ELECTROPHORESIS, V23, P152, DOI 10.1002/1522-2683(200201)23:1<152::AID-ELPS152>3.0.CO;2-T; Philip N, 2001, J NEUROSCI, V21, P8417, DOI 10.1523/JNEUROSCI.21-21-08417.2001; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; Rao A, 2000, HIPPOCAMPUS, V10, P527, DOI 10.1002/1098-1063(2000)10:5<527::AID-HIPO3>3.0.CO;2-B; Riese MJ, 2002, J BIOL CHEM, V277, P12082, DOI 10.1074/jbc.M109039200; Rozental R, 2001, DEV NEUROSCI-BASEL, V23, P420, DOI 10.1159/000048729; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Szabo C, 1998, EUR J PHARMACOL, V350, P1, DOI 10.1016/S0014-2999(98)00249-0; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; Szabo C, 1996, FREE RADICAL BIO MED, V21, P855, DOI 10.1016/0891-5849(96)00170-0; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Tokime T, 1998, J CEREBR BLOOD F MET, V18, P991, DOI 10.1097/00004647-199809000-00008; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Tsukahara F, 2000, MOL PHARMACOL, V58, P1257, DOI 10.1124/mol.58.6.1257; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Wheal HV, 1998, PROG NEUROBIOL, V55, P611, DOI 10.1016/S0301-0082(98)00026-4; YOSHIHARA K, 1994, MOL CELL BIOCHEM, V135, P143, DOI 10.1007/BF00926517; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	49	74	77	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2003	85	3					697	708		10.1046/j.1471-4159.2003.01707.x			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	667XJ	WOS:000182259900016	12694396	Bronze			2022-02-06	
J	Ciallella, JR; Ikonomovic, MD; Paljug, WR; Wilbur, YI; Dixon, CE; Kochanek, PM; Marion, DW; DeKosky, ST				Ciallella, JR; Ikonomovic, MD; Paljug, WR; Wilbur, YI; Dixon, CE; Kochanek, PM; Marion, DW; DeKosky, ST			Changes in expression of amyloid precursor protein and interleukin-1 beta after experimental traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						Alzheimer's disease; amyloid; cytokines; controlled cortical impact; head injury	HUMAN-ENDOTHELIAL-CELLS; ALZHEIMERS-DISEASE; MESSENGER-RNA; HEAD-INJURY; GROWTH-FACTOR; TRANSGENIC MICE; BETA; GENE; APP; IMMUNOREACTIVITY	There is increasing evidence linking neurodegenerative mechanisms in Alzheimer's disease (AD) and traumatic brain injury (TBI), including increased production of amyloid precursor protein (APP), and amyloid-beta (Abeta) peptide. In vitro data indicate that expression of APP may be regulated in part by the inflammatory cytokine IL-1beta To further investigate the mechanisms involved, we measured APP and IL-1beta protein levels and examined immunohistochemical localization of APP in brain tissue from rats subjected to controlled cortical impact (CCI) injury. Animals were examined at time intervals ranging from 3 h to 4 weeks after TBI. The 24-h time point revealed a dramatic increase in APP immunoreactivity, detected with both N- and C-terminal antibodies, in the hippocampus and cortex ipsilateral to injury. This finding was sustained up to 3 days post-injury. At these early time points, APP increase was particularly robust in:the White matter axonal tracts. By 14 days after injury, APP immunoreactivity was not significantly different from sham controls in,cortex but remained slightly elevated in hippocampus. Western blot data corroborated early increases in hippocampal and cortical APP in injured versus control animals. Despite profound APP changes, no Abeta deposits were observed at any time after injury. Hippocampal and cortical IL-1beta increases were even more robust, with IL-1beta levels peaking by 6 h post-injury and returning to baseline by 24-72 h. Our results demonstrate that both APP and IL-1beta,6 are rapidly elevated after injury. Because of the rapidity in the IL-1beta peak increase, it may serve a role in regulation of APP expression after TBI.	Univ Pittsburgh, Med Ctr, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Anesthesiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA		DeKosky, ST (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol, 3471 5th Ave,Ste 811, Pittsburgh, PA 15213 USA.	dekoskyst@msx.upmc.edu	Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318, NS07391] Funding Source: Medline		ABE K, 1991, NEUROSCI LETT, V125, P169, DOI 10.1016/0304-3940(91)90019-P; ALOISI F, 1992, J IMMUNOL, V149, P2358; ALTSTIEL LD, 1991, PROG NEURO-PSYCHOPH, V15, P481, DOI 10.1016/0278-5846(91)90023-T; BEESON JG, 1994, J COMP NEUROL, V342, P69, DOI 10.1002/cne.903420108; Benzing WC, 1999, NEUROBIOL AGING, V20, P581, DOI 10.1016/S0197-4580(99)00065-2; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CIALLELLA JR, 1994, J NEUROSCI RES, V37, P769, DOI 10.1002/jnr.490370611; Ciallella JR, 1999, THROMB HAEMOSTASIS, V81, P630; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; DAVISSALINAS J, 1994, J BIOL CHEM, V269, P22623; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GIULIAN D, 1988, J NEUROSCI, V8, P709; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HOFMAN FM, 1989, NEUROIMMUNE NETWORKS, P65; HUBER G, 1993, BRAIN RES, V603, P348, DOI 10.1016/0006-8993(93)91261-P; IGARASHI K, 1992, BIOCHEM BIOPH RES CO, V185, P1000, DOI 10.1016/0006-291X(92)91726-7; IKONOMOVIC MD, 1995, J COMP NEUROL, V359, P239, DOI 10.1002/cne.903590205; IVERFELDT K, 1993, P NATL ACAD SCI USA, V90, P4146, DOI 10.1073/pnas.90.9.4146; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; OHYAGI Y, 1993, MOL BRAIN RES, V18, P127, DOI 10.1016/0169-328X(93)90181-N; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; Pierce JES, 1996, J NEUROSCI, V16, P1083; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; WALLACE WC, 1995, J NEUROSCI, V15, P4896; WILLOUGHBY DA, 1992, EXP NEUROL, V118, P332, DOI 10.1016/0014-4886(92)90191-R; YANG FM, 1993, BIOCHEM BIOPH RES CO, V191, P1014, DOI 10.1006/bbrc.1993.1318; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	66	74	76	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2002	19	12					1555	1567		10.1089/089771502762300229			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	629UY	WOS:000180070700004	12542857				2022-02-06	
J	Slade, A; Tennant, A; Chamberlain, MA				Slade, A; Tennant, A; Chamberlain, MA			A randomised controlled trial to determine the effect of intensity of therapy upon length of stay in a neurological rehabilitation setting	JOURNAL OF REHABILITATION MEDICINE			English	Article						cerebrovascular accident; brain injuries; length of stay; intensity; rehabilitation; treatment outcomes; delivery of health care; rehabilitation centres; physical therapy	STROKE PATIENTS; BRAIN-INJURY; DISCHARGE; NHS	A randomised single-blind controlled trial was designed to determine whether intensity of therapy (physiotherapy and occupational therapy) shortened length of stay for patients in a rehabilitation unit. Patients were under 65, primarily with stroke, but also with other conditions such as traumatic brain injury, and multiple sclerosis. The experimental group were timetabled to receive 67% more therapy in any given week, than the control group. After controlling for confounders and case mix (as expressed by type of therapy required) patients in the experimental group showed a significant 14-day reduction in length of stay (<0.01). Concurrently average length of stay was increased for both groups by 16 days due to delays in discharge.	Univ Leeds, Rheumatol & Rehabil Res Unit, Acad Unit Musculoskeletal & Rehabil Med, Leeds LS2 9NZ, W Yorkshire, England		Slade, A (corresponding author), Univ Leeds, Rheumatol & Rehabil Res Unit, Acad Unit Musculoskeletal & Rehabil Med, 36 Clarendon Rd, Leeds LS2 9NZ, W Yorkshire, England.		Slade, Anita/M-3246-2017	Slade, Anita/0000-0003-2827-7741			Andrews K., 1991, CLIN REHABIL, V5, P5, DOI DOI 10.1177/026921559100500102; ANDRICH D, RUMM WINDOWS PROGRAM; ANDRICH D, 1991, APPL LATENT TRAIT LA, P59; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; De Weerdt W, 2002, LANCET, V359, P182, DOI 10.1016/S0140-6736(02)07461-5; DENNIS M, 1994, BMJ-BRIT MED J, V309, P1273, DOI 10.1136/bmj.309.6964.1273; Feachem RGA, 2002, BRIT MED J, V324, P135, DOI 10.1136/bmj.324.7330.135; GLADMAN JRF, 1993, J NEUROL NEUROSUR PS, V56, P960, DOI 10.1136/jnnp.56.9.960; Green J, 2002, LANCET, V359, P199, DOI 10.1016/S0140-6736(02)07443-3; Hakim EA, 1998, CLIN REHABIL, V12, P151, DOI 10.1191/026921598676265330; Hands B, 2001, J Appl Meas, V2, P101; HENNEKENS H, 1987, EPIDEMIOLOGY MED, P287; HUTCHESON G, 1999, MULTIVARIATE SOCIAL, P55; KALRA L, 1994, STROKE, V25, P821, DOI 10.1161/01.STR.25.4.821; KINNEAR P, 1997, SPSS WINDOWS MADE SI, P105; KOKMEN E, 1987, MAYO CLIN PROC, V62, P281, DOI 10.1016/S0025-6196(12)61905-3; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; Munjal RK, 2000, CLIN REHABIL, V14, P203, DOI 10.1191/026921500674191340; NORUSIS MJ, 1997, SPSS 7 5 GUIDE DATA, P445; Rasch Georg, 1980, PROBABILISTIC MODELS; Rice-Oxley M, 1999, CLIN REHABIL, V13, P7, DOI 10.1191/026921599668051623; Rudd AG, 1997, BMJ-BRIT MED J, V315, P1039, DOI 10.1136/bmj.315.7115.1039; SHAH S, 1989, J CLIN EPIDEMIOL, V42, P703, DOI 10.1016/0895-4356(89)90065-6; Shiel A, 2001, CLIN REHABIL, V15, P501, DOI 10.1191/026921501680425225; SIVENIUS J, 1985, STROKE, V16, P928, DOI 10.1161/01.STR.16.6.928; SMITH DS, 1981, BMJ-BRIT MED J, V282, P517, DOI 10.1136/bmj.282.6263.517; SMITH EV, 2000, J APPL MEASUREMENT, V3, P303; STOKES LT, 1999, CLIN REHABIL, V13, P3; Tatham, 1998, MULTIVARIATE DATA AN; Treasure T, 1998, BRIT MED J, V317, P362; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5	34	74	81	0	9	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	NOV 1	2002	34	6					260	266		10.1080/165019702760390347			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	606PL	WOS:000178742300003	12440799	gold			2022-02-06	
J	Townend, WJ; Guy, MJ; Pani, MA; Martin, B; Yates, DW				Townend, WJ; Guy, MJ; Pani, MA; Martin, B; Yates, DW			Head injury outcome prediction in the emergency department: a role for protein S-100B?	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN INJURY; RANDOMIZED CONTROLLED TRIAL; ROUTINE FOLLOW-UP; COMPUTED-TOMOGRAPHY; SERUM; SCALE; DAMAGE; SURGERY; MARKERS; EPIDEMIOLOGY	Background: Biochemical markers released after head injury may reflect the degree of brain damage, which is related to subsequent disability. If the serum level of a marker were found to be related to outcome, then earlier identification and intervention would be possible. Objective: To investigate the potential of the serum marker S-100B protein to predict the outcome after head injury. Methods: Blood samples for S-100B concentrations were taken from 148 adults within six hours of a head injury (initial Glasgow coma score 4-15). Patients were recruited from the emergency departments of four hospitals in Greater Manchester, United Kingdom. Outcome was assessed in 119 patients (80%) at one month using the extended Glasgow outcome scale (GOSE). Results: A significant inverse correlation between serum S-100B level and GOSE was found (Spearman's p = -0.349, p < 0.0001). A serum S-100B concentration of > 0.32 mug/l predicted severe disability (GOSE < 5) at one month with a sensitivity of 93% (95% confidence interval 68% to 100%), a specificity of 72% (54% to 79%), and a negative predictive value of 99% (93% to 100%). Conclusion: Serum S-100B concentration can be used in the emergency department to identify patients with head injury who are most likely to have a poor outcome at one month.	Univ Manchester, Hope Hosp, Emergency Dept, Salford M6 8HD, Lancs, England; Univ Manchester, Hope Hosp, Dept Biochem, Salford M6 8HD, Lancs, England; Univ Hosp, Dept Internal Med, Frankfurt, Germany		Townend, WJ (corresponding author), Univ Manchester, Hope Hosp, Emergency Dept, Salford M6 8HD, Lancs, England.						ALTMAN DG, 2000, STAT CONFIDENCE, P110; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hodgkinson D W, 1994, Eur J Emerg Med, V1, P9, DOI 10.1097/00063110-199403000-00003; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; *ROY COLL SURG, 1999, REP WORK PART MAN PA; Sapsed-Byrne S, 1997, PERFUSION-UK, V12, P167, DOI 10.1177/026765919701200304; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; USUI A, 1989, CLIN CHEM, V35, P1942; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	30	74	79	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2002	73	5					542	546		10.1136/jnnp.73.5.542			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	612UK	WOS:000179093700017	12397148	Green Published, Bronze			2022-02-06	
J	Benson, BW; Rose, MS; Meeuwisse, WH				Benson, BW; Rose, MS; Meeuwisse, WH			The impact of face shield use on concussions in ice hockey: a multivariate analysis	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN INJURY; HEAD; SPORT; MANAGEMENT; PLAYERS; NECK	Objective: To identify specific risk factors for concussion severity among ice hockey players wearing full face shields compared with half face shields (visors). Methods: A prospective cohort study was conducted during one varsity hockey season (1997-1998) with 642 male ice hockey players (median age 22 years) from 22 teams participating in the Canadian Inter-University Athletics Union. Half of the teams wore full face shields, and half wore half shields (visors) for every practice and game throughout the season. Team therapists and doctors recorded on structured forms daily injury, participation, and information on face shield use for each athlete. The main outcome measure was any traumatic brain injury requiring assessment or treatment by a team therapist or doctor, categorised by time lost from subsequent participation and compared by type of face shield worn. Results: Players who wore half face shields missed significantly more practices and games per concussion (2.4 times) than players who wore full face shields (4.07 sessions (95% confidence interval (CI) 3,48 to 4.74) v 1.71 sessions (95% Cl 1.32 to 2.18) respectively). Significantly more playing time was lost by players wearing half shields during practices and games, and did not depend on whether the athletes were forwards or defence, rookies or veterans, or whether the concussions were new or recurrent. In addition, players who wore half face shields and no mouthguards at the time of concussion missed significantly more playing time (5.57 sessions per concussion; 95% Cl 4.40 to 6.95) than players who wore half shields and mouthguards (2.76 sessions per concussion; 95% Cl 2.14 to 3.55). Players who wore full face shields and mouthguards at the time of concussion lost no playing time compared with 1.80 sessions lost per concussion (95% Cl 1.38 to 2.34) for players wearing full face shields and no mouthguards. Conclusions: The use of a full face shield compared with half face shield by intercollegiate ice hockey players significantly reduced the playing time lost because of concussion, suggesting that concussion severity may be reduced by the use of a full face shield.	Univ Calgary, Sport Med Ctr, Fac Kinesiol, Calgary, AB T2N 1N4, Canada; Univ Calgary, Fac Med, Calgary, AB T2N 1N4, Canada		Benson, BW (corresponding author), Univ Calgary, Sport Med Ctr, Fac Kinesiol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.						Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; BISHOP PJ, 1979, PHYSICIAN SPORTSMED, V7, P97; Brukner P, 1996, Aust Fam Physician, V25, P1445; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Cantu, 1991, Adolesc Med, V2, P141; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 1997, CLIN J SPORT MED, V7, P83, DOI 10.1097/00042752-199704000-00001; CASTALDI CR, 1993, SAFETY ICE HOCKEY, P164; CLARKE J, 1994, HEAD NECK INJURIES S, P3; Dixon J. L., 1989, SAFETY ICE HOCKEY, P207; GOODWINGERBERIC.S, 1987, CHILD NERV SYST, V3, P59; HENNEKENS CH, 1987, EPIDEMIOLOGY MED; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Jorgensen U, 1986, Br J Sports Med, V20, P7; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; MASTRANGELO FA, 1989, SAFETY ICE HOCKEY, P52; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; Parayre R., 1989, SAFETY ICE HOCKEY, P37; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rampton J, 1997, CLIN J SPORT MED, V7, P162, DOI 10.1097/00042752-199707000-00002; Tellier A, 1999, BRAIN INJURY, V13, P463; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; WALKER AE, 1994, J NEUROSURG, V81, P493, DOI 10.3171/jns.1994.81.3.0493; 1997, MMWR MORB MORTAL WKL, V46, P224	29	74	75	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	FEB	2002	36	1					27	32		10.1136/bjsm.36.1.27			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	521YU	WOS:000173869600011	11867489	Green Published, Bronze			2022-02-06	
J	Kontopoulos, V; Foroglou, N; Patsalas, J; Magras, J; Foroglou, G; Yiannakou-Pephtoulidou, M; Sofianos, E; Anastassiou, H; Tsaoussi, G				Kontopoulos, V; Foroglou, N; Patsalas, J; Magras, J; Foroglou, G; Yiannakou-Pephtoulidou, M; Sofianos, E; Anastassiou, H; Tsaoussi, G			Decompressive craniectomy for the management of patients with refractory hypertension: Should it be reconsidered?	ACTA NEUROCHIRURGICA			English	Article						diffuse brain injury; refractory post-traumatic brain oedema; decompressive craniectomy	SEVERE HEAD-INJURY; TRAUMATIC BRAIN INJURY; INTRACRANIAL HYPERTENSION; PRESSURE; EXPERIENCE	Introduction. The management of refractory post-traumatic cerebral oedema remains a frustrating endeavor for the neurosurgeon and the intensivist. Mortality and morbidity rates remain high, despite refinements in medical and pharmacological means of controlling intracranial hypertension. Method and Material. In this retrospective study we have evaluated the efficacy of decompressive craniectomy as a last resort therapy, from the data of nine patients with severe brain injury and delayed cerebral oedema (diffuse injury type III), treated between January 1997 and September 1999. The following parameters were considered: age, Glascow Coma Scale, injury severity, intracranial pressure, CT findings, pupil reaction/posturing. Follow-up period was over at least 2 years and outcome measured on the GOS. Results. Patients have been operated on post-trauma median day 3, mean age 26 +/- 9, GCS 7 +/- 3.7, mean APACHE II 16 +/- 6.4, mean ISS 27.8 +/- 16.1, mean preoperative ICP 37.7 +/- 10.0, mean postoperative ICP 18.1 +/- 16.01. Seven patients have been operated by a frontotemporoparietal approach (six of them bilateral, one unilateral) and two patients have been operated on by a bilateral subtemporal approach. Mortality rates 22%, severe disability 11%, good recovery 66%. Discussion. Patients with STBI, developing delayed intracranial hypertension caused by diffuse cerebral oedema, definitely benefit from craniectomy when current medical treatment has failed. The encouraging results of outcome in this and more recent studies, indicate the need for a multi-institutional randomized prospective study evaluating early indicators of raised ICP, timing, efficacy of treatment, operative technique and complications of decompressive craniectomy.	Aristotle Univ Thessaloniki, Dept Neurosurg, AHEPA Hosp, Hellas, Greece; AHEPA Hosp, Intens Care Unit, Hellas, Greece		Foroglou, N (corresponding author), Aristotle Univ Thessaloniki, Dept Neurosurg, AHEPA Hosp, Univ Campus, Hellas, Greece.		Foroglou, Nicolaos/AAP-4396-2020	Foroglou, Nikolaos/0000-0003-3660-6293; Patsalas, Ioannis/0000-0002-8672-9497			*APACHE 2 SCOR SYS, 1993, C GRAND TXB TRAUM AN, P71; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P527; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Clifton GL, 2001, J NEUROSURG, V95, P733; Cushing H, 1905, SURG GYNECOL OBSTET, V1, P297; DeWitt D S, 1995, New Horiz, V3, P376; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Jennett B., 1991, NIMODIPINE PHARM CLI, P225; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kunze E, 1998, ACT NEUR S, V71, P16; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LANGFITT TW, 1976, INTRACRANIAL PRESSUR, V3, P67; LUERSSEN TG, 1989, INTRACRANIAL PRESSUR, V7, P598; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHAL LF, 1988, J NEUROSURG, V89, P519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narayan RK, 2001, NEW ENGL J MED, V344, P602, DOI 10.1056/NEJM200102223440810; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Safar P, 2001, NEW ENGL J MED, V345, P66; WHITFIELD PC, 2000, BRIT J NEUROSURG, V14, P292	31	74	76	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		2002	144	8					791	796		10.1007/s00701-002-0948-z			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	588KU	WOS:000177701300011	12181688				2022-02-06	
J	Bogner, JA; Corrigan, JD; Fugate, L; Mysiw, WJ; Clinchot, D				Bogner, JA; Corrigan, JD; Fugate, L; Mysiw, WJ; Clinchot, D			Role of agitation in prediction of outcomes after traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article							CLOSED-HEAD-INJURY; BEHAVIOR SCALE; GALVESTON ORIENTATION; PRACTICAL SCALE; AMNESIA TEST; RECOVERY; REHABILITATION; MANAGEMENT; COGNITION; PATIENT	Objective: To determine the role of agitation in the prediction of traumatic brain injury rehabilitation outcomes. Design: A longitudinal study of 340 consecutive patients admitted to an acute traumatic brain injury rehabilitation unit was conducted. Outcomes under study included rehabilitation length of stay, discharge destination, functional independence at discharge (FIM (TM) instrument), productivity at 1-yr follow-up, and life satisfaction at 1-yr follow-up (Satisfaction with Life Scale). Results: Univariate analyses suggested that the presence of agitation in rehabilitation is predictive of a longer length of stay and decreased functional independence in the cognitive realm at discharge. In addition, individuals who exhibit agitation at any time during rehabilitation are less likely to be discharged to a private residence. However, multivariate analyses indicated that cognitive functioning at admission to rehabilitation (FIM cognitive) mediates the relationship between the presence of agitation and length of rehabilitation, as well as between agitation and FIM cognitive at discharge. Similar results were found when discharge residence was the dependent variable; however, agitation also contributed some unique variance to the prediction. Lower cognitive functioning at admission to rehabilitation was associated with the occurrence of agitation during rehabilitation, longer length of stay, lower cognitive functioning at discharge, and a decreased likelihood that an individual would be discharged to a private residence. Conclusions: The results of the multivariate analyses support the contention that agitation and cognition are intimately related, with the long-term effects of the former being at least partially driven by the latter. These findings support the importance of systematically monitoring both agitation and cognition when applying interventions to reduce agitation.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA		Bogner, JA (corresponding author), 480 W 9th Ave, Columbus, OH 43210 USA.		Bogner, Jennifer/E-2773-2011; Corrigan, John D./E-2921-2011; Mysiw, Walter/E-3724-2011	Clinchot, Daniel/0000-0002-2810-7227			Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Azouvi P, 1999, BRAIN INJURY, V13, P797, DOI 10.1080/026990599121188; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; BOGNER J, 1995, NEUROREHABILITATION, V5, P293, DOI 10.3233/NRE-1995-5403; Bogner JA, 1999, J HEAD TRAUMA REHAB, V14, P91, DOI 10.1097/00001199-199902000-00012; Bogner JA, 2000, J HEAD TRAUMA REHAB, V15, P656, DOI 10.1097/00001199-200002000-00005; BOYESON MG, 1994, J HEAD TRAUMA REHAB, V9, P78, DOI 10.1097/00001199-199409000-00007; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; CANTINI E, 1992, Brain Injury, V6, P193, DOI 10.3109/02699059209029659; CASSIDY JW, 1994, J HEAD TRAUMA REHAB, V9, P43, DOI 10.1097/00001199-199409000-00005; COOK L, 1994, ARCH PHYS MED REHAB, V75, P390, DOI 10.1016/0003-9993(94)90160-0; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P262; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; Dietz M A, 1991, J Stroke Cerebrovasc Dis, V1, P37, DOI 10.1016/S1052-3057(11)80018-2; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDSTEIN LB, 1993, J NEURAL TRANSP PLAS, V4, P175, DOI 10.1155/NP.1993.175; GOLDSTEIN LB, 1990, STROKE, V21, P179; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HASHMI FH, 1998, ANN LONG TERM CARE, V6, P1; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; JACKSON RD, 1989, ARCH PHYS MED REHAB, V70, P33; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; KRAUS J, 1999, REHABILITATION ADULT; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Montgomery P, 1997, Rehabil Nurs, V22, P20; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; MYSIW WJ, 1988, AM J PHYS MED REHAB, V67, P29, DOI 10.1097/00002060-198802000-00006; Mysiw WJ., 1990, J HEAD TRAUMA REHAB, V5, P65; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; ROWLAND TR, 1992, ARCH PHYS MED REHAB, V73, P9653; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Silver J M, 1993, NeuroRehabilitation, V3, P15, DOI 10.3233/NRE-1993-3204; *STAT U NEW YORK B, 1998, GUID UN DAT SET MED; SUTTON RL, 1987, J HEAD TRAUMA REHAB, V2, P50; TEASDALE G, 1974, LANCET, V2, P81; TERI L, 1992, ALZ DIS ASSOC DIS, V6, P77, DOI 10.1097/00002093-199206020-00003; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; Zafonte RD, 1997, J HEAD TRAUMA REHAB, V12, P78, DOI 10.1097/00001199-199704000-00008	52	74	74	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	SEP	2001	80	9					636	644		10.1097/00002060-200109000-00002			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	464ZW	WOS:000170564100002	11523965				2022-02-06	
J	McGeorge, P; Phillips, LH; Crawford, JR; Garden, SE; Della Sala, S; Milne, AB; Hamilton, S; Callender, JS				McGeorge, P; Phillips, LH; Crawford, JR; Garden, SE; Della Sala, S; Milne, AB; Hamilton, S; Callender, JS			Using virtual environments in the assessment of executive dysfunction	PRESENCE-TELEOPERATORS AND VIRTUAL ENVIRONMENTS			English	Article							TRAUMATIC BRAIN INJURY; REHABILITATION; REALITY; TECHNOLOGY; MEMORY; PEOPLE; DAMAGE	A study is reported into the role of virtual environments in the assessment of patients with executive dysfunction. Five patients and five matched controls entered the study. The patients did not differ significantly from normative values on the standard executive dysfunction measure, the Behavioural Assessment of the Dysexecutive Syndrome battery (Wilson, Alderman, Burgess, Emslie, & Evans, 1996); however, care staff reported the patients had problems planning. Patients and controls undertook both real and virtual environment multiple-errand planning tasks. The patients completed significantly fewer errands, and produced significantly worse plans than did controls in both the real and virtual environments. There was a significant correlation between performance in the real and virtual environments. The results suggest that virtual environments may provide a valid means of assessing planning impairments and that there may be patients with executive dysfunction (specifically planning deficits) that may not be detected by the currently available standardized tests.	Univ Aberdeen, Dept Psychol, Neuropsychol Res Grp, Old Aberdeen AB24 2UB, Scotland		McGeorge, P (corresponding author), Univ Aberdeen, Dept Psychol, Neuropsychol Res Grp, Old Aberdeen AB24 2UB, Scotland.		Crawford, John R/A-4165-2008; Phillips, Louise H/A-7952-2008; McGeorge, Peter/A-4233-2008	Crawford, John R/0000-0003-3403-3428; Phillips, Louise H/0000-0003-1005-8567; Phillips, Louise/0000-0002-0988-3028			Alderman N, 1996, NEUROPSYCHOL REHABIL, V6, P161, DOI 10.1080/713755505; Alderman N., 1996, BADS BEHAV ASSESSMEN; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; BENTON A L, 1978, Archives of Neurology, V35, P364; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Crawford JR, 1998, NEUROPSYCHOL REHABIL, V8, P209, DOI 10.1080/713755574; CRAWFORD JR, 1996, BLACKWELL DICT NEURO, P108; Cromby J. J., 1996, P 1 EUR C DIS VIRT R, P103; Cromby JJ, 1996, J INTELL DISABIL RES, V40, P489, DOI 10.1046/j.1365-2788.1996.805805.x; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Heaton R.K., 1981, WISCONSIN CARD SORTI; Hersen M., 1998, COMPREHENSIVE CLIN P, VVol. 7, P133; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; PARKER DM, 1992, HDB NEUROPSYCHOLOGIC, P267; Penfield W, 1935, BRAIN, V58, P115, DOI 10.1093/brain/58.1.115; Phillips L. H, 1997, METHODOLOGY FRONTAL, P191; PHILLIPS LH, 1997, GENERATIONS REV J BR, V7, P14; PONSFORD JL, 1996, RECOVERY TRAUMATIC B; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; ROSE FD, 1994, MED SCI RES, V22, P82; Rose FD, 1996, CURR OPIN NEUROL, V9, P461, DOI 10.1097/00019052-199612000-00012; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Tinson D J, 1989, Int Disabil Stud, V11, P45; WEHMAN P, 1996, RECOVERY TRAUMATIC B; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; Wilson B., 1999, BEHAVIOURAL INATTENT BEHAV INATTENTION TE; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson PN, 1997, DISABIL REHABIL, V19, P213, DOI 10.3109/09638289709166530	33	74	74	2	14	M I T PRESS	CAMBRIDGE	FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA	1054-7460			PRESENCE-TELEOP VIRT	Presence-Teleoper. Virtual Env.	AUG	2001	10	4					375	383		10.1162/1054746011470235			9	Computer Science, Cybernetics; Computer Science, Software Engineering	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Computer Science	492AT	WOS:000172143800004					2022-02-06	
J	McIntosh, AS; McCrory, P				McIntosh, AS; McCrory, P			Impact energy attenuation performance of football headgear	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						football; headgear; helmet; head; concussion	INJURY	Objectives-Commercially available football head protectors were tested to determine their impact energy attenuation performance and ability to reduce the likelihood of concussion. Methods-Prospective study using standardised impact test methods with both rigid (magnesium) and Hybrid III headforms. Results-Eight commercially available head protectors from six manufacturers were tested. The magnitude of the headform accelerations increased as the drop height was increased, ranging ti om a minimum of 64 g from a height of 0.2 m to a maximum of 1132 g from a height of 0.6 m. The head injury criterion and maximum headform acceleration values followed a similar trend. A steep increase was noted in the magnitude of maximum headform acceleration and head injury criterion when the drop height was increased from 0.4 to 0.5 m. This indicates that the foam material was completely compressed at an impact energy above about 20 J and therefore offers little protection against impacts of greater severity. Repeated tests using a drop height of 0.3 m showed that some helmets exhibit a "memory" effect, whereby impact performance is reduced by up to 50% with repeated impacts. Conclusions-Laboratory tests indicate that current commercially available football headgear performance will not reduce the likelihood of concussion. The absence of internationally recognised standards for soft headgear designed to ameliorate concussion is a major deficiency in sports injury prevention.	Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia; Univ Melbourne, Dept Neurol, Austin & Repatriat Med Ctr, Heidelberg, Vic 3084, Australia; Olymp Pk Sports Med Ctr, Melbourne, Vic 3004, Australia		McIntosh, AS (corresponding author), Univ New S Wales, Sch Safety Sci, Sydney, NSW 2052, Australia.		McCrory, Paul/Q-8688-2019				*AUSTR S, 1999, 251211 ASNZS; *AUSTR S, 1998, 25122 ASNZS; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GERRARD DF, 1994, BRIT J SPORT MED, V28, P229, DOI 10.1136/bjsm.28.4.229; HARDY WN, 1993, ACCIDENTAL INJURY BI, P12; *IRB, 1996, LAWS GAM RUGB; McCrory P, 1998, SPORTS NEUROLOGY, P441; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McIntosh AS, 1993, 37 STAPP CAR CRASH C, P43; McIntosh AS, 1995, 39 STAPP CAR CRASH C, P111; NEWMAN J, 1978, P AM ASS AUT MED 22, P279; OMMAYA A, 1990, SPORTS NEUROLOGY, P84; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Wilson BD, 1998, SPORTS MED, V25, P333, DOI 10.2165/00007256-199825050-00005	17	74	74	0	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	OCT	2000	34	5					337	341		10.1136/bjsm.34.5.337			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	363XR	WOS:000089863400009	11049142	Green Published, Bronze			2022-02-06	
J	Dempsey, RJ; Baskaya, MK; Dogan, A				Dempsey, RJ; Baskaya, MK; Dogan, A			Attenuation of brain edema, blood-brain barrier breakdown, and injury volume by ifenprodil, a polyamine-site N-methyl-D-aspartate receptor antagonist, after experimental traumatic brain injury in rats	NEUROSURGERY			English	Article						blood-brain barrier; brain edema; ifenprodil; NMDA receptors; polyamines; traumatic brain injury	EXCITATORY AMINO-ACIDS; FOCAL CEREBRAL-ISCHEMIA; NMDA RECEPTOR; NITRIC-OXIDE; ORNITHINE DECARBOXYLASE; GLUTAMATE NEUROTOXICITY; TRANSIENT ISCHEMIA; GLUCOSE USE; RELEASE; NEURONS	OBJECTIVE: Traumatic brain injury (TBI) has been shown to induce a significant change in polyamine metabolism. Polyamines and polyamine-dependent calcium influx play an important role in mediating the effects of excitotoxic amino acids at the N-methyl-D-aspartate (NMDA) receptor site. We studied the effects of ifenprodil, known as a noncompetitive inhibitor of polyamine sites at the NMDA receptor, on brain edema formation, blood-brain barrier breakdown, and volume of injury after TBI. METHODS: Experimental TBI was induced in Sprague-Dawley rats by a controlled cortical impact device, functioning at a velocity of 3 m/s to produce a 2-mm deformation. Ifenprodil or saline (10 mg/kg) was injected intraperitoneally immediately after the cortical impact injury and then every 90 minutes until 6 hours after TBI. Blood-brain barrier breakdown was evaluated quantitatively 6 hours after injury by fluorometric assay of Evans blue extravasation. Brain water content, an indicator of brain edema, was measured with the wet-dry method 24 hours after TBI. Injury volume was quantitated from the brain slices stained with 2% cresyl violet solution 7 days after TBI. RESULTS: Blood-brain barrier breakdown was significantly lower in the traumatic cortex of the ifenprodil-treated group than in the saline-treated group (84.4 +/- 26.8 mu g/g versus 161.8 +/- 27 mu g/g, respectively, P < 0.05). Brain edema was significantly reduced in the cortex of the ifenprodil-treated group relative to that in the saline-treated group (80.9 +/- 0.5% versus 82.4 +/- 0.6% respectively, P < 0.05). Ifenprodil treatment reduced injury volume significantly (14.9 +/- 8.1 mm(3) versus 24.4 +/- 6.7 mm(3), P < 0.05). CONCLUSION: The polyamine-site NMDA receptor antagonist ifenprodil affords significant neuroprotection in a controlled cortical impact brain injury model and may hold promise for the discovery and treatment of the mechanism of delayed neurological deficits after TBI.	Louisiana State Univ, Hlth Sci Ctr, Dept Neurosurg, Med Ctr, Shreveport, LA 71130 USA; Univ Wisconsin, Dept Neurol Surg, Madison, WI USA		Baskaya, MK (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Neurosurg, Med Ctr, 1501 Kings Highway,POB 33932, Shreveport, LA 71130 USA.		Dogan, Aclan/AAF-8305-2019				ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Badolo L, 1998, EUR J PHARMACOL, V342, pR1, DOI 10.1016/S0014-2999(97)01601-4; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Baskaya MFK, 1996, NEUROSURGERY, V38, P140; Baskaya MK, 1997, NEUROSURGERY, V40, P364; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; CALDWELL M, 1994, EUR J PHARMACOL, V260, P191, DOI 10.1016/0014-2999(94)90337-9; CARRON C, 1971, ARZNEI-FORSCHUNG, V21, P1992; CARTER C, 1989, EUR J PHARMACOL, V164, P611, DOI 10.1016/0014-2999(89)90275-6; CARTER C, 1988, J PHARMACOL EXP THER, V247, P1222; CAVAZZUTI M, 1987, J CEREBR BLOOD F MET, V7, P806, DOI 10.1038/jcbfm.1987.138; CHOI DW, 1985, NEUROSCI LETT, V58, P293, DOI 10.1016/0304-3940(85)90069-2; CHOI DW, 1987, J NEUROSCI, V7, P369; CUDENNEC A, 1994, BRAIN RES, V664, P41, DOI 10.1016/0006-8993(94)91951-8; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; DUVAL D, 1992, NEUROSCI LETT, V137, P193, DOI 10.1016/0304-3940(92)90402-S; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GARTHWAITE G, 1986, NEUROSCIENCE, V18, P437, DOI 10.1016/0306-4522(86)90164-8; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KERWIN JF, 1994, MED RES REV, V14, P23, DOI 10.1002/med.2610140103; KURUMAJI A, 1989, BRAIN RES, V496, P268, DOI 10.1016/0006-8993(89)91074-3; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Morley P, 1998, J CEREBR BLOOD F MET, V18, P396, DOI 10.1097/00004647-199804000-00008; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; REYNOLDS IJ, 1989, MOL PHARMACOL, V36, P758; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN SM, 1985, J NEUROSCI, V5, P1483; SCHOEMAKER H, 1990, EUR J PHARMACOL, V176, P249, DOI 10.1016/0014-2999(90)90539-I; SHALABY IA, 1992, J PHARMACOL EXP THER, V260, P925; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SPROSEN TS, 1990, EUR J PHARMACOL, V179, P477, DOI 10.1016/0014-2999(90)90193-A; SWAN JH, 1990, J CEREBR BLOOD F MET, V10, P343, DOI 10.1038/jcbfm.1990.63; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; WILLIAMS K, 1991, LIFE SCI, V48, P469, DOI 10.1016/0024-3205(91)90463-L; YOUNG AR, 1981, J CEREBR BLOOD F MET, V1, P117, DOI 10.1038/jcbfm.1981.12	45	74	83	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	AUG	2000	47	2					399	404		10.1097/00006123-200008000-00024			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	339WZ	WOS:000088502000066	10942013				2022-02-06	
J	Quaresima, V; Sacco, S; Totaro, R; Ferrari, M				Quaresima, V; Sacco, S; Totaro, R; Ferrari, M			Noninvasive measurement of cerebral hemoglobin oxygen saturation using two near infrared spectroscopy approaches	JOURNAL OF BIOMEDICAL OPTICS			English	Article						cerebral oximetry; near infrared spectroscopy; spatially resolved spectroscopy; oxygenation; tissue oxygen saturation; noninvasive measurements	SPATIALLY-RESOLVED SPECTROSCOPY; CLOSED-HEAD INJURY; CARDIOPULMONARY BYPASS; CAROTID ENDARTERECTOMY; BULB OXIMETRY; BRAIN; INVOS-3100; PHANTOM; SPECTROPHOTOMETERS; MONITORS	Spatially resolved spectroscopy (SRS) is a new near infrared spectroscopy (NIRS) method that, using the multi-distance approach, measures local cerebral cortex hemoglobin oxygen saturation [J. Matcher, P. Kirkpatrick, K. Nahid, M. Cope, and D. T. Delpy, Proc. SPIE 2389, 486-495 (1995)], Using a conventional continuous wave NIRS photometer, cerebral venous oxygen saturation (SvO(2)) can be calculated from oxyhemoglobin and total hemoglobin rise induced by partial occlusion of jugular vein [C. E. Elwell, S. J. Matcher, L. Tyszczuk, J. H. Meek, and D. T. Delpy, Adv. Exp. Med. Biol. 411, 453-460 (1997)]. The aim of this study was to compare direct measurements of forehead tissue oxygenation index (TOI) with the calculated SvO(2) during venous occlusion in 16 adult volunteers using a clinical two-channel SRS oximeter (NIRO-300). Measured TOI and calculated SvO(2) values of either right or left forehead did not significantly differ. A good agreement between the two NIRS methods was also demonstrated. On 16 other subjects, no significant differences were found between the right and left forehead TOI values measured simultaneously, and between the TOI values measured by channel 1 or 2 on the same side. The results confirm that cerebral cortex hemoglobin oxygen saturation, measured directly by the SRS method, reflects predominantly the saturation of the intracranial venous compartment of circulation. (C) 2000 Society of Photo-Optical instrumentation Engineers. [S1083-3668(00)00802-9].	Univ Aquila, Dept Biomed Technol, I-67100 Laquila, Italy; Univ Aquila, Dept Neurol, I-67100 Laquila, Italy		Quaresima, V (corresponding author), Univ Aquila, Dept Biomed Technol, Via Vetoio, I-67100 Laquila, Italy.	vale@univaq.it	Ferrari, Marco/AAF-3486-2019; Quaresima, Valentina/AAQ-7387-2021; Sacco, Simona/I-5253-2012	Sacco, Simona/0000-0003-0651-1939; quaresima, valentina/0000-0001-9884-0304; FERRARI, Marco/0000-0002-3041-2917			Al-Rawi PG, 1999, J BIOMED OPT, V4, P208, DOI 10.1117/1.429911; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Buunk G, 1998, ANAESTHESIA, V53, P13, DOI 10.1046/j.1365-2044.1998.00263.x; Carlin RE, 1998, J CLIN ANESTH, V10, P109, DOI 10.1016/S0952-8180(97)00252-3; CHANCE B, 1988, P NATL ACAD SCI USA, V85, P4971, DOI 10.1073/pnas.85.14.4971; CHANCE B, 1997, PHILOS T R SOC LON B, V352, P647; Colier W N, 1995, Acta Anaesthesiol Scand Suppl, V107, P101; Duncan A, 1996, PEDIATR RES, V39, P889, DOI 10.1203/00006450-199605000-00025; Elwell CE, 1997, ADV EXP MED BIOL, V411, P453; Fantini S, 1999, PHYS MED BIOL, V44, P1543, DOI 10.1088/0031-9155/44/6/308; FERRARI M, 1992, J PHOTOCH PHOTOBIO B, V16, P141, DOI 10.1016/1011-1344(92)80005-G; FERRARI M, 1989, AM J PHYSIOL, V256, pH1493, DOI 10.1152/ajpheart.1989.256.5.H1493; FIRBANK M, 1994, PHYS MED BIOL, V39, P1509, DOI 10.1088/0031-9155/39/9/015; FIRBANK M, 1993, PHYS MED BIOL, V38, P847, DOI 10.1088/0031-9155/38/6/015; Gomersall CD, 1998, ANAESTH INTENS CARE, V26, P548, DOI 10.1177/0310057X9802600512; Grubhofer G, 1999, ACTA ANAESTH SCAND, V43, P470, DOI 10.1034/j.1399-6576.1999.430417.x; Henson LC, 1998, ANESTHESIOLOGY, V88, P58, DOI 10.1097/00000542-199801000-00011; Kurth CD, 1995, PHYS MED BIOL, V40, P2079, DOI 10.1088/0031-9155/40/12/006; KURTH CD, 1993, J CLIN MONITOR, V9, P163, DOI 10.1007/BF01617023; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; Litscher G, 1998, BIOMED TECH, V43, P133, DOI 10.1515/bmte.1998.43.5.133; Madsen PL, 1999, PROG NEUROBIOL, V58, P541, DOI 10.1016/S0301-0082(98)00093-8; MATCHER SJ, 1995, P SOC PHOTO-OPT INS, V2359, P486; McKeating EG, 1997, ANAESTHESIA, V52, P136, DOI 10.1111/j.1365-2044.1997.18-az015.x; Misra M, 1998, NEUROL RES, V20, P137; Nielsen HB, 1999, AM J PHYSIOL-HEART C, V277, pH1045, DOI 10.1152/ajpheart.1999.277.3.H1045; Samra SK, 1996, STROKE, V27, P49, DOI 10.1161/01.STR.27.1.49; Sapire KJ, 1997, CRIT CARE MED, V25, P1655, DOI 10.1097/00003246-199710000-00014; Suzuki S, 1999, P SOC PHOTO-OPT INS, V3597, P582, DOI 10.1117/12.356862; Ter Minassian A, 1999, ANESTHESIOLOGY, V91, P985; Totaro R, 1999, CEREBROVASC DIS, V9, P142, DOI 10.1159/000015943; Totaro R, 1998, CLIN SCI, V95, P497, DOI 10.1042/CS19980122; YOXALL CW, 1995, PEDIATR RES, V38, P319, DOI 10.1203/00006450-199509000-00008	33	74	74	0	11	SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	1083-3668	1560-2281		J BIOMED OPT	J. Biomed. Opt.	APR	2000	5	2					201	205		10.1117/1.429987			5	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	325AU	WOS:000087654800011	10938784				2022-02-06	
J	Kirkpatrick, AW; Chun, R; Brown, R; Simons, RK				Kirkpatrick, AW; Chun, R; Brown, R; Simons, RK			Hypothermia and the trauma patient	CANADIAN JOURNAL OF SURGERY			English	Article							RETROHEPATIC VENOUS INJURY; DAMAGE CONTROL SURGERY; CIRCULATORY ARREST; ACCIDENTAL HYPOTHERMIA; MILD HYPOTHERMIA; ABBREVIATED LAPAROTOMY; MASSIVE TRANSFUSION; HEMORRHAGIC-SHOCK; ABDOMINAL-TRAUMA; DEEP HYPOTHERMIA	Hypothermia has profound effects on every system in the body, causing an overall slowing of enzymatic reactions and reduced metabolic requirements. Hypothermic, acutely injured patients with multisystem trauma have adverse outcomes when compared with normothermic control patients. Trauma patients are inherently predisposed to hypothermia from a variety of intrinsic and iatrogenic causes, Coagulation and cardiac sequelae are the most pertinent physiological concerns. Hypothermia and coagulopathy often mandate a simplified approach to complex surgical problems. A modification of traditional classification systems of hypothermia, applicable to trauma patients is suggested. There are few controlled investigations, but clinical opinion strongly supports the active prevention of hypothermia in the acutely traumatized patient. Preventive measures are simple and inexpensive, but the active reversal of hypothermia is much more complicated, often invasive and controversial. The ideal method of rewarming is unclear but must be individualized to the patient and is institution specific. An algorithm reflecting newer approaches to traumatic injury and technical advances in equipment and techniques is suggested. Conversely, hypothermia has selected clinical benefits when appropriately used in cases of trauma. Severe hypothermia has allowed remarkable survivals in the course of accidental circulatory arrest. The selective application of mild hypothermia in severe traumatic brain injury is an area with promise, Deliberate circulatory arrest with hypothermic cerebral protection has also been used for seemingly unrepairable injuries and is the focus of ongoing research.	Vancouver Hosp & Hlth Sci Ctr, Sect Trauma Serv, Vancouver, BC V5Z 1L7, Canada; Univ Toronto, Anesthesia Training Program, Toronto, ON, Canada		Kirkpatrick, AW (corresponding author), Vancouver Hosp & Hlth Sci Ctr, Sect Trauma Serv, 3rd Floor,855 W 10th Ave, Vancouver, BC V5Z 1L7, Canada.	andykirk@istar.ca					ADAMS F, 1939, GENIUINE WORKS HIPPO, P145; *AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP P; ANTRETTER H, 1994, ANN THORAC SURG, V58, P1786, DOI 10.1016/0003-4975(94)91698-5; ANTRETTER H, 1994, NEW ENGL J MED, V330, P219, DOI 10.1056/NEJM199401203300318; BAUMGARTNER F, 1995, J TRAUMA, V39, P671, DOI 10.1097/00005373-199510000-00009; Bellamy R, 1996, CRIT CARE MED, V24, pS24; BERNABEI AF, 1992, J TRAUMA, V33, P835, DOI 10.1097/00005373-199212000-00007; BEST R, 1985, AM J EMERG MED, V3, P48, DOI 10.1016/0735-6757(85)90013-0; BICKEL KD, 1998, CURRENT SURG THERAPY, P1018; Block EFJ, 1999, CRIT CARE MED, V27, pA172, DOI 10.1097/00003246-199901001-00516; BRITT LD, 1991, SURG CLIN N AM, V71, P345; Burch JM, 1997, SURG CLIN N AM, V77, P779, DOI 10.1016/S0039-6109(05)70583-1; BURCH JM, 1992, ANN SURG, V215, P476, DOI 10.1097/00000658-199205000-00010; Capone A, 1996, J TRAUMA, V40, P388, DOI 10.1097/00005373-199603000-00011; CARRILLO C, 1993, J TRAUMA, V34, P233, DOI 10.1097/00005373-199302000-00009; CHIPPAUX C, 1954, Int Rec Med Gen Pract Clin, V167, P328; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COLLINS JA, 1974, SURGERY, V75, P274; Cullinane D C, 1997, Tenn Med, V90, P323; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Farmer J. Christopher, 1997, P1451; FERRARA A, 1990, AM J SURG, V160, P515, DOI 10.1016/S0002-9610(05)81018-9; FISCHER RP, 1996, TRAUMA, P951; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; Gentilello L M, 1995, J Intensive Care Med, V10, P5; Gentilello LM, 1997, ANN SURG, V226, P439, DOI 10.1097/00000658-199710000-00005; Giesbrecht GG, 1998, RESUSCITATION, V38, P59; Grahn D, 1998, J APPL PHYSIOL, V85, P1643, DOI 10.1152/jappl.1998.85.5.1643; Grant P, 1998, SCOT MED J, V43, P36, DOI 10.1177/003693309804300202; GREGORY JS, 1991, J TRAUMA, V31, P1247, DOI 10.1097/00005373-199109000-00008; GROSSO MA, 1991, J TRAUMA, V31, P395, DOI 10.1097/00005373-199103000-00016; GUBLER KD, 1994, J TRAUMA, V36, P847, DOI 10.1097/00005373-199406000-00015; Hamilton SM, 1996, CAN J SURG, V39, P11; HARNETT RM, 1983, AVIAT SPACE ENVIR MD, V54, P487; HARTMAN AR, 1991, J TRAUMA, V31, P1310, DOI 10.1097/00005373-199109000-00017; HAYWARD JS, 1975, AVIAT SPACE ENVIR MD, V46, P1236; HELM M, 1997, ACTA ANAESTHESIOL S, V111, pS44; HERNANDEZ E, 1993, NEPHRON, V63, P214; Hirshberg A, 1997, SURG CLIN N AM, V77, P813, DOI 10.1016/S0039-6109(05)70586-7; Josephs JD, 1998, CRIT CARE MED, V26, P1944, DOI 10.1097/00003246-199812000-00009; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; Lazar DK, 1997, NEW ENGL J MED, V337, P1545, DOI 10.1056/NEJM199711203372111; LEDINGHAM IM, 1980, BRIT MED J, V280, P1102, DOI 10.1136/bmj.280.6222.1102; LUNA GK, 1987, J TRAUMA, V27, P1014, DOI 10.1097/00005373-198709000-00010; MARELLI D, 1995, J TRAUMA, V38, P609, DOI 10.1097/00005373-199504000-00024; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marion DW, 1996, CRIT CARE MED, V24, pS81; Martin RR, 1997, SURG CLIN N AM, V77, P929, DOI 10.1016/S0039-6109(05)70595-8; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; Mattox KL, 1997, SURG CLIN N AM, V77, P753, DOI 10.1016/S0039-6109(05)70581-8; MENDEZ C, 1998, CURRENT SURG THERAPY, P928; Moore EE, 1996, AM J SURG, V172, P405, DOI 10.1016/S0002-9610(96)00216-4; ORKIN F, 1996, COMPLICATIONS ANESTH, P131; PATT A, 1988, SURG CLIN N AM, V68, P775; PRUECKER S, 1999, CRIT CARE MED, V27, pS105; Robertson CL, 1999, CRIT CARE MED, V27, pA52, DOI 10.1097/00003246-199901001-00090; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; RONCO JJ, 1993, JAMA-J AM MED ASSOC, V270, P1724, DOI 10.1001/jama.270.14.1724; ROSOMOFF HL, 1955, AM J PHYSIOL, V183, P19, DOI 10.1152/ajplegacy.1955.183.1.19; SAFAR P, 1999, CRIT CAR S 199 TECHN, P473; SCHALLER MD, 1990, JAMA-J AM MED ASSOC, V264, P1842, DOI 10.1001/jama.264.14.1842; SCHUBERT A, 1995, J NEUROSURG ANESTH, V7, P139, DOI 10.1097/00008506-199504000-00021; SEDLAK SK, 1995, INT J TRAUMA NURS, V1, P199; Seigler RS, 1998, CRIT CARE MED, V26, P2016, DOI 10.1097/00003246-199812000-00033; Sessler DI, 1994, ANESTHESIA, P1363; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SORI AJ, 1987, AM SURGEON, V53, P706; Stedman TL, 1982, STEDMANS MED DICT; STEINEMANN S, 1990, J TRAUMA, V30, P200, DOI 10.1097/00005373-199002000-00011; STONE HH, 1983, ANN SURG, V197, P532, DOI 10.1097/00000658-198305000-00005; STONER HB, 1969, BRIT J EXP PATHOL, V50, P125; TERASAKI H, 1999, CRIT CAR S 1999 TECH, P481; TERNDRUP TE, 1992, ANN EMERG MED, V21, P1483, DOI 10.1016/S0196-0644(05)80067-8; TISHERMAN SA, 1991, J TRAUMA, V31, P1051, DOI 10.1097/00005373-199131080-00002; TISHERMAN SA, 1999, CRITICAL CARE S 1999, P485; TISHERMAN T, 1992, CRIT CARE MED, V4, pS41; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; Walpoth BH, 1997, NEW ENGL J MED, V337, P1500, DOI 10.1056/NEJM199711203372103; Walpoth BH, 1998, NEW ENGL J MED, V338, P1161; Weinberg AD, 1998, RESUSCITATION, V36, P101, DOI 10.1016/S0300-9572(98)00004-5; WILSON RF, 1987, AM SURGEON, V53, P410; ZELL SC, 1985, ANN EMERG MED, V14, P339, DOI 10.1016/S0196-0644(85)80101-3	83	74	77	0	2	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0008-428X	1488-2310		CAN J SURG	Can. J. Surg.	OCT	1999	42	5					333	343					11	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	243ZM	WOS:000083027400008	10526517				2022-02-06	
J	Brooks, J; Fos, LA; Greve, KW; Hammond, JS				Brooks, J; Fos, LA; Greve, KW; Hammond, JS			Assessment of executive function in patients with mild traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; mild traumatic brain injury; neuropsychology; cognitive testing; executive function	MINOR HEAD-INJURY; STEM RESPONSES; SYMPTOMS; POPULATION; CONCUSSION; RECOVERY; TASK	Background: The nature of functional deficit after mild traumatic brain injury (TBI) defined by Glasgow Coma Score of 13-15 is not fully described. This study explored the sensitivity of several neuropsychological tests to identify sequelae of mild traumatic brain injury (TBI). Methods: Eleven adult patients with mild TBI admitted to a Level 1 trauma center were studied. The battery of tests included the Wechsler Intelligence Scale for Children-Revised: Mazes Subtest, Trails A and B, the Boston Naming Test, The Multilingual Aphasia Examination: Controlled Oral Word Association Test, and the Paced Auditory Serial Addition Task. Results: Control subjects performed significantly better than patients with mild TBI on Trails A and B, the Controlled Oral Word Association Test, and Paced Auditory Serial Addition Task (subtests 2-4). No significant differences in performances between patients and controls was found for the Wechsler Intelligence Scale for Children-Revised: Mazes Subtest, Boston Naming Test, and Paced Auditory Serial Addition Task Subtest Conclusion: The results suggest that tests of specific frontal lobe executive functions are valuable in diagnosing and monitoring recovery from mild TBI.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ 08903 USA; Univ New Orleans, New Orleans, LA 70148 USA		Hammond, JS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, 1 Robert Wood Johnson Pl,POB 19, New Brunswick, NJ 08903 USA.						Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; *AM PSYCH ASS, 1992, AM PSYCH, V0047, P01597, DOI DOI 10.1037/0003-066X.47.12.1597; BARON JB, 1979, INT J NEUROL, V12, P237; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOHNEN N, 1990, HORM METAB RES, V22, P508, DOI 10.1055/s-2007-1004958; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; CLARK E, 1992, CURR PSYCHOL RES REV, V11, P21, DOI 10.1007/BF02686825; Cullum C, 1991, FORENSIC NEUROPSYCHO, P141; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hamster K., 1983, MULTILINGUAL APHASIA; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1982, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; MENDELSON G, 1982, MED J AUSTRALIA, V2, P132, DOI 10.5694/j.1326-5377.1982.tb124267.x; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MINDERHOUD JM, 1984, TRAUMATISCHE HERSENT; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Reitan RM, 1985, HALSTEADREITAN NEURO; REZAI K, 1993, ARCH NEUROL-CHICAGO, V50, P636, DOI 10.1001/archneur.1993.00540060066020; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P670; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; SYMONDS C, 1962, LANCET, V1, P1; TAYLOR AR, 1966, LANCET, V2, P178; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D., 1974, WISCR MANUAL WECHSLE; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	34	74	75	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	1999	46	1					159	163		10.1097/00005373-199901000-00027			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	160DE	WOS:000078214400036	9932700				2022-02-06	
J	Giacino, JT; Cicerone, KD				Giacino, JT; Cicerone, KD			Varieties of deficit unawareness after brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anosognosia; brain injury; deficit awareness; feedback; rehabilitation outcome	IMPLICIT KNOWLEDGE; ANOSOGNOSIA; CONFABULATION; HYPOTHESIS; AWARENESS; STROKE	The failure to recognize the existence of disease is known as anosognosia, This article provides a brief discussion of the evolution of this concept and reviews some qualitative differences in the manner in which the disavowal of neurogenic impairment is expressed. Theoretical explanations for the unawareness of deficit after neurologic illness include motivational-symbolic, cognitive subsystem, and supraordinate system theories. Observations from a clinically derived, structured awareness interview are presented, suggesting three factors that may underlie patients' apparent lack of awareness of deficits after traumatic brain injury. These include diminished awareness of deficits secondary to impaired cognition, especially memory and reasoning deficits; psychological reactance and denial of deficits; and a relatively 'pure" inability to recognize areas of impaired functioning as a direct consequence of brain injury. The causes of unawareness are likely to be complex and multiply determined in any given patient, although it may be possible to identify primary, secondary, and even tertiary contributions according to specific behavioral and phenomenological characteristics. The ability of patients to modify their perceptions and acknowledgment of deficits after objective feedback may have particular diagnostic value and clinical utility in this regard.	JFK Johnson Rehabil Inst, Edison, NJ USA; Seton Hall Univ, Sch Grad Med Educ, Edison, NJ USA		Giacino, JT (corresponding author), 2048 Oak Tree Rd, Edison, NJ 08820 USA.		Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698			Anton G., 1899, ARCH PSYCHIAT NERVEN, V32, P86, DOI DOI 10.1007/BF02126945; Babinski J, 1914, REV NEUROL, V27, P845; BERTHIER M, 1988, ANN NEUROL, V24, P41, DOI 10.1002/ana.410240109; Berti A, 1996, J Int Neuropsychol Soc, V2, P426; Celesia GG, 1997, NEUROLOGY, V49, P88, DOI 10.1212/WNL.49.1.88; CRITCHLE.M, 1974, MT SINAI J MED, V41, P82; CRITCHLEY M, 1966, PARIETAL LOBES; Feinberg TE, 1997, NEUROCASE, V3, P73, DOI 10.1080/13554799708404037; FEINBERG TE, 1995, BRAIN, V118, P789, DOI 10.1093/brain/118.3.789; Gerstmann J, 1942, ARCH NEURO PSYCHIATR, V48, P890, DOI 10.1001/archneurpsyc.1942.02290120042003; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; GOLD M, 1994, NEUROLOGY, V44, P1804, DOI 10.1212/WNL.44.10.1804; HALLIGAN PW, 1995, CORTEX, V31, P173, DOI 10.1016/S0010-9452(13)80115-3; Heilman KM, 1997, J NEUROPSYCH CLIN N, V9, P439, DOI 10.1176/jnp.9.3.439; HEILMAN KM, 1993, CLIN NEUROPSYCHOLOGY; KAPLAN RF, 1990, NEUROLOGY, V40, P1299, DOI 10.1212/WNL.40.8.1299; LEVINE DN, 1990, BRAIN COGNITION, V13, P233, DOI 10.1016/0278-2626(90)90052-P; Lu LH, 1997, NEUROLOGY, V49, P1316, DOI 10.1212/WNL.49.5.1316; Mazzoni M, 1997, NEUROCASE, V3, P223; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Mesulam M., 1985, PRINCIPLES BEHAV NEU; MOSS AD, 1997, J NEUROL NEUROSUR PS, V62, P210; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; Prigatano GP, 1995, BNI Q, V11, P10; RAMACHANDRAN VS, 1995, CONSCIOUS COGN, V4, P22, DOI 10.1006/ccog.1995.1002; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; SHUREN JE, 1995, NEUROLOGY, V45, P376, DOI 10.1212/WNL.45.2.376; Stuss D., 1991, AWARENESS DEFICIT BR, P63; TEGNER R, 1991, J NEUROL NEUROSUR PS, V54, P882, DOI 10.1136/jnnp.54.10.882; von Monakow C., 1885, ARCH PSYCHIAT NERVEN, V16, P151, DOI DOI 10.1007/BF02227304; WARRINGTON EK, 1962, J NEUROL NEUROSUR PS, V25, P208, DOI 10.1136/jnnp.25.3.208; WATSON RT, 1994, ARCH NEUROL-CHICAGO, V51, P1014, DOI 10.1001/archneur.1994.00540220060015; Weinstein E.A., 1955, DENIAL ILLNESS SYMBO; Weinstein EA, 1996, B MENNINGER CLIN, V60, P331; WEINSTEIN EA, 1969, HDB CLIN NEUROLOGY, P4; WEINSTEIN EA, 1963, ARCH GEN PSYCHIAT, V18, P348; [No title captured]; [No title captured]	39	74	74	2	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1998	13	5					1	15		10.1097/00001199-199810000-00003			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	175UU	WOS:000079114600003	9753531				2022-02-06	
J	Murai, H; Pierce, JES; Raghupathi, R; Smith, DH; Saatman, KE; Trojanowski, JQ; Lee, VMY; Loring, JF; Eckman, C; Younkin, S; McIntosh, TK				Murai, H; Pierce, JES; Raghupathi, R; Smith, DH; Saatman, KE; Trojanowski, JQ; Lee, VMY; Loring, JF; Eckman, C; Younkin, S; McIntosh, TK			Twofold overexpression of human beta-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						traumatic brain injury; Alzheimer's disease; beta-amyloid peptides; amyloid plaques	FAMILIAL ALZHEIMERS-DISEASE; CONTROLLED CORTICAL IMPACT; RAT-BRAIN; SENILE PLAQUES; SECRETED FORMS; DOWNS-SYNDROME; HEAD-INJURY; EXPRESSION; DEFICITS; GENE	By using transgenic mice that overexpress human beta-amyloid precursor proteins (APPs) at levels twofold higher than endogenous APPs, following introduction of the human APP gene in a yeast artificial chromosome (YAC), we examined the effects of controlled cortical impact (CCI) brain injury on neuromotor/cognitive dysfunction and the development of Alzheimer's disease (AD)-like neuropathology. Neuropathological analyses included Nissl-staining and immunohistochemistry to detect APPs, beta-amyloid (A beta), neurofilament proteins, and glial fibrillary acidic protein, whereas A beta levels were measured in brain homogenates from mice subjected to CCI and control mice by using a sensitive sandwich enzyme-linked immunosorbent assay. Twenty APP-YAC transgenic mice and 17 wild type (WT) littermate controls were anesthetized and subjected to CCI (velocity, 5 m/second; deformation depth, 1 mm). Sham (anesthetized but uninjured) controls (n = 10 APP-YAC; n = 8 WT) also were studied. Motor function was evaluated by using rotarod, inclined-plane, and forelimb/hindlimb flexion tests. The Morris water maze was used to assess memory. Although CCI induced significant motor dysfunction and cognitive deficits, no differences were observed between brain-injured APP-YAC mice and WT mice at 24 hours and 1 week postinjury. By 1 week postinjury, both cortical and hippocampal CA3 neuron loss as well as extensive astrogliosis were observed in all injured animals, suggesting that overexpression of human APPs exhibited no neuroprotective effects. Although AD-like pathology (including amyloid plaques) was not observed in either sham or brain-injured animals, a significant decrease in brain concentrations of only A beta terminating at amino acid 40 (APx-40) was observed following brain injury in APP-YAC mice (P < 0.05 compared with sham control levels). Our data show that the APP-YAC mice do. not develop AD-like neuropathology following traumatic brain injury. This may be because this injury does not induce elevated levels of the more amyloidogenic forms of human A beta (i.e., A beta x-42/43) in these mice. (C) 1998 Wiley-Liss, Inc.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Mol Dynam, Sunnyvale, CA 94043 USA; Mayo Clin Jacksonville, Jacksonville, FL 32224 USA		McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, 3320 Smith Walk, Philadelphia, PA 19104 USA.	mcintosh@eniac.seas.upenn.edu	Raghupathi, Ramesh/AAX-5538-2021; smith, douglas/A-1321-2007; Loring, Jeanne F/A-1620-2011	Loring, Jeanne F/0000-0001-6226-9767	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01-AG11542] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P01-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER		BUXBAUM JD, 1993, BIOCHEM BIOPH RES CO, V197, P639, DOI 10.1006/bbrc.1993.2527; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; DAS S, 1995, NEURON, V14, P447, DOI 10.1016/0896-6273(95)90300-3; DIXON CE, 1991, J NEUROSCI METH, V39, P1; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HOWLAND DS, 1995, NEUROBIOL AGING, V16, P685, DOI 10.1016/0197-4580(95)00078-S; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1997, MOL MECH DEMENTIA, P39; HUBER G, 1993, BRAIN RES, V603, P348, DOI 10.1016/0006-8993(93)91261-P; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Irizarry MC, 1997, J NEUROSCI, V17, P7053; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Iwatsubo T, 1996, AM J PATHOL, V149, P1823; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Loring JF, 1996, NEUROBIOL AGING, V17, P173, DOI 10.1016/0197-4580(95)02076-4; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Maurice T, 1996, BRAIN RES, V706, P181, DOI 10.1016/0006-8993(95)01032-7; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MORAN PM, 1995, P NATL ACAD SCI USA, V92, P5341, DOI 10.1073/pnas.92.12.5341; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; PEARSON BE, 1993, P NATL ACAD SCI USA, V90, P10578, DOI 10.1073/pnas.90.22.10578; Pierce J. E. S., 1994, Society for Neuroscience Abstracts, V20, P196; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; Pierce JES, 1996, J NEUROSCI, V16, P1083; PRICE DL, 1994, ANNU REV MED, V45, P435; Reaume AG, 1996, J BIOL CHEM, V271, P23380, DOI 10.1074/jbc.271.38.23380; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SMITH DH, 1993, J NEUROTRAUMA S, V10, pS62; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; STEPHENSON DT, 1992, BRAIN RES, V593, P128, DOI 10.1016/0006-8993(92)91274-I; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P281; TOPPER R, 1995, ACTA NEUROPATHOL, V89, P23; WALLACE WC, 1991, MOL BRAIN RES, V10, P173, DOI 10.1016/0169-328X(91)90108-A; WISNIEWSKI KE, 1985, NEUROLOGY, V35, P957, DOI 10.1212/WNL.35.7.957; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; YAMAGUCHI F, 1991, NEUROREPORT, V2, P781, DOI 10.1097/00001756-199112000-00013	62	74	75	0	7	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	MAR 23	1998	392	4					428	438		10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2			11	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	YZ711	WOS:000072283200002	9514508				2022-02-06	
J	Bowen, A; Neumann, V; Conner, M; Tennant, A; Chamberlain, MA				Bowen, A; Neumann, V; Conner, M; Tennant, A; Chamberlain, MA			Mood disorders following traumatic brain injury: identifying the extent of the problem and the people at risk	BRAIN INJURY			English	Article							HEAD-INJURY; DEPRESSION; POPULATION; RELATIVES; SCALE; COMA	The extent of mood disorders following traumatic brain injury (TBI), and the possible risk factors, are investigated. New data are presented from a prospective study of consecutive hospital admissions. Six months post-TBI, 99 adults completed a standardized assessment of emotional state, the Wimbledon Self-Report Scale. Cognitive performance and the impact of the injury on everyday functioning were also assessed. The rate of clinically significant mood disorders (caseness) was 38%. of the demographic or injury characteristics, only pre-injury occupational status predicted post-injury caseness. Those unoccupied pre-injury were more likely to report mood disturbances post-injury. In contrast, post-injury occupational status was not related to caseness either for the whole group or the subgroup of those previously occupied, despite the adverse effects on occupational functioning for a significant proportion of subjects. Associations were found between emotional state and cognitive and everyday functioning 6 months post-injury. Psychosocial disabilities appeared more strongly associated to mood disorders than did physical disabilities. A significant level of unmet need has been highlighted, and possible risk factors identified, which may inform the purchase and provision of TBI rehabilitation services. Follow-up data on these subjects are available and will be reported separately.	Univ Leeds, Rheumatol & Rehabil Res Unit, Leeds, W Yorkshire, England; Univ Manchester, Stroke Assoc, Therapy Res Unit, Manchester, Lancs, England; Univ Leeds, Dept Psychol, Leeds LS2 9JT, W Yorkshire, England		Bowen, A (corresponding author), Hope Hosp, CSB, Dept Geriatr Med, Stroke Assoc,Therapy Res Unit, Salford M6 8HD, Lancs, England.		Bowen, Audrey/K-5544-2012; Conner, Mark/N-9063-2013	Bowen, Audrey/0000-0003-4075-1215; Conner, Mark/0000-0002-6229-8143			Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Benton A., 1978, MULTILINGUAL APHASIA; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BURTON LA, 1988, J NEUROLOGICAL REHAB, V2, P151; BURTON LA, 1994, J NEUROLOGICAL REHAB, V8, P63, DOI DOI 10.1177/136140969400800202; Coughlan AK, 1988, CLIN REHABIL, V2, P207, DOI DOI 10.1177/026921558800200305; Derogatis LR., 1983, SCL 90 ADM SCORING P; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GARSKE GG, 1992, REHABIL COUNS BULL, V36, P44; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; HATHAWAY S, 1951, MMPI MANUAL REVISED; HUGHES D, 1995, TRAUMATIC BRAIN INJU, P66; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Levin HS, 1984, NEUROPSYCHOLOGY MEMO, P247; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; LUNDHOLM J, 1975, SCAND J REHABIL MED, V7, P97; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Najenson T, 1980, Int Rehabil Med, V2, P17; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; Patrick D L, 1982, J R Coll Gen Pract, V32, P429; REITAN, 1983, NEUROPSYCHOLOGICAL A, P557; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; TEASDALE G, 1974, LANCET, V2, P81; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Wechsler D, 1987, MEMORY SCALE REVISED; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	38	74	75	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	1998	12	3					177	190		10.1080/026990598122656			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	ZA456	WOS:000072365100001	9547948				2022-02-06	
J	Inskip, PD; Mellemkjaer, L; Gridley, G; Olsen, JH				Inskip, PD; Mellemkjaer, L; Gridley, G; Olsen, JH			Incidence of intracranial tumors following hospitalization for head injuries (Denmark)	CANCER CAUSES & CONTROL			English	Article						brain neoplasms; Denmark; glioma; head trauma; hemangioblastoma; meningioma	LOS-ANGELES COUNTY; EXPLORATORY CASE-CONTROL; CENTRAL NERVOUS-SYSTEM; BRAIN-TUMORS; RISK-FACTORS; LINDAU DISEASE; TRAUMA; CANCER; MENINGIOMAS; CHILDREN	The incidence of brain and other intracranial tumors following head trauma was evaluated in a cohort of 228,055 Danish residents hospitalized because of concussion, fractured skull, or other head injury between 1977 and 1992 and followed for an average of eight years (maximum, 17 years). Traffic accidents, falls, and sports-related incidents were the usual causes of the injury. Malignant and benign neoplasms were identified by linking the study roster with records of the Danish Cancer Registry for the years 1977 to 1993. This approach precludes differential reporting of injuries by study participants as an explanation for any associations seen. Intracranial tumors of the nervous system occurred more often than expected based on incidence rates for the Danish population; however, most of the excess occurred during the first year after the injury and likely was due to the detection of tumors that were present before the injury occurred. Excluding the first year of follow-up, the standardized incidence ratio (SIR) was 1.15 (95 percent confidence interval [CI] = 0.99-1.32). The same general temporal pattern was seen for the major subtypes of brain tumor as for all types combined. SIRs after the first year were 1.0 for glioma (CI = 0.8-1.2), 1.2 for meningioma (CI = 0.8-1.7), and 0.8 for neurilemmoma (CI = 0.4-1.7). However, hemangioblastoma and hemangioma were more frequent than expected, based on 15 cases (SIR = 2.6, CI = 1.4-4.2). Results indicate that head trauma causes, at most, a small increase in the overall risk of brain tumors during the ensuing 15 years; however, a possible association with intracranial vascular tumors warrants further evaluation.	Texas A&M Univ, Coll Vet Med, Dept Vet Anat & Publ Hlth, College Stn, TX 77843 USA; NCI, Epidemiol & Biostat Program, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA; Danish Canc Soc, Div Canc Epidemiol, Copenhagen, Denmark		Inskip, PD (corresponding author), Texas A&M Univ, Coll Vet Med, Dept Vet Anat & Publ Hlth, College Stn, TX 77843 USA.			Olsen, Jorgen Helge/0000-0001-9633-5662			ANNEGERS JF, 1979, NEUROSURGERY, V4, P203, DOI 10.1227/00006123-197903000-00001; Breslow N. E., 1987, STAT METHODS CANC RE, VII; BUNIN GR, 1994, CANCER EPIDEM BIOMAR, V3, P197; BURCH JD, 1987, J NATL CANCER I, V78, P601; CARPENTER AV, 1987, AM J PUBLIC HEALTH, V77, P1180, DOI 10.2105/AJPH.77.9.1180; CHOI NW, 1970, AM J EPIDEMIOL, V91, P467, DOI 10.1093/oxfordjournals.aje.a121158; CUSHING H, 1962, MENINGIOMAS THEIR CL; *DAN NAT BOARD HLT, 1976, CLASS DIS; Danish National Board of Health, 1981, ACT HOSP CAR SYST; *DANM STAT, 1987, BEF BEV 1985; Gurney JG, 1996, EPIDEMIOLOGY, V7, P485, DOI 10.1097/00001648-199609000-00006; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HOCHBERG F, 1984, NEUROLOGY, V34, P1511, DOI 10.1212/WNL.34.11.1511; HOWE GR, 1989, CANCER RES, V49, P4349; Inskip PD, 1995, EPIDEMIOL REV, V17, P382; KEPES J J, 1989, Neurosurgery (Baltimore), V25, P258; KLEY N, 1995, GLIA, V15, P297, DOI 10.1002/glia.440150310; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LUDWIN SK, 1984, NATURE, V308, P274, DOI 10.1038/308274a0; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; MORANTZ RA, 1978, NEUROSURGERY, V3, P181, DOI 10.1227/00006123-197809000-00009; *NORD MED STAT COM, 1985, NOMESKO PUB, V20; OLSEN JH, 1989, JNCI-J NATL CANCER I, V81, P803, DOI 10.1093/jnci/81.10.803; Parker HL, 1931, J AMER MED ASSOC, V97, P0535, DOI 10.1001/jama.1931.02730080027008; PERLMUTTER I, 1950, SURG GYNECOL OBSTET, V91, P89; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; PRESTONMARTIN S, 1980, JNCI-J NATL CANCER I, V65, P67; PRESTONMARTIN S, 1989, CANCER RES, V49, P6137; PRESTONMARTIN S, 1983, J NATL CANCER I, V70, P863; PRESTONMARTIN S, 1989, BRIT J CANCER, V59, P783, DOI 10.1038/bjc.1989.163; RADHAKRISHNAN K, 1995, ANN NEUROL, V37, P67, DOI 10.1002/ana.410370113; Resche F, 1993, Adv Tech Stand Neurosurg, V20, P197; Sargent P, 1929, BRIT J SURG, V17, P84, DOI 10.1002/bjs.1800176508; Scheithauer B. W., 1993, HISTOLOGICAL TYPING, DOI 10.1007/978-3-642-84988-6; SCHLEHOFER B, 1992, CANCER, V69, P2541, DOI 10.1002/1097-0142(19920515)69:10<2541::AID-CNCR2820691025>3.0.CO;2-H; STORM HH, 1992, CANC INCIDENCE DENMA; *WHO, 1976, INT CLASS DIS ONC	37	74	77	1	3	KLUWER ACADEMIC PUBL	DORDRECHT	SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS	0957-5243			CANCER CAUSE CONTROL	Cancer Causes Control	JAN	1998	9	1					109	116		10.1023/A:1008861722901			8	Oncology; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Public, Environmental & Occupational Health	YV685	WOS:000071852500014	9486470				2022-02-06	
J	Lee, AJ; Garraway, WM				Lee, AJ; Garraway, WM			Epidemiological comparison of injuries in school and senior club rugby	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						prevention; rugby football injuries; schoolboys; senior club players	CONCUSSION; FOOTBALL; PLAYERS	Objective-To determine the frequency, nature, circumstances, and outcome of schoolboy rugby injuries and to compare these injuries with those occurring in senior rugby clubs. Methods-The study was a prospective cohort study, conducted on 1705 (98%) of 1736 eligible players from nine Edinburgh schools and 1169 (96%) of 1216 eligible players from all 26 senior Scottish Rugby Union clubs (South District) who provided personal details before the 1993-1994 rugby season. Adult linkpersons were appointed to notify the circumstances of all injury episodes occurring in matches or in rugby related training. Results-154 school players (9%) experienced 210 separate injuries in 186 injury episodes, 80% of which arose in matches. The prevalence rate of schoolboy match injuries was 86.8 (95% confidence interval 73.4 to 100.2) per 1000 player-seasons. Senior club match injury prevalence was much higher at 367.0 (339.4 to 394.6) per 1000 player-seasons. Club players had a higher rate of match injury than schoolboys for all injury types. One third of schoolboy match injury episodes occurred in September and the majority of match injury episodes were associated with tackling (40%) or with being tackled (24%). Nine per cent of schoolboy match injury episodes were classified as severe, compared to 13% for clubs. Sixteen per cent (n = 23) of all schoolboy match injury episodes resulted in missed school attendance compared with 27% (n = 117) of all senior club match injury episodes which involved loss of employment or education. Conclusions-Schoolboy rugby is much safer than senior club rugby and the outcome of injuries that do occur is less disruptive. The relatively high rate of match injury in September might be reduced by a more intensive period of preseason training.			Lee, AJ (corresponding author), UNIV EDINBURGH,DEPT PUBL HLTH SCI,SCH MED,TEVIOT PL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.						Dalley D., 1989, NZ J SPORTS MED, V20, P2; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; DAVIES JE, 1978, BRIT MED J, V2, P1759, DOI 10.1136/bmj.2.6154.1759; DIXON G, 1993, NZ J SPORTS MED, V2, P18; GARRAWAY M, 1995, LANCET, V345, P1485; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; HOSKINS T, 1979, PRACTICE MED, V223, P265; JANE JA, 1989, MILD MODERATE HEAD I; KEW T, 1991, S AFR MED J, V80, P127; MCQUILLAN R, 1992, IRISH MED J, V85, P72; MYERS PT, 1980, MED J AUSTRALIA, V2, P17, DOI 10.5694/j.1326-5377.1980.tb131804.x; NATHAN M, 1983, S AFR MED J, V64, P132; O'Brien C, 1992, Br J Sports Med, V26, P243; ROUX CE, 1987, S AFR MED J, V71, P307; ROY SP, 1974, S AFR MED J, V48, P2321; SCHER AT, 1991, AM J SPORT MED, V19, P485, DOI 10.1177/036354659101900511; *SCOTT RUGB UN, 1995, COACH MED MAN 1, P22; Silver J R, 1992, Br J Sports Med, V26, P253; Sparks J P, 1981, Br J Sports Med, V15, P30; SUGERMAN S, 1983, AUST J SPORTS MED EX, V15, P5; WATSON AWS, 1981, J SPORT MED PHYS FIT, V21, P417; 1995, IRFB HDB, P106	24	74	75	0	15	BUTTERWORTH-HEINEMANN LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	SEP	1996	30	3					213	217		10.1136/bjsm.30.3.213			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	VJ620	WOS:A1996VJ62000010	8889113	Green Published, Bronze			2022-02-06	
J	Klein, M; Houx, PJ; Jolles, J				Klein, M; Houx, PJ; Jolles, J			Long-term persisting cognitive sequelae of traumatic brain injury and the effect of age	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							MILD HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; FOLLOW-UP; SYMPTOMS; HEALTH	This study examined the notion that mild to moderate traumatic brain injury (TBI) may have persistent effects that become evident upon neurocognitive testing in a phase in which the effects of physiological aging become manifest. Neurocognitive performance was tested in 25 middle-aged and 20 old subjects who had sustained mild to moderate TBI, on average, several decades earlier. The TBI subjects regarded themselves as normal and healthy. The performance of the TBI subjects was inferior to that of matched healthy controls on all aspects of primary and secondary memory and on the majority of tests used to measure speed of performance. There was no interaction between the effects of TBI and those of age, and the performance of middle-aged TBI subjects was similar to that of old controls, The results are taken to indicate that TBI sustained earlier in life may cause permanent sequelae in specific domains of cognitive functioning and that it might attenuate the age-related decline in cognitive functioning. Most striking, however, was that these deficits were not perceived as a limiting factor in everyday life, which suggests that coping strategies may be important.	UNIV LIMBURG,DEPT PSYCHIAT & NEUROPSYCHOL,NL-6200 MD MAASTRICHT,NETHERLANDS		Klein, M (corresponding author), UNIV LIMBURG,MAASTRICHT BRIN & BEHAV INST,UNS 50,POB 616,NL-6200 MD MAASTRICHT,NETHERLANDS.		Klein, Martin/C-4192-2012	Klein, Martin/0000-0003-4160-5746; Klein, Martin/0000-0001-5553-7911			Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BOTWINNICK J, 1981, HDB CLIN NEUROPSYCHO, P135; BRAND N, 1985, J GEN PSYCHOL, V112, P201, DOI 10.1080/00221309.1985.9711004; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Craik F. I. M., 1982, AGING COGNITIVE PROC, P191, DOI [DOI 10.1007/978-1-4684-4178-9_11, 10.1007/978-1-4684-4178-9_11]; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; GREEN J, 1992, CLIN ELECTROENCEPHAL, V23, P79, DOI 10.1177/155005949202300207; Gupta A, 1991, J PERS CLIN STUD, V7, P55; HALL S, 1991, PERCEPT MOTOR SKILL, V72, P1295, DOI 10.2466/PMS.72.4.1295-1298; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; HOUX PJ, 1991, BRAIN COGNITION, V15, P246, DOI 10.1016/0278-2626(91)90029-8; HOUX PJ, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P353; HOUX PJ, 1993, EXP AGING RES, V19, P209, DOI 10.1080/03610739308253934; Houx PJ, 1994, VULNERABLE BRAIN ENV, P25; JOLLES J, 1993, NEUROSCI RES COMMUN, V13, pS47; LEESTMA JE, 1991, FORENSIC NEUROPSYCHO, P45; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LUTEIJN F, 1982, GRONTINGER INTELLIGE; MAZZUCCHI A, 1992, J NEUROL, V239, P256; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Posner MI, 1975, INFORM PROCESSING CO, P55; REEDER KP, 1994, ARCH CLIN NEUROPSYCH, V9, P491, DOI 10.1016/0887-6177(94)90040-X; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Salthouse TimothyA., 1985, HDB PSYCHOL AGING, V2nd ed., P400; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SCHOENHUBER R, 1989, MILD HEAD INJURY, P142; STAMBROOK M, 1993, ARCH CLIN NEUROPSYCH, V8, P95; Sternberg R. J, 1982, HDB HUMAN INTELLIGEN; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SYMONDS C, 1962, LANCET, V1, P1; Tellegen B., 1988, UTRECHTSE COPING LIJ; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANDERMEULEN WRE, 1980, SLEEP 80; Verhage F., 1964, THESIS U GRONINGEN; ZUNG WWK, 1973, ARCH GEN PSYCHIAT, V29, P328; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V9, P334	48	74	74	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	AUG	1996	184	8					459	467		10.1097/00005053-199608000-00002			9	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	VD331	WOS:A1996VD33100002	8752074				2022-02-06	
J	Cargill, RS; Thibault, LE				Cargill, RS; Thibault, LE			Acute alterations in [Ca2+]i in NG108-15 cells subjected to high strain rate deformation and chemical hypoxia: An in vitro model for neural trauma	JOURNAL OF NEUROTRAUMA			English	Article						hypoxia; injury; mechanical injury; NG108-15; TBI	BRAIN INJURY; HEAD-INJURY; INTRACRANIAL-PRESSURE; PATHO-PHYSIOLOGY; CALCIUM; CULTURE; INVITRO; DAMAGE; MITOCHONDRIA; GENERATION	The short-term (less than 2 min) alterations in the intracellular free calcium concentration in differentiated NG108-15 (neuroblastoma cross glioma) cells exposed to dynamic mechanical deformation with and without superimposed chemical hypoxia were determined, A previously developed device, modified for these studies, was used to apply deformations at a magnitude and rate representative of those experienced by neural tissue in Traumatic Brain Injury, Chemical hypoxia was imposed using a combination of 2-deoxy-D-glucose and salicylate, anaerobic and aerobic metabolic blockers, respectively, Real time measurement of intracellular free calcium concentration using Fura-2 and a custom epifluorescence microscopy system provided a quantitative index of cell response, At high rates of deformation (similar to 10 sec(-1)), increases in intracellular free calcium concentration were exponentially related to the magnitude of the applied deformation, Chemical hypoxia had no effect on this acute response, At low rates of deformation, small increases in intracellular free calcium concentration were independent of the magnitude of the deformation, These findings indicate that strategies for seducing severity of TBI should focus on minimizing the rate of deformation of neural cells, Together with data from animal, physical, and finite element models, these data can be employed in the development of physiologic injury tolerance criteria for the whole head.	UNIV PENN,DEPT BIOENGN,PHILADELPHIA,PA 19104						NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL 34005] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR304684] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL034005] Funding Source: NIH RePORTER		AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; BALENTINE JD, 1988, LAB INVEST, V58, P93; BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218; BOOCK RJ, 1993, ANN BIOMED ENG, V21, P645, DOI 10.1007/BF02368644; BOOCK RJ, 1990, INT C BIOM IMP LY FR; BOUMA G, 1992, NEUROTRAUMA, V9, pS333; BRODY TM, 1956, J PHARMACOL EXP THER, V117, P39; COLLINS RC, 1989, ANN INTERN MED, V110, P992, DOI 10.7326/0003-4819-110-12-992; CUNARRO J, 1975, BIOCHIM BIOPHYS ACTA, V387, P234, DOI 10.1016/0005-2728(75)90106-1; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Fung Y., 1993, BIOMECHANICS; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GILBERT JA, 1994, J BIOMECH, V27, P1169, DOI 10.1016/0021-9290(94)90057-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTKNECHT J, 1990, J MEMBRANE BIOL, V115, P253, DOI 10.1007/BF01868640; HAAS R, 1985, BIOCHEM PHARMACOL, V34, P900; HUNG CT, 1993, J BIOMECH, V27, P227; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; KONGSAMUT S, 1985, BIOCHEM BIOPH RES CO, V130, P141, DOI 10.1016/0006-291X(85)90393-6; KURZINGER K, 1980, EUR J BIOCHEM, V103, P597, DOI 10.1111/j.1432-1033.1980.tb05985.x; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MEANEY DF, 1990, INT C BIOM IMP LY FR; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; NICHOLLS DG, 1985, MOL MECH ISCHEMIC BR, P97; NIRENBERG M, 1983, SCIENCE, V222, P794, DOI 10.1126/science.6314503; OHKUMA S, 1994, MOL BRAIN RES, V22, P166, DOI 10.1016/0169-328X(94)90044-2; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; SEARLES CD, 1988, BRAIN RES, V448, P373, DOI 10.1016/0006-8993(88)91280-2; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; THIBAULT LE, 1990, INT C BIOM IMP LY FR; THIBAULT LE, 1982, 35 ACEMB PHIL PENNS; THIBAULT LE, 1987, STAPP CAR CRASH C NE; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WHITEHOUSE MW, 1964, BIOCHEM PHARMACOL, V13, P319, DOI 10.1016/0006-2952(64)90148-0; WILLIAMS JL, 1992, J BIOMECH ENG-T ASME, V114, P377, DOI 10.1115/1.2891398; WINSTON FK, 1989, J APPL PHYSIOL, V67, P397, DOI 10.1152/jappl.1989.67.1.397; WIRTZ HRW, 1990, SCIENCE, V250, P1266, DOI 10.1126/science.2173861	47	74	75	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	1996	13	7					395	407		10.1089/neu.1996.13.395			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	VB732	WOS:A1996VB73200005	8863195				2022-02-06	
J	Massagli, TL; Michaud, LJ; Rivara, FP				Massagli, TL; Michaud, LJ; Rivara, FP			Association between injury indices and outcome after severe traumatic brain injury in children	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP; RECOVERY; ADOLESCENTS; MANAGEMENT; DISABILITY; MOTOR	Objectives: (1) To determine whether indices of traumatic brain injury (TBI) in children are associated with outcome at hospital discharge and 5 to 7 years later; (2) to describe persisting disabilities. Design: Retrospective, uncontrolled study of a cohort of children with severe, nonpenetrating TBI. Setting: Consecutive admissions to a level 1 trauma center over 2 years. Subjects: Seventy-five children younger than 17 years old were previously studied to identify predictors of disability at acute care discharge. Thirty-three of the 50 survivors (66%) were enrolled. Main Outcome Measures: A database of variables abstracted from medical records was available from the previous study. Subjects were surveyed about premorbid problems, school, employment, and current function, and school records were reviewed. Using all information, a Glasgow Outcome Scale (GOS) score was assigned 5 to 7 years after TBI. Associations between database variables and GOS score at discharge and follow-up were examined using nonparametric analyses. The odds ratio for good recovery was calculated for all significant associations. Results: Late GOS was good recovery for 27%, moderate disability for 55%, and severe disability for 18%. Discharge GOS scores were related (p less than or equal to .01) to the head Abbreviated Injury Scale score, Injury Severity Scale score, Glasgow Coma Scale (GCS) score measured in the field and at 6, 24, and 72 hours, the length of coma, and initial discharge site. Late GOS scores were related (p less than or equal to .01) to the same variables except the field and 6-hour GCS scores, as well as pupillary responses in the field and the discharge GOS. At follow-up, 64% were independent in mobility, 70% in self-care, and 24% in cognitive items on the Functional Independence Measure. Seventy percent of children received special education services. Employment histories were poor. Most subjects were not receiving neurological or rehabilitation follow-up. Conclusions: Early and late outcome after severe TBI are related to variables measured at and after injury. Subjects had long-term educational and vocational problems but often did not utilize the medical model of neurorehabilitation. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of physical Medicine and Rehabilitation.	UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; CHILDRENS HOSP PHILADELPHIA,CHILDRENS SEASHORE HOUSE,PHILADELPHIA,PA; UNIV PENN,DEPT REHABIL MED,PHILADELPHIA,PA; UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104; WASHINGTON UNIV,DEPT EPIDEMIOL,SEATTLE,WA; WASHINGTON UNIV,HARBORVIEW INJURY PREVENT & RES CTR,SEATTLE,WA		Massagli, TL (corresponding author), CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,CH-71,POB 5371,SEATTLE,WA 98105, USA.						ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Data Management Service of the Uniform Data System for Medical Rehabilitation and the Center for Functional Assessment Research, 1990, GUIDE USE UNIFORM DA; Dean AG, 1994, EPI INFO VERSION 6 W; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; Epstein J. C., 1977, QUALITY SCH LIFE SCA; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; NORUSIS MJ, 1986, SPSS PC PLUS IBM PCX; RAPHAELY RC, 1980, PEDIATR CLIN N AM, V27, P715; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rosner B, 1986, FUNDAMENTALS BIOSTAT; RUIJS MBM, 1992, DEV MED CHILD NEUROL, V34, P885; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; 1989, GUIDE USE FUNCTIONAL	40	74	74	1	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1996	77	2					125	132		10.1016/S0003-9993(96)90156-2			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	TU541	WOS:A1996TU54100003	8607735				2022-02-06	
J	Germann, G; Steinau, HU				Germann, G; Steinau, HU			The clinical reliability of vein grafts in free-flap transfer	JOURNAL OF RECONSTRUCTIVE MICROSURGERY			English	Article							MICROSURGERY; ANASTOMOSIS; INJURIES; HEAD	The use of interposition vein grafts has been associated in the literature with a high complication and flap failure rate. Ninety-three vein grafts in 55 patients over a 46-month period were analyzed to evaluate the clinical reliability of vein grafts in a predominantly trauma patient population (37/55). Fifty-two arterio-arterial grafts and 41 veno-venous grafts were performed. A-V loops prior to flap transfer were created in 26 patients. The revision rate was 14.8 percent, with a salvage rate of 75 percent. Flap survival was 96.2 percent, compared to 96.7 percent for a large series of flaps without vein grafts. it can be concluded from the study, that the use of vein grafts is not associated with a higher flap failure rate, when technical pitfalls can be avoided, and close monitoring by an experienced staff is guaranteed.			Germann, G (corresponding author), BG TRAUMA HOSP,BURN CTR,DEPT PLAST & HAND SURG,LUDWIG GUTTMANN STR 13,D-67071 LUDWIGSHAFEN,GERMANY.						ACLAND RD, 1994, PLAST RECONSTR SURG, V93, P479; DILLEY RJ, 1986, PLAST RECONSTR SURG, V77, P451, DOI 10.1097/00006534-198603000-00021; DUMINY FJ, 1989, J SURG RES, V46, P189, DOI 10.1016/0022-4804(89)90054-1; ETHRIDGE CP, 1988, BRIT J PLAST SURG, V41, P52, DOI 10.1016/0007-1226(88)90145-2; FUJIKAWA S, 1975, BRIT J PLAST SURG, V28, P244, DOI 10.1016/0007-1226(75)90024-7; GREENBERG BM, 1988, J HAND SURG-AM, V13A, P753, DOI 10.1016/S0363-5023(88)80142-4; GROTTING JC, 1991, CLIN PLAST SURG, V18, P485; HALLOCK G G, 1988, Journal of Reconstructive Microsurgery, V4, P155, DOI 10.1055/s-2007-1006914; HIDALGO DA, 1990, PLAST RECONSTR SURG, V86, P492, DOI 10.1097/00006534-199009000-00019; HIGGS PE, 1993, PLAST RECONSTR SURG, V91, P726, DOI 10.1097/00006534-199304000-00028; HIRASE Y, 1989, BRIT J PLAST SURG, V42, P216, DOI 10.1016/0007-1226(89)90207-5; HORNG SY, 1993, PLAST RECONSTR SURG, V92, P752, DOI 10.1097/00006534-199309001-00031; JONES NF, 1985, J HAND SURG-AM, V10A, P675, DOI 10.1016/S0363-5023(85)80206-9; KHOURI R, 1992, CLIN PLAST SURG, V4, P773; MEHLHOFF TL, 1991, J HAND SURG-AM, V16A, P274, DOI 10.1016/S0363-5023(10)80110-8; MILLER MJ, 1993, J RECONSTR MICROSURG, V9, P245, DOI 10.1055/s-2007-1006652; MITCHELL FL, 1990, J TRAUMA, V30, P336, DOI 10.1097/00005373-199003000-00014; MONEIM MS, 1985, J BONE JOINT SURG AM, V67A, P880, DOI 10.2106/00004623-198567060-00009; MUTIMER KL, 1987, PLAST RECONSTR SURG, V79, P535, DOI 10.1097/00006534-198704000-00003; NAHAI F, 1986, PLAST RECONSTR SURG, V77, P312, DOI 10.1097/00006534-198602000-00028; OLIVA A, 1990, PLAST SURG FORUM, V13, P28; RYAN AD, 1988, PLAST RECONSTR SURG, V81, P414, DOI 10.1097/00006534-198803000-00018; SCHUSTERMAN MA, 1994, PLAST RECONSTR SURG, V93, P472, DOI 10.1097/00006534-199493030-00004; SIDOROV VB, 1992, J RECONSTR MICROSURG, V8, P277, DOI 10.1055/s-2007-1006708; STEVANOVIC MV, 1991, PLAST RECONSTR SURG, V87, P1099, DOI 10.1097/00006534-199106000-00012; TAKATO T, 1991, BRIT J PLAST SURG, V44, P593, DOI 10.1016/0007-1226(91)90096-3; YAFFE B, 1983, PLAST RECONSTR SURG, V72, P526, DOI 10.1097/00006534-198310000-00021; ZEEMAN BJV, 1988, BRIT J PLAST SURG, V41, P509, DOI 10.1016/0007-1226(88)90009-4; ZHANG F, 1994, J RECONSTR MICROSURG, V10, P223, DOI 10.1055/s-2007-1006588; ZHANG F, 1994, J RECONSTR MICROSURG, V10, P229, DOI 10.1055/s-2007-1006589	30	74	75	0	2	THIEME MEDICAL PUBL INC	NEW YORK	381 PARK AVE SOUTH, NEW YORK, NY 10016	0743-684X			J RECONSTR MICROSURG	J. Reconstr. Microsurg.	JAN	1996	12	1					11	17		10.1055/s-2007-1006446			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	TR261	WOS:A1996TR26100004	8618220				2022-02-06	
J	FEENEY, TJ; YLVISAKER, M				FEENEY, TJ; YLVISAKER, M			CHOICE AND ROUTINE - ANTECEDENT BEHAVIORAL INTERVENTIONS FOR ADOLESCENTS WITH SEVERE TRAUMATIC BRAIN INJURY	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							FRONTAL-LOBE DAMAGE; CLOSED-HEAD-INJURY; CHILDREN; DISABILITIES; CHILDHOOD; MOMENTUM; CONSEQUENCES; SEQUELAE; STUDENTS; LESION	Objective: To investigate the effectiveness of an antecedent intervention in reducing aggressive behavior. Design: Three single-subject A-B-C-A (changing treatment) designs. Setting: High school and prevocational settings. Patients: Three adolescent males whose behavior had deteriorated badly over several years after severe traumatic brain injury. Intervention: Integrative intervention that addressed the subjects' cognitive impairment (including their need for well-established routines and advance organizers), their oppositional behavior (associated with their need to be involved in making decisions about their routines), and their history of failure (associated with their need to experience success before attacking difficult tasks). Main Outcome Measures: Frequency counts of aggressive behavior; standardized ratings of severity of aggressive behavior; quantity of assigned work completed. Results: Each subject demonstrated reduction of aggressive behavior to acceptable levels with a concomitant increase in quantity of assigned work completed. Anecdotal follow-up reports indicate that each subject is employed with minimal or no support. Conclusions: The combination of behavioral and cognitive antecedent intervention procedures produced a sufficient reduction in aggressive behavior to enable the subjects to succeed in their educational and subsequent vocational programs. The design was insufficient to identify the relative contribution of each component of the intervention.	COLL ST ROSE, ALBANY, NY USA		FEENEY, TJ (corresponding author), ALBANY SCHENECTADY SCHOHARIE SARATOGA BOARD COOPE, TBI REENTRY PROJECT, ALBANY, NY USA.						ACKERLY SS, 1964, FRONTAL GRANULAR COR; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; AMAN MG, 1988, ABERRANT BEHAVIOR CH; BANNERMAN DJ, 1990, J APPL BEHAV ANAL, V23, P79, DOI 10.1901/jaba.1990.23-79; Benson D.F., 1986, FRONTAL LOBES; BENTON A, 1991, DEV NEUROPSYCHOL, V7, P275, DOI 10.1080/87565649109540495; BERKMAN KA, 1988, J ASSOC PERS SEVERE, V13, P76, DOI 10.1177/154079698801300204; BROWN F, 1991, J ASSOC PERS SEVERE, V16, P75; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHILDS KE, 1994, J APPL BEHAV ANAL, V27, P7, DOI 10.1901/jaba.1994.27-7; DESHLER DD, 1988, ALTERNATIVE ED DELIV; DOSS S, 1989, J ASSOC PERS SEVERE, V14, P101; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; DYER K, 1990, J APPL BEHAV ANAL, V23, P515, DOI 10.1901/jaba.1990.23-515; EAMES P, 1988, J HEAD TRAUMA REHAB, V3, P1; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FRASER RT, 1994, TOP LANG DISORD, V15, P55, DOI 10.1097/00011363-199411000-00006; GOLDSTEIN FC, 1989, INTEGRATING THEORY P; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Harchik A E, 1993, Ann Clin Psychiatry, V5, P151, DOI 10.3109/10401239309148979; HARCHIK AE, 1990, J ASSOC PERS SEVERE, V15, P40; HARING TG, 1990, J APPL BEHAV ANAL, V23, P235, DOI 10.1901/jaba.1990.23-235; HART, 1988, J HEAD TRAUMA REHAB, V3, P53; Hart T, 1993, J HEAD TRAUMA REHAB, V8, P1; HOMER R, 1990, J ASSOC PERS SEVERE, V15, P125; Horner R.H., 1994, J BEHAVIORAL ED, V4, P157, DOI [DOI 10.1007/BF01544110, 10.1007/BF01544110]; Horner R. H, 1988, GENERALIZATION MAINT; HORNER RH, 1991, J APPL BEHAV ANAL, V24, P719, DOI 10.1901/jaba.1991.24-719; HORNER RH, 1985, EDUC TRAIN MENT RET, V20, P39; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; LEVIN HS, 1991, FRANTAL LOBE FUNCTIO; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; MACE FC, 1990, J EXP ANAL BEHAV, V54, P163, DOI 10.1901/jeab.1990.54-163; MACE FC, 1988, J APPL BEHAV ANAL, V21, P123, DOI 10.1901/jaba.1988.21-123; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; NEVIN JA, 1992, J EXP ANAL BEHAV, V57, P301, DOI 10.1901/jeab.1992.57-301; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/PMS.73.8.1139-1150; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; ROSENTHAL M, 1990, REHABILITATION ADULT; Schwartz M. F., 1993, J HEAD TRAUMA REHAB, V8, P59, DOI [10.1097/00001199-199303000-00007, DOI 10.1097/00001199-199303000-00007]; SHEVIN M, 1984, J ASSOC PERS SEVERE, V9, P159; Singh NN, 1994, ABERRANT BEHAVIOR CH; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; STOKES TF, 1977, J APPL BEHAV ANAL, V10, P349, DOI 10.1901/jaba.1977.10-349; SZEKERES S, 1993, SEMIN SPEECH LANG, V13, P293; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WETZEL RJ, 1984, RESIDENTIAL TEACHING; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood RLL, 1990, NEUROBEHAVIORAL SEQU; YLVISAKER M, 1994, TOP LANG DISORD, V15, P37, DOI 10.1097/00011363-199411000-00005; YLVISAKER M, 1993, STAFF DEV CLIN INTER; YLVISAKER M, 1987, COMMUNITY REENTRY HE; Ylvisaker Mark, 1993, Seminars in Speech and Language, V14, P74, DOI 10.1055/s-2008-1064160; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	63	74	74	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1995	10	3					67	86					20	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	RC717	WOS:A1995RC71700007					2022-02-06	
J	FUKUDA, K; TANNO, H; OKIMURA, Y; NAKAMURA, M; YAMAURA, A				FUKUDA, K; TANNO, H; OKIMURA, Y; NAKAMURA, M; YAMAURA, A			THE BLOOD-BRAIN-BARRIER DISRUPTION TO CIRCULATING PROTEINS IN THE EARLY PERIOD AFTER FLUID PERCUSSION BRAIN INJURY IN RATS	JOURNAL OF NEUROTRAUMA			English	Article						BLOOD-BRAIN BARRIER; EXPERIMENTAL BRAIN INJURY; ALBUMIN; HORSERADISH PEROXIDASE	VASCULAR-PERMEABILITY; SUBARACHNOID HEMORRHAGE; FREE-RADICALS; SPINAL-CORD; EDEMA; DAMAGE; EXTRAVASATION; MEDIATORS; ANTIBODY; RELEASE	Breakdown of the blood-brain barrier (BBB) immediately after traumatic brain injury is not clearly understood. In the present study we focused on the integrity of the BBB to circulating proteins within the first hour after injury. For this purpose, vascular permeability to endogenous albumin and to the exogenous protein tracer horseradish peroxidase (HRP) was examined after a lateral fluid percussion brain injury in rats. Albumin was immunolocalized in brain sections at 3 and 60 min after impact. This distribution was compared with the histochemical localization of HRP given before impact at the same time points. In a separate experiment HRP was given prior to sacrifice to determine the time course for the barrier disruption. Permeability to this protein was assessed at 13, 30, and 60 min after impact. Prominent extravasation of albumin occurred within 3 min of injury and was present in multiple foci within the injured hemisphere. At 60 min the extravasated albumin was present in the same sites, where it was widely distributed. Throughout the related brain parenchyma, little difference was found between the extravascular distribution of albumin and HRP. In the delayed administration paradigm breakdown of the BBB was noted in the impact site, hemorrhagic site in the deep cortical layer, hippocampus, thalamus, and midbrain at 13 min after injury. This injured barrier was restored in most regions by 30 min. However, the impact site and hemorrhagic site remained permeable up to 60 min postinjury. In addition, newly developed barrier disruption to HRP occurred in the parasagittal cortex at 30 and 60 min. In conclusion, widespread breakdown of the BBB to circulating proteins occurred within a few minutes after traumatic brain injury. The time course for this barrier disruption is characterized by three different patterns: (1) transient, (2) prolonged, and (3) delayed opening. This variation in the development of barrier disruption may be related to the secondary barrier failure as well as the primary opening after injury.			FUKUDA, K (corresponding author), CHIBA UNIV,SCH MED,DEPT NEUROSURG,CHUO KU,1-8-1 INOHANA,CHIBA 260,JAPAN.						AARABI B, 1979, J NEUROSURG, V51, P779, DOI 10.3171/jns.1979.51.6.0779; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BODSCH W, 1983, J NEUROCHEM, V41, P239, DOI 10.1111/j.1471-4159.1983.tb11833.x; BODSCH W, 1982, BRAIN RES, V249, P111, DOI 10.1016/0006-8993(82)90175-5; Chan P H, 1990, Adv Neurol, V52, P177; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; CHAN PH, 1985, BRAIN EDEMA, P317; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CROCKARD A, 1982, HEAD INJURY BASIC CL, P159; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DOCZI T, 1986, NEUROSURGERY, V18, P733, DOI 10.1227/00006123-198606000-00010; Fukuda Kazumasa, 1994, Brain and Nerve (Tokyo), V46, P1030; GERMANO A, 1992, NEUROSURGERY, V30, P882, DOI 10.1227/00006123-199206000-00011; Houthoff H J, 1980, Adv Neurol, V28, P75; HOUTHOFF HJ, 1982, ACTA NEUROPATHOL, V56, P99, DOI 10.1007/BF00690580; IKEDA Y, 1990, NEUROSURGERY, V27, P1; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JOHANSSON BB, 1992, PROG BRAIN RES, V91, P171; Katayama Y, 1990, Adv Neurol, V52, P105; Kempski O, 1990, Adv Neurol, V52, P219; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; LEVIN E, 1976, DYNAMICS BRAIN EDEMA, P23; LOBERG EM, 1991, ACTA NEUROPATHOL, V81, P479, DOI 10.1007/BF00310126; Nakamura T, 1987, Neurol Med Chir (Tokyo), V27, P396, DOI 10.2176/nmc.27.396; NOBLE LJ, 1983, EXP NEUROL, V79, P188, DOI 10.1016/0014-4886(83)90390-4; OKIMURA Y, 1994, 1994 INT C REC ADV N, V2, P543; OLSSON Y, 1992, PROG BRAIN RES, V91, P197; PERSSON L, 1976, ACTA NEUROPATHOL, V35, P333; PERSSON L, 1976, ACTA NEUROPATHOL, V34, P125, DOI 10.1007/BF00684663; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; RAPOPORT SI, 1986, ANN NY ACAD SCI, V481, P250; SOKRAB TEO, 1988, ACTA NEUROPATHOL, V75, P557, DOI 10.1007/BF00686200; SOKRAB TEO, 1988, ACTA NEUROL SCAND, V77, P387, DOI 10.1111/j.1600-0404.1988.tb05924.x; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Tornheim P A, 1990, Adv Neurol, V52, P377; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; TORNHEIM PA, 1981, J NEUROSURG, V55, P407, DOI 10.3171/jns.1981.55.3.0407; TORNHEIM PA, 1985, CENTRAL NERVOUS SYST, P431; Unterberg A, 1990, Adv Neurol, V52, P211; Villacara A, 1990, Adv Neurol, V52, P195; VORBRODT AW, 1985, ACTA NEUROPATHOL, V66, P265, DOI 10.1007/BF00690958; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; Westergaard E, 1980, Adv Neurol, V28, P55	45	74	75	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1995	12	3					315	324		10.1089/neu.1995.12.315			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	RM331	WOS:A1995RM33100009	7473806				2022-02-06	
J	VANREEKUM, R; BAYLEY, M; GARNER, S; BURKE, IM; FAWCETT, S; HART, A; THOMPSON, W				VANREEKUM, R; BAYLEY, M; GARNER, S; BURKE, IM; FAWCETT, S; HART, A; THOMPSON, W			N OF 1 STUDY - AMANTADINE FOR THE AMOTIVATIONAL-SYNDROME IN A PATIENT WITH TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							BLUNT HEAD-INJURY; RANDOMIZED TRIALS; RELATIVES; DEMENTIA	Severe amotivation, apathy, and abulia, significantly retard rehabilitation following traumatic brain injury. Preliminary, uncontrolled research has suggested possible benefit with amantadine for this behavioural syndrome. This N of 1, double-blind, placebo-controlled study employed amantadine 100 mg three times daily in one such patient. Therapists and nurses completed inventories scoring efforts towards initiation of therapeutic activities during each session, progress in therapy, and participation in therapy. Four treatment periods (two active medication, two placebo), of 2 weeks duration, were completed. Across four therapists, and for both treatment pairs, the average effect score increased from 0.86 on placebo to 1.74 on amantadine (possible range 0-6, 3 = 'average'). There were no side-effects. The study suggests possible benefit with amantadine for patients with amotivational syndrome after traumatic brain injury; a randomized clinical trial appears warranted and required.			VANREEKUM, R (corresponding author), CHEDOKE MCMASTER HOSP,MCMASTER UNIV,PATTERSON BLDG,BOX 2000,HAMILTON,ON L8N 3Z5,CANADA.			Bayley, Mark/0000-0001-7860-9463			ALBERT ML, 1974, J NEUROL NEUROSUR PS, V37, P121, DOI 10.1136/jnnp.37.2.121; Andersson Stein, 1992, Tidsskrift for den Norske Laegeforening, V112, P2070; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; COHEN RA, 1989, ARCH NEUROL-CHICAGO, V46, P676, DOI 10.1001/archneur.1989.00520420096030; ERKULWATER S, 1989, SOUTHERN MED J, V82, P550, DOI 10.1097/00007611-198905000-00004; GUALTIERI T, CLIN NEUROPHARMACOL, V12, P258; GUYATT G, 1988, CAN MED ASSOC J, V139, P497; GUYATT GH, 1990, CONTROL CLIN TRIALS, V11, P88, DOI 10.1016/0197-2456(90)90003-K; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ROCA RP, 1990, J AM GERIATR SOC, V38, P675, DOI 10.1111/j.1532-5415.1990.tb01428.x; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260	12	74	76	0	2	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1995	9	1					49	53		10.3109/02699059509004571			5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	QB052	WOS:A1995QB05200007	7874096				2022-02-06	
J	KAO, GD; GOLDWEIN, JW; SCHULTZ, DJ; RADCLIFFE, J; SUTTON, L; LANGE, B				KAO, GD; GOLDWEIN, JW; SCHULTZ, DJ; RADCLIFFE, J; SUTTON, L; LANGE, B			THE IMPACT OF PERIOPERATIVE FACTORS ON SUBSEQUENT INTELLIGENCE QUOTIENT DEFICITS IN CHILDREN TREATED FOR MEDULLOBLASTOMA POSTERIOR-FOSSA PRIMITIVE NEUROECTODERMAL TUMORS	CANCER			English	Article						MEDULLOBLASTOMA; RADIATION THERAPY; INTELLIGENCE QUOTIENT; NEUROCOGNITIVE DEFICITS; PERIOPERATIVE FACTORS	WHOLE-BRAIN RADIOTHERAPY; CLOSED HEAD-INJURY; BACTERIAL-MENINGITIS; HALSTEAD-REITAN; CHILDHOOD; SEQUELAE; INFECTION; PRESCHOOL; SURVIVAL; AGE	Background. Despite success in treating children with medulloblastoma/posterior fossa primitive neuroectodermal tumor (PF PNET), some children survive with significant neurocognitive sequelae. This study was performed to understand better the significance of perioperative factors on subsequent full scale intelligence quotient (FSIQ) deterioration in these children. Methods. Twenty-eight children who underwent prospective and serial neurocognitive testing were studied. All children underwent surgery followed by radiotherapy with or without chemotherapy between 1983 and 1987 for medulloblastoma/PF PNET and were disease free when this study was conducted. IQ testing was performed before surgery and after the completion of radiation therapy. The clinical courses of the patients were correlated with changes in the corresponding intelligence quotients of each child. Factors correlating with neurocognitive declines were examined by chi-square or Fisher exact test analysis. Differences in mean IQs were examined by the t test. Factors found to be significant were analyzed by exact logistic regression analysis. Results. The presence of adverse factors such as neurologic deficits, meningitis, or shunt infections, or the need for repeat surgery was correlated significantly with IQ deficits after treatment. Of the subset of children with one or more of these factors, 13 of 16 (81%) sustained decreases in FSIQ; 7 of 16 (43.8%) had decreases of 20 points of more. In contrast, only 3 of 12 (25%) of the children without the factors sustained FSIQ decreases, and no child sustained a decrease of more than 13 points. The mean FSIQ change after treatment in the group with factors was -15.7 (95% confidence interval [CI]: -24.0, -8.4), and the median was -18. The mean FSIQ change in the group without factors was 4.8 (95% CI: -0.5, 10.1), and the median was 5. The difference in mean FSIQ change between the two groups was significant (P < 0.0001). On univariate analysis, both the presence of adverse factors and an age less than six years correlated with neurocognitive deficit. On regression analysis, only the presence of adverse factors was significant (odds ratio 11.53; 95% CI, 1.65-116.58; P = 0.009), whereas age was not (P = 0.27). Conclusions. Perioperative events or complications may account for some of the neurocognitive deterioration seen in these children after treatment, especially in the very young. The occurrence of these factors is associated with a significantly greater risk of IQ deterioration. Studies of the neurocognitive effects of treatment for children with medulloblastoma/PF PNET should include an analysis of these postoperative factors.	CHILDRENS HOSP PHILADELPHIA,CHILDRENS SEASHORE HOUSE,PHILADELPHIA,PA 19104; MILLERSVILLE UNIV PENNSYLVANIA,DEPT MATH,MILLERSVILLE,PA 17551; UNIV PENN,CTR CANC,PHILADELPHIA,PA 19104		KAO, GD (corresponding author), HOSP UNIV PENN,DEPT RADIAT ONCOL,2 DONNER,PHILADELPHIA,PA 19104, USA.						ALBRIGHT AL, 1989, PEDIATR NEUROSCI, V15, P276; ALLEN JC, 1982, J NEUROSURG, V57, P446, DOI 10.3171/jns.1982.57.4.0446; ALLEN JC, 1993, NEW ENGL J MED, V328, P1780, DOI 10.1056/NEJM199306173282410; BANICH MT, 1990, NEUROPSYCHOLOGIA, V28, P35, DOI 10.1016/0028-3932(90)90084-2; Bayley N., 1969, BAYLEY SCALES INFANT; BERRY MP, 1981, J NEUROSURG, V55, P43, DOI 10.3171/jns.1981.55.1.0043; Bonner K, 1988, J Neurosci Nurs, V20, P84; BROOKSHIRE B, 1990, NEUROSURGERY, V27, P887, DOI 10.1227/00006123-199012000-00005; BUONAGURO A, 1989, CHILD NERV SYST, V5, P153, DOI 10.1007/BF00272117; CONBOY TJ, 1987, J PEDIATR-US, V111, P343, DOI 10.1016/S0022-3476(87)80451-1; ELLENBERG L, 1987, NEUROSURGERY, V21, P638, DOI 10.1227/00006123-198711000-00006; FADUL C, 1988, NEUROLOGY, V38, P1374, DOI 10.1212/WNL.38.9.1374; FEIGIN RD, 1976, PEDIATR CLIN N AM, V23, P541; GENSEMER IB, 1989, ANN EMERG MED, V18, P9, DOI 10.1016/S0196-0644(89)80303-8; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; HIRSCH JF, 1979, ACTA NEUROCHIR, V48, P1, DOI 10.1007/BF01406016; HOPESTONE HF, 1970, J NEUROSURG, V32, P83, DOI 10.3171/jns.1970.32.1.0083; HOPPEHIRSCH E, 1990, CHILD NERV SYST, V6, P60, DOI 10.1007/BF00307922; HORWITZ NH, 1982, POSTOPERATIVE COMPLI, P32; HUGHES EN, 1988, CANCER, V61, P1992, DOI 10.1002/1097-0142(19880515)61:10<1992::AID-CNCR2820611011>3.0.CO;2-J; JONES RFC, 1967, J NEUROSURG, V26, P313, DOI 10.3171/jns.1967.26.3.0313; KANE RL, 1987, J CONSULT CLIN PSYCH, V55, P783; LANDBERG TG, 1980, CANCER, V45, P670, DOI 10.1002/1097-0142(19800215)45:4<670::AID-CNCR2820450409>3.0.CO;2-K; LANGECOSACK H, 1979, NEUROPADIATRIE, V10, P105, DOI 10.1055/s-0028-1085318; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1982, NEUROBEHAVIORAL CONS, P190; MULHERN RK, 1985, MED PEDIATR ONCOL, V13, P318, DOI 10.1002/mpo.2950130604; PACKER RJ, 1986, ANN NEUROL, V20, P396; PACKER RJ, 1989, J NEUROSURG, V70, P707, DOI 10.3171/jns.1989.70.5.0707; PRIGATANO GP, 1983, CHILD BRAIN, V10, P112; RABBITT P, 1993, Q J EXP PSYCHOL-A, V46, P385, DOI 10.1080/14640749308401055; RADCLIFFE J, 1992, ANN NEUROL, V32, P551, DOI 10.1002/ana.410320411; RENIER D, 1984, J NEUROSURG, V61, P1072, DOI 10.3171/jns.1984.61.6.1072; RICHARDSON F, 1963, DEV MED CHILD NEUROL, V5, P471; RICHARDSON RR, 1989, STEREOT FUNCT NEUROS, V53, P105, DOI 10.1159/000099525; SAMEROFF AJ, 1993, CHILD DEV, V64, P80, DOI 10.1111/j.1467-8624.1993.tb02896.x; SELL SHW, 1972, PEDIATRICS, V49, P212; SILBER JH, 1992, J CLIN ONCOL, V10, P1390, DOI 10.1200/JCO.1992.10.9.1390; STAMBROOK M, 1987, INT J NEUROSCI, V35, P73, DOI 10.3109/00207458708987112; Terman L.M., 1960, STANFORD BINET INTEL; THOMPSON NM, 1991, J CLIN EXP NEUROPSYC, V13, P245, DOI 10.1080/01688639108401041; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 1949, WECHSLER INTELLIGENC; Wechsler D., 1974, WECHSLER INTELLIGENC; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; WILLIAMS JM, 1986, CANCER TREAT REV, V13, P113; Wisoff J H, 1984, Neurosurgery, V15, P707	48	74	74	0	6	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0008-543X			CANCER	Cancer	AUG 1	1994	74	3					965	971		10.1002/1097-0142(19940801)74:3<965::AID-CNCR2820740328>3.0.CO;2-Z			7	Oncology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Oncology	NZ352	WOS:A1994NZ35200027	8039126				2022-02-06	
J	LEVY, ML; REZAI, A; MASRI, LS; LITOFSKY, SN; GIANNOTTA, SL; APUZZO, MLJ; WEISS, MH; MILLER, JD; YOUNG, HF				LEVY, ML; REZAI, A; MASRI, LS; LITOFSKY, SN; GIANNOTTA, SL; APUZZO, MLJ; WEISS, MH; MILLER, JD; YOUNG, HF			THE SIGNIFICANCE OF SUBARACHNOID HEMORRHAGE AFTER PENETRATING CRANIOCEREBRAL INJURY - CORRELATIONS WITH ANGIOGRAPHY AND OUTCOME IN A CIVILIAN POPULATION	NEUROSURGERY			English	Article						HEAD INJURY; PENETRATING CRANIOCEREBRAL INJURY; TRAUMATIC ANEURYSM; TRAUMATIC SUBARACHNOID HEMORRHAGE	TRAUMATIC INTRACRANIAL ANEURYSMS; MISSILE HEAD WOUNDS; GUNSHOT WOUNDS; MANAGEMENT; VASOSPASM; BRAIN; SCAN	CERTAIN CLINICAL FACTORS are considered to nave an effect on patient outcome after penetrating missile injury. These include bilateral hemispheric injury, ventricular hemorrhage, intracerebral hemorrhage, mass effect, and missile or bony fragmentation. The relationship of subarachnoid hemorrhage (SAH) after penetrating craniocerebral injury and outcome is unknown. In addition, controversy exists regarding the role of angiography and the incidence of traumatic intracranial aneurysm in this population. Finally, can we assume that the incidence of traumatic intracranial aneurysm is equal in military and civilian populations, given the absence of penetrating shrapnel injury in civilian populations? Now that computed tomography has supplanted angiography as the primary diagnostic modality, increasing vigilance on the part of the physician and examination of angiography in high-risk patients should allow for enhanced outcome. We evaluated 100 patients with a diagnosis of cerebral gunshot wound over a 12-month period. All patients were evaluated neurologically at the time of admission and had imaging studies. Thirty-one patients with radiological evidence of SAH on computed tomography underwent angiography. Angiograms were limited to the side of the injury in patients with single-lobe or unilateral multilobe injuries and were bilateral in patients with bilateral hemispheric involvement. One intracranial aneurysm (3.2%) was documented and treated surgically. In those patients who died within 48 hours of admission, 68% had SAH as compared with only 17% of those surviving. Outcome was based upon neurological evaluation at the time of discharge and at the time of clinical follow-up at 3 and 6 months. Of those patients admitted with SAH, one remained vegetative, four were severely disabled, five were moderately disabled, and three had good recovery. Eighteen patients died (68%). We report on a statistically significant correlation between SAH and poor outcome after penetrating injury (P < 0.001). We found no correlation between the presence of intracerebral hemorrhage and outcome. The incidence of traumatic intracranial aneurysm in our civilian series did not differ from that in large military populations, despite the absence of shrapnel injury.	UNIV SO CALIF,SCH MED,DEPT NEUROL SURG,1200 N STATE ST,SUITE 5046,LOS ANGELES,CA 90033								AARABI B, 1987, NEUROSURGERY, V20, P610, DOI 10.1227/00006123-198704000-00018; AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACOSTA C, 1972, J NEUROSURG, V36, P531, DOI 10.3171/jns.1972.36.5.0531; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; BARNETT JC, 1955, J NEUROSURG, V12, P34, DOI 10.3171/jns.1955.12.1.0034; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BLACK PM, 1986, NEUROSURGERY, V18, P12, DOI 10.1227/00006123-198601000-00003; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; COLUMELLA F, 1963, ACTA RADIOL DIAGN, V1, P239, DOI 10.1177/028418516300100217; COOPER PR, 1979, NEUROSURGERY, V4, P373, DOI 10.1227/00006123-197905000-00001; CUSHING H, 1918, BRIT MED J, V1, P221; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FALSETTI HL, 1966, DIS CHEST, V49, P420, DOI 10.1378/chest.49.4.420; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; FONHANWEHR RI, 1986, INTRACRANIAL ANEURYS, P96; FOX JL, 1983, INTRACRANIAL ANEURYS, V1, P423; FRASER RAR, 1975, STROKE, V6, P153, DOI 10.1161/01.STR.6.2.153; GIANNOTTA SL, 1982, CLIN NEUR, V29, P288; GIANNOTTA SL, 1985, NEUROSURGERY, P1678; GREITZ T, 1961, ANGIOGRAPHY, P95; GROLIMUND P, 1988, LANCET, V2, P1173; GUIBERT, 1895, ANN OCUL, V113, P314; HADDAD FS, 1978, CAN J SURG, V21, P233; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HUBER P, 1963, Fortschr Geb Rontgenstr Nuklearmed, V98, P292; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KISTLER JP, 1983, NEUROLOGY, V33, P424, DOI 10.1212/WNL.33.4.424; LIN PJ, 1966, ACTA RADIOL, V5, P341; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MCCULLOUGH D, 1971, J TRAUM, V11, P422, DOI 10.1097/00005373-197105000-00007; Meirowsky A., 1965, NEUROLOGICAL SURGERY, P103; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; PASQUALIN A, 1984, NEUROSURGERY, V15, P344, DOI 10.1227/00006123-198409000-00009; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; SCHWARTZ HG, 1948, ANN SURG, V127, P58, DOI 10.1097/00000658-194801000-00006; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; VILATO RJ, 1962, NEURO-CHIR, V8, P217; WANNAMAKER GT, 1954, J NEUROSURG, V11, P151, DOI 10.3171/jns.1954.11.2.0151; WILKINS RH, 1980, CEREBRAL ARTERIAL SP, P472; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	46	74	77	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	APR	1993	32	4					532	540		10.1227/00006123-199304000-00007			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	KV759	WOS:A1993KV75900007	8474643				2022-02-06	
J	BIAGAS, KV; UHL, MW; SCHIDING, JK; NEMOTO, EM; KOCHANEK, PM				BIAGAS, KV; UHL, MW; SCHIDING, JK; NEMOTO, EM; KOCHANEK, PM			ASSESSMENT OF POSTTRAUMATIC POLYMORPHONUCLEAR LEUKOCYTE ACCUMULATION IN RAT-BRAIN USING TISSUE MYELOPEROXIDASE ASSAY AND VINBLASTINE TREATMENT	JOURNAL OF NEUROTRAUMA			English	Article							BLOOD-FLOW; INJURY; INFILTRATION; INFLAMMATION; MACROPHAGES; RELEASE	Polymorphonuclear leukocytes (PMN) are implicated in the pathogenesis of traumatic brain injury. We tested the following hypotheses: (1) leukocyte accumulation is present in brain tissue 24 h posttrauma, (2) leukocyte accumulation represents PMN, and (3) prior systemic PMN depletion attenuates brain tissue PMN accumulation. Trauma was induced in exposed right parietal cortex by weightdrop in anesthetized Wistar rats (n = 24). Of the traumatized rats, 12 were PMN-depleted with vinblastine sulfate i.v. Controls were 12 normal rats and 5 sham-operated rats (craniotomy). Sections of traumatized and contralateral hemispheres were analyzed for myeloperoxidase (MPO) activity. Brain MPO activity was increased fivefold at 24 h posttrauma, but only in the traumatized hemisphere (0.448 +/- 0.133 U/g vs 0.090 +/- 0.022 U/g in trauma vs normal, respectively, p < 0.05, mean +/- SEM). PMN depletion attenuated this increase in MPO activity and decreased circulating PMN counts (0.07 +/- 0.032 x 10(9)/L vs 0.894 +/- 0.294 x 10(9)/L PMN-depleted-trauma vs trauma rats, respectively, p < 0.05). Leukocyte accumulation in the brain posttrauma was confirmed by MPO assay. Inhibition of MPO activity in the PMN-depleted group and the specificity of vinblastine treatment for depletion of circulating PMN suggest that leukocyte accumulation in the brain at 24 h posttrauma is largely due to PMN.	UNIV PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT ANESTHESIOL & CRIT CARE MED, PITTSBURGH, PA 15260 USA					Kochanek, Patrick/0000-0002-2627-913X			Barman T.E., 1985, ENZYME HDB, VI, P234; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BOS A, 1978, BIOCHIM BIOPHYS ACTA, V525, P37, DOI 10.1016/0005-2744(78)90197-3; BOYA J, 1986, ACTA ANAT, V127, P142; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CLARK RA, 1979, J CLIN INVEST, V63, P177, DOI 10.1172/JCI109287; CLARK WM, 1991, STROKE, V22, P877, DOI 10.1161/01.STR.22.7.877; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; DUVAL DL, 1990, LIFE SCI, V47, pPL145, DOI 10.1016/0024-3205(90)90164-M; FARACI FM, 1991, STROKE, V22, P790, DOI 10.1161/01.STR.22.6.790; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GRUNDL P D, 1991, Society for Neuroscience Abstracts, V17, P721; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; KATZ IR, 1990, J NEUROIMMUNOL, V29, P33, DOI 10.1016/0165-5728(90)90145-D; KAUR C, 1987, J ANAT, V154, P215; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; LEMANSKE RF, 1983, J IMMUNOL, V130, P2837; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; RINALDO JE, 1988, AM REV RESPIR DIS, V137, P345, DOI 10.1164/ajrccm/137.2.345; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; UHL MW, IN PRESS ADV EXPT ME; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x	25	74	75	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	WIN	1992	9	4					363	371		10.1089/neu.1992.9.363			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	KH753	WOS:A1992KH75300006	1337917				2022-02-06	
J	ETCOFF, NL; FREEMAN, R; CAVE, KR				ETCOFF, NL; FREEMAN, R; CAVE, KR			CAN WE LOSE MEMORIES OF FACES - CONTENT SPECIFICITY AND AWARENESS IN A PROSOPAGNOSIC	JOURNAL OF COGNITIVE NEUROSCIENCE			English	Article							POSTERIOR CEREBRAL-LESIONS; ASSOCIATIVE VISUAL AGNOSIA; MENTAL-IMAGERY; FACIAL RECOGNITION; REPRESENTATION; ORGANIZATION; KNOWLEDGE; DISORDERS; IDENTITY; CONTOURS	Prosopagnosia is a neurological syndrome in which patients cannot recognize faces. Recently it has been shown that some prosopagnosics give evidence of "covert" recognition: they show greater autonomic responses to familar faces than to unfamiliar ones, and respond differently to familiar faces in learning and interference tasks. Although some patients do not show covert recognition, this has usually been attributed to an "apperceptive" deficit that impairs perceptual analysis of the input. The implication is that prosopagnosia is a deficit in access to, or awareness of, memories of faces: the inducing brain injury does not destroy the memories themselves. We present a case study that challenges this view. LH suffers from prosopagnosia as the result of a closed head injury. He cannot recognize familiar faces or report that they are familiar, nor answer questions about the faces from memory, though he can (1) recognize common objects and subtly varying shapes, (2) match faces while ignoring irrelevant information such as emotional expression or angle of view, (3) recognize sex, age, and likeability from faces, and (4) recognize people by a number of nonfacial channels. The only other categories of shapes that he has marked trouble recognizing are animals and emotional expressions, though even these impairments were not as severe as the one for faces. Three measures (sympathetic skin response, pupil dilation, and learning correct and incorrect names of faces) failed to show any signs of covert face recognition in LH, though the measures were sensitive enough to reflect autonomic reactions in LH to stimuli other than faces, and face familiarity in normal controls. Thus prosopagnosia cannot always be attributed to a mere absence of awareness (i.e., preserved information about faces whose output is disconnected from conscious congnitive processing), to an apperceptive deficit (i.e., preserved information about faces that cannot be accessed due to improperly analyzed perceptual input), or to an inability to recognize complex or subtly varying shapes (i.e., loss or degradation of shape memory in general). We conclude that it is possible for brain injury to eliminate the storage of information about familiar faces and certain related shapes.	MASSACHUSETTS GEN HOSP,NEUROPSYCHOL LAB,BOSTON,MA 02114; BETH ISRAEL HOSP,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; NEW ENGLAND DEACONESS HOSP,DIV NEUROL,BOSTON,MA 02215; UNIV CALIF SAN DIEGO,DEPT PSYCHOL,SAN DIEGO,CA 92103		ETCOFF, NL (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,E10-237A,CAMBRIDGE,MA 02139, USA.						ALBERT ML, 1975, NEUROLOGY, V25, P322, DOI 10.1212/WNL.25.4.322; ALBERT MS, 1979, ARCH NEUROL-CHICAGO, V36, P211, DOI 10.1001/archneur.1979.00500400065010; Bauer R.M., 1986, ASPECTS FACE PROCESS, P253, DOI 10.1007/978-94-009-4420-6_27.; BAUER RM, 1984, NEUROPSYCHOLOGIA, V22, P457, DOI 10.1016/0028-3932(84)90040-X; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BODAMER J, 1947, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V118, P6, DOI 10.1007/BF00352849; Bornstein B., 1963, PROBLEMS DYNAMIC NEU; BRUYER R, 1983, BRAIN COGNITION, V2, P257, DOI 10.1016/0278-2626(83)90014-3; CAREY S, 1982, U SHAPED BEHAVIORAL; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; DAMASIO AR, 1986, ASPECTS FACE PROCESS, P279; DEHAAN EHF, 1987, COGN NEUROPSYCHOL, V4, P385, DOI 10.1080/02643298708252045; Ekman P., 1975, PICTURES FACIAL AFFE; Ellis H. D., 1986, ASPECTS FACE PROCESS, P243, DOI DOI 10.1007/978-94-009-4420-6_26; ETCOFF NL, 1984, NEUROPSYCHOLOGIA, V22, P281, DOI 10.1016/0028-3932(84)90075-7; ETCOFF NL, 1991, INT NEUROPSYCHOLOGIC; FARAH MJ, 1988, COGNITIVE PSYCHOL, V20, P439, DOI 10.1016/0010-0285(88)90012-6; FERRO JM, 1984, CORTEX, V20, P121, DOI 10.1016/S0010-9452(84)80029-5; FINKE RA, 1989, COGNITIVE SCI, V13, P51, DOI 10.1207/s15516709cog1301_2; GARNER WR, 1974, PROCESSING INFORMATI; HECAEN H, 1974, NEUROPSYCHOLOGIA, V12, P447, DOI 10.1016/0028-3932(74)90075-X; Hess E.H., 1972, HDB PSYCHOPHYSIOLOGY, P491, DOI DOI 10.3758/BF03204445; Hooper H., 1958, HOOPER VISUAL ORG TE; Kanisza G., 1982, ORG REPRESENTATION P, P167; KANIZSA G, 1976, SCI AM, V234, P48, DOI 10.1038/scientificamerican0476-48; Kanizsa Gaetano, 1979, ORG VISION ESSAYS GE; LANDIS T, 1986, CORTEX, V22, P243, DOI 10.1016/S0010-9452(86)80048-X; LEVINE DN, 1980, PSYCHOL RES-PSYCH FO, V41, P217, DOI 10.1007/BF00308658; LEVINE DN, 1985, NEUROLOGY, V35, P1010, DOI 10.1212/WNL.35.7.1010; LEVINE DN, 1989, BRAIN COGNITION, V10, P149, DOI 10.1016/0278-2626(89)90051-1; Lissauer H., 1890, ARCH PSYCHIAT NERVEN, V21, P222, DOI [DOI 10.1007/BF02226765, 10.1007/BF02226765]; MARR D, 1978, PROC R SOC SER B-BIO, V200, P269, DOI 10.1098/rspb.1978.0020; Marr D., 1982, VISION; MARSLENWILSON WD, 1975, NEUROPSYCHOLOGIA, V13, P347; MCCARTHY RA, 1986, J NEUROL NEUROSUR PS, V49, P1233, DOI 10.1136/jnnp.49.11.1233; MICHEL F, 1986, REV NEUROL, V142, P545; NEWCOMBE F, 1989, NEUROPSYCHOLOGIA, V27, P179, DOI 10.1016/0028-3932(89)90170-X; PERRETT DI, 1984, HUM NEUROBIOL, V3, P197; PINKER S, 1984, COGNITION, V18, P1, DOI 10.1016/0010-0277(84)90021-0; POSNER MI, 1970, J EXP PSYCHOL, V83, P304, DOI 10.1037/h0028558; POSNER MI, 1968, J EXP PSYCHOL, V77, P353, DOI 10.1037/h0025953; RENAULT B, 1989, NEUROPSYCHOLOGIA, V27, P905, DOI 10.1016/0028-3932(89)90066-3; Schacter D. L., 1988, THOUGHT LANGUAGE; SERGENT J, 1989, BRAIN, V112, P975, DOI 10.1093/brain/112.4.975; SHAHANI BT, 1984, J NEUROL NEUROSUR PS, V47, P536, DOI 10.1136/jnnp.47.5.536; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; TARR MJ, 1989, COGNITIVE PSYCHOL, V21, P233, DOI 10.1016/0010-0285(89)90009-1; TARR MJ, 1989, THESIS MIT; TEUBER HL, 1968, ANAL BEHAVIORAL CHAN; THOMPSON P, 1980, PERCEPTION, V9, P483, DOI 10.1068/p090483; TRANEL D, 1985, SCIENCE, V228, P1453, DOI 10.1126/science.4012303; TRANEL D, 1988, BEHAV BRAIN RES, V30, P235, DOI 10.1016/0166-4328(88)90166-0; Van Allen MW, 1968, CORTEX, V93, P38, DOI [10.1016/S0010-9452(68)80018-8, DOI 10.1016/S0010-9452(68)80018, 10.1016/S0010-9452(68)80018]; VANLANCKER D, 1987, NEUROPSYCHOLOGIA, V25, P829, DOI 10.1016/0028-3932(87)90120-5; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; WARRINGTON E K, 1973, Cortex, V9, P152; WARRINGTON EK, 1978, PERCEPTION, V7, P695, DOI 10.1068/p070695; YOUNG AW, 1988, Q J EXP PSYCHOL-A, V40, P561, DOI 10.1080/02724988843000087; YOUNG AW, 1989, BRAIN COGNITION, V9, P16, DOI 10.1016/0278-2626(89)90042-0; YOUNG AW, 1988, THOUGHT LANGUAGE, V78	60	74	74	0	16	MIT PRESS	CAMBRIDGE	55 HAYWARD ST JOURNALS DEPT, CAMBRIDGE, MA 02142	0898-929X			J COGNITIVE NEUROSCI	J. Cogn. Neurosci.	WIN	1991	3	1					25	41		10.1162/jocn.1991.3.1.25			17	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	FC735	WOS:A1991FC73500004	23964803				2022-02-06	
J	KRIEL, RL; KRACH, LE; PANSER, LA				KRIEL, RL; KRACH, LE; PANSER, LA			CLOSED HEAD-INJURY - COMPARISON OF CHILDREN YOUNGER AND OLDER THAN 6 YEARS OF AGE	PEDIATRIC NEUROLOGY			English	Article											KRIEL, RL (corresponding author), GILLETTE CHILDRENS HOSP,DEPT PEDIAT NEUROL,200 E UNIV AVE,ST PAUL,MN 55101, USA.							0	74	74	0	3	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0887-8994			PEDIATR NEUROL	Pediatr. Neurol.	SEP-OCT	1989	5	5					296	300		10.1016/0887-8994(89)90021-0			5	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	AW661	WOS:A1989AW66100005	2803387				2022-02-06	
J	Vink, R; Faden, AI; McIntosh, TK				Vink, Robert; Faden, Alan I.; McIntosh, Tracy K.			Changes in Cellular Bioenergetic State Following Graded Traumatic Brain Injury in Rats: Determination by Phosphorus 31 Magnetic Resonance Spectroscopy	JOURNAL OF NEUROTRAUMA			English	Article							HUMAN MITOCHONDRIAL MYOPATHIES; P-31 NMR; IN-VIVO; CREATINE-KINASE; ENERGY-STATE; HEAD-INJURY; FREE MG-2+; METABOLISM; MAGNESIUM; PH	Phosphorus 31 magnetic resonance spectroscopy (P-31 MRS) was used to study noninvasively the intracellular free Mg2+ concentration and cellular bioenergetic state of rat brain in vivo before and after fluid percussion-induced traumatic brain injury of graded severity. Brain injury was induced at four levels: low (1.0 +/- 0.5 atm); moderate (2.1 +/- 0.4 atm); high (3.9 +/- 0.9 atm); and severe (5.9 +/- 0.7 atm). Prior to injury, mean intracellular values for all groups (n = 24; mean +/- SE) were as follows: pH = 7.11 +/- 0.03; free [Mg2+] = 0.99 +/- 0.07 mM; cytosolic [ADP] = 25.2 +/- 0.8 nmol/g wet weight; cytosolic [AMP] = 0.29 +/- 0.02 nmol/g wet weight; cytosolic phosphorylation potential = 118.5 +/- 3.1 x 10(3) M-1; free energy of ATP hydrolysis = 62.11 +/- 0.04 kJ/mole; and energy charge = 0.99 +/- 0.01. Following every level of injury, there were decreases in intracellular free Mg2+ concentration, and alterations in the intracellular pH. These posttraumatic changes in Mg2+ and pH induced shifts in the equilibrium constants of the creatine kinase, adenylate kinase, and ATPase reactions, resulting in alterations in [ADP], [AMP], cytosolic phosphorylation potential, and free energy of hydrolysis, but not in the energy charge. The alterations in cytosolic phosphorylation potential following trauma were linearly correlated with the changes in intracellular free Mg2+ concentration. None of the individual bioenergetic parameters could be correlated with the severity of injury over the entire injury range; however, an association between cytosolic phosphorylation potential and reversibility of injury was apparent. These results suggest that reductions in cellular bioenergetic state following traumatic brain injury occur through a posttraumatic decrease in the cells' capacity for oxidative phosphorylation, which itself may be directly related to the intracellular free Mg2+ concentration.	[Vink, Robert; Faden, Alan I.; McIntosh, Tracy K.] Univ Calif San Francisco, Dept Neurol, Ctr Neural Injury, San Francisco, CA USA; [Vink, Robert; Faden, Alan I.; McIntosh, Tracy K.] Vet Adm Med Ctr, San Francisco, CA 94121 USA		Vink, R (corresponding author), James Cook Univ, Dept Chem & Biochem, Townsville, Qld 4811, Australia.		Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [902269]; Veterans Administration Merit ReviewUS Department of Veterans Affairs [79]; Queen Elizabeth II Fellowship [79]	This work was supported, in part, by Centers for Disease Control Grant # 902269 to AIF, and by a Veterans Administration Merit Review to TKM. R. Vink is a recipient of a Queen Elizabeth II Fellowship. We thank Dr. Peter J. Rogers of Griffith University, Australia, for helpful discussions.	Aikawa J.K., 1981, MAGNESIUM ITS BIOL S, V1st ed.; ARGOV Z, 1987, NEUROLOGY, V37, P257, DOI 10.1212/WNL.37.2.257; ARNOLD DL, 1985, ANN NEUROL, V18, P189, DOI 10.1002/ana.410180205; ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; AVISON MJ, 1986, ANNU REV BIOPHYS BIO, V15, P377; BALENTINE JD, 1985, CENTRAL NERVOUS SYST, P455; BINET A, 1975, ARCH BIOCHEM BIOPHYS, V170, P576, DOI 10.1016/0003-9861(75)90153-8; CAMPBELL ID, 1973, J MAGN RESON, V11, P172, DOI 10.1016/0022-2364(73)90004-8; CHANCE B, 1978, P NATL ACAD SCI USA, V75, P4925, DOI 10.1073/pnas.75.10.4925; CHANCE B, 1980, P NATL ACAD SCI-BIOL, V77, P7430, DOI 10.1073/pnas.77.12.7430; CUNNINGHAM CC, 1986, BIOCHIM BIOPHYS ACTA, V885, P12, DOI 10.1016/0167-4889(86)90033-9; DAGANI F, 1987, J NEUROCHEM, V49, P1229, DOI 10.1111/j.1471-4159.1987.tb10015.x; DAWSON MJ, 1980, J PHYSIOL-LONDON, V299, P465, DOI 10.1113/jphysiol.1980.sp013137; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ERECINSKA M, 1982, J MEMBRANE BIOL, V70, P1, DOI 10.1007/BF01871584; EVELHOCH JL, 1985, MAGNET RESON MED, V2, P410, DOI 10.1002/mrm.1910020409; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; GADIAN DG, 1982, NUCL MAGNETIC RESONA; GUNTHER T, 1984, BIOCHEM BIOPH RES CO, V119, P124, DOI 10.1016/0006-291X(84)91627-9; GUPTA RK, 1984, ANNU REV BIOPHYS BIO, V13, P221; GYULAI L, 1985, J BIOL CHEM, V260, P3947; HILBERMAN M, 1984, J CEREBR BLOOD F MET, V4, P334, DOI 10.1038/jcbfm.1984.50; KUBY SA, 1962, ENZYMES, V6, P515; KUSHMERICK MJ, 1986, J BIOL CHEM, V261, P4420; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LJUNGGREN B, 1974, BRAIN RES, V73, P277, DOI 10.1016/0006-8993(74)91049-X; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; Mclntosh T.K., 1989, NEUROSCIENC IN PRESS; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; OGAWA S, 1986, ARCH BIOCHEM BIOPHYS, V248, P43, DOI 10.1016/0003-9861(86)90399-1; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PRICHARD JW, 1986, ANNU REV NEUROSCI, V9, P61; SHOUBRIDGE EA, 1982, FEBS LETT, V140, P288, DOI 10.1016/0014-5793(82)80916-2; Siesj? BK., 1978, BRAIN ENERGY METABOL; Siesjo B.K., 1981, J CEREB BLOOD FLOW M, V1, P1; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VELOSO D, 1973, J BIOL CHEM, V248, P4811; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; VINK R, 1984, BIOCHEMISTRY-US, V23, P3667, DOI 10.1021/bi00311a015; Yamakami I., 1987, ABSTR SOC NEUROSCI, P1501	45	74	77	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma		1988	5	4					315	U90		10.1089/neu.1988.5.315			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	V21VO	WOS:000208235300005	3249310				2022-02-06	
J	Kenny, EM; Fidan, E; Yang, Q; Anthonymuthu, TS; New, LA; Meyer, EA; Wang, H; Kochanek, PM; Dixon, CE; Kagan, VE; Bayir, H				Kenny, Elizabeth M.; Fidan, Emin; Yang, Qin; Anthonymuthu, Tamil S.; New, Lee Ann; Meyer, Elizabeth A.; Wang, Hong; Kochanek, Patrick M.; Dixon, C. Edward; Kagan, Valerian E.; Bayir, Hulya			Ferroptosis Contributes to Neuronal Death and Functional Outcome After Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						baicalein; cell death; ferroptosis; lipid oxidation; lipoxygenase; traumatic brain injury	CONTROLLED CORTICAL IMPACT; POLYUNSATURATED FATTY-ACIDS; GLUTATHIONE-PEROXIDASE 4; OXIDATIVE STRESS; CELL-DEATH; COGNITIVE DEFICITS; LIPID-PEROXIDATION; UNITED-STATES; BAICALEIN; 12/15-LIPOXYGENASE	Objectives: Traumatic brain injury triggers multiple cell death pathways, possibly including ferroptosis-a recently described cell death pathway that results from accumulation of 15-lipoxygenase-mediated lipid oxidation products, specifically oxidized phosphatidylethanolamine containing arachidonic or adrenic acid. This study aimed to investigate whether ferroptosis contributed to the pathogenesis of in vitro and in vivo traumatic brain injury, and whether inhibition of 15-lipoxygenase provided neuroprotection. Design: Cell culture study and randomized controlled animal study. Setting: University research laboratory. Subjects: HT22 neuronal cell line and adult male C57BL/6 mice. Interventions: HT22 cells were subjected to pharmacologic induction of ferroptosis or mechanical stretch injury with and without administration of inhibitors of ferroptosis. Mice were subjected to sham or controlled cortical impact injury. Injured mice were randomized to receive vehicle or baicalein (12/15-lipoxygenase inhibitor) at 10-15 minutes postinjury. Measurements and Main Results: Pharmacologic inducers of ferroptosis and mechanical stretch injury resulted in cell death that was rescued by prototypical antiferroptotic agents including baicalein. Liquid chromatography tandem-mass spectrometry revealed the abundance of arachidonic/adrenic-phosphatidylethanolamine compared with other arachidonic/adrenic acid-containing phospholipids in the brain. Controlled cortical impact resulted in accumulation of oxidized phosphatidylethanolamine, increased expression of 15-lipoxygenase and acyl-CoA synthetase long-chain family member 4 (enzyme that generates substrate for the esterification of arachidonic/adrenic acid into phosphatidylethanolamine), and depletion of glutathione in the ipsilateral cortex. Postinjury administration of baicalein attenuated oxidation of arachidonic/adrenic acid-containing-phosphatidylethanolamine, decreased the number of terminal deoxynucleotidyl transferase dUTP nick-end labeling positive cells in the hippocampus, and improved spatial memory acquisition versus vehicle. Conclusions: Biomarkers of ferroptotic death were increased after traumatic brain injury. Baicalein decreased ferroptotic phosphatidylethanolamine oxidation and improved outcome after controlled cortical impact, suggesting that 15-lipoxygenase pathway might be a valuable therapeutic target after traumatic brain injury. (Crit Care Med 2019; 47:410-418)	[Kenny, Elizabeth M.; Fidan, Emin; Yang, Qin; Anthonymuthu, Tamil S.; New, Lee Ann; Meyer, Elizabeth A.; Bayir, Hulya] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Kenny, Elizabeth M.; Fidan, Emin; Yang, Qin; Anthonymuthu, Tamil S.; New, Lee Ann; Meyer, Elizabeth A.; Kochanek, Patrick M.; Dixon, C. Edward; Bayir, Hulya] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Kenny, Elizabeth M.; Fidan, Emin; Yang, Qin; Anthonymuthu, Tamil S.; Kagan, Valerian E.; Bayir, Hulya] Univ Pittsburgh, Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA 15260 USA; [Wang, Hong] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; [Kagan, Valerian E.; Bayir, Hulya] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15261 USA; [Kagan, Valerian E.; Bayir, Hulya] IM Sechenov Moscow State Med Univ, Inst Regenerat Med, Lab Nav Redox Lipid, Moscow, Russia; [Bayir, Hulya] UPMC Childrens Hosp Pittsburgh, Childrens Neurosci Inst, Pittsburgh, PA 15224 USA		Bayir, H (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Bayir, H (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.; Bayir, H (corresponding author), Univ Pittsburgh, Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA 15260 USA.; Bayir, H (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15261 USA.; Bayir, H (corresponding author), IM Sechenov Moscow State Med Univ, Inst Regenerat Med, Lab Nav Redox Lipid, Moscow, Russia.; Bayir, H (corresponding author), UPMC Childrens Hosp Pittsburgh, Childrens Neurosci Inst, Pittsburgh, PA 15224 USA.	bayihx@ccm.upmc.edu	Anthonymuthu, Tamil/I-5534-2019	Wang, Hong/0000-0003-0477-2908; Kagan, Valerian E./0000-0002-7245-1885	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS061817, NS076511, AI068021, NS079061]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061817, R01NS079061, R01NS076511] Funding Source: NIH RePORTER	Supported, in part, by National Institutes of Health grants (NS061817, NS076511, AI068021, and NS079061).	An CR, 2016, TRANSL STROKE RES, V7, P512, DOI 10.1007/s12975-016-0483-5; Angeli JPF, 2017, TRENDS PHARMACOL SCI, V38, P489, DOI 10.1016/j.tips.2017.02.005; Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; [Anonymous], 2015, C TRAUM BRAIN INJ US; Anthonymuthu TS, 2016, BRAIN RES, V1640, P57, DOI 10.1016/j.brainres.2016.02.006; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bazinet RP, 2014, NAT REV NEUROSCI, V15, P771, DOI 10.1038/nrn3820; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; Cao JY, 2016, CELL MOL LIFE SCI, V73, P2195, DOI 10.1007/s00018-016-2194-1; Chen LJ, 2015, J BIOL CHEM, V290, P28097, DOI 10.1074/jbc.M115.680090; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Coronado VG, 2012, BRAIN INJURY MED PRI, P84100; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/NCHEMBIO.2239, 10.1038/nchembio.2239]; Finkelstein E., 2006, INCIDENCE EC BURDEN; Gascon S, 2016, CELL STEM CELL, V18, P396, DOI 10.1016/j.stem.2015.12.003; Gerlai R, 2001, BEHAV BRAIN RES, V125, P269, DOI 10.1016/S0166-4328(01)00296-0; Gerlai RT, 2002, BRAIN RES BULL, V57, P3, DOI 10.1016/S0361-9230(01)00630-X; Hafting T, 2005, NATURE, V436, P801, DOI 10.1038/nature03721; Hambright WS, 2017, REDOX BIOL, V12, P8, DOI 10.1016/j.redox.2017.01.021; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Im HI, 2005, J PHARMACOL SCI, V98, P185, DOI 10.1254/jphs.SC0050014; Jameson JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104094; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jin G, 2008, STROKE, V39, P2538, DOI 10.1161/STROKEAHA.108.514927; Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/NCHEMBIO.2238, 10.1038/nchembio.2238]; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kuhn H, 2015, BBA-MOL CELL BIOL L, V1851, P308, DOI 10.1016/j.bbalip.2014.10.002; Lapchak PA, 2007, NEUROSCIENCE, V150, P585, DOI 10.1016/j.neuroscience.2007.09.033; Li Q, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90777; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; Lin YL, 2011, J ETHNOPHARMACOL, V138, P373, DOI 10.1016/j.jep.2011.09.014; Linkermann A, 2014, P NATL ACAD SCI USA, V111, P16836, DOI 10.1073/pnas.1415518111; Lok J, 2007, J NEUROTRAUM, V24, P1817, DOI 10.1089/neu.2007.0372; MOSER E, 1993, J NEUROSCI, V13, P3916; Platt SR, 2007, VET J, V173, P278, DOI 10.1016/j.tvjl.2005.11.007; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tonnus W, 2017, IMMUNOL REV, V277, P128, DOI 10.1111/imr.12551; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; van Leyen K, 2006, STROKE, V37, P3014, DOI 10.1161/01.STR.0000249004.25444.a5; Vorhees CV, 2014, ILAR J, V55, P310, DOI 10.1093/ilar/ilu013; Wei N, 2017, NEUROCHEM RES, V42, P1345, DOI 10.1007/s11064-017-2179-y; Wenzel SE, 2017, CELL, V171, P628, DOI 10.1016/j.cell.2017.09.044; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yang WS, 2016, P NATL ACAD SCI USA, V113, pE4966, DOI 10.1073/pnas.1603244113; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Yoo SE, 2012, FREE RADICAL BIO MED, V52, P1820, DOI 10.1016/j.freeradbiomed.2012.02.043; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zille M, 2017, STROKE, V48, P1033, DOI 10.1161/STROKEAHA.116.015609	60	73	77	9	47	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2019	47	3					410	418		10.1097/CCM.0000000000003555			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HL6ZT	WOS:000458886600027	30531185	Green Accepted	Y	N	2022-02-06	
J	Shahim, P; Tegner, Y; Marklund, N; Blennow, K; Zetterberg, H				Shahim, Pashtun; Tegner, Yelverton; Marklund, Niklas; Blennow, Kaj; Zetterberg, Henrik			Neurofilament light and tau as blood biomarkers for sports-related concussion	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; NEUROCHEMICAL AFTERMATH; POSTCONCUSSION SYNDROME; MILITARY PERSONNEL; DAMAGE; PLAYERS; PROTEIN; CHAIN	Objective To compare neurofilament light (NfL) and tau as blood-based biomarkers for acute sports-related concussion (SRC) and determine whether their concentrations at different time points after the injury are associated with prolonged time to return to play (RTP). Methods A total of 288 professional hockey players were followed longitudinally from September 1, 2012, to April 30, 2015. Data collection and biomarker analyses were conducted between 2015 and 2017. Associations were tested between blood concentrations of NfL and tau, and RTP time. Serum concentrations of S100B and neuron-specific enolase (NSE) were also measured for comparison. Results Of 288 players, 105 sustained an SRC. Of these, 87 underwent blood sampling 1, 12, 36, and 144 hours after SRC and at the RTP time point. Serum NfL concentrations 1, 12, 36, and 144 hours after SRC were related to prolonged RTP time, and could separate players with RTP >10 days from those with RTP <= 10 days (area under the receiver operating characteristic curve [AUROC] 0.82). Also, serum NfL 144 hours after SRC discriminated players who resigned from the game due to persistent postconcussion symptoms (PCS) from those who returned to play (AUROC 0.89). Plasma tau 1 hour after SRC was related to RTP but less strongly than NfL, while S100B and NSE showed no such associations. Conclusion Serum NfL outperformed tau, S100B, and NSE as a biomarker for SRC. From a clinical standpoint, serum NfL may be useful to identify individuals at risk of prolonged PCS, and may aid in biomarker-informed decisions with regard to when RTP should be considered.	[Shahim, Pashtun; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden; [Shahim, Pashtun; Blennow, Kaj; Zetterberg, Henrik] Sahlgrens Univ Hosp, Neurochem Lab, Molndal, Sweden; [Shahim, Pashtun] Lulea Univ Technol, Dept Hlth Sci, Div Med Sci, Lulea, Sweden; [Tegner, Yelverton] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Lund, Sweden; [Marklund, Niklas] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England; [Zetterberg, Henrik] UK Dementia Res Inst, London, England		Shahim, P (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden.; Shahim, P (corresponding author), Sahlgrens Univ Hosp, Neurochem Lab, Molndal, Sweden.; Shahim, P (corresponding author), Lulea Univ Technol, Dept Hlth Sci, Div Med Sci, Lulea, Sweden.	pashtun.shahim@gu.se		Tegner, Yelverton/0000-0003-3628-0705	Swedish Research CouncilSwedish Research CouncilEuropean Commission; European Research CouncilEuropean Research Council (ERC)European Commission; Centrum for Idrottsforskning; Torsten Soderberg Foundation; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; VINNOVAVinnova; Frimurarestiftelsen	The study was supported by grants from the Swedish Research Council, the European Research Council, Centrum for Idrottsforskning, the Torsten Soderberg Foundation, the Knut and Alice Wallenberg Foundation, VINNOVA, and Frimurarestiftelsen. The funding source had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.	Alosco Michael L, 2017, Alzheimers Dement (Amst), V7, P33, DOI 10.1016/j.dadm.2016.11.003; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bonneh-Barkay D, 2010, J NEUROTRAUM, V27, P1215, DOI 10.1089/neu.2010.1310; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; Gill J, 2017, NEUROLOGY, V88, P595, DOI 10.1212/WNL.0000000000003587; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Rojas JC, 2016, ANN CLIN TRANSL NEUR, V3, P216, DOI 10.1002/acn3.290; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2017, NEUROLOGY, V88, P1400, DOI 10.1212/WNL.0000000000003816; Shahim P, 2016, JAMA NEUROL, V73, P1308, DOI 10.1001/jamaneurol.2016.2038; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wiley CA, 2015, NEUROPATHOLOGY, V35, P95, DOI 10.1111/neup.12158; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	30	73	73	2	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 15	2018	90	20					E1780	E1788		10.1212/WNL.0000000000005518			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GN6CO	WOS:000439159900006	29653990	Green Published, hybrid			2022-02-06	
J	Ju, MJ; Liu, BF; He, HY; Gu, ZY; Liu, YM; Su, Y; Zhu, DM; Cang, J; Luo, Z				Ju, MinJie; Liu, BoFei; He, HongYu; Gu, ZhunYong; Liu, YiMei; Su, Ying; Zhu, DuMing; Cang, Jing; Luo, Zhe			MicroRNA-27a alleviates LPS-induced acute lung injury in mice via inhibiting inFLammation and apoptosis through modulating TLR4/MyD88/NF-kappa B pathway	CELL CYCLE			English	Article						Acute lung injury; inFLammation and apoptosis; microRNA-27a; TLR4/MyD88/NF-kappa B pathway	RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; DOWN-REGULATION; EXPRESSION; PROTECTS; MIR-27A; CELLS; BCL-2; DEATH	Acute lung injury (ALI) is a critical clinical condition with a high mortality rate, characterized with excessive uncontrolled inflammation and apoptosis. Recently, microRNAs (miRNAs) have been found to play crucial roles in the amelioration of various inflammation-induced diseases, including ALI. However, it remains unknown the biological function and regulatory mechanisms of miRNAs in the regulation of inFLammation and apoptosis in ALI. The aim of this study is to identify and evaluate the potential role of miRNAs in ALI and reveal the underlying molecular mechanisms of their effects. Here, we analyzed microRNA expression profiles in lung tissues from LPS-challenged mice using miRNA microarray. Because microRNA-27a (miR-27a) was one of the miRNAs being most significantly downregulated, which has an important role in regulation of inflammation, we investigated its function. Overexpression of miR-27a by agomir-27a improved lung injury, as evidenced by the reduced histopathological changes, lung wet/dry (W/D) ratio, lung microvascular permeability and apoptosis in the lung tissues, as well as ameliorative survival of ALI mice. This was accompanied by the alleviating of inflammation, such as the reduced total BALF cell and neutrophil counts, decreased levels of tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-6) interleukin-1 beta (IL-1 beta) and myeloperoxidase (MPO) activity in BAL fluid. Toll-like receptor 4 (TLR4), an important regulator of the nuclear factor kappa-B (NF-kappa B) signaling pathway, was identified as a novel target of miR-27a in RAW264.7 cells. Furthermore, our results showed that LPS stimulation increased the expression of MyD88 and NF-kappa B p65 (p-p65), but inhibited the expression of inhibitor of nuclear factor-kappa B-alpha (I kappa B-alpha), suggesting the activation of NF-kappa B signaling pathway. Further investigations revealed that agomir-miR-27a reversed the promoting effect of LPS on NF-kappa B signaling pathway. The results here suggested that miR-27a alleviates LPS-induced ALI in mice via reducing inFLammation and apoptosis through blocking TLR4/MyD88/NF-kappa B activation.	[Ju, MinJie; He, HongYu; Gu, ZhunYong; Liu, YiMei; Su, Ying; Zhu, DuMing; Luo, Zhe] Fudan Univ, Zhongshan Hosp, Dept Critial Care Med, Shanghai, Peoples R China; [Liu, BoFei] 1st People Hosp, Dept Intens Care Med, ZhangjiaGang, Peoples R China; [Cang, Jing] Fudan Univ, Zhongshan Hosp, Dept Anesthesiol, Shanghai, Peoples R China		Luo, Z (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Critial Care Med, Shanghai, Peoples R China.; Cang, J (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Anesthesiol, Shanghai, Peoples R China.	cang.jing@zs-hospital.sh.cn; luo.zhe@zs-hospital.sh.cn					Bao YP, 2013, ASIAN PAC J CANCER P, V14, P3751, DOI 10.7314/APJCP.2013.14.6.3751; Bardales RH, 1996, AM J PATHOL, V149, P845; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Ben DF, 2012, J SURG RES, V174, P326, DOI 10.1016/j.jss.2010.12.005; Bhargava M, 2012, TRANSL RES, V159, P205, DOI 10.1016/j.trsl.2012.01.007; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Brandenberger C, 2018, AGING DIS, V9, P553, DOI 10.14336/AD.2017.0902; Cai Q, 2016, NEURAL REGEN RES, V11, P1285, DOI 10.4103/1673-5374.189194; Chen CS, 2016, CELL BIOL TOXICOL, V32, P169, DOI 10.1007/s10565-016-9322-4; Chen JJ, 2017, AM J CHINESE MED, V45, P137, DOI 10.1142/S0192415X17500100; Cheng YC, 2015, ADV MATER SCI ENG, V2015, DOI 10.1155/2015/947834; Chi GF, 2013, INFLAMMATION, V36, P501, DOI 10.1007/s10753-012-9571-1; Chong AJ, 2004, J THORAC CARDIOV SUR, V128, P170, DOI 10.1016/j.jtcvs.2003.11.036; Deng GM, 2017, BIOMED PHARMACOTHER, V96, P148, DOI 10.1016/j.biopha.2017.09.094; Dengler V, 2013, AM J RESP CELL MOL, V49, P1, DOI 10.1165/rcmb.2012-0472TR; DosReis GA, 2004, J CELL MOL MED, V8, P285, DOI 10.1111/j.1582-4934.2004.tb00318.x; Duan YL, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-4; Eveillard M, 2010, J INFECTION, V60, P154, DOI 10.1016/j.jinf.2009.09.004; Fan HY, 2016, ONCOTARGET, V7, P39497, DOI 10.18632/oncotarget.8347; Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x; Fang L, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/283939; Fang Y, 2017, AM J TRANSL RES, V9, P1287; Ferrari RS, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/590987; Ferruelo A, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.10; Fu XD, 2016, BIOCHEM BIOPH RES CO, V477, P167, DOI 10.1016/j.bbrc.2016.06.038; Guo ZL, 2014, IMMUNOL LETT, V162, P18, DOI 10.1016/j.imlet.2014.06.008; Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013; Jiang KF, 2017, ONCOTARGET, V8, P71038, DOI 10.18632/oncotarget.20298; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; Lee W L, 2001, Curr Opin Crit Care, V7, P1, DOI 10.1097/00075198-200102000-00001; Li WQ, 2016, BIOMED PHARMACOTHER, V84, P1375, DOI 10.1016/j.biopha.2016.10.065; Li XQ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0246-3; Lv YN, 2017, CELL MOL NEUROBIOL, V37, P195, DOI 10.1007/s10571-016-0361-4; Mac Sweeney R, 2013, SEMIN RESP CRIT CARE, V34, P487, DOI 10.1055/s-0033-1351119; Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158; Meduri GU, 2007, LANCET, V370, P384, DOI 10.1016/S0140-6736(07)61184-2; Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269; Mendez JL, 2005, CURR OPIN CRIT CARE, V11, P29, DOI 10.1097/00075198-200502000-00005; Neudecker V, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5360; Parsey MV, 1998, J IMMUNOL, V160, P1007; Rajasekaran S, 2016, J CELL PHYSIOL, V231, P2097, DOI 10.1002/jcp.25316; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Shi DL, 2016, MOL CELLS, V39, P611, DOI 10.14348/molcells.2016.0103; Shi Lei, 2017, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V29, P244, DOI 10.3760/cma.j.issn.2095-4352.2017.03.010; Singh N, 2007, LANCET, V370, P383, DOI 10.1016/S0140-6736(07)61183-0; Song L, 2017, INFLAMMATION, V40, P927, DOI 10.1007/s10753-017-0537-1; Stapleton RD, 2005, CHEST, V128, P525, DOI 10.1378/chest.128.2.525; Su ZQ, 2014, INT IMMUNOPHARMACOL, V22, P371, DOI 10.1016/j.intimp.2014.06.043; Sun CC, 2015, ONCOTARGET, V6, P25533, DOI 10.18632/oncotarget.4575; Sun HY, 2017, CELL BIOL INT, V41, P739, DOI 10.1002/cbin.10768; Sun LQ, 2017, BIOCHEM BIOPH RES CO, V482, P1141, DOI 10.1016/j.bbrc.2016.12.001; Tang RR, 2016, BIOTECHNOL LETT, V38, P1277, DOI 10.1007/s10529-016-2107-2; Tian WF, 2017, CHINESE MED J-PEKING, V130, P859, DOI 10.4103/0366-6999.202735; Wu CT, 2018, INT J BIOCHEM CELL B, V101, P1, DOI 10.1016/j.biocel.2018.04.019; Xue WL, 2015, BIOCHEM BIOPH RES CO, V464, P855, DOI 10.1016/j.bbrc.2015.07.051; Yao H, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00120; Zhang TZ, 2015, TOXICOL MECH METHOD, V25, P665, DOI 10.3109/15376516.2015.1045652; Zhang TZ, 2015, INFLAMMATION, V38, P1529, DOI 10.1007/s10753-015-0127-z; Zhao G, 2017, ONCOTARGET, V8, P68153, DOI 10.18632/oncotarget.19249; Zhao JJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00389; Zhao XH, 2018, J CELL PHYSIOL, V233, P3048, DOI 10.1002/jcp.26053; Zhou T, 2011, TRANSL RES, V157, P180, DOI 10.1016/j.trsl.2011.01.010	64	73	80	1	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-4101	1551-4005		CELL CYCLE	Cell Cycle		2018	17	16					2001	2018		10.1080/15384101.2018.1509635			18	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	GZ6MY	WOS:000449552300006	30231673	Bronze, Green Published			2022-02-06	
J	Davis, GA; Purcell, L; Schneider, KJ; Yeates, KO; Gioia, GA; Anderson, V; Ellenbogen, RG; Echemendia, RJ; Makdissi, M; Sills, A; Iverson, GL; Dvorak, J; McCrory, P; Meeuwisse, W; Patricios, J; Giza, CC; Kutcher, JS				Davis, Gavin A.; Purcell, Laura; Schneider, Kathryn J.; Yeates, Keith Owen; Gioia, Gerard A.; Anderson, Vicki; Ellenbogen, Richard G.; Echemendia, Ruben J.; Makdissi, Michael; Sills, Allen; Iverson, Grant L.; Dvorak, Jiri; McCrory, Paul; Meeuwisse, Willem; Patricios, Jon; Giza, Christopher C.; Kutcher, Jeffrey S.			The Child Sport Concussion Assessment Tool 5th Edition (Child SCAT5): Background and rationale	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; ZURICH	This article presents the Child Sport Concussion Assessment Tool 5th Edition (Child SCAT5). The Sport Concussion Assessment Tool was introduced in 2004, following the 2nd International Conference on Concussion in Sport in Prague, Czech Republic. Following the 4th International Consensus Conference, held in Zurich, Switzerland, in 2012, the SCAT 3rd edition (Child SCAT3) was developed for children aged between 5 and12 years. Research to date was reviewed and synthesised for the 5th International Consensus Conference on Concussion in Sport in Berlin, Germany, leading to the current revision of the test, the Child SCAT5. This article describes the development of the Child SCAT5.	[Davis, Gavin A.; Anderson, Vicki] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Davis, Gavin A.; Makdissi, Michael; McCrory, Paul] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Austin Campus, Heidelberg, Vic, Australia; [Purcell, Laura] McMaster Univ, Dept Pediat, Hamilton, ON, Canada; [Schneider, Kathryn J.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Schneider, Kathryn J.] Univ Calgary, Cumming Sch Med, Alberta Childrens Hosp Res Inst Child & Maternal, Calgary, AB, Canada; [Schneider, Kathryn J.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Yeates, Keith Owen] Univ Calgary, Hotchkiss Brain Inst, Alberta Childrens Res Inst, Dept Psychol, Calgary, AB, Canada; [Gioia, Gerard A.] George Washington Univ, Sch Med, Div Pediat Neuropsychol, Childrens Natl Hlth Syst, Washington, DC USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Pediat & Psychiat & Behav Sci, Washington, DC USA; [Ellenbogen, Richard G.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Echemendia, Ruben J.] Univ Orthopaed Ctr, Concuss Care Clin, State Coll, PA USA; [Echemendia, Ruben J.] Univ Missouri, Kansas City, MO 64110 USA; [Makdissi, Michael] Olymp Pk Sports Med Ctr, Melbourne, Vic, Australia; [Sills, Allen] Vanderbilt Univ, Med Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA; [Iverson, Grant L.] Ctr Hlth & Rehabil Res, Dept Phys Med & Rehabil, Harvard Med Sch, Charlestown, MA USA; [Dvorak, Jiri] Schulthess Clin Zurich, Swiss Concuss Ctr, Zurich, Switzerland; [Meeuwisse, Willem] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Patricios, Jon] Univ Pretoria, Fac Hlth Sci, Sect Sports Med, Pretoria, South Africa; [Patricios, Jon] Univ Witwatersrand, Fac Hlth Sci, Dept Emergency Med, Johannesburg, South Africa; [Giza, Christopher C.] UCLA Steve Tisch BrainSPORT Program, Operat MEND TBI Program, Los Angeles, CA USA; [Kutcher, Jeffrey S.] CORE Inst, Sports Neurol Clin, Southfield, MI USA		Davis, GA (corresponding author), Cabrini Med Ctr, Neurosurg, Suite 53, Malvern, Vic, Australia.	gavin.davis@me.com	McCrory, Paul/Q-8688-2019; Yeates, Keith/AAJ-4223-2020; Echemendia, Ruben/R-6939-2019	Schneider, Kathryn/0000-0002-5951-5899; Yeates, Keith/0000-0001-7680-2892; McCrory, Paul/0000-0003-4850-0568; makdissi, michael/0000-0003-0334-7133; Davis, Gavin/0000-0001-8293-4496; Iverson, Grant/0000-0001-7348-9570; Patricios, Jon/0000-0002-6829-4098	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); AFL; Ad Hoc Committee; International Concussion in Sport Group; Mooney-Reed Charitable Foundation; ImPACT Applications, Inc.; CogState Inc.; Australian Football League; CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA; NCAA; DoDUnited States Department of Defense; Today's and Tomorrow's Children Fund; UCLA Brain Injury Research Center; UCLA Faculty Grants Program; UCLA Steve Tisch BrainSPORT program; Avanir; NINDS Neural Analytics SBIR grant	GAD is an honorary member of the Australian Football League Concussion Working Group and has attended meetings organised by sporting organisations including the NFL (USA), National Rugby League (Australia) and FIFA (Switzerland); however, he has not received any payment, research funding or other monies from these groups other than for travel costs. LP is an expert consultant to mdBriefcase in the development of an online concussion education module and has received speaking honoraria/travel expenses for presentations at scientific meetings. KJS has received speaking honoraria for presentations at scientific meetings. She is a physiotherapy consultant at Evidence Sport and Spinal Therapy in Calgary, Alberta, Canada, and for athletic teams. KOY has received grant funding from NIH and Canadian Institutes of Health Research and book royalties from Guilford Press and Cambridge University Press and has occasionally served as an expert witness in forensic cases; he is President-Elect of the International Neuropsychological Society and a member of the Expert Panel on Acute Diagnosis and Management of Mild Traumatic Brain Injury among Children and Adolescents convened by the Centers for Disease Control and Prevention. RGE is a volunteer co-chairman of the NFL Head Neck and Spine Medical Committee. RJE is a consultant to the NHL, Major League Soccer, US Soccer Federation and Princeton University. He has received financial remuneration for these consulting relationships. He has a clinical practice in sport neuropsychology and serves as an expert (neuropsychology, sport neuropsychology) in medico-legal cases involving traumatic brain injury. He at times has received honoraria and reimbursement of expenses to attend professional meetings. MM is Consultant Sport and Exercise Medicine Physician at Olympic Park Sports Medicine Centre, Team Doctor-Hawthorn football club (Australian Football League(AFL)). AFL research grant-funding for research program on concussion in AFL (collaboration between the AFL and the Florey Institute of Neuroscience & Mental Health). Shareholder-Olympic Park Sports Medicine Centre. IOC-travel and accommodation paid as part of Ad Hoc Committee to evaluate rule changes in boxing. FIFA-Travel and accommodation paid as part of International Concussion in Sport Group. AFL-support for travel to NFL concussion 'think tank' August 2014. CogState Pty Ltd-free access to computerised neuropsychological testing program for research purposes. AFL Doctors Association-paid role as executive officer. Honorary member of the Australian Rugby Union Concussion Advisory Group; World Rugby Concussion working group; Concussion in AFL working group; AFL Concussion Scientific Committee and Member and the International Olympic Committee ad hoc group to evaluate rule change in boxing. AS is an unaffiliated neurotrauma consultant, the NFL. GLI acknowledges philanthropic research support from the Mooney-Reed Charitable Foundation and ImPACT Applications, Inc. He has a medical-legal consulting practice, including expert testimony, in the area of neuropsychology and mild traumatic brain injury. PMcC is a co-investigator, collaborator, or consultant on grants relating to mild TBI funded by several governmental organizations. He is directly employed by the National Health & Medical Research Council of Australia and is based at the Florey Institute of Neuroscience and Mental Health.; He is Co-Chair of the Australian Centre for Research into Sports Injury and its Prevention (ACRISP), which is one of the International University Research Centres for Prevention of Injury and Protection of Athlete Health supported by the International Olympic Committee (IOC). He is co-chair of the International Concussion in Sport Group and is a member of the scientific advisory boards of the International Concussion & Head Injury Research Foundation (London, UK) and the Sports Surgery Clinic (Dublin, Ireland). He has a clinical and consulting practice in general and sports neurology. He receives book royalties from McGraw-Hill and was employed in an editorial capacity by the British Medical Journal Publishing Group from 2001 to 2008. He has been reimbursed by the government, professional scientific bodies, and sporting bodies for travel costs related to presenting research on mild TBI and sport-related concussion at meetings, scientific conferences, and symposiums. He received consultancy fees in 2010 from Axon Sports (US) for the development of educational material (which was not renewed) and has received research funding since 2001 from CogState Inc. The Australian Football League funds research at the Florey Institute under a legal memorandum and Dr. McCrory does not receive any money from this industry funded research. Dr. McCrory is a cofounder and shareholder in two biomedical companies (involved in eHealth and Compression garment technologies) but does not hold any individual shares in any company related to concussion or brain injury assessment or technology. He did not receive any form of financial support directly related to this manuscript. WM is Medical Director for the National Hockey League. JP is concussion consultant to South African Rugby's BokSmart injury prevention programme and a member of World Rugby's Concussion Advisory Group; both organisations have contributed honoraria towards conference expenses. GAG receives royalties as a test author from Psychological Assessment Resources, receives research funding from the CDC and NIH, receives speaking Honoria for professional lectures, and is on the pediatric mild TBI guidelines panel of the CDC. CCG receives grants/research support from NIH, NCAA, DoD, Today's and Tomorrow's Children Fund, UCLA Brain Injury Research Center, UCLA Faculty Grants Program, UCLA Steve Tisch BrainSPORT program, Avanir (research grant 2016-2017), NINDS Neural Analytics SBIR grant (2016-2018) Consultant: NFL-Neurological Care Program, NHLPA, Neural Analytics Inc (2015-16), is on the advisory panel of LoveYourBrain, MLS, NBA, NCAA, USSF, performs medicolegal work 1-2 cases annually, and speaks on the Medical Education Speakers Network. JSK provides consulting to National Basketball Association, National Football League Players' Association, National Hockey League Players' Association, ElMindA, Ltd. VA and JD have nothing to declare.	Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Brooks A, 2015, CLIN J SPORT MED, V25, P214; Davis GA, 2017, BR J SPORTS MED; Echemendia R, 2017, BRIT J SPORTS MED; Echemendia RJ, 2017, REV BR J SPORTS MED; Echemendia RJ., 2017, BR J SPORTS MED; Glaviano NR, 2015, CLIN J SPORT MED, V25, P373, DOI 10.1097/JSM.0000000000000154; Jennings D, 2015, INT J SPORTS PHYS TH, V10, P667; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meeuwisse W, 2017, BR J SPORTS MED; Nelson LD, 2016, CLIN J SPORT MED, P1	13	73	74	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN	2017	51	11					859	861		10.1136/bjsports-2017-097492			3	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	EW3QP	WOS:000402416500005	28446452				2022-02-06	
J	Kessler, RC; Stein, MB; Petukhova, MV; Bliese, P; Bossarte, RM; Bromet, EJ; Fullerton, CS; Gilman, SE; Ivany, C; Lewandowski-Romps, L; Bell, AM; Naifeh, JA; Nock, MK; Reis, BY; Rosellini, AJ; Sampson, NA; Zaslavsky, AM; Ursano, RJ				Kessler, R. C.; Stein, M. B.; Petukhova, M. V.; Bliese, P.; Bossarte, R. M.; Bromet, E. J.; Fullerton, C. S.; Gilman, S. E.; Ivany, C.; Lewandowski-Romps, L.; Bell, A. Millikan; Naifeh, J. A.; Nock, M. K.; Reis, B. Y.; Rosellini, A. J.; Sampson, N. A.; Zaslavsky, A. M.; Ursano, R. J.		Army STARRS Collaborators	Predicting suicides after outpatient mental health visits in the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS)	MOLECULAR PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; US ARMY; MILITARY; SOLDIERS; CARE; PREVENTION; DEATH; DEPLOYMENT; SYSTEM	The 2013 US Veterans Administration/Department of Defense Clinical Practice Guidelines (VA/DoD CPG) require comprehensive suicide risk assessments for VA/DoD patients with mental disorders but provide minimal guidance on how to carry out these assessments. Given that clinician-based assessments are not known to be strong predictors of suicide, we investigated whether a precision medicine model using administrative data after outpatient mental health specialty visits could be developed to predict suicides among outpatients. We focused on male nondeployed Regular US Army soldiers because they account for the vast majority of such suicides. Four machine learning classifiers (naive Bayes, random forests, support vector regression and elastic net penalized regression) were explored. Of the Army suicides in 2004-2009, 41.5% occurred among 12.0% of soldiers seen as outpatient by mental health specialists, with risk especially high within 26 weeks of visits. An elastic net classifier with 10-14 predictors optimized sensitivity (45.6% of suicide deaths occurring after the 15% of visits with highest predicted risk). Good model stability was found for a model using 2004-2007 data to predict 2008-2009 suicides, although stability decreased in a model using 2008-2009 data to predict 2010-2012 suicides. The 5% of visits with highest risk included only 0.1% of soldiers (1047.1 suicides/100 000 person-years in the 5 weeks after the visit). This is a high enough concentration of risk to have implications for targeting preventive interventions. An even better model might be developed in the future by including the enriched information on clinician-evaluated suicide risk mandated by the VA/DoD CPG to be recorded.	[Kessler, R. C.; Petukhova, M. V.; Rosellini, A. J.; Sampson, N. A.; Zaslavsky, A. M.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA; [Stein, M. B.] Univ Calif San Diego, Dept Psychiat & Family & Prevent Med, La Jolla, CA USA; [Stein, M. B.] VA San Diego Healthcare Syst, San Diego, CA USA; [Bliese, P.] Univ South Carolina, Darla Moore Sch Business, Columbia, SC USA; [Bossarte, R. M.] Post Deployment Hlth Serv, Dept Vet Affairs, Washington, DC USA; [Bromet, E. J.] Stony Brook Sch Med, Dept Psychiat & Behav Sci, Stony Brook, NY USA; [Fullerton, C. S.; Naifeh, J. A.; Ursano, R. J.] Uniformed Serv Univ Hlth Sci, Sch Med, Ctr Study Traumat Stress, Dept Psychiat, Bethesda, MD USA; [Gilman, S. E.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, Hlth Behav Branch, Bethesda, MD USA; [Gilman, S. E.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol & Social & Behav Sci, Boston, MA USA; [Ivany, C.] US Army Med Command, Behav Hlth Serv Line, Bethesda, MD USA; [Lewandowski-Romps, L.] Univ Michigan, Inst Social Res, Ann Arbor, MI USA; [Bell, A. Millikan] US Army Publ Hlth Command, Aberdeen Proving Ground, MD USA; [Nock, M. K.] Harvard Univ, Dept Psychol, Cambridge, MA USA; [Reis, B. Y.] Childrens Hosp Boston, Harvard Med Sch, Boston, MA USA		Kessler, RC (corresponding author), Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA.	Kessler@hcp.med.harvard.edu	Nock, Matthew/AAE-8330-2019; Ursano, Robert/ABE-6533-2020; Gilman, Stephen E./E-7632-2010; Bossarte, Robert/AAF-8571-2019	Gilman, Stephen E./0000-0002-8331-6419; Bliese, paul/0000-0002-5384-8879; Ursano, Robert/0000-0002-1861-9173; Naifeh, James/0000-0001-7248-3054	Department of the Army; US Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH) [U01MH087981]; Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [ZIAHD008960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U01MH087981] Funding Source: NIH RePORTER	Army STARRS was sponsored by the Department of the Army and funded under cooperative agreement number U01MH087981 with the US Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH). Dr Gilman's participation in this work was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. We thank Kenneth L Cox for helpful comments on an earlier version of this paper. Although a draft of this manuscript was submitted to the Army and NIMH for review and comment before submission, this was with the understanding that comments would be no more than advisory.	Ahmedani BK, 2014, J GEN INTERN MED, V29, P870, DOI 10.1007/s11606-014-2767-3; Armed Forces Health Surveillance Center (AFHSC), 2012, MSMR, V19, P7; Bachynski KE, 2012, INJURY PREV, V18, P405, DOI 10.1136/injuryprev-2011-040112; Bell NS, 2010, SUICIDE LIFE-THREAT, V40, P407, DOI 10.1521/suli.2010.40.4.407; Berrouiguet S, 2014, PSYCHIAT RES, V217, P154, DOI 10.1016/j.psychres.2014.02.034; Black SA, 2011, MIL PSYCHOL, V23, P433, DOI 10.1080/08995605.2011.590409; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brown GK, 2000, J CONSULT CLIN PSYCH, V68, P371, DOI 10.1037/0022-006X.68.3.371; Brugnoli R, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-83; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; ERDMAN HP, 1987, J CLIN PSYCHIAT, V48, P464; FDB Health. FDB First Databank, 2015, FDB 1 DAT; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gilman SE, 2014, PSYCHOL MED, V44, P2579, DOI 10.1017/S003329171400018X; Grove WM, 2000, PSYCHOL ASSESSMENT, V12, P19, DOI 10.1037/1040-3590.12.1.19; GUSTAFSON DH, 1977, COMPUT BIOMED RES, V10, P83, DOI 10.1016/0010-4809(77)90026-X; GUSTAFSON DH, 1981, COMPUT BIOMED RES, V14, P144, DOI 10.1016/0010-4809(81)90032-X; Hyman J, 2012, AM J PUBLIC HEALTH, V102, pS138, DOI 10.2105/AJPH.2011.300484; Ireland RR, 2012, MIL MED, V177, P1149, DOI 10.7205/MILMED-D-12-00051; Kessler RC, 2015, JAMA PSYCHIAT, V72, P49, DOI 10.1001/jamapsychiatry.2014.1754; Kessler RC, 2013, INT J METH PSYCH RES, V22, P267, DOI 10.1002/mpr.1401; Large MM, 2014, AUSTRALAS PSYCHIATRY, V22, P390, DOI 10.1177/1039856214537128; Leadholm AKK, 2014, J AFFECT DISORDERS, V156, P119, DOI 10.1016/j.jad.2013.12.003; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; Liaw A., 2002, R NEWS, V2, P18, DOI DOI 10.1177/154405910408300516; McCarthy JF, 2015, AM J PUBLIC HEALTH, V105, P1935, DOI 10.2105/AJPH.2015.302737; Meyer D, 2015, PACKAGE E1071 MISC F, P5; Nock MK, 2013, PSYCHIATRY, V76, P97, DOI 10.1521/psyc.2013.76.2.97; Nowrangi MA, 2014, PSYCHOSOMATICS, V55, P430, DOI 10.1016/j.psym.2013.11.006; O'Connor E, 2013, ANN INTERN MED, V158, P741, DOI 10.7326/0003-4819-158-10-201305210-00642; Reger MA, 2015, JAMA PSYCHIAT, V72, P561, DOI 10.1001/jamapsychiatry.2014.3195; Rish I., 2001, EMPIRICAL STUDY NAIV; SAS Institute Inc, SAS STAT SOFTW 9 3 U; Schlesselman JJ., 1982, CASE CONTROL STUDIES; Schoenbaum M, 2014, JAMA PSYCHIAT, V71, P493, DOI 10.1001/jamapsychiatry.2013.4417; Simon GE, 2006, AM J PSYCHIAT, V163, P41, DOI 10.1176/appi.ajp.163.1.41; Simon GE, 2007, BIPOLAR DISORD, V9, P526, DOI 10.1111/j.1399-5618.2007.00408.x; Simon GE, 2013, PSYCHIAT SERV, V64, P1195, DOI 10.1176/appi.ps.201200587; Smola AJ, 2004, STAT COMPUT, V14, P199, DOI 10.1023/B:STCO.0000035301.49549.88; Smolenski D. J., 2013, DEP DEFENSE SUICIDE; Street AE, 2015, PSYCHOL MED, V45, P717, DOI 10.1017/S003329171400258X; Ursano RJ, 2014, PSYCHIATRY, V77, P107, DOI 10.1521/psyc.2014.77.2.107; Valenstein M, 2009, J AFFECT DISORDERS, V112, P50, DOI 10.1016/j.jad.2008.08.020; Veterans Affairs/ Dept of Defense, 2013, ASS MAN PAT RISK SUI; While D, 2012, LANCET, V379, P1005, DOI 10.1016/S0140-6736(11)61712-1; Zamorski MA, 2011, INT REV PSYCHIATR, V23, P173, DOI 10.3109/09540261.2011.562186; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	48	73	73	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	APR	2017	22	4					544	551		10.1038/mp.2016.110			8	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	EP0TP	WOS:000397099900008	27431294	Green Submitted, Green Accepted, Bronze			2022-02-06	
J	Whiteneck, GG; Cuthbert, JP; Corrigan, JD; Bogner, JA				Whiteneck, Gale G.; Cuthbert, Jeffrey P.; Corrigan, John D.; Bogner, Jennifer A.			Prevalence of Self-Reported Lifetime History of Traumatic Brain Injury and Associated Disability: A Statewide Population-Based Survey	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						activities of daily living; epidemiology; mild traumatic brain injury; quality of life; surveys; traumatic brain injury	UNITED-STATES; MILD; RELIABILITY; VALIDITY; HEALTH	Objective: To investigate the prevalence of all severities of traumatic brain injury (TBI), regardless of treatment setting, and their associated negative outcomes. Participants: A total of 2701 adult Coloradoans. Design: A statewide, population-based, random digit-dialed telephone survey. Main Measures: The lifetime history of TBI was assessed by a modification of the Ohio State University TBI Identification Method; activity limitation and life satisfaction were also assessed. Results: The distribution of self-reported lifetime injury was as follows: 19.8%, no injury; 37.7%, injury but no TBI; 36.4%, mild TBI; and 6.0%, moderate-severe TBI. Of those reporting a TBI, 23.1% were hospitalized, 38.5% were treated in an emergency department, 9.8% were treated in a physician's office, and 27.5% did not seek medical care. A clear gradient of activity limitations and low life satisfaction was seen, with the highest proportions of these negative outcomes occurring in people reporting more severe TBI and the lowest proportions in those not reporting a TBI. Approximately twice as many people reported activity limitations and low life satisfaction after nonhospitalized TBI compared with hospitalized TBI. Conclusions: This investigation highlights the seriousness of TBI as a public health problem and the importance of including all severities of TBI, no matter where, or if treated, in estimating the prevalence of disability co-occurring with TBI.	[Whiteneck, Gale G.; Cuthbert, Jeffrey P.] Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA; [Corrigan, John D.; Bogner, Jennifer A.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA		Whiteneck, GG (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	gale@craig-hospital.org			Colorado Injury Control Research Center through Centers for Disease Control and Prevention [R49 CE001168]; National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education, TBI Model System Centers [H133A070029]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001168] Funding Source: NIH RePORTER	This study was supported by the Colorado Injury Control Research Center through grant no. R49 CE001168 from the Centers for Disease Control and Prevention and the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education, TBI Model System Centers, to Ohio State University (H133A070029). The authors thank Cynthia A. Brooks, MSHA, at Craig Hospital for coordinating the survey subcontract with the University of Colorado Cancer Center Survey Research Shared Resource under the direction of Dr Alfred C. Marcus.	ADAMS PF, 1991, VITAL HLTH STAT, V10, P1; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Battaglia M., 2004, P 59 ANN C AM ASS PU, P4740; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bureau of Health Statistics and Data Management, 1998, NEW HAMPSH BEH RISK; Caplan B, 1996, J HEAD TRAUMA REHAB, P1; Center for Disease Control and Prevention, 2008, OV BRFSS 2008; Center for Disease Control and Prevention, BEH RISK FACT SURV S; Centers for Disease Control and Prevention, 2008, BEH RISK FACT SURV S; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P85, DOI 10.1016/S0003-9993(99)90312-X; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; Cuthbert JP, 2016, J HEAD TRAUMA REHAB, V31, pE36, DOI 10.1097/HTR.0000000000000075; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Diener E, 2014, UNDERSTANDING SCORES; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Harrison-Felix C, 1996, ARCH PHYS MED REHAB, V39, DOI [10.1097/00001199-199610000-00002, DOI 10.1097/00001199-199610000-00002]; Health Statistics Section, 2001, COL BEH RISK FACT SU; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Rosenthal M, 1999, REHABILITATION ADULT; Rosenthal M, 1993, J HEAD TRAUMA REHAB, P1; Selassie A, 2003, S CAROLINA TRAUMATIC; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sugerman D., 2012, BRAIN INJURY MED, P45; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; United States Census Bureau, 2012, 2010 CENS POP HOUS P; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	30	73	73	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2016	31	1					E55	E62		10.1097/HTR.0000000000000140			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DK9CN	WOS:000375228000006	25931187				2022-02-06	
J	Skaper, SD; Facci, L; Barbierato, M; Zusso, M; Bruschetta, G; Impellizzeri, D; Cuzzocrea, S; Giusti, P				Skaper, Stephen D.; Facci, Laura; Barbierato, Massimo; Zusso, Morena; Bruschetta, Giuseppe; Impellizzeri, Daniela; Cuzzocrea, Salvatore; Giusti, Pietro			N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution	MOLECULAR NEUROBIOLOGY			English	Article						Microglia; Mast cells; Neuroinflammation; Neuropathic pain; Neurodegeneration; Palmitoylethanolamide; Luteolin; Ultramicronization; Neuroprotection	ACID AMIDE HYDROLASE; MAST-CELLS; SPINAL-CORD; IMMUNE-RESPONSES; OXIDATIVE STRESS; MICROGLIA; LUTEOLIN; RAT; ACTIVATION; MECHANISMS	Inflammation is fundamentally a protective cellular response aimed at removing injurious stimuli and initiating the healing process. However, when prolonged, it can override the bounds of physiological control and becomes destructive. Inflammation is a key element in the pathobiology of chronic pain, neurodegenerative diseases, stroke, spinal cord injury, and neuropsychiatric disorders. Glia, key players in such nervous system disorders, are not only capable of expressing a pro-inflammatory phenotype but respond also to inflammatory signals released from cells of immune origin such as mast cells. Chronic inflammatory processes may be counteracted by a program of resolution that includes the production of lipid mediators endowed with the capacity to switch off inflammation. These naturally occurring lipid signaling molecules include the N-acylethanolamines, N-arachidonoylethanolamine (an endocannabinoid), and its congener N-palmitoylethanolamine (palmitoylethanolamide or PEA). PEA may play a role in maintaining cellular homeostasis when faced with external stressors provoking, for example, inflammation. PEA is efficacious in mast cell-mediated models of neurogenic inflammation and neuropathic pain and is neuroprotective in models of stroke, spinal cord injury, traumatic brain injury, and Parkinson disease. PEA in micronized/ultramicronized form shows superior oral efficacy in inflammatory pain models when compared to na < ve PEA. Intriguingly, while PEA has no antioxidant effects per se, its co-ultramicronization with the flavonoid luteolin is more efficacious than either molecule alone. Inhibiting or modulating the enzymatic breakdown of PEA represents a complementary therapeutic approach to treat neuroinflammation. This review is intended to discuss the role of mast cells and glia in neuroinflammation and strategies to modulate their activation based on leveraging natural mechanisms with the capacity for self-defense against inflammation.	[Skaper, Stephen D.; Facci, Laura; Barbierato, Massimo; Zusso, Morena; Giusti, Pietro] Univ Padua, Dept Pharmaceut & Pharmacol Sci, I-35131 Padua, Italy; [Bruschetta, Giuseppe; Impellizzeri, Daniela; Cuzzocrea, Salvatore] Univ Messina, Dept Biol & Environm Sci, I-98166 Messina, Italy		Skaper, SD (corresponding author), Univ Padua, Dept Pharmaceut & Pharmacol Sci, Largo Egidio Meneghetti 2, I-35131 Padua, Italy.	stephen.skaper@unipd.it		GIUSTi, Pietro/0000-0001-9352-4046; Impellizzeri, Daniela/0000-0001-9492-3161; Cuzzocrea, Salvatore/0000-0001-6131-3690	MIURMinistry of Education, Universities and Research (MIUR) [PON01_02512]	This study was supported in part by MIUR, PON "Ricerca e Competitivita 2007-2013" project PON01_02512.	Amor S, 2014, IMMUNOLOGY, V141, P287, DOI 10.1111/imm.12134; [Anonymous], 2013, Patent application WO, Patent No. [2013121449 A1, 2013121449]; BISRAT M, 1988, INT J PHARM, V47, P223, DOI 10.1016/0378-5173(88)90235-9; Bossers K, 2010, BRAIN, V133, P3699, DOI 10.1093/brain/awq258; BRENNER T, 1994, J NEUROL SCI, V122, P210, DOI 10.1016/0022-510X(94)90300-X; Buckley CD, 2013, NAT REV IMMUNOL, V13, P59, DOI 10.1038/nri3362; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Castellheim A, 2009, SCAND J IMMUNOL, V69, P479, DOI 10.1111/j.1365-3083.2009.02255.x; Cervellati C, 2013, CURR ALZHEIMER RES, V10, P365, DOI 10.2174/1567205011310040003; Chen CC, 2005, P NATL ACAD SCI USA, V102, P11408, DOI 10.1073/pnas.0504197102; Coleta M, 2008, BEHAV BRAIN RES, V189, P75, DOI 10.1016/j.bbr.2007.12.010; Cordaro M, 2016, J NEUROTRAUM, V33, P132, DOI 10.1089/neu.2014.3460; Costanza M, 2012, INT J MOL SCI, V13, P15107, DOI 10.3390/ijms131115107; Crupi R, 2013, CNS NEUROL DISORD-DR, V12, P989, DOI 10.2174/18715273113129990084; Duranti A, 2012, J MED CHEM, V55, P4824, DOI 10.1021/jm300349j; Engler H, 2011, BRAIN BEHAV IMMUN, V25, P1384, DOI 10.1016/j.bbi.2011.04.005; Esposito E, 2011, BRAIN BEHAV IMMUN, V25, P1099, DOI 10.1016/j.bbi.2011.02.006; Fiala M, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-76; Frakes AE, 2014, NEURON, V81, P1009, DOI 10.1016/j.neuron.2014.01.013; Gao YJ, 2010, PHARMACOL THERAPEUT, V126, P56, DOI 10.1016/j.pharmthera.2010.01.002; Gasque P, 1997, AM J PATHOL, V150, P31; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; Gilfillan AM, 2011, ADV EXP MED BIOL, V716, P2, DOI 10.1007/978-1-4419-9533-9_1; Graves MC, 2004, AMYOTROPH LATERAL SC, V5, P213, DOI 10.1080/14660820410020286; Grosso C, 2013, CURR MED CHEM, V20, P4694, DOI 10.2174/09298673113209990155; Hoyer FF, 2014, J MOL CELL CARDIOL, V66, P126, DOI 10.1016/j.yjmcc.2013.11.013; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Impellizzeri D, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0136-0; Joshi J, 2011, J PHARM SCI TECHNOL, V3, P651; Kang HJ, 2012, NAT MED, V18, P1413, DOI 10.1038/nm.2886; Kim DY, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-25; LAMBRACHTHALL M, 1990, DEV BRAIN RES, V56, P151, DOI 10.1016/0165-3806(90)90077-C; LEALBERUMEN I, 1994, J IMMUNOL, V152, P5468; Leung D, 2006, BIOCHEMISTRY-US, V45, P4720, DOI 10.1021/bi060163l; Li Y, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0042558, 10.1371/journal.pone.0043023]; Lindsberg PJ, 2010, J CEREBR BLOOD F MET, V30, P689, DOI 10.1038/jcbfm.2009.282; McGeer PL, 2013, ACTA NEUROPATHOL, V126, P479, DOI 10.1007/s00401-013-1177-7; Morales I, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00112; Myers RR, 2006, DRUG DISCOV TODAY, V11, P8, DOI 10.1016/S1359-6446(05)03637-8; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Noriega DB, 2014, EUR J PEDIATR, V173, P33, DOI 10.1007/s00431-013-2183-4; Oh DM, 1995, ARCH PHARM RES, V18, P427, DOI 10.1007/BF02976347; Olusanmi D, 2014, POWDER TECHNOL, V258, P222, DOI 10.1016/j.powtec.2014.03.032; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Parra-Damas A, 2014, J NEUROSCI, V34, P5776, DOI 10.1523/JNEUROSCI.5288-13.2014; Paterniti I, 2014, CNS NEUROL DISORD-DR, V13, P1530, DOI 10.2174/1871527313666140806124322; Paterniti I, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-91; Peferoen LAN, 2015, J NEUROPATH EXP NEUR, V74, P48, DOI 10.1097/NEN.0000000000000149; Perry VH, 2014, NAT REV NEUROL, V10, P217, DOI 10.1038/nrneurol.2014.38; Pietrzak A, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/427473; Piomelli D, 2014, NAT NEUROSCI, V17, P164, DOI 10.1038/nn.3612; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Radi E, 2014, J ALZHEIMERS DIS, V42, pS125, DOI 10.3233/JAD-132738; Rasenack N, 2004, PHARM DEV TECHNOL, V9, P1, DOI 10.1081/PDT-120027417; Rivat C, 2010, PAIN, V150, P358, DOI 10.1016/j.pain.2010.05.031; Salim S, 2014, CURR NEUROPHARMACOL, V12, P140, DOI 10.2174/1570159X11666131120230309; Sasso O, 2013, PAIN, V154, P350, DOI 10.1016/j.pain.2012.10.018; Saturnino C, 2010, BIOORG MED CHEM LETT, V20, P1210, DOI 10.1016/j.bmcl.2009.11.134; Schafer T, 2010, ALLERGY, V65, P1242, DOI 10.1111/j.1398-9995.2010.02350.x; Siegmund SV, 2013, BIOCHEM BIOPH RES CO, V437, P48, DOI 10.1016/j.bbrc.2013.06.033; Silver R, 2013, TRENDS NEUROSCI, V36, P513, DOI 10.1016/j.tins.2013.06.001; Silverman AJ, 2000, J NEUROSCI, V20, P401, DOI 10.1523/JNEUROSCI.20-01-00401.2000; Skaper SD, 2014, IMMUNOLOGY, V141, P314, DOI 10.1111/imm.12170; Skaper SD, 2012, PHILOS T R SOC B, V367, P3312, DOI 10.1098/rstb.2011.0391; Skaper SD, 2012, FASEB J, V26, P3103, DOI 10.1096/fj.11-197194; Solorzano C, 2009, P NATL ACAD SCI USA, V106, P20966, DOI 10.1073/pnas.0907417106; Tabas I, 2013, SCIENCE, V339, P166, DOI 10.1126/science.1230720; Ueda N, 2013, FEBS J, V280, P1874, DOI 10.1111/febs.12152; Vitale R, 2014, CHEMMEDCHEM, V9, P323, DOI 10.1002/cmdc.201300416; Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544; Xanthos DN, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-42; Xu B, 2010, EUR J PHARMACOL, V627, P99, DOI 10.1016/j.ejphar.2009.10.038; Yamano Y, 2012, BIOORGAN MED CHEM, V20, P3658, DOI 10.1016/j.bmc.2012.03.065	76	73	73	1	21	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	OCT	2015	52	2			SI		1034	1042		10.1007/s12035-015-9253-8			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CQ6AQ	WOS:000360687200022	26055231				2022-02-06	
J	Tian, Y; Salsbery, B; Wang, M; Yuan, HJ; Yang, J; Zhao, ZL; Wu, XP; Zhang, YJ; Konkle, BA; Thiagarajan, P; Li, M; Zhang, JN; Dong, JF				Tian, Ye; Salsbery, Breia; Wang, Min; Yuan, Hengjie; Yang, Jing; Zhao, Zilong; Wu, Xiaoping; Zhang, Yanjun; Konkle, Barbara A.; Thiagarajan, Perumal; Li, Min; Zhang, Jianning; Dong, Jing-fei			Brain-derived microparticles induce systemic coagulation in a murine model of traumatic brain injury	BLOOD			English	Article							NEURON-SPECIFIC ENOLASE; TISSUE-FACTOR; EARLY COAGULOPATHY; LIPID RAFTS; BLOOD; PLATELETS; ACTIVATION; EXPRESSION; SEROTONIN; HISTAMINE	Traumatic brain injury (TBI) is associated with coagulopathy, although it often lacks 2 key risk factors: severe bleeding and significant fluid resuscitation associated with hemorrhagic shock. The pathogenesis of TBI-associated coagulopathy remains poorly understood. We tested the hypothesis that brain-derived microparticles (BDMPs) released from an injured brain induce a hypercoagulable state that rapidly turns into consumptive coagulopathy. Here, we report that mice subjected to fluid percussion injury (1.9 +/- 0.1 atm) developed a BDMP-dependent hypercoagulable state, with peak levels of plasma glial cell and neuronal BDMPs reaching 17 496 +/- 4833/mu L and 18 388 +/- 3657/mu L 3 hours after TBI, respectively. Uninjured mice injected with BDMPs developed a dose-dependent hyper-turned hypocoagulable state measured by a progressively prolonged clotting time, fibrinogen depletion, and microvascular fibrin deposition in multiple organs. The BDMPs were 50 to 300 nm with intact membranes, expressing neuronal or glial cell markers and procoagulant phosphatidylserine and tissue factor. Their procoagulant activity was greater than platelet microparticles and was dose-dependently blocked by lactadherin. Microparticles were produced from injured hippocampal cells, transmigrated through the disrupted endothelial barrier in a platelet-dependent manner, and activated platelets. These data define a novel mechanism of TBI-associated coagulopathy in mice, identify early predictive markers, and provide alternative therapeutic targets.	[Tian, Ye; Yuan, Hengjie; Zhao, Zilong; Zhang, Yanjun; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin Neurol Inst, Tianjin 300052, Peoples R China; [Tian, Ye; Salsbery, Breia; Yuan, Hengjie; Yang, Jing; Wu, Xiaoping; Konkle, Barbara A.; Dong, Jing-fei] Puget Sound Blood Res Inst, Seattle, WA USA; [Wang, Min; Li, Min] Lanzhou Univ, Sch Basic Med Sci, Inst Pathol, Lanzhou 730000, Peoples R China; [Konkle, Barbara A.; Dong, Jing-fei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA; [Thiagarajan, Perumal] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Thiagarajan, Perumal] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Thiagarajan, Perumal] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX USA		Dong, JF (corresponding author), Puget Sound Blood Ctr, Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA.	limin@lzu.edu.cn; jianningzhang@hotmail.com; jfdong@psbc.org	Zhao, Zilong/AAZ-2196-2020; Konkle, Barbara A/AAD-7712-2022; zhang, yanjun/S-5114-2019	Konkle, Barbara A/0000-0002-3959-8797; Zhang, Yanjun/0000-0002-3123-1405	National Institutes of Health, National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL71895, R01HL085769]; National Natural Science Foundation of China State Key Program [81330029]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271361, 81271359, 81372575]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL071895, R01HL085769] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087296] Funding Source: NIH RePORTER	This study is supported by National Institutes of Health, National Heart, Lung, and Blood Institute grants R01HL71895 and R01HL085769 (to J.F.D.), National Natural Science Foundation of China State Key Program grant 81330029 (to J.N.Z.), and National Natural Science Foundation of China research grants 81271361, 81271359 (to J.N.Z.), and 81372575 (to M.L.).	ALKHAMIS TM, 1990, BLOOD, V75, P1568; Bianco F, 2005, J IMMUNOL, V174, P7268, DOI 10.4049/jimmunol.174.11.7268; Biro E, 2005, J THROMB HAEMOST, V3, P2754, DOI 10.1111/j.1538-7836.2005.01646.x; Boilard E, 2010, SCIENCE, V327, P580, DOI 10.1126/science.1181928; BOTTARO D, 1986, J CELL PHYSIOL, V128, P189, DOI 10.1002/jcp.1041280208; Camera M, 2003, ARTERIOSCL THROM VAS, V23, P1690, DOI 10.1161/01.ATV.0000085629.23209.AA; Cloutier N, 2012, BLOOD, V120, P1334, DOI 10.1182/blood-2012-02-413047; Cohen MJ, 2013, J TRAUMA ACUTE CARE, V75, pS40, DOI 10.1097/TA.0b013e31828fa43d; Cohen MJ, 2012, ANN SURG, V255, P379, DOI 10.1097/SLA.0b013e318235d9e6; Dale GL, 2002, NATURE, V415, P175, DOI 10.1038/415175a; Davizon P, 2010, SEMIN THROMB HEMOST, V36, P857, DOI 10.1055/s-0030-1267039; DAY INM, 1984, CLIN CHIM ACTA, V136, P219, DOI 10.1016/0009-8981(84)90295-X; del Conde I, 2005, BLOOD, V106, P1604, DOI 10.1182/blood-2004-03-1095; DELZOPPO GJ, 1992, THROMB HAEMOSTASIS, V68, P642; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Duan SM, 2006, GLIA, V54, P738, DOI 10.1002/glia.20397; Exner T, 2003, BLOOD COAGUL FIBRIN, V14, P773, DOI 10.1097/00001721-200312000-00015; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; Geddings JE, 2013, BLOOD, V122, P1873, DOI 10.1182/blood-2013-04-460139; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Huang XT, 2013, J NEUROTRAUM, V30, P2080, DOI 10.1089/neu.2013.2996; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; Kunzelmann-Marche C, 2000, THROMB HAEMOSTASIS, V83, P282, DOI 10.1055/s-0037-1613800; Lee TH, 2014, J TRAUMA ACUTE CARE, V77, P67, DOI 10.1097/TA.0000000000000255; Lentz BR, 2003, PROG LIPID RES, V42, P423, DOI 10.1016/S0163-7827(03)00025-0; Maani CV, 2009, CURR OPIN ANESTHESIO, V22, P255, DOI 10.1097/ACO.0b013e32832922be; MAJNO G, 1969, J CELL BIOL, V42, P647, DOI 10.1083/jcb.42.3.647; MARANGOS PJ, 1980, J NEUROCHEM, V34, P1254, DOI 10.1111/j.1471-4159.1980.tb09967.x; McNicol A, 1999, THROMB RES, V95, P1, DOI 10.1016/S0049-3848(99)00015-8; Michel CC, 1997, J PHYSIOL-LONDON, V501, P657, DOI 10.1111/j.1469-7793.1997.657bm.x; Mitra B, 2012, INJURY, V43, P22, DOI 10.1016/j.injury.2010.10.015; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Nekludov M, 2014, J NEUROTRAUM, V31, P1927, DOI 10.1089/neu.2013.3168; Neto AC, 2014, NEUROCRIT CARE; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Owens AP, 2011, CIRC RES, V108, P1284, DOI 10.1161/CIRCRESAHA.110.233056; PAUS E, 1989, TUMOR BIOL, V10, P23, DOI 10.1159/000217590; Phillis JW, 2006, BRAIN RES REV, V52, P201, DOI 10.1016/j.brainresrev.2006.02.002; QUINTARELLI G, 1971, J HISTOCHEM CYTOCHEM, V19, P641, DOI 10.1177/19.11.641; Shah MD, 2008, PLATELETS, V19, P365, DOI 10.1080/09537100802054107; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tchaikovski SN, 2007, J THROMB HAEMOST, V5, P2079, DOI 10.1111/j.1538-7836.2007.02719.x; Thiagarajan P, 1997, CIRCULATION, V96, P2339; UiTei K, 1996, NEUROSCI LETT, V203, P191, DOI 10.1016/0304-3940(95)12292-3; Wafaisade A, 2010, EMERG MED J, V27, P934, DOI 10.1136/emj.2009.088484; Wallace PK, 2008, CYTOM PART A, V73A, P1019, DOI 10.1002/cyto.a.20619; Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117; Zhang YJ, 2013, THROMB HAEMOSTASIS, V110, P331, DOI 10.1160/TH12-11-0853; Zillmann A, 2001, BIOCHEM BIOPH RES CO, V281, P603, DOI 10.1006/bbrc.2001.4399; ZWAAL RFA, 1977, NATURE, V268, P358, DOI 10.1038/268358a0	53	73	84	1	12	AMER SOC HEMATOLOGY	WASHINGTON	2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA	0006-4971	1528-0020		BLOOD	Blood	MAR 26	2015	125	13					2151	2159		10.1182/blood-2014-09-598805			9	Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Hematology	CI3CX	WOS:000354626300022	25628471	Green Published, Bronze			2022-02-06	
J	Huusko, N; Romer, C; Ndode-Ekane, XE; Lukasiuk, K; Pitkanen, A				Huusko, Noora; Romer, Christine; Ndode-Ekane, Xavier Ekolle; Lukasiuk, Katarzyna; Pitkanen, Asla			Loss of hippocampal interneurons and epileptogenesis: a comparison of two animal models of acquired epilepsy	BRAIN STRUCTURE & FUNCTION			English	Article						Epileptogenesis; Seizure susceptibility; Status epilepticus; Traumatic brain injury	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; DENTATE GRANULE CELLS; NEUROPEPTIDE-Y; STATUS EPILEPTICUS; INHIBITORY INTERNEURONS; POSTTRAUMATIC EPILEPSY; GABAERGIC INTERNEURONS; RAT HIPPOCAMPUS; ELECTRICAL-STIMULATION	Reduced hippocampal GABAergic inhibition is acknowledged to be associated with epilepsy. However, there are no studies that had quantitatively compared the loss of various interneuron populations in different models of epilepsy. We tested a hypothesis that the more severe the loss of hippocampal interneurons, the more severe was the epilepsy. Epileptogenesis was triggered in adult rats by status epilepticus (SE) (56 SE, 24 controls) or by traumatic brain injury (TBI) (45 TBI, 23 controls). The total number of hippocampal parvalbumin (PARV), cholecystokinin (CCK), calretinin (CR), somatostatin (SOM), or neuropeptide Y (NPY) positive neurons was estimated using unbiased stereology at 1 or 6 months post-insult. The rats with TBI had no spontaneous seizures but showed increased seizure susceptibility. Eleven of the 28 rats (39 %) in the SE group had spontaneous seizures. The most affected hippocampal area after TBI was the ipsilateral dentate gyrus, where 62 % of PARV-immunoreactive (ir) (p < 0.001 compared to controls), 77 % of CR-ir (p < 0.05), 46 % of SOM-ir (p < 0.001), and 59 % of NPY-ir (p < 0.001) cells remained at 1 month after TBI. At 6 months post-TBI, only 35 % of PARV-ir (p < 0.001 compared to controls), 63 % of CCK-ir (p < 0.01), 74 % of CR-ir (p < 0.001), 55 % of SOM-ir (p < 0.001), and 51 % of NPY-ir (p < 0.001) cells were remaining. Moreover, the reduction in PARV-ir, CCK-ir, and CR-ir neurons was bilateral (all p < 0.05). Substantial reductions in different neuronal populations were also found in subfields of the CA3 and CA1. In rats with epilepsy after SE, the number of PARV-ir neurons was reduced in the ipsilateral CA1 (80 % remaining, p < 0.05) and the number of NPY-ir neurons bilaterally in the dentate gyrus (33-37 %, p < 0.01) and the CA3 (54-57 %, p < 0.05). Taken together, interneuron loss was substantially more severe, widespread, progressive, and included more interneuron subclasses after TBI than after SE. Interneurons responsible for perisomatic inhibition were more vulnerable to TBI than those providing dendritic inhibition. Unlike expected, we could not demonstrate any etiology-independent link between the severity of hippocampal interneuron loss and the overall risk of spontaneous seizures.	[Huusko, Noora; Romer, Christine; Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Kuopio 70211, Finland; [Lukasiuk, Katarzyna] Polish Acad Sci, Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, Kuopio 70211, Finland		Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, Kuopio 70211, Finland.	asla.pitkanen@uef.fi	Romer, Christine/AAU-9643-2020; Lukasiuk, Katarzyna/F-4636-2010	Romer, Christine/0000-0002-2592-1071; Lukasiuk, Katarzyna/0000-0002-1582-0920; Ndode-Ekane, Xavier Ekolle/0000-0001-5682-5632	FP6 Grant [LSHM-CT-2006-037315]; Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; North-Savo Regional Fund of The Finnish Cultural FoundationFinnish Cultural Foundation; Finnish Epilepsy Foundation	This study was supported by the FP6 Grant LSHM-CT-2006-037315 (A.P.), Academy of Finland (A.P.), The Sigrid Juselius Foundation (A.P.), The North-Savo Regional Fund of The Finnish Cultural Foundation (N.H.), and The Finnish Epilepsy Foundation (N.H.). We thank Mr Jarmo Hartikainen and Mrs Merja Lukkari for their excellent technical assistance.	Andre V, 2001, HIPPOCAMPUS, V11, P452, DOI 10.1002/hipo.1060; Andrioli A, 2007, NEUROSCIENCE, V149, P131, DOI 10.1016/j.neuroscience.2007.07.029; Arellano JI, 2004, BRAIN, V127, P45, DOI 10.1093/brain/awh004; Bausch SB, 2005, EPILEPSY BEHAV, V7, P390, DOI 10.1016/j.yebeh.2005.07.019; Bering R, 1997, EXP BRAIN RES, V115, P423, DOI 10.1007/PL00005712; Biagini G, 2010, CURR OPIN NEUROL, V23, P170, DOI 10.1097/WCO.0b013e32833735cf; Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; Czuczwar SJ, 2001, CNS DRUGS, V15, P339, DOI 10.2165/00023210-200115050-00001; DeFelipe J, 1999, BRAIN, V122, P1807, DOI 10.1093/brain/122.10.1807; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Dinocourt C, 2003, J COMP NEUROL, V459, P407, DOI 10.1002/cne.10622; Ferrari D, 2008, EPILEPSY BEHAV, V13, P36, DOI 10.1016/j.yebeh.2008.01.001; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Gorter JA, 2001, EUR J NEUROSCI, V13, P657, DOI 10.1046/j.1460-9568.2001.01428.x; Gulyas AI, 1996, J NEUROSCI, V16, P3397; HARTIG W, 1992, NEUROREPORT, V3, P869; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Karetko-Sysa M, 2011, EXP NEUROL, V231, P113, DOI 10.1016/j.expneurol.2011.05.022; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Klausberger T, 2008, SCIENCE, V321, P53, DOI 10.1126/science.1149381; Kuruba R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024493; LEWIS DA, 1986, J COMP NEUROL, V248, P1, DOI 10.1002/cne.902480102; Long LL, 2011, INT J NEUROSCI, V121, P69, DOI 10.3109/00207454.2010.530007; LOSCHER W, 1991, EPILEPSY RES, V9, P1, DOI 10.1016/0920-1211(91)90041-D; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Magloczky Z, 2005, TRENDS NEUROSCI, V28, P334, DOI 10.1016/j.tins.2005.04.002; Magloczky Z, 2000, NEUROSCIENCE, V96, P7, DOI 10.1016/S0306-4522(99)00474-1; Magloczky Z, 2010, EPILEPSY RES, V89, P52, DOI 10.1016/j.eplepsyres.2010.01.002; Maisano X, 2012, J NEUROSCI, V32, P46, DOI 10.1523/JNEUROSCI.2683-11.2012; Mathern GW, 1996, EPILEPSY RES, V26, P151, DOI 10.1016/S0920-1211(96)00052-6; Mathern GW, 1997, NEUROSCIENCE, V77, P1003, DOI 10.1016/S0306-4522(96)00516-7; MATHERN GW, 1995, J NEUROSCI, V15, P3990; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nairismagi J, 2004, EPILEPSIA, V45, P1024, DOI 10.1111/j.0013-9580.2004.08904.x; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Noe F, 2008, BRAIN, V131, P1506, DOI 10.1093/brain/awn079; OJEMANN GA, 1987, J NEUROSURG, V66, P489, DOI 10.3171/jns.1987.66.4.0489; Pavlov I, 2011, NEUROSCIENCE, V194, P208, DOI 10.1016/j.neuroscience.2011.07.074; Pitkanen A, 2005, EPILEPSY RES, V63, P27, DOI 10.1016/j.eplepsyres.2004.10.003; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Rattka M, 2011, NEUROPHARMACOLOGY, V60, P505, DOI 10.1016/j.neuropharm.2010.11.005; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schwaller B, 2004, MOL CELL NEUROSCI, V25, P650, DOI 10.1016/j.mcn.2003.12.006; SCHWARZER C, 1995, NEUROSCIENCE, V69, P831, DOI 10.1016/0306-4522(95)00268-N; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; Sloviter RS, 2001, J COMP NEUROL, V430, P283; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; Soderpalm B, 2002, EUR J PAIN-LONDON, V6, P3, DOI 10.1053/eujp.2001.0315; SPERK G, 1992, NEUROSCIENCE, V50, P831, DOI 10.1016/0306-4522(92)90207-I; Sun CS, 2007, J COMP NEUROL, V500, P876, DOI 10.1002/cne.21207; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thind KK, 2010, J COMP NEUROL, V518, P647, DOI 10.1002/cne.22235; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toth K, 2010, BRAIN, V133, P2763, DOI 10.1093/brain/awq149; Toth Z, 1997, J NEUROSCI, V17, P8106; van Vliet EA, 2004, EXP NEUROL, V187, P367, DOI 10.1016/j.expneurol.2004.01.016; Vezzani A, 2004, NEUROPEPTIDES, V38, P245, DOI 10.1016/j.npep.2004.05.004; Vreugdenhil M, 2003, J NEUROPHYSIOL, V89, P1414, DOI 10.1152/jn.00576.2002; Wasterlain CG, 1996, EPILEPSY RES, V26, P255, DOI 10.1016/S0920-1211(96)00058-7; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wittner L, 2001, NEUROSCIENCE, V108, P587, DOI 10.1016/S0306-4522(01)00446-8; Zhang BL, 2011, CHINESE MED J-PEKING, V124, P740, DOI 10.3760/cma.j.issn.0366-6999.2011.05.020; Zhang BL, 2011, BRAIN RES, V1382, P165, DOI 10.1016/j.brainres.2011.01.065; Zhang NH, 2007, J NEUROSCI, V27, P7520, DOI 10.1523/JNEUROSCI.1555-07.2007; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009	70	73	78	0	11	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1863-2653	1863-2661		BRAIN STRUCT FUNCT	Brain Struct. Funct.	JAN	2015	220	1					153	191		10.1007/s00429-013-0644-1			39	Anatomy & Morphology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anatomy & Morphology; Neurosciences & Neurology	CA5XE	WOS:000348980800013	24096381				2022-02-06	
J	Carney, N; Ghajar, J; Jagoda, A; Bedrick, S; Davis-O'Reilly, C; du Coudray, H; Hack, D; Helfand, N; Huddleston, A; Nettleton, T; Riggio, S				Carney, Nancy; Ghajar, Jamshid; Jagoda, Andy; Bedrick, Steven; Davis-O'Reilly, Cynthia; du Coudray, Hugo; Hack, Dallas; Helfand, Nora; Huddleston, Amy; Nettleton, Tracie; Riggio, Silvana			Concussion Guidelines Step 1: Systematic Review of Prevalent Indicators	NEUROSURGERY			English	Article						Concussion; Indicators of concussion; Systematic review	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; FOOTBALL PLAYERS; MILD; RECOVERY; SPORTS; SYMPTOMS; RETURN	BACKGROUND: Currently, there is no evidence-based definition for concussion that is being uniformly applied in clinical and research settings. OBJECTIVE: To conduct a systematic review of the highest-quality literature about concussion and to assemble evidence about the prevalence and associations of key indicators of concussion. The goal was to establish an evidence-based foundation from which to derive, in future work, a definition, diagnostic criteria, and prognostic indicators for concussion. METHODS: Key questions were developed, and an electronic literature search from 1980 to 2012 was conducted to acquire evidence about the prevalence of and associations among signs, symptoms, and neurologic and cognitive deficits in samples of individuals exposed to potential concussive events. Included studies were assessed for potential for bias and confound and rated as high, medium, or low potential for bias and confound. Those rated as high were excluded from the analysis. Studies were further triaged on the basis of whether the definition of a case of concussion was exclusive or inclusive; only those with wide, inclusive case definitions were used in the analysis. Finally, only studies reporting data collected at fixed time points were used. For a study to be included in the conclusions, it was required that the presence of any particular sign, symptom, or deficit be reported in at least 2 independent samples. RESULTS: From 5437 abstracts, 1362 full-text publications were reviewed, of which 231 studies were included in the final library. Twenty-six met all criteria required to be used in the analysis, and of those, 11 independent samples from 8 publications directly contributed data to conclusions. Prevalent and consistent indicators of concussion are (1) observed and documented disorientation or confusion immediately after the event, (2) impaired balance within 1 day after injury, (3) slower reaction time within 2 days after injury, and/or (4) impaired verbal learning and memory within 2 days after injury. CONCLUSION: The results of this systematic review identify the consistent and prevalent indicators of concussion and their associations, derived from the strongest evidence in the published literature. The product is an evidence-based foundation from which to develop diagnostic criteria and prognostic indicators.	[Carney, Nancy; Davis-O'Reilly, Cynthia; du Coudray, Hugo; Helfand, Nora; Huddleston, Amy; Nettleton, Tracie] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA; [Bedrick, Steven] Oregon Hlth & Sci Univ, Ctr Spoken Language Understanding, Portland, OR 97201 USA; [Ghajar, Jamshid] Brain Trauma Fdn, New York, NY 10007 USA; [Ghajar, Jamshid] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; [Jagoda, Andy] Icahn Sch Med Mt Sinai, Dept Emergency Med, New York, NY 10029 USA; [Riggio, Silvana] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Riggio, Silvana] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [du Coudray, Hugo] Portland State Univ, Dept Psychol, Portland, OR 97207 USA; [Hack, Dallas] US Army Med Res & Materiel Command, US Army Combat Casualty Care Res Program, Ft Detrick, MD USA		Ghajar, J (corresponding author), Brain Trauma Fdn, 7 World Trade Ctr,34th Floor,250 Greenwich St, New York, NY 10007 USA.	ghajar@braintrauma.org		Bedrick, Steven/0000-0002-0163-9397	US Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division [W911QY-11-C-0074]; Brain Trauma Foundation	There are no conflicts of interest. The Brain Trauma Foundation Concussion Guidelines project is supported by the US Army Contracting Command, Aberdeen Proving Ground, Natick Contracting Division, under contract No. W911QY-11-C-0074. The Brain Trauma Foundation provided funding for 2 meetings of the Panel of Technical Experts. Dr Jagoda is a consultant for Banyan Biomarkers. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Dutton RP, 2011, J TRAUMA, V70, P554, DOI 10.1097/TA.0b013e31820d1062; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Geyer C, 2009, J NEUROS-PEDIATR, V4, P339, DOI 10.3171/2009.5.PEDS08481; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kontos AP, 2010, ARCH CLIN NEUROPSYCH, V25, P734, DOI 10.1093/arclin/acq068; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; Ono K, 2007, NEUROL MED-CHIR, V47, P291, DOI 10.2176/nmc.47.291; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Saadat S, 2009, J NEUROSURG, V111, P688, DOI 10.3171/2009.2.JNS08909; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Turedi S, 2008, J EMERG MED, V34, P253, DOI 10.1016/j.jemermed.2007.05.055; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677	31	73	73	0	33	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2014	75			1			S3	S15		10.1227/NEU.0000000000000433			13	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AL3XC	WOS:000339063600002	25006974				2022-02-06	
J	Howell, DR; Osternig, LR; Koester, MC; Chou, LS				Howell, David R.; Osternig, Louis R.; Koester, Michael C.; Chou, Li-Shan			The effect of cognitive task complexity on gait stability in adolescents following concussion	EXPERIMENTAL BRAIN RESEARCH			English	Article						Brain injury; Dual task; Gait; Balance; Recovery	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; POSITION STATEMENT; EXECUTIVE FUNCTION; BALANCE CONTROL; ATTENTION; PERFORMANCE; PARADIGM; LONG	Concussion has been reported to result in disturbances to motor and cognitive functions. One way to examine these disturbances is through a dual-task assessment. Many secondary cognitive tasks have been proposed as appropriate tools during concussion assessment; however, task complexity has not been compared within a dual-task investigation. The purpose of this study was to prospectively examine how gait balance control was affected by three secondary cognitive tasks of varying complexity following concussion. Forty-six adolescents completed a dual-task walking protocol which included walking without any cognitive task (WALK), walking while completing a single auditory Stroop (SAS), multiple auditory Stroop (MAS), and a question and answer task (Q&A). Those who sustained a concussion (n = 23, mean age 15.4 +/- A 1.3 years) reported to the laboratory within 72 h of injury and in the following time increments: 1 week, 2 weeks, 1 month, and 2 months post-injury. Twenty-three healthy control subjects (mean age 15.4 +/- A 1.3 years), individually matched to each concussion subject, completed the same protocol in similar time increments. The concussion group demonstrated greater total center of mass (COM) medial/lateral displacement in the MAS and Q&A conditions compared with the control group. The concussion group also displayed the greatest peak COM anterior velocity in the least complex condition (WALK), and a significant decrease was observed as task complexity increased (SAS > MAS > Q&A). These findings indicate that gait balance control may be affected by task complexity following concussion and represent a way to identify motor recovery following concussion.	[Howell, David R.; Osternig, Louis R.; Chou, Li-Shan] 1240 Univ Oregon, Dept Human Physiol, Eugene, OR 97401 USA; [Koester, Michael C.] Slocum Ctr Orthoped & Sports Med, Eugene, OR USA		Chou, LS (corresponding author), 1240 Univ Oregon, Dept Human Physiol, Eugene, OR 97401 USA.	chou@uoregon.edu	Meijer, Anna/K-5118-2016	Howell, David/0000-0002-2955-0191	Veterans AdministrationUS Department of Veterans Affairs [A4842C8, A4843C]; Department of Defense-TATRCUnited States Department of Defense [W81XWH-11-1-0717]; University of Oregon; Peace Health Oregon Region	This work was supported by the Veterans Administration (Subcontract Awards Nos. A4842C8 and A4843C), the Department of Defense-TATRC (Award No. W81XWH-11-1-0717), and the translational research award from the University of Oregon and Peace Health Oregon Region.	Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bryer EJ, 2013, J INT NEUROPSYCH SOC, V19, P751, DOI 10.1017/S1355617713000490; Bush G, 1998, HUM BRAIN MAPP, V6, P270, DOI 10.1002/(SICI)1097-0193(1998)6:4<270::AID-HBM6>3.3.CO;2-H; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Crews F, 2007, PHARMACOL BIOCHEM BE, V86, P189, DOI 10.1016/j.pbb.2006.12.001; De Beaumont L, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12278; Dreher JC, 2003, CEREB CORTEX, V13, P329, DOI 10.1093/cercor/13.4.329; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Fan J, 2003, NEUROIMAGE, V18, P42, DOI 10.1006/nimg.2002.1319; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hahn ME, 2003, CLIN BIOMECH, V18, P737, DOI 10.1016/S0268-0033(03)00139-6; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Katz-Leurer M, 2011, BRAIN INJURY, V25, P581, DOI 10.3109/02699052.2011.572943; LAJOIE Y, 1993, EXP BRAIN RES, V97, P139; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Luna B, 2004, CHILD DEV, V75, P1357, DOI 10.1111/j.1467-8624.2004.00745.x; Ma R, 2012, J BONE JOINT SURG AM, V94A, P1618, DOI 10.2106/JBJS.K.01127; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCulloch KL, 2010, J HEAD TRAUMA REHAB, V25, P155, DOI 10.1097/HTR.0b013e3181dc82e7; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Purcell JJ, 2011, NEUROIMAGE, V55, P750, DOI 10.1016/j.neuroimage.2010.11.042; Resch JE, 2011, J ATHL TRAINING, V46, P170, DOI 10.4085/1062-6050-46.2.170; Rickard TC, 2000, NEUROPSYCHOLOGIA, V38, P325, DOI 10.1016/S0028-3932(99)00068-8; Ross LM, 2011, J SPORT REHABIL, V20, P296, DOI 10.1123/jsr.20.3.296; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Tallus J, 2012, ACTA NEUROL SCAND, V126, P178, DOI 10.1111/j.1600-0404.2011.01623.x; Teel EF, 2013, J SCI MED SPORT, V16, P190, DOI 10.1016/j.jsams.2012.09.007; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Winter D, 2009, BIOMECHANICS MOTOR C, Vfourth, P86; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7; Yogev G, 2005, EUR J NEUROSCI, V22, P1248, DOI 10.1111/j.1460-9568.2005.04298.x; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720	46	73	73	1	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	JUN	2014	232	6					1773	1782		10.1007/s00221-014-3869-1			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	AI3BC	WOS:000336732400017	24531643				2022-02-06	
J	Schneider, EB; Sur, S; Raymont, V; Duckworth, J; Kowalski, RG; Efron, DT; Hui, X; Selvarajah, S; Hambridge, HL; Stevens, RD				Schneider, Eric B.; Sur, Sandeepa; Raymont, Vanessa; Duckworth, Josh; Kowalski, Robert G.; Efron, David T.; Hui, Xuan; Selvarajah, Shalini; Hambridge, Hali L.; Stevens, Robert D.			Functional recovery after moderate/severe traumatic brain injury A role for cognitive reserve?	NEUROLOGY			English	Article							EDUCATION; CONNECTIVITY; NETWORK	Objective:To evaluate the hypothesis that educational attainment, a marker of cognitive reserve, is a predictor of disability-free recovery (DFR) after moderate to severe traumatic brain injury (TBI).Methods:Retrospective study of the TBI Model Systems Database, a prospective multicenter cohort funded by the National Institute on Disability and Rehabilitation Research. Patients were included if they were admitted for rehabilitation after moderate to severe TBI, were aged 23 years or older, and had at least 1 year of follow-up. The main outcome measure was DFR 1 year postinjury, defined as a Disability Rating Scale score of zero.Results:Of 769 patients included, 214 (27.8%) achieved DFR at 1 year. In total, 185 patients (24.1%) had <12 years of education, while 390 (50.7%) and 194 patients (25.2%) had 12 to 15 years and 16 years of education, respectively. DFR was achieved by 18 patients (9.7%) with <12 years, 120 (30.8%) with 12 to 15 years, and 76 (39.2%) with 16 years of education (p < 0.001). In a logistic regression model controlling for age, sex, and injury- and rehabilitation-specific factors, duration of education of 12 years was independently associated with DFR (odds ratio 4.74, 95% confidence interval 2.70-8.32 for 12-15 years; odds ratio 7.24, 95% confidence interval 3.96-13.23 for 16 years).Conclusion:Educational attainment was a robust independent predictor of 1-year DFR even when adjusting for other prognostic factors. A dose-response relationship was noted, with longer educational exposure associated with increased odds of DFR. This suggests that cognitive reserve could be a factor driving neural adaptation during recovery from TBI.	[Schneider, Eric B.; Efron, David T.; Hui, Xuan; Selvarajah, Shalini; Hambridge, Hali L.] Johns Hopkins Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, Baltimore, MD 21205 USA; [Kowalski, Robert G.; Stevens, Robert D.] Johns Hopkins Sch Med, Div Neurosci Crit Care, Dept Anesthesiol, Baltimore, MD USA; [Kowalski, Robert G.; Stevens, Robert D.] Johns Hopkins Sch Med, Dept Crit Care Med, Baltimore, MD USA; [Stevens, Robert D.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA; [Stevens, Robert D.] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD USA; [Sur, Sandeepa] Tulane Univ, Sch Med, Tulane Ctr Aging, New Orleans, LA 70112 USA; [Raymont, Vanessa; Duckworth, Josh; Stevens, Robert D.] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA; [Raymont, Vanessa] Imperial Coll London, Dept Med, Ctr Mental Hlth, London, England		Schneider, EB (corresponding author), Johns Hopkins Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, Baltimore, MD 21205 USA.	eschnei1@jhmi.edu			National Institute on Disability and Rehabilitation Research; U.S. Department of EducationUS Department of Education	No external funding was provided for this study. The collection of the original data was supported by the National Institute on Disability and Rehabilitation Research and the U.S. Department of Education.	Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; Cader S, 2006, BRAIN, V129, P527, DOI 10.1093/brain/awh670; Chang L, 2004, ANN NEUROL, V56, P259, DOI 10.1002/ana.20190; Elkins JS, 2006, NEUROLOGY, V67, P435, DOI 10.1212/01.wnl.0000228246.89109.98; Fuentes A, 2010, BRAIN INJURY, V24, P995, DOI 10.3109/02699052.2010.489791; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Kemppainen NM, 2008, ANN NEUROL, V63, P112, DOI 10.1002/ana.21212; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Levi Y, 2013, J INT NEUROPSYCH SOC, V19, P664, DOI 10.1017/S1355617713000192; Murray AD, 2011, BRAIN, V134, P3684, DOI 10.1093/brain/awr259; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rentz DM, 2010, ANN NEUROL, V67, P353, DOI 10.1002/ana.21904; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Stern Y, 2008, CEREB CORTEX, V18, P959, DOI 10.1093/cercor/bhm134; Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6; Sumowski JF, 2010, BRAIN, V133, P362, DOI 10.1093/brain/awp307	21	73	75	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 6	2014	82	18					1636	1642		10.1212/WNL.0000000000000379			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AH9XB	WOS:000336497400013	24759845	Green Published			2022-02-06	
J	Stoica, BA; Loane, DJ; Zhao, ZR; Kabadi, SV; Hanscom, M; Byrnes, KR; Faden, AI				Stoica, Bogdan A.; Loane, David J.; Zhao, Zaorui; Kabadi, Shruti V.; Hanscom, Marie; Byrnes, Kimberly R.; Faden, Alan I.			PARP-1 Inhibition Attenuates Neuronal Loss, Microglia Activation and Neurological Deficits after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						microglial activation; controlled cortical impact; neuroprotection; PJ34; PARP-1	APOPTOSIS-INDUCING FACTOR; POLYMERASE-1-DEPENDENT CELL-DEATH; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE SYNTHASE; POLY(ADP-RIBOSE) POLYMERASE-1; NAD(+) DEPLETION; NEUROPROTECTION; MICE; PJ34; IDENTIFICATION	Traumatic brain injury (TBI) causes neuronal cell death as well as microglial activation and related neurotoxicity that contribute to subsequent neurological dysfunction. Poly (ADP-ribose) polymerase (PARP-1) induces neuronal cell death through activation of caspase-independent mechanisms, including release of apoptosis inducing factor (AIF), and microglial activation. Administration of PJ34, a selective PARP-1 inhibitor, reduced cell death of primary cortical neurons exposed to N-Methyl-N'-Nitro-N-Nitrosoguanidine (MNNG), a potent inducer of AIF-dependent cell death. PJ34 also attenuated lipopolysaccharide and interferon-gamma-induced activation of BV2 or primary microglia, limiting NF-kappa B activity and iNOS expression as well as decreasing generation of reactive oxygen species and TNF alpha. Systemic administration of PJ34 starting as late as 24 h after controlled cortical impact resulted in improved motor function recovery in mice with TBI. Stereological analysis demonstrated that PJ34 treatment reduced the lesion volume, attenuated neuronal cell loss in the cortex and thalamus, and reduced microglial activation in the TBI cortex. PJ34 treatment did not improve cognitive performance in a Morris water maze test or reduce neuronal cell loss in the hippocampus. Overall, our data indicate that PJ34 has a significant, albeit selective, neuroprotective effect after experimental TBI, and its therapeutic effect may be from multipotential actions on neuronal cell death and neuroinflammatory pathways.	[Stoica, Bogdan A.; Loane, David J.; Zhao, Zaorui; Kabadi, Shruti V.; Hanscom, Marie; Faden, Alan I.] Univ Maryland, Natl Study Ctr Trauma & EMS, Ctr Shock Trauma & Anesthesiol Res STAR, Dept Anesthesiol,Sch Med, Baltimore, MD 21201 USA; [Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA		Stoica, BA (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Bressler Res Bldg 655 W Baltimore St,Room 6-015, Baltimore, MD 21201 USA.	bstoica@anes.umm.edu	STOICA, BOGDAN/H-9782-2013; Loane, David/ABD-5177-2021	STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503; Hanscom, Marie/0000-0001-8308-135X; Faden, Alan I./0000-0003-0128-2348; Byrnes, Kimberly/0000-0002-7501-7734	 [RO1 NS061839]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061839] Funding Source: NIH RePORTER	We thank Titilola Akintola, Stephanie Custer, Vladimir Senatorov, and William Jeong for expert technical support. This work was supported by grant RO1 NS061839 to Alan Faden.	Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Antolin AA, 2012, ACS CHEM BIOL, V7, P1962, DOI 10.1021/cb300317y; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Besson VC, 2005, BRAIN RES, V1041, P149, DOI 10.1016/j.brainres.2005.01.096; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Clark RSB, 2007, J NEUROTRAUM, V24, P1399, DOI 10.1089/neu.2007.0305; Cohen-Armon M, 2007, TRENDS PHARMACOL SCI, V28, P556, DOI 10.1016/j.tips.2007.08.005; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Faul M, 2010, TRAUMATIC BRAIN INJU; Goebel DJ, 2006, J NEUROCHEM, V98, P1732, DOI 10.1111/j.1471-4159.2006.04065.x; Goldberg S, 2009, J NEUROCHEM, V111, P72, DOI 10.1111/j.1471-4159.2009.06296.x; Haddad M, 2008, EUR J PHARMACOL, V588, P52, DOI 10.1016/j.ejphar.2008.04.013; Hernandez AI, 2009, J NEUROSCI, V29, P9553, DOI 10.1523/JNEUROSCI.1512-09.2009; Iwashita A, 2004, J PHARMACOL EXP THER, V310, P425, DOI 10.1124/jpet.104.066944; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kanai M, 2003, MOL CELL BIOL, V23, P2451, DOI 10.1128/MCB.23.7.2451-2462.2003; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kauppinen TM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-152; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Lai Y, 2008, J NEUROCHEM, V104, P1700, DOI 10.1111/j.1471-4159.2007.05114.x; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Madison DL, 2011, DNA REPAIR, V10, P1003, DOI 10.1016/j.dnarep.2011.07.006; Nguewa PA, 2005, PROG BIOPHYS MOL BIO, V88, P143, DOI 10.1016/j.pbiomolbio.2004.01.001; Phulwani NK, 2008, J NEUROCHEM, V106, P578, DOI 10.1111/j.1471-4159.2008.05403.x; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; Poitras MF, 2007, NEUROSCIENCE, V148, P198, DOI 10.1016/j.neuroscience.2007.04.062; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stoica BA, 2005, MOL CELL NEUROSCI, V29, P355, DOI 10.1016/j.mcn.2005.02.009; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Wahlberg E, 2012, NAT BIOTECHNOL, V30, P283, DOI 10.1038/nbt.2121; Wang YF, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2000902; Wang YF, 2009, J NEUROCHEM, V110, P687, DOI 10.1111/j.1471-4159.2009.06167.x; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511; Zhu DY, 2003, J NEUROSCI, V23, P223	51	73	75	0	21	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2014	31	8					758	772		10.1089/neu.2013.3194			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AD7PX	WOS:000333457200007	24476502	Green Published			2022-02-06	
J	de la Cadena, SC; Hernandez-Fonseca, K; Camacho-Arroyo, I; Massieu, L				Garcia de la Cadena, Selene; Hernandez-Fonseca, Karla; Camacho-Arroyo, Ignacio; Massieu, Lourdes			Glucose deprivation induces reticulum stress by the PERK pathway and caspase-7-and calpain-mediated caspase-12 activation	APOPTOSIS			English	Article						Glucose deprivation; ER stress; PERK pathway; Caspase-12; Caspase-7; Calpain	ELECTRON-MICROSCOPIC FINDINGS; HYPOGLYCEMIC NEURONAL DEATH; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; ENDOPLASMIC-RETICULUM; CELL-DEATH; INCREASED EXPRESSION; TEMPORAL EVOLUTION; INDUCED APOPTOSIS; OXIDATIVE STRESS	Glucose is the main energy source in brain and it is critical for correct brain functioning. Type 1 diabetic patients might suffer from severe hypoglycemia if exceeding insulin administration, which can lead to acute brain injury if not opportunely corrected. The mechanisms leading to hypoglycemic brain damage are not completely understood and the role of endoplasmic reticulum (ER) stress has not been studied. ER stress resulting from the accumulation of unfolded or misfolded proteins in the ER is counteracted by the unfolded protein response (UPR). When the UPR is sustained, apoptotic death might take place. We have examined UPR activation during glucose deprivation (GD) in hippocampal cultured neurons and its role in the induction of apoptosis. Activation of the PERK pathway of the UPR was observed, as increased phosphorylation of eIF2 alpha and elevated levels of the transcription factor ATF4, occurred 30 min after GD and the levels of the chaperone protein, GRP78 and the transcription factor CHOP, increased after 2 h of GD. In addition, we observed an early activation of caspase-7 and 12 during GD, while caspase-3 activity increased only transiently during glucose reintroduction. Inhibition of caspase-3/7 and the calcium-dependent protease, calpain, significantly decreased caspase-12 activity. The ER stress inhibitor, salubrinal prevented neuronal death and caspase-12 activity. Results suggest that the PERK pathway of the UPR is involved in GD-induced apoptotic neuronal death through the activation of caspase-12, rather than the mitochondrial-dependent caspase pathway. In addition, we show that calpain and caspase-7 are soon activated after GD and mediate caspase-12 activation and neuronal death.	[Garcia de la Cadena, Selene; Massieu, Lourdes] Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Neuropatol Mol, Div Neurociencias, Mexico City 04510, DF, Mexico; [Hernandez-Fonseca, Karla] Inst Nacl Psiquiatria Ramon de la Fuente Muniz, Dept Neuroquim, Mexico City, DF, Mexico; [Camacho-Arroyo, Ignacio] Univ Nacl Autonoma Mexico, Fac Quim, Dept Biol, Mexico City 04510, DF, Mexico		Massieu, L (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Neuropatol Mol, Div Neurociencias, AP 70-253, Mexico City 04510, DF, Mexico.	lmassieu@ifc.unam.mx	Camacho-Arroyo, Ignacio/AAM-4654-2021; Hernandez-Fonseca, KARLA/AAG-1500-2020; Camacho-Arroyo, Ignacio/AAM-6757-2021	Camacho-Arroyo, Ignacio/0000-0003-2978-1253; Camacho-Arroyo, Ignacio/0000-0003-2978-1253; Hernandez-Fonseca, Karla/0000-0002-5932-8911	CONACyTConsejo Nacional de Ciencia y Tecnologia (CONACyT) [S112179]; PAPIIT (UNAM)Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)Universidad Nacional Autonoma de Mexico [IN211710-3]; CONACyT fellowshipConsejo Nacional de Ciencia y Tecnologia (CONACyT) [221026]	This work was supported by S112179 CONACyT and IN211710-3 PAPIIT (UNAM) Grants to L.M. and 221026 CONACyT fellowship to S.G.C The authors thank Teresa Montiel for her technical assistance. This study was performed in partial fulfillment of the requirements for the PhD degree in Ciencias Bioquimicas of S. Garcia de la Cadena at the Universidad Nacional Autonoma de Mexico.	AUER RN, 1985, ACTA NEUROPATHOL, V67, P25, DOI 10.1007/BF00688121; AUER RN, 1985, ACTA NEUROPATHOL, V67, P13, DOI 10.1007/BF00688120; Badiola N, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.31; Benavides A, 2005, GLIA, V52, P261, DOI 10.1002/glia.20242; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; BUTCHER SP, 1987, NEUROSCI LETT, V76, P296, DOI 10.1016/0304-3940(87)90418-6; Cryer PE, 2006, J CLIN INVEST, V116, P1470, DOI 10.1172/JCI28735; Dahmer MK, 2005, J NEUROSCI RES, V80, P576, DOI 10.1002/jnr.20471; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Hayashi T, 2005, J CEREBR BLOOD F MET, V25, P41, DOI 10.1038/sj.jcbfm.9600005; Hernandez-Fonseca K, 2012, NEUROENDOCRINOLOGY, V96, P41, DOI 10.1159/000334229; Ibuki T, 2012, NEUROSCI LETT, V518, P45, DOI 10.1016/j.neulet.2012.04.053; Kumar R, 2001, J NEUROCHEM, V77, P1418, DOI 10.1046/j.1471-4159.2001.00387.x; Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Liu HJ, 2009, NEUROL SCI, V30, P227, DOI 10.1007/s10072-009-0086-y; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malagelada C, 2005, NEUROBIOL DIS, V20, P27, DOI 10.1016/j.nbd.2005.01.028; Malhotra JD, 2007, SEMIN CELL DEV BIOL, V18, P716, DOI 10.1016/j.semcdb.2007.09.003; Mao WK, 2006, AM J PHYSIOL-CELL PH, V290, pC1373, DOI 10.1152/ajpcell.00369.2005; Martinez JA, 2010, APOPTOSIS, V15, P1480, DOI 10.1007/s10495-010-0526-4; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Merksamer PI, 2010, J CELL SCI, V123, P1003, DOI 10.1242/jcs.035832; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Minano A, 2008, J NEUROSCI RES, V86, P1734, DOI 10.1002/jnr.21633; Morimoto N, 2007, NEUROSCIENCE, V147, P957, DOI 10.1016/j.neuroscience.2007.04.017; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mouw G, 2002, J MOL NEUROSCI, V14, P183; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakka VP, 2010, NEUROTOX RES, V17, P189, DOI 10.1007/s12640-009-9110-5; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Paramo B, 2010, NEUROSCIENCE, V167, P1057, DOI 10.1016/j.neuroscience.2010.02.074; Paramo B, 2013, INT J BIOCHEM CELL B, V45, P2596, DOI 10.1016/j.biocel.2013.08.013; Paschen W, 2003, J CEREBR BLOOD F MET, V23, P449, DOI 10.1097/01.WCB.0000054216.21675.AC; Raghubir R, 2011, METHOD ENZYMOL, V489, P259, DOI 10.1016/B978-0-12-385116-1.00015-7; Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Rasheva VI, 2009, APOPTOSIS, V14, P996, DOI 10.1007/s10495-009-0341-y; Reijonen S, 2008, EXP CELL RES, V314, P950, DOI 10.1016/j.yexcr.2007.12.025; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; SANDBERG M, 1986, J NEUROCHEM, V47, P178; Saxena S, 2009, NAT NEUROSCI, V12, P627, DOI 10.1038/nn.2297; Shibata M, 2003, NEUROSCIENCE, V118, P491, DOI 10.1016/S0306-4522(02)00910-7; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Suh SW, 2008, J CEREBR BLOOD F MET, V28, P1697, DOI 10.1038/jcbfm.2008.61; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2003, J NEUROSCI, V23, P10681; Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; Tan YF, 2006, J BIOL CHEM, V281, P16016, DOI 10.1074/jbc.M601299200; Tong L, 1998, J NEURAL TRANSM, V105, P905, DOI 10.1007/s007020050101; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Verkhratsky A, 2005, PHYSIOL REV, V85, P201, DOI 10.1152/physrev.00004.2004; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; Xu YY, 2011, BRAIN RES, V1375, P49, DOI 10.1016/j.brainres.2010.12.029; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Zhang AL, 2010, NEUROSCI LETT, V478, P32, DOI 10.1016/j.neulet.2010.04.062; Zhao LH, 2006, CURR OPIN CELL BIOL, V18, P444, DOI 10.1016/j.ceb.2006.06.005	68	73	73	1	30	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1360-8185	1573-675X		APOPTOSIS	Apoptosis	MAR	2014	19	3					414	427		10.1007/s10495-013-0930-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	AB2QA	WOS:000331636000002	24185830				2022-02-06	
J	Bender, A; Heulin, S; Rohrer, S; Mehrkens, JH; Heidecke, V; Straube, A; Pfefferkorn, T				Bender, Andreas; Heulin, Sandrine; Roehrer, Stefan; Mehrkens, Jan-Hinnerk; Heidecke, Volkmar; Straube, Andreas; Pfefferkorn, Thomas			Early cranioplasty may improve outcome in neurological patients with decompressive craniectomy	BRAIN INJURY			English	Article						Cranioplasty; decompressive craniectomy; neurorehabilitation; outcome; stroke; traumatic brain injury	MIDDLE CEREBRAL-ARTERY; TRAUMATIC BRAIN-INJURY; MALIGNANT INFARCTION; CASE SERIES; HEMICRANIECTOMY; MULTICENTER; SURGERY; RECOVERY; INFECTION; TRIAL	Primary objective: Decompressive craniectomy is an effective therapy to relieve intractable intracranial hypertension following acute brain injury. However, little is known about the optimal timing for cranioplasties in the sub-acute phase. The objective of the present study was to analyse the effect of cranioplasty timing on neurological outcomes. Research design: Single-centre observational study. Methods and procedures: One hundred and forty-seven consecutive patients with decompressive craniectomy and cranioplasty during the course of inpatient neurorehabilitation were identified by means of a retrospective hospital database search. This database contains the following prospectively-entered weekly scores: Barthel-Index (BI), Functional Independence Measure (FIM) and Coma Remission Scale (CRS). Additional clinical data were taken retrospectively from patient charts. Regression analysis was used to identify factors that influenced the end-of-rehabilitation outcome. Main outcomes and results: Patients with shorter delays to cranioplasty (<86 days) had a better functional outcome than patients with longer delays of >85 days (60 +/- 29.5 versus 25 +/- 24.1 BI points; p<0.01, respectively). Age, pre-operative BI and CRS scores were additional independent outcome factors. Complication rates were not different between early and late cranioplasty groups. Conclusions: Patients with decompressive craniectomy for management of intracranial hypertension may benefit from early cranioplasty.	[Bender, Andreas; Heulin, Sandrine; Straube, Andreas; Pfefferkorn, Thomas] Univ Munich, Dept Neurol, D-81377 Munich, Germany; [Bender, Andreas; Heulin, Sandrine] Therapiezentrum Burgau, Dept Neurol, D-89331 Burgau, Germany; [Roehrer, Stefan] Univ Ulm, Dept Neurosurg, D-89069 Ulm, Germany; [Roehrer, Stefan] Bezirkskrankenhaus Gunzburg, Dept Neurosurg, Gunzburg, Germany; [Mehrkens, Jan-Hinnerk] Univ Munich, Dept Neurosurg, D-81377 Munich, Germany; [Heidecke, Volkmar] Zent Klinikum, Dept Neurosurg, Augsburg, Germany		Bender, A (corresponding author), Therapiezentrum Burgau, Dept Neurol, Kapuzinerstr 34, D-89331 Burgau, Germany.	anbender@med.uni-muenchen.de		Bender, Andreas/0000-0002-6328-7104			Archavlis E, 2012, ACTA NEUROCHIR, V154, P1055, DOI 10.1007/s00701-012-1333-1; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Bijlenga P, 2007, J NEUROL NEUROSUR PS, V78, P430, DOI 10.1136/jnnp.2006.099242; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; Chun HJ, 2011, J CRANIOFAC SURG, V22, P203, DOI 10.1097/SCS.0b013e3181f753bd; Di Stefano C, 2012, BRIT J NEUROSURG, V26, P827, DOI 10.3109/02688697.2012.692838; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Lippert-Gruner M, 2002, ACT NEUR S, V79, P21; MAHONEY F I, 1965, Md State Med J, V14, P61; Mori K, 2004, SURG NEUROL, V62, P420, DOI 10.1016/j.surneu.2003.12.017; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Sarov M, 2010, STROKE, V41, P560, DOI 10.1161/STROKEAHA.109.568543; Schmidt JH, 2007, J NEUROSURG, V107, P678, DOI 10.3171/JNS-07/09/0678; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Stelling H, 2011, BRIT J NEUROSURG, V25, P407, DOI 10.3109/02688697.2011.566385; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Uhl E, 2004, J NEUROL NEUROSUR PS, V75, P270; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Voss A, 1993, SPECTRUM NEUROREHABI, P112; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43	36	73	78	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2013	27	9					1073	1079		10.3109/02699052.2013.794972			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	180HZ	WOS:000321586100012	23662672				2022-02-06	
J	Azulay, J; Smart, CM; Mott, T; Cicerone, KD				Azulay, Joanne; Smart, Colette M.; Mott, Tasha; Cicerone, Keith D.			A Pilot Study Examining the Effect of Mindfulness-Based Stress Reduction on Symptoms of Chronic Mild Traumatic Brain Injury/Postconcussive Syndrome	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild traumatic brain injury; mindfulness; quality of life; rehabilitation; self-efficacy	MEDITATION; INJURY; PROGRAM; ATTENTION; LIFE; INTERVENTION; INDIVIDUALS; SENSITIVITY; COMPLAINTS; QUALITY	Objective: To evaluate the effectiveness of the mindfulness-based stress reduction (MBSR) program tailored to individuals with mild traumatic brain injury (mTBI). Design: A convenience sample recruited from clinical referrals over a 2-year period completed outcome measures pre- and posttreatment intervention. Setting: Post-acute brain injury rehabilitation center within a suburban medical facility. Participants: Twenty-two individuals with mTBI and a time postinjury more than 7 months. Eleven participants were men and 11 were women, ranging in age from 18 to 62 years. Intervention: A 10-week group (with weekly 2-hour sessions) modeled after the MBSR program of Kabat-Zinn, but with modifications designed to facilitate implementation in a population of individuals with brain injury. (The treatment involved enhancement of attentional skills, in addition to increased awareness of internal and external experiences associated with the perspective change of acceptance and nonjudgmental attitude regarding those experiences). Main Outcome Measures: Perceived Quality of Life Scale, Perceived Self-Efficacy Scale, and the Neurobehavioral Symptom Inventory. Secondary measures included neuropsychological tests, a self-report problem-solving inventory, and a self-report measure of mindfulness. Results: Clinically meaningful improvements were noted on measures of quality of life (Cohen d = 0.43) and perceived self-efficacy (Cohen d = 0.50) with smaller but still significant effects on measures of central executive aspects of working memory and regulation of attention. Conclusion: The MBSR program can be adapted for participants with mTBI. Improved performance on measures associated with improved quality of life and self-efficacy may be related to treatment directed at improving awareness and acceptance, thereby minimizing the catastrophic assessment of symptoms associated with mTBI and chronic disability. Additional research on the comparative effectiveness of the MBSR program for people with mTBI is warranted.	[Azulay, Joanne; Smart, Colette M.; Mott, Tasha; Cicerone, Keith D.] JFK Johnson Rehabil Inst, Edison, NJ USA; [Azulay, Joanne; Smart, Colette M.; Mott, Tasha] New Jersey Neurosci Inst, Edison, NJ USA; [Smart, Colette M.] Univ Victoria, Dept Psychol, Victoria, BC, Canada		Azulay, J (corresponding author), 2048 Oak Tree Rd, Edison, NJ 08820 USA.						Bedard M, 2003, DISABIL REHABIL, V25, P722, DOI 10.1080/0963828031000090489; Bedard M, 2005, J COGN REHABIL, V23, P8, DOI DOI 10.1080/0963828031000090489; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Chambers R, 2008, COGNITIVE THER RES, V32, P303, DOI 10.1007/s10608-007-9119-0; Chiesa A, 2011, CLIN PSYCHOL REV, V31, P449, DOI 10.1016/j.cpr.2010.11.003; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; CICERONE KD, 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; D'Zurilla TJ, 2002, SPSI R SOCIAL PROBLE; Delis D.C., 2000, CALIFORNIA VERBAL LE; Evans S, 2008, J ANXIETY DISORD, V22, P716, DOI 10.1016/j.janxdis.2007.07.005; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Flanagan Steven R, 2008, Neuropsychiatr Dis Treat, V4, P877; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7; Holzel BK, 2011, PSYCHIAT RES-NEUROIM, V191, P36, DOI 10.1016/j.pscychresns.2010.08.006; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555; Kabat-Zinn J, 1998, PSYCHOSOM MED, V60, P625, DOI 10.1097/00006842-199809000-00020; Kabat-Zinn J., 1990, FULL CATASTROPHE LIV; KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3; KABATZINN J, 1985, J BEHAV MED, V8, P163, DOI 10.1007/BF00845519; KABATZINN J, 1992, AM J PSYCHIAT, V149, P936; KAPLAN KH, 1993, GEN HOSP PSYCHIAT, V15, P284, DOI 10.1016/0163-8343(93)90020-O; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Lorig K., 1996, OUTCOME MEASURES HLT; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McMillan T, 2002, NEUROPSYCHOL REHABIL, V12, P117, DOI 10.1080/09602010143000202; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Novakovic-Agopian T, 2011, J HEAD TRAUMA REHAB, V26, P325, DOI 10.1097/HTR.0b013e3181f1ead2; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; PERSINGER MA, 1993, PSYCHOL REP, V72, P1059, DOI 10.2466/pr0.1993.72.3c.1059; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruff RM, 2009, PSYCHOL INJ LAW, V2, P34, DOI 10.1007/s12207-009-9029-4; Rutherford WH, 1989, BRAIN INJURY, V10, P225; Sawechyn JM, J HEAD TRAUMA REHABI, V20, P301; Sayegh A, 2008, J NEUROL NEUROSRG PS, V81, P1; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Speca M, 2000, PSYCHOSOM MED, V62, P613, DOI 10.1097/00006842-200009000-00004; Tang YY, 2007, P NATL ACAD SCI USA, V104, P17152, DOI 10.1073/pnas.0707678104; Tang YY, 2009, TRENDS COGN SCI, V13, P222, DOI 10.1016/j.tics.2009.01.009; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Zylowska L, 2008, J ATTEN DISORD, V11, P737, DOI 10.1177/1087054707308502	58	73	74	3	47	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					323	331		10.1097/HTR.0b013e318250ebda			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900010	22688212				2022-02-06	
J	Edlow, BL; Haynes, RL; Takahashi, E; Klein, JP; Cummings, P; Benner, T; Greer, DM; Greenberg, SM; Wu, O; Kinney, HC; Folkerth, RD				Edlow, Brian L.; Haynes, Robin L.; Takahashi, Emi; Klein, Joshua P.; Cummings, Peter; Benner, Thomas; Greer, David M.; Greenberg, Steven M.; Wu, Ona; Kinney, Hannah C.; Folkerth, Rebecca D.			Disconnection of the Ascending Arousal System in Traumatic Coma	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						ARAS; Ascending reticular activating system; Coma; Consciousness; HARDI; High angular resolution diffusion imaging; TAI; TBI; Tractography; Traumatic axonal injury; Traumatic brain injury	DIFFUSE AXONAL INJURY; AMYLOID PRECURSOR PROTEIN; PERSISTENT VEGETATIVE STATE; SEVERE HEAD-INJURY; BRAIN-INJURY; RETICULAR-FORMATION; WATER RELAXATION; NERVOUS-TISSUE; LATE RECOVERY; CONSCIOUSNESS	Traumatic coma is associated with disruption of axonal pathways throughout the brain, but the specific pathways involved in humans are incompletely understood. In this study, we used high angular resolution diffusion imaging to map the connectivity of axonal pathways that mediate the 2 critical components of consciousness-arousal and awareness-in the postmortem brain of a 62-year-old woman with acute traumatic coma and in 2 control brains. High angular resolution diffusion imaging tractography guided tissue sampling in the neuropathologic analysis. High angular resolution diffusion imaging tractography demonstrated complete disruption of white matter pathways connecting brainstem arousal nuclei to the basal forebrain and thalamic intralaminar and reticular nuclei. In contrast, hemispheric arousal pathways connecting the thalamus and basal forebrain to the cerebral cortex were only partially disrupted, as were the cortical "awareness pathways." Neuropathologic examination, which used beta-amyloid precursor protein and fractin immunomarkers, revealed axonal injury in the white matter of the brainstem and cerebral hemispheres that corresponded to sites of high angular resolution diffusion imaging tract disruption. Axonal injury was also present within the gray matter of the hypothalamus, thalamus, basal forebrain, and cerebral cortex. We propose that traumatic coma may be a subcortical disconnection syndrome related to the disconnection of specific brainstem arousal nuclei from the thalamus and basal forebrain.	[Edlow, Brian L.; Klein, Joshua P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Klein, Joshua P.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Folkerth, Rebecca D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Edlow, Brian L.; Takahashi, Emi; Benner, Thomas; Wu, Ona] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Edlow, Brian L.; Greer, David M.; Greenberg, Steven M.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp,J Philip Kistler Stroke Re, Boston, MA 02115 USA; [Takahashi, Emi] Harvard Univ, Sch Med, Div Newborn Med, Boston Childrens Hosp, Boston, MA USA; [Takahashi, Emi] Harvard Univ, Sch Med, Fetal Neonatal Neuroimaging & Dev Sci Ctr, Boston Childrens Hosp, Boston, MA USA; [Cummings, Peter] Off Chief Med Examiner, Boston, MA USA; [Wu, Ona] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Greer, David M.] Yale Univ, Sch Med, Dept Neurol, Yale New Haven Hosp, New Haven, CT 06510 USA; [Haynes, Robin L.; Kinney, Hannah C.; Folkerth, Rebecca D.] Harvard Univ, Sch Med, Dept Pathol, Boston Childrens Hosp, Boston, MA 02115 USA		Edlow, BL (corresponding author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St Lunder 650, Boston, MA 02114 USA.	bedlow@partners.org	Demchuk, Andrew M/E-1103-2012; Haynes, Robin L/M-4401-2016	Demchuk, Andrew M/0000-0002-4930-7789; Haynes, Robin L/0000-0003-4909-9585; Greer, David/0000-0002-2026-8333; Wu, Ona/0000-0002-5509-9461	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R25NS065743, R01HD20991, R21HD069001, P41EB015896]; Center for Integration of Medicine & Innovative Technology; Neuropathology Division, Department of Pathology; Department of Neurology, Brigham; Women's Hospital, Boston, Mass; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [1S10RR016811-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD020991, R21HD069001] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR014075, S10RR016811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R25NS065743] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health (R25NS065743 to Brian Edlow, R01HD20991 to Hannah Kinney, R21HD069001 to Emi Takahashi, and P41EB015896 to the Athinoula A. Martinos Center for Biomedical Imaging) and the Center for Integration of Medicine & Innovative Technology (to Brian Edlow). This work was also supported by the Neuropathology Division, Department of Pathology, and the Department of Neurology, Brigham and Women's Hospital, Boston, Mass. This work involved the use of instrumentation supported by the National Center for Research Resources (1S10RR016811-01 to the Athinoula A. Martinos Center for Biomedical Imaging).	ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Armstrong RA, 2010, FOLIA NEUROPATHOL, V48, P67; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Benarroch EE, 2007, NEUROLOGY, V69, P1293, DOI 10.1212/01.wnl.0000275537.71623.8e; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004; CLINTON J, 1993, NEUROPATH APPL NEURO, V19, P277, DOI 10.1111/j.1365-2990.1993.tb00438.x; Coote JH, 1995, BIOL SIGNAL, V4, P142; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; D'Arceuil H, 2007, NEUROIMAGE, V36, P64, DOI 10.1016/j.neuroimage.2007.02.039; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Edlow BL, 2012, SEMIN NEUROL, V32, P374, DOI 10.1055/s-0032-1331810; Edlow BL, 2012, J NEUROPATH EXP NEUR, V71, P531, DOI 10.1097/NEN.0b013e3182588293; El-Khodor BF, 2002, J COMP NEUROL, V452, P65, DOI 10.1002/cne.10367; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Faul M, 2010, TRAUMATIC BRAIN INJU; FAVOROV OV, 1990, J COMP NEUROL, V298, P97, DOI 10.1002/cne.902980108; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; Graham DI, 2004, FORENSIC SCI INT, V146, P89, DOI 10.1016/S0379-0738(03)00274-3; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hansen B, 2011, NEUROIMAGE, V57, P1458, DOI 10.1016/j.neuroimage.2011.04.052; Haynes RL, 2008, PEDIATR RES, V63, P656, DOI 10.1203/PDR.0b013e31816c825c; Hortobagyi T, 2007, NEUROPATH APPL NEURO, V33, P226, DOI 10.1111/j.1365-2990.2006.00794.x; Irimia A, 2012, NEUROIMAGE, V60, P1340, DOI 10.1016/j.neuroimage.2012.01.107; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; JENNETT B, 1972, LANCET, V1, P734; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; KINNEY HC, 1994, NEW ENGL J MED, V330, P1469, DOI 10.1056/NEJM199405263302101; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; Kreutzberg GW, 1997, GREENFIELDS NEUROPAT, P124; LECLERC SS, 1993, SOMATOSENS MOT RES, V10, P133, DOI 10.3109/08990229309028829; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Makris N, 2006, NEUROIMAGE, V33, P139, DOI 10.1016/j.neuroimage.2006.04.220; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McNab JA, 2013, NEUROIMAGE, V69, P87, DOI 10.1016/j.neuroimage.2012.11.065; Mcnab JA, 2009, NEUROIMAGE, V46, P775, DOI 10.1016/j.neuroimage.2009.01.008; Miller KL, 2011, NEUROIMAGE, V57, P167, DOI 10.1016/j.neuroimage.2011.03.070; Moll CKE, 2009, PROG BRAIN RES, V177, P125, DOI 10.1016/S0079-6123(09)17710-5; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Morel A, 1997, J COMP NEUROL, V387, P588, DOI 10.1002/(SICI)1096-9861(19971103)387:4<588::AID-CNE8>3.0.CO;2-Z; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Parvizi J, 2001, COGNITION, V79, P135, DOI 10.1016/S0010-0277(00)00127-X; Paxinos G., 1995, ATLAS HUMAN BRAINSTE; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Reese TG, 2009, J MAGN RESON IMAGING, V29, P517, DOI 10.1002/jmri.21497; Reichard RR, 2005, NEUROPATH APPL NEURO, V31, P304, DOI 10.1111/j.1365-2990.2005.00645.x; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2000, J CLIN NEUROPHYSIOL, V17, P438, DOI 10.1097/00004691-200009000-00002; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Selden NR, 1998, BRAIN, V121, P2249, DOI 10.1093/brain/121.12.2249; Shapiro EM, 2004, P NATL ACAD SCI USA, V101, P10901, DOI 10.1073/pnas.0403918101; Shepherd TM, 2009, MAGN RESON MED, V62, P26, DOI 10.1002/mrm.21977; Shepherd TM, 2009, NEUROIMAGE, V44, P820, DOI 10.1016/j.neuroimage.2008.09.054; Shin SS, 2012, J NEUROSURG, V116, P1062, DOI 10.3171/2012.1.JNS111282; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Sisodiya SM, 2000, NEUROREPORT, V11, P2601, DOI 10.1097/00001756-200008030-00050; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Steriade M, 1996, SCIENCE, V272, P225, DOI 10.1126/science.272.5259.225; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; STRICH SJ, 1961, LANCET, V2, P443; TATEOSTROFF B, 1989, P NATL ACAD SCI USA, V86, P745, DOI 10.1073/pnas.86.2.745; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Zoroya G, 2010, TROOPS BRAIN TRAUMA; [No title captured]	87	73	76	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUN	2013	72	6					505	523		10.1097/NEN.0b013e3182945bf6			19	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	151IR	WOS:000319454400006	23656993	Green Accepted, Bronze			2022-02-06	
J	Inaba, K; Menaker, J; Branco, BC; Gooch, J; Okoye, OT; Herrold, J; Scalea, TM; DuBose, J; Demetriades, D				Inaba, Kenji; Menaker, Jay; Branco, Bernardino C.; Gooch, Jonathan; Okoye, Obi T.; Herrold, Joe; Scalea, Thomas M.; DuBose, Joseph; Demetriades, Demetrios			A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	PROMMTT Symposium held at the 71st Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 12-15, 2012	HI	Amer Assoc Surg Trauma		Traumatic brain injury; seizure prophylaxis; phenytoin; levetiracetam; outcomes	BRAIN-INJURY; PREVENTION; TRIAL	BACKGROUND: Brain Trauma Foundation guidelines recommend seizure prophylaxis for preventing early posttraumatic seizure (PTS). Phenytoin (PHE) is commonly used. Despite a paucity of data in traumatic brain injury, levetiracetam (LEV) has been introduced as a potential replacement, which is more costly but does not require serum monitoring. The purpose of this study was to compare the efficacy of PHE with that of LEV for preventing early PTS. METHODS: Consecutive blunt traumatic brain injury patients undergoing seizure prophylaxis were prospectively enrolled at two Level 1 trauma centers during a 33-month period. Seizure prophylaxis was administered according to local protocol. Patients were monitored prospectively throughout their hospital stay for clinical evidence of seizure activity. PHE was compared with LEV with clinical early PTS as the primary outcome measure, defined as a seizure diagnosed clinically, occurring within 7 days of admission. RESULTS: Atotal of 1,191 patients were screened for enrollment, after excluding 378 (31.7%) who did notmeet inclusioncriteria; 813(68.3%) were analyzed (406 LEV and 407 PHE). There were no significant differences between LEV and PHE in age (51.7 [21.3] vs. 53.6 [22.5], p = 0.205), male (73.9% vs. 68.8%, p = 0.108), Injury Severity Score (ISS) (20.0 [10.0] vs. 21.0 [10.6], p = 0.175), Marshall score of 3 or greater (18.5% vs. 14.7%, p = 0.153), or craniectomy (8.4% vs. 11.8%, p = 0.106). There was no difference in seizure rate (1.5% vs. 1.5%, p = 0.997), adverse drug reactions (7.9% vs. 10.3%, p = 0.227), or mortality (5.4% vs. 3.7%, p = 0.236). CONCLUSION: In this prospective evaluation of early PTS prophylaxis, LEV did not outperform PHE. Cost and need for serum monitoring should be considered in guiding the choice of prophylactic agent. (J Trauma Acute Care Surg. 2013; 74: 766-773. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Inaba, Kenji; Branco, Bernardino C.; Okoye, Obi T.; Herrold, Joe] Univ So Calif, Div Trauma & Surg Crit Care, Los Angeles, CA 90033 USA; [Menaker, Jay; Gooch, Jonathan; Scalea, Thomas M.; DuBose, Joseph] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Div Trauma & Surg Crit Care, Baltimore, MD 21201 USA		Inaba, K (corresponding author), Univ So Calif, Div Trauma & Surg Crit Care, 2051 Marengo St,Room C5L100, Los Angeles, CA 90033 USA.	kinaba@surgery.usc.edu		Okoye, Obi/0000-0003-4794-4335			Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; COHEN J, 1977, STAT POWER ANAL BEHA, P183; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cotton BA, 2011, J TRAUMA, V71, P375, DOI 10.1097/TA.0b013e318224d307; Frend V, 2007, CLIN NEUROPHARMACOL, V30, P362, DOI 10.1097/WNF.0b013e318059ae1c; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Klein P, 2012, ARCH NEUROL-CHICAGO, P1; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Pieracci FM, 2012, J TRAUMA ACUTE CARE, V72, P276, DOI 10.1097/TA.0b013e31823df31f; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Steinbaugh LA, 2012, EPILEPSY BEHAV, V23, P280, DOI 10.1016/j.yebeh.2011.12.005; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016; Zafar SN, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-30	18	73	75	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2013	74	3					766	771		10.1097/TA.0b013e3182826e84			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	108UO	WOS:000316321900014	23425733				2022-02-06	
J	Wolf, G; Cifu, D; Baugh, L; Carne, W; Profenna, L				Wolf, George; Cifu, David; Baugh, Laura; Carne, William; Profenna, Leonardo			The Effect of Hyperbaric Oxygen on Symptoms after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						hyperbaric oxygen; post-concussive syndrome; traumatic brain injury	PLACEBO-RESPONSE; MAJOR DEPRESSION; AFGHANISTAN; CONCUSSION; CHECKLIST; THERAPY; IRAQ	In this single-center, double-blind, randomized, sham-controlled, prospective trial at the U. S. Air Force School of Aerospace Medicine, the effects of 2.4 atmospheres absolute (ATA) hyperbaric oxygen (HBO2) on post-concussion symptoms in 50 military service members with at least one combat-related, mild traumatic brain injury were examined. Each subject received 30 sessions of either a sham compression (room air at 1.3 ATA) or HBO2 treatments at 2.4 ATA over an 8-week period. Individual and total symptoms scores on Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT (R)) and composite scores on Post-traumatic Disorder Check List-Military Version (PCL-M) were measured just prior to intervention and 6 weeks after completion of intervention. Difference testing of post-intervention means between the sham-control and HBO2 group revealed no significant differences on the PCL-M composite score (t= -0.205, p = 0.84) or on the ImPACT total score (t= -0.943, p = 0.35), demonstrating no significant effect for HBO2 at 2.4 ATA. PCL-M composite scores and ImPACT total scores for sham-control and HBO2 groups revealed significant improvement over the course of the study for both the sham-control group (t = 3.76, p = 0.001) and the HBO2 group (t = 3.90, p = 0.001), demonstrating no significant HBO2 effect. Paired t-test results revealed 10 ImPACT scale scores in the sham-control group improved from pre- to post-testing, whereas two scale scores significantly improved in the HBO2 group. One PCL-M measure improved from pre- to post-testing in both groups. This study showed that HBO2 at 2.4 ATA pressure had no effect on post-concussive symptoms after mild TBI.	[Wolf, George; Baugh, Laura; Profenna, Leonardo] USAF, Sch Aerosp Med, Hyperbar Med Dept, Wilford Hall Ambulatory Surg Ctr, Lackland AFB, TX USA; [Cifu, David] PM&R Program Off, Dept Vet Affairs, Washington, DC USA; [Cifu, David; Carne, William] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA; [Baugh, Laura] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Carne, William] Richmond Def & Vet Brain Injury Ctr, Richmond, VA USA		Cifu, D (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, 1223 E Marshall St, Richmond, VA 23298 USA.	dcifu@vcu.edu		Cifu, David/0000-0003-1600-9387	Air Force Medical Support Agency Medical Modernization Directorate; 711th Human Performance Wing for the primary study; U.S. Navy Bureau of Medicine and Surgery; U.S. Army Medical Materiel Development Activity; Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-09-2-206]; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs	Funding was provided by the Air Force Medical Support Agency Medical Modernization Directorate and the 711th Human Performance Wing for the primary study. The U.S. Navy Bureau of Medicine and Surgery provided contract funding for temporary duty requirements, and the U.S. Army Medical Materiel Development Activity provided funding for end of the study.; Dr. Cifu's efforts were supported, in part, through a Defense Advanced Research Projects Agency grant (N66001-09-2-206) and a contract from the U.S. Army Medical Materiel Development Activity. Dr. Carne's efforts were supported, in part, through contracts from the U.S. Army Medical Materiel Development Activity and the Defense and Veterans Brain Injury Center. The funding sources had no role in the study design, analysis, interpretation of the data, the writing of the paper, or the decision to submit the paper for publication.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Bennett M.H., 2004, COCHRANE DB SYST REV, V4; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Brunoni AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004824; Cifu D.X., 2011, OVERCOMING POSTDEPOL; Clarke D, 2009, UNDERSEA HYPERBAR M, V36, P13; Defense and Veterans Brain Injury Center, 2011, DOD WORLDW NUMB TBI; ECRI Institute, 2006, 1001 ECRI I CLIN; Gesell L.B., 2008, HYPERBARIC OXYGEN TH; Harch P.G., 2002, P 2 INT S HYP OXYG C; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Health Affairs, 2007, COMMUNICATION; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McDonagh M., 2003, 85 AHRQ; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Naval Sea Systems Command, 2008, SS521AGPRO010 NAV SE; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rockswold SB, 2007, NEUROL RES, V29, P162, DOI 10.1179/016164107X181798; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Stein DJ, 2006, J CLIN PSYCHIAT, V67, P1741, DOI 10.4088/JCP.v67n1111; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; U.S. Department of Veterans Affairs, 2007, PTSD CHECKL PCL; van Ophoven A, 2006, J UROLOGY, V176, P1442, DOI 10.1016/j.juro.2006.06.065; Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weaver L.K., 2012, UNDERSEA HY IN PRESS; Wolf E.G., 2012, UNDERSEA HY IN PRESS	30	73	77	0	25	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	17					2606	2612		10.1089/neu.2012.2549			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	047QU	WOS:000311856400002	23031217				2022-02-06	
J	Piedra, MP; Thompson, EM; Selden, NR; Ragel, BT; Guillaume, DJ				Piedra, Mark P.; Thompson, Eric M.; Selden, Nathan R.; Ragel, Brian T.; Guillaume, Daniel J.			Optimal timing of autologous cranioplasty after decompressive craniectomy in children Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						cranioplasty; intracranial pressure; children decompressive craniectomy; trauma	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; INTRACRANIAL HYPERTENSION; DELAYED CRANIOPLASTY; MULTICENTER; EFFICACY; SURGERY; DEFECTS; REPAIR; FROZEN	Object. The object of this study was to determine if early cranioplasty after decompressive craniectomy for elevated intracranial pressure in children reduces complications. Methods. Sixty-one consecutive cases involving pediatric patients who underwent autologous cranioplasty after decompressive craniectomy for raised intracranial pressure at a single academic children's hospital over 15 years were studied retrospectively. Results. Sixty-one patients were divided into early (< 6 weeks; 28 patients) and late (>= 6 weeks; 33 patients) cranioplasty cohorts. The cohorts were similar except for slightly lower age in the early (8.03 years) than the late (10.8 years) cranioplasty cohort (p < 0.05). Bone resorption after cranioplasty was significantly more common in the late (42%) than the early (14%) cranioplasty cohort (p < 0.05; OR 5.4). No other complication differed in incidence between the cohorts. Conclusions. After decompressive craniectomy for raised intracranial pressure in children, early (< 6 weeks) cranioplasty reduces the occurrence of reoperation for bone resorption, without altering the incidence of other complications. (http://thejns.org/doi/abs/10.3171/2012.6.PEDS1268)	[Piedra, Mark P.; Thompson, Eric M.; Selden, Nathan R.; Ragel, Brian T.; Guillaume, Daniel J.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA		Selden, NR (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol Surg, 3303 SW Bond Ave, Portland, OR 97239 USA.	seldenn@ohsu.edu		Selden, Nathan/0000-0001-6108-9721			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Arnaud E, 2000, CHILD NERV SYST, V16, P659, DOI 10.1007/s003810000321; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chao MT, 2009, PLAST RECONSTR SURG, V123, P976, DOI 10.1097/PRS.0b013e31819ba46f; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; Chun HJ, 2011, J CRANIOFAC SURG, V22, P203, DOI 10.1097/SCS.0b013e3181f753bd; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; HOCKLEY AD, 1991, PEDIATR NEUROSURG, V16, P271, DOI 10.1159/000120540; Hutchinson Peter, 1800, Neurosurg Focus, V22, pE14; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; POCHON JP, 1991, EUR J PEDIATR SURG, V1, P199, DOI 10.1055/s-2008-1042487; PROLO DJ, 1979, NEUROSURGERY, V4, P18, DOI 10.1227/00006123-197901000-00005; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Schuss P, 2012, J NEUROTRAUMA, V29, P2010; Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86; Smith DM, 2011, PLAST RECONSTR SURG, V128, P1053, DOI 10.1097/PRS.0b013e31822b65e4; Sultan SM, 2011, PLAST RECONSTR SURG, V127, P1855, DOI 10.1097/PRS.0b013e31820e89a5; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	30	73	78	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	OCT	2012	10	4					268	272		10.3171/2012.6.PEDS1268			5	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	015YX	WOS:000309485300004	22861195				2022-02-06	
J	Bikson, M; Rahman, A; Datta, A; Fregni, F; Merabet, L				Bikson, Marom; Rahman, Asif; Datta, Abhishek; Fregni, Felipe; Merabet, Lotfi			High-Resolution Modeling Assisted Design of Customized and Individualized Transcranial Direct Current Stimulation Protocols	NEUROMODULATION			English	Article						Electrical stimulation; FEM; fMRI; head model; lesion; modeling; neuromodulation; skull defects; stroke; tDCS; TMS; traumatic brain injury	BRAIN; TOLERABILITY; POLARIZATION; EXCITABILITY; FIELD; TDCS; FEM	Objectives: Transcranial direct current stimulation (tDCS) is a neuromodulatory technique that delivers low-intensity currents facilitating or inhibiting spontaneous neuronal activity. tDCS is attractive since dose is readily adjustable by simply changing electrode number, position, size, shape, and current. In the recent past, computational models have been developed with increased precision with the goal to help customize tDCS dose. The aim of this review is to discuss the incorporation of high-resolution patient-specific computer modeling to guide and optimize tDCS. Methods: In this review, we discuss the following topics: 1) The clinical motivation and rationale for models of transcranial stimulation is considered pivotal in order to leverage the flexibility of neuromodulation; 2) the protocols and the workflow for developing high-resolution models; 3) the technical challenges and limitations of interpreting modeling predictions; and 4) real cases merging modeling and clinical data illustrating the impact of computational models on the rational design of rehabilitative electrotherapy. Conclusions: Though modeling for noninvasive brain stimulation is still in its development phase, it is predicted that with increased validation, dissemination, simplification, and democratization of modeling tools, computational forward models of neuromodulation will become useful tools to guide the optimization of clinical electrotherapy.	[Bikson, Marom; Rahman, Asif] CUNY City Coll, Dept Biomed Engn, New York, NY 10031 USA; [Datta, Abhishek; Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Lab Neuromodulat, Boston, MA USA; [Merabet, Lotfi] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Vis Rehabil Ctr,Dept Ophthalmol, Boston, MA USA		Bikson, M (corresponding author), 160 Convent Ave,Steinman Hall,Rm 403B, New York, NY 10031 USA.	bikson@ccny.cuny.edu	merabet, lotfi/AAU-8259-2020; Merabet, Lotfi B./V-2735-2017	merabet, lotfi/0000-0002-8094-9536; Merabet, Lotfi B./0000-0002-8094-9536; Fregni, Felipe/0000-0001-9359-8643	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S06 GM008168 NS054783, CRCNS 41771]; Andy Grove Foundation; Wallace H Coulter Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [S06GM008168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS054783] Funding Source: NIH RePORTER	Dr. Datta is cofounder of Soterix Medical. The City University of New York has patent applications in Dr. Datta's name on brain stimulation. Dr. Bikson is funded by the National Institutes of Health (nos. S06 GM008168 NS054783, CRCNS 41771), the Andy Grove Foundation, and the Wallace H Coulter Foundation. The City University of New York has patent applications in Dr. Bikson's name on brain stimulation. Dr. Bikson is cofounder of Soterix Medical.	Ardolino G, 2005, J PHYSIOL-LONDON, V568, P653, DOI 10.1113/jphysiol.2005.088310; Bikson M, 2004, J PHYSIOL-LONDON, V557, P175, DOI 10.1113/jphysiol.2003.055772; Bikson M, 2010, CLIN NEUROPHYSIOL, V121, P1976, DOI 10.1016/j.clinph.2010.05.020; Borckardt JJ, 2012, J PAIN, V13, P112, DOI 10.1016/j.jpain.2011.07.001; Brunoni AR, 2011, BRAIN STIMU IN PRESS; DaSilva A, 2012, HEADACHE IN PRESS; Datta A, 2008, J NEURAL ENG, V5, P163, DOI 10.1088/1741-2560/5/2/007; Datta A, 2011, BRAIN STIMUL, V4, P169, DOI 10.1016/j.brs.2010.11.001; Datta A, 2010, NEUROIMAGE, V52, P1268, DOI 10.1016/j.neuroimage.2010.04.252; Datta A, 2009, IEEE ENG MED BIO, P670, DOI 10.1109/IEMBS.2009.5333673; Datta A, 2009, BRAIN STIMUL, V2, P201, DOI 10.1016/j.brs.2009.03.005; Dmochowski JP, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046011; Fregni F, 2006, EPILEPSIA, V47, P335, DOI 10.1111/j.1528-1167.2006.00426.x; Fridriksson J, 2011, J COMMUN DISORD, V44, P557, DOI 10.1016/j.jcomdis.2011.04.009; Halko MA, 2011, NEUROIMAGE, V57, P885, DOI 10.1016/j.neuroimage.2011.05.026; Holsheimer J, 1998, SPINAL CORD, V36, P531, DOI 10.1038/sj.sc.3100717; Joucla S, 2009, BIOPHYS J, V96, P3495, DOI 10.1016/j.bpj.2008.12.3961; Lindenberg R, 2012, NEUROREHABI IN PRESS; Mattai A, 2011, BRAIN STIMUL, V4, P275, DOI 10.1016/j.brs.2011.01.001; Mclntyre CC, 2007, EXPERT REV MED DEVIC, V4, P615, DOI 10.1586/17434440.4.5.615; Mendonca ME, 2011, J PAIN, V12, P610, DOI 10.1016/j.jpain.2010.12.015; Miranda PC, 2007, P ANN INT IEEE EMBS, P1715, DOI 10.1109/IEMBS.2007.4352640; Miranda PC, 2006, CLIN NEUROPHYSIOL, V117, P1623, DOI 10.1016/j.clinph.2006.04.009; Miranda PC, 2009, CLIN NEUROPHYSIOL, V120, P1183, DOI 10.1016/j.clinph.2009.03.023; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Oostendorp TF, 2008, IEEE ENG MED BIO, P4226, DOI 10.1109/IEMBS.2008.4650142; Parazzini M, 2011, IEEE T BIO-MED ENG, V58, P1773, DOI 10.1109/TBME.2011.2116019; Peterchev A, 2011, BRAIN STIMU IN PRESS; RATTAY F, 1986, IEEE T BIO-MED ENG, V33, P974, DOI 10.1109/TBME.1986.325670; RUSH S, 1968, ANESTH ANAL CURR RES, V47, P717; Sadleir RJ, 2010, NEUROIMAGE, V51, P1310, DOI 10.1016/j.neuroimage.2010.03.052; Salvador R, 2010, C P IEEE ENG MED BIO, V2010, P2073; Schneider HD, 2011, CLIN LINGUIST PHONET, V25, P640, DOI 10.3109/02699206.2011.570852; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Suh HS, 2009, C P IEEE ENG MED BIO, P638; Turkeltaub PE, 2011, BRAIN STIMU IN PRESS; Varga ET, 2011, EPILEPSY RES, V97, P142, DOI 10.1016/j.eplepsyres.2011.07.016; Wagner T, 2007, NEUROIMAGE, V35, P1113, DOI 10.1016/j.neuroimage.2007.01.027; Wolters CH, 2006, NEUROIMAGE, V30, P813, DOI 10.1016/j.neuroimage.2005.10.014; ZENTNER J, 1989, NEUROSURGERY, V24, P709, DOI 10.1227/00006123-198905000-00008	40	73	73	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159	1525-1403		NEUROMODULATION	Neuromodulation	JUL-AUG	2012	15	4					306	315		10.1111/j.1525-1403.2012.00481.x			10	Medicine, Research & Experimental; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Neurosciences & Neurology	984VG	WOS:000307219900006	22780230	Green Accepted			2022-02-06	
J	Archavlis, E; Nievas, MCY				Archavlis, E.; Carvi Y Nievas, Mario			The impact of timing of cranioplasty in patients with large cranial defects after decompressive hemicraniectomy	ACTA NEUROCHIRURGICA			English	Article						Cranioplasty; Decompressive craniectomy; Hemicraniectomy; Outcome; Timing	TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; SINKING SKIN FLAP; BLOOD-FLOW; MALIGNANT INFARCTION; CRANIECTOMY; CT; MULTICENTER; METABOLISM; SURGERY	It is unclear how soon after a decompressive hemicraniectomy that cranioplasty be safely performed in a patient in whom the ICP has been normalized. Early surgery has been associated with infection, intracerebral hematoma, and complications due to persistent or recurrent brain edema. Delayed cranioplasty of large cranial defects exposes the patient to different conditions known in the literature as the syndrome of the sinking skin flap. The purpose of this study was to investigate the hypothesis that timing of cranioplasty after decompressive hemicraniectomy influences outcome and complications. We retrospectively examined outcome after cranioplasty performed at < 7 weeks, 7-12 weeks, and > 13 weeks after craniectomy in patients with large cranial defects after decompressive hemicraniectomy in our institution between 1997 and 2008. The time between craniectomy and cranioplasty ranged from 17 days to 4 months depending on several factors such as: the cause of decompression, infection before or after craniectomy, and skin flap concavity. The analysis of the registered postoperative complications revealed that there were no significant differences between the examined groups. The cranioplasty at < 7 weeks, in the form of reimplantation of the own skull flap, led to a GOS improvement of 78 %, at 7-12 weeks 46 % and at > 13 weeks12 %, respectively. Pairwise comparisons showed that the difference between cranioplasty at < 7 weeks versus 7-12 weeks or > 13 weeks cranioplasty groups was statistically significant ( = 0.05 and < 0.001, respectively). Our study suggests that many patients with large cranial defects after decompressive craniectomy can safely undergo cranioplasty in an early stage; direct answers to these questions of timing of cranioplasty are best addressed by prospective studies. Nevertheless, the present study provides a basis for decision-making in certain patients and for the design of future investigations.	[Archavlis, E.] Goethe Univ Frankfurt, Neurosurg Clin, Klinikum Offenbach, Akad Lehrkrankenhaus, D-63069 Offenbach, Germany; [Carvi Y Nievas, Mario] Goethe Univ Frankfurt, Neurosurg Clin, Klinikum Frankfurt Hoechst, Akad Lehrkrankenhaus, D-63069 Offenbach, Germany		Archavlis, E (corresponding author), Goethe Univ Frankfurt, Neurosurg Clin, Klinikum Offenbach, Akad Lehrkrankenhaus, Starkenburgring 66, D-63069 Offenbach, Germany.	neurosurgery@t-online.de		, Eleftherios/0000-0001-5686-9483			Adamo MA, 2008, J NEUROSURG, V108, P174, DOI 10.3171/JNS/2008/108/01/0174; Agner C, 2002, ACTA NEUROCHIR, V144, P1033, DOI 10.1007/s00701-002-0996-4; Arnaud E, 2000, CHILD NERV SYST, V16, P659, DOI 10.1007/s003810000321; Bijlenga P, 2007, J NEUROL NEUROSUR PS, V78, P430, DOI 10.1136/jnnp.2006.099242; CARVI Y, 2006, NEUROL RES, V28, P139, DOI DOI 10.1179/016164106X98008; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; Erman T, 2005, SURG NEUROL, V63, P107, DOI 10.1016/j.surneu.2004.04.024; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Matsuno A, 2006, ACTA NEUROCHIR, V148, P535, DOI 10.1007/s00701-006-0740-6; Regel JP, 2004, NEUROCHIRURGIE, P231; RICHAUD J, 1985, NEUROCHIRURGIE, V31, P183; RISH BL, 1979, NEUROSURGERY, V4, P381, DOI 10.1227/00006123-197905000-00002; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Sarov M, 2010, STROKE, V41, P560, DOI 10.1161/STROKEAHA.109.568543; Schiffer J, 1997, SURG NEUROL, V47, P231, DOI 10.1016/S0090-3019(96)00376-X; Schimidek H., 2000, OPERATIVE NEUROSURGI; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Stiver SI, 2008, J NEUROSURG, V109, P245, DOI 10.3171/JNS/2008/109/8/0245; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Timmons RL, 1982, NEUROLOGICAL SURGERY, V4, P2228; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Yoshida K, 1996, J NEUROL NEUROSUR PS, V61, P166, DOI 10.1136/jnnp.61.2.166	32	73	76	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JUN	2012	154	6					1055	1062		10.1007/s00701-012-1333-1			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	943II	WOS:000304113800015	22527574				2022-02-06	
J	Vespa, P; McArthur, DL; Stein, N; Huang, SC; Shao, W; Filippou, M; Etchepare, M; Glenn, T; Hovda, DA				Vespa, Paul; McArthur, David L.; Stein, Nathan; Huang, Sung-Cheng; Shao, Weber; Filippou, Maria; Etchepare, Maria; Glenn, Thomas; Hovda, David A.			Tight glycemic control increases metabolic distress in traumatic brain injury: A randomized controlled within-subjects trial	CRITICAL CARE MEDICINE			English	Article						cerebral metabolism; glucose; insulin; microdialysis; positron emission tomography; traumatic brain injury	INTENSIVE INSULIN THERAPY; LACTATE/PYRUVATE RATIO; MICRODIALYSIS; GLUCOSE; TISSUE; SEIZURES; ATROPHY; CRISIS; VALUES; PET	Objective: To determine the effects of tight glycemic control on brain metabolism after traumatic brain injury using brain positron emission tomography and microdialysis. Design: Single-center, randomized controlled within-subject crossover observational trial. Setting: Academic intensive care unit. Methods: We performed a prospective, unblinded randomized controlled within-subject crossover trial of tight (80-110 mg/dL) vs. loose (120-150 mg/dL) glycemic control in patients with severe traumatic brain injury to determine the effects of glycemic control on brain glucose metabolism, as measured by [F-18] deoxy-D-glucose brain positron emission tomography. Brain microdialysis was done simultaneously. Measurements and Main Results: Thirteen severely injured traumatic brain injury patients underwent the study between 3 and 8 days (mean 4.8 days) after traumatic brain injury. In ten of these subjects, global brain and gray matter tissues demonstrated higher glucose metabolic rates while glucose was under tight control as compared with loose control (3.2 +/- 0.6 vs. 2.4 + 0.4, p = .02 [whole brain] and 3.8 +/- 1.4 vs. 2.9 +/- 0.8, p = .05 [gray matter]). However, the responses were heterogeneous with pericontusional tissue demonstrating the least state-dependent change. Cerebral microdialysis demonstrated more frequent critical reductions in glucose (p = .02) and elevations of lactate/pyruvate ratio (p = .03) during tight glycemic control. Conclusion: Tight glycemic control results in increased global glucose uptake and an increased cerebral metabolic crisis after traumatic brain injury. The mechanisms leading to the enhancement of metabolic crisis are unclear, but delivery of more glucose through mild hyperglycemia may be necessary after traumatic brain injury. (Crit Care Med 2012; 40:1923-1929)	[Vespa, Paul] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA; [Vespa, Paul; McArthur, David L.; Stein, Nathan; Filippou, Maria; Etchepare, Maria; Glenn, Thomas; Hovda, David A.] Univ Calif Los Angeles, Sch Med, Dept Neurosurg, Los Angeles, CA USA; [Huang, Sung-Cheng; Shao, Weber] Univ Calif Los Angeles, Sch Med, Dept Nucl Med, Los Angeles, CA USA		Vespa, P (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA.	pvespa@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Filippou-Frye, Maria/0000-0001-5516-0384; Glenn, Thomas/0000-0003-4273-3408	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS049471, P01 NS 058489-01A2]; UCLA Brain Injury Research Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489, R01NS049471] Funding Source: NIH RePORTER	Supported, in part, by NINDS NS049471, P01 NS 058489-01A2, and the UCLA Brain Injury Research Center.	Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Coester A, 2010, J TRAUMA, V68, P904, DOI 10.1097/TA.0b013e3181c9afc2; Coles JP, 2009, J CEREBR BLOOD F MET, V29, P965, DOI 10.1038/jcbfm.2009.22; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; HUANG SC, 1980, AM J PHYSIOL, V238, pE69, DOI 10.1152/ajpendo.1980.238.1.E69; ISHIZU K, 1994, J NUCL MED, V35, P1104; Maeda T, 2005, J NEUROTRAUM, V22, P763, DOI 10.1089/neu.2005.22.763; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	25	73	76	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2012	40	6					1923	1929		10.1097/CCM.0b013e31824e0fcc			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	946EZ	WOS:000304335600031	22610193				2022-02-06	
J	Mailles, A; De Broucker, T; Costanzo, P; Martinez-Almoyna, L; Vaillant, V; Stahl, JP				Mailles, Alexandra; De Broucker, Thomas; Costanzo, Pascale; Martinez-Almoyna, Laurent; Vaillant, Veronique; Stahl, Jean-Paul		Steering Comm Investigators Grp	Long-term Outcome of Patients Presenting With Acute Infectious Encephalitis of Various Causes in France	CLINICAL INFECTIOUS DISEASES			English	Article							HERPES-SIMPLEX ENCEPHALITIS; TRAUMATIC BRAIN-INJURY; VIRAL ENCEPHALITIS; MULTICENTER; ACYCLOVIR; RECOVERY; QUESTIONNAIRE; VALIDATION; CHILDHOOD; PROGNOSIS	Background. A prospective study of infectious encephalitis was conducted in France in 2007. In total, 253 patients were enrolled with a proven etiological diagnosis for 52%. The cohort of surviving patients with encephalitis was assessed for sequelae and impairment 3 years after enrollment. Methods. Patients, their family, and general practitioners (GPs) were interviewed by phone to document persisting symptoms, return to work, and past and current leisure activities, with standardized questionnaires. The IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly) was completed with relatives. The global outcome was determined in all patients with the Glasgow outcome scale. Results. In 2010, 20 patients (10%) were unavailable for follow-up, 2 (1%) were excluded, and 18 (9%) had died since hospital discharge. Data were available for 167 survivors and 9 patients whose death was related to the encephalitis. The outcome was favorable in 108 of 176 patients (61%) (71 with complete resolution), 31 (18%) were mildly impaired, 25 (14%) were severely impaired, and 3 (1%) were in a vegetative state. The most frequent symptoms were difficulty concentrating (42%), behavioral disorders (27%), speech disorders (20%), and memory loss (19%). Fifteen of 63 patients (24%) previously employed were still unable to resume work. Long-term outcome was significantly associated with comorbid conditions, age, level of education, and the causative agent of encephalitis. Conclusions. Most patients with encephalitis experienced a favorable outcome 3 years after hospital discharge. However, minor to severe disability persists in a high number of cases with consequences for everyday life. Physical and mental impairment should be evaluated in all patients with encephalitis, and neuropsychological rehabilitation implemented whenever needed.	[Mailles, Alexandra; Vaillant, Veronique] French Inst Publ Hlth Surveillance, St Maurice, France; [De Broucker, Thomas] Hop Delafontaine, Dept Neurol, St Denis, Reunion, France; [Costanzo, Pascale] Hosp Civils Lyon, Neuro Psychol Dept, Lyon, France; [Martinez-Almoyna, Laurent] Univ Joseph Fourier, Ctr Hosp, Dept Neurol, Grenoble, France; [Stahl, Jean-Paul] Univ Joseph Fourier, Grenoble, France; [Stahl, Jean-Paul] Univ Hosp, Grenoble, France		Mailles, A (corresponding author), Inst Veille Sanit, 12 Rue Val dOsne, F-94415 St Maurice, France.	a.mailles@invs.sante.fr	Stahl, Jean Paul/AAM-6425-2020; Lecuit, Marc/J-4073-2013; Rogez, Sylvie/O-8891-2016; Lecuit, Marc/M-4126-2019; Dinh, Aurelien/AAI-5355-2021; GOZLAN, Joel/P-6014-2017; Boutolleau, David/D-9610-2014; Guery, Benoit/D-8089-2017	Lecuit, Marc/0000-0002-4491-1063; Rogez, Sylvie/0000-0002-4092-7164; Lecuit, Marc/0000-0002-4491-1063; Boutolleau, David/0000-0001-9401-4662; lina, bruno/0000-0002-8959-2123; Herrmann, Jean-Louis/0000-0003-2347-6418; Terral, Daniel/0000-0003-3706-6786; Guery, Benoit/0000-0002-6526-0714; Prendki, Virginie/0000-0003-1315-2938; Mailles, Alexandra/0000-0002-8739-1168; Bebear, Cecile/0000-0001-6065-2332; POZZETTO, Bruno/0000-0002-2603-8467; Stahl, Jean Paul/0000-0002-0086-3557			BERLIT P, 1988, J NEUROIMMUNOL, V20, P117, DOI 10.1016/0165-5728(88)90142-7; Daxboeck F, 2004, J CHILD NEUROL, V19, P865, DOI 10.1177/08830738040190110401; Ebaugh FG, 2007, J ATTEN DISORD, V11, P339; Ebaugh Franklin G, 2007, J Atten Disord, V11, P336, DOI 10.1177/1087054707305340; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Fowler A, 2010, PEDIATRICS, V126, pE828, DOI 10.1542/peds.2009-3188; Glaser CA, 2006, CLIN INFECT DIS, V43, P1565, DOI 10.1086/509330; GORDON B, 1990, ARCH NEUROL-CHICAGO, V47, P646, DOI 10.1001/archneur.1990.00530060054017; Granerod J, 2010, LANCET INFECT DIS, V10, P835, DOI 10.1016/S1473-3099(10)70222-X; Haaland KY, 2006, EMERG INFECT DIS, V12, P1260, DOI 10.3201/eid1708.060097; Hokkanen L, 1997, J NEUROL NEUROSUR PS, V63, P222, DOI 10.1136/jnnp.63.2.222; JENNETT B, 1975, LANCET, V1, P480; Jeon IC, 2008, J KOREAN NEUROSURG S, V44, P295, DOI 10.3340/jkns.2008.44.5.295; JORM AF, 1995, PSYCHOL MED, V25, P437; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; LAW S, 1995, BRIT J PSYCHIAT, V167, P541, DOI 10.1192/bjp.167.4.541; Lee WT, 2007, EUR J PAEDIATR NEURO, V11, P302, DOI 10.1016/j.ejpn.2007.02.011; Lefebvre C, 2005, J NEUROL, V252, P1504, DOI 10.1007/s00415-005-0900-2; Liu XD, 2007, CLIN NEUROL NEUROSUR, V109, P571, DOI 10.1016/j.clineuro.2007.05.008; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Mailles A, 2009, CLIN INFECT DIS, V49, P1838, DOI 10.1086/648419; McGrath N, 1997, J NEUROL NEUROSUR PS, V63, P321, DOI 10.1136/jnnp.63.3.321; Michel J A, 2006, Eura Medicophys, V42, P59; Nichols-Larsen DS, 2005, STROKE, V36, P1480, DOI 10.1161/01.STR.0000170706.13595.4f; Raschilas F, 2002, CLIN INFECT DIS, V35, P254, DOI 10.1086/341405; Schmidt A, 2011, CLIN MICROBIOL INFEC, V17, P621, DOI 10.1111/j.1469-0691.2010.03276.x; SKOLDENBERG B, 1991, SCAND J INFECT DIS, P40; Stahl JP, 2012, EPIDEMIOL INFECT, V140, P372, DOI 10.1017/S0950268811000483; Stahl JP, 2011, MED MALADIES INFECT, V41, P453, DOI 10.1016/j.medmal.2011.05.015; THOMAS NH, 1993, ARCH DIS CHILD, V69, P573, DOI 10.1136/adc.69.5.573; Utley TFM, 1997, NEUROPSY NEUROPSY BE, V10, P180; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; World Health Organization, 2004, INT STAT CLASS DIS R, V2	34	73	74	0	16	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1058-4838	1537-6591		CLIN INFECT DIS	Clin. Infect. Dis.	MAY 15	2012	54	10					1455	1464		10.1093/cid/cis226			10	Immunology; Infectious Diseases; Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Infectious Diseases; Microbiology	942MW	WOS:000304049300017	22460967	Bronze			2022-02-06	
J	Chen, HC; Fong, TH; Lee, AW; Chiu, WT				Chen, Hsien-Chih; Fong, Tsorng-Harn; Lee, Ai-Wei; Chiu, Wen-Ta			Autophagy Is Activated in Injured Neurons and Inhibited by Methylprednisolone After Experimental Spinal Cord Injury	SPINE			English	Article						autophagy; spinal cord injury; methylprednisolone; transmission electron microscopy; microtubule-associated protein light chain 3	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CELL-DEATH; RAT MODEL; PATHOGENESIS; APOPTOSIS; PATHWAYS; SYSTEM; LC3	Study Design. Experimental, controlled trial, animal study. Objective. To assess autophagy expression after rat spinal cord injury (SCI) and investigate the effect of methylprednisolone treatment on autophagy. Summary of Background Data. Although it is evident that SCI induces necrosis and apoptosis, its relationship to autophagy is uncertain. Autophagy is implicated in various pathological states in the nervous system, such as neurodegenerative diseases, cerebral ischemia, and traumatic brain injury. Up to now, no autophagy expression was evidenced by transmission electronic microscope (TEM) and the autophagy marker, microtubule-associated protein light chain 3 (LC3) in neural tissue after SCI. Methods. Sixty-six Sprague-Dawley rats were used for the experimental procedure. In the SCI group, laminectomy at T9 were performed, followed by impactor contusion of the spinal cord. In the sham group, only a laminectomy was performed without contusion. We used Western blot to analyze LC3 at 2 hours, 4 hours, 1 day, 3 days, and 7 days after SCI. We also investigated the effect of methylprednisolone on autophagy expression of contused spinal cord. Cellular localization and ultrastructural changes after spinal cord injury were compared with those sham-operated rats using immunofluorescent double labeling and TEM, respectively. Data from the Western blot were analyzed using a nonparametric Kruskal-Wallis test with P < 0.05 being considered significant. Results. We detected significantly elevated level of LC3 2 hours after SCI, and then the level declined until 1 week after SCI. Methylprednisolone decreased LC3 expression at 2 hours after SCI. LC3 positive cells were colocalized with neuronal nuclei, but not with glial fibrillary acidic protein. The existence of autophagy and progress of autophagic cell death after SCI were confirmed by TEM. Conclusion. Through observing the enhanced autophagy expression in neurons soon after contusion injury and the inhibitive effect of methylprednisolone treatment, this study demonstrates the characteristics of autophagy expression after SCI and suggests that autophagic cell death may play a role in neuronal death after spinal cord trauma.	[Chen, Hsien-Chih; Chiu, Wen-Ta] Taipei Med Univ, Coll Med, Sch Med, Grad Inst Clin Med, Taipei 11031, Taiwan; [Chen, Hsien-Chih] Chang Gung Mem Hosp, Dept Neurosurg, Keelung, Taiwan; [Chen, Hsien-Chih] Chang Gung Univ, Sch Med, Tao Yuan, Taiwan; [Fong, Tsorng-Harn; Lee, Ai-Wei] Taipei Med Univ, Coll Med, Sch Med, Dept Anat, Taipei 11031, Taiwan		Chiu, WT (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Grad Inst Clin Med, 250 Wuxing St, Taipei 11031, Taiwan.	wtchiu@tmu.edu.tw			Chang Gung Memorial HospitalChang Gung Memorial Hospital	Chang Gung Memorial Hospital grant funds were received to support this work. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.	Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; DUCKER TB, 1994, SPINE, V19, P2281, DOI 10.1097/00007632-199410150-00006; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Gurusamy N, 2009, METHODS MOL BIOL, V559, P95, DOI 10.1007/978-1-60327-017-5_7; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; He Y, 2008, J CEREBR BLOOD F MET, V28, P897, DOI 10.1038/sj.jcbfm.9600578; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kiffin R, 2006, ANTIOXID REDOX SIGN, V8, P152, DOI 10.1089/ars.2006.8.152; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Sarkar S, 2008, HUM MOL GENET, V17, P170, DOI 10.1093/hmg/ddm294; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412	28	73	84	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	MAR 15	2012	37	6					470	475		10.1097/BRS.0b013e318221e859			6	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	912CN	WOS:000301772300016	21587101				2022-02-06	
J	Brainard, LL; Beckwith, JG; Chu, JJ; Crisco, JJ; Mcallister, TW; Duhaime, AC; Maerlender, AC; Greenwald, RM				Brainard, Lindley L.; Beckwith, Jonathan G.; Chu, Jeffrey J.; Crisco, Joseph J.; Mcallister, Thomas W.; Duhaime, Ann-Christine; Maerlender, Arthur C.; Greenwald, Richard M.			Gender Differences in Head Impacts Sustained by Collegiate Ice Hockey Players	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CONCUSSION; BRAIN INJURY; SPORTS; ICE HOCKEY; GENDER; HEAD IMPACT	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; UNITED-STATES; EPIDEMIOLOGY; ACCELERATION; ASSOCIATION; RECOMMENDATIONS; LOCATION	BRAINARD, L. L., J. G. BECKWITH, J. J. CHU, J. J. CRISCO, T. W. MCALLISTER, A. DUHAIME, A. C. MAERLENDER, and R. M. GREENWALD. Gender Differences in Head Impacts Sustained by Collegiate Ice Hockey Players. Med. Sci. Sports Exerc., Vol. 44, No. 2, pp. 297-304, 2012. Purpose: This study aimed to quantify the frequency, magnitude, and location of head impacts sustained by male and female collegiate ice hockey players during two seasons of play. Methods: During two seasons, 88 collegiate athletes (51 females, 37 males) on two female and male National Collegiate Athletic Association varsity ice hockey teams wore instrumented helmets. Each helmet was equipped with six single-axis accelerometers and a miniature data acquisition system to capture and record head impacts sustained during play. Data collected from the helmets were postprocessed to compute linear and rotational accelerations of the head as well as impact location. The head impact exposure data (frequency, location, and magnitude) were then compared between genders. Results: Female hockey players experienced a significantly lower (P < 0.001) number of impacts per athlete exposure than males (females = 1.7 +/- 0.7, males = 2.9 +/- 1.2). The frequency of impacts by location was the same between genders (P > 0.278) for all locations except the right side of the head, where males received fewer impacts than females (P = 0.031). Female hockey players were 1.1 times more likely than males to sustain an impact less than 50g, whereas males were 1.3 times more likely to sustain an impact greater than 100g. Similarly, males were 1.9 times more likely to sustain an impact with peak rotational acceleration greater than 5000 rad.s(-2) and 3.5 times more likely to sustain an impact greater than 10,000 rad.s(-2). Conclusions: Although the incidence of concussion has typically been higher for female hockey players than male hockey players, female players sustain fewer impacts and impacts resulting in lower head acceleration than males. Further study is required to better understand the intrinsic and extrinsic risk factors that lead to higher rates of concussion for females that have been previously reported.	[Brainard, Lindley L.; Beckwith, Jonathan G.; Chu, Jeffrey J.; Greenwald, Richard M.] Simbex, Lebanon, NH 03766 USA; [Crisco, Joseph J.] Brown Univ, Bioengn Lab, Dept Orthoped, Alpert Med Sch, Providence, RI 02912 USA; [Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI USA; [Mcallister, Thomas W.; Maerlender, Arthur C.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Hanover, NH 03756 USA; [Duhaime, Ann-Christine] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Duhaime, Ann-Christine] Harvard Univ, Sch Med, Boston, MA USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA		Beckwith, JG (corresponding author), Simbex, 10 Water St,Suite 410, Lebanon, NH 03766 USA.	jbeckwith@simbex.com		Crisco, Joseph/0000-0002-8786-0905	National Institute for Child Health and Human Development at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; National Operating Committee on Standards for Athletic Equipment; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	The research for this study was supported by the National Institute for Child Health and Human Development at the National Institutes of Health (grant no. R01HD048638) and the National Operating Committee on Standards for Athletic Equipment. Joseph J. Crisco, Richard M. Greenwald, Jeffrey J. Chu, and Simbex have a financial interest in the instruments (HIT System, Sideline Response System (Riddell, Inc.)) that were used to collect the data reported in this study.	Agel J, 2007, J ATHL TRAINING, V42, P249; [Anonymous], 2008, F104507 ASTM INT, P150; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Beckwith JG, 2010, 8 WORLD C BRAIN INJ, P446; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Chu, 2006, J BIOMECH, V39, DOI https://doi.org/10.1016/s0021-9290(06)83518-9; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2003, J ATHL TRAINING, V38, P238; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Greenwald R.M., 2009, SEVERITY HEAD IMPACT; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Gwin J. T., 2009, J ASTM INT, V6, P1; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McDowell Margaret A, 2005, Adv Data, P1; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; National Committee on Standards for Athletic Equipment, 2006, 08104M04 NOCSAE DOC, P1; Ng TP, 2006, BIOMED SCI INSTRUM, V42, P25; Odelgard B, 1989, ASTM STP, p[1989, 164]; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Piotowski S, 2008, 2008 10 NCAA MENS WO, P178; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Talavage TM, 2010, J NEUROTRAUMA   1001; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; US Department of Labor, TITL 9 ED AM 1972	42	73	73	4	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	FEB	2012	44	2					297	304		10.1249/MSS.0b013e31822b0ab4			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	879FY	WOS:000299316300016	21716150	Green Accepted, Green Published			2022-02-06	
J	Rotaru, H; Stan, H; Florian, IS; Schumacher, R; Park, YT; Kim, SG; Chezan, H; Balc, N; Baciut, M				Rotaru, Horatiu; Stan, Horatiu; Florian, Ioan Stefan; Schumacher, Ralf; Park, Yong-Tae; Kim, Seong-Gon; Chezan, Horea; Balc, Nicolae; Baciut, Mihaela			Cranioplasty With Custom-Made Implants: Analyzing the Cases of 10 Patients	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; CRANIAL DEFECTS; HYDROXYAPATITE CEMENT; RECONSTRUCTION; COMPLICATIONS; CHILDREN; SKULL; IMPROVEMENT; PROSTHESES	Purpose: The aim of this study was to assess quantitatively whether a symmetric reconstruction of the calvaria could be achieved using 3-dimensional (3D) custom-made implants and to examine any complications caused by the cranioplasty. Patients and Methods: Custom-made cranial implants were produced using data obtained from computed tomographic scanning of the defect using computer-aided design and rapid prototyping techniques. Polymethylmethacrylate was used as the reconstruction material and the implant was cast from a silicone rubber mold. These implants were used in 10 patients (9 men and 1 woman) who previously received a craniectomy. The symmetry gained after cranioplasty was quantified by volumetric analysis using 3D reconstructed postoperative computed tomographic imaging. Any complications after cranioplasty also were recorded. Results: The average follow-up was 42.5 months (range, 7 to 85 mo). The esthetic appearance of all patients was much improved. When the volume of the reconstructed right calvaria was compared with the left calvaria, the difference was not statistically significant (P > .05). There were 2 cases of complications. One exhibited a transient seroma collection. Another had a wrinkle formation in the forehead. No infectious episodes or signs of plate rejection were encountered. Conclusions: The custom-made implants for cranioplasty showed a significant improvement in morphology. The implants may be very useful for repairing large and complex-shaped cranial defects. The technique may be useful for the bone reconstruction of other sites. c 2012 American Association of Oral and Maxillofacial Surgeons J Oral Maxillofac Surg 70:e169-e176, 2012	[Park, Yong-Tae; Kim, Seong-Gon] Gangneung Wonju Natl Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Kangnung 210702, South Korea; [Rotaru, Horatiu] Iuliu Hatieganu Univ Med & Pharm, Dept Craniomaxillofacial Surg, Cluj Napoca, Romania; [Stan, Horatiu; Florian, Ioan Stefan] Iuliu Hatieganu Univ Med & Pharm, Dept Neurosurg, Cluj Napoca, Romania; [Schumacher, Ralf] Univ Appl Sci, Med Addit Mfg Grp, Muttenz, Switzerland; [Chezan, Horea] Iuliu Hatieganu Univ Med & Pharm, Natl Rapid Prototyping Lab, Cluj Napoca, Romania; [Baciut, Mihaela] Iuliu Hatieganu Univ Med & Pharm, Dept Implantol & Maxillofacial Surg, Cluj Napoca, Romania; [Balc, Nicolae] Tech Univ, Dept Mfg Engn, Cluj Napoca, Romania		Kim, SG (corresponding author), Gangneung Wonju Natl Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Kangnung 210702, South Korea.	epker@chol.com	Kim, Seong-Gon/AAF-7553-2020; Florian, Ioan Stefan I/D-5934-2016	Kim, Seong-Gon/0000-0001-5088-2732; Florian, Ioan Stefan I/0000-0001-7127-0946	Romanian GovernmentRomanian Government [5/2010, PN I-PCCE-ID 101]; BioGreen21 ProgramRural Development Administration (RDA) [PJ007170201006]; Rural Development Administration, Suwon, Republic of KoreaRural Development Administration (RDA)	This study was supported by grant 5/2010 from the project New Biocompatible Materials for Personalised Implants made by SLS and SLM (BIOMAPIM) PN I-PCCE-ID 101, financed by the Romanian Government, and grant PJ007170201006 from the BioGreen21 Program, Rural Development Administration, Suwon, Republic of Korea.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Agner C, 2002, ACTA NEUROCHIR, V144, P1033, DOI 10.1007/s00701-002-0996-4; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Chiarini L, 2004, J CRANIO MAXILL SURG, V32, P5, DOI 10.1016/j.jcms.2003.08.005; Dean D, 2003, J CRANIOFAC SURG, V14, P819, DOI 10.1097/00001665-200311000-00002; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Durand J L, 1997, Ann Chir Plast Esthet, V42, P75; Durham SR, 2003, NEUROSURGERY, V52, P842, DOI 10.1227/01.NEU.0000054220.01290.8E; EUFINGER H, 1995, INT J ORAL MAX SURG, V24, P104, DOI 10.1016/S0901-5027(05)80870-7; Fallahi B, 1999, NEUROL RES, V21, P281, DOI 10.1080/01616412.1999.11740932; Fantini M, 2008, RAPID PROTOTYPING J, V14, P318, DOI 10.1108/13552540810907992; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Gerber N, 2010, IEEE ENG MED BIO, P3357, DOI 10.1109/IEMBS.2010.5627903; Golz T, 2010, J CLIN NEUROSCI, V17, P617, DOI 10.1016/j.jocn.2009.09.005; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Jang ES, 2010, ORAL SURG ORAL MED O, V109, P831, DOI 10.1016/j.tripleo.2009.10.038; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Korinek AM, 1997, NEUROSURGERY, V41, P1079; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Matic DB, 2004, J CRANIOFAC SURG, V15, P415, DOI 10.1097/00001665-200405000-00012; Mokri B, 2010, HEADACHE, V50, P1206, DOI 10.1111/j.1526-4610.2010.01715.x; Moore K, 2007, ESSENTIAL CLIN ANATO, p[496, 498, 499]; Moreira-Gonzalez A, 2003, J CRANIOFAC SURG, V14, P144, DOI 10.1097/00001665-200303000-00003; Rotaru H, 2006, J CRANIO MAXILL SURG, V34, P242, DOI 10.1016/j.jcms.2006.01.005; Sahoo N, 2010, J CRANIOFAC SURG, V21, P79, DOI 10.1097/SCS.0b013e3181c3ba58; Solaro P, 2008, J NEUROSURG SCI, V52, P113; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Thesleff T, 2011, NEUROSURGERY, V68, P1535, DOI 10.1227/NEU.0b013e31820ee24e; VANPUTTEN MC, 1992, J PROSTHET DENT, V68, P103, DOI 10.1016/0022-3913(92)90294-K; Wong RK, 2011, J CRANIOFAC SURG, V22, P247, DOI 10.1097/SCS.0b013e3181f7b7db; Wulf J, 2005, ST HEAL T, V111, P608	34	73	78	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	FEB	2012	70	2					E169	E176		10.1016/j.joms.2011.09.036			8	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	889DO	WOS:000300053900009	22260919				2022-02-06	
J	Osman, MM; Lulic, D; Glover, L; Stahl, CE; Lau, T; van Loveren, H; Borlongan, CV				Osman, Mohamed M.; Lulic, Dzenan; Glover, Loren; Stahl, Christine E.; Lau, Tsz; van Loveren, Harry; Borlongan, Cesar V.			Cyclosporine-A as a neuroprotective agent against stroke: Its translation from laboratory research to clinical application	NEUROPEPTIDES			English	Article						Immunosuppressant; Neuroprotection; Cerebral ischemia; Mitochondria; Neurological disorders	TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL PERMEABILITY TRANSITION; SPINAL-CORD-INJURY; BRADYKININ RECEPTOR AGONIST; TRANSIENT FOCAL ISCHEMIA; NITRIC-OXIDE SYNTHASE; CEREBRAL-ISCHEMIA; CYCLOPHILIN-D; ADULT RATS; IN-VITRO	Stoke remains a leading cause of death and disability with limited treatment options. Extensive research has been aimed at studying cell death events that accompany stroke and how to use these same cell death pathways as potential therapeutic targets for treating the disease. The mitochondrial permeability transition pore (MPTP) has been implicated as a major factor associated with stroke-induced neuronal cell death. MPTP activation and increased permeability has been shown to contribute to the events that lead to cell death. Cyclosporine A (CsA), a widely used immunosuppressant in transplantation and rheumatic medicine, has been recently shown to possess neuroprotective properties through its ability to block the MPTP, which in turn inhibits neuronal damage. This newfound CsA-mediated neuroprotection pathway prompted research on its use to prevent cell death in stroke and other neurological conditions. Preclinical studies are being conducted in hopes of establishing the safety and efficacy guidelines for CsA use in human trials as a potential neuroprotective agent against stroke. In this review, we provide an overview of the current laboratory and clinical status of CsA neuroprotection. (C) 2011 Elsevier Ltd. All rights reserved.	[Osman, Mohamed M.; Lulic, Dzenan; Glover, Loren; Lau, Tsz; van Loveren, Harry; Borlongan, Cesar V.] Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL 33612 USA; [Stahl, Christine E.] MacDill Air Force Base, Dept Aerosp Med, Tampa, FL 33621 USA		Borlongan, CV (corresponding author), Univ S Florida, Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, 12901 Bruce B Downs Blvd,MDC 78, Tampa, FL 33612 USA.	cborlong@health.usf.edu	Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782	Department of Neurosurgery and Brain Repair; James and Esther King Foundation [1KG01-33966]; Draper Laboratory, Inc. [09KC-05]	This study was supported in part by the Department of Neurosurgery and Brain Repair, the James and Esther King Foundation (1KG01-33966), and the Draper Laboratory, Inc. (09KC-05). C.V.B. is a stockholder and consultant to Maas BiolAB.	Actis GC, 1998, INFLAMM BOWEL DIS, V4, P276, DOI 10.1002/ibd.3780040404; Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Akl KF, 2010, SAUDI J KIDNEY DIS T, V21, P957; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baiza-Duran L, 2010, BRIT J OPHTHALMOL, V94, P1312, DOI 10.1136/bjo.2008.150011; Bartus RT, 1996, EXP NEUROL, V142, P14, DOI 10.1006/exnr.1996.0175; Berth-Jones J, 2005, J DERMATOL TREAT, V16, P258, DOI 10.1080/09546630500423914; Boddie DE, 2003, BRIT J NEUROSURG, V17, P405, DOI 10.1080/02688690310001611198; Borel J F, 1996, Adv Pharmacol, V35, P115, DOI 10.1016/S1054-3589(08)60276-8; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; Borlongan CV, 2005, LIFE SCI, V76, P1503, DOI 10.1016/j.lfs.2004.09.022; Borlongan CV, 2003, BRAIN RES BULL, V60, P297, DOI 10.1016/S0361-9230(03)00043-1; Borlongan CV, 1999, CELL TRANSPLANT, V8, P153, DOI 10.1177/096368979900800107; Borlongan CV, 2002, BRAIN RES, V956, P211, DOI 10.1016/S0006-8993(02)03474-1; Borlongan CV, 2000, NEUROSCI LETT, V279, P73, DOI 10.1016/S0304-3940(99)00962-3; Borlongan CV, 1998, NEUROSCI RES, V32, P195, DOI 10.1016/S0168-0102(98)00088-1; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Callen JP, 2001, SEMIN CUTAN MED SURG, V20, P58, DOI 10.1053/sder.2001.23100; CHOLONGITAS E, 2010, CLIN TRANSPLANT, DOI DOI 10.1111/J.1399.0012.2010.01321.X; Costantini LC, 1998, NEUROBIOL DIS, V5, P97, DOI 10.1006/nbdi.1998.0185; Cousin MA, 2001, TRENDS NEUROSCI, V24, P659, DOI 10.1016/S0166-2236(00)01930-5; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Dawson VL, 1996, J NEUROSCI, V16, P2479; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Domanska-Janik K, 2004, MOL BRAIN RES, V121, P50, DOI 10.1016/j.molbrainres.2003.11.006; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Empey PE, 2006, J NEUROTRAUM, V23, P109, DOI 10.1089/neu.2006.23.109; Gabryel B, 2009, CELL BIOL INT, V33, P739, DOI 10.1016/j.cellbi.2009.04.006; Gerloni V, 2001, RHEUMATOLOGY, V40, P907, DOI 10.1093/rheumatology/40.8.907; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; Goldner FM, 1996, J COMP NEUROL, V372, P283; Hanauer SB, 2004, GASTROENTEROLOGY, V126, P1582, DOI 10.1053/j.gastro.2004.02.071; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Hayashi Y, 2005, J NEUROTRAUM, V22, P1267, DOI 10.1089/neu.2005.22.1267; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Hesselink DA, 2004, TRANSPL P, V36, p99S, DOI 10.1016/j.transproceed.2003.12.047; Hui KKW, 2010, J CELL MOL MED, V14, P671, DOI 10.1111/j.1582-4934.2009.00715.x; Ibarra A, 1996, J NEUROTRAUM, V13, P569, DOI 10.1089/neu.1996.13.569; Iida K, 1998, NEUROSCI RES, V30, P185, DOI 10.1016/S0168-0102(97)00128-4; INAMURA T, 1994, J CEREBR BLOOD F MET, V14, P862, DOI 10.1038/jcbfm.1994.108; JAUCH E, 2010, E MED; KAHAN BD, 1993, TRANSPLANT P, V25, P5; Kaminska B, 2004, J CELL MOL MED, V8, P45, DOI 10.1111/j.1582-4934.2004.tb00259.x; KHAN M, 2008, IMMUNOPHARMACOLOGY, V1, P87; Leger PL, 2010, EXP NEUROL; Leung AWC, 2008, BBA-BIOENERGETICS, V1777, P946, DOI 10.1016/j.bbabio.2008.03.009; Leventhal L, 2000, J COMP NEUROL, V425, P471, DOI 10.1002/1096-9861(20001002)425:4<471::AID-CNE1>3.0.CO;2-U; Malouitre S, 2010, BIOCHEM J, V425, P137, DOI 10.1042/BJ20090332; MARGARITIS A, 1989, BIOTECHNOL LETT, V11, P765, DOI 10.1007/BF01026093; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marsh JD, 2010, J AM COLL CARDIOL, V56, P683, DOI 10.1016/j.jacc.2009.12.072; MATTSON MP, 2003, IMMUNOSUPRESSANT ANA; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; MINONES J, 1994, LANGMUIR, V10, P1888, DOI 10.1021/la00018a045; Miyata K, 2001, NEUROSCIENCE, V105, P571, DOI 10.1016/S0306-4522(01)00225-1; Muramatsu Y, 2007, BRAIN RES, V1149, P181, DOI 10.1016/j.brainres.2007.02.036; Murozono M, 2004, EUR J PHARMACOL, V498, P115, DOI 10.1016/j.ejphar.2004.06.068; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NOMURA T, 1994, BRAIN RES, V659, P62, DOI 10.1016/0006-8993(94)90863-X; Oger J, 2007, J NEUROL SCI, V259, P74, DOI 10.1016/j.jns.2006.05.073; Ouary S, 2000, NEUROSCIENCE, V97, P521, DOI 10.1016/S0306-4522(00)00020-8; PETERSON JW, 1990, STROKE, V21, P133, DOI 10.1161/01.STR.21.1.133; Ramos-Casals M, 2010, JAMA-J AM MED ASSOC, V304, P452, DOI 10.1001/jama.2010.1014; ROMAN ID, 1989, TRANSPLANTATION, V48, P554, DOI 10.1097/00007890-198910000-00003; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; SAEED B, 2008, CYCLOSPORIN INDUCED, V19, P439; Santos JB, 2003, EPILEPSIA, V44, P995, DOI 10.1046/j.1528-1157.2003.66302.x; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Schinkel AH, 1995, AM J CLIN INVEST, V96, P1698; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Serkova N, 2004, MOL INTERV, V4, P97, DOI 10.1124/mi.4.2.7; Sheehan Jason, 2006, Neurosurg Focus, V20, pE9; Shou Y, 2004, BIOCHEM J, V379, P805, DOI 10.1042/BJ20031107; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Snyder SH, 1998, TRENDS PHARMACOL SCI, V19, P21, DOI 10.1016/S0165-6147(97)01146-2; SOKOL PP, 1990, AM J PHYSIOL, V259, pC897, DOI 10.1152/ajpcell.1990.259.6.C897; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Thrift AG, 2001, STROKE, V32, P1732, DOI 10.1161/01.STR.32.8.1732; TINDALL RSA, 1987, NEW ENGL J MED, V316, P719, DOI 10.1056/NEJM198703193161205; TRUWIT CL, 1991, AM J NEURORADIOL, V12, P651; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; WAKITA H, 1995, STROKE, V26, P1415, DOI 10.1161/01.STR.26.8.1415; Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang XY, 2010, STROKE, V41, P2050, DOI 10.1161/STROKEAHA.110.589051; Wang XY, 2009, J NEUROSCI, V29, P2588, DOI 10.1523/JNEUROSCI.5832-08.2009; WHITE DJG, 1982, IMMUNOL REV, V65, P115, DOI 10.1111/j.1600-065X.1982.tb00430.x; WINDEBANK AJ, 1994, J PHARMACOL EXP THER, V268, P1051; WOLINSKY JS, 1990, ANN NEUROL, V27, P591; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Yu GL, 2004, BRAIN RES, V1018, P32, DOI 10.1016/j.brainres.2004.05.056	96	73	76	0	26	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0143-4179			NEUROPEPTIDES	Neuropeptides	DEC	2011	45	6					359	368		10.1016/j.npep.2011.04.002			10	Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Neurosciences & Neurology	859KN	WOS:000297875400001	21592568				2022-02-06	
J	Topolovec-Vranic, J; Pollmann-Mudryj, MA; Ouchterlony, D; Klein, D; Spence, J; Romaschin, A; Rhind, S; Tien, HC; Baker, AJ				Topolovec-Vranic, Jane; Pollmann-Mudryj, Mary-Ann; Ouchterlony, Donna; Klein, David; Spence, Julie; Romaschin, Alexander; Rhind, Shawn; Tien, Homer C.; Baker, Andrew J.			The Value of Serum Biomarkers in Prediction Models of Outcome After Mild Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Adult; Serum biomarkers; Humans; Mild traumatic brain injury; S100B; Neuron-specific enolase	POST-CONCUSSION SYMPTOMS; NEURON-SPECIFIC ENOLASE; MINOR HEAD-INJURY; EMERGENCY-DEPARTMENT ASSESSMENT; FOLLOW-UP; POSTCONCUSSIVE SYMPTOMS; BIOCHEMICAL MARKERS; PROTEIN S-100B; CT FINDINGS; ACUTE-PHASE	Background: To determine, using a civilian model of mild traumatic brain injury (TBI), the added value of biomarker sampling upon prognostication of outcome at 1 week and 6 weeks postinjury. Methods: The Galveston Orientation and Amnesia test was administered, and blood samples for serum protein S100B and neuron-specific enolase (NSE) were collected from 141 emergency department patients within 4 hours of a suspected mild TBI (mTBI). The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) was administered via telephone 3 days postinjury. Patients were assessed by a physician at 1 week (n = 113; 80%) and 6 weeks (n = 95; 67%) postinjury. Neurocognitive and postural stability measures were also administered at these follow-ups. Results: Levels of S100B and NSE were found to be abnormally elevated in 49% and 65% of patients with TBI, respectively. Sixty-eight percent and 38% of the patients were considered impaired at 1 week and 6 weeks postinjury, respectively. Stepwise logistic regression modeling identified admission Galveston Orientation and Amnesia test score, S100B level, and RPQ score at day 3 postinjury to be predictive of poor outcome at 1 week postinjury (c-statistic 0.877); female gender, loss of consciousness, NSE level, and RPQ score at day 3 postinjury were predictive of poor outcome at 6 weeks postinjury (c-statistic 0.895). The discriminative power of the biomarkers alone was limited. Conclusions: Biomarkers, in conjunction with other readily available determinants of outcome assessed in the acute period after injury, add value in the early prognostication of patients with mTBI. Our findings are consistent with the notion that S100B and NSE point to biological mechanisms underlying poor outcome after mTBI.	[Baker, Andrew J.] St Michaels Hosp, Dept Crit Care, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Topolovec-Vranic, Jane; Pollmann-Mudryj, Mary-Ann; Ouchterlony, Donna] St Michaels Hosp, Trauma & Neurosurg Program, Toronto, ON M5B 1W8, Canada; [Spence, Julie] St Michaels Hosp, Emergency Dept, Toronto, ON M5B 1W8, Canada; [Romaschin, Alexander] St Michaels Hosp, Div Clin Chem, Toronto, ON M5B 1W8, Canada; [Rhind, Shawn] Def Res & Dev Canada, Toronto, ON, Canada; [Tien, Homer C.] Sunnybrook Hlth Sci Ctr, Dept Surg, Toronto, ON M4N 3M5, Canada; [Baker, Andrew J.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada		Baker, AJ (corresponding author), St Michaels Hosp, Dept Crit Care, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada.	bakera@smh.ca	Pollmann-Mudryj, Mary Ann/AAC-9047-2019; Topolovec-Vranic, Jane/A-5293-2013	Topolovec-Vranic, Jane/0000-0001-7695-4212; Rhind, Shawn/0000-0003-2300-0620; Pollmann-Mudryj, Mary Ann/0000-0003-2244-8116	Defence Research and Development Canada [W7711-067992]	Supported by Defence Research and Development Canada W7711-067992.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Baker AJ, 2009, J NEUROTRAUM, V26, P1227, DOI 10.1089/neu.2008.0868; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Benton AL, 1994, MULTILINGUAL APHASIA; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Guise E, 2006, J HEAD TRAUMA REHAB, V21, P527, DOI 10.1097/00001199-200611000-00007; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Fridriksson S, 2001, ACTA NEUROL SCAND, V103, P238; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Heaton R. K., 2004, REVISED COMPREHENSIV; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Iverson GL, 2008, BRAIN INJURY, V22, P147, DOI 10.1080/02699050701867407; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McMinn MR., 1988, CLIN NEUROPSYCHOL, V2, P67, DOI DOI 10.1080/13854048808520087; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Muller K, 2009, NEUROSURGERY, V64, P698, DOI 10.1227/01.NEU.0000340978.42892.78; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Reitan RM, 1985, HALSTEADREITAN NEURO; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Smith A., 1991, SYMBOL DIGIT MODALIT; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; Spreen, 2006, COMPENDIUM NEUROPSYC; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tien HCN, 2010, AM J PREV MED, V38, P331, DOI 10.1016/j.amepre.2009.12.012; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x	54	73	76	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71			1			S478	S486		10.1097/TA.0b013e318232fa70			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	849GE	WOS:000297112800016	22072007				2022-02-06	
J	Brittain, JM; Chen, L; Wilson, SM; Brustovetsky, T; Gao, X; Ashpole, NM; Molosh, AI; You, HT; Hudmon, A; Shekhar, A; White, FA; Zamponi, GW; Brustovetsky, N; Chen, JH; Khanna, R				Brittain, Joel M.; Chen, Liang; Wilson, Sarah M.; Brustovetsky, Tatiana; Gao, Xiang; Ashpole, Nicole M.; Molosh, Andrei I.; You, Haitao; Hudmon, Andy; Shekhar, Anantha; White, Fletcher A.; Zamponi, Gerald W.; Brustovetsky, Nickolay; Chen, Jinhui; Khanna, Rajesh			Neuroprotection against Traumatic Brain Injury by a Peptide Derived from the Collapsin Response Mediator Protein 2 (CRMP2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-ASPARTATE RECEPTORS; CONTROLLED CORTICAL IMPACT; NEURONAL DEATH; MITOCHONDRIAL DYSFUNCTION; POSTSYNAPTIC DENSITY-95; CALPAIN CLEAVAGE; CLINICAL-TRIALS; NMDA-RECEPTORS; NR2B SUBUNIT; IN-VITRO	Background: CRMP2 is an axonal guidance protein that has been linked to NMDA receptor-mediated excitotoxicity. Results: A CRMP2 peptide protects against NMDA receptor-mediated excitotoxicity in vitro and in vivo following a traumatic brain injury. Conclusion: CRMP2 is a novel target for neuroprotection. Significance: Targeting CRMP2 could lead to development of neurotherapeutics against traumatic brain injury as well as other neuronal insults.	[Brittain, Joel M.; Wilson, Sarah M.; Ashpole, Nicole M.; Hudmon, Andy; White, Fletcher A.; Brustovetsky, Nickolay; Chen, Jinhui; Khanna, Rajesh] Indiana Univ, Sch Med, Program Med Neurosci, Paul & Carole Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Chen, Liang; Gao, Xiang; Chen, Jinhui] Indiana Univ, Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA; [Brustovetsky, Tatiana; Brustovetsky, Nickolay] Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Ashpole, Nicole M.; Hudmon, Andy] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Molosh, Andrei I.; Shekhar, Anantha] Indiana Univ, Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [White, Fletcher A.] Indiana Univ, Sch Med, Dept Anesthesia, Indianapolis, IN 46202 USA; [Shekhar, Anantha] Indiana Univ, Sch Med, Indiana Clin & Translat Sci Inst, Indianapolis, IN 46202 USA; [White, Fletcher A.; Chen, Jinhui; Khanna, Rajesh] Indiana Univ, Sch Med, Indiana Spinal Cord & Brain Injury Grp, Indianapolis, IN 46202 USA; [You, Haitao; Zamponi, Gerald W.] Univ Calgary, Dept Physiol & Pharmacol, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada		Khanna, R (corresponding author), 950 W Walnut St,R2 Rm 478, Indianapolis, IN 46202 USA.	khanna5@iupui.edu	White, Fletcher/F-3203-2015; White, Fletcher A/F-2895-2012	White, Fletcher/0000-0002-8408-9262; Zamponi, Gerald/0000-0002-0644-9066; Molosh, Andrei/0000-0001-6451-7912; Khanna, Rajesh/0000-0002-9066-2969	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS050131]; Alberta Heritage Foundation for Medical Research (AHFMR)Alberta Heritage Foundation for Medical Research; American Heart AssociationAmerican Heart Association [SDG5280023]; Indiana Clinical and Translational Sciences Institute; National Institutes of Health, National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR025761]; Ralph W. and Grace M. Showalter foundation [A70-0-079212, A70-9-079138]; Elwert Award in Medicine; Larry Kays Medical Neuroscience Fellowship; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631, R01NS050131, R21NS075733, R01NS049136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA026040] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grant R01 NS050131 (to N. B.). This work was also supported by a fellowship from the Alberta Heritage Foundation for Medical Research (AHFMR) (to H. Y.), American Heart Association National Scientist Development Grant SDG5280023 (to R. K.), a grant from the Indiana Clinical and Translational Sciences Institute funded, in part by a Project Development Team Grant Number RR025761 from the National Institutes of Health, National Center for Research Resources, Clinical and Translational Sciences Award (Indiana State Department of Health, Indiana Spinal Cord and Brain Injury Research Fund, Grants A70-0-079212 (to N. B.) and A70-9-079138 (to R. K.)), grants from the Ralph W. and Grace M. Showalter foundation (to A. H., N. B., and R. K.), and the Elwert Award in Medicine (to R. K.).; Recipient of a Larry Kays Medical Neuroscience Fellowship.; An AHFMR Scientist and a Canada Research Chair, supported by the Canadian Institutes of Health Research.	Adamec E, 1998, MOL BRAIN RES, V54, P35, DOI 10.1016/S0169-328X(97)00304-5; Al-Hallaq RA, 2007, J NEUROSCI, V27, P8334, DOI 10.1523/JNEUROSCI.2155-07.2007; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Bretin S, 2006, J NEUROCHEM, V98, P1252, DOI 10.1111/j.1471-4159.2006.03969.x; Brittain JM, 2011, NAT MED, V17, P822, DOI 10.1038/nm.2345; Brittain JM, 2009, J BIOL CHEM, V284, P31375, DOI 10.1074/jbc.M109.009951; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Chen A, 2007, NEUROCHEM INT, V50, P1078, DOI 10.1016/j.neuint.2006.11.008; Chi XX, 2009, J CELL SCI, V122, P4351, DOI 10.1242/jcs.053280; CHOI DW, 1985, NEUROSCI LETT, V58, P293, DOI 10.1016/0304-3940(85)90069-2; Chung HJ, 2004, J NEUROSCI, V24, P10248, DOI 10.1523/JNEUROSCI.0546-04.2004; Chung MA, 2005, NEUROREPORT, V16, P1647, DOI 10.1097/01.wnr.0000176520.49841.e6; Clapp P, 2010, J PHARMACOL EXP THER, V332, P720, DOI 10.1124/jpet.109.158741; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; CRUNELLI V, 1983, J PHYSIOL-LONDON, V341, P627, DOI 10.1113/jphysiol.1983.sp014829; Czogalla A, 2005, CELL MOL LIFE SCI, V62, P1913, DOI 10.1007/s00018-005-5097-0; Dong YN, 2004, J NEUROSCI, V24, P11035, DOI 10.1523/JNEUROSCI.3722-04.2004; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI [10.1089/neu.2008.0744, 10.1089/neu.2008-0744]; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hensley K, 2011, MOL NEUROBIOL, V43, P180, DOI 10.1007/s12035-011-8166-4; Hou ST, 2009, J NEUROCHEM, V111, P870, DOI 10.1111/j.1471-4159.2009.06375.x; Hou ST, 2006, J NEUROSCI, V26, P2241, DOI 10.1523/JNEUROSCI.4485-05.2006; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P1397, DOI 10.1517/13543784.9.6.1397; Jiang SX, 2007, EUR J NEUROSCI, V26, P801, DOI 10.1111/j.1460-9568.2007.05715.x; Kennett SB, 2004, J BIOL CHEM, V279, P3300, DOI 10.1074/jbc.M305734200; Khosravani H, 2008, J CELL BIOL, V181, P551, DOI 10.1083/jcb.200711002; Kopec CD, 2006, J NEUROSCI, V26, P2000, DOI 10.1523/JNEUROSCI.3918-05.2006; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kowara R, 2005, J NEUROCHEM, V95, P466, DOI 10.1111/j.1471-4159.2005.03383.x; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Liu W, 2009, PROTEOMICS, V9, P3712, DOI 10.1002/pmic.200800979; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Molosh AI, 2010, NEUROPSYCHOPHARMACOL, V35, P1333, DOI 10.1038/npp.2010.2; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; Muir KW, 2006, CURR OPIN PHARMACOL, V6, P53, DOI 10.1016/j.coph.2005.12.002; Muir KW, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001244; Nicholls DG, 2004, CURR MOL MED, V4, P149, DOI 10.2174/1566524043479239; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Nong Y, 2003, NATURE, V422, P302, DOI 10.1038/nature01497; PARK CK, 1988, ANN NEUROL, V24, P543, DOI 10.1002/ana.410240411; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; Pickel VM, 2006, NEUROSCIENCE, V142, P671, DOI 10.1016/j.neuroscience.2006.06.059; Prybylowski K, 2005, NEURON, V47, P845, DOI 10.1016/j.neuron.2005.08.016; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shleper M, 2005, J NEUROSCI, V25, P9413, DOI 10.1523/JNEUROSCI.3190-05.2005; Simpkins KL, 2003, J NEUROSCI, V23, P11322; Sonkusare SK, 2005, PHARMACOL RES, V51, P1, DOI 10.1016/j.phrs.2004.05.005; Stanika RI, 2009, P NATL ACAD SCI USA, V106, P9854, DOI 10.1073/pnas.0903546106; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Touma E, 2007, EUR J NEUROSCI, V26, P3368, DOI 10.1111/j.1460-9568.2007.05943.x; Villmann C, 2007, NEUROSCIENTIST, V13, P594, DOI 10.1177/1073858406296259; Volbracht C, 2006, EUR J NEUROSCI, V23, P2611, DOI 10.1111/j.1460-9568.2006.04787.x; Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x; Wang Yuying, 2010, Commun Integr Biol, V3, P172; Wilson S. M., 2011, CHANNELS AU IN PRESS; Wu HY, 2005, J BIOL CHEM, V280, P21588, DOI 10.1074/jbc.M501603200; Yuen EY, 2008, MOL PHARMACOL, V74, P360, DOI 10.1124/mol.108.046813; Zhang S, 2008, J NEUROSCI, V28, P415, DOI 10.1523/JNEUROSCI.1900-07.2008; Zhang Z, 2009, CELL MOL LIFE SCI, V66, P526, DOI 10.1007/s00018-008-8362-1; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078	72	73	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 28	2011	286	43					37778	37792		10.1074/jbc.M111.255455			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	841VD	WOS:000296542400073	21832084	hybrid, Green Published			2022-02-06	
J	Pavlov, I; Huusko, N; Drexel, M; Kirchmair, E; Sperk, G; Pitkanen, A; Walker, MC				Pavlov, I.; Huusko, N.; Drexel, M.; Kirchmair, E.; Sperk, G.; Pitkanen, A.; Walker, M. C.			PROGRESSIVE LOSS OF PHASIC, BUT NOT TONIC, GABA(A) RECEPTOR-MEDIATED INHIBITION IN DENTATE GRANULE CELLS IN A MODEL OF POST-TRAUMATIC EPILEPSY IN RATS	NEUROSCIENCE			English	Article						dentate gyrus; GAB(A) receptors; interneurons; parvalbumin; tonic inhibition; traumatic brain injury	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; STATUS EPILEPTICUS; MOUSE MODEL; ALTERED EXPRESSION; HEAD TRAUMA; HIPPOCAMPUS; NEURONS; SUBUNITS; INTERNEURONS	Traumatic brain injury (TBI) is a risk factor for the development of epilepsy, which can occur months to years after the insult. The hippocampus is particularly vulnerable to the pathophysiological effects of TBI. Here, we determined whether there are long-term changes in inhibition in the dentate gyrus that could contribute to the progressive susceptibility to seizures after TBI. We used severe lateral-fluid percussion brain injury to induce TBI in rats. In this model, spontaneous seizure activity, which involves the hippocampus, appears after a long latent period, resembling the human condition. We demonstrate that synaptic GAB(A), receptor-mediated inhibition is profoundly reduced in ipsilateral dentate granule cells 1 month after TBI. Moreover, synaptic inhibition decreases over time, and by 6 months after TBI, it is also significantly decreased contralaterally. Progressive loss of synaptic inhibition is paralleled by a decline in the number of parvalbumin-positive interneurons, but, in contrast to status epilepticus models, GABA(A) receptor subunit expression is largely unaltered. At both time points, the magnitude of tonic GABA(A) receptor-mediated currents after TBI is maintained, indicating a preservation of the inhibitory constraint of granule cells through tonic inhibition. Our results extend the time window during which strategies to target epileptogenesis may be effective. (C) 2011 IBRO. Published by Elsevier Ltd. All rights reserved.	[Pavlov, I.; Walker, M. C.] UCL Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England; [Huusko, N.; Pitkanen, A.] Univ Eastern Finland, Epilepsy Res Lab, AI Virtanen Inst Mol Sci, Kuopio, Finland; [Drexel, M.; Kirchmair, E.; Sperk, G.] Med Univ Innsbruck, Dept Pharmacol, Innsbruck, Austria; [Pitkanen, A.] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland		Pavlov, I (corresponding author), UCL Inst Neurol, Dept Clin & Expt Epilepsy, London WC1N 3BG, England.	i.pavlov@ucl.ac.uk; skaamcw@ucl.ac.uk	Pavlov, Ivan/B-5939-2008; Walker, Matthew C/C-1577-2008	Pavlov, Ivan/0000-0002-9559-4600; Walker, Matthew C/0000-0002-0812-0352; Drexel, Meinrad/0000-0002-2705-9673; Pavlov, Ivan/0000-0003-1266-6988	European Integrated Project "EPICURE" [EFP6-037315]; Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; Epilepsy Research UK [A0832]; Epilepsy Research UK [F0905] Funding Source: researchfish	We would like to thank Dr. Jari Nissinen and Mr. Jarmo Hartikainen for help with the experiments. This work was supported by the European Integrated Project "EPICURE" (EFP6-037315); the Academy of Finland to A.P.; the Sigrid Juselius Foundation to A.P. and Epilepsy Research UK Fellowship (A0832) to I.P.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Brandon NJ, 2000, J BIOL CHEM, V275, P38856, DOI 10.1074/jbc.M004910200; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Cavelier P, 2005, PROG BIOPHYS MOL BIO, V87, P3, DOI 10.1016/j.pbiomolbio.2004.06.001; CELIO MR, 1994, BRAIN RES REV, V19, P128, DOI 10.1016/0165-0173(94)90006-X; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; COLLINS RC, 1983, BRAIN RES, V280, P25, DOI 10.1016/0006-8993(83)91170-8; Cope DW, 2009, NAT MED, V15, P1392, DOI 10.1038/nm.2058; Coulter DA, 2007, PROG BRAIN RES, V163, P235, DOI 10.1016/S0079-6123(07)63014-3; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Fritschy JM, 1999, NEUROCHEM INT, V34, P435, DOI 10.1016/S0197-0186(99)00040-6; Glykys J, 2008, J NEUROSCI, V28, P1421, DOI 10.1523/JNEUROSCI.4751-07.2008; HARTIG W, 1992, NEUROREPORT, V3, P869; Hunt RF, 2011, J NEUROSCI, V31, P6880, DOI 10.1523/JNEUROSCI.0032-11.2011; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Huusko N, 2010, SOC NEUR SCI ANN M S; Kadam SD, 2010, J NEUROSCI, V30, P404, DOI 10.1523/JNEUROSCI.4093-09.2010; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; Kobayashi M, 2003, J NEUROSCI, V23, P2440; LERANTH C, 1990, J COMP NEUROL, V295, P111, DOI 10.1002/cne.902950110; LEWIS DA, 1986, J COMP NEUROL, V248, P1, DOI 10.1002/cne.902480102; LOTHMAN EW, 1993, EPILEPSIA, V34, pS59, DOI 10.1111/j.1528-1157.1993.tb05907.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lucas EK, 2010, J NEUROSCI, V30, P7227, DOI 10.1523/JNEUROSCI.0698-10.2010; Luebke JI, 2003, J COMP NEUROL, V460, P573, DOI 10.1002/cne.10668; Mann EO, 2010, NAT NEUROSCI, V13, P205, DOI 10.1038/nn.2464; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILNER TA, 1989, J COMP NEUROL, V290, P544, DOI 10.1002/cne.902900409; Mitchell SJ, 2003, NEURON, V38, P433, DOI 10.1016/S0896-6273(03)00200-9; Mody I, 2004, TRENDS NEUROSCI, V27, P569, DOI 10.1016/j.tins.2004.07.002; Mtchedlishvili Z, 2010, NEUROBIOL DIS, V38, P464, DOI 10.1016/j.nbd.2010.03.012; Naylor DE, 2005, J NEUROSCI, V25, P7724, DOI 10.1523/JNEUROSCI.4944-04.2005; Nishimura T, 2005, NEUROSCIENCE, V134, P691, DOI 10.1016/j.neuroscience.2005.04.013; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; Pavlov I, 2009, J NEUROSCI, V29, P15341, DOI 10.1523/JNEUROSCI.2747-09.2009; Peng ZC, 2004, J NEUROSCI, V24, P8629, DOI 10.1523/JNEUROSCI.2877-04.2004; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Rajasekaran K, 2010, NEUROBIOL DIS, V40, P490, DOI 10.1016/j.nbd.2010.07.016; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Schwarzer C, 1997, NEUROSCIENCE, V80, P1001, DOI 10.1016/S0306-4522(97)00145-0; Scimemi A, 2005, J NEUROSCI, V25, P10016, DOI 10.1523/JNEUROSCI.2520-05.2005; Scimemi A, 2006, EUR J NEUROSCI, V24, P1157, DOI 10.1111/j.1460-9568.2006.04989.x; Shao LR, 2005, J NEUROPHYSIOL, V94, P952, DOI 10.1152/jn.01342.2004; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Toth Z, 1997, J NEUROSCI, V17, P8106; Tsunashima K, 1997, NEUROSCIENCE, V80, P1019, DOI 10.1016/S0306-4522(97)00144-9; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Zhan RZ, 2009, J NEUROPHYSIOL; Zhang NH, 2007, J NEUROSCI, V27, P7520, DOI 10.1523/JNEUROSCI.1555-07.2007; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009	56	73	76	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT 27	2011	194						208	219		10.1016/j.neuroscience.2011.07.074			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	829IN	WOS:000295571900020	21840377				2022-02-06	
J	Truettner, JS; Alonso, OF; Bramlett, HM; Dietrich, WD				Truettner, Jessie S.; Alonso, Ofelia F.; Bramlett, Helen M.; Dietrich, W. Dalton			Therapeutic hypothermia alters microRNA responses to traumatic brain injury in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; epigenetics; gene regulation; hypothermia; microscopy	CELL-DEATH MECHANISMS; POSTTRAUMATIC HYPOTHERMIA; EXPRESSION; REGULATORS; MODEL; RNAS; DIFFERENTIATION; ELEGANS	Therapeutic hypothermia promotes protection after traumatic brain injury (TBI). The mechanisms underlying hypothermic protection are multifactorial and may include the modulation of microRNA (miRNA) expression after trauma. We utilized microarrays to examine the effects of posttraumatic hypothermia on the expression of 388 rat miRNAs. Animals were subjected to sham or moderate fluid percussion brain injury, followed by 4 hours of hypothermia (33 degrees C) or normothermia (37 degrees C) and euthanized at 7 or 24 hours. At 7 hours, 47 miRNAs were significantly different (P< 0.05) between TBI and sham (15 higher in TBI and 31 lower). After 24 hours, 15 miRNAs differed by P<0.05 (7 higher and 9 lower). The expression of miRNAs was altered by posttraumatic hypothermia. At 7 hours, seven were higher in hypothermia than normothermia and five were lower. Some miRNAs (e.g., miR874 and miR-451) showed the most difference with hypothermia, with changes verified by quantitative reverse transcriptase-PCR. Regionally specific miRNAs also showed responses to TBI and hypothermia treatments by in situ hybridization. In addition, in vitro neuronal stretch injury studies showed similar temperature-sensitive responses to specific miRNAs. These novel data indicate that the reported beneficial effects of early hypothermia on traumatic outcome may include temperature-sensitive miRNAs involved in basic cell-processing events. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1897-1907; doi:10.1038/jcbfm.2011.33; published online 20 April 2011	[Truettner, Jessie S.; Alonso, Ofelia F.; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bramlett, Helen M.] Bruce W Carter Dept Vet Affairs, Med Ctr, Miami, FL USA		Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136 USA.	ddietrich@miami.edu			NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS042133, NS 030291]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER	This work supported by NIH/NINDS NS042133, NIH/NINDS NS 030291, and The Miami Project to Cure Paralysis.	Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Cao XW, 2006, ANNU REV NEUROSCI, V29, P77, DOI 10.1146/annurev.neuro.29.051605.112839; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Harris A, 2010, AM J TRANSPLANT, V10, P713, DOI 10.1111/j.1600-6143.2010.03032.x; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ivey KN, 2010, CELL STEM CELL, V7, P36, DOI 10.1016/j.stem.2010.06.012; KEANE RW, 1992, TRANSPLANTATION, V54, P520, DOI 10.1097/00007890-199209000-00025; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lee YS, 2006, CURR OPIN INVEST DR, V7, P560; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015; Liu YT, 2010, PHYSIOL GENOMICS, V42A, P39, DOI 10.1152/physiolgenomics.00054.2010; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Madathil SK, 2011, BIOESSAYS, V33, P21, DOI 10.1002/bies.201000069; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Pena JTG, 2009, NAT METHODS, V6, P139, DOI [10.1038/NMETH.1294, 10.1038/nmeth.1294]; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Qurashi A, 2010, CURR PSYCHIAT REP, V12, P154, DOI 10.1007/s11920-010-0102-1; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Sempere LF, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-r13; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Wang WX, 2010, AM J PATHOL, V177, P334, DOI 10.2353/ajpath.2010.091202; Yin KJ, 2010, NEUROBIOL DIS, V38, P17, DOI 10.1016/j.nbd.2009.12.021; Zhou XF, 2008, BBA-GENE REGUL MECH, V1779, P780, DOI 10.1016/j.bbagrm.2008.04.005; ZILLES L, 1985, CORTEX RAT STEREOTAX	40	73	81	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2011	31	9					1897	1907		10.1038/jcbfm.2011.33			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	815KK	WOS:000294524300008	21505482	Bronze, Green Published			2022-02-06	
S	Lok, J; Leung, W; Murphy, S; Butler, W; Noviski, N; Lo, EH		Zhang, JH; Colohan, A		Lok, Josephine; Leung, Wendy; Murphy, Sarah; Butler, William; Noviski, Natan; Lo, Eng H.			Intracranial Hemorrhage: Mechanisms of Secondary Brain Injury	INTRACEREBRAL HEMORRHAGE RESEARCH: FROM BENCH TO BEDSIDE	Acta Neurochirurgica Supplementum		English	Article; Book Chapter						Intracranial hemorrhage; Heme toxicity; Iron toxicity; Coagulation; Inflammation; Vascular response	TRAUMATIC INTRACEREBRAL HEMORRHAGE; CEREBRAL-ARTERY OCCLUSION; SUBARACHNOID HEMORRHAGE; CEREBROSPINAL-FLUID; OXIDATIVE STRESS; RAT MODEL; INFLAMMATION; HEME; HAPTOGLOBIN; HEMOGLOBIN	ICH is a disease with high rates of mortality and morbidity, with a substantial public health impact. Spontaneous ICH (sICH) has been extensively studied, and a large body of data has been accumulated on its pathophysiology. However, the literature on traumatic ICH (tICH) is limited, and further investigations of this important topic are needed. This review will highlight some of the cellular pathways in ICH with an emphasis on the mechanisms of secondary injury due to heme toxicity and to events in the coagulation process that are common to both sICH and tICH.	[Lok, Josephine; Leung, Wendy; Lo, Eng H.] Massachusetts Gen Hosp, Neuroprotect Res Lab, Boston, MA 02114 USA; [Lok, Josephine; Leung, Wendy; Murphy, Sarah; Noviski, Natan] Massachusetts Gen Hosp, Dept Pediat Pediat Crit Care Med, Boston, MA 02114 USA; [Butler, William] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; [Lo, Eng H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Lo, Eng H.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA		Lok, J (corresponding author), Massachusetts Gen Hosp, Neuroprotect Res Lab, Boston, MA 02114 USA.	jlok1@partners.org			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS053560, P01 NS055104, R01 NS053560-05, R01 NS076694, K08 NS057339, R37 NS037074, P01 NS055104-04, K08NS057339, K08 NS057339-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS057339, R37NS037074, R01NS053560, R01NS076694, P01NS055104] Funding Source: NIH RePORTER		Akopov S, 1996, CEREBROVAS BRAIN MET, V8, P11; ALLISON AC, 1957, BRIT MED J, V2, P1137, DOI 10.1136/bmj.2.5054.1137; Armin SS, 2008, ACTA NEUROCHIR SUPPL, V104, P421; Armin SS, 2006, NEUROL RES, V28, P445, DOI 10.1179/016164106X115053; AUER LM, 1985, J CEREBR BLOOD F MET, V5, P517, DOI 10.1038/jcbfm.1985.78; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Bhasin RR, 2002, ACTA NEUROCHIR SUPPL, V81, P249; Buehler PW, 2009, BLOOD, V113, P2578, DOI 10.1182/blood-2008-08-174466; Canolle B, 2004, J NEUROCHEM, V88, P1521, DOI 10.1046/j.1471-4159.2003.02301.x; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; FEIN JM, 1974, J NEUROSURG, V41, P49, DOI 10.3171/jns.1974.41.1.0049; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Gecse A, 1999, INT ARCH ALLERGY IMM, V118, P166, DOI 10.1159/000024057; Gomis P, 2000, HISTOCHEM J, V32, P673, DOI 10.1023/A:1004115432660; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Ishikawa M, 2004, FRONT BIOSCI-LANDMRK, V9, P1339, DOI 10.2741/1330; Jung KH, 2007, J PHARMACOL EXP THER, V322, P1051, DOI 10.1124/jpet.107.120097; Kai Y, 2008, J PHARMACOL SCI, V108, P426, DOI 10.1254/jphs.08R11FM; Keep RF, 2008, ACT NEUR S, V105, P73; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; KHALIL Z, 1990, BRAIN RES, V527, P292, DOI 10.1016/0006-8993(90)91149-B; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; LEE PY, 1990, AGENTS ACTIONS, V30, P67, DOI 10.1007/BF01969000; Mander P, 2005, J NEUROSCI RES, V79, P208, DOI 10.1002/jnr.20285; MAYBERG MR, 1990, J NEUROSURG, V72, P626, DOI 10.3171/jns.1990.72.4.0626; Min KJ, 2006, J NEUROSCI, V26, P1880, DOI 10.1523/JNEUROSCI.3696-05.2006; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Morel O, 2008, PLATELETS, V19, P9, DOI 10.1080/09537100701817232; Muhonen MG, 1997, J NEUROSURG, V87, P301, DOI 10.3171/jns.1997.87.2.0301; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; OBRIEN PJ, 1969, CAN J BIOCHEM CELL B, V47, P493, DOI 10.1139/o69-077; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Regan RF, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-34; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; Schrieber M, 2007, J TRAUMA, V63, P1261; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stern M, 1996, AM J PATHOL, V149, P911; Stoll G, 2004, BRAIN PATHOL, V14, P51, DOI 10.1111/j.1750-3639.2004.tb00497.x; Sugawara T, 2009, STROKE, V40, P1530, DOI 10.1161/STROKEAHA.108.531699; Thiex Ruth, 2007, Neurosurg Focus, V22, pE6; UEMURA Y, 1987, J NEUROSURG, V66, P741, DOI 10.3171/jns.1987.66.5.0741; Van Den Bosch L, 2002, NEUROREPORT, V13, P1067, DOI 10.1097/00001756-200206120-00018; Vergouwen MDI, 2008, J CEREBR BLOOD F MET, V28, P1761, DOI 10.1038/jcbfm.2008.74; WADA T, 1970, J RETICULOENDOTH SOC, V8, P185; Wagner KR, 2003, J CEREBR BLOOD F MET, V23, P629, DOI 10.1097/01.WCB.0000073905.87928.6D; Wang J, 2005, STROKE, V36, P613, DOI 10.1161/01.STR.0000155729.12931.8f; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Wang XY, 2002, STROKE, V33, P1882, DOI 10.1161/01.STR.0000020121.41527.5D; Wang YP, 2001, REDOX REP, V6, P379, DOI 10.1179/135100001101536580; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; YAMAMOTO Y, 1990, NEUROSURGERY, V27, P921, DOI 10.1227/00006123-199012000-00010; Zhao XR, 2009, J NEUROSCI, V29, P15819, DOI 10.1523/JNEUROSCI.3776-09.2009	66	73	77	0	3	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, A-1201 VIENNA, AUSTRIA	0065-1419		978-3-7091-0692-1	ACTA NEUROCHIR SUPPL	Acta Neurochir. Suppl.		2011	111						63	69		10.1007/978-3-7091-0693-8_11	10.1007/978-3-7091-0693-8		7	Medicine, Research & Experimental; Clinical Neurology	Book Citation Index – Science (BKCI-S)	Research & Experimental Medicine; Neurosciences & Neurology	BGT35	WOS:000324076300011	21725733	Green Accepted			2022-02-06	
J	Luo, CL; Chen, XP; Yang, R; Sun, YX; Li, QQ; Bao, HJ; Cao, QQ; Ni, H; Qin, ZH; Tao, LY				Luo, Cheng-Liang; Chen, Xi-Ping; Yang, Rui; Sun, Yu-Xia; Li, Qian-Qian; Bao, Hai-Jun; Cao, Qiang-Qiang; Ni, Hong; Qin, Zheng-Hong; Tao, Lu-Yang			Cathepsin B Contributes to Traumatic Brain Injury-Induced Cell Death Through a Mitochondria-Mediated Apoptotic Pathway	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; cathepsin B; tBid; caspase-3; apoptosis	HIPPOCAMPAL NEURONAL DEATH; CONTROLLED CORTICAL IMPACT; PERMEABILITY; INHIBITION; LYSOSOMES; PRIMATES; NECROSIS; BCL-2	It has been reported that lysosomal proteases play important roles in ischemic and excitotoxic neuronal cell death. We have previously reported that cathepsin B expression increased remarkably after traumatic brain injury (TBI). The present study sought to investigate the effects of a selective cathepsin B inhibitor (CBI) [N-L-3-trans-prolcarbamoyloxirane-2-carbonyl)-L-isoleucyl-L-proline] on cell death and behavioral deficits in our model. We examined the levels of cathepsin B enzymatic activity and its expression by double labelling damaged cells in the brain slice with propidium iodide (PI) and anticathepsin B. The results showed an elevated enzymatic activity associated with TBI-induced increase in a mature form of cathepsin B, suggesting that cathepsin B may play a role in TBI-induced cell injury. PI was found to label cells positive for the neuronal-specific nuclear marker NeuN, whereas fewer GFAP-positive cells were labelled by PI, suggesting that neurons are more sensitive to cell death induced by TBI. Additionally, we found that pretreatment with CBI remarkably attenuated TBI-induced cell death, lesion volume, and motor and cognitive dysfunction. To analyze the mechanism of action of cathepsin B in the cell death signaling pathway, we assessed DNA fragmentation by electrophoresis, BcI-2/Bax protein expression levels, Bid cleavage, cytochrome c release, and caspase-3 activation. The results imply that cathepsin B contributes to TBI-induced cell death through the present programmed cell necrosis and mitochondria-mediated apoptotic pathways. (C) 2010 Wiley-Liss, Inc.	[Luo, Cheng-Liang; Chen, Xi-Ping; Yang, Rui; Sun, Yu-Xia; Li, Qian-Qian; Bao, Hai-Jun; Cao, Qiang-Qiang; Tao, Lu-Yang] Soochow Univ, Dept Forens Med, Suzhou 215123, Peoples R China; [Ni, Hong; Qin, Zheng-Hong; Tao, Lu-Yang] Soochow Univ, Dept Pharmacol, Suzhou 215123, Peoples R China; [Ni, Hong; Qin, Zheng-Hong; Tao, Lu-Yang] Soochow Univ, Lab Aging & Nerves Dis, Suzhou 215123, Peoples R China; [Tao, Lu-Yang] Forens Key Lab Shanghai, Shanghai, Peoples R China		Tao, LY (corresponding author), Soochow Univ, Dept Forens Med, 199 Renai Rd, Suzhou 215123, Peoples R China.	luyang.tao@163.com			National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30571909, 30872666, 30870808]; Shanghai Forensic Key Lab Foundation [KF0904]	Contract grant sponsor: the National Science Foundation of China; Contract grant number: 30571909; Contract grant number: 30872666; Contract grant number: 30870808; Contract grant sponsor: Shanghai Forensic Key Lab Foundation; Contract grant number: KF0904.	Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Arnoult D, 2007, TRENDS CELL BIOL, V17, P6, DOI 10.1016/j.tcb.2006.11.001; Bagci EZ, 2006, BIOPHYS J, V90, P1546, DOI 10.1529/biophysj.105.068122; Chwieralski CE, 2006, APOPTOSIS, V11, P143, DOI 10.1007/s10495-006-3486-y; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Ellis RC, 2005, EXP NEUROL, V193, P19, DOI 10.1016/j.expneurol.2004.11.034; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029; JIANG X, 2000, J BIOL CHEM, V275, P159; Kim R, 2006, CANCER CHEMOTH PHARM, V57, P545, DOI 10.1007/s00280-005-0111-7; Krysko DV, 2008, METHODS, V44, P205, DOI 10.1016/j.ymeth.2007.12.001; Lin KH, 2009, CARDIOVASC RES, V83, P575, DOI 10.1093/cvr/cvp139; MAMMIS A, 2009, REV SURG NEUROL, V74, P527; Qin ZH, 1999, J NEUROSCI, V19, P4023; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Tao LY, 2003, J FORENSIC MED, V19, P4; Tardy C, 2006, BBA-REV CANCER, V1765, P101, DOI 10.1016/j.bbcan.2005.11.003; Tsuchiya K, 1999, EXP NEUROL, V155, P187, DOI 10.1006/exnr.1998.6988; Tsukada T, 2001, J NEUROCHEM, V79, P1196, DOI 10.1046/j.1471-4159.2001.00679.x; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Yamashima T, 1998, EUR J NEUROSCI, V10, P1723, DOI 10.1046/j.1460-9568.1998.00184.x; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4; Zhao Zhi-guo, 2009, Zhonghua Pifuke Zazhi, V42, P49, DOI 10.3760/cma.j.issn.0412-4030.2009.01.019	32	73	76	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	OCT	2010	88	13					2847	2858		10.1002/jnr.22453			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	642OK	WOS:000281225100008	20653046				2022-02-06	
J	Davis, DP; Peay, J; Sise, MJ; Kennedy, F; Simon, F; Tominaga, G; Steele, J; Coimbra, R				Davis, Daniel P.; Peay, Jeremy; Sise, Michael J.; Kennedy, Frank; Simon, Fred; Tominaga, Gail; Steele, John; Coimbra, Raul			Prehospital Airway and Ventilation Management: A Trauma Score and Injury Severity Score-Based Analysis	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the National-Association-of-Emergency-Medical-Services-Educators	NOV 21, 2007	Los Angeles, CA	Natl Assoc EMS Educators		Traumatic brain injury; Head trauma; Oxygenation; Hypocapnia; Air medical; Oxygen; Intubation; Ventilation; Prehospital; Paramedic	ADVANCED LIFE-SUPPORT; ENDOTRACHEAL INTUBATION; MAJOR TRAUMA; BRAIN-INJURY; IMPACT; RESUSCITATION; SURVIVAL; MODERATE; HYPOXIA	Background: Emergent endotracheal intubation (ETI) is considered the standard of care for patients with severe traumatic brain injury (TBI). However, recent evidence suggests that the procedure may be associated with increased mortality, possibly reflecting inadequate training, suboptimal patient selection, or inappropriate ventilation. Objective: To explore prehospital ETI in patients with severe TBI using a novel application of Trauma Score and Injury Severity Score methodology. Methods: Patients with moderate-to-severe TBI (head Abbreviated Injury Scale score 3+) were identified from our county trauma registry. Demographic information, pre-resuscitation vital signs, and injury severity scores were used to calculate a probability of survival for each patient. The relationship between outcome and prehospital ETI, provider type (air vs. ground), and ventilation status were explored using observed survival-predicted survival and the ratio of unexpected survivors/deaths. Results: A total of 11,000 patients were identified with complete data for this analysis. Observed and predicted survivals were similar for both intubated and nonintubated patients. The ratio of unexpected survivors/deaths increased and observed survival exceeded predicted survival for intubated patients with lower predicted survival values. Both intubated and nonintubated patients transported by air medical crews had better outcomes than those transported by ground. Both hypo-and hypercapnia were associated with worse outcomes in intubated but not in nonintubated patients. Conclusions: Prehospital intubation seems to improve outcomes in more critically injured TBI patients. Air medical outcomes are better than predicted for both intubated and nonintubated TBI patients. Iatrogenic hyper- and hypoventilations are associated with worse outcomes.	[Davis, Daniel P.; Peay, Jeremy] Univ Calif San Diego, Dept Emergency Med, San Diego, CA USA; [Sise, Michael J.] Scripps Mercy Hosp, Dept Surg, San Diego, CA USA; [Kennedy, Frank] Sharp Mem Hosp & Rehabil Ctr, Dept Surg, San Diego, CA USA; [Simon, Fred; Tominaga, Gail] Scripps Mem Hosp, Dept Surg, San Diego, CA USA; [Steele, John] Palomar Hosp, Dept Surg, San Diego, CA USA; [Coimbra, Raul] Univ Calif San Diego, Div Trauma, San Diego, CA USA		Davis, DP (corresponding author), 200 W Arbor Dr 8676, San Diego, CA 92103 USA.	davismd@cox.net	Tominaga, Gail/ABE-6303-2021; Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851			Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; BAUER M, 1993, CIRC SHOCK, V40, P187; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Corso CO, 1998, J SURG RES, V80, P210, DOI 10.1006/jsre.1998.5426; Davis DP, 2008, CAN MED ASSOC J, V178, P1171, DOI 10.1503/cmaj.080234; Davis DP, 2007, J TRAUMA, V62, P277, DOI 10.1097/TA.0b013e31802ef4a3; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; FELDMAN J A, 1991, Journal of Emergency Medicine, V9, P465, DOI 10.1016/0736-4679(91)90219-6; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RAMMING S, 1994, J TRAUMA, V37, P705, DOI 10.1097/00005373-199411000-00003; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154; Stockinger ZT, 2004, J TRAUMA, V56, P531, DOI 10.1097/01.TA.0000111755.94642.29; Wang H E, 2001, Prehosp Emerg Care, V5, P134, DOI 10.1080/10903120190939995; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032	25	73	74	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2010	69	2					294	300		10.1097/TA.0b013e3181dc6c7f			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	638JN	WOS:000280890800009	20699737				2022-02-06	
J	Brenner, LA; Terrio, H; Homaifar, BY; Gutierrez, PM; Staves, PJ; Harwood, JEF; Reeves, D; Adler, LE; Ivins, BJ; Helmick, K; Warden, D				Brenner, Lisa A.; Terrio, Heidi; Homaifar, Beeta Y.; Gutierrez, Peter M.; Staves, Pamela J.; Harwood, Jeri E. F.; Reeves, Dennis; Adler, Lawrence E.; Ivins, Brian J.; Helmick, Katherine; Warden, Deborah			Neuropsychological Test Performance in Soldiers With Blast-Related Mild TBI	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; TBI; Iraq; posttraumatic stress disorder; PTSD	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; NEUROPSYCHIATRIC INTERVIEW MINI; HEAD-INJURY; IRAQ; CONCUSSION; AFGHANISTAN; ATTENTION; OUTCOMES; MEMORY	This exploratory study was conducted to increase understanding of neuropsychological test performance in those with blast-related mild traumatic brain injury (mTBI). The two variables of interest for their impact oil test performance were presence of mTBI symptoms and history of posttraumatic stress disorder (PTSD). Forty-five soldiers postblast mTBI, 27 with enduring mTBI symptoms and 18 without, completed a series of neuropsychological tests. Seventeen of the 45 met criteria for PTSD. The Paced Auditory Serial Addition Test (Frencham, Fox, & Mayberry. 2005; Spreen & Strauss, 1998) was the primary Outcome Measure. Two-sided. 2-sample t tests were used to compare scores between groups of interest. Presence of mTBI symptoms did not impact test performance. In addition, no significant differences between soldiers with and without PTSD were identified. Standard neuropsychological assessment may not increase understanding about impairment associated with mTBI symptoms. Further research in this area is indicated.	[Brenner, Lisa A.; Homaifar, Beeta Y.; Gutierrez, Peter M.; Staves, Pamela J.; Adler, Lawrence E.] VA VISN 19 MIRECC, Denver, CO 80220 USA; [Brenner, Lisa A.; Homaifar, Beeta Y.; Gutierrez, Peter M.; Harwood, Jeri E. F.; Adler, Lawrence E.] Univ Colorado Denver, Sch Med, Denver, CO USA; [Terrio, Heidi] Evans Army Community Hosp, Dept Deployment Hlth & Headquarters, Ft Carson, CO USA; [Terrio, Heidi; Ivins, Brian J.; Helmick, Katherine; Warden, Deborah] Def & Vet Brain Injury Ctr, Washington, DC USA; [Reeves, Dennis] Behav Neurosci Syst, Springfield, MO USA		Brenner, LA (corresponding author), VA VISN 19 MIRECC, 1055 Clermont St, Denver, CO 80220 USA.	lisa.brenner@va.gov	Gutierrez, Peter/K-8905-2019; Brenner, Lisa A./AAG-2442-2019	Gutierrez, Peter/0000-0001-8981-8404; 			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; AlRadi E., 2005, MINI INT NEUROPSYCHI; [Anonymous], 2003, COMP WISC CARD SORT; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Blakesley RE, 2009, NEUROPSYCHOLOGY, V23, P255, DOI 10.1037/a0012850; Bleiberg, 2002, ANAM 2001 USERS MANU; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; BRADSHAW D, 2007, TRAUMATIC BRAIN INJU; Bremner JD, 1995, PSYCHIAT RES, V59, P97; Brenner L. A., J HEAD TRAU IN PRESS; BRENNER LA, 2009, MILITARY MED; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; CONDER R, 1992, MANUAL COMPUTERIZED; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Elsmore TF, 2007, ARCH CLIN NEUROPSYCH, V22, pS135, DOI 10.1016/j.acn.2006.10.009; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; Golden CJ, 1978, STROOP COLOR WORD TE; Gurvits TV, 2000, ARCH GEN PSYCHIAT, V57, P181, DOI 10.1001/archpsyc.57.2.181; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heaton R. K., 2004, REVISED COMPREHENSIV; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Lebowitz B. K., 2006, J INT NEUROPSYCHO S1, V12, P217; LETZ R, 2000, NES 3 USERS MANUAL; McNally RJ, 2006, TRENDS COGN SCI, V10, P271, DOI 10.1016/j.tics.2006.04.007; McNally RJ, 1998, CLIN PSYCHOL REV, V18, P971, DOI 10.1016/S0272-7358(98)00036-1; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; Reeves D, 2007, ANN REV CYBERTHERAPY, V5, P173; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Sheehan DV, 1997, EUR PSYCHIAT, V12, P232, DOI 10.1016/S0924-9338(97)83297-X; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Smith A., 1968, LEARN DISORD, V3, P83, DOI 10.1080/13803390591004428; Spitzer R. L., 1990, STRUCTURED CLIN INTE; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); *SRP, 2007, WARR ADM RETR CAS AS; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125	56	73	73	0	14	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2010	24	2					160	167		10.1037/a0017966			8	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	567XV	WOS:000275483100004	20230110				2022-02-06	
J	Dawson, DR; Anderson, ND; Burgess, P; Cooper, E; Krpan, KM; Stuss, DT				Dawson, Deirdre R.; Anderson, Nicole D.; Burgess, Paul; Cooper, Erin; Krpan, Katherine M.; Stuss, Donald T.			Further Development of the Multiple Errands Test: Standardized Scoring, Reliability, and Ecological Validity for the Baycrest Version	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Cognition; Rehabilitation; Stroke	EXECUTIVE FUNCTIONS; BRAIN-INJURY; PERFORMANCE; SEVERITY; DEFICITS; MOTOR; AGE	Dawson DR, Anderson ND, Burgess P, Cooper E, Krpan KM, Stuss DT. Further development of the Multiple Errands Test: standardized scoring, reliability, and ecological validity for the Baycrest version. Arch Phys Med Rehabil 2009;90(11 Suppl 1):S41-51. Objectives: (1) To determine the summary scores on the Baycrest Multiple Errands Test (BMET) that best discriminate between community dwelling people with traumatic brain injury or stroke and matched controls; (2) to determine interrater reliability; (3) to evaluate further the ecological validity. Design: Case-control. Setting: Large, university-affiliated health care center and participants' homes. Participants: People with acquired brain injury (n=27) and healthy matched controls (n=25). Interventions: Not applicable. Main Outcome Measures: (1) BMET; (2) performance-based measure of instrumental activities of daily living: the Assessment of Motor and Process Skills; (3) self-report and significant other report of daily life function, the Dysexecutive Questionnaire, the Sickness Impact Profile, and the Mayo-Portland Adaptability Inventory. Results: Performance on the BMET was significantly different between people with acquired brain injury and controls (P<.05); good to strong correlations (>.50) were found in more than one third of the correlations between the BMET and measures of IADL and everyday function. Interclass correlation coefficients (ICCs) on BMET summary scores were high (ICC=.71-.88), illustrating very good interrater reliability. Conclusions: This study extends the psychometric findings of the Multiple Errands Test, thus further confirming its value for clinical and research purposes. It is a reliable and ecologically valid assessment that provides a standard way of categorizing executive performance errors in a naturalistic environment.	[Dawson, Deirdre R.; Anderson, Nicole D.; Cooper, Erin; Krpan, Katherine M.] Baycrest, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; [Dawson, Deirdre R.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Dawson, Deirdre R.; Stuss, Donald T.] Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada; [Anderson, Nicole D.; Stuss, Donald T.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Anderson, Nicole D.; Krpan, Katherine M.; Stuss, Donald T.] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Stuss, Donald T.] Baycrest, Rotman Res Inst, Toronto, ON, Canada; [Burgess, Paul] Inst Cognit Neurosci, London, England		Dawson, DR (corresponding author), Baycrest, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	ddawson@klaru-baycrest.on.ca	Dawson, Deirdre R/I-8882-2014; Burgess, Paul W/A-1811-2010; Anderson, Nicole D/E-9101-2011	Dawson, Deirdre R/0000-0001-7517-6121; Anderson, Nicole D/0000-0002-5979-2220	McDonnell Foundation 21st Century Collaborative Activity Award; Heart and Stroke Foundation of Ontario Center for Stroke RecoveryHeart & Stroke Foundation of Ontario	Supported by the McDonnell Foundation 21st Century Collaborative Activity Award and the Heart and Stroke Foundation of Ontario Center for Stroke Recovery.	Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Army Individual Test Battery, 1944, MAN DIR SCOR; Baum CM, 2008, AM J OCCUP THER, V62, P446, DOI 10.5014/ajot.62.4.446; Benedict R., 1997, BRIEF VISUOSPATIAL M; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Benson D.F., 1986, FRONTAL LOBES; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Bodenburg S, 2008, J NERV MENT DIS, V196, P75, DOI 10.1097/NMD.0b013e31815faa2b; Bottari C, 2009, BRAIN INJURY, V23, P322, DOI 10.1080/02699050902788436; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Cicerone KD, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P246; Cohen J., 2013, STAT POWER ANAL BEHA; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Delis DC, 1987, CALIFORNIA VERBAL LE; Duran LJ, 1996, ARCH PHYS MED REHAB, V77, P1019, DOI 10.1016/S0003-9993(96)90062-3; Fisher A.G., 2006, ASSESSMENT MOTOR PRO, V1; Fisher AG, 2001, ASSESSMENT MOTOR PRO, VI; Fisher AG, 2001, ASSESSMENT MOTOR PRO, V2; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton R., 2000, WISCONSIN CARD SORTI; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Malec J. F., 2003, MANUAL MAYO PORTLAND; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; MCDOWELL I, 1996, MEASURING HLTH; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RAND D, 2008, NEUROPSYCHOL REHABIL, V1; Reitan RM, 1985, HALSTEADREITAN NEURO; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Sbordone R.J., 2008, NEUROPSYCHOLOGY HDB, P367; Schlesselman JJ., 1982, CASE CONTROL STUDIES; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Smith A., 1978, SYMBOL DIGIT MODALIT; Spreen O, 1991, COMPENDIUM NEUROPSYC; Stauffer LM, 2000, AM J OCCUP THER, V54, P607, DOI 10.5014/ajot.54.6.607; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; Wechsler D, 1985, WECHSLER ADULT INTEL; World Health Organization, 2007, INT CLASS FUNCT DIS	46	73	73	2	21	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2009	90	11		1			S41	S51		10.1016/j.apmr.2009.07.012			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	520XE	WOS:000271882100007	19892074				2022-02-06	
J	Haider, AH; Crompton, JG; Oyetunji, T; Stevens, KA; Efron, DT; Kieninger, AN; Chang, DC; Cornwell, EE; Haut, ER				Haider, Adil H.; Crompton, Joseph G.; Oyetunji, Tolulope; Stevens, Kent A.; Efron, David T.; Kieninger, Alicia N.; Chang, David C.; Cornwell, Edward E., III; Haut, Elliott R.			Females have fewer complications and lower mortality following trauma than similarly injured males: A risk adjusted analysis of adults in the National Trauma Data Bank	SURGERY			English	Article; Proceedings Paper	70th Annual Meeting of the Society-of-University-Surgeons/4th Annual Academic Surgical Congress	FEB 03-06, 2009	Ft Myers, FL	Soc Univ Surg, Assoc Acad Surg			GENDER DIMORPHISM; SEXUAL-DIMORPHISM; HEMORRHAGIC-SHOCK; BRAIN-INJURY; OUTCOMES; MULTICENTER; SURVIVAL; AGE	Background. Studies of sexual dimorphism in trauma outcomes suggest that women have a survival advantage compared to equivalently injured. men. It is unknown if this gender disparity is mediated by potentially life-threatening complications. Objective. To determine (1) if there is a sex-based differences in the odds of developing inpatient complications after trauma, and (2) if are these complications associated with death among trauma patients. Methods. Review of adult trauma patients admitted to hospitals in the National Trauma Data Bank that report complications. Patient and injury severity covariates were adjusted using multiple logistic regression and the independent affect, of sex on developing complications and associated mortality was determined. Results. A total of 681, 730 adult patients met the inclusion criteria of hospital admission >= 3 days. Women demonstrated a 21% lower adjusted risk of death compared to males (OR 0.79, 95% CI 0.76-0.83). Females had decreased adjusted odds of developing life-threatening complications including pneumonia, acute respiratory distress syndrome, acute renal failure and pulmonary embolism. However, when compared to males with 1 fie-threatening complications, females with complications were found to be at greater risk of dying. Conclusion. This study demonstrates that women are less likely than men to develop inpatient complications, suggesting that the survival advantage among women after traumatic injury may involve a reduced susceptibility to developing life-threatening complications. (Surgery 2009;146:308-15.)	[Haider, Adil H.] Johns Hopkins Univ, Sch Med, Dept Surg, Trauma Outcomes Res Grp,Div Acute Care Surg, Baltimore, MD 21287 USA; [Oyetunji, Tolulope; Cornwell, Edward E., III] Howard Univ, Coll Med, Washington, DC USA		Haider, AH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Surg, Trauma Outcomes Res Grp,Div Acute Care Surg, 600 N Wolfe St,Halsted 610, Baltimore, MD 21287 USA.	ahaider1@jhmi.edu	Haut, Elliott R./J-3948-2019; Oyetunji, Tolulope A/D-1447-2011	Haut, Elliott/0000-0001-7075-771X; Oyetunji, Tolulope/0000-0003-3039-7195			*AM COLL SURG COMM, 2008, NTDB VERS 7 0; ANGELE MK, 1998, SURG FORUM, V49, P43; BAKER WA, 1976, INORG CHIM ACTA, V16, P5, DOI 10.1016/S0020-1693(00)91684-0; Berkowitz DM, 2007, CHEST, V132, P1725, DOI 10.1378/chest.07-2001; Bowles BJ, 2003, INJURY, V34, P27; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Croce MA, 2002, J TRAUMA, V53, P889, DOI 10.1097/00005373-200211000-00013; Deitch EA, 2007, ANN SURG, V246, P447, DOI 10.1097/SLA.0b013e318148566; Diodato MD, 2001, CYTOKINE, V14, P162, DOI 10.1006/cyto.2001.0861; Frink M, 2007, SHOCK, V27, P151, DOI 10.1097/01.shk.0000239767.64786.de; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Haider AH, 2007, ARCH SURG-CHICAGO, V142, P875, DOI 10.1001/archsurg.142.9.875; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Haider AH, 2009, J SURG RES, V153, P138, DOI 10.1016/j.jss.2008.04.011; Harbrecht BG, 2001, J TRAUMA, V51, P887, DOI 10.1097/00005373-200111000-00010; Kardooni S, 2008, J TRAUMA, V64, P273, DOI 10.1097/TA.0b013e31816335ae; Magnotti LJ, 2008, J AM COLL SURGEONS, V206, P984, DOI 10.1016/j.jamcollsurg.2007.12.038; Napolitano LM, 2001, J TRAUMA, V50, P274, DOI 10.1097/00005373-200102000-00013; Oberholzer A, 2000, J TRAUMA, V48, P932, DOI 10.1097/00005373-200005000-00019; Offner PJ, 1999, ARCH SURG-CHICAGO, V134, P935, DOI 10.1001/archsurg.134.9.935; Rappold JF, 2002, J TRAUMA, V53, P436, DOI 10.1097/00005373-200209000-00007; Sperry JL, 2008, J LEUKOCYTE BIOL, V83, P499, DOI 10.1189/jlb.0607360; Sperry JL, 2008, CRIT CARE MED, V36, P1838, DOI 10.1097/CCM.0b013e3181760c14; Stallion A, 2007, J TRAUMA, V62, P1262; Wichmann MW, 1996, CYTOKINE, V8, P853, DOI 10.1006/cyto.1996.0114; Wohltmann CD, 2001, AM J SURG, V181, P297, DOI 10.1016/S0002-9610(01)00582-7	26	73	74	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	AUG	2009	146	2					308	315		10.1016/j.surg.2009.05.006			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Surgery	483MY	WOS:000268972200025	19628090				2022-02-06	
J	Provvidenza, CF; Johnston, KM				Provvidenza, C. F.; Johnston, K. M.			Knowledge transfer principles as applied to sport concussion education	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				CONTINUING MEDICAL-EDUCATION; MULTIPLE INTELLIGENCES; COACH EDUCATION; REFLECTION; GUIDELINES; EXPERIENCE; PLAYERS; RETURN	Objective: To (a) examine knowledge transfer literature and optimal learning needs as applied to healthcare professionals, coaches and student athletes; (b) apply the practice of knowledge transfer to sport concussion education resources; and (c) identify needs and make recommendations for optimising concussion education. Design: Qualitative literature review of knowledge transfer and concussion education literature. Intervention: Pubmed, Medline, Psych Info and Sport Discus databases were reviewed. 52 journal articles, 20 websites and 2 books were reviewed. Results: The methods in which individuals experience optimal learning varies and should be considered when developing effective concussion education strategies. Physician knowledge and performance are impacted by education outreach, interaction and reminder messages. Educational strategies associated with optimal learning for physio and athletic therapists include problem and evidence-based practice, socialisation and peer-assisted learning. From a coaching perspective, research supports the reflective process as a learning modality. Student athletes have strengths and weaknesses in different areas and so perform differently on activities requiring distinct strategies. Knowing the impact of sport concussion resources on knowledge enhancement and modifying attitudes and behaviours toward concussion requires evaluation strategies. Review of concussion resources using the perspective of knowledge transfer and methods for improvement is discussed. Conclusions: Knowledge transfer is a relatively new concept in sports medicine and its influence on enhancing concussion education is not well known. The needs and optimal learning styles of target audiences coupled with evaluation need to be a piece of the overall concussion education puzzle to effectively impact knowledge of and attitudes and behaviours towards sport concussion.	[Johnston, K. M.] Toronto Rehabil Inst, Sport Concuss Program, Sport Concuss Clin, Toronto, ON M5G 2A2, Canada; [Johnston, K. M.] Univ Toronto, Dept Neurosurg, Toronto, ON, Canada		Johnston, KM (corresponding author), Toronto Rehabil Inst, Sport Concuss Program, Sport Concuss Clin, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	johnston.karen@torontorehab.on.ca					Abernathy T., 2001, KNOWLEDGE TRANSFER L; Alexander S., 2001, ED TRAINING, V43, P240, DOI DOI 10.1108/00400910110399247; [Anonymous], 2007, KNOWL TRANSF EXCH; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bales J, 2006, SPORT PSYCHOL, V20, P126, DOI 10.1123/tsp.20.2.126; *CAN BROADC CO, 2006, VID GAM CAN RESH ED; *CAN PAED SOC, 2003, J PAEDIATR CHILD H, V8, P301; Cassidy T, 2006, SPORT PSYCHOL, V20, P145, DOI 10.1123/tsp.20.2.145; *COACH ASS CAN, 2005, SUMM NCCP EV PROJ BL; Coutts J, 2005, 7 CHSRF ANN INV WORK; CURRY L, 1981, CAN MED ASSOC J, V124, P563; CURRY L, 1981, CAN MED ASSOC J, V124, P535; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; Davis DA, 1997, CAN MED ASSOC J, V157, P408; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Demorest RA, 2005, PEDIATRICS, V115, P28, DOI 10.1542/peds.2004-0266; *FED AM SCI, 2006, SUMM ED GAM HARN POW; GALLO M, 2007, INTERNET ITS EFFECTS; Gardner H., 1993, MULTIPLE INTELLIGENC; Gardner H., 1983, FRAMES MIND THEORY M; Gilbert WD, 2005, PHYS EDUC-US, V62, P32; Gilbert WD, 2001, J TEACH PHYS EDUC, V21, P16, DOI 10.1123/jtpe.21.1.16; Goodman D, 2006, J ADOLESCENCE, V29, P351, DOI 10.1016/j.adolescence.2005.07.004; Goodman D, 2002, CLIN J SPORT MED, V12, P265, DOI 10.1097/00042752-200209000-00001; Greenhawk J, 1997, EDUC LEADERSHIP, V55, P62; Grimshaw JM, 1998, J ROY SOC MED, V91, P20, DOI 10.1177/014107689809135S06; Grimshaw JM, 2001, MED CARE S2, V39, pII2, DOI DOI 10.1097/00005650-200108002-00002; Gunasekaran A., 2002, IND COMMER TRAIN, V34, P44, DOI DOI 10.1108/00197850210417528; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Hall E, 2005, INT J LIFELONG EDUC, V24, P243, DOI 10.1080/02601370500134933; Henning JM, 2006, J ATHL TRAINING, V41, P102; Horton A. S., 2002, Medicine & Science in Sports & Exercise, V34, pS99, DOI 10.1097/00005768-200205001-00551; JONES A, 2008, ADV PHYSIOTHER, P9; Lindquist I, 2006, PHYSIOTHER RES INT, V11, P129, DOI 10.1002/pri.332; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; McMahon SD, 2004, J EXP EDUC, V73, P41, DOI 10.3200/JEXE.71.1.41-52; Mettetal G, 1997, J EDUC RES, V91, P115, DOI 10.1080/00220679709597529; Nelson LJ, 2006, SPORT PSYCHOL, V20, P174, DOI 10.1123/tsp.20.2.174; Newton A, 2005, HLTH RES TRANSFER NE; Popay J, 1998, J ROY SOC MED, V91, P32, DOI 10.1177/014107689809135S08; Reardon R, 2006, RES PRACTICE KNOWLED; Rossiter K, 2008, SOC SCI MED, V66, P130, DOI 10.1016/j.socscimed.2007.07.021; Solomon Patricia, 1994, Physiotherapy Theory and Practice, V10, P45, DOI 10.3109/09593989409036386; Solomon Patricia, 2005, Physiotherapy Theory and Practice, V21, P37, DOI 10.1080/09593980590911499; Stevenson K, 2004, J EVAL CLIN PRACT, V10, P207, DOI 10.1111/j.1365-2753.2003.00479.x; Stewart C, 2006, J PHYS EDUC RECREAT, V77, P34, DOI 10.1080/07303084.2006.10597861; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; *UVA WEBL, HAV RAD TV BROADC BE; [No title captured], DOI DOI 10.2307/1585790	52	73	73	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I68	I75		10.1136/bjsm.2009.058180			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Sport Sciences	450YO	WOS:000266438100011	19433428				2022-02-06	
J	Ding, JY; Kreipke, CW; Speirs, SL; Schafer, P; Schafer, S; Rafols, JA				Ding, Jamie Y.; Kreipke, Christian W.; Speirs, Susan L.; Schafer, Patrick; Schafer, Steven; Rafols, Jose A.			Hypoxia-inducible factor-1 alpha signaling in aquaporin upregulation after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Close head injury; Brain edema; MnSOD; Hypoxia; 2ME2	FOCAL CEREBRAL-ISCHEMIA; ENDOTHELIAL GROWTH-FACTOR; RAT-BRAIN; ARTERY OCCLUSION; WATER TRANSPORT; MESSENGER-RNA; EXPRESSION; EDEMA; MODEL; VEGF	Previous studies have demonstrated that traumatic brain injury (TBI) causes brain edema via aquaporins (AQPs), the water-transporting proteins. In the present study, we determined the role of hypoxia inducible factor-1 alpha (HIF-1 alpha), which is a transcription factor in response to physiological hypoxia, in regulating expression of AQP4 and AQP9. Adult male Sprague-Dawley rats (400-425 g) received a closed head injury using the Marmarou weight drop model with a 450 g weight and survived for 1, 4, 24 and 48 h. Some animals were administered 30 min after injury with 2-methoxyestradiol (2ME2), a naturally occurring metabolite of estradiol which is known to post-transcriptionally down-regulate HIF-1 alpha expression, and sacrificed 4h after injury. Real-time PCR and Western blot were used, respectively, to detect gene and protein expressions of manganese superoxide dismutase (MnSOD, showing hypoxic stress), HIF-1 alpha, AQP4, and AQP9. ANOVA analysis demonstrated a significant (p < 0.05) increase in gene expression of MnSOD, HIF-1 alpha, AQP4, and AQP9, starting at I h after injury through 48 h. Western blot analysis further indicated a significant (p < 0.05) increase in protein expression of these molecules at the same time points. Pharmacological inhibition of HIF-1 alpha by 2ME2 reduced the up-regulated levels of AQP4 and AQP9 after TBI. The present study suggests that hypoxic conditions determined by MnSOD expression after closed head injury contribute to HIF-1 alpha expression. HIF-1 alpha, in turn, up-regulates expression of AQP4 and AQP9. These results characterize the pathophysiological mechanisms, and suggest possible therapeutic targets for TBI patients. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Ding, Jamie Y.; Kreipke, Christian W.; Speirs, Susan L.; Schafer, Patrick; Schafer, Steven; Rafols, Jose A.] Wayne State Univ, Sch Med, Detroit, MI 48201 USA		Rafols, JA (corresponding author), Wayne State Univ, Sch Med, 9312 Scott Hall,540 E Canfield St, Detroit, MI 48201 USA.	jrafols@med.wayne.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS039860, R01 NS039860-08, NS 39860] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER		Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Agre P, 2004, NEUROSCIENCE, V129, P849, DOI 10.1016/j.neuroscience.2004.10.001; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Aoki K, 2003, ACTA NEUROPATHOL, V106, P121, DOI 10.1007/s00401-003-0709-y; Badaut J, 2004, NEUROSCIENCE, V129, P971, DOI 10.1016/j.neuroscience.2004.06.035; Badaut J, 2001, J CEREBR BLOOD F MET, V21, P477, DOI 10.1097/00004647-200105000-00001; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Bemeur C, 2004, NEUROCHEM INT, V45, P1167, DOI 10.1016/j.neuint.2004.06.010; Carmeliet P, 2002, SEMIN CELL DEV BIOL, V13, P39, DOI 10.1006/scdb.2001.0290; Chen CH, 2007, J NEUROCHEM, V102, P1831, DOI 10.1111/j.1471-4159.2007.04652.x; Danielisova V, 2007, J NEUROL SCI, V253, P61, DOI 10.1016/j.jns.2006.12.001; Ding YC, 2003, NEUROSCI LETT, V353, P173, DOI 10.1016/j.neulet.2003.09.055; Gerard HC, 2002, J RHEUMATOL, V29, P1827; Griesdale DEG, 2004, SURG NEUROL, V61, P418, DOI 10.1016/j.surneu.2003.10.047; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Harmey JH, 2002, BIOESSAYS, V24, P280, DOI 10.1002/bies.10043; Helton R, 2005, J NEUROSCI, V25, P4099, DOI 10.1523/JNEUROSCI.4555-04.2005; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Kleffner I, 2008, STROKE, V39, P1333, DOI 10.1161/STROKEAHA.107.500785; Kreipke CW, 2007, NEUROL RES, V29, P369, DOI 10.1179/016164107X204684; Li LH, 2008, ACTA NEUROPATHOL, V115, P297, DOI 10.1007/s00401-008-0339-5; Mabjeesh NJ, 2003, CANCER CELL, V3, P363, DOI 10.1016/S1535-6108(03)00077-1; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mu DZ, 2003, NEUROBIOL DIS, V14, P524, DOI 10.1016/j.nbd.2003.08.020; Nemethova M, 2008, CELL BIOL INT, V32, P128, DOI 10.1016/j.cellbi.2007.08.023; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 1997, J NEUROSCI, V17, P171; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Rite I, 2008, NEUROCHEM INT, V52, P897, DOI 10.1016/j.neuint.2007.10.004; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; Sorani MD, 2008, HUM MOL GENET, V17, P2379, DOI 10.1093/hmg/ddn138; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zador Z, 2007, PROG BRAIN RES, V161, P185, DOI 10.1016/S0079-6123(06)61012-1	42	73	81	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 27	2009	453	1					68	72		10.1016/j.neulet.2009.01.077			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	426HM	WOS:000264698600016	19429018	Green Accepted			2022-02-06	
J	Barnes, SRS; Haacke, EM				Barnes, Samuel R. S.; Haacke, E. Mark			Susceptibility-Weighted Imaging: Clinical Angiographic Applications	MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA			English	Article						Susceptibility; Susceptibility-weighted imaging; BOLD; Phase; Venography	BLOOD-OXYGEN SATURATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL ARTERIAL-DISEASE; NEAR-INFRARED SPECTROSCOPY; DIFFUSE AXONAL INJURY; IN-VIVO MEASUREMENT; MR-VENOGRAPHY; BRAIN-TUMORS; VENOUS THROMBOSIS; ACUTE STROKE	By combining filtered phase and magnitude information to create a novel and intrinsic source of contrast, susceptibility-weighted imaging (SWI) has shown great promise in clinical angiography and venography. SWI has contributed to new insights into traumatic brain injury, the role of calcification in atherosclerosis, and the possible relationship between blood settling and deep venous thrombosis. A further contribution from SWI to deep venous thrombosis research (and also stroke) involves its application to the noninvasive measurement of oxygen saturation in the brain and in other tissues. Altogether, SWI offers manifold and diverse avenues for further research using angiographic and venographic techniques.	[Haacke, E. Mark] Wayne State Univ, Dept Biomed Engn, MRI Inst Biomed Engn, Detroit, MI 48202 USA; [Barnes, Samuel R. S.] Loma Linda Univ, Med Ctr, Dept Radiol, Loma Linda, CA 92350 USA; [Haacke, E. Mark] Wayne State Univ, Dept Radiol, Detroit, MI 48201 USA		Haacke, EM (corresponding author), Wayne State Univ, Dept Biomed Engn, MRI Inst Biomed Engn, 440 E Ferry St,Unit 2, Detroit, MI 48202 USA.	nmrimaging@aol.com	Barnes, Samuel/B-7673-2013	Barnes, Samuel/0000-0002-1065-8442	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL062983] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL062983-04A2, 2R01 HL062983-04A2, R01 HL062983] Funding Source: Medline		Akbudak E, 1997, MAGNET RESON MED, V38, P990, DOI 10.1002/mrm.1910380619; Aldington S, 2008, INTERN MED J, V38, P133, DOI 10.1111/j.1445-5994.2007.01597.x; AMERI A, 1992, NEUROL CLIN, V10, P87, DOI 10.1016/S0733-8619(18)30235-4; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Barth M, 2003, INVEST RADIOL, V38, P409, DOI 10.1097/00004424-200307000-00005; BOOS M, 1996, P 13 ANN SCI M EUR S, P127; BRISMAR B, 1978, ACTA CHIR SCAND, V144, P125; Cannegieter SC, 2006, PLOS MED, V3, P1258, DOI 10.1371/journal.pmed.0030307; Costes F, 1996, J APPL PHYSIOL, V80, P1345, DOI 10.1152/jappl.1996.80.4.1345; CRIQUI MH, 1985, CIRCULATION, V71, P510, DOI 10.1161/01.CIR.71.3.510; de Souza JM, 2008, AM J NEURORADIOL, V29, P154, DOI 10.3174/ajnr.A0748; Du YP, 2008, MAGN RESON MED, V59, P954, DOI 10.1002/mrm.21581; ELANGOVAN IR, 2006, VERIFICATION MAGNETI; Esaki K, 2005, EUR J APPL PHYSIOL, V95, P361, DOI 10.1007/s00421-005-0008-5; Essig M, 2001, RADIOLOGE, V41, P288, DOI 10.1007/s001170050989; Fernandez-Seara MA, 2006, MAGN RESON MED, V55, P967, DOI 10.1002/mrm.20892; Guzman RJ, 2008, J AM COLL CARDIOL, V51, P1967, DOI 10.1016/j.jacc.2007.12.058; Haacke EM, 2007, AM J NEURORADIOL, V28, P316; Haacke EM, 2005, MAGN RESON IMAGING, V23, P1, DOI 10.1016/j.mri.2004.10.001; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; HAACKE EM, 1995, INT J IMAG SYST TECH, V6, P153, DOI 10.1002/ima.1850060204; Haacke EM, 1997, HUM BRAIN MAPP, V5, P341, DOI 10.1002/(SICI)1097-0193(1997)5:5<341::AID-HBM2>3.0.CO;2-3; HAACKE EM, 2005, P 13 ANN M ISMRM, P13; Harder SL, 2008, AM J NEURORADIOL, V29, P176, DOI 10.3174/ajnr.A0770; Hermier M, 2004, STROKE, V35, P1989, DOI 10.1161/01.STR.0000133341.74387.96; Hinman JM, 2002, EUR J RADIOL, V41, P147, DOI 10.1016/S0720-048X(01)00365-5; Hu J, 2008, J MAGN RESON IMAGING, V28, P300, DOI 10.1002/jmri.21435; Isbell DC, 2007, J CARDIOV MAGN RESON, V9, P71, DOI 10.1080/10976640600843330; Koopmans PJ, 2008, MAGN RESON MATER PHY, V21, P149, DOI 10.1007/s10334-007-0101-3; Li DB, 1998, MAGNET RESON MED, V39, P685, DOI 10.1002/mrm.1910390503; Liang LX, 1999, AM J NEURORADIOL, V20, P1527; MacDonald MJ, 1999, J APPL PHYSIOL, V86, P687, DOI 10.1152/jappl.1999.86.2.687; MAMMEN EF, 2002, CHEST S, V102, pS640; Matsushita T, 2008, ACTA MED OKAYAMA, V62, P159; Mentzel HJ, 2005, PEDIATR RADIOL, V35, P85, DOI 10.1007/s00247-004-1333-2; Pandian DSJ, 2008, J MAGN RESON IMAGING, V28, P727, DOI 10.1002/jmri.21487; PENTECOST MJ, 1994, CIRCULATION, V89, P511, DOI 10.1161/01.CIR.89.1.511; Pinker K, 2007, AM J NEURORADIOL, V28, P1280, DOI 10.3174/ajnr.A0540; Preter M, 1996, STROKE, V27, P243, DOI 10.1161/01.STR.27.2.243; Rauscher A, 2005, MAGNET RESON MED, V54, P87, DOI 10.1002/mrm.20520; Rauscher A, 2003, J MAGN RESON IMAGING, V18, P175, DOI 10.1002/jmri.10346; Reichenbach JR, 1997, JMRI-J MAGN RESON IM, V7, P266, DOI 10.1002/jmri.1880070203; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Schad LR, 2001, NMR BIOMED, V14, P478, DOI 10.1002/nbm.714; Sedlacik J, 2007, MAGN RESON MED, V58, P1035, DOI 10.1002/mrm.21283; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Sehgal V, 2006, J MAGN RESON IMAGING, V24, P41, DOI 10.1002/jmri.20598; Shen YM, 2007, MAGN RESON IMAGING, V25, P219, DOI 10.1016/j.mri.2006.09.018; SHVARTZ E, 1983, J APPL PHYSIOL, V54, P1673, DOI 10.1152/jappl.1983.54.6.1673; Somasundaram S, 2008, NEUROL INDIA, V56, P103; SONNENFELD T, 1979, SCAND J CLIN LAB INV, V39, P577, DOI 10.3109/00365517909108836; Spees WM, 2001, MAGN RESON MED, V45, P533, DOI 10.1002/mrm.1072; Tan IL, 2000, AM J NEURORADIOL, V21, P1039; Tang PH, 2008, ANN ACAD MED SINGAP, V37, P397; Thomas B, 2008, NEURORADIOLOGY, V50, P105, DOI 10.1007/s00234-007-0316-z; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Vink A, 2002, J VASC SURG, V36, P1194, DOI 10.1067/mva.2002.128300; Warmuth C, 2003, RADIOLOGY, V228, P523, DOI 10.1148/radiol.2282020409; WEISSKOFF RM, 1992, MAGNET RESON MED, V24, P375, DOI 10.1002/mrm.1910240219; Wright LB, 2004, RADIOGRAPHICS, V24, P467, DOI 10.1148/rg.242035117; Wycliffe ND, 2004, J MAGN RESON IMAGING, V20, P372, DOI 10.1002/jmri.20130; Wyttenbach R, 2004, CIRCULATION, V110, P1156, DOI 10.1161/01.CIR.0000140672.70862.5B; Xu YB, 2006, MAGN RESON IMAGING, V24, P155, DOI 10.1016/j.mri.2005.10.030; Zimmermann GG, 1997, RADIOLOGY, V204, P769, DOI 10.1148/radiology.204.3.9280257	66	73	86	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1064-9689	1557-9786		MAGN RESON IMAGING C	Magn. Reson. Imaging Clin. N. Am.	FEB	2009	17	1					47	+		10.1016/j.mric.2008.12.002			16	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	445OG	WOS:000266059500005	19364599	Green Accepted, Green Submitted			2022-02-06	
J	Perel, P; Roberts, I; Bouamra, O; Woodford, M; Mooney, J; Lecky, F				Perel, Pablo; Roberts, Ian; Bouamra, Omar; Woodford, Maralyn; Mooney, Jane; Lecky, Fiona			Intracranial bleeding in patients with traumatic brain injury: A prognostic study	BMC EMERGENCY MEDICINE			English	Article							EPIDURAL HEMATOMAS; HEMORRHAGE; VALIDATION; SCORE	Background: Intracranial bleeding (IB) is a common and serious consequence of traumatic brain injury (TBI). IB can be classified according to the location into: epidural haemorrhage (EDH) subdural haemorrhage (SDH) intraparenchymal haemorrhage (IPH) and subarachnoid haemorrhage (SAH). Studies involving repeated CT scanning of TBI patients have found that IB can develop or expand in the 48 hours after injury. If IB enlarges after hospital admission and larger bleeds have a worse prognosis, this would provide a therapeutic rationale for treatments to prevent increase in the extent of bleeding. We analysed data from the Trauma Audit & Research Network (TARN), a large European trauma registry, to evaluate the association between the size of IB and mortality in patients with TBI. Methods: We analysed 13,962 patients presenting to TARN participating hospitals between 2001 and 2008 with a Glasgow Coma Score (GCS) less than 15 at presentation or any head injury with Abbreviated Injury Scale (AIS) severity code 3 and above. The extent of intracranial bleeding was determined by the AIS code. Potential confounders were age, presenting Glasgow Coma Score, mechanism of injury, presence and nature of other brain injuries, and presence of extracranial injuries. The outcomes were in-hospital mortality and haematoma evacuation. We conducted a multivariable logistic regression analysis to evaluate the independent effect of large and small size of IB, in comparison with no bleeding, on patient outcomes. We also conducted a multivariable logistic regression analysis to assess the independent effect on mortality of large IB in comparison with small IB. Results: Almost 46% of patients had at some type of IB. Subdural haemorrhages were present in 30% of the patients, with epidural and intraparenchymal present in approximately 22% each. After adjusting for potential confounders, we found that large IB, wherever located, was associated with increased mortality in comparison with no bleeding. We also found that large IB was associated with an increased risk of mortality in comparison with small IB. The odds ratio for mortality for large SDH, IPH and EDH, in comparison with small bleeds, were: 3.41 (95% CI: 2.684.33), 3.47 (95% CI: 2.265.33) and 2.86 (95% CI: 1.864.38) respectively. Conclusion: Large EDH, SDH and IPH are associated with a substantially higher probability of hospital mortality in comparison with small IB. However, the limitations of our data, such as the large proportion of missing data and lack of data on other confounding factors, such as localization of the bleeding, make the results of this report only explanatory. Future studies should also evaluate the effect of IB size on functional outcomes.	[Perel, Pablo; Roberts, Ian] London Sch Hyg & Trop Med, Epidemiol & Populat Hlth Dept, London, England; [Bouamra, Omar; Woodford, Maralyn; Mooney, Jane; Lecky, Fiona] Univ Manchester, Sch Translat Med, Occupat & Environm Hlth Res Grp, Trauma Audit & Res Network, Manchester, Lancs, England		Perel, P (corresponding author), London Sch Hyg & Trop Med, Epidemiol & Populat Hlth Dept, London, England.	pablo.perel@lshtm.ac.uk; ian.roberts@lshtm.ac.uk; Omar.Bouamra@manchester.ac.uk; maralyn.woodford@manchester.ac.uk; janemooney@hotmail.com; fiona.lecky@manchester.ac.uk		/0000-0002-2342-301X			BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Brain Trauma Foundation (U. S.), 2000, AAONS MAN PROGN SEV; Bullock AR, 2006, NEUROSURGERY, V58, pVI; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chawda MN, 2004, INJURY, V35, P347, DOI 10.1016/S0020-1383(03)00140-2; CHEN TY, 1993, NEUROSURGERY, V32, P176, DOI 10.1227/00006123-199302000-00004; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; MRC CRASH Trial Collaborators, 2008, BMJ-BRIT MED J, V12, P12; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Yadav YR, 2006, NEUROL INDIA, V54, P377, DOI 10.4103/0028-3886.28109; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552	20	73	74	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-227X			BMC EMERG MED	BMC Emerg. Med.		2009	9								15	10.1186/1471-227X-9-15			8	Emergency Medicine	Emerging Sources Citation Index (ESCI)	Emergency Medicine	V55AX	WOS:000210466600015	19650902	Green Published, gold, Green Accepted			2022-02-06	
J	Mueller, SC; Jackson, CPT; Skelton, RW				Mueller, Sven C.; Jackson, Carl P. T.; Skelton, Ron W.			Sex differences in a virtual water maze: An eye tracking and pupillometry study	BEHAVIOURAL BRAIN RESEARCH			English	Article						spatial navigation; eye tracking; pupillometry; sex differences; strategy; allocentric; egocentric; water maze	GENDER-RELATED DIFFERENCES; HUMAN SPATIAL NAVIGATION; TRAUMATIC BRAIN-INJURY; VISUAL-SEARCH; AGE-DIFFERENCES; WORKING-MEMORY; MOVEMENTS; ABILITY; TASK; ENVIRONMENT	Sex differences in human spatial navigation are well known. However, the exact strategies that males and females employ in order to navigate successfully around the environment are unclear. While some researchers propose that males prefer environment-centred (allocentric) and females prefer self-centred (egocentric) navigation, these findings have proved difficult to replicate. In the present study we examined eye movements and physiological measures of memory (pupillometry) in order to compare visual scanning of spatial orientation using a human virtual analogue of the Morris Water Maze task. Twelve women and twelve men (average age= 24 years) were trained on a visible platform and had to locate an invisible platform over a series of trials. On all but the first trial, participants' eye movements were recorded for 3 s and they were asked to orient themselves in the environment. While the behavioural data replicated previous findings of improved spatial performance for males relative to females, distinct sex differences in eye movements were found. Males tended to explore consistently more space early on while females demonstrated initially longer fixation durations and increases in pupil diameter usually associated with memory processing. The eye movement data provides novel insight into differences in navigational strategies between the sexes. Published by Elsevier B.V.	[Mueller, Sven C.; Jackson, Carl P. T.] Univ Nottingham, Sch Psychol, Nottingham NG7 2RD, England; [Jackson, Carl P. T.] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England; [Skelton, Ron W.] Univ Victoria, Dept Psychol, Victoria, BC V8W 2Y2, Canada		Mueller, SC (corresponding author), NIMH, MAP, NIH, Bethesda, MD 20892 USA.	msven@mail.nih.gov	Skelton, Ronald/E-5605-2012	Mueller, Sven/0000-0003-1661-3840			Astur RS, 2002, BEHAV BRAIN RES, V132, P77, DOI 10.1016/S0166-4328(01)00399-0; Astur RS, 1998, BEHAV BRAIN RES, V93, P185, DOI 10.1016/S0166-4328(98)00019-9; Beatty J., 2000, HDB PSYCHOPHYSIOLOGY, V2, P142; Blanch RJ, 2004, CEREB CORTEX, V14, P1207, DOI 10.1093/cercor/bhh081; Blokland A, 2006, BEHAV BRAIN RES, V171, P216, DOI 10.1016/j.bbr.2006.03.033; Brown LN, 1998, ENVIRON BEHAV, V30, P123, DOI 10.1177/0013916598302001; Chen X, 2006, VISION RES, V46, P4118, DOI 10.1016/j.visres.2006.08.008; Colby CL, 1999, ANNU REV NEUROSCI, V22, P319, DOI 10.1146/annurev.neuro.22.1.319; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Dabbs JM, 1998, EVOL HUM BEHAV, V19, P89, DOI 10.1016/S1090-5138(97)00107-4; DEIJEN JB, 1993, J AFFECT DISORDERS, V29, P33, DOI 10.1016/0165-0327(93)90116-2; EICHENBAUM H, 1990, J NEUROSCI, V10, P3531; Galpin AJ, 2005, PERCEPT PSYCHOPHYS, V67, P1313, DOI 10.3758/BF03193637; Gitelman DR, 2002, BEHAV RES METH INS C, V34, P605, DOI 10.3758/BF03195488; Gron G, 2000, NAT NEUROSCI, V3, P404, DOI 10.1038/73980; Iachini T, 2005, BRAIN COGNITION, V59, P52, DOI 10.1016/j.bandc.2005.04.004; Jones CM, 2003, BEHAV NEUROSCI, V117, P403, DOI 10.1037/0735-7044.117.3.403; Jordan K, 2004, NEUROREPORT, V15, P135, DOI 10.1097/00001756-200401190-00026; Jordan K, 2002, NEUROPSYCHOLOGIA, V40, P2397, DOI 10.1016/S0028-3932(02)00076-3; KAHNEMAN D, 1966, SCIENCE, V154, P1583, DOI 10.1126/science.154.3756.1583; Karatekin C, 2007, PSYCHOPHYSIOLOGY, V44, P128, DOI 10.1111/j.1469-8986.2006.00477.x; Lawton CA, 1996, ENVIRON BEHAV, V28, P204, DOI 10.1177/0013916596282003; LINN MC, 1985, CHILD DEV, V56, P1479, DOI 10.2307/1130467; Livingstone SA, 2007, BEHAV BRAIN RES, V185, P21, DOI 10.1016/j.bbr.2007.07.015; Moffat SD, 2007, CEREB CORTEX, V17, P1274, DOI 10.1093/cercor/bhl036; Moffat SD, 1998, EVOL HUM BEHAV, V19, P73, DOI 10.1016/S1090-5138(97)00104-9; Moffat SD, 2001, NEUROBIOL AGING, V22, P787, DOI 10.1016/S0197-4580(01)00251-2; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MUELLER SC, EARLY ANDROGEN UNPUB; New J, 2007, P ROY SOC B-BIOL SCI, V274, P2679, DOI 10.1098/rspb.2007.0826; Newhouse P, 2007, BEHAV BRAIN RES, V183, P1, DOI 10.1016/j.bbr.2007.05.011; Ohnishi T, 2006, NEUROSCI RES, V55, P361, DOI 10.1016/j.neures.2006.04.009; Osaka N, 2002, AM J PSYCHOL, V115, P501, DOI 10.2307/1423525; Porter G, 2007, Q J EXP PSYCHOL, V60, P211, DOI 10.1080/17470210600673818; Reingold EM, 2001, PSYCHOL SCI, V12, P48, DOI 10.1111/1467-9280.00309; ROOF RL, 1992, BRAIN RES, V572, P310, DOI 10.1016/0006-8993(92)90491-Q; Ross S. P., 2006, VIRTUAL REALITY, V10, P175, DOI DOI 10.1007/S10055-006-0041-7; Ryan JD, 2007, MEMORY, V15, P508, DOI 10.1080/09658210701391022; Sandstrom NJ, 1998, COGNITIVE BRAIN RES, V6, P351, DOI 10.1016/S0926-6410(98)00002-0; Sheinberg DL, 2001, J NEUROSCI, V21, P1340; Siegle GJ, 2003, NEUROIMAGE, V20, P114, DOI 10.1016/S1053-8119(03)00298-2; Skelton RW, 2006, BRAIN INJURY, V20, P189, DOI 10.1080/02699050500456410; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; Tatler BW, 2005, Q J EXP PSYCHOL-A, V58, P931, DOI 10.1080/02724980443000430; Underwood G, 2006, EUR J COGN PSYCHOL, V18, P321, DOI 10.1080/09541440500236661; Vogt S, 2007, PERCEPTION, V36, P91, DOI 10.1068/p5262; VOYER D, 1995, PSYCHOL BULL, V117, P250, DOI 10.1037/0033-2909.117.2.250	48	73	77	0	22	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	NOV 21	2008	193	2					209	215		10.1016/j.bbr.2008.05.017			7	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology	350NP	WOS:000259359700008	18602173				2022-02-06	
J	Galloway, NR; Tong, KA; Ashwal, S; Oyoyo, U; Obenaus, A				Galloway, Nicholas R.; Tong, Karen A.; Ashwal, Stephen; Oyoyo, Udochukwu; Obenaus, Andre			Diffusion-Weighted Imaging Improves Outcome Prediction in Pediatric Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	International Symposium on Traumatic Brain Injury Research Priorities	OCT 13-16, 2005	Johnstown, PA	John P Murtha Neursci & Pain Inst, Natl Brain Injury Res, Treatments & Training Fdn, Brain Injury Assoc Amer		apparent diffusion coefficient; children; diffuse axonal injury; magnetic resonance imaging	AXONAL INJURY; HEAD-INJURY; CORPUS-CALLOSUM; INTENSIVE-CARE; CHILDREN; EDEMA; MRI; COEFFICIENT; ANISOTROPY; DISCHARGE	Diffusion-weighted imaging (DWI) and consequent apparent diffusion coefficient (ADC) maps have been used for lesion detection and as a predictor of outcome in adults with traumatic brain injury (TBI), but few studies have been reported in children. We evaluated the role of DWI and ADC for outcome prediction after pediatric TBI (n = 37 TBI; n = 10 controls). Fifteen regions of interest (ROIs) were manually drawn on ADC maps that were grouped for analysis into peripheral gray matter, peripheral white matter, deep gray and white matter, and posterior fossa. All ROIs excluded areas that appeared abnormal on T2-weighted images (T2WI). Acute injury severity was measured using the Glasgow Coma Scale (GCS) score, and 6-12-month outcomes were assessed using the Pediatric Cerebral Performance Category Scale (PCPCS) score. Patients were categorized into five groups: (1) controls; (2) all TBI patients; (3) mild/moderate TBI with good outcomes; (4) severe TBI with good outcomes; and (5) severe TBI with poor outcomes. ADC values in the peripheral white matter were significantly reduced in children with severe TBI with poor outcomes (72.8 +/- 14.4 X 10(-3) mm(2)/sec) compared to those with severe TBI and good outcomes (82.5 +/- 3.8 X 10(-3) mm(2)/sec; p < 0.05). We also found that the average total brain ADC value alone had the greatest ability to predict outcome and could correctly predict outcome in 84% of cases. Assessment of DWI and ADC values in pediatric TBI is useful in evaluating injury, particularly in brain regions that appear normal on conventional imaging. Early identification of children at high risk for poor outcome may assist in aggressive clinical management of pediatric TBI patients.	[Obenaus, Andre] Loma Linda Univ, Dept Radiat Med, Radiobiol Program, Loma Linda, CA 92354 USA; [Tong, Karen A.; Oyoyo, Udochukwu; Obenaus, Andre] Loma Linda Univ, Dept Radiol, Loma Linda, CA 92354 USA; [Ashwal, Stephen] Loma Linda Univ, Dept Pediat, Loma Linda, CA 92354 USA		Obenaus, A (corresponding author), Loma Linda Univ, Dept Radiat Med, Radiobiol Program, CSP A1010, Loma Linda, CA 92354 USA.	aobenaus@dominion.llumc.edu					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Castejon OJ, 2002, BRAIN INJURY, V16, P331, DOI 10.1080/02699050110088209; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; GIZA C, 2006, PEDIAT NEUROLOGY PRI, P1401; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Ichord RN, 2007, J NEUROTRAUM, V24, P106, DOI 10.1089/neu.2006.0087; Jones DK, 2000, NEUROSURGERY, V47, P306, DOI 10.1097/00006123-200008000-00008; Jones RA, 2003, J MAGN RESON IMAGING, V18, P665, DOI 10.1002/jmri.10413; Kidwell CS, 1999, STROKE, V30, P1174, DOI 10.1161/01.STR.30.6.1174; KUROIWA T, 1994, ACTA NEUROCHIR, P158; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; McGraw P, 2002, AM J ROENTGENOL, V179, P1515, DOI 10.2214/ajr.179.6.1791515; Okanishi T, 2007, J NEUROL SCI, V263, P218, DOI 10.1016/j.jns.2007.06.048; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Prayer D, 2003, EUR J RADIOL, V45, P235, DOI 10.1016/S0720-048X(02)00312-1; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; Takayama H, 2000, CLIN NEUROL NEUROSUR, V102, P135, DOI 10.1016/S0303-8467(00)00079-2; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013	33	73	80	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2008	25	10					1153	1162		10.1089/neu.2007.0494			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	370XK	WOS:000260796200003	18842104				2022-02-06	
J	Maikos, JT; Qian, Z; Metaxas, D; Shreiber, DI				Maikos, Jason T.; Qian, Zhen; Metaxas, Dimitris; Shreiber, David I.			Finite element analysis of spinal cord injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						biomechanics; finite element analysis; spinal cord injury	MECHANICAL-PROPERTIES; BRAIN-INJURY; LARGE-DEFORMATION; WHITE-MATTER; GRAY-MATTER; IN-VITRO; TISSUE; BARRIER; TRAUMA; IMPACT	A three-dimensional (3D) finite element model (FEM) that simulates the Impactor weight-drop experimental model of traumatic spinal cord injury (SCI) was developed. The model consists of the rat spinal cord, with distinct element sets for the gray and white matter, the cerebrospinal fluid (CSF), the dura mater, a rigid rat spinal column, and a rigid impactor. Loading conditions were taken from the average impact velocities determined from previous parallel weight-drop experiments employing a 2.5-mm-diameter, 10-g rod dropped from either 12.5 or 25 mm. The mechanical properties were calibrated by comparing the predicted displacement of the spinal cord at the impact site to that measured experimentally. Parametric studies were performed to determine the sensitivity of the model to the relevant material properties, loading conditions, and essential boundary conditions, and it was determined that the shear modulus had the greatest influence on spinal cord displacement. Additional simulations were performed where gray and white matter were prescribed different material properties. These simulations generated similar drop trajectories to the homogeneous model, but the stress and strain distributions better matched patterns of acute albumin extravasation across the blood-spinal cord barrier following weight-drop SCI, as judged by a logit analysis. A final simulation was performed where the impact site was shifted laterally by 0.35 mm. The off-center impact had little effect on the rod trajectory, but caused marked shifts in the location of stress and strain contours. Different combinations of parameter values could reproduce the impactor trajectory, which suggests that another experimental measure of the tissue response is required for validation. The FEM can be a valuable tool for understanding the injury biomechanics associated with experimental SCI to identify areas for improvement in animal models and future research to identify thresholds for injury.	[Maikos, Jason T.; Qian, Zhen; Shreiber, David I.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA; [Metaxas, Dimitris] Rutgers State Univ, Dept Comp Sci, Piscataway, NJ 08854 USA		Shreiber, DI (corresponding author), Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA.	shreiber@rci.rutgers.edu	Shreiber, David/ABE-8254-2021	Shreiber, David/0000-0001-8248-419X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR 221744-01] Funding Source: Medline		Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Bilston LE, 1996, ANN BIOMED ENG, V24, P67; BILSTON LE, 1998, INT IRCOBI C BIOM IM; Blight A, 1988, J Am Paraplegia Soc, V11, P26; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Choo AM, 2007, J NEUROSURG-SPINE, V6, P255, DOI 10.3171/spi.2007.6.3.255; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Cusick JF, 2002, CLIN BIOMECH, V17, P1, DOI 10.1016/S0268-0033(01)00101-2; Fiford RJ, 2005, J BIOMECH, V38, P1509, DOI 10.1016/j.jbiomech.2004.07.009; Fung Y. C., 1993, BIOMECHANICS MECH PR; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; HUNG T-K, 1975, Surgical Neurology, V4, P271; Ichihara K, 2003, J NEUROSURG, V99, P278, DOI 10.3171/spi.2003.99.3.0278; Ichihara K, 2001, J NEUROTRAUM, V18, P361, DOI 10.1089/08977150151071053; Jaeger CB, 1997, EXP NEUROL, V144, P381, DOI 10.1006/exnr.1996.6405; Jin Xin, 2006, Stapp Car Crash J, V50, P637; KEARNEY P A, 1988, Journal of Neurotrauma, V5, P187, DOI 10.1089/neu.1988.5.187; KING AI, 1995, J NEUROTRAUM, V12, P651, DOI 10.1089/neu.1995.12.651; KOENIG G, 1977, J NEUROL NEUROSUR PS, V40, P1203, DOI 10.1136/jnnp.40.12.1203; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; Maikos JT, 2007, J NEUROTRAUM, V24, P492, DOI 10.1089/neu.2006.0149; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Noble LJ, 1996, J COMP NEUROL, V376, P542; NOBLE LJ, 1987, BRAIN RES, V424, P177, DOI 10.1016/0006-8993(87)91208-X; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Scifert Jeffrey, 2002, Pain Physician, V5, P394; SHREIBER D, 1997, J PASSENGERS CARS, V106, P3792; Shreiber DI, 1999, NEUROSCI LETT, V259, P5, DOI 10.1016/S0304-3940(98)00853-2; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; UENO K, 1995, J NEUROTRAUM, V12, P695, DOI 10.1089/neu.1995.12.695; WAGNER FC, 1981, J NEUROSURG, V54, P802, DOI 10.3171/jns.1981.54.6.0802; Wilcox RK, 2004, EUR SPINE J, V13, P481, DOI 10.1007/s00586-003-0625-9; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; YOGANANDAN N, 1994, J SPINAL DISORD, V7, P420; Young W, 2002, PROG BRAIN RES, V137, P231; Zarzur E, 1996, ARQ NEURO-PSIQUIAT, V54, P455, DOI 10.1590/S0004-282X1996000300015; Zhu Q, 2006, DEV NEUROSCI-BASEL, V28, P388, DOI 10.1159/000094165	47	73	76	1	13	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2008	25	7					795	816		10.1089/neu.2007.0423			22	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	326BX	WOS:000257634000007	18627257				2022-02-06	
J	Sun, DA; Deshpande, LS; Sombati, S; Baranova, A; Wilson, MS; Hamm, RJ; DeLorenzo, RJ				Sun, David A.; Deshpande, Laxmikant S.; Sombati, Sompong; Baranova, Anya; Wilson, Margaret S.; Hamm, Robert J.; DeLorenzo, Robert J.			Traumatic brain injury causes a long-lasting calcium (Ca2+)-plateau of elevated intracellular Ca levels and altered Ca2+ homeostatic mechanisms in hippocampal neurons surviving brain injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						acute dissociation of neuron; calcium dynamics; Fura-2/Fura-FF; Sprague-Dawley rats	STROKE-INDUCED EPILEPSY; TEMPORAL-LOBE EPILEPSY; IN-VITRO MODEL; CELL-DEATH; COGNITIVE DEFICITS; ACQUIRED EPILEPSY; CORTICAL-NEURONS; GENE-EXPRESSION; RAT; EXCHANGE	Traumatic brain injury (TBI) survivors often suffer chronically from significant morbidity associated with cognitive deficits, behavioral difficulties and a post-traumatic syndrome and thus it is important to understand the pathophysiology of these long-term plasticity changes after TBI. Calcium (Ca2+) has been implicated in the pathophysiology of TBI-induced neuronal death and other forms of brain injury including stroke and status epilepticus. However, the potential role of long-term changes in neuronal Ca2+ dynamics after TBI has not been evaluated. In the present study, we measured basal free intracellular Ca2+ concentration ([Ca2+](i)) in acutely isolated CA3 hippocampal neurons from Sprague-Dawley rats at 1, 7 and 30 days after moderate central fluid percussion injury. Basal [Ca2+](i) was significantly elevated when measured 1 and 7 days post-TBI without evidence of neuronal death. Basal [Ca2+](i) returned to normal when measured 30 days post-TBI. In contrast, abnormalities in Ca2+ homeostasis were found for as long as 30 days after TBI. Studies evaluating the mechanisms underlying the altered Ca2+ homeostasis in TBI neurons indicated that necrotic or apoptotic cell death and abnormalities in Ca2+ influx and efflux mechanisms could not account for these changes and suggested that long-term changes in Ca2+ buffering or Ca2+ sequestration/release mechanisms underlie these changes in Ca2+ homeostasis after TBI. Further elucidation of the mechanisms of altered Ca2+ homeostasis in traumatized, surviving neurons in TBI may offer novel therapeutic interventions that may contribute to the treatment and relief of some of the morbidity associated with TBI.	[Deshpande, Laxmikant S.; Sombati, Sompong; DeLorenzo, Robert J.] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23298 USA; [Sun, David A.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN 37232 USA; [Baranova, Anya; DeLorenzo, Robert J.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [DeLorenzo, Robert J.] Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; [Baranova, Anya; Hamm, Robert J.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23298 USA; [Wilson, Margaret S.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA		DeLorenzo, RJ (corresponding author), Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23298 USA.	rdeloren@hsc.vcu.edu	Deshpande, Laxmikant S./B-7679-2013	Deshpande, Laxmikant S./0000-0003-1491-1561	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS051505-02, R01 NS051505-03, R01 NS051505, R01NS052529, U01 NS058213-02, R01 NS052529-03, U01 NS058213-01, R01 NS052529-02, U01NS058213, U01 NS058213, R01NS051505, R01 NS052529, R01 NS052529-01A2, U01 NS058213-03, R01 NS051505-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS058213, R01NS051505, R01NS052529] Funding Source: NIH RePORTER		Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; Annunziato L, 2004, PHARMACOL REV, V56, P633, DOI 10.1124/pr.56.4.5; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; *CDCP, 2002, TRAUM BRAIN INJ US; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DeLorenzo RJ, 2005, PHARMACOL THERAPEUT, V105, P229, DOI 10.1016/j.pharmthera.2004.10.004; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P2139, DOI 10.1152/jn.1997.77.4.2139; GLEASON E, 1995, J NEUROSCI, V15, P3612; GOLDMAN WF, 1994, J NEUROSCI, V14, P5834; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haugland R.P., 1996, HDB FLUORESCENT PROB, P503; Hauser WA, 1990, EPILEPSY FREQUENCY C; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Hyrc KB, 2000, CELL CALCIUM, V27, P75, DOI 10.1054/ceca.1999.0092; Kirino T, 2000, NEUROPATHOLOGY, V20, pS95; LIMBRICK DD, 1995, BRAIN RES, V690, P145, DOI 10.1016/0006-8993(95)00552-2; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; Morris TA, 1999, J NEUROSCI, V19, P8234; Morris TA, 2000, MOL BRAIN RES, V79, P138, DOI 10.1016/S0169-328X(00)00112-1; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; National Institute of Neurological Disorders and Stroke, 2002, NIH PUBL, V02-158; Pal S, 2000, CELL CALCIUM, V28, P181, DOI 10.1054/ceca.2000.0146; Pal S, 1999, BRAIN RES, V851, P20, DOI 10.1016/S0006-8993(99)02035-1; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Raza M, 2004, P NATL ACAD SCI USA, V101, P17522, DOI 10.1073/pnas.0408155101; Raza M, 2001, BRAIN RES, V903, P1, DOI 10.1016/S0006-8993(01)02127-8; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sidky AO, 1997, J PHYSIOL-LONDON, V504, P579, DOI 10.1111/j.1469-7793.1997.579bd.x; Sun DA, 2004, CELL CALCIUM, V35, P155, DOI 10.1016/j.ceca.2003.09.003; Sun DA, 2002, EPILEPSIA, V43, P1296, DOI 10.1046/j.1528-1157.2002.09702.x; Tymianski M, 1996, NEUROSURGERY, V38, P1176; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; WHITE RJ, 1995, J NEUROSCI, V15, P1318; Zhou ZW, 2007, J NEUROSURG, V106, P687, DOI 10.3171/jns.2007.106.4.687; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	50	73	75	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	APR	2008	27	7					1659	1672		10.1111/j.1460-9568.2008.06156.x			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	282HX	WOS:000254559600008	18371074	Green Accepted			2022-02-06	
J	Singh, M; Sumien, N; Kyser, C; Simpkins, JW				Singh, Meharvan; Sumien, Nathalie; Kyser, Cheryl; Simpkins, James W.			Estrogens and progesterone as neuroprotectants: what animal models teach us	FRONTIERS IN BIOSCIENCE-LANDMARK			English	Article						estrogens; progestins; neuroprotection; Alzheimer's disease; animal models; review	HEALTH INITIATIVE MEMORY; CEREBRAL-ARTERY OCCLUSION; FEMALE C57BL/6J MICE; CONJUGATED EQUINE ESTROGENS; RANDOMIZED CONTROLLED-TRIAL; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; SPRAGUE-DAWLEY RATS; POSTMENOPAUSAL WOMEN; ISCHEMIC DAMAGE	Estradiol and progesterone are two steroid hormones that target a variety of organ systems, including the heart, the bone and the brain. With respect to the latter, a large volume of basic science studies support the neuroprotective role of estradiol and/or progesterone. In fact, the results of such studies prompted the assessment of these hormones as protective agents against such disorders as Alzheimer's disease, stroke and traumatic brain injury. Interestingly, results from the Women's Health Initiative (WHI) yielded results that appeared to be inconsistent with the data derived from in vitro and in vivo models. However, we argue that the results from the basic science studies were not inconsistent with the clinical trials, but rather, are consistent with, and may even have predicted, the results from the WHI. To illustrate this point, we review here certain in vivo paradigms that have been used to assess the protective effects of estrogens and progesterone, and describe how the results from these animal models point to the importance of the type of hormone, the age of the subjects and the method of hormone administration, in determining whether or not hormones are neuroprotective.	[Singh, Meharvan; Sumien, Nathalie; Kyser, Cheryl; Simpkins, James W.] Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA		Singh, M (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.	msingh@hsc.unt.edu		Singh, Meharvan/0000-0002-8072-1769	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054687, R01NS054651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG010485, P01AG022550, R21AG026672] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21 AG026672, AG 26672, AG 22550, AG 10485, P01 AG022550, P01 AG010485] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS054687-01A2, R01 NS054687, R01 NS054651-01A2, R01 NS054651] Funding Source: Medline		Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JF, 2001, ANESTH ANALG, V92, P1520, DOI 10.1097/00000539-200106000-00033; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Chin M, 2005, AM J PATHOL, V166, P1629, DOI 10.1016/S0002-9440(10)62473-X; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; Culmsee C, 1999, J CEREBR BLOOD F MET, V19, P1263, DOI 10.1097/00004647-199911000-00011; Dabrosin C, 2002, AM J PATHOL, V161, P909, DOI 10.1016/S0002-9440(10)64251-4; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; Fukuda K, 2000, STROKE, V31, P155, DOI 10.1161/01.STR.31.1.155; Gibbs RB, 1998, BRAIN RES, V787, P259, DOI 10.1016/S0006-8993(97)01511-4; Gollapudi L, 1999, J NEUROSCI RES, V56, P99, DOI 10.1002/(SICI)1097-4547(19990401)56:1<99::AID-JNR13>3.0.CO;2-G; GORDON MN, 1986, BIOL REPROD, V35, P1088, DOI 10.1095/biolreprod35.5.1088; Green PS, 2005, ENDOCRINOLOGY, V146, P2774, DOI 10.1210/en.2004-1433; Greenberg LH, 2004, AM J OBSTET GYNECOL, V190, P1788, DOI 10.1016/j.ajog.2004.02.047; Greenberg LH, 2004, AM J OBSTET GYNECOL, V190, P1796; He Z, 2002, J NEUROL SCI, V193, P79, DOI 10.1016/S0022-510X(01)00648-7; HENDERSON VW, 2007, AM ACAD NEUROLOGY; Ibanez C, 2003, PROG NEUROBIOL, V71, P49, DOI 10.1016/j.pneurobio.2003.09.002; IGUCHI T, 1986, ACTA ANAT, V127, P110; Jezierski MK, 2000, MOL BRAIN RES, V85, P77, DOI 10.1016/S0169-328X(00)00244-8; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Jung EY, 2004, J VET MED SCI, V66, P1347, DOI 10.1292/jvms.66.1347; Jung ME, 2002, ALCOHOL, V26, P83, DOI 10.1016/S0741-8329(01)00199-9; KAUR P, 2007, J NEUROSCI RES; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Latham KA, 2003, J IMMUNOL, V171, P5820, DOI 10.4049/jimmunol.171.11.5820; Lee Beom Jun, 2004, J Vet Sci, V5, P227; Littleton-Kearney MT, 2005, J CEREBR BLOOD F MET, V25, P421, DOI 10.1038/sj.jcbfm.9600052; LUINE VN, 1985, EXP NEUROL, V89, P484, DOI 10.1016/0014-4886(85)90108-6; Luine VN, 1998, HORM BEHAV, V34, P149, DOI 10.1006/hbeh.1998.1473; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; Mendelowitsch A, 2001, BRAIN RES, V901, P230, DOI 10.1016/S0006-8993(01)02359-9; Miller L, 1998, J IMMUNOL, V160, P5098; MOBBS CV, 1984, BIOL REPROD, V30, P556, DOI 10.1095/biolreprod30.3.556; MOBBS CV, 1985, BIOL REPROD, V32, P1010, DOI 10.1095/biolreprod32.5.1010; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Nordell VL, 2003, NEUROBIOL AGING, V24, P733, DOI 10.1016/S0197-4580(02)00193-8; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROSENBLUM WI, 1985, THROMB RES, V39, P253, DOI 10.1016/0049-3848(85)90220-8; ROSENBLUM WI, 1985, STROKE, V16, P980, DOI 10.1161/01.STR.16.6.980; Savonenko AV, 2003, NEUROSCIENCE, V119, P821, DOI 10.1016/S0306-4522(03)00213-6; Sawada H, 2000, FASEB J, V14, P1202, DOI 10.1096/fasebj.14.9.1202; Shi J, 2001, STROKE, V32, P987, DOI 10.1161/01.STR.32.4.987; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; SINGH M, 1994, BRAIN RES, V644, P305, DOI 10.1016/0006-8993(94)91694-2; SOHRABJI F, 1994, J NEUROSCI, V14, P459; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; SUGO N, 2001, SOC NEUR 31 ANN M; THEODORSSON A, 2005, PEPTIDES; Tse J, 1999, ATHEROSCLEROSIS, V144, P303, DOI 10.1016/S0021-9150(98)00325-6; van den Berg MP, 2004, PHARM RES-DORDR, V21, P799, DOI 10.1023/B:PHAM.0000026431.55383.69; Verdu EF, 2002, AM J PHYSIOL-GASTR L, V283, pG27, DOI 10.1152/ajpgi.00460.2001; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Wen Y, 2004, BRAIN RES, V1008, P147, DOI 10.1016/j.brainres.2004.02.019; WOOLLEY CS, 1993, J COMP NEUROL, V336, P293, DOI 10.1002/cne.903360210; Yang SH, 2001, J CEREBR BLOOD F MET, V21, P174, DOI 10.1097/00004647-200102000-00009	69	73	73	0	5	FRONTIERS IN BIOSCIENCE INC	IRVINE	16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA	1093-9946	1093-4715		FRONT BIOSCI-LANDMRK	Front. Biosci.	JAN 1	2008	13						1083	1089		10.2741/2746			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	299SQ	WOS:000255775700090	17981614	Green Accepted			2022-02-06	
J	Bowman, SM; Martin, DP; Sharar, SR; Zimmerman, FJ				Bowman, Stephen M.; Martin, Diane P.; Sharar, Sam R.; Zimmerman, Frederick J.			Racial disparities in outcomes of persons with moderate to severe traumatic brain injury	MEDICAL CARE			English	Article						traumatic brain injury; race; disparity; mortality; rehabilitation	EMERGENCY-DEPARTMENT	Background: Although racial differences in hospital outcomes are well known for medical conditions (eg, cardiovascular disease), it is unknown whether differences exist for patients with traumatic brain injury (TBI). Research Design: Using the National Trauma Data Bank, we examined racial and ethnic differences in hospital outcomes of 56,482 patients with moderate to severe TBI who were hospitalized in level I or 11 trauma-designated hospitals between 2000 and 2003. We examined racial and ethnic disparities in in-hospital mortality and the likelihood of survivors receiving postacute care at a rehabilitation center. Results: After multivariable adjustment, compared with whites, we observed increased in-hospital mortality for blacks (odds ratio [OR] = 1.19, P = 0.026) and Asians (OR = 1.41, P = 0.005). We observed a trend toward significance for Hispanics (OR = 1.41, P = 0.077), but not for other races. For survivors, compared with whites, blacks and Hispanics were less likely to be discharged to a rehabilitation center (OR = 0.68, P < 0.001, and OR = 0.67, P = 0.002, respectively). Conclusions: Racial and ethnic disparities exist both in mortality and in discharge to postacute rehabilitation centers among persons with TBI.	Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA		Bowman, SM (corresponding author), Univ Arkansas Med Sci, Dept Pediat, Peds CARE Slot 512-26,800 Marshall St, Little Rock, AR 72202 USA.	bowmanstephenm@uams.edu	Zimmerman, Frederick/AAM-5432-2020; Zimmerman, Frederick/C-7259-2008; Bowman, Stephen/AAF-2154-2019	Zimmerman, Frederick/0000-0002-4163-9893; Zimmerman, Frederick/0000-0002-4163-9893; 			American College of Surgeons, NAT TRAUM DAT BANK 2; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Centers for Disease Control and Prevention, 2001, INJ FACT BOOK 2001 2; COPES WS, 1990, J TRAUMA, V30, P1200, DOI 10.1097/00005373-199010000-00003; *I MED, 2002, UN TREATM HEALTHC PR; *J HOPK U TRI AN I, 1997, ICDMAP 90 INJ SEV CO; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603; Rutland-Brown W, 2005, J HEAD TRAUMA REHAB, V20, P205, DOI 10.1097/00001199-200505000-00004; Sacco WJ, 1999, J TRAUMA, V47, P441, DOI 10.1097/00005373-199909000-00001; Stephenson SCR, 2002, J TRAUMA, V53, P326, DOI 10.1097/00005373-200208000-00023; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *US DHHS, 2005, 2005 NAT HEALTHC DIS; *WASH STAT DEP HLT, 2006, WASH TRAUM REG; Wong MD, 2002, NEW ENGL J MED, V347, P1585, DOI 10.1056/NEJMsa012979; [No title captured]	18	73	74	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0025-7079			MED CARE	Med. Care	JUL	2007	45	7					686	690		10.1097/MLR.0b013e31803dcdf3			5	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health	186OR	WOS:000247788500014	17571018				2022-02-06	
J	Yaka, R; Biegon, A; Grigoriadis, N; Simeonidou, C; Grigoriadis, S; Alexandrovich, AG; Matzner, H; Schumann, J; Trembovler, V; Tsenter, J; Shohami, E				Yaka, Rami; Biegon, Anat; Grigoriadis, Nikolaos; Simeonidou, Constantina; Grigoriadis, Savvas; Alexandrovich, Alexander G.; Matzner, Henri; Schumann, Johanna; Trembovler, Victoria; Tsenter, Jeanna; Shohami, Esther			D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury	FASEB JOURNAL			English	Article						traumatic brain injury; NMDA receptors; synaptic plasticity; BDNF	TRAUMATIC BRAIN-INJURY; FLUID-PERCUSSION INJURY; PERIPHERAL BENZODIAZEPINE-RECEPTORS; FOCAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; NEUROTROPHIC FACTOR; INTRACEREBRAL MICRODIALYSIS; HIPPOCAMPAL-NEURONS; NMDA RECEPTORS; RAT-BRAIN	Traumatic brain injury triggers a massive glutamate efflux, activation of NMDA receptor channels, and cell death. Recently, we reported that NMDA receptors in mice are down-regulated from hours to days following closed head injury (CHI), and treatment with NMDA improved recovery of motor and cognitive functions up to 14 d post-injury. Here we show that a single injection of a low dose of D-cycloserine (DCS), a partial NMDA receptor agonist, in CHI mice 24 h post-injury, resulted in a faster and greater recovery of motor and memory functions as assessed by neurological severity score and object recognition tests, respectively. Moreover, DCS treatment of CHI mice led to a significant improvement of hippocampal long-term potentiation (LTP) in the CA1 region that was completely blunted in CHI control mice. However, DCS did not improve CHI-induced impairment in synaptic glutamate release measured by paired pulse facilitation (PPF) ratio in hippocampal CA1 region. Finally, CHI-induced reduction of brain-derived neurotrophic factor (BDNF) was fully restored following DCS treatment. Since DCS is in clinical use for other indications, the present study offers a novel approach to treat human brain injury.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Brookhaven Natl Lab, Upton, NY 11973 USA; Aristotle Univ Thessaloniki, Fac Med, Dept Physiol, Thessaloniki, Greece; Hadassah Univ Hosp, Dept Neurosurg, IL-91120 Jerusalem, Israel; Hadassah Med Ctr, Dept Rehabil, IL-91120 Jerusalem, Israel		Yaka, R (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, POB 12065, IL-91120 Jerusalem, Israel.	yaka@md.huji.ac.il			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050285] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 050285-01 A2] Funding Source: Medline		Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Albensi BC, 2000, J NEUROSCI RES, V62, P177, DOI 10.1002/1097-4547(20001015)62:2&lt;177::AID-JNR3&gt;3.0.CO;2-D; Andersen JM, 2002, BEHAV BRAIN RES, V129, P211, DOI 10.1016/S0166-4328(01)00318-7; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Biegon A, 2002, J NEUROCHEM, V82, P924, DOI 10.1046/j.1471-4159.2002.01050.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BULLOCK R, 1995, STROKE, V26, P2187, DOI 10.1161/01.STR.26.11.2187; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Cao R, 2006, NEUROSCI LETT, V401, P136, DOI 10.1016/j.neulet.2006.03.005; CHEN M, 1991, ANN NEUROL, V30, P62, DOI 10.1002/ana.410300112; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; Di X, 1996, J NEUROSURG, V85, P655, DOI 10.3171/jns.1996.85.4.0655; Duncan EJ, 2004, SCHIZOPHR RES, V71, P239, DOI 10.1016/j.schres.2004.03.013; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; FRIEDMAN C, 2001, BIOINFORMATICS, V1, P1; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Heresco-Levy U, 2002, INT J NEUROPSYCHOPH, V5, P301, DOI 10.1017/S1461145702003061; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Korte M, 1996, J PHYSIOLOGY-PARIS, V90, P157, DOI 10.1016/S0928-4257(97)81415-5; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; LAAKE K, 2002, COCHRANE DB SYST REV; Lelong V, 2001, NEUROPHARMACOLOGY, V41, P517, DOI 10.1016/S0028-3908(01)00085-5; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Nitsche MA, 2004, NEUROPSYCHOPHARMACOL, V29, P1573, DOI 10.1038/sj.npp.1300517; Owens J, 2000, NUCL MED BIOL, V27, P557, DOI 10.1016/S0969-8051(00)00102-5; Paxinos G, 2000, MOUSE BRAIN STEREOTA; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schneider JS, 2000, BRAIN RES, V860, P190, DOI 10.1016/S0006-8993(00)02036-9; Schwarzbach E, 2006, HIPPOCAMPUS, V16, P541, DOI 10.1002/hipo.20183; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P329; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Simic G, 2000, EXP NEUROL, V165, P12, DOI 10.1006/exnr.2000.7448; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7; THIEL G, 1993, BRAIN PATHOL, V3, P87, DOI 10.1111/j.1750-3639.1993.tb00729.x; WALLACE MC, 1992, J NEUROSURG, V76, P127, DOI 10.3171/jns.1992.76.1.0127; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Yaka R, 2003, J BIOL CHEM, V278, P9630, DOI 10.1074/jbc.M209141200; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037; ZAFRA F, 1992, J NEUROSCI, V12, P4793	53	73	75	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2007	21	9					2033	2041		10.1096/fj.06-7856com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	182JG	WOS:000247500300013	17351125				2022-02-06	
J	Jing, RF; Wilhelmsson, U; Goodwill, W; Li, LZ; Pan, YH; Pekny, M; Skalli, O				Jing, Runfeng; Wilhelmsson, Ulrika; Goodwill, William; Li, Lizhen; Pan, Yihang; Pekny, Milos; Skalli, Omar			Synemin is expressed in reactive astrocytes in neurotrauma and interacts differentially with vimentin and GFAP intermediate filament networks	JOURNAL OF CELL SCIENCE			English	Article						astrocytes; intermediate filament; GFAP; vimentin	FIBRILLARY ACIDIC PROTEIN; MICE LACKING; CELLS EXPRESS; IN-VITRO; ABSENCE; SYSTEM; IDENTIFICATION; HETEROPOLYMERS; PARANEMIN; NESTIN	Immature astrocytes and astrocytoma cells contain synemin and three other intermediate filament (IF) proteins: glial fibrillary acidic protein (GFAP), vimentin and nestin. Here, we show that, after neurotrauma, reactive astrocytes produce synemin and thus propose synemin as a new marker of reactive astrocytes. Comparison of synemin mRNA and protein levels in brain tissues and astrocyte cultures from wild-type, Vim(-/-) and Gfap(-/-) Vim(-/-) mice showed that in the absence of vimentin, synemin protein was undetectable although synemin mRNA was present at wild-type levels. By contrast, in Gfap(-/-) astrocytes, synemin protein and mRNA levels, as well as synemin incorporation into vimentin IFs, were unaltered. Biochemical assays with purified proteins suggested that synemin interacts with GFAP IFs like an IF-associated protein rather than like a polymerization partner, whereas the opposite was true for synemin interaction with vimentin. In transfection experiments, synemin did not incorporate into normal, filamentous GFAP networks, but integrated into vimentin and GFAP heteropolymeric networks. Thus, alongside GFAP, vimentin and nestin, reactive astrocytes contain synemin, whose accumulation is suppressed post-transcriptionally in the absence of a polymerization partner. In astrocytes, this partner is vimentin and not GFAP, which implies a functional difference between these two type III IF proteins.	Louisiana State Univ, Hlth Sci Ctr, Dept Cellular Biol & Anat, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA; Gothenburg Univ, Sahlgrensak Acad, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil,Dept Clin Neurosci & R, S-41390 Gothenburg, Sweden		Skalli, O (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cellular Biol & Anat, Shreveport, LA 71130 USA.	oskall@lsuhsc.edu	Skalli, Omar/D-4980-2013	Wilhelmsson, Ulrika/0000-0003-3227-2687	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS035317, R01NS035317] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-35317] Funding Source: Medline		Bellin RM, 1999, J BIOL CHEM, V274, P29493, DOI 10.1074/jbc.274.41.29493; Bellin RM, 2001, J BIOL CHEM, V276, P32330, DOI 10.1074/jbc.M104005200; Bhosle RC, 2006, BIOCHEM BIOPH RES CO, V346, P768, DOI 10.1016/j.bbrc.2006.05.192; Bilak SR, 1998, ARCH BIOCHEM BIOPHYS, V355, P63, DOI 10.1006/abbi.1998.0702; CALVO JL, 1990, BRAIN RES, V532, P355, DOI 10.1016/0006-8993(90)91784-E; Carlsson L, 2000, HISTOCHEM CELL BIOL, V114, P39; Chang L, 2006, J CELL BIOL, V172, P747, DOI 10.1083/jcb.200511033; Chang L, 2004, NAT REV MOL CELL BIO, V5, P601, DOI 10.1038/nrm1438; CHEN WJ, 1994, J CELL SCI, V107, P2299; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Coulombe PA, 2004, NAT CELL BIOL, V6, P699, DOI 10.1038/ncb0804-699; DAHL D, 1981, EXP NEUROL, V73, P496, DOI 10.1016/0014-4886(81)90283-1; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; Elder GA, 1998, J CELL BIOL, V141, P727, DOI 10.1083/jcb.141.3.727; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Herrmann H, 2004, ANNU REV BIOCHEM, V73, P749, DOI 10.1146/annurev.biochem.73.011303.073823; Herrmann H, 1996, J MOL BIOL, V264, P933, DOI 10.1006/jmbi.1996.0688; Hirako Y, 2003, CELL TISSUE RES, V313, P195, DOI 10.1007/s00441-003-0732-2; ISAACS WB, 1989, J BIOL CHEM, V264, P17953; Izmiryan A, 2006, GLIA, V54, P204, DOI 10.1002/glia.20378; Jacomy H, 1999, J NEUROCHEM, V73, P972, DOI 10.1046/j.1471-4159.1999.0730972.x; Jing RF, 2005, GLIA, V50, P107, DOI 10.1002/glia.20158; KOOIJMAN M, 1995, FEBS LETT, V358, P185, DOI 10.1016/0014-5793(94)01419-2; KULESH DA, 1989, MOL CELL BIOL, V9, P1553, DOI 10.1128/MCB.9.4.1553; Lane EB, 2004, METHOD CELL BIOL, V78, P229; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; Marvin NJ, 1998, J CELL SCI, V111, P1951; Mizuno Y, 2001, P NATL ACAD SCI USA, V98, P6156, DOI 10.1073/pnas.111153298; MOON RT, 1983, P NATL ACAD SCI-BIOL, V80, P5495, DOI 10.1073/pnas.80.18.5495; Omary MB, 2004, NEW ENGL J MED, V351, P2087, DOI 10.1056/NEJMra040319; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pekny M, 1998, EXP CELL RES, V239, P332, DOI 10.1006/excr.1997.3922; Pekny Milos, 2006, P10; PRICE MG, 1983, J CELL BIOL, V97, P1860, DOI 10.1083/jcb.97.6.1860; QUINLAN RA, 1983, EUR J BIOCHEM, V132, P477, DOI 10.1111/j.1432-1033.1983.tb07386.x; RALTON JE, 1994, J CELL SCI, V107, P1935; Reichelt J, 1997, J CELL SCI, V110, P2175; Rogers SD, 1997, EXP NEUROL, V145, P180, DOI 10.1006/exnr.1997.6468; Russell MA, 2006, ARCH BIOCHEM BIOPHYS, V456, P204, DOI 10.1016/j.abb.2006.06.010; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; SANDOVAL IV, 1983, J BIOL CHEM, V258, P2568; SARRIA AJ, 1990, J CELL BIOL, V111, P553, DOI 10.1083/jcb.111.2.553; Schweitzer SC, 2001, J CELL SCI, V114, P1079; Steinert PM, 1999, J BIOL CHEM, V274, P9881, DOI 10.1074/jbc.274.14.9881; Stone DJ, 1998, J NEUROSCI, V18, P3180; Sultana S, 1998, AM J PATHOL, V153, P1157, DOI 10.1016/S0002-9440(10)65660-X; Sultana S, 2000, GLIA, V30, P143, DOI 10.1002/(SICI)1098-1136(200004)30:2<143::AID-GLIA4>3.0.CO;2-Z; Tao GZ, 2003, J CELL SCI, V116, P4629, DOI 10.1242/jcs.00782; Titeux M, 2001, EUR J BIOCHEM, V268, P6435, DOI 10.1046/j.0014-2956.2001.02594.x; TRAUB P, 1983, J CELL SCI, V63, P43; Uyama N, 2006, GUT, V55, P1276, DOI 10.1136/gut.2005.078865; WANG E, 1984, P NATL ACAD SCI-BIOL, V81, P2102, DOI 10.1073/pnas.81.7.2102; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Xue ZG, 2004, EXP CELL RES, V298, P431, DOI 10.1016/j.yexcr.2004.04.023; Yamamichi-Nishina M, 2003, J BIOL CHEM, V278, P7422, DOI 10.1074/jbc.M208458200	62	73	78	1	2	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	0021-9533	1477-9137		J CELL SCI	J. Cell Sci.	APR 1	2007	120	7					1267	1277		10.1242/jcs.03423			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	148VE	WOS:000245103900016	17356066	hybrid			2022-02-06	
J	Iverson, G				Iverson, Grant			Predicting slow recovery from sport-related concussion: The new simple-complex distinction	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; mild traumatic brain injury; neuropsychological testing; classification	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TESTING USEFUL; COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; CONSTRUCT-VALIDITY; MANAGEMENT; IMPACT; PERFORMANCE; STATEMENT	Objective: Following the Second International Conference on Concussion in Sport in 2005, a summary agreement statement was published that introduced new terminology for sport-related concussions. This new classification system is binary (ie, "simple" versus "complex" concussions). Athletes who are slow to recover (ie, >10 days) are classified as having complex concussions. The purpose of this study was to determine if high school football players, retrospectively classified as having a simple or a complex concussion, could be differentiated in the first 48 after injury on the basis of symptom reporting or neuropsychological testing. Design: Case-control study. Setting: Pennsylvania high school football programs. Participants: The total sample consisted of 114 concussed high school football players who were identified through a 3 year prospective cohort study. Interventions: All completed a computerized neuropsychological screening evaluation within 72 hours of injury. They were followed clinically until they recovered and were cleared to return to play. They were classified retrospectively as having a simple (n = 55) or complex (n = 59) concussion based on their recovery times. Main Outcome Measurements: Neurocognitive test performance and symptom ratings. Results: Within 72 hours after injury, athletes with complex concussions performed more poorly on neuropsychological testing and reported more symptoms than those with simple concussions. Athletes with complex concussions who were slow to recover were 18 times more likely to have 3 unusually low neuropsychological test scores than those with simple concussions (95% CI = 2.3-144.9). Athletes with previous concussions did not recover more slowly. Conclusions: This study provides evidence that supports and refutes the clinical usefulness of the new simple-complex concussion classification system.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Riverview Hosp, Vancouver, BC, Canada		Iverson, G (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins M. W., 2007, BRAIN INJURY MED PRI, P407; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2006, BRIT J SPORT MED, V40, P6, DOI 10.1136/bjsm.2005.021683; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson G, 2002, ARCH CLIN NEUROPSYCH, V17, P769; Iverson G.L., 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; IVERSON GL, 2005, J CLIN EXP NEUROPSYC, V27, P1; Janusz A, 2004, BRIT J SPORT MED, V38, P659; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 2006, J ATHL TRAINING, V41, P137; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LOVELL MR, 2006, IN PRESS APPL NEUROP; Macciocchi SN, 2005, J ATHL TRAINING, V40, P152; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104; Randolph C, 2006, J ATHL TRAINING, V41, P138; Randolph C, 2005, J ATHL TRAINING, V40, P139; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044	60	73	74	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2007	17	1					31	37					7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	128QL	WOS:000243673000006	17304003				2022-02-06	
J	Scheibel, RS; Newsome, MR; Steinberg, JL; Pearson, DA; Rauch, RA; Mao, H; Troyanskaya, M; Sharma, RG; Levin, HS				Scheibel, Randall S.; Newsome, Mary R.; Steinberg, Joel L.; Pearson, Deborah A.; Rauch, Ronald A.; Mao, Hui; Troyanskaya, Maya; Sharma, Rajkumar G.; Levin, Harvey S.			Altered brain activation during cognitive control in patients with moderate to severe traumatic brain injury	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						functional magnetic resonance imaging; traumatic brain injury; cognition	ANTERIOR CINGULATE CORTEX; CLOSED-HEAD INJURY; EVENT-RELATED FMRI; WORKING-MEMORY; PREFRONTAL CORTEX; PRACTICAL SCALE; STROOP TASK; INTERFERENCE; INFORMATION; IMPAIRMENT	Background. Persistent deficits in cognitive control have been documented following traumatic brain injury (TBI) but are inconsistently related to the presence and location of focal lesions. Objective. Functional magnetic resonance imaging (fMRI) was used to examine brain activation during a cognitive control task in patients with moderate to severe TBI or orthopedic injury (OI). Methods. Fourteen TBI patients and 10 OI patients underwent fMRI at 3 months postinjury using a stimulus-response compatibility task in which response accuracy and reaction time were measured. Performance between the groups was equated by individually adjusting the amount of training. Groups did not differ in age, gender, or education. Results. Brain activation during stimulus-response incompatibility was greater in TBI patients than in OI patients within the cingulate, medial frontal, middle frontal, and superior frontal gyri. However, the positive regression of activation with response accuracy during stimulus-response incompatibility indicated a stronger relationship for OI patients than the TBI group within the anterior cingulate gyrus, medial frontal, and parietal regions, as well as deep brain structures (eg, brainstem). The number of focal lesions within either the whole brain or within prefrontal areas was not related to brain activation, but there was a relationship between activation and TBI severity. Conclusions. These findings suggest that neural networks mediating cognitive control are altered after moderate to severe TBI, possibly as a result of diffuse axonal injury, and that the typical relationship of brain activation to performance is disrupted.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Cognit Neurosci Lab, Dept Radiol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Houston, TX USA; Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA		Scheibel, RS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	scheibel@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-42772, NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889, R01NS042772] Funding Source: NIH RePORTER		Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Brown JW, 2005, SCIENCE, V307, P1118, DOI 10.1126/science.1105783; Bryant RA, 2005, BIOL PSYCHIAT, V58, P111, DOI 10.1016/j.biopsych.2005.03.021; Calautti C, 2003, STROKE, V34, P1553, DOI 10.1161/01.STR.0000071761.36075.A6; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Easdon C, 2004, BRAIN COGNITION, V54, P136; Fan J, 2003, NEUROIMAGE, V18, P42, DOI 10.1006/nimg.2002.1319; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Gehring WJ, 2002, SCIENCE, V295, P2279, DOI 10.1126/science.1066893; Hillary FG, 2002, J HEAD TRAUMA REHAB, V17, P411, DOI 10.1097/00001199-200210000-00004; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Leung HC, 2000, CEREB CORTEX, V10, P552, DOI 10.1093/cercor/10.6.552; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Liu X, 2004, NEUROIMAGE, V22, P1097, DOI 10.1016/j.neuroimage.2004.02.033; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Price CJ, 2002, NEUROCASE, V8, P345, DOI 10.1076/neur.8.4.345.16186; Rakitin BC, 2005, J EXP PSYCHOL HUMAN, V31, P685, DOI 10.1037/0096-1523.31.4.685; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; SIMON JR, 1969, J APPL PSYCHOL, V53, P433, DOI 10.1037/h0028034; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Turner R, 2002, NEUROIMAGE, V16, P1062, DOI 10.1006/nimg.2002.1082; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y	39	73	74	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JAN-FEB	2007	21	1					36	45		10.1177/1545968306294730			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	119GX	WOS:000243001900004	17172552				2022-02-06	
J	Zhao, CP; Zhang, C; Zhou, SN; Xie, YM; Wang, YH; Huang, H; Shang, YC; Li, WY; Zhou, C; Yu, MJ; Feng, SW				Zhao, C-P; Zhang, C.; Zhou, S-N; Xie, Y-M; Wang, Y-H; Huang, H.; Shang, Y-C; Li, W-Y; Zhou, C.; Yu, M-J; Feng, S-W			Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice	CYTOTHERAPY			English	Article						amyotrophic lateral sclerosis; mesenchymal stromal cells; SOD1-G93A mice therapy; transplantation	AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSGENIC MOUSE MODEL; BONE-MARROW-CELLS; MOTOR-NEURON DEGENERATION; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; CEREBRAL-ISCHEMIA; GROWTH-FACTOR; SPINAL-CORD	Background Amyotrophic lateral sclerosis (ALS) is a progressive, lethal, neurodegenerative disease, currently without any effective therapy. Multiple advantages make mesenchymal stromal cells (MSC) a good candidate for cellular therapy in many intractable diseases such as stroke and brain injury. Until now, no irrefutable evidence exists regarding the outcome of MSC transplantation in the mouse model of ALS. The present study was designed to investigate the therapeutic potential of human MSC (hMSC) in the mouse model of ALS (SOD1-G93A mice). Methods hMSC were isolated from iliac crest aspirates from healthy donors and kept in cell cultures. hMSC of the fifth passage were delivered intravenously into irradiated pre-symptomatic SOD1-G93A mice. Therapeutic effects were analyzed by survival analysis, rotarod test, motor neuron count in spinal cord and electrophysiology. The engraftment and in vivo differentiation of hMSC were examined in the brain and spinal cord of hMSC-transplanted mice. Results After intravenous injection into irradiated pre-symptomatic SOD1-G93A mice, hMSC survived more than 20 weeks in recipient mice, migrated into the parenchyma of brain and spinal cord and showed neuroglia differentiation. Moreover, hMSC-transplanted mice showed significantly delayed disease onset (14 days), increased lifespan (18 days) and delayed disease progression compared with untreated mice. Discussion Our data document the positive effects of hMSC transplantation in the mouse model of ALS. It may signify the potential use of hMSC in treatment of ALS.	Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurol, Guangzhou 510080, Peoples R China; Sun Yat Sen Univ, Stemm Cells & Tissue Engn Res Ctr, Guangzhou 510080, Peoples R China; Shandong Univ, Qi Lu Hosp, Dept Neurol, Jinan, Peoples R China; Univ N Carolina, Dept Neurol, Chapel Hill, NC USA; Affiliated Hosp, Dept Neurosurg, Yang Zhou, Peoples R China		Zhang, C (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Neurol, Guangzhou 510080, Peoples R China.	Zhangch6@mail.sysu.edu.cn	Shang, Yanchang/B-2910-2008	Shang, Yanchang/0000-0002-4200-6000			Akiyama Y, 2002, GLIA, V39, P229, DOI 10.1002/glia.10102; Alberch J, 2002, BRAIN RES BULL, V57, P817, DOI 10.1016/S0361-9230(01)00775-4; Allers C, 2004, TRANSPLANTATION, V78, P503, DOI 10.1097/01.TP.0000128334.93343.B3; Azzouz M, 1997, MUSCLE NERVE, V20, P45, DOI 10.1002/(SICI)1097-4598(199701)20:1<45::AID-MUS6>3.0.CO;2-H; Beaulieu JM, 2000, J NEUROSCI, V20, P5321, DOI 10.1523/JNEUROSCI.20-14-05321.2000; Bentzon JF, 2005, BIOCHEM BIOPH RES CO, V330, P633, DOI 10.1016/j.bbrc.2005.03.072; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; CHIU AY, 1995, MOL CELL NEUROSCI, V6, P349, DOI 10.1006/mcne.1995.1027; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Corti S, 2004, BRAIN, V127, P2518, DOI 10.1093/brain/awh273; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; Francois S, 2006, STEM CELLS, V24, P1020, DOI 10.1634/stemcells.2005-0260; Gaber MW, 2004, BRAIN RES PROTOC, V13, P1, DOI 10.1016/j.brainresprot.2003.11.005; Gao Q, 2005, NEUROSCIENCE, V136, P123, DOI 10.1016/j.neuroscience.2005.06.091; Garbuzova-Davis S, 2002, EXP NEUROL, V174, P169, DOI 10.1006/exnr.2002.7860; Garbuzova-Davis S, 2003, J HEMATOTH STEM CELL, V12, P255, DOI 10.1089/152581603322022990; Gomes FCA, 2001, BRAZ J MED BIOL RES, V34, P611, DOI 10.1590/S0100-879X2001000500008; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Henkel JS, 2006, MOL CELL NEUROSCI, V31, P427, DOI 10.1016/j.mcn.2005.10.016; Hensley K, 2002, J NEUROCHEM, V82, P365, DOI 10.1046/j.1471-4159.2002.00968.x; Honma T, 2006, EXP NEUROL, V199, P56, DOI 10.1016/j.expneurol.2005.05.004; Iihoshi S, 2004, BRAIN RES, V1007, P1, DOI 10.1016/j.brainres.2003.09.084; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Karl T, 2003, EXP TOXICOL PATHOL, V55, P69, DOI 10.1078/0940-2993-00301; Levine JB, 1999, GLIA, V28, P215; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LI Y, 2003, CANCER RES, V63, P5650; Li YQ, 2004, RADIAT RES, V161, P143, DOI 10.1667/RR3117; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mazzini L, 2006, NEUROL RES, V28, P523, DOI 10.1179/016164106X116791; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mohajeri MH, 1998, EXP NEUROL, V150, P329, DOI 10.1006/exnr.1998.6758; Niebroj-Dobosz I, 1999, ACTA NEUROL SCAND, V100, P238; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Pena LA, 2000, CANCER RES, V60, P321; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Rothstein JD, 1996, NEUROLOGY, V47, pS19, DOI 10.1212/WNL.47.4_Suppl_2.19S; Shefner JM, 2002, MUSCLE NERVE, V25, P39, DOI 10.1002/mus.10000; Shibata N, 2001, NEUROPATHOLOGY, V21, P82, DOI 10.1046/j.1440-1789.2001.00361.x; Shinohara C, 1997, CANCER RES, V57, P2694; Silani V, 2004, CURR NEUROVASC RES, V1, P283, DOI 10.2174/1567202043362243; Silani V, 2004, LANCET, V364, P200, DOI 10.1016/S0140-6736(04)16634-8; Sisodia R, 2006, J RADIOL PROT, V26, P227, DOI 10.1088/0952-4746/26/2/007; Solomon JN, 2006, GLIA, V53, P744, DOI 10.1002/glia.20331; Vaquero J, 2006, NEUROSCI LETT, V398, P129, DOI 10.1016/j.neulet.2005.12.072; Villoslada P, 2004, PROG BRAIN RES, V146, P403; Wang Lei, 2002, Hematology, V7, P113; Weydt P, 2003, NEUROREPORT, V14, P1051, DOI 10.1097/01.wnr.0000073685.00308.89; Yuan H, 2003, BRAIN RES, V969, P59, DOI 10.1016/S0006-8993(03)02278-9; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061; Zhong C, 2003, NEUROSCI LETT, V342, P93, DOI 10.1016/S0304-3940(03)00255-6	57	73	75	0	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1465-3249	1477-2566		CYTOTHERAPY	Cytotherapy		2007	9	5					414	426		10.1080/14653240701376413			13	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	206HH	WOS:000249174000002	17786603				2022-02-06	
J	Gardner, MJ; Voos, JE; Wanich, T; Helfet, DL; Lorich, DG				Gardner, Michael J.; Voos, James E.; Wanich, Tony; Helfet, David L.; Lorich, Dean G.			Vascular implications of minimally invasive plating of proximal humerus fractures	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						proximal humerus fracture; vascularity; minimally invasive; locked plating	STABILIZATION SYSTEM; SURGICAL EXPERIENCE; INTERNAL-FIXATION; TIBIA FRACTURES; LOCKING PLATE; HEAD	Objectives: Open reduction and internal fixation of proximal humerus fractures through the anterolateral acromial approach, which uses the anterior deltoid raphe and axillary nerve protection, has recently been advocated as a minimally invasive technique. Several recent reports have indicated variable and unpredictable vascular injuries to the humeral-head blood supply after a proximal humerus fracture, and thus a direct approach that minimizes further vascular compromise may be preferable. The purpose of this study was to define the relationship of this surgical interval to the lateral plating zone of the proximal humerus and to the penetrating vascular supply of the humeral bead. Design: Cadaveric vascular injection study. Setting: Cadaveric dissection laboratory. Patients: Six cadaveric specimens. Intervention: The anterolateral acromial approach was performed on six cadaveric upper-extremity specimens. A locking proximal humerus plate was applied to the lateral proximal humerus, and the axillary artery was cannulated proximal to the circumflex humeral arteries. Dyed latex polymer was injected and allowed to harden, and dissection was performed to visualize the vasculature of the proximal humerus. Plates were then removed and the specimens were further inspected to examine the blood supply. Main Outcome Measurements: The relationship of the anterolateral acromial approach to the lateral plating zone of the proximal humerus and the vascular supply of the humeral head. Results: In all specimens, the filling of the anterior and posterior vessels that supplied the humeral head were undisturbed after use of the anterolateral acromial approach and locked plating. The blood vessels to the head-penetrating vascular branches were not in the surgical field. A bare spot on the lateral proximal humerus existed in the region of the greater tuberosity, which was 30 mm wide and between two penetrating humeral-head epiphyseal vessels. The nearest penetrating vessels were close to the plate, 4 mm anterior and 7 mm posterior. The anterior humeral circumflex vessel and its ascending branch, which provides critical blood supply to the humeral head, coursed directly in the region of the deltopectoral approach. Conclusions: Minimally invasive techniques have many potential benefits for fracture healing, but new surgical approaches often must be used to take full advantage of these newer methods. Splitting the anterior deltoid raphe from the acromion distally allowed direct access to the lateral plating zone of the proximal humerus. The bare spot in this region may be a safe area for plate application, if the plate is placed appropriately with thorough knowledge of the vascular anatomy. These findings may be of particular importance if the vascular supply to the humeral head has already been partially compromised by preceding trauma. This direct approach to the lateral bare spot on the proximal humerus may minimize iatrogenic vascular injury when treating these fractures.	Hosp Special Surg, Dept Orthopaed Surg, New York, NY 10021 USA		Gardner, MJ (corresponding author), Hosp Special Surg, Dept Orthopaed Surg, 535 E 70th St, New York, NY 10021 USA.	gardnerm@hss.edu					ABBOTT LC, 1949, J BONE JOINT SURG AM, V31-A, P235, DOI 10.2106/00004623-194931020-00002; Bathis H, 2001, ZBL CHIR, V126, P211, DOI 10.1055/s-2001-12498; Bjorkenheim JM, 2004, ACTA ORTHOP SCAND, V75, P741, DOI 10.1080/00016470410004120; BROOKS CH, 1993, J BONE JOINT SURG BR, V75, P132, DOI 10.1302/0301-620X.75B1.8421010; Burkhead W Z Jr, 1992, J Shoulder Elbow Surg, V1, P31, DOI 10.1016/S1058-2746(09)80014-1; Cole PA, 2004, J ORTHOP TRAUMA, V18, P528, DOI 10.1097/00005131-200409000-00008; COUDANE H, 2000, J SHOULDER ELB SURG, P548; Determe D, 1996, SURG RADIOL ANAT, V18, P195, DOI 10.1007/BF02346127; Duparc F, 1997, SURG RADIOL ANAT, V19, P127, DOI 10.1007/s00276-997-0127-2; Duparc F, 2001, SURG RADIOL ANAT, V23, P185, DOI 10.1007/s00276-001-0185-9; Duval M J, 1993, Orthop Rev, V22, P1023; Fankhauser F, 2005, CLIN ORTHOP RELAT R, P176, DOI 10.1097/01.blo.0000137554.91189.a9; Gallo RA, 2005, J ORTHOP TRAUMA, V19, P734, DOI 10.1097/01.bot.0000174708.88108.da; Gardner Michael J, 2004, Bull Hosp Jt Dis, V62, P18; Gardner MJ, 2005, CLIN ORTHOP RELAT R, P123, DOI 10.1097/01.blo.0000152872.95806.09; Gardner MJ, 2005, INJURY, V36, P1197, DOI 10.1016/j.injury.2005.06.038; Gautier E, 2000, J BONE JOINT SURG BR, V82B, P679, DOI 10.1302/0301-620X.82B5.10426; GERBER C, 1990, J BONE JOINT SURG AM, V72A, P1486, DOI 10.2106/00004623-199072100-00009; Haidukewych GJ, 2004, J AM ACAD ORTHOP SUR, V12, P205, DOI 10.5435/00124635-200407000-00001; Hertel R, 2004, J SHOULDER ELB SURG, V13, P427, DOI 10.1016/j.jse.2004.01.034; Hockings M, 2003, INJURY, V34, P443, DOI 10.1016/S0020-1383(02)00189-4; JAKOB RP, 1991, J BONE JOINT SURG BR, V73, P295, DOI 10.1302/0301-620X.73B2.2005159; Koukakis A, 2006, CLIN ORTHOP RELAT R, P115, DOI 10.1097/01.blo.0000194678.87258.6e; Kregor PJ, 2004, J ORTHOP TRAUMA, V18, P509, DOI 10.1097/00005131-200409000-00006; KRISTIANSEN B, 1986, ACTA ORTHOP SCAND, V57, P320, DOI 10.3109/17453678608994401; LAFLAMME GY, 2005, ORTH TRAUM ASS ANN M; LAING PG, 1956, J BONE JOINT SURG AM, V38, P1105, DOI 10.2106/00004623-195638050-00013; Lin J, 1999, CLIN ORTHOP RELAT R, P247; Meyer C, 2005, SURG RADIOL ANAT, V27, P232, DOI 10.1007/s00276-005-0318-7; Panagopoulos AM, 2004, INT ORTHOP, V28, P333, DOI 10.1007/s00264-004-0581-y; Plecko Michael, 2005, Oper Orthop Traumatol, V17, P25; Ricci WM, 2004, J ORTHOP TRAUMA, V18, P521, DOI 10.1097/00005131-200409000-00007; SAUDAN M, 2003, ORTH TRAUM ASS ANN M; Schutz M, 2005, ARCH ORTHOP TRAUM SU, V125, P102, DOI 10.1007/s00402-004-0779-x; SPECK M, 1996, SWISS SURG, P51; Stannard JP, 2004, J ORTHOP TRAUMA, V18, P552, DOI 10.1097/00005131-200409000-00012; STURZENEGGER M, 1982, ARCH ORTHOP TRAUM SU, V100, P249, DOI 10.1007/BF00381665; SZYSZKOWITZ R, 1993, CLIN ORTHOP RELAT R, P13; Szyszkowitz R, 1999, UNFALLCHIRURG, V102, P422, DOI 10.1007/s001130050430; Traxler H, 2001, CLIN ANAT, V14, P418, DOI 10.1002/ca.1077; Wijgman AJ, 2002, J BONE JOINT SURG AM, V84A, P1919, DOI 10.2106/00004623-200211000-00002	41	73	84	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	OCT	2006	20	9					602	607		10.1097/01.bot.0000246412.10176.14			6	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	104NR	WOS:000241965600003	17088661				2022-02-06	
J	Alderfer, BS; Arciniegas, DB; Silver, JM				Alderfer, BS; Arciniegas, DB; Silver, JM			Treatment of depression following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						antidepressants; depression; drug interactions; electroconvulsive therapy; monoamine axidase inhibitors; seizures; serotonin uptake inhibitors; tricyclic antidepressive agents; traumatic brain injury	MAJOR DEPRESSION; HEAD-INJURY; PSYCHIATRIC-DISORDERS; FLUOXETINE; MILD; MOOD; REHABILITATION; INDIVIDUALS; SYMPTOMS; ECT	Depression is a common consequence of traumatic brain injury (TBI), and is a source of substantial distress and disability for persons with TBI and their families. This article offers a practical approach to the evaluation and treatment of this condition. Diagnostic and etiologic considerations relevant to this issue are reviewed first. Next, somatic therapies for posttraumatic depression, including antidepressant medications and electroconvulsive therapy, are discussed. Use of these therapies is also considered in the context of the common medical and neurological comorbidities among persons with TBI. Finally, psychosocial interventions relevant to the care of persons with posttraumatic depression are presented.	HealthONE Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA; Univ Colorado, Sch Med, Dept Psychiat, Neuropsychiat Serv, Denver, CO 80202 USA; Vet Integrated Serv Network 19 Mental Illness Res, Rocky Mt Network, Denver, CO USA; Univ Colorado, Sch Med, Dept Neurol, Behav Neurol Sect, Denver, CO 80202 USA; NYU, Sch Med, Dept Psychiat, New York, NY USA		Alderfer, BS (corresponding author), HealthONE Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA.		Arciniegas, David/A-3792-2009				Arciniegas D B, 2000, Semin Clin Neuropsychiatry, V5, P290, DOI 10.1053/scnp.2000.9554; Arciniegas David B, 2004, Phys Med Rehabil Clin N Am, V15, P177, DOI 10.1016/S1047-9651(03)00104-9; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Arciniegas DB, 2000, CURRENT TREATMENT OP, V2, P169; Bay Esther, 2004, Res Theory Nurs Pract, V18, P213, DOI 10.1891/rtnp.18.2.213.61278; BESSETTE RF, 1992, PSYCHOSOMATICS, V33, P224, DOI 10.1016/S0033-3182(92)72001-5; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Breen R, 1997, COMMUNITY MENT HLT J, V33, P359, DOI 10.1023/A:1025007510330; CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; Crow S, 1996, CONVULSIVE THER, V12, P113; DAVIDSON J, 1989, J CLIN PSYCHIAT, V50, P256; DESMET Y, 1982, J NEUROL NEUROSUR PS, V45, P1161, DOI 10.1136/jnnp.45.12.1161; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DUBOIS B, 1990, ANN NEUROL, V28, P117, DOI 10.1002/ana.410280202; DUBOVSKY S, 1992, AM PSYCHIAT PRESS TX; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fujishiro J, 2002, EUR J PHARMACOL, V454, P183, DOI 10.1016/S0014-2999(02)02557-8; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; GRIMSLEY SR, 1991, CLIN PHARMACOL THER, V50, P10, DOI 10.1038/clpt.1991.98; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; JALIL P, 1992, J NEUROL NEUROSUR PS, V55, P412, DOI 10.1136/jnnp.55.5.412-a; JOHNSTON CM, 1991, J CAN DIET ASSOC, V52, P11; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Jurado M A, 1993, Neurologia, V8, P91; Kalpakjian CZ, 2002, BRAIN INJURY, V16, P501, DOI 10.1080/02699050110119123; Kanetani Kouichi, 2003, Journal of Nippon Medical School, V70, P313; Kant R, 1999, J NEUROPSYCH CLIN N, V11, P32, DOI 10.1176/jnp.11.1.32; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Khouzam HR, 1998, GEN HOSP PSYCHIAT, V20, P62, DOI 10.1016/S0163-8343(97)00097-2; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; Liotti M, 2001, J CLIN EXP NEUROPSYC, V23, P121, DOI 10.1076/jcen.23.1.121.1223; Liotti M, 2000, BIOL PSYCHIAT, V48, P30, DOI 10.1016/S0006-3223(00)00874-X; LIPSEY JR, 1983, BRIT J PSYCHIAT, V143, P266, DOI 10.1192/bjp.143.3.266; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Meythaler JM, 2001, BRAIN INJURY, V15, P321, DOI 10.1080/026990501750111274; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; MOBAYED M, 1990, J AFFECT DISORDERS, V19, P237, DOI 10.1016/0165-0327(90)90100-M; Newburn G, 1999, BRAIN INJURY, V13, P637; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; OJEMANN LM, 1987, NEUROLOGY, V37, P1525, DOI 10.1212/WNL.37.9.1525; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Patterson DE, 1997, BRAIN INJURY, V11, P287, DOI 10.1080/026990597123593; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; PINDER RM, 1977, DRUGS, V13, P321, DOI 10.2165/00003495-197713050-00001; POST RM, 1992, AM J PSYCHIAT, V149, P999; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; RICKELS K, 1990, J CLIN PSYCHIAT, V51, P9; Robinson RG, 2000, AM J PSYCHIAT, V157, P351, DOI 10.1176/appi.ajp.157.3.351; RUEDRICH SL, 1983, AM J PSYCHIAT, V140, P928; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; Schmitt JAJ, 2001, J PSYCHOPHARMACOL, V15, P173, DOI 10.1177/026988110101500304; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Seminowicz DA, 2004, NEUROIMAGE, V22, P409, DOI 10.1016/j.neuroimage.2004.01.015; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; SILVER JM, 2005, TXB TRAMATIC BRAIN I; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; SOVNER R, 1991, J CLIN PSYCHOPHARM, V11, P389, DOI 10.1097/00004714-199112000-00018; Spinella M, 2002, BRAIN INJURY, V16, P359, DOI 10.1080/02699050110103319; Stahl S.M, 2000, ESSENTIAL PSYCHOPHAR; Starkstein SE, 2002, NEUROREHABILITATION, V17, P105; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Teng CJ, 2001, BRAIN INJURY, V15, P463, DOI 10.1080/02699050010005931; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Viguier D, 2001, BRAIN INJURY, V15, P263; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; WROBLEWSKI BA, 1990, J CLIN PSYCHOPHARM, V10, P124, DOI 10.1097/00004714-199004000-00009; WROBLEWSKI BA, 1992, AM J PSYCHIAT, V149, P273; ZWIL AS, 1992, CONVULSIVE THER, V8, P103	99	73	80	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2005	20	6					544	562		10.1097/00001199-200511000-00006			19	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	986YF	WOS:000233484900006	16304490				2022-02-06	
J	Davis, DP; Stern, J; Ochs, M; Sise, MJ; Hoyt, DB				Davis, DP; Stern, J; Ochs, M; Sise, MJ; Hoyt, DB			A follow-up analysis of factors associated with head-injury mortality after paramedic rapid sequence intubation	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 29-JUN 01, 2003	BOSTON, MA	Soc Acad Emergency Med			RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN-INJURY; CEREBRAL BLOOD-FLOW; MECHANICAL VENTILATION; LUNG INJURY; HYPERVENTILATION; ASPIRATION; MANAGEMENT; PNEUMONIA; HYPOXIA	Background: The San Diego Paramedic Rapid Sequence Intubation (RSI) Trial documented an increase in mortality after paramedic RSI, with hyperventilation identified as a contributing factor in a small subgroup analysis. Here we explore factors affecting outcome in the entire cohort of patients undergoing paramedic RSI to confirm previous findings. This also represents a synthesis of findings from previous analyses Methods. Adult trauma patients with severe head injury (Glasgow Coma Scale score, 3-8) who could not be intubated without RSI were prospectively enrolled in the trial. This analysis excluded patients without traumatic brain injury (head/neck abbreviated injury score < 2 or failure to meet Major Trauma Outcome Stud), criteria) or death in the field or within 30 minutes of arrival. Each remaining trial patient was matched to two nonintubated historical controls from the county trauma registry based on age, sex, mechanism, abbreviated injury scores for each body system, and Injury Severity Score. Logistic regression, cohort analysis, mean least squares regression, and discordant group analysis were used to explore the impact of various factors on outcome. Results. Of the 426 trial patients, 352 met inclusion criteria for this analysis and were hand-matched to 704 controls. Trial patients and controls were identical with regard to all matching variables. Mortality was increased in RSI patients versus matched controls (31.8 versus 23.7%; odds ratio, 1.5; 95% confidence interval, 1.1-2.0; p < 0.01). Hyperventilation was associated with an increase in mortality, whereas transport by aeromedical crews after paramedic RSI was associated with improved outcomes. The reported incidence of aspiration pneumonia was higher for the RSI patients. Conclusion: Paramedic RSI was associated with an increase in mortality compared with matched historical controls. The association between hyperventilation and mortality was confirmed. In addition, patients transported by helicopter after paramedic RSI had improved outcomes. Paramedic RSI did not seem to prevent aspiration pneumonia.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Surg, Div Trauma, San Diego, CA 92103 USA; Scripps Mercy Hosp, San Diego Cty Emergency Med Serv, San Diego, CA USA; NYU, Sch Med, New York, NY USA		Davis, DP (corresponding author), Univ Calif San Diego, Dept Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	davismd@cox.net					Adnet F, 1996, LANCET, V348, P123, DOI 10.1016/S0140-6736(05)64630-2; Bao Yinghui, 2000, Chin J Traumatol, V3, P210; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2004, J TRAUMA, V56, P808, DOI 10.1097/01.TA.0000100217.05066.87; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Forbes ML, 1998, J NEUROSURG, V88, P549, DOI 10.3171/jns.1998.88.3.0549; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; JOHNSTON I H, 1970, Lancet, V2, P433; Lockey DJ, 1999, ANAESTHESIA, V54, P1097, DOI 10.1046/j.1365-2044.1999.00754.x; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Orr RA, 1997, INT ANESTHESIOL CLIN, V35, P31, DOI 10.1097/00004311-199703530-00005; Pepe PE, 2003, J TRAUMA, V54, P1048, DOI 10.1097/01.TA.0000064280.05372.7C; Poste Jennifer C, 2004, Air Med J, V23, P36, DOI 10.1016/j.amj.2004.04.006; Rello J, 1999, AM J RESP CRIT CARE, V159, P1742, DOI 10.1164/ajrccm.159.6.9808030; ROSSANDA M, 1968, SCAND J CLIN LAB I S, V102, P13; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Uhlig S, 2002, AM J PHYSIOL-LUNG C, V282, pL892, DOI 10.1152/ajplung.00124.2001; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; Wayne M A, 1999, Prehosp Emerg Care, V3, P290, DOI 10.1080/10903129908958956; WHITWAM JG, 1966, BRIT J ANAESTH, V38, P846, DOI 10.1093/bja/38.11.846; Woratyla S P, 1995, Conn Med, V59, P643	30	73	73	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2005	59	2					484	488		10.1097/00005373-200508000-00037			5	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	014BX	WOS:000235454800048	16294099				2022-02-06	
J	Floyd, CL; Gorin, FA; Lyeth, BG				Floyd, CL; Gorin, FA; Lyeth, BG			Mechanical strain injury increases intracellular sodium and reverses Na+/Ca2+ exchange in cortical astrocytes	GLIA			English	Article						traumatic brain injury; Fura-2; calcium; SBFI-AM; KB-R7943; TBOA; glutamate	TRAUMATIC BRAIN-INJURY; EXCITATORY AMINO-ACIDS; STRETCH-INDUCED INJURY; THREO-BETA-BENZYLOXYASPARTATE; RAT HIPPOCAMPAL ASTROCYTES; EXTRACELLULAR ION SHIFTS; CULTURED ASTROCYTES; AXONAL INJURY; GLUTAMATE RELEASE; HYPOXIC/HYPOGLYCEMIC INJURY	Traditionally, astrocytes have been considered less susceptible to injury than neurons. Yet, we have recently shown that astrocyte death precedes neuronal death in a rat model of traumatic brain injury (TBI) (Zhao et al.: Glia 44:140152, 2003). A main mechanism hypothesized to contribute to cellular injury and death after TBI is elevated intracellular calcium ([Ca2+](i)). Since calcium regulation is also influenced by regulation of intracellular sodium ([Na+](i)), we used an in vitro model of strain-induced traumatic injury and live-cell fluorescent digital imaging to investigate alterations in [Na+](i) in cortical astrocytes after injury. Changes in [Na+](i), or [Ca2+](i) were monitored after mechanical injury or L-glutamate exposure by ratiometric imaging of sodium-binding benzofuran isophthalate (SBFI-AM), or Fura-2-AM, respectively. Mechanical strain injury or exogenous glutamate application produced increases in [Na+](i) that were dependent on the severity of injury or concentration. Injury-induced increases in [Na+](i) were significantly reduced, but not completely eliminated, by inhibition of glutamate uptake by DL-threo-beta-benzyloxyaspartate (TBOA). Blockade of sodium-dependent calcium influx through the odium-calcium exchanger with 2-[2-[4-(4-Nitrobenzyloxy)-)phenyl]ethyl]isothiourea mesylate (KB-R7943) reduced Ca2+](i) after injury. KB-R7943 also reduced astrocyte death after injury. These findings suggest that in astrocytes subjected to mechanical injury or glutamate excitotoxicity, in intracellular Na+ may be a critical component in the injury cascade and a therapeutic target for reduction A lasting deficits after traumatic brain injury. (C) 2005 Wiley-Liss, Inc.	Univ Calif Davis, Dept Neurol Surg, Ctr Neurosci, Davis, CA 95616 USA; Univ Calif Davis, Dept Neurol, Ctr Neurosci, Davis, CA 95616 USA		Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, Ctr Neurosci, 1515 Newton Court,1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, F32NS043085, R01NS040489, R01NS045136] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS040489-03, NS 43085, R01 NS040489-01A1, NS 40489, R01 NS040489-02, NS 29995, R01 NS040489, R01 NS029995, F32 NS043085, NS 45136, R01 NS045136] Funding Source: Medline		Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; Anderson CM, 2000, GLIA, V32, P1; Arakawa N, 2000, BIOCHEM BIOPH RES CO, V279, P354, DOI 10.1006/bbrc.2000.3968; Araque A, 1999, CAN J PHYSIOL PHARM, V77, P699, DOI 10.1139/cjpp-77-9-699; ASCHNER M, 1991, NEUROTOXICOLOGY, V12, P505; BARRES BA, 1990, NEURON, V5, P527, DOI 10.1016/0896-6273(90)90091-S; Blaustein MP, 2002, ANN NY ACAD SCI, V976, P356; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Bondarenko A, 2001, GLIA, V34, P134, DOI 10.1002/glia.1048; Bondarenko A, 2001, GLIA, V34, P143, DOI 10.1002/glia.1049; Breder J, 2000, NEUROPHARMACOLOGY, V39, P1779, DOI 10.1016/S0028-3908(00)00027-7; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Chatton JY, 2001, BRAIN RES, V893, P46, DOI 10.1016/S0006-8993(00)03286-8; Chen T, 2004, J NEUROTRAUM, V21, P271, DOI 10.1089/089771504322972068; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CONDORELLI DF, 1993, J NEUROSCI RES, V36, P344, DOI 10.1002/jnr.490360312; Czyz A, 2002, J NEUROCHEM, V83, P1321, DOI 10.1046/j.1471-4159.2002.01227.x; Dong H, 2002, ANN NY ACAD SCI, V976, P159; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Eng DL, 1997, BRAIN RES, V778, P215, DOI 10.1016/S0006-8993(97)01093-7; Fern R, 1997, CLIN NEUROSCI, V4, P246; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Floyd CL, 2004, J NEUROTRAUM, V21, P205, DOI 10.1089/089771504322778668; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GOLDMAN WF, 1994, J NEUROSCI, V14, P5834; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hansson E, 1997, ACT NEUR S, V70, P148; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hertz L, 1998, METHODS, V16, P293, DOI 10.1006/meth.1998.0686; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jeftinija SD, 1996, J NEUROCHEM, V66, P676; Jeremic A, 2001, J NEUROCHEM, V77, P664, DOI 10.1046/j.1471-4159.2001.00272.x; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Li SX, 2000, J NEUROPHYSIOL, V84, P1116; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Longuemare MC, 1999, NEUROSCIENCE, V93, P285, DOI 10.1016/S0306-4522(99)00152-9; MacGregor DG, 2003, J NEUROCHEM, V85, P1402, DOI 10.1046/j.1471-4159.2003.01772.x; MACVICAR BA, 1984, SCIENCE, V226, P1345, DOI 10.1126/science.6095454; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Martin LJ, 1997, ANN NEUROL, V42, P335, DOI 10.1002/ana.410420310; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Newcomb JK, 1999, J NEUROTRAUM, V16, P1, DOI 10.1089/neu.1999.16.1; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pilitsis JG, 2001, BRAIN RES, V916, P192, DOI 10.1016/S0006-8993(01)02896-7; Pintado AJ, 2000, BRIT J PHARMACOL, V130, P1893, DOI 10.1038/sj.bjp.0703519; Povlishock JT, 1999, ACT NEUR S, V73, P15; Rose CR, 1996, J NEUROSCI, V16, P5393; Rose CR, 1998, J NEUROSCI, V18, P3554; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Scemes E, 2000, MOL NEUROBIOL, V22, P167, DOI 10.1385/MN:22:1-3:167; Schroder UH, 1999, NEUROPHARMACOLOGY, V38, P319, DOI 10.1016/S0028-3908(98)00198-1; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Shelton MK, 1999, GLIA, V26, P1, DOI 10.1002/(SICI)1098-1136(199903)26:1<1::AID-GLIA1>3.0.CO;2-Z; Shimamoto K, 1998, MOL PHARMACOL, V53, P195, DOI 10.1124/mol.53.2.195; Somjen George G., 1995, P319; Takahashi S, 2000, EUR J PHARMACOL, V408, P127, DOI 10.1016/S0014-2999(00)00790-1; Tomes Daniel J, 2002, Spine J, V2, P35, DOI 10.1016/S1529-9430(01)00151-6; Waagepetersen HS, 2001, NEUROCHEM RES, V26, P661, DOI 10.1023/A:1010939304104; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	84	73	80	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUL	2005	51	1					35	46		10.1002/glia.20183			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	934IZ	WOS:000229703800004	15779085	Green Accepted			2022-02-06	
